PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Deepa, SS; Carulli, D; Galtrey, C; Rhodes, K; Fukuda, J; Mikami, T; Sugahara, K; Fawcett, JW				Deepa, Sarama Sathyaseelan; Carulli, Daniela; Galtrey, Clare; Rhodes, Kate; Fukuda, Junko; Mikami, Tadahisa; Sugahara, Kazuyuki; Fawcett, James W.			Composition of perineuronal net extracellular matrix in rat brain - A different disaccharide composition for the net-associated proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; PROTEIN-TYROSINE-PHOSPHATASE; HYALURONAN-BINDING PROTEINS; CELL-ADHESION MOLECULES; CARTILAGE LINK PROTEIN; NEURITE OUTGROWTH; SPINAL-CORD; IMMUNOCYTOCHEMICAL LOCALIZATION; CORTICAL-NEURONS; POTENT INHIBITOR	We developed a method to extract differentially chondroitin sulfate proteoglycans (CSPGs) that are diffusely present in the central nervous system (CNS) matrix and CSPGs that are present in the condensed matrix of perineuronal nets (PNNs). Adult rat brain was sequentially extracted with Tris-buffered saline (TBS), TBS-containing detergent, 1 M NaCl, and 6 M urea. Extracting tissue sections with these buffers showed that the diffuse and membrane-bound CSPGs were extracted in the first three buffers, but PNN- associated CSPGs remained and were only removed by 6 M urea. Most of the CSPGs were extracted to some degree with all the buffers, with neurocan, brevican, aggrecan, and versican particularly associated with the stable urea-extractable PNNs. The CSPGs in stable complexes only extractable in urea buffer are found from postnatal day 7-14 coinciding with PNN formation. Disaccharide composition analysis indicated a different glycosaminoglycan (GAG) composition for PGs strongly associated with extracellular matrix (ECM). For CS/dermatan sulfate (DS)-GAG the content of nonsulfated, 6-O-sulfated, 2,6-O-disulfated, and 4,6-O-disulfated disaccharides were higher and for heparan sulfate (HS)-GAG, the content of 6-O-sulfated, 2-N-,6-O-disulfated, 2-O-,2-N-disulfated, and 2-O-, 2-N-, 6-O-trisulfated disaccharides were higher in urea extract compared with other buffer extracts. Digestions with chondroitinase ABC and hyaluronidase indicated that aggrecan, versican, neurocan, brevican, and phosphacan are retained in PNNs through binding to hyaluronan (HA). A comparison of the brain and spinal cord ECM with respect to CSPGs indicated that the PNNs in both parts of the CNS have the same composition.	Univ Cambridge, Ctr Brain Repair, Cambridge CB2 2PY, England; Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 658558, Japan	University of Cambridge; Kobe Pharmaceutical University	Fawcett, JW (corresponding author), Univ Cambridge, Ctr Brain Repair, Fovie Site, Cambridge CB2 2PY, England.	jf108@cam.ac.uk	Messier, Claude/A-2322-2008; Carulli, Daniela/AEQ-2246-2022	Messier, Claude/0000-0002-4791-1763; Fawcett, James/0000-0002-7990-4568; Carulli, Daniela/0000-0003-1365-7063; Deepa, Sathyaseelan/0000-0002-3669-4820	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AQUINO DA, 1984, J CELL BIOL, V99, P1117, DOI 10.1083/jcb.99.3.1117; AQUINO DA, 1984, J CELL BIOL, V99, P1130, DOI 10.1083/jcb.99.3.1130; Asher RA, 2000, J NEUROSCI, V20, P2427; Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; ASHER RA, 1995, GLIA, V13, P294, DOI 10.1002/glia.440130406; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Beggah AT, 2005, NEUROSCIENCE, V133, P749, DOI 10.1016/j.neuroscience.2005.03.005; Bekku Y, 2003, MOL CELL NEUROSCI, V24, P148, DOI 10.1016/S1044-7431(03)00133-7; BIGNAMI A, 1992, BRAIN RES, V579, P173, DOI 10.1016/0006-8993(92)90759-3; BIGNAMI A, 1992, EXP NEUROL, V117, P90, DOI 10.1016/0014-4886(92)90115-7; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brakebusch C, 2002, MOL CELL BIOL, V22, P7417, DOI 10.1128/MCB.22.21.7417-7427.2002; Bruckner G, 1996, J NEUROCYTOL, V25, P333, DOI 10.1007/BF02284806; Bruckner G, 1999, NEUROSCIENCE, V92, P791, DOI 10.1016/S0306-4522(99)00071-8; BRUCKNER G, 1993, GLIA, V8, P183, DOI 10.1002/glia.440080306; Carulli D, 2006, J COMP NEUROL, V494, P559, DOI 10.1002/cne.20822; Celio MR, 1998, TRENDS NEUROSCI, V21, P510, DOI 10.1016/S0166-2236(98)01298-3; CELIO MR, 1994, BRAIN RES REV, V19, P128, DOI 10.1016/0165-0173(94)90006-X; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Corvetti L, 2005, J NEUROSCI, V25, P7150, DOI 10.1523/JNEUROSCI.0683-05.2005; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; De Wit J, 2005, MOL CELL NEUROSCI, V29, P40, DOI 10.1016/j.mcn.2004.12.009; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Engel M, 1996, J COMP NEUROL, V366, P34; Falk J, 2002, BIOL CELL, V94, P327, DOI 10.1016/S0248-4900(02)00006-0; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Gilbert RJ, 2005, MOL CELL NEUROSCI, V29, P545, DOI 10.1016/j.mcn.2005.04.006; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; Hartig W, 1999, BRAIN RES, V842, P15, DOI 10.1016/S0006-8993(99)01784-9; Hayashi N, 2005, NEUROSCIENCE, V131, P331, DOI 10.1016/j.neuroscience.2004.11.017; HOCKFIELD S, 1990, COLD SPRING HARB SYM, V55, P505; HOCKFIELD S, 1983, P NATL ACAD SCI-BIOL, V80, P5758, DOI 10.1073/pnas.80.18.5758; Hu HY, 2001, NAT NEUROSCI, V4, P695, DOI 10.1038/89482; JAWORSKI DM, 1994, J CELL BIOL, V125, P495, DOI 10.1083/jcb.125.2.495; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; KALB RG, 1988, J NEUROSCI, V8, P2350; Kantor DB, 2004, NEURON, V44, P961, DOI 10.1016/j.neuron.2004.12.002; Kappler J, 1997, EUR J NEUROSCI, V9, P306, DOI 10.1111/j.1460-9568.1997.tb01401.x; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Koppe G, 1997, CELL TISSUE RES, V288, P33, DOI 10.1007/s004410050790; Kreuger J, 2005, BIOCHEM J, V389, P145, DOI 10.1042/BJ20042129; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Levine JM, 1996, PERSPECT DEV NEUROBI, V3, P245; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Matsui F, 1998, BRAIN RES, V790, P45, DOI 10.1016/S0006-8993(98)00009-2; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; Milev P, 1998, BIOCHEM BIOPH RES CO, V247, P207, DOI 10.1006/bbrc.1998.8759; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; Miyata S, 2005, NEUROSCIENCE, V136, P95, DOI 10.1016/j.neuroscience.2005.07.031; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Morawski M, 2004, EXP NEUROL, V188, P309, DOI 10.1016/j.expneurol.2004.04.017; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; Oleszewski M, 1999, J BIOL CHEM, V274, P24602, DOI 10.1074/jbc.274.35.24602; Oohashi T, 2002, MOL CELL NEUROSCI, V19, P43, DOI 10.1006/mcne.2001.1061; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; PERIDES G, 1992, J BIOL CHEM, V267, P23883; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Probstmeier R, 2000, J NEUROSCI RES, V60, P21, DOI 10.1002/(SICI)1097-4547(20000401)60:1<21::AID-JNR3>3.0.CO;2-H; Properzi F, 2005, EUR J NEUROSCI, V21, P378, DOI 10.1111/j.1460-9568.2005.03876.x; Rauch U, 2004, MATRIX BIOL, V22, P629, DOI 10.1016/j.matbio.2003.11.007; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Rauch U, 2004, CELL MOL LIFE SCI, V61, P2031, DOI 10.1007/s00018-004-4043-x; Retzler C, 1996, J BIOL CHEM, V271, P27304, DOI 10.1074/jbc.271.44.27304; Rhodes KE, 2004, J ANAT, V204, P33, DOI 10.1111/j.1469-7580.2004.00261.x; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Schmalfeldt M, 2000, J CELL SCI, V113, P807; SEIDENBECHER CI, 1995, J BIOL CHEM, V270, P27206, DOI 10.1074/jbc.270.45.27206; Seidenbecher CI, 2002, J NEUROCHEM, V83, P738, DOI 10.1046/j.1471-4159.2002.01183.x; Seyfried NT, 2005, J BIOL CHEM, V280, P5435, DOI 10.1074/jbc.M411297200; SMITHTHOMAS LC, 1995, J CELL SCI, V108, P1307; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STALLCUP WB, 1983, COLD SPRING HARB SYM, V48, P761, DOI 10.1101/SQB.1983.048.01.078; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Thon N, 2000, EUR J NEUROSCI, V12, P2547, DOI 10.1046/j.1460-9568.2000.00109.x; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Tropea D, 2003, J NEUROSCI, V23, P7034, DOI 10.1523/JNEUROSCI.23-18-07034.2003; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; Woodworth A, 2004, J BIOL CHEM, V279, P10413, DOI 10.1074/jbc.M312466200; Wu YJ, 2004, MOL BIOL CELL, V15, P2093, DOI 10.1091/mbc.E03-09-0667; Yamada H, 1997, J NEUROSCI, V17, P7784; YAMAGATA T, 1966, BIOCHIM BIOPHYS ACTA, V115, P250, DOI 10.1016/0304-4165(66)90077-8; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690	85	255	266	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17789	17800		10.1074/jbc.M600544200	http://dx.doi.org/10.1074/jbc.M600544200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16644727	hybrid			2022-12-25	WOS:000238490300029
J	Goetze, TA; Philippar, K; Ilkavets, I; Soll, J; Wagner, R				Goetze, Tom Alexander; Philippar, Katrin; Ilkavets, Irina; Soll, Jurgen; Wagner, Richard			OEP37 is a new member of the chloroplast outer membrane ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUTE CHANNEL; PROTEIN IMPORT; PREPROTEIN TRANSLOCASE; K+-CHANNEL; ENVELOPE; PORE; CONDUCTANCE; SELECTIVITY; VDAC	The chloroplast outer envelope protein OEP37 is a member of the growing beta-barrel protein family of the outer chloroplast membrane. The reconstituted recombinant protein OEP37 from pea forms a rectifying high conductance channel with a main conductance (lambda) of Lambda = 500 picosiemens (symmetrical 250 mM KCl). The OEP37 channel is cation-selective (PK+/P-Cl- = 14:1) with a voltage-dependent open probability maximal at V-mem = 0 mV. The channel pore reveals an hourglass-shaped form with different diameters for the vestibule and restriction zone. The diameters of the vestibule at the high conductance side were estimated by d = 3.0 nm and the restriction zone by d = 1.5 nm. The OEP37 channel displayed a nanomolar affinity for the precursor of the chloroplast inner membrane protein Tic32, which is imported into the chloroplast through a yet unknown pathway. Pre-proteins imported through the usual Toc pathway and synthetic control peptides, however, did not show a comparable block of the OEP37 channel. In addition to the electrophysiological characterization, we studied the gene expression of OEP37 in the model plant Arabidopsis thaliana. Here, transcripts of AtOEP37 are ubiquitously expressed throughout plant development and accumulate in early germinating seedlings as well as in late embryogenesis. The plastid intrinsic protein could be detected in isolated chloroplasts of cotyledons and rosette leaves. However, the knock-out mutant oep37-1 shows that the proper function of this single copy gene is not essential for development of the mature plant. Moreover, import of Tic32 into chloroplasts of oep37-1 was not impaired when compared with wild type. Thus, OEP37 may constitute a novel peptide-sensitive ion channel in the outer envelope of plastids with function during embryogenesis and germination.	Univ Osnabruck, FB Biol Chem, D-49076 Osnabruck, Germany; Univ Munich, Dept Biol 1, D-80638 Munich, Germany	University Osnabruck; University of Munich	Wagner, R (corresponding author), Univ Osnabruck, FB Biol Chem, Barbarastr 13, D-49076 Osnabruck, Germany.	wagner@uos.de	Philippar, Katrin/F-7942-2018; Goetze, Tom/I-1891-2013	Philippar, Katrin/0000-0002-2140-4907				Alcaraz A, 2004, BIOPHYS J, V87, P943, DOI 10.1529/biophysj.104/043414; Aronsson H, 2002, FEBS LETT, V529, P215, DOI 10.1016/S0014-5793(02)03342-2; Bezrukov SM, 1997, EUR BIOPHYS J BIOPHY, V26, P471, DOI 10.1007/s002490050101; BLUMENTHAL A, 1993, PLANT PHYSIOL, V101, P579, DOI 10.1104/pp.101.2.579; Bolter B, 1999, EMBO J, V18, P5505, DOI 10.1093/emboj/18.20.5505; Bolter B, 1998, P NATL ACAD SCI USA, V95, P15831, DOI 10.1073/pnas.95.26.15831; Bolter B, 2001, EMBO J, V20, P935, DOI 10.1093/emboj/20.5.935; Clausen C, 2004, PLANTA, V220, P30, DOI 10.1007/s00425-004-1325-3; Deeken R, 2000, PLANT J, V23, P285, DOI 10.1046/j.1365-313x.2000.00791.x; Eisenberg RS, 1999, J MEMBRANE BIOL, V171, P1, DOI 10.1007/s002329900554; FLUGGE UI, 1984, FEBS LETT, V169, P85, DOI 10.1016/0014-5793(84)80294-X; Gillespie D, 2002, EUR BIOPHYS J BIOPHY, V31, P454, DOI 10.1007/s00249-002-0239-x; Hemmler R, 2006, J BIOL CHEM, V281, P12020, DOI 10.1074/jbc.M513586200; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hille B, 2001, ION CHANNELS EXCITAB, V3rd, P445; Hills MJ, 2004, CURR OPIN PLANT BIOL, V7, P302, DOI 10.1016/j.pbi.2004.03.003; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; Hormann F, 2004, J BIOL CHEM, V279, P34756, DOI 10.1074/jbc.M402817200; Karimi M, 2002, TRENDS PLANT SCI, V7, P193, DOI 10.1016/S1360-1385(02)02251-3; KRASILNIKOV OV, 1992, FEMS MICROBIOL IMMUN, V105, P93; Linke D, 2004, BIOPHYS J, V86, P1479, DOI 10.1016/S0006-3495(04)74216-2; MUELLER P, 1963, J PHYS CHEM-US, V67, P534, DOI 10.1021/j100796a529; Nada A, 2004, J CELL SCI, V117, P3975, DOI 10.1242/jcs.01265; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Philippar K, 2004, PLANT J, V37, P815, DOI 10.1111/j.1365-313X.2003.02006.x; Pohlmeyer K, 1997, P NATL ACAD SCI USA, V94, P9504, DOI 10.1073/pnas.94.17.9504; Pohlmeyer K, 1998, PLANT CELL, V10, P1207, DOI 10.1105/tpc.10.7.1207; Rassow J, 1999, J MOL BIOL, V286, P105, DOI 10.1006/jmbi.1998.2455; Rohl T, 1999, FEBS LETT, V460, P491, DOI 10.1016/S0014-5793(99)01399-X; Rosso MG, 2003, PLANT MOL BIOL, V53, P247, DOI 10.1023/B:PLAN.0000009297.37235.4a; SABIROV RZ, 1993, GEN PHYSIOL BIOPHYS, V12, P95; Schirmer T, 1999, J MOL BIOL, V294, P1159, DOI 10.1006/jmbi.1999.3326; Schleiff E, 2003, PROTEIN SCI, V12, P748, DOI 10.1110/ps.0237503; Schleiff E, 2003, J CELL BIOL, V160, P541, DOI 10.1083/jcb.200210060; SEEDORF M, 1995, FEBS LETT, V367, P19, DOI 10.1016/0014-5793(95)00529-I; Soll J, 2000, TRENDS PLANT SCI, V5, P137, DOI 10.1016/S1360-1385(00)01579-X; Steinkamp T, 2000, J BIOL CHEM, V275, P11758, DOI 10.1074/jbc.275.16.11758; Sweetlove LJ, 2002, PLANT J, V32, P891, DOI 10.1046/j.1365-313X.2002.01474.x; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; VODYANOY I, 1992, BIOPHYS J, V62, P10, DOI 10.1016/S0006-3495(92)81762-9; Weber APM, 2005, ANNU REV PLANT BIOL, V56, P133, DOI 10.1146/annurev.arplant.56.032604.144228; WOODBURY DJ, 1988, BIOPHYS J, V54, P1053, DOI 10.1016/S0006-3495(88)83042-X	43	40	45	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17989	17998		10.1074/jbc.M600700200	http://dx.doi.org/10.1074/jbc.M600700200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16624824	hybrid			2022-12-25	WOS:000238490300049
J	Kang, X; Hu, YF; Li, Y; Guo, XF; Jiang, XL; Lai, LH; Xia, B; Jin, CW				Kang, Xue; Hu, Yunfei; Li, You; Guo, Xianrong; Jiang, Xiaolu; Lai, Luhua; Xia, Bin; Jin, Changwen			Structural, biochemical, and dynamic characterizations of the hRPB8 subunit of human RNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING SITE; SACCHAROMYCES-CEREVISIAE; NMR-SPECTROSCOPY; C-13/N-15-ENRICHED PROTEINS; CHEMICAL-SHIFT; TRANSCRIPTION; SEQUENCE; YEAST; RELAXATION; FLEXIBILITY	The RPB8 subunit is present in all three types of eukaryotic RNA polymerases and is highly conserved during evolution. It is an essential subunit required for the transcription of nuclear genes, but the detailed mechanism including its interactions with different subunits and oligonucleotides remains largely unclear. Herein, we report the three-dimensional structure of human RPB8 (hRPB8) at high resolution determined by NMR spectroscopy. The protein fold comprises an eight-stranded beta-barrel, six short helices, and a large unstructured Omega-loop. The overall structure of hRPB8 is similar to that of yRPB8 from Saccharomyces cerevisiae and belongs to the oligonucleotide/oligosaccharide-binding fold. However, several features of the tertiary structures are notably different between the two proteins. In particular, hRPB8 has a more clustered positively charged binding interface with the largest subunit RPB1 of the RNA polymerases. We employed biochemical methods to detect its interactions with different single-stranded DNA sequences. In addition, single-stranded DNA titration experiments were performed to identify the residues involved in nonspecific binding with different DNA sequences. Furthermore, we characterized the millisecond time scale conformational flexibility of hRPB8 upon its binding to single-stranded DNA. The current results demonstrate that hRPB8 interacts with single-stranded DNA nonspecifically and adopts significant conformational changes, and the hRPB8/single-stranded DNA complex is a fast exchanging system. The solution structure in conjunction with the biochemical and dynamic studies reveal new aspects of this subunit in the molecular assembly and the biological function of the human nuclear RNA polymerases.	Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China; Peking Univ, Coll Chem & Mol Engn, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China	Peking University; Peking University; Peking University	Jin, CW (corresponding author), Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China.	changwen@pku.edu.cn	Xia, Bin/O-1160-2016	Xia, Bin/0000-0002-2197-6403				Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; Armache KJ, 2005, J BIOL CHEM, V280, P7131, DOI 10.1074/jbc.M413038200; Atkinson RA, 2004, PROG NUCL MAG RES SP, V44, P141, DOI 10.1016/j.pnmrs.2004.01.001; Bates PA, 1999, PROTEINS, P47; BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9; Briand JF, 2001, MOL CELL BIOL, V21, P6056, DOI 10.1128/MCB.21.17.6056-6065.2001; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cramer P, 2004, CURR OPIN GENET DEV, V14, P218, DOI 10.1016/j.gde.2004.01.003; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; del Rio-Portilla F, 1999, NAT STRUCT BIOL, V6, P1039; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; Gerstein M, 2004, CURR OPIN CHEM BIOL, V8, P14, DOI 10.1016/j.cbpa.2003.12.006; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Huang Y, 2001, NUCLEIC ACIDS RES, V29, P2675, DOI 10.1093/nar/29.13.2675; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Kovrigin EL, 2006, BIOCHEMISTRY-US, V45, P2636, DOI 10.1021/bi0525066; Krapp S, 1998, NAT STRUCT BIOL, V5, P110, DOI 10.1038/nsb0298-110; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; LASKOWSKI RA, 1996, J BIOMOL NMR, V8, P51; Loria JP, 1999, J AM CHEM SOC, V121, P2331, DOI 10.1021/ja983961a; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; Meka H, 2005, NUCLEIC ACIDS RES, V33, P6435, DOI 10.1093/nar/gki945; Mulder FAA, 1999, J MOL BIOL, V292, P111, DOI 10.1006/jmbi.1999.3034; Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Reeder RH, 1999, PROG NUCLEIC ACID RE, V62, P293; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; Sims RJ, 2004, CURR OPIN CELL BIOL, V16, P263, DOI 10.1016/j.ceb.2004.04.004; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tossavainen H, 2006, FEBS LETT, V580, P1822, DOI 10.1016/j.febslet.2006.02.042; Voutsina A, 1999, NUCLEIC ACIDS RES, V27, P1047, DOI 10.1093/nar/27.4.1047; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	47	11	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18216	18226		10.1074/jbc.M513241200	http://dx.doi.org/10.1074/jbc.M513241200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16632472	hybrid			2022-12-25	WOS:000238490300074
J	Tallant, C; Garcia-Castellanos, R; Seco, J; Baumann, U; Gomis-Ruth, FX				Tallant, Cynthia; Garcia-Castellanos, Raquel; Seco, Jordi; Baumann, Ulrich; Gomis-Ruth, F. Xavier			Molecular analysis of ulilysin, the structural prototype of a new family of metzincin metalloproteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA PROTEIN-A; MAJOR BASIC-PROTEIN; CRYSTAL-STRUCTURE; BINDING-PROTEINS; ACTIVE-SITE; COMPLEX; SERRALYSINS; COLLAGENASE; GENERATION; ASTACINS	The metzincin clan encompasses several families of zinc-dependent metalloproteases with proven function both in physiology and pathology. They act either as broad spectrum protein degraders or as sheddases, operating through limited proteolysis. Among the structurally uncharacterized metzincin families are the pappalysins, of which the most thoroughly studied member is human pregnancy-associated plasma protein A (PAPP-A), a heavily glycosylated 170-kDa multidomain protein specifically cleaving insulin-like growth factor (IGF)binding proteins (IGFBPs). Proulilysin is a 38-kDa archaeal protein that shares sequence similarity with PAPP-A but encompasses only the pro-domain and the catalytic domain. It undergoes calcium-mediated autolytic activation, and the mature protein adopts a three-dimensional structure with two subdomains separated by an active site cleft containing the catalytic zinc ion. This structure is reminiscent of human members of the adamalysin/ADAMs (a disintegrin and a metalloprotease) family of metzincins. A bound dipeptide yields information on the substrate specificity of ulilysin, which specifically hydrolyzes IGFBP-2 to -6, insulin, and extracellular matrix proteins but not IGFBP-I or IGF-II. Accordingly, ulilysin has higher proteolytic efficiency and a broader substrate specificity than human PAPP-A. The structure of ulilysin represents a prototype for the catalytic domain of pappalysins.	CSIC, Inst Biol Mol Barcelona, Dept Biol Estructural, E-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Gomis-Ruth, FX (corresponding author), CSIC, Inst Biol Mol Barcelona, Dept Biol Estructural, C Jordi Girona 18-26, E-08034 Barcelona, Spain.	xgrcri@ibmb.csic.es	Baumann, Ulrich/B-1220-2013	Tallant, Cynthia/0000-0001-5645-435X; Gomis-Ruth, F. Xavier/0000-0002-6848-6874; Garcia-Castellanos, Raquel/0000-0001-6225-5373				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bach LA, 2005, TRENDS ENDOCRIN MET, V16, P228, DOI 10.1016/j.tem.2005.05.005; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAUMANN U, 1995, J MOL BIOL, V248, P653, DOI 10.1006/jmbi.1995.0249; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Boldt HB, 2004, J BIOL CHEM, V279, P38525, DOI 10.1074/jbc.M405222200; Boldt HB, 2001, BIOCHEM J, V358, P359, DOI 10.1042/0264-6021:3580359; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burger AM, 2005, EUR J CANCER, V41, P1515, DOI 10.1016/j.ejca.2005.04.023; Carranza C., 1999, 9039 CNRSUPR, P89; EVANS PR, 1993, DATA COLLECTION PROC; Fang Peng, 2004, Novartis Found Symp, V262, P215; GALL SA, 1972, INT ARCH ALLER A IMM, V42, P503, DOI 10.1159/000230632; Glerup S, 2005, J BIOL CHEM, V280, P9823, DOI 10.1074/jbc.M413228200; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; Grams F, 1996, NAT STRUCT BIOL, V3, P671, DOI 10.1038/nsb0896-671; Hege T, 2001, J MOL BIOL, V314, P181, DOI 10.1006/jmbi.2001.5125; Hung CY, 2005, INFECT IMMUN, V73, P6689, DOI 10.1128/IAI.73.10.6689-6703.2005; Joh JH, 2004, FEMS MICROBIOL LETT, V239, P57, DOI 10.1016/j.femsle.2004.08.020; KAMIO Y, 2004, HDB PROTEOLYTIC ENZY, V1, P807; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakamura M, 2005, BIOCHEM BIOPH RES CO, V333, P1011, DOI 10.1016/j.bbrc.2005.06.010; Orth P, 2004, J MOL BIOL, V335, P129, DOI 10.1016/j.jmb.2003.10.037; Overgaard MT, 2003, J BIOL CHEM, V278, P2106, DOI 10.1074/jbc.M208777200; Overgaard MT, 2001, J BIOL CHEM, V276, P21849, DOI 10.1074/jbc.M102191200; OXVIG C, 2004, HDB PROTEOLYTIC ENZY, V1, P754; SASAGAWA Y, 1995, BIOSCI BIOTECH BIOCH, V59, P2068, DOI 10.1271/bbb.59.2068; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Sheldrick G.M, 2001, International Tables for Macromolecular Crystallography, P333; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STOCKER W, 1995, PROTEIN SCI, V4, P823; Szebenyi DME, 1981, NATURE, V294, P327, DOI 10.1038/294327a0; WERMTER C, 2004, ANN FALL M GERM SOC; Yiallouros I, 2000, FEBS LETT, V484, P224, DOI 10.1016/S0014-5793(00)02163-3; ZAPF J, 1995, EUR J ENDOCRINOL, V132, P645, DOI 10.1530/eje.0.1320645	43	53	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17920	17928		10.1074/jbc.M600907200	http://dx.doi.org/10.1074/jbc.M600907200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16627477	hybrid			2022-12-25	WOS:000238490300042
J	Bauche, C; Chenal, A; Knapp, O; Bodenreider, C; Benz, R; Chaffotte, A; Ladant, D				Bauche, Cecile; Chenal, Alexandre; Knapp, Oliver; Bodenreider, Christophe; Benz, Roland; Chaffotte, Alain; Ladant, Daniel			Structural and functional characterization of an essential RTX subdomain of Bordetella pertussis adenylate cyclase toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HEMOLYSIN; T-CELL EPITOPES; ANTIGEN-PRESENTING CELLS; GRAM-NEGATIVE BACTERIA; ALPHA-HEMOLYSIN; TARGET-CELLS; BINDING; CALCIUM; PROTEIN; IDENTIFICATION	The adenylate cyclase toxin (CyaA) is one of the major virulence factors of Bordetella pertussis, the causative agent of whooping cough. CyaA is able to invade eukaryotic cells by a unique mechanism that consists in a calcium-dependent, direct translocation of the CyaA catalytic domain across the plasma membrane of the target cells. CyaA possesses a series of a glycine- and aspartate-rich nonapeptide repeats ( residues 1006-1613) of the prototype GGXG(N/D)DX(L/I/F)X ( where X represents any amino acid) that are characteristic of the RTX ( repeat in toxin) family of bacterial cytolysins. These repeats are arranged in a tandem fashion and may fold into a characteristic parallel beta-helix or beta-roll motif that constitutes a novel type of calcium binding structure, as revealed by the three-dimensional structure of the Pseudomonas aeruginosa alkaline protease. Here we have characterized the structure-function relationships of various fragments from the CyaA RTX subdomain. Our results indicate that the RTX functional unit includes both the tandem repeated nonapeptide motifs and the adjacent polypeptide segments, which are essential for the folding and calcium responsiveness of the RTX module. Upon calcium binding to the RTX repeats, a conformational rearrangement of the adjacent non-RTX sequences may act as a critical molecular switch to trigger the CyaA entry into target cells.	Inst Pasteur, Unite Biochim Interact Macromol, CNRS, URA 2185, F-75724 Paris 15, France; Univ Wurzburg, Biozentrum, Theodor Boveri Inst, Biotechnol Lab, D-97074 Wurzburg, Germany; Univ Basel, Biozentrum, Abr Biophys Chem, CH-4056 Basel, Switzerland; Inst Pasteur, CNRS, URA 2185, Unite Resonance Magnet Nucl Biomol, F-75724 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Wurzburg; University of Basel; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Ladant, D (corresponding author), Inst Pasteur, Unite Biochim Interact Macromol, CNRS, URA 2185, 28 Rue Dr Roux, F-75724 Paris 15, France.	ladant@pasteur.fr	Chenal, Alexandre/C-2240-2009	Chenal, Alexandre/0000-0002-4959-1003; LADANT, Daniel/0000-0003-1955-548X; Benz, Roland/0000-0002-9510-9265				BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; Bejerano M, 1999, MOL MICROBIOL, V31, P381, DOI 10.1046/j.1365-2958.1999.01183.x; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1994, J BIOL CHEM, V269, P27231; BOEHM DF, 1990, INFECT IMMUN, V58, P1959, DOI 10.1128/IAI.58.6.1959-1964.1990; Chervaux C, 1996, J BACTERIOL, V178, P1232, DOI 10.1128/jb.178.4.1232-1236.1996; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; Cortajarena AL, 2003, J BIOL CHEM, V278, P19159, DOI 10.1074/jbc.M208552200; El-Azami-El-Idrissi M, 2003, J BIOL CHEM, V278, P38514, DOI 10.1074/jbc.M304387200; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; Gmira S, 2001, RES MICROBIOL, V152, P889, DOI 10.1016/S0923-2508(01)01272-4; Guermonprez P, 2000, METHOD ENZYMOL, V326, P527; Guermonprez P, 2001, J EXP MED, V193, P1035, DOI 10.1084/jem.193.9.1035; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HANSKI E, 1985, J BIOL CHEM, V260, P5526; Hewlett EL, 2006, MOL MICROBIOL, V59, P447, DOI 10.1111/j.1365-2958.2005.04958.x; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; IWAKI M, 1995, MOL MICROBIOL, V17, P1015, DOI 10.1111/j.1365-2958.1995.mmi_17061015.x; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Karimova G, 1998, P NATL ACAD SCI USA, V95, P12532, DOI 10.1073/pnas.95.21.12532; KHELEF N, 1993, INFECT IMMUN, V61, P4064, DOI 10.1128/IAI.61.10.4064-4071.1993; KHELEF N, 1995, FEMS MICROBIOL LETT, V134, P27, DOI 10.1016/0378-1097(95)00375-F; Knapp O, 2003, BIOCHEMISTRY-US, V42, P8077, DOI 10.1021/bi034295f; Ladant D, 1999, TRENDS MICROBIOL, V7, P172, DOI 10.1016/S0966-842X(99)01468-7; LADANT D, 1995, J BIOL CHEM, V270, P3179; LADANT D, 1989, J BIOL CHEM, V264, P4015; Lally ET, 1999, TRENDS MICROBIOL, V7, P356, DOI 10.1016/S0966-842X(99)01530-9; Lilie H, 2000, FEBS LETT, V470, P173, DOI 10.1016/S0014-5793(00)01308-9; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; Masin J, 2005, BIOCHEMISTRY-US, V44, P12759, DOI 10.1021/bi050459b; Mattoo S, 2005, CLIN MICROBIOL REV, V18, P326, DOI 10.1128/CMR.18.2.326-382.2005; Osicka R, 2000, INFECT IMMUN, V68, P247; OSTOLAZA H, 1995, EUR J BIOCHEM, V228, P39, DOI 10.1111/j.1432-1033.1995.tb20225.x; Rhodes CR, 2001, ARCH BIOCHEM BIOPHYS, V395, P169, DOI 10.1006/abbi.2001.2553; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1992, J BIOL CHEM, V267, P22599; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schindel C, 2001, EUR J BIOCHEM, V268, P800, DOI 10.1046/j.1432-1327.2001.01937.x; SEBO P, 1993, MOL MICROBIOL, V9, P999, DOI 10.1111/j.1365-2958.1993.tb01229.x; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; SZABO G, 1994, J BIOL CHEM, V269, P22496; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x	51	81	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16914	16926		10.1074/jbc.M601594200	http://dx.doi.org/10.1074/jbc.M601594200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16627468	hybrid			2022-12-25	WOS:000238326300012
J	Paone, G; Stevens, LA; Levine, RL; Bourgeois, C; Steagall, WK; Gochuico, BR; Moss, J				Paone, Gregorino; Stevens, Linda A.; Levine, Rodney L.; Bourgeois, Christelle; Steagall, Wendy K.; Gochuico, Bernadette R.; Moss, Joel			ADP-ribosyltransferase-specific modification of human neutrophil peptide-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; AIRWAY EPITHELIA; ALPHA-DEFENSINS; INNATE IMMUNITY; PROTEIN; SURFACE; TOXIN; LUNG; ADP-RIBOSYLTRANSFERASE-1; ALPHA-DEFENSIN-1	Epithelial cells lining human airways and cells recruited to airways participate in the innate immune response in part by releasing human neutrophil peptides (HNP). Arginine-specific ADP-ribosyl-transferases ( ART) on the surface of these cells can catalyze the transfer of ADP-ribose from NAD to proteins. We reported that ART1, a mammalian ADP-ribosyltransferase, present in epithelial cells lining the human airway, modified HNP-1, altering its function. ADP-ribosylated HNP-1 was identified in bronchoalveolar lavage fluid (BALF) from patients with asthma, idiopathic pulmonary fibrosis, or a history of smoking ( and having two common polymorphic forms of ART1 that differ in activity), but not in normal volunteers or patients with lymphangioleiomyomatosis. Modified HNP-1 was not found in the sputum of cystic fibrosis patients or in leukocyte granules of normal volunteers. The finding of ADP-ribosylated HNP-1 in BALF but not in leukocyte granules suggests that the modification occurred in the airway. Most of the HNP-1 in the BALF from individuals with a history of smoking was, in fact, mono-or di-ADP-ribosylated. ART1 synthesized in Escherichia coli, glyco-sylphosphatidylinositol-anchored ART1 released with phosphatidylinositol-specific phospholipase C from transfected NMU cells, or ART1 expressed endogenously on C2C12 myotubes modified arginine 14 on HNP-1 with a secondary site on arginine 24. ADP-ribosylation of HNP-1 by ART1 was substantially greater than that by ART3, ART4, ART5, Pseudomonas aeruginosa exoenzyme S, or cholera toxin A subunit. Mouse ART2, which is an NAD: arginine ADP- ribosyltransferase, was able to modify HNP-1, but to a lesser extent than ART1. Although HNP-1 was not modified to a significant degree by ART5, it inhibited ART5 as well as ART1 activities. Human beta-defensin-1 (HBD1) was a poor transferase substrate. Reduction of the cysteine-rich defensins enhanced their ability to serve as ADP- ribose acceptors. We conclude that ADP- ribosylation of HNP-1 appears to be primarily an activity of ART1 and occurs in inflammatory conditions and disease.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Moss, J (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.	mossj@nhlbi.nih.gov	Levine, Rodney L/D-9885-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002543, Z01HL000659, ZIAHL000225, ZIAHL000659, Z01HL000225] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aarbiou J, 2002, J LEUKOCYTE BIOL, V72, P167; Balducci E, 1999, AM J RESP CELL MOL, V21, P337, DOI 10.1165/ajrcmb.21.3.3638; Bals R, 2000, Respir Res, V1, P141, DOI 10.1186/rr25; Bastian A, 2001, REGUL PEPTIDES, V101, P157, DOI 10.1016/S0167-0115(01)00282-8; CERVANTESLAUREAN D, 1993, BIOCHEMISTRY-US, V32, P1528, DOI 10.1021/bi00057a017; Chang TL, 2005, J CLIN INVEST, V115, P765, DOI 10.1172/JCI200521948; Diamond G, 2000, IMMUNOL REV, V173, P27, DOI 10.1034/j.1600-065X.2000.917304.x; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Glowacki G, 2002, PROTEIN SCI, V11, P1657, DOI 10.1110/ps.0200602; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Hiemstra P S, 2001, Paediatr Respir Rev, V2, P306, DOI 10.1053/prrv.2001.0165; Kanaitsuka T, 1997, J IMMUNOL, V159, P2741; Kefalas P, 1999, EUR J BIOCHEM, V259, P866, DOI 10.1046/j.1432-1327.1999.00114.x; Kim C, 2005, P NATL ACAD SCI USA, V102, P4830, DOI 10.1073/pnas.0500508102; KochNolte F, 1997, GENOMICS, V39, P370, DOI 10.1006/geno.1996.4520; Moss J, 1999, MOL CELL BIOCHEM, V193, P109, DOI 10.1023/A:1006924514074; MOSS J, 1976, P NATL ACAD SCI USA, V73, P4424, DOI 10.1073/pnas.73.12.4424; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; Okazaki IJ, 1996, J BIOL CHEM, V271, P22052, DOI 10.1074/jbc.271.36.22052; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Paone G, 2002, P NATL ACAD SCI USA, V99, P8231, DOI 10.1073/pnas.122238899; RICE WG, 1987, BLOOD, V70, P757; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Soong LB, 1997, INFLAMM RES, V46, P98, DOI 10.1007/s000110050114; Spencer LT, 2004, AM J PHYSIOL-LUNG C, V286, pL514, DOI 10.1152/ajplung.00099.2003; Stevens LA, 2003, J BIOL CHEM, V278, P19591, DOI 10.1074/jbc.M210364200; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; van Wetering S, 1999, J ALLERGY CLIN IMMUN, V104, P1131, DOI 10.1016/S0091-6749(99)70004-7; vanWetering S, 1997, AM J PHYSIOL-LUNG C, V272, pL888, DOI 10.1152/ajplung.1997.272.5.L888; Wang W, 2004, J IMMUNOL, V173, P515, DOI 10.4049/jimmunol.173.1.515; Weng BY, 1999, J BIOL CHEM, V274, P31797, DOI 10.1074/jbc.274.45.31797; Yadollahi-Farsani M, 1999, EUR J BIOCHEM, V262, P342, DOI 10.1046/j.1432-1327.1999.00368.x; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; Zolkiewska A, 1998, EXP CELL RES, V240, P86, DOI 10.1006/excr.1998.4002	35	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17054	17060		10.1074/jbc.M603042200	http://dx.doi.org/10.1074/jbc.M603042200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16627471	hybrid			2022-12-25	WOS:000238326300027
J	Canals, M; Jenkins, L; Kellett, E; Milligan, G				Canals, Meritxell; Jenkins, Laura; Kellett, Elaine; Milligan, Graeme			Up-regulation of the angiotensin II type 1 receptor by the MAS proto-oncogene is due to constitutive activation of G(q)/G(11) by MAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; CYTOPLASMIC TAIL; AT(1A) RECEPTOR; PROTEIN; AGONIST; PHOSPHORYLATION; TARGETS	Coexpression of the MAS proto-oncogene with the angiotensin II type 1 (AT(1)) receptor in CHO-K1 cells has been reported to increase the number of [H-3] angiotensin II-binding sites, although MAS does not bind [H-3] angiotensin II. In HEK293 cells stably expressing AT(1) receptor-cyan fluorescent protein (CFP), MAS-yellow fluorescent protein (YFP) expression from an inducible locus caused strong up-regulation of AT(1) receptor-CFP amounts and [H-3] angiotensin II binding levels. The time course of AT(1) receptor-CFP up-regulation was also markedly slower than that of induction of MAS expression. These effects were not mimicked by induced expression of I138D MAS-YFP, a mutant unable to cause constitutive loading of [S-35] guanosine 5'-O-(thiotriphosphate) onto the phospholipase C beta-linked G protein G alpha(11). Protein kinase C (PKC) inhibitors and the selective G alpha(q)/G alpha(11) inhibitor YM-254890 fully blocked MAS-induced upregulation of AT(1) receptor-CFP amounts, whereas the PKC activator phorbol 12-myristate 13-acetate produced strong up-regulation of AT(1) receptor-CFP without induction of MAS-YFP expression and in the presence of I138D MAS-YFP. The C-terminal tail of the AT(1) receptor is a known target for PKC-mediated phosphorylation. In cells stably expressing a C-terminally truncated version of the AT(1) receptor, induction of MAS expression did not up-regulate the truncated construct levels. These data demonstrate that the ability of MAS to up-regulate AT(1) receptor levels reflects the constitutive capacity of MAS to activate G alpha(q)/G alpha(11) and hence stimulate PKC-dependent phosphorylation of the AT(1) receptor.	Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Milligan, G (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Mol Pharmacol Grp, Davidson Bldg,Univ Ave, Glasgow G12 8QQ, Lanark, Scotland.	g.milligan@bio.gla.ac.uk	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519; Canals, Meritxell/0000-0002-7942-5006				AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Carey RM, 2005, CURR OPIN NEPHROL HY, V14, P67, DOI 10.1097/00041552-200501000-00011; Carrillo JJ, 2003, J BIOL CHEM, V278, P42578, DOI 10.1074/jbc.M306165200; Carrillo JJ, 2004, MOL PHARMACOL, V66, P1123, DOI 10.1124/mol.104.001586; de Castro CH, 2005, HYPERTENSION, V46, P937, DOI 10.1161/01.HYP.0000175813.04375.8a; Fleming I, 2006, CURR OPIN NEPHROL HY, V15, P8, DOI 10.1097/01.mnh.0000196146.65330.ea; JACKSON TR, 1989, FEBS LETT, V251, P27, DOI 10.1016/0014-5793(89)81422-X; JACKSON TR, 1998, NATURE, V335, P487; Kostenis E, 2005, CIRCULATION, V111, P1806, DOI 10.1161/01.CIR.0000160867.23556.7D; Lee DK, 2004, J BIOL CHEM, V279, P7901, DOI 10.1074/jbc.M306377200; Milasta S, 2006, MOL PHARMACOL, V69, P479, DOI 10.1124/mol.105.018788; MITCHELL FM, 1991, FEBS LETT, V287, P171, DOI 10.1016/0014-5793(91)80043-3; Olivares-Reyes JA, 2005, MOL PHARMACOL, V68, P356, DOI 10.1124/mol.104.010637; Pascal G, 2005, MOL PHARMACOL, V68, P905, DOI 10.1124/mol.105.013847; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Pietila EM, 2005, J BIOL CHEM, V280, P26622, DOI 10.1074/jbc.M413815200; Qian HW, 1999, BIOCHEM J, V343, P637, DOI 10.1042/0264-6021:3430637; Reudelhuber TL, 2005, HYPERTENSION, V46, P1261, DOI 10.1161/01.HYP.0000193498.07087.83; Ruilope LM, 2005, BLOOD PRESSURE, V14, P196, DOI 10.1080/08037050500230227; Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100; Santos RAS, 2005, EXPERT OPIN INV DRUG, V14, P1019, DOI 10.1517/13543784.14.8.1019; Smith NJ, 2004, CELL MOL LIFE SCI, V61, P2695, DOI 10.1007/s00018-004-4244-3; Smith RD, 1998, MOL PHARMACOL, V54, P935, DOI 10.1124/mol.54.6.935; Stevens PA, 2001, J BIOL CHEM, V276, P35883, DOI 10.1074/jbc.M103816200; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Tang H, 1998, CIRC RES, V82, P523, DOI 10.1161/01.RES.82.5.523; von Bohlen und Halbach O, 2000, J NEUROPHYSIOL, V83, P2012; Werry TD, 2003, BIOCHEM J, V374, P281, DOI 10.1042/BJ20030312; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	30	69	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16757	16767		10.1074/jbc.M601121200	http://dx.doi.org/10.1074/jbc.M601121200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16611642	hybrid			2022-12-25	WOS:000238165700070
J	Relini, A; Canale, C; De Stefano, S; Rolandi, R; Giorgetti, S; Stoppini, M; Rossi, A; Fogolari, F; Corazza, A; Esposito, G; Gliozzi, A; Bellotti, V				Relini, Annalisa; Canale, Claudio; De Stefano, Silvia; Rolandi, Ranieri; Giorgetti, Sofia; Stoppini, Monica; Rossi, Antonio; Fogolari, Federico; Corazza, Alessandra; Esposito, Gennaro; Gliozzi, Alessandra; Bellotti, Vittorio			Collagen plays an active role in the aggregation of beta(2)-microglobulin under physiopathological conditions of dialysis-related amyloidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN AGGREGATION; FIBRILS; GLYCOSAMINOGLYCANS; SUPPRESSION; INSIGHTS; AFFINITY; BINDING; VARIANT; FORM	Dialysis-related amyloidosis is characterized by the deposition of insoluble fibrils of beta(2)-microglobulin(beta(2)-m) in the musculoskeletal system. Atomic force microscopy inspection of ex vivo amyloid material reveals the presence of bundles of fibrils often associated to collagen fibrils. Aggregation experiments were undertaken in vitro with the aim of reproducing the physiopathological fibrillation process. To this purpose, atomic force microscopy, fluorescence techniques, and NMR were employed. We found that in temperature and pH conditions similar to those occurring in periarticular tissues in the presence of flogistic processes, beta(2)-m fibrillogenesis takes place in the presence of fibrillar collagen, whereas no fibrils are obtained without collagen. Moreover, the morphology of beta(2)-m fibrils obtained in vitro in the presence of collagen is extremely similar to that observed in the ex vivo sample. This result indicates that collagen plays a crucial role in beta(2)-m amyloid deposition under physiopathological conditions and suggests an explanation for the strict specificity of dialysis-related amyloidosis for the tissues of the skeletal system. We hypothesize that positively charged regions along the collagen fiber could play a direct role in beta(2)-m fibrillogenesis. This hypothesis is sustained by aggregation experiments performed by replacing collagen with a poly-L-lysine-coated mica surface. As shown by NMR measurements, no similar process occurs when poly-L-lysine is dissolved in solution with beta 2-m. Overall, the findings are consistent with the estimates resulting from a simplified collagen model whereby electrostatic effects can lead to high local concentrations of oppositely charged species, such as beta(2)-m, that decay on moving away from the fiber surface.	Univ Genoa, Dept Phys, I-16146 Genoa, Italy; Univ Pavia, Dept Biochem, Lab Biotecnol, Ist Ricovero & Cura Carattere Sci Policlin San Ma, I-27100 Pavia, Italy; Univ Udine, Dept Biomed Sci & Technol, I-33100 Udine, Italy	University of Genoa; University of Pavia; University of Udine	Relini, A (corresponding author), Univ Genoa, Dept Phys, Via Dodecaneso 33, I-16146 Genoa, Italy.	relini@mail.fisica.unige.it	Relini, Annalisa/AHC-3105-2022; Rolandi, Ranieri/C-4765-2012; Giorgetti, Sofia/AAD-4341-2019; Corazza, Alessandra/AGB-1457-2022; Bellotti, Vittorio/A-6201-2014; Rossi, Antonio/E-9935-2012	Rolandi, Ranieri/0000-0002-0580-1611; Giorgetti, Sofia/0000-0001-9438-6511; Corazza, Alessandra/0000-0003-2272-1928; Bellotti, Vittorio/0000-0001-8678-662X; Fogolari, Federico/0000-0001-9862-250X; RELINI, ANNALISA/0000-0002-4040-9279; Canale, Claudio/0000-0002-7582-6849				BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Chiti F, 2001, J BIOL CHEM, V276, P46714, DOI 10.1074/jbc.M107040200; Corazza A, 2004, J BIOL CHEM, V279, P9176, DOI 10.1074/jbc.M310779200; Drueke TB, 2000, NEPHROL DIAL TRANSPL, V15, P17, DOI 10.1093/oxfordjournals.ndt.a027958; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Floege J, 1996, NEPHRON, V72, P9, DOI 10.1159/000188801; Floege J, 2001, KIDNEY INT, V59, pS164, DOI 10.1046/j.1523-1755.2001.59780164.x; Fogolari F, 1999, BIOPHYS J, V76, P1, DOI 10.1016/S0006-3495(99)77173-0; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; Giorgetti S, 2005, PROTEIN SCI, V14, P696, DOI 10.1110/ps.041194005; Hatters DM, 2003, BIOPHYS J, V85, P3979, DOI 10.1016/S0006-3495(03)74812-7; Heegaard NHH, 2005, BIOCHEMISTRY-US, V44, P4397, DOI 10.1021/bi047594t; HUSZAR G, 1980, ANAL BIOCHEM, V105, P424, DOI 10.1016/0003-2697(80)90481-9; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; Jerschow A, 1997, J MAGN RESON, V125, P372, DOI 10.1006/jmre.1997.1123; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; Kihara M, 2005, J BIOL CHEM, V280, P12012, DOI 10.1074/jbc.M411949200; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LODISH H, 1995, MOL CELL BIOL, P1128; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Mertz EL, 2004, BIOCHEMISTRY-US, V43, P14901, DOI 10.1021/bi048788b; Morgan CJ, 2001, J MOL BIOL, V309, P339, DOI 10.1006/jmbi.2001.4661; MORRIS KF, 1992, J AM CHEM SOC, V114, P3139, DOI 10.1021/ja00034a071; NA GC, 1989, BIOCHEMISTRY-US, V28, P7161, DOI 10.1021/bi00444a005; Ohashi K, 2002, NEPHRON, V90, P158, DOI 10.1159/000049037; Ohhashi Y, 2005, J BIOL CHEM, V280, P32843, DOI 10.1074/jbc.M506501200; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; Relini A, 2004, BBA-MOL BASIS DIS, V1690, P33, DOI 10.1016/j.bbadis.2004.04.007; Relini A, 2004, J MOL BIOL, V338, P943, DOI 10.1016/j.jmb.2004.03.054; Soldi G, 2005, BIOPHYS J, V89, P4234, DOI 10.1529/biophysj.105.067538; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; WARD TT, 1978, AM J MED, V64, P933, DOI 10.1016/0002-9343(78)90446-1; Yamamoto S, 2005, BBA-PROTEINS PROTEOM, V1753, P4, DOI 10.1016/j.bbapap.2005.09.006; Yamamoto S, 2004, J AM SOC NEPHROL, V15, P126, DOI 10.1097/01.ASN.0000103228.81623.C7; Zhu M, 2002, J BIOL CHEM, V277, P50914, DOI 10.1074/jbc.M207225200	38	115	117	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16521	16529		10.1074/jbc.M513827200	http://dx.doi.org/10.1074/jbc.M513827200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16601119	hybrid			2022-12-25	WOS:000238165700042
J	Stebbins, JL; Jung, DW; Leone, M; Zhang, XK; Pellecchia, M				Stebbins, John L.; Jung, Dawoon; Leone, Marilisa; Zhang, Xiao-Kun; Pellecchia, Maurizio			A structure-based approach to retinoid X receptor-alpha inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR RECOGNITION; SCORING FUNCTIONS; FLEXIBLE DOCKING; THYROID-HORMONE; NUCLEAR EXPORT; FATTY-ACIDS; APOPTOSIS; DISCOVERY; LIGANDS; PROTEIN	In this paper we describe a structure-based approach designed to identify novel ligands for retinoid X receptor-alpha (RXR alpha). By using a virtual approach based on a modified scoring function, we have selected 200 potential candidates on the basis of their predicted ability of docking into the ligand-binding site of the target. Subsequent experimental verification of the compounds in in vitro and cell-based assays led to the identification of a number of novel high affinity ligands for RXR alpha. The compounds are capable of displacing 9-cis-retinoic acid with IC50 values in the 10 nM and 5 mu M range and exhibit marked antagonistic activity in cellular assays. The inhibitory scaffolds discovered with this method form the basis for the development of novel RXR alpha ligands with potential therapeutic properties.	Burnham Inst, Ctr Canc, La Jolla, CA 92037 USA; Burnham Inst, Infect & Inflammatory Dis Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute	Pellecchia, M (corresponding author), Burnham Inst, Ctr Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mpellecchia@burnham.org	Pellecchia, Maurizio/Y-7072-2018	LEONE, MARILISA/0000-0002-3811-6960	NATIONAL CANCER INSTITUTE [R01CA109345, U19CA113318] Funding Source: NIH RePORTER; NCI NIH HHS [CA 109345, CA 113318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ J, 2005, VIRTUAL SCREENING DI, P25; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; Cavasotto CN, 2004, J MED CHEM, V47, P4360, DOI 10.1021/jm030651g; Cummings MD, 2005, J MED CHEM, V48, P962, DOI 10.1021/jm049798d; Dawson M. I., 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P199, DOI 10.2174/1568011043352975; Dawson MI, 2004, J MED CHEM, V47, P3518, DOI 10.1021/jm030524k; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Egea PF, 2002, MOL ENDOCRINOL, V16, P987, DOI 10.1210/me.16.5.987; Eldridge MD, 1997, J COMPUT AID MOL DES, V11, P425, DOI 10.1023/A:1007996124545; Fan YY, 2003, CARCINOGENESIS, V24, P1541, DOI 10.1093/carcin/bgg110; Fattorusso R, 2005, J MED CHEM, V48, P1649, DOI 10.1021/jm0493212; Forino M, 2005, P NATL ACAD SCI USA, V102, P9499, DOI 10.1073/pnas.0502733102; Forino M, 2005, J MED CHEM, V48, P2278, DOI 10.1021/jm048962u; GEHLHAAR DK, 1995, CHEM BIOL, V2, P317, DOI 10.1016/1074-5521(95)90050-0; Goldstein JT, 2003, ARCH BIOCHEM BIOPHYS, V420, P185, DOI 10.1016/j.abb.2003.09.034; Hajduk PJ, 1997, J AM CHEM SOC, V119, P12257, DOI 10.1021/ja9715962; Huang JP, 2002, CANCER RES, V62, P4812; James SY, 2003, CANCER RES, V63, P3531; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kolluri SK, 2005, P NATL ACAD SCI USA, V102, P2525, DOI 10.1073/pnas.0409721102; Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Liu Y, 1996, MOL CELL BIOL, V16, P1138; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Mao GE, 2004, CANCER EPIDEM BIOMAR, V13, P383; Muegge I, 2001, REV COMP CH, V17, P1, DOI 10.1002/0471224413.ch1; Pellecchia M, 2002, NAT REV DRUG DISCOV, V1, P211, DOI 10.1038/nrd748; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; Shoichet BK, 2002, CURR OPIN CHEM BIOL, V6, P439, DOI 10.1016/S1367-5931(02)00339-3; Stahl M, 2001, J MED CHEM, V44, P1035, DOI 10.1021/jm0003992; Tautz L, 2005, J BIOL CHEM, V280, P9400, DOI 10.1074/jbc.M413122200; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	37	12	13	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16643	16648		10.1074/jbc.M600318200	http://dx.doi.org/10.1074/jbc.M600318200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16606625	hybrid			2022-12-25	WOS:000238165700057
J	Thompson, AJ; Padgett, CL; Lummis, SCR				Thompson, Andrew J.; Padgett, Claire L.; Lummis, Sarah C. R.			Mutagenesis and molecular modeling reveal the importance of the 5-HT3 receptor F-loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; CRYSTAL-STRUCTURE; BINDING-SITE; DELTA-SUBUNIT; RESIDUES; AGONIST; ANTAGONIST; PROTEIN; CELLS; CA2+	The 5-HT3 receptor is a member of the Cys-loop family of ligand-gated ion channels. The extracellular domains of these proteins contain six amino acid loops (A-F) that converge to form the ligand binding site. In this study we have mutated 21 residues in or close to the 5-HT3 receptor F-loop (Ile(192) to Gly(212)) to Ala or to a residue with similar chemical properties. Mutant receptors were expressed in HEK293 cells, and binding affinity was measured using [H-3] granisetron. Two regions displayed decreases in binding affinity when mutated to Ala (Ile(192)-Arg(196) and Asp(204)-Ser(206)), but only one region was sensitive when mutated to chemically similar residues (Ile(192)-Val(201)). Homology modeling using acetylcholine-binding protein crystal structures with a variety of different bound ligands suggests there may be distinct movements of Trp(195) and Asp(204) upon ligand binding, indicating that these residues and their immediate neighbors have the ability to interact differently with different ligands. The models suggest predominantly lateral movement around Asp(204) and rotational movement around Trp(195), indicating the former is in a more flexible region. Overall our results are consistent with a flexible 5-HT3 receptor F-loop with two regions that have specific but distinct roles in ligand binding.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Mol Biol Lab, Div Neurobiol, Cambridge, England	University of Cambridge; MRC Laboratory Molecular Biology	Lummis, SCR (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	sl120@cam.ac.uk		Thompson, Andrew/0000-0002-7046-6792	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akabas MH, 2004, INT REV NEUROBIOL, V62, P1, DOI 10.1016/S0074-7742(04)62001-0; Arias HR, 2000, NEUROCHEM INT, V36, P595, DOI 10.1016/S0197-0186(99)00154-0; Beene DL, 2002, BIOCHEMISTRY-US, V41, P10262, DOI 10.1021/bi020266d; Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; Deane CM, 2001, J BIOL CHEM, V276, P37962; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; HARGREAVES AC, 1994, MOL PHARMACOL, V46, P1120; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUMMIS SCR, 1993, EUR J PHARMACOL, V243, P7, DOI 10.1016/0014-2999(93)90160-J; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; Morales M, 2002, J NEUROSCI, V22, P6732; Newell JG, 2003, J BIOL CHEM, V278, P13166, DOI 10.1074/jbc.M211905200; Niesler B, 2003, GENE, V310, P101, DOI 10.1016/S0378-1119(03)00503-1; Price KL, 2005, J NEUROSCI METH, V149, P172, DOI 10.1016/j.jneumeth.2005.05.014; Ranna Martin, 2006, BMC Pharmacology, V6, P1, DOI 10.1186/1471-2210-6-1; Reeves DC, 2003, BIOPHYS J, V84, P2338, DOI 10.1016/S0006-3495(03)75039-5; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sedelnikova A, 2005, J BIOL CHEM, V280, P1535, DOI 10.1074/jbc.M409908200; Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139; Solt K, 2005, J PHARMACOL EXP THER, V315, P771, DOI 10.1124/jpet.105.090621; Spier AD, 2000, J BIOL CHEM, V275, P5620, DOI 10.1074/jbc.275.8.5620; Spier AD, 1999, MOL BRAIN RES, V71, P369; Thompson AJ, 2006, BIOPHYS J, V90, P1979, DOI 10.1529/biophysj.105.069385; Thompson AJ, 2005, J BIOL CHEM, V280, P20476, DOI 10.1074/jbc.M413610200; Turchin A, 1999, BIOTECHNIQUES, V26, P672, DOI 10.2144/99264st02; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	39	46	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16576	16582		10.1074/jbc.M601265200	http://dx.doi.org/10.1074/jbc.M601265200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16595668	hybrid			2022-12-25	WOS:000238165700049
J	Mo, R; Rao, SM; Zhu, YJ				Mo, Rigen; Rao, Sambasiva M.; Zhu, Yi-Jun			Identification of the MLL2 complex as a coactivator for estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE METHYLTRANSFERASE COMPLEX; BREAST-CANCER; SACCHAROMYCES-CEREVISIAE; PROTEIN; GENE; TRITHORAX; TRANSCRIPTION; PROTEASOME; EXPRESSION; INTERACTS	A novel estrogen receptor (ER)alpha coactivator complex, the MLL2 complex, which consists of MLL2, ASH2, RBQ3, and WDR5, was identified. ER alpha directly binds to the MLL2 complex through two LXXLL motifs in a region of MLL2 near the C terminus in a ligand-dependent manner. Disrupting the interaction between ER alpha and the MLL2 complex with small interfering RNAs specific against MLL2 or an MLL2 fragment representing the interacting region with ER alpha significantly inhibited the ER alpha transcription activity. The MLL2 complex was recruited on promoters of ER alpha target genes along with ER alpha upon estrogen stimulation. Inhibition of MLL2 expression decreased the estrogen-induced expression of ER alpha target genes cathepsin D and to a lesser extent pS2. In addition, MCF-7 cell growth was also inhibited by the depletion of MLL2. These results demonstrate that the ER alpha signaling pathway is critically dependent on its direct interaction with the MLL2 complex and suggest a central role for the MLL2 complex in the growth of ER alpha-positive cancer cells.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Zhu, YJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	y-zhu2@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA088898, R01CA084472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES000356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84472, CA 88898] Funding Source: Medline; NIEHS NIH HHS [K08 ES 00356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; Anderson E, 2002, BREAST CANCER RES, V4, P197, DOI 10.1186/bcr452; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Kitagawa H, 2002, MOL CELL BIOL, V22, P3698, DOI 10.1128/MCB.22.11.3698-3706.2002; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MITELMAN F, 1983, CYTOGENET CELL GENET, V36, P1, DOI 10.1159/000131930; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Prasad R, 1997, ONCOGENE, V15, P549, DOI 10.1038/sj.onc.1201211; Qi C, 2002, J BIOL CHEM, V277, P28624, DOI 10.1074/jbc.M201053200; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Vaux DL, 2005, NAT REV MOL CELL BIO, V6, P287, DOI 10.1038/nrm1621; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848; Zhu YJ, 2001, P NATL ACAD SCI USA, V98, P10380, DOI 10.1073/pnas.181347498; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	42	117	119	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15714	15720		10.1074/jbc.M513245200	http://dx.doi.org/10.1074/jbc.M513245200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16603732	hybrid			2022-12-25	WOS:000237996000017
J	Laflamme, K; Roberge, CJ; Grenier, G; Remy-Zolghadri, M; Pouliot, S; Baker, K; Labbe, R; D'Orleans-Juste, P; Auger, FA; Germain, L				Laflamme, Karina; Roberge, Charles J.; Grenier, Guillaume; Remy-Zolghadri, Murielle; Pouliot, Stephanie; Baker, Kathleen; Labbe, Raymond; D'Orleans-Juste, Pedro; Auger, Francois A.; Germain, Lucie			Adventitia contribution in vascular tone: insights from adventitia-derived cells in a tissue-engineered human blood vessel	FASEB JOURNAL			English	Article						adventitia; contraction; media; endothelin; blood vessel	NITRIC-OXIDE; RAT AORTA; ENDOTHELIN; EXPRESSION; INHIBITOR; PATHOPHYSIOLOGY; GENERATION; REACTIVITY; PHYSIOLOGY; RECEPTORS	Whether the adventitia component of blood vessels directly participates in the regulation of vascular tone remains to be demonstrated. We have recently developed a human tissue-engineered blood vessel comprising the three tunicae of a native blood vessel using the self-assembly approach. To investigate the role of the adventitia in the modulation of vascular tone, this tissue-engineering method was used to produce three vascular constructs from cells explanted and proliferated from donor vessel tunicae 1) an adventitia + a media, or only 2) an adventitia, or 3) a media. The vasoconstriction responses of these 3 constructs to endothelin, the most potent vasopressor known up-to-date, as well as to nonselective and selective agonists and antagonists, were compared. The adventitia contracted to endothelin-1, -2, whereas the media and the media+adventitia contracted to all three endothelins. Endothelin-induced contraction of the adventitia was dependent on ETA receptors, whereas that of the media and the adventitia+media was ETA and ETB receptor-dependent. RT-PCR studies corroborated these results. SNP induced a dose-dependent relaxation of the three tissue constructs. We also demonstrated that the endothelin-converting enzyme, responsible for the formation of the active endothelin peptides, was present and functional in the adventitia. In conclusion, this is the first direct demonstration that the adventitia has the capacity to contract and relax in response to vasoactive factors. The present study suggests that the adventitia of a blood vessel could play a greater role than expected in the modulation of blood vessel tone.-Laflamme, K., Roberge, C. J., Grenier, G., Remy-Zolghadri, M., Pouliot, S., Baker, K., Labbe, R., D'Orleans-Juste, P., Auger, F. A., Germain, L. Adventitia contribution in vascular tone: insights from adventitia-derived cells in a tissue-engineered human blood vessel.	Univ Quebec, CHA, Lab Organogenese Expt, LOEXl,Hop St Sacrement, Ste Foy, PQ G1S 4L8, Canada; Univ Laval, Dept Surg, Quebec City, PQ, Canada; Univ Sherbrooke, Sch Med, Inst Pharmacol, Sherbrooke, PQ J1K 2R1, Canada	Laval University; University of Quebec; Laval University; University of Sherbrooke	Germain, L (corresponding author), Univ Quebec, CHA, Lab Organogenese Expt, LOEXl,Hop St Sacrement, 1050 Chemin, Ste Foy, PQ G1S 4L8, Canada.	lucie.germain@chg.ulaval.ca		Germain, Lucie/0000-0001-8883-6491				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARNAL JF, 1994, AM J PHYSIOL-HEART C, V267, pH1777, DOI 10.1152/ajpheart.1994.267.5.H1777; BARRA JA, 1986, J THORAC CARDIOV SUR, V92, P330; BATES JN, 1991, BIOCHEM PHARMACOL, V42, pS157, DOI 10.1016/0006-2952(91)90406-U; BATTLE T, 1994, TISSUE CELL, V26, P943, DOI 10.1016/0040-8166(94)90043-4; BAX WA, 1993, EUR J PHARMACOL, V239, P267, DOI 10.1016/0014-2999(93)91010-K; D'Orleans-Juste P, 2003, CAN J PHYSIOL PHARM, V81, P503, DOI 10.1139/Y03-032; DELOMBAERT S, 1994, BIOCHEM BIOPH RES CO, V204, P407, DOI 10.1006/bbrc.1994.2473; Ergul A, 1998, J PHARMACOL EXP THER, V285, P511; Gonzalez MC, 2001, AM J PHYSIOL-HEART C, V280, pH2876, DOI 10.1152/ajpheart.2001.280.6.H2876; Grenier G, 2003, IN VITRO CELL DEV-AN, V39, P131; Hachiya A, 2002, J BIOL CHEM, V277, P5395, DOI 10.1074/jbc.M105874200; HAYNES WG, 1994, LANCET, V344, P852, DOI 10.1016/S0140-6736(94)92827-4; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Jeng AY, 2002, CAN J PHYSIOL PHARM, V80, P440, DOI 10.1139/y02-025; Kemler MA, 1997, PLAST RECONSTR SURG, V99, P1626, DOI 10.1097/00006534-199705010-00024; Korth P, 1999, J HISTOCHEM CYTOCHEM, V47, P447, DOI 10.1177/002215549904700403; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; L'Heureux N, 2001, FASEB J, V15, P515, DOI 10.1096/fj.00-0283com; Laflamme K, 2005, CIRCULATION, V111, P459, DOI 10.1161/01.CIR.0000153850.53419.50; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; LOHMAN R, 1995, ANN PLAS SURG, V35, P60, DOI 10.1097/00000637-199507000-00012; MCMAHON EG, 1993, AM J HYPERTENS, V6, P667, DOI 10.1093/ajh/6.8.667; Miyauchi T, 1999, ANNU REV PHYSIOL, V61, P391, DOI 10.1146/annurev.physiol.61.1.391; MONCADA S, 1991, PHARMACOL REV, V43, P109; Olson LJ, 1997, HYPERTENSION, V29, P254, DOI 10.1161/01.HYP.29.1.254; RHODIN JAG, 1980, HDB PHYSL 2, V2, P1, DOI DOI 10.1002/CPHY.CP020201; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; SCHWARTZ CJ, 1962, CIRCULATION, V26, P73, DOI 10.1161/01.CIR.26.1.73; Scotland R, 1999, CARDIOVASC RES, V41, P237, DOI 10.1016/S0008-6363(98)00223-5; Scotland R, 1999, BRIT J PHARMACOL, V128, P1229, DOI 10.1038/sj.bjp.0702930; SHIMADA K, 1995, BIOCHEM BIOPH RES CO, V207, P807, DOI 10.1006/bbrc.1995.1258; Spratt JCS, 2001, BRIT J PHARMACOL, V134, P648, DOI 10.1038/sj.bjp.0704304; vanderLoo B, 1997, INT J MICROCIRC, V17, P280, DOI 10.1159/000179240; Wang HD, 1999, HYPERTENSION, V33, P1225, DOI 10.1161/01.HYP.33.5.1225; WHITE DG, 1994, EUR J PHARMACOL, V257, P307, DOI 10.1016/0014-2999(94)90144-9; Wilcox JN, 1996, INT J CARDIOL, V54, pS21, DOI 10.1016/S0167-5273(96)02811-2; WILLIAMS JK, 1988, AM J PHYSIOL, V254, pH126, DOI 10.1152/ajpheart.1988.254.1.H126; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zurbrugg HR, 2000, ANN THORAC SURG, V70, P1536, DOI 10.1016/S0003-4975(00)01997-4	41	42	47	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1245	+		10.1096/fj.05-4702fje	http://dx.doi.org/10.1096/fj.05-4702fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16611833				2022-12-25	WOS:000240210300040
J	Shaked, GM; Kummer, MP; Lu, DC; Galvan, V; Bredesen, DE; Koo, EH				Shaked, G. M.; Kummer, M. P.; Lu, D. C.; Galvan, V.; Bredesen, D. E.; Koo, E. H.			A beta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624)	FASEB JOURNAL			English	Article						C31; YENPTY region; APP homo-oligomerization	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; CASPASE CLEAVAGE; NUCLEAR RECEPTOR; IDENTIFICATION; HOMOLOG; FAMILY; ACCUMULATION; APOPTOSIS; TOXICITY	Amyloid beta-peptide (A beta) is postulated to play a central role in the pathogenesis of Alzheimer's disease. We recently proposed a pathway of A beta-induced toxicity that is APP dependent and involves the facilitation of APP complex formation by A beta. The APP-dependent component requires cleavage of APP at position 664 in the cytoplasmic domain, presumably by caspases or caspase-like proteases, with release of a potentially cytotoxic C31 peptide. In this study we show that A beta interacted directly and specifically with membrane-bound APP to facilitate APP homo-oligomerization. Using chimeric APP molecules, this interaction was shown to take place between A beta and its homologous sequence on APP. Consistent with this finding, we demonstrated that A beta also facilitated the oligomerization of beta-secretase cleaved APP C-terminal fragment (C99). We found that the YENPTY domain in the APP cytoplasmic tail and contained within C31 is critical for this cell death pathway. Deletion or alanine- scanning mutagenesis through this domain significantly attenuated cell death apparently without affecting either APP dimerization or cleavage at position 664. This indicated that sequences within C31 are required after its release from APP. As the YENPTY domain has been shown to interact with a number of cytosolic adaptor molecules, it is possible that the interaction of APP, especially dimeric forms of APP, with these molecules contribute to cell death.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Buck Inst Age Res, Novato, CA USA	University of California System; University of California San Diego; Buck Institute for Research on Aging	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci, 9500 Gilman Dr,Mail Code 0691, La Jolla, CA 92093 USA.	edkoo@ucsd.edu	Kummer, Markus/A-3860-2009	Kummer, Markus P./0000-0002-0993-2918	NATIONAL INSTITUTE ON AGING [P50AG005131] Funding Source: NIH RePORTER; NIA NIH HHS [AG05131, P50 AG005131] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Dumanchin-Njock C, 2001, J NEUROCHEM, V78, P1153, DOI 10.1046/j.1471-4159.2001.00513.x; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; Galvan V, 2002, J NEUROCHEM, V82, P283, DOI 10.1046/j.1471-4159.2002.00970.x; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heredia L, 2004, NEUROBIOL DIS, V16, P617, DOI 10.1016/j.nbd.2004.04.015; Kim CM, 2003, VECTOR-BORNE ZOONOT, V3, P17, DOI 10.1089/153036603765627424; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Klein WL, 2004, NEUROBIOL AGING, V25, P569, DOI 10.1016/j.neurobiolaging.2004.02.010; Klein WL, 2002, NEUROBIOL AGING, V23, P231, DOI 10.1016/S0197-4580(01)00312-8; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Levites Y, 2006, J CLIN INVEST, V116, P193, DOI 10.1172/JCI25410; Lorenzo A, 2000, NAT NEUROSCI, V3, P460, DOI 10.1038/74833; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Lu DC, 2003, ANN NEUROL, V54, P781, DOI 10.1002/ana.10761; Lu DC, 2003, J NEUROCHEM, V87, P733, DOI 10.1046/j.1471-4159.2003.02059.x; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Melchor JP, 2000, J BIOL CHEM, V275, P9782, DOI 10.1074/jbc.275.13.9782; Paliga K, 1997, EUR J BIOCHEM, V250, P354, DOI 10.1111/j.1432-1033.1997.0354a.x; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Schwartz CJE, 2001, EMBO J, V20, P510, DOI 10.1093/emboj/20.3.510; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Soriano S, 2001, J BIOL CHEM, V276, P29045, DOI 10.1074/jbc.M102456200; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; Su JH, 2002, ACTA NEUROPATHOL, V104, P1, DOI 10.1007/s00401-002-0548-2; Van Nostrand WE, 2002, J BIOL CHEM, V277, P36392, DOI 10.1074/jbc.M204676200; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Wang YC, 2004, MOL CELL, V15, P343, DOI 10.1016/j.molcel.2004.06.037; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Zhao M, 2003, NEUROBIOL DIS, V14, P391, DOI 10.1016/j.nbd.2003.07.006	43	98	103	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1254	+		10.1096/fj.05-5032fje	http://dx.doi.org/10.1096/fj.05-5032fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636103	Green Accepted			2022-12-25	WOS:000240210300043
J	Sun, C; Shi, Y; Xu, LL; Nageswararao, C; Davis, LD; Segawa, T; Dobi, A; McLeod, DG; Srivastava, S				Sun, C.; Shi, Y.; Xu, L. L.; Nageswararao, C.; Davis, L. D.; Segawa, T.; Dobi, A.; McLeod, D. G.; Srivastava, S.			Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival	ONCOGENE			English	Article						prostate cancer; androgen receptor; mutation; p53; cell proliferation; cell apoptosis	WILD-TYPE P53; DOWN-REGULATION; BINDING DOMAIN; EXPRESSION; GENE; APOPTOSIS; PROGRESSION; CARCINOMA; LEADS	Alteration of the AR functions due to amplication, overexpression and somatic mutation of the AR itself or altered interaction of AR with other cell growth regulatory proteins, may contribute to a significant subset of advanced prostate cancer (CaP). Very little is known about the pathways impacted by AR dysfunctions, although CaP associated AR alterations suggest the biological role of the AR dysfunction in disease progression. Comparative evaluations of wild type (wt) AR and mutant (mt) ARs in appropriate experimental models should provide a better understanding of the functional impact of AR alterations in CaP. Here, we provide direct evidence showing cell growth/cell survival promoting effects of the widely studied CaP associated AR mutation (T877A). In contrast to Ad-wtAR or Ad-control infected LNCaP or LAPC4 cells, Ad-mtAR (T877A) infected LNCaP or LAPC4 cells continued to grow in the androgen-deprived medium and exhibited an androgen independent AR-transcription factor activity. Further, Ad-mtAR (T877A) infected LNCaP or LAPC4 cells exhibited enhanced cell growth in the presence of lower concentrations of the synthetic androgen, R1881. Of note, Ad-mtAR (T877A) infected LNCaP cells showed striking resistance to cell growth inhibition/apoptosis mediated by the wt p53. Taken together, these findings provide novel insights into the AR dysfunctions resulting from the T877A mutation and functionally similar AR alterations may provide selective cell growth/survival advantage for CaP progression. These observations have important implications for developing biology-based prognostic biomarkers and therapeutic strategies for CaP showing such AR dysfunctions.	Uniformed Serv Univ Hlth Sci, Dept Surg, Ctr Prostate Dis Res, Rockville, MD 20852 USA; Walter Reed Army Med Ctr, Serv Urol, Washington, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Srivastava, S (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Surg, Ctr Prostate Dis Res, 1530 E Jefferson St, Rockville, MD 20852 USA.	ssrivastava@cpdr.org						Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Bauer JJ, 1995, CLIN CANCER RES, V1, P1295; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Culig Z, 2000, UROL RES, V28, P211, DOI 10.1007/s002400000111; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEIDENBERG HB, 1995, J UROLOGY, V154, P414, DOI 10.1016/S0022-5347(01)67065-4; Huggins C, 1941, CANCER RES, V1, P293; Ioffe ML, 2004, PROSTATE, V61, P243, DOI 10.1002/pros.20108; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; NAKAO R, 1992, J CLIN ENDOCR METAB, V74, P1152, DOI 10.1210/jc.74.5.1152; RAFFO AJ, 1995, CANCER RES, V55, P4438; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; SCHUURMANS ALG, 1990, J STEROID BIOCHEM, V37, P849, DOI 10.1016/0960-0760(90)90431-J; Segawa T, 1998, CANCER RES, V58, P2282; Shi XB, 2002, CANCER RES, V62, P1496; Small Eric J., 1998, Current Opinion in Oncology, V10, P244, DOI 10.1097/00001622-199805000-00012; Sobel RE, 2005, J UROLOGY, V173, P342, DOI 10.1097/01.ju.0000141580.30910.57; SRIVASTAVA S, 1995, UROLOGY, V46, P843, DOI 10.1016/S0090-4295(99)80355-0; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Tsui KH, 2004, J UROLOGY, V172, P2035, DOI 10.1097/01.ju.0000138053.78518.b2; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Wen Y, 2000, CANCER RES, V60, P6841; Xu LL, 2000, J UROLOGY, V163, P972, DOI 10.1016/S0022-5347(05)67867-6; YANG CL, 1995, CANCER RES, V55, P4210; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	35	59	59	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3905	3913		10.1038/sj.onc.1209424	http://dx.doi.org/10.1038/sj.onc.1209424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16636679				2022-12-25	WOS:000238668800003
J	Xiang, YY; Dong, HH; Wan, YD; Li, JX; Yee, A; Yang, BB; Lu, WY				Xiang, Yun-Yan; Dong, Haiheng; Wan, Yudi; Li, Jingxin; Yee, Albert; Yang, Burton B.; Lu, Wei-Yang			Versican G3 domain regulates neurite growth and synaptic transmission of hippocampal neurons by activation of epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; G3 DOMAIN; SULFATE PROTEOGLYCAN; RAT-BRAIN; P-SELECTIN; CELL-PROLIFERATION; PRODUCT SECRETION; BINDING-PROTEIN; NERVOUS-SYSTEM; DENTATE GYRUS	Versican is one of the major extracellular matrix (ECM) proteins in the brain. ECM molecules and their cleavage products critically regulate the growth and arborization of neurites, hence adjusting the formation of neural networks. Recent findings have revealed that peptide fragments containing the versican C terminus (G3 domain) are present in human brain astrocytoma. The present study demonstrated that a versican G3 domain enhanced cell attachment, neurite growth, and glutamate receptor-mediated currents in cultured embryonic hippocampal neurons. In addition, the G3 domain intensified dendritic spines, increased the clustering of both synaptophysin and the glutamate receptor subunit GluR2, and augmented excitatory synaptic activity. In contrast, a mutated G3 domain lacking the epidermal growth factor (EGF)-like repeats (G3 Delta EGF) had little effect on neurite growth and glutamatergic function. Treating the neurons with the G3-conditioned medium rapidly increased the levels of phosphorylated EGF receptor (pEGFR) and phosphorylated extracellular signal-regulated kinase (pERK), indicating an activation of EGFR-mediated signaling pathways. Blockade of EGFR prevented the G3-induced ERK activation and suppressed the G3-provoked enhancement of neurite growth and glutamatergic function but failed to block the G3-mediated enhancement of cell attachment. These combined results indicate that the versican G3 domain regulates neuronal attachment, neurite outgrowth, and synaptic function of hippocampal neurons via EGFR-dependent and -independent signaling pathway(s). Our findings suggest a role for ECM proteolytic products in neural development and regeneration.	Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Anesthesia, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Physiol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto	Yang, BB (corresponding author), Sunnybrook Hlth Sci Ctr, Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	burton.yang@sri.utoronto.ca; wlu@sri.utoronto.ca	Lu, Wei-Yang/K-4404-2013					Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; BIGNAMI A, 1993, J NEUROSCI RES, V34, P97, DOI 10.1002/jnr.490340110; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Day JM, 2004, J BIOL CHEM, V279, P12511, DOI 10.1074/jbc.M400242200; Dong HH, 2004, J NEUROSCI, V24, P8950, DOI 10.1523/JNEUROSCI.2106-04.2004; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Garcia-Alonso L, 2000, NEURON, V28, P741, DOI 10.1016/S0896-6273(00)00150-1; GOMEZPINILLA F, 1988, BRAIN RES, V438, P385, DOI 10.1016/0006-8993(88)91369-8; Gruenbaum LM, 1999, LEARN MEMORY, V6, P292; Han SW, 2005, INT J CANCER, V113, P109, DOI 10.1002/ijc.20550; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kaczmarek L, 2002, EMBO J, V21, P6643, DOI 10.1093/emboj/cdf676; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Kiani C, 2001, BIOCHEM J, V354, P199, DOI 10.1042/0264-6021:3540199; Labat-Robert J, 2004, AGEING RES REV, V3, P233, DOI 10.1016/j.arr.2003.10.002; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Lee V, 2002, J BIOL CHEM, V277, P22279, DOI 10.1074/jbc.M110227200; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; Llorens F, 2002, FEBS LETT, V510, P149, DOI 10.1016/S0014-5793(01)03252-5; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; Matsumoto K, 2003, J BIOL CHEM, V278, P41205, DOI 10.1074/jbc.M305060200; Milev P, 1998, BIOCHEM BIOPH RES CO, V247, P207, DOI 10.1006/bbrc.1998.8759; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; Murakami T, 2003, ARCH HISTOL CYTOL, V66, P195, DOI 10.1679/aohc.66.195; Navolanic PM, 2003, INT J ONCOL, V22, P237; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Popp S, 2003, DEV DYNAM, V227, P143, DOI 10.1002/dvdy.10282; Reeves TM, 2003, J NEUROSCI, V23, P10182; Russell DL, 2003, J BIOL CHEM, V278, P42330, DOI 10.1074/jbc.M300519200; Ruzicka BB, 1995, MOL BRAIN RES, V34, P209, DOI 10.1016/0169-328X(95)00165-O; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Schmalfeldt M, 1998, J BIOL CHEM, V273, P15758, DOI 10.1074/jbc.273.25.15758; Schmalfeldt M, 2000, J CELL SCI, V113, P807; Schweigreiter R, 2004, MOL CELL NEUROSCI, V27, P163, DOI 10.1016/j.mcn.2004.06.004; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103; Tran KT, 2004, WOUND REPAIR REGEN, V12, P262, DOI 10.1111/j.1067-1927.2004.012302.x; WERNER MH, 1988, J HISTOCHEM CYTOCHEM, V36, P81, DOI 10.1177/36.1.3275713; Westling J, 2004, BIOCHEM J, V377, P787, DOI 10.1042/bj20030896; Williams C, 1998, J COMP NEUROL, V390, P268, DOI 10.1002/(SICI)1096-9861(19980112)390:2<268::AID-CNE9>3.0.CO;2-#; Wu YJ, 2004, MOL BIOL CELL, V15, P2093, DOI 10.1091/mbc.E03-09-0667; Wu YJ, 2002, J BIOL CHEM, V277, P12294, DOI 10.1074/jbc.M110748200; Wu YJ, 2001, J BIOL CHEM, V276, P14178, DOI 10.1074/jbc.M100618200; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200; Yang BL, 2003, LIFE SCI, V73, P3399, DOI 10.1016/j.lfs.2003.06.018; Zhang WD, 2000, HIPPOCAMPUS, V10, P512, DOI 10.1002/1098-1063(2000)10:5<512::AID-HIPO2>3.0.CO;2-M; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; Zheng PS, 2004, J CELL SCI, V117, P5887, DOI 10.1242/jcs.01516; Zheng PS, 2004, FASEB J, V18, P754, DOI 10.1096/fj.03-0545fje; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	63	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19358	19368		10.1074/jbc.M512980200	http://dx.doi.org/10.1074/jbc.M512980200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16648628	hybrid			2022-12-25	WOS:000238847000051
J	Caputo, S; Couprie, J; Duband-Goulet, I; Konde, E; Lin, F; Braud, S; Gondry, M; Gilquin, B; Worman, HJ; Zinn-Justin, S				Caputo, Sandrine; Couprie, Joel; Duband-Goulet, Isabelle; Konde, Emilie; Lin, Feng; Braud, Sandrine; Gondry, Muriel; Gilquin, Bernard; Worman, Howard J.; Zinn-Justin, Sophie			The carboxyl-terminal nucleoplasmic region of MAN1 exhibits a DNA binding winged helix domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER NUCLEAR-MEMBRANE; A-TYPE LAMINS; LEM-DOMAIN; AUTOINTEGRATION FACTOR; TRANSCRIPTION FACTORS; CRYSTAL-STRUCTURE; INTEGRAL PROTEIN; RNA-BINDING; ENVELOPE; MOTIF	MAN1 is an integral protein of the inner nuclear membrane that interacts with nuclear lamins and emerin, thus playing a role in nuclear organization. It also binds to chromatin-associated proteins and transcriptional regulators, including the R-Smads, Smad1, Smad2, and Smad3. Mutations in the human gene encoding MAN1 cause sclerosing bone dysplasias, which sometimes have associated skin abnormalities. At the molecular level, these mutations lead to loss of the MAN1-R-Smads interaction, thus perturbing transforming growth factor beta superfamily signaling pathway. As a first step to understanding the physical basis of MAN1 interaction with R-Smads, we here report the structural characterization of the carboxyl-terminal nucleoplasmic region of MAN1, which is responsible for Smad binding. This region exhibits an amino-terminal globular domain adopting a winged helix fold, as found in several Smad-associated sequence-specific DNA binding factors. Consistently, it binds to DNA through the positively charged recognition helix H3 of its winged helix motif. However, it does not show the predicted carboxyl-terminal U2AF homology domain in solution, suggesting that the folding and stability of such a domain in MAN1 depend upon binding to an unidentified partner. Modeling the complex between DNA and the winged helix domain shows that the regions involved in DNA binding are essentially distinct from those reported to be involved in Smad binding. This suggests that MAN1 binds simultaneously to R-Smads and their targeted DNA sequences.	CEA Saclay, Dept Ingn & Etud Prot, Direct Sci Vivant, F-91191 Gif Sur Yvette, France; Univ Paris 06, Inst Jacques Monod, CNRS, UMR 7592, F-75251 Paris 05, France; Univ Paris 07, F-75251 Paris 05, France; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Columbia University; Columbia University	Zinn-Justin, S (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, Direct Sci Vivant, Batiment 152, F-91191 Gif Sur Yvette, France.	szinn@cea.fr	Caputo, Sandrine M/I-7460-2019; Caputo, Sandrine M./C-3860-2018	Caputo, Sandrine M./0000-0001-5338-9388; Gondry, Muriel/0000-0003-0398-3404; COUPRIE, Joel/0000-0002-1212-6773				Brachner A, 2005, J CELL SCI, V118, P5797, DOI 10.1242/jcs.02701; Braud S, 2005, J PROTEOME RES, V4, P2137, DOI 10.1021/pr050230i; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai ML, 2001, EMBO J, V20, P4399, DOI 10.1093/emboj/20.16.4399; CAPUTO S, 2006, IN PRESS J BIOMOL NM; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; de Oca ROM, 2005, J BIOL CHEM, V280, P42252, DOI 10.1074/jbc.M509917200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dong G, 2004, EMBO J, V23, P1000, DOI 10.1038/sj.emboj.7600115; Frenal K, 2006, BIOCHEMISTRY-US, V45, P4867, DOI 10.1021/bi051948e; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Garcia-Castellanos R, 2004, J BIOL CHEM, V279, P17888, DOI 10.1074/jbc.M313123200; Germain S, 2000, GENE DEV, V14, P435; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Hellemans J, 2004, NAT GENET, V36, P1213, DOI 10.1038/ng1453; Hutchison CJ, 2004, NAT CELL BIOL, V6, P1062, DOI 10.1038/ncb1104-1062; Kellenberger E, 2002, FEBS LETT, V528, P171, DOI 10.1016/S0014-5793(02)03294-5; Kielkopf CL, 2004, GENE DEV, V18, P1513, DOI 10.1101/gad.1206204; Kielkopf CL, 2001, CELL, V106, P595, DOI 10.1016/S0092-8674(01)00480-9; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Laguri C, 2001, STRUCTURE, V9, P503, DOI 10.1016/S0969-2126(01)00611-6; Lin F, 2005, HUM MOL GENET, V14, P437, DOI 10.1093/hmg/ddi040; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Mans BJ, 2004, CELL CYCLE, V3, P1612; Mansharamani M, 2005, J BIOL CHEM, V280, P13863, DOI 10.1074/jbc.M413020200; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Osada SI, 2003, DEVELOPMENT, V130, P1783, DOI 10.1242/dev.00401; Pan D, 2005, J BIOL CHEM, V280, P15992, DOI 10.1074/jbc.M411234200; PaulinLevasseur M, 1996, CHROMOSOMA, V104, P367, DOI 10.1007/s004120050128; Raju GP, 2003, J BIOL CHEM, V278, P428, DOI 10.1074/jbc.M210505200; Randall RA, 2002, EMBO J, V21, P145, DOI 10.1093/emboj/21.1.145; Rodriguez-Navarro S, 2002, YEAST, V19, P43, DOI 10.1002/yea.803; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Savarin P, 2001, J BIOMOL NMR, V19, P49, DOI 10.1023/A:1008311110174; Selenko P, 2003, MOL CELL, V11, P965, DOI 10.1016/S1097-2765(03)00115-1; Selmer M, 2002, EMBO J, V21, P4145, DOI 10.1093/emboj/cdf408; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; VUISTER GW, 1993, J BIOMOL NMR, V3, P67; Wolff N, 2001, FEBS LETT, V501, P171, DOI 10.1016/S0014-5793(01)02649-7; Worman HJ, 2005, INT REV CYTOL, V246, P231, DOI 10.1016/S0074-7696(05)46006-4; Wu W, 2002, J CELL SCI, V115, P1361	44	47	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18208	18215		10.1074/jbc.M601980200	http://dx.doi.org/10.1074/jbc.M601980200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16648637	hybrid			2022-12-25	WOS:000238490300073
J	de Barry, J; Janoshazi, A; Dupont, JL; Procksch, O; Chasserot-Golaz, S; Jeromin, A; Vitale, N				de Barry, Jean; Janoshazi, Agnes; Dupont, Jean Luc; Procksch, Odile; Chasserot-Golaz, Sylvette; Jeromin, Andreas; Vitale, Nicolas			Functional implication of neuronal calcium sensor-1 and phosphoinositol 4-kinase-beta interaction in regulated exocytosis of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4-OH KINASE; SECRETORY GRANULES; PROTEIN; FREQUENIN; BETA; 4,5-BISPHOSPHATE; ACTIVATION; CHROMAFFIN; BINDING; PTDINS(4,5)P-2	Several studies have shown that the neuronal calcium sensor (NCS-1) and phosphoinositol 4-kinase-beta (PI4K-beta) regulate the exo-cytotic process of nerve and neuroendocrine cells. The aim of our study was to investigate their possible interaction at rest and during stimulation in living cells and to decipher the role of this interaction in the secretory process. In PC12 cells, we observed a stimulation-induced recruitment of NCS-1 and PI4K-beta from the intracellular compartment toward the plasma membrane. This recruitment was highly correlated to the intracellular Ca2+ rise induced by secretagogues. Using fluorescence resonance energy transfer between PI4K-beta-ECFP and NCS-1-EYFP, we show that both proteins are interacting in resting cells and that this interaction increases with stimulation. It appears that the membrane insertion of NCS-1 is necessary for the interaction with PI4K-beta, since a mutation that prevented the membrane insertion of NCS-1 abolished NCS-1-PI4K-beta interaction, as revealed by fluorescence resonance energy transfer analysis. Additionally, the overexpression of mutated NCS-1 prevents the stimulatory effect on secretion induced by PI4K-beta, suggesting that the interaction of the two proteins on a membrane compartment is necessary for the secretory function. Moreover, extinction of endogenous PI4K-beta by small interfering RNA inhibits secretion and completely prevents the stimulatory effect of NCS-1 on calcium-evoked exocytosis from permeabilized PC12 cells, showing directly for the first time the functional implication of a NCS-1 center dot PI4K-beta complex in regulated exocytosis.	ULP, CNRS, Inst Neurosci Cellulaires & Integrat, UMR 7168 LC2, F-67084 Strasbourg, France; CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Baylor College of Medicine	de Barry, J (corresponding author), ULP, CNRS, Inst Neurosci Cellulaires & Integrat, UMR 7168 LC2, 5 Rue B Pascal, F-67084 Strasbourg, France.	barry@neurochem.u-strasbg.fr; vitalen@neurochem.u-strasbg.fr	Vitale, Nicolas/G-5967-2014; Chasserot-Golaz, Sylvette/K-7625-2017	Vitale, Nicolas/0000-0002-4752-4907; 				Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Chung SH, 1998, J BIOL CHEM, V273, P10240, DOI 10.1074/jbc.273.17.10240; Dupont JL, 2000, EUR J NEUROSCI, V12, P215, DOI 10.1046/j.1460-9568.2000.00906.x; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; Gasman S, 1998, J BIOL CHEM, V273, P16913, DOI 10.1074/jbc.273.27.16913; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Gromada J, 2005, P NATL ACAD SCI USA, V102, P10303, DOI 10.1073/pnas.0504487102; Haynes LP, 2005, J BIOL CHEM, V280, P6047, DOI 10.1074/jbc.M413090200; Heim R, 1999, METHOD ENZYMOL, V302, P408, DOI 10.1016/S0076-6879(99)02036-4; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Kapp-Barnea Y, 2003, J IMMUNOL, V171, P5320, DOI 10.4049/jimmunol.171.10.5320; Loyet KM, 1998, J BIOL CHEM, V273, P8337, DOI 10.1074/jbc.273.14.8337; Martin TFJ, 1997, BIOCHEM SOC T, V25, P1137, DOI 10.1042/bst0251137; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; O'Callaghan DW, 2002, J BIOL CHEM, V277, P14227, DOI 10.1074/jbc.M111750200; Rajebhosale M, 2003, J BIOL CHEM, V278, P6075, DOI 10.1074/jbc.M204702200; Rousset M, 2003, J BIOL CHEM, V278, P7019, DOI 10.1074/jbc.M209537200; Scalettar BA, 2002, J CELL SCI, V115, P2399; Taverna E, 2002, J CELL SCI, V115, P3909, DOI 10.1242/jcs.00072; Tsujimoto T, 2002, SCIENCE, V295, P2276, DOI 10.1126/science.1068278; Tucker WC, 2003, J CELL BIOL, V162, P199, DOI 10.1083/jcb.200302060; Vitale N, 2005, J BIOL CHEM, V280, P29921, DOI 10.1074/jbc.M413748200; Vitale N, 2002, J CELL BIOL, V159, P79, DOI 10.1083/jcb.200203027; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Waselle L, 2005, MOL ENDOCRINOL, V19, P3097, DOI 10.1210/me.2004-0530; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Werle MJ, 2000, NEUROSCI LETT, V284, P33, DOI 10.1016/S0304-3940(00)01004-1; Xia ZP, 2001, J BIOL CHEM, V276, P1766, DOI 10.1074/jbc.M008741200; Zhao XH, 2001, J BIOL CHEM, V276, P40183, DOI 10.1074/jbc.M104048200; Zheng Q, 2005, J NEUROCHEM, V92, P442, DOI 10.1111/j.1471-4159.2004.02897.x; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	34	48	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18098	18111		10.1074/jbc.M509842200	http://dx.doi.org/10.1074/jbc.M509842200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16638749	hybrid			2022-12-25	WOS:000238490300061
J	de Ruyck, J; Durisotti, V; Oudjama, Y; Wouters, J				de Ruyck, Jerome; Durisotti, Virginie; Oudjama, Yamina; Wouters, Johan			Structural role for Tyr-104 in Escherichia coli isopentenyl-diphosphate isomerase - Site-directed mutagenesis, enzymology, and protein crystallography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MECHANISM	Isopentenyl-diphosphate (IPP): dimethylallyl diphosphate isomerase is a key enzyme in the biosynthesis of isoprenoids. The mechanism of the isomerization reaction involves protonation of the unactivated carbon-carbon double bond in the substrate, but identity of the acidic moiety providing the proton is still not clear. Multiple sequence alignments and geometrical features observed in crystal structures of complexes with IPP isomerase suggest that Tyr-104 could play an important role during catalysis. A series of mutants was constructed by directed mutagenesis and characterized by enzymology. Crystallographic and thermal denaturation data for Y104A and Y104F mutants were obtained. Those data demonstrate the importance of residue Tyr-104 for proper folding of Escherichia coli type I IPP isomerase.	Univ Namur, Lab Chim Biol Struct, B-5000 Namur, Belgium; Inst Rech Microbiol JM Wiame, B-1070 Brussels, Belgium	University of Namur	de Ruyck, J (corresponding author), Univ Namur, Lab Chim Biol Struct, 61 Rue Bruxelles, B-5000 Namur, Belgium.	jerome.deruyck@fundp.ac.be		de Ruyck, Jerome/0000-0003-4397-1870; Wouters, Johan/0000-0002-4920-6857				Bagger HL, 2003, BIOCHEMISTRY-US, V42, P10295, DOI 10.1021/bi034693i; Bonanno JB, 2001, P NATL ACAD SCI USA, V98, P12896, DOI 10.1073/pnas.181466998; Carrigan CN, 2003, J AM CHEM SOC, V125, P9008, DOI 10.1021/ja0350381; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Durbecq V, 2001, EMBO J, V20, P1530, DOI 10.1093/emboj/20.7.1530; HAHN FM, 1995, J BIOL CHEM, V270, P11298, DOI 10.1074/jbc.270.19.11298; Kaneda K, 2001, P NATL ACAD SCI USA, V98, P932, DOI 10.1073/pnas.020472198; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Minetti CASA, 1997, J BIOL CHEM, V272, P10710; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oudjama Y, 2001, ACTA CRYSTALLOGR D, V57, P287, DOI 10.1107/S0907444900017571; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; ROUSSEL A, 1992, TURBO FRODO 92; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; SATTERWHITE DM, 1985, METHOD ENZYMOL, V110, P92; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Steinbacher S, 2003, J MOL BIOL, V329, P973, DOI 10.1016/S0022-2836(03)00527-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wouters J, 2004, PROTEINS, V54, P216, DOI 10.1002/prot.10573; Wouters J, 2003, J AM CHEM SOC, V125, P3198, DOI 10.1021/ja029171p; Wouters J, 2003, J BIOL CHEM, V278, P11903, DOI 10.1074/jbc.M212823200	21	10	16	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17864	17869		10.1074/jbc.M601851200	http://dx.doi.org/10.1074/jbc.M601851200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16617181	hybrid			2022-12-25	WOS:000238490300036
J	Gaccioli, F; Huang, CC; Wang, C; Bevilacqua, E; Franchi-Gazzola, R; Gazzola, GC; Bussolati, O; Snider, MD; Hatzoglou, M				Gaccioli, Francesca; Huang, Charlie C.; Wang, Chuanping; Bevilacqua, Elena; Franchi-Gazzola, Renata; Gazzola, Gian Carlo; Bussolati, Ovidio; Snider, Martin D.; Hatzoglou, Maria			Amino acid starvation induces the SNAT2 neutral amino acid transporter by a mechanism that involves eukaryotic initiation factor 2 alpha phosphorylation and cap-independent translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; SITE-MEDIATED TRANSLATION; SYSTEM-A; MESSENGER-RNA; GENE-EXPRESSION; TRANSCRIPTIONAL CONTROL; ADAPTIVE REGULATION; EIF2-ALPHA KINASE; BINDING-PROTEIN; STRESS	Nutritional stress caused by amino acid starvation involves a coordinated cellular response that includes the global decrease of protein synthesis and the increased production of cell defense proteins. Part of this response is the induction of transport system A for neutral amino acids that leads to the recovery of cell volume and amino acid levels once extracellular amino acid availability is restored. Hypertonic stress also increases system A activity as a mechanism to promote a rapid recovery of cell volume. Both a starvation-dependent and a hypertonic increase of system A transport activity are due to the induction of SNAT2, the ubiquitous member of SLC38 family. The molecular mechanisms underlying SNAT2 induction were investigated in tissue culture cells. We show that the increase in system A transport activity and SNAT2 mRNA levels upon amino acid starvation were blunted in cells with a mutant eIF2 alpha that cannot be phosphorylated. In contrast, the induction of system A activity and SNAT2 mRNA levels by hypertonic stress were independent of eIF2 alpha phosphorylation. The translational control of the SNAT2 mRNA during amino acid starvation was also investigated. It is shown that the 5'-untranslated region contains an internal ribosome entry site that is constitutively active in amino acid-fed and-deficient cells and in a cell-free system. We also show that amino acid starvation caused a 2.5-fold increase in mRNA and protein expression from a reporter construct containing both the SNAT2 intronic amino acid response element and the SNAT2-untranslated region. We conclude that the adaptive response of system A activity to amino acid starvation requires eukaryotic initiation factor 2 alpha phosphorylation, increased gene transcription, and internal ribosome entry site-mediated translation. In contrast, the response to hypertonic stress does not involve eukaryotic initiation factor 2 alpha phosphorylation, suggesting that SNAT2 expression can be modulated by specific signaling pathways in response to different stresses.	Case Western Reserve Univ, Dept Nutr, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Sch Med, Cleveland, OH 44106 USA; Univ Parma, Dept Expt Med, Unit Gen & Clin Pathol, I-43100 Parma, Italy	Case Western Reserve University; Case Western Reserve University; University of Parma	Hatzoglou, M (corresponding author), Case Western Reserve Univ, Dept Nutr, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.	mxh8@po.cwru.edu	Bussolati, Ovidio/B-7589-2013	Bussolati, Ovidio/0000-0002-4301-2939; Gaccioli, Francesca/0000-0001-7178-8921	NIDDK NIH HHS [R01 DK 60596, R01 DK 53307] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060596, R01DK053307] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilera A, 2005, CURR OPIN CELL BIOL, V17, P242, DOI 10.1016/j.ceb.2005.03.001; Alfieri RR, 2001, BIOCHEM BIOPH RES CO, V283, P174, DOI 10.1006/bbrc.2001.4729; Aulak KS, 1999, J BIOL CHEM, V274, P30424, DOI 10.1074/jbc.274.43.30424; Bevilacqua E, 2005, FEBS LETT, V579, P3376, DOI 10.1016/j.febslet.2005.05.002; Bussolati O, 2001, MOL MEMBR BIOL, V18, P27, DOI 10.1080/09687680110033756; Calkhoven CF, 2000, GENE DEV, V14, P1920; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Dresios J, 2006, NAT STRUCT MOL BIOL, V13, P30, DOI 10.1038/nsmb1031; Fernandez J, 2005, MOL CELL, V17, P405, DOI 10.1016/j.molcel.2004.12.024; Fernandez J, 2003, J BIOL CHEM, V278, P50000, DOI 10.1074/jbc.M305903200; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Franchi-Gazzola R, 2004, BBA-BIOMEMBRANES, V1667, P157, DOI 10.1016/j.bbamem.2004.09.012; Franchi-Gazzola R, 2001, AM J PHYSIOL-CELL PH, V280, pC1465, DOI 10.1152/ajpcell.2001.280.6.C1465; Franchi-Gazzola R, 1999, J BIOL CHEM, V274, P28922, DOI 10.1074/jbc.274.41.28922; Gazzola RF, 2001, FEBS LETT, V490, P11; Giltiay NV, 2005, J LIPID RES, V46, P2497, DOI 10.1194/jlr.M500337-JLR200; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; Hyde R, 2001, BIOCHEM J, V355, P563, DOI 10.1042/bj3550563; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kilberg MS, 2005, ANNU REV NUTR, V25, P59, DOI 10.1146/annurev.nutr.24.012003.132145; Kimball SR, 2005, SEMIN CELL DEV BIOL, V16, P21, DOI 10.1016/j.semcdb.2004.11.009; Kimball Sr, 2000, COLD SPRING HARBOR M, V39, P561; Komar AA, 2005, J BIOL CHEM, V280, P23425, DOI 10.1074/jbc.R400041200; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Ling R, 2001, BBA-BIOMEMBRANES, V1512, P15, DOI 10.1016/S0005-2736(01)00310-8; Lopez-Fontanals M, 2003, J GEN PHYSIOL, V122, P5, DOI 10.1085/jgp.200308800; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P784, DOI 10.1007/s00424-003-1117-9; Malandro MS, 1996, AM J PHYSIOL-CELL PH, V271, pC295, DOI 10.1152/ajpcell.1996.271.1.C295; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Morley SJ, 2002, J BIOL CHEM, V277, P32855, DOI 10.1074/jbc.C200376200; Novak D, 2006, BIOCHIMIE, V88, P39, DOI 10.1016/j.biochi.2005.07.002; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; Palii SS, 2004, J BIOL CHEM, V279, P3463, DOI 10.1074/jbc.M310483200; SAIER MH, 1988, J MEMBRANE BIOL, V104, P1, DOI 10.1007/BF01871898; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Thoma Christian, 2004, Methods Mol Biol, V257, P171, DOI 10.1385/1-59259-750-5:171; Trama J, 2002, J IMMUNOL, V169, P5477, DOI 10.4049/jimmunol.169.10.5477; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Vabulas RM, 2005, SCIENCE, V310, P1960, DOI 10.1126/science.1121925; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	55	89	92	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17929	17940		10.1074/jbc.M600341200	http://dx.doi.org/10.1074/jbc.M600341200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16621798	hybrid			2022-12-25	WOS:000238490300043
J	Padovani, D; Labunska, T; Banerjee, R				Padovani, Dominique; Labunska, Tetyana; Banerjee, Ruma			Energetics of interaction between the G-protein chaperone, MeaB, and B-12-dependent methylmalonyl-CoA mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROKARYOTIC GENE ARRANGEMENTS; COMPLEMENTATION GROUP; NICKEL; IDENTIFICATION; BINDING; GTPASE; UREASE; DNA; ADENOSYLTRANSFERASE; CATALYSIS	MeaB is an auxiliary protein that supports the function of the radical B-12-dependent enzyme, methylmalonyl-CoA mutase, although its precise role is not understood. Mutations in the human homolog of MeaB, MMAA, lead to methylmalonic aciduria, an inborn error of metabolism that can be fatal. To obtain insights into the function of this recently discovered protein, we have characterized the entropic and enthalpic contributions to Delta G degrees(assoc) for complexation of MeaB (in the presence and absence of nucleotides) with methylmalonyl-CoA mutase (in the presence and absence of cofactor). The dissociation constant for binding of methylmalonyl-CoA mutase and MeaB ranges from 34 +/- 4 to 524 +/- 66 nM, depending on the combination of nucleotide and mutase form. Holomutase binds MeaB 15-fold more tightly when the nonhydrolyzable GTP analog, GMPPNP, is bound versus GDP. In contrast, the apomutase binds MeaB with similar affinity in the presence of either nucleotide. Our studies reveal that a large structural rearrangement accompanies interaction between these proteins and buries between similar to 4000 and 8600 angstrom(2) of surface area, depending on the combination of ligands in the active sites of the two proteins. Furthermore, we demonstrate that MeaB binds GTP and GDP with similar affinity (K-d of 7.3 +/- 1.9 and 6.2 +/- 0.7 mu M, respectively at 20 degrees C) and has low intrinsic GTPase activity (similar to 0.04 min(-1) at 37 degrees C), which is stimulated similar to 100-fold by methylmalonyl-CoA mutase. These studies provide insights into the energetics of interaction between the radical enzymemethylmalonyl-CoA mutase and MeaB, which are discussed.	Univ Nebraska, Redox Biol Ctr, Lincoln, NE 68588 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Redox Biol Ctr, Lincoln, NE 68588 USA.	rbanerjee1@unl.edu	Dominique, PADOVANI/EUS-9660-2022	PADOVANI, Dominique/0000-0003-1166-5801	NCRR NIH HHS [1P20 RR 17675] Funding Source: Medline; NIDDK NIH HHS [DK 45776] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045776, R29DK045776] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; Banerjee R, 2003, CHEM REV, V103, P2083, DOI 10.1021/cr0204395; Bobik TA, 2001, J BIOL CHEM, V276, P37194, DOI 10.1074/jbc.M107232200; Dobson CM, 2002, HUM MOL GENET, V11, P3361, DOI 10.1093/hmg/11.26.3361; Dobson CM, 2002, P NATL ACAD SCI USA, V99, P15554, DOI 10.1073/pnas.242614799; FREIRE E, 1995, ANNU REV BIOPH BIOM, V24, P141, DOI 10.1146/annurev.bb.24.060195.001041; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; Jeon WB, 2001, J BIOL CHEM, V276, P38602, DOI 10.1074/jbc.M104945200; Korotkova N, 2004, J BIOL CHEM, V279, P13652, DOI 10.1074/jbc.M312852200; Leal NA, 2003, J BIOL CHEM, V278, P9227, DOI 10.1074/jbc.M212739200; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Mehta N, 2003, J BACTERIOL, V185, P726, DOI 10.1128/JB.185.3.726-734.2003; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; Mulrooney SB, 2003, FEMS MICROBIOL REV, V27, P239, DOI 10.1016/S0168-6445(03)00042-1; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; Padovani D, 2006, BIOCHEMISTRY-US, V45, P2951, DOI 10.1021/bi051742d; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; SHEVELL MI, 1992, CAN J NEUROL SCI, V19, P472, DOI 10.1017/S0317167100041676; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Uthaiah RC, 2003, J BIOL CHEM, V278, P29336, DOI 10.1074/jbc.M211973200; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Vlasie MD, 2003, J AM CHEM SOC, V125, P5431, DOI 10.1021/ja029420+; Yamanishi M, 2005, TRENDS BIOCHEM SCI, V30, P304, DOI 10.1016/j.tibs.2005.04.008; Zambelli B, 2005, J BIOL CHEM, V280, P4684, DOI 10.1074/jbc.M408483200	25	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17838	17844		10.1074/jbc.M600047200	http://dx.doi.org/10.1074/jbc.M600047200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16641088	hybrid			2022-12-25	WOS:000238490300033
J	Takayama, S; Rogatsky, I; Schwarcz, LE; Darimont, BD				Takayama, Sachiko; Rogatsky, Inez; Schwarcz, Leslie E.; Darimont, Beatrice D.			The glucocorticoid receptor represses cyclin D1 by targeting the Tcf-beta-catenin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-FACTOR; ANDROGEN RECEPTOR; C-MYC; TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION; DIFFERENTIATING OSTEOBLASTS; LYMPHOBLASTIC-LEUKEMIA; NUCLEAR RECEPTORS; RESPONSE ELEMENT; SIGNALING AXIS	The ability of glucocorticoids (GCs) to regulate cell proliferation plays an important role in their therapeutic use. The canonical Wnt pathway, which promotes the proliferation of many cancers and differentiated tissues, is an emerging target for the actions of GCs, albeit existing links between these signaling pathways are indirect. By screening known Wnt target genes for their ability to respond differently to GCs in cells whose proliferation is either positively or negatively regulated by GCs, we identified c-myc, c-jun, and cyclin D1, which encode rate-limiting factors for G(1) progression of the cell cycle. Here we show that in U2OS/GR cells, which are growth-arrested by GCs, the glucocorticoid receptor (GR) represses cyclin D1 via Tcf-beta-catenin, the transcriptional effector of the canonical Wnt pathway. We demonstrate that GR can bind beta-catenin in vitro, suggesting that GC and Wnt signaling pathways are linked directly through their effectors. Down-regulation of beta-catenin by RNA interference impeded the expression of cyclin D1 but not of c-myc or c-jun and had no significant effect on the proliferation of U2OS/GR cells. Although these results revealed that beta-catenin and cyclin D1 are not essential for the regulation of U2OS/GR cell proliferation, considering the importance of the Wnt pathway for proliferation and differentiation of other cells, the repression of Tcf-beta-catenin activity by GR could open new possibilities for tissue-selective GC therapies.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA; Cornell Univ, Weill Med Coll, Hosp Special Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	University of Oregon; University of Oregon; Cornell University; Cornell University	Darimont, BD (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	bead@molbio.uoregon.edu			NCI NIH HHS [R01 CA 20535] Funding Source: Medline; NIGMS NIH HHS [5T32 GM 07413] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020535] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007413] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amir AL, 2003, J BIOL CHEM, V278, P30828, DOI 10.1074/jbc.M301208200; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Ausserlechner MJ, 2004, CELL DEATH DIFFER, V11, P165, DOI 10.1038/sj.cdd.4401328; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Barrett TJ, 1998, J CELL BIOCHEM, P185; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Cheskis BJ, 2004, J CELL BIOCHEM, V93, P20, DOI 10.1002/jcb.20180; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Fernandes D, 1999, AM J RESP CELL MOL, V21, P77, DOI 10.1165/ajrcmb.21.1.3396; FROST GH, 1994, J STEROID BIOCHEM, V50, P109, DOI 10.1016/0960-0760(94)90017-5; Glass CK, 2000, GENE DEV, V14, P121; Guan Y, 2004, MOL ENDOCRINOL, V18, P214, DOI 10.1210/me.2003-0014; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Kauppi B, 2003, J BIOL CHEM, V278, P22748, DOI 10.1074/jbc.M212711200; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Masiello D, 2004, MOL ENDOCRINOL, V18, P2388, DOI 10.1210/me.2003-0436; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Natsume H, 2003, BIOCHEM BIOPH RES CO, V309, P408, DOI 10.1016/j.bbrc.2003.08.019; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; OBANION MK, 1992, MOL ENDOCRINOL, V6, P1371, DOI 10.1210/me.6.9.1371; Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Poy F, 2001, NAT STRUCT BIOL, V8, P1053, DOI 10.1038/nsb720; Renner K, 2003, CURR MOL MED, V3, P707, DOI 10.2174/1566524033479357; RHEE K, 1995, CANCER RES, V55, P4188; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Rogatsky I, 2003, P NATL ACAD SCI USA, V100, P13845, DOI 10.1073/pnas.2336092100; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Ryves W Jonathan, 2003, Prog Cell Cycle Res, V5, P489; Saag KG, 2003, ENDOCRIN METAB CLIN, V32, P135, DOI 10.1016/S0889-8529(02)00064-6; Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200; Smith E, 2002, J BIOL CHEM, V277, P18191, DOI 10.1074/jbc.M109708200; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Truica CI, 2000, CANCER RES, V60, P4709; Wei P, 1998, MOL ENDOCRINOL, V12, P1322, DOI 10.1210/me.12.9.1322; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Zhu ZJ, 2003, CARCINOGENESIS, V24, P1225, DOI 10.1093/carcin/bgg077	51	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17856	17863		10.1074/jbc.M602290200	http://dx.doi.org/10.1074/jbc.M602290200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16644723	hybrid			2022-12-25	WOS:000238490300035
J	Barber, C; Rosti, J; Rawat, A; Findlay, K; Roberts, K; Seifert, GJ				Barber, Christine; Rosti, Johannes; Rawat, Arun; Findlay, Kim; Roberts, Keith; Seifert, Georg J.			Distinct properties of the five UDP-D-glucose/UDP-D-galactose 4-epimerase isoforms of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE SUGAR INTERCONVERSIONS; D-GLUCURONATE 4-EPIMERASE; FUNCTIONAL CLONING; ENZYMIC ACTIVITIES; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; LELOIR PATHWAY; BIOSYNTHESIS; EXPRESSION; GENE	Plant genomes contain genetically encoded isoforms of most nucleotide sugar interconversion enzymes. Here we show that Arabidopsis thaliana has five genes encoding functional UDP-D-glucose/ UDP-(D)-galactose 4-epimerase (named UGE1 to UGE5). All A. thaliana UDP-(D)-glucose 4-epimerase isoforms are dimeric in solution, maximally active in vitro at 30-40 degrees C, and show good activity between pH 7 and pH 9. In vitro, UGE1, -3, and -5 act independently of externally added NAD(+), whereas cofactor addition stimulates the activity of UGE2 and is particularly important for UGE4 activity. UGE1 and UGE3 are most efficiently inhibited by UDP. The five isoforms display k(cat)(UDP-Gal) values between 23 and 128 s(-1) and K-m(UDP-Gal) values between 0.1 and 0.3mM. This results in enzymatic efficiencies ranging between 97 and 890 mM(-1)s(-1) for UGE4 = UGE1 < UGE3 < UGE5 < UGE2. The K-m(UDP-Glc) values, derived from the Haldane relationship, were 0.76mM for UGE1, 0.56mM for UGE4, and between 0.13 and 0.23 mM for UGE2, -3, and -5. The expression of UGE isoforms is ubiquitous and displays developmental and cell type-dependent variations. UGE1 and -3 expression patterns globally resemble enzymes involved in carbohydrate catabolism, and UGE2, -4, and -5 expression is more related to carbohydrate biosynthesis. UGE1, -2, and -4 are present in the cytoplasm, whereas UGE4 is additionally enriched close to Golgi stacks. All UGE genes tested complement the UGE4(rhd1) phenotype, confer increased galactose tolerance in planta, and complement the galactose metabolization deficiency in the Saccharomyces cerevisiae gal10 mutant. We suggest that plant UGE isoforms function in different metabolic situations and that enzymatic properties, gene expression pattern, and subcellular localization contribute to the differentiation of isoform function.	John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Seifert, GJ (corresponding author), John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England.	georg.seifert@bbsrc.ac.uk	Rawat, Arun/Q-2520-2019; Rawat, Arun/AAD-1534-2019; Rawat, Arun/ABD-6248-2021	Rawat, Arun/0000-0003-0540-2044; Findlay, Kim/0000-0002-1556-0532; Roberts, Keith/0000-0001-9148-6701; Seifert, Georg/0000-0002-4245-791X				Albrecht G, 2003, PLANTA, V217, P252, DOI 10.1007/s00425-003-0995-6; Andeme-Onzighi C, 2002, PLANTA, V215, P949, DOI 10.1007/s00425-002-0836-z; Birnbaum K, 2003, SCIENCE, V302, P1956, DOI 10.1126/science.1090022; Blazquez MA, 1998, PLANT J, V13, P685, DOI 10.1046/j.1365-313X.1998.00063.x; Brahma A, 2004, FEBS LETT, V577, P27, DOI 10.1016/j.febslet.2004.09.056; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; CORNISHBOWDEN A, 2004, FUNDAMENTALS ENZYME, P23; DALESSANDRO G, 1977, BIOCHEM J, V162, P267, DOI 10.1042/bj1620267; DALESSANDRO G, 1977, BIOCHEM J, V162, P281, DOI 10.1042/bj1620281; DARROW RA, 1966, P NATL ACAD SCI USA, V55, P205, DOI 10.1073/pnas.55.1.205; DEY PM, 1984, PHYTOCHEMISTRY, V23, P729, DOI 10.1016/S0031-9422(00)85013-X; Dormann P, 1998, PLANT J, V13, P641, DOI 10.1046/j.1365-313X.1998.00067.x; Dormann P, 1996, ARCH BIOCHEM BIOPHYS, V327, P27, DOI 10.1006/abbi.1996.0088; DRUZHININA T N, 1969, Biokhimiya, V34, P108; FAN DF, 1969, PLANT PHYSIOL, V44, P599, DOI 10.1104/pp.44.4.599; Farre EM, 2001, PLANT PHYSIOL, V127, P685, DOI 10.1104/pp.127.2.685; Feingold D. S., 1982, Encyclopedia of plant physiology. New series. Volume 13 A. Plant carbohydrates.I. Intracellular carbohydrates [Loewus, R.A.; Tanner, W. (Editors)], P3; Gu XG, 2004, PLANT PHYSIOL, V136, P4256, DOI 10.1104/pp.104.052365; Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; Ishiyama N, 2004, J BIOL CHEM, V279, P22635, DOI 10.1074/jbc.M401642200; Jolliffe NA, 2004, PLANT J, V39, P821, DOI 10.1111/j.1365-313X.2004.02167.x; Li XM, 2004, PLANT PHYSIOL, V134, P940, DOI 10.1104/pp.103.036285; Madson M, 2003, PLANT CELL, V15, P1662, DOI 10.1105/tpc.009837; Molhoj M, 2004, PLANT PHYSIOL, V135, P1221, DOI 10.1104/pp.104.043745; Mulichak AM, 2002, BIOCHEMISTRY-US, V41, P15578, DOI 10.1021/bi0266683; Nayar S, 1997, FEBS LETT, V409, P449, DOI 10.1016/S0014-5793(97)00552-8; Novelli G, 2000, MOL GENET METAB, V71, P62, DOI 10.1006/mgme.2000.3073; Oomen RJFJ, 2004, PLANT SCI, V166, P1097, DOI 10.1016/j.plantsci.2003.12.033; Prosselkov PV, 1996, PHYSIOL PLANTARUM, V98, P753, DOI 10.1034/j.1399-3054.1996.980411.x; RAWAT A, 2005, THESIS U E ANGLIA NO; Reiter WD, 2001, PLANT MOL BIOL, V47, P95, DOI 10.1023/A:1010671129803; Ross KL, 2004, MOL GENET METAB, V83, P103, DOI 10.1016/j.ymgme.2004.07.005; Seifert GJ, 2004, CURR OPIN PLANT BIOL, V7, P277, DOI 10.1016/j.pbi.2004.03.004; Seifert GJ, 2004, PLANT CELL, V16, P723, DOI 10.1105/tpc.019661; Seifert GJ, 2002, CURR BIOL, V12, P1840, DOI 10.1016/S0960-9822(02)01260-5; Shaw MP, 2003, MOL BIOCHEM PARASIT, V126, P173, DOI 10.1016/S0166-6851(02)00243-8; Steinhauser D, 2004, BIOINFORMATICS, V20, P3647, DOI 10.1093/bioinformatics/bth398; Thoden JB, 2005, J BIOL CHEM, V280, P21900, DOI 10.1074/jbc.M502411200; Thoden JB, 2001, J BIOL CHEM, V276, P20617, DOI 10.1074/jbc.M101304200; Usadel B, 2004, FEBS LETT, V569, P327, DOI 10.1016/j.febslet.2004.06.005; van Dongen JT, 2003, PLANT PHYSIOL, V131, P1529, DOI 10.1104/pp.102.017202; Winkel BSJ, 2004, ANNU REV PLANT BIOL, V55, P85, DOI 10.1146/annurev.arplant.55.031903.141714; Zhang QS, 2006, BIOCHEM J, V394, P115, DOI 10.1042/BJ20051329; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	45	65	77	1	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17276	17285		10.1074/jbc.M512727200	http://dx.doi.org/10.1074/jbc.M512727200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16644739	hybrid			2022-12-25	WOS:000238326300055
J	Chong, PA; Lin, H; Wrana, JL; Forman-Kay, JD				Chong, P. Andrew; Lin, Hong; Wrana, Jeffrey L.; Forman-Kay, Julie D.			An expanded WW domain recognition motif revealed by the interaction between Smad7 and the E3 ubiquitin ligase Smurf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I RECEPTOR; PROTEIN; COMPLEX; BINDING; DEGRADATION; NMR; AFFINITY; TARGETS; IDENTIFICATION; SPECTROSCOPY	Smurf2 is an E3 ubiquitin ligase that drives degradation of the transforming growth factor-beta receptors and other targets. Recognition of the receptors by Smurf2 is accomplished through an intermediary protein, Smad7. Here we have demonstrated that the WW3 domain of Smurf2 can directly bind to the Smad7 polyproline-tyrosine (PY) motif. Of particular interest, the highly conserved WW domain binding site Trp, which interacts with target PY motifs, is a Phe in the Smurf2 WW3 domain. To examine this interaction, the solution structure of the complex between the Smad7 PY motif region (ELESPPPPYSRYPMD) and the Smurf2 WW3 domain was determined. The structure reveals that, in addition to binding the PY motif, the WW3 domain binds six residues C-terminal to the PY motif (PY-tail). Although the Phe in the WW3 domain binding site decreases affinity relative to the canonical Trp, this is balanced by additional interactions between the PY-tail and the beta 1-strand and beta 1-beta 2 loop of the WW3 domain. The interaction between the Smurf2 WW3 domain and the Smad7 PY motif is the first example of PY motif recognition by a WW domain with a Phe substituted for the binding site Trp. This unusual interaction allows the Smurf2 WW3 domain to recognize a subset of PY motif-containing proteins utilizing an expanded surface to provide specificity.	Hosp Sick Children, Dept Struct Biol & Biochem, Program Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Forman-Kay, JD (corresponding author), Hosp Sick Children, Dept Struct Biol & Biochem, Program Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	forman@sickkids.ca	Wrana, Jeffrey/F-8857-2013	Forman-Kay, Julie/0000-0001-8265-972X				Bai YL, 2004, MOL CELL, V15, P825, DOI 10.1016/j.molcel.2004.07.021; Bauer F, 2005, PROTEIN SCI, V14, P2487, DOI 10.1110/ps.051563605; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chong PA, 2004, J BIOL CHEM, V279, P40707, DOI 10.1074/jbc.M404375200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Henry PC, 2003, J BIOL CHEM, V278, P20019, DOI 10.1074/jbc.M211153200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kanelis V, 2000, J BIOMOL NMR, V16, P253, DOI 10.1023/A:1008355012528; Kanelis V, 2006, STRUCTURE, V14, P543, DOI 10.1016/j.str.2005.11.018; Kanelis V, 2001, IUBMB LIFE, V52, P291, DOI 10.1080/152165401317291147; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Koepf EK, 1999, BIOCHEMISTRY-US, V38, P14338, DOI 10.1021/bi991105l; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Kuratomi G, 2005, BIOCHEM J, V386, P461, DOI 10.1042/BJ20040738; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; Ogunjimi AA, 2005, MOL CELL, V19, P297, DOI 10.1016/j.molcel.2005.06.028; Otte L, 2003, PROTEIN SCI, V12, P491, DOI 10.1110/ps.0233203; PASCAL S, 1994, J MAGN RESON, V101, P197; PELTON JG, 1993, PROTEIN SCI, V2, P543; Pires JR, 2001, J MOL BIOL, V314, P1147, DOI 10.1006/jmbi.2000.5199; Schleinkofer K, 2004, J MOL BIOL, V344, P865, DOI 10.1016/j.jmb.2004.09.063; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; WANG H, 1995, J BIOMOL NMR, V5, P207; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	38	46	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17069	17075		10.1074/jbc.M601493200	http://dx.doi.org/10.1074/jbc.M601493200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16641086	hybrid			2022-12-25	WOS:000238326300029
J	Ellisdon, AM; Thomas, B; Bottomley, SP				Ellisdon, Andrew M.; Thomas, Bronwen; Bottomley, Stephen P.			The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; BETA-PROTEIN FIBRILLOGENESIS; SOLUBLE AMYLOID OLIGOMERS; MACHADO-JOSEPH-DISEASE; IN-VITRO; HUNTINGTONS-DISEASE; ALPHA-SYNUCLEIN; NEURODEGENERATIVE DISORDERS; CONFORMATIONAL DISEASE; MISFOLDING DISEASES	The aggregation of ataxin-3 is associated with spinocerebellar ataxia type 3, which is characterized by the formation of intraneuronal aggregates. However, the mechanism of aggregation is currently not well understood. Ataxin-3 consists of a folded Josephin domain followed by two ubiquitin-interacting motifs and a C-terminal polyglutamine tract, which in the non-pathological form is less than 45 residues in length. We demonstrate that ataxin-3 with 64 glutamines ( at(Q64)) undergoes a two-stage aggregation. The first stage involves formation of SDS-soluble aggregates, and the second stage results in formation of SDS-insoluble aggregates via the poly(Q) region. Both these first and second stage aggregates display typical amyloid-like characteristics. Under the same conditions at (Q15) and at (QHQ) undergo a single step aggregation event resulting in SDS-soluble aggregates, which does not involve the polyglutamine tract. These aggregates do not convert to the SDS-insoluble form. These observations demonstrate that ataxin-3 has an inherent capacity to aggregate through its non-polyglutamine domains. However, the presence of a pathological length polyglutamine tract introduces an additional step resulting in formation of a highly stable amyloid-like aggregate.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Monash University		steve.bottomley@med.monash.edu.au		Ellisdon, Andrew/0000-0002-2248-9914				Bevivino AE, 2001, P NATL ACAD SCI USA, V98, P11955, DOI 10.1073/pnas.211305198; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Cemal CK, 2002, HUM MOL GENET, V11, P1075, DOI 10.1093/hmg/11.9.1075; Chai YH, 2004, J BIOL CHEM, V279, P3605, DOI 10.1074/jbc.M310939200; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Chen SM, 2002, BIOCHEMISTRY-US, V41, P7391, DOI 10.1021/bi011772q; Chow MKM, 2004, CURR MED CHEM, V11, P491, DOI 10.2174/0929867043455936; Chow MKM, 2004, BIOCHEM BIOPH RES CO, V322, P387, DOI 10.1016/j.bbrc.2004.07.131; Chow MKM, 2004, J BIOL CHEM, V279, P47643, DOI 10.1074/jbc.M405799200; Chow MKM, 2004, J MOL BIOL, V335, P333, DOI 10.1016/j.jmb.2003.08.064; Collins SR, 2004, PLOS BIOL, V2, P1582, DOI 10.1371/journal.pbio.0020321; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; de Chiara C, 2005, J MOL BIOL, V354, P883, DOI 10.1016/j.jmb.2005.09.083; Diaz-Hernandez M, 2004, J NEUROSCI, V24, P9361, DOI 10.1523/JNEUROSCI.2365-04.2004; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100; Ellisdon AM, 2004, IUBMB LIFE, V56, P119, DOI 10.1080/15216540410001674003; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Ferrone F, 1999, METHOD ENZYMOL, V309, P256; Gales L, 2005, J MOL BIOL, V353, P642, DOI 10.1016/j.jmb.2005.08.061; Goto J, 1997, NEUROSCI RES, V28, P373, DOI 10.1016/S0168-0102(97)00056-4; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Holmberg M, 1998, HUM MOL GENET, V7, P913, DOI 10.1093/hmg/7.5.913; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Marchal S, 2003, J BIOL CHEM, V278, P31554, DOI 10.1074/jbc.M304205200; Margolis RL, 2001, TRENDS MOL MED, V7, P479, DOI 10.1016/S1471-4914(01)02179-7; Masino L, 2004, J MOL BIOL, V344, P1021, DOI 10.1016/j.jmb.2004.09.065; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Nagai Y, 2003, HUM MOL GENET, V12, P1253, DOI 10.1093/hmg/ddg144; Nagai Y, 2000, J BIOL CHEM, V275, P10437, DOI 10.1074/jbc.275.14.10437; Nicastro G, 2005, P NATL ACAD SCI USA, V102, P10493, DOI 10.1073/pnas.0501732102; Nozaki K, 2001, NEUROREPORT, V12, P3357, DOI 10.1097/00001756-200110290-00042; Padiath QS, 2005, AM J MED GENET B, V133B, P124, DOI 10.1002/ajmg.b.30088; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Poirier MA, 2005, HUM MOL GENET, V14, P765, DOI 10.1093/hmg/ddi071; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Ross CA, 2003, P NATL ACAD SCI USA, V100, P1, DOI 10.1073/pnas.0237018100; Scheel H, 2003, HUM MOL GENET, V12, P2845, DOI 10.1093/hmg/ddg297; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Shehi E, 2003, BIOCHEMISTRY-US, V42, P14626, DOI 10.1021/bi0352825; Slow EJ, 2005, P NATL ACAD SCI USA, V102, P11402, DOI 10.1073/pnas.0503634102; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Tanaka M, 2001, J BIOL CHEM, V276, P45470, DOI 10.1074/jbc.M107502200; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Wanker EE, 2000, BIOL CHEM, V381, P937, DOI 10.1515/BC.2000.114; Warrick JM, 2005, MOL CELL, V18, P37, DOI 10.1016/j.molcel.2005.02.030; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905; Zerovnik E, 2002, EUR J BIOCHEM, V269, P3362, DOI 10.1046/j.1432-1033.2002.03024.x; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	59	136	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16888	16896		10.1074/jbc.M601470200	http://dx.doi.org/10.1074/jbc.M601470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16624810	hybrid			2022-12-25	WOS:000238326300009
J	Wildsmith, KR; Albert, CJ; Anbukumar, DS; Ford, DA				Wildsmith, Kristin R.; Albert, Carolyn J.; Anbukumar, Dhanalakshmi S.; Ford, David A.			Metabolism of myeloperoxidase-derived 2-chlorohexadecanal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; DEPENDENT ALDEHYDE REDUCTASE; LOW-DENSITY-LIPOPROTEIN; HYPOCHLOROUS ACID; MYOCARDIAL-INFARCTION; P-HYDROXYPHENYLACETALDEHYDE; HUMAN-NEUTROPHILS; ESCHERICHIA-COLI; DEHYDROGENASE; PURIFICATION	Numerous studies have suggested relationships between myeloperoxidase (MPO), inflammation, and atherosclerosis. MPO-derived reactive chlorinating species attack membrane plasmalogens releasing alpha-chloro fatty aldehydes including 2-chlorohexadecanal (2-ClHDA), which have been found to accumulate in activated neutrophils, activated monocytes, infarcted myocardium and human atheromas. The present study employed synthetically prepared 2-Cl-[H-3]-HDA as well as stable isotope-labeled 2-ClHDA to elucidate the metabolism of 2-ClHDA. The results herein demonstrate that human coronary artery endothelial cells oxidize and reduce 2-ClHDA to its respective chlorinated fatty acid (alpha-ClFA) and chlorinated fatty alcohol (alpha-ClFOH). Within the first hour of incubations of human coronary artery endothelial cells with 2-Cl-[H-3]HDA, the label was incorporated into the alpha-ClFOH and alpha-ClFA pools. After 1 h, the radiolabel was predominantly found in the alpha-ClFOH pool. Cell-derived alpha-ClFOH and alpha-ClFA were also released into the cell culture medium. Additionally, chlorinated fatty acid was incorporated into complex endothelial cell glycerolipids, including monoglycerides, triglycerides, phosphatidylcholine, and phosphatidylethanolamine. The oxidation and reduction of 2-ClHDA to alpha-ClFA and alpha-ClFOH, respectively, was further supported by mass spectrometric analyses of human coronary artery endothelial cells incubated with either 2-ClHDA or stable isotope-labeled 2-ClHDA (2-Cl-[d4]-HDA). 2-ClHDA was also oxidized to 2-ClFA and reduced to alpha-ClFOH in both control and phorbol 12-myristate 13-acetate-stimulated neutrophils. Taken together, these results show that a family of chlorinated lipidic metabolites is produced from alpha-chloro fatty aldehydes derived from reactive chlorinating species targeting of plasmalogens. These metabolites are incorporated into complex lipids and their biological roles may provide new insights into MPO-mediated disease.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, Hlth Sci Ctr, St Louis, MO 63104 USA	Saint Louis University	Ford, DA (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, Hlth Sci Ctr, 1402 S Grand Blvd, St Louis, MO 63104 USA.	fordda@slu.edu	Ford, David/D-1819-2018	Ford, David/0000-0002-0029-1560	NCRR NIH HHS [RR19232] Funding Source: Medline; NHLBI NIH HHS [HL74214] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019232] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074214] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert CJ, 2001, J BIOL CHEM, V276, P23733, DOI 10.1074/jbc.M101447200; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; Askari AT, 2003, J EXP MED, V197, P615, DOI 10.1084/jem.20021426; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Carlin G, 1988, Free Radic Res Commun, V4, P251, DOI 10.3109/10715768809055150; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DeLaurenzi V, 1996, NAT GENET, V12, P52; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Eaton P, 1999, AM J PHYSIOL-HEART C, V276, pH935, DOI 10.1152/ajpheart.1999.276.3.H935; FERRANTE A, 1980, J IMMUNOL METHODS, V36, P109, DOI 10.1016/0022-1759(80)90036-8; FORD DA, 1994, BIOCHEMISTRY-US, V33, P1216, DOI 10.1021/bi00171a022; FORD DA, 1988, J BIOL CHEM, V263, P2644; HAJRA AK, 1970, BIOCHEM BIOPH RES CO, V39, P1037, DOI 10.1016/0006-291X(70)90663-7; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HARTLEY DP, 1995, ARCH BIOCHEM BIOPHYS, V316, P197, DOI 10.1006/abbi.1995.1028; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 2000, BIOCHEM J, V352, P693, DOI 10.1042/0264-6021:3520693; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; Heller JI, 2000, J BIOL CHEM, V275, P9957, DOI 10.1074/jbc.275.14.9957; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; KAWALEK JC, 1976, ARCH BIOCHEM BIOPHYS, V173, P649, DOI 10.1016/0003-9861(76)90302-7; Kelson TL, 1997, BBA-GEN SUBJECTS, V1335, P99, DOI 10.1016/S0304-4165(96)00126-2; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; LAMPERT MB, 1983, BLOOD, V62, P645; LINDAHL R, 1984, J BIOL CHEM, V259, P1991; Marsche G, 2004, ARTERIOSCL THROM VAS, V24, P2302, DOI 10.1161/01.ATV.0000148703.43429.25; McMillen TS, 2005, CIRCULATION, V111, P2798, DOI 10.1161/CIRCULATIONAHA.104.516278; O'Brien PJ, 2005, CRIT REV TOXICOL, V35, P609, DOI 10.1080/10408440591002183; Park BH, 2004, J LIPID RES, V45, P1992, DOI 10.1194/jlr.M400237-JLR200; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; RIZZO WB, 1987, J BIOL CHEM, V262, P17412; ROSEN H, 1990, P NATL ACAD SCI USA, V87, P10048, DOI 10.1073/pnas.87.24.10048; SEPE SM, 1985, J IMMUNOL, V134, P1896; Siems WG, 1997, J LIPID RES, V38, P612; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; TAKAHASHI N, 1986, J BIOCHEM-TOKYO, V99, P513, DOI 10.1093/oxfordjournals.jbchem.a135506; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; Thukkani AK, 2005, AM J PHYSIOL-HEART C, V288, pH2955, DOI 10.1152/ajpheart.00834.2004; Thukkani AK, 2003, CIRCULATION, V108, P3128, DOI 10.1161/01.CIR.0000104564.01539.6A; Thukkani AK, 2002, J BIOL CHEM, V277, P3842, DOI 10.1074/jbc.M109489200; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; Van den Bergen H, 1999, J BRAZIL CHEM SOC, V10, P1; Vasilyev N, 2005, CIRCULATION, V112, P2812, DOI 10.1161/CIRCULATIONAHA.105.542340; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; Wildsmith KR, 2006, CHEM PHYS LIPIDS, V139, P157, DOI 10.1016/j.chemphyslip.2005.12.003; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z	48	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16849	16860		10.1074/jbc.M602505200	http://dx.doi.org/10.1074/jbc.M602505200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16611638	hybrid			2022-12-25	WOS:000238326300005
J	Zhang, YM; Hurlbert, J; White, SW; Rock, CO				Zhang, Yong-Mei; Hurlbert, Jason; White, Stephen W.; Rock, Charles O.			Roles of the active site water, histidine 303, and phenylalanine 396 in the catalytic mechanism of the elongation condensing enzyme of Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; FATTY-ACID SYNTHASE; ANGSTROM CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; TRIACETIC ACID; BIOSYNTHESIS; INHIBITION; LACTONE; THIOLACTOMYCIN; CONDENSATION	beta-Ketoacyl-ACP synthases catalyze the condensation steps in fatty acid and polyketide synthesis and are targets for the development of novel antibiotics and anti-obesity and anti-cancer agents. The roles of the active site residues in Streptococcus pneumoniae FabF (beta-ketoacyl-ACP synthase II; SpFabF) were investigated to clarify the mechanism for this enzyme superfamily. The nucleophilic cysteine of the active site triad was required for acyl-enzyme formation and the overall condensation activity. The two active site histidines in the elongation condensing enzyme have different electronic states and functions. His(337) is essential for condensation activity, and its protonated N epsilon stabilizes the negative charge developed on the malonyl thioester carbonyl in the transition state. The N epsilon of His(303) accelerated catalysis by deprotonating a structured active site water for nucleophilic attack on the C3 of malonate, releasing bicarbonate. Lys(332) controls the electronic state of His(303) and also plays a critical role in the positioning of His(337). Phe(396) functions as a gatekeeper that controls the order of substrate addition. These data assign specific roles for each active site residue and lead to a revised general mechanism for this important class of enzymes.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale, Memphis, TN 38105 USA.	charles.rock@stjude.org	White, Stephen W/N-8164-2018		NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; Beaudet L, 2001, GENOME RES, V11, P600, DOI 10.1101/gr.172501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCK DJH, 1966, BIOCHEM BIOPH RES CO, V23, P775, DOI 10.1016/0006-291X(66)90469-4; Brown AK, 2005, J BIOL CHEM, V280, P32539, DOI 10.1074/jbc.M413216200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; Cha SH, 2004, BIOCHEM BIOPH RES CO, V317, P301, DOI 10.1016/j.bbrc.2004.03.026; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; Evans W, 1997, CHEM BRIT, V33, P22; Gao S, 2003, P NATL ACAD SCI USA, V100, P5628, DOI 10.1073/pnas.1031698100; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; GREENSPAN MD, 1969, J BIOL CHEM, V244, P6477; Heath Richard J, 2004, Curr Opin Investig Drugs, V5, P146; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khosla C, 2005, SCIENCE, V308, P367, DOI 10.1126/science.1111415; Kursula P, 2005, J MOL BIOL, V347, P189, DOI 10.1016/j.jmb.2005.01.018; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Mathieu M, 1997, J MOL BIOL, V273, P714, DOI 10.1006/jmbi.1997.1331; McGuire KA, 2001, BIOCHEMISTRY-US, V40, P9836, DOI 10.1021/bi0105577; Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; Moche M, 2001, J MOL BIOL, V305, P491, DOI 10.1006/jmbi.2000.4272; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P869; NIXON JE, 1968, J BIOL CHEM, V243, P5471; Olsen JG, 1999, FEBS LETT, V460, P46, DOI 10.1016/S0014-5793(99)01303-4; Olsen JG, 2001, STRUCTURE, V9, P233, DOI 10.1016/S0969-2126(01)00583-4; Price AC, 2003, J BACTERIOL, V185, P4136, DOI 10.1128/JB.185.14.4136-4143.2003; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; Qiu XY, 1999, J BIOL CHEM, V274, P36465, DOI 10.1074/jbc.274.51.36465; Qiu XY, 2001, J MOL BIOL, V307, P341, DOI 10.1006/jmbi.2000.4457; Rock C O, 1981, Methods Enzymol, V72, P397; ROCK CO, 1979, J BIOL CHEM, V254, P7123; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Rock CO, 2002, BIOCHEM BIOPH RES CO, V292, P1155, DOI 10.1006/bbrc.2001.2022; Scarsdale JN, 2001, J BIOL CHEM, V276, P20516, DOI 10.1074/jbc.M010762200; Slade RF, 2003, ANTICANCER RES, V23, P1235; Smith S, 2003, PROG LIPID RES, V42, P289, DOI 10.1016/S0163-7827(02)00067-X; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Takahashi KA, 2004, ENDOCRINOLOGY, V145, P184, DOI 10.1210/en.2003-0337; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; VAGELOS PR, 1960, J BIOL CHEM, V235, P2786; von Wettstein-Knowles P, 2006, FEBS J, V273, P695, DOI 10.1111/j.1742-4658.2005.05101.x; Witkowski A, 2002, BIOCHEMISTRY-US, V41, P10877, DOI 10.1021/bi0259047; YALPANI M, 1969, EUR J BIOCHEM, V8, P495, DOI 10.1111/j.1432-1033.1969.tb00554.x; Zha WJ, 2004, J AM CHEM SOC, V126, P4534, DOI 10.1021/ja0317271; ZHANG L, 2005, J BIOL CHEM, P86200	53	53	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17390	17399		10.1074/jbc.M513199200	http://dx.doi.org/10.1074/jbc.M513199200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16618705	hybrid			2022-12-25	WOS:000238326300065
J	Condo, I; Ventura, N; Malisan, F; Tomassini, B; Testi, R				Condo, Ivano; Ventura, Natascia; Malisan, Florence; Tomassini, Barbara; Testi, Roberto			A pool of extramitochondrial frataxin that promotes cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEDREICH ATAXIA; MITOCHONDRIAL-FUNCTION; OXIDATIVE STRESS; MOUSE MODELS; LIFE-SPAN; IRON; EXPRESSION; PROTEINS; BIOSYNTHESIS; DEFICIENCY	Frataxin is a mitochondrial protein involved in iron metabolism. Defective expression of frataxin causes Friedreich ataxia ( FA), an inherited degenerative syndrome characterized by ataxia, cardiomyopathy, and high incidence of diabetes. Here we report that frataxin-deficient cells are more prone to undergo stress-induced mitochondrial damage and apoptosis, while the overexpression of frataxin confers protection to a variety of cell types. Moreover, we reveal the existence of an extramitochondrial pool of frataxin, which can efficiently prevent mitochondrial damage and apoptosis in different cellular systems. Remarkably, extramitochondrial frataxin can fully replace mitochondrial frataxin in promoting survival of FA cells.	Univ Roma Tor Vergata, Dept Expt Med, Lab Signal Transduct, I-00133 Rome, Italy; Fdn Santa Lucia, I-00179 Rome, Italy	University of Rome Tor Vergata; IRCCS Santa Lucia	Testi, R (corresponding author), Univ Roma Tor Vergata, Dept Expt Med, Lab Signal Transduct, Via Montpellier 1, I-00133 Rome, Italy.	roberto.testi@uniroma2.it	Condò, Ivano/B-4783-2010; Ventura, Natascia/ABF-4279-2020	Condò, Ivano/0000-0001-5421-4846; ventura, natascia/0000-0001-8718-4321; MALISAN, FLORENCE/0000-0002-0213-9407				Acquaviva F, 2005, J CELL SCI, V118, P3917, DOI 10.1242/jcs.02516; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; Cavadini P, 2000, J BIOL CHEM, V275, P41469, DOI 10.1074/jbc.M006539200; Chantrel-Groussard K, 2001, HUM MOL GENET, V10, P2061, DOI 10.1093/hmg/10.19.2061; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; DE MR, 1997, SCIENCE, V277, P1652; Emond M, 2000, NEUROLOGY, V55, P1752, DOI 10.1212/WNL.55.11.1752; Frazzon J, 2002, BIOCHEM SOC T, V30, P680, DOI 10.1042/BST0300680; Gonzalez-Cabo P, 2005, HUM MOL GENET, V14, P2091, DOI 10.1093/hmg/ddi214; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492; Malisan F, 2002, BBA-MOL CELL BIOL L, V1585, P179, DOI 10.1016/S1388-1981(02)00339-6; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; O'Neill HA, 2005, J MOL BIOL, V345, P433, DOI 10.1016/j.jmb.2004.10.074; Patel PI, 2001, AM J HUM GENET, V69, P15, DOI 10.1086/321283; Pianese L, 2002, NEUROSCI LETT, V320, P137, DOI 10.1016/S0304-3940(02)00048-4; Puccio H, 2002, CURR OPIN GENET DEV, V12, P272, DOI 10.1016/S0959-437X(02)00298-8; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Reynolds CP, 2004, CANCER LETT, V206, P169, DOI 10.1016/j.canlet.2003.08.034; Ristow M, 2000, P NATL ACAD SCI USA, V97, P12239, DOI 10.1073/pnas.220403797; Ristow M, 2003, J CLIN INVEST, V112, P527, DOI 10.1172/JCI200318107; Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620; Schulz JB, 2000, NEUROLOGY, V55, P1719, DOI 10.1212/WNL.55.11.1719; Schulz TJ, 2006, J BIOL CHEM, V281, P977, DOI 10.1074/jbc.M511064200; Seznec H, 2005, HUM MOL GENET, V14, P463, DOI 10.1093/hmg/ddi042; Shoichet SA, 2002, HUM MOL GENET, V11, P815, DOI 10.1093/hmg/11.7.815; Simon D, 2004, J NEUROSCI, V24, P1987, DOI 10.1523/JNEUROSCI.4549-03.2004; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; Stehling O, 2004, HUM MOL GENET, V13, P3007, DOI 10.1093/hmg/ddh324; Tan G, 2001, HUM MOL GENET, V10, P2099, DOI 10.1093/hmg/10.19.2099; Tan GL, 2003, HUM MOL GENET, V12, P1699, DOI 10.1093/hmg/ddg187; Thierbach R, 2005, HUM MOL GENET, V14, P3857, DOI 10.1093/hmg/ddi410; Vazquez-Manrique RP, 2005, FASEB J, V19, P172, DOI 10.1096/fj.05-4212fje; Ventura N, 2005, AGING CELL, V4, P109, DOI 10.1111/j.1474-9726.2005.00149.x; Wong A, 1999, HUM MOL GENET, V8, P425, DOI 10.1093/hmg/8.3.425; Yoon T, 2004, J BIOL CHEM, V279, P25943, DOI 10.1074/jbc.C400107200; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i	39	73	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16750	16756		10.1074/jbc.M511960200	http://dx.doi.org/10.1074/jbc.M511960200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16608849	hybrid			2022-12-25	WOS:000238165700069
J	Li, J; Sejas, DP; Rani, R; Koretsky, T; Bagby, GC; Pang, QS				Li, June; Sejas, Daniel P.; Rani, Reena; Koretsky, Tara; Bagby, Grover C.; Pang, Qishen			Nucleophosmin regulates cell cycle progression and stress response in hematopoietic stem/progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELLS; CYTOPLASMIC NUCLEOPHOSMIN; NUCLEAR-PROTEIN; GENE-EXPRESSION; UP-REGULATION; IN-VITRO; IDENTIFICATION; LEUKEMIA; NUMATRIN; PHOSPHORYLATION	Nucleophosmin (NPM) is a multifunctional protein frequently overexpressed in actively proliferating cells. Strong evidence indicates that NPM is required for embryonic development and genomic stability. Here we report that NPM enhances the proliferative potential of hematopoietic stem cells (HSCs) and increases their survival upon stress challenge. Both short term liquid culture and clonogenic progenitor cell assays show a selective expansion of NPM-overexpressing HSCs. Interestingly, HSCs infected with NPM retrovirus show significantly reduced commitment to myeloid differentiation compared with vector-transduced cells, and majority of the NPM-overexpressing cells remains primitive during a 5-day culture. Bone marrow transplantation experiments demonstrate that NPM promotes the self-renewal of long term repopulating HSCs while attenuated their commitment to myeloid differentiation. NPM overexpression induces rapid entry of HSCs into the cell cycle and suppresses the expression of several negative cell cycle regulators that are associated with G(1)-to-S transition. NPM knockdown elevates expression of these negative regulators and exacerbates stress-induced cell cycle arrest. Finally, overexpression of NPM promotes the survival and recovery of HSCs and progenitors after exposure to DNA damage, oxidative stress, and hematopoietic injury both in vivo and in vitro. DNA repair kinetics study suggests that NPM has a role in reducing the susceptibility of chromosomal DNA to damage rather than promoting DNA damage repair. Together, these results indicate that NPM plays an important role in hematopoiesis via mechanisms involving modulation of HSC/progenitor cell cycle progression and stress response.	Cincinnati Childrens Hosp, Ctr Med, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA; Oregon Hlth & Sci Univ, Inst Canc, Sch Med, Portland, OR 97201 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Oregon Health & Science University	Pang, QS (corresponding author), Cincinnati Childrens Hosp, Ctr Med, Div Expt Hematol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	qishen.pang@cchmc.org			NCI NIH HHS [R01 CA 109641] Funding Source: Medline; NHLBI NIH HHS [R01 HL 076712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109641] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alcalay M, 2005, BLOOD, V106, P899, DOI 10.1182/blood-2005-02-0560; Bagby GC, 2003, CURR OPIN HEMATOL, V10, P68, DOI 10.1097/00062752-200301000-00011; Bertoncello I, 2000, METH MOL B, V158, P181; Boissel N, 2005, BLOOD, V106, P3618, DOI 10.1182/blood-2005-05-2174; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chen M, 1996, NAT GENET, V12, P448, DOI 10.1038/ng0496-448; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FEUERSTEIN N, 1991, EXP CELL RES, V194, P289, DOI 10.1016/0014-4827(91)90367-4; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Helma C, 2000, MUTAT RES-GEN TOX EN, V466, P9, DOI 10.1016/S1383-5718(99)00232-6; Kimura S, 1998, P NATL ACAD SCI USA, V95, P1195, DOI 10.1073/pnas.95.3.1195; Li J, 2005, LEUKEMIA RES, V29, P1415, DOI 10.1016/j.leukres.2005.05.005; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Nozawa Y, 1996, J PATHOL, V178, P48; Okuwaki M, 2001, J MOL BIOL, V311, P41, DOI 10.1006/jmbi.2001.4812; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587; Pang QS, 2003, J BIOL CHEM, V278, P41709, DOI 10.1074/jbc.M301392200; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Park SJ, 2004, J BIOL CHEM, V279, P30053, DOI 10.1074/jbc.M403527200; PATTERSON SD, 1995, J BIOL CHEM, V270, P9429, DOI 10.1074/jbc.270.16.9429; Redner RL, 2002, LEUKEMIA, V16, P1927, DOI 10.1038/sj.leu.2402720; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; Saadatzadeh MR, 2004, J BIOL CHEM, V279, P16805, DOI 10.1074/jbc.M313721200; Subong ENP, 1999, PROSTATE, V39, P298; TANAKA M, 1992, CANCER RES, V52, P3372; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93; Wu MH, 2002, J BIOL CHEM, V277, P48234, DOI 10.1074/jbc.M206550200; YonedaKato N, 1996, ONCOGENE, V12, P265; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200; Zhang XL, 2005, BLOOD, V106, P75, DOI 10.1182/blood-2004-08-3033	50	39	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16536	16545		10.1074/jbc.M601386200	http://dx.doi.org/10.1074/jbc.M601386200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16608843	hybrid			2022-12-25	WOS:000238165700044
J	Qiu, ZH; Norflus, F; Singh, B; Swindell, MK; Buzescu, R; Bejarano, M; Chopra, R; Zucker, B; Benn, CL; DiRocco, DP; Cha, JHJ; Ferrante, RJ; Hersch, SM				Qiu, Zhihua; Norflus, Fran; Singh, Bhupinder; Swindell, Mary K.; Buzescu, Rodica; Bejarano, Michelle; Chopra, Raman; Zucker, Birgit; Benn, Caroline L.; DiRocco, Derek P.; Cha, Jang-Ho J.; Ferrante, Robert J.; Hersch, Steven M.			Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; ENDOTHELIAL-CELLS; GENE-EXPRESSION; SYNERGISTIC ACTIVATION; CORTICAL-NEURONS; RECEPTOR GENE; MOUSE MODEL; MICE; INHIBITORS; PROMOTER	Interactions between mutant huntingtin (Htt) and a variety of transcription factors including specificity proteins (Sp) have been suggested as a central mechanism in Huntington disease (HD). However, the transcriptional activity induced by Htt in neurons that triggers neuronal death has yet to be fully elucidated. In the current study, we characterized the relationship of Sp1 to Htt protein aggregation and neuronal cell death. We found increased levels of Sp1 in neuronal-like PC12 cells expressing mutant Htt, primary striatal neurons, and brain tissue of HD transgenic mice. Sp1 levels were also elevated when 3-nitropropionate (3-NP) was used to induce cell death in PC12 cells. To assess the effects of knocking down Sp1 in HD pathology, we used Sp1 siRNA, a heterozygous Sp1 knock-out mouse, and mithramycin A, a DNA-intercalating agent that inhibits Sp1 function. The three approaches consistently yielded reduced levels of Sp1 which ameliorated toxicity caused by either mutant Htt or 3-NP. In addition, when HD mice were crossed with Sp1 heterozygous knock-out mice, the resulting offspring did not experience the loss of dopamine D2 receptor mRNA characteristic of HD mice, and survived longer than their HD counterparts. Our data suggest that enhancement of transcription factor Sp1 contributes to the pathology of HD and demonstrates that its suppression is beneficial.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Massachussets Gen Inst Neurodegenerat Dis,Dept Ne, Charlestown, MA 02129 USA; Bedford Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bedford, MA 01730 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA	Harvard University; Massachusetts General Hospital; Geriatric Research Education & Clinical Center; Boston University; Boston University; Boston University; Boston University	Hersch, SM (corresponding author), Mass Gen Inst Neurodegenerat Dis MGH E, Bldg 114,Suite 2001,114 16th St, Charlestown, MA 02129 USA.	hersch@helix.mgh.harvard.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000613] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [U01AT000613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS045242, R01NS035255, R01NS038106, U01NS045806] Funding Source: NIH RePORTER; NCCIH NIH HHS [AT 00613] Funding Source: Medline; NINDS NIH HHS [NS 35255, NS 045242, NS 038106, NS 045806] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Apostol BL, 2003, P NATL ACAD SCI USA, V100, P5950, DOI 10.1073/pnas.2628045100; Augood SJ, 1997, ANN NEUROL, V42, P215, DOI 10.1002/ana.410420213; BEAL MF, 1993, J NEUROSCI, V13, P4181; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DIETZ K, 1996, SURVIVAL ANALI SELF, P83; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Ferrante RJ, 2004, J NEUROSCI, V24, P10335, DOI 10.1523/JNEUROSCI.2599-04.2004; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300; Fridmacher V, 2003, J NEUROSCI, V23, P9403; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; GUNDERSEN HJG, 1988, J MICROSC-OXFORD, V151, P3, DOI 10.1111/j.1365-2818.1988.tb04609.x; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hersch SM, 2003, CURR OPIN NEUROL, V16, P501, DOI 10.1097/01.wco.0000084229.82329.03; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P7558, DOI 10.1073/pnas.121635798; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Liu YW, 1997, BIOCHEM J, V324, P133, DOI 10.1042/bj3240133; Liu YW, 2003, J IMMUNOL, V171, P821, DOI 10.4049/jimmunol.171.2.821; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu XP, 1997, NAT MED, V3, P686, DOI 10.1038/nm0697-686; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Meissner M, 2004, CIRC RES, V94, P324, DOI 10.1161/01.RES.0000113781.08139.81; MINOWA T, 1994, J BIOL CHEM, V269, P11656; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Nurcombe V, 2001, METH MOL B, V169, P251; Okamoto S, 2002, MOL BRAIN RES, V107, P89, DOI 10.1016/S0169-328X(02)00440-0; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Qiu ZH, 2004, J BIOL CHEM, V279, P34948, DOI 10.1074/jbc.M401055200; Qiu ZH, 1998, J NEUROSCI, V18, P10445; Qiu ZH, 2003, J NEUROIMMUNOL, V139, P51, DOI 10.1016/S0165-5728(03)00158-9; Ryu H, 2003, J NEUROSCI, V23, P3597; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Tanaka T, 2000, J MOL CELL CARDIOL, V32, P1955, DOI 10.1006/jmcc.2000.1228; Tanaka T, 2000, ARTERIOSCL THROM VAS, V20, P392, DOI 10.1161/01.ATV.20.2.392; Xiao S, 2001, EUR J IMMUNOL, V31, P3339, DOI 10.1002/1521-4141(200111)31:11<3339::AID-IMMU3339>3.0.CO;2-U; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200	46	89	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16672	16680		10.1074/jbc.M511648200	http://dx.doi.org/10.1074/jbc.M511648200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16595660	hybrid			2022-12-25	WOS:000238165700061
J	Feliciangeli, SF; Thomas, L; Scott, GK; Subbian, E; Hung, CH; Molloy, SS; Jean, F; Shinde, U; Thomas, G				Feliciangeli, Sylvain F.; Thomas, Laurel; Scott, Gregory K.; Subbian, Ezhilkani; Hung, Chien-Hui; Molloy, Sean S.; Jean, Francois; Shinde, Ujwal; Thomas, Gary			Identification of a pH sensor in the furin propeptide that regulates enzyme activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERTASE-1 PRO-DOMAIN; INTRACELLULAR TRAFFICKING; CRYSTAL-STRUCTURE; INTRAMOLECULAR CHAPERONE; PROPROTEIN CONVERTASES; PROTEIN; LOCALIZATION; ENDOPROTEASE; SPECIFICITY; SUBTILISIN	The folding and activation of furin occur through two pH- and compartment-specific autoproteolytic steps. In the endoplasmic reticulum ( ER), profurin folds under the guidance of its prodomain and undergoes an autoproteolytic excision at the consensus furin site Arg-Thr-Lys-Arg(107) down arrow generating an enzymatically masked furin-propeptide complex competent for transport to late secretory compartments. In the mildly acidic environment of the trans-Golgi network/endosomal system, the bound propeptide is cleaved at the internal site (69)HRGVTKR(75) down arrow, unmasking active furin capable of cleaving substrates in trans. Here, by using cellular, biochemical, and modeling studies, we demonstrate that the conserved His(69) is a pH sensor that regulates the compartment-specific cleavages of the propeptide. In the ER, unprotonated His(69) stabilizes a solvent-accessible hydrophobic pocket necessary for autoproteolytic excision at Arg(107). Profurin molecules unable to form the hydrophobic pocket, and hence, the furin-propeptide complex, are restricted to the ER by a PACS-2- and COPI-dependent mechanism. Once exposed to the acidic pH of the late secretory pathway, protonated His69 disrupts the hydrophobic pocket, resulting in exposure and cleavage of the internal cleavage site at Arg(75) to unmask the enzyme. Together, our data explain the pH- regulated activation of furin and how this His-dependent regulatory mechanism is a model for other proteins.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	Oregon Health & Science University; Oregon Health & Science University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of British Columbia	Thomas, G (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	thomasg@ohsu.edu	Feliciangeli, Sylvain/Q-1292-2016	Feliciangeli, Sylvain/0000-0003-3358-3719	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037274] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI049793, AI49793] Funding Source: Medline; NIDDK NIH HHS [R01 DK037274, DK37274] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Baukrowitz T, 1999, EMBO J, V18, P847, DOI 10.1093/emboj/18.4.847; Bergeron E, 2003, BIOCHEM J, V373, P475, DOI 10.1042/BJ20021630; Bhattacharjya S, 2001, PROTEIN SCI, V10, P934, DOI 10.1110/ps.41301; Bissonnette L, 2004, BIOCHEM J, V379, P757, DOI 10.1042/BJ20031902; Comellas-Bigler M, 2004, STRUCTURE, V12, P1313, DOI 10.1016/j.str.2004.04.013; Crump CM, 2001, EMBO J, V20, P2191, DOI 10.1093/emboj/20.9.2191; Degnin C, 2004, MOL BIOL CELL, V15, P5012, DOI 10.1091/mbc.E04-08-0673; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Inouye M, 2001, NAT STRUCT BIOL, V8, P321, DOI 10.1038/86194; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jensen FB, 2004, ACTA PHYSIOL SCAND, V182, P215, DOI 10.1111/j.1365-201X.2004.01361.x; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; Kottgen M, 2005, EMBO J, V24, P705, DOI 10.1038/sj.emboj.7600566; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; RHODES CJ, 1993, J BIOL CHEM, V268, P4267; Rockwell NC, 2004, TRENDS BIOCHEM SCI, V29, P80, DOI 10.1016/j.tibs.2003.12.006; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; Rotzschke O, 2002, P NATL ACAD SCI USA, V99, P16946, DOI 10.1073/pnas.212643999; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Simmen T, 2005, EMBO J, V24, P717, DOI 10.1038/sj.emboj.7600559; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Subbian E, 2005, J MOL BIOL, V347, P367, DOI 10.1016/j.jmb.2005.01.028; Subbian E, 2004, BIOCHEMISTRY-US, V43, P14348, DOI 10.1021/bi048397x; Tangrea MA, 2002, J MOL BIOL, V320, P801, DOI 10.1016/S0022-2836(02)00543-0; Tangrea MA, 2001, BIOCHEMISTRY-US, V40, P5488, DOI 10.1021/bi0026472; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Wolins N, 1997, J CELL BIOL, V139, P1735, DOI 10.1083/jcb.139.7.1735; YI Z, 1993, J BIOL CHEM, V268, P5615; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	40	52	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16108	16116		10.1074/jbc.M600760200	http://dx.doi.org/10.1074/jbc.M600760200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16601116	Green Accepted, hybrid			2022-12-25	WOS:000237996000064
J	Gong, L; Yeh, ETH				Gong, Limin; Yeh, Edward T. H.			Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEINS; NUCLEAR-PORE COMPLEX; DEPENDENT TRANSCRIPTION; DIFFERENTIAL REGULATION; SENTRIN FAMILY; E3 LIGASE; DEN1; PML; IDENTIFICATION; SUMOYLATION	SUMOylation is a reversible process regulated by a family of sentrin/ SUMO-specific proteases (SENPs). Of the six SENP family members, except for SENP1 and SENP2, the substrate specificities of the rest of SENPs are not well defined. Here, we have described SENP5, which has restricted substrate specificity. SENP5 showed SUMO-3 C-terminal hydrolase activity but could not process pro-SUMO- 1 in vitro. Furthermore, SENP5 showed more limited isopeptidase activity in vitro. In vivo, SENP5 showed isopeptidase activity against SUMO-2 and SUMO-3 conjugates but not against SUMO-1 conjugates. Native SENP5 localized mainly to the nucleolus but was also found in the nucleus. The N terminus of SENP5 contains a stretch of amino acids responsible for the nucleolar localization of SENP5. N-terminal-truncated SENP5 co-localized with PML, a known SUMO substrate. Using PML SUMOylation mutants as model substrates, we showed that SENP5 can remove poly-SUMO- 2 or poly-SUMO-3 from the Lys(160) or Lys(490) positions of PML. However, SENP5 could not remove SUMO-1 from the Lys(160) or Lys(490) positions of PML. Nonetheless, SENP5 could remove SUMO-1, -2, and -3 from the Lys(65) position of PML. Thus, SENP5 also possesses limited SUMO-1 isopeptidase activity. We were also able to show that SENP3 has substrate specificity similar to that of SENP5. Thus, SENP3 and SENP5 constitute a subfamily of SENPs that regulate the formation of SUMO-2 or SUMO-3 conjugates and, to a less extent, SUMO-1 modification.	Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, Unit 449, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Brown Fdn Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Yeh, ETH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, Unit 449, 1515 Holcombe Blvd, Houston, TX 77030 USA.	etyeh@mdanderson.org						Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; Cheng JK, 2005, J BIOL CHEM, V280, P14492, DOI 10.1074/jbc.M412185200; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; Gan-Erdene T, 2003, J BIOL CHEM, V278, P28892, DOI 10.1074/jbc.M302890200; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Owerbach D, 2005, BIOCHEM BIOPH RES CO, V337, P517, DOI 10.1016/j.bbrc.2005.09.090; Pichler A, 2004, NAT STRUCT MOL BIOL, V11, P984, DOI 10.1038/nsmb834; Rajan S, 2005, CELL, V121, P37, DOI 10.1016/j.cell.2005.01.019; Reverter D, 2005, J MOL BIOL, V345, P141, DOI 10.1016/j.jmb.2004.10.022; Reverter D, 2004, STRUCTURE, V12, P1519, DOI 10.1016/j.str.2004.05.023; Rosas-Acosta G, 2005, MOL CELL PROTEOMICS, V4, P56, DOI 10.1074/mcp.M400149-MCP200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Vassileva MT, 2004, MOL CELL BIOL, V24, P3623, DOI 10.1128/MCB.24.9.3623-3632.2004; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Wu K, 2003, J BIOL CHEM, V278, P28882, DOI 10.1074/jbc.M302888200; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	39	190	206	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15869	15877		10.1074/jbc.M511658200	http://dx.doi.org/10.1074/jbc.M511658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16608850	hybrid			2022-12-25	WOS:000237996000036
J	Xu, C; Zhang, JH; Huang, XJ; Sun, JP; Xu, YQ; Tang, YJ; Wu, JH; Shi, YY; Huang, QH; Zhang, QH				Xu, Chao; Zhang, Jiahai; Huang, Xiaojuan; Sun, Jianping; Xu, Yingqi; Tang, Yajun; Wu, Jihui; Shi, Yunyu; Huang, Qiuhua; Zhang, Qinghua			Solution structure of human peptidyl prolyl isomerase-like protein 1 and insights into its interaction with SKIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYCLOPHILIN-A; CRYSTAL-STRUCTURE; CYCLOSPORINE-A; MEDIATED TRANSCRIPTION; NMR; COMPLEX; IDENTIFICATION; COACTIVATOR; COREGULATOR; ACTIVATION	The human PPIL1 ( peptidyl prolyl isomerase-like protein 1) is a specific component of human 35 SU5 small nuclear ribonucleoprotein particle and 45 S activated spliceosome. It is recruited by SKIP, another essential component of 45 S activated spliceosome, into spliceosome just before the catalytic step 1. It stably associates with SKIP, which also exists in 35 S and activated spliceosome as a nuclear matrix protein. We report here the solution structure of PPIL1 determined by NMR spectroscopy. The structure of PPIL1 resembles other members of the cyclophilin family and exhibits PPIase activity. To investigate its interaction with SKIP in vitro, we identified the SKIP contact region by GST pulldown experiments and surface plasmon resonance. We provide direct evidence of PPIL1 stably associated with SKIP. The dissociation constant is 1.25 X 10(-7) M for the N-terminal peptide of SKIP-(59-129) with PPIL1. We also used chemical shift perturbation experiments to show the possible SKIP binding interface on PPIL1. These results illustrated that a novel cyclophilin-protein contact mode exists in the PPIL1-SKIP complex during activation of the spliceosome. The biological implication of this binding with spliceosome rearrangement during activation is discussed.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China; Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, Shanghai 20025, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Shanghai Jiao Tong University	Wu, JH (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China.	wujihui@ustc.edu.cn; yyshi@ustc.edu.cn	Xu, Chao/G-3885-2010; Shi, Yunyu/B-3240-2009	Xu, Chao/0000-0003-0444-7080; Shi, Yunyu/0000-0002-1348-4759				Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burge CB, 1999, RNA WORLD, P525; Dahl R, 1998, ONCOGENE, V16, P1579, DOI 10.1038/sj.onc.1201687; DELAUNAY J, 1995, BLOOD CEL B, V6, P1; DIEHL BE, 1991, GENETICS, V127, P287; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; Folk P, 2004, CELL MOL LIFE SCI, V61, P629, DOI 10.1007/s00018-003-3215-4; Galat A, 2004, PROTEINS, V56, P808, DOI 10.1002/prot.20156; Galat A, 1999, ARCH BIOCHEM BIOPHYS, V371, P149, DOI 10.1006/abbi.1999.1434; Goddard T.D., SPARKY 3; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; KE HM, 1993, P NATL ACAD SCI USA, V90, P11850, DOI 10.1073/pnas.90.24.11850; KE HM, 1992, J MOL BIOL, V228, P539, DOI 10.1016/0022-2836(92)90841-7; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Leong GM, 2001, J BIOL CHEM, V276, P18243, DOI 10.1074/jbc.M010815200; Makarov EM, 2002, SCIENCE, V298, P2205, DOI 10.1126/science.1077783; Makarova OV, 2004, EMBO J, V23, P2381, DOI 10.1038/sj.emboj.7600241; MIKOL V, 1994, P NATL ACAD SCI USA, V91, P5183, DOI 10.1073/pnas.91.11.5183; Nagai K, 2004, BIOCHEM BIOPH RES CO, V316, P512, DOI 10.1016/j.bbrc.2004.02.077; Obama K, 2006, CLIN CANCER RES, V12, P70, DOI 10.1158/1078-0432.CCR-05-0588; Ottiger M, 1997, J MOL BIOL, V272, P64, DOI 10.1006/jmbi.1997.1220; Ozaki K, 1996, CYTOGENET CELL GENET, V72, P242, DOI 10.1159/000134199; Piotukh K, 2005, J BIOL CHEM, V280, P23668, DOI 10.1074/jbc.M503405200; Reidt U, 2000, J BIOL CHEM, V275, P7439, DOI 10.1074/jbc.275.11.7439; Reidt U, 2003, J MOL BIOL, V331, P45, DOI 10.1016/S0022-2836(03)00684-3; Skruzny M, 2001, BBA-GENE STRUCT EXPR, V1521, P146, DOI 10.1016/S0167-4781(01)00301-3; SPITZFADEN C, 1994, J BIOMOL NMR, V4, P463, DOI 10.1007/BF00156614; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Xu C, 2005, J BIOMOL NMR, V31, P179, DOI 10.1007/s10858-004-8238-0; Zhang C, 2003, J BIOL CHEM, V278, P35325, DOI 10.1074/jbc.M305191200; Zhou SF, 2000, J VIROL, V74, P1939, DOI 10.1128/JVI.74.4.1939-1947.2000	36	32	37	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15900	15908		10.1074/jbc.M511155200	http://dx.doi.org/10.1074/jbc.M511155200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595688	hybrid			2022-12-25	WOS:000237996000040
J	Locke, D; Koreen, IV; Harris, AL				Locke, Darren; Koreen, Irina V.; Harris, Andrew L.			Isoelectric points and post-translational modifications of connexin26 and connexin32	FASEB JOURNAL			English	Article						gap junction; hemichannel; IEF; mass spectrometry; Rotofor	GAP-JUNCTION CHANNELS; PROTEIN-KINASE-C; LIPID RAFTS; PHOSPHORYLATION; PURIFICATION; CELL; LIVER; SOLUBILIZATION; IDENTIFICATION; CHROMATOGRAPHY	The isoelectric points of the gap junction proteins connexin26 (Cx26) and connexin32 (Cx32) were determined by isoelectric focusing in free fluids. The isoelectric points were significantly more acidic than predicted from amino acid sequences and different from each other, allowing homomeric channels to be resolved separately. The isoelectric points of the homomeric channels bracketed the isoelectric points of heteromeric Cx26/Cx32 channels. For heteromeric channels, Cx26 and Cx32 were found in overlapping, pH-focused fractions, indicating quaternary structure was retained. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was used to identify post-translational modifications of Cx26 and Cx32 cytoplasmic domains, including the first reported post-translational modifications of Cx26. Suspected modifications were hydroxylation and/or phosphorylation near the amino terminus of both connexins, gamma-carboxyglutamate residues in the cytoplasmic loop of both connexins, phosphorylation in the carboxyl-terminal domain of Cx32, and palmitoylation at the carboxyl-terminus of Cx32. These modifications contribute to the measured acidic isoelectric points of Cx26 and Cx32, whereas their low molecular masses would not appreciably change connexin SDS-PAGE mobility. Most of these modifications have not previously been identified for connexins and may be instrumental in guiding and understanding novel aspects of channel trafficking and molecular mechanisms of channel regulation.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Locke, D (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave, Newark, NJ 07103 USA.	lockeda@umdnj.edu		Harris, Andrew/0000-0002-3782-0550	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061406, R01GM036044] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61406, GM36044] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad S, 2001, EUR J BIOCHEM, V268, P4544, DOI 10.1046/j.1432-1327.2001.02380.x; Amini A, 2000, J CHROMATOGR A, V894, P345, DOI 10.1016/S0021-9673(00)00798-6; Ayad WA, 2006, J BIOL CHEM, V281, P16727, DOI 10.1074/jbc.M600136200; Ayala A, 1998, APPL BIOCHEM BIOTECH, V69, P11, DOI 10.1007/BF02786017; Bandyopadhyay PK, 2002, P NATL ACAD SCI USA, V99, P1264, DOI 10.1073/pnas.022637099; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Bier M, 1998, ELECTROPHORESIS, V19, P1057, DOI 10.1002/elps.1150190703; BUEHLER LK, 1995, BIOPHYS J, V68, P1767, DOI 10.1016/S0006-3495(95)80353-X; Cottrell GT, 2005, BBA-BIOMEMBRANES, V1711, P126, DOI 10.1016/j.bbamem.2004.11.013; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; Herbert B, 1999, ELECTROPHORESIS, V20, P660, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<660::AID-ELPS660>3.0.CO;2-Q; Hertzberg EL, 2004, MOL BIOL CELL, V15, p185A; Huang Y, 2005, J NEUROSCI, V25, P7111, DOI 10.1523/JNEUROSCI.1319-05.2005; Issaq HJ, 2002, ELECTROPHORESIS, V23, P3048, DOI 10.1002/1522-2683(200209)23:17<3048::AID-ELPS3048>3.0.CO;2-L; Kashino Y, 2003, J CHROMATOGR B, V797, P191, DOI 10.1016/S1570-0232(03)00428-8; KONIG N, 1995, J CELL SCI, V108, P3091; Koreen IV, 2004, BIOCHEM J, V383, P111, DOI 10.1042/BJ20040806; Korovkina VP, 2002, CLIN EXP PHARMACOL P, V29, P317, DOI 10.1046/j.1440-1681.2002.03651.x; Krutchinsky AN, 2001, ANAL CHEM, V73, P5066, DOI 10.1021/ac010682o; Kumar Y, 2004, PROTEOMICS, V4, P1672, DOI 10.1002/pmic.200300778; Laird DW, 2005, BBA-BIOMEMBRANES, V1711, P172, DOI 10.1016/j.bbamem.2004.09.009; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Linke S, 2004, J BIOL CHEM, V279, P14391, DOI 10.1074/jbc.M313614200; Locke D, 2005, BIOCHEMISTRY-US, V44, P13027, DOI 10.1021/bi050495a; Locke D, 2004, EXP CELL RES, V298, P643, DOI 10.1016/j.yexcr.2004.05.003; MAZET F, 1990, EXP CELL RES, V188, P312, DOI 10.1016/0014-4827(90)90175-A; Moreno AP, 2005, BBA-BIOMEMBRANES, V1711, P164, DOI 10.1016/j.bbamem.2005.02.016; Muller DJ, 2002, EMBO J, V21, P3598, DOI 10.1093/emboj/cdf365; Nelsestuen GL, 2000, VITAM HORM, V58, P355, DOI 10.1016/S0083-6729(00)58031-5; O'Connell KMS, 2004, TRENDS CARDIOVAS MED, V14, P37, DOI 10.1016/j.tcm.2003.10.002; Peracchia C, 2000, J BIOL CHEM, V275, P26220, DOI 10.1074/jbc.M004007200; Presnell SR, 2001, BIOCHEMISTRY-US, V40, P11723, DOI 10.1021/bi010332w; Purnick PEM, 2000, ARCH BIOCHEM BIOPHYS, V381, P181, DOI 10.1006/abbi.2000.1989; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; Righetti PG, 2003, PROTEOMICS, V3, P1397, DOI 10.1002/pmic.200300472; Rucker P, 1997, PROTEIN ENG, V10, P967, DOI 10.1093/protein/10.8.967; SAEZ JC, 1990, EUR J BIOCHEM, V192, P263, DOI 10.1111/j.1432-1033.1990.tb19223.x; SIKERWAR SS, 1983, CELL BIOL INT REP, V7, P897, DOI 10.1016/0309-1651(83)90208-4; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Solan JL, 2005, BBA-BIOMEMBRANES, V1711, P154, DOI 10.1016/j.bbamem.2004.09.013; Sosinsky GE, 2001, METH MOL B, V154, P57; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; Stockert RJ, 1999, HEPATOLOGY, V30, P740, DOI 10.1002/hep.510300304; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; Thaler F, 2003, ANAL BIOANAL CHEM, V376, P366, DOI 10.1007/s00216-003-1919-9; Thimm J, 2005, J BIOL CHEM, V280, P10646, DOI 10.1074/jbc.M412749200; Tillman TS, 2003, CELL BIOCHEM BIOPHYS, V38, P161, DOI 10.1385/CBB:38:2:161; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; Wei CJ, 2004, ANNU REV CELL DEV BI, V20, P811, DOI 10.1146/annurev.cellbio.19.111301.144309; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILLECKE K, 1988, GAP JUNCTIONS, V7, P41; Zhang N, 2004, J PROTEOME RES, V3, P719, DOI 10.1021/pr034116g	57	37	40	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1221	+		10.1096/fj.05-5309fje	http://dx.doi.org/10.1096/fj.05-5309fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16645047				2022-12-25	WOS:000240210300032
J	Zhang, J; Lahti, JM; Bruce, A; He, L; Parihar, K; Fan, C; Grenet, J; Liu, L; Kidd, VJ; Cormier, S; Tang, D				Zhang, J.; Lahti, J. M.; Bruce, A.; He, L.; Parihar, K.; Fan, C.; Grenet, J.; Liu, L.; Kidd, V. J.; Cormier, S.; Tang, D.			Identification of an ataxia telangiectasia-mutated protein mediated surveillance system to regulate Bcl-2 overexpression	ONCOGENE			English	Article						Bcl-2; ATM; p53; oncogene surveillance system	CELL-CYCLE ENTRY; NEGATIVE BREAST-CANCER; DNA-DAMAGE; TUMOR-SUPPRESSOR; PARADOXICAL INHIBITION; PROGNOSTIC MARKERS; TRANSGENIC MICE; CYTOCHROME-C; P53; APOPTOSIS	Bcl-2 can both promote and attenuate tumorigenesis. Although the former function is relatively well characterized, the mechanism of the latter remains elusive. We report here that enforced Bcl-2 expression in MCF7 cells stabilizes p53, induces phosphorylation of p53 serine 15 (p53pSer15) and inhibits MCF7 cell growth. Consistent with p53 Ser15 being a target of ataxia telangiectasia mutated protein(ATM)/ATR (ATM- and rad3-related) in the DNA damage response, Bcl-2 activates ATM by inducing ATM Ser1981 phosphorylation, which is accompanied with the phosphorylaton of two additional ATM substrates, Chk2 Thr68 and H2AX Ser139. Downregulation of ATM using a specific small interference RNA fragment (ATMRNAi) abolished Bcl-2-induced p53pSer15 and Bcl-2-mediated growth inhibition of MCF7 cells. Ectopic expression of a dominant-negative p53 mutant, p53175H, partially rescued this growth inhibition. Taken together, these observations demonstrate the contribution of ATM-p53 function to Bcl-2-mediated inhibition of MCF7 cell growth, indicating an ATM- mediated surveillance system for regulating Bcl-2 overexpression. Consistent with this concept, we found that MCF7 cells express Bcl-2 heterogeneously with 34.5% of cells being Bcl-2 negative. In general, Bcl-2-positive MCF7 cells proliferate slower than those of Bcl-2 negative. Thus, we provide evidence suggesting that activation of ATM suppresses Bcl-2-induced tumorigenesis, and that attenuation of ATM function may be an important event in breast cancer progression.	St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada; McMaster Univ, St Josephs Hosp, Father Sean OSullivan Res Inst, Hamilton, ON, Canada	St Jude Children's Research Hospital; McMaster University; McGill University; McMaster University	Lahti, JM (corresponding author), St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38105 USA.	jill.lahti@stjude.org.or; damut@mcmaster.ca	Tang, Damu/AAQ-1786-2021; Lahti, Jari/P-7987-2018	Tang, Damu/0000-0002-3282-9521; Lahti, Jari/0000-0002-4310-5297	NATIONAL CANCER INSTITUTE [R56CA067938, R01CA067938] Funding Source: NIH RePORTER; NCI NIH HHS [CA67938] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chang J, 2003, CANCER-AM CANCER SOC, V97, P545, DOI 10.1002/cncr.11083; Charpin C, 1998, J CLIN ONCOL, V16, P2025, DOI 10.1200/JCO.1998.16.6.2025; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; Daidone MG, 1999, ENDOCR-RELAT CANCER, V6, P61, DOI 10.1677/erc.0.0060061; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; de la Coste A, 1999, CANCER RES, V59, P5017; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; GEE JMW, 1994, INT J CANCER, V59, P619, DOI 10.1002/ijc.2910590508; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; HELLEMANS P, 1995, BRIT J CANCER, V72, P354, DOI 10.1038/bjc.1995.338; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Jager JJ, 2002, APOPTOSIS, V7, P361, DOI 10.1023/A:1016179530785; JOENSUU H, 1994, AM J PATHOL, V145, P1191; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kirkin V, 2004, BBA-MOL CELL RES, V1644, P229, DOI 10.1016/j.bbamcr.2003.08.009; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Le MG, 1999, INT J CANCER, V84, P562, DOI 10.1002/(SICI)1097-0215(19991222)84:6<562::AID-IJC4>3.0.CO;2-0; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Li YX, 2004, ONCOGENE, V23, P7355, DOI 10.1038/sj.onc.1207957; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LIPPONEN P, 1995, J PATHOL, V177, P49, DOI 10.1002/path.1711770109; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; TSUIMOTO Y, 1984, SCIENCE, V266, P1097; Vairo G, 1996, ONCOGENE, V13, P1511; vanSlooten HJ, 1996, BRIT J CANCER, V74, P78, DOI 10.1038/bjc.1996.319; YANG J, 1997, SCIENCE, V275, P1132; Youn CK, 2005, NAT CELL BIOL, V7, P137, DOI 10.1038/ncb1215; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	48	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5601	5611		10.1038/sj.onc.1209565	http://dx.doi.org/10.1038/sj.onc.1209565			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636671				2022-12-25	WOS:000240599100002
J	Caslini, C; D Capo-Chichi, C; Roland, IH; Nicolas, E; T Yeung, A; Xu, XX				Caslini, C.; D Capo-Chichi, C.; Roland, I. H.; Nicolas, E.; T Yeung, A.; Xu, X-X			Histone modifications silence the GATA transcription factor genes in ovarian cancer	ONCOGENE			English	Article						ovarian epithelial cells; ovarian carcinomas; chromatin; transcription repression; GATA transcription factors; Disabled-2 (DAB2)	TUMOR-SUPPRESSOR GENE; H3 LYSINE 9; METHYLATION PATTERNS; HYPERSENSITIVE SITE; GASTRIC-CANCER; ALLELIC LOSS; ACETYLATION; EXPRESSION; DNA; CARCINOMAS	Altered expression of GATA factors was found and proposed as the underlying mechanism for dedifferentiation in ovarian carcinogenesis. In particular, GATA6 is lost or excluded from the nucleus in 85% of ovarian tumors and GATA4 expression is absent in majority of ovarian cancer cell lines. Here, we evaluated their DNA and histone epigenetic modi. cations in five ovarian epithelial and carcinoma cell lines (human 'immortalized' ovarian surface epithelium (HIO)-117, HIO-114, A2780, SKOV3 and ES2). GATA4 and GATA6 gene silencing was found to correlate with hypoacetylation of histones H3 and H4 and loss of histone H3/lysine K4 trimethylation at their promoters in all lines. Conversely, histone H3/lysine K9 di-methylation and HP1 gamma association were not observed, excluding reorganization of GATA genes into heterochromatic structures. The histone deacetylase inhibitor trichostatin A, but not the DNA methylation inhibitor 5'-aza-2'-deoxycytidine, re-established the expression of GATA4 and/or GATA6 in A2780 and HIO-114 cells, correlating with increased histone H3 and H4 acetylation, histone H3 lysine K4 methylation and DNase I sensitivity at the promoters. Therefore, altered histone modi. cation of the promoter loci is one mechanism responsible for the silencing of GATA transcription factors and the subsequent loss of a target gene, the tumor suppressor Disabled-2, in ovarian carcinogenesis.	Fox Chase Canc Ctr, Ovarian Canc Program, Dept Med Oncol, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Tumor Cell Biol Program, Dept Med Oncol, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Basic Sci & Fannie E Rippel Biochem & Biotechnol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center; Fox Chase Cancer Center; Fox Chase Cancer Center	Xu, XX (corresponding author), Fox Chase Canc Ctr, Ovarian Canc Program, Dept Med Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA.	xiangxi.xu@fccc.edu	Caslini, Corrado/A-1689-2012; Caslini, Corrado/W-6123-2019	Caslini, Corrado/0000-0001-8326-8368; Caslini, Corrado/0000-0001-8326-8368; CAPO-CHICHI, D. Callinice/0000-0003-4941-7301	NATIONAL CANCER INSTITUTE [P30CA006927, R01CA075389, R01CA079716, P50CA083638] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA79716, P50 CA083638, R01 CA75389, P30 CA006927, CA006927, P50 CA83638, R01 CA079716] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BOVA GS, 1993, CANCER RES, V53, P3869; Capo-Chichi CD, 2003, CANCER RES, V63, P4967; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Gong QH, 1996, MOL CELL BIOL, V16, P6055; Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187; Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; JACKSON PD, 1985, P NATL ACAD SCI USA, V82, P2296, DOI 10.1073/pnas.82.8.2296; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lassus H, 2001, LAB INVEST, V81, P517, DOI 10.1038/labinvest.3780260; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morrisey EE, 2000, J BIOL CHEM, V275, P19949, DOI 10.1074/jbc.M001331200; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Nemer G, 1999, MAMM GENOME, V10, P993, DOI 10.1007/s003359901146; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Umlauf David, 2004, Methods Mol Biol, V287, P99; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; WAKANA K, 2005, CANC LETT; Yang DH, 2002, DEV BIOL, V251, P27, DOI 10.1006/dbio.2002.0810; Yang DH, 2002, CANCER-AM CANCER SOC, V94, P2380, DOI 10.1002/cncr.10497; ZHENG JP, 1995, J NATL CANCER I, V87, P1146, DOI 10.1093/jnci/87.15.1146; ZHENG JP, 1993, CANCER RES, V53, P4138	44	81	84	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5446	5461		10.1038/sj.onc.1209533	http://dx.doi.org/10.1038/sj.onc.1209533			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16607277	Green Accepted			2022-12-25	WOS:000240144900009
J	Stevens, TA; Meech, R				Stevens, T. A.; Meech, R.			BARX2 and estrogen receptor-alpha (ESR1) coordinatelyregulate the production of alternatively spliced ESR1 isoforms and control breast cancer cell growth and invasion	ONCOGENE			English	Article						homeobox; estrogen; breast cancer; invasion; splicing	ANCHORAGE INDEPENDENT GROWTH; HOMEODOMAIN PROTEIN BARX2; SERUM RESPONSE FACTOR; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; BRANCHING MORPHOGENESIS; NUCLEAR RECEPTOR; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; GENE-EXPRESSION	The estrogen receptor-alpha gene (ESR1) was previously identified as a direct target of the homeobox transcription factor BARX2 in MCF7 cells. Here, we show that BARX2 and ESR1 proteins bind to different ESR1 gene promoters and regulate the expression of alternatively spliced mRNAs that encode 66 and 46 kDa ESR1 protein isoforms. BARX2 increases the expression of both ESR1 isoforms; however, it has a greater effect on the 46 kDa isoform, leading to an increased ratio between the 46 and 66 kDa proteins. BARX2 also influences estrogen-dependent processes such as anchorage-independent growth and modulates the expression of the estrogen-responsive genes SOX5, RBM15, Dynein and Mortalin. In addition, BARX2 expression promotes cellular invasion and increases the expression of active matrix metalloproteinase-9 (MMP9). BARX2 also increases the expression of the tissue inhibitor of metalloproteinase (TIMP) genes, TIMP1 and TIMP3, in cooperation with estrogen signaling. Overall, these data indicate that BARX2 and ESR1 may coordinately regulate cell growth, survival and invasion pathways that are critical to breast cancer progression.	Scripps Res Inst, Dept Neurobiol, La Jolla, CA 92037 USA	Scripps Research Institute	Meech, R (corresponding author), Scripps Res Inst, Dept Neurobiol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rmeech@scripps.edu		Meech, Robyn/0000-0002-6831-0801				Auboeuf D, 2005, MOL CELL BIOL, V25, P5307, DOI 10.1128/MCB.25.13.5307-5316.2005; Auboeuf D, 2004, MOL CELL BIOL, V24, P442, DOI 10.1128/MCB.24.1.442-453.2004; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Balduyck M, 2000, CLIN EXP METASTAS, V18, P171, DOI 10.1023/A:1006762425323; Care A, 2001, CANCER RES, V61, P6532; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fasco MJ, 2000, MOL CELL ENDOCRINOL, V162, P167, DOI 10.1016/S0303-7207(00)00194-5; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; FIENBERG AA, 1987, CURR TOP DEV BIOL, V23, P23; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Flouriot G, 1998, MOL ENDOCRINOL, V12, P1939, DOI 10.1210/me.12.12.1939; Gill SE, 2003, DEV BIOL, V261, P313, DOI 10.1016/S0012-1606(03)00318-X; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Herring BP, 2001, J BIOL CHEM, V276, P14482, DOI 10.1074/jbc.M011585200; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Jones FS, 1997, P NATL ACAD SCI USA, V94, P2632, DOI 10.1073/pnas.94.6.2632; Krasner A, 2000, GENE, V250, P171, DOI 10.1016/S0378-1119(00)00169-4; Lambertini E, 2003, BIOCHEM J, V372, P831, DOI 10.1042/BJ20021633; Lelongt B, 1997, J CELL BIOL, V136, P1363, DOI 10.1083/jcb.136.6.1363; Li GY, 1999, CANCER RES, V59, P6267; Liu D, 2001, EUR J CANCER, V37, P268, DOI 10.1016/S0959-8049(00)00392-0; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; McDowell N, 1999, SEMIN CELL DEV BIOL, V10, P311, DOI 10.1006/scdb.1999.0307; Meech R, 2003, J BIOL CHEM, V278, P8269, DOI 10.1074/jbc.M207617200; Meech R, 2005, DEVELOPMENT, V132, P2135, DOI 10.1242/dev.01811; Metivier R, 2004, EMBO J, V23, P3653, DOI 10.1038/sj.emboj.7600377; Nguyen M, 1998, J BIOL CHEM, V273, P5400, DOI 10.1074/jbc.273.9.5400; Nothnick WB, 2004, BIOL REPROD, V70, P500, DOI 10.1095/biolreprod.103.020834; O'Doherty A, 2002, BRIT J CANCER, V86, P282, DOI 10.1038/sj.bjc.6600028; PENOT G, 2005, ENDOCRINOLOGY, V8, P8; Rayala SK, 2005, EMBO REP, V6, P538, DOI 10.1038/sj.embor.7400417; Samady L, 2004, CANCER BIOL THER, V3, P317, DOI 10.4161/cbt.3.3.698; Satoh K, 2004, J MAMMARY GLAND BIOL, V9, P195, DOI 10.1023/B:JOMG.0000037162.84758.b5; Schratt G, 2002, J CELL BIOL, V156, P737, DOI 10.1083/jcb.200106008; Sellar GC, 2001, CANCER RES, V61, P6977; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Sivak JM, 2004, MOL CELL BIOL, V24, P245, DOI 10.1128/MCB.24.1.245-257.2004; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; Stevens TA, 2004, J BIOL CHEM, V279, P14520, DOI 10.1074/jbc.M310259200; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yoshiji H, 1996, INT J CANCER, V69, P131, DOI 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C; Zhao YG, 2004, CANCER RES, V64, P590, DOI 10.1158/0008-5472.CAN-03-1932; ZUGMAIER G, 1991, J STEROID BIOCHEM, V39, P681, DOI 10.1016/0960-0760(91)90367-E	52	45	46	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5426	5435		10.1038/sj.onc.1209529	http://dx.doi.org/10.1038/sj.onc.1209529			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16636675				2022-12-25	WOS:000240144900007
J	Cuajungco, MP; Grimm, C; Oshima, K; D'hoedt, D; Nilius, B; Mensenkamp, AR; Bindels, RJM; Plomann, M; Heller, S				Cuajungco, Math P.; Grimm, Christian; Oshima, Kazuo; D'hoedt, Dieter; Nilius, Bernd; Mensenkamp, Arjen R.; Bindels, Rene J. M.; Plomann, Markus; Heller, Stefan			PACSINs bind to the TRPV4 cation channel - PACSIN 3 modulates the subcellular localization of TRPV4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-EVOKED ACTIVATION; SH3 DOMAIN; ENDOTHELIAL-CELLS; ION-CHANNEL; PROTEIN; DYNAMIN; EXPRESSION; FAMILY; ENDOCYTOSIS; TRAFFICKING	TRPV4 is a cation channel that responds to a variety of stimuli including mechanical forces, temperature, and ligand binding. We set out to identify TRPV4-interacting proteins by performing yeast two-hybrid screens, and we isolated with the avian TRPV4 amino terminus the chicken orthologues of mammalian PACSINs 1 and 3. The PACSINs are a protein family consisting of three members that have been implicated in synaptic vesicular membrane trafficking and regulation of dynamin-mediated endocytotic processes. In biochemical interaction assays we found that all three murine PACSIN isoforms can bind to the amino terminus of rodent TRPV4. No member of the PACSIN protein family was able to biochemically interact with TRPV1 and TRPV2. Co-expression of PACSIN 3, but not PACSINs 1 and 2, shifted the ratio of plasma membrane-associated versus cytosolic TRPV4 toward an apparent increase of plasma membrane-associated TRPV4 protein. A similar shift was also observable when we blocked dynamin-mediated endocytotic processes, suggesting that PACSIN 3 specifically affects the endocytosis of TRPV4, thereby modulating the subcellular localization of the ion channel. Mutational analysis shows that the interaction of the two proteins requires both a TRPV4-specific proline-rich domain upstream of the ankyrin repeats of the channel and the carboxyl-terminal Src homology 3 domain of PACSIN 3. Such a functional interaction could be important in cell types that show distribution of both proteins to the same subcellular regions such as renal tubule cells where the proteins are associated with the luminal plasma membrane.	Stanford Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Katholieke Univ Leuven, Dept Physiol, B-3000 Louvain, Belgium; Radboud Univ Nijmegen, Dept Physiol, NL-6500 Nijmegen, Netherlands; Univ Cologne, Cellular Neurobiol Unit, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med, D-50931 Cologne, Germany	Stanford University; Stanford University; KU Leuven; Radboud University Nijmegen; University of Cologne; University of Cologne	Heller, S (corresponding author), Stanford Univ, Sch Med, Dept Otolaryngol & Mol & Cellular Physiol, 801 Welsh Rd, Stanford, CA 94305 USA.	hellers@stanford.edu	Grimm, Christian/ABF-9121-2020; Cuajungco, Math/B-2647-2008; Mensenkamp, Arjen/L-4520-2015; Bindels, René JM/B-9824-2013	Grimm, Christian/0000-0002-0177-5559; Cuajungco, Math/0000-0003-0749-9564; Mensenkamp, Arjen/0000-0003-3805-877X; Bindels, René JM/0000-0003-1167-1339	NIDCD NIH HHS [DC04563] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004563] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Alessandri-Haber N, 2004, J NEUROSCI, V24, P4444, DOI 10.1523/JNEUROSCI.0242-04.2004; Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; Delany NS, 2001, PHYSIOL GENOMICS, V4, P165, DOI 10.1152/physiolgenomics.2001.4.3.165; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gopinath Preethi, 2005, BMC Womens Health, V5, P2, DOI 10.1186/1472-6874-5-2; Guler AD, 2002, J NEUROSCI, V22, P6408; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Heller S, 1998, P NATL ACAD SCI USA, V95, P11400, DOI 10.1073/pnas.95.19.11400; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Jentsch TJ, 2004, NAT CELL BIOL, V6, P1039, DOI 10.1038/ncb1104-1039; Kessels MM, 2004, J CELL SCI, V117, P3077, DOI 10.1242/jcs.01290; Kottgen M, 2005, EMBO J, V24, P705, DOI 10.1038/sj.emboj.7600566; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; MIKI H, 1994, J BIOL CHEM, V269, P5489; Modregger J, 2000, J CELL SCI, V113, P4511; Mott HR, 2005, BIOCHEMISTRY-US, V44, P10977, DOI 10.1021/bi050374a; Nilius B, 2003, PFLUG ARCH EUR J PHY, V446, P298, DOI 10.1007/s00424-003-1028-9; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; PaltaufDoburzynska J, 1997, CELL CALCIUM, V21, P43, DOI 10.1016/S0143-4160(97)90095-6; Plomann M, 1998, EUR J BIOCHEM, V256, P201, DOI 10.1046/j.1432-1327.1998.2560201.x; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Sumoy L, 2001, GENE, V262, P199, DOI 10.1016/S0378-1119(00)00531-X; Sun M, 2000, HUM MOL GENET, V9, P2471, DOI 10.1093/hmg/9.17.2471; Suzuki M, 2003, NEUROSCI LETT, V353, P189, DOI 10.1016/j.neulet.2003.09.041; Suzuki M, 2003, J BIOL CHEM, V278, P51448, DOI 10.1074/jbc.M308212200; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Tian W, 2004, AM J PHYSIOL-RENAL, V287, pF17, DOI 10.1152/ajprenal.00397.2003; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Xu HS, 2003, J BIOL CHEM, V278, P11520, DOI 10.1074/jbc.M211061200; ZHOU Z, 1993, PFLUG ARCH EUR J PHY, V425, P511, DOI 10.1007/BF00374879	44	134	144	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18753	18762		10.1074/jbc.M602452200	http://dx.doi.org/10.1074/jbc.M602452200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16627472	hybrid, Green Published			2022-12-25	WOS:000238687300056
J	Gong, R; Park, CS; Abbassi, NR; Tang, SJ				Gong, Ruomu; Park, Chang Sin; Abbassi, Nima Rezaei; Tang, Shao-Jun			Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CYTOPLASMIC POLYADENYLATION ELEMENT; SYNAPTIC ACTIVATION CAUSES; CAMKII MESSENGER-RNA; BINDING PROTEIN; KINASE-II; BC1 RNA; TRANSLATION; ALPHA; MEMORY	Local protein synthesis in neuronal dendrites is critical for synaptic plasticity. However, the signaling cascades that couple synaptic activation to dendritic protein synthesis remain elusive. The purpose of this study is to determine the role of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling in regulating dendritic protein synthesis in live neurons. We first characterized the involvement of various subtypes of glutamate receptors and the mTOR kinase in regulating dendritic synthesis of a green fluorescent protein (GFP) reporter controlled by alpha CaMKII 5' and 3' untranslated regions in cultured hippocampal neurons. Specific antagonists of N-methyl-D-aspartic acid (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and metabotropic glutamate receptors abolished glutamate-induced dendritic GFP synthesis, whereas agonists of NMDA and metabotropic but not AMPA glutamate receptors activated GFP synthesis in dendrites. Inhibitions of the mTOR signaling, as well as its upstream activators, phosphatidylinositol 3-kinase and AKT, blocked NMDA receptor-dependent dendritic GFP synthesis. Conversely, activation of mTOR signaling stimulated dendritic GFP synthesis. In addition, we also found that inhibition of the mTOR kinase blocked dendritic synthesis of the endogenous alpha CaMKII and MAP2 proteins induced by tetanic stimulations in hippocampal slices. These results identify critical roles of NMDA receptors and the mTOR signaling pathway for control of synaptic activity-induced dendritic protein synthesis in hippocampal neurons.	Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Dept Neurobiol & Behav, Irvine, CA 92697 USA	University of California System; University of California Irvine	Tang, SJ (corresponding author), Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Dept Neurobiol & Behav, 303 Qureshey Res Lab, Irvine, CA 92697 USA.	stang@uci.edu						Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Angenstein F, 1998, P NATL ACAD SCI USA, V95, P15078, DOI 10.1073/pnas.95.25.15078; Atkins CM, 2004, J NEUROSCI, V24, P5193, DOI 10.1523/JNEUROSCI.0854-04.2004; Banko JL, 2004, J NEUROCHEM, V91, P462, DOI 10.1111/j.1471-4159.2004.02734.x; BASSELL GJ, 1994, NEURON, V12, P571, DOI 10.1016/0896-6273(94)90213-5; Bear MF, 2001, SYNAPSES, P455; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bradshaw KD, 2003, EUR J NEUROSCI, V18, P3150, DOI 10.1111/j.1460-9568.2003.03054.x; Cammalleri M, 2003, P NATL ACAD SCI USA, V100, P14368, DOI 10.1073/pnas.2336098100; Cracco JB, 2005, HIPPOCAMPUS, V15, P551, DOI 10.1002/hipo.20078; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Goslin K., 1998, CULTURING NERVE CELL, P339; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hou LF, 2004, J NEUROSCI, V24, P6352, DOI 10.1523/JNEUROSCI.0995-04.2004; Huang F, 2005, J NEUROSCI, V25, P7199, DOI 10.1523/JNEUROSCI.1779-05.2005; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Huber KM, 2000, SCIENCE, V288, P1254, DOI 10.1126/science.288.5469.1254; Job C, 2001, P NATL ACAD SCI USA, V98, P13037, DOI 10.1073/pnas.231485698; Kacharmina JE, 2000, P NATL ACAD SCI USA, V97, P11545, DOI 10.1073/pnas.97.21.11545; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kelleher RJ, 2004, CELL, V116, P467, DOI 10.1016/S0092-8674(04)00115-1; Knowles RB, 1996, J NEUROSCI, V16, P7812; Lenz G, 2005, J BIOL CHEM, V280, P38121, DOI 10.1074/jbc.C500363200; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; Mayford M, 1996, P NATL ACAD SCI USA, V93, P13250, DOI 10.1073/pnas.93.23.13250; McCarthy JB, 2003, NEUROREPORT, V14, P1357, DOI 10.1097/00001756-200307180-00015; Menon KP, 2004, NEURON, V44, P663, DOI 10.1016/j.neuron.2004.10.028; Miller S, 2002, NEURON, V36, P507, DOI 10.1016/S0896-6273(02)00978-9; Mori Y, 2000, NAT NEUROSCI, V3, P1079, DOI 10.1038/80591; Ostroff LE, 2002, NEURON, V35, P535, DOI 10.1016/S0896-6273(02)00785-7; Ouyang Y, 1999, J NEUROSCI, V19, P7823; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Raymond CR, 2000, J NEUROSCI, V20, P969, DOI 10.1523/JNEUROSCI.20-03-00969.2000; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; Scheetz AJ, 2000, NAT NEUROSCI, V3, P211, DOI 10.1038/72915; Schratt GM, 2004, J NEUROSCI, V24, P7366, DOI 10.1523/JNEUROSCI.1739-04.2004; Sherff CM, 1999, SCIENCE, V285, P1911, DOI 10.1126/science.285.5435.1911; Shiina N, 2005, J NEUROSCI, V25, P4420, DOI 10.1523/JNEUROSCI.0382-05.2005; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Smart FM, 2003, P NATL ACAD SCI USA, V100, P14403, DOI 10.1073/pnas.2436349100; Smith WB, 2005, NEURON, V45, P765, DOI 10.1016/j.neuron.2005.01.015; Steward O, 2001, NEURON, V30, P227, DOI 10.1016/S0896-6273(01)00275-6; Steward O, 1999, J NEUROSCI, V19, P7834; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; Sutton MA, 2004, SCIENCE, V304, P1979, DOI 10.1126/science.1096202; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; Tischmeyer W, 2003, EUR J NEUROSCI, V18, P942, DOI 10.1046/j.1460-9568.2003.02820.x; Tsokas P, 2005, J NEUROSCI, V25, P5833, DOI 10.1523/JNEUROSCI.0599-05.2005; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; Wang HD, 2002, J NEUROSCI, V22, P10232; WEILER IJ, 1993, P NATL ACAD SCI USA, V90, P7168, DOI 10.1073/pnas.90.15.7168; Wells DG, 2001, J NEUROSCI, V21, P9541, DOI 10.1523/JNEUROSCI.21-24-09541.2001; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Ye B, 2004, CURR BIOL, V14, P314, DOI 10.1016/j.cub.2004.01.052; Yin Y, 2002, P NATL ACAD SCI USA, V99, P2368, DOI 10.1073/pnas.042693699; Zalfa F, 2003, CELL, V112, P317, DOI 10.1016/S0092-8674(03)00079-5	62	195	199	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18802	18815		10.1074/jbc.M512524200	http://dx.doi.org/10.1074/jbc.M512524200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16651266	hybrid			2022-12-25	WOS:000238687300061
J	Ishihara, K; Yamazaki, T; Ishida, Y; Suzuki, T; Oda, K; Nagao, M; Yamaguchi-Iwai, Y; Kambe, T				Ishihara, Kaori; Yamazaki, Tomohiro; Ishida, Yoko; Suzuki, Tomoyuki; Oda, Kimimitsu; Nagao, Masaya; Yamaguchi-Iwai, Yuko; Kambe, Taiho			Zinc transport complexes contribute to the homeostatic maintenance of secretory pathway function in vertebrate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; NONSPECIFIC ALKALINE-PHOSPHATASE; ER STRESS; TRANSCRIPTION; GENES; ELEMENT; IDENTIFICATION; XBP1; ACTIVATION; CHAPERONE	Zinc transporters play important roles in a wide range of biochemical processes. Here we report an important function of ZnT5/ZnT6 hetero-oligomeric complexes in the secretory pathway. The activity of human tissue- nonspecific alkaline phosphatase (ALP) expressed in ZnT5(-)ZnT7(-/-) cells was significantly reduced compared with that expressed in wild-type cells as in the case of endogenous chicken tissue- nonspecific ALP activity. The inactive human tissue- nonspecific ALP in ZnT5(-)ZnT7(-/-) cells was degraded by proteasome-mediated degradation without being trafficked to the plasma membrane. ZnT5(-)ZnT7(-/-) cells showed exacerbation of the unfolded protein response as did the wild-type cells cultured under a zinc-deficient condition, revealing that both complexes play a role in homeostatic maintenance of secretory pathway function. Furthermore, we showed that expression of ZnT5 mRNA was up-regulated by the endoplasmic reticulum stress in various cell lines. The up-regulation of the hZnT5 transcript was mediated by transcription factor XBP1 through the TGACGTGG sequence in the hZnT5 promoter, and this sequence was highly conserved in the ZnT5 genes of mouse and chicken. These results suggest that zinc transport into the secretory pathway is strictly regulated for the homeostatic maintenance of secretory pathway function in vertebrate cells.	Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Kyoto 6068502, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Div Biochem, Niigata 9518514, Japan	Kyoto University; Niigata University	Kambe, T (corresponding author), Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Kyoto 6068502, Japan.	kambe1@kais.kyoto-u.ac.jp						Bruhat A, 2002, J BIOL CHEM, V277, P48107, DOI 10.1074/jbc.M206149200; CLAUSS IM, 1993, DEV DYNAM, V197, P146, DOI 10.1002/aja.1001970207; Clauss IM, 1996, NUCLEIC ACIDS RES, V24, P1855, DOI 10.1093/nar/24.10.1855; Devergnas S, 2004, BIOCHEM PHARMACOL, V68, P699, DOI 10.1016/j.bcp.2004.05.024; Ellis CD, 2005, J BIOL CHEM, V280, P28811, DOI 10.1074/jbc.M505500200; Ellis CD, 2004, J CELL BIOL, V166, P325, DOI 10.1083/jcb.200401157; Fukushi M, 1998, BIOCHEM BIOPH RES CO, V246, P613, DOI 10.1006/bbrc.1998.8674; Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Inoue K, 2002, HUM MOL GENET, V11, P1775, DOI 10.1093/hmg/11.15.1775; Ishida Y, 2003, J BIOCHEM, V134, P63, DOI 10.1093/jb/mvg114; Iwawaki T, 2004, NAT MED, V10, P98, DOI 10.1038/nm970; Kambe T, 2000, BLOOD, V96, P3265, DOI 10.1182/blood.V96.9.3265.h8003265_3265_3271; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kambe T, 1998, BLOOD, V91, P1185, DOI 10.1182/blood.V91.4.1185; Kambe Taiho, 2006, Genomics Proteomics & Bioinformatics, V4, P1, DOI 10.1016/S1672-0229(06)60010-7; Kanemoto S, 2005, BIOCHEM BIOPH RES CO, V331, P1146, DOI 10.1016/j.bbrc.2005.04.039; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; Le Du MH, 2001, J BIOL CHEM, V276, P9158, DOI 10.1074/jbc.M009250200; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Liu JW, 2000, J BIOL CHEM, V275, P5214, DOI 10.1074/jbc.275.7.5214; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; Narisawa S, 1997, DEV DYNAM, V208, P432, DOI 10.1002/(SICI)1097-0177(199703)208:3<432::AID-AJA13>3.0.CO;2-1; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shen XH, 2005, PLOS GENET, V1, P355, DOI 10.1371/journal.pgen.0010037; Shen XH, 2004, J CHEM NEUROANAT, V28, P79, DOI 10.1016/j.jchemneu.2004.02.006; Suzuki T, 2005, J BIOL CHEM, V280, P637, DOI 10.1074/jbc.M411247200; Suzuki T, 2005, J BIOL CHEM, V280, P30956, DOI 10.1074/jbc.M506902200; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Wang Y, 2000, J BIOL CHEM, V275, P27013; WHYTE MP, 1994, ENDOCR REV, V15, P439, DOI 10.1210/er.15.4.439; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Yuan DS, 2000, GENETICS, V156, P45; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zurutuza L, 1999, HUM MOL GENET, V8, P1039, DOI 10.1093/hmg/8.6.1039	43	77	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17743	17750		10.1074/jbc.M602470200	http://dx.doi.org/10.1074/jbc.M602470200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636052	hybrid			2022-12-25	WOS:000238490300024
J	Arandjelovic, S; Van Sant, CL; Gonias, SL				Arandjelovic, Sanja; Van Sant, Cristina L.; Gonias, Steven L.			Limited mutations in full-length tetrameric human alpha(2)-macroglobulin abrogate binding of platelet-derived growth factor-BB and transforming growth factor- beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; BETA-AMYLOID PEPTIDE; HUMAN ALPHA-2-MACROGLOBULIN; ALPHA-MACROGLOBULIN; THIOL-ESTER; ACTIVATED ALPHA(2)-MACROGLOBULIN; SIGNAL-TRANSDUCTION; COMPLEX-FORMATION; PRIMARY AMINES; BAIT REGION	alpha 2-Macroglobulin (alpha M-2) inhibits diverse extracellular proteases, binds growth factors such as platelet-derived growth factor-BB (PDGF-BB) and transforming growth factor-beta 1 (TGF-beta 1), and carries beta-amyloid peptide. alpha M-2 may also trigger cell signaling by binding to the low density lipoprotein receptor-related protein (LRP-1) and/or other cell surface receptors. Based on studies with recombinant alpha M-2 fragments expressed in bacteria and synthetic peptides, we previously localized a growth factor- binding site near the center of the alpha M-2 subunit. However, because intact alpha M-2 forms a hollow cylinder structure, an alternative model for growth factor binding involves nonspecific entrapment within the alpha M-2 core. To distinguish between these two models, we engineered mutations in the putative growth factor binding sequence of full-length alpha M-2. These mutations did not perturb the tetrameric structure of alpha M-2, reaction with proteases, the thiol ester bonds, or binding to LRP-1. A single mutation (E730R) completely blocked binding of platelet-derived growth factor-BB to intact alpha M-2. E730R did not alter TGF-alpha 1 binding; however, this mutation in combination with mutations at Glu714 and Asp719 eliminated the increase in TGF-alpha 1 binding associated with alpha M-2 conformational change. These studies demonstrate that growth factor binding to intact alpha M-2 is specific, involving a defined region of the alpha M-2 subunit. The exact sequences required for binding different growth factors may be non-identical, mimicking the model of the bait region in which different proteases target adjacent and sometimes overlapping sequences.	Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA	University of California System; University of California San Diego; University of Virginia	Gonias, SL (corresponding author), Univ Calif San Diego, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	sgonias@ucsd.edu			NCI NIH HHS [CA-53462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Arandjelovic S, 2005, ARCH BIOCHEM BIOPHYS, V438, P29, DOI 10.1016/j.abb.2005.03.019; Arandjelovic S, 2003, BIOCHEMISTRY-US, V42, P6121, DOI 10.1021/bi0342158; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BJORK I, 1982, BIOCHEM J, V207, P347; BONNER JC, 1992, J BIOL CHEM, V267, P12837; BONNER JC, 1995, J BIOL CHEM, V270, P6389, DOI 10.1074/jbc.270.11.6389; BONNER JC, 1995, J BIOL CHEM, V270, P16236, DOI 10.1074/jbc.270.27.16236; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; FEINMAN RD, 1983, ANN NY ACAD SCI, V421, P178, DOI 10.1111/j.1749-6632.1983.tb18108.x; Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007; GETTINS PGW, 1994, FEBS LETT, V339, P276, DOI 10.1016/0014-5793(94)80430-3; GETTINS PGW, 1995, J BIOL CHEM, V270, P14160, DOI 10.1074/jbc.270.23.14160; GONIAS SL, 1983, BIOCHEM J, V209, P99, DOI 10.1042/bj2090099; GONIAS SL, 1994, ANN NY ACAD SCI, V737, P273, DOI 10.1111/j.1749-6632.1994.tb44318.x; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; Gonias SL, 2000, J BIOL CHEM, V275, P5826, DOI 10.1074/jbc.275.8.5826; GONIAS SL, 1992, EXP HEMATOL, V20, P302; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HALL SW, 1992, BIOCHEM J, V281, P569, DOI 10.1042/bj2810569; Harthun NL, 1998, J IMMUNOTHER, V21, P85, DOI 10.1097/00002371-199803000-00001; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; Huang W, 2000, J BIOL CHEM, V275, P1089, DOI 10.1074/jbc.275.2.1089; Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; Jenner L, 1998, STRUCTURE, V6, P595, DOI 10.1016/S0969-2126(98)00061-6; LAMARRE J, 1991, LAB INVEST, V65, P3; LAMARRE J, 1993, J CLIN INVEST, V91, P1219, DOI 10.1172/JCI116283; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mettenburg JM, 2002, J BIOL CHEM, V277, P13338, DOI 10.1074/jbc.M106792200; MEYERINGOLD W, 1995, CELL BIOL INT, V19, P389, DOI 10.1006/cbir.1995.1084; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; Nielsen KL, 1996, J BIOL CHEM, V271, P12909, DOI 10.1074/jbc.271.22.12909; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; RAINES EW, 1984, P NATL ACAD SCI-BIOL, V81, P3424, DOI 10.1073/pnas.81.11.3424; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SALVESEN GS, 1981, BIOCHEM J, V195, P453, DOI 10.1042/bj1950453; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Suda SA, 1997, J BIOL CHEM, V272, P31107, DOI 10.1074/jbc.272.49.31107; SWENSON RP, 1979, J BIOL CHEM, V254, P4452; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; UMANS L, 1995, J BIOL CHEM, V270, P19778, DOI 10.1074/jbc.270.34.19778; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; Webb DJ, 2000, PROTEIN SCI, V9, P1986, DOI 10.1110/ps.9.10.1986; WEBB DJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P487, DOI 10.1016/0003-9861(92)90020-W; Webb DJ, 1998, J BIOL CHEM, V273, P13339, DOI 10.1074/jbc.273.21.13339; Webb DJ, 1996, J BIOL CHEM, V271, P24982, DOI 10.1074/jbc.271.40.24982; Wu LH, 2004, J CELL BIOCHEM, V93, P1169, DOI 10.1002/jcb.20288	54	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17061	17068		10.1074/jbc.M602217200	http://dx.doi.org/10.1074/jbc.M602217200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16641085	hybrid			2022-12-25	WOS:000238326300028
J	Ichikawa, T; Horie-Inoue, K; Ikeda, K; Blumberg, B; Inoue, S				Ichikawa, Tomoe; Horie-Inoue, Kuniko; Ikeda, Kazuhiro; Blumberg, Bruce; Inoue, Satoshi			Steroid and xenobiotic receptor SXR mediates vitamin K-2-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MINERAL DENSITY; HIP FRACTURE; BIGLYCAN; MENATETRENONE; EXPRESSION; MATRILIN-2; DIFFERENTIATION; CHONDROADHERIN; VITAMIN-K2; ACTIVATION	Vitamin K-2 is a critical nutrient required for blood coagulation. It also plays a key role in bone homeostasis and is a clinically effective therapeutic agent for osteoporosis. We previously demonstrated that vitamin K2 is a transcriptional regulator of bone marker genes in osteoblastic cells and that it may potentiate bone formation by activating the steroid and xenobiotic receptor, SXR. To explore the SXR-mediated vitamin K2 signaling network in bone homeostasis, we identified genes up-regulated by both vitamin K-2 and the prototypical SXR ligand, rifampicin, in osteoblastic cells using oligonucleotide microarray analysis and quantitative reverse transcription-PCR. Fourteen genes were up-regulated by both ligands. Among these, tsukushi, matrilin-2, and CD14 antigen were shown to be primary SXR target genes. Moreover, collagen accumulation in osteoblastic MG63 cells was enhanced by vitamin K2 treatment. Gain- and loss-of-function analyses showed that the small leucine-rich proteoglycan, tsukushi, contributestovitamin K-2-mediated enhancement of collagen accumulation. Our results suggest a new function for vitamin K2 in bone formation as a transcriptional regulator of extracellular matrix-related genes, that are involved in the collagen assembly.	Saitama Med Sch, Div Gene Regulat & Signal Transduct, Res Ctr Genom Med, Hidaka, Saitama 3501241, Japan; Univ Calif Irvine, Dept Cell & Dev Biol, Irvine, CA 92697 USA; Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Tokyo 1338655, Japan	Saitama Medical University; University of California System; University of California Irvine; University of Tokyo	Inoue, S (corresponding author), Saitama Med Sch, Div Gene Regulat & Signal Transduct, Res Ctr Genom Med, 1397-1 Yamane, Hidaka, Saitama 3501241, Japan.	s_inoue@saitama-med.ac.jp						AKEDO Y, 1992, BIOCHEM BIOPH RES CO, V187, P814, DOI 10.1016/0006-291X(92)91269-V; AKIYAMA Y, 1994, EUR J PHARMACOL, V263, P181, DOI 10.1016/0014-2999(94)90539-8; BAILEY AJ, 1993, CONNECT TISSUE RES, V29, P119, DOI 10.3109/03008209309014239; Bhalla S, 2004, J BIOL CHEM, V279, P45139, DOI 10.1074/jbc.M405423200; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Booth SL, 2000, AM J CLIN NUTR, V71, P1201; Corsi A, 2002, J BONE MINER RES, V17, P1180, DOI 10.1359/jbmr.2002.17.7.1180; Deak F, 1997, J BIOL CHEM, V272, P9268; Filipp D, 2001, P NATL ACAD SCI USA, V98, P603, DOI 10.1073/pnas.98.2.603; Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200; HARA K, 1995, BONE, V16, P179, DOI 10.1016/8756-3282(94)00027-W; KAY R, 1991, J IMMUNOL, V147, P1412; Koshihara Y, 2003, J ENDOCRINOL, V176, P339, DOI 10.1677/joe.0.1760339; Koshihara Y, 1997, J BONE MINER RES, V12, P431, DOI 10.1359/jbmr.1997.12.3.431; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Manabe N, 2001, J IMMUNOL, V167, P2625, DOI 10.4049/jimmunol.167.5.2625; Mansson B, 2001, J BIOL CHEM, V276, P32883, DOI 10.1074/jbc.M101680200; Mizuno M, 1996, CALCIFIED TISSUE INT, V59, P163, DOI 10.1007/s002239900103; Murshed M, 2004, J CELL BIOL, V165, P625, DOI 10.1083/jcb.200402046; Ogushi T, 2005, CANCER RES, V65, P3700, DOI 10.1158/0008-5472.CAN-04-3497; Ohta K, 2004, DEV CELL, V7, P347, DOI 10.1016/j.devcel.2004.08.014; Piecha D, 2002, BIOCHEM J, V367, P715, DOI 10.1042/BJ20021069; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; Plaza SM, 2005, ALTERN MED REV, V10, P24; PRICE PA, 1980, J BIOL CHEM, V255, P1660; Roman-Roman S, 2003, BONE, V32, P474, DOI 10.1016/S8756-3282(03)00052-8; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; Shiraki M, 2000, J BONE MINER RES, V15, P515, DOI 10.1359/jbmr.2000.15.3.515; Tabb MM, 2003, J BIOL CHEM, V278, P43919, DOI 10.1074/jbc.M303136200; Tullberg-Reinert H, 1999, HISTOCHEM CELL BIOL, V112, P271, DOI 10.1007/s004180050447; Vergnaud P, 1997, J CLIN ENDOCR METAB, V82, P719, DOI 10.1210/jc.82.3.719; Waddington R. J., 2003, European Cells & Materials, V6, P12; Wiberg C, 2003, J BIOL CHEM, V278, P37698, DOI 10.1074/jbc.M304638200; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746	38	157	177	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16927	16934		10.1074/jbc.M600896200	http://dx.doi.org/10.1074/jbc.M600896200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16606623	hybrid			2022-12-25	WOS:000238326300013
J	Milleron, RS; Bratton, SB				Milleron, Rania S.; Bratton, Shawn B.			Heat shock induces apoptosis independently of any known initiator caspase-activating complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; CYTOCHROME-C RELEASE; CELL-DEATH; MEDIATED APOPTOSIS; APAF-1; MITOCHONDRIA; REQUIREMENT; UPSTREAM; RECEPTOR; PROTEIN	Adaptive responses to mild heat shock are among the most widely conserved and studied in nature. More intense heat shock, however, induces apoptosis through mechanisms that remain largely unknown. Herein, we present evidence that heat shock activates an apical protease that stimulates mitochondrial outer membrane permeabilization and processing of the effector caspase-3 in a benzyloxycarbonyl-VAD-fluoromethyl ketone (polycaspase inhibitor)- and Bcl-2-inhibitable manner. Surprisingly, however, neither FADD(.)caspase-8 nor RAIDD(.)caspase-2 PIDDosome (p53-induced protein with a death domain) complexes were detected in dying cells, and neither of these initiator caspases nor the endoplasmic reticulum stress-activated caspases-4/12 were required for mitochondrial outer membrane permeabilization. Similarly, although cytochrome c was released from mitochondria following heat shock, functional Apaf-1(.)caspase- 9 apoptosome complexes were not formed, and caspase-9 was not essential for the activation of caspase-3 or the induction of apoptosis. Thus, heat shock does not require any of the known initiator caspases or their activating complexes to promote apoptotic cell death but instead relies upon the activation of an apparently novel apical protease with caspase-like activity.	Univ Texas, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78712 USA; Univ Texas, Ctr Res Environm Dis, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Bratton, SB (corresponding author), Univ Texas, Coll Pharm, Div Pharmacol & Toxicol, 2409 Univ Ave, Austin, TX 78712 USA.	sbbratton@mail.utexas.edu		Bratton, Shawn/0000-0003-2895-5020	NCI NIH HHS [5T32 CA09480] Funding Source: Medline; NIEHS NIH HHS [P30 ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Bratton SB, 2003, CELL DEATH DIFFER, V10, P4, DOI 10.1038/sj.cdd.4401176; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Coffeen WC, 2004, PLANT CELL, V16, P857, DOI 10.1105/tpc.017947; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Ekert PG, 2004, J CELL BIOL, V165, P835, DOI 10.1083/jcb.200312031; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Marsden VS, 2004, J CELL BIOL, V165, P775, DOI 10.1083/jcb.200312030; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tu S, 2006, NAT CELL BIOL, V8, P72, DOI 10.1038/ncb1340; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wilkinson JC, 2004, MOL CELL BIOL, V24, P7003, DOI 10.1128/MCB.24.16.7003-7014.2004; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200	37	51	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16991	17000		10.1074/jbc.M512754200	http://dx.doi.org/10.1074/jbc.M512754200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16618700	hybrid			2022-12-25	WOS:000238326300021
J	Yu, IM; Oldham, ML; Zhang, JQ; Chen, J				Yu, I-Mei; Oldham, Michael L.; Zhang, Jingqiang; Chen, Jue			Crystal structure of the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein dimerization domain reveals evolutionary linkage between Corona- and Arteriviridae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAIN; DEHYDROGENASE-ELEVATING VIRUS; SEMLIKI-FOREST-VIRUS; SPIKE PROTEIN; MOLECULAR-BIOLOGY; TERMINAL DOMAIN; CORE PROTEIN; DENGUE VIRUS; AMINO-ACIDS; SEQUENCE	The causative agent of severe acute respiratory syndrome (SARS) is the SARS-associated coronavirus, SARS-CoV. The nucleocapsid (N) protein plays an essential role in SARS-CoV genome packaging and virion assembly. We have previously shown that SARS-CoV N protein forms a dimer in solution through its C-terminal domain. In this study, the crystal structure of the dimerization domain, consisting of residues 270-370, is determined to 1.75 angstrom resolution. The structure shows a dimer with extensive interactions between the two subunits, suggesting that the dimeric form of the N protein is the functional unit in vivo. Although lacking significant sequence similarity, the dimerization domain of SARS-CoV N protein has a fold similar to that of the nucleocapsid protein of the porcine reproductive and respiratory syndrome virus. This finding provides structural evidence of the evolutionary link between Coronaviridae and Arteriviridae, suggesting that the N proteins of both viruses have a common origin.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Ctr Canc, W Lafayette, IN 47907 USA; Zhongshan Univ, State Key Lab Biocontrol, Guangzhou 510275, Peoples R China	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Sun Yat Sen University	Chen, J (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	chenjue@purdue.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI055672] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI055672] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babcock GJ, 2004, J VIROL, V78, P4552, DOI 10.1128/JVI.78.9.4552-4560.2004; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bos E C, 1995, Adv Exp Med Biol, V380, P283; Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003; BRINTONDARNELL M, 1975, J VIROL, V16, P420, DOI 10.1128/JVI.16.2.420-433.1975; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavanagh D, 1997, ARCH VIROL, V142, P629; Chang CK, 2005, FEBS LETT, V579, P5663, DOI 10.1016/j.febslet.2005.09.038; Choi HK, 1997, PROTEINS, V27, P345, DOI 10.1002/(SICI)1097-0134(199703)27:3<345::AID-PROT3>3.0.CO;2-C; CHOI HK, 1991, NATURE, V354, P37, DOI 10.1038/354037a0; Doan DNP, 2003, STRUCTURE, V11, P1445, DOI 10.1016/j.str.2003.09.018; Dokland T, 2004, STRUCTURE, V12, P1157, DOI 10.1016/j.str.2004.04.024; Fan H, 2005, STRUCTURE, V13, P1859, DOI 10.1016/j.str.2005.08.021; GODENY EK, 1993, VIROLOGY, V194, P585, DOI 10.1006/viro.1993.1298; GOFF SP, 2001, RETROVIRIDAE VIRUSES, V2, P1871; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; He RT, 2004, BIOCHEM BIOPH RES CO, V316, P476, DOI 10.1016/j.bbrc.2004.02.074; He RT, 2003, BIOCHEM BIOPH RES CO, V311, P870, DOI 10.1016/j.bbrc.2003.10.075; Huang QL, 2004, BIOCHEMISTRY-US, V43, P6059, DOI 10.1021/bi036155b; Hurst KR, 2005, J VIROL, V79, P13285, DOI 10.1128/JVI.79.21.13285-13297.2005; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krueger DK, 2001, J VIROL, V75, P2792, DOI 10.1128/JVI.75.6.2792-2802.2001; KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Lai M.M.C., 2001, FIELDS VIROLOGY, P1163; Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8; Ma LX, 2004, P NATL ACAD SCI USA, V101, P3414, DOI 10.1073/pnas.0305892101; MACNAUGHTON MR, 1978, J GEN VIROL, V39, P545, DOI 10.1099/0022-1317-39-3-545; MASTERS PS, 1992, ARCH VIROL, V125, P141, DOI 10.1007/BF01309634; Nelson GW, 2000, J GEN VIROL, V81, P181, DOI 10.1099/0022-1317-81-1-181; NELSON GW, 1993, J GEN VIROL, V74, P1975, DOI 10.1099/0022-1317-74-9-1975; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENG D, 1995, J VIROL, V69, P5475, DOI 10.1128/JVI.69.9.5475-5484.1995; Pletnev SV, 2001, CELL, V105, P127, DOI 10.1016/S0092-8674(01)00302-6; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Rudolph MG, 2003, STRUCTURE, V11, P1219, DOI 10.1016/j.str.2003.08.011; Snijder EJ, 1998, J GEN VIROL, V79, P961, DOI 10.1099/0022-1317-79-5-961; SNIJDER EJ, 2001, FIELDS VIROLOGY, V1, P1205; Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775; STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980; Tahara SM, 1998, ADV EXP MED BIOL, V440, P313; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x; Yu IM, 2005, J BIOL CHEM, V280, P23280, DOI 10.1074/jbc.M501015200; Zhang W, 2002, J VIROL, V76, P11645, DOI 10.1128/JVI.76.22.11645-11658.2002; Zhang Y, 2003, EMBO J, V22, P2604, DOI 10.1093/emboj/cdg270	49	92	101	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17134	17139		10.1074/jbc.M602107200	http://dx.doi.org/10.1074/jbc.M602107200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16627473	hybrid, Green Published			2022-12-25	WOS:000238326300037
J	Degousee, N; Angoulvant, D; Fazel, S; Stefanski, E; Saha, S; Iliescu, K; Lindsay, TF; Fish, JE; Marsden, PA; Li, RK; Audoly, LP; Jakobsson, PJ; Rubin, BB				Degousee, Norbert; Angoulvant, Denis; Fazel, Shafie; Stefanski, Eva; Saha, Sipra; Iliescu, Karina; Lindsay, Thomas F.; Fish, Jason E.; Marsden, Philip A.; Li, Ren-Ke; Audoly, Laurent P.; Jakobsson, Per-Johan; Rubin, Barry B.			c-Jun N-terminal kinase-mediated stabilization of microsomal prostaglandin E-2 synthase-1 mRNA regulates delayed microsomal prostaglandin E-2 synthase-1 expression and prostaglandin E-2 biosynthesis by cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; AU-RICH ELEMENTS; CARDIAC MYOCYTES; PHOSPHOLIPASE A-2; CYCLOOXYGENASE-2; JNK; IDENTIFICATION; STABILITY; PROLIFERATION; DEGRADATION	Microsomal prostaglandin (PG) E-2 synthase-1 (mPGES-1) catalyzes the terminal step in the biosynthesis of PGE(2), a key proinflammatory mediator. The purpose of this study was to elucidate the regulation of mPGES-1mRNA expression in cardiomyocytes, define the role of JNK enzymes in this process, and characterize the role of mPGES-1 in cardiomyocyte PGE2 biosynthesis. In neonatal cardiomyocytes, interleukin-1 beta and lipopolysaccharide (LPS) both stimulated mPGES-1 mRNA expression and increased mPGES-1 mRNA stability and protein synthesis but failed to increase mPGES-1 mRNA transcription. Treatment with the JNK1/2 inhibitor, SP600125, abrogated the increases in mPGES-1 mRNA stability, mPGES-1 protein synthesis, and PGE2 release induced by interleukin-1 beta or LPS. mPGES-1 protein synthesis was observed in LPS-stimulated neonatal cardiomyocytes from jnk1(-/-) or jnk2(-/-) mice. In contrast, infection of jnk1(-/-) cardiomyocytes with an adenovirus encoding phosphorylation-resistant JNK2(ad-JNK2-DN), or of jnk2(-/-) cardiomyocytes with ad-JNK1-DN, significantly decreased LPS-stimulated mPGES-1 protein synthesis. Similarly, co-infection with ad-JNK1-DN and ad-JNK2-DN attenuated LPS-stimulated mPGES-1 protein synthesis in cardiomyocytes from wild type mice. Targeted deletion of the gene encoding mPGES-1 led to a 3.2-fold decrease in LPS-stimulated PGE2 release by cardiomyocytes in comparison with wild type cells but had no effect on COX-1, COX-2, mPGES-2, or cytosolic PGES mRNA levels. These studies provide direct evidence that mPGES-1 mRNA levels in cardiomyocytes are augmented by stabilization of mPGES-1 mRNA, that JNK1 or JNK2 can participate in the regulation of mPGES-1 protein synthesis in these cells, and that mPGES-1 catalyzes the majority of LPS-induced PGE(2) biosynthesis by cardiomyocytes.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Toronto, Toronto Gen Hosp, Univ Hlth Network, Res Inst,Div Vasc Surg, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Gen Hosp, Univ Hlth Network, Res Inst,Div Cardiac Surg, Toronto, ON M5G 2C4, Canada; Univ Toronto, St Michaels Hosp, Div Renal, Toronto, ON M5S 1A8, Canada; Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5S 1A8, Canada; Pfizer Global Res & Dev, Groton Labs, Groton, CT 06340 USA	Karolinska Institutet; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Pfizer	Jakobsson, PJ (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	per-johan.jakobsson@mbb.ki.se; barry.rubin@uhn.on.ca	angoulvant, denis/A-6239-2009; Angoulvant, Denis/Q-9743-2019; Jakobsson, Per-Johan/ABC-5594-2021; Marsden, Philip A/B-1441-2012	Angoulvant, Denis/0000-0003-0788-8092; Li, Ren-Ke/0000-0002-2584-060X; Fish, Jason/0000-0003-0640-7277				Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Beamish R E, 1985, Can J Cardiol, V1, P66; Catley MC, 2003, FEBS LETT, V547, P75, DOI 10.1016/S0014-5793(03)00672-0; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cheng S, 2004, J BIOL CHEM, V279, P22057, DOI 10.1074/jbc.M402828200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152; Degousee N, 2003, CIRC RES, V92, P757, DOI 10.1161/01.RES.0000067929.01404.03; Degousee N, 2001, J BIOL CHEM, V276, P43842, DOI 10.1074/jbc.M101516200; Egan KM, 2005, CIRCULATION, V111, P334, DOI 10.1161/01.CIR.0000153386.95356.78; Giannico G, 2005, AM J PHYSIOL-HEART C, V288, pH165, DOI 10.1152/ajpheart.00726.2004; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Holzberg D, 2003, J BIOL CHEM, V278, P40213, DOI 10.1074/jbc.M304058200; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; LaPointe MC, 1999, HYPERTENSION, V33, P276, DOI 10.1161/01.HYP.33.1.276; Liang QR, 2003, EMBO J, V22, P5079, DOI 10.1093/emboj/cdg474; Mendez M, 2002, HYPERTENSION, V39, P382, DOI 10.1161/hy02t2.102808; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Ng DCH, 2001, J BIOL CHEM, V276, P29490, DOI 10.1074/jbc.M100699200; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHROR K, 1993, EUR HEART J, V14, P34; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Thoren S, 2000, EUR J BIOCHEM, V267, P6428, DOI 10.1046/j.1432-1327.2000.01735.x; Toh WH, 2004, J BIOL CHEM, V279, P44713, DOI 10.1074/jbc.M407672200; Trebino CE, 2005, J BIOL CHEM, V280, P16579, DOI 10.1074/jbc.M412075200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Watanabe K, 1999, BBA-MOL CELL BIOL L, V1439, P406, DOI 10.1016/S1388-1981(99)00084-0; Xiao CY, 2004, CIRCULATION, V109, P2462, DOI 10.1161/01.CIR.0000128046.54681.97	39	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16443	16452		10.1074/jbc.M602815200	http://dx.doi.org/10.1074/jbc.M602815200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16627484	hybrid			2022-12-25	WOS:000238165700034
J	Stossi, F; Likhite, VS; Katzenellenbogen, JA; Katzenellenbogen, BS				Stossi, Fabio; Likhite, Varsha S.; Katzenellenbogen, John A.; Katzenellenbogen, Benita S.			Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; DEPENDENT TRANSCRIPTION; NUCLEAR RECEPTORS; ALPHA; DOMAIN; MECHANISMS; LIGANDS; BETA; SP1; TRANSACTIVATION	Estrogens, acting through their nuclear receptors have a broad impact on target cells, eliciting a transcriptional response program that involves gene repression as well as gene stimulation. While much is known about the mechanisms by which the estrogen-occupied estrogen receptor ( ER) stimulates gene expression, the molecular events that lead to gene repression by the hormone-ER complex are largely unknown. Because estradiol represses expression of the cyclin G2 gene, which encodes a negative regulator of the cell cycle, our aim was to understand the mechanism by which cyclin G2 is repressed by estrogen. We show that cyclin G2 is a primary ER target gene in MCF-7 breast cancer cells that is rapidly and robustly down-regulated by estrogen. Promoter analysis reveals a responsive region containing a half-estrogen response element and GC-rich region that interact with ER and Sp1 proteins. Mutation of the half-ERE abrogates hormone-mediated repression. Mutational mapping of receptor reveals a requirement for its N-terminal region and DNA binding domain to support cyclin G2 repression. Following estradiol treatment of cells, chromatin immunoprecipitation analyses reveal recruitment of ER to the cyclin G2 regulatory region, dismissal of RNA polymerase II, and recruitment of a complex containing N-CoR and histone deacetylases, leading to a hypoacetylated chromatin state. Our study provides evidence for a mechanism by which the estrogen-occupied ER is able to actively repress gene expression in vivo and indicates a role for nuclear receptor corepressors and associated histone deacetylase activity in mediating negative gene regulation by this hormone-occupied nuclear receptor.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	katzenel@uiuc.edu			NATIONAL CANCER INSTITUTE [R01CA018119, R37CA018119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015556, R01DK015556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007326] Funding Source: NIH RePORTER; NCI NIH HHS [CA 18119] Funding Source: Medline; NIDDK NIH HHS [DK 15556] Funding Source: Medline; NIEHS NIH HHS [T32 ES 07326] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Charpentier AH, 2000, CANCER RES, V60, P5977; Dostert A, 2004, CURR PHARM DESIGN, V10, P2807; Ediger TR, 2002, MOL ENDOCRINOL, V16, P1828, DOI 10.1210/me.2001-0290; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Glass CK, 2000, GENE DEV, V14, P121; Hall JM, 2002, MOL ENDOCRINOL, V16, P469, DOI 10.1210/me.16.3.469; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; Hewitt SC, 2005, MOL ENDOCRINOL, V19, P657, DOI 10.1210/me.2004-0142; Hodges LC, 2003, MOL CANCER RES, V1, P300; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Huang HJ, 2002, MOL ENDOCRINOL, V16, P1778, DOI 10.1210/me.2002-0089; INCE BA, 1993, J BIOL CHEM, V268, P14026; Jepsen K, 2002, J CELL SCI, V115, P689; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Katzenellenbogen BS, 2004, SEMIN ONCOL, V31, P28, DOI 10.1053/j.seminoncol.2004.01.004; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Kraus WL, 2002, EUR J BIOCHEM, V269, P2275, DOI 10.1046/j.1432-1033.2002.02889.x; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; Lazennec G, 1997, MOL ENDOCRINOL, V11, P1375, DOI 10.1210/me.11.9.1375; Li C, 2001, ENDOCRINOLOGY, V142, P1546, DOI 10.1210/en.142.4.1546; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martinez-Gac L, 2004, MOL CELL BIOL, V24, P2181, DOI 10.1128/MCB.24.5.2181-2189.2004; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Metivier R, 2000, MOL ENDOCRINOL, V14, P1849, DOI 10.1210/me.14.11.1849; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Nettles KW, 2005, ANNU REV PHYSIOL, V67, P309, DOI 10.1146/annurev.physiol.66.032802.154710; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Oesterreich S, 2003, CANCER RES, V63, P5203; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Schodin DJ, 1995, J BIOL CHEM, V270, P31163, DOI 10.1074/jbc.270.52.31163; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; Stossi F, 2004, ENDOCRINOLOGY, V145, P3473, DOI 10.1210/en.2003-1682; TAMURA K, 1993, ONCOGENE, V8, P2113; Varshochi R, 2005, J BIOL CHEM, V280, P3185, DOI 10.1074/jbc.M408063200; Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384; Watanabe H, 2002, GENES CELLS, V7, P497, DOI 10.1046/j.1365-2443.2002.00535.x; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	64	99	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16272	16278		10.1074/jbc.M513405200	http://dx.doi.org/10.1074/jbc.M513405200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16608856	hybrid			2022-12-25	WOS:000238165700013
J	Sun, AQ; Balasubramaniyan, N; Chen, HJ; Shahid, M; Suchy, FJ				Sun, An-Qiang; Balasubramaniyan, Natarajan; Chen, Haijun; Shahid, Mohammad; Suchy, Frederick J.			Identification of functionally relevant residues of the rat ileal apical sodium-dependent bile acid cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; BINDING PROTEIN; FATTY-ACID; TRANSPORT; LIVER; NA+; TAUROCHOLATE; RABBIT	The mechanisms underlying the transport of bile acids by apical sodium-dependent bile acid transporter (Asbt) are not well defined. To further identify the functionally relevant residues, thirteen conserved negatively (Asp and Glu) and positively (Lys and Arg) charged residues plus Cys-270 of rat Asbt were replaced with Ala or Gln by site-directed mutagenesis. Seven of the fourteen residues of rat Asbt were identified as functionally important by taurocholate transport studies, substrate inhibition assays, confocal microscopy, and electrophysiological methods. The results showed that Asp-122, Lys-191, Lys-225, Lys-256, Glu-261, and Lys-312, Lys-313 residues of rat Asbt are critical for transport function and may determine substrate specificity. Arg-64 may be located at a different binding site to assist in interaction with non-bile acid organic anions. For bile acid transport by Asbt, Na+ ion movement is a voltage-dependent process that tightly companied with taurocholate movement. Asp-122 and Glu-261 play a critical role in the interaction of a Na+ ion and ligand with Asbt. Cys-270 is not essential for the transport process. These studies provide new details about the amino acid residues of Asbt involved in binding and transport of bile acids and Na+.	Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Icahn School of Medicine at Mount Sinai; Yale University	Sun, AQ (corresponding author), Mt Sinai Sch Med, Dept Pediat, Box 1664,1 Gustave L Levy Pl, New York, NY 10029 USA.	An-Qiang.Sun@mssm.edu	Chen, Haijun/C-7334-2011		NCI NIH HHS [5R24 CA 095823-04] Funding Source: Medline; NCRR NIH HHS [1S10 RR 09145-01] Funding Source: Medline; NICHD NIH HHS [5R37 HD 020632-21] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020632] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R24CA095823] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alrefai WA, 2005, AM J PHYSIOL-GASTR L, V288, pG978, DOI 10.1152/ajpgi.00379.2004; Baringhaus KH, 1999, J LIPID RES, V40, P2158; BARNARD JA, 1987, GASTROENTEROLOGY, V93, P925, DOI 10.1016/0016-5085(87)90553-1; Chen HJ, 2003, BIOPHYS J, V84, P3679, DOI 10.1016/S0006-3495(03)75097-8; Chen HJ, 2003, NEURON, V40, P15, DOI 10.1016/S0896-6273(03)00570-1; Hallen S, 2000, BIOCHEMISTRY-US, V39, P6743, DOI 10.1021/bi000577t; Hallen S, 1999, BIOCHEMISTRY-US, V38, P11379, DOI 10.1021/bi990554i; Hallen S, 2002, BIOCHEMISTRY-US, V41, P14916, DOI 10.1021/bi0205404; Ho RH, 2004, J BIOL CHEM, V279, P7213, DOI 10.1074/jbc.M305782200; KRAMER W, 1994, J BIOL CHEM, V269, P10621; Kramer W, 1999, J LIPID RES, V40, P1604; Lucke C, 2000, EUR J BIOCHEM, V267, P2929, DOI 10.1046/j.1432-1327.2000.01307.x; Meinild AK, 2001, BIOCHEMISTRY-US, V40, P11897, DOI 10.1021/bi011026l; Nichesola D, 2004, BIOCHEMISTRY-US, V43, P14072, DOI 10.1021/bi0489661; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; PETZINGER E, 1994, REV PHYSIOL BIOCH P, V123, P47, DOI 10.1007/BFb0030903; Quick M, 1997, BIOCHEMISTRY-US, V36, P4631, DOI 10.1021/bi963063w; Sun AQ, 2004, J BIOL CHEM, V279, P16295, DOI 10.1074/jbc.M312838200; Sun AQ, 1998, AM J PHYSIOL-GASTR L, V275, pG1045, DOI 10.1152/ajpgi.1998.275.5.G1045; Sun AQ, 2003, J BIOL CHEM, V278, P4000, DOI 10.1074/jbc.M207163200; Sun AQ, 2001, J BIOL CHEM, V276, P6825, DOI 10.1074/jbc.M008797200; Swaan PW, 1997, J COMPUT AID MOL DES, V11, P581, DOI 10.1023/A:1007919704457; Weinman SA, 1998, J BIOL CHEM, V273, P34691, DOI 10.1074/jbc.273.52.34691; WESS G, 1994, J MED CHEM, V37, P873, DOI 10.1021/jm00033a001; Xia XF, 2004, J BIOL CHEM, V279, P44931, DOI 10.1074/jbc.M400969200; Zahner D, 2003, EUR J BIOCHEM, V270, P1117, DOI 10.1046/j.1432-1033.2003.03463.x; Zhang EY, 2004, BIOCHEMISTRY-US, V43, P11380, DOI 10.1021/bi049270a	27	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16410	16418		10.1074/jbc.M600034200	http://dx.doi.org/10.1074/jbc.M600034200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16608845	hybrid			2022-12-25	WOS:000238165700030
J	Tran, UC; Marbois, B; Gin, P; Gulmezian, M; Jonassen, T; Clarke, CF				Tran, UyenPhuong C.; Marbois, Beth; Gin, Peter; Gulmezian, Melissa; Jonassen, Tanya; Clarke, Catherine F.			Complementation of Saccharomyces cerevisiae COQ7 mutants by mitochondrial targeting of the Escherichia coli UbiF polypeptide - Two functions of yeast COQ7 Polypeptide in coenzyme Q biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE SYSTEM; UBIQUINONE BIOSYNTHESIS; MULTISUBUNIT COMPLEX; CYTOPLASMIC MUTANTS; GENETIC-EVIDENCE; METHYLTRANSFERASE; PROTEIN; CLK-1; ENCODES; NUCLEAR	Coenzyme Q(ubiquinone or Q) functions in the respiratory electron transport chain and serves as a lipophilic antioxidant. In the budding yeast Saccharomyces cerevisiae, Q biosynthesis requires nine Coq proteins (Coq1 - Coq9). Previous work suggests both an enzymatic activity and a structural role for the yeast Coq7 protein. To define the functional roles of yeast Coq7p we test whether Escherichia coli ubiF can functionally substitute for yeast COQ7. The ubiF gene encodes a flavin-dependent monooxygenase that shares no homology to the Coq7 protein and is required for the final monooxygenase step of Q biosynthesis in E. coli. The ubiF gene expressed at low copy restores growth of a coq7 point mutant (E194K) on medium containing a non-fermentable carbon source, but fails to rescue a coq7 null mutant. However, expression of ubiF from a multicopy vector restores growth and Q synthesis for both mutants, although with a higher efficiency in the point mutant. We attribute the more efficient rescue of the coq7 point mutant to higher steady state levels of the Coq3, Coq4, and Coq6 proteins and to the presence of demethoxyubiquinone, the substrate of UbiF. Coq7p co-migrates with the Coq3 and Coq4 polypeptides as a high molecular mass complex. Here we show that addition of Q to the growth media also stabilizes the Coq3 and Coq4 polypeptides in the coq7 null mutant. The data suggest that Coq7p, and the lipid quinones (demethoxyubiquinone and Q) function to stabilize other Coq polypeptides.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, CF (corresponding author), 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	cathy@chem.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM045952, GM 45952, R01 GM045952-08] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi A, 2003, FEBS LETT, V543, P174, DOI 10.1016/S0014-5793(03)00419-8; Baba SW, 2004, J BIOL CHEM, V279, P10052, DOI 10.1074/jbc.M313712200; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BECKMANN JD, 1989, J BIOL CHEM, V264, P3713; Belogrudov GI, 2001, ARCH BIOCHEM BIOPHYS, V392, P48, DOI 10.1006/abbi.2001.2448; Berthold DA, 2003, ANNU REV PLANT BIOL, V54, P497, DOI 10.1146/annurev.arplant.54.031902.134915; Burke D., 2000, METHODS YEAST GENETI; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; Gin P, 2005, J BIOL CHEM, V280, P2676, DOI 10.1074/jbc.M411527200; Gin P, 2003, J BIOL CHEM, V278, P25308, DOI 10.1074/jbc.M303234200; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GORDON PA, 1969, BIOCHIM BIOPHYS ACTA, V177, P358, DOI 10.1016/0304-4165(69)90150-0; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hagerman RA, 2002, FREE RADICAL RES, V36, P485, DOI 10.1080/10715760290021360; HARRINGTON MG, 1990, METHOD ENZYMOL, V182, P488; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Johnson A, 2005, J BIOL CHEM, V280, P31397, DOI 10.1074/jbc.M503277200; Jonassen T, 2000, J BIOL CHEM, V275, P12381, DOI 10.1074/jbc.275.17.12381; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; Kwon O, 2000, FEMS MICROBIOL LETT, V186, P157, DOI 10.1016/S0378-1097(00)00134-8; Lenaz G., 1985, COENZYME Q, P165; Marbois B, 2005, J BIOL CHEM, V280, P20231, DOI 10.1074/jbc.M501315200; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; Padilla S, 2004, J BIOL CHEM, V279, P25995, DOI 10.1074/jbc.M400001200; POON WW, 1995, ARCH BIOCHEM BIOPHYS, V320, P305, DOI 10.1016/0003-9861(95)90014-4; Poon WW, 1997, MOL ASPECTS MED, V18, pS121; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Santos-Ocana C, 2002, J BIOL CHEM, V277, P10973, DOI 10.1074/jbc.M112222200; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; SIKORSKI RS, 1989, GENETICS, V122, P19; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8236; TZAGOLOFF A, 1975, J BACTERIOL, V122, P826, DOI 10.1128/JB.122.3.826-831.1975; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	43	45	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16401	16409		10.1074/jbc.M513267200	http://dx.doi.org/10.1074/jbc.M513267200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16624818	hybrid, Green Accepted			2022-12-25	WOS:000238165700029
J	Li, W; Serpell, LC; Carter, WJ; Rubinsztein, DC; Huntington, JA				Li, Wei; Serpell, Louise C.; Carter, Wendy J.; Rubinsztein, David C.; Huntington, James A.			Expression and characterization of full-length human Huntingtin, an elongated HEAT repeat protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE GENE HOMOLOG; MUTANT HUNTINGTIN; EMBRYONIC LETHALITY; POLYGLUTAMINE TRACT; CELL MODELS; CLEAVAGE; TOXICITY; REVEALS; TRANSCRIPTION; AGGREGATION	Huntington disease is an inherited neurodegenerative disorder that is caused by expanded CAG trinucleotide repeats, resulting in a polyglutamine stretch of > 37 on the N terminus of the protein huntingtin (htt). htt is a large (347 kDa), ubiquitously expressed protein. The precise functions of htt are not clear, but its importance is underscored by the embryonic lethal phenotype in htt knock-out mice. Despite the fact that the htt gene was cloned 13 years ago, little is known about the properties of the full-length protein. Here we report the expression and preliminary characterization of recombinant full-length wild-type human htt. Our results support a model of htt composed entirely of HEAT repeats that stack to form an elongated superhelix.	Univ Cambridge, Cambridge Inst Med Inst, Dept Haematol, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Inst, Dept Med Genet, Cambridge CB2 2XY, England; Univ Sussex, Dept Biochem, Brighton BN1 9QG, E Sussex, England	University of Cambridge; University of Cambridge; University of Sussex	Huntington, JA (corresponding author), Univ Cambridge, Cambridge Inst Med Inst, Dept Haematol, Cambridge CB2 2XY, England.	jah52@cam.ac.uk	Rubinsztein, David C/C-3472-2011	Serpell, Louise/0000-0001-9335-7751	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Bao J, 1996, P NATL ACAD SCI USA, V93, P5037, DOI 10.1073/pnas.93.10.5037; BATES G, 2002, HUNTINGTONS DIS; Beddoe T, 2004, J BIOL CHEM, V279, P46448, DOI 10.1074/jbc.M405639200; Bohm G, 1996, BIOPHYS CHEM, V59, P1, DOI 10.1016/0301-4622(95)00120-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cattaneo E, 2005, NAT REV NEUROSCI, V6, P919, DOI 10.1038/nrn1806; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Dyer RB, 2001, NAT GENET, V29, P270, DOI 10.1038/ng745; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Goehler H, 2004, MOL CELL, V15, P853, DOI 10.1016/j.molcel.2004.09.016; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Goldenberg SJ, 2004, CELL, V119, P517, DOI 10.1016/j.cell.2004.10.019; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Harjes P, 2003, TRENDS BIOCHEM SCI, V28, P425, DOI 10.1016/S0968-0004(03)00168-3; Harper PS, 1991, HUNTINGTONS DIS; Ho LW, 2001, J MED GENET, V38, P450, DOI 10.1136/jmg.38.7.450; Kegel KB, 2005, J BIOL CHEM, V280, P36464, DOI 10.1074/jbc.M503672200; Kost TA, 2005, NAT BIOTECHNOL, V23, P567, DOI 10.1038/nbt1095; La Spada AR, 2003, NEURON, V38, P681, DOI 10.1016/S0896-6273(03)00328-3; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; Li Z, 1999, HUM MOL GENET, V8, P1807, DOI 10.1093/hmg/8.9.1807; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; Luo SQ, 2005, J CELL BIOL, V169, P647, DOI 10.1083/jcb.200412071; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Neuwald AF, 2000, GENOME RES, V10, P1445, DOI 10.1101/gr.147400; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; SAPP E, 1995, NEUROSCIENCE, V64, P397, DOI 10.1016/0306-4522(94)00427-7; STINE OC, 1995, HUM MOL GENET, V4, P15, DOI 10.1093/hmg/4.1.15; Sugars KL, 2004, J BIOL CHEM, V279, P4988, DOI 10.1074/jbc.M310226200; Takano H, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-15; Van Raamsdonk JM, 2005, HUM MOL GENET, V14, P1379, DOI 10.1093/hmg/ddi147; Wellington CL, 2002, J NEUROSCI, V22, P7862; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; Zweifel ME, 2001, BIOCHEMISTRY-US, V40, P14357, DOI 10.1021/bi011436+	45	61	61	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15916	15922		10.1074/jbc.M511007200	http://dx.doi.org/10.1074/jbc.M511007200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595690	hybrid			2022-12-25	WOS:000237996000042
J	Miyoshi, H; Souza, SC; Zhang, HH; Strissel, KJ; Christoffolete, MA; Kovsan, J; Rudich, A; Kraemer, FB; Bianco, AC; Obin, MS; Greenberg, AS				Miyoshi, Hideaki; Souza, Sandra C.; Zhang, Hui-Hong; Strissel, Katherine J.; Christoffolete, Marcelo A.; Kovsan, Julia; Rudich, Assaf; Kraemer, Fredric B.; Bianco, Antonio C.; Obin, Martin S.; Greenberg, Andrew S.			Perilipin promotes hormone-sensitive lipase-mediated adipocyte lipolysis via phosphorylation-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MUTATIONAL ANALYSIS; LIPID DROPLETS; TRANSLOCATION; STORAGE; STIMULATION; PROTEIN; KINASE; EXPRESSION; BLOCKS	Hormone-sensitive lipase (HSL) is the predominant lipase effector of catecholamine-stimulated lipolysis in adipocytes. HSL-dependent lipolysis in response to catecholamines is mediated by protein kinase A (PKA)-dependent phosphorylation of perilipin A (Peri A), an essential lipid droplet (LD)-associated protein. It is believed that perilipin phosphorylation is essential for the translocation of HSL from the cytosol to the LD, a key event in stimulated lipolysis. Using adipocytes retrovirally engineered from murine embryonic fibroblasts of perilipin null mice (Peri(-/-) MEF), we demonstrate by cell fractionation and confocal microscopy that up to 50% of cellular HSL is LD-associated in the basal state and that PKA-stimulated HSL translocation is fully supported by adenoviral expression of a mutant perilipin lacking all six PKA sites (Peri A Delta 1-6). PKA-stimulated HSL translocation was confirmed in differentiated brown adipocytes from perilipin null mice expressing an adipose-specific Peri A Delta 1-6 transgene. Thus, PKA-induced HSL translocation was independent of perilipin phosphorylation. However, Peri A Delta 1-6 failed to enhance PKA-stimulated lipolysis in either MEF adipocytes or differentiated brown adipocytes. Thus, the lipolytic action(s) of HSL at the LD surface requires PKA-dependent perilipin phosphorylation. In Peri(-/-) MEF adipocytes, PKA activation significantly enhanced the amount of HSL that could be cross-linked to and co-immunoprecipitated with ectopic Peri A. Notably, this enhanced cross-linking was blunted in Peri(-/-) MEF adipocytes expressing Peri A Delta 1-6. This suggests that PKA-dependent perilipin phosphorylation facilitates (either direct or indirect) perilipin interaction with LD-associated HSL. These results redefine and expand our understanding of how perilipin regulates HSL-mediated lipolysis in adipocytes.	Tufts Univ, Jean Mayer USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan; Brigham & Womens Hosp, Boston, MA 02111 USA; Harvard Univ, Sch Med, Boston, MA 02111 USA; Ben Gurion Univ Negev, IL-84105 Beer Sheva, Israel; Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA 94305 USA; Stanford Univ, Stanford, CA 94305 USA	Tufts University; United States Department of Agriculture (USDA); Hokkaido University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Ben Gurion University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Obin, MS (corresponding author), Tufts Univ, Jean Mayer USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA.	martin.obin@tufts.edu; andrew.greenberg@tufts.edu	MIYOSHI, HIDEAKI/G-3971-2012; Kraemer, Fredric/AAC-3633-2019; Bianco, Antonio/AAK-6336-2020; Bianco, Antonio C/A-4965-2008	Bianco, Antonio/0000-0001-7737-6813; Bianco, Antonio C/0000-0001-7737-6813; Christoffolete, Marcelo/0000-0003-0374-0795; Rudich, Assaf/0000-0002-1366-1444; Kraemer, Fredric/0000-0003-2468-7807	NIA NIH HHS [AG024635] Funding Source: Medline; NIDDK NIH HHS [IH DK-50647, P30 DK-34928] Funding Source: Medline; NINDS NIH HHS [P30 NS047243] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050647, P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG024635] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arner P, 2005, BEST PRACT RES CL EN, V19, P471, DOI 10.1016/j.beem.2005.07.004; ARNER P, 1995, INT J OBES RELAT S4, V19, P18; Belfrage P, 1982, Prog Clin Biol Res, V102 Pt C, P213; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; Clifford GM, 2001, METABOLISM, V50, P1264, DOI 10.1053/meta.2001.27216; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; COPPACK SW, 1994, J LIPID RES, V35, P177; Dodt C, 2003, ACTA PHYSIOL SCAND, V177, P351, DOI 10.1046/j.1365-201X.2003.01077.x; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; Frayn KN, 2003, BIOCHEM SOC T, V31, P1115, DOI 10.1042/BST0311115; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; Gross DN, 2004, MOL CELL BIOL, V24, P7151, DOI 10.1128/MCB.24.16.7151-7162.2004; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795; Londos C, 2005, BIOCHIMIE, V87, P45, DOI 10.1016/j.biochi.2004.12.010; Marcinkiewicz A, 2006, J BIOL CHEM, V281, P11901, DOI 10.1074/jbc.M600171200; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Martinez-deMena R, 2002, AM J PHYSIOL-ENDOC M, V282, pE1119, DOI 10.1152/ajpendo.00433.2001; Moore HPH, 2005, J BIOL CHEM, V280, P43109, DOI 10.1074/jbc.M506336200; Morimoto C, 2001, J LIPID RES, V42, P120; Ohashi M, 2003, J BIOL CHEM, V278, P36819, DOI 10.1074/jbc.M301408200; Robidoux J, 2004, ANNU REV PHARMACOL, V44, P297, DOI 10.1146/annurev.pharmtox.44.101802.121659; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Sell H, 2004, INT J BIOCHEM CELL B, V36, P2098, DOI 10.1016/j.biocel.2004.04.003; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; SOKAL RR, 1969, BIOMETRY, P607; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Su CL, 2003, J BIOL CHEM, V278, P43615, DOI 10.1074/jbc.M301809200; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2004, IUBMB LIFE, V56, P379, DOI 10.1080/15216540400009968; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Wang J, 2005, BIOCHEMISTRY-US, V44, P1953, DOI 10.1021/bi049206t; Wyne KL, 2003, AM J MED, V115, P29, DOI 10.1016/j.amjmed.2003.09.004; Yeaman SJ, 2004, BIOCHEM J, V379, P11, DOI 10.1042/BJ20031811; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200	43	226	239	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15837	15844		10.1074/jbc.M601097200	http://dx.doi.org/10.1074/jbc.M601097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595669	Green Published, hybrid			2022-12-25	WOS:000237996000032
J	Ungureanu, NH; Cloutier, M; Lewis, SM; de Silva, N; Blais, JD; Bell, JC; Holcik, M				Ungureanu, Nicoleta Hosszu; Cloutier, Mireille; Lewis, Stephen M.; de Silva, Naomi; Blais, Jaime D.; Bell, John C.; Holcik, Martin			Internal ribosome entry site-mediated translation of Apaf-1, but not XIAP, is regulated during UV-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROTEIN; APOPTOSIS; ACTIVATION; INITIATION; STRESS; PHOSPHORYLATION; INHIBITOR; RELEASE; OCCURS	Components of the cellular translation machinery are targets of caspase-mediated cleavage during apoptosis that correlates with the inhibition of protein synthesis, which accompanies apoptosis. Paradoxically, protein synthesis is required for apoptosis to occur in many experimental settings. Previous studies showed that two proteins that regulate apoptosis by controlling caspase activity, XIAP and Apaf-1, are translated by a unique, cap-independent mechanism mediated by an internal ribosome entry site (IRES) that is used preferentially under conditions in which normal cap-dependent translation is repressed. We investigated the regulation of XIAP and Apaf-1 following UVC irradiation. We show that UVC irradiation leads to the inhibition of translation and cell death. Furthermore, IRES-mediated translation of Apaf-1, but not XIAP, is enhanced by UVC irradiation, and this increase in Apaf-1 translation correlated with cell death. The enhanced Apaf-1 IRES-mediated translation is caspase-independent but is negatively modulated by the eIF2 alpha kinase protein kinase RNA-like endoplasmic reticulum kinase. These data suggest that progression of UV-induced apoptosis requires IRES-mediated translation of Apaf-1 to ensure continuous levels of Apaf-1 despite an overall suppression of protein synthesis.	Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, Ottawa, ON K1H 8L1, Canada; Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Ottawa Hospital Research Institute	Holcik, M (corresponding author), Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, Ottawa, ON K1H 8L1, Canada.	martin@mgcheo.med.uottawa.ca	Holcik, Martin/AAC-6660-2019; Lewis, Stephen/E-5533-2010; Holcik, Martin/E-5372-2011; Holcik, Martin/A-9768-2008	Holcik, Martin/0000-0002-1922-5299; Lewis, Stephen/0000-0001-9537-5822; 				Adams JM, 2002, CURR OPIN CELL BIOL, V14, P715, DOI 10.1016/S0955-0674(02)00381-2; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; Fernandez J, 2003, J BIOL CHEM, V278, P50000, DOI 10.1074/jbc.M305903200; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Fu WN, 2003, ONCOGENE, V22, P451, DOI 10.1038/sj.onc.1206147; Gerlitz G, 2002, EUR J BIOCHEM, V269, P2810, DOI 10.1046/j.1432-1033.2002.02974.x; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Henis-Korenblit S, 2002, P NATL ACAD SCI USA, V99, P5400, DOI 10.1073/pnas.082102499; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Holcik M, 2005, RNA, V11, P1605, DOI 10.1261/rna.2158605; Holcik M, 2004, CURR CANCER DRUG TAR, V4, P299, DOI 10.2174/1568009043333005; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Jiang HY, 2005, BIOCHEM J, V385, P371, DOI 10.1042/BJ20041164; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lewis SM, 2005, CELL DEATH DIFFER, V12, P547, DOI 10.1038/sj.cdd.4401602; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; Nevins TA, 2003, J BIOL CHEM, V278, P3572, DOI 10.1074/jbc.M206781200; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Takasawa R, 2003, APOPTOSIS, V8, P291, DOI 10.1023/A:1023629023696; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	33	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15155	15163		10.1074/jbc.M511319200	http://dx.doi.org/10.1074/jbc.M511319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16595687	hybrid			2022-12-25	WOS:000237922200018
J	Wang, H; DellaVecchia, MJ; Skorvaga, M; Croteau, DL; Erie, DA; Van Houten, B				Wang, Hong; DellaVecchia, Matthew J.; Skorvaga, Milan; Croteau, Deborah L.; Erie, Dorothy A.; Van Houten, Bennett			UvrB domain 4, an autoinhibitory gate for regulation of DNA binding and ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; UVRABC NUCLEASE SYSTEM; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; (A)BC EXCINUCLEASE; THERMUS-THERMOPHILUS; PREINCISION COMPLEX; DAMAGE RECOGNITION; DEPENDENT ATPASE; PROTEIN COMPLEX	UvrB, a central DNA damage recognition protein in bacterial nucleotide excision repair, has weak affinity for DNA, and its ATPase activity is activated by UvrA and damaged DNA. Regulation of DNA binding and ATP hydrolysis by UvrB is poorly understood. Using atomic force microscopy and biochemical assays, we found that truncation of domain 4 of Bacillus caldotenax UvrB (UvrB Delta 4) leads to multiple changes in protein function. Protein dimerization decreases with an similar to 8-fold increase of the equilibrium dissociation constant and an increase in DNA binding. Loss of domain 4 causes the DNA binding mode of UvrB to change from dimer to monomer, and affinity increases with the apparent dissociation constants on nondamaged and damaged single-stranded DNA decreasing 22- and 14-fold, respectively. ATPase activity by UvrB Delta 4 increases 14- and 9-fold with and without single-stranded DNA, respectively, and UvrB Delta 4 supports UvrA-independent damage-specific incision by Cho on a bubble DNA substrate. We propose that other than its previously discovered role in regulating protein-protein interactions, domain 4 is an autoinhibitory domain regulating the DNA binding and ATPase activities of UvrB.	NIEHS, Mol Genet Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Slovak Acad Sci, Inst Canc Res, Dept Mol Genet, Bratislava 83391, Slovakia; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Slovak Academy of Sciences; University of North Carolina; University of North Carolina Chapel Hill	Van Houten, B (corresponding author), NIEHS, Mol Genet Lab, NIH, Dept Hlth & Human Serv, 111 Alexander Dr,POB 12233, Res Triangle Pk, NC 27709 USA.	vanhout1@niehs.nih.gov	Wang, Hong/F-3164-2014; Skorvaga, Milan/AAO-2360-2021; Van Houten, Bennett/K-2284-2019; Croteau, Deb/AAP-5933-2020	Wang, Hong/0000-0003-0165-3559; Croteau, Deborah/0000-0002-6094-4084	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES061060] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alexandrovich A, 2001, J BIOMOL STRUCT DYN, V19, P219, DOI 10.1080/07391102.2001.10506734; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10891, DOI 10.1093/nar/16.22.10891; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10903, DOI 10.1093/nar/16.22.10903; Coleman RA, 1999, MOL CELL, V4, P451, DOI 10.1016/S1097-2765(00)80453-0; DellaVecchia MJ, 2004, J BIOL CHEM, V279, P45245, DOI 10.1074/jbc.M408659200; Eryilmaz J, 2006, J MOL BIOL, V357, P62, DOI 10.1016/j.jmb.2005.12.059; Goosen N, 2001, RES MICROBIOL, V152, P401, DOI 10.1016/S0923-2508(01)01211-6; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Gordienko I, 1997, EMBO J, V16, P889, DOI 10.1093/emboj/16.4.889; Gordienko I, 1997, EMBO J, V16, P880, DOI 10.1093/emboj/16.4.880; Hildebrand EL, 1999, J BIOL CHEM, V274, P27885, DOI 10.1074/jbc.274.39.27885; Hildebrand EL, 1998, J BIOL CHEM, V273, P7818, DOI 10.1074/jbc.273.14.7818; HSU DS, 1995, J BIOL CHEM, V270, P8319, DOI 10.1074/jbc.270.14.8319; KACINSKI BM, 1981, NATURE, V294, P480, DOI 10.1038/294480a0; Machius M, 1999, P NATL ACAD SCI USA, V96, P11717, DOI 10.1073/pnas.96.21.11717; Malta E, 2006, J BIOL CHEM, V281, P2184, DOI 10.1074/jbc.M508901200; Moolenaar GF, 2000, J BIOL CHEM, V275, P8038, DOI 10.1074/jbc.275.11.8038; Moolenaar GF, 2002, P NATL ACAD SCI USA, V99, P1467, DOI 10.1073/pnas.032584099; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; Nakagawa N, 1999, J BIOCHEM, V126, P986, DOI 10.1093/oxfordjournals.jbchem.a022566; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PANUSKA JR, 1980, J BIOL CHEM, V255, P5208; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; Ratcliff GC, 2001, J AM CHEM SOC, V123, P5632, DOI 10.1021/ja005750n; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; Schofield MJ, 1998, BIOCHEMISTRY-US, V37, P7733, DOI 10.1021/bi980399s; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; Skorvaga M, 2002, J BIOL CHEM, V277, P1553, DOI 10.1074/jbc.M108847200; Sohi M, 2000, FEBS LETT, V465, P161, DOI 10.1016/S0014-5793(99)01690-7; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Theis K, 2000, MUTAT RES-DNA REPAIR, V460, P277, DOI 10.1016/S0921-8777(00)00032-X; THIAGALINGAM S, 1993, J BIOL CHEM, V268, P18382; Truglio JJ, 2006, NAT STRUCT MOL BIOL, V13, P360, DOI 10.1038/nsmb1072; Truglio JJ, 2004, EMBO J, V23, P2498, DOI 10.1038/sj.emboj.7600263; Van Houten B, 2005, MUTAT RES-FUND MOL M, V577, P92, DOI 10.1016/j.mrfmmm.2005.03.013; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; Verhoeven EEA, 2002, EMBO J, V21, P4196, DOI 10.1093/emboj/cdf396; Verhoeven EEA, 2001, EMBO J, V20, P601, DOI 10.1093/emboj/20.3.601; Wang H, 2003, P NATL ACAD SCI USA, V100, P14822, DOI 10.1073/pnas.2433654100; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; Yamagata A, 2000, J BIOL CHEM, V275, P13235, DOI 10.1074/jbc.275.18.13235; Yang Y, 2003, METHODS, V29, P175, DOI 10.1016/S1046-2023(02)00308-0; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889; ZOU Y, 1995, BIOCHEMISTRY-US, V34, P13582, DOI 10.1021/bi00041a038; Zou Y, 1997, J BIOL CHEM, V272, P4820, DOI 10.1074/jbc.272.8.4820	49	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15227	15237		10.1074/jbc.M601476200	http://dx.doi.org/10.1074/jbc.M601476200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16595666	hybrid			2022-12-25	WOS:000237922200026
J	Norwood, LE; Moss, TJ; Margaryan, NV; Cook, SL; Wright, L; Seftor, EA; Hendrix, MJC; Kirschmann, DA; Wallrath, LL				Norwood, Laura E.; Moss, Timothy J.; Margaryan, Naira V.; Cook, Sara L.; Wright, Lindsay; Seftor, Elisabeth A.; Hendrix, Mary J. C.; Kirschmann, Dawn A.; Wallrath, Lori L.			A requirement for dimerization of HP1(Hs alpha) in suppression of breast cancer invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONHISTONE CHROMOSOMAL-PROTEIN; HETEROCHROMATIN PROTEIN-1; CELL-CYCLE; HISTONE METHYLTRANSFERASE; METASTATIC PHENOTYPE; LYSINE 9; HP1; DROSOPHILA; BINDING; DOMAIN	The development and progression of cancer is controlled by gene expression, often regulated through chromatin packaging. Heterochromatin protein 1(Hs alpha) (HP1(Hs alpha)), one of three human HP1 family members, participates in heterochromatin formation and gene regulation. HP1(Hs alpha) possesses an amino-terminal chromodomain, which binds methylated lysine 9 of histone H3 (meK9 H3), and a carboxyl-terminal chromoshadow domain (CSD) that is required for dimerization and interaction with partner proteins. HP1(Hs alpha) is down-regulated in invasive metastatic breast cancer cells compared with poorly invasive nonmetastatic breast cancer cells. Expression of EGFP-HP1(Hs alpha) in highly invasive MDA-MB-231 cells causes a reduction in in vitro invasion, without affecting cell growth. Conversely, knock-down of HP1(Hs alpha) levels in the poorly invasive breast cancer cell line MCF-7 increased invasion, without affecting cell growth. To determine whether functions of the CSD were required for the regulation of invasion, mutant forms of HP1(Hs alpha) were expressed in MDA-MB-231 cells. A W174A mutation that disrupts interactions between HP1(Hs alpha) and PXVXL-containing partner proteins reduced invasion similar to that of the wild type protein. In contrast, an I165E mutation that disrupts dimerization of HP1(Hs alpha) did not decrease invasion. No gross changes in localization and abundance of HP1(Hs alpha), HP1(Hs gamma), and meK9 H3 were observed upon expression of wild type and mutant forms of HP1(Hs alpha) in MDA-MB-231 cells. Taken together, these data demonstrate that modulation of HP1(Hs alpha) alters the invasive potential of breast cancer cells through mechanisms requiring HP1 dimerization, but not interactions with PXVXL-containing proteins.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Childrens Mem Res Ctr, Chicago, IL 60611 USA	University of Iowa; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Wallrath, LL (corresponding author), Univ Iowa, Dept Biochem, 3136 Med Educ Res Facil, Iowa City, IA 52242 USA.	lori-wallrath@uiowa.edu		Wallrath, Lori/0000-0002-4391-7199	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adriance MC, 2005, BREAST CANCER RES, V7, P190, DOI 10.1186/bcr1286; Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; Balmain A, 2001, NAT REV CANCER, V1, P77, DOI 10.1038/35094086; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Bocchetta M, 2004, ONCOGENE, V23, P6484, DOI 10.1038/sj.onc.1207855; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; Cowieson NP, 2000, CURR BIOL, V10, P517, DOI 10.1016/S0960-9822(00)00467-X; Cryderman DE, 1998, CHROMOSOMA, V107, P277, DOI 10.1007/s004120050309; Cryderman DE, 2005, DEV DYNAM, V232, P767, DOI 10.1002/dvdy.20310; Danzer JR, 2004, DEVELOPMENT, V131, P3571, DOI 10.1242/dev.01223; De Lucia F, 2005, NUCLEIC ACIDS RES, V33, P2852, DOI 10.1093/nar/gki584; de Wit E, 2005, GENOME RES, V15, P1265, DOI 10.1101/gr.3198905; Debies MT, 2001, J MAMMARY GLAND BIOL, V6, P441, DOI 10.1023/A:1014739131690; Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Fresh facts, 2005, NZ HORT FACTS FIG 20; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayakawa T, 2003, J CELL SCI, V116, P3327, DOI 10.1242/jcs.00635; Hayes DF, 2001, J MAMMARY GLAND BIOL, V6, P375, DOI 10.1023/A:1014778713034; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; Khanna C, 2005, CARCINOGENESIS, V26, P513, DOI 10.1093/carcin/bgh261; Kirschmann DA, 2000, CANCER RES, V60, P3359; Kirschmann DA, 1999, BREAST CANCER RES TR, V55, P127; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lechner MS, 2005, BIOCHEM BIOPH RES CO, V331, P929, DOI 10.1016/j.bbrc.2005.04.016; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699; Lippman ME, 2005, BREAST CANCER RES TR, V90, P1, DOI 10.1007/s10549-004-1288-x; Lukasova E, 2005, J LEUKOCYTE BIOL, V77, P100, DOI 10.1189/jlb.0704388; Mimori K, 2005, CLIN EXP METASTAS, V22, P59, DOI 10.1007/s10585-005-4417-y; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Minc E, 2000, CYTOGENET CELL GENET, V90, P279, DOI 10.1159/000056789; Minc E., 2001, Methods in Cell Science, V23, P171, DOI 10.1023/A:1013168323754; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Nielsen AL, 2002, EMBO J, V21, P5797, DOI 10.1093/emboj/cdf560; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Norwood LE, 2004, GENE, V336, P37, DOI 10.1016/j.gene.2004.04.003; NORWOOD LE, 2004, CHEMTRACTS BIOCH MOL, V17, P308; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; PRICE JE, 1990, CANCER-AM CANCER SOC, V66, P1313, DOI 10.1002/1097-0142(19900915)66:14+<1313::AID-CNCR2820661403>3.0.CO;2-4; Sharma GG, 2003, MOL CELL BIOL, V23, P8363, DOI 10.1128/MCB.23.22.8363-8376.2003; Steeg Patricia S, 2003, Clin Breast Cancer, V4, P51, DOI 10.3816/CBC.2003.n.012; Steeg PS, 2004, JNCI-J NATL CANCER I, V96, DOI 10.1093/jnci/djh107; Sugimoto K, 2001, CELL STRUCT FUNCT, V26, P705, DOI 10.1247/csf.26.705; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiru A, 2004, EMBO J, V23, P489, DOI 10.1038/sj.emboj.7600088; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Verschure PJ, 2005, MOL CELL BIOL, V25, P4552, DOI 10.1128/MCB.25.11.4552-4564.2005; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wasenius VM, 2003, CLIN CANCER RES, V9, P68; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; Yamada T, 1999, J BIOCHEM, V125, P832, DOI 10.1093/oxfordjournals.jbchem.a022356; Yamamoto K, 2003, BIOCHEM BIOPH RES CO, V301, P287, DOI 10.1016/S0006-291X(02)03021-8; Yasuhara JC, 2005, P NATL ACAD SCI USA, V102, P10958, DOI 10.1073/pnas.0503424102; Yoshida BA, 2000, JNCI-J NATL CANCER I, V92, P1717, DOI 10.1093/jnci/92.21.1717	65	47	48	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18668	18676		10.1074/jbc.M512454200	http://dx.doi.org/10.1074/jbc.M512454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16648629	hybrid			2022-12-25	WOS:000238687300047
J	Matsuda, S; Matsuda, K; Yuzaki, M				Matsuda, Shinji; Matsuda, Keiko; Yuzaki, Michisuke			A new motif necessary and sufficient for stable localization of the delta 2 glutamate receptors at postsynaptic spines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HIPPOCAMPAL-NEURONS; DOMAIN-CONTAINING PROTEINS; AMPA RECEPTORS; SURFACE EXPRESSION; DENDRITIC SPINES; NMDA RECEPTOR; PURKINJE-CELLS; TRAFFICKING; SUBUNIT; PHOSPHORYLATION	The number of each subclass of ionotropic glutamate receptors (iGluRs) at the spines is differentially regulated either constitutively or in a neuronal activity-dependent manner. The delta 2 glutamate receptor (GluR delta 2) is abundantly expressed at the spines of Purkinje cell dendrites and controls synaptic plasticity in the cerebellum. To obtain clues to the trafficking mechanism of the iGluRs, we expressed wildtype or mutant GluR delta 2 in cultured hippocampal and Purkinje neurons and analyzed their intracellular localization using immunocytochemical techniques. Quantitative analysis revealed that deletion of the 20 amino acids at the center of the C terminus (region E) significantly reduced the amount of GluR delta 2 protein at the spines in both types of neurons. This effect was partially antagonized by the inhibition of endocytosis by high dose sucrose treatment or coexpression of dominant negative dynamin. In addition, mutant GluR delta 2 lacking the E region (GluR delta 2(Delta E)), but not wild-type GluR delta 2, was found to colocalize with the endosomal markers Rab4 and Rab7. Moreover, the antibody-feeding assay revealed that GluR delta 2(Delta E) was internalized more rapidly than GluR delta 2(wt). These results indicate that the E region (more specifically, a 12-amino-acid-long segment of the E2 region) is necessary for rendering GluR delta 2 resistant to endocytosis from the cell surface at the spines. Furthermore, insertion of the E2 region alone into the C terminus of the GluR1 subtype of iGluRs was sufficient to increase the amount of GluR1 proteins in the spines. Therefore, we propose that the E2 region of GluR delta 2 is necessary, and also sufficient, to inhibit endocytosis of the receptor from postsynaptic membranes.	Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan	Keio University	Yuzaki, M (corresponding author), Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	myuzaki@sc.itc.keio.ac.jp	Matsuda, Shinji/L-4727-2013; Yuzaki, Michisuke/K-5328-2013; Matsuda, Keiko/L-5778-2013; Matsuda, Shinji/GRR-5226-2022	Yuzaki, Michisuke/0000-0002-5750-3544; 				Agassandian C, 2000, BRAIN RES, V887, P444, DOI 10.1016/S0006-8993(00)03030-4; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Allison DW, 1998, J NEUROSCI, V18, P2423; Arnold FJL, 2005, J PHYSIOL-LONDON, V564, P3, DOI 10.1113/jphysiol.2004.077446; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Chung HJ, 2000, J NEUROSCI, V20, P7258; Dingledine R, 1999, PHARMACOL REV, V51, P7; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Hall RA, 1997, J BIOL CHEM, V272, P4135, DOI 10.1074/jbc.272.7.4135; Hall RA, 1997, NEUROSCIENCE, V78, P361, DOI 10.1016/S0306-4522(96)00525-8; Hayashi K, 1996, J NEUROSCI, V16, P7161; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hirai H, 1999, NEUROSCI RES, V34, P281, DOI 10.1016/S0168-0102(99)00061-9; Hirai H, 2003, NAT NEUROSCI, V6, P869, DOI 10.1038/nn1086; Hirai H, 2001, EUR J NEUROSCI, V14, P73, DOI 10.1046/j.0953-816x.2001.01630.x; Kohda K, 2003, MOL BRAIN RES, V110, P27, DOI 10.1016/S0169-328X(02)00561-2; Landsend AS, 1997, J NEUROSCI, V17, P834, DOI 10.1523/jneurosci.17-02-00834.1997; Lee SH, 2002, NEURON, V36, P661, DOI 10.1016/S0896-6273(02)01024-3; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Matsuda K, 2003, J NEUROSCI, V23, P10064; Matsuda S, 1999, J NEUROCHEM, V73, P1765, DOI 10.1046/j.1471-4159.1999.731765.x; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; Matsuda S, 2004, EUR J NEUROSCI, V19, P1683, DOI 10.1111/j.1460-9568.2004.03307.x; Matsuda S, 2002, EUR J NEUROSCI, V16, P1507, DOI 10.1046/j.1460-9568.2002.02219.x; MAYAT E, 1995, J NEUROSCI, V15, P2533, DOI 10.1523/JNEUROSCI.15-03-02533.1995; Osterweil E, 2005, J CELL BIOL, V168, P329, DOI 10.1083/jcb.200410091; Park M, 2004, SCIENCE, V305, P1972, DOI 10.1126/science.1102026; Schulz TW, 2004, J NEUROSCI, V24, P8584, DOI 10.1523/JNEUROSCI.2100-04.2004; Shen L, 2000, J NEUROSCI, V20, P7932; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Takayama C, 1996, DEV BRAIN RES, V92, P147, DOI 10.1016/0165-3806(95)00212-X; TAKEUCHI T, 2002, ABSTR ANN M SOC NEUR, V139, P139; Uemura T, 2004, MOL CELL NEUROSCI, V26, P330, DOI 10.1016/j.mcn.2004.02.007; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Wang Y, 2003, EUR J NEUROSCI, V17, P1581, DOI 10.1046/j.1460-9568.2003.02595.x; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Wyszynski M, 1998, J NEUROSCI, V18, P1383; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Yuzaki M, 2003, NEUROSCI RES, V46, P11, DOI 10.1016/S0168-0102(03)00036-1	44	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17501	17509		10.1074/jbc.M600240200	http://dx.doi.org/10.1074/jbc.M600240200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16636065	hybrid			2022-12-25	WOS:000238326300076
J	Park, CK; Kim, MS; Fang, Z; Li, HY; Jung, SJ; Choi, SY; Lee, SJ; Park, K; Kim, JS; Oh, SB				Park, Chul-Kyu; Kim, Mi Sun; Fang, Zhi; Li, Hai Ying; Jung, Sung Jun; Choi, Se-Young; Lee, Sung Joong; Park, Kyungpyo; Kim, Joong Soo; Oh, Seog Bae			Functional expression of thermo- transient receptor potential channels in dental primary afferent neurons - Implication for tooth pain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOCICEPTIVE NEURONS; SENSORY NEURONS; MESSENGER-RNA; TRP CHANNELS; NOXIOUS HEAT; RAT; CAPSAICIN; SENSATION; DISTINCT; CELLS	Temperature signaling can be initiated by members of transient receptor potential family (thermo-TRP) channels. Hot and cold substances applied to teeth usually elicit pain sensation. This study investigated the expression of thermo-TRP channels in dental primary afferent neurons of the rat identified by retrograde labeling with a fluorescent dye in maxillary molars. Single cell reverse transcription-PCR and immunohistochemistry revealed expression of TRPV1, TRPM8, and TRPA1 in subsets of such neurons. Capsaicin (a TRPV1 agonist), menthol (a TRPM8 agonist), and icilin (a TRPM8 and TRPA1 agonist) increased intracellular calcium and evoked cationic currents in subsets of neurons, as did the appropriate temperature changes (> 43 degrees, < 25 degrees, and < 17 degrees C, respectively). Some neurons expressed more than one TRP channel and responded to two or three corresponding stimuli (ligands or thermal stimuli). Immunohistochemistry and single cell reverse transcription-PCR following whole cell recordings provided direct evidence for the association between the responsiveness to thermo-TRP ligands and expression of thermo-TRP channels. The results suggest that activation of thermo-TRP channels expressed by dental afferent neurons contributes to tooth pain evoked by temperature stimuli. Accordingly, blockade of thermo-TRP channels will provide a novel therapeutic intervention for the treatment of tooth pain.	Seoul Natl Univ, Coll Dent, Dept Physiol, Seoul 110749, South Korea; Seoul Natl Univ, Coll Dent, Mol & Cellular Neurosci Program, Seoul 110749, South Korea; Seoul Natl Univ, Inst Dent Res, Seoul 110749, South Korea; Kangweon Natl Univ, Coll Med, Dept Physiol, Chunchon 200701, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Kangwon National University	Oh, SB (corresponding author), Seoul Natl Univ, Coll Dent, Dept Physiol, 28-2 Yeongeon Dong, Seoul 110749, South Korea.	odolbae@snu.ac.kr	OH, Seog Bae/AAQ-2478-2020	Choi, Se-Young/0000-0001-7534-5167				Abe J, 2005, MOL BRAIN RES, V136, P91, DOI 10.1016/j.molbrainres.2005.01.013; Andrew D, 2000, J PHYSIOL-LONDON, V529, P791, DOI 10.1111/j.1469-7793.2000.00791.x; Babes A, 2004, EUR J NEUROSCI, V20, P2276, DOI 10.1111/j.1460-9568.2004.03695.x; Brannstrom M, 1967, Caries Res, V1, P310; BRANNSTROM M, 1972, INT DENT J, V22, P219; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chaudhary P, 2001, J DENT RES, V80, P1518, DOI 10.1177/00220345010800060801; Chuang HH, 2004, NEURON, V43, P859, DOI 10.1016/j.neuron.2004.08.038; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Cook SP, 1997, NATURE, V387, P505, DOI 10.1038/387505a0; Dirajlal S, 2003, J NEUROPHYSIOL, V89, P513, DOI 10.1152/jn.00371.2002; DONG WK, 1985, BRAIN RES, V334, P389, DOI 10.1016/0006-8993(85)90239-2; Eckert SP, 1997, J NEUROSCI METH, V77, P183, DOI 10.1016/S0165-0270(97)00125-8; FORS U, 1984, PAIN, V18, P397, DOI 10.1016/0304-3959(84)90052-6; Galoyan SM, 2003, EUR J NEUROSCI, V18, P535, DOI 10.1046/j.1460-9568.2003.02775.x; Goodman MB, 2003, TRENDS NEUROSCI, V26, P643, DOI 10.1016/j.tins.2003.09.013; Hunt SP, 2001, NAT REV NEUROSCI, V2, P83, DOI 10.1038/35053509; Lai J, 2004, ANNU REV PHARMACOL, V44, P371, DOI 10.1146/annurev.pharmtox.44.101802.121627; Magloire H, 2003, J DENT RES, V82, P542, DOI 10.1177/154405910308200711; McKemy DD, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-16; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; MENGEL MKC, 1993, PAIN, V55, P159, DOI 10.1016/0304-3959(93)90145-F; Moran MM, 2004, CURR OPIN NEUROBIOL, V14, P362, DOI 10.1016/j.conb.2004.05.003; Morgan CR, 2005, J OROFAC PAIN, V19, P248; Nair PNR, 1995, ORAL SURG ORAL MED O, V80, P710; Nealen ML, 2003, J NEUROPHYSIOL, V90, P515, DOI 10.1152/jn.00843.2002; Okazawa M, 2004, NEUROSCI LETT, V359, P33, DOI 10.1016/j.neulet.2004.01.074; Pashley DH, 1996, CRIT REV ORAL BIOL M, V7, P104, DOI 10.1177/10454411960070020101; Patapoutian A, 2003, NAT REV NEUROSCI, V4, P529, DOI 10.1038/nrn1141; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Petruska JC, 2000, J NEUROPHYSIOL, V84, P2365, DOI 10.1152/jn.2000.84.5.2365; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Silbert SC, 2003, J NEUROSCI, V23, P34; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Stucky CL, 1999, J NEUROSCI, V19, P6497; TADDESE A, 1995, SCIENCE, V270, P1366, DOI 10.1126/science.270.5240.1366; Tominaga M, 2004, J NEUROBIOL, V61, P3, DOI 10.1002/neu.20079; Tracey WD, 2003, CELL, V113, P261, DOI 10.1016/S0092-8674(03)00272-1; Yang BH, 2003, J DENT RES, V82, P781, DOI 10.1177/154405910308201004	39	99	103	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17304	17311		10.1074/jbc.M511072200	http://dx.doi.org/10.1074/jbc.M511072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16595689	hybrid			2022-12-25	WOS:000238326300057
J	Zeng, Y; Zhuang, SH; Gloddek, J; Tseng, CC; Boss, GR; Pilz, RB				Zeng, Ying; Zhuang, Shunhui; Gloddek, Jutta; Tseng, Chi-Chuan; Boss, Gerry R.; Pilz, Renate B.			Regulation of cGMP-dependent protein kinase expression by Rho and Krurppel-like transcription factor-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; ARTERIAL SMOOTH-MUSCLE; SERUM RESPONSE FACTOR; GTP-BINDING PROTEIN; GROWTH-FACTOR-BETA; GENE-EXPRESSION; FAMILY GTPASES; NITRIC-OXIDE; CYCLIC-GMP; I-ALPHA	Type I cGMP-dependent protein kinase (PKG I) plays a major role in vascular homeostasis by mediating smooth muscle relaxation in response to nitric oxide, but little is known about the regulation of PKGI expression in smooth muscle cells. We found opposing effects of RhoA and Rac1 on cellular PKG I expression: (i) cell density-dependent changes in PKGI expression varied directly with Rac1 activity and inversely with RhoA activity; (ii) RhoA activation by calpeptin suppressed PKG I, whereas RhoA down-regulation by small interfering RNA increased PKG I expression; and (iii) PKG I promoter activity was suppressed in cells expressing active RhoA or Rho-kinase but was enhanced in cells expressing active Rac1 or a dominant negative RhoA. Sp1 consensus sequences in the PKG I promoter were required for Rho regulation and bound nuclear proteins in a cell density-dependent manner, including the Kruppel-like factor 4 (KLF4). KLF4 was identified as a major trans-acting factor at two proximal Sp1 sites; active RhoA suppressed KLF4 DNA binding and trans-activation potential on the PKG I promoter. Experiments with actin-binding agents suggested that RhoA could regulate KLF4 via its ability to induce actin polymerization. Regulation of PKG I expression by RhoA may explain decreased PKG I levels in vascular smooth muscle cells found in some models of hypertension and vascular injury.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Boston Univ, Sch Med, Gastroenterol Sect, Boston, MA 02118 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Boston University	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	rpilz@ucsd.edu		Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [R33CA089828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NCI NIH HHS [CA89828] Funding Source: Medline; NIAMS NIH HHS [AR051300] Funding Source: Medline; NIGMS NIH HHS [GM55586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Anderson PG, 2000, ARTERIOSCL THROM VAS, V20, P2192, DOI 10.1161/01.ATV.20.10.2192; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bois PRJ, 2005, MOL CELL BIOL, V25, P7645, DOI 10.1128/MCB.25.17.7645-7656.2005; Bonnevier J, 2004, J BIOL CHEM, V279, P5146, DOI 10.1074/jbc.M306532200; Browner NC, 2004, AM J PHYSIOL-CELL PH, V287, pC88, DOI 10.1152/ajpcell.00039.2004; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Casteel DE, 2002, J BIOL CHEM, V277, P32003, DOI 10.1074/jbc.M112332200; Chen JC, 2003, J BIOL CHEM, V278, P2807, DOI 10.1074/jbc.M207943200; Chen ZY, 2005, MOL PHARMACOL, V68, P1203, DOI 10.1124/mol.105.014944; Chen ZY, 2002, J BIOL CHEM, V277, P46831, DOI 10.1074/jbc.M204816200; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; CORNWELL TL, 1994, J VASC RES, V31, P330, DOI 10.1159/000159061; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Delarue FL, 2001, ONCOGENE, V20, P6531, DOI 10.1038/sj.onc.1204801; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Feil R, 2005, REV NEUROSCIENCE, V16, P23; Feinberg MW, 2005, J BIOL CHEM, V280, P38247, DOI 10.1074/jbc.M509378200; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Gao YS, 2004, AM J PHYSIOL-LUNG C, V286, pL786, DOI 10.1152/ajplung.00314.2003; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; Gudi T, 2002, J BIOL CHEM, V277, P37382, DOI 10.1074/jbc.M204491200; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; King KE, 2003, J BIOL CHEM, V278, P11661, DOI 10.1074/jbc.M211337200; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; Lin GT, 2004, J CELL BIOCHEM, V92, P104, DOI 10.1002/jcb.20043; Liu Y, 2003, J BIOL CHEM, V278, P48004, DOI 10.1074/jbc.M301902200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; Melichar VO, 2004, P NATL ACAD SCI USA, V101, P16671, DOI 10.1073/pnas.0405509101; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Moriki N, 2004, HYPERTENS RES, V27, P263, DOI 10.1291/hypres.27.263; Muniyappa R, 2000, AM J PHYSIOL-HEART C, V278, pH1762, DOI 10.1152/ajpheart.2000.278.6.H1762; Munzel T, 2003, CIRCULATION, V108, P2172, DOI 10.1161/01.CIR.0000094403.78467.C3; Nakagawa M, 2001, J CELL SCI, V114, P1829; Nickenig G, 2002, FASEB J, V16, P1077, DOI 10.1096/fj.01-0570com; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Orstavik S, 1997, GENOMICS, V42, P311, DOI 10.1006/geno.1997.4743; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ritt MG, 2000, CANCER LETT, V158, P73, DOI 10.1016/S0304-3835(00)00507-3; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Ruetten H, 1999, CIRC RES, V85, P534, DOI 10.1161/01.RES.85.6.534; Ruiz-Velasco N, 2004, BIOCHEM PHARMACOL, V67, P303, DOI 10.1016/j.bcp.2003.09.006; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Seasholtz TM, 2004, MOL INTERV, V4, P348, DOI 10.1124/mi.4.6.8; Seasholtz TM, 2001, CIRC RES, V89, P488, DOI 10.1161/hh1801.096337; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Seko T, 2003, CIRC RES, V92, P411, DOI 10.1161/01.RES.0000059987.90200.44; Sellak H, 2005, J BIOL CHEM, V280, P18425, DOI 10.1074/jbc.M500775200; Sellak H, 2002, CIRC RES, V90, P405, DOI 10.1161/hh0402.105898; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Sinnaeve P, 2002, CIRCULATION, V105, P2911, DOI 10.1161/01.CIR.0000018169.59205.CA; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Soff GA, 1997, J CLIN INVEST, V100, P2580, DOI 10.1172/JCI119801; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; Wang DZ, 2004, CURR OPIN GENET DEV, V14, P558, DOI 10.1016/j.gde.2004.08.003; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Wollert KC, 2002, HYPERTENSION, V39, P87, DOI 10.1161/hy1201.097292; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhuang SH, 2004, J BIOL CHEM, V279, P10397, DOI 10.1074/jbc.M313048200; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	76	28	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16951	16961		10.1074/jbc.M602099200	http://dx.doi.org/10.1074/jbc.M602099200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16632465	hybrid			2022-12-25	WOS:000238326300016
J	Ayad, WA; Locke, D; Koreen, IV; Harris, AL				Ayad, Wafaa A.; Locke, Darren; Koreen, Irina V.; Harris, Andrew L.			Heteromeric, but not homomeric, connexin channels are selectively permeable to inositol phosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; GUINEA-PIG LIVER; XENOPUS-OOCYTES; HELA-CELLS; SIZE; 1,4,5-TRISPHOSPHATE; PROTEINS; FORM; RAT; 1,3,4,5-TETRAKISPHOSPHATE	Previous work has shown that channels formed by both connexin (Cx)26 and Cx32 (heteromeric Cx26/Cx32 hemichannels) are selectively permeable to cAMP and cGMP. To further investigate differential connexin channel permeability among second messengers, and the influence of connexin channel composition on the selectivity, the permeability of inositol phosphates with one to four phosphate groups through homomeric Cx26, homomeric Cx32, and heteromeric Cx26/Cx32 channels was examined. Connexin channels were purified from transfected HeLa cells and from rat, mouse, and guinea pig livers, resulting in channels with a broad range of Cx26/Cx32 aggregate ratios. Permeability to inositol phosphates was assessed by flux through reconstituted channels. Surprisingly, myoinositol and all inositol phosphates tested were permeable through homomeric Cx32 and homomeric Cx26 channels. Even more surprising, heteromeric Cx26/Cx32 channels showed striking differences in permeability among inositol phosphates with three or four phosphate groups and among isomers of inositol triphosphate. Thus, heteromeric channels are selectively permeable among inositol phosphates, whereas the corresponding homomeric channels are not. There was no discernible difference in the permeability of channels with similar Cx26/Cx32 ratios purified from native and heterologous sources. The molecular selectivity of heteromeric channels among three inositol triphosphates could not be accounted for by simple connexin isoform stoichiometry distributions and therefore may depend on specific isoform radial arrangements within the hexameric channels. Dynamic regulation of channel composition in vivo may effectively and efficiently modulate intercellular signaling by inositol phosphates.	Univ Med & Dent New Jersey, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Ayad, WA (corresponding author), Univ Med & Dent New Jersey, Dept Physiol & Pharmacol, Newark, NJ 07103 USA.	elsayewa@umdnj.edu		Harris, Andrew/0000-0002-3782-0550	NIGMS NIH HHS [GM 61406, GM 36044] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061406, R01GM036044] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander DB, 2003, CURR MED CHEM, V10, P2045, DOI 10.2174/0929867033456927; Banach K, 2000, PFLUG ARCH EUR J PHY, V439, P248, DOI 10.1007/s004240050936; Bedner P, 2006, J BIOL CHEM, V281, P6673, DOI 10.1074/jbc.M511235200; Bedner P, 2003, EXP CELL RES, V291, P25, DOI 10.1016/S0014-4827(03)00323-9; Bevans CG, 1999, J BIOL CHEM, V274, P3711, DOI 10.1074/jbc.274.6.3711; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Bevans CG, 1999, J BIOL CHEM, V274, P3720, DOI 10.1074/jbc.274.6.3720; BEVANS CG, 1998, THESIS J HOPKINS U; Beyer EC, 2000, BRAZ J MED BIOL RES, V33, P391, DOI 10.1590/S0100-879X2000000400004; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; BRISSETTE JL, 1994, P NATL ACAD SCI USA, V91, P6453, DOI 10.1073/pnas.91.14.6453; Bruzzone R, 1996, BIOESSAYS, V18, P709, DOI 10.1002/bies.950180906; Cao FL, 1998, J CELL SCI, V111, P31; Cheley S, 2002, CHEM BIOL, V9, P829, DOI 10.1016/S1074-5521(02)00172-2; Cottrell GT, 2005, BBA-BIOMEMBRANES, V1711, P126, DOI 10.1016/j.bbamem.2004.11.013; Cottrell GT, 2002, AM J PHYSIOL-CELL PH, V282, pC1469, DOI 10.1152/ajpcell.00484.2001; CULLEN PJ, 1990, BIOCHEM J, V271, P549, DOI 10.1042/bj2710549; De Maio A, 2000, SHOCK, V14, P53, DOI 10.1097/00024382-200014010-00010; Diez JA, 1999, EUR J BIOCHEM, V262, P142, DOI 10.1046/j.1432-1327.1999.00343.x; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; Goldberg GS, 1998, EXP CELL RES, V239, P82, DOI 10.1006/excr.1997.3872; Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200; Gong XQ, 2001, CELL COMMUN ADHES, V8, P187, DOI 10.3109/15419060109080721; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; GREEN CR, 1988, PROC R SOC SER B-BIO, V233, P165, DOI 10.1098/rspb.1988.0016; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI [10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P, 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X]; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Harris AL, 2001, METH MOL B, V154, P357; HARRIS AL, 1989, J MEMBRANE BIOL, V109, P243, DOI 10.1007/BF01870281; HARRIS AL, 1992, MOL BRAIN RES, V15, P269, DOI 10.1016/0169-328X(92)90118-U; HEHRE W, 1973, GUIDE MOL MECH QUANT; Hermosura MC, 2000, NATURE, V408, P735, DOI 10.1038/35047115; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Koreen IV, 2004, BIOCHEM J, V383, P111, DOI 10.1042/BJ20040806; Kumar NM, 1999, NOVART FDN SYMP, V219, P6; KURAOKA A, 1993, J HISTOCHEM CYTOCHEM, V41, P971, DOI 10.1177/41.7.8390496; KURAOKA A, 2002, ZASSHI FUKUOKA ACTA, V93, P178; LAMPE PD, 1991, J STRUCT BIOL, V107, P281, DOI 10.1016/1047-8477(91)90053-Y; Locke D, 2004, EXP CELL RES, V298, P643, DOI 10.1016/j.yexcr.2004.05.003; Locke D, 2004, J BIOL CHEM, V279, P22883, DOI 10.1074/jbc.M401980200; LOCKE D, 2006, BIOPHYS J, V90, pA77; Martinez AD, 2002, CIRC RES, V90, P1100, DOI 10.1161/01.RES.0000019580.64013.31; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MESNIL M, 1995, CANCER RES, V55, P629; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; Murphy CT, 1996, MOL PHARMACOL, V50, P1223; Nicholson BJ, 2000, BRAZ J MED BIOL RES, V33, P369, DOI 10.1590/S0100-879X2000000400002; Nitsche JM, 2004, BIOPHYS J, V86, P2058, DOI 10.1016/S0006-3495(04)74267-8; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; Sims CE, 1998, J BIOL CHEM, V273, P4052, DOI 10.1074/jbc.273.7.4052; Smith PM, 2000, BIOCHEM J, V347, P77, DOI 10.1042/0264-6021:3470077; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; VEENSTRA RD, 1995, CIRC RES, V77, P1156, DOI 10.1161/01.RES.77.6.1156; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; WANG SSH, 1995, J GEN PHYSIOL, V105, P149, DOI 10.1085/jgp.105.1.149; Weber PA, 2004, BIOPHYS J, V87, P958, DOI 10.1529/biophysj.103.036350; Wei CJ, 2004, ANNU REV CELL DEV BI, V20, P811, DOI 10.1146/annurev.cellbio.19.111301.144309; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; White TW, 2003, NEWS PHYSIOL SCI, V18, P95, DOI 10.1152/nips.01430.2002; WHITE TW, 1994, J CELL BIOL, V125, P879, DOI 10.1083/jcb.125.4.879; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076	68	52	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16727	16739		10.1074/jbc.M600136200	http://dx.doi.org/10.1074/jbc.M600136200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16601118	hybrid			2022-12-25	WOS:000238165700067
J	Chilibeck, KA; Wu, T; Liang, C; Schellenberg, MJ; Gesner, EM; Lynch, JM; MacMillan, AM				Chilibeck, Kaari A.; Wu, Tao; Liang, Chao; Schellenberg, Matthew J.; Gesner, Emily M.; Lynch, Jeffrey M.; MacMillan, Andrew M.			FRET analysis of in vivo dimerization by RNA-editing enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DSRNA-BINDING DOMAIN; PRE-MESSENGER-RNAS; ADENOSINE-DEAMINASE; INOSINE; SIMILARITIES; ABUNDANT; CLONING; ADAR	Members of the ADAR (adenosine deaminase that acts on RNA) enzyme family catalyze the hydrolytic deamination of adenosine to inosine within double-stranded RNAs, a poorly understood process that is critical to mammalian development. We have performed fluorescence resonance energy transfer experiments in mammalian cells transfected with fluorophore-bearing ADAR1 and ADAR2 fusion proteins to investigate the relationship between these proteins. These studies conclusively demonstrate the homodimerization of ADAR1 and ADAR2 and also show that ADAR1 and ADAR2 form heterodimers in human cells. RNase treatment of cells expressing these fusion proteins changes their localization but does not affect dimerization. Taken together these results suggest that homo- and heterodimerization are important for the activity of ADAR family members in vivo and that these associations are RNA independent.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta	MacMillan, AM (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	andrew.macmillan@ualberta.ca						Athanasiadis A, 2004, PLOS BIOL, V2, P2144, DOI 10.1371/journal.pbio.0020391; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; Blow M, 2004, GENOME RES, V14, P2379, DOI 10.1101/gr.2951204; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; Carmell MA, 2004, NAT STRUCT MOL BIOL, V11, P214, DOI 10.1038/nsmb729; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Cho DSC, 2003, J BIOL CHEM, V278, P17093, DOI 10.1074/jbc.M213127200; DeCerbo J, 2005, CURR OPIN CELL BIOL, V17, P302, DOI 10.1016/j.ceb.2005.04.008; Desterro JMP, 2003, J CELL SCI, V116, P1805, DOI 10.1242/jcs.00371; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Gallo A, 2003, EMBO J, V22, P3421, DOI 10.1093/emboj/cdg327; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; Gerber A, 1997, RNA, V3, P453; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; Hough RF, 1997, RNA, V3, P356; Hurst SR, 1995, RNA, V1, P1051; Jaikaran DCJ, 2002, J BIOL CHEM, V277, P37624, DOI 10.1074/jbc.M204126200; Kent OA, 2004, ORG BIOMOL CHEM, V2, P1957, DOI 10.1039/b404932m; Kim DDY, 2004, GENOME RES, V14, P1719, DOI 10.1101/gr.2855504; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; Macbeth MR, 2005, SCIENCE, V309, P1534, DOI 10.1126/science.1113150; Macbeth MR, 2004, RNA, V10, P1563, DOI 10.1261/rna.7920904; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Morse DP, 1997, BIOCHEMISTRY-US, V36, P8429, DOI 10.1021/bi9709607; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120; Polson AG, 1996, NATURE, V380, P454; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Sansam CL, 2003, P NATL ACAD SCI USA, V100, P14018, DOI 10.1073/pnas.2336131100; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Tonkin LA, 2003, SCIENCE, V302, P1725, DOI 10.1126/science.1091340; Vitali P, 2005, J CELL BIOL, V169, P745, DOI 10.1083/jcb.200411129; Wang QD, 2004, J BIOL CHEM, V279, P4952, DOI 10.1074/jbc.M310162200; Yang JH, 2003, J BIOL CHEM, V278, P45833, DOI 10.1074/jbc.M308612200	45	52	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16530	16535		10.1074/jbc.M511831200	http://dx.doi.org/10.1074/jbc.M511831200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16618704	hybrid			2022-12-25	WOS:000238165700043
J	Lee, EW; Lai, YR; Zhang, HX; Unadkat, JD				Lee, Eun-Woo; Lai, Yurong; Zhang, Huixia; Unadkat, Jashvant D.			Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1) - Implications for interspecies differences in mitochondrial toxicity of fialuridine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EQUILIBRATIVE NUCLEOSIDE TRANSPORTERS; OUTER-MEMBRANE PROTEIN; FUNCTIONAL-CHARACTERIZATION; POLYMERASE-GAMMA; HEPATITIS-B; CELL-LINE; EXPRESSION; DNA; IMPORT; FIAU	We have previously shown that the human equilibrative nucleoside transporter 1 (hENT1) is expressed and functional in the mitochondrial membrane and that this expression enhances the mitochondrial toxicity of the nucleoside drug, fialuridine (FIAU) (Lai, Y., Tse, C. M., and Unadkat, J. D. (004) J. Biol. Chem. 279, 4490 4497). Here we report on identification of the mitochondrial targeting sequence of hENT1. Using confocal microscopy and different truncated and point mutants of hENT1-YFP (yellow fluorescent protein) expressed in Madin-Darby canine kidney cells, we identified amino acid residues Pro(71), Glu(72), and Asn(74) (the PEXN motif) of hENT1 as important in mitochondrial targeting of hENT1. Identification of this mitochondrial targeting sequence provides a possible explanation for the dramatic difference in mitochondrial toxicity of FIAU between humans and rodents. Although the mouse ENT1 (mENT1), expressed in Madin-Darby canine kidney cells, can transport FIAU, confocal microscopy showed that mENT1-GFP (green fluorescent protein) was not localized to the mitochondria. Consistent with this observation, mitochondria isolated from mouse livers did not transport FIAU. Sequence alignment of hENT1, mENT1, and rat ENT1 (rENT1) showed that the PEXN motif of hENT1 was substituted with a PAXS motif in both mENT1 and rENT1. Substitution of PAXS in mENT1 with PEXN (to create mENT1-PEXN-GFP) and of PEXN in hENT1 with PAXS (to create hENT1-PAXS-YFP) resulted in partial mitochondrial localization of mENT1-PEXN-GFP and loss of mitochondrial localization of hENT1-PAXS-YFP. This is the first time that the mitochondrial targeting signal of hENT1 has been identified. Our data suggest that the lack of mitochondrial toxicity of FIAU in mice is due to the lack of mENT1 targeting to and expression in the mitochondria.	Univ Washington, Dept Pharmaceut, Sch Pharm, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Unadkat, JD (corresponding author), Univ Washington, Dept Pharmaceut, Sch Pharm, Box 357610, Seattle, WA 98195 USA.	jash@u.washington.edu	Lai, Yurong/ABG-4485-2021; Lai, Yurong/GWV-6243-2022	Lai, Yurong/0000-0001-9505-333X; Unadkat, Jashvant/0000-0002-4820-8455	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054447] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54447] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Baldwin SA, 2005, J BIOL CHEM, V280, P15880, DOI 10.1074/jbc.M414337200; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; Cabrita MA, 2002, BIOCHEM CELL BIOL, V80, P623, DOI 10.1139/O02-153; Choi DS, 2004, NAT NEUROSCI, V7, P855, DOI 10.1038/nn1288; Colacino JM, 1996, ANTIVIR RES, V29, P125, DOI 10.1016/0166-3542(95)00836-5; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; *FOOD DRUG ADM, 1993, REP FDA TASK FORC HE; Hickman D, 1998, DRUG METAB DISPOS, V26, P207; Horn DM, 1997, ANTIVIR RES, V34, P71, DOI 10.1016/S0166-3542(96)01027-3; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; Kiss A, 2000, BIOCHEM J, V352, P363, DOI 10.1042/0264-6021:3520363; Kugawa F, 2004, LIFE SCI, V75, P287, DOI 10.1016/j.lfs.2003.11.032; Lai YR, 2004, J BIOL CHEM, V279, P4490, DOI 10.1074/jbc.M307938200; Lai YR, 2002, J BIOL CHEM, V277, P37711, DOI 10.1074/jbc.M204986200; LEWIS W, 1994, BIOCHEMISTRY-US, V33, P14620, DOI 10.1021/bi00252a030; Lewis W, 1996, P NATL ACAD SCI USA, V93, P3592, DOI 10.1073/pnas.93.8.3592; MANNING F, 1995, COMMITTEE REV FIALUR, P98; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; Morton DM, 1998, TOXICOL LETT, V103, P545, DOI 10.1016/S0378-4274(98)00263-X; Neve EPA, 2001, J BIOL CHEM, V276, P11317, DOI 10.1074/jbc.M008640200; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Pennycooke M, 2001, BIOCHEM BIOPH RES CO, V280, P951, DOI 10.1006/bbrc.2000.4205; PFANNER N, 1987, J BIOL CHEM, V262, P14851; Rapaport D, 2003, EMBO REP, V4, P948, DOI 10.1038/sj.embor.embor937; Rehling P, 2003, J MOL BIOL, V326, P639, DOI 10.1016/S0022-2836(02)01440-7; RETTIE AE, 1989, DRUG METAB DISPOS, V17, P265; RICHARDSON FC, 1994, P NATL ACAD SCI USA, V91, P12003, DOI 10.1073/pnas.91.25.12003; Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P11527, DOI 10.1074/jbc.273.19.11527; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; Yamada H, 2004, FEBS LETT, V578, P331, DOI 10.1016/j.febslet.2004.11.017	34	80	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16700	16706		10.1074/jbc.M513825200	http://dx.doi.org/10.1074/jbc.M513825200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16595656	hybrid			2022-12-25	WOS:000238165700064
J	Stockdale, C; Flaus, A; Ferreira, H; Owen-Hughes, T				Stockdale, Chris; Flaus, Andrew; Ferreira, Helder; Owen-Hughes, Tom			Analysis of nucleosome repositioning by yeast ISWI and Chd1 chromatin remodeling complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-PAIR RESOLUTION; RNA-POLYMERASE-II; HISTONE OCTAMER; IN-VIVO; DNA; BINDING; SITE; MOBILIZATION; TERMINATION; RADICALS	ISWI proteins form the catalytic core of a subset of ATP-dependent chromatin remodeling activities in eukaryotes from yeast to man. Many of these complexes have been found to reposition nucleosomes but with different directionalities. We find that the yeast Isw1a, Isw2, and Chd1 enzymes preferentially move nucleosomes toward more central locations on short DNA fragments whereas Isw1b does not. Importantly, the inherent positioning properties of the DNA play an important role in determining where nucleosomes are relocated to by all of these enzymes. However, a key difference is that the Isw1a, Isw2, and Chd1 enzymes are unable to move nucleosomes to positions closer than 15 bp from a DNA end, whereas Isw1b can. We also find that there is a correlation between the inability of enzymes to move nucleosomes close to DNA ends and the preferential binding to nucleosomes bearing linker DNA. These observations suggest that the accessibility of linker DNA together with the positioning properties of the underlying DNA play important roles in determining the outcome of remodeling by these enzymes.	Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Owen-Hughes, T (corresponding author), Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland.	t.a.owenhughes@dundee.ac.uk	Flaus, Andrew/D-5076-2011; Ferreira, Helder/K-9440-2013	Flaus, Andrew/0000-0002-5720-7139; Ferreira, Helder/0000-0001-9143-504X; Owen-Hughes, Tom/0000-0002-0618-8185	Wellcome Trust [064414] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alen C, 2002, MOL CELL, V10, P1441, DOI 10.1016/S1097-2765(02)00778-5; BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; Bruno M, 2004, METHOD ENZYMOL, V375, P211; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; DREW HR, 1991, J MOL BIOL, V219, P391, DOI 10.1016/0022-2836(91)90179-A; Eberharter A, 2001, EMBO J, V20, P3781, DOI 10.1093/emboj/20.14.3781; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; Fazzio TG, 2003, MOL CELL, V12, P1333, DOI 10.1016/S1097-2765(03)00436-2; Flaus A, 1999, METHOD ENZYMOL, V304, P251; Flaus A, 2003, MOL CELL BIOL, V23, P7767, DOI 10.1128/MCB.23.21.7767-7779.2003; Flaus A, 1996, P NATL ACAD SCI USA, V93, P1370, DOI 10.1073/pnas.93.4.1370; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Kagalwala MN, 2004, EMBO J, V23, P2092, DOI 10.1038/sj.emboj.7600220; Kang JG, 2002, EMBO J, V21, P1406, DOI 10.1093/emboj/21.6.1406; Kassabov SR, 2003, MOL CELL, V11, P391, DOI 10.1016/S1097-2765(03)00039-X; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Lusser A, 2005, NAT STRUCT MOL BIOL, V12, P160, DOI 10.1038/nsmb884; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Morillon A, 2003, CELL, V115, P425, DOI 10.1016/S0092-8674(03)00880-8; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Tran HG, 2000, EMBO J, V19, P2323, DOI 10.1093/emboj/19.10.2323; Tsukiyama T, 2002, NAT REV MOL CELL BIO, V3, P422, DOI 10.1038/nrm828; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Vary JC, 2003, MOL CELL BIOL, V23, P80, DOI 10.1128/MCB.23.1.80-91.2003; Zofall M, 2004, MOL CELL BIOL, V24, P10047, DOI 10.1128/MCB.24.22.10047-10057.2004	34	144	146	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16279	16288		10.1074/jbc.M600682200	http://dx.doi.org/10.1074/jbc.M600682200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16606615	Green Accepted, hybrid, Green Published, Green Submitted			2022-12-25	WOS:000238165700014
J	Ago, H; Oda, M; Takahashi, M; Tsuge, H; Ochi, S; Katunuma, N; Miyano, M; Sakurai, J				Ago, Hideo; Oda, Masataka; Takahashi, Masaya; Tsuge, Hideaki; Ochi, Sadayuki; Katunuma, Nobuhiko; Miyano, Masashi; Sakurai, Jun			Structural basis of the sphingomyelin phosphodiesterase activity in neutral sphingomyelinase from Bacillus cereus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUREUS ALPHA-TOXIN; CRYSTAL-STRUCTURE; ENDONUCLEASE; PROTEIN; SYSTEM; DOMAIN; SMCL	Sphingomyelinase (SMase) from Bacillus cereus (Bc-SMase) hydrolyzes sphingomyelin to phosphocholine and ceramide in a divalent metal ion-dependent manner. Bc-SMase is a homologue of mammalian neutral SMase (nSMase) and mimics the actions of the endogenous mammalian nSMase in causing differentiation, development, aging, and apoptosis. Thus Bc-SMase may be a good model for the poorly characterized mammalian nSMase. The metal ion activation of sphingomyelinase activity of Bc-SMase was in the order Co2+ >= Mn2+ >= Mg2+ >> Ca2+ >= Sr2+. The first crystal structures of Bc-SMase bound to Co2+, Mg2+, or Ca2+ were determined. The water-bridged double divalent metal ions at the center of the cleft in both the Co2+- and Mg2+-bound forms were concluded to be the catalytic architecture required for sphingomyelinase activity. In contrast, the architecture of Ca2+ binding at the site showed only one binding site. A further single metal-binding site exists at one side edge of the cleft. Based on the highly conserved nature of the residues of the binding sites, the crystal structure of Bc-SMase with bound Mg2+ or Co2+ may provide a common structural framework applicable to phosphohydrolases belonging to the DNase I-like folding superfamily. In addition, the structural features and site-directed mutagenesis suggest that the specific beta-hairpin with the aromatic amino acid residues participates in binding to the membrane-bound sphingomyelin substrate.	RIKEN, SPring Ctr 8, Harima Inst, Struct Biophys Lab, Sayo, Hyogo 675148, Japan; Tokushima Bunri Univ, Fac Pharmaceut Sci, Tokushima 7708514, Japan; Tokushima Bunri Univ, Inst Hlth Sci, Tokushima 7708514, Japan; Fujita Hlth Univ, Sch Med, Toyoake, Aichi 4701192, Japan	RIKEN; Tokushima Bunri University; Tokushima Bunri University; Fujita Health University	Ago, H (corresponding author), RIKEN, SPring Ctr 8, Harima Inst, Struct Biophys Lab, 1-1-1 Kouto, Sayo, Hyogo 675148, Japan.	ago@spring8.or.jp; sakurai@ph.bunri-u.ac.jp	Tsuge, Hideaki/ABF-6424-2021; Oda, Masataka/ABG-6047-2020; Miyano, Masashi/R-2785-2016	Miyano, Masashi/0000-0003-2253-6175; Tsuge, Hideaki/0000-0003-0166-9163; Ago, Hideo/0000-0002-9040-488X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benson DA, 2005, NUCLEIC ACIDS RES, V33, pD34, DOI 10.1093/nar/gki063; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BROWN ID, 1988, ACTA CRYSTALLOGR B, V44, P545, DOI 10.1107/S0108768188007712; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COLEMAN D, 1991, MOL MICROBIOL, V5, P933, DOI 10.1111/j.1365-2958.1991.tb00768.x; Fujii S, 1998, J BIOCHEM-TOKYO, V124, P1178, DOI 10.1093/oxfordjournals.jbchem.a022236; Goni FM, 2002, FEBS LETT, V531, P38, DOI 10.1016/S0014-5793(02)03482-8; Gonzalez-Zorn B, 1999, MOL MICROBIOL, V33, P510, DOI 10.1046/j.1365-2958.1999.01486.x; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; IKEZAWA H, 1978, BIOCHIM BIOPHYS ACTA, V528, P247; IKEZAWA H, 1986, ARCH BIOCHEM BIOPHYS, V249, P588, DOI 10.1016/0003-9861(86)90037-8; IKEZAWA H, 1980, ARCH BIOCHEM BIOPHYS, V199, P572, DOI 10.1016/0003-9861(80)90315-X; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Maita N, 2004, J BIOL CHEM, V279, P41067, DOI 10.1074/jbc.M406556200; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nesic D, 2004, NATURE, V429, P429, DOI 10.1038/nature02532; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Obama T, 2003, BIOL PHARM BULL, V26, P920; Obama T, 2003, J BIOCHEM, V133, P279, DOI 10.1093/jb/mvg038; Ochi S, 2004, J BIOL CHEM, V279, P12181, DOI 10.1074/jbc.M307046200; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; Openshaw AEA, 2005, J BIOL CHEM, V280, P35011, DOI 10.1074/jbc.M506800200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; TOMITA M, 1983, ARCH BIOCHEM BIOPHYS, V223, P202, DOI 10.1016/0003-9861(83)90586-6; TOMITA T, 1992, BIOCHIM BIOPHYS ACTA, V1104, P325, DOI 10.1016/0005-2736(92)90047-P; TOMITA T, 1992, J BIOL CHEM, V267, P13391; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9; Weichenrieder O, 2004, STRUCTURE, V12, P975, DOI 10.1016/j.str.2004.04.011; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V	38	66	67	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16157	16167		10.1074/jbc.M601089200	http://dx.doi.org/10.1074/jbc.M601089200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595670	hybrid			2022-12-25	WOS:000237996000069
J	Schomer-Miller, B; Higashimoto, T; Lee, YK; Zandi, E				Schomer-Miller, Beth; Higashimoto, Tomoyasu; Lee, Yung-Kang; Zandi, Ebrahim			Regulation of I kappa B kinase (IKK) complex by IKK gamma-dependent phosphorylation of the T-loop and C terminus of IKK beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; ACTIVATION; ALPHA; SUBUNIT; NEMO; COMPONENT; REQUIRES; PROTEIN; ENZYME; TAK1	The mechanistic relationship of phosphorylation of the C terminus of IKK beta with phosphorylation of its T-loop kinase domain within the IKK complex remained unclear. We investigated the regulatory role of the serine cluster residing immediately adjacent to the HLH domain and of the serines in the NEMO/IKK gamma-binding domain (NBD/gamma BD) in the C-terminal portion of IKK beta in MEFs deficient in IKK beta and IKK beta and in yeast reconstitution system. We show that phosphorylation events at the C terminus of IKK beta can be divided into autophosphorylation of the serine cluster adjacent to the HLH domain and phosphorylation of the NBD/gamma BD. Autophosphorylation of the serine cluster occurs immediately after IKK activation and requires IKK gamma. In MEFs, this autophosphorylation does not have the down-regulatory function on the IKK complex that was previously described ( 1). On the other hand, phosphorylation of the NBD/gamma BD regulates IKK gamma-dependent phosphorylation of the T-loop activation domain in IKK beta and, hence, IKK complex activation. Our study suggests that, within the IKK complex, modulation of the NBD/gamma BD by IKK gamma is upstream to the T-loop phosphorylation.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Pharm, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Zandi, E (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Mol Microbiol & Immunol, 1441 Eastlake Ave,Norris 6429, Los Angeles, CA 90033 USA.	Zandi@usc.edu		Higashimoto, Tomoyasu/0000-0003-0435-065X	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007578] Funding Source: NIH RePORTER; NIAAA NIH HHS [T32 AA07578] Funding Source: Medline; PHS HHS [R01 MG065325] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; BRUNET A, 1994, ONCOGENE, V9, P3379; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Huynh QK, 2000, J BIOL CHEM, V275, P25883, DOI 10.1074/jbc.M000296200; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Krappmann D, 2005, EMBO REP, V6, P321, DOI 10.1038/sj.embor.7400380; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; May MJ, 2004, J BIOL CHEM, V279, P45528, DOI 10.1074/jbc.M408579200; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; Prajapati S, 2004, J BIOL CHEM, V279, P1739, DOI 10.1074/jbc.M306273200; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Strack P, 2000, ONCOGENE, V19, P3529, DOI 10.1038/sj.onc.1203647; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	36	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15268	15276		10.1074/jbc.M513793200	http://dx.doi.org/10.1074/jbc.M513793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16597623	hybrid			2022-12-25	WOS:000237922200030
J	Li, AQ; Guo, H; Luo, XY; Sheng, JS; Yang, S; Yin, YQ; Zhou, JW; Zhou, JW				Li, Aiqun; Guo, Hong; Luo, Xiaoying; Sheng, Jiansong; Yang, Shuo; Yin, Yanqing; Zhou, Jianwei; Zhou, Jiawei			Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons	FASEB JOURNAL			English	Article						striatum; neurotrophic factor; PD; signal transduction	FIBROBLAST-GROWTH-FACTOR; BINDING PROTEIN-PHOSPHORYLATION; PARKINSONS-DISEASE; ENDOTHELIAL-CELLS; DEPLETED STRIATUM; FACTOR-2 ISOFORMS; GENE-EXPRESSION; RAT-BRAIN; C-FOS; RELEASE	Apomorphine (APO), a potent D1/D2 dopamine receptor agonist, is currently used as an antiparkinsonian drug. We have shown previously that APO stimulates synthesis and release of multiple trophic factors, such as brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), in both mesencephalic and striatal neurons, thereby effectively preventing dopaminergic neuron loss in vitro. The present study was designed to investigate the effects of APO on fibroblast growth factor-2 (FGF-2) expression and regulation in astrocytes, and furthermore, to identify signaling mechanisms underlying these effects. Here, we show that FGF-2 expression is robustly induced in cultured astrocytes in response to APO. FGF-2 expression was proportional to APO concentration and time-dependent. Conversely, treatment with S-APO, a derivative of R-APO lacking DA receptor agonist activity, did not alter FGF-2 levels. APO treatment resulted in enhanced cytosol FGF-2 immunoreactivity, export of high MW forms of FGF-2 to the cytoplasm from the nucleus and increased extracellular release of FGF-2. Interestingly, both high and low MW forms of FGF-2 were detectable in conditioned medium of APO-treated cultures. This APO-induced effect was correlated with activation of D1 and D2 receptors, as it could be either mimicked by dopamine receptor agonists (SKF38393, quinpirole) or partially blocked by antagonists (SCH23390, SKF83566, haloperidol). Activation of the D1 receptor preferentially increased PKA activity, whereas activation of the D2 receptor only promoted phosphorylation of MAPK. Importantly, APO-modulated FGF-2 expression was independent of Akt/phosphoinositide 3-kinase signaling. These data suggest that APO can enhance biosynthesis and release of FGF-2 through activation of dopamine receptors in striatal astrocytes. Both cAMP/PKA and MEK/MAPK signaling cascades are major steps mediating this process. -Li, A., Guo, H., Luo, X., Sheng, J., Yang, S., Yin, Y., Zhou, J., and Zhou, J. Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons.	Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China; Nanjing Med Univ, Inst Publ Hlth, Nanjing, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Nanjing Medical University	Zhou, JW (corresponding author), Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	jwzhou@sibs.ac.cn	SHENG, JIANSONG/K-1914-2013	Zhou, Jiawei/0000-0002-1844-9178				BAL A, 1994, MOL BRAIN RES, V23, P204, DOI 10.1016/0169-328X(94)90227-5; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911; Claus P, 2004, NEUROSCI LETT, V360, P117, DOI 10.1016/j.neulet.2004.01.046; COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2; Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Gerfen CR, 2002, J NEUROSCI, V22, P5042, DOI 10.1523/JNEUROSCI.22-12-05042.2002; Girault JA, 2004, ARCH NEUROL-CHICAGO, V61, P641, DOI 10.1001/archneur.61.5.641; Grothe C, 2000, NEUROSCIENCE, V100, P73, DOI 10.1016/S0306-4522(00)00247-5; Grunblatt E, 2001, J NEUROCHEM, V78, P1, DOI 10.1046/j.1471-4159.2001.00397.x; Guo H, 2002, EUR J NEUROSCI, V16, P1861, DOI 10.1046/j.1460-9568.2002.02256.x; Jang CG, 2002, ARCH PHARM RES, V25, P370, DOI 10.1007/BF02976641; Keefe KA, 1996, J COMP NEUROL, V367, P165, DOI 10.1002/(SICI)1096-9861(19960401)367:2<165::AID-CNE1>3.0.CO;2-3; KEEFE KA, 1995, NEUROSCIENCE, V66, P903, DOI 10.1016/0306-4522(95)00024-D; Kyriazis M, 2003, J ANTI-AGING MED, V6, P21, DOI 10.1089/109454503765361551; Lee HT, 2004, J BIOL CHEM, V279, P32325, DOI 10.1074/jbc.M405208200; Liu FC, 1996, NEURON, V17, P1133, DOI 10.1016/S0896-6273(00)80245-7; Manson AJ, 2001, BRAIN, V124, P331, DOI 10.1093/brain/124.2.331; Maragnoli ME, 2004, BIOL PSYCHIAT, V55, P1095, DOI 10.1016/j.biopsych.2004.02.003; Menet V, 2001, J NEUROSCI, V21, P6147; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Miyazaki I, 2004, BRAIN RES, V1029, P120, DOI 10.1016/j.brainres.2004.09.014; Moffett J, 1998, MOL BIOL CELL, V9, P2269, DOI 10.1091/mbc.9.8.2269; Ohta M, 2000, BIOCHEM BIOPH RES CO, V272, P18, DOI 10.1006/bbrc.2000.2732; OMALLEY EK, 1994, BRAIN RES, V647, P83, DOI 10.1016/0006-8993(94)91401-X; OTTO D, 1993, EUR J NEUROSCI, V5, P927, DOI 10.1111/j.1460-9568.1993.tb00943.x; OTTO D, 1993, J NEUROSCI RES, V34, P382, DOI 10.1002/jnr.490340403; PAUL ML, 1992, J NEUROSCI, V12, P3729, DOI 10.1523/jneurosci.12-10-03729.1992; Peng H, 2001, MOL BIOL CELL, V12, P449, DOI 10.1091/mbc.12.2.449; Piotrowicz RS, 1999, J CELL PHYSIOL, V178, P144, DOI 10.1002/(SICI)1097-4652(199902)178:2<144::AID-JCP3>3.0.CO;2-Z; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; Reuss B, 2003, CELL TISSUE RES, V313, P139, DOI 10.1007/s00441-003-0756-7; Sheng JS, 2004, EUR J NEUROSCI, V20, P873, DOI 10.1111/j.1460-9568.2004.03567.x; Smith GM, 1997, J NEUROSCI, V17, P9624; Taverna S, 2003, J BIOL CHEM, V278, P51911, DOI 10.1074/jbc.M304192200; TOOYAMA I, 1993, NEUROLOGY, V43, P372, DOI 10.1212/WNL.43.2.372; UBEDA A, 1993, FREE RADICAL BIO MED, V15, P159, DOI 10.1016/0891-5849(93)90055-Y; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Vincent SR, 1998, SYNAPSE, V29, P29, DOI 10.1002/(SICI)1098-2396(199805)29:1<29::AID-SYN3>3.3.CO;2-T; Wakisaka N, 2002, CANCER RES, V62, P6337; WOODWARD WR, 1992, J NEUROSCI, V12, P142; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; Yan Z, 1999, P NATL ACAD SCI USA, V96, P11607, DOI 10.1073/pnas.96.20.11607; Zanassi P, 1999, J NEUROSCI RES, V58, P544, DOI 10.1002/(SICI)1097-4547(19991115)58:4<544::AID-JNR7>3.0.CO;2-9; Zeng ZZ, 2002, J BIOL CHEM, V277, P41213, DOI 10.1074/jbc.M204508200	47	47	54	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8								10.1096/fj.05-5510fje	http://dx.doi.org/10.1096/fj.05-5510fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636101				2022-12-25	WOS:000240210300046
J	Sprangers, M; Feldhahn, N; Liedtke, S; Jumaa, H; Siebert, R; Muschen, M				Sprangers, M.; Feldhahn, N.; Liedtke, S.; Jumaa, H.; Siebert, R.; Mueschen, M.			SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells	ONCOGENE			English	Article						V(D)J recombination; pre-B cell receptor; leukemia; SH2-domain; DNA rearrangement	EXPRESSION; REARRANGEMENT; TRANSITION; SELECTION; RECEPTOR	Perpetual V(D)J recombinase activity involving multiple DNA double-strand break events in B-cell lineage leukemia and lymphoma cells may introduce secondary genetic aberrations leading towards malignant progression. Here, we investigated defective negative feedback signaling through the (pre-)B-cell receptor as a possible reason for deregulated V(D)J recombinase activity in B-cell malignancy. On studying 28 cases of pre-B-lymphoblastic leukemia and 27 B-cell lymphomas, expression of the (pre-) B-cell receptor-related linker molecule SLP65 (SH2 domain-containing lymphocyte protein of 65 kDa) was found to be defective in seven and five cases, respectively. SLP65 deficiency correlates with RAG1/2 expression and unremitting V-H gene rearrangement activity. Reconstitution of SLP65 expression in SLP65-deficient leukemia and lymphoma cells results in downregulation of RAG1/2 expression and prevents both de novo V-H-DJ(H) rearrangements and secondary V-H replacement. We conclude that iterative V-H gene rearrangement represents a frequent feature in B-lymphoid malignancy, which can be attributed to SLP65 deficiency in many cases.	Univ Dusseldorf, Lab Mol Stem Cell Biol, D-40225 Dusseldorf, Germany; Max Planck Inst Immunbiol, D-7800 Freiburg, Germany; Univ Hosp Schleswig, Inst Human Genet, Kiel, Germany	Heinrich Heine University Dusseldorf; Max Planck Society; University of Kiel; Schleswig Holstein University Hospital	Muschen, M (corresponding author), Univ Dusseldorf, Lab Mol Stem Cell Biol, Moorenstr 5, D-40225 Dusseldorf, Germany.	markus.mueschen@uni-duesseldorf.de	Siebert, Reiner/A-8049-2010					Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Hayashi K, 2003, IMMUNITY, V18, P825, DOI 10.1016/S1074-7613(03)00142-0; Height SE, 1996, BLOOD, V87, P5242, DOI 10.1182/blood.V87.12.5242.bloodjournal87125242; Imai C, 2004, LEUKEMIA, V18, P922, DOI 10.1038/sj.leu.2403349; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Klein F, 2005, J IMMUNOL, V174, P367, DOI 10.4049/jimmunol.174.1.367; Klein F, 2004, J EXP MED, V199, P673, DOI 10.1084/jem.20031637; Zhang ZX, 2003, IMMUNITY, V19, P21, DOI 10.1016/S1074-7613(03)00170-5	10	12	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5180	5186		10.1038/sj.onc.1209520	http://dx.doi.org/10.1038/sj.onc.1209520			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16636677				2022-12-25	WOS:000240063700011
J	Sakai, S; Akiyama, H; Sato, Y; Yoshioka, Y; Linhardt, RJ; Goda, Y; Maitani, T; Toida, T				Sakai, Shinobu; Akiyama, Hiroshi; Sato, Yuji; Yoshioka, Yasuo; Linhardt, Robert J.; Goda, Yukihiro; Maitani, Tamio; Toida, Toshihiko			Chondroitin sulfate intake inhibits the IgE-mediated allergic response by down-regulating Th2 responses in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-E PRODUCTION; DELTA-T-CELLS; ORAL TOLERANCE; HISTAMINE-RELEASE; AUTOIMMUNE-DISEASES; IMMUNE-RESPONSES; PROTEIN ANTIGENS; HEPARAN-SULFATE; RBL-2H3 CELLS; FOOD ALLERGY	Chondroitin sulfate ( CS) was administered orally to BALB/c mice immunized intraperitoneally with ovalbumin ( OVA) and/or dinitrophenylated OVA. The titers of antigen-specific IgE and IgG1 in mouse sera were determined. The antigen-specific IgE production by mice fed ad libitum with CS was significantly inhibited. We also examined the effect of feeding CS on immediate-type hypersensitivity. One hour after antigen stimulation, the ears of mice fed with CS swelled less than those of the control mice. Furthermore, the rise in serum histamine in the mice fed with CS under active systemic anaphylaxis was significantly lower than that in the controls. We next examined the pattern of cytokine production by splenocytes from mice followed by re-stimulation with OVA in vitro. The splenocytes from the mice fed with CS produced less interleukin (IL)-5, IL-10, and IL-13 than those from the control group. In contrast, the production of interferon-gamma and IL-2 by the splenocytes of mice fed with CS was not significantly different from those in the control mice. In addition, the production of transforming growth factor-beta from the splenocytes of mice fed with CS was significantly higher than that of the control mice. Furthermore, we showed that the percentages of CD4(+) cells, CD8(+) cells, and CD4(+) CD25(+) cells in the splenocytes of mice fed with CS are significantly higher than those of the control. These findings suggest that oral intake of CS inhibits the specific IgE production and antigen-induced anaphylactic response by up-regulating regulatory T-cell differentiation, followed by down-regulating the Th2 response.	Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan; Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan; Rensselaer Polytech Inst, Dept Chem, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Biol, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Chem & Biol Engn, Troy, NY 12180 USA	Chiba University; National Institute of Health Sciences - Japan; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute	Akiyama, H (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.	akiyama@nihs.go.jp			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052622, R01HL062244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL062244-05A1, R01 HL062244-06, R01 HL052622-09, R01 HL052622, R01 HL062244] Funding Source: Medline; NIGMS NIH HHS [R01 GM038060-16A2, R01 GM038060, R01 GM038060-17] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL MK, 1984, J ALLERGY CLIN IMMUN, V74, P687, DOI 10.1016/0091-6749(84)90231-8; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Akiyama H, 2005, FEBS LETT, V579, P4485, DOI 10.1016/j.febslet.2005.07.019; Akiyama H, 2004, BIOCHEM J, V382, P269, DOI 10.1042/BJ20031851; Akiyama H, 1999, BIOL PHARM BULL, V22, P551, DOI 10.1248/bpb.22.551; Alpan O, 2004, NAT IMMUNOL, V5, P615, DOI 10.1038/ni1077; BAICI A, 1992, RHEUMATOL INT, V12, P81, DOI 10.1007/BF00290259; Bali JP, 2001, SEMIN ARTHRITIS RHEU, V31, P58, DOI 10.1053/sarh.2000.24874; Beren J, 2001, EXP BIOL MED, V226, P144, DOI 10.1177/153537020122600213; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; Bourgeois P, 1998, OSTEOARTHR CARTILAGE, V6, P25, DOI 10.1016/S1063-4584(98)80008-3; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; COFFMAN RL, 1986, J IMMUNOL, V136, P949; Conrozier T, 1998, PRESSE MED, V27, P1862; CONTE A, 1995, ARZNEIMITTEL-FORSCH, V45-2, P918; Forchielli ML, 2005, BRIT J NUTR, V93, pS41, DOI 10.1079/BJN20041356; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; HUSBY S, 1994, J IMMUNOL, V152, P4663; Husby S, 2000, J PEDIATR GASTR NUTR, V30, pS13, DOI 10.1097/00005176-200001001-00003; Ishizeki K, 1997, INT J DEV BIOL, V41, P83; Kalliomaki M, 2003, CURR OPIN ALLERGY CL, V3, P15, DOI [10.1097/00130832-200302000-00003, 10.1097/01.all.0000053262.39029.a1]; KAWABE H, 1987, BIOCHEM BIOPH RES CO, V143, P467, DOI 10.1016/0006-291X(87)91377-5; KAWASAKI M, 1994, BIOL PHARM BULL, V17, P1321; Kelly G S, 1998, Altern Med Rev, V3, P27; KIMATA K, 1973, MOL CELL BIOCHEM, V1, P211, DOI 10.1007/BF01659331; MARKS DR, 1993, POSTGRAD MED, V93, P191; Matsuo N, 1997, ALLERGY, V52, P58, DOI 10.1111/j.1398-9995.1997.tb02546.x; Matsuzaki T, 1998, J DAIRY SCI, V81, P48, DOI 10.3168/jds.S0022-0302(98)75549-3; McCarty MF, 2000, MED HYPOTHESES, V54, P798, DOI 10.1054/mehy.1999.0954; MCKNIGHT AJ, 1994, J IMMUNOL, V152, P2172; MCMENAMIN C, 1995, J IMMUNOL, V154, P4390; Mosmann TR, 2005, J IMMUNOL, V175, P5; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; Mowat AM, 2004, ANN NY ACAD SCI, V1029, P1, DOI 10.1196/annals.1309.001; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Nagafuchi S, 2000, BIOSCI BIOTECH BIOCH, V64, P1459, DOI 10.1271/bbb.64.1459; Okunuki H, 2003, BIOL PHARM BULL, V26, P1260; Omata T, 1999, ARZNEIMITTELFORSCH, V49, P577; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROVETTA G, 1991, DRUG EXP CLIN RES, V17, P53; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakai S, 2002, ANAL BIOCHEM, V302, P169, DOI 10.1006/abio.2001.5545; Sakai S, 2002, IMMUNOL LETT, V84, P211, DOI 10.1016/S0165-2478(02)00181-5; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sato Y, 2004, BIOL PHARM BULL, V27, P978, DOI 10.1248/bpb.27.978; Scott JE, 2001, PATHOL BIOL, V49, P284, DOI 10.1016/S0369-8114(01)00152-3; Shibata Y, 2000, J IMMUNOL, V164, P1314, DOI 10.4049/jimmunol.164.3.1314; Shida K, 1998, INT ARCH ALLERGY IMM, V115, P278, DOI 10.1159/000069458; Sugai M, 2003, NAT IMMUNOL, V4, P25, DOI 10.1038/ni874; SWAIN SL, 1990, J IMMUNOL, V145, P3796; TESHIMA R, 1990, J AGR FOOD CHEM, V38, P1618, DOI 10.1021/jf00097a040; Theoharides TC, 2000, BRIT J PHARMACOL, V131, P1039, DOI 10.1038/sj.bjp.0703672; Tlaskalova-Hogenova H, 2004, IMMUNOL LETT, V93, P97, DOI 10.1016/j.imlet.2004.02.005; TOIDA T, 1993, ANAL SCI, V9, P53, DOI 10.2116/analsci.9.53; TOYODA H, 1988, ANAL SCI, V4, P381, DOI 10.2116/analsci.4.381; Toyoda H, 1999, J CHROMATOGR A, V830, P197, DOI 10.1016/S0021-9673(98)00854-1; VanHouten N, 1996, J IMMUNOL, V157, P1337; Wrenshall LE, 1999, J LEUKOCYTE BIOL, V66, P391, DOI 10.1002/jlb.66.3.391; YUNGINGER JW, 1992, ANN ALLERGY, V69, P87	62	23	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19872	19880		10.1074/jbc.M509058200	http://dx.doi.org/10.1074/jbc.M509058200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16624819	Green Accepted, hybrid			2022-12-25	WOS:000239038200010
J	Kasahara, T; Ishiguro, M; Kasahara, M				Kasahara, Toshiko; Ishiguro, Masaji; Kasahara, Michihiro			Eight amino acid residues in transmembrane segments of yeast glucose transporter Hxt2 are required for high affinity transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR FACILITATOR SUPERFAMILY; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; STRUCTURAL MODEL; GAL2 TRANSPORTER; MECHANISM; RECOGNITION; FAMILY; GLUT1	Hxt2 and Hxt1 are high affinity and low affinity facilitative glucose transporter paralogs of Saccharomyces cerevisiae, respectively, that differ at 75 amino acid positions in their 12 transmembrane segments (TMs). Comprehensive analysis of chimeras of these two proteins has previously revealed that TMs 1, 5, 7, and 8 of Hxt2 are required for high affinity glucose transport activity and that leucine 201 in TM5 is the most important in this regard of the 20 amino acid residues in these regions that differ between Hxt2 and Hxt1. To evaluate the importance of the remaining residues, we systematically shuffled the amino acids at these positions and screened the resulting proteins for high affinity and high capacity glucose transport activity. In addition to leucine 201 (TM5), four residues of Hxt2 (leucine 59 and leucine 61 in TM1, asparagine 331 in TM7, and phenylalanine 366 in TM8) were found to be important for such activity. Furthermore, phenylalanine 198 (TM5), alanine 363 (TM8), and either valine 316 (TM7) or alanine 368 (TM8) were found to be supportive of maximal activity. Construction of a homology model suggested that asparagine 331 interacts directly with the substrate and that the other identified residues may contribute to maintenance of protein conformation.	Teikyo Univ, Sch Med, Biophys Lab, Hachioji, Tokyo 1920395, Japan; Teikyo Univ, Genome Res Ctr, Hachioji, Tokyo 1920395, Japan; Suntory Inst Bioorgan Res, Shimamoto, Osaka 6188503, Japan	Teikyo University; Teikyo University; Suntory Holdings Ltd	Kasahara, M (corresponding author), Teikyo Univ, Sch Med, Biophys Lab, Hachioji, Tokyo 1920395, Japan.	kasahara@main.teikyo-u.ac.jp						Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Hirai T, 2003, J BACTERIOL, V185, P1712, DOI 10.1128/JB.185.5.1712-1718.2003; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Kasahara M, 1996, FEBS LETT, V389, P174, DOI 10.1016/0014-5793(96)00567-4; Kasahara M, 1997, J BIOL CHEM, V272, P16721, DOI 10.1074/jbc.272.27.16721; Kasahara T, 2004, J BIOL CHEM, V279, P30274, DOI 10.1074/jbc.M403762200; Kasahara T, 2003, BIOCHEM J, V372, P247, DOI 10.1042/BJ20030044; Kasahara T, 1996, BIOCHEM J, V315, P177, DOI 10.1042/bj3150177; Kasahara T, 2000, J BIOL CHEM, V275, P4422, DOI 10.1074/jbc.275.6.4422; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; Manolescu A, 2005, J BIOL CHEM, V280, P42978, DOI 10.1074/jbc.M508678200; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Salas-Burgos A, 2004, BIOPHYS J, V87, P2990, DOI 10.1529/biophysj.104.047886; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vardy E, 2004, PROTEIN SCI, V13, P1832, DOI 10.1110/ps.04657704; Wood JM, 2005, BIOCHEMISTRY-US, V44, P5634, DOI 10.1021/bi047383o; Ye L, 1999, J BACTERIOL, V181, P4673, DOI 10.1128/JB.181.15.4673-4675.1999	19	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18532	18538		10.1074/jbc.M602123200	http://dx.doi.org/10.1074/jbc.M602123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16636054	hybrid			2022-12-25	WOS:000238687300032
J	Gu, XS; Ke, S; Liu, D; Sheng, T; Thomas, PE; Rabson, AB; Gallo, MA; Xie, W; Tian, YN				Gu, Xinsheng; Ke, Sui; Liu, Duan; Sheng, Tao; Thomas, Paul E.; Rabson, Arnold B.; Gallo, Michael A.; Xie, Wen; Tian, Yanan			Role of NF-kappa B in regulation of PXR-mediated gene expression - A mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; ARYL-HYDROCARBON RECEPTOR; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL ACTIVATION; DRUG-METABOLISM; AH RECEPTOR; NUCLEAR; LIVER; INFLAMMATION; CYP3A4	It is a long-standing observation that inflammatory responses and infections decrease drug metabolism capacity in human and experimental animals. Cytochrome P-450 3A4 cyp304 is responsible for the metabolism of over 50% of current prescription drugs, and cyp3a4 expression is transcriptionally regulated by pregnane X receptor (PXR), which is a ligand-dependent transcription factor. In this study, we report that NF-kappa B activation by lipopolysaccharide and tumor necrosis factor-alpha plays a pivotal role in the suppression of cyp3a4 through interactions of NF-kappa B with the PXR . retinoid X receptor (RXR) complex. Inhibition of NF-kappa B by NF-kappa B-specific suppressor SRI kappa B alpha reversed the suppressive effects of lipopolysaccharide and tumor necrosis factor-alpha. Furthermore, we showed that NF-kappa B p65 disrupted the association of the PXR . RXR alpha complex with DNA sequences as determined by electrophoretic mobility shift assay and chromatin immunoprecipitation assays. NF-kappa B p65 directly interacted with the DNA-binding domain of RXR alpha and may prevent its binding to the consensus DNA sequences, thus inhibiting the transactivation by the PXR . RXR alpha complex. This mechanism of suppression by NF-kappa B activation may be extended to other nuclear receptor-regulated systems where RXR alpha is a dimerization partner.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15213 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Rutgers State Univ, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, EOSHI, Piscataway, NJ 08854 USA; Univ Texas, Med Branch, Galveston, TX 77555 USA	Texas A&M University System; Texas A&M University College Station; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Texas System; University of Texas Medical Branch Galveston	Tian, YN (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, Mail Stop 4466, College Stn, TX 77843 USA.	ytian@cvm.tamu.edu	Xie, Wen/M-1768-2016		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009859, P30ES009106, P30ES005022] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 09106, P30 ES005022, ES 09859] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdulla D, 2005, DRUG METAB DISPOS, V33, P1521, DOI 10.1124/dmd.105.004564; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Bairoch A, 2005, NUCLEIC ACIDS RES, V33, pD154, DOI 10.1093/nar/gki070; Beigneux AP, 2002, BIOCHEM BIOPH RES CO, V293, P145, DOI 10.1016/S0006-291X(02)00196-1; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Goodwin B, 2004, TRENDS PHARMACOL SCI, V25, P437, DOI 10.1016/j.tips.2004.06.007; Goralski KB, 2005, AM J PHYSIOL-GASTR L, V289, pG434, DOI 10.1152/ajpgi.00562.2004; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Guo GL, 2002, MOL PHARMACOL, V61, P832, DOI 10.1124/mol.61.4.832; Handschin C, 2003, PHARMACOL REV, V55, P649, DOI 10.1124/pr.55.4.2; Honkakoski P, 2003, ANN MED, V35, P172, DOI 10.1080/07853890310008224; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Ke S, 2001, J BIOL CHEM, V276, P39638, DOI 10.1074/jbc.M106286200; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kullak-Ublick GA, 2004, GASTROENTEROLOGY, V126, P322, DOI 10.1053/j.gastro.2003.06.005; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; Li N, 2004, MOL PHARMACOL, V66, P694; Martinez-Jimenez CP, 2005, MOL PHARMACOL, V67, P2088, DOI 10.1124/mol.104.008169; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; Morgan ET, 1997, DRUG METAB REV, V29, P1129, DOI 10.3109/03602539709002246; Morgan ET, 2002, TOXICOLOGY, V181, P207, DOI 10.1016/S0300-483X(02)00283-4; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; PIROVINO M, 1989, GASTROENTEROLOGY, V96, P1589, DOI 10.1016/0016-5085(89)90531-3; Quattrochi LC, 2001, DRUG METAB DISPOS, V29, P615; Renton KW, 2004, CURR DRUG METAB, V5, P235, DOI 10.2174/1389200043335559; Richardson TA, 2005, J PHARMACOL EXP THER, V314, P703, DOI 10.1124/jpet.105.085456; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Tian YN, 2003, J BIOL CHEM, V278, P44041, DOI 10.1074/jbc.M306443200; Tian YN, 2002, CHEM-BIOL INTERACT, V141, P97, DOI 10.1016/S0009-2797(02)00068-6; Wang S, 2004, J BIOL CHEM, V279, P13593, DOI 10.1074/jbc.M312274200; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Xiao CC, 2005, ADV EXP MED BIOL, V560, P41; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800	39	242	256	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17882	17889		10.1074/jbc.M601302200	http://dx.doi.org/10.1074/jbc.M601302200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16608838	hybrid			2022-12-25	WOS:000238490300038
J	Shen, G; Saunee, NA; Williams, SR; Gallo, EF; Schluchter, WM; Bryant, DA				Shen, Gaozhong; Saunee, Nicolle A.; Williams, Shervonda R.; Gallo, Eduardo F.; Schluchter, Wendy M.; Bryant, Donald A.			Identification and characterization of a new class of bilin lyase - The cpcT gene encodes a bilin lyase responsible for attachment of phycocyanobilin to CYS-153 on the beta-subunit of phycocyanin in synechococcus sp PCC 7002	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM MASTIGOCLADUS-LAMINOSUS; LIGHT-HARVESTING PROTEINS; ANABAENA SP PCC-7120; SP STRAIN PCC-7942; C-PHYCOCYANIN; ALPHA-SUBUNIT; LINKER-POLYPEPTIDE; ENERGY-TRANSFER; CHROMOPHORE ATTACHMENT; CRYSTAL-STRUCTURE	Synechococcus sp. PCC 7002 and all other cyanobacteria that synthesize phycocyanin have a gene, cpcT, that is paralogous to cpeT, a gene of unknown function affecting phycoerythrin synthesis in Fremyella diplosiphon. A cpcT null mutant contains 40% less phycocyanin than wild type and produces smaller phycobilisomes with red-shifted absorbance and fluorescence emission maxima. Phycocyanin from the cpcT mutant has an absorbance maximum at 634 nm compared with 626 nm for the wild type. The phycocyanin beta-subunit from the cpcT mutant has slightly smaller apparent molecular weight on SDS-PAGE. Purified phycocyanins from the cpcT mutant and wild type were cleaved with formic acid, and the products were analyzed by SDS-PAGE. No phycocyanobilin chromophore was bound to the peptide containing Cys-153 derived from the phycocyanin beta-subunit of the cpcT mutant. Recombinant CpcT was used to perform in vitro bilin addition assays with apophycocyanin (CpcA/CpcB) and phycocyanobilin. Depending on the source of phycocyanobilin, reaction products with CpcT had absorbance maxima between 597 and 603 nm as compared with 638 nm for the control reactions, in which mesobiliverdin becomes covalently bound. After trypsin digestion and reverse phase high performance liquid chromatography, the CpcT reaction product produced one major phycocyanobilin-containing peptide. This peptide had a retention time identical to that of the tryptic peptide that includes phycocyanobilin-bound, cysteine 153 of wild-type phycocyanin. The results from characterization of the cpcT mutant as well as the in vitro biochemical assays demonstrate that CpcT is a new phycocyanobilin lyase that specifically attaches phycocyanobilin to Cys-153 of the phycocyanin beta-subunit.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ New Orleans, Dept Biol Sci, New Orleans, LA 70148 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Louisiana System; University of New Orleans	Bryant, DA (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	dab14@psu.edu	Schluchter, Wendy/G-9662-2013; Gallo, Eduardo/GPP-1460-2022	Gallo, Eduardo F./0000-0001-9906-1425	NIGMS NIH HHS [GM 31625] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031625] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson LK, 1998, MOL MICROBIOL, V30, P467, DOI 10.1046/j.1365-2958.1998.01081.x; ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; ARCIERO DM, 1988, J BIOL CHEM, V263, P18350; BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; BETZ M, 1993, BIOL CHEM H-S, V374, P435, DOI 10.1515/bchm3.1993.374.7-12.435; BHALERAO RP, 1995, PHOTOCHEM PHOTOBIOL, V61, P298, DOI 10.1111/j.1751-1097.1995.tb03975.x; BRYANT DA, 1978, J BIOL CHEM, V253, P220; BRYANT DA, 1976, ARCH MICROBIOL, V110, P61, DOI 10.1007/BF00416970; BRYANT DA, 1979, ARCH MICROBIOL, V123, P113, DOI 10.1007/BF00446810; Cai YA, 2001, ANAL BIOCHEM, V290, P186, DOI 10.1006/abio.2000.4979; COBLEY J, 2000, 10 INT S PHOT PROK B, P81; Cobley JG, 2002, MOL MICROBIOL, V44, P1517, DOI 10.1046/j.1365-2958.2002.02966.x; COLLIER JL, 1992, J BACTERIOL, V174, P4718, DOI 10.1128/JB.174.14.4718-4726.1992; DEBRECZENY MP, 1995, J PHYS CHEM-US, V99, P8420, DOI 10.1021/j100020a081; DEBRECZENY MP, 1993, J PHYS CHEM-US, V97, P9852, DOI 10.1021/j100140a050; DELORIMIER R, 1990, ARCH MICROBIOL, V153, P541, DOI 10.1007/BF00245263; Dolganov N, 1999, J BACTERIOL, V181, P610, DOI 10.1128/JB.181.2.610-617.1999; Douglas S, 2001, NATURE, V410, P1091, DOI 10.1038/35074092; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; DUERRING M, 1990, J MOL BIOL, V211, P633, DOI 10.1016/0022-2836(90)90270-V; Enggist E, 2003, J BACTERIOL, V185, P175, DOI 10.1128/JB.185.1.175-183.2003; FAIRCHILD CD, 1994, J BIOL CHEM, V269, P8686; FAIRCHILD CD, 1992, P NATL ACAD SCI USA, V89, P7017, DOI 10.1073/pnas.89.15.7017; Frankenberg N, 2003, J BIOL CHEM, V278, P9219, DOI 10.1074/jbc.M211643200; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; GLAUSER M, 1993, PHOTOCHEM PHOTOBIOL, V57, P344, DOI 10.1111/j.1751-1097.1993.tb02298.x; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GLAZER AN, 1975, J BIOL CHEM, V250, P5487; GLAZER AN, 1971, P NATL ACAD SCI USA, V68, P1398, DOI 10.1073/pnas.68.7.1398; GLAZER AN, 1973, J BIOL CHEM, V248, P659; Herdman M, 2000, J MOL EVOL, V51, P205, DOI 10.1007/s002390010082; JUNG LJ, 1995, J BIOL CHEM, V270, P12877, DOI 10.1074/jbc.270.21.12877; Kahn K, 1997, J BACTERIOL, V179, P998, DOI 10.1128/jb.179.4.998-1006.1997; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; Kohchi T, 2001, PLANT CELL, V13, P425, DOI 10.1105/tpc.13.2.425; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamparter T, 2003, J BIOL CHEM, V278, P33786, DOI 10.1074/jbc.M305563200; Li H, 2002, ARCH MICROBIOL, V178, P256, DOI 10.1007/s00203-002-0446-y; Mann NH, 2005, J BACTERIOL, V187, P3188, DOI 10.1128/JB.187.9.3188-3200.2005; Martin KA, 2003, PHOTOSYNTH RES, V75, P211, DOI 10.1023/A:1023990402346; MIMURO M, 1986, BIOCHIM BIOPHYS ACTA, V848, P155, DOI 10.1016/0005-2728(86)90037-X; Mutsuda M, 2003, J BIOL CHEM, V278, P19102, DOI 10.1074/jbc.M213255200; OFFNER GD, 1983, J BIOL CHEM, V258, P9931; ONG LJ, 1987, J BIOL CHEM, V262, P6323; PARTIS MD, 1990, Z NATURFORSCH C, V45, P987; PIERCE AT, 2003, CHARACTERIZATION GEN; PLANK T, 1995, J BACTERIOL, V177, P6798, DOI 10.1128/jb.177.23.6798-6803.1995; PLANK T, 1995, J BACTERIOL, V177, P6804, DOI 10.1128/jb.177.23.6804-6809.1995; PORTER RD, 1988, METHOD ENZYMOL, V167, P703; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; Quest B, 2004, EUR J BIOCHEM, V271, P1117, DOI 10.1111/j.1432-1033.2004.04015.x; RAPS S, 1990, PLANT PHYSIOL, V92, P358, DOI 10.1104/pp.92.2.358; Ritter S, 1999, J STRUCT BIOL, V126, P86, DOI 10.1006/jsbi.1999.4106; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; SAUER K, 1987, PHOTOCHEM PHOTOBIOL, V46, P427, DOI 10.1111/j.1751-1097.1987.tb04790.x; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; SCHLUCHTER WM, 1994, THESIS PENNSYLVANIA; SCHLUCHTER WM, 1999, BIOSYNTHESIS PHYCOBI, P83; Schmitz O, 2000, SCIENCE, V289, P765, DOI 10.1126/science.289.5480.765; Shen G., 2004, PS 2004 LIGHT HARV S, P14; SHEN GZ, 1995, PHOTOSYNTH RES, V44, P41, DOI 10.1007/BF00018295; Steglich C, 2005, ENVIRON MICROBIOL, V7, P1611, DOI 10.1111/j.1462-2920.2005.00855.x; STEVENS SE, 1980, P NATL ACAD SCI-BIOL, V77, P6052, DOI 10.1073/pnas.77.10.6052; Storf M, 2001, BIOCHEMISTRY-US, V40, P12444, DOI 10.1021/bi010776s; SWANSON RV, 1992, J BIOL CHEM, V267, P16146; Tasler R, 2005, FEBS J, V272, P1927, DOI 10.1111/j.1742-4658.2005.04623.x; TERRY MJ, 1993, J BIOL CHEM, V268, P26099; Toole CM, 1998, MOL MICROBIOL, V30, P475, DOI 10.1046/j.1365-2958.1998.01082.x; Tooley AJ, 2002, J BACTERIOL, V184, P4666, DOI 10.1128/JB.184.17.4666-4671.2002; Wu SH, 2000, BIOCHEMISTRY-US, V39, P13487, DOI 10.1021/bi001123z; Zhao JD, 2001, BBA-BIOENERGETICS, V1505, P248, DOI 10.1016/S0005-2728(01)00175-X; Zhao KH, 2006, J BIOL CHEM, V281, P8573, DOI 10.1074/jbc.M513796200; Zhao KH, 2005, BIOCHEMISTRY-US, V44, P8126, DOI 10.1021/bi0500168; Zhao KH, 2005, BBA-BIOENERGETICS, V1706, P81, DOI 10.1016/j.bbabio.2004.09.008; Zhao KH, 2004, BIOCHEMISTRY-US, V43, P11576, DOI 10.1021/bi0491548; Zhao KH, 2004, BBA-BIOENERGETICS, V1657, P131, DOI 10.1016/j.bbabio.2004.04.010; Zhao KH, 2002, EUR J BIOCHEM, V269, P4542, DOI 10.1046/j.1432-1033.2002.03148.x; Zhao KH, 2000, FEBS LETT, V469, P9, DOI 10.1016/S0014-5793(00)01245-X; ZHOU J, 1992, THESIS PENNSYLVANIA; ZHOU JH, 1992, J BIOL CHEM, V267, P16138	81	74	80	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17768	17778		10.1074/jbc.M602563200	http://dx.doi.org/10.1074/jbc.M602563200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16644722	hybrid			2022-12-25	WOS:000238490300027
J	Sugimura, Y; Hosono, M; Wada, F; Yoshimura, T; Maki, M; Hitomi, K				Sugimura, Yoshiaki; Hosono, Masayo; Wada, Fumitaka; Yoshimura, Tohru; Maki, Masatoshi; Hitomi, Kiyotaka			Screening for the preferred substrate sequence of transglutaminase using a phage-displayed peptide library - Identification of peptide substrates for TGase 2 and Factor XIIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING ENZYMES; TISSUE TRANSGLUTAMINASE; CELIAC-DISEASE; GENE FAMILY; PROTEIN; SITES; DONOR; SPECIFICITY; ACCEPTOR; LYSINE	Mammalian transglutaminase (TGase) catalyzes covalent cross-linking of peptide-bound lysine residues or incorporation of primary amines to limited glutamine residues in substrate proteins. Using an unbiased M13 phage display random peptide library, we developed a screening system to elucidate primary structures surrounding reactive glutamine residue(s) that are preferred by TGase. Screening was performed by selecting phage clones expressing peptides that incorporated biotin-labeled primary amine by the catalytic reactions of TGase 2 and activated Factor XIII ( Factor XIIIa). We identified several amino acid sequences that were preferred as glutamine donor substrates, most of which have a marked tendency for individual TGases: TGase 2, QxP phi D( P), QxP phi, and Qxx phi DP; Factor XIIIa, Qxx phi xWP (where x and phi represent a non-conserved and a hydrophobic amino acid, respectively). We further confirmed that the sequences were favored for transamidation using modified glutathione S-transferase (GST) for recombinant peptide-GST fusion proteins. Most of the fusion proteins exhibited a considerable increase in incorporation of primary amines over that of modified GST alone. Furthermore, we identified the amino acid sequences that demonstrated higher specificity and inhibitory activity in the cross-linking reactions by TGase 2 and Factor XIIIa.	Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan	Nagoya University	Hitomi, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan.	hitomi@agr.nagoya-u.ac.jp	Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491				AbdAlla S, 2004, CELL, V119, P343, DOI 10.1016/j.cell.2004.10.006; ACHYUTHAN KE, 1993, J BIOL CHEM, V268, P21284; AESCHLIMANN D, 1992, J BIOL CHEM, V267, P11316; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Eckert RL, 2005, J INVEST DERMATOL, V124, P481, DOI 10.1111/j.0022-202X.2005.23627.x; Esposito C, 2005, FEBS J, V272, P615, DOI 10.1111/j.1742-4658.2004.04476.x; Facchiano AM, 2003, NUCLEIC ACIDS RES, V31, P379, DOI 10.1093/nar/gkg042; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Fleckenstein B, 2002, J BIOL CHEM, V277, P34109, DOI 10.1074/jbc.M204521200; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; GROENEN PJTA, 1992, EUR J BIOCHEM, V205, P671, DOI 10.1111/j.1432-1033.1992.tb16827.x; GROOTJANS JJ, 1995, J BIOL CHEM, V270, P22855, DOI 10.1074/jbc.270.39.22855; Hettasch JM, 1997, J BIOL CHEM, V272, P25149, DOI 10.1074/jbc.272.40.25149; Hitomi K, 2005, EUR J DERMATOL, V15, P313; Ichinose A, 2001, THROMB HAEMOSTASIS, V86, P57; ICHINOSE A, 1983, FEBS LETT, V153, P369, DOI 10.1016/0014-5793(83)80645-0; IKURA K, 1989, BIOCHEMISTRY-US, V28, P2344, DOI 10.1021/bi00431a054; LORAND L, 1991, P NATL ACAD SCI USA, V88, P82, DOI 10.1073/pnas.88.1.82; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Lowman H.B, 2004, PHAGE DISPLAY; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; Nishiura H, 1996, J BIOL CHEM, V271, P878, DOI 10.1074/jbc.271.2.878; Ostrowski M, 2002, J VIROL, V76, P4241, DOI 10.1128/JVI.76.9.4241-4250.2002; Pan WJ, 2003, J BIOL CHEM, V278, P27820, DOI 10.1074/jbc.M304436200; PARAMESWARAN KN, 1990, P NATL ACAD SCI USA, V87, P8472, DOI 10.1073/pnas.87.21.8472; Pastor MT, 1999, FEBS LETT, V451, P231, DOI 10.1016/S0014-5793(99)00572-4; PUCCI P, 1988, BIOCHEM BIOPH RES CO, V154, P735, DOI 10.1016/0006-291X(88)90201-X; Qiao SW, 2005, J IMMUNOL, V175, P254, DOI 10.4049/jimmunol.175.1.254; Ruoppolo M, 2003, PROTEIN SCI, V12, P1290, DOI 10.1110/ps.0239103; Schalkwijk J, 1999, BIOCHEM J, V340, P569, DOI 10.1042/0264-6021:3400569; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; Sollid LM, 2002, NAT REV IMMUNOL, V2, P647, DOI 10.1038/nri885; Standeven KF, 2005, BLOOD REV, V19, P275, DOI 10.1016/j.blre.2005.01.003; Terpe K, 2003, APPL MICROBIOL BIOT, V60, P523, DOI 10.1007/s00253-002-1158-6; Vader LW, 2002, J EXP MED, V195, P643, DOI 10.1084/jem.20012028; Wada F, 2002, EUR J BIOCHEM, V269, P3451, DOI 10.1046/j.1432-1033.2002.03026.x; Zeeuwen PLJM, 1997, J BIOL CHEM, V272, P20471, DOI 10.1074/jbc.272.33.20471	41	133	136	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17699	17706		10.1074/jbc.M513538200	http://dx.doi.org/10.1074/jbc.M513538200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636049	hybrid			2022-12-25	WOS:000238490300019
J	Zhang, WZ; Xia, XF; Reisenauer, MR; Hemenway, CS; Kone, BC				Zhang, Wenzheng; Xia, Xuefeng; Reisenauer, Mary Rose; Hemenway, Charles S.; Kone, Bruce C.			Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaC alpha in an aldosterone-sensitive manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; DUCT CELL-LINE; FUSION PARTNER; SET DOMAIN; METHYLATION; TRANSCRIPTION; SUBUNIT; MOUSE; RAD6; GENE	Aldosterone is a major regulator of epithelial Na+ absorption and acts in large part through induction of the epithelial Na+ channel (ENaC) gene in the renal collecting duct. We previously identified Dot1a as an aldosterone early repressed gene and a repressor of ENaC alpha transcription through mediating histone H3 Lys-79 methylation associated with the ENaC alpha promoter. Here, we report a novel aldosterone-signaling network involving AF9, Dot1a, and ENaC alpha. AF9 and Dot1a interact in vitro and in vivo as evidenced in multiple assays and colocalize in the nuclei of mIMCD3 renal collecting duct cells. Overexpression of AF9 results in hypermethylation of histone H3 Lys-79 at the endogenous ENaC alpha promoter at most, but not all subregions examined, repression of endogenous ENaC alpha mRNA expression and acts synergistically with Dot1a to inhibit ENaC alpha promoter-luciferase constructs. In contrast, RNA interference-mediated knockdown of AF9 causes the opposite effects. Chromatin immunoprecipitation assays reveal that overexpressed FLAG-AF9, endogenous AF9, and Dot1a are each associated with the ENaC alpha promoter. Aldosterone negatively regulates AF9 expression at both mRNA and protein levels. Thus, Dot1a-AF9 modulates histone H3 Lys-79 methylation at the ENaC alpha promoter and represses ENaC alpha transcription in an aldosterone-sensitive manner. This mechanism appears to be more broadly applicable to other aldosterone-regulated genes because overexpression of AF9 alone or in combination with Dot1a inhibited mRNA levels of three other known aldosterone-inducible genes in mIMCD3 cells.	Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA; Univ Texas, Ctr Hlth Sci, Dept Internal Med, Houston, TX 77030 USA; Univ Texas, Ctr Hlth Sci, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; Univ Texas, Ctr Hlth Sci, Brown Fdn Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA	University of Texas System; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Tulane University; Tulane University	Kone, BC (corresponding author), Univ Texas, Sch Med, Dept Internal Med, 6431 Fannin,MSB 1-150, Houston, TX 77030 USA.	Bruce.C.Kone@uth.tmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK075065, K01DK070834, R01DK047981] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK075065, R01 DK 47981, R01 DK 075065, R01 DK047981, K01 DK070834-02, K01 DK070834-01, K01 DK070834, K01 DK 70834] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asher C, 1996, AM J PHYSIOL-CELL PH, V271, pC605, DOI 10.1152/ajpcell.1996.271.2.C605; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Eaton DC, 2001, J MEMBRANE BIOL, V184, P313, DOI 10.1007/s00232-001-0098-x; Erfurth F, 2004, LEUKEMIA, V18, P92, DOI 10.1038/sj.leu.2403200; Escoubet B, 1997, AM J PHYSIOL-CELL PH, V272, pC1482, DOI 10.1152/ajpcell.1997.272.5.C1482; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Gumz ML, 2003, AM J PHYSIOL-RENAL, V285, pF664, DOI 10.1152/ajprenal.00353.2002; Hemenway CS, 2001, ONCOGENE, V20, P3798, DOI 10.1038/sj.onc.1204478; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; IIDA S, 1993, JPN J CANCER RES, V84, P532, DOI 10.1111/j.1349-7006.1993.tb00172.x; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kohler S, 2001, BBA-GENE STRUCT EXPR, V1519, P106, DOI 10.1016/S0167-4781(01)00228-7; Kuncewicz T, 2001, AM J PHYSIOL-RENAL, V281, pF326, DOI 10.1152/ajprenal.2001.281.2.F326; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Mick VE, 2001, MOL ENDOCRINOL, V15, P575, DOI 10.1210/me.15.4.575; Min JR, 2003, CELL, V112, P711, DOI 10.1016/S0092-8674(03)00114-4; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Ng HH, 2003, P NATL ACAD SCI USA, V100, P1820, DOI 10.1073/pnas.0437846100; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Poindexter BJ, 2005, J BURNS WOUNDS, V4, P101; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Srinivasan RS, 2003, ONCOGENE, V22, P3395, DOI 10.1038/sj.onc.1206361; Stockand JD, 2002, AM J PHYSIOL-RENAL, V282, pF559, DOI 10.1152/ajprenal.00320.2001; Stokes JB, 1998, AM J PHYSIOL-CELL PH, V274, pC1699, DOI 10.1152/ajpcell.1998.274.6.C1699; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Thomas CP, 2004, CURR OPIN NEPHROL HY, V13, P541, DOI 10.1097/00041552-200409000-00010; Turner SD, 2002, MOL CELL BIOL, V22, P4011, DOI 10.1128/MCB.22.12.4011-4019.2002; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zentner MD, 2001, J BIOL CHEM, V276, P29805, DOI 10.1074/jbc.M103153200; Zhang WZ, 2004, AM J PHYSIOL-RENAL, V286, pF1171, DOI 10.1152/ajprenal.00043.2003; Zhang WZ, 2006, AM J PHYSIOL-CELL PH, V290, pC936, DOI 10.1152/ajpcell.00431.2005; Zhang WZ, 2004, BIOCHEM J, V377, P641, DOI 10.1042/BJ20030839; Zhang WZ, 2002, AM J PHYSIOL-RENAL, V283, pF904, DOI 10.1152/ajprenal.00156.2002	43	132	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18059	18068		10.1074/jbc.M601903200	http://dx.doi.org/10.1074/jbc.M601903200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636056	Green Accepted, hybrid			2022-12-25	WOS:000238490300057
J	Buan, NR; Escalante-Semerena, JC				Buan, Nicole R.; Escalante-Semerena, Jorge C.			Purification and initial biochemical characterization of ATP : Cob(I)alamin adenosyltransferase (EutT) enzyme of Salmonella enterica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-CORRINOID ADENOSYLTRANSFERASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; TYPHIMURIUM LT2; GENE; COBA; ETHANOLAMINE; PROTEIN; COBALAMIN; ENCODES	ATP:cob(I) alamin adenosyltransferase (EutT) of Salmonella enterica was overproduced and enriched to similar to 70% homogeneity, and its basic kinetic parameters were determined. Abundant amounts of EutT protein were produced, but all of it remained insoluble. Soluble active EutT protein ( similar to 70% homogeneous) was obtained after treatment with detergent. Under conditions in which cobalamin (Cbl) was saturating, K-m(ATP) = 10 mu M, k(cat) = 0.03 s(-1), and V-max = 54.5 nM min(-1). Similarly, under conditions in which MgATP was saturating, K-m(Cbl) = 4.1 mu M, k(cat) = 0.06 s(-1), and V-max = 105 nM min(-1). Unlike other ATP: co(I)rrinoid adenosyltransferases in the cell (i.e. CobA and PduO), EutT activity was >= 50-fold higher with ATP versus GTP, and EutT retained 80% of its activity with ADP substituted for ATP and was completely inactive with AMP as substrate, indicating that the enzyme requires the beta-phosphate group of the nucleotide substrate. The data suggest that the amino group of adenine might play a role in nucleotide recognition and/or binding. Unlike the housekeeping CobA enzyme, EutT was not inhibited by inorganic tripolyphosphate (PPPi). Results from P-31 NMR spectroscopy studies identified PPi and P-i as by-products of the EutT reaction. In the absence of Cbl, EutT cleaved ATP into adenosine and PPPi, suggesting that PPPi is broken down into PPi and P-i. Electron transfer protein partners for EutT were not encoded by the eut operon. EutT-dependent activity was detected in cell-free extracts of cobA strains enriched for EutT when FMN and NADH were used to reduce cob(III) alamin to cob(I) alamin.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53726 USA	University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, 1710 Univ Ave, Madison, WI 53726 USA.	escalante@bact.wisc.edu			NIGMS NIH HHS [R01 GM040313, R01 GM40313] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040313] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1976, APPL ENVIRON MICROB, V32, P781, DOI 10.1128/AEM.32.6.781-791.1976; Bauer CB, 2001, BIOCHEMISTRY-US, V40, P361, DOI 10.1021/bi002145o; BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; Bertani G, 2004, J BACTERIOL, V186, P595, DOI 10.1128/JB.186.3.595-600.2004; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; Bobik TA, 1997, J BACTERIOL, V179, P6633, DOI 10.1128/jb.179.21.6633-6639.1997; Brindley AA, 2003, J BIOL CHEM, V278, P22388, DOI 10.1074/jbc.M302468200; Brinsmade SR, 2005, J BACTERIOL, V187, P8039, DOI 10.1128/JB.187.23.8039-8046.2005; Buan NR, 2004, J BACTERIOL, V186, P5708, DOI 10.1128/JB.186.17.5708-5714.2004; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; Fonseca MV, 2001, J BIOL CHEM, V276, P32101, DOI 10.1074/jbc.M102510200; Fonseca MV, 2002, J BIOL CHEM, V277, P33127, DOI 10.1074/jbc.M203893200; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Havemann GD, 2002, J BACTERIOL, V184, P1253, DOI 10.1128/JB.184.5.1253-1261.2002; Johnson CLV, 2001, J BACTERIOL, V183, P1577, DOI 10.1128/JB.183.5.1577-1584.2001; Johnson CLV, 2004, J BACTERIOL, V186, P7881, DOI 10.1128/JB.186.23.7881-7887.2004; Kakuta Y, 2001, BIOCHEMISTRY-US, V40, P11007, DOI 10.1021/bi010544t; Kerfeld CA, 2005, SCIENCE, V309, P936, DOI 10.1126/science.1113397; Kofoid E, 1999, J BACTERIOL, V181, P5317, DOI 10.1128/JB.181.17.5317-5329.1999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leal NA, 2004, J BIOL CHEM, V279, P47536, DOI 10.1074/jbc.M405449200; Leal NA, 2003, J BIOL CHEM, V278, P9227, DOI 10.1074/jbc.M212739200; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; RYU J, 1990, BIOTECHNIQUES, V8, P43; Saridakis V, 2004, J BIOL CHEM, V279, P23646, DOI 10.1074/jbc.M401395200; Sheppard DE, 2004, J BACTERIOL, V186, P7635, DOI 10.1128/JB.186.22.7635-7644.2004; Stich TA, 2005, J AM CHEM SOC, V127, P8710, DOI 10.1021/ja042142p; STOJILJKOVIC I, 1995, J BACTERIOL, V177, P1357, DOI 10.1128/jb.177.5.1357-1366.1995; SUH SJ, 1995, J BACTERIOL, V177, P921, DOI 10.1128/jb.177.4.921-925.1995; SUH SJ, 1993, GENE, V129, P93, DOI 10.1016/0378-1119(93)90701-4	33	24	24	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16971	16977		10.1074/jbc.M603069200	http://dx.doi.org/10.1074/jbc.M603069200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16636051	Green Published, hybrid			2022-12-25	WOS:000238326300018
J	Kishi, Y; Okudaira, S; Tanaka, M; Hama, K; Shida, D; Kitayama, J; Yamori, T; Aoki, J; Fujimaki, T; Arai, H				Kishi, Yasuhiro; Okudaira, Shinichi; Tanaka, Masayuki; Hama, Kotaro; Shida, Dai; Kitayama, Joji; Yamori, Takao; Aoki, Junken; Fujimaki, Takamitsu; Arai, Hiroyuki			Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine TO lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; HUMAN GLIOMA-CELLS; LYSOPHOSPHOLIPASE-D; OVER-EXPRESSION; CANCER CELLS; IN-VITRO; CARCINOMA; IDENTIFICATION; MIGRATION; PLASMA	Autotaxin (ATX) is a multifunctional phosphodiesterase originally isolated from melanoma cells as a potent cell motility-stimulating factor. ATX is identical to lysophospholipase D, which produces a bioactive phospholipid, lysophosphatidic acid (LPA), from lysophosphatidylcholine (LPC). Although enhanced expression of ATX in various tumor tissues has been repeatedly demonstrated, and thus, ATX is implicated in progression of tumor, the precise role of ATX expressed by tumor cells was unclear. In this study, we found that ATX is highly expressed in glioblastoma multiforme (GBM), the most malignant glioma due to its high infiltration into the normal brain parenchyma, but not in tissues from other brain tumors. In addition, LPA(1), an LPA receptor responsible for LPA-driven cell motility, is predominantly expressed in GBM. One of the glioblastomas that showed the highest ATX expression (SNB-78), as well as ATX-stable transfectants, showed LPA(1)-dependent cell migration in response to LPA in both Boyden chamber and wound healing assays. Interestingly these ATX-expressing cells also showed chemotactic response to LPC. In addition, knockdown of the ATX level using small interfering RNA technique in SNB-78 cells suppressed their migratory response to LPC. These results suggest that the autocrine production of LPA by cancer cell-derived ATX and exogenously supplied LPC contribute to the invasiveness of cancer cells and that LPA(1), ATX, and LPC-producing enzymes are potential targets for cancer therapy, including GBM.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Mol Pharmacol, Toshima Ku, Tokyo 1708455, Japan; Teikyo Univ, Sch Med, Dept Neurosurg, Itabashi Ku, Tokyo 1738605, Japan	University of Tokyo; University of Tokyo; Japanese Foundation for Cancer Research; Teikyo University	Aoki, J (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	jaoki@mol.f.u-tokyo.ac.jp		Shida, Dai/0000-0003-3294-1924; Aoki, Junken/0000-0001-9435-1896				An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURGER PC, 1983, J NEUROSURG, V58, P159, DOI 10.3171/jns.1983.58.2.0159; Euer N, 2002, ANTICANCER RES, V22, P733; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; FUJIMAKI T, 1991, CANCER, V67, P1629, DOI 10.1002/1097-0142(19910315)67:6<1629::AID-CNCR2820670626>3.0.CO;2-E; FUJIMAKI T, 2000, NEUROL MED CHIR TOKY, V40, P1; GIESE A, 1994, CANCER RES, V54, P3897; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Haugland HK, 1997, ANTICANCER RES, V17, P1035; HOFFMAN RD, 1982, P NATL ACAD SCI-BIOL, V79, P3285, DOI 10.1073/pnas.79.10.3285; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kehlen A, 2004, INT J CANCER, V109, P833, DOI 10.1002/ijc.20022; Kishimoto T, 2002, CLIN BIOCHEM, V35, P411, DOI 10.1016/S0009-9120(02)00327-2; Kitayama J, 2004, BREAST CANCER RES, V6, pR640, DOI 10.1186/bcr935; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; Mills Gordon B, 2002, Cancer Treat Res, V107, P259; Mulder C, 2003, J NEURAL TRANSM, V110, P949, DOI 10.1007/s00702-003-0007-9; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PEDERSEN PH, 1995, INT J CANCER, V62, P767, DOI 10.1002/ijc.2910620620; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; RYBORG AK, 1994, ARCH DERMATOL RES, V286, P462, DOI 10.1007/BF00371572; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Schulte KM, 2001, INT J CANCER, V92, P249, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1166>3.0.CO;2-D; SEITZ RJ, 1987, ACTA NEUROPATHOL, V73, P145, DOI 10.1007/BF00693780; Shida D, 2004, LAB INVEST, V84, P1352, DOI 10.1038/labinvest.3700146; Shida D, 2003, CANCER RES, V63, P1706; Stassar MJJG, 2001, BRIT J CANCER, V85, P1372, DOI 10.1054/bjoc.2001.2074; Stefan C, 1999, BBA-MOL CELL RES, V1450, P45, DOI 10.1016/S0167-4889(99)00031-2; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Sturm A, 1999, GASTROENTEROLOGY, V117, P368, DOI 10.1053/gast.1999.0029900368; Tanaka M, 2004, FEBS LETT, V571, P197, DOI 10.1016/j.febslet.2004.06.083; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WOLFF M, 1989, CLIN NEUROPATHOL, V8, P72; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200; Yamori T, 1999, CANCER RES, V59, P4042; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Yang Y, 1999, AM J RESP CELL MOL, V21, P216, DOI 10.1165/ajrcmb.21.2.3667; Zhang GX, 1999, CHINESE MED J-PEKING, V112, P330; Zhao Z, 1999, Zhonghua Gan Zang Bing Za Zhi, V7, P140	51	190	202	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17492	17500		10.1074/jbc.M601803200	http://dx.doi.org/10.1074/jbc.M601803200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16627485	hybrid			2022-12-25	WOS:000238326300075
J	Mehle, A; Thomas, ER; Rajendran, KS; Gabuzda, D				Mehle, Andrew; Thomas, Elaine R.; Rajendran, Kottampatty S.; Gabuzda, Dana			A zinc-binding region in vif binds cul5 and determines cullin selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; UBIQUITIN LIGASE COMPLEXES; LARGE T-ANTIGEN; HIV-1 VIF; PROTEIN BINDS; V-PROTEIN; SOCS-BOX; CYTIDINE DEAMINATION; ANTIVIRAL ACTIVITY; VIRAL INFECTIVITY	Human immunodeficiency virus-1 (HIV-1) Vif overcomes the antiviral activity of APOBEC3G by targeting it for ubiquitination via a Cullin 5-ElonginB-ElonginC (Cul5-EloBC) E3 ligase. Vif associates with Cul5-EloBC through a BC-box motif that binds EloC, but the mechanism by which Vif selectively recruits Cul5 is poorly understood. Here we report that a region of Vif (residues 100-142) upstream of the BC-box binds selectively to Cul5 in the absence of EloC. This region contains a zinc coordination site HX5CX17-18CX3-5H (HCCH), with His/Cys residues at positions 108, 114, 133, and 139 coordinating one zinc ion. The HCCH zinc coordination site, which is conserved among primate lentivirus Vif proteins, does not correspond to any known class of zinc-binding motif. Mutations of His/Cys residues in the HCCH motif impair zinc coordination, Cul5 binding, and APOBEC3G degradation. Mutations of conserved hydrophobic residues (Ile-120, Ala-123, and Leu-124) located between the two Cys residues in the HCCH motif disrupt binding of the zinc-coordinating region to Cul5 and inhibit APOBEC3G degradation. The Vif binding site maps to the first cullin repeat in the N terminus of Cul5. These data suggest that the zinc-binding region in Vif is a novel cullin interaction domain that mediates selective binding to Cul5. We propose that the HCCH zinc-binding motif facilitates Vif-Cul5 binding by playing a structural role in positioning hydrophobic residues for direct contact with Cul5.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Gabuzda, D (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, JF816,44 Binney St, Boston, MA 02115 USA.	dana_gabuzda@dfci.harvard.edu		Mehle, Andrew/0000-0001-6060-4330	NIAID NIH HHS [AI368186, AI62555] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Ali SH, 2004, J VIROL, V78, P2749, DOI 10.1128/JVI.78.6.2749-2757.2004; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; BERG JM, 1990, J BIOL CHEM, V265, P6513; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Boyer JL, 2000, J BIOL CHEM, V275, P14969, DOI 10.1074/jbc.M000566200; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Dettenhofer M, 2000, J VIROL, V74, P8938, DOI 10.1128/JVI.74.19.8938-8945.2000; Doehle BP, 2005, VIROLOGY, V339, P281, DOI 10.1016/j.virol.2005.06.005; GONCALVES J, 1994, J VIROL, V68, P704, DOI 10.1128/JVI.68.2.704-712.1994; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Huang C, 2000, J VIROL, V74, P7834, DOI 10.1128/JVI.74.17.7834-7841.2000; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; Kao Sandra, 2004, Retrovirology, V1, P27, DOI 10.1186/1742-4690-1-27; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Luo K, 2005, P NATL ACAD SCI USA, V102, P11444, DOI 10.1073/pnas.0502440102; MA XY, 1994, J VIROL, V68, P1714, DOI 10.1128/JVI.68.3.1714-1720.1994; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; PATERSON RG, 1995, VIROLOGY, V208, P121, DOI 10.1006/viro.1995.1135; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROSE PE, 1995, J VIROL, V69, P2842, DOI 10.1128/JVI.69.5.2842-2849.1995; Santa-Marta M, 2005, J BIOL CHEM, V280, P8765, DOI 10.1074/jbc.M409309200; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; Seibert V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-22; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066; Ulane CM, 2005, J VIROL, V79, P10180, DOI 10.1128/JVI.79.16.10180-10189.2005; Ulane CM, 2003, J VIROL, V77, P6385, DOI 10.1128/JVI.77.11.6385-6393.2003; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; XIAO Z, 2006, VIROLOGY; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yang B, 2003, J BIOL CHEM, V278, P6596, DOI 10.1074/jbc.M210164200; Yang SC, 2001, J BIOL CHEM, V276, P4889, DOI 10.1074/jbc.M004895200; Yu Q, 2004, J BIOL CHEM, V279, P53379, DOI 10.1074/jbc.M408802200; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhang H, 2000, J VIROL, V74, P8252, DOI 10.1128/JVI.74.18.8252-8261.2000; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	58	155	156	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17259	17265		10.1074/jbc.M602413200	http://dx.doi.org/10.1074/jbc.M602413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16636053	hybrid			2022-12-25	WOS:000238326300053
J	Plank, JL; Hsieh, TS				Plank, Jody L.; Hsieh, Tao-shih			A novel, topologically constrained DNA molecule containing a double Holliday junction - Design, synthesis, and initial biochemical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; SYNAPTONEMAL COMPLEX-FORMATION; DROSOPHILA-MELANOGASTER; MEIOTIC RECOMBINATION; MEIOSIS; SITE; RESOLUTION; CROSSOVER; IDENTIFICATION; TRANSITION	The double Holliday junction (dHJ) is a central intermediate to homologous recombination, but biochemical analysis of the metabolism of this structure has been hindered by the lack of a substrate that adequately replicates the endogenous structure. We have synthesized a novel dHJ substrate that consists of two small, double stranded DNA circles conjoined by two Holliday junctions (HJs). Its biochemical synthesis is based on the production of two pairs of single stranded circles from phagemids, followed by their sequential annealing with reverse gyrase. The sequence between the two HJs is identical on both strands, allowing the HJs to migrate without the generation of unpaired regions of DNA, whereas the distance between the HJs is on the order of gene conversion tracts thus far measured in Drosophila and mouse model systems. The structure of this substrate also provides similar topological constraint as would occur in an endogenous dHJ. Digestion of the dHJ substrate by T7 endonuclease I resolves the substrate into crossover and non-crossover products, as predicted by the Szostak model of double strand break repair. This substrate will greatly facilitate the examination of the mechanism of resolution of double Holliday junctions.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hsieh, TS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	hsieh@biochem.duke.edu	Plank, Jody/B-4827-2009; Hsieh, Tao-shih/G-9305-2012; Wu, Wan-lin/G-8937-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029006] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM029006, GM29006, R01 GM029006-25] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Blanton HL, 2005, PLOS GENET, V1, P343, DOI 10.1371/journal.pgen.0010040; Borner GV, 2004, CELL, V117, P29, DOI 10.1016/S0092-8674(04)00292-2; Bregeon D, 2004, BIOTECHNIQUES, V37, P760, DOI 10.2144/04375ST01; COLLINS I, 1994, CELL, V76, P65, DOI 10.1016/0092-8674(94)90173-2; DICKIE P, 1987, J BIOL CHEM, V262, P14826; FU TJ, 1994, J MOL BIOL, V236, P91, DOI 10.1006/jmbi.1994.1121; Guillon H, 2005, MOL CELL, V20, P563, DOI 10.1016/j.molcel.2005.09.021; HEARST JE, 1981, ANNU REV BIOPHYS BIO, V10, P69, DOI 10.1146/annurev.bb.10.060181.000441; Heyer WD, 2003, TRENDS BIOCHEM SCI, V28, P548, DOI 10.1016/j.tibs.2003.08.011; Heyer WD, 2004, CURR BIOL, V14, pR56, DOI 10.1016/j.cub.2003.12.043; HILLIKER AJ, 1994, GENETICS, V137, P1019; Hunter N, 2001, CELL, V106, P59, DOI 10.1016/S0092-8674(01)00430-5; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Plank JL, 2005, J BIOL CHEM, V280, P3564, DOI 10.1074/jbc.M411337200; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; Rodriguez AC, 2002, EMBO J, V21, P418, DOI 10.1093/emboj/21.3.418; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; Symington LS, 2004, SCIENCE, V303, P184, DOI 10.1126/science.1093959; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; ZHEN WP, 1986, BIOCHEMISTRY-US, V25, P6598, DOI 10.1021/bi00369a039	28	18	18	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17510	17516		10.1074/jbc.M602933200	http://dx.doi.org/10.1074/jbc.M602933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16608853	hybrid, Green Accepted			2022-12-25	WOS:000238326300077
J	Sellick, CA; Reece, RJ				Sellick, Christopher A.; Reece, Richard J.			Contribution of amino acid side chains to sugar binding specificity in a galactokinase, Gal1p, and a transcriptional inducer, Gal3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GALACTOKINASE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-STRUCTURE; SUBSTRATE-SPECIFICITY; YEAST GALACTOKINASE; GLUCOSE REPRESSION; II GALACTOSEMIA; IN-VIVO; GENE; PURIFICATION	The crystal structure of the yeast galactokinase, Gal1p, in the presence of its substrates has been solved recently. We systematically mutated each of the amino acid side chains that, from the structure, are implicated to be involved in direct contact with the hydroxyl groups of the galactose ring. One of these mutations, D62A, abolished all detectable galactokinase activity but retained the ability to use D-glucose as a substrate. Mutation of Asp-62 to either leucine, phenylalanine, or histidine resulted in the formation of protein with similar characteristics to D62A. Yeast galactokinase is highly similar to Gal3p, the ligand sensor and transcriptional inducer of the GAL genes. Equivalent mutations in Gal3p also abolished its ability to respond to galactose and uncovered its ability to respond to D-glucose. It therefore appears that Gal1p and Gal3p respond to their substrates in a similar, perhaps identical, fashion. This work also validates the approach of screening for mutants in an easily assayable system prior to mutant analysis in a more experimentally difficult transcriptional regulator.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Reece, RJ (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	richard.reece@manchester.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Frolova E, 1999, NUCLEIC ACIDS RES, V27, P1350, DOI 10.1093/nar/27.5.1350; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; Hartley A, 2004, J MOL BIOL, V337, P387, DOI 10.1016/j.jmb.2004.01.043; HEINRICH MR, 1964, J BIOL CHEM, V239, P50; Holden HM, 2004, CELL MOL LIFE SCI, V61, P2471, DOI 10.1007/s00018-004-4160-6; Inagaki E, 2006, ACTA CRYSTALLOGR F, V62, P169, DOI 10.1107/S1744309106001813; JOHNSTON M, 1994, MOL CELL BIOL, V14, P3834, DOI 10.1128/MCB.14.6.3834; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; Platt A, 2000, P NATL ACAD SCI USA, V97, P3154, DOI 10.1073/pnas.97.7.3154; Reece RJ, 1997, BIOESSAYS, V19, P1001, DOI 10.1002/bies.950191110; SCHELL MA, 1977, J BIOL CHEM, V252, P1162; Sellick CA, 2005, TRENDS BIOCHEM SCI, V30, P405, DOI 10.1016/j.tibs.2005.05.007; Thoden JB, 2005, J BIOL CHEM, V280, P36905, DOI 10.1074/jbc.M508446200; Thoden JB, 2005, J BIOL CHEM, V280, P9662, DOI 10.1074/jbc.M412916200; Thoden JB, 2003, J BIOL CHEM, V278, P33305, DOI 10.1074/jbc.M304789200; Timson David J, 2003, BMC Biochem, V4, P16, DOI 10.1186/1471-2091-4-16; Timson DJ, 2002, BIOCHIMIE, V84, P265, DOI 10.1016/S0300-9084(02)01399-8; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; Yang J, 2005, CHEM BIOL, V12, P657, DOI 10.1016/j.chembiol.2005.04.009; Yang J, 2003, ORG LETT, V5, P2223, DOI 10.1021/ol034642d	27	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17150	17155		10.1074/jbc.M602086200	http://dx.doi.org/10.1074/jbc.M602086200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16603548	hybrid			2022-12-25	WOS:000238326300039
J	Skamel, C; Ploss, M; Bottcher, B; Stehle, T; Wallich, R; Simon, MM; Nassal, M				Skamel, Claudia; Ploss, Martin; Boettcher, Bettina; Stehle, Thomas; Wallich, Reinhard; Simon, Markus M.; Nassal, Michael			Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYME-DISEASE SPIROCHETE; CRYSTAL-STRUCTURE; CORE PARTICLES; A OSPA; ANTIGEN; EPITOPE; DIVERSITY; VACCINE; MODEL; MICE	Hepatitis B virus capsid-like particles (CLPs), icosahedral assemblies formed by 90 or 120 core protein dimers, hold promise as immune-enhancing vaccine carriers for heterologous antigens. Insertions into the immunodominant c/e1B cell epitope, a surface-exposed loop, are especially immunogenic. However, display of whole proteins, desirable to induce multispecific and possibly neutralizing antibody responses, can be restrained by an unsuitable structure of the foreign protein and by its propensity to undergo homomeric interactions. Here we analyzed CLP formation by core fusions with two distinct variants of the dimeric outer surface lipoprotein C (OspC) of the Lyme disease agent Borrelia burgdorferi. Although the topology of the termini in the OspC dimer does not match that of the insertion sites in the carrier dimer, both fusions, coreOspC(a) and coreOspC(b), efficiently formed stable CLPs. Electron cryomicroscopy clearly revealed the surface disposition of the OspC domains, possibly with OspC dimerization occurring across different core protein dimers. In mice, both CLP preparations induced high-titered antibody responses against the homologous OspC variant, but with substantial cross-reactivity against the other variant. Importantly, both conferred protection to mice challenged with B. burgdorferi. These data show the principal applicability of hepatitis B virus CLPs for the display of dimeric proteins, demonstrate the presence in OspC of hitherto uncharacterized epitopes, and suggest that OspC, despite its genetic variability, may be a valid vaccine candidate.	Univ Hosp Freiburg, Inst Immunol, D-79106 Freiburg, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	University of Freiburg; European Molecular Biology Laboratory (EMBL); Max Planck Society	Nassal, M (corresponding author), Univ Hosp Freiburg, Inst Immunol, Hugstetter Str 55, D-79106 Freiburg, Germany.	nassal2@ukl.uni-freiburg.de	Nassal, Michael/U-4529-2019; Bottcher, Bettina/E-9397-2010	Nassal, Michael/0000-0003-2204-9158; Bottcher, Bettina/0000-0002-7962-4849				Auwaerter Paul G., 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404007276; Belnap DM, 2003, P NATL ACAD SCI USA, V100, P10884, DOI 10.1073/pnas.1834404100; Billaud JN, 2005, J VIROL, V79, P13641, DOI 10.1128/JVI.79.21.13641-13655.2005; Billaud JN, 2005, J VIROL, V79, P13656, DOI 10.1128/JVI.79.21.13656-13666.2005; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; Bottcher B, 1996, STRUCTURE, V4, P387; Bottcher B, 2006, J MOL BIOL, V356, P812, DOI 10.1016/j.jmb.2005.11.053; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; Bunikis J, 2004, MICROBIOL-SGM, V150, P1741, DOI 10.1099/mic.0.26944-0; Connolly SE, 2005, NAT REV MICROBIOL, V3, P411, DOI 10.1038/nrmicro1149; Conway JF, 1998, J MOL BIOL, V279, P1111, DOI 10.1006/jmbi.1998.1845; Conway JF, 1997, NATURE, V386, P91, DOI 10.1038/386091a0; Conway JF, 2003, J VIROL, V77, P6466, DOI 10.1128/JVI.77.11.6466-6473.2003; CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2; Earnhart CG, 2005, INFECT IMMUN, V73, P7869, DOI 10.1128/IAI.73.12.7869-7877.2005; Eicken C, 2001, J BIOL CHEM, V276, P10010, DOI 10.1074/jbc.M010062200; Fehr T, 1998, P NATL ACAD SCI USA, V95, P9477, DOI 10.1073/pnas.95.16.9477; Geldmacher A, 2004, VIROLOGY, V323, P108, DOI 10.1016/j.virol.2004.02.022; Gilmore RD, 1999, INFECT IMMUN, V67, P5463, DOI 10.1128/IAI.67.10.5463-5469.1999; Gilmore RD, 1996, INFECT IMMUN, V64, P2234, DOI 10.1128/IAI.64.6.2234-2239.1996; Grimm D, 2004, P NATL ACAD SCI USA, V101, P3142, DOI 10.1073/pnas.0306845101; HATTON T, 1992, J VIROL, V66, P5232, DOI 10.1128/JVI.66.9.5232-5241.1992; Jegerlehner A, 2002, VACCINE, V20, P3104, DOI 10.1016/S0264-410X(02)00266-9; KENNEY JM, 1995, STRUCTURE, V3, P1009, DOI 10.1016/S0969-2126(01)00237-4; KRAMER MD, 1990, IMMUNOBIOLOGY, V181, P357, DOI 10.1016/S0171-2985(11)80504-8; Kratz PA, 1999, P NATL ACAD SCI USA, V96, P1915, DOI 10.1073/pnas.96.5.1915; Kumaran D, 2001, EMBO J, V20, P971, DOI 10.1093/emboj/20.5.971; Li H, 1997, P NATL ACAD SCI USA, V94, P3584, DOI 10.1073/pnas.94.8.3584; Liang FT, 2004, INFECT IMMUN, V72, P5759, DOI 10.1128/IAI.72.10.5759-5767.2004; Lovrich SD, 2005, CLIN DIAGN LAB IMMUN, V12, P746, DOI 10.1128/CDLI.12.6.746-751.2005; Mathiesen MJ, 1998, INFECT IMMUN, V66, P4073; Mbow ML, 1999, INFECT IMMUN, V67, P5470, DOI 10.1128/IAI.67.10.5470-5472.1999; Milich DR, 1997, P NATL ACAD SCI USA, V94, P14648, DOI 10.1073/pnas.94.26.14648; Nassal M, 2005, EUR J IMMUNOL, V35, P655, DOI 10.1002/eji.200425449; NASSAL M, 1992, J VIROL, V66, P4107, DOI 10.1128/JVI.66.7.4107-4116.1992; Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Pal U, 2004, CELL, V119, P457, DOI 10.1016/j.cell.2004.10.027; Pumpens P, 2001, INTERVIROLOGY, V44, P98, DOI 10.1159/000050037; Ramamoorthi N, 2005, NATURE, V436, P573, DOI 10.1038/nature03812; Rosa P, 2005, NAT MED, V11, P831, DOI 10.1038/nm0805-831; Roseman AM, 2005, P NATL ACAD SCI USA, V102, P15821, DOI 10.1073/pnas.0504874102; SALFELD J, 1989, J VIROL, V63, P798, DOI 10.1128/JVI.63.2.798-808.1989; SALLBERG M, 1991, MOL IMMUNOL, V28, P719, DOI 10.1016/0161-5890(91)90114-Y; SCHAIBLE UE, 1990, P NATL ACAD SCI USA, V87, P3768, DOI 10.1073/pnas.87.10.3768; Simon MM, 1996, EUR J IMMUNOL, V26, P2831, DOI 10.1002/eji.1830261206; SIMON MM, 1991, IMMUNOL TODAY, V12, P11, DOI 10.1016/0167-5699(91)90106-4; Steere AC, 2004, J CLIN INVEST, V113, P1093, DOI [10.1172/JCI200421681, 10.1172/JCI21681]; Steere AC, 2004, NAT REV IMMUNOL, V4, P143, DOI 10.1038/nri1267; Ulrich R, 1998, ADV VIRUS RES, V50, P141, DOI 10.1016/S0065-3527(08)60808-8; van Heel M, 2000, Q REV BIOPHYS, V33, P307, DOI 10.1017/S0033583500003644; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Vogel M, 2005, FEBS LETT, V579, P5211, DOI 10.1016/j.febslet.2005.08.044; Vogel M, 2005, PROTEINS, V58, P478, DOI 10.1002/prot.20312; Watts NR, 2002, EMBO J, V21, P876, DOI 10.1093/emboj/21.5.876; Wynne SA, 1999, MOL CELL, V3, P771, DOI 10.1016/S1097-2765(01)80009-5; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhong WM, 1999, EUR J IMMUNOL, V29, P946, DOI 10.1002/(SICI)1521-4141(199903)29:03&lt;946::AID-IMMU946&gt;3.0.CO;2-P; Zhong WM, 1997, P NATL ACAD SCI USA, V94, P12533, DOI 10.1073/pnas.94.23.12533; Zucker WR, 2001, J BIOL CHEM, V276, P457, DOI 10.1074/jbc.M008449200	60	41	45	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17474	17481		10.1074/jbc.M513571200	http://dx.doi.org/10.1074/jbc.M513571200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16621801	hybrid			2022-12-25	WOS:000238326300073
J	Yao, NY; Johnson, A; Bowman, GD; Kuriyan, J; O'Donnell, M				Yao, Nina Y.; Johnson, Aaron; Bowman, Greg D.; Kuriyan, John; O'Donnell, Mike			Mechanism of proliferating cell nuclear antigen clamp opening by replication factor C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE III HOLOENZYME; LAGGING-STRAND REPLICATION; DNA-DAMAGE CHECKPOINT; ESCHERICHIA-COLI; SLIDING CLAMPS; LOADER COMPLEX; STRUCTURAL-ANALYSIS; CRYSTAL-STRUCTURE; GAMMA COMPLEX; DELTA-SUBUNIT	The eukaryotic replication factor C (RFC) clamp loader is an AAA+spiral-shaped heteropentamer that opens and closes the circular proliferating cell nuclear antigen (PCNA) clamp processivity factor on DNA. In this study, we examined the roles of individual RFC subunits in opening the PCNA clamp. Interestingly, Rfc1, which occupies the position analogous to the delta clamp-opening subunit in the Escherichia coli clamp loader, is not required to open PCNA. The Rfc5 subunit is required to open PCNA. Consistent with this result, Rfc2 (.) 3 (.) 4 (.) 5 and Rfc2 (.) 5 subassemblies are capable of opening and unloading PCNA from circular DNA. Rfc5 is positioned opposite the PCNA interface from Rfc1, and therefore, its action with Rfc2 in opening PCNA indicates that PCNA is opened from the opposite side of the interface that the E. coli delta wrench acts upon. This marks a significant departure in the mechanism of eukaryotic and prokaryotic clamp loaders. Interestingly, the Rad (.) RFC DNA damage checkpoint clamp loader unloads PCNA clamps from DNA. We propose that Rad (.) RFC may clear PCNA from DNA to facilitate shutdown of replication in the face of DNA damage.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; Rockefeller University; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	O'Donnell, M (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.	odonnel@mail.rockefeller.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM066586] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM066586-01, F32 GM066586-02, F32 GM066586] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P10237, DOI 10.1073/pnas.1434308100; Bowman GD, 2005, FEBS LETT, V579, P863, DOI 10.1016/j.febslet.2004.11.038; Bowman GD, 2004, NATURE, V429, P724, DOI 10.1038/nature02585; Bylund GO, 2005, MOL CELL BIOL, V25, P5445, DOI 10.1128/MCB.25.13.5445-5455.2005; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Finkelstein J, 2003, ANAL BIOCHEM, V319, P78, DOI 10.1016/S0003-2697(03)00273-2; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Goedken ER, 2005, NAT STRUCT MOL BIOL, V12, P183, DOI 10.1038/nsmb889; Gomes XV, 2001, J BIOL CHEM, V276, P34768, DOI 10.1074/jbc.M011631200; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Kazmirski SL, 2005, P NATL ACAD SCI USA, V102, P13801, DOI 10.1073/pnas.0506430102; Kazmirski SL, 2004, P NATL ACAD SCI USA, V101, P16750, DOI 10.1073/pnas.0407904101; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; Leu FP, 2000, J BIOL CHEM, V275, P34609, DOI 10.1074/jbc.M005495200; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; Miyata T, 2005, P NATL ACAD SCI USA, V102, P13795, DOI 10.1073/pnas.0506447102; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; Oyama T, 2001, MOL CELL, V8, P455, DOI 10.1016/S1097-2765(01)00328-8; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Reynolds N, 1999, NUCLEIC ACIDS RES, V27, P462, DOI 10.1093/nar/27.2.462; Shimomura T, 1998, MOL CELL BIOL, V18, P5485, DOI 10.1128/MCB.18.9.5485; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Yao N, 2000, J BIOL CHEM, V275, P11440, DOI 10.1074/jbc.275.15.11440; Yao N, 2003, J BIOL CHEM, V278, P50744, DOI 10.1074/jbc.M309206200; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Yao N, 2000, J BIOL CHEM, V275, P1421, DOI 10.1074/jbc.275.2.1421; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; Zhuang ZH, 2006, P NATL ACAD SCI USA, V103, P2546, DOI 10.1073/pnas.0511263103	43	55	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17528	17539		10.1074/jbc.M601273200	http://dx.doi.org/10.1074/jbc.M601273200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16608854	hybrid			2022-12-25	WOS:000238326300079
J	Cole, AR; Causeret, F; Yadirgi, G; Hastie, CJ; Mclauchlan, H; McManus, EJ; Hernandez, F; Eickholt, BJ; Nikolic, M; Sutherland, C				Cole, Adam R.; Causeret, Frederic; Yadirgi, Gokhan; Hastie, C. James; McLauchlan, Hilary; McManus, Edward J.; Hernandez, Felix; Eickholt, Britta J.; Nikolic, Margareta; Sutherland, Calum			Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-CONE COLLAPSE; BETA-CATENIN; SUBSTRATE SPECIFICITIES; ALZHEIMERS-DISEASE; PHOSPHORYLATION; CRMP-2; CDK5; GSK3; INSULIN; NEURODEGENERATION	Collapsin response mediator proteins (CRMPs) are a family of neuron-enriched proteins that regulate neurite outgrowth and growth cone dynamics. Here, we show that Cdk5 phosphorylates CRMP1, CRMP2, and CRMP4, priming for subsequent phosphorylation by GSK3 in vitro. In contrast, DYRK2 phosphorylates and primes CRMP4 only. The Cdk5 and DYRK2 inhibitor purvalanol decreases the phosphorylation of CRMP proteins in neurons, whereas CRMP1 and CRMP2, but not CRMP4, phosphorylation is decreased in Cdk5(-/-) cortices. Stimulation of neuroblastoma cells with IGF1 or TPA decreases GSK3 activity concomitantly with CRMP2 and CRMP4 phosphorylation. Conversely, increased GSK3 activity is not sufficient to increase CRMP phosphorylation. However, the growth cone collapse-inducing protein Sema3A increases Cdk5 activity and promotes phosphorylation of CRMP2 ( but not CRMP4). Therefore, inhibition of GSK3 alters phosphorylation of all CRMP isoforms; however, individual isoforms can be differentially regulated by their respective priming kinase. This is the first GSK3 substrate found to be regulated in this manner and may explain the hyperphosphorylation of CRMP2 observed in Alzheimer's disease.	Univ Dundee, Ninewells Hosp, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland; Imperial Coll Sch Med, Div Neurosci & Mental Hlth, London W6 8RP, England; Univ London Kings Coll, MRC, Ctr Dev Neurobiol, London SE1 1UL, England; Univ Dundee, Sch Life Sci, Div Signal Transduct Therapy, Dundee DD1 5EH, Scotland; Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Univ Autonoma Madrid, CSIC, Ctr Mol Biol, E-28049 Madrid, Spain	University of Dundee; Imperial College London; University of London; King's College London; University of Dundee; University of Dundee; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	Sutherland, C (corresponding author), Univ Dundee, Ninewells Hosp, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland.	c.d.sutherland@dundee.ac.uk	Causeret, Frédéric/C-3195-2017; Hernandez, Felix/L-2114-2015; Yadirgi, Gokhan/F-4944-2011; Cole, Adam/B-9785-2011; Eickholt, Britta/C-5337-2009	Causeret, Frédéric/0000-0002-0543-4938; Hernandez, Felix/0000-0001-8753-8249; Sutherland, Calum/0000-0003-4398-7434; Eickholt, Britta/0000-0001-7873-8687; Hastie, James/0000-0001-7164-4098	Alzheimers Research UK [ART-PG2005-1] Funding Source: researchfish; Medical Research Council [G9900989B] Funding Source: researchfish; Biotechnology and Biological Sciences Research Council [C18727] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Brown M, 2004, J NEUROSCI, V24, P8994, DOI 10.1523/JNEUROSCI.3184-04.2004; Campbell LE, 2002, FEBS LETT, V510, P31, DOI 10.1016/S0014-5793(01)03221-5; Cole AR, 2004, J BIOL CHEM, V279, P50176, DOI 10.1074/jbc.C400412200; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Eickholt BJ, 2002, J CELL BIOL, V157, P211, DOI 10.1083/jcb.200201098; Eickholt BJ, 1997, MOL CELL NEUROSCI, V9, P358, DOI 10.1006/mcne.1997.0636; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Kimura T, 2005, J NEUROCHEM, V93, P1371, DOI 10.1111/j.1471-4159.2005.03063.x; Liu XX, 2005, CURR BIOL, V15, P1989, DOI 10.1016/j.cub.2005.10.050; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Paglini G, 1998, J NEUROSCI, V18, P9858; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Ricard D, 2000, MOL CELL NEUROSCI, V16, P324, DOI 10.1006/mcne.2000.0888; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; Smith D, 2003, NEUROSIGNALS, V12, P239, DOI 10.1159/000074626; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Wagman AS, 2004, CURR PHARM DESIGN, V10, P1105, DOI 10.2174/1381612043452668; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012	36	175	182	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16591	16598		10.1074/jbc.M513344200	http://dx.doi.org/10.1074/jbc.M513344200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16611631	Green Accepted, hybrid			2022-12-25	WOS:000238165700051
J	Saelzler, MP; Spackman, CC; Liu, Y; Martinez, LC; Harris, JP; Abe, MK				Saelzler, Matthew P.; Spackman, Christy C.; Liu, Yuru; Martinez, Lesly C.; Harris, Jeremy P.; Abe, Mark K.			ERK8 down-regulates transactivation of the glucocorticoid receptor through Hic-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ANDROGEN RECEPTOR; TRANSCRIPTIONAL ACTIVATION; PROTEIN-KINASES; ZINC-FINGER; LIM DOMAIN; LUNG; COACTIVATOR; EXPRESSION; BINDING	Extracellular signal-regulated kinase 8 (ERK8) is the most recently identified member of the ERK subfamily of MAPKs. Although other members of the ERK subfamily are established regulators of signaling pathways involved in cell growth and/or differentiation, less is known about ERK8. To understand the cellular function of ERK8, a yeast two-hybrid screen of a human lung library was performed to identify binding partners. One binding partner identified was Hic-5 (also known as ARA55), a multiple LIM domain containing protein implicated in focal adhesion signaling and the regulation of specific nuclear receptors, including the androgen receptor and the glucocorticoid receptor (GR). Co-immunoprecipitation experiments in mammalian cells confirmed the interaction between Hic-5 and both ERK8 and its rodent ortholog ERK7. The C-terminal region of ERK8 was not required for the interaction. Although the LIM3 and LIM4 domains of Hic-5 were sufficient and required for this interaction, the specific zinc finger motifs in these domains were not. Transcriptional activation reporter assays revealed that ERK8 can negatively regulate transcriptional co-activation of androgen receptor and GR alpha by Hic-5 in a kinase-independent manner. Knockdown of endogenous ERK8 in human airway epithelial cells enhanced dexamethasone-stimulated transcriptional activity of endogenous GR. Transcriptional regulation of GR alpha and interaction with its ligand binding domain by ERK8 were dependent on the presence of Hic-5. These results provide the first physiological function for human ERK8 as a negative regulator of human GR alpha, acting through Hic-5, and suggest a broader role for ERK8 in the regulation of nuclear receptors beyond estrogen receptor alpha.	Univ Chicago, Dept Pediat, Chicago, IL 60637 USA	University of Chicago	Abe, MK (corresponding author), Univ Chicago, Dept Pediat, 5841 S Maryland Ave,MC4064, Chicago, IL 60637 USA.	mabe@peds.bsd.uchicago.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073132] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 073132, HL 07605] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Abe MK, 2002, J BIOL CHEM, V277, P16733, DOI 10.1074/jbc.M112483200; Abe MK, 2001, J BIOL CHEM, V276, P21272, DOI 10.1074/jbc.M100026200; Abe MK, 1999, MOL CELL BIOL, V19, P1301; Adcock Ian M, 2004, Proc Am Thorac Soc, V1, P247, DOI 10.1513/pats.200402-001MS; Adcock IM, 1996, AM J RESP CRIT CARE, V154, P771, DOI 10.1164/ajrccm.154.3.8810618; Araki I, 2004, UROLOGY, V64, P1255, DOI 10.1016/j.urology.2004.06.064; Barbry P, 1997, AM J PHYSIOL-GASTR L, V273, pG571, DOI 10.1152/ajpgi.1997.273.3.G571; Bogoyevitch MA, 2004, CELL SIGNAL, V16, P1345, DOI 10.1016/j.cellsig.2004.05.004; Bolt RJ, 2001, PEDIATR PULM, V32, P76, DOI 10.1002/ppul.1092; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Drori S, 2005, GENE DEV, V19, P362, DOI 10.1101/gad.1240705; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Fujita H, 1998, J BIOL CHEM, V273, P26516, DOI 10.1074/jbc.273.41.26516; Gao ZL, 2005, FEBS LETT, V579, P5651, DOI 10.1016/j.febslet.2005.08.086; Guerrero-Santoro J, 2004, J CELL BIOCHEM, V92, P810, DOI 10.1002/jcb.20109; Heitzer MD, 2006, MOL ENDOCRINOL, V20, P56, DOI 10.1210/me.2005-0065; Henrich LM, 2003, MOL CELL BIOL, V23, P5979, DOI 10.1128/MCB.23.17.5979-5988.2003; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Matsuda S, 2005, INVEST OPHTH VIS SCI, V46, P1062, DOI 10.1167/iovs.04-0761; Nishiya N, 2001, MOL CELL BIOL, V21, P5332, DOI 10.1128/MCB.21.16.5332-5345.2001; Peng X, 1996, J NEUROCHEM, V66, P1191; Rajatapiti P, 2005, J CLIN ENDOCR METAB, V90, P4309, DOI 10.1210/jc.2005-0556; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Sayegh R, 1999, J BIOL CHEM, V274, P12431, DOI 10.1074/jbc.274.18.12431; Schumacher S, 2004, EMBO J, V23, P4770, DOI 10.1038/sj.emboj.7600467; Seternes OM, 2004, EMBO J, V23, P4780, DOI 10.1038/sj.emboj.7600489; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; TEAM MGC, 2002, P NATL ACAD SCI USA, V99, P16899, DOI DOI 10.1073/PNAS; Thomas SM, 1999, J CELL SCI, V112, P181; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; Wang X, 2002, J BIOL CHEM, V277, P15426, DOI 10.1074/jbc.M111218200; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WEBSTER LC, 1991, P NATL ACAD SCI USA, V88, P9989, DOI 10.1073/pnas.88.22.9989; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007; Zhang J, 2000, MOL CARCINOGEN, V27, P177, DOI 10.1002/(SICI)1098-2744(200003)27:3<177::AID-MC4>3.3.CO;2-J	44	33	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16821	16832		10.1074/jbc.M512418200	http://dx.doi.org/10.1074/jbc.M512418200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16624805	hybrid			2022-12-25	WOS:000238165700077
J	Shen, R; Wang, XM; Drissi, H; Liu, F; O'Keefe, RJ; Chen, D				Shen, Run; Wang, Xiumei; Drissi, Hicham; Liu, Fang; O'Keefe, Regis J.; Chen, Di			Cyclin D1-Cdk4 induce Runx2 ubiquitination and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-TYPE CYCLINS; OSTEOBLAST DIFFERENTIATION; CHONDROCYTE DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; TRANSCRIPTION FACTOR; CELL-CYCLE; IN-VIVO; ANTIPROLIFERATIVE FUNCTION; CBFA1-DEFICIENT MICE; CBFA1	Runx2 is a Runt domain transcription factor involved in the activation of genes encoding osteoblast and chondrocyte-specific proteins. Runx2 activity is regulated by transcriptional and post-transcriptional mechanisms. The functional significance of the post-translational modification of Runx2 has not been fully defined. We show that cyclin D1-Cdk4 induce Runx2 degradation in an ubiquitination-proteasome-dependent manner. Mutagenesis of Runx2 serine-472, a consensus Cdk site, to alanine increases the half-life of Runx2 and causes loss of sensitivity to cyclin D1-induced Runx2 degradation. The targeted Runx2 degradation by cyclin D1 identifies a novel mechanism through which Runx2 activity is regulated coordinately with the cell cycle machinery in bone cells.	Univ Rochester, Sch Med, Dept Orthopaed, Ctr Musculoskeletal Res, Rochester, NY 14642 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA	University of Rochester; Rutgers State University New Brunswick	Chen, D (corresponding author), Univ Rochester, Sch Med, Dept Orthopaed, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.	di_chen@urmc.rochester.edu		drissi, hicham/0000-0002-3322-281X	NIAMS NIH HHS [AR 38945, R01 AR054465, R01 AR051189-04, R01 AR051189, R01 AR038945, AR 051189, R01 AR051189-03, K02 AR052411, K02 AR052411-01A2, R03 AR048920, AR 048920, R01 AR054465-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038945, R01AR054465, R29AR038945, R01AR051189, K02AR052411, R03AR048920] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200; Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Shen R, 2006, J BIOL CHEM, V281, P3569, DOI 10.1074/jbc.M506761200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zheng QP, 2003, J CELL BIOL, V162, P833, DOI 10.1083/jcb.200211089	35	94	97	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16347	16353		10.1074/jbc.M603439200	http://dx.doi.org/10.1074/jbc.M603439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16613857	Green Accepted, hybrid			2022-12-25	WOS:000238165700022
J	Wijma, HJ; Jeuken, LJC; Verbeet, MP; Armstrong, FA; Canters, GW				Wijma, Hein J.; Jeuken, Lars J. C.; Verbeet, Martin P.; Armstrong, Fraser A.; Canters, Gerard W.			A random-sequential mechanism for nitrite binding and active site reduction in copper-containing nitrite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCALIGENES-FAECALIS S-6; X-RAY-STRUCTURE; INTRAMOLECULAR ELECTRON-TRANSFER; ACHROMOBACTER-CYCLOCLASTES; TYPE-2 COPPER; ENZYME ELECTROKINETICS; DISSIMILATORY NITRITE; SUBSTRATE-BINDING; PH-DEPENDENCE; REDOX PARTNER	The homotrimeric copper-containing nitrite reductase ( NiR) contains one type-1 and one type-2 copper center per monomer. Electrons enter through the type-1 site and are shuttled to the type-2 site where nitrite is reduced to nitric oxide. To investigate the catalytic mechanism of NiR the effects of pH and nitrite on the turnover rate in the presence of three different electron donors at saturating concentrations were measured. The activity of NiR was also measured electrochemically by exploiting direct electron transfer to the enzyme immobilized on a graphite rotating disk electrode. In all cases, the steady-state kinetics fitted excellently to a random-sequential mechanism in which electron transfer from the type-1 to the type-2 site is rate-limiting. At low [ NO2-] reduction of the type-2 site precedes nitrite binding, at high [ NO2-] the reverse occurs. Below pH 6.5, the catalytic activity diminished at higher nitrite concentrations, in agreement with electron transfer being slower to the nitrite-bound type-2 site than to the water-bound type-2 site. Above pH 6.5, substrate activation is observed, in agreement with electron transfer to the nitrite-bound type-2 site being faster than electron transfer to the hydroxyl-bound type-2 site. To study the effect of slower electron transfer between the type-1 and type-2 site, NiR M150T was used. It has a type-1 site with a 125-mV higher midpoint potential and a 0.3-eV higher reorganization energy leading to an similar to 50-fold slower intramolecular electron transfer to the type-2 site. The results confirm that NiR employs a random-sequential mechanism.	Leiden Univ, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands; Univ Leeds, Inst Mol Biophys, Leeds LS2 9JT, W Yorkshire, England; Univ Oxford, Inorgan Chem Lab, Oxford OX1 3QR, England	Leiden University; Leiden University - Excl LUMC; University of Leeds; University of Oxford	Canters, GW (corresponding author), Leiden Univ, Leiden Inst Chem, POB 9502, NL-2300 RA Leiden, Netherlands.	Canters@chem.leidenuniv.nl	Wijma, Hein Jakob/A-8761-2014; Jeuken, Lars J C/A-6234-2008	Wijma, Hein Jakob/0000-0003-0891-6972; Jeuken, Lars J C/0000-0001-7810-3964	Biotechnology and Biological Sciences Research Council [JF19090] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Abraham ZHL, 1997, BIOCHEM J, V324, P511, DOI 10.1042/bj3240511; ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; ADMAN ET, 2001, HDB METALLOPROTEINS, P1181; Astier Y, 2005, CHEMPHYSCHEM, V6, P1114, DOI 10.1002/cphc.200400384; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; Bange HW, 2000, NATURE, V408, P301, DOI 10.1038/35042656; Boulanger MJ, 2003, PROTEIN SCI, V12, P248, DOI 10.1110/ps.0224503; Boulanger MJ, 2001, BIOCHEMISTRY-US, V40, P9132, DOI 10.1021/bi0107400; Boulanger MJ, 2000, J BIOL CHEM, V275, P23957, DOI 10.1074/jbc.M001859200; BRENNER AJ, 1995, ANAL BIOCHEM, V226, P80, DOI 10.1006/abio.1995.1194; Cardinale JA, 2000, INFECT IMMUN, V68, P4368, DOI 10.1128/IAI.68.7.4368-4369.2000; Casella L, 1996, INORG CHEM, V35, P1101, DOI 10.1021/ic950392o; Deligeer, 2002, J INORG BIOCHEM, V91, P132, DOI 10.1016/S0162-0134(02)00442-7; Dodd FE, 1997, ACTA CRYSTALLOGR D, V53, P406, DOI 10.1107/S0907444997002667; Dodd FE, 1998, J MOL BIOL, V282, P369, DOI 10.1006/jmbi.1998.2007; Ellis MJ, 2001, ACTA CRYSTALLOGR D, V57, P1110, DOI 10.1107/S0907444901008654; FERSHT A, 1985, ENZYME STRUCTURE MEC, P55; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HALFEN JA, 1994, J AM CHEM SOC, V116, P2173, DOI 10.1021/ja00084a079; Heering HA, 1998, J PHYS CHEM B, V102, P6889, DOI 10.1021/jp981023r; Hough MA, 2005, J MOL BIOL, V350, P300, DOI 10.1016/j.jmb.2005.04.006; HULSE CL, 1989, J AM CHEM SOC, V111, P2322, DOI 10.1021/ja00188a067; Ichiki H, 2001, J BACTERIOL, V183, P4149, DOI 10.1128/JB.183.14.4149-4156.2001; Impagliazzo A, 2004, J AM CHEM SOC, V126, P5658, DOI 10.1021/ja049619h; IWASAKI H, 1972, J BIOCHEM, V71, P645; Jones AK, 2003, J AM CHEM SOC, V125, P8505, DOI 10.1021/ja035296y; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; KAKUTANI T, 1981, J BIOCHEM, V89, P453, DOI 10.1093/oxfordjournals.jbchem.a133220; KASHEM MA, 1987, BIOCHEM BIOPH RES CO, V145, P563, DOI 10.1016/0006-291X(87)91357-X; Kataoka K, 2000, J BIOCHEM-TOKYO, V127, P345, DOI 10.1093/oxfordjournals.jbchem.a022613; Kobayashi K, 1999, J BIOCHEM, V126, P408, DOI 10.1093/oxfordjournals.jbchem.a022465; Kukimoto M, 1996, J BIOL CHEM, V271, P13680, DOI 10.1074/jbc.271.23.13680; KUKIMOTO M, 1995, PROTEIN ENG, V8, P153, DOI 10.1093/protein/8.2.153; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; Leger C, 2001, BIOCHEMISTRY-US, V40, P11234, DOI 10.1021/bi010889b; LIBBY E, 1992, BIOCHEM BIOPH RES CO, V187, P1529, DOI 10.1016/0006-291X(92)90476-2; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; Monzani E, 2000, J BIOL INORG CHEM, V5, P251, DOI 10.1007/s007750050369; MURPHY MEP, 1995, BIOCHEMISTRY-US, V34, P12107, DOI 10.1021/bi00038a003; Murphy MEP, 1997, J BIOL CHEM, V272, P28455, DOI 10.1074/jbc.272.45.28455; Robertson GP, 2000, SCIENCE, V289, P1922, DOI 10.1126/science.289.5486.1922; Rock JD, 2005, BIOCHEM SOC T, V33, P134, DOI 10.1042/BST0330134; Sasaki S, 1998, BIOSENS BIOELECTRON, V13, P1, DOI 10.1016/S0956-5663(97)00100-0; STANKOVICH MT, 1980, ANAL BIOCHEM, V109, P295, DOI 10.1016/0003-2697(80)90652-1; Strange RW, 1999, J MOL BIOL, V287, P1001, DOI 10.1006/jmbi.1999.2648; Suzuki S, 1999, COORDIN CHEM REV, V190, P245, DOI 10.1016/S0010-8545(99)00069-7; Suzuki S, 1997, J BIOL INORG CHEM, V2, P265, DOI 10.1007/s007750050132; Suzuki S, 2000, INORG REACT MECH, V2, P129; Tocheva EI, 2004, SCIENCE, V304, P867, DOI 10.1126/science.1095109; VANLEEUWEN JW, 1983, EUR J BIOCHEM, V135, P601; Wasser IM, 2002, CHEM REV, V102, P1201, DOI 10.1021/cr0006627; Wijma HJ, 2004, BIOCHEMISTRY-US, V43, P10467, DOI 10.1021/bi0496687; Wijma HJ, 2003, BIOCHEMISTRY-US, V42, P4075, DOI 10.1021/bi027270+; Wu Q, 1997, ANAL CHEM, V69, P4856, DOI 10.1021/ac970595p; Zhao YW, 2002, BIOCHEMISTRY-US, V41, P7464, DOI 10.1021/bi0256274; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	56	66	67	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16340	16346		10.1074/jbc.M601610200	http://dx.doi.org/10.1074/jbc.M601610200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16613859	Green Published, hybrid			2022-12-25	WOS:000238165700021
J	Layer, G; Pierik, AJ; Trost, M; Rigby, SE; Leech, HK; Grage, K; Breckau, D; Astner, I; Jansch, L; Heathcote, P; Warren, MJ; Heinz, DW; Jahn, D				Layer, Gunhild; Pierik, Antonio J.; Trost, Matthias; Rigby, Steve E.; Leech, Helen K.; Grage, Katrin; Breckau, Daniela; Astner, Isabel; Jaensch, Lothar; Heathcote, Peter; Warren, Martin J.; Heinz, Dirk W.; Jahn, Dieter			The substrate radical of Escherichia coli oxygen-independent coproporphyrinogen III oxidase HemN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINE 2,3-AMINOMUTASE REACTION; ELECTRON SPIN RESONANCE; PYRUVATE FORMATE-LYASE; S-ADENOSYLMETHIONINE; ALLYLIC ANALOG; UROPORPHYRINOGEN DECARBOXYLASE; INTERMEDIATE; BIOSYNTHESIS; ENZYMES; PARTICIPATION	During porphyrin biosynthesis the oxygen-independent coproporphyrinogen III oxidase ( HemN) catalyzes the oxidative decarboxylation of the propionate side chains of rings A and B of coproporphyrinogen III to form protoporphyrinogen IX. The enzyme utilizes a 5'-deoxyadenosyl radical to initiate the decarboxylation reaction, and it has been proposed that this occurs by stereo-specific abstraction of the pro-S-hydrogen atom at the beta-position of the propionate side chains leading to a substrate radical. Here we provide EPR-spectroscopic evidence for intermediacy of the latter radical by observation of an organic radical EPR signal in reduced HemN upon addition of S-adenosyl-L-methionine and the substrate coproporphyrinogen III. This signal (g(av) = 2.0029) shows a complex pattern of well resolved hyperfine splittings from at least five different hydrogen atoms. The radical was characterized using regiospecifically labeled ( deuterium or N-15) coproporphyrinogen III molecules. They had been generated from a multienzyme mixture and served as efficient substrates. Reaction of HemN with coproporphyrinogen III, perdeuterated except for the methyl groups, led to the complete loss of resolved proton hyperfine splittings. Substrates in which the hydrogens at both alpha- and beta- positions, or only at the beta-positions of the propionate side chains, or those of the methylene bridges, were deuterated showed that there is coupling with hydrogens at the alpha-, beta-, and methylene bridge positions. Deuterium or 15N labeling of the pyrrole nitrogens without labeling the side chains only led to a slight sharpening of the radical signal. Together, these observations clearly identified the radical signal as substrate-derived and indicated that, upon abstraction of the pro-S-hydrogen atom at the beta-position of the propionate side chain by the 5'-deoxyadenosyl radical, a comparatively stable delocalized substrate radical intermediate is formed in the absence of electron acceptors. The observed hyperfine constants and g values show that this coproporphyrinogenyl radical is allylic and encompasses carbon atoms 3', 3, and 4.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany; Univ Marburg, Dept Microbiol, D-35032 Marburg, Germany; German Res Ctr Biotechnol, Dept Cell Biol, D-38124 Braunschweig, Germany; Queen Mary Univ London, Sch Biol & Chem Sci, London E1 4NS, England; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; German Res Ctr Biotechnol, Div Struct Biol, D-38124 Braunschweig, Germany	Braunschweig University of Technology; Philipps University Marburg; Helmholtz Association; Helmholtz-Center for Infection Research; University of London; Queen Mary University London; University of Kent; Helmholtz Association; Helmholtz-Center for Infection Research	Layer, G (corresponding author), CEA, Lab Chim & Biochim, Ctr Redox Biol, 17 Rue Martyrs, F-38054 Grenoble, France.	gunhild.layer@cea.fr	Trost, Matthias/A-9999-2009; Pierik, Antonio J/G-1108-2010; Heathcote, Peter/B-3749-2011	Trost, Matthias/0000-0002-5732-700X; Pierik, Antonio J/0000-0002-1509-6370; Warren, Martin/0000-0002-6028-6456; Jahn, Dieter/0000-0002-4064-9205	Biotechnology and Biological Sciences Research Council [BB/C504686/1, B19356/2] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BALLINGER MD, 1992, BIOCHEMISTRY-US, V31, P949, DOI 10.1021/bi00119a001; BALLINGER MD, 1995, BIOCHEMISTRY-US, V34, P10086, DOI 10.1021/bi00031a033; BALLINGER MD, 1992, BIOCHEMISTRY-US, V31, P10782, DOI 10.1021/bi00159a020; Baysse C, 2003, MICROBIOL-SGM, V149, P3543, DOI 10.1099/mic.0.26566-0; Breckau D, 2003, J BIOL CHEM, V278, P46625, DOI 10.1074/jbc.M308553200; BUTLER AR, 1992, TETRAHEDRON, V48, P7879, DOI 10.1016/S0040-4020(01)80465-8; Cheek J, 2002, J AM CHEM SOC, V124, P2860, DOI 10.1021/ja017784g; Dailey HA, 2002, BIOCHEM SOC T, V30, P590, DOI 10.1042/bst0300590; FALK JE, 1964, PORPHYRINS METALLOPO; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; Frankenberg N, 2003, APPL MICROBIOL BIOT, V63, P115, DOI 10.1007/s00253-003-1432-2; FREY M, 1994, J BIOL CHEM, V269, P12432; Frey PA, 2003, CHEM REV, V103, P2129, DOI 10.1021/cr020422m; GRANDCHAMP B, 1982, ENZYME, V28, P196, DOI 10.1159/000459102; HELLER C, 1960, J CHEM PHYS, V32, P1535, DOI 10.1063/1.1730955; Jarrett JT, 2003, CURR OPIN CHEM BIOL, V7, P174, DOI 10.1016/S1367-5931(03)00022-X; Layer G, 2005, J BIOL CHEM, V280, P29038, DOI 10.1074/jbc.M501275200; Layer G, 2002, J BIOL CHEM, V277, P34136, DOI 10.1074/jbc.M205247200; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Magnusson OT, 2001, BIOCHEMISTRY-US, V40, P7773, DOI 10.1021/bi0104569; Magnusson OT, 1999, J AM CHEM SOC, V121, P9764, DOI 10.1021/ja9925507; MORTON JR, 1964, CHEM REV, V64, P453, DOI 10.1021/cr60230a005; MOSS M, 1987, J BIOL CHEM, V262, P14859; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; Petrovich RM, 1997, BIOCHEMISTRY-US, V36, P13421, DOI 10.1021/bi971642a; Phillips JD, 2003, EMBO J, V22, P6225, DOI 10.1093/emboj/cdg606; Phillips JD, 1997, PROTEIN SCI, V6, P1343, DOI 10.1002/pro.5560060624; Raux E, 2003, BIOCHEM J, V370, P505, DOI 10.1042/BJ20021443; Retey J., 1999, Chemistry and biochemistry of B12., P271; Schobert M, 2002, J MOL MICROB BIOTECH, V4, P287; SEEHRA JS, 1983, BIOCHEM J, V209, P709, DOI 10.1042/bj2090709; SHOOLINGINJORDA.PM, 2000, COMPREHENSIVE NATURA, V4, P61; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Ugulava NB, 2003, BIOCHEMISTRY-US, V42, P2708, DOI 10.1021/bi0261084; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WU WM, 1995, BIOCHEMISTRY-US, V34, P10532, DOI 10.1021/bi00033a027; Wu WM, 2000, BIOCHEMISTRY-US, V39, P9561, DOI 10.1021/bi000658p	37	64	66	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15727	15734		10.1074/jbc.M512628200	http://dx.doi.org/10.1074/jbc.M512628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16606627	hybrid			2022-12-25	WOS:000237996000019
J	Prabakaran, P; Gan, JH; Feng, Y; Zhu, ZY; Choudhry, V; Xiao, XD; Ji, XH; Dimitrov, DS				Prabakaran, Ponraj; Gan, Jianhua; Feng, Yang; Zhu, Zhongyu; Choudhry, Vidita; Xiao, Xiaodong; Ji, Xinhua; Dimitrov, Dimiter S.			Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCLONAL-ANTIBODIES; ANGIOTENSIN-CONVERTING ENZYME-2; COV S-GLYCOPROTEIN; SARS CORONAVIRUS; POTENT NEUTRALIZATION; SPIKE PROTEIN; VIRUS; IDENTIFICATION; VACCINES; CELLS	The severe acute respiratory syndrome coronavirus (SARS-CoV, or SCV), which caused a world-wide epidemic in 2002 and 2003, binds to a receptor, angiotensin-converting enzyme 2 (ACE2), through the receptor-binding domain (RBD) of its envelope (spike, S) glycoprotein. The RBD is very immunogenic; it is a major SCV neutralization determinant and can elicit potent neutralizing antibodies capable of out- competing ACE2. However, the structural basis of RBD immunogenicity, RBD-mediated neutralization, and the role of RBD in entry steps following its binding to ACE2 have not been elucidated. By mimicking immune responses with the use of RBD as an antigen to screen a large human antibody library derived from healthy volunteers, we identified a novel potent cross-reactive SCV-neutralizing monoclonal antibody, m396, which competes with ACE2 for binding to RBD, and determined the crystal structure of the RBD-antibody complex at 2.3-angstrom resolution. The antibody-bound RBD structure is completely defined, revealing two previously unresolved segments (residues 376-381 and 503-512) and a new disulfide bond (between residues 378 and 511). Interestingly, the overall structure of the m396-bound RBD is not significantly different from that of the ACE2-bound RBD. The antibody epitope is dominated by a 10-residue-long protruding beta 6-beta 7 loop with two putative ACE2-binding hotspot residues (Ile-489 and Tyr-491). These results provide a structural rationale for the function of a major determinant of SCV immunogenicity and neutralization, the development of SCV therapeutics based on the antibody paratope and epitope, and a retrovaccinology approach for the design of anti-SCV vaccines. The available structural information indicates that the SCV entry may not be mediated by ACE2-induced conformational changes in the RBD but may involve other conformational changes or/and yet to be identified coreceptors.	NCI, Prot Interact Grp, Ctr Canc Res Nanobiol Program, NIH, Frederick, MD 21702 USA; Sci Applicat Int Corp, Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Ji, XH (corresponding author), NCI, Biomol Struct Sect, MCL, NIH, POB B,Bldg 539,Rm 124, Frederick, MD 21702 USA.	jix@ncifcrf.gov	Ji, Xinhua/C-9664-2012; Ponraj, Prabakaran/D-6325-2011	Ji, Xinhua/0000-0001-6942-1514; Ponraj, Prabakaran/0000-0002-4049-4813	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400, N01-CO-24000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010701, Z01BC010326] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Babcock GJ, 2004, J VIROL, V78, P4552, DOI 10.1128/JVI.78.9.4552-4560.2004; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891; Chakraborti S, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-73; Chen ZW, 2005, J VIROL, V79, P2678, DOI 10.1128/JVI.79.5.2678-2688.2005; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908; He YX, 2005, VIROLOGY, V334, P74, DOI 10.1016/j.virol.2005.01.034; He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106; Holmes KV, 2003, NEW ENGL J MED, V348, P1948, DOI 10.1056/NEJMp030078; Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398; HUBER R, 1986, SCIENCE, V233, P702, DOI 10.1126/science.2426777; Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480; Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nybakken GE, 2005, NATURE, V437, P764, DOI 10.1038/nature03956; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823; Stanfield RL, 2006, J MOL BIOL, V357, P1566, DOI 10.1016/j.jmb.2006.01.023; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101; Sui JH, 2005, J VIROL, V79, P5900, DOI 10.1128/JVI.79.10.5900-5906.2005; Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200; Xiao X, 2004, CELL MOL LIFE SCI, V61, P2428, DOI 10.1007/s00018-004-4257-y; Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054; Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102; Yi CE, 2005, J VIROL, V79, P11638, DOI 10.1128/JVI.79.18.11638-11646.2005; Zhang MY, 2005, CURR OPIN MOL THER, V7, P151; Zhu ZY, 2006, J VIROL, V80, P891, DOI 10.1128/JVI.80.2.891-899.2006	40	175	189	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15829	15836		10.1074/jbc.M600697200	http://dx.doi.org/10.1074/jbc.M600697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16597622	hybrid, Green Published			2022-12-25	WOS:000237996000031
J	Nagamori, I; Yomogida, K; Adams, PD; Sassone-Corsi, P; Nojima, H				Nagamori, Ippei; Yomogida, Kentaro; Adams, Peter D.; Sassone-Corsi, Paolo; Nojima, Hiroshi			Transcription factors, cAMP-responsive element modulator (CREM) and Tisp40, act in concert in postmeiotic transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALE GERM-CELLS; HISTONE H3.3; PROTEIN; ACTIVATION; EXPRESSION; SPERMATOGENESIS; APOPTOSIS; CHROMATIN; FAMILY; GENES	We previously isolated 80 TISP ( transcript induced in spermiogenesis) genes whose transcription is dramatically induced during spermiogenesis. Our analysis here of the expression of these genes in the testis of the cAMP-responsive element modulator(CREM)-nullmouse revealed that 54 TISP genes are under the transcriptional regulation of CREM. One CREM-regulated gene is TISP40, which encodes a basic leucine zipper (bZip)-type transcription factor bearing a transmembrane domain that generates the two proteins Tisp40 alpha and Tisp40 beta. Both of these proteins function by binding to UPRE( unfolded protein-response element) but do not recognize CRE motifs. We show here that Tisp40 alpha mRNA is generated under the direct transcriptional regulation of CREM. CREM tau and Tisp40 form a heterodimer, which functions through CRE but not through UPRE. Furthermore, binding ability of CREM to CRE is dramatically up-regulated by forming a heterodimer with Tisp40 alpha Delta TM, a truncated form of Tisp40 alpha that lacks the transmembrane domain. We confirmed that Tisp40 and CREM actually bind to the Tisp40 promoter in vivo by chromatin immunoprecipitation assay. Finally, we demonstrate that the Tisp40 Delta TM-CREM tau heterodimer acts as a recruiter of HIRA, a histone chaperone, to CRE. Taken together, we propose that Tisp40 is an important transcriptional regulator during spermiogenesis.	Osaka Univ, Res Inst Microbial Dis, Dept Mol Genet, Suita, Osaka 5650871, Japan; Mukogawa Womens Univ, Sch Human Environm Sci, Nishinomiya, Hyogo 6638558, Japan; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Osaka University; Mukogawa Women's University; Fox Chase Cancer Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Nojima, H (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Mol Genet, Yamadaoka 3-1, Suita, Osaka 5650871, Japan.	snj-0212@biken.osaka-u.ac.jp	Sassone-Corsi, Paolo/H-6182-2011	Adams, Peter/0000-0002-0684-1770				Adham IM, 2005, MOL CELL BIOL, V25, P7657, DOI 10.1128/MCB.25.17.7657-7664.2005; Akhmanova A, 1997, CHROMOSOMA, V106, P335, DOI 10.1007/s004120050255; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CARLOS EC, 2002, BIOL REP, V66, P785; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Fujii T, 1999, GENOMICS, V57, P94, DOI 10.1006/geno.1998.5738; Fujii T, 2002, EMBO REP, V3, P367, DOI 10.1093/embo-reports/kvf073; Govin J, 2004, EUR J BIOCHEM, V271, P3459, DOI 10.1111/j.1432-1033.2004.04266.x; Haraguchi CM, 2004, J HISTOCHEM CYTOCHEM, V52, P1393, DOI 10.1369/jhc.4A6275.2004; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Ike A, 2004, FEBS LETT, V559, P159, DOI 10.1016/S0014-5793(04)00065-1; Kimmins S, 2005, NATURE, V434, P583, DOI 10.1038/nature03368; Kondo S, 2005, NAT CELL BIOL, V7, P186, DOI 10.1038/ncb1213; Kotaja N, 2005, J BIOL CHEM, V280, P31739, DOI 10.1074/jbc.M505971200; Kotaja N, 2004, P NATL ACAD SCI USA, V101, P10620, DOI 10.1073/pnas.0401947101; Macho B, 2002, SCIENCE, V298, P2388, DOI 10.1126/science.1077265; Miki K, 2002, DEV BIOL, V248, P331, DOI 10.1006/dbio.2002.0728; Monaco L, 2004, INT J ANDROL, V27, P322, DOI 10.1111/j.1365-2605.2004.00494.x; Morales CR, 2002, DEV BIOL, V246, P480, DOI 10.1006/dbio.2002.0679; Nagamori I, 2005, GENES CELLS, V10, P575, DOI 10.1111/j.1365-2443.2005.00860.x; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Nelson DM, 2002, MOL CELL BIOL, V22, P7459, DOI 10.1128/MCB.22.21.7459-7472.2002; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; Niu JX, 2001, CURR BIOL, V11, P1686, DOI 10.1016/S0960-9822(01)00530-9; Sassone-Corsi P, 2000, MOL REPROD DEV, V56, P228, DOI 10.1002/(SICI)1098-2795(200006)56:2+<228::AID-MRD2>3.0.CO;2-B; Schwartz BE, 2005, GENE DEV, V19, P804, DOI 10.1101/gad.1259805; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; Shcherbik N, 2004, J CELL BIOCHEM, V93, P11, DOI 10.1002/jcb.20130; Shirley CR, 2004, BIOL REPROD, V71, P1220, DOI 10.1095/biolreprod.104.029363; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Tanaka H, 2005, CELL MOL LIFE SCI, V62, P344, DOI 10.1007/s00018-004-4394-y; Vijayaraghavan S, 1999, MOL ENDOCRINOL, V13, P705, DOI 10.1210/me.13.5.705; Wirbelauer C, 2005, GENE DEV, V19, P1761, DOI 10.1101/gad.347705; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Zhang KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040	38	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15073	15081		10.1074/jbc.M602051200	http://dx.doi.org/10.1074/jbc.M602051200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16595651	hybrid			2022-12-25	WOS:000237922200009
J	Voss, C; Eyol, E; Frank, M; von der Lieth, CW; Berger, MR				Voss, Cristina; Eyol, Ergul; Frank, Martin; von der Lieth, Claus-W.; Berger, Martin R.			Identification and characterization of riproximin, a new type II ribosome-inactivating protein with antineoplastic activity from Ximenia americana	FASEB JOURNAL			English	Article						anticancer agent; plant protein; lectin; peroral activity; liver metastasis model	RAT-LIVER METASTASIS; RICIN-A-CHAIN; ENDOPLASMIC-RETICULUM; AVISCUMINE RVISCUMIN; CRYSTAL-STRUCTURE; SOLID TUMORS; CELL-LINES; PHASE-I; LECTIN; BINDING	The aim of this study was to identify and characterize the active component(s) of Ximenia americana plant material used to treat cancer in African traditional medicine. By a combination of preextraction, extraction, ion exchange and affinity chromatography, a mixture of two cytotoxic proteins was isolated. Using degenerated primers designed on the de novo sequence of two tryptic peptides from one of these proteins, a DNA fragment was amplified and the sequence obtained was used to determine the complete cDNA sequence by the RACE method. Sequence analysis and molecular modeling showed that the new protein, riproximin, belongs to the family of type II ribosome inactivating proteins. These results are in good agreement with the ability of riproximin to inhibit protein synthesis in a cell-free system, as well as with the cytotoxicity of riproximin, as demonstrated by its IC50 value of 0.5 pM in MCF7, 1.1 pM in HELA and 0.6 pM in CC531-lacZ cells. To assess the antineoplastic efficacy of the purified riproximin in vivo, the CC531-lacZ colorectal cancer rat metastasis model was used. Significant anticancer activity was found after administration of total dosages of 100 (perorally) and 10 (intraperitoneally) pmol riproximin/kg. These results suggest that riproximin has distinct potential for cancer treatment.	Deutsch Krebsforschungszentrum, Toxicol & Chemotherapy Unit, D-69120 Heidelberg, Germany; German Canc Res Ctr, Cent Spectroscop Dept, D-6900 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Berger, MR (corresponding author), Deutsch Krebsforschungszentrum, Toxicol & Chemotherapy Unit, E100,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.berger@dkfz.de		Frank, Martin/0000-0002-1006-6746				ADAM KP, 2000, ANAL BIOGENER ARZNEI, P470; Barbieri L, 2004, FEBS LETT, V563, P219, DOI 10.1016/S0014-5793(04)00286-8; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Battelli MG, 2004, MINI-REV MED CHEM, V4, P513, DOI 10.2174/1389557043403819; Battelli MG, 2004, CELL MOL LIFE SCI, V61, P1975, DOI 10.1007/s00018-004-4171-3; CITORES L, 2003, CELL MOL BIOL, P49; Deeks ED, 2002, BIOCHEMISTRY-US, V41, P3405, DOI 10.1021/bi011580v; Eck J, 1999, EUR J BIOCHEM, V264, P775, DOI 10.1046/j.1432-1327.1999.00638.x; Girbes T, 2003, CELL MOL BIOL, V49, P537; Girbes T, 1996, CELL MOL BIOL, V42, P461; Hartley MR, 2004, MINI-REV MED CHEM, V4, P487, DOI 10.2174/1389557043403828; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; KINTER M, 1952, PROTEIN SEQUENCING I, P81; Kinter M, 2000, PROTEIN SEQUENCING I, V1st, P152; Konstantinov SM, 1998, INT J CANCER, V77, P778, DOI 10.1002/(SICI)1097-0215(19980831)77:5<778::AID-IJC18>3.0.CO;2-Y; Krauspenhaar R, 1999, BIOCHEM BIOPH RES CO, V257, P418, DOI 10.1006/bbrc.1999.0470; Kreitman RJ, 2003, CURR OPIN MOL THER, V5, P44; Langer M, 1996, ANAL BIOCHEM, V243, P150, DOI 10.1006/abio.1996.0493; LIN JY, 1970, NATURE, V227, P292, DOI 10.1038/227292a0; Lord JM, 2003, BIOCHEM SOC T, V31, P1260; Lord Michael J., 2003, Toxicological Reviews, V22, P53, DOI 10.2165/00139709-200322010-00006; Marsden CJ, 2004, EUR J BIOCHEM, V271, P153, DOI 10.1046/j.1432-1033.2003.03914.x; Mishra V, 2005, J BIOL CHEM, V280, P20712, DOI 10.1074/jbc.M500735200; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Munoz R, 2001, CANCER LETT, V167, P163, DOI 10.1016/S0304-3835(01)00477-3; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628; Pryme IF, 2004, CANCER DETECT PREV, V28, P52, DOI 10.1016/j.cdp.2003.10.003; Pusztai A, 1998, J NUTR BIOCHEM, V9, P31, DOI 10.1016/S0955-2863(97)00164-2; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P240, DOI 10.1002/prot.340100308; Saenger J, 2004, J CANCER RES CLIN, V130, P203, DOI 10.1007/s00432-003-0523-x; Schoffski P, 2005, EUR J CANCER, V41, P1431, DOI 10.1016/j.ejca.2005.03.019; Schoffski P, 2004, ANN ONCOL, V15, P1816, DOI 10.1093/annonc/mdh469; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Stirpe F, 2004, TOXICON, V44, P371, DOI 10.1016/j.toxicon.2004.05.004; VOSS C, 2005, TOXICOL APPL PHARM; Wittmer A, 1999, CLIN EXP METASTAS, V17, P369, DOI 10.1023/A:1006643831825	39	37	37	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1194	+		10.1096/fj.05-5231fje	http://dx.doi.org/10.1096/fj.05-5231fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16641197				2022-12-25	WOS:000240210300023
J	Zhang, J; Liu, Q; Chen, Q; Liu, NQ; Li, FL; Lu, ZB; Qin, C; Zhu, H; Huang, YY; He, W; Zhao, BL				Zhang, Jie; Liu, Qiang; Chen, Qi; Liu, Nian-Qing; Li, Fu-ang Li; Lu, Zhong-Bing; Qin, Chuan; Zhu, Hua; Huang, Yu-Ying; He, Wei; Zhao, Bao-Lu			Nicotine attenuates beta-amyloid-induced neurotoxicity by regulating metal homeostasis	FASEB JOURNAL			English	Article						Alzheimer's disease; A beta; copper	ALZHEIMER A-BETA; COPPER CHAPERONE; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; DISEASE; PROTEIN; EXPRESSION; BINDING; BRAIN; IRON	Nicotine reduces beta-amyloidosis and has a beneficial effect against Alzheimer's disease (AD), but the underlying mechanism is not clear. The abnormal interactions of beta-amyloid (A beta) with metal ions such as copper and zinc are implicated in the process of A beta deposition in AD brains. In the present study, we investigated the effect of nicotine on metal homeostasis in the hippocampus and cortex of APP(V717I) ( London mutant form of APP) transgenic mice. A significant reduction in the metal contents of copper and zinc in senile plaques and neuropil is observed after nicotine treatment. The densities of copper and zinc distributions in a subfield of the hippocampus CA1 region are also reduced after nicotine treatment. We further studied the mechanism of nicotine-mediated effect on metal homeostasis by using SH-SY5Y cells overexpressing the Swedish mutant form of human APP (APPsw). Nicotine treatment decreases the intracellular copper concentration and attenuates A beta-mediated neurotoxicity facilitated by the addition of copper, and these effects are independent of the activation of nicotinic acetylcholine-receptor. These data suggest that the effect of nicotine on reducing beta-amyloidosis is partly mediated by regulating metal homeostasis.	Acad Sinica, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing 100101, Peoples R China; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Acad Sinica, Lab Nucl Analyt Tech, Inst High Energy Phys, Beijing 100101, Peoples R China; Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing 100037, Peoples R China; Acad Sinica, Inst High Energy Phys, Sychrotron Radiat Lab, Beijing 100101, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Salk Institute; Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Laboratory Animal Science - CAMS; Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Zhao, BL (corresponding author), Acad Sinica, Inst Biophys, State Key Lab Brain & Cognit Sci, 15 Datun Rd, Beijing 100101, Peoples R China.	zhaobl@sun5.ibp.ac.cn	Liu, Qiang/E-9245-2011; Zhang, Jie/A-5426-2010	Lu, Zhongbing/0000-0002-2717-4698				Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200; Bertinato J, 2003, J BIOL CHEM, V278, P35071, DOI 10.1074/jbc.M302242200; Bertinato J, 2003, J NUTR, V133, P28, DOI 10.1093/jn/133.1.28; Borchardt T, 1999, BIOCHEM J, V344, P461, DOI 10.1042/0264-6021:3440461; Bush AI, 2002, NAT NEUROSCI, V5, P919, DOI 10.1038/nn1002-919a; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Bush AI, 2002, NEUROBIOL AGING, V23, P1031, DOI 10.1016/S0197-4580(02)00120-3; Cerpa WF, 2004, FASEB J, V18, P1701, DOI 10.1096/fj.03-1349fje; Ektessabi A, 2001, X-RAY SPECTROM, V30, P44, DOI 10.1002/xrs.466; ESPEN PV, 1987, CHEM INTELL LAB SYST, V1, P109; HAENDLER HM, 1990, ACTA CRYSTALLOGR C, V46, P2054, DOI 10.1107/S0108270190001950; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Haugabook SJ, 2001, FASEB J, V15, P16; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Ishihara R, 2002, NEUROREPORT, V13, P1817, DOI 10.1097/00001756-200210070-00026; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; LEBECH B, 1990, NEUTRON NEWS, V2, P7; Liu NQ, 2004, SPECTROCHIM ACTA B, V59, P255, DOI 10.1016/j.sab.2003.12.006; Liu Q, 2004, BRIT J PHARMACOL, V141, P746, DOI 10.1038/sj.bjp.0705653; Liu Q, 2003, APPL MAGN RESON, V24, P105, DOI 10.1007/BF03166682; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Lynch T, 2000, EXP GERONTOL, V35, P445, DOI 10.1016/S0531-5565(00)00112-1; Maritz GS, 2000, REPROD FERT DEVELOP, V12, P97, DOI 10.1071/RD98127; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; MCARDLE HJ, 1988, J CELL PHYSIOL, V134, P509, DOI 10.1002/jcp.1041340326; MORITA A, 1994, BIOL TRACE ELEM RES, V42, P165, DOI 10.1007/BF02785387; Multhaup G, 2002, FREE RADICAL BIO MED, V33, P45, DOI 10.1016/S0891-5849(02)00806-7; Newhouse PA, 2001, BIOL PSYCHIAT, V49, P268, DOI 10.1016/S0006-3223(00)01069-6; Nordberg A, 2002, J NEUROCHEM, V81, P655, DOI 10.1046/j.1471-4159.2002.00874.x; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Paxinos G., 1996, RAT BRAIN STEREOTAXI; Rogers SW, 1998, J NEUROSCI, V18, P4825; Salomon AR, 1996, BIOCHEMISTRY-US, V35, P13568, DOI 10.1021/bi9617264; Sayre LM, 2000, J NEUROCHEM, V74, P270, DOI 10.1046/j.1471-4159.2000.0740270.x; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Strausak D, 2001, BRAIN RES BULL, V55, P175, DOI 10.1016/S0361-9230(01)00454-3; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; VEKEMANS B, 1994, X-RAY SPECTROM, V23, P278, DOI 10.1002/xrs.1300230609; Vickers JC, 2000, PROG NEUROBIOL, V60, P139, DOI 10.1016/S0301-0082(99)00023-4; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; Zamani MR, 2001, BIOL PSYCHIAT, V49, P221, DOI 10.1016/S0006-3223(00)01108-2; Zanardi A, 2002, TOXICOL LETT, V127, P207, DOI 10.1016/S0378-4274(01)00502-1; Zeng H, 2001, BIOL PSYCHIAT, V49, P248, DOI 10.1016/S0006-3223(00)01111-2	48	52	70	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1212	+		10.1096/fj.05-5214fje	http://dx.doi.org/10.1096/fj.05-5214fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16627626				2022-12-25	WOS:000240210300029
J	Chapman, EJ; Hurst, CD; Pitt, E; Chambers, P; Aveyard, JS; Knowles, MA				Chapman, E. J.; Hurst, C. D.; Pitt, E.; Chambers, P.; Aveyard, J. S.; Knowles, M. A.			Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway	ONCOGENE			English	Article						urothelial; immortalisation; telomerase; p16; p53	HUMAN UROEPITHELIAL CELLS; REPLICATIVE LIFE-SPAN; BLADDER-CANCER; TELOMERASE ACTIVITY; CELLULAR SENESCENCE; ECTOPIC EXPRESSION; COPY NUMBER; 20Q GAIN; P53; PROLIFERATION	The CDKN2A locus is frequently inactivated in urothelial cell carcinoma (UCC), yet how this alteration contributes to bladder tumorigenesis is not known. Although most UCC express telomerase, inactivation of the p16/Rb pathway is generally required for in vitro immortalisation. This and the involvement of p16 in senescence of normal human urothelial cells (NHUC) suggest that CDKN2A deletion may aid bypass of senescence and allow immortalisation. CDKN2A encodes p16 and p14(ARF) and therefore inactivation of this locus can disrupt both the Rb and p53 tumour suppressor pathways. Retrovirus-mediated transduction was used to specifically modulate the p16/Rband/or p53 tumour suppressor pathways in NHUC and to express human telomerase reverse transcriptase (hTERT). Expression of hTERT bypassed Rb and p53 pathway-dependent barriers to proliferation and immortalised NHUC. TERT-NHUC had normal karyotypes, were non-tumorigenic and unexpectedly retained CDKN2A. Thus, the phenotypic significance of inactivation of CDKN2A in UCC may not be solely related to bypass of senescence. Phenotypic assays in human urothelial cells have relied on cell strains derived from invasive tumours or NHUC immortalised by expression of SV40-large T. The production of genetically normal but immortal NHUC lines now provides a valuable platform for experiments to examine the timing and combination of events necessary for UCC tumorigenesis.	St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Canc Res UK Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds; Saint James's University Hospital	Knowles, MA (corresponding author), St James Univ Hosp, Canc Res UK Clin Ctr, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk	Chambers, Philip/AAK-8549-2020; Chapman, Emma/AAD-7425-2019	Chambers, Philip/0000-0002-0926-717X; Chapman, Emma/0000-0003-2859-2020; Knowles, Margaret/0000-0002-9363-8657				Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Aveyard JS, 2004, J MOL DIAGN, V6, P356, DOI 10.1016/S1525-1578(10)60532-6; Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bond J, 2004, EXP CELL RES, V292, P151, DOI 10.1016/j.yexcr.2003.09.021; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Chapman EJ, 2005, CLIN CANCER RES, V11, P5740, DOI 10.1158/1078-0432.CCR-05-0411; Cote RJ, 1998, CANCER RES, V58, P1090; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; Cuthill S, 1999, GENE CHROMOSOME CANC, V26, P304, DOI 10.1002/(SICI)1098-2264(199912)26:4<304::AID-GCC4>3.0.CO;2-1; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Diggle CP, 2000, J LIPID RES, V41, P1509; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; Elmore LW, 2002, J BIOL CHEM, V277, P35509, DOI 10.1074/jbc.M205477200; Esteller M, 2000, CANCER RES, V60, P129; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Harada H, 2003, MOL CANCER RES, V1, P729; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; HUTTON KAR, 1993, J UROLOGY, V150, P721, DOI 10.1016/S0022-5347(17)35597-0; Knowles MA, 2001, J CLIN PATHOL-MOL PA, V54, P215, DOI 10.1136/mp.54.4.215; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Markl IDC, 1998, CANCER RES, V58, P5348; Muntoni A, 2003, ONCOGENE, V22, P7804, DOI 10.1038/sj.onc.1207085; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Puthenveettil JA, 1999, ADV EXP MED BIOL, V462, P83; Rahat MA, 1999, CANCER, V85, P919; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Reznikoff CA, 1996, CANCER RES, V56, P2886; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Sarkar S, 2000, CANCER RES, V60, P3862; Savelieva E, 1997, ONCOGENE, V14, P551, DOI 10.1038/sj.onc.1200868; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wootton M, 2003, HUM GENE THER, V14, P1473, DOI 10.1089/104303403769211682; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; YEAGER T, 1995, CANCER RES, V55, P493; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163	46	77	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5037	5045		10.1038/sj.onc.1209513	http://dx.doi.org/10.1038/sj.onc.1209513			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16619045				2022-12-25	WOS:000239921300009
J	Xu, JH; Christian, B; Jump, DB				Xu, Jinghua; Christian, Barbara; Jump, Donald B.			Regulation of rat hepatic L-pyruvate kinase promoter composition and activity by glucose, n-3 polyunsaturated fatty acids, and peroxisome proliferator-activated receptor-alpha agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE RESPONSE ELEMENT; HEPATOCYTE NUCLEAR FACTOR-4; BINDING PROTEIN CHREBP; S14 GENE-TRANSCRIPTION; METABOLIC-REGULATION; SYNTHASE GENE; MESSENGER-RNA; PPAR-ALPHA; LIVER; EXPRESSION	Carbohydrate regulatory element-binding protein (ChREBP), MAX-like factor X(MLX), and hepatic nuclear factor-4 alpha(HNF-4 alpha) are key transcription factors involved in the glucose-mediated induction of hepatic L-type pyruvate kinase (L-PK) gene transcription. n-3 polyunsaturated fatty acids (PUFA) and WY14643 (peroxisome proliferator-activated receptor alpha(PPAR alpha) agonist) interfere with glucose-stimulated L-PK gene transcription in vivo and in rat primary hepatocytes. Feeding rats a diet containing n-3 PUFA or WY14643 suppressed hepatic mRNA(L-PK) but did not suppress hepatic ChREBP or HNF-4 alpha nuclear abundance. Hepatic MLX nuclear abundance, however, was suppressed by n-3 PUFA but not WY14643. In rat primary hepatocytes, glucose-stimulated accumulation of mRNA(LPK) and L-PK promoter activity correlated with increased ChREBP nuclear abundance. This treatment also increased L-PK promoter occupancy by RNA polymerase II (RNA pol II), acetylated histone H3 (Ac-H3), and acetylated histone H4 (Ac-H4) but did not significantly impact L-PK promoter occupancy by ChREBP or HNF-4 alpha . Inhibition of L-PK promoter activity by n-3 PUFA correlated with suppressed RNA pol II, Ac-H3, and Ac-H4 occupancy on the L-PK promoter. Although n-3 PUFA transiently suppressed ChREBP and MLX nuclear abundance, this treatment did not impact ChREBP-LPK promoter interaction. HNF4 alpha-LPK promoter interaction was transiently suppressed by n-3 PUFA. Inhibition of L-PK promoter activity by WY14643 correlated with a transient decline in ChREBP nuclear abundance and decreased Ac-H4 interaction with the L-PK promoter. WY14643, however, had no impact on MLX nuclear abundance or HNF4 alpha-LPK promoter interaction. Although overexpressed ChREBP or HNF-4 alpha did not relieve n-3 PUFA suppression of L-PK gene expression, overexpressed MLX fully abrogated n-3 PUFA suppression of L-PK promoter activity and mRNA(L-PK) abundance. Overexpressed ChREBP, but not MLX, relieved the WY14643 inhibition of L-PK. In conclusion, n-3 PUFA and WY14643/PPAR alpha target different transcription factors to control L-PK gene transcription. MLX, the heterodimer partner for ChREBP, has emerged as a novel target for n-3 PUFA regulation.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Jump, DB (corresponding author), Michigan State Univ, Dept Physiol, 3165 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	Jump@msu.edu			NIDDK NIH HHS [DK43220, R01 DK043220-14, R01 DK043220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMY CM, 1990, BIOCHEM J, V271, P675, DOI 10.1042/bj2710675; BEALE EG, 1985, J BIOL CHEM, V260, P748; Botolin D, 2006, J LIPID RES, V47, P181, DOI 10.1194/jlr.M500365-JLR200; Botolin D, 2003, J BIOL CHEM, V278, P6959, DOI 10.1074/jbc.M212846200; COGNET M, 1987, J MOL BIOL, V196, P11, DOI 10.1016/0022-2836(87)90507-9; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; Dennis AP, 2005, J STEROID BIOCHEM, V93, P139, DOI 10.1016/j.jsbmb.2004.12.015; Dentin R, 2005, J CLIN INVEST, V115, P2843, DOI 10.1172/JCI25256; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Dobrzyn A, 2005, BIOCHEM BIOPH RES CO, V332, P892, DOI 10.1016/j.bbrc.2005.05.026; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; Eilers AL, 2002, MOL CELL BIOL, V22, P8514, DOI 10.1128/MCB.22.24.8514-8526.2002; Epperson A, 2000, AM J PHYSIOL-CELL PH, V279, pC529, DOI 10.1152/ajpcell.2000.279.2.C529; Fulgencio JP, 2001, BIOCHEM PHARMACOL, V62, P439, DOI 10.1016/S0006-2952(01)00679-7; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hertz R, 2005, J BIOL CHEM, V280, P24451, DOI 10.1074/jbc.M500732200; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Hong YH, 2003, J BIOL CHEM, V278, P27495, DOI 10.1074/jbc.M304112200; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; JUMP DB, 1990, J BIOL CHEM, V265, P3474; Jump DB, 2005, J NUTR, V135, P2503, DOI 10.1093/jn/135.11.2503; Jump DB, 2004, CRIT REV CL LAB SCI, V41, P41, DOI 10.1080/10408360490278341; Kabashima T, 2003, P NATL ACAD SCI USA, V100, P5107, DOI 10.1073/pnas.0730817100; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kawaguchi T, 2002, J BIOL CHEM, V277, P3829, DOI 10.1074/jbc.M107895200; Kawaguchi T, 2001, P NATL ACAD SCI USA, V98, P13710, DOI 10.1073/pnas.231370798; Large V, 1999, DIABETES, V48, P1251, DOI 10.2337/diabetes.48.6.1251; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; LIU ZR, 1993, J BIOL CHEM, V268, P12787; Ma L, 2005, J BIOL CHEM, V280, P12019, DOI 10.1074/jbc.M413063200; Marrapodi M, 2000, J LIPID RES, V41, P514; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; Nawaz Z, 2004, MOL ENDOCRINOL, V18, P493, DOI 10.1210/me.2003-0388; O'Callaghan BL, 2001, J BIOL CHEM, V276, P16033, DOI 10.1074/jbc.M101557200; ODDOS J, 1989, NUCLEIC ACIDS RES, V17, P8877, DOI 10.1093/nar/17.21.8877; Pan DA, 2000, J LIPID RES, V41, P742; Pawar A, 2003, J BIOL CHEM, V278, P40736, DOI 10.1074/jbc.M307973200; Pawar A, 2003, J BIOL CHEM, V278, P35931, DOI 10.1074/jbc.M306238200; Rufo C, 2001, J BIOL CHEM, V276, P21969, DOI 10.1074/jbc.M100461200; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Stoeckman AK, 2004, J BIOL CHEM, V279, P15662, DOI 10.1074/jbc.M311301200; Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200; Suchankova G, 2005, BIOCHEM BIOPH RES CO, V326, P851, DOI 10.1016/j.bbrc.2004.11.114; Talukdar I, 2005, J BIOL CHEM, V280, P40660, DOI 10.1074/jbc.M505531200; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; Towle HC, 2005, TRENDS ENDOCRIN MET, V16, P489, DOI 10.1016/j.tem.2005.10.003; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Uyeda K, 2002, BIOCHEM PHARMACOL, V63, P2075, DOI 10.1016/S0006-2952(02)01012-2; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Wang Y, 2005, J LIPID RES, V46, P706, DOI 10.1194/jlr.M400335-JLR200; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0	61	58	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18351	18362		10.1074/jbc.M601277200	http://dx.doi.org/10.1074/jbc.M601277200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16644726	Green Accepted, hybrid			2022-12-25	WOS:000238687300012
J	Cheung, BB; Bell, J; Raif, A; Bohlken, A; Yan, J; Roediger, B; Poljak, A; Smith, S; Lee, M; Thomas, WD; Kavallaris, M; Norris, M; Haber, M; Liu, HL; Zajchowski, D; Marshall, GM				Cheung, Belamy B.; Bell, Jessica; Raif, Anna; Bohlken, Andrew; Yan, Joanne; Roediger, Ben; Poljak, Anne; Smith, Stewart; Lee, Michelle; Thomas, Wayne D.; Kavallaris, Maria; Norris, Murray; Haber, Michelle; Liu, Hsiao-Lai; Zajchowski, Deborah; Marshall, Glenn M.			The estrogen-responsive B box protein is a novel regulator of the retinoid signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-RECEPTOR-BETA; ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN ANDROGEN RECEPTOR; GLYCOSYLATION TYPE-I; CANCER CELL-LINES; CONGENITAL DISORDERS; INTERACTION DOMAINS; GROWTH-INHIBITION; NUCLEAR RECEPTORS; INDUCED APOPTOSIS	Retinoic acid (RA) induces growth arrest, cell death, and differentiation in many human cancer cells in vitro and has entered routine clinical use for the treatment of several human cancer types. One mechanism by which cancer cells evade retinoid-induced effects is through repression of retinoic acid receptor beta (RAR beta) gene transcription. The RA response element beta (beta RARE) is the essential DNA sequence required for retinoid-induced RAR beta transcription. Here we show that the estrogen-responsive B box protein (EBBP), a member of the RING-B box-coiled-coil protein family, is a beta RARE-binding protein. EBBP undergoes serine threonine phosphorylation and enhanced protein stability after RA treatment. Following RA treatment, we also observed increased nuclear EBBP levels in aggregates with the promyelocytic leukemia protein at promyelocytic leukemia nuclear bodies. EBBP enhanced RA-responsive RAR beta transcription in RA-sensitive and -resistant cancer cells, which were resistant to both a histone deacetylase inhibitor and a demethylating agent. EBBP-specific small interfering RNA reduced basal and RA-induced RAR beta expression. EBBP increased beta RARE-transactivating function through its coiled-coil domain. Taken together, our work suggests that EBBP may have a pivotal role in the retinoid anti-cancer signal.	Sydney Childrens Hosp, Ctr Childrens Canc & Blood Disorders, Randwick, NSW 2031, Australia; Berlex Biosci, Dept Canc, Richmond, CA 94804 USA; Univ New S Wales, Bioanalyt Mass Spectrometry Facil, Randwick, NSW 2031, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia; Childrens Canc Inst Australia Med Res, Randwick, NSW 2031, Australia	University of New South Wales Sydney; University of Sydney; Children's Cancer Institute	Marshall, GM (corresponding author), Sydney Childrens Hosp, Ctr Childrens Canc & Blood Disorders, Randwick, NSW 2031, Australia.	g.marshall@unsw.edu.au	Kavallaris, Maria/J-5240-2014	Haber, Michelle/0000-0003-2036-8817; Roediger, Ben/0000-0002-4593-091X; Norris, Murray/0000-0002-0632-4589; Cheung, Belamy/0000-0001-8784-860X; Poljak, Anne/0000-0001-9953-1984; Bell, Jessica/0000-0002-8875-0943				Bastien J, 2002, J BIOL CHEM, V277, P28683, DOI 10.1074/jbc.M203623200; Beer HD, 2002, J BIOL CHEM, V277, P20740, DOI 10.1074/jbc.M111233200; Benedetti L, 1997, BLOOD, V90, P1175, DOI 10.1182/blood.V90.3.1175.1175_1175_1185; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; BORDOW SB, 1994, CANCER RES, V54, P5036; Buchner G, 1999, HUM MOL GENET, V8, P1397, DOI 10.1093/hmg/8.8.1397; Cainarca S, 1999, HUM MOL GENET, V8, P1387, DOI 10.1093/hmg/8.8.1387; Cao TY, 1998, J CELL SCI, V111, P1319; Cheung B, 1998, ONCOGENE, V17, P751, DOI 10.1038/sj.onc.1201982; Cheung B, 2003, INT J CANCER, V105, P856, DOI 10.1002/ijc.11153; Cok SJ, 2004, J BIOL CHEM, V279, P8196, DOI 10.1074/jbc.M308475200; Cote S, 1997, ANTI-CANCER DRUG, V8, P56; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Fulton RJ, 1997, CLIN CHEM, V43, P1749; Geisen C, 2000, INT J CANCER, V85, P289, DOI 10.1002/(SICI)1097-0215(20000115)85:2<289::AID-IJC22>3.0.CO;2-T; Glass CK, 2000, GENE DEV, V14, P121; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hesketh AR, 2002, MOL MICROBIOL, V46, P917, DOI 10.1046/j.1365-2958.2002.03219.x; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Lesecq S, 1996, J BIOL CHEM, V271, P17211, DOI 10.1074/jbc.271.29.17211; Li Y, 1998, INT J CANCER, V75, P88, DOI 10.1002/(SICI)1097-0215(19980105)75:1<88::AID-IJC14>3.0.CO;2-9; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Liu HLC, 1998, MOL ENDOCRINOL, V12, P1733, DOI 10.1210/me.12.11.1733; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; Marquardt T, 2003, EUR J PEDIATR, V162, P359, DOI 10.1007/s00431-002-1136-0; MARSHALL GM, 1995, ONCOGENE, V11, P485; MARSHALL GM, 1994, ANTICANCER RES, V14, P437; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mills K, 2003, GLYCOBIOLOGY, V13, P73, DOI 10.1093/glycob/cwg026; Mills K, 2001, CLIN CHEM, V47, P2012; Mills P, 2001, BIOCHEM J, V359, P249, DOI 10.1042/0264-6021:3590249; Mozziconacci MJ, 1998, GENE CHROMOSOME CANC, V22, P241, DOI 10.1002/(SICI)1098-2264(199807)22:3<241::AID-GCC10>3.0.CO;2-R; Nason-Burchenal K, 1998, BLOOD, V92, P1758, DOI 10.1182/blood.V92.5.1758.417k28_1758_1767; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Peng HZ, 2002, J MOL BIOL, V320, P629, DOI 10.1016/S0022-2836(02)00477-1; PIELES U, 1993, NUCLEIC ACIDS RES, V21, P3191, DOI 10.1093/nar/21.14.3191; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sirchia SM, 2002, CANCER RES, V62, P2455; STAMATIADIS D, 1992, J STEROID BIOCHEM, V41, P43, DOI 10.1016/0960-0760(92)90223-6; Suh YA, 2002, CANCER RES, V62, P3945; Tarrade A, 2005, ONCOGENE, V24, P2277, DOI 10.1038/sj.onc.1208402; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; White KA, 2005, J BIOL CHEM, V280, P7829, DOI 10.1074/jbc.M412707200; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Zampieri S, 2001, ANN RHEUM DIS, V60, P72, DOI 10.1136/ard.60.1.72	54	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18246	18256		10.1074/jbc.M600879200	http://dx.doi.org/10.1074/jbc.M600879200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636064	hybrid			2022-12-25	WOS:000238490300077
J	Mohan, J; Gandhi, AA; Bhavya, BC; Rashmi, R; Karunagaran, D; Indu, R; Santhoshkumar, TR				Mohan, John; Gandhi, Alankaram Arul; Bhavya, Balan Chandrika; Rashmi, Ramachandran; Karunagaran, Devarajan; Indu, Ramachandran; Santhoshkumar, Thankayyan Ratnabhai			Caspase-2 triggers Bax-Bak-dependent and -independent cell death in colon cancer cells treated with resveratrol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; DRUG-INDUCED APOPTOSIS; KAPPA-B; INDUCED ACTIVATION; TRANS-RESVERATROL; PROAPOPTOTIC BAX; FAMILY PROTEINS; DOWN-REGULATION; BCL-2 FAMILY; GROWTH	Polyphenol phytoalexin (resveratrol), found in grapes and red wine is a strong chemopreventive agent with promising safety records with human consumption and unique forms of cell death induction in a variety of tumor cells. However, the mechanism of resveratrol-induced apoptosis upstream of mitochondria is still not defined. The results from this study suggest that caspase-2 activation occurs upstream of mitochondria in resveratrol-treated cells. The upstream activation of caspase-2 is not dependent on its antioxidant property or NF-kappa B inhibition. The activated caspase-2 triggers mitochondrial apoptotic events by inducing conformational changes in Bax/Bak with subsequent release of cytochrome c, apoptosis-inducing factor, and endonuclease G. Caspase-8 activation seems to be independent of these events and does not appear to be mediated by classical death receptor processing or downstream caspases. Both caspase-2 and caspase-8 contribute toward the mitochondrial translocation of Bid, since neither caspase-8 inhibition nor caspase-2 inhibition could prevent translocation of Bid DsRed into mitochondria. Caspase-2 inhibitors or antisense silencing of caspase-2 prevented cell death induced by resveratrol and partially prevented processing of downstream caspases, including caspase-9, caspase-3, and caspase-8. Studies using mouse embryonic fibroblasts deficient for both Bax and Bak indicate the contribution of both Bax and Bak in mediating cell death induced by resveratrol and the existence of Bax/Bak-independent cell death possibly through caspase-8- or caspase-2-mediated mitochondria-independent downstream caspase processing.	Rajiv Gandhi Ctr Biotechnol, Dept Canc Biol, Trivandrum 695014, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Santhoshkumar, TR (corresponding author), Rajiv Gandhi Ctr Biotechnol, Dept Canc Biol, Trivandrum 695014, Kerala, India.	santhaltr@yahoo.com	Karunagaran, Devarajan/A-8148-2010; Pillai, Rashmi Ramachandran/B-8130-2012	Karunagaran, Devarajan/0000-0001-9331-8947; Pillai, Rashmi Ramachandran/0000-0002-1619-7763				Aggarwal BB, 2004, ANTICANCER RES, V24, P2783; Ahmad KA, 2004, CANCER RES, V64, P1452, DOI 10.1158/0008-5472.CAN-03-2414; Alonso M, 2003, MOL CANCER THER, V2, P139; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Banerjee S, 2002, CANCER RES, V62, P4945; Bernhard D, 2000, CELL DEATH DIFFER, V7, P834, DOI 10.1038/sj.cdd.4400719; Bhat KPL, 2001, ANTIOXID REDOX SIGN, V3, P1041, DOI 10.1089/152308601317203567; Clement MV, 1998, BLOOD, V92, P996; Corsi MM, 2002, DRUG EXP CLIN RES, V28, P235; Delmas D, 2004, ONCOGENE, V23, P8979, DOI 10.1038/sj.onc.1208086; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Diaz GD, 2003, CANCER RES, V63, P1254; Dirsch VM, 2003, CANCER RES, V63, P8869; Dorrie J, 2001, CANCER RES, V61, P4731; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Gao ZH, 2005, J BIOL CHEM, V280, P38271, DOI 10.1074/jbc.M506488200; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Holmes-McNary M, 2000, CANCER RES, V60, P3477; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; IKEGAKI N, 1994, CANCER RES, V54, P6; Jang JH, 2001, MUTAT RES-GEN TOX EN, V496, P181, DOI 10.1016/S1383-5718(01)00233-9; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jazirehi AR, 2004, MOL CANCER THER, V3, P71; Kimura Y, 2001, J NUTR, V131, P1844, DOI 10.1093/jn/131.6.1844; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lin CF, 2004, J BIOL CHEM, V279, P40755, DOI 10.1074/jbc.M404726200; Mahyar-Roemer M, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-27; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Mgbonyebi OP, 1998, INT J ONCOL, V12, P865; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Pozo-Guisado E, 2005, INT J CANCER, V115, P74, DOI 10.1002/ijc.20856; Pozo-Guisado E, 2002, BIOCHEM PHARMACOL, V64, P1375, DOI 10.1016/S0006-2952(02)01296-0; Rashmi R, 2005, CARCINOGENESIS, V26, P713, DOI 10.1093/carcin/bgi025; Reed JC, 1997, SEMIN HEMATOL, V34, P9; REED JC, 1997, APOPTOSIS CANC; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Ruiz-Vela A, 2005, EMBO REP, V6, P379, DOI 10.1038/sj.embor.7400375; Scarlatti F, 2003, FASEB J, V17, P2339, DOI 10.1096/fj.03-0292fje; Schneider Y, 2000, CANCER LETT, V158, P85, DOI 10.1016/S0304-3835(00)00511-5; She QB, 2001, CANCER RES, V61, P1604; Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827; Soleas GJ, 2001, METHOD ENZYMOL, V335, P145; Subbaramaiah K, 1999, ANN NY ACAD SCI, V889, P214, DOI 10.1111/j.1749-6632.1999.tb08737.x; Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Wang GQ, 2001, J EXP MED, V194, P1325, DOI 10.1084/jem.194.9.1325; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	57	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17599	17611		10.1074/jbc.M602641200	http://dx.doi.org/10.1074/jbc.M602641200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16617056	hybrid			2022-12-25	WOS:000238490300009
J	Yu, L; Mohamed, AJ; Vargas, L; Berglof, A; Finn, G; Lu, KP; Smith, CIE				Yu, Liang; Mohamed, Abdalla J.; Vargas, Leonardo; Berglof, Anna; Finn, Greg; Lu, Kun Ping; Smith, C. I. Edvard			Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase Pin1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; CELL ANTIGEN RECEPTOR; PLECKSTRIN HOMOLOGY DOMAIN; SRC FAMILY; TRANSCRIPTIONAL ACTIVITY; PROTEASOME INHIBITORS; MEMBRANE ASSOCIATION; CYCLOPHILIN-A; BTK FUNCTION; SH3 DOMAIN	Bruton tyrosine kinase (Btk) is expressed in B-lymphocytes. Mutations in Btk cause X-linked agammaglobulinemia in humans. However, the mechanism of activation and signaling of this enzyme has not been fully investigated. We have here shown that the peptidylprolyl cis/trans isomerase (PPIase) Pin1 is a negative regulator of Btk, controlling its expression level by reducing its half-life, whereas the catalytic activity of Btk was unaffected. The negative regulatory effect of Pin1 was observed both in cell lines and in Pin(-/-) mice and was found to be dependent on a functionally intact Btk. This may constitute a feedback loop for the regulation of Btk. The target region in Btk was localized to the pleckstrin homology domain suggesting that interphase phosphorylation of serine 115 (Ser-115) in Btk is required, whereas mitosis phosphorylation of serine 21 (Ser-21) is critical. Accordingly, Pin 1 was shown to associate with Btk through binding to Ser-21 and -115, respectively, both of which lie in a classical Pin1-binding pocket. Using a phosphomitotic antibody, it was found that Btk harbors a bona fide MPM2 epitope corresponding to a phosphorylated serine or threonine residue followed by a proline. Our results indicate that the peptidylprolyl isomerase Pin1 interacts with Btk in a cell cycle-dependent manner, regulating the Btk expression level.	Karolinska Inst, Clin Res Ctr, Dept Lab Med, SE-14186 Stockholm, Sweden; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Hematol Oncol,Canc Biol Program, Boston, MA 02215 USA	Karolinska Institutet; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Mohamed, AJ (corresponding author), Karolinska Inst, Clin Res Ctr, Dept Lab Med, SE-14186 Stockholm, Sweden.	abdalla.m.jama@kfc.ki.se; edvard.smith@ki.se		SMITH, C. I. Edvard/0000-0003-1907-3392	NIGMS NIH HHS [GM 58556] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058556] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antony P, 2003, EXP CELL RES, V291, P11, DOI 10.1016/S0014-4827(03)00338-0; Atchison FW, 2003, DEVELOPMENT, V130, P3579, DOI 10.1242/dev.00584; Backesjo CM, 2002, BIOCHEM BIOPH RES CO, V299, P510, DOI 10.1016/S0006-291X(02)02643-8; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Brazin KN, 2002, P NATL ACAD SCI USA, V99, P1899, DOI 10.1073/pnas.042529199; Cetkovic H, 2004, GENOMICS, V83, P743, DOI 10.1016/j.ygeno.2003.09.010; Colgan J, 2004, IMMUNITY, V21, P189, DOI 10.1016/j.immuni.2004.07.005; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Dombroski D, 2005, J IMMUNOL, V174, P1385, DOI 10.4049/jimmunol.174.3.1385; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Hansson H, 1998, BIOCHEMISTRY-US, V37, P2912, DOI 10.1021/bi972409f; Hao SL, 2003, EMBO J, V22, P4166, DOI 10.1093/emboj/cdg401; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; Lindvall JM, 2005, IMMUNOL REV, V203, P200, DOI 10.1111/j.0105-2896.2005.00225.x; Lindvall JM, 2004, EUR J IMMUNOL, V34, P1981, DOI 10.1002/eji.200324051; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Lu KP, 2004, TRENDS BIOCHEM SCI, V29, P200, DOI 10.1016/j.tibs.2004.02.002; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, NATURE, V399, P784; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; Middendorp S, 2003, J IMMUNOL, V171, P5988, DOI 10.4049/jimmunol.171.11.5988; Mohamed AJ, 2000, J BIOL CHEM, V275, P40614, DOI 10.1074/jbc.M006952200; Nore BF, 2000, EUR J IMMUNOL, V30, P145, DOI 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0; Novina CD, 1999, MOL CELL BIOL, V19, P5014; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; SMITH CIE, 1994, J IMMUNOL, V152, P557; Smith CIE, 2001, BIOESSAYS, V23, P436, DOI 10.1002/bies.1062; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 1996, CRIT REV IMMUNOL, V16, P251, DOI 10.1615/CritRevImmunol.v16.i3.20; Vihinen M, 1997, FEBS LETT, V413, P205, DOI 10.1016/S0014-5793(97)00912-5; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	64	40	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18201	18207		10.1074/jbc.M603090200	http://dx.doi.org/10.1074/jbc.M603090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16644721	hybrid			2022-12-25	WOS:000238490300072
J	Ohkubo, S; Tanaka, T; Taya, Y; Kitazato, K; Prives, C				Ohkubo, Shuichi; Tanaka, Tomoaki; Taya, Yoichi; Kitazato, Kenji; Prives, Carol			Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; TUMOR-SUPPRESSOR PROTEIN; C-TERMINAL DOMAIN; DNA-DAMAGE; P53 PROTEIN; ONCOPROTEIN MDM2; UBIQUITIN LIGASE; NUCLEAR EXPORT; G(2) ARREST; IN-VIVO	Mutational inactivation of p53 is only one of the ways that tumors lose p53 function. An alternate route is through overexpression of HDM2, the negative regulator of p53. To further understand how excess HDM2 regulates p53-mediated functions, we generated H1299 cell clones that constitutively express both ectopic HDM2 and tetracycline-regulated inducible p53. We found that over a range of p53 concentrations constitutively expressed HDM2 did not affect the levels of p53 protein. Nevertheless, cells with excess HDM2 displayed numerous changes in their response to p53. After DNA damage, such cells had both increased p53-mediated G(2) arrest and reduced cell death. They also showed selective impairment of p53 target gene induction in that some p53 targets were unaffected whereas others were markedly less well induced in the presence of extra HDM2 protein. We also found that excess HDM2 was correlated with reduced p53 acetylation but did not affect p53 association with target promoters in vivo. Indeed, there was no significant difference in the amount of HDM2 associated with p53 at target promoters that differed in their expression depending on the presence of extra HDM2. Thus, HDM2 can selectively down-regulate the transcription function of p53 without either degrading p53 or affecting the interaction of p53 with target promoters.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Taisho Pharmaceut Co Ltd, Canc Res Lab, Hanno, Saitama 3578527, Japan; Natl Inst Canc Res, Chuo Ku, Tokyo 1040045, Japan	Columbia University; Taisho Pharmaceutical Holdings Co Ltd; National Cancer Center - Japan	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	clp3@columbia.edu			NCI NIH HHS [CA87497, CA58316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA087497, R37CA058316, R01CA058316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Arva NC, 2005, J BIOL CHEM, V280, P26776, DOI 10.1074/jbc.M505203200; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Kaeser MD, 2004, ONCOGENE, V23, P4007, DOI 10.1038/sj.onc.1207536; Knights CD, 2003, J BIOL CHEM, V278, P52890, DOI 10.1074/jbc.M300279200; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakamura S, 2002, ONCOGENE, V21, P2102, DOI 10.1038/sj.onc.1205251; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Poyurovsky MV, 2003, MOL CELL, V12, P875, DOI 10.1016/S1097-2765(03)00400-3; Prives C, 1999, J PATHOL, V187, P112; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhao L, 2003, MOL CANCER RES, V1, P195	62	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16943	16950		10.1074/jbc.M601388200	http://dx.doi.org/10.1074/jbc.M601388200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16624812	hybrid			2022-12-25	WOS:000238326300015
J	Ghosh, M; Loper, R; Gelb, MH; Leslie, CC				Ghosh, Moumita; Loper, Robyn; Gelb, Michael H.; Leslie, Christina C.			Identification of the expressed form of human cytosolic phospholipase A(2)beta (cPLA(2)beta) - cPLA(2)beta 3 is a novel variant localized to mitochondria and early endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; C2 DOMAIN; GROUP-IV; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; BINDING DOMAIN; MICE DEFICIENT; KINASE-C; PROTEIN; TRANSLOCATION	In this study, we identify the principal splice variant of human cytosolic phospholipase A(2)beta (cPLA(2)beta) ( also known as Group IVB cPLA(2)) present in cells. In human lung, spleen, and ovary and in a lung epithelial cell line (BEAS-2B), cPLA(2)beta is expressed as a 100-kDa protein, not the 114-kDa form originally predicted. Using RNA interference, the 100-kDa protein in BEAS-2B cells was confirmed to be cPLA(2)beta. BEAS-2B cells contain three different RNA splice variants of cPLA(2)beta (beta 1, beta 2, and beta 3). cPLA(2)beta 1 is identical to the previously cloned cPLA(2)beta, predicted to encode a 114-kDa protein. However, cPLA(2)beta(2) and cPLA(2)beta 3 splice variants are smaller and contain internal deletions in the catalytic domain. The 100-kDa cPLA(2)beta in BEAS-2B cells is the translated product of cPLA(2)beta 3. cPLA(2)beta 3 exhibits calcium-dependent PLA(2) activity against palmitoylarachidonyl-phosphatidylethanolamine and low level lysophospholipase activity but no activity against phosphatidylcholine. Unlike Group IVA cPLA(2)alpha, cPLA(2)beta 3 is constitutively bound to membrane in unstimulated cells, localizing to mitochondria and early endosomes. cPLA(2)beta 3 is widely expressed in tissues, suggesting that it has a generalized function at these unique sites.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA; Univ Washington, Dept Chem & Biochem, Seattle, WA 98195 USA; Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80206 USA	National Jewish Health; University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leslie, CC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.	lesliec@njc.org		gelb, michael/0000-0001-7000-5219	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, R01HL061378, R01HL050040] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 50040, HL 61378, HL 34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayoub N, 2003, MOL CELL BIOL, V23, P4356, DOI 10.1128/MCB.23.12.4356-4370.2003; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Bonventre JV, 2002, ADV EXP MED BIOL, V507, P25; Cartegni L, 2003, NAT STRUCT BIOL, V10, P120, DOI 10.1038/nsb887; Chan D, 2004, MOL BIOL CELL, V15, P1871, DOI 10.1091/mbc.e03-09-0644; Chiba H, 2004, J BIOL CHEM, V279, P12890, DOI 10.1074/jbc.M305801200; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Connolly S, 2002, J MED CHEM, V45, P1348, DOI 10.1021/jm011050x; de Figueiredo P, 2001, J BIOL CHEM, V276, P47361, DOI 10.1074/jbc.M108508200; DECARVALHO MGS, 1995, J BIOL CHEM, V270, P20439, DOI 10.1074/jbc.270.35.20439; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Downey P, 2001, AM J PHYSIOL-RENAL, V280, pF607, DOI 10.1152/ajprenal.2001.280.4.F607; Dugast M, 2005, J BIOL CHEM, V280, P19656, DOI 10.1074/jbc.M501357200; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Ghomashchi F, 1999, BBA-BIOMEMBRANES, V1420, P45, DOI 10.1016/S0005-2736(99)00056-5; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Haq S, 2003, NAT MED, V9, P944, DOI 10.1038/nm891; Hide WA, 2001, GENOME RES, V11, P1848, DOI 10.1101/gr.188001; Jimenez JL, 2003, J MOL BIOL, V333, P621, DOI 10.1016/j.jmb.2003.08.052; Lancaster DE, 2004, BIOCHEM SOC T, V32, P943, DOI 10.1042/BST0320943; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; Leslie Christina C, 2004, Methods Mol Biol, V284, P229; Lindbom J, 2002, J INTERF CYTOK RES, V22, P947, DOI 10.1089/10799900260286650; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Ohto T, 2005, J BIOL CHEM, V280, P24576, DOI 10.1074/jbc.M413711200; Pan Q, 2005, TRENDS GENET, V21, P73, DOI 10.1016/j.tig.2004.12.004; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Shah M, 2006, J BIOL CHEM, V281, P7302, DOI 10.1074/jbc.M508527200; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Song H, 2002, DEVELOPMENT, V129, P2879; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Stewart A, 2002, J BIOL CHEM, V277, P29526, DOI 10.1074/jbc.M204856200; Su ZX, 2006, GENOME RES, V16, P182, DOI 10.1101/gr.4197006; Sugnet CW, 2006, PLOS COMPUT BIOL, V2, P22, DOI 10.1371/journal.pcbi.0020004; Tabuchi S, 2003, ACT NEUR S, V86, P169; TAI G, 2005, BIOL CELL, V404, P442; Trewick SC, 2005, EMBO REP, V6, P315, DOI 10.1038/sj.embor.7400379; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874; Young SP, 2000, FEBS LETT, V466, P135, DOI 10.1016/S0014-5793(99)01774-3; Yuan ZA, 2001, DNA CELL BIOL, V20, P807, DOI 10.1089/104454901753438624	60	43	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16615	16624		10.1074/jbc.M601770200	http://dx.doi.org/10.1074/jbc.M601770200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16617059	hybrid			2022-12-25	WOS:000238165700054
J	Nilsson, LM; Thomas, WE; Trintchina, E; Vogel, V; Sokurenko, EV				Nilsson, Lina M.; Thomas, Wendy E.; Trintchina, Elena; Vogel, Viola; Sokurenko, Evgeni V.			Catch bond-mediated adhesion without a shear threshold - Trimannose versus monomannose interactions with the FimH adhesin of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 FIMBRIAL LECTIN; PIGEON EGG-WHITE; MAJOR GLYCOPROTEINS; BACTERIAL ADHESION; PLATELET-ADHESION; CELL RECOGNITION; FORCE; KINETICS; STRESS; EXPRESSION	The FimH protein is the adhesive subunit of Escherichia coli type 1 fimbriae. It mediates shear-dependent bacterial binding to monomannose (1M)-coated surfaces manifested by the existence of a shear threshold for binding, below which bacteria do not adhere. The 1M-specific shear-dependent binding of FimH is consistent with so-called catch bond interactions, whose lifetime is increased by tensile force. We show here that the oligosaccharide-specific interaction of FimH with another of its ligands, trimannose (3M), lacks a shear threshold for binding, since the number of bacteria binding under static conditions is higher than under any flow. However, similar to 1M, the binding strength of surface-interacting bacteria is enhanced by shear. Bacteria transition from rolling into firm stationary surface adhesion as the shear increases. The shear-enhanced bacterial binding on 3M is mediated by catch bond properties of the 1M-binding subsite within the extended oligosaccharide-binding pocket of FimH, since structural mutations in the putative force-responsive region and in the binding site affect 1M- and 3M-specific binding in an identical manner. A shear-dependent conversion of the adhesion mode is also exhibited by P-fimbriated E. coli adhering to digalactose surfaces.	Swiss Fed Inst Technol, ETH Honggerberg, Dept Math, Lab Biol Oriented Mat, CH-8093 Zurich, Switzerland; Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Vogel, V (corresponding author), Swiss Fed Inst Technol, ETH Honggerberg, Dept Mat Sci, Lab Biol Oriented Mat, ETH Wolfgang Pauli Str 10,HCI F443, CH-8093 Zurich, Switzerland.	viola.vogel@mat.ethz.ch; evs@u.washington.edu	Vogel, Viola/O-8025-2015	Vogel, Viola/0000-0003-2898-7671; Thomas, Wendy/0000-0001-8602-0819	NIAID NIH HHS [AI 50940, AI 45820] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050940, R01AI045820] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Bouckaert J, 2005, MOL MICROBIOL, V55, P441, DOI 10.1111/j.1365-2958.2004.04415.x; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; Doggett TA, 2002, BIOPHYS J, V83, P194, DOI 10.1016/S0006-3495(02)75161-8; Edwards RA, 1998, TRENDS MICROBIOL, V6, P282, DOI 10.1016/S0966-842X(98)01288-8; Essig M, 2003, CURR OPIN NEPHROL HY, V12, P31, DOI 10.1097/00041552-200301000-00006; Evans E, 2001, ANNU REV BIOPH BIOM, V30, P105, DOI 10.1146/annurev.biophys.30.1.105; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; FINI JM, 1995, ANN REV BIOMOL STRUC, V24, P551; Forero M, 2004, NANO LETT, V4, P1593, DOI 10.1021/nl049329z; FU DT, 1994, CARBOHYD RES, V261, P173, DOI 10.1016/0008-6215(94)84015-6; Holden NJ, 2001, MOL MICROBIOL, V42, P319, DOI 10.1046/j.1365-2958.2001.02656.x; Hommais F, 2003, INFECT IMMUN, V71, P3619, DOI 10.1128/IAI.71.6.3619-3622.2003; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hung CS, 2002, MOL MICROBIOL, V44, P903, DOI 10.1046/j.1365-2958.2002.02915.x; KARLSSON KA, 1992, APMIS, V100, P71; Klemm P, 2000, INT J MED MICROBIOL, V290, P27; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; Lawrence MB, 1997, J CELL BIOL, V137, P261; Lindhorst TK, 1998, GLYCOCONJUGATE J, V15, P605, DOI 10.1023/A:1006920027641; Marshall BT, 2003, NATURE, V423, P190, DOI 10.1038/nature01605; Nilsson LM, 2006, APPL ENVIRON MICROB, V72, P3005, DOI 10.1128/AEM.72.4.3005-3010.2006; Ofek I., 1990, CURR TOP MICROBIOL, V151, P91; Rockendorf N, 2002, AUST J CHEM, V55, P87, DOI 10.1071/CH02025; Sarangapani KK, 2004, J BIOL CHEM, V279, P2291, DOI 10.1074/jbc.M310396200; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SHARON N, 1987, FEBS LETT, V217, P145, DOI 10.1016/0014-5793(87)80654-3; Snyder JA, 2005, INFECT IMMUN, V73, P7588, DOI 10.1128/IAI.73.11.7588-7596.2005; Sokurenko EV, 2004, MOL BIOL EVOL, V21, P1373, DOI 10.1093/molbev/msh136; Sokurenko EV, 1997, J BIOL CHEM, V272, P17880, DOI 10.1074/jbc.272.28.17880; Sokurenko EV, 1998, P NATL ACAD SCI USA, V95, P8922, DOI 10.1073/pnas.95.15.8922; Sokurenko EV, 2001, MOL MICROBIOL, V41, P675, DOI 10.1046/j.1365-2958.2001.02545.x; Suzuki N, 2001, J BIOL CHEM, V276, P23221, DOI 10.1074/jbc.M101379200; Takahashi N, 2001, J BIOL CHEM, V276, P23230, DOI 10.1074/jbc.M101380200; Thomas W, 2006, BIOPHYS J, V90, P753, DOI 10.1529/biophysj.105.066548; Thomas WE, 2004, MOL MICROBIOL, V53, P1545, DOI 10.1111/j.1365-2958.2004.04226.x; Thomas WE, 2002, CELL, V109, P913, DOI 10.1016/S0092-8674(02)00796-1	39	73	74	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16656	16663		10.1074/jbc.M511496200	http://dx.doi.org/10.1074/jbc.M511496200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16624825	hybrid			2022-12-25	WOS:000238165700059
J	Yang, BX; Zhao, D; Verkman, AS				Yang, Baoxue; Zhao, Dan; Verkman, A. S.			Evidence against functionally significant aquaporin expression in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER CHANNEL; GASTROINTESTINAL-TRACT; RAT HEPATOCYTES; IMMUNOLOCALIZATION; PHENOTYPE; MEMBRANE; CELLS; LIVER; AQP9; MICE	Recent reports suggest the expression of aquaporin ( AQP)-type water channels in mitochondria from liver ( AQP8) ( Calamita, G., Ferri, D., Gena, P., Liquori, G. E., Cavalier, A., Thomas, D., and Svelto, M. ( 2005) J. Biol. Chem. 280, 17149 - 17153) and brain ( AQP9) ( Amiry-Moghaddam, M., Lindland, H., Zelenin, S., Roberg, B. A., Gundersen, B. B., Petersen, P., Rinvik, E., Torgner, I. A., and Ottersen, O. P. ( 2005) FASEB J. 19, 1459 - 1467), where they were speculated to be involved in metabolism, apoptosis, and Parkinson disease. Here, we systematically examined the functional consequence of AQP expression in mitochondria by measurement of water and glycerol permeabilities in mitochondrial membrane preparations from rat brain, liver, and kidney and from wild-type versus knock-out mice deficient in AQPs- 1, -4, or -8. Osmotic water permeability, measured by stopped-flow light scattering, was similar in all mitochondrial preparations, with a permeability coefficient P-f similar to 0.009 cm/s. Glycerol permeability was also similar ( similar to 5 x 10(-6) cm/s) in the various preparations. HgCl2 slowed osmotic equilibration comparably in mitochondria from wild-type and AQP-deficient mice, although the slowing was explained by altered mitochondrial size rather than reduced P-f. Immunoblot analysis of mouse liver mitochondria failed to detect AQP8 expression, with liver homogenates from wild-type/AQP8 null mice as positive/negative controls. Our results provide evidence against functionally significant AQP expression in mitochondria, which is consistent with the high mitochondrial surface-to-volume ratio producing millisecond osmotic equilibration, even when intrinsic membrane water permeability is not high.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R21DK066194, R37DK035124, P30DK072517] Funding Source: NIH RePORTER; NEI NIH HHS [EY 13574] Funding Source: Medline; NHLBI NIH HHS [HL 73856, HL 59198] Funding Source: Medline; NIBIB NIH HHS [EB 00415] Funding Source: Medline; NIDDK NIH HHS [DK 35124, DK 66194, DK 72517] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amiry-Moghaddam M, 2005, FASEB J, V19, P1459, DOI 10.1096/fj.04-3515com; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; Calamita G, 2005, J BIOL CHEM, V280, P17149, DOI 10.1074/jbc.C400595200; Calamita G, 2001, EUR J CELL BIOL, V80, P711, DOI 10.1078/0171-9335-00210; Calamita G, 2001, BIOCHEM BIOPH RES CO, V288, P619, DOI 10.1006/bbrc.2001.5810; Carbrey JM, 2003, P NATL ACAD SCI USA, V100, P2945, DOI 10.1073/pnas.0437994100; Elkjaer ML, 2001, AM J PHYSIOL-RENAL, V281, pF1047, DOI 10.1152/ajprenal.0158.2001; Ferri D, 2003, HEPATOLOGY, V38, P947, DOI 10.1053/jhep.2003.50397; Garcia F, 2001, J BIOL CHEM, V276, P12147, DOI 10.1074/jbc.M009403200; Huebert RC, 2002, J BIOL CHEM, V277, P22710, DOI 10.1074/jbc.M202394200; Hurley PT, 2001, AM J PHYSIOL-GASTR L, V280, pG701, DOI 10.1152/ajpgi.2001.280.4.G701; La Porta CAM, 2006, BIOL CELL, V98, P89, DOI 10.1042/BC20040153; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 1997, BIOCHEM BIOPH RES CO, V240, P324, DOI 10.1006/bbrc.1997.7664; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Masyuk AI, 2006, HEPATOLOGY, V43, pS75, DOI 10.1002/hep.20996; Noda Y, 2005, BIOL CELL, V97, P885; Rojek AM, 2005, FASEB J, V19, pA637; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Verkman AS, 2005, J CELL SCI, V118, P3225, DOI 10.1242/jcs.02519; Verkman AS, 2000, J MEMBRANE BIOL, V173, P73, DOI 10.1007/s002320001009; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; Wellner RB, 2006, PFLUG ARCH EUR J PHY, V451, P642, DOI 10.1007/s00424-005-1489-0; Yang BX, 2005, AM J PHYSIOL-CELL PH, V288, pC1161, DOI 10.1152/ajpcell.00564.2004; Yasui M, 1999, P NATL ACAD SCI USA, V96, P5808, DOI 10.1073/pnas.96.10.5808	26	67	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16202	16206		10.1074/jbc.M601864200	http://dx.doi.org/10.1074/jbc.M601864200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16624821	hybrid			2022-12-25	WOS:000238165700005
J	Lifshitz, Y; Lindzen, M; Garty, H; Karlish, SJD				Lifshitz, Yael; Lindzen, Moshit; Garty, Haim; Karlish, Steven J. D.			Functional interactions of phospholemman (PLM) (FXYD1) with Na+,K+-ATPase - Purification of alpha 1/beta 1/PLM complexes expressed in Pichia pastoris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NA-K-ATPASE; SHARK RECTAL GLANDS; GAMMA-SUBUNIT; ALPHA-SUBUNIT; IMMUNOCYTOCHEMICAL LOCALIZATION; SODIUM-PUMP; INDUCED PHOSPHORYLATION; MOLECULAR-CLONING; NA,K-ATPASE	Human FXYD1 ( phospholemman, PLM) has been expressed in Pichia pastoris with porcine alpha(1)/His(10)-alpha 1 subunits of Na+,K+-ATPase or alone. Dodecyl-beta-maltoside-soluble complexes of alpha(1)/beta(1)/PLM have been purified by metal chelate chromatography, either from membranes co-expressing alpha(1), His(10)-beta(1), and PLM or by in vitro reconstitution of PLM with alpha(1)/His(10)-beta(1) subunits. Comparison of functional properties of purified alpha(1)/His(10)-beta(1) and alpha(1)/His(10)-beta(1)/PLM complexes show that PLM lowered K-0.5 for Na+ ions moderately (approximate to 30%) but did not affect the turnover rate or Km of ATP for activating Na+, K+-ATPase activity. PLM also stabilized the alpha(1)/His(10)-beta(1) complex. In addition, PLM markedly (> 3-fold) reduced the K-0.5 of Na+ ions for activating Na+-ATPase activity. In membranes co-expressing alpha(1)/His(10)-beta(1) with PLM the K-0.5 of Na+ ions was also reduced, compared with the control, excluding the possibility that detergent or lipid in purified complexes compromise functional interactions. When expressed in HeLa cells with rat alpha(1), rat PLM significantly raised the K-0.5 of Na+ ions, whereas for a chimeric molecule consisting of transmembranes segments of PLM and extramembrane segments of FXYD4, the K-0.5 of Na+ ions was significantly reduced, compared with the control. The opposite functional effects in P. pastoris and HeLa cells are correlated with endogenous phosphorylation of PLM at Ser(68) or unphosphorylated PLM, respectively, as detected with antibodies, which recognize PLM phosphorylated at Ser68 ( protein kinase A site) or unphosphorylated PLM. We hypothesize that PLM interacts with alpha(1)/His10-beta(1) subunits at multiple locations, the different functional effects depending on the degree of phosphorylation at Ser68. We discuss the role of PLM in regulation of Na+, K+-ATPase in cardiac or skeletal muscle cells.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Steven.Karlish@weizmann.ac.il						ARTY H, 2006, ANNU REV PHYSIOL, V68, P431; BEAUGE LA, 1979, J PHYSIOL-LONDON, V289, P17, DOI 10.1113/jphysiol.1979.sp012722; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bogaev RC, 2001, GENE, V271, P69, DOI 10.1016/S0378-1119(01)00497-8; Bossuyt J, 2005, CIRC RES, V97, P558, DOI 10.1161/01.RES.0000181172.27931.c3; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; Capurro C, 1996, AM J PHYSIOL-CELL PH, V271, pC753, DOI 10.1152/ajpcell.1996.271.3.C753; Cohen E, 2005, J BIOL CHEM, V280, P16610, DOI 10.1074/jbc.M414290200; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Davis CE, 2004, NEUROCHEM RES, V29, P177, DOI 10.1023/B:NERE.0000010447.24128.ac; Despa S, 2005, CIRC RES, V97, P252, DOI 10.1161/01.RES.0000176532.97731.e5; Farman N, 2003, ANN NY ACAD SCI, V986, P428, DOI 10.1111/j.1749-6632.2003.tb07225.x; Feschenko MS, 2003, J NEUROSCI, V23, P2161; Fuller W, 2004, FASEB J, V18, P197, DOI 10.1096/fj.03-0213fje; Fuzesi M, 2005, J BIOL CHEM, V280, P18291, DOI 10.1074/jbc.M500080200; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P175, DOI 10.1113/jphysiol.1967.sp008295; Garty H, 2005, SEMIN NEPHROL, V25, P304, DOI 10.1016/j.semnephrol.2005.03.005; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; Geering K, 2003, ANN NY ACAD SCI, V986, P388, DOI 10.1111/j.1749-6632.2003.tb07219.x; Geering K, 2006, AM J PHYSIOL-RENAL, V290, pF241, DOI 10.1152/ajprenal.00126.2005; GLYNN LM, 1975, J PHYSL, V250, pP33; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Jia LG, 2005, AM J PHYSIOL-HEART C, V288, pH1982, DOI 10.1152/ajpheart.00142.2004; JONES LR, 1979, J BIOL CHEM, V254, P530; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; LANSBERY KL, 2005, AM J PHYSIOL, V290, pC1275; Li CM, 2004, J BIOL CHEM, V279, P38895, DOI 10.1074/jbc.M406697200; Lifshitz Y, 2005, J GEN PHYSIOL, V126, p51A; Lindzen M, 2006, J BIOL CHEM, V281, P5947, DOI 10.1074/jbc.M512063200; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; LU KP, 1994, J BIOL CHEM, V269, P6603; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Mahmmoud YA, 2005, J BIOL CHEM, V280, P27776, DOI 10.1074/jbc.M503150200; Mahmmoud YA, 2003, J BIOL CHEM, V278, P37427, DOI 10.1074/jbc.M305126200; Mahmmoud YA, 2002, BIOPHYS J, V82, P1907, DOI 10.1016/S0006-3495(02)75540-9; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; Moorman JR, 1998, ADV EXP MED BIOL, V442, P219; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; Mounsey JP, 2000, J BIOL CHEM, V275, P23362, DOI 10.1074/jbc.M000899200; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; Pedersen PA, 1996, BIOCHEMISTRY-US, V35, P16085, DOI 10.1021/bi961614c; Pihakaski-Maunsbach K, 2003, ANN NY ACAD SCI, V986, P401, DOI 10.1111/j.1749-6632.2003.tb07221.x; POST RL, 1972, J BIOL CHEM, V247, P6530; PRESTI CF, 1985, J BIOL CHEM, V260, P3879; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Rembold CM, 2005, J VASC RES, V42, P483, DOI 10.1159/000088102; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shi HK, 2001, AM J PHYSIOL-RENAL, V280, pF505, DOI 10.1152/ajprenal.2001.280.3.F505; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; Strugatsky D, 2003, J BIOL CHEM, V278, P46064, DOI 10.1074/jbc.M308303200; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; WALAAS SI, 1988, BIOCHIM BIOPHYS ACTA, V968, P127, DOI 10.1016/0167-4889(88)90052-3; Wetzel RK, 2003, AM J PHYSIOL-RENAL, V285, pF121, DOI 10.1152/ajprenal.00241.2002; Wetzel RK, 2001, AM J PHYSIOL-RENAL, V281, pF531, DOI 10.1152/ajprenal.2001.281.3.F531	58	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15790	15799		10.1074/jbc.M601993200	http://dx.doi.org/10.1074/jbc.M601993200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16608841	hybrid			2022-12-25	WOS:000237996000027
J	Upreti, M; Lyle, CS; Skaug, B; Du, LH; Chambers, TC				Upreti, Meenakshi; Lyle, Christopher S.; Skaug, Brian; Du, Lihua; Chambers, Timothy C.			Vinblastine-induced apoptosis is mediated by discrete alterations in subcellular location, oligomeric structure, and activation status of specific Bcl-2 family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BAX; PHOSPHORYLATION; MITOCHONDRIA; PACLITAXEL; PROTEIN; AGENTS; HOMODIMERIZATION; ASSOCIATION; BCL-X(L); XL	To gain a broader insight into the role of Bcl-2 proteins in apoptosis induced after mitotic arrest, we investigated the subcellular location, oligomeric structure, and protein interactions of Bax, Bcl-2, and Bcl-xL in vinblastine-treated KB-3 cells. Vinblastine induced the translocation of Bax from the cytosol to the mitochondria, which was accompanied by conformational activation and oligomerization of Bax. Bcl-2 was located in the mitochondria, underwent multisite phosphorylation after vinblastine treatment, and was strictly monomeric under all conditions. In contrast, in control cells, Bcl-xL existed in both monomeric (30 kDa) and oligomeric (150 kDa) forms. Treatment with agents that induced Bcl-xL phosphorylation ( microtubule inhibitors) caused loss of the 150-kDa form, but this species was unaffected by apoptotic stimuli that did not stimulate phosphorylation. Vinblastine also promoted Bax activation and Bax oligomerization in HCT116 colon cancer cells. Both wild-type and Bax-deficient HCT116 cells expressed the 150-kDa form of Bcl-xL, which was depleted similarly in both cell lines upon vinblastine treatment. Co-immunoprecipitation studies revealed that in untreated KB-3 cells inactive cytosolic Bax interacted with Bcl-xL, whereas in vinblastine-treated cells, activated mitochondrial Bax did not interact with Bcl-xL. Interaction of Bcl-2 with Bax was not observed under any condition. Overexpression of Bcl-xL inhibited vinblastine-induced Bax activation and Bax dimerization and in parallel inhibited apoptosis. The results indicate that vinblastine-induced apoptosis requires translocation, activation, and oligomerization of Bax and is associated with specific changes in the oligomeric properties of Bcl-xL, which occur independently of Bax.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Chambers, TC (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Mail Slot 516,4301 W Markham St, Little Rock, AR 72205 USA.	chamberstimothyc@uams.edu	Skaug, Brian/AAD-6152-2022	Skaug, Brian/0000-0002-6689-4655	NCI NIH HHS [R01 CA075577, CA10982, CA75577, R01 CA109821] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109821, R01CA075577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Conus S, 2000, EMBO J, V19, P1534, DOI 10.1093/emboj/19.7.1534; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Du LH, 2005, ONCOGENE, V24, P107, DOI 10.1038/sj.onc.1208189; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Longuet M, 2004, INT J ONCOL, V25, P309; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Rowinsky E. K., 1998, CHEMOTHERAPY SOURCE, P387; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Salah-Eldin AE, 2003, INT J CANCER, V103, P53, DOI 10.1002/ijc.10782; Taguchi T, 2004, ONCOL REP, V11, P421; Takada N, 2005, APOPTOSIS, V10, P1211, DOI 10.1007/s10495-005-1391-4; Takehara T, 2003, CANCER RES, V63, P3054; van Delft MF, 2006, CELL RES, V16, P203, DOI 10.1038/sj.cr.7310028; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yamaguchi H, 2004, J BIOL CHEM, V279, P39431, DOI 10.1074/jbc.M401530200; Yamaguchi H, 2002, CANCER RES, V62, P466; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	28	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15941	15950		10.1074/jbc.M512586200	http://dx.doi.org/10.1074/jbc.M512586200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16574665	Green Accepted, hybrid			2022-12-25	WOS:000237996000045
J	Potrykus, K; Vinella, D; Murphy, H; Szalewska-Palasz, A; D'Ari, R; Cashel, M				Potrykus, Katarzyna; Vinella, Daniel; Murphy, Helen; Szalewska-Palasz, Agnieszka; D'Ari, Richard; Cashel, Michael			Antagonistic regulation of Escherichia coli ribosomal RNA rrnB P1 promoter activity by GreA and DksA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPT CLEAVAGE FACTORS; POLYMERASE SECONDARY CHANNEL; CRYSTAL-STRUCTURE; IN-VITRO; MOLECULAR-MECHANISM; ANGSTROM RESOLUTION; STRINGENT CONTROL; MICROCIN J25; PPGPP; INITIATION	The Escherichia coli proteins DksA, GreA, and GreB are all structural homologs that bind the secondary channel of RNApolymerase ( RNAP) but are thought to act at different levels of transcription. DksA, with its co-factor ppGpp, inhibits rrnB P1 transcription initiation, whereas GreA and GreB activate RNAP to cleave backtracked RNA during elongational pausing. Here, in vivo and in vitro evidence reveals antagonistic regulation of rrnB P1 transcription initiation by Gre factors ( particularly GreA) and DksA; GreA activates and DksA inhibits. DksA inhibition is epistatic to GreA activation. Both modes of regulation are ppGpp-independent in vivo but DksA inhibition requires ppGpp in vitro. Kinetic experiments and studies of rrnB P1-RNA polymerase complexes suggest that GreA mediates conformational changes at an initiation step in the absence of NTP substrates, even before DksA acts. GreA effects on rrnB P1 open complex conformation reveal a new feature of GreA distinct from its general function in elongation. Our findings support the idea that a balance of the interactions between the three secondary channel-binding proteins and RNAP can provide a new mode for regulating transcription.	NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA; Univ Paris 06, CNRS, Inst Jacques Monod, F-7251 Paris 05, France; Univ Paris 07, CNRS, Inst Jacques Monod, F-7251 Paris 05, France	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Cashel, M (corresponding author), NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA.	mcashel@nih.gov	Szalewska-Palasz, Agnieszka/AAI-4826-2020; vinella, daniel/G-5504-2012	Potrykus, Katarzyna/0000-0002-4902-3348; Szalewska-Palasz, Agnieszka/0000-0001-8013-4057	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000067] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000067] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Adelman K, 2004, MOL CELL, V14, P753, DOI 10.1016/j.molcel.2004.05.017; Artsimovitch I, 2004, CELL, V117, P299, DOI 10.1016/S0092-8674(04)00401-5; Aviv M, 1996, FEMS MICROBIOL LETT, V140, P71; Borukhov S, 2005, MOL MICROBIOL, V55, P1315, DOI 10.1111/j.1365-2958.2004.04481.x; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Brown L, 2002, J BACTERIOL, V184, P4455, DOI 10.1128/JB.184.16.4455-4465.2002; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; FENG GH, 1994, J BIOL CHEM, V269, P22282; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; Kettenberger H, 2003, CELL, V114, P347, DOI 10.1016/S0092-8674(03)00598-1; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; Lamour V, 2006, J MOL BIOL, V356, P179, DOI 10.1016/j.jmb.2005.10.083; Laptenko O, 2003, EMBO J, V22, P6322, DOI 10.1093/emboj/cdg610; Maitra A, 2005, MOL CELL, V17, P817, DOI 10.1016/j.molcel.2005.02.026; MILLER JG, 1972, SHORT COURSE BACTERI; Mukhopadhyay J, 2004, MOL CELL, V14, P739, DOI 10.1016/j.molcel.2004.06.010; Nickels BE, 2004, CELL, V118, P281, DOI 10.1016/j.cell.2004.07.021; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Opalka N, 2003, CELL, V114, P335, DOI 10.1016/S0092-8674(03)00600-7; Paul BJ, 2005, P NATL ACAD SCI USA, V102, P7823, DOI 10.1073/pnas.0501170102; Paul BJ, 2004, ANNU REV GENET, V38, P749, DOI 10.1146/annurev.genet.38.072902.091347; Paul BJ, 2004, CELL, V118, P311, DOI 10.1016/j.cell.2004.07.009; Perederina A, 2004, CELL, V118, P297, DOI 10.1016/j.cell.2004.06.030; Potrykus K, 2004, J BIOL CHEM, V279, P19860, DOI 10.1074/jbc.M313378200; Prather DA, 2005, MOL CELL BIOL, V25, P2650, DOI 10.1128/MCB.25.7.2650-2659.2005; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; Sen R, 2001, GENES CELLS, V6, P389, DOI 10.1046/j.1365-2443.2001.00436.x; Sosunova E, 2003, P NATL ACAD SCI USA, V100, P15469, DOI 10.1073/pnas.2536698100; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; Susa M, 2006, MOL MICROBIOL, V59, P1807, DOI 10.1111/j.1365-2958.2006.05058.x; Symersky J, 2006, J BIOL CHEM, V281, P1309, DOI 10.1074/jbc.C500405200; Trautinger BW, 2005, MOL CELL, V19, P247, DOI 10.1016/j.molcel.2005.06.004; TRAVERS AA, 1980, J BACTERIOL, V141, P973, DOI 10.1128/JB.141.2.973-976.1980; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Vinella D, 2000, GENETICS, V156, P1483; XIAO H, 1991, J BIOL CHEM, V266, P5980; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	41	64	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15238	15248		10.1074/jbc.M601531200	http://dx.doi.org/10.1074/jbc.M601531200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16597620	hybrid, Green Submitted			2022-12-25	WOS:000237922200027
J	Smith, DP; Smith, DG; Curtain, CC; Boas, JF; Pilbrow, JR; Ciccotosto, GD; Lau, TL; Tew, DJ; Perez, K; Wade, JD; Bush, AI; Drew, SC; Separovic, F; Masters, CL; Cappai, R; Barnham, KJ				Smith, David P.; Smith, Danielle G.; Curtain, Cyril C.; Boas, John F.; Pilbrow, John R.; Ciccotosto, Giuseppe D.; Lau, Tong-Lay; Tew, Deborah J.; Perez, Keyla; Wade, John D.; Bush, Ashley I.; Drew, Simon C.; Separovic, Frances; Masters, Colin L.; Cappai, Roberto; Barnham, Kevin J.			Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; ALZHEIMERS-DISEASE; HYDROGEN-PEROXIDE; LIPID-PEROXIDATION; PEPTIDE; MEMBRANE; BINDING; CHOLESTEROL; ZINC; AGGREGATION	Amyloid-beta peptide (A beta) is pivotal to the pathogenesis of Alzheimer disease. Here we report the formation of a toxic A beta-Cu2+ complex formed via a histidine-bridged dimer, as observed at Cu2+/ peptide ratios of > 0.6:1 by EPR spectroscopy. The toxicity of the A beta-Cu2+ complex to cultured primary cortical neurons was attenuated when either the pi- or tau-nitrogen of the imidazole side chains of His were methylated, thereby inhibiting formation of the His bridge. Toxicity did not correlate with the ability to form amyloid or perturb the acyl-chain region of a lipid membrane as measured by diphenyl- 1,3,5-hexatriene anisotropy, but did correlate with lipid peroxidation and dityrosine formation. P-31 magic angle spinning solid-state NMR showed that A beta and A beta-Cu2+ complexes interacted at the surface of a lipid membrane. These findings indicate that the generation of the A beta toxic species is modulated by the Cu2+ concentration and the ability to form an intermolecular His bridge.	Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; Univ Melbourne, Ctr Neurosci, Melbourne, Vic 3010, Australia; Univ Melbourne, Sch Chem, Melbourne, Vic 3010, Australia; Monash Univ, Sch Phys, Clayton, Vic 3800, Australia; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lab Oxidat Biol, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Aging Res Unit, Charlestown, MA 02129 USA; Univ Queensland, Ctr Magnet Resonance, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Met Biol, Brisbane, Qld 4072, Australia	University of Melbourne; University of Melbourne; University of Melbourne; Monash University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Queensland; University of Queensland	Barnham, KJ (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.	kbarnham@unimelb.edu.au	Cappai, Roberto/B-3347-2010; Bush, Ashley/Y-2457-2019; Drew, Simon/ABB-8102-2021; Separovic, Frances/D-9698-2011; Bush, Ashley I/A-1186-2007	Cappai, Roberto/0000-0002-9505-8496; Bush, Ashley/0000-0001-8259-9069; Drew, Simon/0000-0002-1459-9865; Separovic, Frances/0000-0002-6484-2763; Bush, Ashley I/0000-0001-8259-9069; Smith, David/0000-0001-5177-8574; Curtain, Cyril/0000-0001-6955-320X; Wade, John/0000-0002-1352-6568				Antzutkin ON, 2004, MAGN RESON CHEM, V42, P231, DOI 10.1002/mrc.1341; Atwood CS, 2004, BIOCHEMISTRY-US, V43, P560, DOI 10.1021/bi0358824; Avdulov NA, 1997, J NEUROCHEM, V68, P2086; Barnham KJ, 2004, FASEB J, V18, P1427, DOI 10.1096/fj.04-1890fje; Barnham KJ, 2003, J BIOL CHEM, V278, P42959, DOI 10.1074/jbc.M305494200; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bokvist M, 2004, J MOL BIOL, V335, P1039, DOI 10.1016/j.jmb.2003.11.046; Bonev B, 2001, PHYS CHEM CHEM PHYS, V3, P2904, DOI 10.1039/b103352m; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Butterfield DA, 2004, BRAIN PATHOL, V14, P426; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Ciccotosto GD, 2004, J BIOL CHEM, V279, P42528, DOI 10.1074/jbc.M406465200; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Curtain CC, 2003, J BIOL CHEM, V278, P2977, DOI 10.1074/jbc.M205455200; Di Vaira M, 2004, INORG CHEM, V43, P3795, DOI 10.1021/ic0494051; Eckert GP, 2005, SUB CELL BIOCHEM, V38, P319; Hanson GR, 2004, J INORG BIOCHEM, V98, P903, DOI 10.1016/j.jinorgbio.2004.02.003; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Ji SR, 2002, J BIOL CHEM, V277, P6273, DOI 10.1074/jbc.M104146200; Kagan BL, 2002, PEPTIDES, V23, P1311, DOI 10.1016/S0196-9781(02)00067-0; Karr JW, 2005, BIOCHEMISTRY-US, V44, P5478, DOI 10.1021/bi047611e; Karr JW, 2004, J AM CHEM SOC, V126, P13534, DOI 10.1021/ja0488028; Kawahara M, 2004, CURR ALZHEIMER RES, V1, P87, DOI 10.2174/1567205043332234; Lau TL, 2006, J MOL BIOL, V356, P759, DOI 10.1016/j.jmb.2005.11.091; Muller WE, 2001, BIOCHEM SOC T, V29, P617, DOI 10.1042/BST0290617; Narayanan S, 2005, BIOCHEMISTRY-US, V44, P1444, DOI 10.1021/bi048264b; Ohtsu H, 2000, J AM CHEM SOC, V122, P5733, DOI 10.1021/ja994050j; Opazo C, 2003, BIOMETALS, V16, P91, DOI 10.1023/A:1020795422185; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; PEISACH J, 1974, ARCH BIOCHEM BIOPHYS, V165, P691, DOI 10.1016/0003-9861(74)90298-7; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Puglielli L, 2005, J CLIN INVEST, V115, P2556, DOI 10.1172/JCI23610; Raman B, 2005, J BIOL CHEM, V280, P16157, DOI 10.1074/jbc.M500309200; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; SAKAGUCHI U, 1979, J CHEM SOC DALTON, P600, DOI 10.1039/dt9790000600; SMITH TD, 1974, COORDIN CHEM REV, V13, P173, DOI 10.1016/S0010-8545(00)80255-6; Subasinghe S, 2003, J NEUROCHEM, V84, P471, DOI 10.1046/j.1471-4159.2003.01552.x; Syme CD, 2004, J BIOL CHEM, V279, P18169, DOI 10.1074/jbc.M313572200; Tabner BJ, 2005, J BIOL CHEM, V280, P35789, DOI 10.1074/jbc.C500238200; Tickler AK, 2005, J BIOL CHEM, V280, P13355, DOI 10.1074/jbc.M414178200; Tickler AK, 2001, J PEPT SCI, V7, P488, DOI 10.1002/psc.342; WERTZ JE, 1961, DISCUSS FARADAY SOC, P140, DOI 10.1039/df9613100140; Zirah S, 2006, J BIOL CHEM, V281, P2151, DOI 10.1074/jbc.M504454200	46	156	164	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15145	15154		10.1074/jbc.M600417200	http://dx.doi.org/10.1074/jbc.M600417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16595673	hybrid			2022-12-25	WOS:000237922200017
J	Wang, Y; Xu, L; Duan, HZ; Pasek, DA; Eu, JP; Meissner, G				Wang, Ying; Xu, Le; Duan, Hongzhe; Pasek, Daniel A.; Eu, Jerry P.; Meissner, Gerhard			Knocking down type 2 but not type 1 calsequestrin reduces calcium sequestration and release in C2C12 skeletal muscle myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM LUMENAL CA2+; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; CARDIAC CALSEQUESTRIN; INOSITOL TRISPHOSPHATE; LUMINAL CA2+; TRIADIN; CHANNEL; PROTEIN; EXPRESSION	We examined the roles of type 1 and type 2 calsequestrins ( CSQ1 and CSQ2) in stored Ca2+ release of C2C12 skeletal muscle myotubes. Transduction of C2C12 myoblasts with CSQ1 or CSQ2 small interfering RNAs effectively reduced the expression of targeted CSQ protein to near undetectable levels. As compared with control infected or CSQ1 knockdown myotubes, CSQ2 and CSQ1/CSQ2 knockdown myotubes had significantly reduced stored Ca2+ release evoked by activators of intracellular Ca2+ release channel/ryanodine receptor ( 10mM caffeine, 200 mu M 4-chloro-m-cresol, or 10mM KCl). Thus, CSQ1 is not essential for effective stored Ca2+ release in C2C12 myotubes despite our in vitro studies suggesting that CSQ1 may enhance ryanodine receptor channel activity. To determine the basis of the reduced stored Ca2+ release in CSQ2 knockdown myotubes, we performed immunoblot analyses and found a significant reduction in both sarco/endoplasmic reticulum Ca2+-ATPase and skeletal muscle ryanodine receptor proteins in CSQ2 and CSQ1/CSQ2 knockdown myotubes. Moreover, these knockdown myotubes exhibited reduced Ca2+ uptake and reduced stored Ca2+ release by UTP ( 400 mu M) that activates a different family of intracellular Ca2+ release channels ( inositol 1,4,5-trisphosphate receptors). Taken together, our data suggest that knocking down CSQ2, but not CSQ1, leads to reduced Ca2+ storage and release in C2C12 myotubes.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University	Meissner, G (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	meissner@med.unc.edu	Xu, Le/HDN-9623-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018687, R01AR018687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 73051] Funding Source: Medline; NIAMS NIH HHS [AR18687] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARAI M, 1991, GENE, V109, P275, DOI 10.1016/0378-1119(91)90621-H; ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; Beard NA, 2005, BIOPHYS J, V88, P3444, DOI 10.1529/biophysj.104.051441; Beard NA, 2002, BIOPHYS J, V82, P310, DOI 10.1016/S0006-3495(02)75396-4; Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRAL D, 1992, FEBS LETT, V299, P175, DOI 10.1016/0014-5793(92)80241-8; CALA SE, 1983, J BIOL CHEM, V258, P1932; DAMIANI E, 1994, J MUSCLE RES CELL M, V15, P86, DOI 10.1007/BF00130421; DeSmedt H, 1997, BIOCHEM J, V322, P575; Ferrington DA, 1998, J BIOL CHEM, V273, P5885, DOI 10.1074/jbc.273.10.5885; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; Gyorke I, 2004, BIOPHYS J, V86, P2121, DOI 10.1016/S0006-3495(04)74271-X; IKEMOTO N, 1974, J BIOL CHEM, V249, P2357; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; Lahat H, 2001, AM J HUM GENET, V69, P1378, DOI 10.1086/324565; LEE HB, 1994, J BIOL CHEM, V269, P13305; Lee JM, 2004, J BIOL CHEM, V279, P6994, DOI 10.1074/jbc.M312446200; Li JA, 1997, J VIROL, V71, P5236, DOI 10.1128/JVI.71.7.5236-5243.1997; Mackrill JJ, 1997, BIOCHEM J, V327, P251, DOI 10.1042/bj3270251; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MARTONOSI A, 1964, J BIOL CHEM, V239, P648; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MEISSNER G, 1975, BIOCHIM BIOPHYS ACTA, V389, P51, DOI 10.1016/0005-2736(75)90385-5; Ohkura M, 1998, BIOCHEMISTRY-US, V37, P12987, DOI 10.1021/bi972803d; Paolini C, 2005, BIOPHYS J, V88, p321A; Park HJ, 2004, J BIOL CHEM, V279, P18026, DOI 10.1074/jbc.M311553200; Park KW, 1998, GENE, V217, P25, DOI 10.1016/S0378-1119(98)00372-2; Postma AV, 2002, CIRC RES, V91, pE21, DOI 10.1161/01.RES.0000038886.18992.6B; Protasi F, 2000, BIOPHYS J, V79, P2494, DOI 10.1016/S0006-3495(00)76491-5; QUINN SJ, 1988, P NATL ACAD SCI USA, V85, P5754, DOI 10.1073/pnas.85.15.5754; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SACCHETTO R, 1993, J MUSCLE RES CELL M, V14, P646, DOI 10.1007/BF00141561; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Shin DW, 2003, J BIOL CHEM, V278, P3286, DOI 10.1074/jbc.M209045200; Shin DW, 2000, FEBS LETT, V486, P178, DOI 10.1016/S0014-5793(00)02246-8; Sutko JL, 1997, PHARMACOL REV, V49, P53; Szegedi C, 1999, BIOCHEM J, V337, P19, DOI 10.1042/0264-6021:3370019; Terentyev D, 2003, P NATL ACAD SCI USA, V100, P11759, DOI 10.1073/pnas.1932318100; Tripathy A, 1996, BIOPHYS J, V70, P2600, DOI 10.1016/S0006-3495(96)79831-4; Wang Y, 2005, BIOPHYS J, V88, p639A; Wang Y, 2005, BIOPHYS J, V89, P256, DOI 10.1529/biophysj.104.056002; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Xu L, 1999, J BIOL CHEM, V274, P32680, DOI 10.1074/jbc.274.46.32680; Xu L, 1998, BIOPHYS J, V75, P2302, DOI 10.1016/S0006-3495(98)77674-X; YAMAGUCHI N, 1995, BIOCHEM BIOPH RES CO, V210, P648, DOI 10.1006/bbrc.1995.1709; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	52	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15572	15581		10.1074/jbc.M600090200	http://dx.doi.org/10.1074/jbc.M600090200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16595676	Green Published, hybrid			2022-12-25	WOS:000237922200064
J	Xiao, JP; Dai, RJ; Negyessy, L; Bergson, C				Xiao, Jiping; Dai, Rujuan; Negyessy, Laszlo; Bergson, Clare			Calcyon, a novel partner of clathrin light chain, stimulates clathrin-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERACTING PROTEIN-1 HIP1; AMPA RECEPTOR TRAFFICKING; COATED VESICLES; DENDRITIC SPINES; IN-VIVO; TRANSFERRIN RECEPTOR; BINDING; MEMBRANE; ACTIN; INTERNALIZATION	In the central nervous system, clathrin-mediated endocytosis is crucial for efficient synaptic transmission. Clathrin-coated vesicle assembly and disassembly is regulated by some 30 adaptor and accessory proteins, most of which interact with clathrin heavy chain. Using the calcyon cytosolic domain as bait, we isolated clathrin light chain in a yeast two-hybrid screen. The interaction domain was mapped to the heavy chain binding domain and C-terminal regions of light chain. Further, the addition of the calcyon C terminus stimulated clathrin self-assembly in a dose-dependent fashion. Calcyon, which is a single transmembrane protein predominantly expressed in brain, localized to vesicular compartments within pre-and postsynaptic structures. There was a high degree of overlap in the distribution of LC and calcyon in neuronal dendrites, spines, and cell bodies. Co-immunoprecipitation studies further suggested an association of calcyon with the clathrin-mediated endocytic machinery. Compared with controls, HEK293 cells overexpressing calcyon exhibited significantly enhanced transferrin uptake but equivalent levels of recycling. Conversely, transferrin uptake was largely abolished in neocortical neurons obtained from mice homozygous for a calcyon null allele, whereas recycling proceeded at wild type levels. Collectively, these data indicate a role for calcyon in clathrin-mediated endocytosis in brain.	Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Virginia Polytech Inst & State Univ, Dept Immunol, Blacksburg, VA 24061 USA; Hungarian Acad Sci, United Res Org, Neurobiol Res Grp, H-1094 Budapest, Hungary; Semmelweis Univ, H-1094 Budapest, Hungary	University System of Georgia; Augusta University; Virginia Polytechnic Institute & State University; Hungarian Academy of Sciences; Semmelweis University	Bergson, C (corresponding author), Med Coll Georgia, Dept Pharmacol & Toxicol, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	cbergson@mail.mcg.edu	Négyessy, László/C-9632-2012; Négyessy, László/G-6283-2019	Négyessy, László/0000-0002-4369-0406	NIMH NIH HHS [P50 MH068789, MH068789, R01 MH063271, MH063271] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH068789, R01MH063271] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACTON SL, 1993, MOL BIOL CELL, V4, P647, DOI 10.1091/mbc.4.6.647; Ali MK, 2003, J BIOL CHEM, V278, P51654, DOI 10.1074/jbc.M305803200; Blanpied TA, 2002, NEURON, V36, P435, DOI 10.1016/S0896-6273(02)00979-0; Blondeau F, 2004, P NATL ACAD SCI USA, V101, P3833, DOI 10.1073/pnas.0308186101; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BRODSKY FM, 1991, TRENDS BIOCHEM SCI, V16, P208, DOI 10.1016/0968-0004(91)90087-C; BRODSKY FM, 1985, J CELL BIOL, V101, P2055, DOI 10.1083/jcb.101.6.2055; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Chen CY, 2005, J BIOL CHEM, V280, P6109, DOI 10.1074/jbc.M408454200; Cooney JR, 2002, J NEUROSCI, V22, P2215, DOI 10.1523/JNEUROSCI.22-06-02215.2002; Dai RJ, 2003, GENE, V311, P111, DOI 10.1016/S0378-1119(03)00564-X; DEBAIGT C, 2004, J BIOL CHEM; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Dickman DK, 2005, CELL, V123, P521, DOI 10.1016/j.cell.2005.09.026; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Fotin A, 2004, NATURE, V432, P573, DOI 10.1038/nature03079; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; ITOH K, 1979, BRAIN RES, V175, P341, DOI 10.1016/0006-8993(79)91013-8; Iwasato T, 2000, NATURE, V406, P726, DOI 10.1038/35021059; Lee SH, 2002, NEURON, V36, P661, DOI 10.1016/S0896-6273(02)01024-3; Legendre-Guillemin V, 2002, J BIOL CHEM, V277, P19897, DOI 10.1074/jbc.M112310200; Legendre-Guillemin V, 2005, J BIOL CHEM, V280, P6101, DOI 10.1074/jbc.M408430200; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; Man HY, 2003, NEURON, V38, P611, DOI 10.1016/S0896-6273(03)00228-9; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; Park M, 2004, SCIENCE, V305, P1972, DOI 10.1126/science.1102026; Peters A, 1991, FINE STRUCTURE NERVO, P70; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; PLEY UM, 1995, J BIOL CHEM, V270, P2395, DOI 10.1074/jbc.270.5.2395; Racz B, 2004, NAT NEUROSCI, V7, P917, DOI 10.1038/nn1303; Redmond L, 2002, NEURON, V34, P999, DOI 10.1016/S0896-6273(02)00737-7; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Scott L, 2002, P NATL ACAD SCI USA, V99, P1661, DOI 10.1073/pnas.032654599; Steiner P, 2005, EMBO J, V24, P2873, DOI 10.1038/sj.emboj.7600755; Steiner P, 2002, J CELL BIOL, V157, P1197, DOI 10.1083/jcb.200202022; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; van Dam EM, 2002, J BIOL CHEM, V277, P48876, DOI 10.1074/jbc.M206271200; van Dam EM, 2002, MOL BIOL CELL, V13, P169, DOI 10.1091/mbc.01-07-0380; Ybe JA, 1998, EMBO J, V17, P1297, DOI 10.1093/emboj/17.5.1297	46	31	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15182	15193		10.1074/jbc.M600265200	http://dx.doi.org/10.1074/jbc.M600265200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16595675	hybrid			2022-12-25	WOS:000237922200021
J	Metzler, M; Forster, A; Pannell, R; Arends, MJ; Daser, A; Lobato, MN; Rabbitts, TH				Metzler, M.; Forster, A.; Pannell, R.; Arends, M. J.; Daser, A.; Lobato, M. N.; Rabbitts, T. H.			A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology	ONCOGENE			English	Article						MLL; AF4; chromosomal translocations; invertor model; Cre-loxP; leukaemia	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; RETROVIRAL INSERTION; HUMAN CANCER; WILD-TYPE; CRE-LOXP; MLL-ELL; GENE; MICE	MLL-AF4 fusion is the most common consequence of chromosomal translocations in infant leukaemia and is associated witha poor prognosis. MLL-AF4 is thought to be required in haematopoietic stem cells to elicit leukaemia and may be involved in tumour phenotype specification as it is only found in B-cell tumours in humans. We have employed the invertor conditional technology to create a model of MLL-AF4, in which a floxed AF4 cDNA was knocked into Mll in the opposite orientation for transcription. Cell-specific Cre expression was used to generate Mll-AF4 expression. The mice develop exclusively B-cell lineage neoplasias, whether the Cre gene was controlled by B- or T-cell promoters, but of a more mature phenotype than normally observed in childhood leukaemia. These findings show that the MLL-AF4 fusion protein does not have a mandatory role in multi-potent haematopoietic stem cells to cause cancer and indicates that MLL-AF4 has an instructive function in the phenotype of the tumour.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	MRC Laboratory Molecular Biology; University of Cambridge	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	thr@mrc-lmb.cam.ac.uk	Metzler, Markus/AAS-2066-2021; Rabbitts, Terence/D-6262-2016	Metzler, Markus/0000-0002-4523-1676; Rabbitts, Terence/0000-0002-4982-2609	Medical Research Council [G0600914] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALBERT H, 1995, PLANT J, V7, P649, DOI 10.1046/j.1365-313X.1995.7040649.x; Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Christiansen DH, 2001, LEUKEMIA, V15, P1848, DOI 10.1038/sj.leu.2402246; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; Codrington R, 2005, PLOS BIOL, V3, P1459, DOI 10.1371/journal.pbio.0030242; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Daser A, 2004, GENE DEV, V18, P965, DOI 10.1101/gad.1195504; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Drynan LF, 2005, EMBO J, V24, P3136, DOI 10.1038/sj.emboj.7600760; Forster A, 2005, NAT METHODS, V2, P27, DOI 10.1038/NMETH727; Forster A, 2003, CANCER CELL, V3, P449, DOI 10.1016/S1535-6108(03)00106-5; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; Hotfilder M, 2005, CANCER RES, V65, P1442, DOI 10.1158/0008-5472.CAN-04-1356; Jamal R, 2001, GENE CHROMOSOME CANC, V31, P187; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; McCormack MP, 2003, MOL CELL BIOL, V23, P9003, DOI 10.1128/MCB.23.24.9003-9013.2003; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Nakamura T, 1996, ONCOGENE, V13, P2235; Nam CH, 2006, MOL THER, V13, P15, DOI 10.1016/j.ymthe.2005.09.010; Peham M, 2002, BRIT J HAEMATOL, V117, P315, DOI 10.1046/j.1365-2141.2002.03428.x; Pui CH, 2002, LANCET, V359, P1909, DOI 10.1016/S0140-6736(02)08782-2; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUBNITZ JE, 1994, BLOOD, V84, P1747; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Wright G, 2003, P NATL ACAD SCI USA, V100, P9991, DOI 10.1073/pnas.1732008100	39	77	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3093	3103		10.1038/sj.onc.1209636	http://dx.doi.org/10.1038/sj.onc.1209636			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16607274				2022-12-25	WOS:000237951000001
J	Limaye, A; Koya, V; Samsam, M; Daniell, H				Limaye, Arati; Koya, Vijay; Samsam, Mohtashem; Daniell, Henry			Receptor-mediated oral delivery of a bioencapsulated green fluorescent protein expressed in transgenic chloroplasts into the mouse circulatory system	FASEB JOURNAL			English	Article						transmucosal carrier; furin; ganglioside receptors; genetically modified crops	TOXIN B-SUBUNIT; CHOLERA-TOXIN; PROPROTEIN CONVERTASE; PROTECTIVE ANTIGEN; CRYSTAL-STRUCTURE; GOLGI-APPARATUS; FURIN; INSULIN; VACCINE; GENE	Oral delivery of biopharmaceutical proteins expressed in plant cells should reduce their cost of production, purification, processing, cold storage, transportation, and delivery. However, poor intestinal absorption of intact proteins is a major challenge. To overcome this limitation, we investigate here the concept of receptor-mediated oral delivery of chloroplast-expressed foreign proteins. Therefore, the transmucosal carrier cholera toxin B-subunit and green fluorescent protein (CTB-GFP), separated by a furin cleavage site, was expressed via the tobacco chloroplast genome. Polymerase chain reaction (PCR) and Southern blot analyses confirmed site-specific transgene integration and homoplasmy. Immunoblot analysis and ELISA confirmed expression of monomeric and pentameric forms of CTB-GFP, up to 21.3% of total soluble proteins. An in vitro furin cleavage assay confirmed integrity of the engineered furin cleavage site, and a GM(1) binding assay confirmed the functionality of CTB-GFP pentamers. Following oral administration of CTB-GFP expressing leaf material to mice, GFP was observed in the mice intestinal mucosa, liver, and spleen in fluorescence and immunohistochemical studies, while CTB remained in the intestinal cell. This report of receptor-mediated oral delivery of a foreign protein into the circulatory system opens the door for low-cost production and delivery of human therapeutic proteins.	Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32816 USA	State University System of Florida; University of Central Florida	Daniell, H (corresponding author), Univ Cent Florida, Dept Mol Biol & Microbiol, 4000 Cent Florida Blvd,Bldg 20,Rm 336, Orlando, FL 32816 USA.	daniell@mail.ucf.edu	Daniell, Henry/L-3655-2019	Daniell, Henry/0000-0003-4485-1176	NIGMS NIH HHS [R01 GM063879, R01GM63879] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063879] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alisky JM, 2002, EXP NEUROL, V178, P139, DOI 10.1006/exnr.2002.8031; Arakawa T, 1998, NAT BIOTECHNOL, V16, P934, DOI 10.1038/nbt1098-934; Arntzen C, 2005, VACCINE, V23, P1753, DOI 10.1016/j.vaccine.2005.01.090; Badizadegan K, 2000, INT J MED MICROBIOL, V290, P403; Berghoff M, 2005, MOL CELL NEUROSCI, V28, P118, DOI 10.1016/j.mcn.2004.09.001; Boonyarattanakalin S, 2004, J AM CHEM SOC, V126, P16379, DOI 10.1021/ja046663o; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Daniell H, 2005, VACCINE, V23, P1779, DOI 10.1016/j.vaccine.2004.11.004; Daniell H, 2005, METH MOL B, V286, P111; Daniell H, 2005, TRENDS BIOTECHNOL, V23, P238, DOI 10.1016/j.tibtech.2005.03.008; Daniell H, 2001, J MOL BIOL, V311, P1001, DOI 10.1006/jmbi.2001.4921; Daniell H, 2002, NAT BIOTECHNOL, V20, P581, DOI 10.1038/nbt0602-581; Daniell H, 2004, MOL FARMING, P113; DANIELL H, 1997, METHOD MOL BIOL, V62, P453; De Cosa B, 2001, NAT BIOTECHNOL, V19, P71, DOI 10.1038/83559; DeGray G, 2001, PLANT PHYSIOL, V127, P852, DOI 10.1104/pp.010233; Feng Y, 2004, EMBO REP, V5, P596, DOI 10.1038/sj.embor.7400152; Fernandez-San Millan A, 2003, PLANT BIOTECHNOL J, V1, P71, DOI 10.1046/j.1467-7652.2003.00008.x; Fujinaga Y, 2003, MOL BIOL CELL, V14, P4783, DOI 10.1091/mbc.E03-06-0354; Giddings G, 2000, NAT BIOTECHNOL, V18, P1151, DOI 10.1038/81132; GRANGER DN, 1997, ESSENTIAL MED PHYSL, P217; Grevich JJ, 2005, CRIT REV PLANT SCI, V24, P83, DOI 10.1080/07352680590935387; GROSKREUTZ DJ, 1994, J BIOL CHEM, V269, P6241; Hagemann R, 2004, MOLECULAR BIOLOGY AND BIOTECHNOLOGY OF PLANT ORGANELLES: CHLOROPLASTS AND MITOCHONDRIA, P93, DOI 10.1007/978-1-4020-3166-3_4; Hamman JH, 2005, BIODRUGS, V19, P165, DOI 10.2165/00063030-200519030-00003; Hay CW, 2003, J MOL ENDOCRINOL, V31, P597, DOI 10.1677/jme.0.0310597; Heath JP, 1996, CELL BIOL INT, V20, P139, DOI 10.1006/cbir.1996.0018; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Ito M, 2005, DIABETOLOGIA, V48, P1614, DOI 10.1007/s00125-005-1825-0; Jepson MA, 1998, TRENDS MICROBIOL, V6, P359, DOI 10.1016/S0966-842X(98)01337-7; Kong QX, 2001, P NATL ACAD SCI USA, V98, P11539, DOI 10.1073/pnas.191617598; Koya V, 2005, INFECT IMMUN, V73, P8266, DOI 10.1128/IAI.73.12.8266-8274.2005; Kumar S, 2004, PLANT PHYSIOL, V136, P2843, DOI 10.1104/pp.104.045187; Kumar Shashi, 2004, Methods Mol Biol, V267, P365; Leelavathi S, 2003, MOL BREEDING, V11, P49, DOI 10.1023/A:1022114427971; Lelivelt CLC, 2005, PLANT MOL BIOL, V58, P763, DOI 10.1007/s11103-005-7704-8; LENCER WI, 1995, P NATL ACAD SCI USA, V92, P10094, DOI 10.1073/pnas.92.22.10094; Lencer WI, 2001, AM J PHYSIOL-GASTR L, V280, pG781, DOI 10.1152/ajpgi.2001.280.5.G781; Ling H, 1998, BIOCHEMISTRY-US, V37, P1777, DOI 10.1021/bi971806n; Mason HS, 2002, TRENDS MOL MED, V8, P324, DOI 10.1016/S1471-4914(02)02360-2; Mason HS, 1998, VACCINE, V16, P1336, DOI 10.1016/S0264-410X(98)80020-0; Mayer G, 2004, CELL TISSUE RES, V316, P55, DOI 10.1007/s00441-004-0866-x; MERRITT EA, 1994, PROTEIN SCI, V3, P166; MERRITT EA, 1995, CURR OPIN STRUC BIOL, V5, P165, DOI 10.1016/0959-440X(95)80071-9; Molina A, 2005, VIROLOGY, V342, P266, DOI 10.1016/j.virol.2005.08.009; Molina A, 2004, PLANT BIOTECHNOL J, V2, P141, DOI 10.1046/j.1467-7652.2004.00057.x; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nishigori T, 1996, PEPTIDES, V17, P789, DOI 10.1016/0196-9781(96)00077-0; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PETRIDES D, 1995, BIOTECHNOL BIOENG, V48, P529, DOI 10.1002/bit.260480516; Quesada-Vargas T, 2005, PLANT PHYSIOL, V138, P1746, DOI 10.1104/pp.105.063040; Ruiz ON, 2005, PLANT PHYSIOL, V138, P1232, DOI 10.1104/pp.104.057729; RUIZ ON, 2003, PLANT PHYSIOL, V132, P1; Samsam M, 2003, J NEUROSCI, V23, P2833; Shaw JAM, 2002, J ENDOCRINOL, V172, P653, DOI 10.1677/joe.0.1720653; Short DK, 1998, AM J PHYSIOL-ENDOC M, V275, pE748, DOI 10.1152/ajpendo.1998.275.5.E748; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Watson J, 2004, VACCINE, V22, P4374, DOI 10.1016/j.vaccine.2004.01.069; YANAGITA M, 1992, FEBS LETT, V311, P55, DOI 10.1016/0014-5793(92)81366-T	62	73	91	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					959	+		10.1096/fj.05-5134fje	http://dx.doi.org/10.1096/fj.05-5134fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16603603	Green Accepted, Green Submitted			2022-12-25	WOS:000240157700021
J	Jeng, W; Ramkissoon, A; Parman, T; Wells, PG				Jeng, Winnie; Ramkissoon, Annmarie; Parman, Toufan; Wells, Peter G.			Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration	FASEB JOURNAL			English	Article; Proceedings Paper	43rd Annual Meeting of the Society-of-Toxicology	MAR 21-25, 2004	Baltimore, MD	Soc Toxicol		MDMA; methamphetamine; brainstem; DNA oxidation	RAT-BRAIN; CHEMICAL TERATOGENESIS; METHAMPHETAMINE ABUSERS; ALZHEIMERS-DISEASE; MITOCHONDRIAL-DNA; KNOCKOUT MICE; COLON-CANCER; DOPAMINE; ECSTASY; DAMAGE	Reactive oxygen species (ROS) are implicated in amphetamine-initiated neurodegeneration, but the mechanism is unclear. Here, we show that amphetamines are bioactivated by CNS prostaglandin H synthase (PHS) to free radical intermediates that cause ROS formation and neurodegenerative oxidative DNA damage. In vitro incubations of purified PHS-1 with 3,4-methylenedioxyamphetamine (MDA) and methamphetamine ( METH) demonstrated PHS-catalyzed time- and concentration-dependent formation of an amphetamine carbon- and/or nitrogen-centered free radical intermediate, and stereoselective oxidative DNA damage, evidenced by 8-oxo-2'-deoxyguanosine (8-oxo-dG) formation. Similarly in vivo, MDA and METH caused dose- and time- dependent DNA oxidation in multiple brain regions, remarkably dependent on the regional PHS levels, including the striatum and substantia nigra, wherein neurodegeneration of dopaminergic nerve terminals was evidenced by decreased immunohistochemical staining of tyrosine hydroxylase. Motor impairment using the rotarod test was evident within 3 wk after the last drug dose, and persisted for at least 6 months. Pretreatment with the PHS inhibitor acetylsalicylic acid blocked MDA-initiated DNA oxidation and protected against functional motor impairment for at least 1.5 months after drug treatment. This is the first direct evidence for PHS-catalyzed bioactivation of amphetamines causing temporal and regional differences in CNS oxidative DNA damage directly related to structural and functional neurodegenerative consequences. - Jeng, J., Ramkissoon, A., Parman, T., Wells, P. G. Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration.	Univ Toronto, Fac Pharm, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 2S2, Canada	University of Toronto; University of Toronto	Wells, PG (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.	pg.wells@utoronto.ca						Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; Bolla KI, 1998, NEUROLOGY, V51, P1532, DOI 10.1212/WNL.51.6.1532; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; COLADO MI, 1995, BRIT J PHARMACOL, V115, P1281, DOI 10.1111/j.1476-5381.1995.tb15037.x; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; ELING TE, 1990, ANNU REV PHARMACOL, V30, P1, DOI 10.1146/annurev.pa.30.040190.000245; Feng ZH, 2002, NEUROSCI LETT, V329, P354, DOI 10.1016/S0304-3940(02)00704-8; Frederick DL, 1997, NEUROSCI BIOBEHAV R, V21, P67, DOI 10.1016/0149-7634(95)00064-X; FREEMAN BA, 1982, LAB INVEST, V47, P412; Gluck MR, 2001, J NEUROCHEM, V79, P152, DOI 10.1046/j.1471-4159.2001.00549.x; Guilarte TR, 2001, NEUROTOXICOLOGY, V22, P725, DOI 10.1016/S0161-813X(01)00046-8; HALLIWELL B, 1999, FREEE RADICALS BIOL; Jeng W, 2003, TOXICOL SCI, V72, P72; JENG W, 2004, TOXICOL SCI, V78, P413; JOHNSON M, 1988, J PHARMACOL EXP THER, V244, P977; JOHNSON MP, 1986, EUR J PHARMACOL, V132, P269, DOI 10.1016/0014-2999(86)90615-1; KALANT H, 2001, CMAJ, V165, P915; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Kita T, 2000, NEUROPHARMACOLOGY, V39, P399, DOI 10.1016/S0028-3908(99)00175-6; Laposa RR, 2004, FASEB J, V18, P896, DOI 10.1096/fj.03-0903fje; Launer LJ, 2003, DRUGS, V63, P731, DOI 10.2165/00003495-200363080-00001; LIM HK, 1988, CHEM RES TOXICOL, V1, P370, DOI 10.1021/tx00006a008; Lin LY, 1997, DRUG METAB DISPOS, V25, P1059; LIU L, 1995, FREE RADICAL BIO MED, V19, P639, DOI 10.1016/0891-5849(95)00082-9; Markwell M A, 1981, Methods Enzymol, V72, P296; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; MARNETT LJ, 1983, REV BIOCHEM TOXICOL, P135; MARNETT LJ, 1995, PREV MED, V24, P103, DOI 10.1006/pmed.1995.1017; MARQUARDT GM, 1978, TOXICOL APPL PHARM, V45, P675, DOI 10.1016/0041-008X(78)90161-8; MARQUARDT GM, 1978, PSYCHOPHARMACOLOGY H, P84; McGuire P, 2000, TOXICOL LETT, V112, P153, DOI 10.1016/S0378-4274(99)00219-2; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Mecocci P, 1996, NEUROSCI LETT, V207, P129, DOI 10.1016/0304-3940(96)12509-X; Mintzer S, 1999, NEW ENGL J MED, V340, P1443, DOI 10.1056/NEJM199905063401817; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Nicol CJ, 2000, FASEB J, V14, P111, DOI 10.1096/fasebj.14.1.111; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; NICOL CJ, 1995, IN PRESS NAT GENET, V11, P104; Obrocki J, 1999, BRIT J PSYCHIAT, V175, P186, DOI 10.1192/bjp.175.2.186; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; Oka A, 1997, NEUROREPORT, V8, P1161, DOI 10.1097/00001756-199703240-00020; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Parman T, 1998, J BIOL CHEM, V273, P25079, DOI 10.1074/jbc.273.39.25079; Parman T, 2002, FASEB J, V16, P1001, DOI 10.1096/fj.01-0140com; Parrott AC, 2002, HUM PSYCHOPHARM CLIN, V17, P309, DOI 10.1002/hup.415; Pelkonen O, 1998, XENOBIOTICA, V28, P1203, DOI 10.1080/004982598238886; Pompl PN, 2003, FASEB J, V17, P725, DOI 10.1096/fj.02-0876fje; Ricaurte GA, 2000, NEUROPSYCHOBIOLOGY, V42, P5, DOI 10.1159/000026664; ROBERTS LJ, 2001, PHARMACOL BASIS THER, P689; SASAME HA, 1977, BIOCHEM BIOPH RES CO, V78, P919, DOI 10.1016/0006-291X(77)90510-1; SCHMIDT CJ, 1987, EUR J PHARMACOL, V136, P81, DOI 10.1016/0014-2999(87)90782-5; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; SPRAGUE JE, 1995, J PHARMACOL EXP THER, V273, P667; Teismann P, 2001, SYNAPSE, V39, P167, DOI 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U; Thomas DM, 2005, J PHARMACOL EXP THER, V313, P870, DOI 10.1124/jpet.104.080242; TUCKER GT, 1994, BIOCHEM PHARMACOL, V47, P1151, DOI 10.1016/0006-2952(94)90386-7; Valyi-Nagy T, 1999, J NEUROPATH EXP NEUR, V58, P1269, DOI 10.1097/00005072-199912000-00008; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Volkow ND, 2001, AM J PSYCHIAT, V158, P377, DOI 10.1176/appi.ajp.158.3.377; Volkow ND, 2001, J NEUROSCI, V21, P9414, DOI 10.1523/JNEUROSCI.21-23-09414.2001; Walsh DT, 2000, GLIA, V29, P392, DOI 10.1002/(SICI)1098-1136(20000215)29:4<392::AID-GLIA10>3.0.CO;2-C; Warner M, 1997, MUTAT RES-FUND MOL M, V376, P79, DOI 10.1016/S0027-5107(97)00053-5; WARNER M, 1994, P NATL ACAD SCI USA, V91, P1019, DOI 10.1073/pnas.91.3.1019; Wells Peter G, 2005, Toxicol Appl Pharmacol, V207, P354, DOI 10.1016/j.taap.2005.01.061; Wells PG, 1996, CRIT REV BIOCHEM MOL, V31, P1, DOI 10.3109/10409239609110574; Wells PG, 1997, MUTAT RES-FUND MOL M, V396, P65, DOI 10.1016/S0027-5107(97)00175-9; WELLS PG, 1997, HANDB EXP PHARM I, V124, P453; White SR, 1996, PROG NEUROBIOL, V49, P455, DOI 10.1016/0301-0082(96)00027-5; Winn LM, 1997, FREE RADICAL BIO MED, V22, P607, DOI 10.1016/S0891-5849(96)00340-1; Winn LM, 1999, FREE RADICAL BIO MED, V26, P266, DOI 10.1016/S0891-5849(98)00193-2; Wong A., 2004, TOXICOL SCI, V78, P380	77	39	41	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2006	20	6					638	650		10.1096/fj.05-5271com	http://dx.doi.org/10.1096/fj.05-5271com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581972				2022-12-25	WOS:000240130900010
J	Chalovich, EM; Zhu, JH; Caltagarone, J; Bowser, R; Chu, CT				Chalovich, Elisabeth M.; Zhu, Jian-Hui; Caltagarone, John; Bowser, Robert; Chu, Charleen T.			Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; OXIDATIVE STRESS; BINDING PROTEIN; REACTIVE OXYGEN; DOPAMINERGIC-NEURONS; GENE-EXPRESSION; KINASE PHOSPHORYLATION; SUBSTANTIA-NIGRA; ACTIVATION; DEATH	Impaired survival signaling may represent a central mechanism in neurodegeneration. 6-Hydroxydopamine (6-OHDA) is an oxidative neurotoxin used to injure catecholaminergic cells of the central and peripheral nervous systems. Although 6-OHDA elicits phosphorylation of several kinases, downstream transcriptional effects that influence neuronal cell death are less defined. The cAMP response element (CRE) is present in the promoter sequences of several important neuronal survival factors. Treatment of catecholaminergic neuronal cell lines (B65 and SH-SY5Y) with 6-OHDA resulted in repression of basal CRE transactivation. Message levels of CRE-driven genes such as brain-derived neurotrophic factor and the survival factor Bcl-2 were decreased in 6-OHDA-treated cells, but message levels of genes lacking CRE sequences were not affected. Repression of CRE could be reversed by delayed treatment with cAMP several hours after initiation of 6-OHDA injury. Furthermore, restoration of CRE-driven transcription was associated with significant neuroprotection. In contrast to observations in other model systems, the mechanism of CRE repression did not involve decreased phosphorylation of its binding protein CREB. Instead, total CREB and phospho-CREB (pCREB) were increased in the cytoplasm and decreased in the nucleus of 6-OHDA-treated cells. 6-OHDA also decreased nuclear pCREB in dopaminergic neurons of primary mouse midbrain cultures. Co-treatment with cAMP promoted/restored nuclear localization of pCREB in both immortalized and primary culture systems. Increased cytoplasmic pCREB was observed in degenerating human Parkinson/Lewy body disease substantia nigra neurons but not in age-matched controls. Notably, cytoplasmic accumulation of activated upstream CREB kinases has been observed previously in both 6-OHDA-treated cells and degenerating human neurons, supporting a potential role for impaired nuclear import of phosphorylated signaling proteins.	UPMC Presbyterian, Sch Med, Dept Pathol, Div Neuropathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	Chu, CT (corresponding author), UPMC Presbyterian, Sch Med, Dept Pathol, Div Neuropathol, 200 Lothrop St, Pittsburgh, PA 15213 USA.	ctc4@pitt.edu	Chu, Charleen T/B-1601-2008	Chu, Charleen T/0000-0002-5052-8271	NINDS NIH HHS [NS 40817, NS 053777, R01 NS040817, R21 NS053777] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS053777, R01NS040817] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Asanuma M, 1998, NEUROSCIENCE, V85, P907, DOI 10.1016/S0306-4522(97)00665-9; Barkats M, 2002, J NEUROCHEM, V82, P101, DOI 10.1046/j.1471-4159.2002.00952.x; Barlow C, 2006, AM J RESP CELL MOL, V34, P7, DOI 10.1165/rcmb.2005-0153OC; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Callio J, 2005, J BIOL CHEM, V280, P18536, DOI 10.1074/jbc.M413224200; Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7; Castro-Obregon S, 2004, J BIOL CHEM, V279, P17543, DOI 10.1074/jbc.M312363200; Chandran UR, 1996, J BIOL CHEM, V271, P20412, DOI 10.1074/jbc.271.34.20412; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Choi WS, 2004, J BIOL CHEM, V279, P20451, DOI 10.1074/jbc.M311164200; Chu CT, 2006, J NEUROPATH EXP NEUR, V65, P423, DOI 10.1097/01.jnen.0000229233.75253.be; Chu CT, 2005, J NEUROCHEM, V94, P1685, DOI 10.1111/j.1471-4159.2005.03329.x; Chu CT, 2004, EUR J BIOCHEM, V271, P2060, DOI 10.1111/j.1432-1033.2004.04132.x; COHEN G, 1974, J BIOL CHEM, V249, P2447; DECKER DE, 1993, RES COMMUN CHEM PATH, V79, P195; Ellerby LM, 2000, METHOD ENZYMOL, V322, P413; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Engele J, 1996, CELL TISSUE RES, V286, P235, DOI 10.1007/s004410050692; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; Gomez-Santos C, 2002, BRAIN RES, V935, P32, DOI 10.1016/S0006-8993(02)02422-8; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Guo X, 2001, EUR J NEUROSCI, V13, P1683, DOI 10.1046/j.0953-816x.2001.01542.x; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; Holtz WA, 2003, J BIOL CHEM, V278, P19367, DOI 10.1074/jbc.M211821200; Horbinski C, 2005, FREE RADICAL BIO MED, V38, P2, DOI 10.1016/j.freeradbiomed.2004.09.030; Howells DW, 2000, EXP NEUROL, V166, P127, DOI 10.1006/exnr.2000.7483; Hulley P, 1995, J NEURAL TRANSM-SUPP, P217; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Ito Y, 1999, NEUROSCI RES, V35, P321, DOI 10.1016/S0168-0102(99)00097-8; Jordan J, 2004, J NEUROCHEM, V89, P124, DOI 10.1046/j.1471-4159.2003.02299.x; Jordan-Sciutto KL, 1999, J BIOL CHEM, V274, P35262, DOI 10.1074/jbc.274.49.35262; Jordan-Sciutto KL, 2000, AM J PATHOL, V157, P497, DOI 10.1016/S0002-9440(10)64561-0; Keller JN, 2004, INT J BIOCHEM CELL B, V36, P2376, DOI 10.1016/j.biocel.2004.05.003; Klein RL, 1999, BRAIN RES, V847, P314, DOI 10.1016/S0006-8993(99)02116-2; Kulich SM, 2003, J BIOSCIENCES, V28, P83, DOI 10.1007/BF02970136; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; Lee J, 2005, J BIOL CHEM, V280, P40398, DOI 10.1074/jbc.C500140200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mabuchi T, 2001, J NEUROSCI, V21, P9204, DOI 10.1523/JNEUROSCI.21-23-09204.2001; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mogi M, 1999, NEUROSCI LETT, V270, P45, DOI 10.1016/S0304-3940(99)00463-2; Natsume A, 2001, EXP NEUROL, V169, P231, DOI 10.1006/exnr.2001.7671; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Oury TD, 2002, AM J PHYSIOL-LUNG C, V283, pL777, DOI 10.1152/ajplung.00011.2002; Petit A, 2005, J BIOL CHEM, V280, P34025, DOI 10.1074/jbc.M505143200; Przedborski S, 2005, ANTIOXID REDOX SIGN, V7, P685, DOI 10.1089/ars.2005.7.685; Rozen S, 2000, Methods Mol Biol, V132, P365; Ryu EJ, 2005, NEUROBIOL DIS, V18, P54, DOI 10.1016/j.nbd.2004.08.016; Sanchez S, 2001, J NEUROCHEM, V78, P468, DOI 10.1046/j.1471-4159.2001.00453.x; Schor NF, 2004, BIOCHEMISTRY-MOSCOW+, V69, P38, DOI 10.1023/B:BIRY.0000016349.75384.e6; See V, 2001, J BIOL CHEM, V276, P35049, DOI 10.1074/jbc.M104988200; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Stevenson AS, 2001, EXP CELL RES, V263, P118, DOI 10.1006/excr.2000.5107; TIFFANYCASTIGLIONI E, 1982, BIOCHEM PHARMACOL, V31, P181, DOI 10.1016/0006-2952(82)90208-8; Tokuyama W, 1998, MOL BRAIN RES, V62, P206, DOI 10.1016/S0169-328X(98)00261-7; Troadec JD, 2002, MOL PHARMACOL, V62, P1043, DOI 10.1124/mol.62.5.1043; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wang ZQ, 2003, J BIOL CHEM, V278, P11138, DOI 10.1074/jbc.M209108200; Wu AS, 2003, J NEUROCHEM, V85, P142, DOI 10.1046/j.1471-4159.2003.01639.x; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Yamada M, 1999, P NATL ACAD SCI USA, V96, P4078, DOI 10.1073/pnas.96.7.4078; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9; Zhang BC, 2004, HEPATOLOGY, V39, P1343, DOI 10.1002/hep.20200; Zhu JH, 2003, BRAIN PATHOL, V13, P473; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2	69	88	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17870	17881		10.1074/jbc.M602632200	http://dx.doi.org/10.1074/jbc.M602632200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16621793	hybrid, Green Accepted			2022-12-25	WOS:000238490300037
J	Cristea, M; Oliw, EH				Cristea, Mirela; Oliw, Ernst H.			A G316A mutation of manganese lipoxygenase augments hydroperoxide isomerase activity - Mechanism of biosynthesis of epoxyalcohols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; POSITIONAL SPECIFICITY; SOYBEAN LIPOXYGENASE-1; LINOLEIC-ACID; FATTY-ACIDS; ORGANELLE DEGRADATION; LIQUID-CHROMATOGRAPHY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; SUBSTRATE	Lipoxygenases with R stereospecificity have a conserved Gly residue, whereas (S)-lipoxygenases have an Ala residue. Site-directed mutagenesis has shown that these residues control position and S/R stereospecificity of oxygenation. Recombinant Mn-LO was expressed in Pichia pastoris, and its conserved Gly-316 residue was mutated to Ala, Ser, Val, and Thr. The G316A mutant was catalytically active. We compared the catalytic properties of Mn-LO and the G316A mutant with 17: 3n-3, 18: 2n-6, 18: 3n-3, and 19: 3n-3 as substrates. Increasing the fatty acid chain length from C17 to C19 shifted the oxygenation by Mn-LO from the n-6 toward the n-8 carbon. The G316A mutant increased the oxygenation at the n-8 carbon of 17:3n-3 and at the n-10 carbon of the C17 and C18 fatty acids (from 1-2% to 7-11%). The most striking effect of the G316A mutant was a 2-, 7-, and 15-fold increase in transformation of the n-6 hydroperoxides of 19:3n-3, 18:3n-3, and 17:3n-3, respectively, to keto fatty acids and epoxyalcohols. The n-3 double bond was essential. An experiment under an oxygen-18 atmosphere showed that both oxygen atoms were retained in the epoxyalcohols. ( R)Hydroperoxides at n-6 of C17:3, 18:3, and 19:3 were transformed 5 times faster than S stereoisomers. The G316A mutant converted (13R)-hydroperoxylinolenic acid to 13-ketolinolenic acid (with an apparent Km of 0.01 mM) and to epoxyalcohols (viz. erythro-and threo-11-hydroxy-(12R, 13R)-epoxy-( 9Z, 15Z)-octadecadienoic acids and one of the corresponding cis-epoxides as major products). A reducing lipoxygenase inhibitor stimulated the hydroperoxide isomerase activity, whereas a suicide-type lipoxygenase inhibitor reduced this activity. The n-3 double bond also appeared to influence the anaerobic formation of epoxyalcohols by Mn-LO, since 18:2n-6 and 18:3n-3 yielded different profiles of epoxyalcohols. Our results suggest that the G316A mutant augmented the hydroperoxide isomerase activity by positioning the hydroperoxy group at the n- 6 carbon of n- 3 fatty acids closer to the reduced catalytic metal.	Uppsala Univ, Dept Pharmaceut Biosci, Div Biochem Pharmacol, SE-75124 Uppsala, Sweden; Uppsala Univ, Dept Pharmaceut Biosci, Biomed Ctr, SE-75124 Uppsala, Sweden	Uppsala University; Uppsala University	Oliw, EH (corresponding author), Uppsala Univ, Dept Pharmaceut Biosci, Div Biochem Pharmacol, POB 591, SE-75124 Uppsala, Sweden.	Ernst.Oliw@farmbio.uu.se		Oliw, Ernst/0000-0002-7986-8130				BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; CHAMULITRAT W, 1992, J BIOL CHEM, V267, P9574; CHAN HWS, 1979, CHEM PHYS LIPIDS, V24, P245, DOI 10.1016/0009-3084(79)90030-6; Chang MS, 1996, BIOCHEMISTRY-US, V35, P464, DOI 10.1021/bi952081v; Coffa G, 2005, J BIOL CHEM, V280, P38756, DOI 10.1074/jbc.M504870200; Coffa G, 2005, BIOCHEM BIOPH RES CO, V338, P87, DOI 10.1016/j.bbrc.2005.07.185; Coffa G, 2004, P NATL ACAD SCI USA, V101, P15579, DOI 10.1073/pnas.0406727101; Cristea M, 2005, ARCH BIOCHEM BIOPHYS, V434, P201, DOI 10.1016/j.abb.2004.10.026; DIX TA, 1985, J BIOL CHEM, V260, P5351; Eckl KM, 2005, HUM MUTAT, V26, P351, DOI 10.1002/humu.20236; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GARDNER HW, 1981, BIOCHIM BIOPHYS ACTA, V665, P113, DOI 10.1016/0005-2760(81)90239-3; GARSSEN GJ, 1976, EUR J BIOCHEM, V62, P33, DOI 10.1111/j.1432-1033.1976.tb10094.x; GARSSEN GJ, 1971, BIOCHEM J, V122, P327, DOI 10.1042/bj1220327; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; Grullich C, 2001, FEBS LETT, V489, P51, DOI 10.1016/S0014-5793(01)02080-4; Hamberg M, 1999, LIPIDS, V34, P1131, DOI 10.1007/s11745-999-0464-7; Hamberg M, 1998, J BIOL CHEM, V273, P13080, DOI 10.1074/jbc.273.21.13080; HANSON RM, 2002, EPOXIDE MIGRATION PA, P1; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Hornsten L, 2002, EUR J BIOCHEM, V269, P2690, DOI 10.1046/j.1432-1033.2002.02936.x; Hornung E, 1999, P NATL ACAD SCI USA, V96, P4192, DOI 10.1073/pnas.96.7.4192; Hughes RK, 2001, EUR J BIOCHEM, V268, P1030, DOI 10.1046/j.1432-1327.2001.01964.x; Jisaka M, 2000, J BIOL CHEM, V275, P1287, DOI 10.1074/jbc.275.2.1287; Jobard F, 2002, HUM MOL GENET, V11, P107, DOI 10.1093/hmg/11.1.107; Kitaguchi H, 2005, J AM CHEM SOC, V127, P6605, DOI 10.1021/ja044345j; Knapp MJ, 2001, J AM CHEM SOC, V123, P2931, DOI 10.1021/ja003855k; KUHN H, 1984, EUR J BIOCHEM, V139, P577, DOI 10.1111/j.1432-1033.1984.tb08044.x; Kuhn H, 2005, BIOCHEM BIOPH RES CO, V338, P93, DOI 10.1016/j.bbrc.2005.08.238; KUHN H, 1987, ANAL BIOCHEM, V160, P24, DOI 10.1016/0003-2697(87)90609-9; Lutteke T, 2003, BIOINFORMATICS, V19, P2482, DOI 10.1093/bioinformatics/btg337; MATTHEW JA, 1977, LIPIDS, V12, P324, DOI 10.1007/BF02533358; Meruvu S, 2005, J BIOL CHEM, V280, P36633, DOI 10.1074/jbc.M508260200; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; Oldham ML, 2005, J BIOL CHEM, V280, P39545, DOI 10.1074/jbc.M506675200; Oliw EH, 1998, LIPIDS, V33, P843, DOI 10.1007/s11745-998-0280-0; Oliw EH, 2004, LIPIDS, V39, P319, DOI 10.1007/s11745-004-1235-1; Oliw EH, 2002, PROSTAG OTH LIPID M, V68-9, P313, DOI 10.1016/S0090-6980(02)00037-0; OLIW EH, 2006, IN PRESS ANAL BIOCH; Reeder BJ, 2004, ANTIOXID REDOX SIGN, V6, P954, DOI 10.1089/ars.2004.6.954; REYNOLDS CH, 1988, BIOCHEM PHARMACOL, V37, P4531, DOI 10.1016/0006-2952(88)90669-7; RIENDEAU D, 1991, BIOCHEM J, V274, P287, DOI 10.1042/bj2740287; Schenk G, 2003, BIOCHEMISTRY-US, V42, P7294, DOI 10.1021/bi027380g; Schwarz K, 2000, BIOCHEMISTRY-US, V39, P14515, DOI 10.1021/bi001447n; Schwarz K, 2001, J BIOL CHEM, V276, P773, DOI 10.1074/jbc.M005114200; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; Su C, 1998, J BIOL CHEM, V273, P13072, DOI 10.1074/jbc.273.21.13072; Tomchick DR, 2001, BIOCHEMISTRY-US, V40, P7509, DOI 10.1021/bi002893d; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; VANOS CPA, 1982, BIOCHIM BIOPHYS ACTA, V713, P173; Yu ZY, 2005, BBA-MOL CELL BIOL L, V1686, P238, DOI 10.1016/j.bbalip.2004.10.007; Yu ZY, 2003, P NATL ACAD SCI USA, V100, P9162, DOI 10.1073/pnas.1633612100	54	19	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17612	17623		10.1074/jbc.M510311200	http://dx.doi.org/10.1074/jbc.M510311200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16641090	hybrid			2022-12-25	WOS:000238490300010
J	Bookwalter, CS; Trybus, KM				Bookwalter, Carol S.; Trybus, Kathleen M.			Functional consequences of a mutation in an expressed human alpha-cardiac actin at a site implicated in familial hypertrophic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE MYOSIN; ACTOMYOSIN INTERACTIONS; DILATED CARDIOMYOPATHY; PROTEIN; MUTANT; ASSAY; GENE; TROPOMYOSIN; INHIBITION; FILAMENTS	Point mutations in human alpha-cardiac actin cause familial hypertrophic cardiomyopathy. Functional characterization of these actin mutants has been limited by the lack of a high level expression system for human cardiac actin. Here, wild-type (WT) human alpha-cardiac actin and a mutant E99K actin have been expressed and purified from the baculovirus/insect cell expression system. Glu-99 in subdomain 1 of actin is thought to interact with a positively charged cluster located in the lower 50-kDa domain of the myosin motor domain. Actin-activated ATPase measurements using the expressed actins and beta-cardiac myosin showed that the mutation increased the K-m for actin 4-fold (4.7 +/- 0.7 mu M for WT versus 19.1 +/- 3.0 mu M for the mutant), whereas the V-max values were similar. The mutation slightly decreased the affinity of actin for S1 in the absence of nucleotide, which can partly be accounted for by a slower rate of association. The in vitro motility for the E99K mutant was consistently lower than WT over a range of ionic strengths, which is likely related to the lower average force supported by the mutant actin. The thermal stability of the E99K was comparable to that of WT-actin, implying no folding defects. The lower density of negative charge in subdomain 1 of actin therefore weakens the actomyosin interaction sufficiently to decrease the force and motion generating capacity of E99K actin, thus providing the primary insult that ultimately leads to the disease phenotype.	Univ Vermont, Dept Mol Physiol & Biophys, Hlth Sci Res Facil 130, Burlington, VT 05405 USA	University of Vermont	Trybus, KM (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, Hlth Sci Res Facil 130, Burlington, VT 05405 USA.	kathleen.trybus@uvm.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059408] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 059408] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayscough KR, 1996, ANNU REV CELL DEV BI, V12, P129, DOI 10.1146/annurev.cellbio.12.1.129; Bing W, 2000, BIOCHEM J, V350, P693, DOI 10.1042/0264-6021:3500693; Bing W, 1998, J BIOL CHEM, V273, P15016, DOI 10.1074/jbc.273.24.15016; BLIKSTAD I, 1978, CELL, V15, P935, DOI 10.1016/0092-8674(78)90277-5; Dunn AY, 2001, J STRUCT BIOL, V135, P176, DOI 10.1006/jsbi.2001.4380; FRANKEL S, 1990, J BIOL CHEM, V265, P17980; Joel PB, 2004, BIOCHEMISTRY-US, V43, P11554, DOI 10.1021/bi048899a; JOHARA M, 1993, P NATL ACAD SCI USA, V90, P2127, DOI 10.1073/pnas.90.6.2127; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Malmqvist UP, 2004, BIOCHEMISTRY-US, V43, P15058, DOI 10.1021/bi0495329; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MILLER CJ, 1995, BIOCHEMISTRY-US, V34, P2694, DOI 10.1021/bi00008a037; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P16557, DOI 10.1021/bi962388+; Milligan RA, 1996, P NATL ACAD SCI USA, V93, P21, DOI 10.1073/pnas.93.1.21; Mogensen J, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.010447; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Olson TM, 2000, J MOL CELL CARDIOL, V32, P1687, DOI 10.1006/jmcc.2000.1204; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Razzaq A, 1999, J BIOL CHEM, V274, P28321, DOI 10.1074/jbc.274.40.28321; Schuler H, 2000, EUR J BIOCHEM, V267, P476, DOI 10.1046/j.1432-1327.2000.01023.x; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Sherwood JJ, 2004, P NATL ACAD SCI USA, V101, P10973, DOI 10.1073/pnas.0401699101; Trybus KM, 2000, METHODS, V22, P327, DOI 10.1006/meth.2000.1085; Van Driest SL, 2003, CIRCULATION, V108, P445, DOI 10.1161/01.CIR.0000080896.52003.DF; Vang S, 2005, FEBS J, V272, P2037, DOI 10.1111/j.1742-4658.2005.04630.x; Volkmann N, 2000, NAT STRUCT BIOL, V7, P1147; WALLER GS, 1995, J BIOL CHEM, V270, P15348, DOI 10.1074/jbc.270.25.15348; Wong WNW, 1999, BIOCHEMISTRY-US, V38, P1365, DOI 10.1021/bi982467g; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H	32	47	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16777	16784		10.1074/jbc.M512935200	http://dx.doi.org/10.1074/jbc.M512935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16611632	hybrid			2022-12-25	WOS:000238165700072
J	de Meis, L; Arruda, AP; da Costa, RM; Benchimol, M				de Meis, Leopoldo; Arruda, Ana Paula; da Costa, Rodrigo Madeiro; Benchimol, Marlene			Identification of a Ca2+-ATPase in brown adipose tissue mitochondria - Regulation of thermogenesis by ATP and Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; UNCOUPLING PROTEIN; HEAT-PRODUCTION; MECHANISM; MEMBRANE; RELEASE; HISTORY; OLD	In brown adipose tissue ( BAT) adrenaline promotes a rise of the cytosolic Ca2+ concentration from 0.05 up to 0.70 mu M. It is not known how the rise of Ca2+ concentration activates BAT thermogenesis. In this report we compared the effects of Ca2+ in BAT and liver mitochondria. Using electron microscopy and immunolabeling we identified a sarco/endoplasmic reticulum ( ER) Ca2+-ATPase bound to the inner membrane of BAT mitochondria. A Ca2+-dependent ATPase activity was detected in BAT mitochondria when the respiratory substrates malate and pyruvate were included in the medium. ATP and Ca2+ enhanced the amount of heat produced by BAT mitochondria during respiration. The Ca2+ concentration needed for half-maximal activation of the ATPase activity and rate of heat production were the same and varied between 0.1 and 0.2 mu M. Heat production was partially inhibited by the proton ionophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone and abolished by thapsigargin, a specific ER Ca2+-ATPase inhibitor, and by both rotenone and KCN, two substances that inhibit the electron transfer trough the mitochondrial cytochrome chain. In liver mitochondria Ca2+ did not stimulate the ATPase activity nor increase the rate of heat production. Thapsigargin had no effect on liver mitochondria. In conclusion, this is the first report of a Ca2+-ATPase in mitochondria that is BAT-specific and can generate heat in the presence of Ca2+ concentrations similar to those noted in the cell during adrenergic stimulation.	Univ Fed Rio de Janeiro, Inst Bioquim Med Predio CCS, BR-21941590 Rio De Janeiro, Brazil; Univ Santa Ursula, Lab Ultraestrutura Celular, BR-22231010 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	de Meis, L (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim Med Predio CCS, Cidade Univ, BR-21941590 Rio De Janeiro, Brazil.	demeis@bioqmed.ufrj.br	Arruda, Ana Paula/AAA-6008-2022; Madeiro, Rodrigo/M-6433-2017	Madeiro, Rodrigo/0000-0001-5646-8858; Arruda, Ana Paula/0000-0001-6179-2687				Andrienko T, 2003, J EXP BIOL, V206, P2059, DOI 10.1242/jeb.00242; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; BOVERIS A, 1977, ANAL BIOCHEM, V80, P145, DOI 10.1016/0003-2697(77)90634-0; BREITWIESER GE, 2002, AM J PHYSIOL, V282, P980; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; CHIESI M, 1979, J BIOL CHEM, V254, P370; da-Silva WS, 2004, J BIOL CHEM, V279, P39846, DOI 10.1074/jbc.M403835200; de Meis L, 2003, J BIOL CHEM, V278, P41856, DOI 10.1074/jbc.M308280200; de Meis L, 2001, J BIOL CHEM, V276, P25078, DOI 10.1074/jbc.M103318200; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; INESI G, 1968, ARCH BIOCHEM BIOPHYS, V126, P469, DOI 10.1016/0003-9861(68)90431-1; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; Jaburek M, 2003, J BIOL CHEM, V278, P25825, DOI 10.1074/jbc.M302126200; JANSKY L, 1995, PHYSIOL REV, V75, P237, DOI 10.1152/physrev.1995.75.2.237; KLINGENBERG M, 1988, BIOCHEMISTRY-US, V27, P781, DOI 10.1021/bi00402a044; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANOUE KF, 1986, J BIOL CHEM, V261, P298; Leaver EV, 2002, AM J PHYSIOL-CELL PH, V282, pC1016, DOI 10.1152/ajpcell.00204.2001; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL P, 1969, EUR J BIOCHEM, V7, P471, DOI 10.1111/j.1432-1033.1969.tb19633.x; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Nicholls DG, 2005, BBA-BIOENERGETICS, V1710, P63, DOI 10.1016/j.bbabio.2005.09.002; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Nicholls DG, 2001, BIOCHEM SOC T, V29, P751, DOI 10.1042/bst0290751; Nicholls DG, 1999, J BIOENERG BIOMEMBR, V31, P399, DOI 10.1023/A:1005436121005; Reis M, 2002, MOL MEMBR BIOL, V19, P301, DOI 10.1080/09687680210166217; RIAL E, 1983, EUR J BIOCHEM, V137, P197, DOI 10.1111/j.1432-1033.1983.tb07815.x; Ribeiro MO, 2001, J CLIN INVEST, V108, P97, DOI 10.1172/JCI12584; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; Shkryl VM, 2006, J BIOL CHEM, V281, P1547, DOI 10.1074/jbc.M505024200; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; SORENSON MM, 1986, J MEMBRANE BIOL, V90, P219, DOI 10.1007/BF01870128; VERCESI AE, 1993, J BIOL CHEM, V268, P8564; Wieckowski MR, 1998, FEBS LETT, V423, P339, DOI 10.1016/S0014-5793(98)00118-5	40	33	34	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16384	16390		10.1074/jbc.M600678200	http://dx.doi.org/10.1074/jbc.M600678200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16608844	hybrid			2022-12-25	WOS:000238165700027
J	Jackson, MW; Patt, LE; LaRusch, GA; Donner, DB; Stark, GR; Mayo, LD				Jackson, Mark W.; Patt, Linnea E.; LaRusch, Gretchen A.; Donner, David B.; Stark, George R.; Mayo, Lindsey D.			Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; P53; MDM2; PHOSPHORYLATION; PATHWAY; DEGRADATION; EXPRESSION; RAS; ACTIVATION; PROMOTER	Insulin-like growth factor (IGF)-I receptor activation leads to enhanced proliferation and cell survival via the MAP kinase and phosphatidylinositol 3-kinase-signaling pathways. Upon stimulation by IGF-I, the Hdm2 oncoprotein is phosphorylated by AKT, leading to its rapid nuclear translocation and subsequent inhibition of p53. We now show that IGF-I stimulation regulates the nuclear export of Hdm2 and p53 via the MAP kinase pathway. Inhibition of p38 MAPK or MEK via pharmacological means or expression of dominant negative proteins inhibited the cytoplasmic accumulation of Hdm2 and increased Hdm2 and p53 protein levels, whereas constitutively active p90Rsk promoted the nuclear export of Hdm2. Expression of constitutively active p90Rsk with E1A, oncogenic H-Ras, and hTERT resulted in the anchorage-independent growth of normal human fibroblasts. Our findings link p90Rsk-mediated modulation of Hdm2 nuclear to cytoplasmic shuttling with the diminished ability of p53 to regulate cell cycle checkpoints that ultimately leads to transformation.	Case Western Reserve Univ, Dept Radiat Oncol & Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Dept Mol Genet, Lerner Res Inst, Cleveland, OH 44195 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Cleveland Clinic Foundation; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Case Western Reserve University	Mayo, LD (corresponding author), Case Western Reserve Univ, Dept Radiat Oncol & Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	ldm11@case.edu			NATIONAL CANCER INSTITUTE [T32CA059366, R01CA109262, P30CA043703] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL072661] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 59366, R01 CA 109262, P30 CA 43703] Funding Source: Medline; NHLBI NIH HHS [F32 HL 072661] Funding Source: Medline; NIGMS NIH HHS [R01 GM 049345] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt S, 2003, J CELL BIOCHEM, V88, P76, DOI 10.1002/jcb.10311; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Onel K, 2004, MOL CANCER RES, V2, P1; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Phelps M, 2005, J BIOL CHEM, V280, P16651, DOI 10.1074/jbc.M412334200; Phelps M, 2003, CANCER RES, V63, P2616; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Shapiro P, 2002, CRIT REV CL LAB SCI, V39, P285, DOI 10.1080/10408360290795538; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weber HO, 2005, ONCOGENE, V24, P1965, DOI 10.1038/sj.onc.1208389; Wu YP, 2003, CANCER RES, V63, P4384; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	25	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16814	16820		10.1074/jbc.M511617200	http://dx.doi.org/10.1074/jbc.M511617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16621805	hybrid			2022-12-25	WOS:000238165700076
J	Luo, Y; DeFranco, DB				Luo, Yue; DeFranco, Donald B.			Opposing roles for ERK1/2 in neuronal oxidative toxicity - Distinct mechanisms of ERK1/2 action at early versus late phases of oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; METABOTROPIC GLUTAMATE RECEPTORS; PROTEIN-KINASE PATHWAY; CYSTEINE LIGASE GCL; MAP KINASE; NERVE-CELLS; ACTIVATION; GLUTATHIONE; INHIBITION; METABOLISM	Glutamate-induced oxidative toxicity is mediated by glutathione depletion in the HT22 mouse hippocampal cell line. Previous results with pharmacological agents implicated the extracellular signal-regulated kinases-1/2 (ERK1/2) in glutamate toxicity in HT22 cells and immature embryonic rat cortical neurons. In this report, we definitively establish a role for ERK1/2 in oxidative toxicity using dominant negative MEK1 expression in transiently transfected HT22 cells to block glutamate-induced cell death. In contrast, chronic activation of ERK (i.e. brought about by transfection of constitutively active ERK2 chimera) is not sufficient to trigger HT22 cell death demonstrating that ERK1/2 activation is not sufficient for toxicity. Activation of ERK1/2 in HT22 cells has a distinct kinetic profile with an initial peak occurring between 30 min and 1 h of glutamate treatment and a second peak typically emerging after 6 h. We demonstrate here that the initial phase of ERK1/2 induction is because of activation of metabotropic glutamate receptor type I (mGluRI). ERK1/2 activation by mGluRI contributes to an HT22 cell adaptive response to oxidative stress as glutamate-induced toxicity is enhanced upon pharmacological inhibition of mGluRI. The protective effect of ERK1/2 activation at early times after glutamate treatment is mediated by a restoration of glutathione (GSH) levels that are reduced because of depletion of intracellular cysteine pools. Thus, ERK1/2 appears to play dual roles in HT22 cells acting as part of a cellular adaptive response during the initial phases of glutamate-induced oxidative stress and contributing to toxicity during later stages of stress.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15216 USA; Univ Pittsburgh, Sch Med, Ctr Neurosci, Pittsburgh, PA 15216 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	DeFranco, DB (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, E1352 BST, Pittsburgh, PA 15216 USA.	dod1@pitt.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038319] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 38319] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; Chu CT, 2004, EUR J BIOCHEM, V271, P2060, DOI 10.1111/j.1432-1033.2004.04132.x; Colucci-D'Amato L, 2003, BIOESSAYS, V25, P1085, DOI 10.1002/bies.10355; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; D'Onofrio M, 2001, J NEUROCHEM, V78, P435, DOI 10.1046/j.1471-4159.2001.00435.x; DAVIS JB, 1994, BRAIN RES, V652, P169, DOI 10.1016/0006-8993(94)90334-4; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Dickinson DA, 2003, BIOL CHEM, V384, P527, DOI 10.1515/BC.2003.061; Dickinson DA, 2002, BIOCHEM PHARMACOL, V64, P1019, DOI 10.1016/S0006-2952(02)01172-3; FORMAN HJ, 1995, METHOD ENZYMOL, V252, P66; FOYER CH, 1994, BIOCHEM SOC T, V22, P909, DOI 10.1042/bst0220909; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Grant ER, 2001, BIOCHEM PHARMACOL, V62, P283, DOI 10.1016/S0006-2952(01)00665-7; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Hansen JM, 2004, TOXICOL SCI, V81, P371, DOI 10.1093/toxsci/kfh154; Hetman M, 2004, EUR J BIOCHEM, V271, P2050, DOI 10.1111/j.1432-1033.2004.04133.x; Iacovelli L, 2002, J NEUROCHEM, V82, P216, DOI 10.1046/j.1471-4159.2002.00929.x; Iles KE, 2005, FREE RADICAL BIO MED, V38, P547, DOI 10.1016/j.freeradbiomed.2004.11.012; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; KETTERER B, 1982, DRUG METAB REV, V13, P161, DOI 10.3109/03602538209002234; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; Levinthal DJ, 2005, J BIOL CHEM, V280, P5875, DOI 10.1074/jbc.M410771200; Levinthal DJ, 2004, J BIOL CHEM, V279, P11206, DOI 10.1074/jbc.M314261200; Li YH, 1998, P NATL ACAD SCI USA, V95, P7748, DOI 10.1073/pnas.95.13.7748; Maher P, 2001, J NEUROSCI, V21, P2929, DOI 10.1523/JNEUROSCI.21-09-02929.2001; Maher P, 1996, J NEUROSCI, V16, P6394; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Rahman I, 1996, BIOCHEM BIOPH RES CO, V229, P832, DOI 10.1006/bbrc.1996.1888; RATAN RR, 1994, J NEUROCHEM, V62, P376; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rossler OG, 2004, J NEUROCHEM, V88, P1240, DOI 10.1046/j.1471-4159.2003.02255.x; Sagara Y, 1998, J NEUROSCI, V18, P6662; SHI MM, 1994, AM J PHYSIOL-LUNG C, V267, pL414, DOI 10.1152/ajplung.1994.267.4.L414; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Spencer JPE, 2003, J BIOL CHEM, V278, P34783, DOI 10.1074/jbc.M305063200; Spillson AB, 2003, EXP NEUROL, V184, pS97, DOI 10.1016/j.expneurol.2003.08.001; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.3.489	42	99	100	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16436	16442		10.1074/jbc.M512430200	http://dx.doi.org/10.1074/jbc.M512430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16621802	hybrid			2022-12-25	WOS:000238165700033
J	Bergeron, MJ; Gagnon, E; Caron, L; Isenring, P				Bergeron, Marc J.; Gagnon, dith; Caron, Luc; Isenring, Paul			Identification of key functional domains in the C terminus of the K+-Cl- cotransporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE-CELLS; CATION-CHLORIDE COTRANSPORTERS; MESSENGER-RNA EXPRESSION; ALANINE-RICH KINASE; MOLECULAR-CLONING; NA-K-2CL COTRANSPORT; BUMETANIDE BINDING; INTRACELLULAR-CL; NERVOUS-SYSTEM	The K+-Cl- cotransporter (KCC) isoforms constitute a functionally heterogeneous group of ion carriers. Emerging evidence suggests that the C terminus (Ct) of these proteins is important in conveying isoform-specific traits and that it may harbor interacting sites for 4 beta-phorbol 12-myristate 13-acetate (PMA)-induced effectors. In this study, we have generated KCC2-KCC4 chimeras to identify key functional domains in the Ct of these carriers and single point mutations to determine whether canonical protein kinase C sites underlie KCC2-specific behaviors. Functional characterization of wild-type (wt) and mutant carriers in Xenopus laevis oocytes showed for the first time that the KCCs do not exhibit similar sensitivities to changes in osmolality and that this distinguishing feature as well as differences in transport activity under both hypotonic and isotonic conditions are in part determined by the residue composition of the distal Ct. At the same time, several mutations in this domain and in the proximal Ct of the KCCs were found to generate allosteric-like effects, suggesting that the regions analyzed are important in defining conformational ensembles and that isoform-specific structural configurations could thus account for variant functional traits as well. Characterization of the other mutants in this work showed that KCC2 is not inhibited by PMA through phosphorylation of its canonical protein kinase C sites. Intriguingly, however, the substitutions N728S and S940A were seen to alter the PMA effect paradoxically, suggesting again that allosteric changes in the Ct are important determinants of transport activity and, furthermore, that the structural configuration of this domain can convey specific functional traits by defining the accessibility of cotransporter sites to regulatory intermediates such as PMA-induced effectors.	Univ Laval, Nephrol Res Grp, Hotel Dieu Quebec Inst, Dept Med,Fac Med, Quebec City, PQ G1R 2J6, Canada	Laval University	Isenring, P (corresponding author), CHUQ, Hotel Dieu, 10 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	paul.isenring@crhdq.ulaval.ca						Adragna NC, 2004, J MEMBRANE BIOL, V201, P109, DOI 10.1007/s00232-004-0695-6; Bergeron MJ, 2003, AM J PHYSIOL-RENAL, V285, pF68, DOI 10.1152/ajprenal.00032.2003; Bize I, 1999, AM J PHYSIOL-CELL PH, V277, pC926, DOI 10.1152/ajpcell.1999.277.5.C926; Boettger T, 2002, NATURE, V416, P874, DOI 10.1038/416874a; Brunet GM, 2005, J GEN PHYSIOL, V126, P325, DOI 10.1085/jgp.200509334; COOPER GJ, 2002, AM J PHYSIOL, V284, pC331; DeFranceschi L, 1997, J CLIN INVEST, V99, P220, DOI 10.1172/JCI119150; Di Fulvio M, 2003, NITRIC OXIDE-BIOL CH, V9, P165, DOI 10.1016/j.niox.2003.11.004; Di Fulvio M, 2001, J BIOL CHEM, V276, P44534, DOI 10.1074/jbc.M104899200; Di Fulvio M, 2001, J BIOL CHEM, V276, P21046, DOI 10.1074/jbc.M100901200; EVELOFF J, 1987, AM J PHYSIOL, V252, pF883, DOI 10.1152/ajprenal.1987.252.5.F883; Ferrell CM, 2000, J MEMBRANE BIOL, V177, P81, DOI 10.1007/s002320001101; Gagnon E, 2004, J BIOL CHEM, V279, P5648, DOI 10.1074/jbc.M311218200; Gagnon E, 2003, AM J PHYSIOL-CELL PH, V284, pC365, DOI 10.1152/ajpcell.00262.2002; Gagnon KBE, 2006, AM J PHYSIOL-CELL PH, V290, pC134, DOI 10.1152/ajpcell.00037.2005; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; Gamba G, 2005, PHYSIOL REV, V85, P423, DOI 10.1152/physrev.00011.2004; GAMBA G, 2005, BIOCHEM J, V391, pC1; Garon L, 2000, J BIOL CHEM, V275, P32027, DOI 10.1074/jbc.M000108200; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; GUGGINO WB, 1985, J GEN PHYSIOL, V86, P31, DOI 10.1085/jgp.86.1.31; Guizouarn H, 1999, AM J PHYSIOL-CELL PH, V276, pC210, DOI 10.1152/ajpcell.1999.276.1.C210; Hebert SC, 2004, PFLUG ARCH EUR J PHY, V447, P580, DOI 10.1007/s00424-003-1066-3; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; JENNINGS ML, 1991, J GEN PHYSIOL, V97, P799, DOI 10.1085/jgp.97.4.799; Jennings ML, 2001, AM J PHYSIOL-CELL PH, V281, pC825, DOI 10.1152/ajpcell.2001.281.3.C825; Karadsheh MF, 2004, NEUROSCIENCE, V123, P381, DOI 10.1016/j.neuroscience.2003.10.004; KIM HD, 1989, AM J PHYSIOL, V256, pC772, DOI 10.1152/ajpcell.1989.256.4.C772; Klein JD, 1999, AM J PHYSIOL-CELL PH, V277, pC425, DOI 10.1152/ajpcell.1999.277.3.C425; LAUF PK, 1992, AM J PHYSIOL, V263, pC917, DOI 10.1152/ajpcell.1992.263.5.C917; LAUF PK, 1985, J MEMBRANE BIOL, V88, P1, DOI 10.1007/BF01871208; Liedtke CM, 2002, AM J PHYSIOL-LUNG C, V282, pL1151, DOI 10.1152/ajplung.00143.2001; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lytle C, 2002, AM J PHYSIOL-CELL PH, V283, pC1422, DOI 10.1152/ajpcell.00130.2002; Marshall WS, 2005, J EXP BIOL, V208, P1063, DOI 10.1242/jeb.01491; Mercado A, 2006, J BIOL CHEM, V281, P1016, DOI 10.1074/jbc.M509972200; Mercado A, 2000, J BIOL CHEM, V275, P30326, DOI 10.1074/jbc.M003112200; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Piechotta K, 2003, J BIOL CHEM, V278, P52848, DOI 10.1074/jbc.M309436200; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Simard CF, 2004, J BIOL CHEM, V279, P40769, DOI 10.1074/jbc.M406458200; STARKE LC, 1993, AM J PHYSIOL, V264, pC118, DOI 10.1152/ajpcell.1993.264.1.C118; Strange K, 2000, AM J PHYSIOL-CELL PH, V279, pC860, DOI 10.1152/ajpcell.2000.279.3.C860; Velazquez H, 2003, AM J PHYSIOL-RENAL, V285, pF49, DOI 10.1152/ajprenal.00389.2002; Williams JR, 1999, J BIOL CHEM, V274, P12656, DOI 10.1074/jbc.274.18.12656; Woo NS, 2002, HIPPOCAMPUS, V12, P258, DOI 10.1002/hipo.10014; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201; Zhong Z, 2005, DIABETOLOGIA, V48, P187, DOI 10.1007/s00125-004-1602-5; Zhou JG, 2005, J BIOL CHEM, V280, P7301, DOI 10.1074/jbc.M412813200	58	35	35	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15959	15969		10.1074/jbc.M600015200	http://dx.doi.org/10.1074/jbc.M600015200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595678	hybrid			2022-12-25	WOS:000237996000047
J	Ng, KM; Catalano, MG; Pinos, T; Selva, DM; Avvakumov, GV; Munell, F; Hammond, GL				Ng, Kwong-Man; Catalano, Maria G.; Pinos, Tomas; Selva, David M.; Avvakumov, George V.; Munell, Francina; Hammond, Geoffrey L.			Evidence that fibulin family members contribute to the steroid-dependent extravascular sequestration of sex hormone-binding globulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; EXTRACELLULAR-MATRIX; CELL-ADHESION; EXPRESSION; PROTEIN; RECEPTOR; RESOLUTION; ESTRADIOL; GLYCOSYLATION; PROGESTERONE	Sex hormone-binding globulin (SHBG) binds steroids in the blood but is also present in the extravascular compartments of some tissues. Mice expressing a human SHBG transgene in the liver have human SHBG in their blood. In these animals, human SHBG accumulates within the stromal matrix of the endometrium and epididymis. This is remarkable because these tissues do not express the transgene. Human SHBG administered intravenously to wild- type mice in the presence of estradiol is rapidly sequestered within the endometrial stroma, and this prompted us to search for SHBG interacting proteins. Yeast two-hybrid screens revealed that fibulin-1D and fibulin-2 interact with the amino-terminal laminin G domain of SHBG. These interactions were verified in GST-pull down assays in which human SHBG bound the carboxyl-terminal domains of fibulin-1D and fibulin-2 in a steroid-dependent manner, with estradiol being the most effective ligand, and were enhanced by reducing the N-glycosylation of human SHBG. Like human SHBG, fibulin-1 and fibulin-2 concentrate within the endometrial stroma. In addition, SHBG co-immunoprecipitates with these fibulins in a proestrus uterine extract. These matrix-associated proteins may therefore sequester plasma SHBG within uterine stroma where it can control sex-steroid access to target cells. Given the interplay between fibulins and numerous proteins within the basal lamina, interactions between SHBG and matrix proteins may exert novel biological effects.	Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V5Z 4H4, Canada; Univ Turin, Dept Clin Pathophysiol, I-10126 Turin, Italy; Hosp Gen Valle Hebron, Grup Recerca Endocrinol Mol, Barcelona 08035, Spain; Univ Toronto, Struct Genom Consortium, Toronto, ON MSG 1L5, Canada	Child & Family Research Institute; University of British Columbia; University of Turin; Hospital Universitari Vall d'Hebron; University of Toronto; Structural Genomics Consortium	Hammond, GL (corresponding author), Child & Family Res Inst, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	ghammond@cw.bc.ca	Catalano, Maria Graziella/J-4320-2016; Selva, David Martínez/O-6444-2016	Catalano, Maria Graziella/0000-0002-1170-8245; Munell Casadesus, Francina/0000-0001-8580-2819; Hammond, Geoffrey/0000-0002-4639-7336				Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; Avvakumov GV, 2000, J BIOL CHEM, V275, P25920, DOI 10.1074/jbc.M004484200; AVVAKUMOV GV, 1986, BIOCHIM BIOPHYS ACTA, V881, P489, DOI 10.1016/0304-4165(86)90043-7; Avvakumov GV, 2001, J BIOL CHEM, V276, P34453, DOI 10.1074/jbc.M106274200; BOCCHINFUSO WP, 1992, ENDOCRINOLOGY, V131, P2331, DOI 10.1210/en.131.5.2331; BOCCHINFUSO WP, 1991, MOL ENDOCRINOL, V5, P1723, DOI 10.1210/mend-5-11-1723; CATALANO MG, 2000, INT C END ICE 2000 S; COWAN RA, 1976, J ENDOCRINOL, V71, P121, DOI 10.1677/joe.0.0710121; FORTUNATI N, 1993, J STEROID BIOCHEM, V45, P435, DOI 10.1016/0960-0760(93)90012-L; Grishkovskaya I, 2000, EMBO J, V19, P504, DOI 10.1093/emboj/19.4.504; Grishkovskaya I, 2002, J BIOL CHEM, V277, P32086, DOI 10.1074/jbc.M203999200; Grishkovskaya I, 2002, J MOL BIOL, V318, P621, DOI 10.1016/S0022-2836(02)00169-9; Haendler B, 2004, MOL REPROD DEV, V68, P279, DOI 10.1002/mrd.20079; Hammes A, 2005, CELL, V122, P751, DOI 10.1016/j.cell.2005.06.032; HAMMOND GL, 1983, CLIN CHIM ACTA, V132, P101, DOI 10.1016/0009-8981(83)90237-1; HAMMOND GL, 1995, J STEROID BIOCHEM, V53, P543, DOI 10.1016/0960-0760(95)00110-L; HAMMOND GL, 1987, FEBS LETT, V215, P100, DOI 10.1016/0014-5793(87)80121-7; Hammond GL, 2002, OBSTET GYN CLIN N AM, V29, P411, DOI 10.1016/S0889-8545(02)00008-6; HAMMOND GL, 1984, FERTIL STERIL, V42, P44; Hansen RK, 2000, ENDOCR-RELAT CANCER, V7, P95, DOI 10.1677/erc.0.0070095; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HILDEBRAND C, 1995, BIOCHEMISTRY-US, V34, P3231, DOI 10.1021/bi00010a012; Horwitz AR, 1998, CURR OPIN CELL BIOL, V10, P563, DOI 10.1016/S0955-0674(98)80029-X; HRYB DJ, 1989, J BIOL CHEM, V264, P5378; HRYB DJ, 1990, J BIOL CHEM, V265, P6048; Hryb DJ, 2002, J BIOL CHEM, V277, P26618, DOI 10.1074/jbc.M202495200; Janne M, 1998, MOL ENDOCRINOL, V12, P123; Janne M, 1999, ENDOCRINOLOGY, V140, P4166, DOI 10.1210/en.140.9.4166; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Lee WM, 1997, J ENDOCRINOL, V153, P373, DOI 10.1677/joe.0.1530373; MARCONDES F. K., 2002, Braz. J. Biol., V62, P609, DOI 10.1590/S1519-69842002000400008; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MENDEL CM, 1989, ENDOCR REV, V10, P232, DOI 10.1210/edrv-10-3-232; Misao R, 1998, INT J CANCER, V77, P828; Nakamoto T, 2005, HUM REPROD, V20, P1447, DOI 10.1093/humrep/deh841; Okada H, 2003, GYNECOL ENDOCRINOL, V17, P271, DOI 10.1080/713603290; PELLINIEMI LJ, 1981, ENDOCRINOLOGY, V108, P925, DOI 10.1210/endo-108-3-925; PFAFF M, 1995, EXP CELL RES, V219, P87, DOI 10.1006/excr.1995.1208; Pope SN, 2005, J STEROID BIOCHEM, V94, P203, DOI 10.1016/j.jsbmb.2005.01.007; PORTO CS, 1991, ENDOCRINOLOGY, V129, P436, DOI 10.1210/endo-129-1-436; PORTO CS, 1992, ENDOCRINOLOGY, V130, P2931, DOI 10.1210/en.130.5.2931; ROSNER W, 1990, ENDOCR REV, V11, P80, DOI 10.1210/edrv-11-1-80; Rudenko G, 2001, TRENDS BIOCHEM SCI, V26, P363, DOI 10.1016/S0968-0004(01)01832-1; SIITERI PK, 1982, RECENT PROG HORM RES, V38, P457; SINNECKER G, 1990, HORM METAB RES, V22, P47, DOI 10.1055/s-2007-1004847; Sinnecker G, 1988, Steroids, V52, P335, DOI 10.1016/0039-128X(88)90134-1; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; WALMER DK, 1992, ENDOCRINOLOGY, V131, P1458, DOI 10.1210/en.131.3.1458; WESTPHAL U, 1986, MONOGRAPHS ENDOCRINO, P276; Woodward TL, 2000, ENDOCRINOLOGY, V141, P2814, DOI 10.1210/en.141.8.2814	50	44	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15853	15861		10.1074/jbc.M512370200	http://dx.doi.org/10.1074/jbc.M512370200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16601122	hybrid			2022-12-25	WOS:000237996000034
J	Ng, YP; Cheung, ZH; Ip, NY				ng, Yu Po Ng; Cheung, Zelda H.; Ip, Nancy Y.			STAT3 as a downstream mediator of Trk signaling and functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; SERINE PHOSPHORYLATION; PC12 CELLS; TRANSCRIPTION FACTOR; NEURITE OUTGROWTH; FACTOR-RECEPTOR; DNA-BINDING; EXPRESSION; TYROSINE	Signal transducer and activator of transcription 3 (STAT3) has long been shown to regulate gene transcription in response to cytokines and growth factors. Recent evidence suggests that STAT3 activation may also occur downstream of receptor-tyrosine kinase activation. In the current study we have identified STAT3 as a novel signal transducer for TrkA, the receptor-tyrosine kinase that mediates the functions of nerve growth factor (NGF). Activation of TrkA by NGF triggered STAT3 phosphorylation at Ser-727, and enhanced the DNA binding and transcriptional activities of STAT3. More importantly, neurotrophin-induced increase in STAT3 activation was observed to underlie several downstream functions of neurotrophin signaling. First of all, knockdown of STAT3 expression using the RNA interference approach attenuated NGF-induced transcription of immediate early genes in PC12 cells. Furthermore, reduced STAT3 expression in PC12 cells suppressed NGF-induced cyclin D1 expression, thereby inhibiting growth arrest normally triggered by NGF treatment. Finally, inhibition of STAT3 expression decreased brain-derived neurotrophic factor-promoted neurite outgrowth in primary hippocampal neurons. Together, our finding shave identified STAT3 as an essential component of neurotrophin signaling and functions.	Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neuosci Ctr, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Ip, NY (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Clear Water Bay, Hong Kong, Hong Kong, Peoples R China.	boip@ust.hk	Cheung, Zelda Hiu Yee/C-1402-2012	Ip, Nancy Yuk-Yu/0000-0002-2763-8907				Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Fu AKY, 2004, P NATL ACAD SCI USA, V101, P6728, DOI 10.1073/pnas.0307606100; Gartsbein M, 2006, J CELL SCI, V119, P470, DOI 10.1242/jcs.02744; Gollob JA, 1999, J IMMUNOL, V162, P4472; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; IP FCF, 1995, J NEUROCHEM, V65, P2393; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Labelle C, 2000, DEV BRAIN RES, V123, P1, DOI 10.1016/S0165-3806(00)00069-9; Lai KO, 2004, J BIOL CHEM, V279, P13383, DOI 10.1074/jbc.M313356200; Laszlo GS, 2003, J BIOL CHEM, V278, P27750, DOI 10.1074/jbc.M303670200; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Lo RKH, 2003, J BIOL CHEM, V278, P52154, DOI 10.1074/jbc.M307299200; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; Munzberg H, 2005, CELL MOL LIFE SCI, V62, P642, DOI 10.1007/s00018-004-4432-1; Ng YP, 2003, J BIOL CHEM, V278, P38731, DOI 10.1074/jbc.M304623200; NG YP, 2006, HDB NEUROCHEMISTRY M; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Qiu J, 2005, J NEUROSCI, V25, P1645, DOI 10.1523/JNEUROSCI.3269-04.2005; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Schuringa JJ, 2001, FEBS LETT, V495, P71, DOI 10.1016/S0014-5793(01)02354-7; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; Shen YH, 2004, MOL CELL BIOL, V24, P407, DOI 10.1128/MCB.24.1.407-419.2004; Taga T, 2005, CLIN REV ALLERG IMMU, V28, P249, DOI 10.1385/CRIAI:28:3:249; Tolwani RJ, 2002, NEUROSCIENCE, V114, P795, DOI 10.1016/S0306-4522(02)00301-9; Tong LQ, 1999, NEUROCHEM RES, V24, P1431, DOI 10.1023/A:1022540925099; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vinkemeier U, 2004, J CELL BIOL, V167, P197, DOI 10.1083/jcb.200407163; Wang R, 2005, J BIOL CHEM, V280, P11528, DOI 10.1074/jbc.M413930200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAN GZ, 1995, J NEUROSCI, V15, P6200; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhao H, 2004, BIOCHEM BIOPH RES CO, V325, P541, DOI 10.1016/j.bbrc.2004.10.075; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	51	90	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15636	15644		10.1074/jbc.M601863200	http://dx.doi.org/10.1074/jbc.M601863200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16611639	hybrid			2022-12-25	WOS:000237996000007
J	Zheng, H; Yu, X; Collin-Osdoby, P; Osdoby, P				Zheng, Hong; Yu, Xuefeng; Collin-Osdoby, Patricia; Osdoby, Philip			RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts - An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappa B that restrains osteoclastogenesis and bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ACTIVATOR; CHEMOTACTIC RECRUITMENT; INFLAMMATORY CYTOKINES; INHIBITION; LIGAND; NO; OSTEOPROTEGERIN; MACROPHAGES; REGULATOR; SURVIVAL	Nitric oxide ( NO) is a multifunctional signaling molecule and a key vasculoprotective and potential osteoprotective factor. NO regulates normal bone remodeling and pathological bone loss in part through affecting the recruitment, formation, and activity of bone-resorbing osteoclasts. Using murine RAW 264.7 and primary bone marrow cells or osteoclasts formed from them by receptor activator of NF-kappa B ligand (RANKL) differentiation, we found that inducible nitric-oxide synthase (iNOS) expression and NO generation were stimulated by interferon (IFN)-gamma or lipopolysaccharide, but not by interleukin-1 or tumor necrosis factor-alpha. Surprisingly, iNOS expression and NO release were also triggered by RANKL. This response was time- and dose-dependent, required NF-kappa B activation and new protein synthesis, and was specifically blocked by the RANKL decoy receptor osteoprotegerin. Preventing RANKL-induced NO (via iNOS-selective inhibition or use of marrow cells from iNOS(-/-) mice) increased osteoclast formation and bone pit resorption, indicating that such NO normally restrains RANKL-mediated osteoclastogenesis. Additional studies suggested that RANKL-induced NO inhibition of osteoclast formation does not occur via NO activation of a cGMP pathway. Because IFN-beta is also a RANKL-induced autocrine negative feedback inhibitor that limits osteoclastogenesis, we investigated whether IFN-beta is involved in this novel RANKL/iNOS/NO autoregulatory pathway. IFN-beta was induced by RANKL and stimulated iNOS expression and NO release, and a neutralizing antibody to IFN-gamma inhibited iNOS/NO elevation in response to RANKL, thereby enhancing osteoclast formation. Thus, RANKL-induced IFN-gamma triggers iNOS/NO as an important negative feedback signal during osteoclastogenesis. Specifically targeting this novel autoregulatory pathway may provide new therapeutic approaches to combat various osteolytic bone diseases.	Washington Univ, Dept Biol, St Louis, MO 63130 USA; Washington Univ, Div Bone & Mineral Metab, St Louis, MO 63130 USA	Washington University (WUSTL); Washington University (WUSTL)	Osdoby, P (corresponding author), Washington Univ, Dept Biol, 1229 McDonnell Hall,POB 1229, St Louis, MO 63130 USA.	osdoby@biology.wustl.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042715, T32AR007033] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42715, 5 T32 AR07033-31] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Armour KJ, 2001, ARTHRITIS RHEUM, V44, P2790, DOI 10.1002/1529-0131(200112)44:12<2790::AID-ART466>3.0.CO;2-X; BLAIR H, 2005, BIOCHEM J, V364, P329; BRANDI ML, 1995, P NATL ACAD SCI USA, V92, P2954, DOI 10.1073/pnas.92.7.2954; Chae HJ, 1997, J PHARM PHARMACOL, V49, P897, DOI 10.1111/j.2042-7158.1997.tb06132.x; Chole RA, 1998, ACTA OTO-LARYNGOL, V118, P705; Collin-Osdoby P, 2003, METH MOLEC MED, V80, P153; Collin-Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200; Collin-Osdoby P, 2000, J BONE MINER RES, V15, P474, DOI 10.1359/jbmr.2000.15.3.474; Cuzzocrea S, 2003, ENDOCRINOLOGY, V144, P1098, DOI 10.1210/en.2002-220597; Diwan AD, 2000, J BONE MINER RES, V15, P342, DOI 10.1359/jbmr.2000.15.2.342; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Gyurko R, 2005, BONE, V36, P472, DOI 10.1016/j.bone.2004.12.002; Hayashi T, 2002, J BIOL CHEM, V277, P27880, DOI 10.1074/jbc.M203836200; Heymann D, 2005, DRUG DISCOV TODAY, V10, P242, DOI 10.1016/S1359-6446(04)03265-9; Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226; HOLLIDAY L, 1997, AM J PHYSIOL, V272, pF282; Jamal SA, 1998, J BONE MINER RES, V13, P1755, DOI 10.1359/jbmr.1998.13.11.1755; KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569; Kostenuik PJ, 2001, CURR PHARM DESIGN, V7, P613, DOI 10.2174/1381612013397807; Lee SK, 2004, EXP CELL RES, V298, P359, DOI 10.1016/j.yexcr.2004.04.039; Lerner UH, 2004, CRIT REV ORAL BIOL M, V15, P64, DOI 10.1177/154411130401500202; MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; McCartney-Francis NL, 2001, J IMMUNOL, V166, P2734, DOI 10.4049/jimmunol.166.4.2734; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Park SW, 2005, MOL CELL PROTEOMICS, V4, P300, DOI 10.1074/mcp.M400195-MCP200; Pfeilschifter J, 2003, J AM SOC NEPHROL, V14, pS237, DOI 10.1097/01.ASN.0000077409.55250.84; RALSTON SH, 1995, J BONE MINER RES, V10, P1040; Ralston SH, 1996, BONE, V19, P29, DOI 10.1016/8756-3282(96)00101-9; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; SILVERTON SF, 1995, ENDOCRINOLOGY, V136, P5244, DOI 10.1210/en.136.11.5244; Sunyer T, 1996, J CELL BIOCHEM, V60, P469, DOI 10.1002/(SICI)1097-4644(19960315)60:4<469::AID-JCB4>3.0.CO;2-Q; Sunyer T, 1997, ENDOCRINOLOGY, V138, P2148, DOI 10.1210/en.138.5.2148; Takada Y, 2004, BLOOD, V104, P4113, DOI 10.1182/blood-2004-04-1607; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; TSKAHARA H, 1996, AM J PHYSIOL, V270, pE840; van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365-2567.2001.01261.x; van't Hof RJ, 2000, P NATL ACAD SCI USA, V97, P7993, DOI 10.1073/pnas.130511497; VantHof RJ, 1997, J BONE MINER RES, V12, P1797, DOI 10.1359/jbmr.1997.12.11.1797; Veihelmann A, 2001, ARTHRITIS RHEUM-US, V44, P1420, DOI 10.1002/1529-0131(200106)44:6<1420::AID-ART237>3.0.CO;2-K; Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290; WEISZ A, 1994, J BIOL CHEM, V269, P8324; Wimalawansa SJ, 2000, CALCIFIED TISSUE INT, V66, P56, DOI 10.1007/s002230050011; Wright LM, 2005, BONE, V36, P840, DOI 10.1016/j.bone.2005.01.021; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404; Yu XF, 2004, J BONE MINER RES, V19, P2065, DOI 10.1359/JBMR.040910	47	106	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15809	15820		10.1074/jbc.M513225200	http://dx.doi.org/10.1074/jbc.M513225200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16613848	hybrid			2022-12-25	WOS:000237996000029
J	Drobni, M; Olsson, IM; Eriksson, C; Almqvist, F; Stromberg, N				Drobni, Mirva; Olsson, Ing-Marie; Eriksson, Christer; Almqvist, Fredrik; Stromberg, Nicklas			Multivariate design and evaluation of a set of RGRPQ-derived innate immunity peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PROTEINS; STREPTOCOCCUS-GORDONII; BACTERIAL ADHESION; SALIVARY; ASSOCIATION; COMMENSAL	Oral commensal Streptococcus gordonii proteolytically cleave the salivary PRP-1 polypeptide into an RGRPQ innate peptide. The Arg and Gln termini are crucial for RGRPQ-mediated ammonia production and proliferation by S. gordonii SK12 and adhesion inhibition and desorption by Actinomyces naeslundii T14V, respectively. Here we have applied (i) a multivariate approach using RGRPQ-related peptides varied at amino acids 2, 3, and 4 simultaneously and ( ii) size and N- and C-terminal modifications of RGRPQ to generate structure activity information. While the N- terminal arginine motif mediated ammonia production independent of peptide size, other responses required more or less full-length peptide motifs. The motifs for adhesion inhibition and desorption were the same. The adhesion and proliferation motifs required similarily a hydrophobic/low polarity amino acid 4 but differentially a hydrophilic or hydrophobic character of amino acids 2/3, respectively; polar peptides with small/hydrophilic and hydrophilic amino acids 2 and 3, respectively, had high adhesion inhibition/desorption activity, and lipophilic peptides with large/hydrophobic amino acids 2 and 3 had high proliferation activity. Accordingly, while RIWWQ had increased proliferation but abolished adhesion/desorption activity, peptides designed with hydrophilic amino acids 2 and 3 were predicted to behave in the opposite way. Moreover, a RGRPQ mimetic for all three responses should mimic small hydrophilic, large nitrogen-containing, and hydrophobic/low polarity amino acids 2, 3, and 4, respectively. Peptides fulfilling these criteria were 1-1.6-fold improved in all three responses. Thus, both mimetics and peptides with differential proliferation and adhesion activities may be generated for evaluation in biofilm models.	Umea Univ, Dept Odontol Cardiol, SE-90187 Umea, Sweden; Umea Univ, Dept Chem Organ Chem, SE-90187 Umea, Sweden	Umea University; Umea University	Stromberg, N (corresponding author), Umea Univ, Dept Odontol Cardiol, SE-90187 Umea, Sweden.	Nicklas.Stromberg@odont.umu.se		Almqvist, Fredrik/0000-0002-0504-4446				Ayad M, 2000, J DENT RES, V79, P976, DOI 10.1177/00220345000790041401; AZEN EA, 1993, CRIT REV ORAL BIOL M, V4, P479, DOI 10.1177/10454411930040033201; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; *CHEM COMP GROUP I, 2002, MOE SOFTW; deAguiar PF, 1995, CHEMOMETR INTELL LAB, V30, P199, DOI 10.1016/0169-7439(94)00076-X; DUMOUCHEL W, 1994, TECHNOMETRICS, V36, P37, DOI 10.2307/1269197; DUNN WJ, 1989, CHEMOMETR INTELL LAB, V6, P181, DOI 10.1016/0169-7439(89)80083-8; Emtenas H, 2002, J COMB CHEM, V4, P630, DOI 10.1021/cc020032d; Eriksson L, 1996, CHEMOMETR INTELL LAB, V34, P1, DOI 10.1016/0169-7439(96)00023-8; GIBBONS RJ, 1989, J DENT RES, V68, P750, DOI 10.1177/00220345890680050101; GIBBONS RJ, 1991, INFECT IMMUN, V59, P2948, DOI 10.1128/IAI.59.9.2948-2954.1991; Havarstein LS, 1996, MOL MICROBIOL, V21, P863, DOI 10.1046/j.1365-2958.1996.521416.x; HAY DI, 1994, J DENT RES, V73, P1717, DOI 10.1177/00220345940730110701; HELLBERG S, 1987, J MED CHEM, V30, P1126, DOI 10.1021/jm00390a003; HOSKULDSSON A, 1995, J CHEMOMETR, V9, P91, DOI 10.1002/cem.1180090203; KILIAN M, 1989, INT J SYST BACTERIOL, V39, P471, DOI 10.1099/00207713-39-4-471; LAMKIN MS, 1993, CRIT REV ORAL BIOL M, V4, P251, DOI 10.1177/10454411930040030101; Larsson A, 2005, J MED CHEM, V48, P935, DOI 10.1021/jm040818l; Lazazzera BA, 1998, TRENDS MICROBIOL, V6, P288, DOI 10.1016/S0966-842X(98)01313-4; Li T, 2000, INFECT IMMUN, V68, P5425, DOI 10.1128/IAI.68.9.5425-5429.2000; Li T, 2001, INFECT IMMUN, V69, P7224, DOI 10.1128/IAI.69.12.7224-7233.2001; LI T, 2001, THESIS UMEA U UMEA S; Linusson A, 1998, MOL DIVERS, V4, P103, DOI 10.1023/A:1026416430656; O'Toole G, 2000, ANNU REV MICROBIOL, V54, P49, DOI 10.1146/annurev.micro.54.1.49; PERINPANAYAGAM HER, 1995, J DENT RES, V74, P345, DOI 10.1177/00220345950740011001; Putsep K, 2002, LANCET, V360, P1144, DOI 10.1016/S0140-6736(02)11201-3; STENBERG M, 1988, J IMMUNOL METHODS, V113, P3, DOI 10.1016/0022-1759(88)90376-6; Stenudd C, 2001, J DENT RES, V80, P2005, DOI 10.1177/00220345010800111101; TERLECKYJ B, 1975, INFECT IMMUN, V11, P649, DOI 10.1128/IAI.11.4.649-655.1975; *UMETRICS, 2001, MODDE 6 0 SOFTW 7 0; *UMETRICS, 2002, SIMCA P 10 0 SOFTW 1; WIJEYEWEERA RL, 1989, ARCH ORAL BIOL, V34, P43, DOI 10.1016/0003-9969(89)90045-9; Wold S., 1987, J CHEMOMETR, V1, P41, DOI DOI 10.1002/CEM.1180010107	33	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15164	15171		10.1074/jbc.M511727200	http://dx.doi.org/10.1074/jbc.M511727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16595685	hybrid			2022-12-25	WOS:000237922200019
J	Kim, MS; Merlo, X; Wilson, C; Lough, J				Kim, Min-Su; Merlo, Xanthi; Wilson, Catherine; Lough, John			Co-activation of atrial natriuretic factor promoter by Tip60 and serum response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-ACETYLTRANSFERASE ACTIVITY; INTERACTIVE PROTEIN TIP60; GENE-EXPRESSION; RECEPTOR COACTIVATOR; ANDROGEN RECEPTOR; TAT; IDENTIFICATION; ACETYLATION; ACTIVATION; COMPLEX	Tat-interactive protein 60 (Tip60) is a member of the MYST family of histone acetyltransferases (HATs). In addition to its HAT domain, Tip contains a heterochromatin-associated protein 1-like chromodomain and a zinc finger-like domain. Several alternative splice variants of Tip60 have been characterized, including full-length Tip60 alpha, Tip60 beta (which lacks exon V encoded by the Tip60 gene), and Tip55 ( which encodes a novel 103-amino-acid C terminus). We report here that isoproteins recognized by a pan-Tip60 antibody are strongly and transiently expressed between embryonic days 8 and 11 in the embryonic mouse myocardium. A functional role for Tip60 isoproteins in cardiac myocyte differentiation is suggested by immunoprecipitation experiments showing that Tip60 alpha, Tip60 alpha, and Tip55 can bind serum response factor (SRF) and by transient transfection assessments showing that Tip60 and SRF cooperatively activate the atrial natriuretic factor promoter. Although this combinatorial activity is inhibited by histone deacetylase 7, it was unexpectedly enhanced by point mutation of the HAT domain. Ablation of the chromodomain from Tip60 beta caused derepression. These findings suggest that Tip60 modulates expression of SRF-dependent cardiac genes.	Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Ctr Cardiovasc, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Lough, J (corresponding author), Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jlough@mcw.edu						Barron MR, 2005, J BIOL CHEM, V280, P11816, DOI 10.1074/jbc.M412408200; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gavaravarapu S, 2000, BIOCHEM BIOPH RES CO, V269, P758, DOI 10.1006/bbrc.2000.2358; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Hass MR, 2005, J BIOL CHEM, V280, P36895, DOI 10.1074/jbc.M502861200; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hlubek F, 2001, J BIOCHEM-TOKYO, V129, P635, DOI 10.1093/oxfordjournals.jbchem.a002901; Houweling AC, 2002, ANAT RECORD, V266, P93, DOI 10.1002/ar.10042; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jones DO, 2000, BIOESSAYS, V22, P124, DOI 10.1002/(SICI)1521-1878(200002)22:2&lt;124::AID-BIES4&gt;3.0.CO;2-E; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kao HY, 2000, GENE DEV, V14, P55; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Lough JW, 2002, DEV DYNAM, V223, P419, DOI 10.1002/dvdy.10058; McAllister D, 2002, GENE, V289, P169, DOI 10.1016/S0378-1119(02)00546-2; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Ran QT, 2000, GENE, V258, P141, DOI 10.1016/S0378-1119(00)00410-8; SEIDMAN CE, 1988, P NATL ACAD SCI USA, V85, P4104, DOI 10.1073/pnas.85.11.4104; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Sliva D, 1999, BIOCHEM BIOPH RES CO, V263, P149, DOI 10.1006/bbrc.1999.1083; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595	32	12	12	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15082	15089		10.1074/jbc.M513593200	http://dx.doi.org/10.1074/jbc.M513593200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16597624	hybrid			2022-12-25	WOS:000237922200010
J	Hennige, AM; Stefan, N; Kapp, K; Lehmann, R; Weigert, C; Beck, A; Moeschel, K; Mushack, J; Schleicher, E; Haring, HU				Hennige, Anita M.; Stefan, Norbert; Kapp, Katja; Lehmann, Rainer; Weigert, Cora; Beck, Alexander; Moeschel, Klaus; Mushack, Joanne; Schleicher, Erwin; Haering, Hans-Ulrich			Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1	FASEB JOURNAL			English	Article						protein kinase C; obesity; Irs protein; insulin resistance	PROTEIN-KINASE-C; SKELETAL-MUSCLE CELLS; RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; C2C12 MYOTUBES; JANUS KINASE-2; GLUCOSE-UPTAKE; FATTY-ACIDS; RESISTANCE	Insulin resistance in skeletal muscle is found in obesity and type 2 diabetes. A mechanism for impaired insulin signaling in peripheral tissues is the inhibition of insulin action through serine phosphorylation of insulin receptor substrate (Irs) proteins that abolish the coupling of Irs proteins to the activated insulin receptor. Recently, we described serine-318 as a protein kinase C (PKC)-dependent phosphorylation site in Irs1 (Ser-318) activated by hyperinsulinemia. Here we show in various cell models that the adipose hormone leptin, a putative mediator in obesity-related insulin resistance, promotes phosphorylation of Ser318 in Irs1 by a janus kinase 2, Irs2, and PKC-dependent pathway. Mutation of Ser-318 to alanine abrogates the inhibitory effect of leptin on insulin-induced Irs1 tyrosine phosphorylation and glucose uptake in L6 myoblasts. In C57Bl/6 mice, Ser-318 phosphorylation levels in muscle tissue were enhanced by leptin and insulin administration in lean animals while in diet-induced obesity Ser-318 phosphorylation levels were already up-regulated in the basal state, and further stimulation was diminished. In analogy, in lymphocytes of obese hyperleptinemic human subjects basal Ser-318 phosphorylation levels were increased compared to lean individuals. During a hyperinsulinemic euglycemic clamp, the increment in Ser-318 phosphorylation observed in lean individuals was absent in obese. In summary, these data suggest that phosphorylation of Ser-318 in Irs1 mediates the inhibitory signal of leptin on the insulin-signaling cascade in obese subjects.	Univ Tubingen, Dept Internal Med 4, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Haring, HU (corresponding author), Univ Tubingen, Dept Internal Med 4, Morgenstelle 1, D-72076 Tubingen, Germany.	hans-ulrich.haering@med.uni-tuebingen.de		Stefan, Norbert/0000-0002-2186-9595				Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Argiles JM, 2005, MED RES REV, V25, P49, DOI 10.1002/med.20010; Beck A, 2003, J AM SOC MASS SPECTR, V14, P401, DOI 10.1016/S1044-0305(03)00122-3; Berti L, 1997, DIABETOLOGIA, V40, P606, DOI 10.1007/s001250050722; Bjorbaek C, 2004, RECENT PROG HORM RES, V59, P305, DOI 10.1210/rp.59.1.305; Boden G, 2002, CURR OPIN CLIN NUTR, V5, P545, DOI 10.1097/00075197-200209000-00014; Boden G, 1997, J CLIN INVEST, V100, P1107, DOI 10.1172/JCI119621; Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319; Brabant G, 2005, FASEB J, V19, P1048, DOI 10.1096/fj.04-2846fje; Cardenas C, 2004, J BIOL CHEM, V279, P39122, DOI 10.1074/jbc.M401044200; Carlson CJ, 2004, BIOCHEM BIOPH RES CO, V316, P533, DOI 10.1016/j.bbrc.2004.02.082; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Ceddia RB, 2002, FASEB J, V16, DOI 10.1096/fj.02-0158rev; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Eiras S, 2004, J CELL PHYSIOL, V201, P214, DOI 10.1002/jcp.20046; Facchinetti MM, 1999, CELL SIGNAL, V11, P39, DOI 10.1016/S0898-6568(98)00029-1; FULOP T, 1995, FEBS LETT, V375, P69, DOI 10.1016/0014-5793(95)01179-I; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; Hennige AM, 2003, J CLIN INVEST, V112, P1521, DOI 10.1172/JCI200318581; Ignatoski KMW, 2003, MOL CANCER RES, V1, P551; Itani SI, 2000, DIABETES, V49, P1353, DOI 10.2337/diabetes.49.8.1353; Javor ED, 2005, DIABETES, V54, P1994, DOI 10.2337/diabetes.54.7.1994; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kellerer M, 1997, DIABETOLOGIA, V40, P1358, DOI 10.1007/s001250050832; Kellerer M, 2001, DIABETOLOGIA, V44, P1125, DOI 10.1007/s001250100614; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; Lazar MA, 2005, SCIENCE, V307, P373, DOI 10.1126/science.1104342; Liu YF, 2004, MOL CELL BIOL, V24, P9668, DOI 10.1128/MCB.24.21.9668-9681.2004; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Moeschel K, 2004, J BIOL CHEM, V279, P25157, DOI 10.1074/jbc.M402477200; Perez C, 2004, DIABETES, V53, P347, DOI 10.2337/diabetes.53.2.347; Pirola L, 2004, DIABETOLOGIA, V47, P170, DOI 10.1007/s00125-003-1313-3; ROTH RA, 1994, HORM RES, V41, P51, DOI 10.1159/000183961; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Sahu A, 2004, ENDOCRINOLOGY, V145, P2613, DOI 10.1210/en.2004-0032; Sahu A, 1998, ENDOCRINOLOGY, V139, P795, DOI 10.1210/en.139.2.795; Sahu A, 2002, J NEUROENDOCRINOL, V14, P796, DOI 10.1046/j.1365-2826.2002.00840.x; Sanchez-Margalet V, 2003, CLIN EXP IMMUNOL, V133, P11, DOI 10.1046/j.1365-2249.2003.02190.x; Schwartz MW, 2001, J CLIN INVEST, V108, P963, DOI 10.1172/JCI200114127; Serrano R, 2005, J MOL ENDOCRINOL, V34, P153, DOI 10.1677/jme.1.01635; Smith U, 2002, INT J OBESITY, V26, P897, DOI 10.1038/sj.ijo.0802028; Sweeney G, 2001, ENDOCRINOLOGY, V142, P4806, DOI 10.1210/en.142.11.4806; Szanto I, 2000, P NATL ACAD SCI USA, V97, P2355, DOI 10.1073/pnas.050580497; Tajmir P, 2003, J CELL PHYSIOL, V197, P122, DOI 10.1002/jcp.10351; Ueno M, 2005, DIABETOLOGIA, V48, P506, DOI 10.1007/s00125-004-1662-6; Vollenweider P, 2002, DIABETES, V51, P1052, DOI 10.2337/diabetes.51.4.1052; Weigert C, 2005, J BIOL CHEM, V280, P37393, DOI 10.1074/jbc.M506134200; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; ZICK Y, 2005, SCI STKE, pE4; Zimmet PZ, 1998, INT J OBESITY, V22, P171, DOI 10.1038/sj.ijo.0800559	56	73	77	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1206	+		10.1096/fj.05-4635fje	http://dx.doi.org/10.1096/fj.05-4635fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16611834				2022-12-25	WOS:000240210300027
J	Ruminy, P; Jardin, F; Picquenot, JM; Gaulard, P; Parmentier, F; Buchonnet, G; Maisonneuve, C; Tilly, H; Bastard, C				Ruminy, P.; Jardin, F.; Picquenot, J. M.; Gaulard, P.; Parmentier, F.; Buchonnet, G.; Maisonneuve, C.; Tilly, H.; Bastard, C.			Two patterns of chromosomal breakpoint locations on the immunoglobulin heavy-chain locus in B-cell lymphomas with t(3;14)(q27;q32): relevance to histology	ONCOGENE			English	Article						non-Hodgkin's B-cell lymphoma; BCL6; t(3;14)(q27;q32)	NON-HODGKINS-LYMPHOMAS; FOLLICULAR LYMPHOMA; GENE FUSION; MESSENGER-RNA; BCL6 GENE; GRADE 3B; TRANSLOCATIONS; EXPRESSION; REARRANGEMENT; 3Q27	The t(3;14)(q27;q32) is the most common translocation involving BCL6 in B-cell lymphoma. Although this translocation was predominantly associated with diffuse large B-cell lymphoma (DLBCL), recent studies have shown that it can also be found in follicular lymphomas (FL), often associated with a large cell component. To further investigate the relationship that might exist between this translocation and the phenotype of the tumors, we studied 34 lymphomas with a t(3;14)(q27;q32). Twenty cases were DLBCL, 14 FL and most cases, regardless of histology, were negative for the expression of CD10 (26/32, 81%). We identified the IGH switch region involved in the translocation for 32 cases. Our data indicate that in DLBCL most breakpoints involve the switch mu (17/19; 89%), whereas in FL most involve a switch gamma (9/13; 70%) (P = 0.0016, Fisher's exact test). This correlation between the histology and the structure of the translocated allele suggests that the lymphomas with S mu and S gamma translocations may originate from different cells, or that the substituted regulatory regions that come to deregulate BCL6 may affect the presentation of the disease.	INSERM, Ctr Henri Becquerel, Grp Etud Proliferat Lymphoides, U614,IFR23, Rouen, France; CHU Henri Mondor, Dept Pathol, INSERM, U617, F-94010 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Henri Becquerel; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bastard, C (corresponding author), INSERM, Ctr Henri Becquerel, Grp Etud Proliferat Lymphoides, U614,IFR23, Rue Amiens, Rouen, France.	chrbas@rouen.fnclcc.fr						Akasaka H, 2000, CANCER RES, V60, P2335; Akasaka T, 2000, BLOOD, V96, P2907; Akasaka T, 2003, BLOOD, V102, P1443, DOI 10.1182/blood-2002-08-2482; Barrans SL, 2002, BRIT J HAEMATOL, V117, P322, DOI 10.1046/j.1365-2141.2002.03435.x; BASTARD C, 1994, BLOOD, V83, P2423; Bosga-Bouwer AG, 2003, BLOOD, V101, P1149, DOI 10.1182/blood.V101.3.1149; Butler MP, 2002, CANCER RES, V62, P4089; Falini B, 2000, BLOOD, V95, P2084, DOI 10.1182/blood.V95.6.2084; HORSMAN DE, 1995, BRIT J HAEMATOL, V89, P569, DOI 10.1111/j.1365-2141.1995.tb08365.x; ISLAM KB, 1994, CLIN EXP IMMUNOL, V95, P3; Jaffe E.S., 2001, PATHOLOGY GENETICS T, VVolume 3; Jardin F, 2003, BLOOD, V102, P1872, DOI 10.1182/blood-2002-12-3630; Jardin F, 2002, LEUKEMIA, V16, P2318, DOI 10.1038/sj.leu.2402657; Katzenberger T, 2004, AM J PATHOL, V165, P481, DOI 10.1016/S0002-9440(10)63313-5; Kawakami K, 2004, INT J HEMATOL, V79, P474, DOI 10.1532/IJH97.03105; Kawamata N, 1998, BRIT J HAEMATOL, V100, P484, DOI 10.1046/j.1365-2141.1998.00603.x; LO CF, 1994, BLOOD, V83, P1757; Lossos IS, 2003, LEUKEMIA, V17, P1390, DOI 10.1038/sj.leu.2402997; Lossos IS, 2001, BLOOD, V98, P945, DOI 10.1182/blood.V98.4.945; MERTENS F, 1995, CANCER GENET CYTOGEN, V83, P176, DOI 10.1016/0165-4608(95)00066-X; Nagaoka H, 2002, J EXP MED, V195, P529, DOI 10.1084/jem.20012144; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; Ott G, 2002, BLOOD, V99, P3806, DOI 10.1182/blood.V99.10.3806; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Schaffer A, 1999, J IMMUNOL, V162, P5327; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; Ueda C, 2002, BLOOD, V99, P2624, DOI 10.1182/blood-2001-11-0117; Ueda C, 2002, LEUKEMIA LYMPHOMA, V43, P1375, DOI 10.1080/10428190290033305; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; WLODARSKA I, 1995, GENE CHROMOSOME CANC, V14, P1, DOI 10.1002/gcc.2870140102; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x	35	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4947	4954		10.1038/sj.onc.1209512	http://dx.doi.org/10.1038/sj.onc.1209512			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16619046				2022-12-25	WOS:000239687100012
J	Holmes, SF; Santangelo, TJ; Cunningham, CK; Roberts, JW; Erie, DA				Holmes, Shannon F.; Santangelo, Thomas J.; Cunningham, Candice K.; Roberts, Jeffrey W.; Erie, Dorothy A.			Kinetic investigation of Escherichia coli RNA polymerase mutants that influence nucleotide discrimination and transcription fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION COMPLEX STRUCTURE; NTP-DRIVEN TRANSLOCATION; 3.3 ANGSTROM RESOLUTION; II ACTIVE-CENTER; STRUCTURAL BASIS; NUCLEOSIDE TRIPHOSPHATES; CRYSTAL-STRUCTURE; ALLOSTERIC BINDING; DNA; MECHANISM	Recent RNA polymerase (RNAP) structures led to a proposed three-step model of nucleoside triphosphate (NTP) binding, discrimination, and incorporation. NTPs are thought to enter through the secondary channel, bind to an E site, rotate into a pre-insertion (PS) site, and ultimately align in the catalytic (A) site. We characterized the kinetics of correct and incorrect incorporation for several Escherichia coli RNAPs with substitutions in the proposed NTP entry pore (secondary channel). Substitutions of the semi-conserved residue beta Asp(675), which is > 10 angstrom away from these sites, significantly reduce fidelity; however, substitutions of the totally conserved residues beta Arg(678) and beta Asp(814) do not significantly alter the correct or incorrect incorporation kinetics, even though the corresponding residues in RNAPII crystal structures appear to be interacting with the NTP phosphate groups and coordinating the second magnesium ion in the active site, respectively. Structural analysis suggests that the lower fidelity of the beta Asp(675) mutants most likely results from reduction of the negative potential of a small pore between the E and PS sites and elimination of several structural interactions around the pore. We suggest a mechanism of nucleotide discrimination that is governed both by rotation of the NTP through this pore and subsequent rearrangement or closure of RNAP to align the NTP in the A site.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Appl & Mat Sci, Chapel Hill, NC 27599 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Cornell University	Erie, DA (corresponding author), Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA.	derie@unc.edu	Santangelo, Tom/L-8206-2019	Santangelo, Tom/0000-0003-4559-3244	NIGMS NIH HHS [GM 54316, GM 21941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021941, R01GM021941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; Armache KJ, 2005, J BIOL CHEM, V280, P7131, DOI 10.1074/jbc.M413038200; Artsimovitch I, 2003, SCIENCE, V302, P650, DOI 10.1126/science.1087526; Batada NN, 2004, P NATL ACAD SCI USA, V101, P17361, DOI 10.1073/pnas.0408168101; BLANK A, 1986, BIOCHEMISTRY-US, V25, P5920, DOI 10.1021/bi00368a013; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Burton ZF, 2005, BIOCHEM CELL BIOL, V83, P486, DOI 10.1139/O05-059; Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0; Cramer P, 2004, ADV PROTEIN CHEM, V67, P1; Cramer P, 2002, CURR OPIN STRUC BIOL, V12, P89, DOI 10.1016/S0959-440X(02)00294-4; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Erie DA, 2002, BBA-GENE STRUCT EXPR, V1577, P224, DOI 10.1016/S0167-4781(02)00454-2; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gong XQ, 2005, MOL CELL, V18, P461, DOI 10.1016/j.molcel.2005.04.011; Holmes SF, 2003, J BIOL CHEM, V278, P35597, DOI 10.1074/jbc.M304496200; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Kettenberger H, 2004, MOL CELL, V16, P955, DOI 10.1016/j.molcel.2004.11.040; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Landick R, 2004, CELL, V116, P351, DOI 10.1016/S0092-8674(04)00121-7; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Nedialkov YA, 2003, J BIOL CHEM, V278, P18303, DOI 10.1074/jbc.M301103200; Santangelo TJ, 2003, GENE DEV, V17, P1281, DOI 10.1101/gad.1082103; Sosunov V, 2003, EMBO J, V22, P2234, DOI 10.1093/emboj/cdg193; Temiakov D, 2005, MOL CELL, V19, P655, DOI 10.1016/j.molcel.2005.07.020; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; Uptain SM, 1997, P NATL ACAD SCI USA, V94, P13548, DOI 10.1073/pnas.94.25.13548; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Westover KD, 2004, CELL, V119, P481, DOI 10.1016/j.cell.2004.10.016; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5; Zhang CF, 2005, MOL CELL BIOL, V25, P3583, DOI 10.1128/MCB.25.9.3583-3595.2005; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	37	20	20	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18677	18683		10.1074/jbc.M600543200	http://dx.doi.org/10.1074/jbc.M600543200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16621791	Green Published, hybrid			2022-12-25	WOS:000238687300048
J	Feng, H; Ren, M; Wu, SL; Hall, DH; Rubin, CS				Feng, Hui; Ren, Min; Wu, Shi-Lan; Hall, David H.; Rubin, Charles S.			Characterization of a novel protein kinase D - Caenorhabditis elegans DKF-1 is activated by translocation-phosphorylation and regulates movement and growth in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; RNA INTERFERENCE; DEVELOPMENTAL REGULATION; GENETIC INTERFERENCE; MOLECULAR-CLONING; ANCHOR PROTEIN; INTACT-CELLS; KAPPA-B; D PKD; EXPRESSION	Protein kinase D (PKD) isoforms are protein kinase C (PKC) effectors in diacylglycerol (DAG)-regulated signaling pathways. Key physiological processes are placed under DAG control by the distinctive substrate specificity and intracellular distribution of PKDs. Comprehension of the roles of PKDs in homeostasis and signal transduction requires further knowledge of regulatory interplay among PKD and PKC isoforms, analysis of PKC-independent PKD activation, and characterization of functions controlled by PKDs in vivo. Caenorhabditis elegans and mammals share conserved signaling mechanisms, molecules, and pathways Thus, characterization of the C. elegans PKDs could yield insights into regulation and functions that apply to all eukaryotic PKDs. C. elegans DKF-1 (D kinase family-1) contains tandemDAGbinding (C1) modules, a PH (pleckstrin homology) domain, and a Ser/Thr protein kinase segment, which are homologous with domains in classical PKDs. DKF-1 and PKDs have similar substrate specificities. Phorbol 12- myristate 13-acetate (PMA) switches on DKF-1 catalytic activity in situ by promoting phosphorylation of a single amino acid Thr(588) in the activation loop. DKF-1 phosphorylation and activation are unaffected when PKC activity is eliminated by inhibitors. Both phosphorylation and kinase activity of DKF-1 are extinguished by substituting Ala for Thr(588) or Gln for Lys(455) ("kinase dead") or incubating with protein phosphatase 2C. Thus, DKF-1 is a PMA-activated, PKC-independent D kinase. In vivo, dkf-1 gene promoter activity is evident in neurons. Both dkf-1 gene disruption (null phenotype) and RNA interference-mediated depletion of DKF-1 protein cause lower body paralysis. Targeted DKF-1 expression corrected this locomotory defect in dkf-1 null animals. Supraphysiological expression of DKF-1 limited C. elegans growth to similar to 60% of normal length.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rubin, CS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rubin@aecom.yu.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR012596] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [R24OD010943] Funding Source: NIH RePORTER; NCRR NIH HHS [R24 RR012596] Funding Source: Medline; NIH HHS [R24 OD010943] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BLUMENTHAL T, 1997, C ELEGANS, V2, P117; Braz JC, 2004, NAT MED, V10, P248, DOI 10.1038/nm1000; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; Chen J, 2005, MOL PHARMACOL, V67, P152, DOI 10.1124/mol.104.004200; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Fay DS, 2005, SEMIN CELL DEV BIOL, V16, P397, DOI 10.1016/j.semcdb.2005.02.002; Feinberg EH, 2003, SCIENCE, V301, P1545, DOI 10.1126/science.1087117; Feng H, 2006, J BIOL CHEM, V281, P17815, DOI 10.1074/jbc.M511898200; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harbinder S, 1997, P NATL ACAD SCI USA, V94, P13128, DOI 10.1073/pnas.94.24.13128; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; He ZH, 2004, CIRCULATION, V110, P7, DOI 10.1161/01.CIR.0000133428.02295.6C; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; Hobert O, 2003, J NEUROBIOL, V54, P203, DOI 10.1002/neu.10168; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HU E, 1991, J BIOL CHEM, V266, P19796; HU ED, 1990, J BIOL CHEM, V265, P5072; Huang P, 2005, CYTOKINE GROWTH F R, V16, P151, DOI 10.1016/j.cytogfr.2005.03.002; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; IslasTrejo A, 1997, J BIOL CHEM, V272, P6629, DOI 10.1074/jbc.272.10.6629; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Koya D, 2000, FASEB J, V14, P439, DOI 10.1096/fasebj.14.3.439; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; Labouesse M, 1999, TRENDS GENET, V15, P307, DOI 10.1016/S0168-9525(99)01750-3; LAND M, 1994, J BIOL CHEM, V269, P9234; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; May RC, 2005, METHOD ENZYMOL, V392, P308, DOI 10.1016/S0076-6879(04)92018-6; McKinsey TA, 2005, J CLIN INVEST, V115, P538, DOI 10.1172/JCI200524144; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mihailovic T, 2004, CANCER RES, V64, P8939, DOI 10.1158/0008-5472.CAN-04-0981; Moerman Donald G., 1997, Cold Spring Harbor Monograph Series, V33, P417; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Nance J, 2005, BIOESSAYS, V27, P126, DOI 10.1002/bies.20175; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohki-Hamazaki H, 2005, INT J DEV BIOL, V49, P293, DOI 10.1387/ijdb.041954ho; Patterson GI, 2000, TRENDS GENET, V16, P27, DOI 10.1016/S0168-9525(99)01916-2; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Rossi EA, 1999, J BIOL CHEM, V274, P27201, DOI 10.1074/jbc.274.38.27201; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P313, DOI 10.1016/S0079-6107(98)00059-5; Spitaler M, 2004, NAT IMMUNOL, V5, P785, DOI 10.1038/ni1097; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Tobin DM, 2004, J NEUROBIOL, V61, P161, DOI 10.1002/neu.20082; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Vlahos CJ, 2003, NAT REV DRUG DISCOV, V2, P99, DOI 10.1038/nrd1009; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waterston R., 1988, NEMATODE C ELEGANS, P281; Wu SL, 1998, J BIOL CHEM, V273, P1130, DOI 10.1074/jbc.273.2.1130; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200; Zhang W, 2005, J BIOL CHEM, V280, P19036, DOI 10.1074/jbc.M414674200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	88	17	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17801	17814		10.1074/jbc.M511899200	http://dx.doi.org/10.1074/jbc.M511899200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16613841	hybrid			2022-12-25	WOS:000238490300030
J	Matsumoto, K; Kamiya, N; Suwan, K; Atsumi, F; Shimizu, K; Shinomura, T; Yamada, Y; Kimata, K; Watanabe, H				Matsumoto, Kazu; Kamiya, Nobuhiro; Suwan, Keittisak; Atsumi, Fukiko; Shimizu, Katsuji; Shinomura, Tamayuki; Yamada, Yoshihiko; Kimata, Koji; Watanabe, Hideto			Identification and characterization of versican/PG-M aggregates in cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HUMAN ARTICULAR-CARTILAGE; GROWTH-FACTOR; PG-M; PERICELLULAR MATRIX; LECTIN DOMAINS; LINK PROTEIN; LIMB BUD; IN-VIVO; AGGRECAN	Versican/PG-M is a large chondroitin sulfate proteoglycan of the extracellular matrix with a common domain structure to aggrecan and is present in cartilage at low levels. Here, we characterized cartilage versican during development and growth. Immunostaining showed that versican was mainly localized in the interterritorial zone of the articular surface at 2 weeks in mice, whereas aggrecan was in the pericellular zone of prehypertrophic and hypertrophic cells of the growth plate. Although its transcription level rapidly diminished during growth, versican remained in the articular cartilage. Biochemical analysis of normal articular cartilage and aggrecan-null cartilage from cmd (cartilage matrix deficiency)/cmd mice revealed that versican was present as a proteoglycan aggregate with both link protein and hyaluronan. Chondroitin sulfate chains of versican digested with chondroitinase ABC contained 71% nonsulfated and 28% 4-sulfated unsaturated disaccharides, whereas those of aggrecan contained 25% nonsulfated and 70% 4-sulfated. Link protein overexpression in chondrocytic N1511 cells at the early stage of differentiation, in which versican is expressed, enhanced versican deposition in the matrix and prevented subsequent aggrecan deposition. These results suggest that versican is present as an aggregate distinct from the aggrecan aggregate and may play specific roles in the articular surface.	Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; Gifu Univ, Sch Med, Dept Orthopaed Surg, Gifu 5008705, Japan; Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Tokyo 1138549, Japan; NIDCR, Craniofacial & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Aichi Medical University; Gifu University; Tokyo Medical & Dental University (TMDU); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Watanabe, H (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Karimata 21, Nagakute, Aichi 4801195, Japan.	wannabee@aichi-med-u.ac.jp		Suwan, Keittisak/0000-0001-6542-5841; Watanabe, Hideto/0000-0001-5291-0696	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000483] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Day JM, 2004, J BIOL CHEM, V279, P12511, DOI 10.1074/jbc.M400242200; Evanko SP, 2001, ARCH BIOCHEM BIOPHYS, V394, P29, DOI 10.1006/abbi.2001.2507; FALTZ LL, 1979, J BIOL CHEM, V254, P1375; GROVER J, 1993, BIOCHEM J, V291, P361, DOI 10.1042/bj2910361; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Kamiya N, 2006, J BIOL CHEM, V281, P2390, DOI 10.1074/jbc.M509341200; Kamiya N, 2002, J BONE MINER RES, V17, P1832, DOI 10.1359/jbmr.2002.17.10.1832; KIMATA K, 1986, J BIOL CHEM, V261, P3517; Kishimoto J, 1999, P NATL ACAD SCI USA, V96, P7336, DOI 10.1073/pnas.96.13.7336; KOLETTAS E, 1995, J CELL SCI, V108, P1991; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; Matsumoto K, 2003, J BIOL CHEM, V278, P41205, DOI 10.1074/jbc.M305060200; Nishida Y, 1994, Osteoarthritis Cartilage, V2, P43, DOI 10.1016/S1063-4584(05)80005-6; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Schmalfeldt M, 1998, J BIOL CHEM, V273, P15758, DOI 10.1074/jbc.273.25.15758; Shibata S, 2003, J ANAT, V203, P425, DOI 10.1046/j.1469-7580.2003.00226.x; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Sztrolovics R, 2002, J ORTHOPAED RES, V20, P257, DOI 10.1016/S0736-0266(01)00110-3; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; UJITA M, 1994, J BIOL CHEM, V269, P27603; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; YAMAGATA M, 1993, J CELL SCI, V106, P55; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x	35	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18257	18263		10.1074/jbc.M510330200	http://dx.doi.org/10.1074/jbc.M510330200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16648631	hybrid			2022-12-25	WOS:000238490300078
J	Miller, DJ; Zhang, YM; Rock, CO; White, SW				Miller, Darcie J.; Zhang, Yong-Mei; Rock, Charles O.; White, Stephen W.			Structure of RhlG, an essential beta-ketoacyl reductase in the rhamnolipid Biosynthetic pathway of Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; SIZE-DISTRIBUTION ANALYSIS; ESCHERICHIA-COLI; SWARMING MOTILITY; CYSTIC-FIBROSIS; SYNTHASE-III; ULTRACENTRIFUGATION; INHIBITION; EXPRESSION; SURFACTANT	Rhamnolipids are extracellular biosurfactants and virulence factors secreted by the opportunistic human pathogen Pseudomonas aeruginosa that are required for swarming motility. The rhlG gene is essential for rhamnolipid formation, and the RhlG enzyme is thought to divert fatty acid synthesis intermediates into the rhamnolipid biosynthetic pathway based on its similarity to FabG, the beta-ketoacyl-acyl carrier protein (ACP) reductase of type II fatty acid synthesis. Crystallographic analysis reveals that the overall structures of the RhlG . NADP(+) and FabG . NADP(+) complexes are indeed similar, but there are key differences related to function. RhlG does not undergo the conformational changes upon NADP(H) binding at the active site that in FabG are the structural basis of negative allostery. Also, the acyl chain-binding pocket of RhlG is narrow and rigid compared with the larger, flexible substrate-binding subdomain in FabG. Finally, RhlG lacks a positively charged/hydrophobic surface feature adjacent to the active site that is found on enzymes like FabG that recognize the ACP of fatty acid synthesis. RhlG catalyzed the NADPH-dependent reduction of beta-ketodecanoyl-ACP to beta-D-hydroxydecanoyl-ACP. However, the enzyme was 2000-fold less active than FabG in carrying out the same reaction. These structural and biochemical studies establish RhlG as aNADPH-dependent beta-ketoacyl reductase of the SDR protein superfamily and further suggest that the ACP of fatty acid synthesis does not carry the substrates for RhlG.	St Jude Childrens Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	White, SW (corresponding author), St Jude Childrens Hosp, Dept Biol Struct, 332 N Lauderdale St,MS 311, Memphis, TN 38105 USA.	stephen.white@stjude.org	White, Stephen W/N-8164-2018		NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Caiazza NC, 2005, J BACTERIOL, V187, P7351, DOI 10.1128/JB.187.21.7351-7361.2005; Calfee MW, 2005, INFECT IMMUN, V73, P878, DOI 10.1128/IAI.73.2.878-882.2005; Campos-Garcia J, 1998, J BACTERIOL, V180, P4442; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cosson P, 2002, J BACTERIOL, V184, P3027, DOI 10.1128/JB.184.11.3027-3033.2002; Davey ME, 2003, J BACTERIOL, V185, P1027, DOI 10.1128/JB.185.3.1027-1036.2003; Deziel E, 2000, BBA-MOL CELL BIOL L, V1485, P145, DOI 10.1016/S1388-1981(00)00039-1; Deziel E, 2003, MICROBIOL-SGM, V149, P2005, DOI 10.1099/mic.0.26154-0; Evans DJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1284, DOI 10.1152/ajpcell.1998.275.5.C1284; Evans W, 1997, CHEM BRIT, V33, P22; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; JOHNSON MK, 1980, INFECT IMMUN, V29, P1028; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kohler T, 2000, J BACTERIOL, V182, P5990, DOI 10.1128/JB.182.21.5990-5996.2000; KOWNATZKI R, 1987, LANCET, V1, P1026; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang S, 1999, APPL MICROBIOL BIOT, V51, P22, DOI 10.1007/s002530051358; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lequette Y, 2005, J BACTERIOL, V187, P37, DOI 10.1128/JB.187.1.37-44.2005; LESLIE AGW, 1997, MED RES COUNCIL LAB; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; Lyczak JB, 2002, CLIN MICROBIOL REV, V15, P194, DOI 10.1128/CMR.15.2.194-222.2002; MCCLURE CD, 1992, J LEUKOCYTE BIOL, V51, P97, DOI 10.1002/jlb.51.2.97; McClure CD, 1996, CURR MICROBIOL, V33, P109, DOI 10.1007/s002849900084; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P869; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Noordman WH, 2002, APPL ENVIRON MICROB, V68, P4502, DOI 10.1128/AEM.68.9.4502-4508.2002; OCHSNER UA, 1994, J BIOL CHEM, V269, P19787; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Price AC, 2001, BIOCHEMISTRY-US, V40, P12772, DOI 10.1021/bi010737g; Price AC, 2004, STRUCTURE, V12, P417, DOI 10.1016/j.str.2004.02.008; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAFFERTY JB, 1994, J MOL BIOL, V237, P240, DOI 10.1006/jmbi.1994.1225; Rahim R, 2001, MOL MICROBIOL, V40, P708, DOI 10.1046/j.1365-2958.2001.02420.x; Rashid MH, 2000, P NATL ACAD SCI USA, V97, P4885, DOI 10.1073/pnas.060030097; Raychaudhuri A, 2005, BIOCHEMISTRY-US, V44, P2974, DOI 10.1021/bi048005m; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P501, DOI 10.1107/S0907444998012657; ZHAN GYM, 2003, J LIPID RES, V44, P1; Zhang YM, 2003, J BIOL CHEM, V278, P52935, DOI 10.1074/jbc.M309874200; Zhang YM, 2001, J BIOL CHEM, V276, P8231, DOI 10.1074/jbc.M008042200	46	25	28	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18025	18032		10.1074/jbc.M601687200	http://dx.doi.org/10.1074/jbc.M601687200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16624803	hybrid			2022-12-25	WOS:000238490300053
J	Ding, M; Feng, RT; Wang, SY; Bowman, L; Lu, YJ; Qian, Y; Castranova, V; Jiang, BH; Shi, XL				Ding, Min; Feng, Rentian; Wang, Shiow Y.; Bowman, Linda; Lu, Yongju; Qian, Yong; Castranova, Vincent; Jiang, Bing-Hua; Shi, Xianglin			Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; FACTOR-KAPPA-B; NEOPLASTIC TRANSFORMATION; CANCER CHEMOPREVENTION; SIGNALING PATHWAYS; ANTHOCYANIN-RICH; MAP KINASES; INHIBITION; CYCLOOXYGENASE-2; TUMORIGENESIS	Epidemiological data suggest that consumption of fruits and vegetables has been associated with a lower incidence of cancer. Cyanidin-3- glucoside (C3G), a compound found in blackberry and other food products, was shown to possess chemopreventive and chemotherapeutic activity in the present study. In cultured JB6 cells, C3G was able to scavenge ultraviolet B-induced (OH)-O-center dot and O-2(center dot). radicals. In vivo studies indicated that C3G treatment decreased the number of non-malignant and malignant skin tumors per mouse induced by 12-O-tetradecanolyphorbol-13-acetate (TPA) in 7,12-dimethylbenz[a] anthracene-initiated mouse skin. Pretreatment of JB6 cells with C3G inhibited UVB- and TPA-induced transactivation of NF-kappa B and AP-1 and expression of cyclooxygenase-2 and tumor necrosis factor-alpha. These inhibitory effects appear to be mediated through the inhibition of MAPK activity. C3G also blocked TPAinduced neoplastic transformation in JB6 cells. In addition, C3G inhibited proliferation of a human lung carcinoma cell line, A549. Animal studies showed that C3G reduced the size of A549 tumor xenograft growth and significantly inhibited metastasis in nude mice. Mechanistic studies indicated that C3G inhibited migration and invasion of A549 tumor cells. These finding demonstrate for the first time that a purified compound of anthocyanin inhibits tumor promoter- induced carcinogenesis and tumor metastasis in vivo.	NIOSH, Pathol & Physiol Res Branch, Hlth Effect Lab Div, Morgantown, WV 26505 USA; USDA, Beltsville Agr Res Ctr, Fruit Lab, Beltsville, MD 20705 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); United States Department of Agriculture (USDA); West Virginia University	Ding, M (corresponding author), NIOSH, Pathol & Physiol Res Branch, Hlth Effect Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.	mid5@cdc.gov	Shi, Xianglin/B-8588-2012	Jiang, Bing-Hua/0000-0003-4526-2031				Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; Afaq F, 2003, ONCOGENE, V22, P9254, DOI 10.1038/sj.onc.1207035; Afaq F, 2005, INT J CANCER, V113, P423, DOI 10.1002/ijc.20587; Aggarwal BB, 2003, ANTICANCER RES, V23, P363; [Anonymous], 1996, CA Cancer J Clin, V46, P325; Bagchi D, 2004, BIOCHEMISTRY-MOSCOW+, V69, P75, DOI 10.1023/B:BIRY.0000016355.19999.93; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Castonguay A, 1997, CARCINOGENESIS, V18, P491, DOI 10.1093/carcin/18.3.491; Chen T, 2006, CANCER RES, V66, P2853, DOI 10.1158/0008-5472.CAN-05-3279; Chung TW, 2004, FASEB J, V18, P1670, DOI 10.1096/fj.04-2126com; Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; Ding M, 2004, J BIOL CHEM, V279, P10670, DOI 10.1074/jbc.M311465200; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Gupta S, 2001, SKIN PHARMACOL APPL, V14, P373, DOI 10.1159/000056371; Hou DX, 2004, CARCINOGENESIS, V25, P29, DOI 10.1093/carcin/bgg184; Hou DX, 2003, CURR MOL MED, V3, P149, DOI 10.2174/1566524033361555; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KUNDU JK, 2004, MUTAT RES, V2, P555; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Li JJ, 1997, CANCER RES, V57, P3569; Lochter A, 1999, APMIS, V107, P128, DOI 10.1111/j.1699-0463.1999.tb01535.x; Lu YP, 2002, P NATL ACAD SCI USA, V99, P12455, DOI 10.1073/pnas.182429899; Ma Q, 2003, MOL PHARMACOL, V64, P211, DOI 10.1124/mol.64.2.211; Marrogi AJ, 2000, CLIN CANCER RES, V6, P4739; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; NAITO M, 1988, CARCINOGENESIS, V9, P639, DOI 10.1093/carcin/9.4.639; Nishino H, 2005, ONCOLOGY-BASEL, V69, P38, DOI 10.1159/000086631; Paik J, 2002, ADV EXP MED BIOL, V507, P503; Qian Y, 2003, J BIOL CHEM, V278, P16189, DOI 10.1074/jbc.M207517200; REDDY BS, 1987, CANCER RES, V47, P5340; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Rigas B, 2005, J PHARMACOL EXP THER, V314, P1, DOI 10.1124/jpet.104.080564; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Seifried HE, 2003, CANCER RES, V63, P4295; Singh B, 2005, INT J ONCOL, V26, P1393; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; SPANO IP, 2004, B CANC, V91, P109; Sturm MW, 2003, INT J CANCER, V107, P11, DOI 10.1002/ijc.11320; Subbaramaiah K, 2002, CANCER RES, V62, P2522; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Weidner Noel, 1996, P167; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zheng W, 2003, J AGR FOOD CHEM, V51, P502, DOI 10.1021/jf020728u	54	231	245	4	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17359	17368		10.1074/jbc.M600861200	http://dx.doi.org/10.1074/jbc.M600861200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16618699	Green Submitted, hybrid			2022-12-25	WOS:000238326300062
J	Lin, S; Perl, AKT; Shannon, JM				Lin, Sui; Perl, Anne-Karina T.; Shannon, John M.			Erm/thyroid transcription factor 1 interactions modulate surfactant protein C transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; EMBRYONIC TRACHEAL EPITHELIUM; II CELL-DIFFERENTIATION; MESENCHYME-FREE CULTURE; HUMAN T-CELLS; GENE-EXPRESSION; ETS-DOMAIN; LUNG MORPHOGENESIS; TRANSGENIC MICE; FUNCTIONAL INTERACTION	Expression of surfactant protein C (SP-C), which is restricted to alveolar type II epithelial cells of the adult lung, is critically dependent on thyroid transcription factor 1 (TTF-1). In the present study we have demonstrated that Erm, a member of the Ets family of transcription factors, is expressed in the distal lung epithelium during development and is also restricted to alveolar type II cells in the adult. Erm was up-regulated by fibroblast growth factors (FGFs) in culture, and blocking FGF signaling inhibited Erm expression both in vivo and in vitro. The SP-C minimal promoter was found to contain two potential Ets binding sites, and electrophoretic mobility shift assays showed that two 20-bp wild-type oligonucleotides containing the 5'-GGA(A/T)-3' Ets consensus binding motif were shifted by nuclear extracts from MLE15 cells. Co-transfection assays showed that Erm by itself had little effect on SP-C promoter activity but that Erm significantly enhanced TTF-1-mediated SP-C transcription. Mutation of one of the Ets binding sites reduced SP-C transcription to background levels, whereas mutation of the other site resulted in increased SP-C transcription. Protein-protein interactions between Erm and TTF-1 were demonstrated by mammalian two-hybrid assays and by co-immunoprecipitation assays. Mapping studies showed that the Ets domain of Erm and the combined N terminus and homeodomain of TTF-1 were critical for this interaction. Treatment of primary cultures of adult alveolar type II cells with siRNA targeting Erm diminished expression of both Erm and SP-C but had no effect on beta-actin or GAPDH (glyceraldehyde-3-phosphate dehydrogenase). Taken together, these results demonstrate that Erm is involved in SP-C regulation, which results from an interaction with TTF-1.	Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Shannon, JM (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	john.shannon@cchmc.org	Perl, Anne-Karina T/M-7174-2013	Perl, Anne-Karina T/0000-0002-8445-4565	NHLBI NIH HHS [HL 071898, HL 56387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071898, P01HL056387, P50HL056387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bachurski CJ, 2003, MOL CELL BIOL, V23, P9014, DOI 10.1128/MCB.23.24.9014-9024.2003; Bachurski CJ, 1997, J BIOL CHEM, V272, P32759, DOI 10.1074/jbc.272.52.32759; Baert JL, 2002, J BIOL CHEM, V277, P1002, DOI 10.1074/jbc.M107139200; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; Cardoso WV, 1997, DEV DYNAM, V208, P398, DOI 10.1002/(SICI)1097-0177(199703)208:3<398::AID-AJA10>3.0.CO;2-X; Chotteau-Lelievre A, 2003, DEV BIOL, V259, P241, DOI 10.1016/S0012-1606(03)00182-9; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; Deterding RR, 1996, AM J PHYSIOL-LUNG C, V271, pL495, DOI 10.1152/ajplung.1996.271.4.L495; DETERDING RR, 1995, J CLIN INVEST, V95, P2963, DOI 10.1172/JCI118004; Firnberg N, 2002, DEV BIOL, V247, P237, DOI 10.1006/dbio.2002.0696; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; Glasser SW, 2000, AM J PHYSIOL-LUNG C, V278, pL933, DOI 10.1152/ajplung.2000.278.5.L933; Hokuto I, 2003, J BIOL CHEM, V278, P415, DOI 10.1074/jbc.M208328200; Holzinger A, 1996, HYBRIDOMA, V15, P49, DOI 10.1089/hyb.1996.15.49; Hyatt BA, 2002, DEV DYNAM, V225, P153, DOI 10.1002/dvdy.10145; Janknecht R, 1996, ONCOGENE, V13, P1745; KALINA M, 1992, AM J RESPIR CELL MOL, V6, P595; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kurpios NA, 2003, J MAMMARY GLAND BIOL, V8, P177, DOI 10.1023/A:1025948823955; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lin S, 2002, CHEST, V121, p80S, DOI 10.1378/chest.121.3_suppl.80S-a; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Liu YR, 2003, DEV BIOL, V261, P10, DOI 10.1016/S0012-1606(03)00359-2; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MASON RJ, 1997, LUNG SCI FDN, P543; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; Naltner A, 2000, J BIOL CHEM, V275, P56, DOI 10.1074/jbc.275.1.56; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200; Perl AKT, 2003, DEV BIOL, V258, P154, DOI 10.1016/S0012-1606(03)00106-4; Raible F, 2001, MECH DEVELOP, V107, P105, DOI 10.1016/S0925-4773(01)00456-7; Rameil P, 2000, ONCOGENE, V19, P2086, DOI 10.1038/sj.onc.1203542; Rice WR, 2002, AM J PHYSIOL-LUNG C, V283, pL256, DOI 10.1152/ajplung.00302.2001; Roehl H, 2001, CURR BIOL, V11, P503, DOI 10.1016/S0960-9822(01)00143-9; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Shannon JM, 1998, DEV DYNAM, V212, P482, DOI 10.1002/(SICI)1097-0177(199808)212:4<482::AID-AJA2>3.0.CO;2-D; SHANNON JM, 1987, BIOCHIM BIOPHYS ACTA, V931, P143, DOI 10.1016/0167-4889(87)90200-X; Shannon JM, 1999, DEVELOPMENT, V126, P1675; SHANNON JM, 1994, DEV BIOL, V166, P600, DOI 10.1006/dbio.1994.1340; SHANNON JM, 1996, J JPN MED SOC BIOL, V26, P47; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; TADERERA JV, 1967, DEV BIOL, V16, P489, DOI 10.1016/0012-1606(67)90061-9; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Wilkinson DG., 1992, SITU HYBRIDIZATION P, P75; Williams MC, 2003, ANNU REV PHYSIOL, V65, P669, DOI 10.1146/annurev.physiol.65.092101.142446; Zhang LQ, 1997, BBA-GENE STRUCT EXPR, V1350, P359, DOI 10.1016/S0167-4781(96)00180-7	55	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16716	16726		10.1074/jbc.M602221200	http://dx.doi.org/10.1074/jbc.M602221200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16613858	hybrid			2022-12-25	WOS:000238165700066
J	Shinozaki, F; Minami, M; Chiba, T; Suzuki, M; Yoshimatsu, K; Ichikawa, Y; Terasawa, K; Emori, Y; Matsumoto, K; Kurosaki, T; Nakai, A; Tanaka, K; Minami, Y				Shinozaki, Fumika; Minami, Michiko; Chiba, Tomoki; Suzuki, Miho; Yoshimatsu, Katsuhiko; Ichikawa, Yoshimasa; Terasawa, Kazuya; Emori, Yasufumi; Matsumoto, Ken; Kurosaki, Tomohiro; Nakai, Akira; Tanaka, Keiji; Minami, Yasufumi			Depletion of Hsp90 beta induces multiple defects in B cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; SHOCK TRANSCRIPTIONAL RESPONSE; NEWLY SYNTHESIZED PROTEINS; JUN NH2-TERMINAL KINASE; IN-VIVO FUNCTION; HEAT-SHOCK; ANTIGEN RECEPTOR; MOLECULAR CHAPERONES; MESSENGER-RNA; MORPHOLOGICAL EVOLUTION	Hsp90 participates in many distinct aspects of cellular functions and accomplishes these roles by interacting with multiple client proteins. To gain insight into the interactions between Hsp90 and its clients, here we have reduced the protein level of Hsp90 in avian cells by gene targeting in an attempt to elicit the otherwise undetectable ( because of the vast amount of cellular Hsp90) Hsp90-interacting proteins. Hsp90 beta-deficient cells can grow, albeit more slowly than wild-type cells. B cell antigen receptor signaling is multiply impaired in these mutant cells; in particular, the amount of immunoglobulin M heavy chain protein is markedly reduced. Furthermore, serum activation does not promote ERK phosphorylation in Hsp90 beta-deficient cells. These multifaceted depressive effects seem to be provoked independently of each other and possibly recapitulate the proteome- wide in vivo functions of Hsp90. Reintroduction of the Hsp90 beta gene efficiently restores all of the defects. Unexpectedly, however, introducing the Hsp90 beta gene is also effective in restoration; thus, these defects might be caused by a reduction in the total expression of Hsp90 rather than by loss of Hsp90 beta-specific function.	Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Sci, Undergrad Program Bioinformat & Syst Biol, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Gakugei Univ, Fac Educ, Dept Nat & Environm Sci, Tokyo 1848501, Japan; Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Core Technol & Res Ctr, Bunkyo Ku, Tokyo 1138613, Japan; RIKEN, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Lymphocyte Differentiat, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Yamaguchi Univ, Sch Med, Dept Biochem & Mol Biol, Ube, Yamaguchi 7758505, Japan	University of Tokyo; University of Tokyo; Tokyo Gakugei University; University of Tokyo; Tokyo Metropolitan Institute of Medical Science; RIKEN; RIKEN; Yamaguchi University	Minami, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	yminami@biochem.s.u-tokyo.ac.jp	Matsumoto, Ken/F-9083-2013; Kurosaki, Tomohiro/D-1306-2009	Matsumoto, Ken/0000-0002-7864-3394; Kurosaki, Tomohiro/0000-0002-6352-304X				Birnby DA, 2000, GENETICS, V155, P85; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Deuerling E, 2004, CRIT REV BIOCHEM MOL, V39, P261, DOI 10.1080/10409230490892496; Evdokimova V, 2006, MOL CELL BIOL, V26, P277, DOI 10.1128/MCB.26.1.277-292.2006; Foy SP, 2001, IMMUNOL LETT, V78, P149, DOI 10.1016/S0165-2478(01)00256-5; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; GRUPP SA, 1995, J EXP MED, V181, P161, DOI 10.1084/jem.181.1.161; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Hendriks RW, 2004, TRENDS IMMUNOL, V25, P249, DOI 10.1016/j.it.2004.02.011; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kawazoe Y, 1999, EUR J BIOCHEM, V265, P688, DOI 10.1046/j.1432-1327.1999.00762.x; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lele Z, 1999, DEV BIOL, V210, P56, DOI 10.1006/dbio.1999.9262; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002; Matsumoto K, 2005, MOL CELL BIOL, V25, P1779, DOI 10.1128/MCB.25.5.1779-1792.2005; MATSUUCHI L, 1992, P NATL ACAD SCI USA, V89, P3404, DOI 10.1073/pnas.89.8.3404; Matsuuchi L, 2001, CURR OPIN IMMUNOL, V13, P270, DOI 10.1016/S0952-7915(00)00215-6; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; MENG X, 1995, BIOCHEM BIOPH RES CO, V206, P644, DOI 10.1006/bbrc.1995.1091; MENG X, 1993, BIOCHEM BIOPH RES CO, V190, P630, DOI 10.1006/bbrc.1993.1095; Millson SH, 2005, EUKARYOT CELL, V4, P849, DOI 10.1128/EC.4.5.849-860.2005; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pike KA, 2004, J IMMUNOL, V172, P2210, DOI 10.4049/jimmunol.172.4.2210; Pike KA, 2002, SEMIN IMMUNOL, V14, P351, DOI 10.1016/S1044-5323(02)00068-4; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Tanabe M, 1998, EMBO J, V17, P1750, DOI 10.1093/emboj/17.6.1750; Terasawa K, 2005, FEBS J, V272, P4684, DOI 10.1111/j.1742-4658.2005.04884.x; Terasawa K, 2005, J BIOCHEM, V137, P443, DOI 10.1093/jb/mvi056; Tirosh B, 2005, J EXP MED, V202, P505, DOI 10.1084/jem.20050575; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; Voss AK, 2000, DEVELOPMENT, V127, P1; Wettey FR, 2002, SCIENCE, V297, P1521, DOI 10.1126/science.1074222; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Yue L, 1999, GENETICS, V151, P1065; Zeng SX, 2003, J BIOL CHEM, V278, P7453, DOI 10.1074/jbc.M209030200; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024	71	20	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16361	16369		10.1074/jbc.M600891200	http://dx.doi.org/10.1074/jbc.M600891200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16617057	hybrid			2022-12-25	WOS:000238165700024
J	Kuhn, JH; Radoshitzky, SR; Guth, AC; Warfield, KL; Li, WH; Vincent, MJ; Towner, JS; Nichol, ST; Bavari, S; Choe, H; Aman, MJ; Farzan, M				Kuhn, Jens H.; Radoshitzky, Sheli R.; Guth, Alexander C.; Warfield, Kelly L.; Li, Wenhui; Vincent, Martin J.; Towner, Jonathan S.; Nichol, Stuart T.; Bavari, Sina; Choe, Hyeryun; Aman, M. Javad; Farzan, Michael			Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN CORONAVIRUS NL63; DC-SIGN; SPIKE PROTEIN; ENVELOPE GLYCOPROTEINS; TYROSINE SULFATION; SARS CORONAVIRUS; MEMBRANE-FUSION; SURFACE PROTEIN; S-PROTEIN	The GP(1,2) envelope glycoproteins (GP) of filoviruses (marburg- and ebolaviruses) mediate cell-surface attachment, membrane fusion, and entry into permissive cells. Here we show that a 151-amino acid fragment of the Lake Victoria marburgvirus GP1 subunit bound filovirus-permissive cell lines more efficiently than full-length GP1. An homologous 148-amino acid fragment of the Zaire ebolavirus GP1 subunit similarly bound the same cell lines more efficiently than a series of longer GP1 truncation variants. Neither the marburgvirus GP1 fragment nor that of ebolavirus bound a nonpermissive lymphocyte cell line. Both fragments specifically inhibited replication of infectious Zaire ebolavirus, as well as entry of retroviruses pseudotyped with either Lake Victoria marburgvirus or Zaire ebolavirus GP(1,2). These studies identify the receptor-binding domains of both viruses, indicate that these viruses utilize a common receptor, and suggest that a single small molecule or vaccine can be developed to inhibit infection of all filoviruses.	Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Dept Microbiol & Mol Genet, Southborough, MA 01772 USA; Free Univ Berlin, Dept Biol, D-14195 Berlin, Germany; USA, Med Res Inst Infect Dis, Frederick, MD 21702 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Special Pathogens Branch, Atlanta, GA 30332 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Pediat, Boston, MA 02115 USA	Harvard University; Free University of Berlin; Centers for Disease Control & Prevention - USA; Harvard University; Boston Children's Hospital; Harvard Medical School	Farzan, M (corresponding author), Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Dept Microbiol & Mol Genet, 1 Pine Hill Dr, Southborough, MA 01772 USA.	farzan@hms.harvard.edu	Radoshitzky, Sheli S/F-2766-2019; Towner, Jonathan/ABC-3780-2020; Radoshitzky, Sheli/L-8410-2019; Kuhn, Jens H./B-7615-2011; Bavari, Sina/L-3642-2019	Radoshitzky, Sheli/0000-0001-8976-8056; Kuhn, Jens H./0000-0002-7800-6045; Bavari, Sina/0000-0001-8424-5635; Farzan, Michael/0000-0002-2990-5319; Li, Wenhui/0000-0003-1305-7404	NIAID NIH HHS [AI057159] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057159] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 2005, SURVEYOFCLUSTERINGAL, V16, DOI [DOI 10.1086/503836, 10.1109/TNN.2005, DOI 10.1109/TNN.2005]; Baribaud Frederic, 2002, Expert Opin Ther Targets, V6, P423, DOI 10.1517/14728222.6.4.423; Barnett AL, 2003, J VIROL, V77, P2717, DOI 10.1128/JVI.77.4.2717-2729.2003; BECKER S, 1995, J GEN VIROL, V76, P393, DOI 10.1099/0022-1317-76-2-393; Becker S, 1996, VIROLOGY, V225, P145, DOI 10.1006/viro.1996.0582; Chan SY, 2000, J VIROL, V74, P4933, DOI 10.1128/JVI.74.10.4933-4937.2000; Chan SY, 2001, CELL, V106, P117, DOI 10.1016/S0092-8674(01)00418-4; Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656; Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7; Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Fass D, 1997, SCIENCE, V277, P1662, DOI 10.1126/science.277.5332.1662; Feldmann H, 2001, J GEN VIROL, V82, P2839, DOI 10.1099/0022-1317-82-12-2839; Gallaher WR, 1996, CELL, V85, P477, DOI 10.1016/S0092-8674(00)81248-9; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geisbert TW, 1995, VIRUS RES, V39, P129, DOI 10.1016/0168-1702(95)00080-1; Gramberg T, 2005, VIROLOGY, V340, P224, DOI 10.1016/j.virol.2005.06.026; He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908; Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102; Hovette P, 2005, Med Trop (Mars), V65, P127; Huang IC, 2006, J BIOL CHEM, V281, P3198, DOI 10.1074/jbc.M508381200; Ito H, 1999, J VIROL, V73, P8907, DOI 10.1128/JVI.73.10.8907-8912.1999; Jeffers SA, 2002, J VIROL, V76, P12463, DOI 10.1128/JVI.76.24.12463-12472.2002; Kolesnikova L, 2004, J VIROL, V78, P12277, DOI 10.1128/JVI.78.22.12277-12287.2004; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Lin G, 2003, J VIROL, V77, P1337, DOI 10.1128/JVI.77.2.1337-1346.2003; Manicassamy B, 2005, J VIROL, V79, P4793, DOI 10.1128/JVI.79.8.4793-4805.2005; MARIYANKOVA RF, 1993, VOP VIRUSOL+, V38, P74; Marzi A, 2004, J VIROL, V78, P12090, DOI 10.1128/JVI.78.21.12090-12095.2004; Medina MF, 2003, MOL THER, V8, P777, DOI 10.1016/S1525-0016(03)00266-1; Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004; Ohshiro Y, 1996, MICROBIOL IMMUNOL, V40, P827, DOI 10.1111/j.1348-0421.1996.tb01148.x; Pringle CR, 1997, SEMIN VIROL, V8, P49, DOI 10.1006/smvy.1997.0105; Ruiz-Arguello MB, 1998, J VIROL, V72, P1775; Ryabchikova E, 2004, EBOLA AND MARBURG VIRUSES: MOLECULAR AND CELLULAR BIOLOGY, P239; SANCHEZ A, 1993, VIRUS RES, V29, P215, DOI 10.1016/0168-1702(93)90063-S; Sanchez A, 1998, J VIROL, V72, P6442, DOI 10.1128/JVI.72.8.6442-6447.1998; Schornberg K, 2006, J VIROL, V80, P4174, DOI 10.1128/JVI.80.8.4174-4178.2006; Simmons G, 2003, J VIROL, V77, P13433, DOI 10.1128/JVI.77.24.13433-13438.2003; Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730; Simmons G, 2002, J VIROL, V76, P2518, DOI 10.1128/JVI.76.5.2518-2528.2002; Takada A, 2004, J VIROL, V78, P2943, DOI 10.1128/JVI.78.6.2943-2947.2004; Takada A, 2000, VIROLOGY, V278, P20, DOI 10.1006/viro.2000.0601; Takada A, 1997, P NATL ACAD SCI USA, V94, P14764, DOI 10.1073/pnas.94.26.14764; Towner JS, 2005, VIROLOGY, V332, P20, DOI 10.1016/j.virol.2004.10.048; TOWNER JS, 2006, IN PRESS J VIROL; Volchkov VE, 2000, VIROLOGY, V268, P1, DOI 10.1006/viro.1999.0110; Volchkov VE, 2004, EBOLA AND MARBURG VIRUSES: MOLECULAR AND CELLULAR BIOLOGY, P59; Volchkov VE, 1998, P NATL ACAD SCI USA, V95, P5762, DOI 10.1073/pnas.95.10.5762; Watanabe S, 2000, J VIROL, V74, P10194, DOI 10.1128/JVI.74.21.10194-10201.2000; WHO, 2005, WKLY EPIDEMIOL REC, V80, P298; Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200; Wool-Lewis RJ, 1998, J VIROL, V72, P3155, DOI 10.1128/JVI.72.4.3155-3160.1998; Yang ZY, 2000, NAT MED, V6, P886, DOI 10.1038/78654	56	104	113	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15951	15958		10.1074/jbc.M601796200	http://dx.doi.org/10.1074/jbc.M601796200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595665	hybrid			2022-12-25	WOS:000237996000046
J	Levenson, JM; Roth, TL; Lubin, FD; Miller, CA; Huang, IC; Desai, P; Malone, LM; Sweatt, JD				Levenson, Jonathan M.; Roth, Tania L.; Lubin, Farah D.; Miller, Courtney A.; Huang, I. -Chia; Desai, Priyanka; Malone, Lauren M.; Sweatt, J. David			Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; ERK MAP KINASE; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSOR; QUANTITATIVE PCR; MEMORY FORMATION; GENE-EXPRESSION; METHYLATION; BINDING; MECP2	DNA (cytosine-5) methylation represents one of the most widely used mechanisms of enduring cellular memory. Stable patterns of DNA methylation are established during development, resulting in creation of persisting cellular phenotypes. There is growing evidence that the nervous system has co-opted a number of cellular mechanisms used during development to subserve the formation of long term memory. In this study, we examined the role DNA (cytosine-5) methyltransferase (DNMT) activity might play in regulating the induction of synaptic plasticity. We found that the DNA within promoters for reelin and brain-derived neurotrophic factor, genes implicated in the induction of synaptic plasticity in the adult hippocampus, exhibited rapid and dramatic changes in cytosine methylation when DNMT activity was inhibited. Moreover, zebularine and 5-aza-2-deoxycytidine, inhibitors of DNMT activity, blocked the induction of long term potentiation at Schaffer collateral synapses. Activation of protein kinase C in the hippocampus decreased reelin promoter methylation and increased DNMT3A gene expression. Interestingly, DNMT activity is required for protein kinase C-induced increases in histone H3 acetylation. Considered together, these results suggest that DNMT activity is dynamically regulated in the adult nervous system and that DNMT may play a role in regulating the induction of synaptic plasticity in the mature CNS.	Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA	Baylor College of Medicine	Sweatt, JD (corresponding author), Univ Alabama, Dept Neurobiol, SHEL 1010,1530 3rd Ave S, Birmingham, AL 35294 USA.	dsweatt@nrc.uab.edu	feng, jian/G-9313-2011; Miller, Courtney A/E-8651-2010	Miller, Courtney A/0000-0001-8628-4902; Sweatt, J. David/0000-0003-3567-485X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057014] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57014] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abel T, 1998, BRAIN RES REV, V26, P360, DOI 10.1016/S0165-0173(97)00050-7; Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401; Alarcon JM, 2004, NEURON, V42, P947, DOI 10.1016/j.neuron.2004.05.021; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; Beffert U, 2005, NEURON, V47, P567, DOI 10.1016/j.neuron.2005.07.007; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; Brooks PJ, 1996, J NEUROSCI, V16, P939; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; de Ortiz SP, 2003, NEUROREPORT, V14, P1141, DOI 10.1097/01.wnr.00000.74771.23712.4f; de Ortiz SP, 2001, J NEUROSCI RES, V63, P72; Deng C, 1998, BIOL CHEM, V379, P1113, DOI 10.1515/bchm.1998.379.8-9.1113; Deng J, 1999, MOL BRAIN RES, V71, P23, DOI 10.1016/S0169-328X(99)00147-3; Doerfler W, 2005, BIOCHEMISTRY-MOSCOW+, V70, P505, DOI 10.1007/s10541-005-0145-9; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Endres M, 2001, NEUROREPORT, V12, P3763, DOI 10.1097/00001756-200112040-00032; Endres M, 2000, J NEUROSCI, V20, P3175, DOI 10.1523/JNEUROSCI.20-09-03175.2000; Fan GP, 2001, J NEUROSCI, V21, P788, DOI 10.1523/JNEUROSCI.21-03-00788.2001; Feng J, 2005, J NEUROSCI RES, V79, P734, DOI 10.1002/jnr.20404; GOTO K, 1994, DIFFERENTIATION, V56, P39, DOI 10.1046/j.1432-0436.1994.56120039.x; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; Impagnatiello F, 1998, P NATL ACAD SCI USA, V95, P15718, DOI 10.1073/pnas.95.26.15718; Inano K, 2000, J BIOCHEM-TOKYO, V128, P315, DOI 10.1093/oxfordjournals.jbchem.a022755; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Korzus E, 2004, NEURON, V42, P961, DOI 10.1016/j.neuron.2004.06.002; Levenson JM, 2005, NAT REV NEUROSCI, V6, P108, DOI 10.1038/nrn1604; Levenson JM, 2004, J BIOL CHEM, V279, P40545, DOI 10.1074/jbc.M402229200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOVINGER DM, 1987, BRAIN RES, V436, P177, DOI 10.1016/0006-8993(87)91573-3; LOVINGER DM, 1986, BRAIN RES, V399, P205, DOI 10.1016/0006-8993(86)91510-6; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; Mitchell CP, 2005, J NEUROCHEM, V93, P483, DOI 10.1111/j.1471-4159.2005.03040.x; MONK M, 1987, DEVELOPMENT, V99, P371; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pittenger C, 1998, CR ACAD SCI III-VIE, V321, P91, DOI 10.1016/S0764-4469(97)89807-1; Pruitt K, 2005, J BIOL CHEM, V280, P23363, DOI 10.1074/jbc.M503083200; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Salozhin SV, 2005, BIOCHEMISTRY-MOSCOW+, V70, P525, DOI 10.1007/s10541-005-0146-8; Selcher JC, 2003, LEARN MEMORY, V10, P26, DOI 10.1101/lm.51103; Selcher JC, 2002, NEUROSCIENTIST, V8, P122, DOI 10.1177/107385840200800208; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P1255, DOI 10.1093/nar/18.5.1255; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1991, J BIOL CHEM, V266, P10027; Veldic M, 2004, P NATL ACAD SCI USA, V101, P348, DOI 10.1073/pnas.2637013100; Wang JP, 2003, LEARN MEMORY, V10, P503, DOI 10.1101/lm.63003; Weeber EJ, 2002, J BIOL CHEM, V277, P39944, DOI 10.1074/jbc.M205147200; Wood MA, 2005, LEARN MEMORY, V12, P111, DOI 10.1101/lm.86605; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	59	457	480	0	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15763	15773		10.1074/jbc.M511767200	http://dx.doi.org/10.1074/jbc.M511767200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16606618	hybrid			2022-12-25	WOS:000237996000024
J	Li, LY; Shin, OH; Rhee, JS; Arac, D; Rah, JC; Rizo, J; Sudhof, T; Rosenmund, C				Li, Liyi; Shin, Ok-Ho; Rhee, Jeong-Seop; Arac, Demet; Rah, Jong-Cheol; Rizo, Josep; Sudhof, Thomas; Rosenmund, Christian			Phosphatidylinositol phosphates as co-activators of Ca2+ binding to C-2 domains of synaptotagmin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HIPPOCAMPAL-NEURONS; PROTEIN-KINASE-C; C2B DOMAIN; NEUROTRANSMITTER RELEASE; SYNAPTIC-TRANSMISSION; PHOSPHOLIPID-BINDING; TRANSMITTER RELEASE; MUTATIONAL ANALYSIS; AUTONOMOUS FUNCTION; CALCIUM SENSOR	Ca2+-dependent phospholipid binding to the C(2)A and C2B domains of synaptotagmin 1 is thought to trigger fast neurotransmitter release, but only Ca2+ binding to the C2B domain is essential for release. To investigate the underlying mechanism, we have compared the role of basic residues in Ca2+/phospholipid binding and in release. Mutations in a polybasic sequence on the side of the C2B domain beta-sandwich or in a basic residue in a top Ca2+-binding loop of the C(2)A domain (R233) cause comparable decreases in the apparent Ca2+ affinity of synaptotagmin 1 and the Ca2+ sensitivity of release, whereas mutation of the residue homologous to Arg(233) in the C2B domain (Lys(366)) has no effect. Phosphatidylinositol polyphosphates co-activate Ca2+-dependent and -independent phospholipid binding to synaptotagmin 1, but the effects of these mutations on release only correlate with their effects on the Ca2+-dependent component. These results reveal clear distinctions in the Ca2+-dependent phospholipid binding modes of the synaptotagmin 1 C-2 domains that may underlie their functional asymmetry and suggest that phosphatidylinositol polyphosphates may serve as physiological modulators of Ca2+ affinity of synaptotagmin 1 in vivo.	Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Dept Human Mol Genet, Houston, TX 77030 USA; Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany; Univ Texas, SW Med Ctr Dallas, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA	Baylor College of Medicine; Baylor College of Medicine; Max Planck Society; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rosenmund, C (corresponding author), Baylor Coll Med, Dept Neurosci, 1 Baylor Plaza,Rm 833E, Houston, TX 77030 USA.	rosenmun@bcm.tmc.edu	Rosenmund, Christian/AAC-3596-2020; li, li/AAT-2097-2020; li, li/GPX-3938-2022; LI, LI QING/GRR-8855-2022; LI, LI/GVS-5344-2022; Li, Li/AEM-3636-2022	Rosenmund, Christian/0000-0002-3905-2444; Rah, Jong-Cheol/0000-0003-3780-0522	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040944, R01NS050655] Funding Source: NIH RePORTER; NINDS NIH HHS [NS40944, NS50655] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arac D, 2006, NAT STRUCT MOL BIOL, V13, P209, DOI 10.1038/nsmb1056; Ashery U, 1999, EUR J CELL BIOL, V78, P525, DOI 10.1016/S0171-9335(99)80017-X; Atlas D, 2001, CELL MOL NEUROBIOL, V21, P717, DOI 10.1023/A:1015104105262; Bai JH, 2003, METHOD ENZYMOL, V360, P238; Bai JH, 2004, NAT STRUCT MOL BIOL, V11, P36, DOI 10.1038/nsmb709; BENFENATI F, 1989, J CELL BIOL, V108, P1851, DOI 10.1083/jcb.108.5.1851; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Catherine CR, 2005, MOL CELL NEUROSCI, V29, P462, DOI 10.1016/j.mcn.2005.03.015; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; DEUTSCH JW, 1981, BIOCHEMISTRY-US, V20, P378, DOI 10.1021/bi00505a024; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fernandez-Chacon R, 2002, J NEUROSCI, V22, P8438; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Han WP, 2004, NEURON, V41, P85, DOI 10.1016/S0896-6273(03)00820-1; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Mackler JM, 2001, J COMP NEUROL, V436, P4, DOI 10.1002/cne.1049; Maximov A, 2005, NEURON, V48, P547, DOI 10.1016/j.neuron.2005.09.006; Mehrotra B, 2000, BIOCHEMISTRY-US, V39, P9679, DOI 10.1021/bi000487o; Nishiki T, 2004, J NEUROSCI, V24, P6127, DOI 10.1523/JNEUROSCI.1563-04.2004; Nishiki T, 2004, J NEUROSCI, V24, P8542, DOI 10.1523/JNEUROSCI.2545-04.2004; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Pyott SJ, 2002, J PHYSIOL-LONDON, V539, P523, DOI 10.1113/jphysiol.2001.013277; Rhee JS, 2005, P NATL ACAD SCI USA, V102, P18664, DOI 10.1073/pnas.0509153102; Rickman C, 2004, J BIOL CHEM, V279, P12574, DOI 10.1074/jbc.M310710200; Robinson IM, 2002, NATURE, V418, P336, DOI 10.1038/nature00915; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Seagar M, 1998, J BIOENERG BIOMEMBR, V30, P347, DOI 10.1023/A:1021937605818; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; Shin OH, 2003, NEURON, V37, P99, DOI 10.1016/S0896-6273(02)01145-5; Shin OH, 2002, NAT NEUROSCI, V5, P649, DOI 10.1038/nn869; Stevens CF, 2003, NEURON, V39, P299, DOI 10.1016/S0896-6273(03)00432-X; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Ubach J, 2001, BIOCHEMISTRY-US, V40, P5854, DOI 10.1021/bi010340c; Wenk MR, 2003, NAT BIOTECHNOL, V21, P813, DOI 10.1038/nbt837; Wu Y, 2003, P NATL ACAD SCI USA, V100, P2082, DOI 10.1073/pnas.0435872100; Yoshihara M, 2002, NEURON, V36, P897, DOI 10.1016/S0896-6273(02)01065-6; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zhang XY, 1998, BIOCHEMISTRY-US, V37, P12395, DOI 10.1021/bi9807512	55	89	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15845	15852		10.1074/jbc.M600888200	http://dx.doi.org/10.1074/jbc.M600888200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595652	hybrid, Green Published			2022-12-25	WOS:000237996000033
J	Tan, YF; Dourdin, N; Wu, C; De Veyra, T; Elce, JS; Greer, PA				Tan, Yinfei; Dourdin, Nathalie; Wu, Chao; De Veyra, Teresa; Elce, John S.; Greer, Peter A.			Ubiquitous calpains promote caspase-12 and JNK activation during endoplasmic reticulum stress-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED APOPTOSIS; SMALL-SUBUNIT GENE; CELL-DEATH; ER STRESS; KINASE; BAX; CLEAVAGE; PROTEIN; FIBROBLASTS; PATHWAY	Ubiquitously expressed mu- and m-calpain proteases are implicated in development and apoptosis. They consist of 80-kDa catalytic subunits encoded by the capn1 and capn2 genes, respectively, and a common 28-kDa regulatory subunit encoded by the capn4 gene. The regulatory subunit is required to maintain the stability and activity of mu- and m-calpains. Accordingly, genetic disruption of capn4 in the mouse eliminated both ubiquitous calpain activities. In embryonic fibroblasts derived from these mice, calpain deficiency correlated with resistance to endoplasmic reticulum (ER) stress-induced apoptosis, and this was directly related to a calpain requirement for activation of both caspase-12 and the ASK1-JNK cascade. This study provides compelling genetic evidence for calpain's role in caspase-12 activation at the ER, and reveals a novel role for the ubiquitous calpains in ER-stress induced apoptosis and JNK activation.	Queens Univ, Inst Canc Res, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada; McMaster University; Queens University - Canada; Queens University - Canada	Greer, PA (corresponding author), Queens Univ, Inst Canc Res, Div Canc Biol & Genet, Botterell Hall,Rm A309, Kingston, ON K7L 3N6, Canada.	greerp@post.queensu.ca						Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Arthur JSC, 1998, BBA-PROTEIN STRUCT M, V1388, P247, DOI 10.1016/S0167-4838(98)00166-6; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; CRISSMAN HA, 1993, EUR J HISTOCHEM, V37, P129; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Dupe V, 1997, DEVELOPMENT, V124, P399; Elce JS, 1997, BIOCHEM J, V326, P31, DOI 10.1042/bj3260031; Gil-Parrado S, 2003, J BIOL CHEM, V278, P16336, DOI 10.1074/jbc.M208657200; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gu F, 2004, J BIOL CHEM, V279, P49689, DOI 10.1074/jbc.C400261200; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Hirpara JL, 2000, BLOOD, V95, P1773, DOI 10.1182/blood.V95.5.1773.005k17_1773_1780; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hood JL, 2004, J BIOL CHEM, V279, P43126, DOI 10.1074/jbc.M408100200; Jayanthi S, 2004, FASEB J, V18, P238, DOI 10.1096/fj.03-0295com; Johnson JD, 2004, J BIOL CHEM, V279, P24794, DOI 10.1074/jbc.M401216200; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Larsen AK, 2004, PROTEIN EXPRES PURIF, V33, P246, DOI 10.1016/j.pep.2003.10.005; Liou AKF, 2005, FASEB J, V19, P1350, DOI 10.1096/fj.04-3258fje; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Morishima N, 2004, J BIOL CHEM, V279, P50375, DOI 10.1074/jbc.M408493200; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Ruiz-Vela A, 2005, EMBO REP, V6, P379, DOI 10.1038/sj.embor.7400375; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Takeda K, 2004, EMBO REP, V5, P161, DOI 10.1038/sj.embor.7400072; Thomenius MJ, 2003, J BIOL CHEM, V278, P6243, DOI 10.1074/jbc.M208878200; TODARO GJ, 1963, J CELL COMPAR PHYSL, V62, P257, DOI 10.1002/jcp.1030620305; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Zhou GF, 2004, J BIOL CHEM, V279, P46595, DOI 10.1074/jbc.M408320200; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	55	196	221	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16016	16024		10.1074/jbc.M601299200	http://dx.doi.org/10.1074/jbc.M601299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16597616	hybrid			2022-12-25	WOS:000237996000053
J	Li, CH; Matter, A; Kelly, A; Petty, TJ; Najafi, H; MacMullen, C; Daikhin, Y; Nissim, I; Lazarow, A; Kwagh, J; Collins, HW; Hsu, BYL; Nissim, I; Yudkoff, M; Matschinsky, FM; Stanley, CA				Li, Changhong; Matter, Andrea; Kelly, Andrea; Petty, Thomas J.; Najafi, Habiba; MacMullen, Courtney; Daikhin, Yevgeny; Nissim, Ilana; Lazarow, Adam; Kwagh, Jae; Collins, Heather W.; Hsu, Betty Y. L.; Nissim, Itzhak; Yudkoff, Marc; Matschinsky, Franz M.; Stanley, Charles A.			Effects of a GTP-insensitive mutation of glutamate dehydrogenase on insulin secretion in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERINSULINISM/HYPERAMMONEMIA SYNDROME; REGULATORY MUTATIONS; CONGENITAL HYPERINSULINISM; GLUCOSE; CHILDREN; GENE; HYPOGLYCEMIA; LEUCINE; METABOLISM; OXIDATION	Glutamate dehydrogenase (GDH) plays an important role in insulin secretion as evidenced in children by gain of function mutations of this enzyme that cause a hyperinsulinism-hyperammonemia syndrome (GDH-HI) and sensitize beta-cells to leucine stimulation. GDH transgenic mice were generated to express the human GDH-HI H454Y mutation and human wild-type GDH in islets driven by the rat insulin promoter. H454Y transgene expression was confirmed by increased GDH enzyme activity in islets and decreased sensitivity to GTP inhibition. The H454Y GDH transgenic mice had hypoglycemia with normal growth rates. H454Y GDH transgenic islets were more sensitive to leucine-and glutamine-stimulated insulin secretion but had decreased response to glucose stimulation. The fluxes via GDH and glutaminase were measured by tracing N-15 flux from [2-N-15] glutamine. The H454Y transgene in islets had higher insulin secretion in response to glutamine alone and had 2-fold greater GDH flux. High glucose inhibited both glutaminase and GDH flux, and leucine could not override this inhibition. (NH4Cl)-N-15 tracing studies showed N-15 was not incorporated into glutamate in either H454Y transgenic or normal islets. In conclusion, we generated a GDH-HI disease mouse model that has a hypoglycemia phenotype and confirmed that the mutation of H454Y is disease causing. Stimulation of insulin release by the H454Y GDH mutation or by leucine activation is associated with increased oxidative deamination of glutamate via GDH. This study suggests that GDH functions predominantly in the direction of glutamate oxidation rather than glutamate synthesis in mouse islets and that this flux is tightly controlled by glucose.	Childrens Hosp Philadelphia, Div Endocrinol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Child Dev & Pediat Rehabil, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Diabet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania	Stanley, CA (corresponding author), Childrens Hosp Philadelphia, Div Endocrinol, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	stanleyc@e-mail.chop.edu	Petty, Tom/A-6758-2011	Petty, Tom/0000-0002-4007-6515; STANLEY, CHARLES/0000-0003-4881-9392	NICHD NIH HHS [HD26979] Funding Source: Medline; NIDDK NIH HHS [K12 DK63682, DK19525, DK22122, DK56268, DK53761, DK53012] Funding Source: Medline; NINDS NIH HHS [NS37915] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD026979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K12DK063682, R37DK022122, R01DK053012, R37DK056268, P30DK019525, R01DK056268, R01DK053761, R56DK053761, R01DK022122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037915] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen A, 2004, BIOCHEMISTRY-US, V43, P14431, DOI 10.1021/bi048817i; Clayton PT, 2001, J CLIN INVEST, V108, P457; Eaton S, 2003, BIOCHEM SOC T, V31, P1137; Fang J, 2002, BIOCHEM J, V363, P81, DOI 10.1042/0264-6021:3630081; Gao Z, 1999, DIABETES, V48, P1535, DOI 10.2337/diabetes.48.8.1535; Gloyn AL, 2003, DIABETES, V52, P2433, DOI 10.2337/diabetes.52.9.2433; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Henwood MJ, 2005, J CLIN ENDOCR METAB, V90, P789, DOI 10.1210/jc.2004-1604; Hsu BYL, 2001, J PEDIATR-US, V138, P383, DOI 10.1067/mpd.2001.111818; Hussain K, 2005, J PEDIATR-US, V146, P706, DOI 10.1016/j.jpeds.2005.01.032; Kelly A, 2001, J CLIN ENDOCR METAB, V86, P3724, DOI 10.1210/jc.86.8.3724; Li CH, 2004, J BIOL CHEM, V279, P13393, DOI 10.1074/jbc.M311502200; Li CH, 2003, J BIOL CHEM, V278, P2853, DOI 10.1074/jbc.M210577200; MacMullen C, 2001, J CLIN ENDOCR METAB, V86, P1782, DOI 10.1210/jc.86.4.1782; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Molven A, 2004, DIABETES, V53, P221, DOI 10.2337/diabetes.53.1.221; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; PAGLIARA AS, 1974, J CLIN INVEST, V54, P819, DOI 10.1172/JCI107822; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; Raizen DM, 2005, J PEDIATR-US, V146, P388, DOI 10.1016/j.jpeds.2004.10.040; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; Shiota C, 2002, J BIOL CHEM, V277, P37176, DOI 10.1074/jbc.M206757200; Smith TJ, 2001, J MOL BIOL, V307, P707, DOI 10.1006/jmbi.2001.4499; Stanley CA, 2000, DIABETES, V49, P667, DOI 10.2337/diabetes.49.4.667; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Stanley CA, 2004, MOL GENET METAB, V81, pS45, DOI 10.1016/j.ymgme.2003.10.013; Thornton PS, 2003, DIABETES, V52, P2403, DOI 10.2337/diabetes.52.9.2403	29	54	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15064	15072		10.1074/jbc.M600994200	http://dx.doi.org/10.1074/jbc.M600994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574664	hybrid			2022-12-25	WOS:000237922200008
J	Wegener, JW; Schulla, V; Koller, A; Klugbauer, N; Feil, R; Hofmann, F				Wegener, Joerg W.; Schulla, Verena; Koller, Angela; Klugbauer, Norbert; Feil, Robert; Hofmann, Franz			Control of intestinal motility by the Ca(v)1.2 L-type calcium channel in mice	FASEB JOURNAL			English	Article						intestinal contraction; constipation; SKF96365; store-operated channels	LONGITUDINAL SMOOTH-MUSCLE; CAPACITATIVE CA2+ ENTRY; ENTERIC MOTOR-NEURONS; INTERSTITIAL-CELLS; GUINEA-PIG; ELECTRICAL RHYTHMICITY; C-KIT; CAJAL; CONTRACTIONS; STIMULATION	The Ca(v)1.2 L-type Ca2+ channel is the dominant voltage- activated Ca2+ channel in heart and smooth muscle. The functional significance of this channel was studied in intestinal smooth muscle from mice carrying a smooth muscle-specific, conditional inactivation of the Ca(v)1.2 gene (Ca(v)1.2(SMACKO) mice). Inactivation was complete within 4 wk after tamoxifen treatment and confirmed by RT-PCR, Western blot and functional analysis. Ca(v)1.2(SMACKO) mice show reduced feces excretion, absence of rhythmic contractions in small and large intestinal muscle and signs of paralytic ileus. Extracellular field stimulation evoked smaller contractions in jejunum muscles from Ca(v)1.2(SMACKO) than from CTR mice, whereas carbachol-induced contractions of similar magnitude in both muscles. The Ca2+ needed for contraction in jejunum was provided mainly by Cav1.2 channels and by store-operated channels in muscles from CTR and Ca(v)1.2(SMACKO) mice, respectively. In conclusion, the Cav1.2 channel is essential for electromechanical coupling and important for pharmaco-mechanical coupling in intestinal smooth muscle and cannot be substituted functionally by other Ca2+ entry pathways.-Wegener, J. W., Schulla, V., Koller, A., Klugbauer, N., Feil, R., Hofmann, F. Control of intestinal motility by the Ca(v)1.2 L-type calcium channel in mice.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	Technical University of Munich	Wegener, JW (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.	wegener@ipt.med.tu-muenchen.de	Feil, Robert/B-8918-2014	Feil, Robert/0000-0002-7335-4841; Wegener, Jorg/0000-0002-8129-1537				BLACKWOOD AM, 1993, BRIT J PHARMACOL, V109, P1029, DOI 10.1111/j.1476-5381.1993.tb13725.x; BRADING AF, 1980, BRIT J PHARMACOL, V70, P229, DOI 10.1111/j.1476-5381.1980.tb07928.x; Cousins HM, 2003, J PHYSIOL-LONDON, V550, P829, DOI 10.1113/jphysiol.2003.042176; Daniel EE, 2004, AM J PHYSIOL-GASTR L, V286, pG253, DOI 10.1152/ajpgi.00221.2003; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; Dietrich A, 2005, MOL CELL BIOL, V25, P6980, DOI 10.1128/MCB.25.16.6980-6989.2005; Gibson A, 1998, TRENDS PHARMACOL SCI, V19, P266; Hansen MB, 2003, PHYSIOL RES, V52, P1; Horowitz B, 1999, ANNU REV PHYSIOL, V61, P19, DOI 10.1146/annurev.physiol.61.1.19; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Kim TW, 2003, J PHYSIOL-LONDON, V546, P415, DOI 10.1113/jphysiol.2002.028977; Kim YC, 2002, J PHYSIOL-LONDON, V541, P797, DOI 10.1113/jphysiol.2002.018796; Kuhbandner S, 2000, GENESIS, V28, P15, DOI 10.1002/1526-968X(200009)28:1<15::AID-GENE20>3.0.CO;2-C; Lecci A, 2002, CURR OPIN PHARMACOL, V2, P630, DOI 10.1016/S1471-4892(02)00225-4; MAEDA H, 1992, DEVELOPMENT, V116, P369; MASON MJ, 1993, AM J PHYSIOL, V264, pC654, DOI 10.1152/ajpcell.1993.264.3.C654; Matsui M, 2002, J NEUROSCI, V22, P10627; McDaniel SS, 2001, AM J PHYSIOL-LUNG C, V280, pL870, DOI 10.1152/ajplung.2001.280.5.L870; McFadzean I, 2002, BRIT J PHARMACOL, V135, P1, DOI 10.1038/sj.bjp.0704468; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; PRESTWICH SA, 1995, BRIT J PHARMACOL, V114, P119, DOI 10.1111/j.1476-5381.1995.tb14915.x; Sanders KM, 2006, ANNU REV PHYSIOL, V68, P307, DOI 10.1146/annurev.physiol.68.040504.094718; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; Uchiyama Toshimitsu, 2004, Journal of Smooth Muscle Research, V40, P237, DOI 10.1540/jsmr.40.237; Unno T, 2005, BRIT J PHARMACOL, V146, P98, DOI 10.1038/sj.bjp.0706300; Wang XY, 2000, CELL TISSUE RES, V302, P331, DOI 10.1007/s004410000272; Wang XY, 1999, CELL TISSUE RES, V295, P247, DOI 10.1007/s004410051231; Wang XY, 2003, NEUROGASTROENT MOTIL, V15, P531, DOI 10.1046/j.1365-2982.2003.00429.x; Wang XY, 2003, AM J PHYSIOL-GASTR L, V285, pG593, DOI 10.1152/ajpgi.00421.2002; WARD SM, 1994, J PHYSIOL-LONDON, V480, P91, DOI 10.1113/jphysiol.1994.sp020343; Ward SM, 2000, J NEUROSCI, V20, P1393; Ward SM, 1998, GASTROENTEROLOGY, V115, P314, DOI 10.1016/S0016-5085(98)70198-2; Wegener JW, 2004, FASEB J, V18, P1159, DOI 10.1096/fj.04-1516fje; Xu M, 2003, J BIOL CHEM, V278, P40837, DOI 10.1074/jbc.M307598200; Zholos AV, 1997, BRIT J PHARMACOL, V122, P885, DOI 10.1038/sj.bjp.0701438	36	38	43	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1260	+		10.1096/fj.05-5292fje	http://dx.doi.org/10.1096/fj.05-5292fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636102				2022-12-25	WOS:000240210300045
J	Wang, H; Traub, LM; Weixel, KM; Hawryluk, MJ; Shah, N; Edinger, RS; Perry, CJ; Kester, L; Butterworth, MB; Peters, KW; Kleyman, TR; Frizzell, RA; Johnson, JP				Wang, Huamin; Traub, Linton M.; Weixel, Kelly M.; Hawryluk, Mathew J.; Shah, Nirav; Edinger, Robert S.; Perry, Clint J.; Kester, Lauren; Butterworth, Michael B.; Peters, Kathryn W.; Kleyman, Thomas R.; Frizzell, Raymond A.; Johnson, John P.			Clathrin-mediated endocytosis of the epithelial sodium channel - Role of epsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; A6 CELLS; BINDING; ENAC; EXPRESSION; UBIQUITIN; MEMBRANE; BIOSYNTHESIS; DEGRADATION; DROSOPHILA	Here we present evidence that the epithelial sodium channel ( ENaC), a heteromeric membrane protein whose surface expression is regulated by ubiquitination, is present in clathrin-coated vesicles in epithelial cells that natively express ENaC. The channel subunits are ubiquitinated and co-immunoprecipitate with both epsin and clathrin adaptor proteins, and epsin, as expected, co-immunoprecipitates with clathrin adaptor proteins. The functional significance of these interactions was evaluated in a Xenopus oocyte expression system where co-expression of epsin and ENaC resulted in a down-regulation of ENaC activity; conversely, co-expression of epsin sub-domains acted as dominant-negative effectors and stimulated ENaC activity. These results identify epsin as an accessory protein linking ENaC to the clathrin-based endocytic machinery thereby regulating the activity of this ion channel at the cell surface.	Univ Pittsburgh, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Physiol & Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Johnson, JP (corresponding author), 935 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	johnson@dom.pitt.edu		Traub, Linton/0000-0002-1303-0298	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057718, R56DK065161, R01DK053249, R01DK054814, R01DK065161] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 54814, DK 65161, DK 57718, DK 53249] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barriere H, 2006, TRAFFIC, V7, P282, DOI 10.1111/j.1600-0854.2006.00384.x; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Butterworth MB, 2005, J GEN PHYSIOL, V125, P81, DOI 10.1085/jgp.2004.09124; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Carattino MD, 2003, J BIOL CHEM, V278, P36202, DOI 10.1074/jbc.M300312200; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Hawryluk MJ, 2006, TRAFFIC, V7, P262, DOI 10.1111/j.1600-0854.2006.00383.x; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Lebowitz J, 2004, J BIOL CHEM, V279, P41985, DOI 10.1074/jbc.M403923200; Malik B, 2005, AM J PHYSIOL-RENAL, V289, pF107, DOI 10.1152/ajprenal.00179.2002; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Overstreet E, 2004, DEVELOPMENT, V131, P5355, DOI 10.1242/dev.01434; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Staruschenko A, 2005, J BIOL CHEM, V280, P39161, DOI 10.1074/jbc.M509608200; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; Tian XL, 2004, DEVELOPMENT, V131, P5807, DOI 10.1242/dev.01459; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; Vandewalle A, 1999, CURR OPIN NEPHROL HY, V8, P581, DOI 10.1097/00041552-199909000-00009; Wang WD, 2004, DEVELOPMENT, V131, P5367, DOI 10.1242/dev.01413; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Wendland B, 2002, NAT REV MOL CELL BIO, V3, P971, DOI 10.1038/nrm970	37	72	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14129	14135		10.1074/jbc.M512511200	http://dx.doi.org/10.1074/jbc.M512511200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16574660	hybrid			2022-12-25	WOS:000237512300036
J	Chou, YT; Wang, H; Chen, Y; Danielpour, D; Yang, YC				Chou, Y-T; Wang, H.; Chen, Y.; Danielpour, D.; Yang, Y-C			Cited2 modulates TGF-beta-mediated upregulation of MMP9	ONCOGENE			English	Article						Cited2; TGF-beta; MMP9; Smad3; p300	GROWTH-FACTOR-BETA; BREAST-CANCER CELLS; CREB-BINDING-PROTEIN; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; MELANOCYTE-SPECIFIC GENE; MATRIX METALLOPROTEINASES; TRANSFORMING GROWTH-FACTOR-BETA-1; SMAD PROTEINS; TRANSCRIPTIONAL COACTIVATOR; P300/CREB-BINDING PROTEIN	Cited ((C) under bar BP/p300-interacting transactivators with glutamic acid ((E) under bar )n/ aspartic acid ((D) under bar)-rich C-terminal domain) 2, which is a CBP/p300-binding transcription co-activator without typical DNA-binding domains, has been implicated in control of cell growth and malignant transformation in Rat1 cells. In this report, we provide evidence that Cited2 is an important regulator of transforming growth factor (TGF)-beta signaling. Overexpression of Cited2 enhanced TGF-beta-mediated transcription of a Smad-Binding Element-containing luciferase reporter construct, SBE4-Luc. This may occur through a direct physical association of Cited2 with Smads 2 and 3, as supported by co-immunoprecipitation, mammalian two-hybrid and glutathione S-transferase- pull down assays. The transcription factor p300, which binds to Smad3, was shown to further enhance the interaction between Cited2 and Smad3, and the transcriptional responses of Smad3 by Cited2 in reporter assays. Cited2 enhances TGF-beta-mediated upregulation of matrix metalloproteinase 9 (MMP9) in Cited2 inducible mouse embryo. broblasts. Overexpression of Cited2 enhanced TGF-beta-mediated MMP9 promoter reporter activity. Moreover, knockdown of Cited2 in MDA-MB-231 cells attenuated TGF-beta-mediated upregulation of MMP9 and TGF-beta-mediated cell invasion. Chromatin immunoprecipitation showed that Cited2 and Smad3 were recruited to MMP9 promoter upon TGF-beta stimulation. This is the first demonstration that Cited2 functions as a Smad3/p300-interacting transcriptional coactivator in modulating the expression of MMP9, which could affect tumor cell invasion mediated by TGF-beta.	Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Canc, Sch Med, Cleveland, OH 44106 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46204 USA; Walther Canc Inst, Indianapolis, IN USA	Case Western Reserve University; Case Western Reserve University; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Yang, YC (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, 2109 Adelbert Rd,W353, Cleveland, OH 44106 USA.	yxy36@cwru.edu		Chou, Yu-Ting/0000-0001-9274-8603	NATIONAL CANCER INSTITUTE [R01CA078433] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA78433] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrews JE, 2000, MECH DEVELOP, V95, P305, DOI 10.1016/S0925-4773(00)00362-2; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; Bannikov GA, 2002, J BIOL CHEM, V277, P16022, DOI 10.1074/jbc.M110931200; Barbera JPM, 2002, HUM MOL GENET, V11, P283, DOI 10.1093/hmg/11.3.283; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Braganca J, 2003, J BIOL CHEM, V278, P16021, DOI 10.1074/jbc.M208144200; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Dennler S, 2005, ONCOGENE, V24, P1936, DOI 10.1038/sj.onc.1208343; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fox SB, 2004, CANCER RES, V64, P6075, DOI 10.1158/0008-5472.CAN-04-0708; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Fridman R, 2003, CANCER METAST REV, V22, P153, DOI 10.1023/A:1023091214123; Futaki S, 2003, J BIOL CHEM, V278, P50691, DOI 10.1074/jbc.M304985200; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Guo BL, 2005, KIDNEY INT, V68, P972, DOI 10.1111/j.1523-1755.2005.00491.x; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Ilunga K, 2004, INT J EXP PATHOL, V85, P373, DOI 10.1111/j.0959-9673.2004.00406.x; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Javelaud D, 2005, ONCOGENE, V24, P7624, DOI 10.1038/sj.onc.1208900; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kranc KR, 2003, MOL CELL BIOL, V23, P7658, DOI 10.1128/MCB.23.21.7658-7666.2003; Leung MK, 1999, GENOMICS, V61, P307, DOI 10.1006/geno.1999.5970; Luo XP, 2005, ENDOCRINOLOGY, V146, P1097, DOI 10.1210/en.2004-1377; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MELCHIORI A, 1987, ANTICANCER RES, V7, P475; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Ogawa K, 2004, BIOCHEM J, V381, P413, DOI 10.1042/BJ20040058; Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Santibanez JF, 2002, BIOCHEM BIOPH RES CO, V296, P267; SATO H, 1993, ONCOGENE, V8, P395; Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200; Selvamurugan N, 2004, J BIOL CHEM, V279, P19327, DOI 10.1074/jbc.M314048200; Selvamurugan N, 2002, FEBS LETT, V532, P31, DOI 10.1016/S0014-5793(02)03620-7; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; Shioda T, 1997, GENE, V204, P235, DOI 10.1016/S0378-1119(97)00551-9; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Tardif G, 2001, J RHEUMATOL, V28, P1631; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tien ES, 2004, J BIOL CHEM, V279, P24053, DOI 10.1074/jbc.M401489200; Tobin SW, 2002, ONCOGENE, V21, P108, DOI 10.1038/sj.onc.1205026; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Warner DR, 2004, BIOCHEM BIOPH RES CO, V324, P70, DOI 10.1016/j.bbrc.2004.09.017; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3864, DOI 10.1128/MCB.8.9.3864; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yin Z, 2002, P NATL ACAD SCI USA, V99, P10488, DOI 10.1073/pnas.162371799; Yokota H, 2003, J BIOL CHEM, V278, P47275, DOI 10.1074/jbc.M304652200; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	74	79	84	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5547	5560		10.1038/sj.onc.1209552	http://dx.doi.org/10.1038/sj.onc.1209552			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619037				2022-12-25	WOS:000240370400008
J	Minami, T; Miura, M; Aird, WC; Kodama, T				Minami, Takashi; Miura, Mai; Aird, William C.; Kodama, Tatsuhiko			Thrombin-induced autoinhibitory factor, Down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; CYCLOSPORINE-A; GROWTH-FACTOR; SIGNALING PATHWAYS; GENE; TRANSCRIPTION; CALCINEURIN; MECHANISM; ATHEROSCLEROSIS; PROLIFERATION	Activation and dysfunction of the endothelium underlie many vascular disorders including atherosclerosis, tumor growth, and inflammation. We recently reported that thrombin and vascular endothelial growth factor, but not tumor necrosis factor-alpha, results in dramatic up-regulation of Down syndrome critical region (DSCR)-1 gene in endothelial cells, a negative feedback regulator of calcineurin-NFAT signaling. Constitutive expression of DSCR-1 in activated endothelial cells markedly impaired NFAT nuclear localization, proliferation, tube formation, and tumor growth. The goal of the present study was to elucidate the relative roles of NFAT/DSCR-1 and NF-kappa B/I-kappa B in mediating thrombin-responsive gene expression in endothelial cells. DNA microarrays of thrombin-treated human umbilical vein endothelial cells overexpressing DSCR-1 or constitutive active I kappa B alpha revealed genes that were dependent on NFAT and/or NF-kappa B activity. Vascular cell adhesion molecule-1 was inhibited both by DSCR-1 and I-kappa B at the level of mRNA, protein, promoter activity, and function (monocyte adhesion). Using a combination of transient transfections, electrophoretic mobility shift assays, and chromatin immunoprecipitation, thrombin was shown to induce time-dependent coordinate binding of RelA and NFATc to a tandem NF-kappa B element in the upstream promoter region of vascular cell adhesion molecule-1. Together, these findings suggest that thrombin-mediated activation of endothelial cells involves an interplay between NFAT and NF-kappa B signaling pathways and their negative feedback inhibitors, DSCR-1 and I-kappa B, respectively. As natural brakes in the inflammatory process, DSCR-1 and I-kappa B may lend themselves to therapeutic manipulation in vasculopathic disease states.	Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Mol & Vasc Med, Boston, MA 02215 USA	University of Tokyo; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Minami, T (corresponding author), Univ Tokyo, Adv Sci & Technol Res Ctr, 4-6-1 34 Komaba, Tokyo 1538904, Japan.	minami@med.rcast.u-tokyo.ac.jp			NHLBI NIH HHS [HL36028] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036028] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez-Arroyo MV, 2002, CIRC RES, V91, P202, DOI 10.1161/01.RES.0000027562.91075.56; Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; Brigstock David R., 2002, Angiogenesis, V5, P153, DOI 10.1023/A:1023823803510; Chan B, 2005, P NATL ACAD SCI USA, V102, P13075, DOI 10.1073/pnas.0503846102; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; Edelstein LC, 2005, J BIOL CHEM, V280, P11192, DOI 10.1074/jbc.M412997200; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; Gando S, 2002, THROMB HAEMOSTASIS, V88, P943, DOI 10.1055/s-0037-1613338; Giffin MJ, 2003, NAT STRUCT BIOL, V10, P800, DOI 10.1038/nsb981; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Jin L, 2003, NAT STRUCT BIOL, V10, P807, DOI 10.1038/nsb975; Kumbrink J, 2005, J BIOL CHEM, V280, P42785, DOI 10.1074/jbc.M511079200; Mammucari C, 2005, DEV CELL, V8, P665, DOI 10.1016/j.devcel.2005.02.016; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McNamara CA, 1996, SEMIN THROMB HEMOST, V22, P139, DOI 10.1055/s-2007-999001; Meng CQ, 2004, J MED CHEM, V47, P6420, DOI 10.1021/jm049685u; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200; Minami T, 2005, TRENDS CARDIOVAS MED, V15, P174, DOI 10.1016/j.tcm.2005.06.002; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Minami T, 2001, J BIOL CHEM, V276, P5395, DOI 10.1074/jbc.M008798200; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Mirzapoiazova T, 2005, J CELL PHYSIOL, V203, P520, DOI 10.1002/jcp.20244; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; OKAZAKI H, 1992, CIRC RES, V71, P1285, DOI 10.1161/01.RES.71.6.1285; Puri KD, 2004, BLOOD, V103, P3448, DOI 10.1182/blood-2003-05-1667; Rahman A, 2004, AM J PHYSIOL-LUNG C, V287, pL1017, DOI 10.1152/ajplung.00072.2004; Rahman A, 2002, CIRC RES, V91, P398, DOI 10.1161/01.RES.0000033520.95242.A2; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rothermel BA, 2003, TRENDS CARDIOVAS MED, V13, P15, DOI 10.1016/S1050-1738(02)00188-3; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VANDINTHERJANSSEN ACHM, 1991, J IMMUNOL, V147, P4207; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Zhu XY, 2004, CYTOKINE, V26, P262, DOI 10.1016/j.cyto.2004.03.007	44	61	64	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20503	20520		10.1074/jbc.M513112200	http://dx.doi.org/10.1074/jbc.M513112200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16627481	hybrid			2022-12-25	WOS:000239038200073
J	Lescop, E; Hu, YF; Xu, HM; Hu, W; Chen, J; Xia, B; Jin, CW				Lescop, Ewen; Hu, Yunfei; Xu, Huimin; Hu, Wei; Chen, Juan; Xia, Bin; Jin, Changwen			The solution structure of Escherichia coli Wzb reveals a novel substrate recognition mechanism of prokaryotic low molecular weight protein-tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PHOSPHOTYROSYL PHOSPHATASE; MYCOBACTERIUM-TUBERCULOSIS; DIPOLAR COUPLINGS; NMR EXPERIMENTS; BOVINE HEART; PHOSPHORYLATION; KINASE; EXOPOLYSACCHARIDE; RESOLUTION	Low molecular weight protein-tyrosine phosphatases (LMW-PTPs) are small enzymes that ubiquitously exist in various organisms and play important roles in many biological processes. In Escherichia coli, the LMW-PTP Wzb dephosphorylates the autokinase Wzc, and the Wzc/Wzb pair regulates colanic acid production. However, the substrate recognition mechanism of Wzb is still poorly understood thus far. To elucidate the molecular basis of the catalytic mechanism, we have determined the solution structure of Wzb at high resolution by NMR spectroscopy. The Wzb structure highly resembles that of the typical LMW-PTP fold, suggesting that Wzb may adopt a similar catalytic mechanism with other LMW-PTPs. Nevertheless, in comparison with eukaryotic LMW-PTPs, the absence of an aromatic amino acid at the bottom of the active site significantly alters the molecular surface and implicates Wzb may adopt a novel substrate recognition mechanism. Furthermore, a structure-based multiple sequence alignment suggests that a class of the prokaryotic LMW-PTPs may share a similar substrate recognition mechanism with Wzb. The current studies provide the structural basis for rational drug design against the pathogenic bacteria.	Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Peking Univ, Coll Chem & Mol Engn, Beijing 100871, Peoples R China	Peking University; Peking University; Peking University	Jin, CW (corresponding author), Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China.	changwen@pku.edu.cn	Hu, Wei/ABH-1470-2021; Lescop, Ewen/AAA-8700-2019	Hu, Wei/0000-0002-0392-6939; Lescop, Ewen/0000-0002-2623-9365				Bucciantini M, 1999, FEBS LETT, V456, P73, DOI 10.1016/S0014-5793(99)00828-5; Bucciantini M, 1998, FEBS LETT, V422, P213, DOI 10.1016/S0014-5793(98)00009-X; Bugert P, 1997, FEBS LETT, V400, P252, DOI 10.1016/S0014-5793(96)01398-1; Case D. A., 2002, AMBER 7; Castandet J, 2005, RES MICROBIOL, V156, P1005, DOI 10.1016/j.resmic.2005.05.013; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V238, P676, DOI 10.1006/bbrc.1997.7355; Chiarugi P, 2000, J BIOL CHEM, V275, P37619, DOI 10.1074/jbc.M006375200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cozzone AJ, 2004, ARCH MICROBIOL, V181, P171, DOI 10.1007/s00203-003-0640-6; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dosset P, 2001, J BIOMOL NMR, V20, P223, DOI 10.1023/A:1011206132740; Duggan BM, 2001, J BIOMOL NMR, V19, P321, DOI 10.1023/A:1011227824104; Evans B, 1996, BIOCHEMISTRY-US, V35, P13609, DOI 10.1021/bi9605651; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Grangeasse C, 2003, J BIOL CHEM, V278, P39323, DOI 10.1074/jbc.M305134200; Grangeasse C, 1998, J MOL BIOL, V278, P339, DOI 10.1006/jmbi.1998.1650; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Ilan O, 1999, EMBO J, V18, P3241, DOI 10.1093/emboj/18.12.3241; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jung YS, 2004, J BIOMOL NMR, V30, P11, DOI 10.1023/B:JNMR.0000042954.99056.ad; Kennelly Peter J., 1999, Frontiers in Bioscience, V4, pD372, DOI 10.2741/Kennelly; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Koul A, 2000, J BACTERIOL, V182, P5425, DOI 10.1128/JB.182.19.5425-5432.2000; Kuhnert P, 2000, FEMS MICROBIOL REV, V24, P107, DOI 10.1111/j.1574-6976.2000.tb00535.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li Y, 1996, J BACTERIOL, V178, P136, DOI 10.1128/jb.178.1.136-142.1996; LOGAN TM, 1994, BIOCHEMISTRY-US, V33, P11087, DOI 10.1021/bi00203a005; Madhurantakam C, 2005, J BACTERIOL, V187, P2175, DOI 10.1128/JB.187.6.2175-2181.2005; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; MONDESERT O, 1994, J BIOL CHEM, V269, P27996; Nakar D, 2003, J BACTERIOL, V185, P1001, DOI 10.1128/JB.185.3.1001-1009.2003; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Ramponi G, 1997, BBA-PROTEIN STRUCT M, V1341, P137, DOI 10.1016/S0167-4838(97)00087-3; Raugei G, 2002, CELL MOL LIFE SCI, V59, P941, DOI 10.1007/s00018-002-8481-z; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Soulat D, 2002, J BACTERIOL, V184, P5194, DOI 10.1128/JB.184.18.5194-5199.2002; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Vincent C, 1999, J BACTERIOL, V181, P3472, DOI 10.1128/JB.181.11.3472-3477.1999; Vincent C, 2000, J MOL BIOL, V304, P311, DOI 10.1006/jmbi.2000.4217; Wang SS, 2000, BIOCHEMISTRY-US, V39, P1903, DOI 10.1021/bi991348d; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; Xu HM, 2006, J BACTERIOL, V188, P1509, DOI 10.1128/JB.188.4.1509-1517.2006; Zabell APR, 2006, J BIOL CHEM, V281, P6520, DOI 10.1074/jbc.M506285200; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; Zhang M, 1998, J BIOL CHEM, V273, P21714, DOI 10.1074/jbc.273.34.21714; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	54	25	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19570	19577		10.1074/jbc.M601263200	http://dx.doi.org/10.1074/jbc.M601263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16651264	hybrid			2022-12-25	WOS:000238847000071
J	Iwama, T; Ito, Y; Aoki, H; Sakamoto, H; Yamagata, S; Kawai, K; Kawagishi, I				Iwama, Tomonori; Ito, Yasuaki; Aoki, Hisaaki; Sakamoto, Hiroshi; Yamagata, Shuzo; Kawai, Keiichi; Kawagishi, Ikuro			Differential recognition of citrate and a metal-citrate complex by the bacterial chemoreceptor Tcp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; ESCHERICHIA-COLI; ASPARTATE RECEPTOR; SALMONELLA-TYPHIMURIUM; SIGNAL-TRANSDUCTION; TAR CHEMORECEPTOR; SERINE CHEMORECEPTOR; CHEMOTAXIS; MALTOSE; PROTEIN	The chemoreceptor Tcp of Salmonella enterica serovar Typhimurium can sense citrate and a metal-citrate complex as distinct attractants. In this study, we tried to investigate the molecular mechanism of this discrimination. That citrate binds directly to Tcp was verified by the site-specific thiol modification assays using membrane fractions prepared from Escherichia coli cells expressing the mutant Tcp receptors in which single Cys residues were introduced at positions in the putative ligand-binding pocket. To determine the region responsible for the ligand discrimination, we screened for mutations defective in taxis to magnesium in the presence of citrate. All of the isolated mutants from random mutagenesis with hydroxylamine were defective in both citrate and metal-citrate sensing, and the mutated residues are located in or near the alpha 1-alpha 2 and alpha 3-alpha 4 loops within the periplasmic domain. Further analyses with site-directed replacements around these regions demonstrated that the residue Asn(67), which is presumed to lie at the subunit interface of the Tcp homodimer, plays a critical role in the recognition of the metal-citrate complex but not that of citrate. Various amino acids at this position differentially affect the citrate and metal-citrate sensing abilities. Thus, for the first time, the abilities to sense the two attractants were genetically dissected. Based on the results obtained in this study, we propose models in which the discrimination of the metal-citrate complex from citrate involves cooperative interaction at Asn67 and allosteric switching.	Gifu Univ, Fac Appl Biol Sci, Dept Appl Life Sci, Gifu 5011193, Japan; Nagoya Univ, Inst Adv Res, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Gifu University; Nagoya University	Iwama, T (corresponding author), Gifu Univ, Fac Appl Biol Sci, Dept Appl Life Sci, Gifu 5011193, Japan.	iwamatom@cc.gifu-u.ac.jp						ADLER J, 1973, J GEN MICROBIOL, V74, P77, DOI 10.1099/00221287-74-1-77; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; Bjorkman AM, 2001, J BIOL CHEM, V276, P2808, DOI 10.1074/jbc.M009593200; Bren A, 2000, J BACTERIOL, V182, P6865, DOI 10.1128/JB.182.24.6865-6873.2000; Chi YI, 1997, FEBS LETT, V414, P327, DOI 10.1016/S0014-5793(97)01027-2; Coleman MD, 2005, BIOCHEMISTRY-US, V44, P7687, DOI 10.1021/bi0501479; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; GARDINA P, 1992, J BACTERIOL, V174, P1528, DOI 10.1128/jb.174.5.1528-1536.1992; Gardina PJ, 1998, MOL MICROBIOL, V29, P1147, DOI 10.1046/j.1365-2958.1998.00964.x; GOMI S, 1994, OLFACTION TAXTE, V11, P210; GOMI S, 1993, J BIOCHEM-TOKYO, V133, P208; HAZELBAUER GL, 1990, BIOL CHEMOTACTIC RES, V46, P107; INGOLIA TD, 1979, J BACTERIOL, V140, P798, DOI 10.1128/JB.140.3.798-804.1979; IWAMA T, 1995, J BACTERIOL, V177, P2218, DOI 10.1128/jb.177.8.2218-2221.1995; Iwama T, 2000, J BACTERIOL, V182, P1437, DOI 10.1128/JB.182.5.1437-1441.2000; Iwama T, 1997, J BIOL CHEM, V272, P13810, DOI 10.1074/jbc.272.21.13810; JEFFERY CJ, 1993, PROTEIN SCI, V2, P559; KIHARA M, 1979, J BACTERIOL, V140, P297, DOI 10.1128/JB.140.1.297-300.1979; Kolodziej AF, 1996, BIOCHEMISTRY-US, V35, P14782, DOI 10.1021/bi961481v; Koshland DE, 1996, CURR OPIN STRUC BIOL, V6, P757, DOI 10.1016/S0959-440X(96)80004-2; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; LEE L, 1988, J BACTERIOL, V170, P4769, DOI 10.1128/jb.170.10.4769-4774.1988; MANSON MD, 1985, J BIOL CHEM, V260, P9727; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLER MH, 1992, SHORT COURSE BACTERI, P291; MOWBRAY SL, 1990, J BIOL CHEM, V265, P15638; MOWBRAY SL, 1987, CELL, V50, P171, DOI 10.1016/0092-8674(87)90213-3; NIMMO H, 1987, ESCHERICHIA COLI SAL, P156; Parkinson JS, 2005, CURR OPIN MICROBIOL, V8, P116, DOI 10.1016/j.mib.2005.02.008; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; Sourjik V, 2004, TRENDS MICROBIOL, V12, P569, DOI 10.1016/j.tim.2004.10.003; SPRINGER MS, 1977, P NATL ACAD SCI USA, V74, P3312, DOI 10.1073/pnas.74.8.3312; Stock J, 2000, CURR BIOL, V10, pR11, DOI 10.1016/S0960-9822(99)00248-1; Umemura T, 1998, J BIOL CHEM, V273, P30110, DOI 10.1074/jbc.273.46.30110; Umemura T, 2002, J BIOL CHEM, V277, P1593, DOI 10.1074/jbc.M109930200; Wadhams GH, 2004, NAT REV MOL CELL BIO, V5, P1024, DOI 10.1038/nrm1524; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WOLFE AJ, 1989, P NATL ACAD SCI USA, V86, P6973, DOI 10.1073/pnas.86.18.6973; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; YAMAMOTO K, 1993, P NATL ACAD SCI USA, V90, P217, DOI 10.1073/pnas.90.1.217; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507; Zhulin IB, 2001, ADV MICROB PHYSIOL, V45, P157, DOI 10.1016/S0065-2911(01)45004-1	44	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17727	17735		10.1074/jbc.M601038200	http://dx.doi.org/10.1074/jbc.M601038200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636062	hybrid			2022-12-25	WOS:000238490300022
J	Metlitskaya, A; Kazakov, T; Kommer, A; Pavlova, O; Praetorius-Ibba, M; Ibba, M; Krasheninnikov, I; Kolb, V; Khmel, I; Severinov, K				Metlitskaya, Anastasia; Kazakov, Teymur; Kommer, Aigar; Pavlova, Olga; Praetorius-Ibba, Mette; Ibba, Michael; Krasheninnikov, Igor; Kolb, Vyacheslav; Khmel, Inessa; Severinov, Konstantin			Aspartyl-tRNA synthetase is the target of peptide nucleotide antibiotic Microcin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID GENES; TRANSLATION; J25; POLYMERASE; ACTIVATION; INHIBITOR; PROTEIN; B17; C51	Microcin C is a ribosome-synthesized heptapeptide that contains a modified adenosine monophosphate covalently attached to the C-terminal aspartate. Microcin C is a potent inhibitor of bacterial cell growth. Based on the in vivo kinetics of inhibition of macromolecular synthesis, Microcin C targets translation, through a mechanism that remained undefined. Here, we show that Microcin C is a subject of specific degradation inside the sensitive cell. The product of degradation, a modified aspartyl-adenylate containing an N-acylphosphoramidate linkage, strongly inhibits translation by blocking the function of aspartyl-tRNA synthetase.	Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia; Russian Acad Sci, Inst Prot Res, Pushchino 142292, Russia; Moscow MV Lomonosov State Univ, Dept Virol, Moscow 119899, Russia; Moscow MV Lomonosov State Univ, Dept Mol Biol, Moscow 119899, Russia; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Rutgers State Univ, Waksman Inst, Dept Biochem & Mol Biol, Piscataway, NJ 08854 USA	Russian Academy of Sciences; Russian Academy of Sciences; Lomonosov Moscow State University; Lomonosov Moscow State University; University System of Ohio; Ohio State University; Rutgers State University New Brunswick	Severinov, K (corresponding author), Russian Acad Sci, Inst Mol Genet, Kurchatov Sq, Moscow 123182, Russia.	severik@waksman.rutgers.edu	Kolb, Vyacheslav/A-7438-2016; Severinov, Konstantin/C-8545-2016		NIGMS NIH HHS [R01 GM 64530, R01 GM 65183] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065183, R01GM064530] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman K, 2004, MOL CELL, V14, P753, DOI 10.1016/j.molcel.2004.05.017; Ahel I, 2002, J BIOL CHEM, V277, P34743, DOI 10.1074/jbc.M206928200; Bayro MJ, 2003, J AM CHEM SOC, V125, P12382, DOI 10.1021/ja036677e; Bernier S, 2005, BIOORGAN MED CHEM, V13, P69, DOI 10.1016/j.bmc.2004.09.055; BRAUN V, 1983, J BACTERIOL, V156, P308, DOI 10.1128/JB.156.1.308-315.1983; Braun V, 2002, BIOCHIMIE, V84, P365, DOI 10.1016/S0300-9084(02)01427-X; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Destoumieux-Garzon D, 2002, BIOCHIMIE, V84, P511, DOI 10.1016/S0300-9084(02)01411-6; Fomenko DE, 2003, ANTIMICROB AGENTS CH, V47, P2868, DOI 10.1128/AAC.47.9.2868-2874.2003; GONZALEZPASTOR JE, 1995, J BACTERIOL, V177, P7131, DOI 10.1128/jb.177.24.7131-7140.1995; GUIJARRO JI, 1995, J BIOL CHEM, V270, P23520, DOI 10.1074/jbc.270.40.23520; Kolb VA, 2000, J BIOL CHEM, V275, P16597, DOI 10.1074/jbc.M002030200; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Li YM, 1996, SCIENCE, V274, P1188, DOI 10.1126/science.274.5290.1188; METLITSKAYA AZ, 1995, FEBS LETT, V357, P235, DOI 10.1016/0014-5793(94)01345-2; Moreno F, 2002, BIOCHIMIE, V84, P521, DOI 10.1016/S0300-9084(02)01452-9; Moriguchi T, 2000, J ORG CHEM, V65, P8229, DOI 10.1021/jo0008338; Moulinier L, 2001, EMBO J, V20, P5290, DOI 10.1093/emboj/20.18.5290; Mukhopadhyay J, 2004, MOL CELL, V14, P739, DOI 10.1016/j.molcel.2004.06.010; PHILLIPS DR, 1993, J ORG CHEM, V58, P854, DOI 10.1021/jo00056a017; Pierrat OA, 2005, BIOCHEMISTRY-US, V44, P4204, DOI 10.1021/bi0478751; Pons AM, 2002, BIOCHIMIE, V84, P531, DOI 10.1016/S0300-9084(02)01416-5; Reader JS, 2005, SCIENCE, V309, P1533, DOI 10.1126/science.1116841; Rosengren KJ, 2003, J AM CHEM SOC, V125, P12464, DOI 10.1021/JA0367703; Shaloiko LA, 2004, BIOTECHNOL BIOENG, V88, P730, DOI 10.1002/bit.20267; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Wilson KA, 2003, J AM CHEM SOC, V125, P12475, DOI 10.1021/JA036756q; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	28	120	126	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18033	18042		10.1074/jbc.M513174200	http://dx.doi.org/10.1074/jbc.M513174200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16574659	Green Published, hybrid			2022-12-25	WOS:000238490300054
J	Ramana, KV; Bhatnagar, A; Srivastava, S; Yadav, UC; Awasthi, S; Awasthi, YC; Srivastava, SK				Ramana, Kota V.; Bhatnagar, Aruni; Srivastava, Sanjay; Yadav, Umesh C.; Awasthi, Sanjay; Awasthi, Yogesh C.; Srivastava, Satish K.			Mitogenic responses of vascular smooth muscle cells to lipid peroxidation-derived aldehyde 4-hydroxy-trans-2-nonenal (HNE) - Role of aldose reductase-catalyzed reduction of the HNE-glutathione conjugates in regulating cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; OXIDATIVE STRESS; ENDOTHELIAL-CELLS; REACTIVE OXYGEN; 1,N-2-PROPANODEOXYGUANOSINE ADDUCTS; 4-HYDROXYNONENAL-INDUCED APOPTOSIS; NEURODEGENERATIVE DISEASE; SIGNAL-TRANSDUCTION; REDOX REGULATION; FREE-RADICALS	Products of lipid peroxidation such as 4-hydroxy-trans-2-nonenal (HNE) trigger multiple signaling cascades that variably affect cell growth, differentiation, and apoptosis. Because glutathiolation is a significant metabolic fate of these aldehydes, we tested the possibility that the bioactivity of HNE depends upon its conjugation with glutathione. Addition of HNE or the cell-permeable esters of glutathionyl-4-hydroxynonenal (GS-HNE) or glutathionyl-1,4-dihydroxynonene (GS-DHN) to cultures of rat aortic smooth muscle cells stimulated protein kinase C, NF-kappa B, and AP-1, and increased cell growth. The mitogenic effects of HNE, but not GS-HNE or GS-DHN, were abolished by glutathione depletion. Pharmacological inhibition or antisense ablation of aldose reductase (which catalyzes the reduction of GS-HNE to GS-DHN) prevented protein kinase C, NF-kappa B, and AP-1 stimulation and the increase in cell growth caused by HNE and GS-HNE, but not GS-DHN. The growth stimulating effect of GS-DHN was enhanced in cells treated with antibodies directed against the glutathione conjugate transporters RLIP76 (Ral-binding protein) or the multidrug resistance protein-2. Overexpression of RLIP76 abolished the mitogenic effects of HNE and its glutathione conjugates, whereas ablation of RLIP76 using RNA interference promoted the mitogenic effects. Collectively, our findings suggest that the mitogenic effects of HNE are mediated by its glutathione conjugate, which has to be reduced by aldose reductase to stimulate cell growth. These results raise the possibility that the glutathione conjugates of lipid peroxidation products are novel mediators of cell signaling and growth.	Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; Univ Louisville, Dept Med, Div Cardiol, Louisville, KY 40202 USA; Univ Texas, Dept Chem & Biochem, Arlington, TX 76019 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Louisville; University of Texas System; University of Texas Arlington	Srivastava, SK (corresponding author), Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.	ssrivast@utmb.Du	Srivastava, Sanjay/D-3921-2012; Ramana, Kota/C-5460-2012; Yadav, Umesh/C-7858-2012; Bhatnagar, Aruni/H-7791-2013; Awasthi, Sanjay/R-4904-2019	Awasthi, Sanjay/0000-0002-5214-5717; Ramana, Kota/0000-0001-6502-7800	NATIONAL EYE INSTITUTE [R01EY001677] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065618, R01HL059378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036118, R01DK036118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071036] Funding Source: NIH RePORTER; NEI NIH HHS [EY 01677] Funding Source: Medline; NHLBI NIH HHS [HL 59378, HL 65618] Funding Source: Medline; NIDDK NIH HHS [DK 36118] Funding Source: Medline; NIGMS NIH HHS [GM 71036] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JD, 1993, FREE RADICAL BIO MED, V15, P187, DOI 10.1016/0891-5849(93)90058-3; Anders MW, 1998, ANNU REV PHARMACOL, V38, P501, DOI 10.1146/annurev.pharmtox.38.1.501; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Benderdour M, 2003, J BIOL CHEM, V278, P45154, DOI 10.1074/jbc.M306285200; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Chen K, 2003, FREE RADICAL BIO MED, V35, P117, DOI 10.1016/S0891-5849(03)00239-9; Cheng JZ, 2001, J BIOL CHEM, V276, P41213, DOI 10.1074/jbc.M106838200; Cheng JZ, 2001, ARCH BIOCHEM BIOPHYS, V392, P197, DOI 10.1006/abbi.2001.2452; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; Chong ZZ, 2005, BRAIN RES REV, V49, P1, DOI 10.1016/j.brainresrev.2004.11.005; DITTBERNER U, 1995, MUTAT RES-ENVIR MUTA, V335, P259, DOI 10.1016/0165-1161(95)00029-1; Dixit BL, 2000, J BIOL CHEM, V275, P21587, DOI 10.1074/jbc.M909235199; DOWNEY JM, 1990, ANNU REV PHYSIOL, V52, P487, DOI 10.1146/annurev.ph.52.030190.002415; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Eaton P, 1999, AM J PHYSIOL-HEART C, V276, pH935, DOI 10.1152/ajpheart.1999.276.3.H935; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7; Gerk PM, 2002, J PHARMACOL EXP THER, V302, P407, DOI 10.1124/jpet.102.035014; Giordano FJ, 2005, J CLIN INVEST, V115, P500, DOI 10.1172/JCI200524408; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; He NG, 1999, TOXICOL APPL PHARM, V158, P177, DOI 10.1006/taap.1999.8700; He NG, 1996, BBA-GEN SUBJECTS, V1291, P182, DOI 10.1016/S0304-4165(96)00064-5; HINCHMAN CA, 1994, J TOXICOL ENV HEALTH, V41, P387, DOI 10.1080/15287399409531852; Hoffmann U, 2004, DRUG METAB REV, V36, P669, DOI 10.1081/DMR-200033473; HORVATH JJ, 1992, TOXICOL APPL PHARM, V117, P200, DOI 10.1016/0041-008X(92)90238-N; Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Lucas DT, 1999, P NATL ACAD SCI USA, V96, P6689, DOI 10.1073/pnas.96.12.6689; Madamanchi NR, 2005, ARTERIOSCL THROM VAS, V25, P950, DOI 10.1161/01.ATV.0000161050.77646.68; Monks TJ, 1998, ANNU REV PHARMACOL, V38, P229, DOI 10.1146/annurev.pharmtox.38.1.229; Montine KS, 1997, J NEUROPATH EXP NEUR, V56, P866, DOI 10.1097/00005072-199708000-00004; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Napoli C, 1997, J CLIN INVEST, V100, P2680, DOI 10.1172/JCI119813; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Nath RG, 1996, CANCER RES, V56, P452; Nathan C, 2003, J CLIN INVEST, V111, P769, DOI 10.1172/JCI200318174; NELSON E, 1992, CRIT REV TOXICOL, V22, P371, DOI 10.3109/10408449209146313; Nian M, 2004, CIRC RES, V94, P1543, DOI 10.1161/01.RES.0000130526.20854.fa; Olsson M, 1999, ARTERIOSCL THROM VAS, V19, P1218, DOI 10.1161/01.ATV.19.5.1218; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; Powis G, 1997, Adv Pharmacol, V38, P329; Ramana KV, 2000, BIOCHEMISTRY-US, V39, P12172, DOI 10.1021/bi000796e; Ramana KV, 2005, DIABETES, V54, P818, DOI 10.2337/diabetes.54.3.818; Ramana KV, 2004, FASEB J, V18, P1209, DOI 10.1096/fj.04-1650com; Ramana KV, 2004, DIABETES, V53, P2910, DOI 10.2337/diabetes.53.11.2910; Ramana KV, 2002, J BIOL CHEM, V277, P32063, DOI 10.1074/jbc.M202126200; Rittner HL, 1999, J CLIN INVEST, V103, P1007, DOI 10.1172/JCI4711; Ruef J, 1998, CIRCULATION, V97, P1071, DOI 10.1161/01.CIR.97.11.1071; Ruef J, 2000, ARTERIOSCL THROM VAS, V20, P1745, DOI 10.1161/01.ATV.20.7.1745; Salomon RG, 2000, CHEM RES TOXICOL, V13, P557, DOI 10.1021/tx000007u; Sawyer DB, 2002, J MOL CELL CARDIOL, V34, P379, DOI 10.1006/jmcc.2002.1526; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Sharma R, 2003, INVEST OPHTH VIS SCI, V44, P3438, DOI 10.1167/iovs.03-0051; Sharma R, 2001, ARCH BIOCHEM BIOPHYS, V391, P171, DOI 10.1006/abbi.2001.2395; SINGHAL SS, 1995, INVEST OPHTH VIS SCI, V36, P142; Soh YJ, 2000, MOL PHARMACOL, V58, P535, DOI 10.1124/mol.58.3.535; Srivastava S, 1999, BIOCHEMISTRY-US, V38, P42, DOI 10.1021/bi981794l; Srivastava S, 2000, FREE RADICAL BIO MED, V29, P642, DOI 10.1016/S0891-5849(00)00351-8; Srivastava S, 2002, AM J PHYSIOL-HEART C, V283, pH2612, DOI 10.1152/ajpheart.00592.2002; Srivastava S, 2001, ATHEROSCLEROSIS, V158, P339, DOI 10.1016/S0021-9150(01)00454-3; Srivastava S, 2001, CHEM-BIOL INTERACT, V130, P563, DOI 10.1016/S0009-2797(00)00299-4; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Usatyuk PV, 2004, J BIOL CHEM, V279, P11789, DOI 10.1074/jbc.M311184200; Yang YS, 2003, J BIOL CHEM, V278, P41380, DOI 10.1074/jbc.M305766200; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Zhou XF, 2005, J BIOL CHEM, V280, P25377, DOI 10.1074/jbc.M503079200	71	121	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17652	17660		10.1074/jbc.M600270200	http://dx.doi.org/10.1074/jbc.M600270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16648138	hybrid			2022-12-25	WOS:000238490300014
J	White, AR; Du, T; Laughton, KM; Volitakis, I; Sharples, RA; Xilinas, ME; Hoke, DE; Holsinger, RMD; Evin, G; Cherny, RA; Hill, AF; Barnham, KJ; Li, QX; Bush, AI; Masters, CL				White, Anthony R.; Du, Tai; Laughton, Katrina M.; Volitakis, Irene; Sharples, Robyn A.; Xilinas, Michel E.; Hoke, David E.; Holsinger, R. M. Damian; Evin, Genevieve; Cherny, Robert A.; Hill, Andrew F.; Barnham, Kevin J.; Li, Qiao-Xin; Bush, Ashley I.; Masters, Colin L.			Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; PRECURSOR PROTEIN; TRANSGENIC MICE; SECRETASE CLEAVAGE; IN-VIVO; KAPPA-B; ACTIVATION; COPPER; CLIOQUINOL; ZINC	Biometals play an important role in Alzheimer disease, and recent reports have described the development of potential therapeutic agents based on modulation of metal bioavailability. The metal ligand clioquinol (CQ) has shown promising results in animal models and small phase clinical trials; however, the actual mode of action in vivo has not been determined. We now report a novel effect of CQ on amyloid beta-peptide (A beta) metabolism in cell culture. Treatment of Chinese hamster ovary cells overexpressing amyloid precursor protein with CQ and Cu2+ or Zn2+ resulted in an similar to 85-90% reduction of secreted A beta-(1-40) and A beta-(1-42) compared with untreated controls. Analogous effects were seen in amyloid precursor protein-overexpressing neuroblastoma cells. The secreted A beta was rapidly degraded through up-regulation of matrix metalloprotease (MMP)-2 and MMP-3 after addition of CQ and Cu2+. MMP activity was increased through activation of phosphoinositol 3-kinase and JNK. CQ and Cu2+ also promoted phosphorylation of glycogen synthase kinase-3, and this potentiated activation of JNK and loss of A beta-(1-40). Our findings identify an alternative mechanism of action for CQ in the reduction of A beta deposition in the brains of CQ-treated animals and potentially in Alzheimer disease patients.	Univ Melbourne, Dept Pathol & Biochem, Melbourne, Vic 3010, Australia; Univ Melbourne, Ctr Neurosci, Melbourne, Vic 3010, Australia; Mental Hlth Res Inst, Parkville, Vic 3052, Australia; Mol Biol & Biotechnol Inst Bio21, Parkville, Vic 3052, Australia	University of Melbourne; University of Melbourne; Florey Institute of Neuroscience & Mental Health	White, AR (corresponding author), Univ Melbourne, Dept Pathol & Biochem, Melbourne, Vic 3010, Australia.	arwhite@unimelb.edu.au	Bush, Ashley/Y-2457-2019; Evin, Genevieve M/E-5891-2013; Holsinger, R. M. Damian/B-4650-2012; Hill, Andrew F/B-4527-2009; Hill, Andrew F./AAH-2854-2020; Hill, Andrew F./GZL-4124-2022; Bush, Ashley I/A-1186-2007; White, Anthony/P-5596-2016	Bush, Ashley/0000-0001-8259-9069; Holsinger, R. M. Damian/0000-0002-4447-0835; Hill, Andrew F/0000-0001-5581-2354; Hill, Andrew F./0000-0001-5581-2354; Bush, Ashley I/0000-0001-8259-9069; White, Anthony/0000-0003-1802-9891; Volitakis, Irene/0000-0003-0766-817X	NIA NIH HHS [R01 AG 12686, AG 05887] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012686] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adamson IYR, 2003, EXP LUNG RES, V29, P375, DOI 10.1080/01902140303753; Backstrom JR, 1996, J NEUROSCI, V16, P7910; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100; Benvenisti-Zarom L, 2005, NEUROPHARMACOLOGY, V49, P687, DOI 10.1016/j.neuropharm.2005.04.023; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Chung KC, 2000, J NEUROSCI RES, V59, P117, DOI 10.1002/(SICI)1097-4547(20000101)59:1<117::AID-JNR14>3.0.CO;2-Q; de Souza AP, 2000, DENT MATER, V16, P103, DOI 10.1016/S0109-5641(99)00084-6; Deb S, 1999, J NEUROSCI RES, V55, P44, DOI 10.1002/(SICI)1097-4547(19990101)55:1<44::AID-JNR6>3.0.CO;2-G; Di Vaira M, 2004, INORG CHEM, V43, P3795, DOI 10.1021/ic0494051; Ding WQ, 2005, CANCER RES, V65, P3389, DOI 10.1158/0008-5472.CAN-04-3577; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; Hofmann UB, 2005, BIOCHIMIE, V87, P307, DOI 10.1016/j.biochi.2005.01.013; Hoke DE, 2005, FEBS J, V272, P5544, DOI 10.1111/j.1742-4658.2005.04950.x; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; Kubiatowski T, 2001, J NEUROSURG, V95, P480, DOI 10.3171/jns.2001.95.3.0480; LaRochelle O, 2001, J BIOL CHEM, V276, P41879, DOI 10.1074/jbc.M108313200; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Li JX, 2004, J CELL BIOL, V165, P77, DOI 10.1083/jcb.200401004; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Liu SY, 2004, J BIOL CHEM, V279, P51075, DOI 10.1074/jbc.M408607200; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATSUKI Y, 1987, ARCH TOXICOL, V59, P374, DOI 10.1007/BF00295093; Matsumoto K, 2004, EXP CELL RES, V297, P404, DOI 10.1016/j.yexcr.2004.03.041; Miyata Y, 2004, MOL CANCER THER, V3, P839; Ostrakhovitch EA, 2002, ARCH BIOCHEM BIOPHYS, V397, P232, DOI 10.1006/abbi.2001.2559; Pei JJ, 2003, ACTA NEUROPATHOL, V105, P381, DOI 10.1007/s00401-002-0657-y; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Phinney AL, 2003, P NATL ACAD SCI USA, V100, P14193, DOI 10.1073/pnas.2332851100; Rapala-Kozik M, 1998, J PEPT RES, V52, P315; Ritchie CW, 2004, EXPERT OPIN INV DRUG, V13, P1585, DOI 10.1517/13543784.13.12.1585; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; ROHER AE, 1994, BIOCHEM BIOPH RES CO, V205, P1755, DOI 10.1006/bbrc.1994.2872; Shimoke K, 1999, DEV BRAIN RES, V112, P245, DOI 10.1016/S0165-3806(98)00172-2; Stix B, 2001, AM J PATHOL, V159, P561, DOI 10.1016/S0002-9440(10)61727-0; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Treiber C, 2004, J BIOL CHEM, V279, P51958, DOI 10.1074/jbc.M407410200; White AR, 2003, J NEUROSCI RES, V71, P889, DOI 10.1002/jnr.10537; Wu WD, 1999, AM J PHYSIOL-LUNG C, V277, pL924, DOI 10.1152/ajplung.1999.277.5.L924; Wu WD, 2004, AM J RESP CELL MOL, V30, P540, DOI 10.1165/rcmb.2003-0233OC; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x	43	249	257	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17670	17680		10.1074/jbc.M602487200	http://dx.doi.org/10.1074/jbc.M602487200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16648635	hybrid			2022-12-25	WOS:000238490300016
J	Collins, HM; Kindle, KB; Matsuda, S; Ryan, C; Troke, PJF; Kalkhoven, E; Heery, DM				Collins, Hilary M.; Kindle, Karin B.; Matsuda, Sachiko; Ryan, Colm; Troke, Philip J. F.; Kalkhoven, Eric; Heery, David M.			MOZ-TIF2 alters cofactor recruitment and histone modification at the RAR beta 2 promoter - Differential effects of MOZ fusion proteins on CBP- AND MOZ-dependent activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER; NUCLEAR RECEPTORS; LEUKEMIA; ACETYLTRANSFERASE; TRANSCRIPTION; TARGET; LIVER; IDENTIFICATION; ACETYLATION; EXPRESSION	MOZ-TIF2 and MOZ-CBP are leukemogenic fusion proteins associated with therapy-induced acute myeloid leukemia. These proteins are thought to subvert normal gene expression in differentiating hematopoietic progenitor cells. We have previously shown that MOZ-TIF2 inhibits transcription by CREB-binding protein (CBP)/p300-dependent activators such as nuclear receptors and p53. Here we have shown that MOZ-TIF2 associates with the RAR beta 2 promoter in vivo, resulting in altered recruitment of CBP/p300, aberrant histone modification, and down-regulation of the RAR beta 2 gene. In contrast, MOZ-TIF2 up-regulated transcription mediated by the MOZ/MYST3-dependent activator AML1/RUNX1. Both wild type MOZ and MOZ-TIF2 were found to colocalize with AML1, and MOZ-TIF2 was recruited to an AML1 target promoter. A MOZ-CBP fusion protein showed similar functions to MOZ-TIF2 in that it inhibited retinoic acid receptor-mediated transcription but enhanced AML1 reporter activation. Although it contains almost the entire CBP sequence, MOZ-CBP does not appear to associate with PML bodies. In summary, our results indicate that leukemogenic MOZ fusion proteins have differential effects on the activities of CBP-dependent and MOZ-dependent activators because of their ability to alter cofactor recruitment and chromatin modification at target promoters.	Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England; Univ Utrecht, Med Ctr, Dept Metab & Endocrine Dis, NL-3584 EA Utrecht, Netherlands	University of Nottingham; Utrecht University	Heery, DM (corresponding author), Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England.	david.heery@nottingham.ac.uk		Garrie, Karin/0000-0003-2204-9975; Collins, Hilary/0000-0001-6220-1236; Heery, David/0000-0002-5035-2392				Aguiar RCT, 1997, BLOOD, V90, P3130, DOI 10.1182/blood.V90.8.3130; Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Akhtar A, 2001, EMBO REP, V2, P113, DOI 10.1093/embo-reports/kve022; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Billio Atto, 2002, Haematologica, V87, pECR15; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Hug BA, 2004, J BIOL CHEM, V279, P825, DOI 10.1074/jbc.M309524200; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Kindle KB, 2005, MOL CELL BIOL, V25, P988, DOI 10.1128/MCB.25.3.988-1002.2005; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miller CT, 2004, DEVELOPMENT, V131, P2443, DOI 10.1242/dev.01134; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Surapureddi S, 2002, P NATL ACAD SCI USA, V99, P11836, DOI 10.1073/pnas.182426699; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Troke PJF, 2006, BIOCHEM SOC SYMP, V73, P23; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301	28	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17124	17133		10.1074/jbc.M602633200	http://dx.doi.org/10.1074/jbc.M602633200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16613851	hybrid			2022-12-25	WOS:000238326300036
J	Stenglein, MD; Harris, RS				Stenglein, Mark D.; Harris, Reuben S.			APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EDITING ENZYME APOBEC3G; CYTIDINE DEAMINASES; ANTIRETROVIRAL DEFENSE; LTR-RETROTRANSPOSON; POTENT INHIBITORS; VIF PROTEIN; IN-VIVO; HIV-1; HYPERMUTATION; EVOLUTION	The most common transposable genetic element in humans, long interspersed element 1 (L1), constitutes about 20% of the genome. The activity of L1 and related transposons such as Alu elements causes disease and contributes to speciation. Little is known about the cellular mechanisms that control their spread. We show that expression of human APOBEC3B or APOBEC3F decreased the rate of L1 retrotransposition by 5-10-fold. Expression of two related proteins, APOBEC3D or APOBEC3G, had little effect. The mechanism of L1 inhibition did not correlate with an obvious subcellular protein distribution as APOBEC3B appeared predominantly nuclear and APOBEC3F was mostly cytosolic. Two lines of evidence indicated that these APOBEC3 proteins use a deamination-independent mechanism to inhibit L1. First, a catalytically inactive APOBEC3B mutant maintained L1 inhibition activity. Second, cDNA strand-specific C 3 T hypermutations were not detected among L1 elements that had replicated in the presence of APOBEC3B or APOBEC3F. In addition, lower levels of retrotransposed L1 DNA accumulated in the presence of APOBEC3B and APOBEC3F. Together, these data combined to suggest a model in which APOBEC3B or APOBEC3F provide a preintegration barrier to L1 retrotransposition. A particularly high level of APOBEC3F protein in human testes and an inverse correlation between L1 activity and APOBEC3 gene number suggest the relevance of this mechanism to mammals.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Inst Mol Virol, Minneapolis, MN 55455 USA; Univ Minnesota, Beckman Ctr Transposon Res, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Harris, RS (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Inst Mol Virol, 321 Church St SE,6-155 Jackson Hall, Minneapolis, MN 55455 USA.	rsh@umn.edu	Stenglein, Mark/E-3541-2017	Stenglein, Mark/0000-0002-0993-813X	NIAID NIH HHS [AI064046] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI064046, R37AI064046, R01AI064046] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Bogerd HP, 2006, NUCLEIC ACIDS RES, V34, P89, DOI 10.1093/nar/gkj416; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Cullen BR, 2006, J VIROL, V80, P1067, DOI 10.1128/JVI.80.3.1067-1076.2006; Deininger PL, 2003, CURR OPIN GENET DEV, V13, P651, DOI 10.1016/j.gde.2003.10.013; Delebecque F, 2006, J VIROL, V80, P605, DOI 10.1128/JVI.80.2.605-614.2006; Dutko JA, 2005, CURR BIOL, V15, P661, DOI 10.1016/j.cub.2005.02.051; Esnault C, 2005, NATURE, V433, P430, DOI 10.1038/nature03238; Hache G, 2005, J BIOL CHEM, V280, P10920, DOI 10.1074/jbc.M500382200; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Khan H, 2006, GENOME RES, V16, P78, DOI 10.1101/gr.4001406; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Ostertag EM, 2000, NUCLEIC ACIDS RES, V28, P1418, DOI 10.1093/nar/28.6.1418; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Rosler C, 2005, HEPATOLOGY, V42, P301, DOI 10.1002/hep.20801; Russell RA, 2005, J VIROL, V79, P8724, DOI 10.1128/JVI.79.14.8724-8731.2005; Sasada A, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-32; Sawyer SL, 2004, PLOS BIOL, V2, P1278, DOI 10.1371/journal.pbio.0020275; Schumacher AJ, 2005, P NATL ACAD SCI USA, V102, P9854, DOI 10.1073/pnas.0501694102; Seppen J, 2004, J HEPATOL, V41, P1068, DOI 10.1016/j.jhep.2004.10.008; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Suspene R, 2005, P NATL ACAD SCI USA, V102, P8321, DOI 10.1073/pnas.0408223102; Turelli P, 2004, J BIOL CHEM, V279, P43371, DOI 10.1074/jbc.C400334200; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Yu Q, 2004, J BIOL CHEM, V279, P53379, DOI 10.1074/jbc.M408802200; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	36	216	221	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16837	16841		10.1074/jbc.M602367200	http://dx.doi.org/10.1074/jbc.M602367200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16648136	hybrid			2022-12-25	WOS:000238326300003
J	Zhou, X; Vink, M; Klaver, B; Verhoef, K; Marzio, G; Das, AT; Berkhout, B				Zhou, Xue; Vink, Monique; Klaver, Bep; Verhoef, Koen; Marzio, Giuseppe; Das, Atze T.; Berkhout, Ben			The genetic stability of a conditional live HIV-1 variant can be improved by mutations in the tet-on regulatory system that restrain evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; ANTIBIOTIC-RESISTANCE; VACCINE DEVELOPMENT; TYPE-1 REPLICATION; STEPWISE SELECTION; GAMMA-INTERFERON; DRUG-RESISTANCE; MAMMALIAN-CELLS; ADULT MACAQUES	Live attenuated human immunodeficiency virus type 1 (HIV-1) vaccines are considered unsafe because more quickly replicating pathogenic virus variants may evolve after vaccination. As an alternative vaccine approach, we have previously presented a doxycycline (dox)-dependent HIV-1 variant that was constructed by incorporating the tetracycline-inducible gene expression system (Tet-On system) into the viral genome. Replication of this HIV-rtTA variant is driven by the dox-inducible transcriptional activator rtTA and can be switched on and off at will. A large scale evolution study was performed to test the genetic stability of this conditional live vaccine candidate. In several long term cultures, we selected for HIV-rtTA variants that no longer required dox for replication. These evolved variants acquired a typical amino acid substitution either at position 19 or 37 in the rtTA protein. Both mutations caused rtTA activity and viral replication in the absence of dox. We designed a novel rtTA variant with a higher genetic barrier toward these undesired evolutionary routes. The corresponding HIV-rtTA variant did not lose dox control in long term cultures, demonstrating its improved genetic stability.	Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Berkhout, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	b.berkhout@amc.uva.nl						ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; Baba TW, 1999, NAT MED, V5, P194, DOI 10.1038/5557; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Baldwin CE, 2004, J VIROL, V78, P12428, DOI 10.1128/JVI.78.22.12428-12437.2004; Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; Berkhout B, 2004, AIDS, V18, P1861, DOI 10.1097/00002030-200409030-00022; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Berkhout B, 2002, VIRUS RES, V82, P103; Berkhout B, 1999, J VIROL, V73, P1138, DOI 10.1128/JVI.73.2.1138-1145.1999; Berkhout B, 2001, Science, V292, P7; Blancou P, 2004, J VIROL, V78, P1080, DOI 10.1128/JVI.78.3.1080-1092.2004; Brady J, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-69; Brooks DG, 2005, CURR HIV RES, V3, P377; Das AT, 2005, J VIROL, V79, P3855, DOI 10.1128/JVI.79.6.3855-3858.2005; Das AT, 2004, METHOD ENZYMOL, V388, P359; Das AT, 2004, J BIOL CHEM, V279, P18776, DOI 10.1074/jbc.M313895200; Das AT, 1997, J VIROL, V71, P2346, DOI 10.1128/JVI.71.3.2346-2356.1997; Das Atze T, 2002, Expert Rev Vaccines, V1, P293, DOI 10.1586/14760584.1.3.293; Desrosiers RC, 1998, NAT MED, V4, P982, DOI 10.1038/1949; Giavedoni L, 1997, J VIROL, V71, P866, DOI 10.1128/JVI.71.2.866-872.1997; Giavedoni LD, 1996, J VIROL, V70, P2247, DOI 10.1128/JVI.70.4.2247-2251.1996; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gundlach BR, 1997, J VIROL, V71, P2225, DOI 10.1128/JVI.71.3.2225-2232.1997; Helbl V, 1998, J MOL BIOL, V276, P319, DOI 10.1006/jmbi.1997.1539; Helbl V, 1998, J MOL BIOL, V276, P313, DOI 10.1006/jmbi.1997.1540; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; Hofmann-Lehmann R, 2003, AIDS, V17, P157, DOI 10.1097/00002030-200301240-00004; Jeeninga RE, 2005, CANCER RES, V65, P3347, DOI 10.1158/0008-5472.CAN-04-4280; Johnson RP, 1999, J VIROL, V73, P4952, DOI 10.1128/JVI.73.6.4952-4961.1999; Keulen W, 1997, J VIROL, V71, P3346, DOI 10.1128/JVI.71.4.3346-3350.1997; Keulen W, 1996, ANTIVIR RES, V31, P45, DOI 10.1016/0166-3542(96)00944-8; Kiselyeva Y, 2004, VIROLOGY, V328, P1, DOI 10.1016/j.virol.2004.07.014; KISKER C, 1995, J MOL BIOL, V247, P260, DOI 10.1006/jmbi.1994.0138; Kuwata T, 2000, AIDS RES HUM RETROV, V16, P465, DOI 10.1089/088922200309124; Marzio G, 2002, J VIROL, V76, P3084, DOI 10.1128/JVI.76.6.3084-3088.2002; Marzio G, 2001, P NATL ACAD SCI USA, V98, P6342, DOI 10.1073/pnas.111031498; Mazur X, 1999, BIOTECHNOL BIOENG, V65, P144; Mills J, 2000, AIDS RES HUM RETROV, V16, P1453, DOI 10.1089/088922200750005976; Orth P, 2000, NAT STRUCT BIOL, V7, P215; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; Quinto I, 1999, J BIOL CHEM, V274, P17567, DOI 10.1074/jbc.274.25.17567; Ruijter JM, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-2; Saenger W, 2000, ANGEW CHEM INT EDIT, V39, P2042, DOI 10.1002/1521-3773(20000616)39:12<2042::AID-ANIE2042>3.0.CO;2-C; Smith SM, 1996, P NATL ACAD SCI USA, V93, P7955, DOI 10.1073/pnas.93.15.7955; Smith SM, 2001, J BIOL CHEM, V276, P32184, DOI 10.1074/jbc.M101604200; Stebbings R, 2004, VIROLOGY, V330, P249, DOI 10.1016/j.virol.2004.09.026; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; Verhoef K, 2001, J VIROL, V75, P979, DOI 10.1128/JVI.75.2.979-987.2001	52	22	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17084	17091		10.1074/jbc.M513400200	http://dx.doi.org/10.1074/jbc.M513400200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16627480	hybrid			2022-12-25	WOS:000238326300031
J	Yang, XF; Xu, PY; Xiao, Y; Xiong, X; Xu, T				Yang, Xiaofei; Xu, Pingyong; Xiao, Yang; Xiong, Xiong; Xu, Tao			Domain requirement for the membrane trafficking and targeting of syntaxin 1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED FLUORESCENT PROTEIN; VESICLE DOCKING; MONOMERIC RED; EXOCYTOSIS; FUSION; SNAP-25; CELLS; COMPLEX; SNARES; SYNAPTOBREVIN	Syntaxin plays a key role in intracellular membrane fusion in eukaryotic cells. The function of syntaxin relies on its proper trafficking to and targeting at the target membrane. The mechanisms underlying the trafficking and targeting of syntaxin to its physiological sites remain poorly understood. Here we have analyzed the trafficking of syntaxin 1A in INS-1 and CHO cells. We have identified the transmembrane domain together with several flanking positive-charged amino acids as the minimal domain required for the membrane delivery. Interestingly, we found that SNARE motif-exposed syntaxin 1A mutants were retained in endoplasmic reticulum ( ER) and failed to transport to the cell surface in the absence of SNAP-25, suggesting that the exposure of the SNARE motif causes ER retention and complexation with SNAP-25 helps the ER escape. Finally, our data propose two key roles for the H-abc domain: to protect nonspecific interaction by masking the SNARE motif and to participate in the clustering of syntaxin 1A to the fusion sites in the plasma membrane.	Huazhong Univ Sci & Technol, Joint Lab Inst Biophys, Wuhan 430074, Peoples R China; Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Wuhan 430074, Peoples R China; Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Chinese Academy of Sciences; Institute of Biophysics, CAS	Xu, PY (corresponding author), Huazhong Univ Sci & Technol, Joint Lab Inst Biophys, Wuhan 430074, Peoples R China.	pyxu@moon.ibp.ac.cn; xutao@ibp.ac.cn	Xu, Pingyong/G-5472-2010; Xu, Tao/G-5474-2010					ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BINZ T, 1994, J BIOL CHEM, V269, P1617; Borgese N, 2003, J CELL BIOL, V161, P1013, DOI 10.1083/jcb.200303069; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Gonelle-Gispert C, 2002, BIOCHEM J, V368, P223, DOI 10.1042/BJ20020896; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Hong WJ, 2005, BBA-MOL CELL RES, V1744, P120, DOI 10.1016/j.bbamcr.2005.03.014; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jahn R, 2004, ANN NY ACAD SCI, V1014, P170, DOI 10.1196/annals.1294.018; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Lam PPL, 2005, DIABETES, V54, P2744, DOI 10.2337/diabetes.54.9.2744; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; LOMNETH R, 1993, NEUROPHARMACOLOGY, V32, P285, DOI 10.1016/0028-3908(93)90113-H; Loranger SS, 2002, J BIOL CHEM, V277, P34303, DOI 10.1074/jbc.M202125200; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Mitchell SJ, 2004, J NEUROSCI, V24, P4884, DOI 10.1523/JNEUROSCI.0174-04.2004; Miyagishi M, 2004, J GENE MED, V6, P715, DOI 10.1002/jgm.556; Rowe J, 1999, J CELL SCI, V112, P1865; Saifee O, 1998, MOL BIOL CELL, V9, P1235, DOI 10.1091/mbc.9.6.1235; Sanders JD, 1998, J NEUROSCI RES, V53, P670, DOI 10.1002/(SICI)1097-4547(19980915)53:6<670::AID-JNR5>3.3.CO;2-H; Sankaranarayanan S, 2000, BIOPHYS J, V79, P2199, DOI 10.1016/S0006-3495(00)76468-X; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Stojilkovic SS, 2005, TRENDS ENDOCRIN MET, V16, P81, DOI 10.1016/j.tem.2005.02.002; Toonen RFG, 2005, J NEUROCHEM, V93, P1393, DOI 10.1111/j.1471-4159.2005.03128.x; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yang SN, 1999, P NATL ACAD SCI USA, V96, P10164, DOI 10.1073/pnas.96.18.10164; Yang XF, 2005, BIOCHEM BIOPH RES CO, V330, P914, DOI 10.1016/j.bbrc.2005.03.054; Zhang W, 2000, J BIOL CHEM, V275, P41521, DOI 10.1074/jbc.M005479200	35	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15457	15463		10.1074/jbc.M513246200	http://dx.doi.org/10.1074/jbc.M513246200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16595658	hybrid			2022-12-25	WOS:000237922200052
J	Szegedi, V; Juhasz, G; Rozsa, E; Juhasz-Vedres, G; Datki, Z; Fulop, L; Bozso, Z; Lakatos, A; Laczko, I; Farkas, T; Kis, Z; Toth, G; Soos, K; Zarandi, M; Denes, B; Toldi, J; Penke, B				Szegedi, Viktor; Juhasz, Gabor; Rozsa, Eva; Juhasz-Vedres, Gabriella; Datki, Zsolt; Fulop, Livia; Bozso, Zsolt; Lakatos, Andrea; Laczko, Ilona; Farkas, Tamas; Kis, Zsolt; Toth, Geza; Soos, Katalin; Zarandi, Marta; Denes, Budai; Toldi, Jozsef; Penke, Botond			Endomorphin-2, an endogenous tetrapeptide, protects against A beta 1-42 in vitro and in vivo	FASEB JOURNAL			English	Article						Alzheimer's disease; fibrillogenesis; circular dichroism; single-unit; transmission electronmicroscopy; rat	MU-OPIOID RECEPTORS; BETA-AMYLOID PEPTIDES; ALZHEIMERS-DISEASE; NEUROTOXICITY; ENHANCEMENT; INHIBITION; REDUCTION; PREVENTS; NEURONS; GENES	The underlying cause of Alzheimer's disease ( AD) is thought to be the beta-amyloid aggregates formed mainly by A beta 1-42 peptide. Protective pentapeptides [ e. g., Leu-Pro-Phe-Phe-Asp (LPFFD)] have been shown to prevent neuronal toxicity of A beta 1-42 by arresting and reversing fibril formation. Here we report that an endogenous tetrapeptide, endomorphin-2 (End-2, amino acid sequence: YPFF), defends against A beta 1-42 induced neuromodulatory effects at the cellular level. Although End-2 does not interfere with the kinetics of A beta fibrillogenesis according to transmission electron microscopic studies and quasielastic light scattering measurements, it binds to A beta 1-42 during aggregation, as revealed by tritium-labeled End-2 binding assay and circular dichroism measurements. The tetrapeptide attenuates the inhibitory effect on cellular redox activity of A beta 1-42 in a dose-dependent manner, as measured by 3-(4,5-dimethylthiazolyl-2)-2,-5-diphenyltetrazolium bromide (MTT) assay. In vitro and in vivo electrophysiological experiments show that End-2 also protects against the field excitatory postsynaptic potential attenuating and the NMDA-evoked responseenhancing effect of A beta 1-42. Studies using [D-Ala ( 2), N-Me-Phe (4), Gly (5)-ol]-enkephalin (DAMGO), a mu-opioid receptor agonist, show that the protective effects of the tetrapeptide are not mu-receptor modulated. The endogenous tetrapeptide End-2 may serve as a lead compound for the drug development in the treatment of AD.	Univ Szeged, Dept Med Chem, H-6720 Szeged, Hungary; Univ Szeged, Dept Comparat Physiol, H-6720 Szeged, Hungary; Univ Szeged, Dept Analyt & Inorgan Chem, H-6720 Szeged, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Biophys, H-1051 Budapest, Hungary; Univ Szeged, Juhasz Gyula Coll, Dept Biol, H-6720 Szeged, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Biochem, H-6701 Szeged, Hungary	Szeged University; Szeged University; Szeged University; Hungarian Academy of Sciences; Hungarian Biological Research Center; Szeged University; Hungarian Academy of Sciences; Hungarian Biological Research Center	Szegedi, V (corresponding author), Univ Szeged, Dept Med Chem, Dom Sq 8, H-6720 Szeged, Hungary.	szegv@mdche.szote.u-szeged.hu	Fülöp, Livia/E-2543-2011; Toldi, József/M-4858-2018; Farkas, Tamas/B-7193-2008; Kis, Zsolt/A-4583-2009; Fülöp, Livia/GRX-8140-2022; Szegedi, Viktor/A-3549-2008	Toldi, József/0000-0001-7355-0503; Kis, Zsolt/0000-0002-6896-5883; Szegedi, Viktor/0000-0003-4191-379X; Juhasz, Gabor/0000-0001-6912-5109; Fulop, Livia/0000-0002-8010-0129				Barghorn S, 2005, J NEUROCHEM, V95, P834, DOI 10.1111/j.1471-4159.2005.03407.x; Bores GM, 1998, BRAIN RES BULL, V46, P423, DOI 10.1016/S0361-9230(97)00382-1; Budai Denes, 2004, Acta Biologica Szegediensis, V48, P13; Chacon MA, 2004, MOL PSYCHIATR, V9, P953, DOI 10.1038/sj.mp.4001516; Chen QS, 2000, J NEUROSCI RES, V60, P65, DOI 10.1002/(SICI)1097-4547(20000401)60:1<65::AID-JNR7>3.0.CO;2-Q; Datki Z, 2004, NEUROBIOL DIS, V17, P507, DOI 10.1016/j.nbd.2004.08.007; Datki Z, 2003, BRAIN RES BULL, V62, P223, DOI 10.1016/j.brainresbull.2003.09.011; Drake CT, 2002, HIPPOCAMPUS, V12, P119, DOI 10.1002/hipo.1107; Drake CT, 1999, BRAIN RES, V849, P203, DOI 10.1016/S0006-8993(99)01910-1; ElKhoury J, 1996, NATURE, V382, P716; FUKUYAMA R, 1994, BRAIN RES, V667, P269, DOI 10.1016/0006-8993(94)91505-9; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; Harkany T, 2000, EUR J NEUROSCI, V12, P2735, DOI 10.1046/j.1460-9568.2000.00164.x; Hertel C, 1996, J NEUROCHEM, V67, P272; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Iglesias M, 2003, NEUROPHARMACOLOGY, V44, P482, DOI 10.1016/S0028-3908(03)00024-8; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; JOACHIM C, 1991, AM J PATHOL, V138, P373; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Lahiri DK, 2003, CURR DRUG TARGETS, V4, P97, DOI 10.2174/1389450033346957; LAMBERT MP, 1994, J NEUROSCI RES, V39, P377, DOI 10.1002/jnr.490390404; Liao SL, 2003, NEUROSCI LETT, V345, P169, DOI 10.1016/S0304-3940(03)00540-8; Lin X, 2003, BBA-MOL BASIS DIS, V1639, P195, DOI 10.1016/j.bbadis.2003.09.007; Liu YB, 1997, J NEUROCHEM, V69, P2285; Louzada PR, 2004, FASEB J, V18, P511, DOI 10.1096/fj.03-0739com; Luhrs T, 2005, P NATL ACAD SCI USA, V102, P17342, DOI 10.1073/pnas.0506723102; Malmo C, 2005, FASEB J, V19, P346, DOI 10.1096/fj.05-4652je; Martin-Schild S, 1999, J COMP NEUROL, V405, P450, DOI 10.1002/(SICI)1096-9861(19990322)405:4<450::AID-CNE2>3.0.CO;2-#; McQuiston AR, 2003, J NEUROPHYSIOL, V90, P1936, DOI 10.1152/jn.01150.2002; Molnar Z, 2004, NEUROREPORT, V15, P1649, DOI 10.1097/01.wnr.0000134471.06244.d2; Muehlhauser F, 2001, CLIN CHEM LAB MED, V39, P313, DOI 10.1515/CCLM.2001.048; Nitta A, 1997, JPN J PHARMACOL, V73, P51, DOI 10.1254/jjp.73.51; Palotas A, 2002, BRAIN RES BULL, V58, P203, DOI 10.1016/S0361-9230(02)00773-6; Pappolla M, 1998, J BIOL CHEM, V273, P7185, DOI 10.1074/jbc.273.13.7185; Permanne B, 2002, FASEB J, V16, P860, DOI 10.1096/fj.01-0841fje; Phinney AL, 2003, NEUROL RES, V25, P590, DOI 10.1179/016164103101202020; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Rocchi A, 2003, BRAIN RES BULL, V61, P1, DOI 10.1016/S0361-9230(03)00067-4; Savvateeva E V, 1999, Ross Fiziol Zh Im I M Sechenova, V85, P167; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Soto C, 1999, MOL MED TODAY, V5, P343, DOI 10.1016/S1357-4310(99)01508-7; Stephan A, 2001, J NEUROSCI, V21, P5703, DOI 10.1523/JNEUROSCI.21-15-05703.2001; Szegedi V, 2005, BRAIN RES, V1062, P120, DOI 10.1016/j.brainres.2005.09.014; Szegedi V, 2005, NEUROBIOL DIS, V18, P499, DOI 10.1016/j.nbd.2004.12.008; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Trommer BL, 2005, NEUROBIOL DIS, V18, P75, DOI 10.1016/j.nbd.2004.08.011; Vass E, 2003, CHEM REV, V103, P1917, DOI 10.1021/cr000100n; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Wogulis M, 2005, J NEUROSCI, V25, P1071, DOI 10.1523/JNEUROSCI.2381-04.2005; Yao PJ, 2003, NEUROBIOL DIS, V12, P97, DOI 10.1016/S0969-9961(02)00009-8; Yu SP, 1998, NEUROBIOL DIS, V5, P81, DOI 10.1006/nbdi.1998.0186; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0; Zadina JE, 1999, ANN NY ACAD SCI, V897, P136, DOI 10.1111/j.1749-6632.1999.tb07885.x	57	23	25	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1191	+		10.1096/fj.05-4891fje	http://dx.doi.org/10.1096/fj.05-4891fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636106				2022-12-25	WOS:000240210300022
J	Wang, RS; Zhang, YW; Zhang, X; Liu, RZ; Zhang, X; Hong, SG; Xia, K; Xia, JH; Zhang, ZH; Xu, HX				Wang, Ruishan; Zhang, Yun-Wu; Zhang, Xian; Liu, Runzhong; Zhang, Xue; Hong, Shuigen; Xia, Kun; Xia, Jiahui; Zhang, Zhuohua; Xu, Huaxi			Transcriptional regulation of APH-1A and increased gamma-secretase cleavage of APP and Notch by HIF-1 and hypoxia	FASEB JOURNAL			English	Article						Alzheimer's disease; AP4; promoter	AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; PROTEOLYTIC RELEASE; MISSENSE MUTATIONS; GENE-EXPRESSION; SPLICE VARIANT; BETA-APP; NICASTRIN; PRESENILIN-1	The proteolytic cleavage of Alzheimer beta-amyloid precursor protein (APP) and signaling receptor Notch is mediated by the PS/gamma-secretase complex, which consists of presenilins, nicastrin, APH-1, and PEN-2. Although the four components are known to coordinately regulate each other at the protein level, information regarding their transcription regulation is scarce. Here we characterized the 5'-flanking region of the human APH-1A gene and identified a 271-bp fragment containing the transcription initiation site for the promoter activity. Sequence analysis, mutagenesis, and gel shift studies revealed a binding of AP4 and HIF-1 to the promoter, which affects the promoter activity. Activation of HIF-1 by short- term NiCl2 treatments ( a condition of chemical hypoxia) dramatically increased APH-1A mRNA and protein expression, accompanied by increased secretion of A beta and decreased APP CTFs formation, indicative of an increase in gamma-secretase activity. NiCl2 treatments had little effect on APP and the other three components of the gamma-secretase complex. The cellular concentration of Notch intracellular domain (NICD) was also increased by the hypoxic treatment. Our results demonstrate that APH-1A expression and the gamma-secretase mediated A beta and Notch NICD generation are regulated by HIF-1, and the specific control of APH-1A expression may imply physiological functions uniquely assigned to APH-1A. Wang, R., Zhang, Y-w., Zhang, X., Liu, R., Zhang, X., Hong, S., Xia, K., Xia, J., Zhang, Z., Xu, H. Transcriptional regulation of APH-1A and increased gamma-secretase cleavage of APP and Notch by HIF-1 and hypoxia.	Cent S Univ, Xiang Ya Hosp, Natl Lab Med Genet China, Changsha 410078, Hunan, Peoples R China; Xiamen Univ, Mol & Cellular Neurosci Lab, Sch Life Sci, Xiamen, Peoples R China; Xiamen Univ, Biomed Res Inst, Xiamen, Peoples R China; Burnham Inst Med Res, Ctr Neurosci & Aging, La Jolla, CA USA	Central South University; Xiamen University; Xiamen University; Sanford Burnham Prebys Medical Discovery Institute	Xu, HX (corresponding author), Cent S Univ, Xiang Ya Hosp, Natl Lab Med Genet China, Changsha 410078, Hunan, Peoples R China.	xuh@burnham.org	Liu, Runzhong/B-8217-2012; Zhang, Xian/AAV-7491-2021; Zhang, YW/G-3999-2010; XIA, KUN/AAO-3525-2020; Xu, Huaxi/AAV-7177-2021	Zhang, Yun-wu/0000-0002-7152-7630	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG024895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006497] Funding Source: NIH RePORTER; NIA NIH HHS [F32 AG024895, R01 AG024895] Funding Source: Medline; NIDCD NIH HHS [R01 DC006497] Funding Source: Medline; NINDS NIH HHS [R01 NS046673] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bazan NG, 2002, J BIOL CHEM, V277, P30359, DOI 10.1074/jbc.M203201200; Cheng CK, 2003, MOL ENDOCRINOL, V17, P1175, DOI 10.1210/me.2002-0418; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; CHUNG SL, 2001, W PAC EARTH SCI, V1, P1; Costa M, 2005, MUTAT RES-FUND MOL M, V592, P79, DOI 10.1016/j.mrfmmm.2005.06.008; DE SB, 1999, NATURE, V398, P518; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Golde TE, 2005, BRAIN PATHOL, V15, P84, DOI 10.1111/j.1750-3639.2005.tb00104.x; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Greenfield JP, 2000, FRONT BIOSCI, V5, pD72, DOI 10.2741/Greenfield; Greenfield JP, 2002, J BIOL CHEM, V277, P12128, DOI 10.1074/jbc.M110009200; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Kang DE, 2005, J BIOL CHEM, V280, P31537, DOI 10.1074/jbc.M500833200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 2003, J BIOL CHEM, V278, P33445, DOI 10.1074/jbc.M301288200; Li T, 2003, J NEUROSCI, V23, P3272; Lu HT, 2005, MOL CELL BIOCHEM, V279, P45, DOI 10.1007/s11010-005-8215-2; Lu S, 2002, BBA-GENE STRUCT EXPR, V1574, P152, DOI 10.1016/S0167-4781(01)00359-1; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Ma GJ, 2005, J NEUROSCI, V25, P192, DOI 10.1523/JNEUROSCI.3814-04.2005; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Maxwell P, 2004, CANCER BIOL THER, V3, P29, DOI 10.4161/cbt.3.1.547; Mitsuda N, 2001, J BIOL CHEM, V276, P9688, DOI 10.1074/jbc.M006153200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Pastorcic M, 2004, EUR J BIOCHEM, V271, P4485, DOI 10.1111/j.1432-1033.2004.04453.x; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rogaev EI, 1997, GENOMICS, V40, P415, DOI 10.1006/geno.1996.4523; Saito S, 2005, BIOCHEM BIOPH RES CO, V330, P1068, DOI 10.1016/j.bbrc.2005.03.096; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seta K, 2002, ANN NY ACAD SCI, V971, P379, DOI 10.1111/j.1749-6632.2002.tb04500.x; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shirotani K, 2004, J BIOL CHEM, V279, P41340, DOI 10.1074/jbc.M405768200; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Sisodia SS, 1999, AM J HUM GENET, V65, P7, DOI 10.1086/302475; Smith MJ, 2004, MOL BRAIN RES, V127, P128, DOI 10.1016/j.molbrainres.2004.05.019; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Tarassishin L, 2004, P NATL ACAD SCI USA, V101, P17050, DOI 10.1073/pnas.0408007101; Thinakaran G, 2004, PHARMACOL RES, V50, P411, DOI 10.1016/j.phrs.2003.12.026; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Wang H, 2004, J BIOL CHEM, V279, P40560, DOI 10.1074/jbc.M404345200; Wang RS, 2006, MOL CELL BIOL, V26, P1347, DOI 10.1128/MCB.26.4.1347-1354.2006; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Xu HX, 1996, P NATL ACAD SCI USA, V93, P4081, DOI 10.1073/pnas.93.9.4081; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yoon SO, 2005, CANCER RES, V65, P2761, DOI 10.1158/0008-5472.CAN-04-4122; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang YW, 2005, J BIOL CHEM, V280, P17020, DOI 10.1074/jbc.M409467200	55	81	86	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1275	+		10.1096/fj.06-5839fje	http://dx.doi.org/10.1096/fj.06-5839fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16645044				2022-12-25	WOS:000240210300050
J	Dumitru, CA; Gulbins, E				Dumitru, C. A.; Gulbins, E.			TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis	ONCOGENE			English	Article						ceramide; acid sphingomyelinase; TRAIL; apoptosis; tumor therapy; redox	RICH MEMBRANE RAFTS; CYTOTOXIC LIGAND TRAIL; COLON-CANCER CELLS; LIPID RAFTS; SIGNALING COMPLEX; DEATH RECEPTOR; CASPASE-8 ACTIVATION; DENDRITIC CELLS; DOWN-REGULATION; IN-VIVO	We have previously shown that activation of the acid sphingomyelinase (ASM), the release of ceramide and the formation of ceramide-enriched membrane domains are central for the induction of apoptosis by CD95. Here, we demonstrate that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and CD95 activate the ASM via a redox mechanism resulting in release of ceramide and formation of ceramide-enriched membrane platforms. Ceramide-enriched membrane platforms serve to cluster DR5 upon stimulation. Antioxidants prevent TRAIL-mediated stimulation of ASM, the release of ceramide, the formation of ceramide-enriched membrane platforms and the induction of apoptosis by TRAIL. Further, ASM-deficient splenocytes fail to cluster DR5 in ceramide-enriched membrane domains upon TRAIL stimulation and resist TRAIL-induced apoptosis, events that were restored by addition of natural C-16-ceramide. A dose-response analysis indicates that ceramide-enriched membrane platforms greatly sensitized tumor cells to TRAIL-induced apoptosis. Our data indicate that ceramide-enriched membrane platforms are required for the signaling of TRAIL-DR5 complexes under physiological conditions.	Univ Duisburg Essen, Dept Mol Biol, D-45122 Essen, Germany	University of Duisburg Essen	Gulbins, E (corresponding author), Univ Duisburg Essen, Dept Mol Biol, Hufeandstr 55, D-45122 Essen, Germany.	erich.gulbins@uni-essen.de	Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342				Andrieu-Abadie N, 1999, FASEB J, V13, P1501, DOI 10.1096/fasebj.13.12.1501; Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Bhardwaj A, 2003, J CLIN IMMUNOL, V23, P317, DOI 10.1023/A:1025319031417; Bock J, 2003, FEBS LETT, V534, P169, DOI 10.1016/S0014-5793(02)03784-5; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Delmas D, 2004, ONCOGENE, V23, P8979, DOI 10.1038/sj.onc.1208086; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; El-Zawahry A, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-2; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Eramo A, 2004, EUR J IMMUNOL, V34, P1930, DOI 10.1002/eji.200324786; Esen M, 2001, APOPTOSIS, V6, P431, DOI 10.1023/A:1012445925628; Fanzo JC, 2003, CANCER BIOL THER, V2, P392, DOI 10.4161/cbt.2.4.442; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Fulda S, 2004, BBA-REV CANCER, V1705, P27, DOI 10.1016/j.bbcan.2004.09.003; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; Gulbins E, 1996, IMMUNOLOGY, V89, P205, DOI 10.1046/j.1365-2567.1996.d01-743.x; Gulbins E, 2000, METHOD ENZYMOL, V322, P382; Hayakawa Y, 2004, J IMMUNOL, V172, P123, DOI 10.4049/jimmunol.172.1.123; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; Jendrossek V, 2002, CANCER CHEMOTH PHARM, V50, P71, DOI 10.1007/s00280-002-0440-8; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Nurminen TA, 2002, J AM CHEM SOC, V124, P12129, DOI 10.1021/ja017807r; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Qiu HW, 2003, J BIOL CHEM, V278, P32744, DOI 10.1074/jbc.M303022200; Reinehr R, 2005, J BIOL CHEM, V280, P27179, DOI 10.1074/jbc.M414361200; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; ROSENMAN SJ, 1993, J LEUKOCYTE BIOL, V53, P1; Scheel-Toellner D, 2004, BIOCHEM SOC T, V32, P679, DOI 10.1042/BST0320679; Scheel-Toellner D, 2004, BLOOD, V104, P2557, DOI 10.1182/blood-2004-01-0191; Scheel-Toellner D, 2002, BIOCHEM BIOPH RES CO, V297, P876, DOI 10.1016/S0006-291X(02)02311-2; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Shakor ABA, 2004, J BIOL CHEM, V279, P36778, DOI 10.1074/jbc.M402170200; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Um HD, 1996, J IMMUNOL, V156, P3469; Ursini-Siegel J, 2002, J IMMUNOL, V169, P5505, DOI 10.4049/jimmunol.169.10.5505; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Voelkel-Johnson C, 2005, MOL CANCER THER, V4, P1320, DOI 10.1158/1535-7163.MCT-05-0086; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; YIN XM, 2005, HEPATOLOGY, V42, P956	68	123	129	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2006	25	41					5612	5625		10.1038/sj.onc.1209568	http://dx.doi.org/10.1038/sj.onc.1209568			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636669				2022-12-25	WOS:000240599100003
J	Pramoonjago, P; Baras, AS; Moskaluk, CA				Pramoonjago, P.; Baras, A. S.; Moskaluk, C. A.			Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells	ONCOGENE			English	Article						adenoid cystic carcinoma; Sox4; RNAi; apoptosis	ADENOID CYSTIC CARCINOMA; TRANSCRIPTIONAL PROFILES; CANCER; GENE; PROTEINS; DEATH; MICE; IDENTIFICATION; ACTIVATION; PATHWAY	Microarray RNA gene expression pro. ling analysis has shown that Sox4 (Sry-related high mobility group (HMG) box 4) is one of the most upregulated genes in adenoid cystic carcinoma (ACC), relative to non-neoplastic tissue of origin. Here, we show that Sox4 protein is similarly upregulated in ACC by immunohistochemistry of 28 primary cancers and 20 normal tissues. To elucidate the functional significance of these findings, RNA interference (RNAi)-mediated RNA silencing was used to down-regulate Sox4 expression in the ACC-derived cell line, ACC3. With confirmed knockdown of Sox4 protein, cell viability was reduced by 51%, with a corresponding increase of apoptosis to 85% as compared to 12% in controls. Apoptosis was confirmed by cell morphology, DNA fragmentation and flow cytometry. Cells could be rescued from the proapoptotic effects of Sox4 RNAi by co-transfection with a construct expressing functional Sox4. Microarray gene expression pro. ling of RNAi knockdown experiments shows that downregulation of Sox4-modulated expression of critical genes involved in apoptosis and cell cycle control. Overall, our findings suggest that Sox4 contributes to the malignant phenotype of ACC cells by promoting cell survival.	Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Moskaluk, CA (corresponding author), Univ Virginia, Dept Pathol, POB 800214, Charlottesville, VA 22908 USA.	cam5p@virginia.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE-14694] Funding Source: Medline; NIGMS NIH HHS [T32 GM007267] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; CHENG J, 1995, VIRCHOWS ARCH, V426, P577; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Du Y, 2005, BLOOD, V106, P2498, DOI 10.1182/blood-2004-12-4840; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FARR CJ, 1993, MAMM GENOME, V4, P577, DOI 10.1007/BF00361388; Frierson HF, 2002, AM J PATHOL, V161, P1315, DOI 10.1016/S0002-9440(10)64408-2; HE RG, 1988, W CHIN J STOMATOL, V6, P1; Hunt SMN, 1999, BIOL REPROD, V61, P476, DOI 10.1095/biolreprod61.2.476; Hur EH, 2004, BIOCHEM BIOPH RES CO, V325, P59, DOI 10.1016/j.bbrc.2004.09.215; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Kan LX, 2004, DEV BIOL, V269, P580, DOI 10.1016/j.ydbio.2004.02.005; Kimura S, 1999, J BIOCHEM-TOKYO, V125, P406, DOI 10.1093/oxfordjournals.jbchem.a022301; Lu HF, 2004, FOOD CHEM TOXICOL, V42, P1543, DOI 10.1016/j.fct.2003.06.001; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; McCracken S, 1997, ONCOGENE, V15, P2929, DOI 10.1038/sj.onc.1201474; McEleny K, 2004, BJU INT, V94, P402, DOI 10.1111/j.1464-410X.2004.04936.x; Munakata R, 1996, J ORAL PATHOL MED, V25, P441, DOI 10.1111/j.1600-0714.1996.tb00294.x; Nguyen JT, 2003, P NATL ACAD SCI USA, V100, P7533, DOI 10.1073/pnas.1031631100; Panda DK, 2001, J BIOL CHEM, V276, P41229, DOI 10.1074/jbc.M104231200; Reichling T, 2005, CANCER RES, V65, P166; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Schmahl J, 2000, DEVELOPMENT, V127, P65; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Sowter HM, 2001, CANCER RES, V61, P6669; Su AI, 2001, CANCER RES, V61, P7388; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tamm I, 1998, CANCER RES, V58, P5315; Van Huffel S, 2001, J BIOL CHEM, V276, P30216, DOI 10.1074/jbc.M100048200; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vander Poorten VLM, 1999, CANCER, V85, P2255, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2255::AID-CNCR22>3.3.CO;2-4; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Welsh JB, 2001, CANCER RES, V61, P5974; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794	40	80	85	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5626	5639		10.1038/sj.onc.1209566	http://dx.doi.org/10.1038/sj.onc.1209566			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636670				2022-12-25	WOS:000240599100004
J	Karakas, B; Weeraratna, A; Abukhdeir, A; Blair, BG; Konishi, H; Arena, S; Becker, K; Wood, W; Argani, P; De Marzo, AM; Bachman, KE; Park, BH				Karakas, B.; Weeraratna, A.; Abukhdeir, A.; Blair, B. G.; Konishi, H.; Arena, S.; Becker, K.; Wood, W., III; Argani, P.; De Marzo, A. M.; Bachman, K. E.; Park, B. H.			Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells	ONCOGENE			English	Article						p21; TGF-beta; IL-1alpha; breast cancer	BREAST-CANCER CELLS; TGF-BETA; CYCLE ARREST; EXPRESSION; BINDING; GENE; REPRESSION; TGF-BETA-1; LINES; CDK	Transforming growth factor-beta type 1 (TGF-beta) has been implicated as both a tumor suppressor and a tumor promoter in many solid epithelial cancers. We have previously demonstrated that the cyclin dependent kinase (CDK) inhibitor p21 acts as a molecular switch in determining a growth inhibitory versus growth proliferative response to TGF-beta in the spontaneously immortalized human mammary epithelial cell line MCF-10A. We now demonstrate that this proliferative effect of TGF-beta is mediated through the proinflammatory cytokine, interleukin-1 alpha (IL-1 alpha). Using gene expression array analysis, we identified IL-1 alpha as a cytokine specifically upregulated only in cells lacking p21 and only upon TGF-beta stimulation. Cell proliferation assays verified that recombinant IL-1 alpha was capable of inducing a growth proliferative response in p21 null MCF-10A cells, while neutralizing antibodies against IL-1 alpha prevented the growth proliferative effects of TGF-beta. Mechanistically, both the CDK and proliferating cell nuclear antigen (PCNA) inhibitory functions of p21 were responsible for preventing TGF-beta induced cell proliferation, but only PCNA inhibition by p21 regulated IL-1 alpha gene expression. These studies demonstrate a novel role for IL-1 alpha in mediating a proliferative response to TGF-beta signaling, and suggest that therapies directed against IL-1 alpha could abate the growth proliferative effects of TGF-beta without compromising its tumor suppressive function.	Johns Hopkins Univ, Dept Oncol, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA; NIA, Baltimore, MD 21224 USA; Johns Hopkins Univ, Dept Pathol, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore	Park, BH (corresponding author), Johns Hopkins Univ, Dept Oncol, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, 1650 Orleans St,Room 1M42, Baltimore, MD 21231 USA.	bpark2@jhmi.edu	Arena, Sabrina/H-4985-2012	Arena, Sabrina/0000-0002-1318-2494; Abukhdeir, Abde/0000-0003-1172-5819; Konishi, Hiroyuki/0000-0003-1131-4905; Becker, Kevin/0000-0002-6794-6656	NATIONAL CANCER INSTITUTE [R01CA109274, P50CA088843] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [P50 CA88843, R01CA109274-01A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Bachman KE, 2004, CANCER BIOL THER, V3, P221, DOI 10.4161/cbt.3.2.666; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Grille SJ, 2003, CANCER RES, V63, P2172; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Iavarone A, 1997, NATURE, V387, P417; Islam S, 2000, J CELL BIOCHEM, V78, P141, DOI 10.1002/(SICI)1097-4644(20000701)78:1<141::AID-JCB13>3.0.CO;2-R; KLOEN P, 1994, EUR J CANCER, V30A, P678, DOI 10.1016/0959-8049(94)90544-4; KLOEN P, 1994, INT J CANCER, V58, P440, DOI 10.1002/ijc.2910580323; Lei XF, 2002, ONCOGENE, V21, P7514, DOI 10.1038/sj.onc.1205966; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Theocharis SE, 2004, HISTOPATHOLOGY, V45, P103, DOI 10.1111/j.1365-2559.2004.01922.x; TURNER M, 1989, J IMMUNOL, V143, P3556; WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	23	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2006	25	40					5561	5569		10.1038/sj.onc.1209540	http://dx.doi.org/10.1038/sj.onc.1209540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619041				2022-12-25	WOS:000240370400009
J	Masumi, A; Fukazawa, H; Shimazu, T; Yoshida, M; Ozato, K; Komuro, K; Yamaguchi, K				Masumi, A.; Fukazawa, H.; Shimazu, T.; Yoshida, M.; Ozato, K.; Komuro, K.; Yamaguchi, K.			Nucleolin is involved in interferon regulatory factor-2-dependent transcriptional activation	ONCOGENE			English	Article						IRF-2; nucleolin; acetylation	HISTONE ACETYLASE PCAF; H4 GENE-TRANSCRIPTION; HIV-1 TAT; BINDING PROTEIN; FACTOR FAMILY; IRF FAMILY; P300; ACETYLTRANSFERASE; FACTOR-2; COMPLEX	We have previously shown that interferon regulatory factor-2 (IRF-2) is acetylated in a cell growth-dependent manner, which enables it to contribute to the transcription of cell growth-regulated promoters. To clarify the function of acetylation of IRF-2, we investigated the proteins that associate with acetylated IRF-2. In 293T cells, the transfection of p300/CBP-associated factor (PCAF) enhanced the acetylation of IRF-2. In cells transfected with both IRF-2 and PCAF, IRF-2 associated with endogenous nucleolin, while in contrast, minimal association was observed when IRF-2 was transfected with a PCAF histone acetyl transferase (HAT) deletion mutant. In a pull-down experiment using stable transfectants, acetylation-defective mutant IRF-2 (IRF-2K75R) recruited nucleolin to a much lesser extent than wild-type IRF-2, suggesting that nucleolin preferentially associates with acetylated IRF-2. Nucleolin in the presence of PCAF enhanced IRF-2-dependent H4 promoter activity in NIH3T3 cells. Nucleolin knock-down using siRNA reduced the IRF-2/PCAF-mediated promoter activity. Chromatin immunoprecipitation analysis indicated that PCAF transfection increased nucleolin binding to IRF-2 bound to the H4 promoter. We conclude that nucleolin is recruited to acetylated IRF-2, thereby contributing to gene regulation crucial for the control of cell growth.	Natl Inst Infect Dis, Dept Safety Res Blood & Biol Prod, Tokyo 2080011, Japan; Natl Inst Infect Dis, Dept Bioact Mol, Tokyo, Japan; RIKEN, Chem Genet Lab, Wako, Saitama, Japan; NICHHD, Lab Mol Growth & Regulat, NIH, Bethesda, MD 20892 USA	National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID); RIKEN; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Masumi, A (corresponding author), Natl Inst Infect Dis, Dept Safety Res Blood & Biol Prod, 4-7-1,Gakuen, Tokyo 2080011, Japan.	amasumi@nih.go.jp	Yoshida, Minoru/C-8049-2014; SHIMAZU, Tadahiro/ABC-3950-2020	Yoshida, Minoru/0000-0002-4376-5674; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001310] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001310] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Caillaud A, 2002, J BIOL CHEM, V277, P49417, DOI 10.1074/jbc.M207484200; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Ginisty H, 1999, J CELL SCI, V112, P761; Grinstein E, 2002, J EXP MED, V196, P1067, DOI 10.1084/jem.20011053; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Hirano M, 2003, J BIOL CHEM, V278, P5109, DOI 10.1074/jbc.M207629200; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Klibanov SA, 2001, J CELL SCI, V114, P1867; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; Lau OD, 2000, J BIOL CHEM, V275, P21953, DOI 10.1074/jbc.M003219200; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Masumi A, 2003, J BIOL CHEM, V278, P25401, DOI 10.1074/jbc.M213037200; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Santos-Rosa H, 2003, NUCLEIC ACIDS RES, V31, P4285, DOI 10.1093/nar/gkg655; Schaefer BC, 1997, MOL CELL BIOL, V17, P873, DOI 10.1128/MCB.17.2.873; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Stellacci E, 2004, BIOCHEM J, V377, P367, DOI 10.1042/BJ20031166; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Trievel RC, 2000, ANAL BIOCHEM, V287, P319, DOI 10.1006/abio.2000.4855; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang IM, 1996, MOL CELL BIOL, V16, P6313; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Xie RL, 2001, J BIOL CHEM, V276, P18624, DOI 10.1074/jbc.M010391200; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Ying GG, 2000, J BIOL CHEM, V275, P4152, DOI 10.1074/jbc.275.6.4152; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	52	26	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5113	5124		10.1038/sj.onc.1209522	http://dx.doi.org/10.1038/sj.onc.1209522			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16582966				2022-12-25	WOS:000240063700004
J	Ma, Z; Izumi, H; Kanai, M; Kabuyama, Y; Ahn, NG; Fukasawa, K				Ma, Z.; Izumi, H.; Kanai, M.; Kabuyama, Y.; Ahn, N. G.; Fukasawa, K.			Mortalin controls centrosome duplication via modulating centrosomal localization of p53	ONCOGENE			English	Article						mortalin; p53; centrosome; centrosome duplication	CHROMOSOME INSTABILITY; FAMILY; CELLS; CYCLE; PHOSPHORYLATION; AMPLIFICATION; INDUCTION; ARREST; MEMBER; BINDS	Abnormal amplification of centrosomes, commonly found in human cancer, is the major cause of mitotic defects and chromosome instability in cancer cells. Like DNA, centrosomes duplicate once in each cell cycle, hence the defect in the mechanism that ensures centrosome duplication to occur once and only once in each cell cycle results in abnormal amplification of centrosomes and mitotic defects. Centrosomes are non-membranous organelles, and undergo dynamic changes in its constituents during the centrosome duplication cycle. Through a comparative mass spectrometric analysis of unduplicated and duplicated centrosomes, we identified mortalin, a member of heat shock protein family, as a protein that associates preferentially with duplicated centrosomes. Further analysis revealed that mortalin localized to centrosomes in late G1 before centrosome duplication, remained at centrosomes during S and G2, and dissociated from centrosomes during mitosis. Overexpression of mortalin overrides the p53-dependent suppression of centrosome duplication, and mortalin-driven centrosome duplication requires physical interaction between mortalin and p53. Moreover, mortalin promotes dissociation of p53 from centrosomes through physical interaction. The p53 mutant that lacks the ability to bind to mortalin remains at centrosomes, and suppresses centrosome duplication in a transactivation function-independent manner. Thus, our present findings not only identify mortalin as an upstream molecule of p53 but also provide evidence for the involvement of centrosomally localized p53 in the regulation of centrosome duplication.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University System of Ohio; University of Cincinnati; University of Colorado System; University of Colorado Boulder	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.	kenji.fukasawa@uc.edu			NCI NIH HHS [CA90522, CA95925] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090522, R01CA095925] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Hadari YR, 1997, J BIOL CHEM, V272, P657; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Kaul SC, 2002, EXP GERONTOL, V37, P1157, DOI 10.1016/S0531-5565(02)00135-3; Kaul SC, 2001, NEOPLASIA, V3, P110, DOI 10.1038/sj.neo.7900139; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Lange BMH, 1996, TRENDS CELL BIOL, V6, P348, DOI 10.1016/0962-8924(96)10033-7; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Oakley BR, 2000, CURR TOP DEV BIOL, V49, P27; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ran QT, 2000, BIOCHEM BIOPH RES CO, V275, P174, DOI 10.1006/bbrc.2000.3237; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; STEWART N, 1995, ONCOGENE, V10, P109; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; TIMSON J, 1975, MUTAT RES, V32, P115, DOI 10.1016/0165-1110(75)90002-0; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; WADHWA R, 1995, EXP CELL RES, V216, P101, DOI 10.1006/excr.1995.1013; WADHWA R, 1993, EXP CELL RES, V207, P442, DOI 10.1006/excr.1993.1213; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; Wadhwa R, 2002, EXP CELL RES, V274, P246, DOI 10.1006/excr.2002.5468; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	31	69	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5377	5390		10.1038/sj.onc.1209543	http://dx.doi.org/10.1038/sj.onc.1209543			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16619038				2022-12-25	WOS:000240144900003
J	Zhang, Z; Huettner, PC; Nguyen, L; Bidder, M; Funk, MC; Li, J; Rader, JS				Zhang, Z.; Huettner, P. C.; Nguyen, L.; Bidder, M.; Funk, M. C.; Li, J.; Rader, J. S.			Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer	ONCOGENE			English	Article						POU2F3; promoter; hypermethylation; cervical cancer	HISTONE DEACETYLASE INHIBITION; HUMAN CHROMOSOME-11; DOMAIN FACTORS; EXPRESSION; TRANSCRIPTION; DIFFERENTIATION; CELLS; HETEROZYGOSITY; DEMETHYLATION; CARCINOMA	POU2F3 (OCT11, Skn-1a) is a keratinocyte-specific POU transcription factor whose expression is tied to squamous epithelial strati. cation. It is also a candidate tumor suppressor gene in cervical cancer (CC) because it lies in a critical loss of heterozygosity region on11q23.3 in that cancer, and its expression is lost in more than 50% of CC tumors and cell lines. We now report that the loss of POU2F3 expression is tied to the hypermethylation of CpG islands in the POU2F3 promoter. Bisulfite sequencing analysis revealed that methylation of specific CpG sites (-287 to -70 bp) correlated with POU2F3 expression, which could be reactivated with a demethylating agent. Combined bisulfite restriction analysis revealed aberrant methylation of the POU2F3 promoter in 18 of 46 (39%) cervical tumors but never in normal epithelium. POU2F3 expression was downregulated and inversely correlated with promoter hypermethylation in 10 out of 11 CC cell lines. Immunohistochemical analysis on a cervical tissue microarray detected POU2F3 protein in the epithelium above the basal layer. As the disease progressed, expression also decreased, especially in invasive squamous cell cancer (70% loss). Thus, aberrant DNA methylation of the CpG island in POU2F3 promoter appears to play a key role in silencing this gene expression in human CC. The results suggested that POU2F3 might be one of the CC-related tumor suppressor genes, which are disrupted by both epigenetic and genetic mechanisms.	Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Rader, JS (corresponding author), Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, 4911 Barnes Jewish Hosp Plaza,Campus Box 8064, St Louis, MO 63110 USA.	raderj@wustl.edu	Funk, Margo/AAC-2265-2020		NATIONAL CANCER INSTITUTE [R01CA094141, P30CA091842] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA91842, CA94141-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Andersen B, 1997, J BIOL CHEM, V272, P15905, DOI 10.1074/jbc.272.25.15905; Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Davey CS, 2004, NUCLEIC ACIDS RES, V32, P4322, DOI 10.1093/nar/gkh749; Enomoto Y, 2004, ONCOGENE, V23, P5014, DOI 10.1038/sj.onc.1207653; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; GOLDSBOROUGH AS, 1993, NUCLEIC ACIDS RES, V21, P127, DOI 10.1093/nar/21.1.127; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hietala KA, 1997, J PATHOL, V183, P305; Hildesheim J, 2001, J CELL SCI, V114, P1913; HOWLEY PM, 1991, CANCER RES, V51, pS5019; Huettner PC, 1998, HUM PATHOL, V29, P364, DOI 10.1016/S0046-8177(98)90117-4; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kukimoto I, 2001, J VIROL, V75, P9302, DOI 10.1128/JVI.75.19.9302-9311.2001; Li JD, 2005, GYNECOL ONCOL, V96, P150, DOI 10.1016/j.ygyno.2004.08.050; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; O'Sullivan MJ, 2001, HUM PATHOL, V32, P475, DOI 10.1053/hupa.2001.24317; Pennings Sari, 2005, Briefings in Functional Genomics & Proteomics, V3, P351, DOI 10.1093/bfgp/3.4.351; Rader JS, 1996, ONCOGENE, V13, P2737; RADER JS, 1990, ONCOGENE, V5, P571; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; YUKAWA K, 1993, GENE, V133, P163; Yukawa K, 1996, J VIROL, V70, P10, DOI 10.1128/JVI.70.1.10-16.1996; Zhang ZY, 2005, GENE CHROMOSOME CANC, V43, P95, DOI 10.1002/gcc.20151	30	32	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5436	5445		10.1038/sj.onc.1209530	http://dx.doi.org/10.1038/sj.onc.1209530			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16607278				2022-12-25	WOS:000240144900008
J	Chavez-Gutierrez, L; Matta-Camacho, E; Osuna, J; Horjales, E; Joseph-Bravo, P; Maigret, B; Charli, JL				Chavez-Gutierrez, Lucia; Matta-Camacho, Edna; Osuna, Joel; Horjales, Eduardo; Joseph-Bravo, Patricia; Maigret, Bernard; Charli, Jean-Louis			Homology modeling and site-directed mutagenesis of pyroglutamyl peptidase II - Insights into omega-versus aminopeptidase specificity in the M1 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; GUINEA-PIG BRAIN; SUBSTRATE-SPECIFICITY; DEGRADING ECTOENZYME; ESCHERICHIA-COLI; RAT-BRAIN; ASPARTATE-AMINOTRANSFERASE; EXOPEPTIDASE SPECIFICITY; OXYTOCINASE SUBFAMILY; BOVINE BRAIN	Pyroglutamyl peptidase II (PPII), a highly specific membrane-bound omegapeptidase, removes N-terminal pyroglutamyl from thyrotropin-releasing hormone (< Glu-His-Pro-NH2), inactivating the peptide in the extracellular space. PPII and enzymes with distinct specificities such as neutral aminopeptidase (APN), belong to the M1 metallopeptidase family. M1 aminopeptidases recognize the N-terminal amino group of substrates or inhibitors through hydrogen-bonding to two conserved residues (Gln-213 and exopeptidase motif Glu-355 in human APN), whereas interactions involved in recognition of pyroglutamyl residue by PPII are unknown. In rat PPII, the conserved exopeptidase residue is Glu-408, whereas the other one is Ser-269. Given that variations in M1 peptidase specificity are likely due to changes in the catalytic region, we constructed three-dimensional models for the catalytic domains of PPII and APN. The models showed a salt bridge interaction between PPII-Glu-408 and PPII-Lys-463, whereas the equivalent APN-Glu-355 did not participate in a salt bridge. Docking of thyrotropin-releasing hormone in PPII model suggested that the pyroglutamyl residue interacted with PPII-Ser-269. According to our models, PPII-S269Q and -K463N mutations should leave Glu-408 in a physicochemical context similar to that found in M1 aminopeptidases; alternatively, PPII-S269E replacement might be sufficient to transform PPII into an aminopeptidase. These hypotheses were supported by site-directed mutagenesis; the mutants lost omegapeptidase but displayed alanyl-aminopeptidase activity. In conclusion, recognition of a substrate without an N-terminal charge requires neutralization of the aminopeptidase anionic binding site; furthermore, shortening of side chain at PPII-269 position is required for adjustment to the pyroglutamyl residue.	Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Genet Desarrollo & Fisiol Mol, Cuernavaca 62271, Morelos, Mexico; Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Ingn Celular & Biocatalisis, Cuernavaca 62271, Morelos, Mexico; Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Med Mol & Bioproc, Cuernavaca 62271, Morelos, Mexico; Univ Henri Poincare, CNRS, UMR7565, Equipe Dynam Assemblages Membranaires, Nancy, France	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Lorraine	Charli, JL (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Genet Desarrollo & Fisiol Mol, Av Univ 2001, Cuernavaca 62271, Morelos, Mexico.	charli@ibt.unam.mx	charli, jean-louis/K-2546-2014; Chávez-Gutiérrez, Lucía/E-2657-2017	charli, jean-louis/0000-0002-3021-0688; Osuna, Joel/0000-0002-8904-0724				Albiston AL, 2004, PROTEIN PEPTIDE LETT, V11, P491, DOI 10.2174/0929866043406643; BARRET AJ, 1998, HDB PROTEOLYTIC ENZY, P994; BAUER K, 1994, EUR J BIOCHEM, V224, P387, DOI 10.1111/j.1432-1033.1994.00387.x; Bauer K., 1997, CELL SURFACE PEPTIDA, P239; Bourdais J, 2000, NEUROPEPTIDES, V34, P83, DOI 10.1054/npep.2000.0796; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chandu D, 2003, MICROBIOL-SGM, V149, P3437, DOI 10.1099/mic.0.26518-0; Charli J L, 1998, Neurobiology (Bp), V6, P45; CHARLI JL, 1988, NEUROCHEM INT, V13, P237, DOI 10.1016/0197-0186(88)90060-5; CHARLI JL, 1989, NEUROPEPTIDES, V14, P191, DOI 10.1016/0143-4179(89)90044-9; Chavez-Gutierrez L, 2005, J NEUROCHEM, V92, P807, DOI 10.1111/j.1471-4159.2004.02916.x; Chow MA, 2004, BIOCHEMISTRY-US, V43, P12780, DOI 10.1021/bi0487544; Diaz-Perales A, 2005, J BIOL CHEM, V280, P14310, DOI 10.1074/jbc.M413222200; ELMORE MA, 1990, NEUROPEPTIDES, V15, P31, DOI 10.1016/0143-4179(90)90157-T; FRIEDMAN TC, 1986, J NEUROCHEM, V46, P1231, DOI 10.1111/j.1471-4159.1986.tb00643.x; Gallagher SP, 1998, INT J BIOCHEM CELL B, V30, P115, DOI 10.1016/S1357-2725(97)00074-5; Gary KA, 2003, J PHARMACOL EXP THER, V305, P410, DOI 10.1124/jpet.102.044040; GRIFFITHS EC, 1985, REGUL PEPTIDES, V10, P145, DOI 10.1016/0167-0115(85)90009-6; Horita A, 1998, LIFE SCI, V62, P1443, DOI 10.1016/S0024-3205(98)00087-3; Kelly JA, 2000, J BIOL CHEM, V275, P16746, DOI 10.1074/jbc.M910386199; Kelly JA, 2005, BIOCHEM J, V389, P569, DOI 10.1042/BJ20041722; Kelly JA, 1995, ESSAYS BIOCHEM, V30, P133; Kyrieleis OJP, 2005, J MOL BIOL, V349, P787, DOI 10.1016/j.jmb.2005.03.070; Lodeiro S, 2005, J AM CHEM SOC, V127, P14132, DOI 10.1021/ja053791j; Luciani N, 1998, BIOCHEMISTRY-US, V37, P686, DOI 10.1021/bi971705p; Lund O., 2002, CASP5 C, pA102; MORLEY JE, 1979, LIFE SCI, V25, P1539, DOI 10.1016/0024-3205(79)90435-1; Nanus DM, 2003, CLIN CANCER RES, V9, P6307; Nillni EA, 1999, ENDOCR REV, V20, P599, DOI 10.1210/er.20.5.599; Nobeli I, 2005, J MOL BIOL, V347, P415, DOI 10.1016/j.jmb.2005.01.061; OCONNOR B, 1984, EUR J BIOCHEM, V144, P271, DOI 10.1111/j.1432-1033.1984.tb08460.x; OCONNOR B, 1985, EUR J BIOCHEM, V150, P47, DOI 10.1111/j.1432-1033.1985.tb08986.x; OCUINN G, 1990, J NEUROCHEM, V54, P1, DOI 10.1111/j.1471-4159.1990.tb13276.x; OLEARY R, 1995, J NEUROCHEM, V65, P953; OLEARY RM, 1995, INT J BIOCHEM CELL B, V27, P881, DOI 10.1016/1357-2725(95)00065-W; ONUFFER JJ, 1995, PROTEIN SCI, V4, P1750, DOI 10.1002/pro.5560040910; Papadopoulos T, 2001, BIOCHEMISTRY-US, V40, P9347, DOI 10.1021/bi010695w; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; Rozenfeld R, 2003, BIOCHEMISTRY-US, V42, P14785, DOI 10.1021/bi034358u; Rozenfeld R, 2002, J BIOL CHEM, V277, P29242, DOI 10.1074/jbc.M204406200; Rudberg PC, 2002, J BIOL CHEM, V277, P1398, DOI 10.1074/jbc.M106577200; Sato Y, 2004, BIOL PHARM BULL, V27, P772, DOI 10.1248/bpb.27.772; SCHAUDER B, 1994, P NATL ACAD SCI USA, V91, P9534, DOI 10.1073/pnas.91.20.9534; Schomburg L, 1999, EUR J BIOCHEM, V265, P415, DOI 10.1046/j.1432-1327.1999.00753.x; Smits G, 2002, MOL ENDOCRINOL, V16, P722, DOI 10.1210/me.16.4.722; Tanaka T, 2004, BIOCHEM BIOPH RES CO, V323, P947, DOI 10.1016/j.bbrc.2004.08.191; Tanioka T, 2003, J BIOL CHEM, V278, P32275, DOI 10.1074/jbc.M305076200; Thunnissen MMGM, 2001, NAT STRUCT BIOL, V8, P131, DOI 10.1038/84117; Tsujimoto M, 2005, BBA-PROTEINS PROTEOM, V1751, P9, DOI 10.1016/j.bbapap.2004.09.011; UMEZAWA H, 1985, J ANTIBIOT, V38, P1629, DOI 10.7164/antibiotics.38.1629; Urban A, 1997, NUCLEIC ACIDS RES, V25, P2227, DOI 10.1093/nar/25.11.2227; Vazeux G, 1998, BIOCHEM J, V334, P407, DOI 10.1042/bj3340407; WILK S, 1989, NEUROCHEM INT, V15, P81, DOI 10.1016/0197-0186(89)90079-X; Zhang HG, 2002, GENETICS, V162, P1283; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968	55	16	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18581	18590		10.1074/jbc.M601392200	http://dx.doi.org/10.1074/jbc.M601392200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16611635	hybrid			2022-12-25	WOS:000238687300037
J	Kato, K; Jeanneau, C; Tarp, MA; Benet-Pages, A; Lorenz-Depiereux, B; Bennett, EP; Mandel, U; Strom, TM; Clausen, H				Kato, Kentaro; Jeanneau, Charlotte; Tarp, Mads Agervig; Benet-Pages, Anna; Lorenz-Depiereux, Bettina; Bennett, Eric Paul; Mandel, Ulla; Strom, Tim M.; Clausen, Henrik			Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis - Secretion of fibroblast growth factor 23 requires O-glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; DOMINANT HYPOPHOSPHATEMIC RICKETS; LOW-DENSITY-LIPOPROTEIN; N-ACETYLGALACTOSAMINYLTRANSFERASE; UDP-GALNAC; MEDIATED ENDOCYTOSIS; PROTEOLYTIC CLEAVAGE; MOLECULAR-CLONING; CAUSATIVE FACTOR; ST6GALNAC I	Mutations in the gene encoding the glycosyltransferase polypeptide GalNAc-T3, which is involved in initiation of O-glycosylation, were recently identified as a cause of the rare autosomal recessive metabolic disorder familial tumoral calcinosis (OMIM 211900). Familial tumoral calcinosis is associated with hyperphosphatemia and massive ectopic calcifications. Here, we demonstrate that the secretion of the phosphaturic factor fibroblast growth factor 23 (FGF23) requires O-glycosylation, and that GalNAc-T3 selectively directs O-glycosylation in a subtilisin-like proprotein convertase recognition sequence motif, which blocks processing of FGF23. The study suggests a novel posttranslational regulatory model of FGF23 involving competing O-glycosylation and protease processing to produce intact FGF23.	Univ Copenhagen, Dept Med Biochem & Genet, Fac Hlth Sci, DK-2200 Copenhagen N, Denmark; GSF Munich, Natl Res Ctr, Inst Human Genet, D-85764 Munich, Germany; Univ Copenhagen, Sch Dent, Fac Hlth Sci, DK-2200 Copenhagen N, Denmark; Tech Univ, Klinikum Rechts Isar, Inst Human Genet, D-81675 Munich, Germany	University of Copenhagen; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Copenhagen; Technical University of Munich	Clausen, H (corresponding author), Univ Copenhagen, Dept Med Biochem & Genet, Fac Hlth Sci, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	hc@imbg.ku.dk	clausen, henrik/AAD-8016-2021	Clausen, Henrik/0000-0002-0915-5055; Kato, Kentaro/0000-0003-4890-567X; Bennett, Eric Paul/0000-0002-4976-0647; Mandel, Ulla/0000-0001-7012-9836				Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Araya K, 2005, J CLIN ENDOCR METAB, V90, P5523, DOI 10.1210/jc.2005-0301; Atiya-Nasagi Y, 2005, J CELL SCI, V118, P1363, DOI 10.1242/jcs.01710; Benet-Pages A, 2005, HUM MOL GENET, V14, P385, DOI 10.1093/hmg/ddi034; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Beret-Pages A, 2004, BONE, V35, P455, DOI 10.1016/j.bone.2004.04.002; Berois N, 2006, J HISTOCHEM CYTOCHEM, V54, P317, DOI 10.1369/jhc.5A6783.2005; BIRCH NP, 1991, FEBS LETT, V290, P191, DOI 10.1016/0014-5793(91)81257-9; Campagnoli MF, 2006, J CLIN PATHOL, V59, P440, DOI 10.1136/jcp.2005.026369; Cao J, 2005, J BIOL CHEM, V280, P10974, DOI 10.1074/jbc.M412370200; Duguay SJ, 1998, J BIOL CHEM, V273, P18443, DOI 10.1074/jbc.273.29.18443; George SK, 2001, J AM CHEM SOC, V123, P11117, DOI 10.1021/ja015570t; Harduin-Lepers A, 2000, BIOCHEM J, V352, P37, DOI 10.1042/0264-6021:3520037; Hassan H, 2000, CARBOHYDRATES CHEM B, P273, DOI DOI 10.1002/9783527618255.CH55; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; Hizuka N, 1998, J CLIN ENDOCR METAB, V83, P2875, DOI 10.1210/jc.83.8.2875; Ichikawa S, 2005, J CLIN ENDOCR METAB, V90, P2420, DOI 10.1210/jc.2004-2302; Ikehara Y, 1999, GLYCOBIOLOGY, V9, P1213, DOI 10.1093/glycob/9.11.1213; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Jin WJ, 2005, J BIOL CHEM, V280, P36551, DOI 10.1074/jbc.M502264200; Ju TZ, 2002, J BIOL CHEM, V277, P178, DOI 10.1074/jbc.M109060200; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; Kono M, 2000, BIOCHEM BIOPH RES CO, V272, P94, DOI 10.1006/bbrc.2000.2745; KOZARSKY KF, 1988, MOL CELL BIOL, V8, P3357, DOI 10.1128/MCB.8.8.3357; Kurosawa N, 2000, J BIOCHEM-TOKYO, V127, P845, DOI 10.1093/oxfordjournals.jbchem.a022678; Larsson T, 2005, ENDOCRINOLOGY, V146, P3883, DOI 10.1210/en.2005-0431; Larsson T, 2003, EUR J ENDOCRINOL, V148, P269, DOI 10.1530/eje.0.1480269; Leuenberger B, 2003, BIOCHEM J, V369, P659, DOI 10.1042/BJ20021398; Mandel U, 1999, GLYCOBIOLOGY, V9, P43, DOI 10.1093/glycob/9.1.43; Manzi AE, 2000, GLYCOBIOLOGY, V10, P669, DOI 10.1093/glycob/10.7.669; Marcos NT, 2004, CANCER RES, V64, P7050, DOI 10.1158/0008-5472.CAN-04-1921; Marth JD, 1996, GLYCOBIOLOGY, V6, P701, DOI 10.1093/glycob/6.7.701; Nehrke K, 1998, GLYCOBIOLOGY, V8, P367, DOI 10.1093/glycob/8.4.367; Pratt MR, 2004, CHEM BIOL, V11, P1009, DOI 10.1016/j.chembiol.2004.05.009; Proszynski TJ, 2004, MOL BIOL CELL, V15, P1533, DOI 10.1091/mbc.E03-07-0511; SASAKI H, 1988, BIOCHEMISTRY-US, V27, P8618, DOI 10.1021/bi00423a017; Schwientek T, 2002, J BIOL CHEM, V277, P22623, DOI 10.1074/jbc.M202684200; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Shimada T, 2002, ENDOCRINOLOGY, V143, P3179, DOI 10.1210/en.143.8.3179; Shimada T, 2001, BONE, V28, pS89; Sorensen AL, 2006, GLYCOBIOLOGY, V16, P96, DOI 10.1093/glycob/cwj044; SPECKTOR P, 2006, IN PRESS J HUM GENET; Spodsberg N, 2001, J BIOL CHEM, V276, P46597, DOI 10.1074/jbc.M108187200; Sutherlin ME, 1997, CANCER RES, V57, P4744; Ten Hagen KG, 2002, J BIOL CHEM, V277, P22616, DOI 10.1074/jbc.M201807200; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Tenno M, 2005, GLYCOBIOLOGY, V15, P1238; Topaz O, 2004, NAT GENET, V36, P579, DOI 10.1038/ng1358; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; White KE, 2006, ENDOCR REV, V27, P221, DOI 10.1210/er.2005-0019; White KE, 2001, KIDNEY INT, V60, P2079, DOI 10.1046/j.1523-1755.2001.00064.x; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Young WW, 2003, GLYCOBIOLOGY, V13, P549, DOI 10.1093/glycob/cwg062; Zhang Y, 2003, J BIOL CHEM, V278, P573, DOI 10.1074/jbc.M203094200; Zheng XL, 2002, J BIOL CHEM, V277, P6858, DOI 10.1074/jbc.M109857200; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	63	315	328	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18370	18377		10.1074/jbc.M602469200	http://dx.doi.org/10.1074/jbc.M602469200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16638743	hybrid			2022-12-25	WOS:000238687300014
J	Chen, YH; Reilly, K; Chang, YC				Chen, Yonghui; Reilly, Kevin; Chang, Yongchang			Evolutionarily conserved allosteric network in the Cys loop family of ligand-gated ion channels revealed by statistical covariance analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GABA(A) RECEPTOR; AGONIST BINDING; AMINO-ACID; TRANSMEMBRANE DOMAIN; RECOMBINANT HUMAN; CRYSTAL-STRUCTURE; M2-M3 LOOP; MUTATIONS; RESIDUE	The Cys loop family of ligand-gated ion channels mediate fast synaptic transmission for communication between neurons. They are allosteric proteins, in which binding of a neurotransmitter to its binding site in the extracellular amino-terminal domain triggers structural changes in distant transmembrane domains to open a channel for ion flow. Although the locations of binding site and channel gating machinery are well defined, the structural basis of the activation pathway coupling binding and channel opening remains to be determined. In this paper, by analyzing amino acid covariance in a multiple sequence alignment, we have identified an energetically interconnected network in the Cys loop family of ligand-gated ion channels. Statistical coupling and correlated mutational analyses along with clustering revealed a highly coupled cluster. Mapping the positions in the cluster onto a three-dimensional structural model demonstrated that these highly coupled positions form an interconnected network linking experimentally identified binding domains through the coupling region to the gating machinery. In addition, these highly coupled positions are also condensed in the transmembrane domains, which are a recent focus for the sites of action of many allosteric modulators. Thus, our results revealed a genetically interconnected network that potentially plays an important role in the allosteric activation and modulation of the Cys loop family of ligand-gated ion channels.	Barrow Neurol Inst, Div Neurobiol, Phoenix, AZ 85013 USA; Univ Alabama Birmingham, Dept Comp & Informat Sci, Birmingham, AL 35294 USA	Barrow Neurological Institute; University of Alabama System; University of Alabama Birmingham	Chang, YC (corresponding author), Barrow Neurol Inst, Div Neurobiol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	yongchang.chang@chw.edu						Absalom NL, 2004, EXP PHYSIOL, V89, P145, DOI 10.1113/expphysiol.2003.026815; Amin J, 1999, MOL PHARMACOL, V55, P411; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Boileau AJ, 1999, J NEUROSCI, V19, P10213; Boileau AJ, 2002, J BIOL CHEM, V277, P2931, DOI 10.1074/jbc.M109334200; Bouzat C, 2000, J GEN PHYSIOL, V115, P663, DOI 10.1085/jgp.115.5.663; Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; Bouzat C, 2002, BIOPHYS J, V82, P1920, DOI 10.1016/S0006-3495(02)75541-0; Breitinger HG, 2004, CHEM BIOL, V11, P1339, DOI 10.1016/j.chembiol.2004.07.008; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CamposCaro A, 1996, P NATL ACAD SCI USA, V93, P6118, DOI 10.1073/pnas.93.12.6118; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; Chakrapani S, 2004, J GEN PHYSIOL, V123, P341, DOI 10.1085/jgp.200309004; Chang CSS, 2003, J BIOL CHEM, V278, P42821, DOI 10.1074/jbc.M306978200; Chang YC, 1999, BIOPHYS J, V77, P2542, DOI 10.1016/S0006-3495(99)77089-X; Chang YC, 1996, J NEUROSCI, V16, P5415; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; Chang YC, 1999, NAT NEUROSCI, V2, P219, DOI 10.1038/6313; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Davies M, 2001, J NEUROCHEM, V79, P55, DOI 10.1046/j.1471-4159.2001.00527.x; De Rosa MJ, 2002, MOL PHARMACOL, V62, P406, DOI 10.1124/mol.62.2.406; Filizola M, 2002, PROTEIN ENG, V15, P881, DOI 10.1093/protein/15.11.881; Fodor AA, 2004, PROTEINS, V56, P211, DOI 10.1002/prot.20098; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GOBEL U, 1994, PROTEINS, V18, P309, DOI 10.1002/prot.340180402; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Hatley ME, 2003, P NATL ACAD SCI USA, V100, P14445, DOI 10.1073/pnas.1835919100; Hemmings HC, 2005, TRENDS PHARMACOL SCI, V26, P503, DOI 10.1016/j.tips.2005.08.006; Jensen ML, 2005, J NEUROCHEM, V92, P962, DOI 10.1111/j.1471-4159.2004.02970.x; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kash TL, 2004, J BIOL CHEM, V279, P4887, DOI 10.1074/jbc.M311441200; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; Lee WY, 2005, NATURE, V438, P243, DOI 10.1038/nature04156; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; LO DC, 1991, NEURON, V6, P31, DOI 10.1016/0896-6273(91)90119-K; Lobitz N, 2001, MOL PHARMACOL, V59, P844, DOI 10.1124/mol.59.4.844; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Lummis SCR, 2005, NATURE, V438, P248, DOI 10.1038/nature04130; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; MCLACHLAN AD, 1971, J MOL BIOL, V61, P409, DOI 10.1016/0022-2836(71)90390-1; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miko A, 2004, J BIOL CHEM, V279, P22833, DOI 10.1074/jbc.M402577200; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Morris KDW, 2004, MOL PHARMACOL, V66, P56, DOI 10.1124/mol.66.1.56; Newell JG, 2004, J NEUROSCI, V24, P11226, DOI 10.1523/JNEUROSCI.3746-04.2004; Nishikawa K, 2003, ANESTHESIOLOGY, V99, P678, DOI 10.1097/00000542-200309000-00024; Olmea O, 1999, J MOL BIOL, V293, P1221, DOI 10.1006/jmbi.1999.3208; Olsen RW, 2004, BIOCHEM PHARMACOL, V68, P1675, DOI 10.1016/j.bcp.2004.07.026; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Pan ZH, 1997, P NATL ACAD SCI USA, V94, P6490, DOI 10.1073/pnas.94.12.6490; Pan ZH, 2000, NEUROSCIENCE, V98, P333, DOI 10.1016/S0306-4522(00)00114-7; Pratt MB, 2000, J BIOL CHEM, V275, P29441, DOI 10.1074/jbc.M004710200; Reeves DC, 2005, J NEUROSCI, V25, P9358, DOI 10.1523/JNEUROSCI.1045-05.2005; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; Rovira JC, 1999, PFLUG ARCH EUR J PHY, V439, P86, DOI 10.1007/s004240051131; Sedelnikova A, 2005, J BIOL CHEM, V280, P1535, DOI 10.1074/jbc.M409908200; Shulman AI, 2004, CELL, V116, P417, DOI 10.1016/S0092-8674(04)00119-9; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; Torres VI, 2002, J BIOL CHEM, V277, P43741, DOI 10.1074/jbc.M202007200; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Wotring VE, 2003, J PHYSIOL-LONDON, V548, P527, DOI 10.1113/jphysiol.2002.032045; Xiu XN, 2005, J BIOL CHEM, V280, P41655, DOI 10.1074/jbc.M508635200	68	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18184	18192		10.1074/jbc.M600349200	http://dx.doi.org/10.1074/jbc.M600349200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16595655	hybrid			2022-12-25	WOS:000238490300070
J	Crouch, E; McDonald, B; Smith, K; Cafarella, T; Seaton, B; Head, J				Crouch, Erika; McDonald, Barbara; Smith, Kelly; Cafarella, Tanya; Seaton, Barbara; Head, James			Contributions of phenylalanine 335 to ligand recognition by human surfactant protein D - Ring interactions with SP-D ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; CARBOHYDRATE-RECOGNITION; CRYSTAL-STRUCTURE; CONCANAVALIN-A; DOMAIN; SYSTEM	Surfactant protein D (SP-D) is an innate immune effector that contributes to antimicrobial host defense and immune regulation. Interactions of SP-D with microorganisms and organic antigens involve binding of glycoconjugates to the C-type lectin carbohydrate recognition domain (CRD). A trimeric fusion protein encoding the human neck + CRD bound to the aromatic glycoside p-nitrophenyl-alpha-D-maltoside with nearly a log-fold higher affinity than maltose, the prototypical competitor. Maltotriose, which has the same linkage pattern as the maltoside, bound with intermediate affinity. Site-directed substitution of leucine for phenylalanine 335 (Phe-335) decreased affinities for the maltoside and maltotriose without significantly altering the affinity for maltose or glucose, and substitution of tyrosine or tryptophan for leucine restored preferential binding to maltotriose and the maltoside. A mutant with alanine at this position failed to bind to mannan or maltose-substituted solid supports. Crystallographic analysis of the human neck + CRD complexed with maltotriose or p-nitrophenyl-maltoside showed stacking of the terminal glucose or nitrophenyl ring with the aromatic ring of Phe-335. Our studies indicate that Phe-335, which is evolutionarily conserved in all known SP-Ds, plays important, if not critical, roles in SP-D function.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	Washington University (WUSTL); Boston University	Crouch, E (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	crouch@path.wustl.edu		Seaton, Barbara/0000-0003-4654-7709; Head, James/0000-0002-6226-4146	NHLBI NIH HHS [HL 44015, HL 29594] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044015, P01HL029594] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clark H, 2002, IMMUNOBIOLOGY, V205, P619, DOI 10.1078/0171-2985-00159; Crouch E, 2005, J BIOL CHEM, V280, P17046, DOI 10.1074/jbc.M413932200; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Crouch E C, 2000, Respir Res, V1, P93; Crouch EC, 2003, INFEC DIS S, P205; DEBOECK H, 1984, J BIOL CHEM, V259, P7067; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; HASSING GS, 1970, EUR J BIOCHEM, V16, P549, DOI 10.1111/j.1432-1033.1970.tb01116.x; Hawgood S, 2001, ANNU REV PHYSIOL, V63, P495, DOI 10.1146/annurev.physiol.63.1.495; Head JF, 2003, J BIOL CHEM, V278, P43254, DOI 10.1074/jbc.M305628200; Holmskov UL, 2000, APMIS, V108, P7; Ikegami M, 2005, AM J PHYSIOL-LUNG C, V288, pL552, DOI 10.1152/ajplung.00142.2004; JONES TA, 1992, O MANUAL; Kanellopoulos PN, 1996, J STRUCT BIOL, V116, P345, DOI 10.1006/jsbi.1996.0052; Kleywegt G. J., 1995, CCP4 ESF EACBM NEWSL, V31, P45; Mullin NP, 1997, J BIOL CHEM, V272, P5668, DOI 10.1074/jbc.272.9.5668; MULLIN NP, 1994, J BIOL CHEM, V269, P28405; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; Shrive AK, 2003, J MOL BIOL, V331, P509, DOI 10.1016/S0022-2836(03)00761-7; Taylor ME, 2003, METHOD ENZYMOL, V363, P3; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Zelensky AN, 2003, PROTEINS, V52, P466, DOI 10.1002/prot.10626	27	27	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18008	18014		10.1074/jbc.M601749200	http://dx.doi.org/10.1074/jbc.M601749200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636058	hybrid			2022-12-25	WOS:000238490300051
J	Hirabayashi, N; Sato, NS; Suzuki, T				Hirabayashi, Naomi; Sato, Neuza mi Sato; Suzuki, Tsutomu			Conserved loop sequence of Helix 69 in Escherichia coli 23 S rRNA is involved in A-site tRNA binding and translational fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; RIBOSOMAL-RNA; ANGSTROM RESOLUTION; ACTIVE-ROLE; TERMINATION; SUBUNIT; PSEUDOURIDINES; VISUALIZATION	Ribosomal (r) RNAs play a crucial role in the fundamental structure and function of the ribosome. Helix 69 (H69) (position 1906 1924), a highly conserved stem-loop in domain IV of the 23 S rRNA of bacterial 50 S subunits, is located on the surface for intersubunit association with the 30 S subunit by connecting with helix 44 of 16 S rRNA with the bridge B2a. H69 directly interacts with A/T-, A-, and P-site tRNAs during each translation step. To investigate the functional importance of the highly conserved loop sequence (1912 1918) of H69, we employed a genetic method that we named SSER (systematic selection of functional sequences by enforced replacement). This method allowed us to identify and select from the randomized loop sequences of H69 in Escherichia coli 23 S rRNA functional sequences that are absolutely required for ribosomal function. From a library consisting of 16,384 sequence variations, 13 functional variants were obtained. A1912 and U(Psi) 1917 were selected as essential residues in all variants. An E. coli strain having 23 S rRNA with a U to A mutation at position 1915 showed a severe growth phenotype and low translational fidelity. The result could be explained by the fact that the A1915-ribosome variant has weak subunit association, weak A-site tRNA binding, and decreased translational activity. This study proposes that H69 plays an important role in the control of translational fidelity by modulating A-site tRNA binding during the decoding process.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biochem, Bunkyo Ku, Tokyo 1138656, Japan	University of Tokyo	Suzuki, T (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	ts@chembio.t.u-tokyo.ac.jp	Suzuki, Tsutomu/J-1776-2015; SATO, Neuza/C-8102-2012	Suzuki, Tsutomu/0000-0002-9731-1731; 				Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Asai T, 1999, P NATL ACAD SCI USA, V96, P1971, DOI 10.1073/pnas.96.5.1971; Cochella L, 2005, SCIENCE, V308, P1178, DOI 10.1126/science.1111408; CORNISHBOWDEN A, 1985, NUCLEIC ACIDS RES, V13, P3021, DOI 10.1093/nar/13.9.3021; Dallas A, 2001, MOL CELL, V8, P855, DOI 10.1016/S1097-2765(01)00356-2; Daviter T, 2005, SCIENCE, V308, P1123, DOI 10.1126/science.1113415; GUTELL RR, 1988, NUCLEIC ACIDS RES, V16, pR175, DOI 10.1093/nar/16.suppl.r175; Gutgsell NS, 2005, RNA, V11, P1141, DOI 10.1261/rna.2550105; Hanada T, 2001, GENES CELLS, V6, P1019, DOI 10.1046/j.1365-2443.2001.00491.x; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HIRSH, 1971, J MOL BIOL, V58, P439, DOI 10.1016/0022-2836(71)90362-7; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; Klaholz BP, 2004, NATURE, V427, P862, DOI 10.1038/nature02332; Liiv A, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-18; Miller JH., 1992, SHORT COURSE BACTERI, P72; OCONNOR M, 1995, J MOL BIOL, V254, P838, DOI 10.1006/jmbi.1995.0659; Ofengand J, 2001, METHODS, V25, P365, DOI 10.1006/meth.2001.1249; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; Raychaudhuri S, 1998, RNA, V4, P1407, DOI 10.1017/S1355838298981146; Saka K, 2005, DNA RES, V12, P63, DOI 10.1093/dnares/12.1.63; Schuwirth BS, 2005, SCIENCE, V310, P827, DOI 10.1126/science.1117230; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; SPEDDING G, 1990, ISOLATION ANAL RIBOS, P1; Valle M, 2003, NAT STRUCT BIOL, V10, P899, DOI 10.1038/nsb1003; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; Wilson DN, 2005, EMBO J, V24, P251, DOI 10.1038/sj.emboj.7600525; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	28	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17203	17211		10.1074/jbc.M511728200	http://dx.doi.org/10.1074/jbc.M511728200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16621804	hybrid			2022-12-25	WOS:000238326300046
J	Simpson, RE; Ciruela, A; Cooper, DMF				Simpson, Rachel E.; Ciruela, Antonio; Cooper, Dermot M. F.			The role of calmodulin recruitment in Ca2+ stimulation of adenylyl cyclase type 8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; ADENYLYL-CYCLASE; CA2+-DEPENDENT INACTIVATION; TARGET RECOGNITION; PLASMA-MEMBRANE; CALCIUM; DOMAINS; BINDING; CELLS; PROTEIN	Ca2(+) stimulation of adenylyl cyclase type 8 (AC8) is mediated by calmodulin (CaM). An earlier study identified two CaM binding sites in AC8; one that was apparently not essential for AC8 activity, located at the N terminus, and a second site that was critical for Ca2+ stimulation, found at the C terminus (Gu, C., and Cooper, D. M. F. (1999) J. Biol. Chem. 274, 8012-8021). This study explores the role of these two CaM binding domains and their interaction in regulating AC8 activity, employing binding and functional studies with mutant CaM and modified AC8 species. We report that the N-terminal CaM binding domain of AC8 has a role in recruiting CaM and that this recruitment is essential to permit stimulation by Ca2+ in vivo. Using Ca2+ insensitive mutants of CaM, we found that partially liganded CaM can bind to AC8, but only fully liganded Ca2+/CaM can stimulate AC8 activity. Moreover, partially liganded CaM inhibited AC8 activity in vivo. The results indicate that CaM pre- associates with the N terminus of AC8, and we suggest that this recruited CaM is used by the C terminus of AC8 to mediate Ca2+ stimulation.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	Cooper, DMF (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	dmfc2@cam.ac.uk			NIGMS NIH HHS [GM 32483] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; Bradley J, 2004, NAT NEUROSCI, V7, P705, DOI 10.1038/nn1266; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cooper DMF, 2003, BIOCHEM J, V375, P517, DOI 10.1042/BJ20031061; Crossthwaite AJ, 2005, J BIOL CHEM, V280, P6380, DOI 10.1074/jbc.M411987200; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Drum CL, 2000, J BIOL CHEM, V275, P36334, DOI 10.1074/jbc.M004778200; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Fagan KA, 2000, J BIOL CHEM, V275, P26530, DOI 10.1074/jbc.M001369200; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Gaertner TR, 2004, J BIOL CHEM, V279, P39374, DOI 10.1074/jbc.M405352200; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Kim J, 2004, J BIOL CHEM, V279, P45004, DOI 10.1074/jbc.M407286200; Krueger JK, 2001, J BIOL CHEM, V276, P4535, DOI 10.1074/jbc.C000857200; Mori MX, 2004, SCIENCE, V304, P432, DOI 10.1126/science.1093490; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; Persechini A, 1999, J BIOL CHEM, V274, P6827, DOI 10.1074/jbc.274.11.6827; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Smith KE, 2002, J BIOL CHEM, V277, P6025, DOI 10.1074/jbc.M109615200; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sonnenburg WK, 1995, J BIOL CHEM, V270, P30989, DOI 10.1074/jbc.270.52.30989; Tran QK, 2003, J BIOL CHEM, V278, P24247, DOI 10.1074/jbc.C300165200; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Xiong LW, 2005, J BIOL CHEM, V280, P7070, DOI 10.1074/jbc.M410558200	41	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17379	17389		10.1074/jbc.M510992200	http://dx.doi.org/10.1074/jbc.M510992200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16613843	hybrid			2022-12-25	WOS:000238326300064
J	Rist, W; Graf, C; Bukau, B; Mayer, MP				Rist, Wolfgang; Graf, Christian; Bukau, Bernd; Mayer, Matthias P.			Amide hydrogen exchange reveals conformational changes in Hsp70 chaperones important for allosteric regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; SUBSTRATE-BINDING DOMAIN; MOLECULAR CHAPERONE; ATPASE FRAGMENT; DNAK CHAPERONE; INTERDOMAIN COMMUNICATION; TRANSCRIPTION FACTOR; MASS-SPECTROMETRY; STRUCTURAL BASIS; SWISS-MODEL	Hsp70 chaperones assist protein folding processes by a nucleotide-driven cycle of substrate binding and release. Although structural information is available for the isolated nucleotide-binding (NBD) and substrate-binding domains (SBD) in the high affinity conformation, the low affinity conformations and the conformational changes associated with mutual allosteric regulation remained largely enigmatic. By using amide hydrogen exchange in combination with mass spectrometry, we analyzed the Escherichia coli Hsp70 homologue DnaK as full-length protein and its individual domains in the nucleotide-free and ATP-bound conformation. We found a surprising degree of flexibility in both domains. The comparison of the full-length protein with the isolated domains demonstrates a mutual stabilization of both domains. This protection from solvent was most pronounced and in addition was nucleotide-dependent in the lower beta-sheet of the SBD and the loop that connects the last beta-strand with helix alpha A. Interestingly, the linker region, which connects NBD and SBD and which is close to the protected loop in the SBD, is solvent-exposed in the absence of nucleotide and completely protected from hydrogen exchange in the presence of ATP. Peptide binding to DnaK.ATP reverts the ATP-induced conformational changes in the linker and selected parts of the NBD. Our data outline a pathway for allosteric interdomain control and suggest an important role of the linker and the base of helix alpha A.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bukau, B (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	Bukau@zmbh.uni-heidelberg.de; M.Mayer@zmbh.uni-heidelberg.de	Mayer, Matthias P./B-9340-2013; Gimenez, Luis E Diaz/D-9291-2011	Mayer, Matthias P./0000-0002-7859-3112; Bukau, Bernd/0000-0003-0521-7199; Rist, Wolfgang/0000-0002-0626-3544				Barthel TK, 2001, J BACTERIOL, V183, P5482, DOI 10.1128/JB.183.19.5482-5490.2001; Bertelsen EB, 1999, PROTEIN SCI, V8, P343; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; Jiang JW, 2005, MOL CELL, V20, P513, DOI 10.1016/j.molcel.2005.09.028; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Mayer MP, 2000, BIOL CHEM, V381, P877, DOI 10.1515/BC.2000.109; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Revington M, 2005, J MOL BIOL, V349, P163, DOI 10.1016/j.jmb.2005.03.033; Revington M, 2004, J BIOL CHEM, V279, P33958, DOI 10.1074/jbc.M313967200; Rist W, 2005, ANAL BIOCHEM, V342, P160, DOI 10.1016/j.ab.2004.11.043; Rist W, 2005, PROTEIN SCI, V14, P626, DOI 10.1110/ps.041098305; Rist W, 2003, J BIOL CHEM, V278, P51415, DOI 10.1074/jbc.M307160200; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P16749, DOI 10.1021/bi981738k; Sousa MC, 1998, BIOCHEMISTRY-US, V37, P15392, DOI 10.1021/bi981510x; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Vogel M, 2006, MOL CELL, V21, P359, DOI 10.1016/j.molcel.2005.12.017; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; Zhang YB, 2004, P NATL ACAD SCI USA, V101, P10272, DOI 10.1073/pnas.0401313101; Zhang ZQ, 1998, J AM SOC MASS SPECTR, V9, P225, DOI 10.1016/S1044-0305(97)00284-5; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	36	107	107	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16493	16501		10.1074/jbc.M600847200	http://dx.doi.org/10.1074/jbc.M600847200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16613854	hybrid			2022-12-25	WOS:000238165700039
J	Zheng, Y; Rodrik, V; Toschi, A; Shi, M; Hui, L; Shen, YJ; Foster, DA				Zheng, Yang; Rodrik, Vanessa; Toschi, Alfredo; Shi, Ming; Hui, Li; Shen, Yingjie; Foster, David A.			Phospholipase D couples survival and migration signals in stress response of human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; PHOSPHATIDIC-ACID; FIBER FORMATION; RALA; ACTIVATION; ARF; METASTASIS; EXPRESSION; SECRETION; 3-KINASE	MDA-MB-231 human breast cancer cells belong to a highly invasive metastatic cell line that depends on phospholipase D (PLD) activity for survival when deprived of serum growth factors. In response to the stress of serum withdrawal, there is a rapid and dramatic increase in PLD activity. Concomitant with increased PLD activity, there was an increase in the ability of MDA-MB-231 cells to both migrate and invade Matrigel (TM). The ability of MDA-MB-231 cells to both migrate and invade Matrigel (TM) was dependent on both PLD and mTOR, a downstream target of PLD signals. Serum withdrawal also led to a PLD-dependent increase in the expression of the stress factor, hypoxia-inducible factor-alpha. These data reveal that PLD survival signals not only prevent apoptosis but also stimulate cell migration and invasion, linking the ability to suppress apoptosis with the ability to metastasize.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu			NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2003, CURR TOP MICROBIOL, V279, P299; Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHEN Y, 2001, MOL CELL BIOL, V21, P595; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Feig SA, 2005, BREAST J, V11, pS3, DOI 10.1111/j.1075-122X.2005.217161.x; Feinstein E, 2005, ONCOGENE, V24, P326, DOI 10.1038/sj.onc.1208252; Foster DA, 2003, MOL CANCER RES, V1, P789; FOSTER DA, 2006, IN PRESS CURRENT SIG; Foster David A, 2004, Expert Rev Anticancer Ther, V4, P691, DOI 10.1586/14737140.4.4.691; Freije JMP, 2003, ADV EXP MED BIOL, V532, P91; Gotzsche PC, 2000, LANCET, V355, P129, DOI 10.1016/S0140-6736(99)06065-1; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hui L, 2004, MOL CELL BIOL, V24, P5677, DOI 10.1128/MCB.24.13.5677-5686.2004; Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Kam Y, 2001, MOL CELL BIOL, V21, P4055, DOI 10.1128/MCB.21.12.4055-4066.2001; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; Rodrik V, 2005, MOL CELL BIOL, V25, P7917, DOI 10.1128/MCB.25.17.7917-7925.2005; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Schafer DA, 2000, TRAFFIC, V1, P892; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2000, CANCER METAST REV, V19, P59, DOI 10.1023/A:1026544214667; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; Tchevkina E, 2005, ONCOGENE, V24, P329, DOI 10.1038/sj.onc.1208094; Uchida H, 1999, ANTICANCER RES, V19, P671; Uchida N, 1997, J CANCER RES CLIN, V123, P280, DOI 10.1007/s004320050060; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Williger BT, 1999, J BIOL CHEM, V274, P735, DOI 10.1074/jbc.274.2.735; WILLIGER BT, 1995, J BIOL CHEM, V270, P29656; Xu LZ, 2003, MOL CELL BIOL, V23, P645, DOI 10.1128/MCB.23.2.645-654.2003; Yoshida M, 1998, ONCOL RES, V10, P399; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	51	107	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15862	15868		10.1074/jbc.M600660200	http://dx.doi.org/10.1074/jbc.M600660200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595654	hybrid			2022-12-25	WOS:000237996000035
J	Zhang, X; Li, F; Bulloj, A; Zhang, YW; Tong, G; Zhang, ZH; Liao, FF; Xu, HX				Zhang, Xue; Li, Feng; Bulloj, Ayelen; Zhang, Yun-wu; Tong, Gang; Zhang, Zhuohua; Liao, Francesca-Fang; Xu, Huaxi			Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules	FASEB JOURNAL			English	Article						Alzheimer's disease; tauopathy; PIP3/Akt	GLYCOGEN-SYNTHASE KINASE-3; GROWTH-FACTOR-I; DISEASE-LIKE PHOSPHORYLATION; ALZHEIMERS-DISEASE; PROTEIN-TAU; ABNORMAL PHOSPHORYLATION; CELL-SURVIVAL; FETAL-TAU; INSULIN; GENE	Neurofibrillary tangles (NFTs), consisting of abnormally hyperphosphorylated tau, are implicated in the pathogenesis of several neurodegenerative diseases including Alzheimer's disease (AD). The molecular mechanisms underlying the regulation of tau phosphorylation are largely unknown. While the PI3K/ Akt pathway has been shown to regulate multiple cellular events pertinent to AD pathogenesis, potential functions of tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) in AD pathogenesis have not been explored. Here, we examine the effects of PTEN on tau phosphorylation, its microtubule association and formation of aggregates, and consequentially neuronal morphology. In cultured cells, overexpression of wild-type (WT) PTEN alters tau phosphorylation at several sites, increases tau-microtubule association and decreases formation of tau aggregates. In addition, the phosphatase-null PTEN increases tau aggregation and impairs tau binding to microtubule and neurite outgrowth of neurons expressing the mutant PTEN. We also found a significant loss of PTEN in AD patient brains correlated with a dramatically increased concentration of phospho-tau at Ser-214 in NFTs. Together, our results demonstrate that PTEN regulates tau phosphorylation, binding to micro-tubules and formation of aggregates and neurite outgrowth. These findings suggest a link between malfunction of PTEN and tauopathy, and imply PTEN as a therapeutic target for tauopathy.-Zhang, X., Li, F., Bulloj, A., Zhang, Y.-w., Tong, G., Zhang, Z., Liao, F.-F., Xu, H. Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules.	Burnham Med Res Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Xu, HX (corresponding author), Burnham Med Res Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA.	xuh@burnham.org	Xu, Huaxi/AAV-7177-2021	Zhang, Yun-wu/0000-0002-7152-7630	NIA NIH HHS [R01 AG024895, AG05131, K12-AG00975] Funding Source: Medline; NIDCD NIH HHS [R01 DC006497] Funding Source: Medline; NINDS NIH HHS [R01 NS046673] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG024895, K12AG000975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006497] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Bondy CA, 2004, EUR J PHARMACOL, V490, P25, DOI 10.1016/j.ejphar.2004.02.042; Carro E, 2004, EUR J PHARMACOL, V490, P127, DOI 10.1016/j.ejphar.2004.02.050; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; Derkinderen P, 2005, J NEUROSCI, V25, P6584, DOI 10.1523/JNEUROSCI.1487-05.2005; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; Ducruet AP, 2005, ANNU REV PHARMACOL, V45, P725, DOI 10.1146/annurev.pharmtox.45.120403.100040; Fraser MM, 2004, CANCER RES, V64, P7773, DOI 10.1158/0008-5472.CAN-04-2487; Gasparini L, 2003, TRENDS NEUROSCI, V26, P404, DOI 10.1016/S0166-2236(03)00163-2; Gouras GK, 1998, J NEUROCHEM, V71, P1920; Griffin RJ, 2005, J NEUROCHEM, V93, P105, DOI 10.1111/j.1471-4159.2004.02949.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; Imahori K, 1998, NEUROBIOL AGING, V19, pS93, DOI 10.1016/S0197-4580(98)00025-6; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; KENESSEY A, 1993, BRAIN RES, V629, P40, DOI 10.1016/0006-8993(93)90478-6; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Ksiezak-Reding H, 2003, BBA-MOL BASIS DIS, V1639, P159, DOI 10.1016/j.bbadis.2003.09.001; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Lesort M, 2000, NEUROSCIENCE, V99, P305, DOI 10.1016/S0306-4522(00)00200-1; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; Michikawa M, 2003, MOL NEUROBIOL, V27, P1, DOI 10.1385/MN:27:1:1; MORENO FJ, 1995, FEBS LETT, V372, P65, DOI 10.1016/0014-5793(95)00934-2; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Pei JJ, 2003, ACTA NEUROPATHOL, V105, P381, DOI 10.1007/s00401-002-0657-y; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Pyo HK, 2004, NEUROSCIENCE, V127, P649, DOI 10.1016/j.neuroscience.2004.05.036; Rickle A, 2004, NEUROREPORT, V15, P955, DOI 10.1097/00001756-200404290-00005; Schubert M, 2003, J NEUROSCI, V23, P7084, DOI 10.1523/JNEUROSCI.23-18-07084.2003; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles B, 2004, DEV BIOL, V273, P175, DOI 10.1016/j.ydbio.2004.06.008; Stokoe D, 2001, CURR BIOL, V11, pR502, DOI 10.1016/S0960-9822(01)00303-7; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687	58	52	52	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1272	+		10.1096/fj.06-5721fje	http://dx.doi.org/10.1096/fj.06-5721fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16645045				2022-12-25	WOS:000240210300049
J	Yang, XP; Doser, TA; Fang, CX; Nunn, JM; Janardhanan, R; Zhu, MJ; Sreejayan, N; Quinn, MT; Ren, J				Yang, Xiaoping; Doser, Thomas A.; Fang, Cindy X.; Nunn, Jennifer M.; Janardhanan, Rajiv; Zhu, Meijun; Sreejayan, Nair; Quinn, Mark T.; Ren, Jun			Metallothionein prolongs survival and antagonizes senescence-associated cardiomyocyte diastolic dysfunction: role of oxidative stress	FASEB JOURNAL			English	Article						contraction; oxidative stress; antioxidant; longevity	MITOCHONDRIAL NADP(+)-ISOCITRATE DEHYDROGENASE; CARDIAC CONTRACTILE DYSFUNCTION; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; DIABETIC MICE; EXPRESSION; TARGETS; DAMAGE; HEART; OVEREXPRESSION	Senescence is accompanied by oxidative stress and cardiac dysfunction, although the link between the two remains unclear. This study examined the role of antioxidant metallothionein on cardiomyocyte function, superoxide generation, the oxidative stress biomarker aconitase activity, cytochrome c release, and expression of oxidative stress-related proteins, such as the GTPase RhoA and NADPH oxidase protein p47(phox) in young (5-6 mo) and aged (26-28 mo) FVB wild-type (WT) and cardiac-specific metallothionein transgenic mice. Metallothionein mice showed a longer life span (by similar to 4 mo) than FVB mice evaluated by the Kaplan-Meier survival curve. Compared with young cardiomyocytes, aged myocytes displayed prolonged TR90, reduced tolerance to high stimulus frequency, and slowed intracellular Ca2+ decay, all of which were nullified by metallothionein. Aging increased superoxide generation, active RhoA abundance, cytochrome c release, and p47(phox) expression and suppressed aconitase activity without affecting protein nitrotyrosine formation in the hearts. These aging-induced changes in oxidative stress and related protein biomarkers were attenuated by metallothionein. Aged metallothionein mouse myocytes were more resistant to the superoxide donor pyrogallol-induced superoxide generation and apoptosis. In addition, aging-associated prolongation in TR90 was blunted by the Rho kinase inhibitor Y-27632. Collectively, our data demonstrated that metallothionein may alleviate aging-induced cardiac contractile defects and oxidative stress, which may contribute to prolonged life span in metallothionein transgenic mice.	Univ Wyoming, Div Pharmaceut Sci, Laramie, WY 82071 USA; Univ Wyoming, Ctr Cardiovasc Res & Alternat Med, Laramie, WY 82071 USA; Univ Wyoming, Dept Anim Sci, Laramie, WY 82071 USA; Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59717 USA	University of Wyoming; University of Wyoming; University of Wyoming; Montana State University System; Montana State University Bozeman	Ren, J (corresponding author), Univ Wyoming, Div Pharmaceut Sci, Laramie, WY 82071 USA.	jren@uwyo.edu	Zhu, Mei-Jun/A-4248-2013; Ren, Jun/ACG-5366-2022	Ren, Jun/0000-0002-0275-0783; Quinn, Mark/0000-0001-8114-5073	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG021324] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66575] Funding Source: Medline; NIA NIH HHS [AG21324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alexeyev MF, 2004, CLIN SCI, V107, P355, DOI 10.1042/CS20040148; Benderdour M, 2004, AM J PHYSIOL-HEART C, V287, pH2122, DOI 10.1152/ajpheart.00378.2004; Benderdour M, 2003, J BIOL CHEM, V278, P45154, DOI 10.1074/jbc.M306285200; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Cai H, 2003, TRENDS PHARMACOL SCI, V24, P471, DOI 10.1016/S0165-6147(03)00233-5; Cai L, 2005, DIABETES, V54, P1829, DOI 10.2337/diabetes.54.6.1829; Cai L, 2001, Cardiovasc Toxicol, V1, P181, DOI 10.1385/CT:1:3:181; Ceconi C, 2003, ARCH BIOCHEM BIOPHYS, V420, P217, DOI 10.1016/j.abb.2003.06.002; Chung L, 2006, BBA-MOL BASIS DIS, V1762, P103, DOI 10.1016/j.bbadis.2005.08.003; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; Dhalla N S, 2001, Expert Opin Ther Targets, V5, P205, DOI 10.1517/14728222.5.2.205; Dhalla NS, 2000, J HYPERTENS, V18, P655, DOI 10.1097/00004872-200018060-00002; Dong F, 2005, CLIN SCI, V109, P277, DOI 10.1042/CS20040278; Dong F, 2005, BRIT J PHARMACOL, V145, P323, DOI 10.1038/sj.bjp.0706193; Duan JH, 2003, AM J PHYSIOL-ENDOC M, V284, pE366, DOI 10.1152/ajpendo.00254.2002; Esberg Lucy B, 2004, Cardiovasc Toxicol, V4, P375, DOI 10.1385/CT:4:4:375; Fang CX, 2005, DIABETOLOGIA, V48, P2412, DOI 10.1007/s00125-005-1940-y; Fridovich I, 2004, AGING CELL, V3, P13, DOI 10.1046/j.1474-9728.2003.00075.x; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Hool LC, 2005, CARDIOVASC RES, V67, P624, DOI 10.1016/j.cardiores.2005.04.025; Jin LM, 2004, AM J PHYSIOL-HEART C, V287, pH1495, DOI 10.1152/ajpheart.01006.2003; KANDA T, 2005, IN PRESS FASEB J; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; Kasapoglu M, 2001, EXP GERONTOL, V36, P209, DOI 10.1016/S0531-5565(00)00198-4; Kawamura H, 2004, ARTERIOSCL THROM VAS, V24, P276, DOI 10.1161/01.ATV.0000112012.33770.2a; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lakatta EG, 2003, CIRCULATION, V107, P139, DOI 10.1161/01.CIR.0000048892.83521.58; Li SY, 2005, AGING CELL, V4, P57, DOI 10.1111/j.1474-9728.2005.00146.x; Luo JD, 2003, CURR MED CHEM, V10, P1593, DOI 10.2174/0929867033457205; Matsuoka Y, 2001, NEUROSCIENCE, V104, P609, DOI 10.1016/S0306-4522(01)00115-4; Miao LY, 2001, MECH AGEING DEV, V122, P1757, DOI 10.1016/S0047-6374(01)00297-4; Monahan KD, 2004, AM J PHYSIOL-HEART C, V286, pH2113, DOI 10.1152/ajpheart.01054.2003; Ren J, 2005, ACTA PHARMACOL SIN, V26, P279, DOI 10.1111/j.1745-7254.2005.00059.x; Rikitake Y, 2005, CIRCULATION, V111, P3261, DOI 10.1161/CIRCULATIONAHA.105.534024; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Song Y, 2005, AM J PATHOL, V167, P17, DOI 10.1016/S0002-9440(10)62949-5; Sowers JR, 2004, AM J PHYSIOL-HEART C, V286, pH1597, DOI 10.1152/ajpheart.00026.2004; Stadtman E R, 1992, EXS, V62, P64; Wang GW, 1999, AM J PHYSIOL-HEART C, V276, pH167, DOI 10.1152/ajpheart.1999.276.1.H167; Xu Y, 2004, AM J PHYSIOL-HEART C, V287, pH165, DOI 10.1152/ajpheart.00037.2004; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; Yang XP, 2005, ENDOCRINE, V26, P127, DOI 10.1385/ENDO:26:2:127; Yarian CS, 2005, BIOCHEM BIOPH RES CO, V330, P151, DOI 10.1016/j.bbrc.2005.02.135; Ye G, 2003, DIABETES, V52, P777, DOI 10.2337/diabetes.52.3.777	47	110	117	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					1024	+		10.1096/fj.05-5288fje	http://dx.doi.org/10.1096/fj.05-5288fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585059				2022-12-25	WOS:000240157700043
J	Yeung, D; Zablocki, K; Lien, CF; Jiang, TW; Arkle, S; Brutkowski, W; Brown, J; Lochmuller, H; Simon, J; Barnard, EA; Gorecki, DC				Yeung, Davy; Zablocki, Krzysztof; Lien, Chun-Fu; Jiang, Taiwen; Arkle, Stephen; Brutkowski, Wojciech; Brown, James; Lochmuller, Hanns; Simon, Joseph; Barnard, Eric A.; Gorecki, Dariusz C.			Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells	FASEB JOURNAL			English	Article						Duchenne muscular dystrophy; ATP; P2X receptor; myoblast; mdx mouse	MAMMALIAN SKELETAL-MUSCLE; MUSCULAR-DYSTROPHY; EXTRACELLULAR ATP; EXPRESSION; PURINOCEPTOR; ACTIVATION; MECHANISMS; MEMBRANE; CLONING; RELEASE	Pathological cellular hallmarks of Duchenne muscular dystrophy (DMD) include, among others, abnormal calcium homeostasis. Changes in the expression of specific receptors for extracellular ATP in dystrophic muscle have been recently documented: here, we demonstrate that at the earliest, myoblast stage of developing dystrophic muscle a purinergic dystrophic phenotype arises. In myoblasts of a dystrophin-negative muscle cell line established from the mdx mouse model of DMD but not in normal myoblasts, exposure to extracellular ATP triggered a strong increase in cytoplasmic Ca2+ concentrations. Influx of extracellular Ca2+ was stimulated by ATP and BzATP and inhibited by zinc, Coomassie Brilliant Blue-G, and KN-62, demonstrating activation of P2X7 receptors. Significant expression of P2X4 and P2X7 proteins was immunodetected in dystrophic myoblasts. Therefore, full-length dystrophin appears, surprisingly, to play an important role in myoblasts in controlling responses to ATP. Our results suggest that altered function of P2X receptors may be an important contributor to pathogenic Ca2+ entry in dystrophic mouse muscle and may have implications for the pathogenesis of muscular dystrophies. Treatments aiming at inhibition of specific ATP receptors could be of a potential therapeutic benefit. - Yeung, D., Zablocki, K., Lien, C.-F., Jiang, T., Arkle, S., Brutkowski, W., Brown, J., Lochmuller, H., Simon, J., Barnard, E. A., Gorecki, D. C. Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells.	Inst Biomed & Biomol Sci, Sch Pharm & Biomed Sci, Portsmouth PO1 2DT, Hants, England; M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; Univ Munich, Friedrich Baur Inst, Dept Neurol, Munich, Germany; Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England	University of Portsmouth; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; University of Munich; University of Cambridge	Gorecki, DC (corresponding author), Inst Biomed & Biomol Sci, Sch Pharm & Biomed Sci, St Michaels Bldg,White Swan Rd, Portsmouth PO1 2DT, Hants, England.	darek.gorecki@port.ac.uk	; Zablocki, Krzysztof/R-4181-2016	Gorecki, Dariusz/0000-0003-3584-1654; Brown, James/0000-0002-3901-6814; Zablocki, Krzysztof/0000-0002-9987-1257; Lochmuller, Hanns/0000-0003-2324-8001	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adriouch S, 2002, J IMMUNOL, V169, P4108, DOI 10.4049/jimmunol.169.8.4108; Araya R, 2004, BRAIN RES REV, V47, P174, DOI 10.1016/j.brainresrev.2004.06.003; Atkinson L, 2004, NEUROSCIENCE, V123, P761, DOI 10.1016/j.neuroscience.2003.08.065; Betto R, 1999, J BIOL CHEM, V274, P7907, DOI 10.1074/jbc.274.12.7907; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407; Brun C, 2003, CELL MOL LIFE SCI, V60, P557, DOI 10.1007/s000180300047; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Chakfe Y, 2002, J NEUROSCI, V22, P3061, DOI 10.1523/JNEUROSCI.22-08-03061.2002; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Chessell IP, 1998, FEBS LETT, V439, P26, DOI 10.1016/S0014-5793(98)01332-5; Chessell IP, 1997, BRIT J PHARMACOL, V121, P1429, DOI 10.1038/sj.bjp.0701278; Choi RCY, 2003, J NEUROSCI, V23, P4445; Collet C, 2002, PFLUG ARCH EUR J PHY, V443, P771, DOI 10.1007/s00424-001-0758-9; Collo G, 1996, J NEUROSCI, V16, P2495; Cox JA, 2001, GENE, V270, P145, DOI 10.1016/S0378-1119(01)00484-X; Cseri J, 2002, PFLUG ARCH EUR J PHY, V443, P731, DOI 10.1007/s00424-001-0757-x; Dalkilic I, 2003, CURR OPIN GENET DEV, V13, P231, DOI 10.1016/S0959-437X(03)00048-0; De Man JG, 2003, BRIT J PHARMACOL, V140, P1108, DOI 10.1038/sj.bjp.0705536; Ekokoski E, 2001, J CELL PHYSIOL, V187, P166, DOI 10.1002/jcp.1070; Feng YH, 2005, AM J PHYSIOL-CELL PH, V288, pC1342, DOI 10.1152/ajpcell.00315.2004; FERRARI D, 1994, AM J PHYSIOL-CELL PH, V267, pC886, DOI 10.1152/ajpcell.1994.267.4.C886; Freedman BD, 1999, EUR J IMMUNOL, V29, P1635, DOI 10.1002/(SICI)1521-4141(199905)29:05<1635::AID-IMMU1635>3.3.CO;2-2; Geng Y, 1991, Neuromuscul Disord, V1, P125, DOI 10.1016/0960-8966(91)90060-6; HAGGBLAD J, 1988, FEBS LETT, V235, P133, DOI 10.1016/0014-5793(88)81248-1; Henning RH, 1997, PHARMACOL THERAPEUT, V74, P115, DOI 10.1016/S0163-7258(97)00015-6; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hibell AD, 2000, BRIT J PHARMACOL, V130, P167, DOI 10.1038/sj.bjp.0703302; Humphreys BD, 1998, MOL PHARMACOL, V54, P22, DOI 10.1124/mol.54.1.22; Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82; Jiang TW, 2005, NEUROMUSCULAR DISORD, V15, P225, DOI 10.1016/j.nmd.2004.11.008; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEDERFEIN D, 1993, HUM MOL GENET, V2, P1883, DOI 10.1093/hmg/2.11.1883; LOVE DR, 1989, NATURE, V4, P55; LU Z, 1991, J PHYSIOL-LONDON, V436, P45, DOI 10.1113/jphysiol.1991.sp018538; Mallouk N, 2000, P NATL ACAD SCI USA, V97, P4950, DOI 10.1073/pnas.97.9.4950; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Munroe SH, 2004, J CELL BIOCHEM, V93, P664, DOI 10.1002/jcb.20252; Noguchi S, 1999, BIOCHEM BIOPH RES CO, V262, P88, DOI 10.1006/bbrc.1999.1163; Noguchi S, 2000, EUR J BIOCHEM, V267, P640, DOI 10.1046/j.1432-1327.2000.00998.x; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Papp L, 2004, NEUROREPORT, V15, P2387, DOI 10.1097/00001756-200410250-00017; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Pulido SM, 1998, FEBS LETT, V439, P357, DOI 10.1016/S0014-5793(98)01399-4; Robert V, 2001, J BIOL CHEM, V276, P4647, DOI 10.1074/jbc.M006337200; Ruegg Urs T., 1999, Trends in Pharmacological Sciences, V20, P351, DOI 10.1016/S0165-6147(99)01377-2; Ryten M, 2004, FASEB J, V18, P1404, DOI 10.1096/fj.03-1175fje; Ryten M, 2002, J CELL BIOL, V158, P345, DOI 10.1083/jcb.200202025; Ryten M, 2001, DEV DYNAM, V221, P331, DOI 10.1002/dvdy.1147; Sandona D, 2005, FASEB J, V19, P1184, DOI 10.1096/fj.04-3333fje; Sandona D, 2004, BIOCHEM J, V381, P105, DOI 10.1042/BJ20031644; SHIVERS RR, 1984, AM J PATHOL, V116, P482; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Sim JA, 2004, J NEUROSCI, V24, P6307, DOI 10.1523/JNEUROSCI.1469-04.2004; Sneddon P, 1999, PROG BRAIN RES, V120, P11; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Sperlagh B, 2001, NEUROCHEM RES, V26, P951, DOI 10.1023/A:1012336601854; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Tsim KWK, 2002, NEUROSIGNALS, V11, P58, DOI 10.1159/000057322; Tung EKK, 2004, MOL PHARMACOL, V66, P794, DOI 10.1124/mol.104.003269; Virginio C, 1997, NEUROPHARMACOLOGY, V36, P1285, DOI 10.1016/S0028-3908(97)00141-X; Yeung D, 2004, NEUROBIOL DIS, V15, P212, DOI 10.1016/j.nbd.2003.10.014	64	43	43	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					610	620		10.1096/fj.05-4022com	http://dx.doi.org/10.1096/fj.05-4022com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581969				2022-12-25	WOS:000240130900007
J	Singh, SR; Zhen, W; Zheng, Z; Wang, H; Oh, SW; Liu, W; Zbar, B; Schmidt, LS; Hou, SX				Singh, S. R.; Zhen, W.; Zheng, Z.; Wang, H.; Oh, S-W; Liu, W.; Zbar, B.; Schmidt, L. S.; Hou, S. X.			The Drosophila homolog of the human tumor suppressor gene BHD interacts with the JAK-STAT and Dpp signaling pathways in regulating male germline stem cell maintenance	ONCOGENE			English	Article						tumor suppressor; Drosophila BHD homolog; male germline stem cell; stem cell maintenance; JAK/STAT signaling pathway; Dpp signaling pathway	SELF-RENEWAL; SPONTANEOUS PNEUMOTHORAX; DIFFERENTIATION; PROTEIN; MUTATIONS; FOLLICLE; ENCODES	Birt-Hogg-Dube syndrome (BHD) is a rare, inherited genodermatosis characterized by hair follicle hamartomas, kidney tumors and spontaneous pneumothorax. The BHD locus was mapped to chromosome 17p11.2 by linkage analysis, and germ line mutations in a novel gene ( BHD) were identified in a panel of BHD families. Using RNA interference to decrease expression of the Drosophila BHD homolog (DBHD), we have demonstrated that DBHD is required for male germline stem cell (GSC) maintenance in the fly testis. Reduction of DBHD gene activity suppresses the GSC overproliferation phenotype associated with overexpression of either unpaired (upd) or decapentaplegic (dpp). Further genetic interaction experiments suggest that DBHD regulates GSC maintenance downstream or in parallel of the JAK/STAT and Dpp signal-transduction pathways. These findings suggest that the BHD protein may regulate tumorigenesis through modulating stem cells in human.	NCI, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA; NCI, Immunobiol Lab, NIH, Frederick, MD 21702 USA; NCI, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Singh, SR (corresponding author), NCI, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA.	sshreeram@ncifcrf.gov; shou@mail.ncifcrf.gov	Singh/B-7614-2008	Singh/0000-0001-6545-583X	NATIONAL CANCER INSTITUTE [Z01SC006659, Z01BC010738] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 CA999999] Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baksa K, 2002, DEV BIOL, V243, P166, DOI 10.1006/dbio.2001.0539; BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brawley C, 2004, SCIENCE, V304, P1331, DOI 10.1126/science.1097676; Chen DH, 2005, CURR BIOL, V15, P179, DOI 10.1016/j.cub.2005.01.004; Chen DH, 2003, CURR BIOL, V13, P1786, DOI 10.1016/j.cub.2003.09.033; Chen HW, 2002, GENE DEV, V16, P388, DOI 10.1101/gad.955202; CHOMETTE G, 1985, TESTICULAR CANC, P35; Fabrizio JJ, 2003, DEV BIOL, V258, P117, DOI 10.1016/S0012-1606(03)00127-1; Fuller Margaret T., 1993, P71; Fuller MT, 1998, SEMIN CELL DEV BIOL, V9, P433, DOI 10.1006/scdb.1998.0227; Gilboa L, 2004, CURR BIOL, V14, P981, DOI 10.1016/j.cub.2004.05.049; Giordano E, 2002, GENETICS, V160, P637; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Kawase E, 2004, DEVELOPMENT, V131, P1365, DOI 10.1242/dev.01025; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; Lingaas F, 2003, HUM MOL GENET, V12, P3043, DOI 10.1093/hmg/ddg336; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Pavlovich CP, 2002, AM J SURG PATHOL, V26, P1542, DOI 10.1097/00000478-200212000-00002; Pignoni F, 1997, DEVELOPMENT, V124, P271; Schmidt LS, 2001, AM J HUM GENET, V69, P876, DOI 10.1086/323744; Szakmary A, 2005, CURR BIOL, V15, P171, DOI 10.1016/j.cub.2005.01.005; Tran J, 2000, NATURE, V407, P754, DOI 10.1038/35037613; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; Vocke CD, 2005, J NATL CANCER I, V97, P931, DOI 10.1093/jnci/dji154; Youngren KK, 2005, NATURE, V435, P360, DOI 10.1038/nature03595; Zbar B, 2002, CANCER EPIDEM BIOMAR, V11, P393	29	43	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5933	5941		10.1038/sj.onc.1209593	http://dx.doi.org/10.1038/sj.onc.1209593			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16636660				2022-12-25	WOS:000240826300002
J	Pole, JCM; Courtay-Cahen, C; Garcia, MJ; Blood, KA; Cooke, SL; Alsop, AE; Tse, DML; Caldas, C; Edwards, PAW				Pole, J. C. M.; Courtay-Cahen, C.; Garcia, M. J.; Blood, K. A.; Cooke, S. L.; Alsop, A. E.; Tse, D. M. L.; Caldas, C.; Edwards, P. A. W.			High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation	ONCOGENE			English	Article						8p12; breast cancer; array CGH; chromosome translocation; chromosome inversion; deletion	COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER; IN-SITU HYBRIDIZATION; CARCINOMA CELL-LINES; GAMMA-HEREGULIN; CYTOGENETIC ANALYSIS; COLORECTAL-CANCER; BLADDER-CANCER; POOR-PROGNOSIS; GROWTH-FACTOR	The short arm of chromosome 8, 8p, is often rearranged in carcinomas, typically showing distal loss by unbalanced translocation. We analysed 8p rearrangements in 48 breast, pancreatic and colon cancer cell lines by fluorescence in situ hybridization (FISH) and array comparative genomic hybridization, with a tiling path of 0.2 Mb resolution over 8p12 and 1 Mb resolution over chromosome 8. Selected breast lines (MDA-MB-134, MDA-MB-175, MDA-MB-361, T-47D and ZR-75-1) were analysed further. Most cell lines showed loss of 8p distal to a break that was between 31 Mb (5' to NRG1) and the centromere, but the translocations were accompanied by variable amplifications, deletions and inversions proximal to this break. The 8p12 translocation in T-47D was flanked by an inversion of 4 Mb, with a 100 kb deletion at the proximal end. The dicentric t(8; 11) in ZR-75-1 carries multiple rearrangements including interstitial deletions, a triplicated translocation junction between NRG1 and a fragment of 11q (unconnected to CCND1), and two separate amplifications, of FGFR1 and CCND1. We conclude that if there is a tumour suppressor gene on 8p it may be near 31 Mb, for example WRN; but the complexity of 8p rearrangements suggests that they target various genes proximal to 31 Mb including NRG1 and the amplicon centred around ZNF703/FLJ14299.	Univ Cambridge, Hutchison MRC Res Ctr, Dept Pathol, Canc Genom Program, Cambridge CB2 2XZ, England; Univ Cambridge, Hutchison MRC Res Ctr, Dept Oncol, Cambridge CB2 2XZ, England	University of Cambridge; University of Cambridge	Edwards, PAW (corresponding author), Univ Cambridge, Hutchison MRC Res Ctr, Dept Pathol, Canc Genom Program, Cambridge CB2 2XZ, England.	pawe1@cam.ac.uk	Edwards, Paul A/M-8291-2014; Caldas, Carlos/U-7250-2019; Caldas, Carlos/A-7543-2008; García, María J/G-1361-2016	Edwards, Paul A/0000-0002-4789-3374; Caldas, Carlos/0000-0003-3547-1489; García, María J/0000-0002-2236-9912	Breast Cancer Now [2005NOV68] Funding Source: Medline	Breast Cancer Now		Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Adams J, 2005, CANCER RES, V65, P66; Adelaide J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218; Alsop AE, 2006, CANCER GENET CYTOGEN, V164, P97, DOI 10.1016/j.cancergencyto.2005.09.011; Arakawa H, 2004, NAT REV CANCER, V4, P978, DOI 10.1038/nrc1504; Asatiani E, 2005, CANCER RES, V65, P1164, DOI 10.1158/0008-5472.CAN-04-2688; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Bernardino L, 1998, GENE CHROMOSOME CANC, V23, P100, DOI 10.1002/(SICI)1098-2264(199810)23:2<100::AID-GCC2>3.0.CO;2-6; Birnbaum D, 2003, LANCET ONCOL, V4, P639, DOI 10.1016/S1470-2045(03)01225-7; Courtay-Cahen C, 2000, GENOMICS, V66, P15, DOI 10.1006/geno.2000.6178; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; DIB A, 1995, ONCOGENE, V10, P995; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Gribble SM, 2005, J MED GENET, V42, P8, DOI 10.1136/jmg.2004.024141; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Hinck L, 2004, DEV CELL, V7, P783, DOI 10.1016/j.devcel.2004.11.002; Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Hwang ES, 2004, CLIN CANCER RES, V10, P5160, DOI 10.1158/1078-0432.CCR-04-0165; Karan D, 2003, INT J CANCER, V103, P285, DOI 10.1002/ijc.10813; Klaus M, 2003, CANCER GENET CYTOGEN, V144, P36, DOI 10.1016/S0165-4608(02)00876-2; Krane IM, 1996, ONCOGENE, V12, P1781; Lemieux N, 1996, CANCER GENET CYTOGEN, V90, P75, DOI 10.1016/0165-4608(96)00061-1; Liu XF, 1999, ONCOGENE, V18, P7110, DOI 10.1038/sj.onc.1203136; Mann SM, 1997, CHROMOSOME RES, V5, P145, DOI 10.1023/A:1018426426477; Margolin AA, 2005, BIOINFORMATICS, V21, P3308, DOI 10.1093/bioinformatics/bti500; Morris JS, 1997, GENE CHROMOSOME CANC, V20, P120, DOI 10.1002/(SICI)1098-2264(199710)20:2<120::AID-GCC3>3.0.CO;2-5; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Paris PL, 2003, AM J PATHOL, V162, P763, DOI 10.1016/S0002-9440(10)63873-4; Prentice LM, 2005, ONCOGENE, V24, P7281, DOI 10.1038/sj.onc.1208892; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Rousseau-Merck MF, 1999, CANCER RES, V59, P3152; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Sinclair PB, 2000, BLOOD, V95, P738, DOI 10.1182/blood.V95.3.738.003k21_738_743; Sirivatanauksorn V, 2001, INT J CANCER, V91, P350, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.3.CO;2-3; Teixeira MR, 2002, GENE CHROMOSOME CANC, V33, P1, DOI 10.1002/gcc.1206; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Toomes C, 2003, GENE CHROMOSOME CANC, V37, P132, DOI 10.1002/gcc.10191; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Van Limbergen H, 2001, GENE CHROMOSOME CANC, V30, P274, DOI 10.1002/1098-2264(2000)9999:9999<1::AID-GCC1089>3.3.CO;2-T; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; Veltman JA, 2003, CANCER RES, V63, P2872; Volik S, 2003, P NATL ACAD SCI USA, V100, P7696, DOI 10.1073/pnas.1232418100; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950	48	71	76	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5693	5706		10.1038/sj.onc.1209570	http://dx.doi.org/10.1038/sj.onc.1209570			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636668				2022-12-25	WOS:000240599100011
J	Gloire, G; Charlier, E; Rahmouni, S; Volanti, C; Chariot, A; Erneux, C; Piette, J				Gloire, G.; Charlier, E.; Rahmouni, S.; Volanti, C.; Chariot, A.; Erneux, C.; Piette, J.			Restoration of SHIP-1 activity in human leukemic cells modifies NF-kappa B activation pathway and cellular survival upon oxidative stress	ONCOGENE			English	Article						NF-kappa B; oxidative stress; SHIP-1; IKK; leukemic cells; apoptosis	TYROSINE PHOSPHORYLATION; PHOSPHOINOSITIDE 3-KINASE; HEMATOPOIETIC-CELLS; 5-PHOSPHATASE SHIP; INVOLVEMENT; ALPHA; PHOSPHATASE; APOPTOSIS; TRANSDUCTION; COMPLEX	Nuclear factor-kappa B (NF-kappa B) is an important prosurvival transcription factor activated in response to a large array of external stimuli, including reactive oxygen species (ROS). Previous works have shown that NF-kappa B activation by ROS involved tyrosine phosphorylation of the inhibitor I kappa B alpha through an I kappa B kinase (IKK)-independent mechanism. In the present work, we investigated with more details NF-kappa B redox regulation in human leukemic cells. By using different cell lines (CEM, Jurkat and the subclone Jurkat JR), we clearly showed that NF-kappa B activation by hydrogen peroxide (H2O2) is cell-type dependent: it activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha in Jurkat cells, whereas it induces an IKK-mediated I kappa B alpha phosphorylation on S32 and 36 in CEM and Jurkat JR cells. We showed that this H2O2-induced IKK activation in CEM and Jurkat JR cells is mediated by SH2-containing inositol 5'-phosphatase 1 (SHIP-1), a lipid phosphatase that is absent in Jurkat cells. Indeed, the complementation of SHIP-1 in Jurkat cells made them shift to an IKK-dependent mechanism upon oxidative stress stimulation. We also showed that Jurkat cells expressing SHIP-1 are more resistant to H2O2-induced apoptosis than the parental cells, suggesting that SHIP-1 has an important role in leukemic cell responses to ROS in terms of signal transduction pathways and apoptosis resistance, which can be of interest in improving ROS-mediated chemotherapies.	CBIG, GIGA, Virol & Immunol Unit, Inst Pathol, B-4000 Liege, Belgium; Univ Liege, Virol Immunol Unit, B-4000 Liege, Belgium; Univ Liege, Pathol Unit, B-4000 Liege, Belgium; Univ Liege, CBIG, GIGA, Med Chem Unit, B-4000 Liege, Belgium; Univ Brussels, IRIBHM, Brussels, Belgium	University of Liege; University of Liege; University of Liege; Universite Libre de Bruxelles	Piette, J (corresponding author), CBIG, GIGA, Virol & Immunol Unit, Inst Pathol, B23, B-4000 Liege, Belgium.	jpiette@ulg.ac.be		Chariot, Alain/0000-0002-1691-4347				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Ambruso DR, 2004, MOL GENET METAB, V81, P313, DOI 10.1016/j.ymgme.2004.01.009; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Backers K, 2003, ADV ENZYME REGUL, V43, P15, DOI 10.1016/S0065-2571(02)00043-2; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Boer AK, 2001, LEUKEMIA, V15, P1750, DOI 10.1038/sj.leu.2402261; Bruyns C, 1999, BIOL CHEM, V380, P969, DOI 10.1515/BC.1999.120; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chandra J, 2003, BLOOD, V102, P4512, DOI 10.1182/blood-2003-02-0562; Chou WC, 2005, CURR OPIN HEMATOL, V12, P1, DOI 10.1097/01.moh.0000148552.93303.45; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fang HQ, 2004, J IMMUNOL, V173, P360, DOI 10.4049/jimmunol.173.1.360; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hildeman DA, 2004, FREE RADICAL BIO MED, V36, P1496, DOI 10.1016/j.freeradbiomed.2004.03.023; Horn S, 2004, LEUKEMIA, V18, P1839, DOI 10.1038/sj.leu.2403529; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Kim H, 2005, ONCOGENE, V24, P1252, DOI 10.1038/sj.onc.1208282; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Livolsi A, 2001, EUR J BIOCHEM, V268, P1508, DOI 10.1046/j.1432-1327.2001.02028.x; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; Ogawa Y, 2003, INT J MOL MED, V11, P27; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Ravet E, 2002, J HEMATOTH STEM CELL, V11, P327, DOI 10.1089/152581602753658510; Robson JD, 2004, MOL CELL BIOL, V24, P2332, DOI 10.1128/MCB.24.6.2332-2343.2004; Rohrschneider LR, 2000, GENE DEV, V14, P505; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tomlinson MG, 2004, J BIOL CHEM, V279, P55089, DOI 10.1074/jbc.M408141200; van Dijk TB, 2000, BLOOD, V96, P3406; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2	38	46	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5485	5494		10.1038/sj.onc.1209542	http://dx.doi.org/10.1038/sj.onc.1209542			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619039				2022-12-25	WOS:000240370400002
J	Hsu, LC; Huang, X; Seasholtz, S; Potter, DM; Gollin, SM				Hsu, L-C; Huang, X.; Seasholtz, S.; Potter, D. M.; Gollin, S. M.			Gene amplification and overexpression of protein phosphatase 1 alpha in oral squamous cell carcinoma cell lines	ONCOGENE			English	Article						PP1 alpha; cyclin D1; gene amplification; OSCC tumorigenesis	ANTISENSE CYCLIN D1; CATALYTIC SUBUNIT; HUMAN CANCER; RETINOBLASTOMA PROTEIN; HEPATOMA-CELLS; BAND 11Q13; HEAD; NECK; ONCOGENES; TYPE-1	Gene amplification of chromosomal band 11q13 is observed frequently in oral squamous cell carcinomas (OSCC). Several genes have been identified in the 11q13 amplicon, including FGF3, FGF4, CCND1, EMS1 and TAOS1. Some of these genes show good correlation between gene copy number and gene expression, and are thought to play a role in driving 11q13 amplification. The PPP1CA gene, which encodes the catalytic subunit of serine/threonine protein phosphatase protein phosphatase 1 alpha (PP1 alpha), is also located in 11q13. Protein phosphatase 1a, one of the isoforms of PP1, regulates critical cellular events, such as cell cycle progression, and apoptosis. We sought to explore the possibility that PPP1CA was amplified and overexpressed in OSCC cells. Indeed, some OSCC cell lines had PPP1CA gene amplification, as analysed by fluorescence in situ hybridization. We have also demonstrated that PPP1CA gene copy number is increased in 21% of the OSCC cell lines determined by quantitative microsatellite analysis. PP1a RNA expression determined by quantitative reverse transcription-polymerase chain reaction was significantly higher in OSCC cell lines with 11q13 amplification compared to those without 11q13 amplification (P= 0.011). The difference was even more significant between cell lines with at least three copies of the PPP1CA gene and those with less than three copies of the gene (P= 0.00045). Relative PP1a protein levels were also significantly associated with PPP1CA gene copy number (P= 0.014). Furthermore, knockdown of PP1 alpha and/or cyclin D1 by small interfering RNA suppressed OSCC cell growth, at least in part by modulating pRB phosphorylation, resulting in G0 growth arrest. These data suggest that like the cyclin D1 gene, CCND1, amplification and overexpression of the PP1a gene, PPP1CA, may be involved in OSCC tumorigenesis and/or progression.	Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Sch Med, Magee Womens Res Inst, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hsu, LC (corresponding author), Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Sch Med, Magee Womens Res Inst, 204 Craft Ave, Pittsburgh, PA 15213 USA.	rsilh@mwri.magee.edu		Gollin, Susanne/0000-0001-5438-6808; HSU, LIH-CHING/0000-0002-7816-3825	NCI NIH HHS [P30 CA47904, R01 CA111436] Funding Source: Medline; NIDCR NIH HHS [R01 DE14729] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA047904, R01CA111436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014729] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKERVALL JA, 1995, CANCER, V76, P853, DOI 10.1002/1097-0142(19950901)76:5<853::AID-CNCR2820760520>3.0.CO;2-6; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Ayllon V, 2001, J IMMUNOL, V166, P7345, DOI 10.4049/jimmunol.166.12.7345; BARKER HM, 1990, GENOMICS, V7, P159, DOI 10.1016/0888-7543(90)90536-4; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Chu EC, 2004, MED SCI MONITOR, V10, pRA235; Cohen PTW, 2002, J CELL SCI, V115, P241; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; Ginzinger DG, 2000, CANCER RES, V60, P5405; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; Imai Y, 1999, INT J ONCOL, V14, P121; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Jin YS, 1998, GENE CHROMOSOME CANC, V22, P312, DOI 10.1002/(SICI)1098-2264(199808)22:4<312::AID-GCC7>3.0.CO;2-Y; Kohno T, 1999, CANCER RES, V59, P4170; LESE CM, 1995, GENE CHROMOSOME CANC, V12, P288, DOI 10.1002/gcc.2870120409; Liu Y, 2002, CANCER RES, V62, P6357; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; Reshmi SC, 2004, GENE CHROMOSOME CANC, V41, P38, DOI 10.1002/gcc.20064; SAADAT M, 1995, CANCER LETT, V94, P165, DOI 10.1016/0304-3835(95)03846-O; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shuster MI, 2000, GENE CHROMOSOME CANC, V28, P153, DOI 10.1002/(SICI)1098-2264(200006)28:2<153::AID-GCC4>3.0.CO;2-9; Sogawa K, 1997, CANCER LETT, V112, P263, DOI 10.1016/S0304-3835(96)04589-2; Wang MB, 1998, OTOLARYNG HEAD NECK, V119, P593, DOI 10.1016/S0194-5998(98)70017-8; Wang SJ, 2001, OTOLARYNG HEAD NECK, V124, P656, DOI 10.1067/mhn.2001.116039	35	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5517	5526		10.1038/sj.onc.1209563	http://dx.doi.org/10.1038/sj.onc.1209563			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619035				2022-12-25	WOS:000240370400005
J	Hoe, HS; Magill, LA; Guenette, S; Fu, ZY; Vicini, S; Rebeck, GW				Hoe, Hyang-Sook; Magill, Laura Ann; Guenette, Suzanne; Fu, Zhanyan; Vicini, Stefano; Rebeck, G. William			FE65 interaction with the ApoE receptor ApoEr2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; DENSITY-LIPOPROTEIN RECEPTOR; ADAPTER PROTEIN; ALZHEIMERS-DISEASE; CYTOPLASMIC DOMAIN; BINDING PROTEIN; F-SPONDIN; IN-VITRO; APP; LRP	The adaptor protein FE65 interacts with the beta-amyloid precursor protein (APP) via its C-terminal phosphotyrosine binding (PTB) domain and affects APP processing and A beta production. Our previous data demonstrate that the apoE receptor ApoEr2 co-precipitated with APP and suggest that there are extracellular and intracellular interactions between these two transmembrane proteins. We hypothesized that FE65 acts as an intracellular link between ApoEr2 and APP. Co-immunoprecipitation experiments in COS7 cells demonstrated an interaction between ApoEr2 and FE65 that depended on the N-terminal PTB domain of FE65. Full-length FE65 increased co-immunoprecipitation of ApoEr2 and APP. Full-length FE65 also increased surface expression of ApoEr2, as determined by surface protein biotinylation and live cell surface staining. Constructs containing both the C-and N-terminal PTB domains of FE65 increased secreted APP, secreted ApoEr2, APPC-terminal fragment, and ApoEr2 C-terminal fragment, but constructs containing only single PTB domains did not affect APP or ApoEr2 processing. In addition, full-length FE65 decreased A beta to a significantly greater extent than individual FE65 domains. These data suggest that FE65 can bind APP and ApoEr2 at the same time and affect the processing of each.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Physiol & Biophys, Washington, DC 20057 USA; MassGen Inst Neurodegenerat Dis, Genet & Aging Res Unit, Charlestown, MA 02129 USA	Georgetown University; Georgetown University	Rebeck, GW (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW, Washington, DC 20057 USA.	gwr2@georgetown.edu	Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X; Vicini, Stefano/0000-0001-8671-5194; Sack, Laura/0000-0003-1186-1335	NIA NIH HHS [AG14473] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014473, R29AG014473] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; Chang Y, 2003, J BIOL CHEM, V278, P51100, DOI 10.1074/jbc.M309561200; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Guenette S, 2006, EMBO J, V25, P420, DOI 10.1038/sj.emboj.7600926; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Guenette SY, 1999, J NEUROCHEM, V73, P985, DOI 10.1046/j.1471-4159.1999.0730985.x; Guenette SY, 2002, J NEUROCHEM, V82, P755, DOI 10.1046/j.1471-4159.2002.01009.x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Ho A, 2004, P NATL ACAD SCI USA, V101, P2548, DOI 10.1073/pnas.0308655100; Hoe HS, 2005, MOL CELL BIOL, V25, P9259, DOI 10.1128/MCB.25.21.9259-9268.2005; Hoe HS, 2005, MOL BRAIN RES, V137, P31, DOI 10.1016/j.molbrainres.2005.02.013; Horikoshi Y, 2004, BIOCHEM BIOPH RES CO, V319, P733, DOI 10.1016/j.bbrc.2004.05.051; Hu QB, 2005, J BIOL CHEM, V280, P12548, DOI 10.1074/jbc.M411855200; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Qiu Z, 2003, NEUROSCIENCE, V122, P291, DOI 10.1016/j.neuroscience.2003.08.017; Sabo SL, 2003, J NEUROSCI, V23, P5407; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Santiard-Baron D, 2005, J NEUROCHEM, V93, P330, DOI 10.1111/j.1471-4159.2005.03026.x; Sinagra M, 2005, J NEUROSCI, V25, P6127, DOI 10.1523/JNEUROSCI.1757-05.2005; Spoelgen R, 2006, J NEUROSCI, V26, P418, DOI 10.1523/JNEUROSCI.3882-05.2006; Standen CL, 2003, MOL CELL NEUROSCI, V24, P851, DOI 10.1016/j.mcn.2003.07.002; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Wang P, 2005, J NEUROSCI, V25, P1219, DOI 10.1523/JNEUROSCI.4660-04.2005; Weeber EJ, 2002, J BIOL CHEM, V277, P39944, DOI 10.1074/jbc.M205147200	36	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24521	24530		10.1074/jbc.M600728200	http://dx.doi.org/10.1074/jbc.M600728200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16638748	hybrid			2022-12-25	WOS:000239847800048
J	Fulda, S; Debatin, KM				Fulda, S.; Debatin, K-M			5-aza-2 '-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8	ONCOGENE			English	Article						caspase-8; apoptosis; TRAIL; interferon-gamma; resistance	DRUG-INDUCED APOPTOSIS; BREAST-TUMOR CELLS; NEUROBLASTOMA-CELLS; DEATH RECEPTOR; INTERFERON-GAMMA; DNA METHYLATION; DECOY RECEPTORS; CANCER-THERAPY; CD95 APO-1/FAS; EXPRESSION	Resistance of tumors to cytotoxic therapy remains a major obstacle in cancer treatment and is often caused by defects in apoptosis programs. Caspase-8, a key mediator of death receptor-induced apoptosis, has previously been reported to be frequently inactivated by epigenetic silencing in many tumors, for example in neuroblastoma or medulloblastoma. Here, we provide for the first time evidence that combined treatment with suboptimal concentrations of the demethylating agent 5-Aza-2'-deoxycytidine (5-dAzaC) and interferon-gamma (IFN-gamma) cooperated to upregulate caspase-8 expression in neuroblastoma and medulloblastoma cells lacking caspase-8. Consequently, activation of caspase-8 and downstream caspases upon addition of TNF-related apoptosis-inducing ligand (TRAIL) was restored by pretreatment with 5-dAzaC and IFN-gamma. Importantly, pretreatment with 5-dAzaC and IFN-gamma acted in concert to significantly enhance TRAIL-induced apoptosis in neuroblastoma and medulloblastoma cells. Inhibition of caspase-8 by dominant-negative caspase-8 or by the relatively specific caspase-8 inhibitior zIETD.fmk inhibited the increase in apoptosis provided by 5-dAzaC and IFN-gamma, indicating that caspase-8 is a key mediator of this sensitization effect. Thus, by demonstrating that 5-dAzaC and IFN-gamma at relatively low individual concentrations cooperate to restore caspase-8 expression and sensitize resistant neuroblastoma and medulloblastoma cells to TRAIL-induced apoptosis, our findings have important implications for novel strategies targeting defective apoptosis pathways in neuroectodermal tumors.	Univ Childrens Hosp, Dept Hematol Oncol, D-89075 Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fulda, S (corresponding author), Univ Childrens Hosp, Dept Hematol Oncol, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333; Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Casciano I, 2004, CELL DEATH DIFFER, V11, P131, DOI 10.1038/sj.cdd.4401327; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Eggert A, 2001, CANCER RES, V61, P1314; Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10; Fan WM, 1998, ONCOL REP, V5, P1035; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fulda S, 2004, CURR CANCER DRUG TAR, V4, P569, DOI 10.2174/1568009043332763; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2004, VITAM HORM, V67, P275; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kontny HU, 2001, CELL DEATH DIFFER, V8, P506, DOI 10.1038/sj.cdd.4400836; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Ruiz-Ruiz C, 2004, J BIOL CHEM, V279, P19712, DOI 10.1074/jbc.M313023200; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Yang XZ, 2003, CANCER RES, V63, P1122	35	78	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5125	5133		10.1038/sj.onc.1209518	http://dx.doi.org/10.1038/sj.onc.1209518			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16607283				2022-12-25	WOS:000240063700005
J	Ono, Y; Torii, F; Ojima, K; Doi, N; Yoshioka, K; Kawabata, Y; Labeit, D; Labeit, S; Suzuki, K; Abe, K; Maeda, T; Sorimachi, H				Ono, Yasuko; Torii, Fukuyo; Ojima, Koichi; Doi, Naoko; Yoshioka, Katsuhide; Kawabata, Yukiko; Labeit, Dietmar; Labeit, Siegfried; Suzuki, Koichi; Abe, Keiko; Maeda, Tatsuya; Sorimachi, Hiroyuki			Suppressed disassembly of autolyzing p94/CAPN3 by N2A connectin/titin in a genetic reporter system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC CALPAIN; DYSTROPHY TYPE 2A; MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; SACCHAROMYCES-CEREVISIAE; PROTEOLYTIC-ENZYME; ACTIVE-SITE; MDM MOUSE; IN-VIVO; P94	p94/calpain 3 is a skeletal muscle-specific member of the Ca2+-regulated cytosolic cysteine protease family, the calpains. Defective p94 protease activity originating from gene mutations causes a muscular dystrophy called calpainopathy, indicating the indispensability of p94 for muscle survival. Because of the existence of the p94-specific regions IS1 and IS2, p94 undergoes very rapid and exhaustive autolysis. To elucidate the physiological relevance of this unique activity, the autolytic profiles of p94 and the effect of the p94 binding protein, connectin/titin, on this process were investigated. In vitro analysis of p94 autolysis showed that autolysis in IS1 proceeds without immediate disassembly into fragments and that the newly identified cryptic autolytic site in IS2 is critical for disassembling autolyzed fragments. As a genetic system to assay p94 autolysis semiquantitatively, p94 was expressed in yeast as a hybrid protein between the DNA binding and activation domains of the yeast transcriptional activator Gal4. Transcriptional activation by the Gal4-p94: WT hybrid protein is precluded by p94 autolysis. Complete or partial loss of autolytic activity by C129S active site mutation, limb girdle muscular dystrophy type 2A pathogenic missense mutations, or PCR-based random mutagenesis could be detected by semiquantitative restoration of Gal4-dependent beta-galactosidase gene expression. Using this system, the N2A connectin fragment that binds to p94 was shown to suppress p94 autolytic disassembly. The proximity of the IS2 autolytic and connectin-binding sites in p94 suggested that N2A connectin suppresses IS2 autolysis. These data indicate the importance of p94-connectin interaction in the control of p94 functions by regulating autolytic decay of p94.	Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Rinshoken, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Heidelberg Univ, Klinikum Mannheim, Inst Anasthesiol & Operat Intensivmed, D-68167 Mannheim, Germany; Toray Industries Ltd, New Frontiers Res Labs, Kanagawa 2488555, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan	Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Ruprecht Karls University Heidelberg; Toray Industries, Inc.; University of Tokyo	Sorimachi, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Rinshoken, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 113, Japan.	sorimach@rinshoken.or.jp	Sorimachi, Hiroyuki/C-6448-2009; Maeda, Tatsuya/L-5540-2019	Sorimachi, Hiroyuki/0000-0001-9509-6727; Ojima, Koichi/0000-0002-5973-1073				Anderson LVB, 1998, AM J PATHOL, V153, P1169, DOI 10.1016/S0002-9440(10)65661-1; ARTHUR JSC, 1995, FEBS LETT, V368, P397, DOI 10.1016/0014-5793(95)00691-2; Barco A, 1997, J BIOL CHEM, V272, P12683, DOI 10.1074/jbc.272.19.12683; *CLONT, 2001, PUBL CLONT; DASMAHAPATRA B, 1992, P NATL ACAD SCI USA, V89, P4159, DOI 10.1073/pnas.89.9.4159; Dautin N, 2000, J BACTERIOL, V182, P7060, DOI 10.1128/JB.182.24.7060-7066.2000; Diaz BG, 2004, J BIOL CHEM, V279, P27656, DOI 10.1074/jbc.M313290200; Fukiage C, 2002, J BIOL CHEM, V277, P20678, DOI 10.1074/jbc.M200697200; Garvey SM, 2002, GENOMICS, V79, P146, DOI 10.1006/geno.2002.6685; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Haravuori H, 2001, NEUROLOGY, V56, P869, DOI 10.1212/WNL.56.7.869; Herasse M, 1999, MOL CELL BIOL, V19, P4047; Huebsch KA, 2005, HUM MOL GENET, V14, P2801, DOI 10.1093/hmg/ddi313; Keira Y, 2003, J BIOCHEM, V133, P659, DOI 10.1093/jb/mvg084; Kinbara K, 1997, ARCH BIOCHEM BIOPHYS, V342, P99, DOI 10.1006/abbi.1997.0108; Kinbara K, 1998, BIOCHEM J, V335, P589, DOI 10.1042/bj3350589; Kramerova I, 2004, HUM MOL GENET, V13, P1373, DOI 10.1093/hmg/ddh153; LIEBIG HD, 1991, P NATL ACAD SCI USA, V88, P5979, DOI 10.1073/pnas.88.14.5979; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Ma H, 2000, INVEST OPHTH VIS SCI, V41, P4232; MULLERSEITZ M, 1993, GENOMICS, V18, P559, DOI 10.1016/S0888-7543(05)80356-8; Ono Y, 2004, J BIOL CHEM, V279, P2761, DOI 10.1074/jbc.M308789200; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; Rey MA, 2002, FEBS LETT, V532, P401, DOI 10.1016/S0014-5793(02)03722-5; Richard I, 1999, AM J HUM GENET, V64, P1524, DOI 10.1086/302426; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Sato N, 2003, MOL CELL BIOL, V23, P6662, DOI 10.1128/MCB.23.18.6662-6671.2003; Shih M, 2006, EXP EYE RES, V82, P146, DOI 10.1016/j.exer.2005.06.011; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; Spencer MJ, 2002, P NATL ACAD SCI USA, V99, P8874, DOI 10.1073/pnas.132269299; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; Taveau M, 2003, MOL CELL BIOL, V23, P9127, DOI 10.1128/MCB.23.24.9127-9135.2003; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Wittt CC, 2004, J MOL BIOL, V336, P145, DOI 10.1016/j.jmb.2003.12.021	37	50	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18519	18531		10.1074/jbc.M601029200	http://dx.doi.org/10.1074/jbc.M601029200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16627476	hybrid			2022-12-25	WOS:000238687300031
J	Oh, E; Thurmond, DC				Oh, Eunjin; Thurmond, Debbie C.			The stimulus-induced tyrosine phosphorylation of Munc18c facilitates vesicle exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; PROTEIN-PROTEIN INTERACTIONS; TRANSCRIPTION FACTOR NFAT1; SYNTAXIN-BINDING PROTEIN; MEMBRANE-FUSION COMPLEX; UNC-18 GENE ENCODES; GLUT4 TRANSLOCATION; INSULIN-SECRETION; 3T3-L1 ADIPOCYTES; BETA-CELLS	Stimulus-induced tyrosine phosphorylation of Munc18c was investigated as a potential regulatory mechanism by which the Munc18c-Syntaxin 4 complex can be dissociated in response to divergent stimuli in multiple cell types. Use of [P-32] orthophosphate incorporation, pervanadate treatment, and phosphotyrosine-specific antibodies demonstrated that Munc18c underwent tyrosine phosphorylation. Phosphorylation was apparent under basal conditions, but levels were significantly increased within 5 min of glucose stimulation in MIN6 beta cells. Tyrosine phosphorylation of Munc18c was also detected in 3T3L1 adipocytes and increased with insulin stimulation, suggesting that this may be a conserved mechanism. Syntaxin 4 binding to Munc18c decreased as Munc18c phosphorylation levels increased in pervanadate-treated cells, suggesting that phosphorylation dissociates the Munc18c-Syntaxin 4 complex. Munc18c phosphorylation was localized to the N-terminal 255 residues. Mutagenesis of one residue in this region, Y219F, significantly increased the affinity of Munc18c for Syntaxin 4, whereas mutation of three other candidate sites was without effect. Moreover, Munc18c-Y219F expression in MIN6 cells functionally inhibited glucose-stimulated SNARE complex formation and insulin granule exocytosis. These data support a novel and conserved mechanism for the dissociation of Munc18c-Syntaxin 4 complexes in a stimulus-dependent manner to facilitate the increase in Syntaxin 4-VAMP2 association and to promote vesicle/granule fusion.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Ctr Diabet Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Thurmond, DC (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Ctr Diabet Res, 635 Barnhill Dr,MS 4053, Indianapolis, IN 46202 USA.	dthurmon@iupui.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067912] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 067912, R01 DK067912, R01 DK067912-03] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; Bhaskar K, 2004, NEUROCHEM INT, V44, P35, DOI 10.1016/S0197-0186(03)00099-8; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; Donelan MJ, 2002, J BIOL CHEM, V277, P24232, DOI 10.1074/jbc.M203345200; Dresbach T, 1998, J NEUROSCI, V18, P2923; Dubois T, 2002, EUR J BIOCHEM, V269, P909, DOI 10.1046/j.0014-2956.2001.02725.x; Dulubova I, 2003, P NATL ACAD SCI USA, V100, P32, DOI 10.1073/pnas.232701299; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Fu J, 2005, J BIOL CHEM, V280, P3178, DOI 10.1074/jbc.M410044200; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; Goldstein BJ, 2005, DIABETES, V54, P311, DOI 10.2337/diabetes.54.2.311; Grabowski R, 1997, FEBS LETT, V411, P169, DOI 10.1016/S0014-5793(97)00720-5; Grusovin J, 2000, BIOCHEM J, V350, P741, DOI 10.1042/0264-6021:3500741; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; HUBBARD AL, 1983, J CELL BIOL, V96, P230, DOI 10.1083/jcb.96.1.230; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; Huynh H, 2004, NAT CELL BIOL, V6, P831, DOI 10.1038/ncb1164; Imai A, 2004, ARCH BIOCHEM BIOPHYS, V422, P175, DOI 10.1016/j.abb.2003.12.021; James DE, 2005, J CLIN INVEST, V115, P219, DOI 10.1172/JCI200524158; Kanda H, 2005, J CLIN INVEST, V115, P291, DOI 10.1172/JCI200522681; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Khan AH, 2001, J BIOL CHEM, V276, P4063, DOI 10.1074/jbc.M007419200; Kowluru A, 1996, BIOCHEM J, V313, P97, DOI 10.1042/bj3130097; Lemons PP, 1997, BLOOD, V90, P1490, DOI 10.1182/blood.V90.4.1490.1490_1490_1500; Lilja L, 2004, J BIOL CHEM, V279, P29534, DOI 10.1074/jbc.M312711200; Misura KMS, 2000, CURR OPIN STRUC BIOL, V10, P662, DOI 10.1016/S0959-440X(00)00151-2; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Mulder H, 2001, J BIOL CHEM, V276, P6479, DOI 10.1074/jbc.M010364200; Murray J, 2003, BRIT J PHARMACOL, V139, P388, DOI 10.1038/sj.bjp.0705265; Nevins AK, 2005, J BIOL CHEM, V280, P1944, DOI 10.1074/jbc.M409528200; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Oh E, 2005, DIABETES, V54, P638, DOI 10.2337/diabetes.54.3.638; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PIPER RC, 1991, AM J PHYSIOL, V260, P570; Pufall MA, 2005, SCIENCE, V309, P142, DOI 10.1126/science.1111915; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Robertson RP, 2003, DIABETES, V52, P581, DOI 10.2337/diabetes.52.3.581; Saito T, 2003, J BIOL CHEM, V278, P36718, DOI 10.1074/jbc.M305114200; Salazar C, 2003, J MOL BIOL, V327, P31, DOI 10.1016/S0022-2836(03)00085-8; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Schraw TD, 2003, BIOCHEM J, V374, P207, DOI 10.1042/BJ20030610; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Spurlin BA, 2004, DIABETES, V53, P2223, DOI 10.2337/diabetes.53.9.2223; Spurlin BA, 2003, DIABETES, V52, P1910, DOI 10.2337/diabetes.52.8.1910; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Thurmond DC, 2000, MOL CELL BIOL, V20, P379, DOI 10.1128/MCB.20.1.379-388.2000; Thurmond DC, 2000, EMBO J, V19, P3565, DOI 10.1093/emboj/19.14.3565; Thurmond DC, 2003, MOL ENDOCRINOL, V17, P732, DOI 10.1210/me.2002-0333; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Thurmond DC, 2001, MOL MEMBR BIOL, V18, P237; Tian JH, 2003, J BIOL CHEM, V278, P26265, DOI 10.1074/jbc.M300492200; TURNER CE, 1993, J CELL SCI, V105, P637; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Wasmeier C, 1999, BIOCHEM J, V341, P563, DOI 10.1042/0264-6021:3410563; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yang CM, 2001, J CLIN INVEST, V107, P1311, DOI 10.1172/JCI12274	79	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17624	17634		10.1074/jbc.M601581200	http://dx.doi.org/10.1074/jbc.M601581200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16638745	Green Accepted, hybrid			2022-12-25	WOS:000238490300011
J	Ojeda, L; Keller, G; Muhlenhoff, U; Rutherford, JC; Lill, R; Winge, DR				Ojeda, Luis; Keller, Greg; Muhlenhoff, Ulrich; Rutherford, Julian C.; Lill, Roland; Winge, Dennis R.			Role of glutaredoxin-3 and glutaredoxin-4 in the iron regulation of the Aft1 transcriptional activator in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFUR-PROTEIN BIOGENESIS; CYTOSOLIC FE/S PROTEINS; MONOTHIOL GLUTAREDOXIN; CLUSTER BIOSYNTHESIS; ESCHERICHIA-COLI; OXIDATIVE STRESS; GENE-EXPRESSION; YEAST; MITOCHONDRIAL; MATURATION	The transcription factors Aft1 and Aft2 from Saccharomyces cerevisiae regulate the expression of genes involved in iron homeostasis. These factors induce the expression of iron regulon genes in iron-deficient yeast but are inactivated in iron-replete cells. Iron inhibition of Aft1/Aft2 was previously shown to be dependent on mitochondrial components required for cytosolic iron sulfur protein biogenesis. We presently show that the nuclear monothiol glutaredoxins Grx3 and Grx4 are critical for iron inhibition of Aft1 in yeast cells. Cells lacking both glutaredoxins show constitutive expression of iron regulon genes. Overexpression of Grx4 attenuates wild type Aft1 activity. The thioredoxin-like domain in Grx3 and Grx4 is dispensable in mediating iron inhibition of Aft1 activity, whereas the conserved cysteine that is part of the conserved CGFS motif in monothiol glutaredoxins is essential for this function. Grx3 and Grx4 interact with Aft1 as shown by two-hybrid interactions and co-immunoprecipitation assays. The interaction between glutaredoxins and Aft1 is not modulated by the iron status of cells but is dependent on the conserved glutaredoxin domain Cys residue. Thus, Grx3 and Grx4 are novel components required for Aft1 iron regulation that most likely occurs in the nucleus.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Philipps University Marburg	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010	Lill, Roland/0000-0002-8345-6518	NCI NIH HHS [CA 61286] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061286] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balk J, 2005, MOL CELL BIOL, V25, P10833, DOI 10.1128/MCB.25.24.10833-10841.2005; Balk J, 2004, EMBO J, V23, P2105, DOI 10.1038/sj.emboj.7600216; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Belli G, 2004, J BIOL CHEM, V279, P12386, DOI 10.1074/jbc.M311879200; Belli G, 2002, J BIOL CHEM, V277, P37590, DOI 10.1074/jbc.M201688200; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Chen OS, 2004, J BIOL CHEM, V279, P29513, DOI 10.1074/jbc.M403209200; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Chung WH, 2005, BIOCHEM BIOPH RES CO, V330, P604, DOI 10.1016/j.bbrc.2005.02.183; Courel M, 2005, MOL CELL BIOL, V25, P6760, DOI 10.1128/MCB.25.15.6760-6771.2005; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; Fernandes AP, 2005, J BIOL CHEM, V280, P24544, DOI 10.1074/jbc.M500678200; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Fladvad M, 2005, J BIOL CHEM, V280, P24553, DOI 10.1074/jbc.M500679200; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Garrido EO, 2002, MOL MICROBIOL, V43, P993, DOI 10.1046/j.1365-2958.2002.02795.x; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Lopreiato R, 2004, BIOCHEM J, V377, P395, DOI 10.1042/BJ20030638; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Molina MM, 2004, J BIOL CHEM, V279, P51923, DOI 10.1074/jbc.M410219200; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Puig S, 2005, CELL, V120, P99, DOI 10.1016/j.cell.2004.11.032; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; ROSE IA, 1967, J BIOL CHEM, V242, P1870; Roy A, 2003, EMBO J, V22, P4826, DOI 10.1093/emboj/cdg455; Rutherford JC, 2005, J BIOL CHEM, V280, P10135, DOI 10.1074/jbc.M413731200; Rutherford JC, 2004, EUKARYOT CELL, V3, P1, DOI 10.1128/EC.3.1.1-13.2004; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; Shenton D, 2002, J BIOL CHEM, V277, P16853, DOI 10.1074/jbc.M200559200; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Sipos K, 2002, J BIOL CHEM, V277, P26944, DOI 10.1074/jbc.M200677200; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; Ueta R, 2003, J BIOL CHEM, V278, P50120, DOI 10.1074/jbc.M305046200; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540	44	194	199	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17661	17669		10.1074/jbc.M602165200	http://dx.doi.org/10.1074/jbc.M602165200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16648636	hybrid			2022-12-25	WOS:000238490300015
J	Rezvani, HR; Mazurier, F; Cario-Andre, M; Pain, C; Ged, C; Taieb, A; de Verneuil, H				Rezvani, Hamid Reza; Mazurier, Frederic; Cario-Andre, Muriel; Pain, Catherine; Ged, Cecile; Taieb, Alain; de Verneuil, Hubert			Protective effects of catalase overexpression on UVB-induced apoptosis in normal human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; SUNBURN CELL-FORMATION; DNA-DAMAGE; CASPASE ACTIVATION; ULTRAVIOLET-LIGHT; GENE-TRANSFER; KAPPA-B; OXYGEN; P53; PATHWAYS	UV-induced apoptosis in keratinocytes is a highly complex process in which various molecular pathways are involved. These include the extrinsic pathway via triggering of death receptors and the intrinsic pathway via DNA damage and reactive oxygen species (ROS) formation. In this study we investigated the effect of catalase and CuZn-superoxide dismutase (SOD) overexpression on apoptosis induced by UVB exposure at room temperature or 4 C on normal human keratinocytes. Irradiation at low temperature reduced UV-induced apoptosis by 40% in normal keratinocytes independently of any change in p53 and with a decrease in caspase-8 activation. Catalase overexpression decreased apoptosis by 40% with a reduction of caspase-9 activation accompanied by a decrease in p53. Keeping cells at low temperature and catalase overexpression had additive effects. CuZn-SOD overexpression had no significant effect on UVB-induced apoptosis. UVB induced an increase in ROS levels at two distinct stages: immediately following irradiation and around 3 h after irradiation. Catalase overexpression inhibited only the late increase in ROS levels. We conclude that catalase overexpression has a protective role against UVB irradiation by preventing DNA damage mediated by the late ROS increase.	Univ Bordeaux 2, INSERM, E0217, F-33000 Bordeaux, France; Ctr Hosp Univ Bordeaux, Dept Dermatol, Hop St Andre, F-33000 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux	de Verneuil, H (corresponding author), Univ Bordeaux 2, INSERM, E0217, F-33000 Bordeaux, France.	verneuil@u-bordeaux2.fr	Cario, Muriel/AAM-2633-2020; TAIEB, ALAIN/AAB-1085-2021; Rezvani, Hamid Reza/G-3734-2013; Mazurier, FrÃ©dÃ©ric/O-1619-2018	Cario, Muriel/0000-0003-0462-5684; Rezvani, Hamid Reza/0000-0001-8067-1338; GED, Cecile/0000-0001-7257-8264; Mazurier, Frederic/0000-0002-6984-7096				Achanta G, 2004, CANCER RES, V64, P6233, DOI 10.1158/0008-5472.CAN-04-0494; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Assefa Z, 2003, FEBS LETT, V540, P125, DOI 10.1016/S0014-5793(03)00238-2; Beak SM, 2004, BIOCHIMIE, V86, P425, DOI 10.1016/j.biochi.2004.06.010; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cario-Andre M, 2002, J PHOTOCH PHOTOBIO B, V68, P79, DOI 10.1016/S1011-1344(02)00328-7; Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148; Cudre-Mauroux C, 2003, HUM GENE THER, V14, P1525, DOI 10.1089/104303403322495034; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Geronimi F, 2003, STEM CELLS, V21, P472, DOI 10.1634/stemcells.21-4-472; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; Kulms D, 2002, ONCOGENE, V21, P5844, DOI 10.1038/sj.onc.1205743; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Maalouf S, 2002, MOL CARCINOGEN, V34, P121, DOI 10.1002/mc.10055; MASAKI H, 1995, BIOCHEM BIOPH RES CO, V206, P474, DOI 10.1006/bbrc.1995.1067; Mates JM, 2000, TOXICOLOGY, V153, P83, DOI 10.1016/S0300-483X(00)00306-1; Michiels C, 2002, FREE RADICAL BIO MED, V33, P1231, DOI 10.1016/S0891-5849(02)01045-6; Morley N, 2003, J PHOTOCH PHOTOBIO B, V72, P55, DOI 10.1016/j.jphotobiol.2003.06.004; Murphy G, 2001, EXP DERMATOL, V10, P155, DOI 10.1034/j.1600-0625.2001.010003155.x; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Pelle E, 2003, J INVEST DERMATOL, V121, P177, DOI 10.1046/j.1523-1747.2003.12330.x; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Peus D, 1999, J INVEST DERMATOL, V112, P751, DOI 10.1046/j.1523-1747.1999.00584.x; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; SCAFFIDI C, 1909, EMBO J, V7, P1675; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; Stege H, 2000, P NATL ACAD SCI USA, V97, P1790, DOI 10.1073/pnas.030528897; Takasawa R, 2005, APOPTOSIS, V10, P1121, DOI 10.1007/s10495-005-0901-8; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Tyrrell RM, 1995, BIOCHEM SOC SYMP, P47, DOI 10.1042/bss0610047; Wang HJ, 2005, FREE RADICAL BIO MED, V38, P890, DOI 10.1016/j.freeradbiomed.2004.12.005; WOLF P, 1995, J INVEST DERMATOL, V104, P287, DOI 10.1111/1523-1747.ep12612828; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	41	96	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17999	18007		10.1074/jbc.M600536200	http://dx.doi.org/10.1074/jbc.M600536200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16644728	hybrid			2022-12-25	WOS:000238490300050
J	Feng, YH; Li, X; Wang, LQ; Zhou, LY; Gorodeski, GI				Feng, Ying-Hong; Li, Xin; Wang, Liqin; Zhou, Lingying; Gorodeski, George I.			A truncated P2X(7) receptor variant (P2X(7-j)) endogenously expressed in cervical cancer cells antagonizes the full-length P2X(7) receptor through hetero-oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE FORMATION; P2X7 RECEPTOR; ALA POLYMORPHISM; EPITHELIAL-CELLS; XENOPUS OOCYTES; CYTOLYTIC PORE; ATP; TRAFFICKING; RAT; IDENTIFICATION	A truncated naturally occurring variant of the human receptor P2X(7) was identified in cancer cervical cells. The novel protein (P2X(7-j)), a polypeptide of 258 amino acids, lacks the entire intracellular carboxyl terminus, the second transmembrane domain, and the distal third of the extracellular loop of the full-length P2X(7) receptor. The P2X(7-j) was expressed in the plasma membrane; it showed diminished ligand-binding and channel function capacities and failed to form pores and mediate apoptosis in response to treatment with the P2X(7) receptor agonist benzoyl-ATP. The P2X(7-j) interacted with the full-length P2X(7) in a manner suggesting hetero-oligomerization and blocked the P2X(7)-mediated actions. Interestingly, P2X(7-j) immunoreactivity and mRNA expression were similar in lysates of human cancer and normal cervical tissues, but full-length P2X(7) immunoreactivity and mRNA expression were higher in normal than in cancer tissues, and cancer tissues lacked 205-kDa P2X(7) immunoreactivity suggesting lack of P2X(7) homo(tri)-oligomerization. These results identify a novel P2X(7) variant with apoptosis-inhibitory actions, and demonstrate a distinct regulatory property for a truncated variant to antagonize its full-length counterpart through hetero-oligomerization. This may represent a general paradigm for regulation of a protein function by its variant.	Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; Case Western Reserve Univ, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Oncol, Cleveland, OH 44106 USA	Uniformed Services University of the Health Sciences - USA; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Gorodeski, GI (corresponding author), Univ Hosp Cleveland, Univ MacDonald Womens Hosp, 11100 Euclid Ave, Cleveland, OH 44106 USA.	gig@cwru.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029924] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R55AG015955, R01AG015955] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL065492, HL65492] Funding Source: Medline; NIA NIH HHS [R01 AG015955-09, AG15955, R01 AG015955] Funding Source: Medline; NICHD NIH HHS [HD29924] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adriouch S, 2002, J IMMUNOL, V169, P4108, DOI 10.4049/jimmunol.169.8.4108; Bardini M, 2000, CELL TISSUE RES, V299, P105, DOI 10.1007/s004410050010; Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; Boldt W, 2003, AM J PHYSIOL-CELL PH, V284, pC749, DOI 10.1152/ajpcell.00042.2002; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; Buell GN, 1998, RECEPTOR CHANNEL, V5, P347; Cabrini G, 2005, J IMMUNOL, V175, P82, DOI 10.4049/jimmunol.175.1.82; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; Cheewatrakoolpong B, 2005, BIOCHEM BIOPH RES CO, V332, P17, DOI 10.1016/j.bbrc.2005.04.087; Denlinger LC, 2003, J IMMUNOL, V171, P1304, DOI 10.4049/jimmunol.171.3.1304; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Feng YH, 2005, AM J PHYSIOL-CELL PH, V288, pC1342, DOI 10.1152/ajpcell.00315.2004; FRANKE H, 2004, J NEUROPATHOL EXP NE, V636, P86; Georgiou JG, 2005, J INVEST DERMATOL, V125, P482, DOI 10.1111/j.0022-202X.2005.23835.x; Gu BJ, 2004, J BIOL CHEM, V279, P31287, DOI 10.1074/jbc.M313902200; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; GUERRA L, 2001, DURG DEV RES, V53, P91; Jiang LH, 2003, J NEUROSCI, V23, P8903; Khakh BS, 2001, PHARMACOL REV, V53, P107; Kim M, 1997, BIOCHEM BIOPH RES CO, V240, P618, DOI 10.1006/bbrc.1997.7713; Kim M, 2001, J BIOL CHEM, V276, P23262, DOI 10.1074/jbc.M102253200; Klapperstuck M, 2000, BBA-BIOMEMBRANES, V1467, P444, DOI 10.1016/S0005-2736(00)00245-5; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Le Stunff H, 2004, J BIOL CHEM, V279, P16918, DOI 10.1074/jbc.M313064200; Lee HY, 2000, J UROLOGY, V163, P2002, DOI 10.1016/S0022-5347(05)67618-5; Li CM, 2002, J INFECT DIS, V186, P1458, DOI 10.1086/344351; Li CM, 2002, FEBS LETT, V531, P127, DOI 10.1016/S0014-5793(02)03424-5; Li GH, 2000, J BIOL CHEM, V275, P29107, DOI 10.1074/jbc.M910277199; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Menzies J, 2003, AUTON NEUROSCI-BASIC, V106, P103, DOI 10.1016/S1566-0702(03)00078-X; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Petrou S, 1997, FEBS LETT, V411, P339, DOI 10.1016/S0014-5793(97)00700-X; Ralevic V, 1998, PHARMACOL REV, V50, P413; Saslow D, 2002, CA-CANCER J CLIN, V52, P342, DOI 10.3322/canjclin.52.6.342; Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC766, DOI 10.1152/ajpcell.1999.277.4.C766; Smart ML, 2003, J BIOL CHEM, V278, P8853, DOI 10.1074/jbc.M211094200; Smart ML, 2002, AM J PHYSIOL-CELL PH, V283, pC77, DOI 10.1152/ajpcell.00456.2001; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Soto F, 1997, J MEMBRANE BIOL, V160, P91, DOI 10.1007/s002329900298; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; Stoilov P, 2002, DNA CELL BIOL, V21, P803, DOI 10.1089/104454902320908450; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Tagliarino C, 2001, J BIOL CHEM, V276, P19150, DOI 10.1074/jbc.M100730200; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Torres GE, 1999, J BIOL CHEM, V274, P22359, DOI 10.1074/jbc.274.32.22359; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Wang LQ, 2005, ENDOCRINOLOGY, V146, P164, DOI 10.1210/en.2004-1026; Wang QF, 2004, ENDOCRINOLOGY, V145, P5568, DOI 10.1210/en.2004-0807; Wang QF, 2004, AM J PHYSIOL-CELL PH, V287, pC1349, DOI 10.1152/ajpcell.00256.2004; Wiley JS, 2003, J BIOL CHEM, V278, P17108, DOI 10.1074/jbc.M212759200; [No title captured]	54	116	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17228	17237		10.1074/jbc.M602999200	http://dx.doi.org/10.1074/jbc.M602999200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16624800	Green Accepted, hybrid			2022-12-25	WOS:000238326300049
J	Liu, XM; Pei, DS; Guan, QH; Sun, YF; Wang, XT; Zhang, QX; Zhang, GY				Liu, Xiao-Mei; Pei, Dong-Sheng; Guan, Qiu-Hua; Sun, Ya-Feng; Wang, Xiao-Tian; Zhang, Qing-Xiu; Zhang, Guang-Yi			Neuroprotection of Tat-GluR6-9c against neuronal death induced by kainate in rat hippocampus via nuclear and non-nuclear pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAINIC ACID; CELL-DEATH; INDUCED SEIZURES; ACTIVATION; JNK; CA1; BAX; TRANSDUCTION; STIMULATION; POPULATIONS	Previous studies have suggested that glutamate receptor 6 (GluR6) subunit- and JNK-deficient mice can resist kainate-induced epileptic seizure and neuronal toxicity ( Yang, D. D., Kuan, C.-Y., Whitmarsh, A. J., Rinocn, M., Zheng, T. S., Davis, R. J., Rakic, P., and Flavell, R. A. ( 1997) Nature 389, 865-870; Mulle, C., Seiler, A., Perez-Otano, I., Dickinson-Anson, H., Castillo, P. E., Bureau, I., Maron, C., Gage, F. H., Mann, J. R., Bettler, B., and Heinemmann, S. F. ( 1998) Nature 392, 601-605). In this study, we show that kainate can enhance the assembly of the GluR6-PSD95-MLK3 module and facilitate the phosphorylation of JNK in rat hippocampal CA1 and CA3/dentate gyrus (DG) subfields. More important, a peptide containing the Tat protein transduction sequence (Tat-GluR6-9c) perturbed the assembly of the GluR6-PSD95-MLK3 signaling module and suppressed the activation of MLK3, MKK7, and JNK. As a result, the inhibition of JNK activation by Tat-GluR6-9c diminished the phosphorylation of the transcription factor c-Jun and down-regulated Fas ligand expression in hippocampal CA1 and CA3/DG regions. The inhibition of JNK activation by Tat-Glur6-9c attenuated Bax translocation, the release of cytochrome c, and the activation of caspase-3 in CA1 and CA3/DG subfields. Furthermore, kainate-induced neuronal loss in hippocampal CA1 and CA3 subregions was prevented by intracerebroventricular injection of Tat-Glur6-9c. Taken together, our findings strongly suggest that the GluR6PSD95-MLK3 signaling module mediates activation of the nuclear and non-nuclear pathways of JNK, which is involved in brain injury induced by kainate. Tat-GluR6-9c, the peptide we constructed, gives new insight into seizure therapy.	Xuzhou Med Coll, Res Ctr Biochem & Mol Biol, Xuzhou 221002, Jiangsu, Peoples R China	Xuzhou Medical University	Zhang, GY (corresponding author), Xuzhou Med Coll, Res Ctr Biochem & Mol Biol, 84 W Huai Hai Rd, Xuzhou 221002, Jiangsu, Peoples R China.	gyzhang@xzmc.edu.cn						BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Bureau I, 1999, J NEUROSCI, V19, P653; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Fujikawa DG, 2000, EPILEPSIA, V41, pS9, DOI 10.1111/j.1528-1157.2000.tb01549.x; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Guan QH, 2005, BRAIN RES, V1035, P51, DOI 10.1016/j.brainres.2004.11.050; Henshall DC, 2002, J NEUROSCI, V22, P8458; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Henshall DC, 2001, CELL DEATH DIFFER, V8, P1169, DOI 10.1038/sj.cdd.4400921; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KIYOKAZU O, 2003, J NEUROCHEM, V85, P1336; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsuoka Y, 1999, EUR J NEUROSCI, V11, P3617, DOI 10.1046/j.1460-9568.1999.00781.x; Mehta S, 2001, J BIOL CHEM, V276, P16092, DOI 10.1074/jbc.M100643200; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Pei DS, 2006, BRAIN, V129, P465, DOI 10.1093/brain/awh700; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Savinainen A, 2001, J BIOL CHEM, V276, P11382, DOI 10.1074/jbc.M100190200; Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; SPERK G, 1983, NEUROSCIENCE, V10, P1301, DOI 10.1016/0306-4522(83)90113-6; Tian H, 2003, NEUROSCI RES, V46, P191, DOI 10.1016/S0168-0102(03)00057-9; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Wang RM, 2005, J NEUROSCI RES, V80, P391, DOI 10.1002/jnr.20433; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YURI B, 2000, J NEUROSCI, V20, P8643	37	48	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17432	17445		10.1074/jbc.M513490200	http://dx.doi.org/10.1074/jbc.M513490200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16624817	hybrid			2022-12-25	WOS:000238326300069
J	Cai, CX; Lin, PH; Cheung, KH; Li, N; Levchook, C; Pan, Z; Ferrante, C; Boulianne, GL; Foskett, JK; Danielpour, D; Ma, JJ				Cai, Chuanxi; Lin, Peihui; Cheung, King-Ho; Li, Na; Levchook, Christina; Pan, Zui; Ferrante, Christopher; Boulianne, Gabrielle L.; Foskett, J. Kevin; Danielpour, David; Ma, Jianjie			The presenilin-2 loop peptide perturbs intracellular Ca2+ homeostasis and accelerates apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; CAPACITATIVE CALCIUM-ENTRY; SINGLE-CHANNEL KINETICS; PROTEIN TRANSDUCTION; ENDOPLASMIC-RETICULUM; MISSENSE MUTATIONS; MAMMALIAN-CELLS; CLEAVAGE; NEURONS; GENE	In cells undergoing apoptosis, a 22-amino-acidpresenilin-2-loop peptide (PS2-LP, amino acids 308-329 in presenilin-2) is generated through cleavage of the carboxyl-terminal fragment of presenilin- 2 by caspase-3. The impact of PS2-LP on the progression of apoptosis, however, is not known. Here we show that PS2-LP is a potent inducer of the mitochondrial-dependent cell death pathway when transduced as a fusion protein with HIV-TAT. Biochemical and functional studies demonstrate that TAT-PS2-LP can interact with the inositol 1,4,5-trisphosphate receptor and activate Ca2(+) release from the endoplasmic reticulum. These results indicate that PS2LP-mediated alteration of intracellular Ca2(+) homeostasis may be linked to the acceleration of apoptosis. Therefore, targeting the function of PS2-LP could provide a useful therapeutic tool for the treatment of cancer and degenerative diseases.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Univ Toronto, Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Pennsylvania; Case Western Reserve University	Ma, JJ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Ln, Piscataway, NJ 08854 USA.	maj2@umdnj.edu	Foskett, Kevin/R-2549-2019; Cai, Chuanxi/AAW-1488-2020; /B-3424-2011	Pan, Zui/0000-0003-4105-901X; Foskett, J. Kevin/0000-0002-8854-0268; /0000-0001-8683-1654	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059937] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 95379] Funding Source: Medline; NHLBI NIH HHS [R01 HL 69000] Funding Source: Medline; NIGMS NIH HHS [R01 GM 056328] Funding Source: Medline; NIMH NIH HHS [R01 MH059937] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Araki W, 2001, J NEUROCHEM, V79, P1161, DOI 10.1046/j.1471-4159.2001.00638.x; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Bursztajn S, 1998, J NEUROSCI, V18, P9790; da Costa CA, 2003, J BIOL CHEM, V278, P12064, DOI 10.1074/jbc.M212379200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; DANIELPOUR D, 1994, CANCER RES, V54, P3413; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; Fantin VR, 2005, CANCER RES, V65, P6891, DOI 10.1158/0008-5472.CAN-05-0395; Fraser PE, 2000, BBA-MOL BASIS DIS, V1502, P1, DOI 10.1016/S0925-4439(00)00028-4; Guo Q, 1997, J NEUROSCI, V17, P4212; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Lin PH, 2005, CELL RES, V15, P160, DOI 10.1038/sj.cr.7290281; Mak DOD, 1997, J GEN PHYSIOL, V109, P571, DOI 10.1085/jgp.109.5.571; Mak DOD, 1998, P NATL ACAD SCI USA, V95, P15821, DOI 10.1073/pnas.95.26.15821; MAK DOD, 2005, METHODS CALCIUM SIGN, P203; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Pan Z, 2002, NAT CELL BIOL, V4, P379, DOI 10.1038/ncb788; Putney JW, 2001, J CELL SCI, V114, P2223; Qin F, 2000, BIOPHYS J, V79, P1915, DOI 10.1016/S0006-3495(00)76441-1; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Stutzmann GE, 2004, J NEUROSCI, V24, P508, DOI 10.1523/JNEUROSCI.4386-03.2004; Tesco G, 1998, J BIOL CHEM, V273, P33909, DOI 10.1074/jbc.273.51.33909; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Unkila M, 2001, J BIOL CHEM, V276, P39132, DOI 10.1074/jbc.M104986200; van de Craen M, 1999, FEBS LETT, V445, P149, DOI 10.1016/S0014-5793(99)00108-8; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Wedhas N, 2005, FASEB J, V19, P1986, DOI 10.1096/fj.05-4198com; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0	45	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16649	16655		10.1074/jbc.M512026200	http://dx.doi.org/10.1074/jbc.M512026200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16603547	hybrid			2022-12-25	WOS:000238165700058
J	Griffin, EE; Chan, DC				Griffin, Erik E.; Chan, David C.			Domain interactions within Fzo1 oligomers are essential for mitochondrial fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; DOMINANT OPTIC ATROPHY; VIRAL MEMBRANE-FUSION; OUTER-MEMBRANE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN HOMOLOGS; COILED COILS; PROTEIN; MGM1P; MECHANISMS	Mitofusins are conserved GTPases essential for the fusion of mitochondria. These mitochondrial outer membrane proteins contain a GTPase domain and two or three regions with hydrophobic heptad repeats, but little is known about how these domains interact to mediate mitochondrial fusion. To address this issue, we have analyzed the yeast mitofusin Fzo1p and find that mutation of any of the three heptad repeat regions (HRN, HR1, and HR2) leads to a null allele. Specific pairs of null alleles show robust complementation, indicating that functional domains need not exist on the same molecule. Biochemical analysis indicates that this complementation is due to Fzo1p oligomerization mediated by multiple domain interactions. Moreover, we find that two non-overlapping protein fragments, one consisting of HRN/GTPase and the other consisting of HR1/HR2, can form a complex that reconstitutes Fzo1p fusion activity. Each of the null alleles disrupts the interaction of these two fragments, suggesting that we have identified a key interaction involving the GTPase domain and heptad repeats essential for fusion.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Chan, DC (corresponding author), CALTECH, Div Biol, 1200 E Calif Blvd,MC114-96, Pasadena, CA 91125 USA.	dchan@caltech.edu			NIGMS NIH HHS [GM 62967] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062967] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eura Y, 2003, J BIOCHEM, V134, P333, DOI 10.1093/jb/mvg150; Fritz S, 2001, J CELL BIOL, V152, P683, DOI 10.1083/jcb.152.4.683; GUNTHRIE C, 1991, GUIDE YEAST GENETICS; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Kijima K, 2005, HUM GENET, V116, P23, DOI 10.1007/s00439-004-1199-2; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; Lawson VH, 2005, NEUROLOGY, V65, P197, DOI 10.1212/01.wnl.0000168898.76071.70; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Rojo M, 2002, J CELL SCI, V115, P1663; Sesaki H, 2004, J BIOL CHEM, V279, P28298, DOI 10.1074/jbc.M401363200; Sesaki H, 2003, MOL BIOL CELL, V14, P2342, DOI 10.1091/mbc.E02-12-0788; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Sesaki H, 2001, J CELL BIOL, V152, P1123, DOI 10.1083/jcb.152.6.1123; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Wong ED, 2003, J CELL BIOL, V160, P303, DOI 10.1083/jcb.200209015; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	29	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16599	16606		10.1074/jbc.M601847200	http://dx.doi.org/10.1074/jbc.M601847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16624808	hybrid, Green Accepted			2022-12-25	WOS:000238165700052
J	Jeon, EJ; Lee, KY; Choi, NS; Lee, MH; Kim, HN; Jin, YH; Ryoo, HM; Choi, JY; Yoshida, M; Nishino, N; Oh, BC; Lee, KS; Lee, YH; Bae, SC				Jeon, Eun-Joo; Lee, Kwang-Youl; Choi, Nam-Sook; Lee, Mi-Hye; Kim, Hyun-Nam; Jin, Yun-Hye; Ryoo, Hyun-Mo; Choi, Je-Yong; Yoshida, Minoru; Nishino, Norikazu; Oh, Byung-Chul; Lee, Kyeong-Sook; Lee, Yong Hee; Bae, Suk-Chul			Bone morphogenetic protein-2 stimulates Runx2 acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITORS; TRANSCRIPTION FACTOR CBFA1; GROWTH-FACTOR BETA-1; FORMATION IN-VITRO; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; FUNCTIONAL COOPERATION; MEDIATED DEGRADATION; TGF-BETA; EXPRESSION	Runx2/Cbfa1/Pebp2aA is a global regulator of osteogenesis and is crucial for regulating the expression of bone-specific genes. Runx2 is a major target of the bone morphogenetic protein (BMP) pathway. Genetic analysis has revealed that Runx2 is degraded through a Smurf-mediated ubiquitination pathway, and its activity is inhibited by HDAC4. Here, we demonstrate the molecular link between Smurf, HDACs and Runx2, in BMP signaling. BMP-2 signaling stimulates p300-mediated Runx2 acetylation, increasing transactivation activity and inhibiting Smurf1-mediated degradation of Runx2. HDAC4 and HDAC5 dea-cetylate Runx2, allowing the protein to undergo Smurf-mediated degradation. Inhibition of HDAC increases Runx2 acetylation, and potentiates BMP-2-stimulated osteoblast differentiation and increases bone formation. These results demonstrate that the level of Runx2 is controlled by a dynamic equilibrium of acetylation, deacetylation, and ubiquitination. These findings have important medical implications because BMPs and Runx2 are of tremendous interest with regard to the development of therapeutic agents against bone diseases.	Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea; Chungbuk Natl Univ, Inst Tumor Res, Cheongju 361763, South Korea; Seoul Natl Univ, Sch Dent, Dept Cell & Dev Biol, Seoul 110749, South Korea; Kyungpook Natl Univ, Sch Med, Dept Biochem, Taegu 700422, South Korea; RIKEN, Discovery Res Inst, Chem Genet Lab, Wako, Saitama 3510198, Japan; Kyushu Inst Technol, Grad Sch Life Sci & Syst Engn, Kitakyushu, Fukuoka 8080196, Japan	Chungbuk National University; Chungbuk National University; Seoul National University (SNU); Kyungpook National University; RIKEN; Kyushu Institute of Technology	Bae, SC (corresponding author), Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea.	scbae@chungbuk.ac.kr	Ryoo, Hyun-Mo/D-5839-2012; Yoshida, Minoru/C-8049-2014; jin, yun/GQZ-6618-2022	Ryoo, Hyun-Mo/0000-0001-6769-8341; Yoshida, Minoru/0000-0002-4376-5674; Lee, Mi-Hye/0000-0002-5484-3383; Oh, Byung-Chul/0000-0002-4277-7083				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Cho HH, 2005, J CELL BIOCHEM, V96, P533, DOI 10.1002/jcb.20544; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Garrett IR, 2003, METH MOLEC MED, V80, P183; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Komatsu Y, 2001, CANCER RES, V61, P4459; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Lian JB, 1998, J CELL BIOCHEM, P62, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<62::AID-JCB10>3.0.CO;2-S; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Melton LJ, 2004, J BONE MINER RES, V19, P1055, DOI 10.1359/JBMR.040316; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nishino N, 2003, ORG LETT, V5, P5079, DOI 10.1021/ol036098e; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otte L, 2003, PROTEIN SCI, V12, P491, DOI 10.1110/ps.0233203; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813; Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200; Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002-0122; Shi MJ, 1998, J IMMUNOL, V161, P6751; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhou YX, 2000, HUM MOL GENET, V9, P2001, DOI 10.1093/hmg/9.13.2001	59	261	286	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16502	16511		10.1074/jbc.M512494200	http://dx.doi.org/10.1074/jbc.M512494200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16613856	hybrid			2022-12-25	WOS:000238165700040
J	Marjuki, H; Alam, MI; Ehrhardt, C; Wagner, R; Planz, O; Klenk, HD; Ludwig, S; Pleschka, S				Marjuki, Henju; Alam, Mohammad I.; Ehrhardt, Christina; Wagner, Ralf; Planz, Oliver; Klenk, Hans-D.; Ludwig, Stephan; Pleschka, Stephan			Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase C alpha-mediated activation of ERK signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LIPID RAFT MICRODOMAINS; ABORTIVE REPLICATION; RECEPTOR-BINDING; PLASMA-MEMBRANE; T-LYMPHOCYTES; CELLS; INFECTION; CHOLESTEROL; PROPAGATION	Replication and transcription of the influenza virus genome takes place exclusively within the nucleus of the infected cells. The viral RNA genome, polymerase subunits, and nucleoprotein form ribonucleoprotein (RNP) complexes. Late in the infectious cycle RNPs have to be exported from the nucleus to be enwrapped into budding progeny virions at the cell membrane. This process requires viral activation of the cellular Raf/MEK/ERK (mitogen-activated protein kinase ( MAPK)) signaling cascade that is activated late in the infection cycle. Accordingly, block of the cascade results in retardation of RNP export and reduced titers of progeny virus. In the present study we have analyzed the importance of cell-membrane association of the viral hemagglutinin glycoprotein for viral MAPK activation. We show that hemagglutinin membrane accumulation and its tight association with lipid-raft domains trigger activation of the MAPK cascade via protein kinase C alpha activation and induces RNP export. This may represent an auto-regulative mechanism that coordinates timing of RNP export to a point when all viral components are ready for virus budding.	Univ Giessen, Inst Med Virol, D-35392 Giessen, Germany; Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Fed Res Inst Anim Hlth, Friedrich Loeffler Inst, Inst Immunol, D-72076 Tubingen, Germany; Univ Munster, Inst Mol Virol, D-48149 Munster, Germany	Justus Liebig University Giessen; Philipps University Marburg; Friedrich Loeffler Institute; University of Munster	Pleschka, S (corresponding author), Univ Giessen, Inst Med Virol, Frankfurter St 107, D-35392 Giessen, Germany.	stephan.pleschka@mikro.bio.uni-giessen.de	Pleschka, Stephan/HGU-9354-2022	Ludwig, Stephan/0000-0003-4490-3052; Pleschka, Stephan/0000-0002-7372-7089				Arora DJS, 1998, ARCH VIROL, V143, P2029, DOI 10.1007/s007050050439; Barber SA, 2002, J VIROL, V76, P817, DOI 10.1128/JVI.76.2.817-828.2002; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Bruder JT, 1997, J VIROL, V71, P398, DOI 10.1128/JVI.71.1.398-404.1997; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen WZ, 2000, EXP LUNG RES, V26, P13, DOI 10.1080/019021400269934; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Cros JF, 2003, VIRUS RES, V95, P3, DOI 10.1016/S0168-1702(03)00159-X; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Ehrhardt C, 2004, FEBS LETT, V567, P230, DOI 10.1016/j.febslet.2004.04.069; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; FRISCHHOLZ KW, 1984, ARCH VIROL, V80, P163, DOI 10.1007/BF01310656; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; GUJULUVA CN, 1994, VIROLOGY, V204, P491, DOI 10.1006/viro.1994.1563; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kujime K, 2000, J IMMUNOL, V164, P3222, DOI 10.4049/jimmunol.164.6.3222; LAMB RA, 1996, VIROLOGY, P1487; LOHMEYER J, 1979, J GEN VIROL, V42, P73, DOI 10.1099/0022-1317-42-1-73; Ludwig S, 2006, CELL MICROBIOL, V8, P375, DOI 10.1111/j.1462-5822.2005.00678.x; Ludwig S, 1999, VIRAL IMMUNOL, V12, P175, DOI 10.1089/vim.1999.12.175; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Ludwig S, 2004, FEBS LETT, V561, P37, DOI 10.1016/S0014-5793(04)00108-5; Ludwig S, 2003, TRENDS MOL MED, V9, P46, DOI 10.1016/S1471-4914(02)00010-2; Ludwig S, 2001, J BIOL CHEM, V276, P10990, DOI 10.1074/jbc.M009902200; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Nayak DP, 2004, VIRUS RES, V106, P147, DOI 10.1016/j.virusres.2004.08.012; Nimmerjahn F, 2004, J GEN VIROL, V85, P2347, DOI 10.1099/vir.0.79958-0; NOBUSAWA E, 1991, VIROLOGY, V182, P475, DOI 10.1016/0042-6822(91)90588-3; NUGENT KM, 1984, ARCH VIROL, V81, P163, DOI 10.1007/BF01309305; Planz O, 2001, J VIROL, V75, P4871, DOI 10.1128/JVI.75.10.4871-4877.2001; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Popik W, 2000, J VIROL, V74, P2558, DOI 10.1128/JVI.74.6.2558-2566.2000; PORTINCASA P, 1990, VIRUS RES, V18, P29, DOI 10.1016/0168-1702(90)90087-R; Prydz K, 2001, BIOCHEM J, V357, P11, DOI 10.1042/0264-6021:3570011; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rodems SM, 1998, J VIROL, V72, P9173, DOI 10.1128/JVI.72.11.9173-9180.1998; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038; SCHUY W, 1986, EMBO J, V5, P2831, DOI 10.1002/j.1460-2075.1986.tb04576.x; Sieczkarski SB, 2003, J VIROL, V77, P460, DOI 10.1128/JVI.77.1.460-469.2003; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Sun XJ, 2003, J VIROL, V77, P12543, DOI 10.1128/JVI.77.23.12543-12551.2003; Takeda M, 2003, P NATL ACAD SCI USA, V100, P14610, DOI 10.1073/pnas.2235620100; Terstegen L, 2001, J IMMUNOL, V167, P5209, DOI 10.4049/jimmunol.167.9.5209; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VEIT M, 1991, J VIROL, V65, P2491, DOI 10.1128/JVI.65.5.2491-2500.1991; Vreede FT, 2004, J VIROL, V78, P9568, DOI 10.1128/JVI.78.17.9568-9572.2004; Wagner R, 2005, J VIROL, V79, P6449, DOI 10.1128/JVI.79.10.6449-6458.2005; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wurzer WJ, 2004, J BIOL CHEM, V279, P30931, DOI 10.1074/jbc.M403258200; Wurzer WJ, 2003, EMBO J, V22, P2717, DOI 10.1093/emboj/cdg279; Zhang J, 2000, J VIROL, V74, P4634, DOI 10.1128/JVI.74.10.4634-4644.2000	61	104	110	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16707	16715		10.1074/jbc.M510233200	http://dx.doi.org/10.1074/jbc.M510233200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16608852	hybrid			2022-12-25	WOS:000238165700065
J	Zhou, Q; Cadrin, M; Herrmann, H; Chen, CH; Chalkley, RJ; Burlingame, AL; Omary, MB				Zhou, Qin; Cadrin, Monique; Herrmann, Harald; Chen, Che-Hong; Chalkley, Robert J.; Burlingame, Alma L.; Omary, M. Bishr			Keratin 20 serine 13 phosphorylation is a stress and intestinal goblet cell marker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENTS; TRANSGENIC MICE; CULTURED-CELLS; LIVER-DISEASE; I KERATINS; APOPTOSIS; MUTATION; ORGANIZATION; CYTOKERATINS; EXPRESSION	Keratin polypeptide 20 (K20) is an intermediate filament protein with preferential expression in epithelia of the stomach, intestine, uterus, and bladder and in Merkel cells of the skin. K20 expression is used as a marker to distinguish metastatic tumor origin, but nothing is known regarding its regulation and function. We studied K20 phosphorylation as a first step toward understanding its physiologic role. K20 phosphorylation occurs preferentially on serine, with a high stoichiometry as compared with keratin polypeptides 18 and 19. Mass spectrometry analysis predicted that either K20 Ser(13) or Ser(14) was a likely phosphorylation site, and Ser(13) was confirmed as the phospho-moiety using mutation and transfection analysis and generation of an anti-K20-phospho-Ser(13) antibody. K20 Ser(13) phosphorylation increases after protein kinase C activation, and Ser(13)-to- Ala mutation interferes with keratin filament reorganization in transfected cells. In physiological contexts, K20 degradation and associated Ser(13) hyperphosphorylation occur during apoptosis, and chemically induced mouse colitis also promotes Ser(13) phosphorylation. Among mouse small intestinal enterocytes, K20 Ser(13) is preferentially phosphorylated in goblet cells and undergoes dramatic hyperphosphorylation after starvation and mucin secretion. Therefore, K20 Ser(13) is a highly dynamic protein kinase C-related phosphorylation site that is induced during apoptosis and tissue injury. K20 Ser(13) phosphorylation also serves as a unique marker of small intestinal goblet cells.	Palo Alto Vet Affairs Med Ctr, Palo Alto, CA 94304 USA; Vet Affairs Palo Alto Hlth Care Syst, Dept Med, Palo Alto, CA 94304 USA; Stanford Univ, Ctr Digest Dis, Stanford, CA 94305 USA; Univ Quebec Trois Rivieres, Trois Rivieres, PQ G9A 5H7, Canada; Univ Calif San Francisco, San Francisco, CA 94143 USA; German Canc Res Ctr, D-69120 Heidelberg, Germany	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; University of Quebec; University of Quebec Trois Rivieres; University of California System; University of California San Francisco; Helmholtz Association; German Cancer Research Center (DKFZ)	Zhou, Q (corresponding author), Palo Alto Vet Affairs Med Ctr, Mail Code 154J,3801 Miranda Ave, Palo Alto, CA 94304 USA.	qzhou@stanford.edu		Omary, Bishr/0000-0002-8624-2347; Chalkley, Robert/0000-0002-9757-7302	NCRR NIH HHS [RR 01614] Funding Source: Medline; NIDDK NIH HHS [DK 56339, DK 52951] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056339, R01DK052951] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Badock V, 2001, CELL DEATH DIFFER, V8, P308, DOI 10.1038/sj.cdd.4400812; BIEMANN K, 1990, METHOD ENZYMOL, V193, P888, DOI 10.1016/0076-6879(90)93461-S; Cadrin M, 2000, J HEPATOL, V33, P199, DOI 10.1016/S0168-8278(00)80360-8; CALNEK D, 1993, DIFFERENTIATION, V53, P95, DOI 10.1111/j.1432-0436.1993.tb00649.x; CHANDLER JS, 1991, J BIOL CHEM, V266, P11932; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Coulombe PA, 2004, NAT CELL BIOL, V6, P699, DOI 10.1038/ncb0804-699; Denk H, 2000, J HEPATOL, V32, P689, DOI 10.1016/S0168-8278(00)80233-0; Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906; Feng L, 1999, J CELL SCI, V112, P2081; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Green KJ, 2005, ADV PROTEIN CHEM, V70, P143, DOI 10.1016/S0065-3233(04)70006-6; Hofmann I, 1997, EUR J CELL BIOL, V72, P122; Kochin V, 2004, METHOD CELL BIOL, V78, P373; Ku NO, 2004, METHOD CELL BIOL, V78, P489; Ku NO, 2000, J CELL BIOL, V149, P547, DOI 10.1083/jcb.149.3.547; Ku NO, 1997, J BIOL CHEM, V272, P7556, DOI 10.1074/jbc.272.11.7556; Ku NO, 2003, HEPATOLOGY, V37, P1006, DOI 10.1053/jhep.2003.50181; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; Ku NO, 1998, J CELL BIOL, V143, P2023, DOI 10.1083/jcb.143.7.2023; Ku NO, 2002, P NATL ACAD SCI USA, V99, P4373, DOI 10.1073/pnas.072624299; Ku NO, 2002, J BIOL CHEM, V277, P10775, DOI 10.1074/jbc.M107623200; Ku NO, 2001, J BIOL CHEM, V276, P26792, DOI 10.1074/jbc.M103315200; Ku NO, 2001, NEW ENGL J MED, V344, P1580, DOI 10.1056/NEJM200105243442103; Leech SN, 2001, J CLIN PATHOL, V54, P727, DOI 10.1136/jcp.54.9.727; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; LOWTHERT LA, 1995, BIOCHEM BIOPH RES CO, V206, P370, DOI 10.1006/bbrc.1995.1051; Magin TM, 2004, METHOD CELL BIOL, V78, P65; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1992, AM J PATHOL, V140, P427; Okada S, 2003, FEBS LETT, V540, P157, DOI 10.1016/S0014-5793(03)00256-4; Omary MB, 2004, NEW ENGL J MED, V351, P2087, DOI 10.1056/NEJMra040319; Omary MB, 2002, HEPATOLOGY, V35, P251, DOI 10.1053/jhep.2002.31165; OMARY MB, 2006, IN PRESS TRENDS BIOC; Oshima RG, 2002, CELL DEATH DIFFER, V9, P486, DOI 10.1038/sj.cdd.4400988; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PHLLIPS TE, 1984, AM J PHYSIOL, V247, pG682; Shea TB, 2003, TRENDS NEUROSCI, V26, P397, DOI 10.1016/S0166-2236(03)00199-1; SPECIAN RD, 1984, GASTROENTEROLOGY, V87, P1313; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; Strnad P, 2002, J CELL SCI, V115, P4133, DOI 10.1242/jcs.00096; Stumptner C, 2000, AM J PATHOL, V156, P77, DOI 10.1016/S0002-9440(10)64708-6; Tao GZ, 2003, J CELL SCI, V116, P4629, DOI 10.1242/jcs.00782; Toivola DA, 2004, HEPATOLOGY, V40, P459, DOI 10.1002/hep.20277; Toivola DM, 2005, TRENDS CELL BIOL, V15, P608, DOI 10.1016/j.tcb.2005.09.004; Toivola DM, 2004, J CELL BIOL, V164, P911, DOI 10.1083/jcb.200308103; Toivola DM, 2002, MOL BIOL CELL, V13, P1857, DOI 10.1091/mbc.01-12-0591; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Wildi S, 1999, CLIN CANCER RES, V5, P2840; Zhong BH, 2004, J CELL SCI, V117, P1709, DOI 10.1242/jcs.01016; Zhou Q, 2003, MOL BIOL CELL, V14, P2959, DOI 10.1091/mbc.E03-02-0059; Zhou XJ, 1999, J BIOL CHEM, V274, P12861, DOI 10.1074/jbc.274.18.12861	55	28	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16453	16461		10.1074/jbc.M512284200	http://dx.doi.org/10.1074/jbc.M512284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16608857	hybrid			2022-12-25	WOS:000238165700035
J	Hansen, MDH; Beckerle, MC				Hansen, Marc D. H.; Beckerle, Mary C.			Opposing roles of zyxin/LPP ACTA repeats and the LIM domain region in cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LISTERIA-MONOCYTOGENES; PROTEIN; CADHERIN; COMPLEX; POLYMERIZATION; VINCULIN; GENE; REORGANIZATION; CYTOSKELETON; MECHANISMS	Cadherins mediate cell-cell adhesion by linking cell junctions to actin networks. Although several actin regulatory systems have been implicated in cell-cell adhesion, it remains unclear how such systems drive cadherin-actin network formation and how they are regulated to coincide with initiation of adhesion. Previous work implicated VASP in assembly of cell-cell junctions in keratinocytes and the VASP-binding protein zyxin colocalizes with VASP at cell-cell junctions. Here we examine how domains in zyxin and its relative LPP contribute to cell-cell junction assembly. Using a quantitative assay for cell-cell adhesion, we demonstrate that zyxin and LPP function to increase the rate of early cell-cell junction assembly through the VASP-binding ActA repeat region. We also identify the LIM region of zyxin and LPP to be a regulatory domain that blocks function of these proteins. Deletion of the LIM domains drives adhesion and increases VASP level in detergent insoluble cadherin-actin. Dominant-negative zyxin/LPP mutants reduce the rate of adhesion, lower VASP levels in detergent-insoluble cadherin-actin networks, and allow for the accumulation of capping protein at cell-cell contacts. These data implicate the LIM domains of zyxin and LPP in regulating cell-cell junction assembly through VASP.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84102 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Hansen, MDH (corresponding author), Brigham Young Univ, 574 WIDB, Provo, UT 84602 USA.	marchansen@byu.edu			NCI NIH HHS [T32CA93247] Funding Source: Medline; NIGMS NIH HHS [R01 GM050877, GM050877] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA093247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050877] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; BERSHADSKY A, 1998, GUIDEBOOK EXTRACELLU, P3; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Fradelizi J, 2001, NAT CELL BIOL, V3, P699, DOI 10.1038/35087009; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; Helwani FM, 2004, J CELL BIOL, V164, P899, DOI 10.1083/jcb.200309034; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hoffman LM, 2003, MOL CELL BIOL, V23, P70, DOI 10.1128/MCB.23.1.70-79.2003; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; KNUDSEN KA, 1995, J CELL BIOL, V130, P367; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Verma S, 2004, J BIOL CHEM, V279, P34062, DOI 10.1074/jbc.M404814200	32	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16178	16188		10.1074/jbc.M512771200	http://dx.doi.org/10.1074/jbc.M512771200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16613855	hybrid			2022-12-25	WOS:000237996000071
J	Jenkins, CM; Yan, W; Mancuso, DJ; Gross, RW				Jenkins, Christopher M.; Yan, Wei; Mancuso, David J.; Gross, Richard W.			Highly selective hydrolysis of fatty acyl-CoAs by calcium-independent phospholipase A(2)beta - Enzyme autoacylation and acyl-CoA-mediated reversal of calmodulin inhibition of phospholipase A(2) activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; PROTEIN ALPHA-SUBUNITS; MECHANISM-BASED DISCRIMINATION; MASS-SPECTROMETRY; MOLECULAR-CLONING; PANCREATIC-ISLETS; MEMBRANE PHOSPHOLIPIDS; MYOCARDIAL-ISCHEMIA; SUICIDE INHIBITION; BIOLOGICAL SAMPLES	Calcium-independent phospholipase A(2)beta (iPLA(2)beta) participates in numerous diverse cellular processes, such as arachidonic acid release, insulin secretion, calcium signaling, and apoptosis. Herein, we demonstrate the highly selective iPLA(2)beta-catalyzed hydrolysis of saturated long-chain fatty acyl-CoAs (palmitoyl-CoA approximate to myristoyl-CoA "stearoyl-CoA" oleoyl-CoA approximate to arachidonoyl-CoA) present either as monomers in solution or guests in host membrane bilayers. Site-directed mutagenesis of the iPLA(2)beta catalytic serine (S465A) completely abolished acyl-CoA thioesterase activity, demonstrating that Ser-465 catalyzes both phospholipid and acyl-CoA hydrolysis. Remarkably, incubation of iPLA(2)beta with oleoyl-CoA, but not other long-chain acyl-CoAs, resulted in robust stoichiometric covalent acylation of the enzyme. Moreover, S465A mutagenesis or pretreatment of wild-type iPLA(2)beta with (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2- one unexpectedly increased acylation of the enzyme, indicating the presence of a second reactive nucleophilic residue that participates in the formation of the fatty acyl-iPLA(2)beta adduct. Radiolabeling of intact Sf9 cells expressing iPLA(2)beta with [H-3] oleic acid demonstrated oleoylation of the membrane-associated enzyme. Partial trypsinolysis of oleoylated iPLA(2)beta and matrix-assisted laser desorption ionization mass spectrometry analysis localized the acylation site to a hydrophobic 25-kDa fragment (residues similar to 400-600) spanning the active site to the calmodulin binding domain. Intriguingly, calmodulin-Ca2+ blocked acylation of iPLA(2)beta by oleoyl-CoA. Remarkably, the addition of low micromolar concentrations ( 5 mu M) of oleoyl-CoA resulted in reversal of calmodulin-mediated inhibition of iPLA(2)beta phospholipase A(2) activity. These results collectively identify the molecular species-specific acyl-CoA thioesterase activity of iPLA(2)beta, demonstrate the presence of a second active site that mediates iPLA(2)beta autoacylation, and identify long-chain acyl-CoAs as potential candidates mediating calcium influx factor activity.	Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Dept Chem, St Louis, MO 63130 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Gross, RW (corresponding author), Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Med, Campus Box 8020,600 S Euclid Ave, St Louis, MO 63110 USA.	rgross@wustl.edu			NHLBI NIH HHS [5R01HL41250-12, 5P01HL57278-08] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041250, P01HL057278] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS DL, 1988, BIOCHEM J, V252, P199, DOI 10.1042/bj2520199; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Bolotina VM, 2005, TRENDS BIOCHEM SCI, V30, P378, DOI 10.1016/j.tibs.2005.05.009; BOLOTINA VM, 2004, SCI STKE, pPE34; CAMP LA, 1994, J BIOL CHEM, V269, P23212; Chiba H, 2004, J BIOL CHEM, V279, P12890, DOI 10.1074/jbc.M305801200; CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Eichacker LA, 2004, J BIOL CHEM, V279, P50915, DOI 10.1074/jbc.M405875200; Ford DA, 1998, BIOCHEMISTRY-US, V37, P11953, DOI 10.1021/bi980565w; Forsell PKAL, 1999, EUR J BIOCHEM, V262, P575, DOI 10.1046/j.1432-1327.1999.00418.x; GROSS RW, 1984, BIOCHIM BIOPHYS ACTA, V802, P197, DOI 10.1016/0304-4165(84)90161-2; GROSS RW, 1983, BIOCHEMISTRY-US, V22, P5641, DOI 10.1021/bi00293a028; Han XL, 2004, BIOCHEMISTRY-US, V43, P15584, DOI 10.1021/bi048307o; Han XL, 2004, ANAL BIOCHEM, V330, P317, DOI 10.1016/j.ab.2004.04.004; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; Han XL, 2005, MASS SPECTROM REV, V24, P367, DOI 10.1002/mas.20023; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; Hendrickson SC, 1997, MOL CELL BIOCHEM, V166, P85, DOI 10.1023/A:1006886601825; Hertz R, 2005, J BIOL CHEM, V280, P24451, DOI 10.1074/jbc.M500732200; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Jenkins CM, 2003, BIOCHEMISTRY-US, V42, P11798, DOI 10.1021/bi034611q; Jenkins CM, 2001, J BIOL CHEM, V276, P7129, DOI 10.1074/jbc.M010439200; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; LEHNER R, 1993, J BIOL CHEM, V268, P24726; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Ma ZM, 1997, J BIOL CHEM, V272, P11118; Mancuso DJ, 2003, J BIOL CHEM, V278, P22231, DOI 10.1074/jbc.C300033200; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; McHowat J, 1998, AM J PHYSIOL-CELL PH, V274, pC447, DOI 10.1152/ajpcell.1998.274.2.C447; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NESTERENKO MV, 1994, J BIOCHEM BIOPH METH, V28, P239, DOI 10.1016/0165-022X(94)90020-5; Nocito M, 1996, BBA-LIPID LIPID MET, V1299, P17, DOI 10.1016/0005-2760(95)00176-X; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Quach TTT, 2003, J PROTEOME RES, V2, P543, DOI 10.1021/pr0340126; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Ramanadham S, 2004, BIOCHEMISTRY-US, V43, P918, DOI 10.1021/bi035536m; Ramanadham S, 2003, BIOCHEMISTRY-US, V42, P13929, DOI 10.1021/bi034843p; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Roshak AK, 2000, J BIOL CHEM, V275, P35692, DOI 10.1074/jbc.M002273200; Schaller J, 2000, METH MOL B, V146, P425, DOI 10.1385/1-59259-045-4:425; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SEGEL IH, 1975, ENZYME KINETICS BEHA, P384; Simonsen AC, 2003, FEBS LETT, V552, P253, DOI 10.1016/S0014-5793(03)00970-0; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Smani T, 2003, J BIOL CHEM, V278, P11909, DOI 10.1074/jbc.M210878200; Soyombo AA, 1997, J BIOL CHEM, V272, P27456, DOI 10.1074/jbc.272.43.27456; Su X, 2004, J BIOL CHEM, V279, P21740, DOI 10.1074/jbc.M314166200; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tay HK, 2004, J BIOL CHEM, V279, P22505, DOI 10.1074/jbc.M308788200; Tessier C, 2002, FEBS LETT, V520, P111, DOI 10.1016/S0014-5793(02)02779-5; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Wang ZP, 2005, J BIOL CHEM, V280, P6840, DOI 10.1074/jbc.M405287200; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Williams SD, 2002, BIOCHEM J, V362, P23, DOI 10.1042/bj3620023; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; WOLF RA, 1985, J BIOL CHEM, V260, P7295; Zischka H, 2004, PROTEOMICS, V4, P3776, DOI 10.1002/pmic.200400851; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	79	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15615	15624		10.1074/jbc.M511623200	http://dx.doi.org/10.1074/jbc.M511623200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595686	hybrid			2022-12-25	WOS:000237996000005
J	Kaufman, SB; Gonzalez-Lebrero, RM; Rossi, RC; Garrahan, PJ				Kaufman, Sergio B.; GonzaLez-Lebrero, Rodolfo M.; Rossi, Rolando C.; Garrahan, Patricio J.			Binding of a single Rb+ increases Na+/K+-ATPase, activating dephosphorylation without stoichiometric occlusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATE; STEADY-STATE; SODIUM-PUMP; POTASSIUM; NA,K-ATPASE; KINETICS; NA+,K+-ATPASE; TRANSPORT; IONS	We used partially purified Na+/K+-ATPase from pig kidney to study dephosphorylation, occlusion, and ATPase activity in the same enzyme preparation and in media of identical composition containing 10 mu M ATP and different concentrations of Rb+, used as a K+ congener. The experiments were performed using a rapid-mixing apparatus with a time resolution of 3.5 ms. The main findings were as follows. (i) At sufficiently low Rb+ concentration the initial rate of dephosphorylation was higher than that of occlusion, (ii) as [Rb+] tended to zero the slope of the time course of occlusion but not that of the time course of dephosphorylation approached zero and, (iii) as Rb+ concentration increased, ATPase activity first increased and, after passing through a maximum, tended to a value that was lower than that observed in media without Rb+. None of these results is compatible with the currently held idea that binding of a single Rb+ to the E2P conformer of the ATPase does not modify the rate of dephosphorylation and strongly suggest that a single Rb+ does promote dephosphorylation through a mechanism that is not stoichiometrically coupled to Rb+ occlusion. If this mechanism is included in the currently accepted scheme for ATP hydrolysis by the Na+/K+-ATPase, a reasonable prediction of the experimental results is obtained.	Univ Buenos Aires, Inst Quim & Fisicoquim Biol, Fac Farm & Bioquim, RA-1113 Buenos Aires, DF, Argentina; Univ Buenos Aires, Dept Quim Biol, Fac Farm & Bioquim, RA-1113 Buenos Aires, DF, Argentina	University of Buenos Aires; University of Buenos Aires	Rossi, RC (corresponding author), Univ Buenos Aires, Inst Quim & Fisicoquim Biol, Fac Farm & Bioquim, Junin 956, RA-1113 Buenos Aires, DF, Argentina.	rcr@mail.retina.ar		Gonzalez Lebrero, Rodolfo M./0000-0002-3832-2270; Kaufman, Sergio Benjamin/0000-0002-8763-4086				BEAUGE LA, 1979, J PHYSIOL-LONDON, V295, pP88; BEAUGE LA, 1979, NATURE, V280, P510, DOI 10.1038/280510a0; BLOSTEIN R, 1973, J BIOL CHEM, V248, P1772; FORBUSH B, 1988, J BIOL CHEM, V263, P7961; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P217, DOI 10.1113/jphysiol.1967.sp008297; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; Gonzalez-Lebrero RM, 2002, J BIOL CHEM, V277, P5910, DOI 10.1074/jbc.M105886200; HEYSE S, 1994, J GEN PHYSIOL, V104, P197, DOI 10.1085/jgp.104.2.197; JENSEN J, 1984, J PHYSIOL-LONDON, V346, P219, DOI 10.1113/jphysiol.1984.sp015018; Kaufman SB, 2003, ANN NY ACAD SCI, V986, P155, DOI 10.1111/j.1749-6632.2003.tb07153.x; Kaufman SB, 1999, J BIOL CHEM, V274, P20779, DOI 10.1074/jbc.274.30.20779; POST RL, 1972, J BIOL CHEM, V247, P6530; ROSSI RC, 1989, BIOCHIM BIOPHYS ACTA, V981, P105, DOI 10.1016/0005-2736(89)90087-4; Rossi RC, 1999, ANAL BIOCHEM, V270, P276, DOI 10.1006/abio.1999.4094; ROSSI RC, 1993, J BIOL CHEM, V268, P12579; SCHWARZBAUM PJ, 1995, BBA-BIOMEMBRANES, V1233, P33, DOI 10.1016/0005-2736(94)00229-I; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; Vilsen B, 1999, BIOCHEMISTRY-US, V38, P11389, DOI 10.1021/bi990951t	19	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15721	15726		10.1074/jbc.M600953200	http://dx.doi.org/10.1074/jbc.M600953200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16603545	hybrid			2022-12-25	WOS:000237996000018
J	Petaja-Repo, UE; Hogue, M; Leskela, TT; Markkanen, PMH; Tuusa, JT; Bouvier, M				Petaja-Repo, Ulla E.; Hogue, Mireille; Leskela, Tarja T.; Markkanen, Piia M. H.; Tuusa, Jussi T.; Bouvier, Michel			Distinct subcellular localization for constitutive and agonist-modulated palmitoylation of the human delta opioid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN FATTY ACYLTRANSFERASE; LUTEINIZING-HORMONE RECEPTOR; PHEROMONE RESPONSE PATHWAY; NITRIC-OXIDE SYNTHASE; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; CELL-SURFACE; FUNCTIONAL EXPRESSION; REGULATED ENDOCYTOSIS; ALPHA-SUBUNIT	Protein palmitoylation is a reversible lipid modification that plays important roles for many proteins involved in signal transduction, but relatively little is known about the regulation of this modification and the cellular location where it occurs. We demonstrate that the human delta opioid receptor is palmitoylated at two distinct cellular locations in human embryonic kidney 293 cells and undergoes dynamic regulation at one of these sites. Although palmitoylation could be readily observed for the mature receptor (M-r 55,000), [H-3] palmitate incorporation into the receptor precursor ( Mr 45,000) could be detected only following transport blockade with brefeldin A, nocodazole, and monensin, indicating that the modification occurs initially during or shortly after export from the endoplasmic reticulum. Blocking of palmitoylation with 2-bromopalmitate inhibited receptor cell surface expression, indicating that it is needed for efficient intracellular transport. However, cell surface biotinylation experiments showed that receptors can also be palmitoylated once they have reached the plasma membrane. At this location, palmitoylation is regulated in a receptor activation-dependent manner, as was indicated by the opioid agonist-promoted increase in the turnover of receptor-bound palmitate. This agonist mediated effect did not require receptor-G protein coupling and occurred at the cell surface with out the need for internalization or recycling. The activation-dependent modulation of receptor palmitoylation may thus contribute to the regulation of receptor function at the plasma membrane.	Univ Montreal, Fac Med, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Oulu, Bioctr, FI-90014 Oulu, Finland; Univ Oulu, Dept Anat & Cell Biol, FI-90014 Oulu, Finland	Universite de Montreal; University of Oulu; University of Oulu	Petaja-Repo, UE (corresponding author), Univ Montreal, Fac Med, Dept Biochim, POB 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	Ulla.Petaja-Repo@oulu.fi	Bouvier, Michel/H-2758-2014; Petäjä-Repo, Ulla/AAV-6115-2021; Markkanen, Piia/ABD-8843-2020	Bouvier, Michel/0000-0003-1128-0100; Markkanen, Piia/0000-0002-7200-6490				Apaja PM, 2006, MOL BIOL CELL, V17, P2243, DOI 10.1091/mbc.E05-09-0875; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; BERGER M, 1985, FEBS LETT, V187, P289, DOI 10.1016/0014-5793(85)81261-8; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; BONATTI S, 1989, J BIOL CHEM, V264, P12590; Bradbury FA, 1997, J BIOL CHEM, V272, P5921, DOI 10.1074/jbc.272.9.5921; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Chen CA, 2000, J BIOL CHEM, V275, P23516, DOI 10.1074/jbc.M003439200; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; Drisdel RC, 2004, J NEUROSCI, V24, P10502, DOI 10.1523/JNEUROSCI.3315-04.2004; Duncan JA, 2002, J BIOL CHEM, V277, P31740, DOI 10.1074/jbc.M202505200; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; Fukata M, 2004, NEURON, V44, P987, DOI 10.1016/j.neuron.2004.12.005; Givan SA, 1997, MOL BIOL CELL, V8, P1317, DOI 10.1091/mbc.8.7.1317; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; Hawtin SR, 2001, J BIOL CHEM, V276, P38139; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; Huang K, 2004, NEURON, V44, P977, DOI 10.1016/j.neuron.2004.11.027; Kao LR, 1996, MOL CELL BIOL, V16, P168; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; Keller CA, 2004, J NEUROSCI, V24, P5881, DOI 10.1523/JNEUROSCI.1037-04.2004; KENNEDY ME, 1994, J BIOL CHEM, V269, P31915; KINET JP, 1985, BIOCHEMISTRY-US, V24, P7342, DOI 10.1021/bi00346a048; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KNAPP RJ, 1994, LIFE SCI, V54, pPL463, DOI 10.1016/0024-3205(94)90138-4; Krueger KM, 1997, J BIOL CHEM, V272, P5; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Lippincott-Schwartz J, 2000, ANNU REV CELL DEV BI, V16, P557, DOI 10.1146/annurev.cellbio.16.1.557; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/bi00185a017; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; OBRIEN PJ, 1984, J BIOL CHEM, V259, P5054; OMARY MB, 1981, J BIOL CHEM, V256, P4715; Parat MO, 2001, J BIOL CHEM, V276, P15776, DOI 10.1074/jbc.M006722200; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Pietila EM, 2005, J BIOL CHEM, V280, P26622, DOI 10.1074/jbc.M413815200; Ponimaskin EG, 2002, J BIOL CHEM, V277, P2534, DOI 10.1074/jbc.M106529200; Ponimaskin EG, 2001, BIOCHEM J, V353, P627, DOI 10.1042/0264-6021:3530627; Pryciak PM, 1996, MOL CELL BIOL, V16, P2614; Qanbar R, 2004, BIOCHEMISTRY-US, V43, P12275, DOI 10.1021/bi049176u; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; SIMONIN F, 1994, MOL PHARMACOL, V46, P1015; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; STAUFENBIEL M, 1988, J BIOL CHEM, V263, P13615; STJULES RS, 1986, EXP EYE RES, V43, P929, DOI 10.1016/0014-4835(86)90071-0; Swarthout JT, 2005, J BIOL CHEM, V280, P31141, DOI 10.1074/jbc.M504113200; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; van de Loo JWHP, 2000, BIOCHEM J, V352, P827, DOI 10.1042/0264-6021:3520827; VEIT M, 1993, FEBS LETT, V336, P243, DOI 10.1016/0014-5793(93)80812-9; von Zastrow M, 2003, CURR OPIN NEUROBIOL, V13, P348, DOI 10.1016/S0959-4388(03)00069-2; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Yeh DC, 1999, J BIOL CHEM, V274, P33148, DOI 10.1074/jbc.274.46.33148; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	71	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15780	15789		10.1074/jbc.M602267200	http://dx.doi.org/10.1074/jbc.M602267200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595649	hybrid			2022-12-25	WOS:000237996000026
J	Zhou, DW; Pawlik, KM; Ren, JX; Sun, CW; Townes, TM				Zhou, Dewang; Pawlik, Kevin M.; Ren, Jinxiang; Sun, Chiao-Wang; Townes, Tim M.			Differential binding of erythroid Krupple-like factor to embryonic/fetal globin gene promoters during development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GAMMA-GLOBIN; TRANSCRIPTION FACTOR GATA-1; LOCUS ACTIVATION REGION; FACTOR EKLF; TRANSGENIC MICE; IN-VIVO; MAMMALIAN CHROMATIN; EXPRESSION; PU.1; METHYLATION	The competition model for beta-like globin gene switching during development predicts that differential binding of transcription factors to globin gene promoters and/or proximal enhancers regulate the competitive interactions of globin gene family members with the powerful locus control region (LCR). Direct interactions of individual genes with the LCR are essential for high level expression in erythroid cells. In this paper, we have demonstrated, by chromatin immunoprecipitation, that erythroid-Krupple-like factor (EKLF) binds to embryonic/fetal globin gene promoters in primitive (but not in definitive) erythroid cells. EKLF binds strongly to adult globin gene promoters and to LCR sequences HS4, HS3, HS2, and HS1 in both primitive and definitive erythroid cells. Trimethylation of histone H3K4 and H3K27 at the embryonic/fetal and adult globin gene promoters is equivalent in definitive cells; therefore, the differential binding of EKLF to these promoters does not appear to result from changes in chromatin configuration. Interestingly, the level of EKLF in definitive cells is 3-fold higher than the level in primitive cells. These results suggest that temporal-specific changes in EKLF abundance result in differential binding of this essential erythroid transcription factor to embryonic/fetal globin gene promoters during development and that these changes in EKLF binding specificity mediate the competitive interactions of globin gene family members with the LCR.	Univ Alabama, Dept Biochem & Mol Genet, Sch Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Sch Dent, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Townes, TM (corresponding author), Univ Alabama, Dept Biochem & Mol Genet, Sch Med, Kaul Human Genet Bldg,Rm 502,720 20th St S, Birmingham, AL 35294 USA.	ttownes@uab.edu						Basu P, 2005, BLOOD, V106, P2566, DOI 10.1182/blood-2005-02-0674; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Chen WY, 2000, P NATL ACAD SCI USA, V97, P377, DOI 10.1073/pnas.97.1.377; Chen XY, 2004, MOL CELL BIOL, V24, P10416, DOI 10.1128/MCB.24.23.10416-10424.2004; Chen XY, 2001, MOL CELL BIOL, V21, P3118, DOI 10.1128/MCB.21.9.3118-3125.2001; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Drissen R, 2004, GENE DEV, V18, P2485, DOI 10.1101/gad.317004; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; Filipe A, 1999, EMBO J, V18, P687, DOI 10.1093/emboj/18.3.687; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Im H, 2005, P NATL ACAD SCI USA, V102, P17065, DOI 10.1073/pnas.0506164102; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Migliaccio AR, 2003, J EXP MED, V197, P281, DOI 10.1084/jem.20021149; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Omori A, 2005, MOL CELL BIOL, V25, P3443, DOI 10.1128/MCB.25.9.3443-3451.2005; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; Palstra RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/ng1244; Pandya K, 2001, J BIOL CHEM, V276, P8239, DOI 10.1074/jbc.M008457200; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rhodes J, 2005, DEV CELL, V8, P97, DOI 10.1016/j.devcel.2004.11.014; Rosenbauer F, 2005, BLOOD, V106, P1519, DOI 10.1182/blood-2005-02-0717; Ryan TM, 2000, NUCLEIC ACIDS RES, V28, P2736, DOI 10.1093/nar/28.14.2736; Sargent TG, 2001, J BIOL CHEM, V276, P41817, DOI 10.1074/jbc.M103073200; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Southwood CM, 1996, DEV DYNAM, V206, P248, DOI 10.1002/(SICI)1097-0177(199607)206:3<248::AID-AJA3>3.0.CO;2-I; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS; Tanimoto K, 2000, GENE DEV, V14, P2778, DOI 10.1101/gad.822500; Tewari R, 1998, EMBO J, V17, P2334, DOI 10.1093/emboj/17.8.2334; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhou DW, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh128	49	37	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16052	16057		10.1074/jbc.M601182200	http://dx.doi.org/10.1074/jbc.M601182200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16606611	hybrid			2022-12-25	WOS:000237996000057
J	Kilic, E; Kilic, U; Wang, YM; Bassetti, CL; Marti, HH; Hermann, DM				Kilic, Ertugrul; Kilic, Ulkan; Wang, Yaoming; Bassetti, Claudio L.; Marti, Hugo H.; Hermann, Dirk M.			The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia	FASEB JOURNAL			English	Article							ENDOTHELIAL GROWTH-FACTOR; EXPRESSION; ANGIOGENESIS; ACTIVATION; LEAKAGE; INJURY	Based on its trophic influence on neurons and vascular cells, vascular endothelial growth factor (VEGF) is a promising candidate for stroke treatment. VEGF's survival-promoting effects are purchased at the expense of an increased blood brain barrier permeability, which potentially compromises tissue survival. The mechanisms via which VEGF protects the brain against ischemia remained unknown. We examined signaling pathways underlying VEGF's neuroprotective activity in our transgenic mouse line, which expresses human VEGF165 under a neuron-specific enolase (NSE) promoter. We show that VEGF receptor-2 (Flk-1) is expressed on ischemic neurons and astrocytes and is activated by VEGF. Following 90-min episodes of middle cerebral artery occlusion, VEGF increased phosphorylated ( but not total) Akt and ERK1/-2 and reduced phosphorylated mitogen activated protein kinase/p38 and c-Jun NH2-terminal kinase (JNK)-1/-2 levels, at the same time decreasing inducible NO synthase expression in ischemic neurons. Inhibition of Akt with Wortmannin reversed VEGF's neuroprotective properties, diminished brain swelling, and restored the vascular permeability induced by VEGF to below levels in WT animals. The aggravation of brain injury by Wortmannin was associated with the restitution of p38, but not of JNK-1/-2, ERK-1/-2, or inducible NOS ( iNOS). Our data demonstrate that VEGF mediates both neuroprotection and blood brain barrier permeability via the phosphatidylinositol-3 kinase (PI3K)/Akt pathway. Based on our observation that VEGF neuroprotection and vascular leakage depend on PI3K/Akt, which is putatively regulated by VEGF receptor-2, we predict that it may not easily be possible to make use of VEGF's neuroprotective function without accepting its unfavorable consequence, the increased vascular permeability.	Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; Heidelberg Univ, Inst Physiol & Pathophysiol, Heidelberg, Germany	University of Zurich; University Zurich Hospital; Ruprecht Karls University Heidelberg	Kilic, E (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklinstr 26, CH-8091 Zurich, Switzerland.	ertugrul.kilic@usz.ch	Kilic, Ertugrul/W-4563-2018; Hermann, Dirk M./AAT-3652-2021; Hermann, Dirk M/AAP-5538-2020; Hermann, Dirk/GZB-9350-2022	Kilic, Ertugrul/0000-0001-6494-8923; Hermann, Dirk M./0000-0003-0198-3152; Marti, Hugo/0000-0002-8456-334X; Bassetti, Claudio/0000-0002-4535-0245				DALKARA T, 1994, BRAIN PATHOL, V4, P49; Fischer S, 2004, J CELL PHYSIOL, V198, P359, DOI 10.1002/jcp.10417; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hermann DM, 1998, NEUROREPORT, V9, P1917, DOI 10.1097/00001756-199806010-00046; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Issbrucker K, 2002, FASEB J, V16, P262, DOI 10.1096/fj.02-0329fje; Jin K, 2001, NEUROSCIENCE, V108, P351, DOI 10.1016/S0306-4522(01)00154-3; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kaya D, 2005, J CEREBR BLOOD F MET, V25, P1111, DOI 10.1038/sj.jcbfm.9600109; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356; Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865; Marti HH, 1998, P NATL ACAD SCI USA, V95, P15809, DOI 10.1073/pnas.95.26.15809; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Matsuzaki H, 2001, FASEB J, V15, P1218, DOI 10.1096/fj.00-0495fje; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200; Schoch HJ, 2002, BRAIN, V125, P2549, DOI 10.1093/brain/awf257; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Vogel J, 2004, J CEREBR BLOOD F MET, V24, P849, DOI 10.1097/01.WCB.0000126564.89011.11; Wang YM, 2005, BRAIN, V128, P52, DOI 10.1093/brain/awh325; Wick A, 2002, J NEUROSCI, V22, P6401; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369	24	184	196	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1185	+		10.1096/fj.05-4829fje	http://dx.doi.org/10.1096/fj.05-4829fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16641198				2022-12-25	WOS:000240210300020
J	von Gunten, S; Simon, HU				von Gunten, Stephan; Simon, Hans-Uwe			Sialic acid binding immunoglobulin-like lectins may regulate innate immune responses by modulating the life span of granulocytes	FASEB JOURNAL			English	Article						apoptosis; caspases; eosinophils; inflammation; neutrophils; non-apoptotic cell death; Siglecs	APOPTOTIC PATHWAYS; FAS LIGAND; DEATH; EXPRESSION; SIGLECS; CD22; NEUTROPHILS; ACTIVATION; MECHANISM; AUTOPHAGY	The regulation of cell death is a key element in building up and maintaining both innate and adaptive immunity. A critical role in this process plays the tumor necrosis factor (TNF)/nerve growth factor (NGF) receptor family of death receptors. Recent work suggests that sialic acid binding immunoglobulin (Ig) -like lectins (Siglecs) are also empowered to transmit death signals, at least into myeloid cells. Strikingly, death induction by Siglecs is enhanced when cells are exposed to proinflammatory survival cytokines. Based on these recent insights, we hypothesize that at least some members of the Siglec family regulate immune responses via the activation of caspase-dependent and caspase-independent cell death pathways. von Gunten, S., Simon, H.-U. Sialic acid binding immunoglobulinlike lectins ( Siglecs) may regulate innate immune responses by modulating the life span of granulocytes.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland	University of Bern	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736; von Gunten, Stephan/0000-0002-2753-8738				Altznauer F, 2004, J BIOL CHEM, V279, P5947, DOI 10.1074/jbc.M308576200; Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com; Baumann R, 2004, EUR J IMMUNOL, V34, P2268, DOI 10.1002/eji.200424863; Blixt O, 2003, J BIOL CHEM, V278, P31007, DOI 10.1074/jbc.M304331200; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; Bruno A, 2005, J IMMUNOL, V174, P8090, DOI 10.4049/jimmunol.174.12.8090; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Daigle I, 2002, NAT MED, V8, P61, DOI 10.1038/nm0102-61; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Erickson LD, 1996, INT IMMUNOL, V8, P1121, DOI 10.1093/intimm/8.7.1121; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104; Hayakawa T, 2005, SCIENCE, V309, P1693, DOI 10.1126/science.1114321; Hoeberichts FA, 2003, BIOESSAYS, V25, P47, DOI 10.1002/bies.10175; Irie A, 1998, J BIOL CHEM, V273, P15866, DOI 10.1074/jbc.273.25.15866; Kavurma MM, 2003, CELL DEATH DIFFER, V10, P36, DOI 10.1038/sj.cdd.4401179; MEDAWAR PB, 1945, J ANAT, V79, P157; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nitschke L, 2004, TRENDS IMMUNOL, V25, P543, DOI 10.1016/j.it.2004.08.002; Nutku E, 2005, BIOCHEM BIOPH RES CO, V336, P918, DOI 10.1016/j.bbrc.2005.08.202; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Rapoport E, 2003, BIOORG MED CHEM LETT, V13, P675, DOI 10.1016/S0960-894X(02)00998-8; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; Streilein JW, 2000, J LEUKOCYTE BIOL, V67, P479, DOI 10.1002/jlb.67.4.479; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vitale C, 2001, P NATL ACAD SCI USA, V98, P5764, DOI 10.1073/pnas.091097198; von Gunten S, 2005, BLOOD, V106, P1423, DOI 10.1182/blood-2004-10-4112; Yousefi S, 2003, CELL DEATH DIFFER, V10, P861, DOI 10.1038/sj.cdd.4401262; Yousefi S, 2003, SEMIN IMMUNOL, V15, P195, DOI 10.1016/S1044-5323(03)00033-2; Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200	42	32	37	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					601	605		10.1096/fj.05-5401hyp	http://dx.doi.org/10.1096/fj.05-5401hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581967				2022-12-25	WOS:000240130900005
J	Neiman, PE; Kimmel, R; Icreverzi, A; Elsaesser, K; Bowers, SJ; Burnside, J; Delrow, J				Neiman, P. E.; Kimmel, R.; Icreverzi, A.; Elsaesser, K.; Bowers, S. -J.; Burnside, J.; Delrow, J.			Genomic instability during myc-induced lymphomagenesis in the bursa of fabricius	ONCOGENE			English	Article						myc oncogene; gene amplification; DNA palindromes	B-CELL DEVELOPMENT; SHORT INVERTED REPEATS; LARGE DNA PALINDROME; GENE AMPLIFICATION; HUMAN CANCERS; HL60 CELLS; CHICKEN; EXPRESSION; CDNA; HAMSTER	Retroviral vector-mediated overexpression of c-myc in embryonic bursal precursors induces multi-staged tumorigenesis beginning with preneoplastic-transformed follicles (TF) and progressing to clonal metastatic B-cell lymphomas. Using a 13K chicken cDNA microarray, specifically enriched for chicken immune system expressed sequence tagged (ESTs), we carried out array-based comparative genomic hybridization (array-CGH) and detected significant DNA copy number change at many loci on most or all chromosomes in both early TF and end-stage lymphomas. Formation of long palindromes, through breakage-fusion-bridge cycles, is thought to play an early role in gene amplification. Employing genome-wide analysis of palindrome formation (GAPF), we detected extensive palindrome formation in early TF and end-stage lymphomas. The population of loci showing amplification by array-CGH was enriched for palindromes detected by GAPF providing strong evidence for genetic instability early in Myc-induced tumorigenesis and further support for the role of palindromes in gene amplification. Comparing gene copy number change and RNA expression changes pro. led on the same cDNA array, we detected very little consistent contribution of gene copy number change to RNA expression changes. Palindromic loci in TF and tumors, however, were expressed, many at high levels, suggesting an abundance of RNA species with long double-stranded segments generated during tumorigenesis.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; Univ Delaware, Dept Anim & Food Sci, Newark, DE USA; Fred Hutchinson Canc Res Ctr, DNA Array Facil, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Delaware; Fred Hutchinson Cancer Center	Neiman, PE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,C2-023, Seattle, WA 98109 USA.	pneiman@fhcrc.org	Nolen, Danielle/A-5250-2010; Crozier, Laura B/C-5891-2011		NATIONAL CANCER INSTITUTE [R01CA020068, R01CA109365] Funding Source: NIH RePORTER; NCI NIH HHS [CA-20068, CA-109365] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boardman PE, 2002, CURR BIOL, V12, P1965, DOI 10.1016/S0960-9822(02)01296-4; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Brown CY, 2004, DEV COMP IMMUNOL, V28, P619, DOI 10.1016/j.dci.2003.09.017; Burnside J, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-13; Butler DK, 1996, CELL, V87, P1115, DOI 10.1016/S0092-8674(00)81805-X; Chang H, 2004, CHROMOSOME RES, V12, P299, DOI 10.1023/B:CHRO.0000021947.17128.96; Ellerman V., 1908, ZENTR BAKTERIOL PARA, V46, P595; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; ESKOLA J, 1974, CELL IMMUNOL, V13, P459, DOI 10.1016/0008-8749(74)90265-2; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Feo S, 1996, ONCOGENE, V13, P1521; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hillier LW, 2004, NATURE, V432, P695, DOI 10.1038/nature03154; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Kittler R, 2004, NATURE, V432, P1036, DOI 10.1038/nature03159; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LOONEY JE, 1987, MOL CELL BIOL, V7, P569, DOI 10.1128/MCB.7.2.569; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; Mai S, 1996, ONCOGENE, V12, P277; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; Mangano R, 1998, ONCOGENE, V17, P2771, DOI 10.1038/sj.onc.1202434; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; NEIMAN P, 1985, P NATL ACAD SCI USA, V82, P222, DOI 10.1073/pnas.82.1.222; NEIMAN P, 1980, J VIROL, V34, P178, DOI 10.1128/JVI.34.1.178-186.1980; NEIMAN P, 2006, REV PROTOCOLS DT40 R; NEIMAN PE, 1975, CELL, V4, P311; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NEIMAN PE, 1994, ADV IMMUNOL, V56, P467, DOI 10.1016/S0065-2776(08)60457-5; Neiman PE, 2003, ONCOGENE, V22, P1073, DOI 10.1038/sj.onc.1206070; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Tanaka H, 2005, NAT GENET, V37, P320, DOI 10.1038/ng1515; Tanaka H, 2002, P NATL ACAD SCI USA, V99, P8772, DOI 10.1073/pnas.132275999; THOMPSON CB, 1987, CELL, V51, P371, DOI 10.1016/0092-8674(87)90633-7; Tlsty TD, 1997, CURR TOP MICROBIOL, V221, P37; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; YASUDA LF, 1991, CELL, V67, P505, DOI 10.1016/0092-8674(91)90525-4; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	42	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2006	25	47					6325	6335		10.1038/sj.onc.1209646	http://dx.doi.org/10.1038/sj.onc.1209646			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16652139				2022-12-25	WOS:000241218200009
J	Ohlenschlager, O; Seiboth, T; Zengerling, H; Briese, L; Marchanka, A; Ramachandran, R; Baum, M; Korbas, M; Meyer-Klaucke, W; Durst, M; Gorlach, M				Ohlenschlaeger, O.; Seiboth, T.; Zengerling, H.; Briese, L.; Marchanka, A.; Ramachandran, R.; Baum, M.; Korbas, M.; Meyer-Klaucke, W.; Duerst, M.; Goerlach, M.			Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7	ONCOGENE			English	Article						human papilloma virus; E7; carcinogenesis; NMR solution structure	HUMAN-PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA TUMOR-SUPPRESSOR; TORSION ANGLE DYNAMICS; E7 ONCOPROTEIN; HPV E7; HUMAN KERATINOCYTES; ADENOVIRUS E1A; ZINC-BINDING; RB BINDING; PROTEIN	The oncoprotein E7 of human papilloma viruses (HPV) is involved in the pathogenesis and maintenance of human cervical cancers. The most prevalent HPV types found in cervix carcinomas are HPV16, 18 and 45. The structure of the E7 dimer from HPV45 (PDB 2F8B) was determined by nuclear magnetic resonance spectroscopy. Each monomer comprises an unfolded N-terminus and a well-structured C-terminal domain with a beta 1 beta 2 alpha 1 beta 3 alpha 2 topology representing a unique zinc-binding fold found only for E7. Dimerization occurs through the alpha 1/alpha 1' helices and intermolecular beta-sheet formation but excludes the zinc-binding sites. E7 is reported to interact with a number of cellular proteins (e.g. pRb, p21(CIP1)). Binding of a peptide derived from the C-terminus of p21(CIP1) to the C-terminal domain of E7 was characterized by monitoring chemical shift perturbations of the amide groups of E7. This provides direct evidence that a shallow groove situated between alpha 1 and beta 1 of the E7 C-terminal domain is interacting with the C-terminus of p21CIP1. Intriguingly, this binding site overlaps with the low-affinity binding site on E7 for the C-domain of pRb.	Fritz Lipmann Inst, NMR Spectroscopy, D-07745 Jena, Germany; DESY, European Mol Biol Lab, D-2000 Hamburg, Germany; Univ Jena, Frauenklin, D-6900 Jena, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Friedrich Schiller University of Jena	Gorlach, M (corresponding author), Fritz Lipmann Inst, NMR Spectroscopy, Beutenbergstr 11, D-07745 Jena, Germany.	mago@fli-leibniz.de	Korbas, Malgorzata/B-4024-2009; Meyer-Klaucke, Wolfram/G-1148-2010	Korbas, Malgorzata/0000-0003-3064-0132; Ohlenschlaeger, Oliver/0000-0002-6428-4423; Marchanka, Alexander/0000-0003-0810-2020				Alonso LG, 2002, BIOCHEMISTRY-US, V41, P10510, DOI 10.1021/bi025579n; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BINSTED N, 1992, BIOCHEMISTRY-US, V31, P12117, DOI 10.1021/bi00163a021; Bischof O, 2005, MOL CELL BIOL, V25, P1013, DOI 10.1128/MCB.25.3.1013-1024.2005; Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3; Braspenning J, 1998, ONCOGENE, V16, P1085, DOI 10.1038/sj.onc.1201617; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Clements A, 2000, BIOCHEMISTRY-US, V39, P16033, DOI 10.1021/bi002111g; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Guntert P, 1998, J BIOMOL NMR, V12, P543, DOI 10.1023/A:1008391403193; Helt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Liu X, 2006, J BIOL CHEM, V281, P578, DOI 10.1074/jbc.M508455200; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; MUNGER K, 1989, J VIROL, V63, P4417; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; Schlott B, 2002, J MOL BIOL, V318, P533, DOI 10.1016/S0022-2836(02)00014-1; Singh M, 2005, J BIOL CHEM, V280, P37868, DOI 10.1074/jbc.M504877200; Villa LL, 1997, ADV CANCER RES, V71, P321, DOI 10.1016/S0065-230X(08)60102-5; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q; Zwerschke W, 2000, ADV CANCER RES, V78, P1	43	82	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5953	5959		10.1038/sj.onc.1209584	http://dx.doi.org/10.1038/sj.onc.1209584			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16636661				2022-12-25	WOS:000240826300004
J	Noda, D; Itoh, S; Watanabe, Y; Inamitsu, M; Dennler, S; Itoh, F; Koike, S; Danielpour, D; ten Dijke, P; Kato, M				Noda, D.; Itoh, S.; Watanabe, Y.; Inamitsu, M.; Dennler, S.; Itoh, F.; Koike, S.; Danielpour, D.; Dijke, P. ten; Kato, M.			ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells	ONCOGENE			English	Article						ELAC2; cell proliferation; p21; Smad TGF-beta	BETA TYPE-I; SMAD PROTEINS; SIGNALING PATHWAY; EPITHELIAL-CELLS; FAMILY-MEMBERS; RECEPTOR; EXPRESSION; PROMOTER; SP1; ACTIVATION	Transforming growth factor-beta (TGF-beta) elicits a potent growth inhibitory effect on many normal cells by binding to specific serine/threonine kinase receptors and activating specific Smad proteins, which regulate the expression of cell cycle genes, including the p21 cyclin-dependent kinase (CDK) inhibitor gene. Interestingly, cancer cells are often insensitive to the anti-mitogenic effects of TGF-beta for which the molecular mechanisms are not well understood. In this study, we found that the candidate prostate cancer susceptibility gene ELAC2 potentiates TGF-beta/Smad-induced transcriptional responses. ELAC2 associates with activated Smad2; the C-terminal MH2 domain of Smad2 interacts with the N-terminal region of ELAC2. Small interfering siRNA-mediated knock-down of ELAC2 in prostate cells suppressed TGF-beta-induced growth arrest. Moreover, ELAC2 was shown to specifically associate with the nuclear Smad2 partner, FAST-1 and to potentiate the interaction of activated Smad2 with transcription factor Sp1. Furthermore, activation of the p21 CDK inhibitor promoter by TGF-beta is potentiated by ELAC2. Taken together our data indicate an important transcriptional scaffold function for ELAC2 in TGF-beta/Smad signaling mediated growth arrest.	Univ Tsukuba, Dept Expt Pathol, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan; Yamagata Univ, Sch Med, Dept Otolaryngol, Yamagata 990, Japan; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands	University of Tsukuba; Yamagata University; Netherlands Cancer Institute; Case Western Reserve University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Itoh, S (corresponding author), Univ Tsukuba, Dept Expt Pathol, Grad Sch Comprehens Human Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	sitoh@md.tsukuba.ac.jp	Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Itoh, Susumu/0000-0002-7967-0730; Itoh, Fumiko/0000-0002-6134-5331				Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Chen GC, 2005, J BIOL CHEM, V280, P36355, DOI 10.1074/jbc.M506147200; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen Y, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-12; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Guo YP, 1999, CANCER RES, V59, P1366; Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO;2-1; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Korver W, 2003, INT J CANCER, V104, P283, DOI 10.1002/ijc.10945; Kundu SD, 2000, PROSTATE, V43, P118; Larisch-Bloch S, 2000, CELL GROWTH DIFFER, V11, P1; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Minagawa A, 2005, CANCER LETT, V222, P211, DOI 10.1016/j.canlet.2004.09.013; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Moustakas A, 2001, J CELL SCI, V114, P4359; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nicolas FJ, 2004, J CELL SCI, V117, P4113, DOI 10.1242/jcs.01289; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shea PR, 2002, HUM GENET, V111, P398, DOI 10.1007/s00439-002-0816-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SONG K, 2000, CANCER RES, V63, P4358; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; Tang BW, 1999, CANCER RES, V59, P4834; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Wang L, 2001, CANCER RES, V61, P6494; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	45	33	36	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5591	5600		10.1038/sj.onc.1209571	http://dx.doi.org/10.1038/sj.onc.1209571			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636667				2022-12-25	WOS:000240599100001
J	Gaffre, M; Dupre, A; Valuckaite, R; Suziedelis, K; Jessus, C; Haccard, O				Gaffre, M.; Dupre, A.; Valuckaite, R.; Suziedelis, K.; Jessus, C.; Haccard, O.			Deciphering the H-Ras pathway in Xenopus oocyte	ONCOGENE			English	Article						Ras; Xenopus oocyte; meiotic maturation; Cdc2; MAPK; PI3K	CLASSICAL PROGESTERONE-RECEPTOR; MATURATION-PROMOTING FACTOR; MOS PROTO-ONCOGENE; MEIOTIC MATURATION; CELL-CYCLE; SIGNALING PATHWAY; MAP KINASE; C-MOS; PHOSPHOINOSITIDE 3-KINASE; DISTINCT MECHANISMS	Xenopus oocytes are arrested in prophase of the first meiotic division. In response to progesterone, they re-enter meiosis and arrest again in metaphase of the second meiotic division. This process, called meiotic maturation, is under the control of the Cyclin B-Cdc2 complex, Mphase promoting factor (MPF). Injection of a constitutively active Xenopus H-Ras protein activates MPF, suggesting that Ras proteins could be implicated in the progesterone transduction pathway. The aim of this study was (1) to elucidate the pathway triggered by H-Ras leading to MPF activation in Xenopus oocytes and (2) to investigate whether endogenous H-Ras is involved in the physiological process of meiotic maturation. We generated three constitutively active double mutants, each of them recruiting a single effector in mammalian cells, mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) or RalGDS. Our results show that the activation of a PI3K-related enzyme is crucial for H-Ras-induced MPF activation, whereas the recruitment of either MAPK or RalGDS is not. However, although the H-Ras/PI3K pathway is functional in Xenopus oocytes, it is not the physiological transducer of progesterone responsible for meiotic resumption.	Univ Paris 06, CNRS, UMR 7622, Dev Biol Lab, F-75252 Paris 05, France; Vilnius State Univ, Dept Biochem & Biophys, Vilnius, Lithuania; Inst Oncol, Vilnius, Lithuania	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Vilnius University	Haccard, O (corresponding author), Univ Paris 06, CNRS, UMR 7622, Dev Biol Lab, Boite 24,9 Quai St Bernard, F-75252 Paris 05, France.	olh@ccr.jussieu.fr		Haccard, Olivier/0000-0002-4305-2746				Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Andersen CB, 1998, J BIOL CHEM, V273, P18705, DOI 10.1074/jbc.273.30.18705; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Castro A, 2001, BIOL CELL, V93, P15, DOI 10.1016/S0248-4900(01)01128-5; De Smedt V, 2002, J BIOL CHEM, V277, P28592, DOI 10.1074/jbc.M202742200; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Dupre A, 2002, EMBO J, V21, P4026, DOI 10.1093/emboj/cdf400; Dupre A, 2002, ONCOGENE, V21, P6425, DOI 10.1038/sj.onc.1205827; Fisher DL, 2000, EMBO J, V19, P1516, DOI 10.1093/emboj/19.7.1516; Frank-Vaillant M, 1999, MOL BIOL CELL, V10, P3279, DOI 10.1091/mbc.10.10.3279; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Haccard O, 2006, EMBO REP, V7, P321, DOI 10.1038/sj.embor.7400611; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hiraoka D, 2004, DEV BIOL, V276, P330, DOI 10.1016/j.ydbio.2004.08.036; Hochegger H, 2001, DEVELOPMENT, V128, P3795; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Jessus C, 1998, BIOL CELL, V90, P573, DOI 10.1016/S0248-4900(99)80015-X; JESSUS C, 1991, DEVELOPMENT, V111, P813; Karaiskou A, 1999, J CELL SCI, V112, P3747; Karaiskou A, 2001, BIOL CELL, V93, P35, DOI 10.1016/S0248-4900(01)01126-1; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lebreton S, 2004, MECH DEVELOP, V121, P1481, DOI 10.1016/j.mod.2004.07.008; LEGUELLEC R, 1991, BIOL CELL, V72, P39, DOI 10.1016/0248-4900(91)90076-Y; Liu XS, 2005, DEV BIOL, V283, P180, DOI 10.1016/j.ydbio.2005.04.011; Liu YS, 2005, CHEM BIOL, V12, P99, DOI 10.1016/j.chembiol.2004.11.009; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Perdiguero E, 2004, CELL CYCLE, V3, P733; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Prober DA, 2002, GENE DEV, V16, P2286, DOI 10.1101/gad.991102; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; STACEY DW, 1991, ONCOGENE, V6, P2297; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang J, 2004, J CELL SCI, V117, P5107, DOI 10.1242/jcs.01383; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100	52	7	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5155	5162		10.1038/sj.onc.1209523	http://dx.doi.org/10.1038/sj.onc.1209523			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16607282				2022-12-25	WOS:000240063700008
J	Robinson, HMR; Jones, R; Walker, M; Zachos, G; Brown, R; Cassidy, J; Gillespie, DAF				Robinson, H. M. R.; Jones, R.; Walker, M.; Zachos, G.; Brown, R.; Cassidy, J.; Gillespie, D. A. F.			Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil	ONCOGENE			English	Article						Chk1; 5-fluorouracil; cell cycle checkpoint	DNA-DAMAGE; CHECKPOINT ABROGATION; CHK1; MECHANISMS; PATHWAYS; ARREST; ACTIVATION; SURVIVAL; CANCER; RNA	Chk1 plays a crucial role in the DNA damage and replication checkpoints in vertebrates and may therefore be an important determinant of tumour cell responses to genotoxic anticancer drugs. To evaluate this concept we compared the effects of the nucleoside analogue 5-fluorouracil (5FU) on cell cycle progression and clonogenic survival in DT40 B-lymphoma cells with an isogenic mutant derivative in which Chk1 function was ablated by gene targeting. We show that 5FU activates Chk1 in wild-type DT40 cells and that 5FU-treated cells accumulate in the S phase of the cell cycle due to slowing of the overall rate of DNA replication. In marked contrast, Chk1-deficient DT40 cells fail to slow DNA replication upon initial exposure to 5FU, despite equivalent inhibition of the target enzyme thymidylate synthase, and instead accumulate progressively in the G1 phase of the following cell cycle. This G1 accumulation cannot be reversed rapidly by exogenous thymidine or removal of 5FU, and is associated with increased incorporation of 5FU into genomic DNA and severely diminished clonogenic survival. Taken together, these results demonstrate that a Chk1-dependent replication checkpoint which slows S phase progression can protect tumour cells against the cytotoxic effects of 5FU.	Univ Glasgow, Canc Res Campaign Beatson Lab, Inst Biomed & Life Sci, Glasgow G61 1BD, Lanark, Scotland; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, CRUK Ctr Oncol & Appl Pharmacol, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow; Beatson Institute; Beatson Institute; University of Glasgow	Gillespie, DAF (corresponding author), Univ Glasgow, Canc Res Campaign Beatson Lab, Inst Biomed & Life Sci, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	d.gillespie@beatson.gla.ac.uk	Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544; Brown, Robert/0000-0001-7960-5755				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; GLAZER RI, 1982, MOL PHARMACOL, V21, P468; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3225, DOI 10.1021/bi00359a022; INGRAHAM HA, 1980, CANCER RES, V40, P998; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KUFE DW, 1981, J BIOL CHEM, V256, P9802; Liu XJ, 2005, CANCER RES, V65, P6874, DOI 10.1158/0008-5472.CAN-05-0288; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; MAURO DJ, 1993, MOL PHARMACOL, V43, P854; Meyers M, 2005, J BIOL CHEM, V280, P5516, DOI 10.1074/jbc.M412105200; Meyers M, 2001, CANCER RES, V61, P5193; Morgan MA, 2005, CANCER RES, V65, P6835, DOI 10.1158/0008-5472.CAN-04-2246; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Rhind N, 2000, J CELL SCI, V113, P3889; Sampath D, 2003, ONCOGENE, V22, P9063, DOI 10.1038/sj.onc.1207229; SANTI DV, 1974, BIOCHEMISTRY-US, V13, P471, DOI 10.1021/bi00700a012; Shi Z, 2001, CANCER RES, V61, P1065; Tajima A, 2004, GASTROENTEROLOGY, V127, P1678, DOI 10.1053/j.gastro.2004.10.001; Xiao Z, 2005, ONCOGENE, V24, P1403, DOI 10.1038/sj.onc.1208309; Zachos G, 2005, MOL CELL BIOL, V25, P563, DOI 10.1128/MCB.25.2.563-574.2005; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	27	40	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5359	5369		10.1038/sj.onc.1209532	http://dx.doi.org/10.1038/sj.onc.1209532			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16619043				2022-12-25	WOS:000240144900001
J	Bhatia, N; Thiyagarajan, S; Elcheva, I; Saleem, M; Dlugosz, A; Mukhtar, H; Spiegelman, VS				Bhatia, Neehar; Thiyagarajan, Saravanan; Elcheva, Irina; Saleem, Mohammed; Dlugosz, Andrzej; Mukhtar, Hasan; Spiegelman, Vladimir S.			Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIR FOLLICLE DEVELOPMENT; FLOOR PLATE; TRANSCRIPTION FACTOR; CUBITUS INTERRUPTUS; HEDGEHOG; CANCER; ACTIVATION; DIFFERENTIATION; INHIBITION; EXPRESSION	The Hedgehog (Hh) signaling pathway plays a crucial role in embryogenesis and has been linked to the development of several human malignancies. The transcription factor Gli2 plays a key role in the transduction of Hh signals by modulating transcription of some Hh target genes, yet the mechanisms that control Gli2 protein expression are largely unknown. Here we report that beta-transducin repeat-containing protein (beta-TrCP) E3 ubiquitin ligase is required for Gli2 degradation. beta-TrCP2 directly binds wild type Gli2 and promotes its ubiquitination. Single amino acid substitution in Gli2 putative binding site inhibits its interaction with beta-TrCP2, its ubiquitination, and stabilizes the Gli2 protein. Stable Gli2 mutant is expressed in higher levels and is more potent in the activation of Gli-dependent transcription as compared with wild type Gli2. We also found that GLI2 protein is expressed highly in prostate cancer cell lines and primary tumors, whereas the level of GLI2 mRNA is not appreciably different in normal and neoplastic prostate. These data identify beta-TrCP2 as a pivotal regulator of Gli2 expression and point to an important role for post-translational modulation of GLI2 protein levels in Hh pathway-associated human prostate cancer.	Univ Wisconsin, Sch Med, Dept Dermatol, Madison, WI 53706 USA; Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Wisconsin System; University of Wisconsin Madison; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Spiegelman, VS (corresponding author), Univ Wisconsin, Sch Med, Dept Dermatol, 1300 Univ Ave,B-25, Madison, WI 53706 USA.	spiegelman@dermatology.wisc.edu	Saleem, Mohammad/GVS-9221-2022	Saleem, Mohammad/0000-0002-7422-7967; Spiegelman, Vladimir S/0000-0003-4847-155X	NATIONAL CANCER INSTITUTE [R01CA087837] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA087837-07, R01 CA087837] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Bai CB, 2002, DEVELOPMENT, V129, P4753; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bijlsma MF, 2004, BIOESSAYS, V26, P387, DOI 10.1002/bies.20007; Cohen MM, 2003, AM J MED GENET A, V123A, P5, DOI 10.1002/ajmg.a.20495; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Ding Q, 1998, DEVELOPMENT, V125, P2533; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416; Kumar KGS, 2003, EMBO J, V22, P5480; Lamm MLG, 2002, DEV BIOL, V249, P349, DOI 10.1006/dbio.2002.0774; Lewis MT, 2001, DEV BIOL, V238, P133, DOI 10.1006/dbio.2001.0410; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Matise MP, 1998, DEVELOPMENT, V125, P2759; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Mullor JL, 2002, TRENDS CELL BIOL, V12, P562, DOI 10.1016/S0962-8924(02)02405-4; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Regl G, 2004, ONCOGENE, V23, P1263, DOI 10.1038/sj.onc.1207240; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Roessler E, 2003, P NATL ACAD SCI USA, V100, P13424, DOI 10.1073/pnas.2235734100; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Sheng T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-29; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493	41	111	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19320	19326		10.1074/jbc.M513203200	http://dx.doi.org/10.1074/jbc.M513203200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16651270	hybrid			2022-12-25	WOS:000238847000047
J	Ogawa, T; Kapadia, H; Feng, JQ; Raghow, R; Peters, H; D'Souza, RN				Ogawa, Takuya; Kapadia, Hitesh; Feng, Jian Q.; Raghow, Rajendra; Peters, Heiko; D'Souza, Rena N.			Functional consequences of interactions between Pax9 and Msx1 genes in normal and abnormal tooth development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISSENSE MUTATION; BINDING PROTEIN; CLEFT-PALATE; AGENESIS; EXPRESSION; BMP; IDENTIFICATION; HOMEOPROTEINS; ACTIVATION; GENETICS	Pax9 and Msx1 encode transcription factors that are known to be essential for the switch in odontogenic potential from the epithelium to the mesenchyme. Multiple lines of evidence suggest that these molecules play an important role in the maintenance of mesenchymal Bmp4 expression, which ultimately drives morphogenesis of the dental organ. Here we demonstrate that Pax9 is able to directly regulate Msx1 expression and interact with Msx1 at the protein level to enhance its ability to transactivate Msx1 and Bmp4 expression during tooth development. In addition, we tested how a missense mutation (T62C) in the paired domain of PAX9 that is responsible for human tooth agenesis (1) affects its functions. Our data indicate that although the mutant Pax9 protein (L21P) can bind to the Msx1 protein, it fails to transactivate the Msx1 and Bmp4 promoter, presumably because of its inability to bind cognate paired domain recognition sequences. In addition, synergistic transcriptional activation of the Bmp4 promoter was lost with coexpression of mutant Pax9 and wild-type Msx1. This suggests that Pax9 is critical for the regulation of Bmp4 expression through its paired domain rather than Msx1. Our findings demonstrate the partnership of Pax9 and Msx1 in a signaling pathway that involves Bmp4. Furthermore, the regulation of Bmp4 expression by the interaction of Pax9 with Msx1 at the level of transcription and through formation of a protein complex determines the fate of the transition from bud to cap stage during tooth development.	Baylor Coll Dent, Dept Biomed Sci, Dallas, TX 75246 USA; Univ Texas, Hlth Sci Ctr, Houston Dent Branch, Dept Orthodont, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Program Genes & Dev, Grad Sch Biomed Sci, Houston, TX 77030 USA; MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; Univ Tennessee, Hlth Sci Ctr, Dept Pharmacol, Memphis, TN 38104 USA; Dept Vet Affairs Med Ctr, Memphis, TN 38104 USA; Univ Newcastle, Int Ctr Life, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Missouri System; University of Missouri Kansas City; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Newcastle University - UK	D'Souza, RN (corresponding author), Baylor Coll Dent, Dept Biomed Sci, 3302 Gaston Ave, Dallas, TX 75246 USA.	rdsouza@bcd.tamhsc.edu		D'Souza, Rena/0000-0002-1505-5173	Medical Research Council [G0400679] Funding Source: Medline; NIDCR NIH HHS [DE 16436, K08 DE14237, R01 DE13668] Funding Source: Medline; MRC [G0400679] Funding Source: UKRI; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K08DE014237, R01DE013668] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bei M, 1998, DEVELOPMENT, V125, P4325; Bendall AJ, 1998, DIFFERENTIATION, V63, P151, DOI 10.1046/j.1432-0436.1998.6330151.x; Chen YP, 1996, DEVELOPMENT, V122, P3035; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Das P, 2003, AM J MED GENET A, V118A, P35, DOI 10.1002/ajmg.a.10011; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Frazier-Bowers SA, 2002, J DENT RES, V81, P129, DOI 10.1177/154405910208100209; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kettunen P, 1998, DEV DYNAM, V211, P256, DOI 10.1002/(SICI)1097-0177(199803)211:3<256::AID-AJA7>3.0.CO;2-G; Klein ML, 2005, J DENT RES, V84, P43, DOI 10.1177/154405910508400107; Lammi L, 2004, AM J HUM GENET, V74, P1043, DOI 10.1086/386293; Lammi L, 2003, EUR J HUM GENET, V11, P866, DOI 10.1038/sj.ejhg.5201060; Laurikkala J, 2003, DEV BIOL, V264, P91, DOI 10.1016/j.ydbio.2003.08.011; Lee H, 2004, SCIENCE, V304, P1675, DOI 10.1126/science.1098096; Mensah JK, 2004, J BIOL CHEM, V279, P5924, DOI 10.1074/jbc.M305648200; Mostowska A, 2003, EUR J ORAL SCI, V111, P365, DOI 10.1034/j.1600-0722.2003.00069.x; Mostowska A, 2003, EUR J ORAL SCI, V111, P272, DOI 10.1034/j.1600-0722.2003.00036.x; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; Nieminen P, 2001, EUR J HUM GENET, V9, P743, DOI 10.1038/sj.ejhg.5200715; PETERS H, 1995, DEV DYNAM, V203, P1, DOI 10.1002/aja.1002030102; Peters H, 1998, EUR J ORAL SCI, V106, P38, DOI 10.1111/j.1600-0722.1998.tb02151.x; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; Shetty S, 1999, BIOCHEM J, V339, P751, DOI 10.1042/0264-6021:3390751; Stockton DW, 2000, NAT GENET, V24, P18, DOI 10.1038/71634; Takahashi T, 1997, J BIOL CHEM, V272, P22667, DOI 10.1074/jbc.272.36.22667; Vastardis H, 1996, NAT GENET, V13, P417, DOI 10.1038/ng0896-417; Vastardis H, 2000, AM J ORTHOD DENTOFAC, V117, P650, DOI 10.1016/S0889-5406(00)70173-9; Vieira AR, 2004, J DENT RES, V83, P723, DOI 10.1177/154405910408300913; Vieira AR, 2003, J DENT RES, V82, P162, DOI 10.1177/154405910308200303; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920; Zhang ZY, 2002, DEVELOPMENT, V129, P4135	32	94	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18363	18369		10.1074/jbc.M601543200	http://dx.doi.org/10.1074/jbc.M601543200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16651263	hybrid			2022-12-25	WOS:000238687300013
J	Alfano, D; Iaccarino, I; Stoppelli, MP				Alfano, Daniela; Iaccarino, Ingram; Stoppelli, M. Patrizia			Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; INDUCED APOPTOSIS; DOWN-REGULATION; BREAST-CANCER; CELLULAR-SURVIVAL; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; GLIOMA-CELLS; IN-VIVO; GROWTH	The acquired capabilities of resistance to apoptotic cell death and tissue invasion are considered to be obligate steps in tumor progression. The binding of the serine protease urokinase (uPA) to its receptor ( uPAR) plays a central role in the molecular events coordinating tumor cell adhesion, migration, and invasion. Here we investigate whether uPAR signaling may also prevent apoptosis following loss of anchorage (anoikis) or DNA damage. If nontransformed human retinal pigment epithelial cells are pre-exposed to uPA or to its noncatalytic amino-terminal region (residues 1-135), they exhibit a markedly reduced susceptibility to anoikis as well as to UV-induced apoptosis. This anti-apoptotic effect is retained by a uPA-derived synthetic peptide corresponding to the receptor binding domain and is inhibited by anti-uPAR polyclonal antibodies. Furthermore, the stable reduction of uPA or uPAR expression by RNA interference leads to an increased susceptibility to UV-, cisplatin, and detachment-induced apoptosis. In particular, the level of uPAR expression positively correlates with cell resistance to anoikis. The protective ability of uPA is prevented by UO126, LY294002, by an MAPK targeting small interference RNA, and by a dominant negative Akt variant. Accordingly, incubation of retinal pigment epithelial cells with uPA elicits a time-dependent enhancement of MAPK and phosphatidylinositol 3-kinase activities as well as the transcriptional activation of Bcl-xL anti-apoptotic factor. Vice versa, the silencing of Bcl-xL expression prevents uPA protection from anoikis. In conclusion, the data show that ligand engagement of uPAR promotes cell survival by activating Bcl-xL transcription through the MEK/ERK- and phosphatidylinositol 3-kinase/Akt-dependent pathways.	Inst Genet & Biophys Adriano Buzzati Traverso, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Stoppelli, MP (corresponding author), Inst Genet & Biophys Adriano Buzzati Traverso, Via P Castellino 111, I-80131 Naples, Italy.	stoppell@igb.cnr.it	Iaccarino, Ingram/B-9086-2015	Iaccarino, Ingram/0000-0001-7324-993X				Adachi Y, 2001, J BIOL CHEM, V276, P47171, DOI 10.1074/jbc.M104334200; Alfano D, 2005, THROMB HAEMOSTASIS, V93, P205, DOI 10.1160/TH04-09-0592; Amundson SA, 2000, CANCER RES, V60, P6101; APPELLA E, 1987, J BIOL CHEM, V262, P4437; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bu XY, 2004, LAB INVEST, V84, P667, DOI 10.1038/labinvest.3700089; Carriero MV, 1999, CANCER RES, V59, P5307; Chandrasekar N, 2003, ONCOGENE, V22, P392, DOI 10.1038/sj.onc.1206164; Chiaradonna F, 1999, EMBO J, V18, P3013, DOI 10.1093/emboj/18.11.3013; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; CORTI A, 1989, THROMB HAEMOSTASIS, V62, P934; Danilkovitch-Miagkova A, 2001, APOPTOSIS, V6, P183, DOI 10.1023/A:1011384609811; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DELVECCHIO S, 1993, CANCER RES, V53, P3198; Elner SG, 2003, EXP EYE RES, V76, P585, DOI 10.1016/S0014-4835(03)00028-9; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gargiulo L, 2005, J BIOL CHEM, V280, P25225, DOI 10.1074/jbc.M412605200; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Gutierrez LS, 2000, CANCER RES, V60, P5839; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbeck N, 2002, CANCER RES, V62, P4617; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIRCHHEIMER JC, 1989, P NATL ACAD SCI USA, V86, P5424, DOI 10.1073/pnas.86.14.5424; Knoop A, 1998, BRIT J CANCER, V77, P932, DOI 10.1038/bjc.1998.154; Krishnamoorthy B, 2001, CLIN CANCER RES, V7, P4195; Kugler MC, 2003, CURR PHARM DESIGN, V9, P1565, DOI 10.2174/1381612033454658; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Lakka SS, 2005, J BIOL CHEM, V280, P21882, DOI 10.1074/jbc.M408520200; List K, 2000, BIOCHEMISTRY-US, V39, P508, DOI 10.1021/bi991701f; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; Ma Z, 2001, J CELL SCI, V114, P3387; Meilhac O, 2003, FASEB J, V17, P1301, DOI 10.1096/fj.02-0687fje; Montuori N, 2002, J BIOL CHEM, V277, P46932, DOI 10.1074/jbc.M207494200; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; Porstmann T, 2005, ONCOGENE, V24, P6465, DOI 10.1038/sj.onc.1208802; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Pulukuri SM, 2005, J BIOL CHEM, V280, P36529, DOI 10.1074/jbc.M503111200; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Rossignol P, 2004, J BIOL CHEM, V279, P10346, DOI 10.1074/jbc.M310964200; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shapiro RL, 1996, CANCER RES, V56, P3597; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; Sturge J, 2002, J CELL SCI, V115, P699; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; Wang X, 2004, J BIOL CHEM, V279, P5237, DOI 10.1074/jbc.M309271200; Wei L, 2001, CANCER RES, V61, P2439; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Yanamandra N, 2001, CLIN EXP METASTAS, V18, P611, DOI 10.1023/A:1011941114862; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767; Zhang X, 2003, MOL VIS, V9, P238	61	73	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17758	17767		10.1074/jbc.M601812200	http://dx.doi.org/10.1074/jbc.M601812200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16632475	hybrid			2022-12-25	WOS:000238490300026
J	Sajan, MP; Rivas, J; Li, PF; Standaert, ML; Farese, RV				Sajan, Mini P.; Rivas, Jose; Li, Pengfei; Standaert, Mary L.; Farese, Robert V.			Repletion of atypical protein kinase C following RNA interference-mediated depletion restores insulin-stimulated glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKC-ZETA; GLUT4 TRANSLOCATION; RAT ADIPOCYTES; POTENTIAL ROLE; LAMBDA; ACTIVATION; ALPHA; CELLS; BETA	The role of atypical protein kinase C (aPKC) in insulin-stimulated glucose transport in myocytes and adipocytes is controversial. Whereas studies involving the use of adenovirally mediated expression of kinase-inactive aPKC in L6 myocytes and 3T3/L1 and human adipocytes, and data from knock-out of aPKC in adipocytes derived from mouse embryonic stem cells and subsequently derived adipocytes, suggest that aPKCs are required for insulin-stimulated glucose transport, recent findings in studies of aPKC knockdown by small interfering RNA(RNAi) in 3T3/L1 adipocytes are conflicting. Moreover, there are no reports of a PKC knockdown in myocytes, wherein insulin effects on glucose transport are particularly relevant for understanding whole body glucose disposal. Presently, we exploited the fact that L6 myotubes and 3T3/L1 adipocytes have substantially different (30% nonhomology) major aPKCs, viz. PKC-zeta in L6 myotubes and PKC-lambda in 3T3/L1 adipocytes, that nevertheless can function interchangeably for glucose transport. Accordingly, in L6 myotubes, RNAi-targeting PKC-zeta, but not PKC-lambda, markedly depleted aPKC and concomitantly inhibited insulin-stimulated glucose transport; more importantly, these depleting/inhibitory effects were rescued by adenovirally mediated expression of PKC-lambda. Conversely, in 3T3/L1 adipocytes, RNAi constructs targeting PKC-zeta, but not PKC-lambda, markedly depleted aPKC and concomitantly inhibited insulin-stimulated glucose transport; here again, these depleting/ inhibitory effects were rescued by adenovirally mediated expression of PKC-zeta. These findings in knockdown and, more convincingly, rescue studies, strongly support the hypothesis that aPKCs are required for insulin-stimulated glucose transport in myocytes and adipocytes.	Univ S Florida, Coll Med, Res Serv, James A Haley Vet Med Ctr, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida	Farese, RV (corresponding author), Univ S Florida, Coll Med, Res Serv, James A Haley Vet Med Ctr, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	rfarese@hsc.usf.edu	Farese, Robert/B-3605-2015		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030879, R01DK065969] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065969, 2R01-DK-30879-09A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Bandyopadhyay G, 2000, ENDOCRINOLOGY, V141, P4120, DOI 10.1210/en.141.11.4120; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Bandyopadhyay G, 2002, J CLIN ENDOCR METAB, V87, P716, DOI 10.1210/jc.87.2.716; Bandyopadhyay G, 2004, MOL ENDOCRINOL, V18, P373, DOI 10.1210/me.2003-0087; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Condorelli G, 2001, DIABETES, V50, P1244, DOI 10.2337/diabetes.50.6.1244; Etgen GJ, 1999, J BIOL CHEM, V274, P22139, DOI 10.1074/jbc.274.32.22139; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Huang C, 2005, J BIOL CHEM, V280, P19426, DOI 10.1074/jbc.M412317200; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Zhou QL, 2004, BIOCHEM SOC T, V32, P817, DOI 10.1042/BST0320817	21	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17466	17473		10.1074/jbc.M510803200	http://dx.doi.org/10.1074/jbc.M510803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16644736	hybrid			2022-12-25	WOS:000238326300072
J	Yan, HHN; Cheng, CY				Yan, Helen H. N.; Cheng, C. Yan			Laminin alpha 3 forms a complex with beta 3 and gamma 3 chains that serves as the ligand for alpha 6 beta 1-integrin at the apical ectoplasmic specialization in adult rat testes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHERENS JUNCTION DYNAMICS; 67-KDA LAMININ RECEPTOR; GERM CELL-INTERACTIONS; SEMINIFEROUS EPITHELIUM; BASEMENT-MEMBRANE; EXTRACELLULAR-MATRIX; IV COLLAGEN; DEVELOPMENTAL EXPRESSION; PROTEIN COMPLEX; CROSS-TALK	Apical ectoplasmic specialization (ES) is a testis-specific hybrid cell/cell actin-based adherens junction and cell/matrix focal contact anchoring junction type restricted to the interface between Sertoli cells and developing spermatids. Recent studies have shown that laminin gamma 3, restricted to elongating spermatids, is a putative binding partner of alpha 6 beta 1-integrin localized in Sertoli cells at the apical ES. However, the identity of the alpha and beta chains, which constitute a functional laminin ligand with the gamma 3 chain at the apical ES, is not known. Using reverse transcription-PCR and immunoblotting to survey all laminin chains in cells of the seminiferous epithelium, it was noted that alpha 2, alpha 3, beta 1, beta 2, beta 3, and gamma 3 chains were found in germ cells, whereas alpha 1, alpha 2, alpha 4, alpha 5, beta 1, beta 2, gamma 1, gamma 2, and gamma 3 chains were found in Sertoli cells, implying that alpha 3 and beta 3 are the plausible laminin chains restricted to germ cells that may be the bona fide partners of gamma 3. To verify this postulate, recombinant proteins based on domain G of alpha 3 and domain I of beta 3 and gamma 3 chains were produced and used to obtain the corresponding specific polyclonal antibodies. Additional studies have demonstrated that the laminin alpha 3, beta 3, and gamma 3 chains indeed are restricted to germ cells at the apical ES, co-localizing with each other and with beta 1-integrin. Furthermore, co-immunoprecipitation studies have confirmed the interactions among laminin alpha 3, beta 3, and gamma 3, as well as beta 1-integrin. When the functional laminin ligand at the apical ES was disrupted via blocking antibodies, such as using anti-laminin alpha 3 or gamma 3 IgG, this treatment perturbed adhesion between Sertoli and germ cells (mostly spermatids), leading to germ cell loss from the epithelium. More important, a transient disruption of the blood-testis barrier was also detected.	Populat Council, Biomed Res Ctr, New York, NY 10021 USA	Population Council	Cheng, CY (corresponding author), Populat Council, Biomed Res Ctr, 1230 York Ave, New York, NY 10021 USA.	Y-Cheng@popcbr.rockefeller.edu		Cheng, C Yan/0000-0003-3117-3791; Yan, Hoi Ning Helen/0000-0001-5693-8231	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD029990] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD045908] Funding Source: NIH RePORTER; NICHD NIH HHS [U01 HD045908, U54 HD029990] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Airenne T, 2000, CELL TISSUE RES, V300, P129, DOI 10.1007/s004410050054; Aravindan GR, 1996, J CELL PHYSIOL, V168, P123; Aumailley M, 1998, J ANAT, V193, P1, DOI 10.1046/j.1469-7580.1998.19310001.x; Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; CASTRONOVO V, 1991, J BIOL CHEM, V266, P20440; Cheng CY, 2002, PHYSIOL REV, V82, P825, DOI 10.1152/physrev.00009.2002; CHENG CY, 1988, BIOCHEMISTRY-US, V27, P4079, DOI 10.1021/bi00411a026; CHENG CY, 1987, J BIOL CHEM, V262, P12768; Chung NPY, 2001, BIOL REPROD, V65, P1340, DOI 10.1095/biolreprod65.5.1340; Chung SSW, 1998, J ANDROL, V19, P686; DYM M, 1994, ENDOCR REV, V15, P102, DOI 10.1210/er.15.1.102; Frojdman K, 1999, DIFFERENTIATION, V64, P151, DOI 10.1046/j.1432-0436.1999.6430151.x; FULCHER KD, 1993, BIOL REPROD, V48, P674, DOI 10.1095/biolreprod48.3.674; GELLY JL, 1989, HISTOCHEMISTRY, V93, P31, DOI 10.1007/BF00266844; Gersdorff N, 2005, J BIOL CHEM, V280, P22146, DOI 10.1074/jbc.M501875200; Givant-Horwitz V, 2005, CANCER LETT, V223, P1, DOI 10.1016/j.canlet.2004.08.030; Givant-Horwitz V, 2004, CANCER RES, V64, P3572, DOI 10.1158/0008-5472.CAN-03-3424; HADLEY MA, 1987, BIOL REPROD, V37, P1283, DOI 10.1095/biolreprod37.5.1283; Hager M, 2005, AM J PATHOL, V167, P823, DOI 10.1016/S0002-9440(10)62054-8; Hallmann R, 2005, PHYSIOL REV, V85, P979, DOI 10.1152/physrev.00014.2004; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; Kishi M, 2003, BIOSCI BIOTECH BIOCH, V67, P1154, DOI 10.1271/bbb.67.1154; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Lee NPY, 2003, BIOL REPROD, V68, P489, DOI 10.1095/biolreprod.102.005793; Lee NPY, 2005, J CELL PHYSIOL, V202, P344, DOI 10.1002/jcp.20119; Lee NPY, 2004, J ANDROL, V25, P200; Libby RT, 1996, INVEST OPHTH VIS SCI, V37, P1651; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; Lu W, 2001, HISTOCHEM J, V33, P629, DOI 10.1023/A:1016350316926; Magnifico A, 1996, J BIOL CHEM, V271, P31179, DOI 10.1074/jbc.271.49.31179; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022; Mruk DD, 2004, TRENDS ENDOCRIN MET, V15, P439, DOI 10.1016/j.tem.2004.09.009; Mruk DD, 1999, J BIOL CHEM, V274, P27056, DOI 10.1074/jbc.274.38.27056; Mulholland DJ, 2001, BIOL REPROD, V64, P396, DOI 10.1095/biolreprod64.1.396; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; PALOMBI F, 1992, BIOL REPROD, V47, P1173, DOI 10.1095/biolreprod47.6.1173; POLLANEN PP, 1985, INT J ANDROL, V8, P337, DOI 10.1111/j.1365-2605.1985.tb00846.x; RUSSELL L, 1977, AM J ANAT, V148, P313, DOI 10.1002/aja.1001480303; RUSSELL L, 1977, TISSUE CELL, V9, P475, DOI 10.1016/0040-8166(77)90007-6; SALANOVA M, 1995, BIOL REPROD, V52, P79, DOI 10.1095/biolreprod52.1.79; Salanova M, 1998, BIOL REPROD, V58, P371, DOI 10.1095/biolreprod58.2.371; SAMYELLOWE TY, 1988, J CELL BIOL, V106, P1507, DOI 10.1083/jcb.106.5.1507; SANTAMARIA L, 1990, INT J ANDROL, V13, P135, DOI 10.1111/j.1365-2605.1990.tb00970.x; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; Sasaki T, 2004, J CELL BIOL, V164, P959, DOI 10.1083/jcb.200401058; Sasaki T, 2002, EXP CELL RES, V275, P185, DOI 10.1006/excr.2002.5499; SCHALLER J, 1993, HUM REPROD, V8, P1873, DOI 10.1093/oxfordjournals.humrep.a137952; Siu MKY, 2005, J BIOL CHEM, V280, P25029, DOI 10.1074/jbc.M501049200; Siu MKY, 2004, BIOESSAYS, V26, P978, DOI 10.1002/bies.20099; Siu MKY, 2004, BIOL REPROD, V70, P945, DOI 10.1095/biolreprod.103.023606; Siu MKY, 2003, ENDOCRINOLOGY, V144, P2141, DOI 10.1210/en.2002-221035; TUNG PS, 1984, BIOL REPROD, V30, P213, DOI 10.1095/biolreprod30.1.213; WANG F, 1992, J CELL BIOL, V119, P977, DOI 10.1083/jcb.119.4.977; Wong CH, 2005, ENDOCRINOLOGY, V146, P1192, DOI 10.1210/en.2004-1275; Yan HHN, 2005, P NATL ACAD SCI USA, V102, P11722, DOI 10.1073/pnas.0503855102; Zhang JY, 2005, ENDOCRINOLOGY, V146, P1268, DOI 10.1210/en.2004-1194	57	105	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17286	17303		10.1074/jbc.M513218200	http://dx.doi.org/10.1074/jbc.M513218200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16608848	hybrid			2022-12-25	WOS:000238326300056
J	Yap, LL; Samoilova, RI; Gennis, RB; Dikanov, SA				Yap, Lai Lai; Samoilova, Rimma I.; Gennis, Robert B.; Dikanov, Sergei A.			Characterization of the exchangeable protons in the immediate vicinity of the semiquinone radical at the Q(H) site of the cytochrome bo(3) from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; NUCLEAR DOUBLE-RESONANCE; QUADRUPOLE-RESONANCE; UBIQUINOL OXIDASE; QUINOL OXIDASE; BINDING-SITE; Q(H)(CENTER-DOT-) UBISEMIQUINONE; BOUND UBIQUINONE; REACTION CENTERS; ENDOR	The cytochrome bo(3) ubiquinol oxidase from Escherichia coli resides in the bacterial cytoplasmic membrane and catalyzes the two-electron oxidation of ubiquinol-8 and four-electron reduction of O-2 to water. The one-electron reduced semiquinone forms transiently during the reaction, and the enzyme has been demonstrated to stabilize the semiquinone. Two-dimensional electron spin echo envelope modulation has been applied to explore the exchangeable protons involved in hydrogen bonding to the semiquinone by substitution of (H2O)-H-1 by (H2O)-H-2. Three exchangeable protons possessing different isotropic and anisotropic hyperfine couplings were identified. The strength of the hyperfine interaction with one proton suggests a significant covalent O-H binding of carbonyl oxygen O1 that is a characteristic of a neutral radical, an assignment that is also supported by the unusually large hyperfine coupling to the methyl protons. The second proton with a large anisotropic coupling also forms a strong hydrogen bond with a carbonyl oxygen. This second hydrogen bond, which has a significant out-of-plane character, is from an NH2 or NH nitrogen, probably from an arginine (Arg-71) known to be in the quinone binding site. Assignment of the third exchangeable proton with smaller anisotropic coupling is more ambiguous, but it is clearly not involved in a direct hydrogen bond with either of the carbonyl oxygens. The results support a model that the semiquinone is bound to the protein in a very asymmetric manner by two strong hydrogen bonds from Asp-75 and Arg-71 to the O1 carbonyl, while the O4 carbonyl is not hydrogen-bonded to the protein.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Russian Acad Sci, Inst Chem Kinet & Combust, Novosibirsk 630090, Russia; Univ Illinois, Dept Vet Clin Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; Russian Academy of Sciences; Voevodsky Institute of Chemical Kinetics & Combustion SB RAS; University of Illinois System; University of Illinois Urbana-Champaign	Gennis, RB (corresponding author), Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.	r-gennis@uiuc.edu; dikanov@uiuc.edu	Samoilova, Rimma Ivanovna/T-7956-2017	Samoilova, Rimma Ivanovna/0000-0002-1649-1487	NCRR NIH HHS [S10-RR15878] Funding Source: Medline; NIGMS NIH HHS [GM62954] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062954] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; ASHBY CIH, 1980, J AM CHEM SOC, V102, P2990, DOI 10.1021/ja00529a020; BLINC R, 1974, CHEM PHYS LETT, V28, P158, DOI 10.1016/0009-2614(74)80041-2; Deligiannakis Y, 1999, J AM CHEM SOC, V121, P7653, DOI 10.1021/ja984209c; DIKANOV SA, 1995, J MAGN RESON SER A, V116, P125, DOI 10.1006/jmra.1995.1199; DIKANOV SA, 1995, J MAGN RESON SER B, V108, P99, DOI 10.1006/jmrb.1995.1110; DIKANOV SA, 1992, ELECT SPIN ECHO ENVE, P198; EDMONDS DT, 1971, PHYS LETT A, VA 34, P325, DOI 10.1016/0375-9601(71)90894-2; Elmi F, 2005, J PHYS CHEM A, V109, P1729, DOI 10.1021/jp046216v; Flores M, 2003, CHEM PHYS, V294, P401, DOI 10.1016/S0301-0104(03)00321-5; Grimaldi S, 2003, BIOCHEMISTRY-US, V42, P5632, DOI 10.1021/bi034010z; Grimaldi S, 2001, BIOCHEMISTRY-US, V40, P1037, DOI 10.1021/bi001641+; Hastings SF, 2000, EUR J BIOCHEM, V267, P5638, DOI 10.1046/j.1432-1327.2000.01643.x; Hellwig P, 1999, BIOCHEMISTRY-US, V38, P14683, DOI 10.1021/bi991267h; Hellwig P, 2002, BIOCHEMISTRY-US, V41, P10675, DOI 10.1021/bi012146w; Hellwig P, 2001, BIOCHEMISTRY-US, V40, P1077, DOI 10.1021/bi002154x; HOFER P, 1986, CHEM PHYS LETT, V132, P279, DOI 10.1016/0009-2614(86)80124-5; INGLEDEW WJ, 1995, EUR J BIOCHEM, V227, P903, DOI 10.1111/j.1432-1033.1995.tb20217.x; Joela H, 1997, ACTA CHEM SCAND, V51, P233, DOI 10.3891/acta.chem.scand.51-0233; KASPRZAK S, 2006, J AM CHEM SOC, V128, P5661; Kobayashi K, 2000, BIOCHEMISTRY-US, V39, P15620, DOI 10.1021/bi0014094; Lendzian F, 1996, BER BUNSEN PHYS CHEM, V100, P2036, DOI 10.1002/bbpc.19961001219; Lubitz W, 1999, APPL MAGN RESON, V17, P1, DOI 10.1007/BF03162067; MacMillan F, 1995, MAGN RESON CHEM, V33, pS81, DOI 10.1002/mrc.1260331314; MCCONNELL HM, 1956, J CHEM PHYS, V24, P764, DOI 10.1063/1.1742605; MCMILLAN F, 2003, 5 M EUR FED EPR GROU; Mogi T, 1999, FEBS LETT, V457, P223, DOI 10.1016/S0014-5793(99)01047-9; Musser SM, 1997, BIOCHEMISTRY-US, V36, P894, DOI 10.1021/bi961723r; O'Malley PJ, 1998, CHEM PHYS LETT, V291, P367, DOI 10.1016/S0009-2614(98)00571-5; OMALLEY PJ, 1986, J AM CHEM SOC, V108, P3995, DOI 10.1021/ja00274a024; Osborne JP, 1998, KEIO UNIV SYMP LIFE, V1, P33; Osokin D. Ya., 1977, NUCL QUADRUPOLE RESO, P182; PALMER M, 1984, Z NATURFORSCH A, V39, P1108, DOI 10.1515/zna-1984-1115; PEDERSEN JA, 1985, HDB EPR SPECTRA QUIN, P203; Puustinen A, 1996, P NATL ACAD SCI USA, V93, P1545, DOI 10.1073/pnas.93.4.1545; RABBANI SR, 1987, J MAGN RESON, V72, P230, DOI 10.1016/0022-2364(87)90285-X; Rumbley JN, 1997, BBA-PROTEIN STRUCT M, V1340, P131, DOI 10.1016/S0167-4838(97)00036-8; SAMOILOVA RI, 1994, J CHEM SOC PERK T 2, P609, DOI 10.1039/p29940000609; Sato-Watanabe M, 1998, BIOCHEMISTRY-US, V37, P5356, DOI 10.1021/bi9727592; Sato-Watanabe M, 1998, BIOCHEMISTRY-US, V37, P12744, DOI 10.1021/bi981184l; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28908; Schultz BE, 1998, BIOCHEMISTRY-US, V37, P4160, DOI 10.1021/bi971714y; Schweiger A., 2001, PRINCIPLES PULSE ELE, P359; Sinnecker S, 2004, J AM CHEM SOC, V126, P3280, DOI 10.1021/ja0392014; Spoyalov AP, 1996, CHEM PHYS LETT, V263, P715, DOI 10.1016/S0009-2614(96)01255-9; Veselov AV, 2000, BIOCHEMISTRY-US, V39, P3169, DOI 10.1021/bi9926835	46	33	34	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16879	16887		10.1074/jbc.M602544200	http://dx.doi.org/10.1074/jbc.M602544200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16624801	hybrid			2022-12-25	WOS:000238326300008
J	Liang, XB; Peters, KW; Butterworth, MB; Frizzell, RA				Liang, Xiubin; Peters, Kathryn W.; Butterworth, Michael B.; Frizzell, Raymond A.			14-3-3 isoforms are induced by aldosterone and participate in its regulation of epithelial sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; NEDD4-2 PHOSPHORYLATION; EXPRESSION; SERUM; ENAC; PROTEINS; KINASE; TRANSPORT; KIDNEY; SGK	Aldosterone increases sodium absorption across renal collecting duct cells primarily by increasing the apical membrane expression of ENaC, the sodium entry channel. Nedd4-2, a ubiquitin-protein isopeptide ligase, tags ENaC with ubiquitin for internalization and degradation, but when it is phosphorylated by the aldosterone-induced kinase, SGK1, Nedd4-2 is inhibited and apical ENaC density and sodium absorption increase. We evaluated the hypothesis that 14-3-3 proteins participate in the aldosterone-mediated regulation of ENaC by associating with phosphorylated Nedd4-2. Mouse cortical collecting duct ( mCCD) epithelia cultured on filters expressed several 14-3-3 isoforms; this study focused on an isoform whose expression was induced 3-fold by aldosterone, 14-3-3 beta. In polarized mCCD epithelia, aldosterone elicited significant, time-dependent increases in the expression of alpha-ENaC, SGK1, phospho-Nedd4-2, and 14-3-3 beta without altering total Nedd4-2. Aldosterone decreased the interaction of alpha-ENaC with Nedd4-2, and with similar kinetics increased the association of 14-3-3 beta with phospho-Nedd4-2. Short interfering RNA-induced knockdown of 14-3-3 beta blunted the aldosterone-induced increase in alpha-ENaC expression, returned alpha-ENaC-Nedd4-2 binding toward pre-aldosterone levels, and blocked the aldosterone-stimulated increase in transepithelial sodium transport. Incubation of cell extracts with a selective phospho-Nedd4-2 antibody blocked the aldosterone-induced association of 14-3-3 beta with Nedd4-2, implicating SGK1 phosphorylation at Ser-328 as the primary site of 14-3-3 beta binding. Our studies show that aldosterone increases the expression of 14-3-3 beta, which interacts with phospho-Nedd4-2 to block its interaction with ENaC, thus enhancing sodium absorption by increasing apical membrane ENaC density.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, 3500 Terrace St, Pittsburgh, PA 15261 USA.	frizzell@pitt.edu		Butterworth, Michael/0000-0002-2173-8333	NIDDK NIH HHS [DK 72506, DK 54814] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054814, P30DK072506] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Asher C, 2003, BBA-BIOMEMBRANES, V1612, P59, DOI 10.1016/S0005-2736(03)00083-X; Bhalla V, 2005, MOL ENDOCRINOL, V19, P3073, DOI 10.1210/me.2005-0193; Bonny O, 2002, J AM SOC NEPHROL, V13, P2399, DOI 10.1097/01.ASN.0000028641.59030.B2; Boyd C, 2005, AM J PHYSIOL-RENAL, V288, pF505, DOI 10.1152/ajprenal.00242.2004; Butterworth MB, 2005, J GEN PHYSIOL, V125, P81, DOI 10.1085/jgp.2004.09124; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chun J, 2004, MOL CELLS, V18, P360; De la Rosa DA, 2003, AM J PHYSIOL-CELL PH, V284, pC404, DOI 10.1152/ajpcell.00398.2002; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Faletti CJ, 2002, AM J PHYSIOL-CELL PH, V282, pC494, DOI 10.1152/ajpcell.00408.2001; Flores SY, 2005, J AM SOC NEPHROL, V16, P2279, DOI 10.1681/ASN.2004100828; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Helms MN, 2003, AM J PHYSIOL-RENAL, V284, pF480, DOI 10.1152/ajprenal.00299.2002; Hou JH, 2002, J AM SOC NEPHROL, V13, P1190, DOI 10.1097/01.ASN.0000013702.73570.3B; Ichimura T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Liang XB, 2003, J AM SOC NEPHROL, V14, P1443, DOI 10.1097/01.ASN.0000067860.64692.C0; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Muller OG, 2003, J AM SOC NEPHROL, V14, P1107, DOI 10.1097/01.ASN.0000061777.67332.77; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Naray-Fejes-Toth A, 2004, MOL CELL ENDOCRINOL, V217, P197, DOI 10.1016/j.mce.2003.10.043; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Qi WQ, 2005, INT J CANCER, V113, P359, DOI 10.1002/ijc.20492; REIF MC, 1986, J CLIN INVEST, V77, P1291, DOI 10.1172/JCI112433; Rimessi A, 2005, J BIOL CHEM, V280, P37195, DOI 10.1074/jbc.M504921200; Schild L, 2004, REV PHYSIOL BIOCH P, V151, P93, DOI 10.1007/s10254-004-0023-7; Snyder PM, 2005, ENDOCRINOLOGY, V146, P5079, DOI 10.1210/en.2005-0894; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Snyder PM, 2004, J BIOL CHEM, V279, P5042, DOI 10.1074/jbc.M312477200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Stockand JD, 2002, AM J PHYSIOL-RENAL, V282, pF559, DOI 10.1152/ajprenal.00320.2001; Stokes JB, 1999, KIDNEY INT, V56, P2318, DOI 10.1046/j.1523-1755.1999.00803.x; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Velic A, 2005, AM J TRANSPLANT, V5, P1276, DOI 10.1111/j.1600-6143.2005.00890.x; Vinciguerra M, 2003, MOL BIOL CELL, V14, P2677, DOI 10.1091/mbc.E02-11-0720; Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015; Wilker EW, 2005, J BIOL CHEM, V280, P18891, DOI 10.1074/jbc.M500982200; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zhou RF, 2005, J BIOL CHEM, V280, P4518, DOI 10.1074/jbc.M411053200	48	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16323	16332		10.1074/jbc.M601360200	http://dx.doi.org/10.1074/jbc.M601360200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16613846	hybrid			2022-12-25	WOS:000238165700019
J	Yamamoto, Y; Moore, R; Hess, HA; Guo, GL; Gonzalez, FJ; Korach, KS; Maronpot, RR; Negishi, M				Yamamoto, Yukio; Moore, Rick; Hess, Holly A.; Guo, Grace L.; Gonzalez, Frank J.; Korach, Kenneth S.; Maronpot, Robert R.; Negishi, Masahiko			Estrogen receptor alpha mediates 17 alpha-ethynylestradiol causing hepatotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ANDROSTANE RECEPTOR; PREGNANE-X-RECEPTOR; SALT EXPORT PUMP; PRIMARY BILIARY-CIRRHOSIS; HEPATIC GENE-EXPRESSION; BILE-ACID SYNTHESIS; NUCLEAR RECEPTORS; INTRAHEPATIC CHOLESTASIS; LIPID HOMEOSTASIS; LIVER TOXICITY	Estrogens are known to cause hepatotoxicity such as intrahepatic cholestasis in susceptible women during pregnancy, after administration of oral contraceptives, or during postmenopausal replacement therapy. Enterohepatic nuclear receptors including farnesoid X receptor (FXR), pregnane X receptor (PXR), and constitutive active/androstane receptor (CAR) are important in maintaining bile acid homeostasis and protecting the liver from bile acid toxicity. However, no nuclear receptor has been implicated in the mechanism for estrogen-induced hepatotoxicity. Here Era(-/-), Erb(-/-), Fxr(-/-), Pxr(-/-), and Car(-/-) mice were employed to show that Era(-/-) mice were resistant to synthetic estrogen 17 alpha-ethynylestradiol (EE2)-induced hepatotoxicity as indicated by the fact that the EE2-treated Era(-/-) mice developed none of the hepatotoxic phenotypes such as hepatomegaly, elevation in serum bile acids, increase of alkaline phosphatase activity, liver degeneration, and inflammation. Upon EE2 treatment, estrogen receptor alpha(ER alpha) repressed the expression of bile acid and cholesterol transporters ( bile salt export pump (BSEP), Na+/taurocholate cotransporting polypeptide (NTCP), OATP1, OATP2, ABCG5, and ABCG8) in the liver. Consistently, biliary secretions of both bile acids and cholesterol were markedly decreased in EE2-treated wild-type mice but not in the EE2-treated Era(-/-) mice. In addition, ER alpha up-regulated the expression of CYP7B1 and down-regulated the CYP7A1 and CYP8B1, shifting bile acid synthesis toward the acidic pathway to increase the serum level of beta-muricholic acid. ER beta, FXR, PXR, and CAR were not involved in regulating the expression of bile acid transporter and biosynthesis enzyme genes following EE2 exposure. Taken together, these results suggest that ER alpha- mediated repression of hepatic transporters and alterations of bile acid biosynthesis may contribute to development of the EE2-induced hepatotoxicity.	NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Expt Pathol, NIH, Res Triangle Pk, NC 27709 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Negishi, M (corresponding author), NIEHS, Reprod & Dev Toxicol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928; Yamamoto, Yukio/0000-0002-8530-0701; Korach, Kenneth/0000-0002-7765-418X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080040, ZIAES070065, Z01ES080040, Z01ES070065] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Assem M, 2004, J BIOL CHEM, V279, P22250, DOI 10.1074/jbc.M314111200; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; GRODSTEIN F, 1994, OBSTET GYNECOL, V84, P207; Guo GL, 2003, J BIOL CHEM, V278, P45062, DOI 10.1074/jbc.M307145200; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Inoue Y, 2004, J BIOL CHEM, V279, P2480, DOI 10.1074/jbc.M311015200; Invernizzi P, 2004, HEPATOLOGY, V39, P1175, DOI 10.1002/hep.20164; Jansen PLM, 2001, HEPATOLOGY, V34, P1067, DOI 10.1053/jhep.2001.29625; Karpen SJ, 2002, J HEPATOL, V36, P832, DOI 10.1016/S0168-8278(02)00129-0; Kitada H, 2003, J BIOL CHEM, V278, P17838, DOI 10.1074/jbc.M210634200; Koopen NR, 1999, J LIPID RES, V40, P100; Lammert Frank, 2003, Curr Treat Options Gastroenterol, V6, P123, DOI 10.1007/s11938-003-0013-x; Lee JM, 2000, GASTROENTEROLOGY, V118, P163, DOI 10.1016/S0016-5085(00)70425-2; Liu YP, 2003, J CLIN INVEST, V112, P1678, DOI 10.1172/JCI200318945; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Moschetta A, 2004, NAT MED, V10, P1352, DOI 10.1038/nm1138; Pauli-Magnus C, 2004, PHARMACOGENETICS, V14, P91, DOI 10.1097/00008571-200402000-00003; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; Reddy A, 2004, LIVER INT, V24, P194, DOI 10.1111/j.1478-3231.2004.00920.x; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Reyes H, 1997, J GASTROEN HEPATOL, V12, P211, DOI 10.1111/j.1440-1746.1997.tb00410.x; Riely Caroline A, 2004, Clin Liver Dis, V8, P167, DOI 10.1016/S1089-3261(03)00131-4; Rodriguez-Garay Emilio Alberto, 2003, Ann Hepatol, V2, P150; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Savander M, 2003, GUT, V52, P1025, DOI 10.1136/gut.52.7.1025; SCHREIBER AJ, 1983, HEPATOLOGY, V3, P607; Simon FR, 1996, AM J PHYSIOL-GASTR L, V271, pG1043, DOI 10.1152/ajpgi.1996.271.6.G1043; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Stedman CAM, 2005, P NATL ACAD SCI USA, V102, P2063, DOI 10.1073/pnas.0409794102; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Uppal H, 2005, HEPATOLOGY, V41, P168, DOI 10.1002/hep.20512; Wang HH, 2004, GASTROENTEROLOGY, V127, P239, DOI 10.1053/j.gastro.2004.03.059; Wang RX, 2001, P NATL ACAD SCI USA, V98, P2011, DOI 10.1073/pnas.031465498; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Yamamoto Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P207, DOI 10.1016/S0003-9861(02)00456-3; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Zhang J, 2004, J BIOL CHEM, V279, P49517, DOI 10.1074/jbc.M409041200; Zollner G, 2001, HEPATOLOGY, V33, P633, DOI 10.1053/jhep.2001.22646	43	132	138	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16625	16631		10.1074/jbc.M602723200	http://dx.doi.org/10.1074/jbc.M602723200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16606610	hybrid			2022-12-25	WOS:000238165700055
J	Fender, A; Sauter, C; Messmer, M; Putz, J; Giege, R; Florentz, C; Sissler, M				Fender, Aurelie; Sauter, Claude; Messmer, Marie; Putz, Joern; Giege, Richard; Florentz, Catherine; Sissler, Marie			Loss of a primordial identity element for a mammalian mitochondrial aminoacylation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASES; SPECIES-SPECIFIC DIFFERENCES; YEAST TRANSFER RNAASP; ESCHERICHIA-COLI; GENETIC-CODE; ACCEPTOR STEM; AMINO-ACIDS; RECOGNITION; SEQUENCE; TRNA(ASP)	In mammalian mitochondria the translational machinery is of dual origin with tRNAs encoded by a simplified and rapidly evolving mitochondrial (mt) genome and aminoacyl-tRNA synthetases (aaRS) coded by the nuclear genome, and imported. Mt-tRNAs are atypical with biased sequences, size variations in loops and stems, and absence of residues forming classical tertiary interactions, whereas synthetases appear typical. This raises questions about identity elements in mt-tRNAs and adaptation of their cognate mt-aaRSs. We have explored here the human mt-aspartate system in which a prokaryotic-type AspRS, highly similar to the Escherichia coli enzyme, recognizes a bizarre tRNAAsp. Analysis of human mt-tRNA(Asp) transcripts confirms the identity role of the GUC anticodon as in other aspartylation systems but reveals the non-involvement of position 73. This position is otherwise known as the site of a universally conserved major aspartate identity element, G73, also known as a primordial identity signal. In mt-tRNA(Asp), position 73 can be occupied by any of the four nucleotides without affecting aspartylation. Sequence alignments of various AspRSs allowed placing Gly-269 at a position occupied by Asp-220, the residue contacting G73 in the crystallographic structure of E. coli AspRS-tRNA(Asp) complex. Replacing this glycine by an aspartate renders human mt-AspRS more discriminative to G73. Restriction in the aspartylation identity set, driven by a rapid mutagenic rate of the mt-genome, suggests a reverse evolution of the mt-tRNA(Asp) identity elements in regard to its bacterial ancestor.	Univ Strasbourg, Inst Biol Mol & Cellulaire, CNRS, Unite Propre Rech 9002,Dept Machineries Traduct, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Florentz, C (corresponding author), Univ Strasbourg, Inst Biol Mol & Cellulaire, CNRS, Unite Propre Rech 9002,Dept Machineries Traduct, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	C.Florentz@ibmc.u-strasbg.fr		sauter, claude/0000-0002-8766-287X; SISSLER, Marie/0000-0001-8594-5238				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; AULD DS, 1995, SCIENCE, V267, P1994, DOI 10.1126/science.7701322; Auld DS, 1996, EMBO J, V15, P1142, DOI 10.1002/j.1460-2075.1996.tb00452.x; Becker HD, 1996, BIOCHEMISTRY-US, V35, P7447, DOI 10.1021/bi9601058; Beuning PJ, 1999, BIOPOLYMERS, V52, P1; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; Bonnefond L, 2005, RNA, V11, P558, DOI 10.1261/rna.7246805; Bonnefond L, 2005, BIOCHEMISTRY-US, V44, P4805, DOI 10.1021/bi047527z; BONNET J, 1972, EUR J BIOCHEM, V31, P335, DOI 10.1111/j.1432-1033.1972.tb02538.x; Bullard JM, 2000, BBA-GENE STRUCT EXPR, V1490, P245, DOI 10.1016/S0167-4781(99)00240-7; Bullard JN, 1999, J MOL BIOL, V288, P567, DOI 10.1006/jmbi.1999.2708; Chihade JW, 2000, P NATL ACAD SCI USA, V97, P12153, DOI 10.1073/pnas.220388797; Chimnaronk S, 2005, EMBO J, V24, P3369, DOI 10.1038/sj.emboj.7600811; Connolly SA, 2004, BIOCHEMISTRY-US, V43, P962, DOI 10.1021/bi035708f; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; de Pouplana LR, 2000, CELL MOL LIFE SCI, V57, P865, DOI 10.1007/PL00000729; Duchene AM, 2005, P NATL ACAD SCI USA, V102, P16484, DOI 10.1073/pnas.0504682102; Duchene AM, 2001, J BIOL CHEM, V276, P15275, DOI 10.1074/jbc.M011525200; Eiler S, 1999, EMBO J, V18, P6532, DOI 10.1093/emboj/18.22.6532; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5; Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1; FRUGIER M, 1994, BIOCHEMISTRY-US, V33, P9912, DOI 10.1021/bi00199a013; Frugier M, 1998, J BIOL CHEM, V273, P11605, DOI 10.1074/jbc.273.19.11605; FRUGIER M, 1994, EMBO J, V13, P2218, DOI 10.1002/j.1460-2075.1994.tb06499.x; Galtier N, 2006, GENOME RES, V16, P215, DOI 10.1101/gr.4305906; Giege R, 1996, BIOCHIMIE, V78, P605, DOI 10.1016/S0300-9084(96)80007-1; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; Giege R, 1998, CURR OPIN STRUC BIOL, V8, P286, DOI 10.1016/S0959-440X(98)80060-2; Giege R, 2003, MOL B INT U, P1; Giege R., 2005, AMINOACYL TRNA SYNTH, P210; Gray MW, 2001, GENOME BIOL, V2; HASEGAWA T, 1989, BIOCHEM BIOPH RES CO, V163, P1534, DOI 10.1016/0006-291X(89)91154-6; Hauenstein S, 2004, NAT STRUCT MOL BIOL, V11, P1134, DOI 10.1038/nsmb849; Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047; Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064; Jorgensen R, 2000, J BIOL CHEM, V275, P16820, DOI 10.1074/jbc.275.22.16820; Kelley SO, 2000, NAT STRUCT BIOL, V7, P862, DOI 10.1038/79612; KUMAZAWA Y, 1991, J BIOCHEM, V109, P421, DOI 10.1093/oxfordjournals.jbchem.a123397; Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884; Lue SW, 2005, BIOCHEMISTRY-US, V44, P3010, DOI 10.1021/bi047901v; Lynch M, 1996, MOL BIOL EVOL, V13, P209, DOI 10.1093/oxfordjournals.molbev.a025557; Margulis L., 1993, SYMBIOSIS CELL EVOLU; McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014; Moulinier L, 2001, EMBO J, V20, P5290, DOI 10.1093/emboj/20.18.5290; NAMEKI N, 1992, BIOCHEM BIOPH RES CO, V189, P856, DOI 10.1016/0006-291X(92)92282-3; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PERRET V, 1990, BIOCHIMIE, V72, P735, DOI 10.1016/0300-9084(90)90158-D; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; Roy H, 2005, J BIOL CHEM, V280, P38186, DOI 10.1074/jbc.M508281200; Ryckelynck M, 2003, J BIOL CHEM, V278, P9683, DOI 10.1074/jbc.M211035200; Saks ME, 1996, EMBO J, V15, P2843, DOI 10.1002/j.1460-2075.1996.tb00645.x; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHIMMEL P, 1995, J MOL EVOL, V40, P531; SCHMITT E, 1993, J MOL BIOL, V233, P615, DOI 10.1006/jmbi.1993.1540; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; Shiba K, 1997, TRENDS BIOCHEM SCI, V22, P453, DOI 10.1016/S0968-0004(97)01135-3; SHIMADA N, 2002, NUCL ACIDS RES S, V2, P79; Sissler M, 2004, RNA, V10, P841, DOI 10.1261/rna.5267604; Sissler M., 2005, AMINOACYL TRNA SYNTH, P271; Small I, 1998, PLANT MOL BIOL, V38, P265, DOI 10.1023/A:1006081903354; Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5; Spencer AC, 2004, BIOCHEMISTRY-US, V43, P9743, DOI 10.1021/bi049639w; Sprinzl M, 2005, NUCLEIC ACIDS RES, V33, pD139, DOI 10.1093/nar/gki012; Stehlin C, 1998, BIOCHEMISTRY-US, V37, P8605, DOI 10.1021/bi980364s; UEDA T, 1992, NUCLEIC ACIDS RES, V20, P2217, DOI 10.1093/nar/20.9.2217; Wakasugi K, 1998, EMBO J, V17, P297, DOI 10.1093/emboj/17.1.297; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000	71	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15980	15986		10.1074/jbc.M511633200	http://dx.doi.org/10.1074/jbc.M511633200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16597625	Green Published, hybrid			2022-12-25	WOS:000237996000049
J	Hryciw, DH; Ekberg, J; Ferguson, C; Lee, A; Wang, DS; Parton, RG; Pollock, CA; Yun, CC; Poronnik, P				Hryciw, Deanne H.; Ekberg, Jenny; Ferguson, Charles; Lee, Aven; Wang, Dongsheng; Parton, Robert G.; Pollock, Carol A.; Yun, Chris C.; Poronnik, Philip			Regulation of albumin endocytosis by PSD95/Dlg/ZO-1 (PDZ) scaffolds - Interaction of Na+-H+ exchange regulatory factor-2 with ClC-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-MEDIATED INHIBITION; RENAL PROXIMAL TUBULE; CHLORIDE CHANNEL; BRUSH-BORDER; IMPAIRS ENDOCYTOSIS; ACTIN CYTOSKELETON; APICAL MEMBRANE; NHERF ISOFORMS; DENTS-DISEASE; OK CELLS	The constitutive reuptake of albumin from the glomerular filtrate by receptor-mediated endocytosis is a key function of the renal proximal tubules. Both the Cl- channel ClC-5 and the Na+-H+ exchanger isoform 3 are critical components of the macromolecular endocytic complex that is required for albumin uptake, and therefore the cell-surface levels of these proteins may limit albumin endocytosis. This study was undertaken to investigate the potential roles of the epithelial PDZ scaffolds, Na+-H+ exchange regulatory factors, NHERF1 and NHERF2, in albumin uptake by opossum kidney ( OK) cells. We found that ClC-5 co-immunoprecipitates with NHERF2 but not NHERF1 from OK cell lysate. Experiments using fusion proteins demonstrated that this was a direct interaction between an internal binding site in the C terminus of ClC-5 and the PDZ2 module of NHERF2. In OK cells, NHERF2 is restricted to the intravillar region while NHERF1 is located in the microvilli. Silencing NHERF2 reduced both cell-surface levels of ClC-5 and albumin uptake. Conversely, silencing NHERF1 increased cell-surface levels of ClC-5 and albumin uptake, presumably by increasing the mobility of NHE3 in the membrane and its availability to the albumin uptake complex. Surface biotinylation experiments revealed that both NHERF1 and NHERF2 were associated with the plasma membrane and that NHERF2 was recruited to the membrane in the presence of albumin. The importance of the interaction between NHERF2 and the cytoskeleton was demonstrated by a significant reduction in albumin uptake in cells overexpressing an ezrin binding-deficient mutant of NHERF2. Thus NHERF1 and NHERF2 differentially regulate albumin uptake by mechanisms that ultimately alter the cell-surface levels of ClC-5.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld 4072, Australia; Univ Sydney, Royal N Shore Hosp, Dept Med, Kolling Inst, St Leonards, NSW 2065, Australia; Emory Univ, Div Digest Dis, Dept Med, Atlanta, GA 30322 USA	University of Queensland; University of Queensland; University of Queensland; Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; Emory University	Poronnik, P (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	p.poronnik@uq.edu.au	Ekberg, Jenny/AAV-2006-2020; Parton, Robert G/C-5673-2009; Hryciw, Deanne/P-2642-2019	Parton, Robert G/0000-0002-7494-5248; Hryciw, Deanne/0000-0003-1697-8890; Ekberg, Jenny/0000-0001-5151-4966; Poronnik, Philip/0000-0002-6246-528X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061418] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK061418-03, R01 DK061418, R01 DK061418-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander RT, 2005, P NATL ACAD SCI USA, V102, P12253, DOI 10.1073/pnas.0409197102; Biemesderfer D, 2001, J BIOL CHEM, V276, P10161, DOI 10.1074/jbc.M008098200; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; Birn H, 2000, J CLIN INVEST, V105, P1353, DOI 10.1172/JCI8862; Cha BY, 2004, J CELL SCI, V117, P3353, DOI 10.1242/jcs.01180; Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562, DOI 10.1152/ajprenal.2001.280.4.F562; Christensen EI, 2003, P NATL ACAD SCI USA, V100, P8472, DOI 10.1073/pnas.1432873100; Czekay RP, 1997, MOL BIOL CELL, V8, P517, DOI 10.1091/mbc.8.3.517; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; Drumm K, 2003, CELL PHYSIOL BIOCHEM, V13, P199, DOI 10.1159/000072422; Drumm K, 2002, CELL PHYSIOL BIOCHEM, V12, P187, DOI 10.1159/000066278; Gekle M, 1996, AM J PHYSIOL-RENAL, V271, pF286, DOI 10.1152/ajprenal.1996.271.2.F286; Gekle M, 1999, J PHYSIOL-LONDON, V520, P709, DOI 10.1111/j.1469-7793.1999.00709.x; Gekle M, 2005, ANNU REV PHYSIOL, V67, P573, DOI 10.1146/annurev.physiol.67.031103.154845; Gekle M, 2004, AM J PHYSIOL-RENAL, V287, pF469, DOI 10.1152/ajprenal.00059.2004; Gekle M, 2002, AM J PHYSIOL-RENAL, V283, pF549, DOI 10.1152/ajprenal.00206.2001; Gekle M, 1997, AM J PHYSIOL-RENAL, V272, pF668, DOI 10.1152/ajprenal.1997.272.5.F668; Gekle M, 2001, J PHYSIOL-LONDON, V531, P619, DOI 10.1111/j.1469-7793.2001.0619h.x; Hernando N, 2004, CURR OPIN NEPHROL HY, V13, P569, DOI 10.1097/00041552-200409000-00014; Hernando N, 2002, P NATL ACAD SCI USA, V99, P11957, DOI 10.1073/pnas.182412699; Hryciw DH, 2006, INT J BIOCHEM CELL B, V38, P1036, DOI 10.1016/j.biocel.2005.09.009; Hryciw DH, 2004, CLIN EXP PHARMACOL P, V31, P372, DOI 10.1111/j.1440-1681.2004.04001.x; Hryciw DH, 2005, AM J PHYSIOL-RENAL, V288, pF1227, DOI 10.1152/ajprenal.00428.2003; Hryciw DH, 1998, J BIOL CHEM, V273, P4304, DOI 10.1074/jbc.273.8.4304; Hryciw DH, 2003, J BIOL CHEM, V278, P40169, DOI 10.1074/jbc.M307890200; Hryciw DH, 2004, J BIOL CHEM, V279, P54996, DOI 10.1074/jbc.M411491200; Kocinsky HS, 2005, AM J PHYSIOL-RENAL, V289, pF249, DOI 10.1152/ajprenal.00082.2004; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Lee EM, 2003, AM J PHYSIOL-RENAL, V285, pF748, DOI 10.1152/ajprenal.00442.2002; Li JQ, 2005, J BIOL CHEM, V280, P37634, DOI 10.1074/jbc.M502305200; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Maack T, 2000, KIDNEY PHYSL PATHOPH, P3005; Marshansky V, 2002, CURR OPIN NEPHROL HY, V11, P527, DOI 10.1097/00041552-200209000-00009; McDonough AA, 2003, CURR OPIN NEPHROL HY, V12, P533, DOI 10.1097/00041552-200309000-00009; Moulin P, 2003, KIDNEY INT, V63, P1285, DOI 10.1046/j.1523-1755.2003.00851.x; Norden AGW, 2001, KIDNEY INT, V60, P1885, DOI 10.1046/j.1523-1755.2001.00016.x; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Remuzzi G, 2002, NEW ENGL J MED, V346, P1145, DOI 10.1056/NEJMcp011773; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; Shenolikar S, 2004, PHYSIOLOGY, V19, P362, DOI 10.1152/physiol.00020.2004; Thelin WR, 2005, J PHYSIOL-LONDON, V567, P13, DOI 10.1113/jphysiol.2005.091041; Wade JB, 2003, AM J PHYSIOL-CELL PH, V285, pC1494, DOI 10.1152/ajpcell.00092.2003; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Wang SS, 2000, HUM MOL GENET, V9, P2937, DOI 10.1093/hmg/9.20.2937; Wang YH, 2005, AM J PHYSIOL-RENAL, V289, pF850, DOI 10.1152/ajprenal.00011.2005; Weinman EJ, 2002, PATHOBIOLOGY, V70, P314, DOI 10.1159/000071271; Weinman EJ, 2003, FEBS LETT, V536, P141, DOI 10.1016/S0014-5793(03)00043-7; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weinman EJ, 2001, AM J PHYSIOL-RENAL, V281, pF374, DOI 10.1152/ajprenal.2001.281.2.F374; WEINMAN EJ, 2001, AM J PHYSIOL, V81, pF374; Yun CC, 2005, AM J PHYSIOL-CELL PH, V289, pC2, DOI 10.1152/ajpcell.00610.2004; Yun CC, 2002, J BIOL CHEM, V277, P7676, DOI 10.1074/jbc.M107768200; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	58	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16068	16077		10.1074/jbc.M512559200	http://dx.doi.org/10.1074/jbc.M512559200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16601121	hybrid			2022-12-25	WOS:000237996000059
J	Malorni, W; Fiorentini, C				Malorni, Walter; Fiorentini, Carla			Is the Rac GTPase-activating toxin CNF1 a smart hijacker of host cell fate?	FASEB JOURNAL			English	Article						mitotic catastrophe; multipolar mitosis; Rac GT-Pase; CNF1; autophagy	MITOTIC CATASTROPHE; RHO-GTPASES; APOPTOSIS; DEATH; AUTOPHAGY; KINASE-1; CANCER; BCL-2; CYCLE	The term mitotic catastrophe ( MC) was coined to describe the mammalian cell death caused by aberrant mitosis. MC occurs with features that are fundamentally different from those typifying other forms of cell death, including apoptosis. We report here for the first time that the Rac-activating toxin CNF1 interferes with the occurrence of MC and leads to aneuploidy and multinucleation. This seems to be in line with the anti-apoptotic activity of the toxin and consistent with the hypothesis that points at CNF1 as a toxin bearing a carcinogenic potential. - Malorni, W., Fiorentini, C. Is the Rac GTPase- activating toxin CNF1 a smart hijacker of host cell fate?.	Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Malorni, W (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	malorni@iss.it	Fiorentini, Carla/Q-2088-2015; FIORENTINI, CARLA/AAG-8005-2019; Malorni, Walter/G-5874-2016	Fiorentini, Carla/0000-0003-1707-6282; FIORENTINI, CARLA/0000-0003-1707-6282; malorni, walter/0000-0002-1223-7000				Boyer L, 2004, MOL BIOL CELL, V15, P1124, DOI 10.1091/mbc.E03-05-0301; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; D'Amato G, 1998, CRIT REV ONCOGENESIS, V9, P275; Eskelinen EL, 2005, CELL DEATH DIFFER, V12, P1468, DOI 10.1038/sj.cdd.4401721; Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; Fiorentini C, 1998, EXP CELL RES, V242, P341, DOI 10.1006/excr.1998.4057; Fiorentini C, 2003, CELL DEATH DIFFER, V10, P147, DOI 10.1038/sj.cdd.4401151; Fiorentini C, 1998, CELL DEATH DIFFER, V5, P921, DOI 10.1038/sj.cdd.4400422; Fiorentini C, 2001, MOL BIOL CELL, V12, P2061, DOI 10.1091/mbc.12.7.2061; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Lax AJ, 2005, NAT REV MICROBIOL, V3, P343, DOI 10.1038/nrmicro1130; Lock RB, 1996, CANCER RES, V56, P4006; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Malorni W, 2003, J IMMUNOL, V171, P4195, DOI 10.4049/jimmunol.171.8.4195; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Quimby BB, 2003, CURR OPIN CELL BIOL, V15, P338, DOI 10.1016/S0955-0674(03)00046-2; Sato N, 2000, ONCOGENE, V19, P5281, DOI 10.1038/sj.onc.1203902; Travaglione S, 2005, CELL DEATH DIFFER, V12, P78, DOI 10.1038/sj.cdd.4401522	26	28	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					606	609		10.1096/fj.05-4706hyp	http://dx.doi.org/10.1096/fj.05-4706hyp			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581968				2022-12-25	WOS:000240130900006
J	Warraich, RS; Griffiths, E; Falconar, A; Pabbathi, V; Bell, C; Angelini, G; Suleiman, MS; Yacoub, MH				Warraich, Rahat S.; Griffiths, Elinor; Falconar, Andrew; Pabbathi, Vijay; Bell, Chris; Angelini, Gianni; Suleiman, M. -Saadeh; Yacoub, Magdi H.			Human cardiac myosin autoantibodies impair myocyte contractility: a cause-and-effect relationship	FASEB JOURNAL			English	Article						dilated cardiomyopathy; antimyosin autoantibodies; myocyte contractility	DILATED CARDIOMYOPATHY; CALCIUM; HEART; ANTIBODIES; IMMUNOGLOBULINS; DYSFUNCTION; INHIBITION; PROTEINS; FAILURE; SERA	The functional relevance of autoantibodies (Abs) against cardiac myosin ( CM) in clinical idiopathic dilated cardiomyopathy (DCM) remains controversial. The study sought to determine effects of human Abs affinity-purified (AF) by immunoaffinity column chromotography on excitation-contraction coupling in isolated myocytes. Effects of CM-Abs from heart failure patients with DCM (n = 19) and ischemic heart disease (IHD, n = 19) on contractility, L-type Ca2+ current, and Ca2+ transients in continuously perfused rat ventricular myocytes were studied. Immunofluorescence studies using confocal microscopy were carried out to determine whether Abs were internalized. AF-Abs from either group did not differ in IgG titer but differed in their elution profiles. The IgG3 subclass response was higher in AF fractions from DCM (21%) than IHD (5%) patients. The Abs reduced the capacity of field-stimulated myocytes to contract in a dose-dependent manner. Inhibition of contraction, as a percentage of untreated cells, was greater with DCM than IHD-Abs ( P = 0.004), and the effect was independent of Ab titer. An increase in frequency of the beating myocytes (0.2 to 3.0 Hz) raised peak systolic and diastolic levels of [Ca2+](i) of cells treated with DCM but not IHD-Abs ( P < 0.005). The AF-Abs were not internalized by myocytes and had no effect on L-type Ca2+ currents. The altered sensitivity of the myofilaments to [Ca2+](i) by CM-Abs may represent a potential mechanism of autoantibody-mediated impairment in clinical DCM. -Warraich, R. S., Griffiths, E., Falconar, A., Pabbathi, V., Bell, C., Angelini, G., Suleiman, M.-S., Yacoub, M. H. Human cardiac myosin autoantibodies impair myocyte contractility: a cause-and-effect relationship.	Harefield Hosp, Royal Brompton & Harefield Trust, Imperial Coll Sch Med, Natl Heart & Lung Inst,Dept Cardiothorac Surg, Harefield UB9 6JH, Middx, England; Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; London Sch Hyg & Trop Med, London WC1, England	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Bristol Royal Infirmary; University of Bristol; University of London; London School of Hygiene & Tropical Medicine	Warraich, RS (corresponding author), Harefield Hosp, Royal Brompton & Harefield Trust, Imperial Coll Sch Med, Natl Heart & Lung Inst,Dept Cardiothorac Surg, Harefield UB9 6JH, Middx, England.	rwarraich@lycos.com	Suleiman, M.-Saadeh/AAF-2946-2019	Suleiman, M.-Saadeh/0000-0001-6080-480X; angelini, gianni/0000-0002-1753-3730				ANSARI AA, 1994, J IMMUNOL, V153, P4754; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; CAFORIO ALP, 1992, CIRCULATION, V85, P1734, DOI 10.1161/01.CIR.85.5.1734; Caforio ALP, 1997, HEART, V77, P62, DOI 10.1136/hrt.77.1.62; Caforio ALP, 1995, EUR HEART J, V16, P68, DOI 10.1093/eurheartj/16.suppl_O.68; DESCHEERDER IK, 1991, EUR HEART J, V12, P88, DOI 10.1093/eurheartj/12.suppl_D.88; GOLDMAN JH, 1995, BRIT HEART J, V74, P598; Griffiths EJ, 1999, FEBS LETT, V453, P400, DOI 10.1016/S0014-5793(99)00726-7; Griffiths EJ, 1997, AM J PHYSIOL-CELL PH, V273, pC37, DOI 10.1152/ajpcell.1997.273.1.C37; Harding SE, 1998, ANN MED, V30, P14; Jana CK, 1999, J IMMUNOL METHODS, V225, P95, DOI 10.1016/S0022-1759(99)00032-0; Knowlton AA, 1998, J MOL CELL CARDIOL, V30, P811, DOI 10.1006/jmcc.1998.0646; LAUER B, 1994, J AM COLL CARDIOL, V23, P146, DOI 10.1016/0735-1097(94)90513-4; Li M, 2002, FEBS LETT, V513, P247, DOI 10.1016/S0014-5793(02)02322-0; LIMAS CJ, 1989, CIRC RES, V64, P97, DOI 10.1161/01.RES.64.1.97; Mandi Y, 2000, PATHOBIOLOGY, V68, P150, DOI 10.1159/000055916; NEUMANN DA, 1990, J AM COLL CARDIOL, V16, P839; Owen VJ, 1999, CIRCULATION, V99, P2565, DOI 10.1161/01.CIR.99.19.2565; Ravens U, 1996, MOL CELL BIOCHEM, V157, P245; Schultheiss H P, 1985, Adv Myocardiol, V6, P311; SCHULTHEISS HP, 1988, J EXP MED, V168, P2105, DOI 10.1084/jem.168.6.2105; SHARAF AR, 1994, CIRCULATION, V89, P1217, DOI 10.1161/01.CIR.89.3.1217; Tabakyan EA, 2002, KARDIOLOGIYA, V42, P42; WAGNER JA, 1986, SCIENCE, V232, P515, DOI 10.1126/science.3008330; Warraich RS, 1999, BIOCHEM BIOPH RES CO, V259, P255, DOI 10.1006/bbrc.1999.0761; Warraich RS, 2005, AM HEART J, V150, P263, DOI 10.1016/j.ahj.2004.09.008; Warraich RS, 2002, AM HEART J, V143, P1076, DOI 10.1067/mhj.2002.124406; Warraich RS, 2000, TRANSPLANTATION, V69, P1609; Witchel HJ, 2002, FEBS LETT, V512, P59, DOI 10.1016/S0014-5793(01)03320-8	29	26	28	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					651	660		10.1096/fj.04-3001com	http://dx.doi.org/10.1096/fj.04-3001com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581973				2022-12-25	WOS:000240130900011
J	Sekine, Y; Tsuji, S; Ikeda, O; Sato, N; Aoki, N; Aoyama, K; Sugiyama, K; Matsuda, T				Sekine, Y.; Tsuji, S.; Ikeda, O.; Sato, N.; Aoki, N.; Aoyama, K.; Sugiyama, K.; Matsuda, T.			Regulation of STAT3-mediated signaling by LMW-DSP2	ONCOGENE			English	Article						IL-6; LIF; STAT3; phosphatase; transcriptional regulation	DUAL-SPECIFICITY PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; CELL ANTIGEN RECEPTOR; FUNCTIONAL INTERACTIONS; NEGATIVE REGULATOR; STATS; TRANSDUCTION; ACTIVATION; PATHWAY; CLONING	Signal transducer and activator of transcription 3 (STAT3), which mediates biological actions in many physiological processes, is activated by cytokines and growth factors, and has been reported to be constitutively activated in numerous cancer cells. In this study, we examined whether low molecular weight-dual specificity phosphatase two (LMW-DSP2) is involved in the regulation of the interleukin 6 (IL-6)/leukemia inhibitory factor (LIF)/STAT3-mediated signaling pathway. IL-6/LIF-induced LMW-DSP2 expression in murine testicular or hepatoma cell lines, while LMW-DSP2 overexpression in 293T cells suppressed IL-6-induced phosphorylation and activation of STAT3. Furthermore, LMW-DSP2 suppressed the expression of IL-6-induced endogenous genes. In contrast, small-interfering RNA-mediated reduction of LMW-DSP2 expression enhanced IL-6-induced STAT3-dependent transcription. In fact, LMW-DSP2 interacted with STAT3 in vivo and endogenous LMW-DSP2 bound to STAT3 in murine testicular GC-1 cells. These results strongly suggest that LMW-DSP2 acts as a negative regulator of the IL-6/LIF/STAT3-mediated signaling pathway.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Mie Univ, Dept Life Sci, Fac Bioresources, Lab Mol Food Chem & Biochem, Tsu, Mie 514, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi, Japan; Nippon Boehringer Ingelheim Co Ltd, Kawanishi Pharma Res Inst, Kawanishi, Hyogo, Japan	Hokkaido University; Mie University; Nagoya University; Boehringer Ingelheim	Matsuda, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Sekine, Yuichi/S-8813-2019; Matsuda, Tadashi/A-3835-2012	Sekine, Yuichi/0000-0002-2861-603X; Matsuda, Tadashi/0000-0002-3089-3757				Alonso A, 2004, TOP CURR GENET, V5, P333; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Aoki N, 2002, MOL ENDOCRINOL, V16, P58, DOI 10.1210/me.16.1.58; Aoki N, 2001, J BIOCHEM, V130, P133, DOI 10.1093/oxfordjournals.jbchem.a002952; Aoyama K, 2001, J BIOL CHEM, V276, P27575, DOI 10.1074/jbc.M100408200; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Chen AJ, 2002, J BIOL CHEM, V277, P36592, DOI 10.1074/jbc.M200453200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Muromoto R, 2004, J IMMUNOL, V172, P2985, DOI 10.4049/jimmunol.172.5.2985; Najarro P, 2001, J VIROL, V75, P3185, DOI 10.1128/JVI.75.7.3185-3196.2001; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Sekine Y, 2005, J BIOL CHEM, V280, P8188, DOI 10.1074/jbc.M411692200; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	25	62	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5801	5806		10.1038/sj.onc.1209578	http://dx.doi.org/10.1038/sj.onc.1209578			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16636663	Bronze, Green Submitted			2022-12-25	WOS:000240765800010
J	Thompson, JR; Ryan, ZC; Salisbury, JL; Kumar, R				Thompson, James R.; Ryan, Zachary C.; Salisbury, Jeffrey L.; Kumar, Rajiv			The structure of the human centrin 2-xeroderma pigmentosum group C protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CENTRIN-2; CALCIUM-BINDING; TERMINAL DOMAIN; CENTROSOME; CALMODULIN; EXPRESSION; EXCISION; YEAST; EVOLUTION; ISOFORMS	Human centrin-2 plays a key role in centrosome function and stimulates nucleotide excision repair by binding to the xeroderma pigmentosum group C protein. To determine the structure of human centrin-2 and to develop an understanding of molecular interactions between centrin and xeroderma pigmentosum group C protein, we characterized the crystal structure of calcium-loaded full-length centrin-2 complexed with a xeroderma pigmentosum group C peptide. Our structure shows that the carboxyl-terminal domain of centrin-2 binds this peptide and two calcium atoms, whereas the amino-terminal lobe is in a closed conformation positioned distantly by an ordered alpha-helical linker. A stretch of the amino-terminal domain unique to centrins appears disordered. Two xeroderma pigmentosum groupCpeptides both bound to centrin-2 also interact to form an alpha-helical coiled-coil. The interface between centrin-2 and each peptide is predominantly nonpolar, and key hydrophobic residues of XPC have been identified that lead us to propose a novel binding motif for centrin.	Mayo Clin & Mayo Fdn, Dept Physiol & Biomed Engn, Coll Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Coll Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Coll Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Proteom Res Ctr, Coll Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Thompson, JR (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biomed Engn, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.	thompson.james@mayo.edu		Kumar, Rajiv/0000-0003-3497-3057; Salisbury, Jeffrey/0000-0001-9257-4578	NIDDK NIH HHS [R01 DK065830, R21 DK073369, DK65830, DK58546] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK073369, R01DK065830, R01DK058546] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araki M, 2001, J BIOL CHEM, V276, P18665, DOI 10.1074/jbc.M100855200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cox JA, 2005, BIOCHEMISTRY-US, V44, P840, DOI 10.1021/bi048294e; CRAIG TA, 2006, IN PRESS J AM SOC MA; Drohat AC, 1996, BIOCHEMISTRY-US, V35, P11577, DOI 10.1021/bi9612226; Durussel I, 2000, FEBS LETT, V472, P208, DOI 10.1016/S0014-5793(00)01452-6; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gavet O, 2003, MOL BIOL CELL, V14, P1818, DOI 10.1091/mbc.E02-11-0709; Giessl A, 2004, J BIOL CHEM, V279, P51472, DOI 10.1074/jbc.M406770200; Hu HT, 2004, J BIOL CHEM, V279, P50895, DOI 10.1074/jbc.M404233200; Hu HT, 2003, J MOL BIOL, V330, P473, DOI 10.1016/S0022-2836(03)00619-3; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Ireton GC, 2004, ACTA CRYSTALLOGR D, V60, P601, DOI 10.1107/S0907444903029664; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; Keller LC, 2005, CURR BIOL, V15, P1090, DOI 10.1016/j.cub.2005.05.024; Kilmartin JV, 2003, J CELL BIOL, V162, P1211, DOI 10.1083/jcb.200307064; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; LINSE S, 1991, J BIOL CHEM, V266, P8050; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; Matei E, 2003, BIOCHEMISTRY-US, V42, P1439, DOI 10.1021/bi0269714; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Middendorp S, 2000, J CELL BIOL, V148, P405, DOI 10.1083/jcb.148.3.405; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473, DOI 10.1146/annurev.bb.23.060194.002353; Nishi R, 2005, MOL CELL BIOL, V25, P5664, DOI 10.1128/MCB.25.13.5664-5674.2005; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Popescu A, 2003, J BIOL CHEM, V278, P40252, DOI 10.1074/jbc.M302546200; Pulvermuller A, 2002, MOL CELL BIOL, V22, P2194, DOI 10.1128/MCB.22.7.2194-2203.2002; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rogue Patrick J., 1999, EMBO (European Molecular Biology Organization) Journal, V18, P5147, DOI 10.1093/emboj/18.19.5147; Salisbury JL, 2002, CURR BIOL, V12, P1287, DOI 10.1016/S0960-9822(02)01019-9; Salisbury JL, 2004, CURR BIOL, V14, pR27, DOI 10.1016/j.cub.2003.12.019; SALISBURY JL, 1988, J CELL BIOL, V107, P635, DOI 10.1083/jcb.107.2.635; SANDERS MA, 1989, J CELL BIOL, V108, P1751, DOI 10.1083/jcb.108.5.1751; Suhre K, 2004, NUCLEIC ACIDS RES, V32, pW610, DOI 10.1093/nar/gkh368; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P1174, DOI 10.1107/S0907444903009922; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tourbez M, 2004, J BIOL CHEM, V279, P47672, DOI 10.1074/jbc.M404996200; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Veeraraghavan S, 2002, J BIOL CHEM, V277, P28564, DOI 10.1074/jbc.M112232200; WEBER C, 1994, J BIOL CHEM, V269, P15795; Wiech H, 1996, J BIOL CHEM, V271, P22453, DOI 10.1074/jbc.271.37.22453; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wolfrum U, 1998, EXP CELL RES, V242, P10, DOI 10.1006/excr.1998.4038; Wolfrum U, 2002, ADV EXP MED BIOL, V514, P155; Yang A, 2006, BIOCHEMISTRY-US, V45, P880, DOI 10.1021/bi051397s; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914	55	76	81	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18746	18752		10.1074/jbc.M513667200	http://dx.doi.org/10.1074/jbc.M513667200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16627479	hybrid			2022-12-25	WOS:000238687300055
J	Gupta, M; Gupta, SK; Hoffman, B; Liebermann, DA				Gupta, Mamta; Gupta, Shiv Kumar; Hoffman, Barbara; Liebermann, Dan A.			Gadd45a and Gadd45b protect hematopoietic cells from UV-induced apoptosis via distinct signaling pathways, including p38 activation and JNK inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RESPONSE GENE MYD118; GROWTH-ARREST; EXPRESSION; FAMILY; MAPK; P53; GADD45A-DEFICIENT; SUPPRESSION; INDUCTION	Gadd45a, Gadd45b, and Gadd45g (Gadd45/MyD118/CR6) are genes that are rapidly induced by genotoxic stress and have been implicated in genotoxic stress-induced responses, notably in apoptosis. Recently, using myeloid-enriched bone marrow (BM) cells obtained from wild-type (WT), Gadd45a-deficient, and Gadd45b-deficient mice, we have shown that in hematopoietic cells Gadd45a and Gadd45b play a survival function to protect hematopoietic cells from DNA-damaging agents, including ultra violet (UV)-induced apoptosis. The present study was undertaken to decipher the molecular paths that mediate the survival functions of Gadd45a and Gadd45b against genotoxic stress induced by UV radiation. It is shown that in hematopoietic cells exposed to UV radiation Gaddd45a and Gadd45b cooperate to promote cell survival via two distinct signaling pathways involving activation of the GADD45a-p38-NF-kappa B-mediated survival pathway and GADD45b-mediated inhibition of the stress response MKK4-JNK pathway.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@temple.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070530] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 70530-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; Gupta M, 2005, ONCOGENE, V24, P7170, DOI 10.1038/sj.onc.1208847; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jijon H, 2004, CELL SIGNAL, V16, P1023, DOI 10.1016/j.cellsig.2004.02.005; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Liebermann DA, 2002, LEUKEMIA, V16, P527, DOI 10.1038/sj.leu.2402477; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vairapandi M, 1996, ONCOGENE, V12, P2579; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885	36	101	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17552	17558		10.1074/jbc.M600950200	http://dx.doi.org/10.1074/jbc.M600950200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636063	hybrid			2022-12-25	WOS:000238490300004
J	McFie, PJ; Wang, GL; Timchenko, NA; Wilson, HL; Hu, XB; Roesler, WJ				McFie, Pamela J.; Wang, Guo-Li; Timchenko, Nicholai A.; Wilson, Heather L.; Hu, Xiaobin; Roesler, William J.			Identification of a co-repressor that inhibits the transcriptional and growth-arrest activities of CCAAT/enhancer-binding protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-ALPHA; CELL-PROLIFERATION; GENE PROMOTER; RECEPTOR; BETA; DOMAINS; MEDIATE; CA150; TRANSACTIVATION; SPECIFICITY	We used a yeast two-hybrid screening approach to identify novel interactors of CCAAT/enhancer-binding protein alpha (C/EBP alpha) that may offer insight into its mechanism of action and regulation. One clone obtained was that for CA150, a nuclear protein previously characterized as a transcriptional elongation factor. In this report, we show that CA150 is a widely expressed co-repressor of C/EBP proteins. Two-hybrid and co-immunoprecipitation analyses indicated that CA150 interacts with C/EBP alpha. Overexpression of CA150 inhibited the transactivation produced by C/EBP alpha and was also able to reverse the enhancing effect of the co-activator p300 on C/EBP beta-mediated transactivation. Analysis of C/EBP alpha mutants indicated that CA150 interacts with C/EBP alpha primarily through a domain spanning amino acids 135-150. Chromatin immunoprecipitation assays showed that CA150 was present on a promoter that is repressed by C/EBP alpha but not present on a promoter that is activated by C/EBP alpha. Finally, we showed that in cells in which growth arrest had been induced by ectopic expression of C/EBP alpha, CA150 was able to release them from growth arrest. Interestingly, CA150 could not reverse the growth arrest produced by the minimal growth-arrest domain of C/EBP alpha (amino acids 175-217), suggesting that the effect of CA150 was directed at a region of C/EBP alpha outside of this minimal domain, consistent with our two-hybrid analysis. Taken together, these data indicate that CA150 is a co-repressor of C/EBP proteins and provides a possible mechanism for how C/EBP alpha can repress transcription of specific genes.	Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada	University of Saskatchewan; Baylor College of Medicine; Baylor College of Medicine; University of Saskatchewan	Roesler, WJ (corresponding author), Univ Saskatchewan, Dept Biochem, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	bill.roesler@usask.ca	Wilson, Heather/B-4575-2011	Wilson, Heather/0000-0002-1261-0901	NIGMS NIH HHS [R01 GM 55188] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055188] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGNON YJ, 1990, CELL GROWTH DIFFER, V1, P647; Bohne J, 2000, MAMM GENOME, V11, P930, DOI 10.1007/s003350010162; Carty SM, 2000, P NATL ACAD SCI USA, V97, P9015, DOI 10.1073/pnas.160266597; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Davies G F, 1999, Mol Cell Biol Res Commun, V2, P202, DOI 10.1006/mcbr.2000.0176; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Felinski EA, 1999, J BIOL CHEM, V274, P11672, DOI 10.1074/jbc.274.17.11672; Ikeda H, 2006, J BIOL CHEM, V281, P6734, DOI 10.1074/jbc.M513014200; Johnson TA, 2001, BIOTECHNIQUES, V31, P740, DOI 10.2144/01314bm05; Jurado LA, 2002, J BIOL CHEM, V277, P27606, DOI 10.1074/jbc.M201429200; King TR, 2000, J BIOL CHEM, V275, P36450, DOI 10.1074/jbc.M004720200; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; Rastegar M, 2000, ENDOCRINOLOGY, V141, P1686, DOI 10.1210/en.141.5.1686; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Sune C, 1999, MOL CELL BIOL, V19, P4719; Sune C, 1997, MOL CELL BIOL, V17, P6029, DOI 10.1128/MCB.17.10.6029; Tan EH, 2005, CANCER RES, V65, P10330, DOI 10.1158/0008-5472.CAN-04-4486; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; TRAUTWEIN C, 1995, J BIOL CHEM, V270, P15130, DOI 10.1074/jbc.270.25.15130; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wilson HL, 2001, MOL CELL ENDOCRINOL, V181, P27, DOI 10.1016/S0303-7207(01)00540-8; Zhang WH, 2001, J BIOL CHEM, V276, P40373, DOI 10.1074/jbc.C100505200	45	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18069	18080		10.1074/jbc.M512734200	http://dx.doi.org/10.1074/jbc.M512734200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16644732	hybrid			2022-12-25	WOS:000238490300058
J	Ivanov, D; Emonet, C; Foata, F; Affolter, M; Delley, M; Fisseha, M; Blum-Sperisen, S; Kochhar, S; Arigoni, F				Ivanov, Dmitri; Emonet, Celine; Foata, Francis; Affolter, Michael; Delley, Michelle; Fisseha, Makda; Blum-Sperisen, Stephanie; Kochhar, Sunil; Arigoni, Fabrizio			A serpin from the gut bacterium Bifidobacterium longum inhibits eukaryotic elastase-like serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ALPHA-1-PROTEINASE INHIBITOR; SUPERFAMILY; OVALBUMIN; MECHANISM; INFLAMMATION; NEUTROPHIL; PROBIOTICS; RESOLUTION; EVOLUTION	Serpins form a large class of protease inhibitors involved in regulation of a wide spectrum of physiological processes. Recently identified prokaryotic members of this protein family may provide a key to the evolutionary origins of the unique serpin fold and the associated inhibitory mechanism. We performed a biochemical characterization of a serpin from Bifidobacterium longum, an anaerobic Gram-positive bacterium that naturally colonizes human gastrointestinal tract. The B. longum serpin was shown to efficiently inhibit eukaryotic elastase-like proteases with a stoichiometry of inhibition close to 1. Porcine pancreatic elastase and human neutrophil elastase were inhibited with the second order association constants of 4.7 x 10(4) M-1 s(-1) and 2.1 x 10(4) M-1 s(-1), respectively. The B. longum serpin is expected to be active in the gastrointestinal tract, because incubation of the purified recombinant serpin with mouse feces produces a stable covalent serpin-protease adduct readily detectable by SDS-PAGE. Bifidobacteria may encounter both pancreatic elastase and neutrophil elastase in their natural habitat and protection against exogenous proteolysis may play an important role in the interaction between these commensal bacteria and their host.	Nestec Ltd, Nestle Res Ctr, CH-1000 Lausanne, Switzerland	Nestle SA	Ivanov, D (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Cambridge, MA 02140 USA.	dmitri_ivanov@hms.harvard.edu; fabrizio.arigoni@rdls.nestle.com	Ivanov, Dmitri/B-4600-2011	Affolter, Michael/0000-0003-1568-4516				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BIETH JG, 1980, CLIN RES PROC, V16, P183; Burg ND, 2001, CLIN IMMUNOL, V99, P7, DOI 10.1006/clim.2001.5007; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; Eggers CT, 2004, BIOCHEM J, V379, P107, DOI 10.1042/BJ20031790; Fulton KF, 2005, J BIOL CHEM, V280, P8435, DOI 10.1074/jbc.M410206200; Furrie E, 2005, GUT, V54, P242, DOI 10.1136/gut.2004.044834; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; GRENIER D, 1994, FEMS MICROBIOL LETT, V119, P13; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Irving JA, 2003, STRUCTURE, V11, P387, DOI 10.1016/S0969-2126(03)00057-1; Irving JA, 2002, MOL BIOL EVOL, V19, P1881, DOI 10.1093/oxfordjournals.molbev.a004012; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Isolauri E, 2002, GUT, V50, P54, DOI 10.1136/gut.50.suppl_3.iii54; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; Marvin-Guy L, 2005, PROTEOMICS, V5, P2561, DOI 10.1002/pmic.200401265; Marvin-Guy LF, 2004, J AM SOC MASS SPECTR, V15, P1222, DOI 10.1016/j.jasms.2004.04.035; O'Mahony L, 2005, GASTROENTEROLOGY, V128, P541, DOI 10.1053/j.gastro.2004.11.050; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Roberts TH, 2004, J MOL EVOL, V59, P437, DOI 10.1007/s00239-004-2635-6; Sansonetti PJ, 2004, NAT REV IMMUNOL, V4, P953, DOI 10.1038/nri1499; Sartor RB, 2004, GASTROENTEROLOGY, V126, P1620, DOI 10.1053/j.gastro.2004.03.024; Schechter NM, 2004, METHODS, V32, P159, DOI 10.1016/S1046-2023(03)00207-X; Schell MA, 2002, P NATL ACAD SCI USA, V99, P14422, DOI 10.1073/pnas.212527599; Shiga Y, 1995, BIOSCI BIOTECH BIOCH, V59, P2348, DOI 10.1271/bbb.59.2348; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SZIEGOLEIT A, 1989, CLIN BIOCHEM, V22, P85, DOI 10.1016/S0009-9120(89)80003-7; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WRIGHT HT, 1990, J MOL BIOL, V213, P513	33	119	150	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17246	17252		10.1074/jbc.M601678200	http://dx.doi.org/10.1074/jbc.M601678200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16627467	hybrid			2022-12-25	WOS:000238326300051
J	Musri, MM; Corominola, H; Casamitjana, R; Gomis, R; Parrizas, M				Musri, Melina M.; Corominola, Helena; Casamitjana, Roser; Gomis, Ramon; Parrizas, Marcelina			Histone H3 lysine 4 dimethylation signals the transcriptional competence of the adiponectin promoter in preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-GAMMA; ADIPOCYTE DIFFERENTIATION; GENE-EXPRESSION; CODING REGIONS; PPAR-GAMMA; METHYLATION PATTERNS; BINDING-PROTEIN; C/EBP-ALPHA; IN-VIVO; H3	Adipogenesis is regulated by a coordinated cascade of sequence-specific transcription factors and coregulators with chromatin-modifying activities that are between them responsible for the establishment of the gene expression pattern of mature adipocytes. Here we examine the histone H3 post-translational modifications occurring at the promoters of key adipogenic genes during adipocyte differentiation. We show that the promoters of apM1, glut4, gpd1, and leptin are enriched in dimethylated histone H3 Lys(4) (H3-K4) in 3T3-L1 fibroblasts, where none of these genes are yet expressed. A detailed study of the apM1 locus shows that H3-K4 dimethylation is restricted to the promoter region in undifferentiated cells and associates with RNA polymerase II (pol II) loading. The beginning of apM1 transcription at the early stages of adipogenesis coincides with promoter H3 hyperacetylation and H3-K4 trimethylation. At the coding region, H3 acetylation and dimethylation, as well as pol II binding, are found in cells at later stages of differentiation, when apM1 transcription reaches its maximal peak. This same pattern of histone modifications is detected in mouse primary preadipocytes and adipocytes but not in a related fibroblast cell line that is not committed to an adipocyte fate. Inhibition of H3-K4 methylation by treatment of 3T3-L1 cells with methylthioadenosine results in decreased apM1 gene expression as well as decreased adipogenesis. Taken together, our data indicate that H3-K4 dimethylation and pol II binding to the promoter of key adipogenic genes are distinguishing marks of cells that have undergone determination to a preadipocyte stage.	Hosp Clin Barcelona, Dept Biochem & Mol Genet, Barcelona 08036, Spain; Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed, Endocrinol & Nutr Unit, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona	Parrizas, M (corresponding author), Hosp Clin Barcelona, Dept Biochem & Mol Genet, Villarroel 170,Esc 9,Pl 5, Barcelona 08036, Spain.	mparrizas@ambtu.bcn.es	Parrizas, Marcelina/AAS-3629-2021; Musri, Melina M/C-9078-2015	Musri, Melina M/0000-0002-9159-5497; Parrizas, Marcelina/0000-0003-1296-8302				Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Chen SY, 2000, J BIOL CHEM, V275, P3733, DOI 10.1074/jbc.275.6.3733; Dimitrova DS, 2002, J CELL SCI, V115, P4037, DOI 10.1242/jcs.00087; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fish JE, 2005, J BIOL CHEM, V280, P24824, DOI 10.1074/jbc.M502115200; Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005; Kristjuhan A, 2004, EMBO J, V23, P4243, DOI 10.1038/sj.emboj.7600433; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Lagace DC, 2004, J BIOL CHEM, V279, P18851, DOI 10.1074/jbc.M312795200; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Martens JHA, 2003, MOL CELL BIOL, V23, P1808, DOI 10.1128/MCB.23.5.1808-1816.2003; Miao F, 2005, MOL CELL BIOL, V25, P4650, DOI 10.1128/MCB.25.11.4650-4661.2005; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Myers FA, 2001, J BIOL CHEM, V276, P20197, DOI 10.1074/jbc.M009472200; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Parrizas M, 2001, MOL CELL BIOL, V21, P3234, DOI 10.1128/MCB.21.9.3234-3243.2001; Parrizas Marcelina, 2003, Methods Mol Med, V83, P61; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Qiao LP, 2005, DIABETES, V54, P1744, DOI 10.2337/diabetes.54.6.1744; Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; SADOWSKI HB, 1992, J BIOL CHEM, V267, P4722; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Takahashi N, 2002, J BIOL CHEM, V277, P16906, DOI 10.1074/jbc.M200585200; Talasz H, 2005, J BIOL CHEM, V280, P38814, DOI 10.1074/jbc.M505563200; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; WATERBORG JH, 1993, J BIOL CHEM, V268, P4918; Williams RRE, 2006, J CELL SCI, V119, P132, DOI 10.1242/jcs.02727; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; WOODCOCK DM, 1983, NUCLEIC ACIDS RES, V11, P489, DOI 10.1093/nar/11.2.489; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; Yoo EJ, 2006, J BIOL CHEM, V281, P6608, DOI 10.1074/jbc.M508982200; Yu JG, 2002, DIABETES, V51, P2968, DOI 10.2337/diabetes.51.10.2968; Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002	50	74	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17180	17188		10.1074/jbc.M601295200	http://dx.doi.org/10.1074/jbc.M601295200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16613853	hybrid			2022-12-25	WOS:000238326300043
J	Porras, P; Padilla, CA; Krayl, M; Voos, W; Barcena, JA				Porras, Pablo; Padilla, C. Alicia; Krayl, Martin; Voos, Wolfgang; Barcena, J. Antonio			One single in-frame AUG codon is responsible for a diversity of subcellular localizations of glutaredoxin 2 in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PRESEQUENCES; CYTOSOLIC ISOFORMS; PRECURSOR PROTEINS; REDOX REGULATION; OUTER-MEMBRANE; YEAST; IMPORT; THIOREDOXIN; TRANSLATION; GLUTATHIONE	Glutaredoxins belong to a family of small proteins with glutathione-dependent disulfide oxidoreductase activity involved in cellular defense against oxidative stress. The product of the yeast GRX2 gene is a protein that is localized both in the cytosol and mitochondria. To throw light onto the mechanism responsible for the dual subcellular distribution of Grx2 we analyzed mutant constructs containing different targeting information. By altering amino acid residues around the two in-frame translation initiation start sites of the GRX2 gene, we could demonstrate that the cytosolic isoform of Grx2 was synthesized from the second AUG, lacking an N-terminal extension. Translation from the first AUG resulted in a long isoform carrying a mitochondrial targeting presequence. The mitochondrial targeting properties of the presequence and the influence of the mature part of Grx2 were analyzed by the characterization of the import kinetics of specific fusion proteins. Import of the mitochondrial isoform is relatively inefficient and results in the accumulation of a substantial amount of unprocessed form in the mitochondrial outer membrane. Substitution of Met35, the second translation start site, to Val resulted in an exclusive targeting to the mitochondrial matrix. Our results show that a plethora of Grx2 subcellular localizations could spread its antioxidant functions all over the cell, but one single Ala to Glymutation converts Grx2 into a typical protein of the mitochondrial matrix.	Univ Cordoba, Dept Biochem & Mol Biol, E-14071 Cordoba, Spain; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany	Universidad de Cordoba; University of Freiburg; University of Freiburg	Barcena, JA (corresponding author), Univ Cordoba, Dept Biochem & Mol Biol, E-14071 Cordoba, Spain.	bb1barua@uco.es	Porras, Pablo/AAH-6223-2020; Bárcena, José Antonio/I-2622-2015; Padilla, C. Alicia/H-4736-2015	Porras, Pablo/0000-0002-8429-8793; Bárcena, José Antonio/0000-0002-5626-5943; Padilla, C. Alicia/0000-0002-9503-8284				Beer SM, 2004, J BIOL CHEM, V279, P47939, DOI 10.1074/jbc.M408011200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEUTSCH J, 1983, METHOD ENZYMAT AN, V3, P190; Enoksson M, 2005, BIOCHEM BIOPH RES CO, V327, P774, DOI 10.1016/j.bbrc.2004.12.067; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; Gakh E, 2002, BBA-MOL CELL RES, V1592, P63, DOI 10.1016/S0167-4889(02)00265-3; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; Halliwell B., 1999, FREE RADICALS BIOL M, P617; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holbrook JD, 2002, J BIOL CHEM, V277, P2336, DOI 10.1074/jbc.M107047200; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Ito A, 1999, BIOCHEM BIOPH RES CO, V265, P611, DOI 10.1006/bbrc.1999.1703; Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200; JOHANSSON C, 2000, THIOREDOXINS RELATED, P37; Karniely S, 2005, EMBO REP, V6, P420, DOI 10.1038/sj.embor.7400394; Kiley PJ, 2004, PLOS BIOL, V2, P1714, DOI 10.1371/journal.pbio.0020400; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lemaire SD, 2004, PHOTOSYNTH RES, V79, P305, DOI 10.1023/B:PRES.0000017174.60951.74; Lopreiato R, 2004, BIOCHEM J, V377, P395, DOI 10.1042/BJ20030638; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Molina MM, 2004, J BIOL CHEM, V279, P51923, DOI 10.1074/jbc.M410219200; Muto T, 2001, J MOL BIOL, V306, P137, DOI 10.1006/jmbi.2000.4397; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Outten CE, 2004, J BIOL CHEM, V279, P7785, DOI 10.1074/jbc.M312421200; Pedrajas JR, 2002, BIOCHEM J, V364, P617, DOI 10.1042/BJ20020570; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; Pestova TV, 2001, RNA, V7, P1496, DOI 10.1017/S135583820101038X; Porras P, 2002, BIOCHEM BIOPH RES CO, V295, P1046, DOI 10.1016/S0006-291X(02)00771-4; Rapaport D, 2005, J CELL BIOL, V171, P419, DOI 10.1083/jcb.200507147; Rassow J, 1999, J MOL BIOL, V286, P105, DOI 10.1006/jmbi.1998.2455; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Roise D, 1997, J BIOENERG BIOMEMBR, V29, P19, DOI 10.1023/A:1022403604273; Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; SIKORSKI RS, 1989, GENETICS, V122, P19; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Strub A, 2000, BIOL CHEM, V381, P943, DOI 10.1515/BC.2000.115; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Xia B, 2001, J MOL BIOL, V310, P907, DOI 10.1006/jmbi.2001.4721	57	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16551	16562		10.1074/jbc.M600790200	http://dx.doi.org/10.1074/jbc.M600790200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16606613	hybrid			2022-12-25	WOS:000238165700046
J	Jiang, XF; Sun, YL; Chen, SJ; Roy, K; Price, BD				Jiang, Xiaofeng; Sun, Yingli; Chen, Shujuan; Roy, Kanaklata; Price, Brendan D.			The FATC domains of PIKK proteins are functionally equivalent and participate in the Tip60-dependent activation of DNA-PKcs and ATM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE CATALYTIC SUBUNIT; HISTONE ACETYLTRANSFERASE COMPLEX; DOUBLE-STRAND BREAKS; IONIZING-RADIATION; IN-VITRO; AUTOPHOSPHORYLATION; DAMAGE; PHOSPHORYLATION; CHROMATIN; SITES	Members of the phosphatidylinositol 3-kinase-related kinase (PIKK) family, including the ATM, DNA-PKcs, Atr, and Trrap proteins, function in signal transduction pathways that activate the DNA damage response. PIKK proteins contain a conserved C-terminal FAT/kinase domain/FATC domain structure. The FATC domain of ATM mediates the interaction between ATM and Tip60, a histone acetyltransferase that regulates activation of ATM. Here, we examined whether the FATC domains of DNA-PKcs, Atr, and Trrap were also able to interact with Tip60. Deletion of the FATC domain of ATM blocked the interaction between ATM and Tip60 and suppressed the activation of ATM kinase activity by DNA damage. Replacement of the FATC domain of ATM with the FATC domains of DNA-PKcs, Atr, or Trrap restored the activation of ATM and its association with Tip60. These results indicate that the FATC domains of DNA-PKcs, Atr, Trrap, and ATM are functionally equivalent. Immunoprecipitation experiments demonstrated that Tip60 is constitutively associated with DNA-PKcs and that the histone acetyltransferase activity associated with DNA-PKcs is up-regulated by DNA damage. When Tip60 expression was suppressed by small interfering RNA, the activation of DNA-PKcs ( measured by autophosphorylation of DNA-PKcs at serine 2056 and threonine 2609) was inhibited, demonstrating a key role for Tip60 in the activation of DNA-PKcs by DNA damage. The conserved FATC domain of PIKK proteins may therefore function as a binding domain for the Tip60 histone acetyltransferase. Further, the ability of Tip60 to regulate the activation of both ATM and DNA-PKcs in response to DNA damage demonstrates that Tip60 is a key component of the DNA damage-signaling network.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Div Gen Stabil & DNA Repair, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Div Gen Stabil & DNA Repair, 44 Binney St,JF5 16, Boston, MA 02115 USA.	brendan_price@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA064585] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA064585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Austen B, 2005, BLOOD, V106, P3175, DOI 10.1182/blood-2004-11-4516; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beamish HJ, 2000, NUCLEIC ACIDS RES, V28, P1506, DOI 10.1093/nar/28.7.1506; Block WD, 2004, NUCLEIC ACIDS RES, V32, P4351, DOI 10.1093/nar/gkh761; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Boudreault AA, 2003, GENE DEV, V17, P1415, DOI 10.1101/gad.1056603; Brewerton SC, 2004, J STRUCT BIOL, V145, P295, DOI 10.1016/j.jsb.2003.11.024; Cai Y, 2003, J BIOL CHEM, V278, P42733, DOI 10.1074/jbc.C300389200; Cairns BR, 2005, CURR OPIN GENET DEV, V15, P185, DOI 10.1016/j.gde.2005.01.003; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; Dames SA, 2005, J BIOL CHEM, V280, P20558, DOI 10.1074/jbc.M501116200; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Doyon Y, 2004, CURR OPIN GENET DEV, V14, P147, DOI 10.1016/j.gde.2004.02.009; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FERNANDES N, 2005, J BIOL CHEM; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lou ZK, 2004, J BIOL CHEM, V279, P46359, DOI 10.1074/jbc.C400375200; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Nakada D, 2005, MOL BIOL CELL, V16, P5227, DOI 10.1091/mbc.E05-05-0405; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Priestley A, 1998, NUCLEIC ACIDS RES, V26, P1965, DOI 10.1093/nar/26.8.1965; Reddy YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/jbc.M406432200; Rivera-Calzada A, 2005, STRUCTURE, V13, P243, DOI 10.1016/j.str.2004.12.006; Scott SP, 2002, P NATL ACAD SCI USA, V99, P925, DOI 10.1073/pnas.012329699; Soubeyrand S, 2003, CANCER RES, V63, P1198; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Takahashi T, 2000, GENES CELLS, V5, P765, DOI 10.1046/j.1365-2443.2000.00365.x; Turenne GA, 2001, ONCOGENE, V20, P5100, DOI 10.1038/sj.onc.1204665	41	104	108	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15741	15746		10.1074/jbc.M513172200	http://dx.doi.org/10.1074/jbc.M513172200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16603769	hybrid			2022-12-25	WOS:000237996000021
J	Yamada, M; Ikeda, Y; Yano, M; Yoshimura, K; Nishino, S; Aoyama, H; Wang, LL; Aoki, H; Matsuzaki, M				Yamada, Michio; Ikeda, Yasuhiro; Yano, Masafumi; Yoshimura, Koichi; Nishino, Shizuka; Aoyama, Hidekazu; Wang, Lili; Aoki, Hiroki; Matsuzaki, Masunori			Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy	FASEB JOURNAL			English	Article						gene transfer; protein kinase A; phosphorylation; phospholamban	CHANNEL RYANODINE RECEPTOR; DELTA-SARCOGLYCAN GENE; N-TERMINAL KINASE; DILATED CARDIOMYOPATHY; CARDIAC-FUNCTION; SARCOPLASMIC-RETICULUM; PROTEIN PHOSPHATASE-1; DEFECTIVE REGULATION; MEMBRANE-PROTEINS; FAILING HEARTS	The type 1 protein phosphatase (PP1) has been reported to be overactivated in the failing heart, leading to a depression in cardiac function. We investigated whether in vivo PP1 inhibition by myocardial gene transfer of inhibitor-2 (INH-2), an endogenous PP1 inhibitor, alleviates heart failure (HF) progression in the cardiomyopathic (CM) hamster, a well-established HF model. Adenoviral INH-2 gene delivery improved % fractional shortening of the left ventricle (LV) accompanied by reduced chamber size at 1 wk. In vivo myocardial INH-2 gene delivery induced an increase in cytosolic PP1 catalytic subunit alpha (PP1C alpha) without inducing the corresponding increase in cytosolic PP1 activity. On the other hand, INH-2 delivery induced a decrease in microsomal PP1C alpha, resulting in a preferential decrease in microsomal PP1 activity, thereby increasing in phospholamban phosphorylation at Ser16. INH-2 gene transfer alleviated brain natriuretic peptide expression, presumably reflecting improved cardiac function. Moreover, adeno-associated virus-mediated INH-2 gene delivery significantly extended the survival time for 3 mo. These results indicate that increased PP1 activity is an exacerbating factor during progression of genetic cardiomyopathy and modulation of PP1 activity by INH-2 provides a potential new treatment for HF without activating protein kinase A signaling in cardiomyocytes.	Yamaguchi Univ, Sch Med, Dept Mol Cardiovasc Biol, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Grad Sch Med, Div Cardiol, Dept Med & Clin Sci, Ube, Yamaguchi 7558505, Japan; Univ Penn, Dept Med, Div Med Genet, Philadelphia, PA 19104 USA	Yamaguchi University; Yamaguchi University; University of Pennsylvania	Ikeda, Y (corresponding author), Yamaguchi Univ, Sch Med, Dept Mol Cardiovasc Biol, 1-1-1 Minamikogushi, Ube, Yamaguchi 7558505, Japan.	ysikeda@yamaguchi-u.ac.jp		Wang, Lili/0000-0001-9347-3939				Antos CL, 2001, CIRC RES, V89, P997, DOI 10.1161/hh2301.100003; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bartel S, 1996, MOL CELL BIOCHEM, V157, P171; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bisognano JD, 2000, J MOL CELL CARDIOL, V32, P817, DOI 10.1006/jmcc.2000.1123; BOHM M, 1994, CARDIOVASC RES, V28, P1713, DOI 10.1093/cvr/28.11.1713; Boknik P, 2000, N-S ARCH PHARMACOL, V362, P222, DOI 10.1007/s002100000283; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Cohen PTW, 2002, J CELL SCI, V115, P241; Cohn JN, 1997, CIRCULATION, V95, P766; CRUICKSHANK JM, 1993, CARDIOVASC DRUG THER, V7, P655, DOI 10.1007/BF00877818; Dodge-Kafka KL, 2005, NATURE, V437, P574, DOI 10.1038/nature03966; El-Armouche A, 2003, FASEB J, V17, P437, DOI 10.1096/fj.02-0057fje; Freeman K, 2001, J CLIN INVEST, V107, P967, DOI 10.1172/JCI12083; Gupta RC, 2003, AM J PHYSIOL-HEART C, V285, pH2373, DOI 10.1152/ajpheart.00442.2003; Hoshijima M, 2002, NAT MED, V8, P864, DOI 10.1038/nm739; Huang BY, 1999, CIRC RES, V85, P848, DOI 10.1161/01.RES.85.9.848; Ikeda Y, 2000, AM J PHYSIOL-HEART C, V278, pH1362, DOI 10.1152/ajpheart.2000.278.4.H1362; Ikeda Y, 2002, CIRCULATION, V105, P502, DOI 10.1161/hc0402.102953; Iwanaga Y, 2004, J CLIN INVEST, V113, P727, DOI 10.1172/JCI200418716; Karkkainen S, 2003, J MOL MED-JMM, V81, P795, DOI 10.1007/s00109-003-0480-5; Kirchhefer U, 2005, CARDIOVASC RES, V68, P98, DOI 10.1016/j.cardiores.2005.05.019; MACKINTOSH K, 1993, PROTEIN PHOSPHORYLAR, P167; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; NEUMANN J, 1993, AM J PHYSIOL, V265, pH257, DOI 10.1152/ajpheart.1993.265.1.H257; Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271; Okuda S, 2004, CIRCULATION, V109, P911, DOI 10.1161/01.CIR.0000115526.92541.D2; Pathak A, 2005, CIRC RES, V96, P756, DOI 10.1161/01.RES.0000161256.85833.fa; Reiken S, 2003, CIRCULATION, V107, P2459, DOI 10.1161/01.CIR.0000068316.53218.49; Reiken S, 2003, J CELL BIOL, V160, P919, DOI 10.1083/jcb.200211012; Sande JB, 2002, CARDIOVASC RES, V53, P382, DOI 10.1016/S0008-6363(01)00489-8; Sato Y, 2001, J BIOL CHEM, V276, P9392, DOI 10.1074/jbc.M006889200; SCHWINGER RHG, 1995, CIRCULATION, V92, P3220, DOI 10.1161/01.CIR.92.11.3220; Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224; Wehrens XHT, 2004, SCIENCE, V304, P292, DOI 10.1126/science.1094301; Wehrens XHT, 2004, NAT REV DRUG DISCOV, V3, P565, DOI 10.1038/nrd1440; Xiao BL, 2005, CIRC RES, V96, P847, DOI 10.1161/01.RES.0000163276.26083.e8; Yano M, 2000, CIRCULATION, V102, P2131, DOI 10.1161/01.CIR.102.17.2131; Yoshimura K, 2005, NAT MED, V11, P1330, DOI 10.1038/nm1335	41	60	62	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1197	+		10.1096/fj.05-5299fje	http://dx.doi.org/10.1096/fj.05-5299fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16627625				2022-12-25	WOS:000240210300024
J	Raynard, S; Bussen, W; Sung, P				Raynard, Steven; Bussen, Wendy; Sung, Patrick			A double Holliday junction dissolvasome comprising BLM, topoisomerase III alpha, and BLAP75	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; HOMOLOGOUS RECOMBINATION; DNA; HELICASES; PROTEIN; PATHWAY; GENOME	Bloom syndrome (BS), an autosomal recessive disorder, is marked by a high incidence of cancer early in life. Cells derived from BS patients are unstable genetically and exhibit frequent sister chromatid exchanges, reflective of homologous recombination (HR) deregulation. BLM, the RecQ-like helicase mutated in BS, is found in several cellular protein complexes, all of which contain topoisomerase III alpha (Topo III alpha) and a novel protein BLAP75. Here, using highly purified human proteins, we show that BLAP75 associates independently with both Topo III alpha and BLM. Even though BLM and Topo III alpha can dissolve the double Holliday junction (DHJ) to yield non-crossover recombinants (1), under physiological conditions, DHJ dissolution becomes completely dependent on BLAP75. The effect of BLAP75 on BLM-Topo III alpha is highly specific, as it is not seen with the combination of Topo III alpha and Escherichia coli RecQ helicase or another human RecQ-like helicase WRN. Thus, BLM, Topo III alpha, and BLAP75 constitute a dissolvasome complex that processes HR intermediates to limit DNA crossover formation. This function of the BLM-Topo III alpha-BLAP75 dissolvasome is likely indispensable for genome maintenance and cancer avoidance.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	Yale University; University of Texas System; University of Texas Health San Antonio	Sung, P (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St,C130 Sterling Hall Med, New Haven, CT 06520 USA.	Patrick.Sung@yale.edu			NCI NIH HHS [R01CA110415] Funding Source: Medline; NIGMS NIH HHS [R01GM57814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA110415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		FU TJ, 1994, J MOL BIOL, V236, P91, DOI 10.1006/jmbi.1994.1121; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Klein H, 2001, GENETICS, V157, P557; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Pichierri P, 2004, EMBO J, V23, P3154, DOI 10.1038/sj.emboj.7600277; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Wu L, 2006, P NATL ACAD SCI USA, V103, P4068, DOI 10.1073/pnas.0508295103; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Yin JH, 2005, EMBO J, V24, P1465, DOI 10.1038/sj.emboj.7600622	15	183	194	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13861	13864		10.1074/jbc.C600051200	http://dx.doi.org/10.1074/jbc.C600051200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16595695	hybrid			2022-12-25	WOS:000237512300004
J	Marini, P; Denzinger, S; Schiller, D; Kauder, S; Welz, S; Humphreys, R; Daniel, PT; Jendrossek, V; Budach, W; Belka, C				Marini, P.; Denzinger, S.; Schiller, D.; Kauder, S.; Welz, S.; Humphreys, R.; Daniel, P. T.; Jendrossek, V.; Budach, W.; Belka, C.			Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo	ONCOGENE			English	Article						TRAIL receptor antibodies; HGS-ETR1; HGS-ETR2; radiotherapy; apoptosis; molecular targeted therapy	APOPTOSIS-INDUCING LIGAND; IRRADIATION-INDUCED APOPTOSIS; CELL-DEATH PATHWAY; NF-KAPPA-B; IONIZING-RADIATION; MONOCLONAL-ANTIBODIES; CANCER-THERAPY; CYTOCHROME-C; DNA-DAMAGE; BAX	We and others have demonstrated already that TRAIL (TNF-related apoptosis-inducing ligand) is a very promising candidate for molecular targeted anticancer therapy, especially when combined with ionizing radiation or other DNA-damaging agents. Agonist monoclonal antibodies that activate and are specific for the death signaling TRAIL receptors are an alternative method to stimulate the programmed cell death pathway. Phase 1 clinical trials have subsequently been conducted and shown a very good tolerability of these antibodies. In order to assess the efficacy of TRAIL receptor stimulation to induce cell death by this alternate method, we studied the combination of the agonistic-TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 with radiation in vitro and in vivo. Induction of apoptosis after combined treatment with TRAIL receptor antibodies HGS-ETR1 and/or HGS-ETR2 (0.01, 0.1, 1.0 mg/ml) and irradiation with 2, 5 or 10 Gy was determined by fluorescence microscopy and Western blot analysis of caspase-8 and PARP. The colorectal tumour cell lines Colo 205, HCT 116 and HCT-15 were used for in vitro experiments. Growth delay experiments were performed with combined treatment with fractionated irradiation (days 1-5 and 3Gy single dose/day) and the receptor antibodies (intraperitonially, three different concentrations, application on days 1, 4 and 8) on Colo 205 xenograft-bearing NMRI (nu/nu) nude mice. HGS-ETR1 and HGS-ETR2 induced apoptotic cell death in a dose-dependent fashion and significantly increased cell death in combination with irradiation in vitro when compared to either irradiation or antibody treatment alone. The efficacy of the combined treatment seems to be at least partially Bax-dependent. Similar to the results from cell culture experiments, in vivo experiments demonstrated a dose-dependent delay in tumour growth after combined treatment. In vivo, in the Colo205 xenograft model, HGS-ETR2 revealed a higher activity than HGS-ETR1. This is the first study to demonstrate significant efficacy of combined treatment with the monoclonal agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and ionising radiation in in vitro and in vivo models. We postulate that HGS-ETR1 and HGS-ETR2 will be very promising new agents in the field of molecular targeted multi-modality anticancer therapy.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Univ Dusseldorf, Dept Radiat Oncol & Radiotherapy, D-4000 Dusseldorf, Germany; Human Genome Sci Inc, Dev Sci & Res, Rockville, MD USA; Humboldt Univ, Berlin, Germany	Eberhard Karls University of Tubingen; Heinrich Heine University Dusseldorf; GlaxoSmithKline; Human Genome Sciences Inc; Humboldt University of Berlin	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	claus.belka@uni-tuebingen.de	Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				ALDERSON RF, 2003, 94 AACR ANN M; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; ATTARD G, 2005, AACRNCIEORTC INT C M; Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Buchsbaum DJ, 2003, CLIN CANCER RES, V9, P3731; Cecconi F, 1999, CELL DEATH DIFFER, V6, P1087, DOI 10.1038/sj.cdd.4400602; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; DEBONO JS, 2004, 16 EORTCNCIAACR S MO; El-Zawahry A, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-2; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; FUDLA S, 2002, NAT MED, V8, P808; Griffith TS, 1999, J IMMUNOL, V162, P2597; Hamasu T, 2005, J RADIAT RES, V46, P103, DOI 10.1269/jrr.46.103; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HOTTE SJ, 2004, 94 AACR ANN M GEN SW; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kim MR, 2001, FEBS LETT, V505, P179, DOI 10.1016/S0014-5793(01)02816-2; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luciano F, 2002, LEUKEMIA, V16, P700, DOI 10.1038/sj.leu.2402401; Marini P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-5; Marini P, 2003, RADIOTHER ONCOL, V68, P189, DOI 10.1016/S0167-8140(03)00186-5; Marini Patrizia, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P334, DOI 10.2174/1568011033482297; MIYASHITA T, 1995, CELL, V80, P293; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Rubel A, 2006, RADIAT ONCOL, V1, DOI 10.1186/1748-717X-1-6; SALCEDO TW, 2002, AM ASS CANC RES 93 A; SARANTOPOULOS J, 2005, AACRNCIEORTC INT C M; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Shankar S, 2004, PROSTATE, V61, P35, DOI 10.1002/pros.20069; Shankar S, 2004, INT J ONCOL, V24, P1133; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Stuben G, 1994, Strahlenther Onkol, V170, P36; STUSCHKE M, 1990, RADIAT RES, V122, P172, DOI 10.2307/3577603; TOLCHER AW, 2004, AM SOC CLIN ONC ANN; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052; Weinmann M, 2004, FASEB J, V18, P1906, DOI 10.1096/fj.04-1918fje; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	58	91	96	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5145	5154		10.1038/sj.onc.1209516	http://dx.doi.org/10.1038/sj.onc.1209516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16636678				2022-12-25	WOS:000240063700007
J	Werbowetski-Ogilvie, TE; Sadr, MS; Jabado, N; Angers-Loustau, A; Agar, NYR; Wu, J; Bjerkvig, R; Antel, JP; Faury, D; Rao, Y; Del Maestro, RF				Werbowetski-Ogilvie, T. E.; Sadr, M. Seyed; Jabado, N.; Angers-Loustau, A.; Agar, N. Y. R.; Wu, J.; Bjerkvig, R.; Antel, J. P.; Faury, D.; Rao, Y.; Del Maestro, R. F.			Inhibition of medulloblastoma cell invasion by Slit	ONCOGENE			English	Article						Slit; medulloblastoma; glioma; invasion; inhibitor	ROUNDABOUT RECEPTOR; AXON GUIDANCE; CANCER-CELLS; TUMOR; MIGRATION; CDC42; GENE; PROTEINS; GLIOMAS; GROWTH	Invasion of brain tumor cells has made primary malignant brain neoplasms among the most recalcitrant to therapeutic strategies. We tested whether the secreted protein Slit2, which guides the projection of axons and developing neurons, could modulate brain tumor cell invasion. Slit2 inhibited the invasion of medulloblastoma cells in a variety of in vitro models. The effect of Slit2 was inhibited by the Robo ectodomain. Time-lapse videomicroscopy indicated that Slit2 reduced medulloblastoma invasion rate without affecting cell direction or proliferation. Both medulloblastoma and glioma tumors express Robo1 and Slit2, but only medulloblastoma invasion is inhibited by recombinant Slit2 protein. Downregulation of activated Cdc42 may contribute to this differential response. Our findings reinforce the concept that neurodevelopmental cues such as Slit2 may provide insights into brain tumor invasion.	Montreal Neurol Hosp & Inst, Brain Tumor Res Ctr, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Neurol Inst, Brain Tumor Res Ctr, Montreal, PQ, Canada; Montreal Childrens Hosp, Inst Res, Dept Pediat, Montreal, PQ H3H 1P3, Canada; Northwestern Univ, Feinberg Med Sch, Robert H Lurie Comprehens Canc Ctr, Ctr Genet Med, Chicago, IL 60611 USA; Univ Bergen, Dept Anat & Cell Biol, Bergen, Norway; McGill Univ, Montreal Neurol Inst, Neuroimmunol Unit, Montreal, PQ, Canada; Northwestern Univ, Feinberg Med Sch, Dept Neurol, Chicago, IL 60611 USA	McGill University; McGill University; McGill University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; University of Bergen; McGill University; Northwestern University; Feinberg School of Medicine	Del Maestro, RF (corresponding author), Montreal Neurol Hosp & Inst, Brain Tumor Res Ctr, 3801 Rue Univ St,BT 210, Montreal, PQ H3A 2B4, Canada.	y-rao@northwestern.edu; rolando.delmaestro@mcgill.ca	Xiao, Yang/B-5668-2012; Jabado, Nada/AAN-4026-2020	Angers-Loustau, Alexandre/0000-0003-1425-4143; antel, jack/0000-0002-5148-0636; Werbowetski-Ogilvie, Tamra/0000-0002-5469-0559	NCI NIH HHS [R01 CA114197-01A2, R01 CA114197] Funding Source: Medline; NEI NIH HHS [R01 EY014576, R01 EY014576-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967, R01 GM070967-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Corcoran A, 2003, NEUROSURGERY, V53, P174, DOI 10.1227/01.NEU.0000072442.26349.14; Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687; Dallol A, 2003, CANCER RES, V63, P1054; Dallol A, 2002, CANCER RES, V62, P5874; Del Duca D, 2004, J NEURO-ONCOL, V67, P295, DOI 10.1023/B:NEON.0000024220.07063.70; Del Maestro R, 2001, J NEURO-ONCOL, V53, P87, DOI 10.1023/A:1012236830230; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fan XP, 2003, NEURON, V40, P113, DOI 10.1016/S0896-6273(03)00591-9; Gilthorpe JD, 2002, DEVELOPMENT, V129, P4719; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; JACOBSEN PF, 1985, J NEUROPATH EXP NEUR, V44, P472, DOI 10.1097/00005072-198509000-00003; Jen JC, 2004, SCIENCE, V304, P1509, DOI 10.1126/science.1096437; Joki T, 2001, NAT BIOTECHNOL, V19, P35, DOI 10.1038/83481; Keles GE, 1995, ONCOL RES, V7, P493; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Lundstrom A, 2004, GENE DEV, V18, P2161, DOI 10.1101/gad.310204; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Marillat V, 2004, NEURON, V43, P69, DOI 10.1016/j.neuron.2004.06.018; Marillat V, 2002, J COMP NEUROL, V442, P130, DOI 10.1002/cne.10068; Mason HA, 2001, J NEUROSCI, V21, P7654, DOI 10.1523/JNEUROSCI.21-19-07654.2001; Nguyen-Ba-Charvet KT, 2004, J NEUROSCI, V24, P1497, DOI 10.1523/JNEUROSCI.4729-03.2004; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Prasad A, 2004, J BIOL CHEM, V279, P9115, DOI 10.1074/jbc.M308083200; RAFFEL C, 1993, NEUROSURGERY, V33, P301, DOI 10.1227/00006123-199308000-00018; Raffel C, 2004, NEOPLASIA, V6, P310, DOI 10.1593/neo.03454; RAFFEL C, 1995, NEUROSURGERY, V36, P971, DOI 10.1227/00006123-199505000-00013; Read TA, 2001, NAT BIOTECHNOL, V19, P29, DOI 10.1038/83471; Rossi MR, 2005, GENE, V356, P85, DOI 10.1016/j.gene.2005.04.018; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Ruffini F, 2004, AM J PATHOL, V165, P2167, DOI 10.1016/S0002-9440(10)63266-X; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Werbowetski T, 2004, J NEUROBIOL, V60, P71, DOI 10.1002/neu.10335; Werbowetski-Ogilvie TE, 2006, CANCER RES, V66, P1464, DOI 10.1158/0008-5472.CAN-05-1913; Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616; Zhao YX, 2004, ANAL CHEM, V76, P1817, DOI 10.1021/ac0354037	43	54	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5103	5112		10.1038/sj.onc.1209524	http://dx.doi.org/10.1038/sj.onc.1209524			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16636676	Green Accepted			2022-12-25	WOS:000240063700003
J	Lim, CP; Phan, TT; Lim, IJ; Cao, X				Lim, C. P.; Phan, T-T; Lim, I. J.; Cao, X.			Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration	ONCOGENE			English	Article						Stat3; keloid; scar; fibroblasts; collagen; migration	POTENT ANTITUMOR-ACTIVITY; GROWTH-FACTOR-BETA; GENE-REGULATION; CANCER-CELLS; FIBROBLASTS; ACTIVATION; SCAR; TRANSCRIPTION; DISRUPTION; EXPRESSION	Keloids, partially considered as benign tumors, represent the most extreme example of cutaneous scarring that uniquely afflicts humans as a pathological response to wound healing. It is characterized by excessive deposition of collagen and other extracellular matrix components by dermal fibroblasts. Upon cutaneous injury, cocktails of chemokines, cytokines and growth factors are secreted temporally and spatially to direct appropriate responses from neutrophils, macrophages, keratinocytes and fibroblasts to facilitate normal wound healing. Signal transducer and activator of transcription 3 (Stat3) is an oncogene and a latent transcription factor activated by various cytokines and growth factors. We investigated the possible role of Stat3 in keloid scar pathogenesis by examining skin tissue and cultured fibroblasts from keloid-scarred patients. We observed enhanced expression and phosphorylation of Stat3 in keloid scar tissue, and in cultured keloid fibroblasts (KFs) in vitro. Increased activation of Janus kinase (Jak)2, but not Jak1, was detected in KFs, and suppression of Jak2 by its inhibitor repressed Stat3 Y705 phosphorylation. Inhibition of Stat3 expression and phosphorylation by short interfering RNA or Cucurbitacin I resulted in the loss of collagen production, impaired proliferation and delayed cell migration in KFs. We show, for the first time, a role of Stat3 in keloid pathogenesis. Inhibitors of Stat3 may be useful therapeutic strategies for the prospective treatment of keloid scars.	Inst Mol & Cell Biol, Cell Signaling Lab, Proteos, Singapore 138673, Singapore; Natl Univ Singapore, Dept Surg, Singapore 117548, Singapore; Natl Univ Singapore, Dept Bioengn, Singapore 117548, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore	Cao, X (corresponding author), Inst Mol & Cell Biol, Cell Signaling Lab, Proteos, 61 Biopolis Dr, Singapore 138673, Singapore.	mcbcaoxm@imcb.a-star.edu.sg	Phan, Toan Thang/A-5527-2009					ABERGEL RP, 1985, J INVEST DERMATOL, V84, P384, DOI 10.1111/1523-1747.ep12265471; Alster TS, 2003, AM J CLIN DERMATOL, V4, P235, DOI 10.2165/00128071-200304040-00003; BABU M, 1992, J INVEST DERMATOL, V99, P650, DOI 10.1111/1523-1747.ep12668146; BABU M, 1989, MOL CELL BIOL, V9, P1642, DOI 10.1128/MCB.9.4.1642; Blaskovich MA, 2003, CANCER RES, V63, P1270; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Calderon M, 1996, J SURG RES, V61, P343, DOI 10.1006/jsre.1996.0127; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; COSMAN B, 1961, PLAST RECONSTR SURG, V27, P335, DOI 10.1097/00006534-196104000-00001; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; DIEGELMANN RF, 1979, J CELL PHYSIOL, V98, P341, DOI 10.1002/jcp.1040980210; Edmondson SR, 2003, ENDOCR REV, V24, P737, DOI 10.1210/er.2002-0021; HAISA M, 1994, J INVEST DERMATOL, V103, P560, DOI 10.1111/1523-1747.ep12396856; Lee TY, 1999, ANN PLAS SURG, V43, P179; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Lim IJ, 2002, AM J PHYSIOL-CELL PH, V283, pC212, DOI 10.1152/ajpcell.00555.2001; Mustoe TA, 2004, BRIT MED J, V328, P1329, DOI 10.1136/bmj.328.7452.1329; Naitoh M, 2001, BIOCHEM BIOPH RES CO, V280, P1316, DOI 10.1006/bbrc.2001.4257; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Ragoowansi R, 2001, BRIT J PLAST SURG, V54, P504, DOI 10.1054/bjps.2001.3656; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Sun JZ, 2005, ONCOGENE, V24, P3236, DOI 10.1038/sj.onc.1208470; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Takeda K, 2000, CYTOKINE GROWTH F R, V11, P199, DOI 10.1016/S1359-6101(00)00005-8; Tuan TL, 1998, MOL MED TODAY, V4, P19, DOI 10.1016/S1357-4310(97)80541-2; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wu YD, 2004, AM J PHYSIOL-CELL PH, V286, pC905, DOI 10.1152/ajpcell.00200.2003; Xue H, 2000, J SURG RES, V89, P74, DOI 10.1006/jsre.1999.5805; Yang GP, 2003, WOUND REPAIR REGEN, V11, P411, DOI 10.1046/j.1524-475X.2003.11604.x; Yoshimoto H, 1999, AM J PATHOL, V154, P883, DOI 10.1016/S0002-9440(10)65335-7; YOUNAI S, 1994, ANN PLAS SURG, V33, P148, DOI 10.1097/00000637-199408000-00005	38	82	99	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5416	5425		10.1038/sj.onc.1209531	http://dx.doi.org/10.1038/sj.onc.1209531			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16619044				2022-12-25	WOS:000240144900006
J	Back, SH; Lee, K; Vink, E; Kaufman, RJ				Back, Sung Hoon; Lee, Kyungho; Vink, Elizabeth; Kaufman, Randal J.			Cytoplasmic IRE1 alpha-mediated XBP1 mRNA splicing in the absence of nuclear processing and endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN-RESPONSE; ER-STRESS; TRANSCRIPTION FACTOR; TRANSLATIONAL CONTROL; MAMMALIAN-CELLS; POLYMERASE-II; IN-VIVO; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEIN; CYCLIN D1	Accumulation of unfolded proteins in the endoplasmic reticulum ( ER) activates an intracellular signal transduction program termed the unfolded protein response (UPR). In mammalian cells, the UPR is signaled in part through dimerization of ER membrane-localized IRE1 alpha to activate its protein kinase and endoribonuclease activities. Activated IRE1 alpha cleaves XBP1 mRNA at two sites to initiate an unconventional splicing reaction. The 5' and 3' fragments are subsequently joined by an RNA ligase activity, thereby removing a 26-base intron. This splicing reaction creates a translational frameshift to produce a functional XBP1 transcription factor. However, the cellular location and physiological processes required for splicing of XBP1 mRNA are not well characterized. To study these processes, XBP1 mRNAs were engineered in which translation of enhanced green fluorescence protein or luciferase required splicing of the XBP1 intron. Using cell lines that continuously or transiently express these reporter constructs, we show that cytoplasmic unspliced XBP1 mRNA is efficiently spliced by activated IRE1 alpha and requires ongoing cellular transcription but not active translation. The XBP1 intron was effectively removed from RNA substrates transcribed from T7 RNA polymerase or delivered directly to the cytoplasm by RNA transfection, thus indicating that the splicing reaction does not require nuclear processing of the RNA substrate. Analysis of nuclear and cytoplasmic RNA fractions demonstrated that XBP1 mRNA splicing occurs in the cytoplasm. Moreover, an artificial F-v-IRE1 alpha Delta N was engineered that was able to splice XBP1 mRNA upon chemical-induced dimerization. These findings demonstrate that IRE1 alpha dimerization is sufficient to activate XBP1 mRNA splicing in the absence of the UPR. We propose that XBP1 mRNA cytoplasmic splicing provides a novel mechanism to rapidly induce translation of a transcription factor in response to a specific stimulus.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.	kaufmanr@umich.edu	Longo, Kenneth A/A-5631-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042394, R01DK042394] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL052173] Funding Source: Medline; NIDDK NIH HHS [DK42394] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abelson J, 1998, J BIOL CHEM, V273, P12685, DOI 10.1074/jbc.273.21.12685; Back SH, 2000, PROTEIN EXPRES PURIF, V20, P196, DOI 10.1006/prep.2000.1301; Back SH, 2002, J VIROL, V76, P2529, DOI 10.1128/JVI.76.5.2529-2542.2002; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Culver GM, 1997, J BIOL CHEM, V272, P13203, DOI 10.1074/jbc.272.20.13203; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; Dahlberg J, 2005, MOL CELL, V19, P292, DOI 10.1016/j.molcel.2005.07.009; DENG H, 1991, GENE, V109, P193, DOI 10.1016/0378-1119(91)90609-F; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DUNN JJ, 1988, GENE, V68, P259, DOI 10.1016/0378-1119(88)90028-5; ELROYSTEIN O, 1990, P NATL ACAD SCI USA, V87, P6743, DOI 10.1073/pnas.87.17.6743; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; Glanzer J, 2005, P NATL ACAD SCI USA, V102, P16859, DOI 10.1073/pnas.0503783102; Gonzalez TN, 1999, EMBO J, V18, P3119, DOI 10.1093/emboj/18.11.3119; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hopper AK, 2003, GENE DEV, V17, P162, DOI 10.1101/gad.1049103; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Iwawaki T, 2001, NAT CELL BIOL, V3, P158, DOI 10.1038/35055065; Kamath RV, 2001, MOL BIOL CELL, V12, P3808, DOI 10.1091/mbc.12.12.3808; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KAUFMAN RJ, 1985, MOL CELL BIOL, V5, P1750, DOI 10.1128/MCB.5.7.1750; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; Kim R, 2006, APOPTOSIS, V11, P5, DOI 10.1007/s10495-005-3088-0; LASKI FA, 1983, J BIOL CHEM, V258, P1974; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Liu CY, 2002, J BIOL CHEM, V277, P18346, DOI 10.1074/jbc.M112454200; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Miyoshi K, 2000, MOL BRAIN RES, V85, P68, DOI 10.1016/S0169-328X(00)00243-6; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mori K, 2000, P NATL ACAD SCI USA, V97, P4660, DOI 10.1073/pnas.050010197; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Phizicky EM, 2005, P NATL ACAD SCI USA, V102, P11127, DOI 10.1073/pnas.0504843102; RAJALAKSHMI S, 1971, BIOCHEM BIOPH RES CO, V42, P259, DOI 10.1016/0006-291X(71)90096-9; Ruegsegger U, 2001, CELL, V107, P103, DOI 10.1016/S0092-8674(01)00505-0; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shang J, 2004, BIOCHEM BIOPH RES CO, V317, P390, DOI 10.1016/j.bbrc.2004.03.058; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Spinelli SL, 1998, P NATL ACAD SCI USA, V95, P14136, DOI 10.1073/pnas.95.24.14136; Stephens SB, 2005, MOL BIOL CELL, V16, P5819, DOI 10.1091/mbc.E05-07-0685; Szegezdi E, 2003, ANN NY ACAD SCI, V1010, P186, DOI 10.1196/annals.1299.032; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Topisirovic I, 2002, MOL CELL BIOL, V22, P6183, DOI 10.1128/MCB.22.17.6183-6198.2002; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; WETTSTEIN FO, 1964, BIOCHIM BIOPHYS ACTA, V87, P525, DOI 10.1016/0926-6550(64)90131-8; WINICOV I, 1982, MOL CELL BIOL, V2, P241, DOI 10.1128/MCB.2.3.241; Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2006, J CELL BIOL, V172, P565, DOI 10.1083/jcb.200508145; Yoshihisa T, 2003, MOL BIOL CELL, V14, P3266, DOI 10.1091/mbc.E02-11-0757; Zhang KZ, 2006, NEUROLOGY, V66, pS102, DOI 10.1212/01.wnl.0000192306.98198.ec; Zhang KZ, 2005, J CLIN INVEST, V115, P268, DOI 10.1172/JCI200521848; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410	85	102	108	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18691	18706		10.1074/jbc.M602030200	http://dx.doi.org/10.1074/jbc.M602030200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16644724	hybrid			2022-12-25	WOS:000238687300050
J	Grasberger, H; Refetoff, S				Grasberger, Helmut; Refetoff, Samuel			Identification of the maturation factor for dual oxidase - Evolution of an eukaryotic operon equivalent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE; PLASMA-MEMBRANE; PROTEIN; EXPRESSION; PREDICTION; PORCINE; CLONING; GENES; CDNAS	Dual oxidase 2 (DUOX2), an NADPH:O-2 oxidoreductase flavoprotein, is a component of the thyroid H2O2 generator crucial for hormone synthesis at the apical membrane. Mutations in DUOX2 produce congenital hypothyroidism in humans. However, no functional DUOX-based NADPH oxidase has ever been reconstituted at the plasma membrane of transfected cells. It has been proposed that DUOX retention in the endo-plasmatic reticulum (ER) of heterologous systems is due to the lack of an unidentified component required for functional maturation of the enzyme. By data mining of a massively parallel signature sequencing tissue expression data base, we identified an uncharacterized gene named DUOX maturation factor (DUOXA2) arranged head-to-head to and co-expressed with DUOX2. A paralog (DUOXA1) was similarly linked to DUOX1. The genomic rearrangement leading to linkage of ancient DUOX and DUOXA genes could be traced back before the divergence of echino-derms. We demonstrate that co-expression of DUOXA2, an ER-resident transmembrane protein, allows ER-to-Golgi transition, maturation, and translocation to the plasma membrane of functional DUOX2 in a heterologous system. The identification of DUOXA genes has important implications for studies of the molecular mechanisms controlling DUOX expression and the molecular genetics of congenital hypothyroidism.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Committee Genet, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Grasberger, H (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC3090, Chicago, IL 60637 USA.	hgrasber@uchicago.edu	Refetoff, Samuel/ABB-1263-2021; Grasberger, Helmut/C-4148-2015	Refetoff, Samuel/0000-0003-0164-8231; Grasberger, Helmut/0000-0002-4065-4418	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015070, P60DK020595, P30DK020595, R01DK015070] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20595, DK15070] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ameziane-El-Hassani R, 2005, J BIOL CHEM, V280, P30046, DOI 10.1074/jbc.M500516200; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; De Deken X, 2002, EXP CELL RES, V273, P187, DOI 10.1006/excr.2001.5444; Douzery EJP, 2004, P NATL ACAD SCI USA, V101, P15386, DOI 10.1073/pnas.0403984101; Dubnau J, 2003, CURR BIOL, V13, P286, DOI 10.1016/S0960-9822(03)00064-2; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; El Hassani RA, 2005, AM J PHYSIOL-GASTR L, V288, pG933, DOI 10.1152/ajpgi.00198.2004; GAVALAS A, 1993, MOL CELL BIOL, V13, P4784, DOI 10.1128/MCB.13.8.4784; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; Grasberger H, 2005, MOL ENDOCRINOL, V19, P1779, DOI 10.1210/me.2004-0426; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Ha EM, 2005, SCIENCE, V310, P847, DOI 10.1126/science.1117311; Jongeneel CV, 2005, GENOME RES, V15, P1007, DOI 10.1101/gr.4041005; Kall L, 2004, J MOL BIOL, V338, P1027, DOI 10.1016/j.jmb.2004.03.016; Morand S, 2003, ENDOCRINOLOGY, V144, P1241, DOI 10.1210/en.2002-220981; Morand S, 2004, J BIOL CHEM, V279, P30244, DOI 10.1074/jbc.M405406200; Moreno JC, 2002, NEW ENGL J MED, V347, P95, DOI 10.1056/NEJMoa012752; Pachucki J, 2004, MOL CELL ENDOCRINOL, V214, P53, DOI 10.1016/j.mce.2003.11.026; Qin HJ, 2004, J BIOL CHEM, V279, P11304, DOI 10.1074/jbc.M311733200; Wang DT, 2005, J BIOL CHEM, V280, P3096, DOI 10.1074/jbc.M407709200; Wong JL, 2004, DEV CELL, V7, P801, DOI 10.1016/j.devcel.2004.10.014; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	23	231	243	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18269	18272		10.1074/jbc.C600095200	http://dx.doi.org/10.1074/jbc.C600095200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16651268	hybrid			2022-12-25	WOS:000238687300002
J	Pikis, A; Hess, S; Arnold, I; Erni, B; Thompson, J				Pikis, Andreas; Hess, Sonja; Arnold, Ingrid; Erni, Bernhard; Thompson, John			Genetic requirements for growth of Escherichia coli K12 on methyl-alpha-D-glucopyranoside and the five alpha-D-glucosyl-D-fructose isomers of sucrose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; THERMOTOGA-MARITIMA; BACILLUS-SUBTILIS; FAMILY 4; FUSOBACTERIUM-MORTIFERUM; KLEBSIELLA-PNEUMONIAE; COLI K-12; BACTERIAL PHOSPHOENOLPYRUVATE; CARBOHYDRATE TRANSPORTERS; ENZYMES-II	Strains of Escherichia coli K12, including MG-1655, accumulate methyl-alpha-D-glucopyranoside via the phosphoenolpyruvate-dependent glucose: phosphotransferase system (IICBGlc/IIA(Glc)). High concentrations of intracellular methyl-alpha-D-glucopyranoside 6-phosphate are toxic, and cell growth is prevented. However, transformation of E. coli MG-1655 with a plasmid (pAP1) encoding the gene aglB from Klebsiella pneumoniae resulted in excellent growth of the transformant MG-1655 (pAP1) on the glucose analog. AglB is an unusual NAD(+)/Mn2+-dependent phospho-alpha-glucosidase that promotes growth of MG-1655 (pAP1) by catalyzing the in vivo hydrolysis of methyl-alpha-D-glucopyranoside 6-phosphate to yield glucose 6-phosphate and methanol. When transformed with plasmid pAP2 encoding the K. pneumoniae genes aglB and aglA (an alpha-glucoside-specific transporter AglA (IICBAgl)), strain MG-1655 (pAP2) metabolized a variety of other alpha-linked glucosides, including maltitol, isomaltose, and the following five isomers of sucrose: trehalulose alpha(1 -> 1), turanose alpha(1 -> 3), maltulose alpha(1 -> 4), leucrose alpha(1 -> 5), and palatinose alpha(1 -> 6). Remarkably, MG-1655 (pAP2) failed to metabolize sucrose alpha(1 -> 2). The E. coli K12 strain ZSC112L (ptsG:: cat manXYZ nagE glk lac) can neither grow on glucose nor transport methyl-alpha-D-glucopyranoside. However, when transformed with pTSGH11 (encoding ptsG) or pAP2, this organism provided membranes that contained either the PtsG or AglA transporters, respectively. In vitro complementation of transporter-specific membranes with purified general phosphotransferase components showed that although PtsG and AglA recognized glucose and methyl-alpha-D-glucopyranoside, only AglA accepted other alpha-D-glucosides as substrates. Complementation experiments also revealed that IIA(Glc) was required for functional activity of both PtsG and AglA transporters. We conclude that AglA, AglB, and IIAGlc are necessary and sufficient for growth of E. coli K12 on methyl-alpha-D-glucoside and related alpha-D-glucopyranosides.	NIDCR, NIH, Dept Hlth & Human Serv, Microbial Biochem & Genet Unit,Oral Infect & Immu, Bethesda, MD 20892 USA; NIDDK, Proteom & Mass Spectrometry Facil, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Bern	Thompson, J (corresponding author), NIDCR, NIH, Dept Hlth & Human Serv, Microbial Biochem & Genet Unit,Oral Infect & Immu, Bldg 30,Rm 325,Convent Dr MSC-4350, Bethesda, MD 20892 USA.	jthompson@dir.nidcr.nih.gov	PIKIS, ANDREAS/AFU-1192-2022; Hess, Sonja/K-4842-2013	Hess, Sonja/0000-0002-5904-9816	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK070004] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bouma CL, 1997, J BACTERIOL, V179, P4129, DOI 10.1128/jb.179.13.4129-4137.1997; BUHR A, 1992, J BIOL CHEM, V267, P3847; Coutinho PM, 1999, ROY SOC CH, P3; Dahl MK, 1997, FEMS MICROBIOL LETT, V148, P233, DOI 10.1016/S0378-1097(97)00039-6; GACHELIN G, 1970, EUR J BIOCHEM, V16, P342, DOI 10.1111/j.1432-1033.1970.tb01088.x; HAGIHIRA H, 1963, BIOCHIM BIOPHYS ACTA, V78, P505, DOI 10.1016/0006-3002(63)90912-0; HAGUENAUER R, 1971, BIOCHIMIE, V53, P99, DOI 10.1016/S0300-9084(71)80087-1; HAGUENAUER R, 1972, BIOCHIMIE, V54, P505, DOI 10.1016/S0300-9084(72)80235-9; HOFFEE P, 1962, P NATL ACAD SCI USA, V48, P1759, DOI 10.1073/pnas.48.10.1759; HOFFEE P, 1964, BIOCHIM BIOPHYS ACTA, V79, P337; IMMEL S, 1995, LIEBIGS ANN, P1925, DOI 10.1002/jlac.1995199511272; KESSLER DP, 1963, BIOCHEM BIOPH RES CO, V10, P482, DOI 10.1016/0006-291X(63)90383-8; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; LENGELER JW, 1982, J BACTERIOL, V151, P468, DOI 10.1128/JB.151.1.468-471.1982; LENGELER JW, 1990, PHILOS T ROY SOC B, V326, P489, DOI 10.1098/rstb.1990.0027; Lodge JA, 2003, J BIOL CHEM, V278, P19151, DOI 10.1074/jbc.M211626200; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; Pikis A, 2002, MICROBIOL-SGM, V148, P843, DOI 10.1099/00221287-148-3-843; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Raasch C, 2000, EXTREMOPHILES, V4, P189, DOI 10.1007/PL00010711; Rajan SS, 2004, STRUCTURE, V12, P1619, DOI 10.1016/j.str.2004.06.020; REIZER J, 1994, PROTEIN SCI, V3, P440; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; ROGERS D, 1962, J BACTERIOL, V84, P877, DOI 10.1128/JB.84.5.877-881.1962; ROSEMAN S, 1989, FEMS MICROBIOL LETT, V63, P3, DOI 10.1016/0168-6445(89)90003-X; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; Sambrook J., 2002, MOL CLONING LAB MANU; SAPICO V, 1968, J BACTERIOL, V96, P51, DOI 10.1128/JB.96.1.51-54.1968; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3; SPRENGER GA, 1988, J GEN MICROBIOL, V134, P1635; SUTRINA SL, 1990, J BIOL CHEM, V265, P18581; Thompson J, 1999, J BACTERIOL, V181, P7339, DOI 10.1128/JB.181.23.7339-7345.1999; Thompson J, 1998, J BIOL CHEM, V273, P27347, DOI 10.1074/jbc.273.42.27347; Thompson J, 2004, J BIOL CHEM, V279, P1553, DOI 10.1074/jbc.M310733200; Thompson J, 2001, J BIOL CHEM, V276, P37415, DOI 10.1074/jbc.M106504200; THOMPSON J, 1995, J BACTERIOL, V177, P2505, DOI 10.1128/jb.177.9.2505-2512.1995; Thompson J, 2001, CARBOHYD RES, V331, P149, DOI 10.1016/S0008-6215(01)00028-3; Varrot A, 2005, J MOL BIOL, V346, P423, DOI 10.1016/j.jmb.2004.11.058; WINKLER HH, 1971, J BACTERIOL, V106, P362, DOI 10.1128/JB.106.2.362-368.1971; Yip VLY, 2006, BIOCHEMISTRY-US, V45, P571, DOI 10.1021/bi052054x; Yip VLY, 2004, J AM CHEM SOC, V126, P8354, DOI 10.1021/ja047632w	45	14	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17900	17908		10.1074/jbc.M601183200	http://dx.doi.org/10.1074/jbc.M601183200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636060	hybrid			2022-12-25	WOS:000238490300040
J	Gasser, A; Bruhn, S; Guse, AH				Gasser, Andreas; Bruhn, Soren; Guse, Andreas H.			Second messenger function of nicotinic acid adenine dinucleotide phosphate revealed by an improved enzymatic cycling assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; NAADP MOBILIZES CA2+; SEA-URCHIN EGGS; T-LYMPHOCYTES; ADP-RIBOSE; RYANODINE RECEPTOR; INOSITOL TRISPHOSPHATE; CALCIUM-RELEASE; REVERSED-PHASE; CONCANAVALIN-A	Nicotinic acid adenine dinucleotide phosphate ( NAADP) is the most potent activator of Ca2+ release from intracellular stores known today. Although recent reports have suggested an important function of NAADP in human T lymphocytes, direct evidence for receptor-induced formation of NAADP is yet missing in these cells. Thus, we developed a highly sensitive and specific enzyme assay capable of quantifying low fmol amounts of NAADP. In unstimulated T cells, the NAADP concentration amounted to 4.4 +/- 1.6 nM (0.055 +/- 0.028 pmol/mg of protein). Stimulation of the cells via the T cell receptor/CD3 complex resulted in biphasic elevation kinetics of cellular NAADP levels and was characterized by a bell-shaped concentration-response curve for NAADP. In contrast, the NAADP concentration was elevated neither upon activation of the ADP-ribose/TRPM2 channel Ca2+ signaling system nor by an increase of the intracellular Ca2+ concentration upon thapsigargin stimulation. T cell receptor/CD3 complex-mediated NAADP formation was dependent on the activity of tyrosine kinases because genistein completely blocked NAADP elevation. Thus, we propose a regulated formation of NAADP upon specific stimulation of the T cell receptor/CD3 complex, suggesting a function of NAADP as a Ca2+ mobilizing second messenger during T cell activation.	Univ Hamburg, Med Ctr Eppendorf, Ctr Med Expt,Calcium Signalling Grp, Inst Biochem & Mol Biol Cellular Signal Transduct, D-20246 Hamburg, Germany	University of Hamburg	Guse, AH (corresponding author), Univ Hamburg, Med Ctr Eppendorf, Ctr Med Expt,Calcium Signalling Grp, Inst Biochem & Mol Biol Cellular Signal Transduct, Martinistr 52, D-20246 Hamburg, Germany.	guse@uke.uni-hamburg.de			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Bak J, 2001, CURR BIOL, V11, P987, DOI 10.1016/S0960-9822(01)00269-X; Bak J, 1999, CURR BIOL, V9, P751, DOI 10.1016/S0960-9822(99)80335-2; Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Billington RA, 2000, BIOCHEM BIOPH RES CO, V276, P112, DOI 10.1006/bbrc.2000.3444; Billington RA, 2002, J PHYSIOL-LONDON, V544, P107, DOI 10.1113/jphysiol.2002.030098; Boittin FX, 2002, CIRC RES, V91, P1168, DOI 10.1161/01.RES.0000047507.22487.85; Bootman MD, 2002, CURR BIOL, V12, pR563, DOI 10.1016/S0960-9822(02)01055-2; Churamani D, 2004, BIOCHEM J, V380, P449, DOI 10.1042/BJ20031754; Churchill GC, 2000, J BIOL CHEM, V275, P38687, DOI 10.1074/jbc.M005827200; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Dammermann W, 2005, J BIOL CHEM, V280, P21394, DOI 10.1074/jbc.M413085200; Galione A, 2005, MOL INTERV, V5, P73, DOI 10.1124/mi.5.2.4; Gasser A, 2006, J BIOL CHEM, V281, P2489, DOI 10.1074/jbc.M506525200; Gasser A, 2005, J CHROMATOGR B, V821, P181, DOI 10.1016/j.jchromb.2005.05.002; Genazzani AA, 1997, BRIT J PHARMACOL, V121, P1489, DOI 10.1038/sj.bjp.0701295; Gerasimenko JV, 2003, J CELL BIOL, V163, P271, DOI 10.1083/jcb.200306134; Gerasimenko JV, 2006, J CELL SCI, V119, P226, DOI 10.1242/jcs.02721; GOLDBERG ND, 1969, ANAL BIOCHEM, V28, P523, DOI 10.1016/0003-2697(69)90208-5; Graeff R, 2002, BIOCHEM J, V367, P163, DOI 10.1042/BJ20020644; Guse AH, 1998, CRIT REV IMMUNOL, V18, P419, DOI 10.1615/CritRevImmunol.v18.i5.20; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; GUSE AH, 1995, J CHROMATOGR B, V672, P189, DOI 10.1016/0378-4347(95)00219-9; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Guse Andreas H., 2002, Current Molecular Medicine (Hilversum), V2, P273, DOI 10.2174/1566524024605707; Hohenegger M, 2002, BIOCHEM J, V367, P423, DOI 10.1042/BJ20020584; KATO T, 1973, ANAL BIOCHEM, V53, P86, DOI 10.1016/0003-2697(73)90409-0; Kinnear NP, 2004, J BIOL CHEM, V279, P54319, DOI 10.1074/jbc.M406132200; Langhorst MF, 2004, CELL SIGNAL, V16, P1283, DOI 10.1016/j.cellsig.2004.03.013; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; Lee HC, 2003, CURR BIOL, V13, pR186, DOI 10.1016/S0960-9822(03)00120-9; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 2005, J BIOL CHEM, V280, P33693, DOI 10.1074/jbc.R500012200; Magni G, 1997, METHOD ENZYMOL, V280, P241; Masgrau R, 2003, CURR BIOL, V13, P247, DOI 10.1016/S0960-9822(03)00041-1; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Mojzisova A, 2001, PFLUG ARCH EUR J PHY, V441, P674, DOI 10.1007/s004240000465; Nagase F, 1998, MICROBIOL IMMUNOL, V42, P567, DOI 10.1111/j.1348-0421.1998.tb02325.x; Rutter Guy A, 2003, Biochem J, V373, pe3, DOI 10.1042/BJ20030472COM; Schwarzmann N, 2002, J BIOL CHEM, V277, P50636, DOI 10.1074/jbc.M209061200; STEPHON RL, 1992, ANAL BIOCHEM, V202, P6, DOI 10.1016/0003-2697(92)90197-F; Suen YK, 2000, APOPTOSIS, V5, P369, DOI 10.1023/A:1009691727077; WANG W, 1995, ANAL BIOCHEM, V227, P274, DOI 10.1006/abio.1995.1280; WERNER A, 1993, J CHROMATOGR-BIOMED, V618, P3, DOI 10.1016/0378-4347(93)80024-X; Yamasaki M, 2005, CURR BIOL, V15, P874, DOI 10.1016/j.cub.2005.04.033; Yamasaki M, 2005, FEBS J, V272, P4598, DOI 10.1111/j.1742-4658.2005.04860.x; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200	48	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16906	16913		10.1074/jbc.M601347200	http://dx.doi.org/10.1074/jbc.M601347200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16627475	hybrid			2022-12-25	WOS:000238326300011
J	Navadgi, VM; Chandra, BR; Mishra, PC; Sharma, A				Navadgi, Vasundhara M.; Chandra, Beeram Ravi; Mishra, Prakash Chandra; Sharma, Amit			The two Plasmodium falciparum nucleosome assembly proteins play distinct roles in histone transport and chromatin assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIVISION CYCLE; DNA-REPLICATION; INTRACELLULAR-LOCALIZATION; NAP1; MALARIA; REPAIR; TRANSCRIPTION; CHAPERONE; MACHINES; KINASE	The malarial parasite Plasmodium falciparum has two nucleosome assembly proteins, PfNapS and PfNapL ( Chandra, B. R., Olivieri, A., Silvestrini, F., Alano, P., and Sharma, A. ( 2005) Mol. Biochem. Parasitol. 142, 237-247). We show that both PfNapS and PfNapL interact with histone oligomers but only PfNapS is able to deposit histones onto DNA. This property of PfNapS is divalent cation-dependent and ATP-independent. Deletion of the terminal subdomains of PfNapS abolishes its nucleosome assembly capabilities, but the truncated protein retains its ability to bind histones. Both PfNapS and PfNapL show binding to the linker histone H1 suggesting their probable role in extraction of H1 from chromatin fibers. Our data suggests distinct sites of interaction for H1 versus H3/H4 on PfNapS. We show that PfNapS and PfNapL are phosphorylated both in vivo and in vitro by casein kinase-II, and this modification is specifically inhibited by heparin. Circular dichroism, fluorescence spectroscopy, and chymotrypsin fingerprinting data together suggest that PfNapL may undergo very small and subtle structural changes upon phosphorylation. Specifically, phosphorylation of PfNapL increases its affinity 3-fold for core histones H3, H4, and for the linker histone H1. Finally, we demonstrate that PfNapS is able to extract histones from both phosphorylated and unphosphorylated PfNapL, potentially for histone deposition onto DNA. Based on these results, we suggest that the P. falciparum NapL is involved in the nucleocytoplasmic relay of histones, whereas PfNapS is likely to be an integral part of the chromatin assembly motors in the parasite nucleus.	Int Ctr Genet Engn & Biotechnol, Struct & Computat Biol Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Sharma, A (corresponding author), Int Ctr Genet Engn & Biotechnol, Struct & Computat Biol Grp, Aruna Asaf Ali Marg, New Delhi 110067, India.	asharma@icgeb.res.in		Mishra, Prakash Chandra/0000-0002-6059-7174				Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; Chandra BR, 2005, MOL BIOCHEM PARASIT, V142, P237, DOI 10.1016/j.molbiopara.2005.04.006; Chandra BR, 2004, PROTEIN ENG DES SEL, V17, P175, DOI 10.1093/protein/gzh024; Corona DFV, 2004, BBA-GENE STRUCT EXPR, V1677, P113, DOI 10.1016/j.bbaexp.2003.09.018; Dong AW, 2005, PLANT PHYSIOL, V138, P1446, DOI 10.1104/pp.105.060509; Dong AW, 2003, PLANTA, V216, P561, DOI 10.1007/s00425-002-0910-6; Eberharter A, 2004, J CELL SCI, V117, P3707, DOI 10.1242/jcs.01175; Ehrenhofer-Murray AE, 2004, EUR J BIOCHEM, V271, P2335, DOI 10.1111/j.1432-1033.2004.04162.x; Fyodorov DV, 2003, METHOD ENZYMOL, V371, P499; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Ito T, 1996, MOL CELL BIOL, V16, P3112; Johnson CN, 2005, BIOCHEM CELL BIOL, V83, P405, DOI 10.1139/O05-115; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KELLOGG DR, 1995, J CELL BIOL, V130, P675, DOI 10.1083/jcb.130.3.675; Kepert JF, 2005, J BIOL CHEM, V280, P34063, DOI 10.1074/jbc.M507322200; Krude T, 2001, CELL MOL LIFE SCI, V58, P665, DOI 10.1007/PL00000890; LaCount DJ, 2005, NATURE, V438, P103, DOI 10.1038/nature04104; Lankenau S, 2003, GENETICS, V163, P611; Levchenko V, 2004, BIOCHEMISTRY-US, V43, P2359, DOI 10.1021/bi035737q; Li MF, 1999, J MOL BIOL, V293, P1067, DOI 10.1006/jmbi.1999.3207; Lusser A, 2005, NAT STRUCT MOL BIOL, V12, P160, DOI 10.1038/nsmb884; Lusser A, 2003, BIOESSAYS, V25, P1192, DOI 10.1002/bies.10359; Marheineke K, 1998, J BIOL CHEM, V273, P15279, DOI 10.1074/jbc.273.24.15279; Miyaji-Yamaguchi M, 2003, MOL CELL BIOL, V23, P6672, DOI 10.1128/MCB.23.18.6672-6684.2003; Ohkuni K, 2003, BIOCHEM BIOPH RES CO, V306, P5, DOI 10.1016/S0006-291X(03)00907-0; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; Penrose KJ, 2004, J BIOL CHEM, V279, P22430, DOI 10.1074/jbc.M314340200; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Raha T, 2000, PROTEIN ENG, V13, P437, DOI 10.1093/protein/13.6.437; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; Rodriguez P, 2000, J MOL BIOL, V298, P225, DOI 10.1006/jmbi.2000.3674; Rogner UC, 2000, NAT GENET, V25, P431, DOI 10.1038/78124; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Shiff C, 2002, CLIN MICROBIOL REV, V15, P278, DOI 10.1128/CMR.15.2.278-293.2002; Shintomi K, 2005, P NATL ACAD SCI USA, V102, P8210, DOI 10.1073/pnas.0500822102; Singh GP, 2004, MOL BIOCHEM PARASIT, V137, P307, DOI 10.1016/j.molbiopara.2004.05.016; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Strick R, 2001, J CELL BIOL, V155, P899, DOI 10.1083/jcb.200105026; Suthram S, 2005, NATURE, V438, P108, DOI 10.1038/nature04135; Tanaka Y, 2004, METHODS, V33, P3, DOI 10.1016/j.ymeth.2003.10.024; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4	43	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16978	16984		10.1074/jbc.M602243200	http://dx.doi.org/10.1074/jbc.M602243200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16638744	hybrid			2022-12-25	WOS:000238326300019
J	Oh, W; Lee, EW; Sung, YH; Yang, MR; Ghim, J; Lee, HW; Song, JW				Oh, Wonkyung; Lee, Eun-Woo; Sung, Young Hoon; Yang, Mi-Ran; Ghim, Jaewang; Lee, Han-Woong; Song, Jaewhan			Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-BINDING PROTEIN-1; KINASE INHIBITOR P27(KIP1); RING-FINGER DOMAIN; NUCLEAR EXPORT; COP9 SIGNALOSOME; MDM2; EXPRESSION; JAB1/CSN5; UBIQUITINATION; LIGASE	The biological mechanisms for maintaining the basal level of p53 in normal cells require nuclear exclusion and cytoplasmic degradation. Here, we showed that Jab1 facilitates p53 nuclear exclusion and its subsequent degradation in coordination with Hdm2. p53 was excluded from the nucleus in the presence of Jab1; this exclusion was prevented by leptomycin B treatment. Nuclear export of p53 was accompanied by a decrease in the levels of p53, as well as of its target proteins, which include p21 and Bax. Domain analyses of Jab1 showed that the N-terminal domain, 1-110, was capable of inducing cytoplasmic translocation of p53. Furthermore, 110-191 was required to facilitate the degradation of p53. Neither of these mutants incorporated into the CSN complex, indicating that Jab1 could affect the levels of p53 independent of intact CSN complex. Conversely, Jab1 was incapable of translocating and degrading two p53 mutants, W23S and 6KR, neither of which could be modified by Hdm2. Moreover, Jab1 did not affect the cellular localization or protein levels of p53 in p53 and Hdm2 double-null mouse embryo fibroblasts. We further observed that the ablation of endogenous Jab1 by small interfering RNA prevented Hdm2-mediated p53 nuclear exclusion. Under stressed conditions, which could sequester Hdm2 in its inactive state, Jab1 did not affect p53. Our studies implicate that Jab1 is required to remove post-translationally modified p53 and provide a novel target for p53-related cancer therapies.	Yonsei Univ, Dept Biochem, Seoul 120749, South Korea; Sungkyunkwan Univ, Fac Life Sci & Technol, Dept Food Sci & Biotechnol, Suwon 440746, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	Yonsei University; Sungkyunkwan University (SKKU); Seoul National University (SNU)	Lee, HW (corresponding author), Yonsei Univ, Dept Biochem, Seoul 120749, South Korea.	hwl@yonsei.ac.kr; jso678@skku.edu	Lee, Eun-Woo/AAP-9603-2020	Song, Jaewhan/0000-0001-8152-9210; Lee, Eun-Woo/0000-0002-5156-0003				Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Callige M, 2005, MOL CELL BIOL, V25, P4349, DOI 10.1128/MCB.25.11.4349-4358.2005; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fukumoto A, 2004, ONCOL REP, V11, P277; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Goto A, 2004, PATHOL INT, V54, P675, DOI 10.1111/j.1440-1827.2004.01679.x; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Inoue T, 2001, J BIOL CHEM, V276, P45255, DOI 10.1074/jbc.M107477200; Ito Y, 2003, ANTICANCER RES, V23, P4121; Kim BC, 2004, MOL CELL BIOL, V24, P2251, DOI 10.1128/MCB.24.6.2251-2262.2004; Korbonits M, 2002, J CLIN ENDOCR METAB, V87, P2635, DOI 10.1210/jc.87.6.2635; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Kurki S, 2003, J CELL SCI, V116, P3917, DOI 10.1242/jcs.00714; LANE DP, 1992, NATURE, V358, P16; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; LUNA RMD, 1995, NATURE, V378, P203; O'Brate A, 2003, DRUG RESIST UPDATE, V6, P313, DOI 10.1016/j.drup.2003.10.004; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shen LS, 2000, INT J ONCOL, V17, P749; Shintani S, 2003, ONCOLOGY-BASEL, V65, P355, DOI 10.1159/000074649; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; SUI L, 2003, CLIN CANCER RES, V7, P4130; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tomoda K, 2004, J BIOL CHEM, V279, P43013, DOI 10.1074/jbc.M406559200; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Yu ZK, 2000, ONCOGENE, V19, P5892, DOI 10.1038/sj.onc.1203980	43	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17457	17465		10.1074/jbc.M601857200	http://dx.doi.org/10.1074/jbc.M601857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16624822	hybrid			2022-12-25	WOS:000238326300071
J	Ceresa, E; de Borne, KV; Peeters, M; Lijnen, HR; Declerck, PJ; Gils, A				Ceresa, Erik; de Borne, Kirsten Van; Peeters, Miet; Lijnen, Henri Roger; Declerck, Paul J.; Gils, Ann			Generation of a stable activated thrombin activable fibrinolysis inhibitor variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLASMA; PROCARBOXYPEPTIDASE-U; CARBOXYPEPTIDASE-B; THERMAL-STABILITY; TAFI LEVELS; INSTABILITY; THRESHOLD; MECHANISM; RESPECT; PROTEIN	Activated thrombin activable fibrinolysis inhibitor (TAFIa), generated upon activation of TAFI, exerts an antifibrinolytic effect. TAFIa is a thermolabile enzyme, inactivated through a conformational change. The objective of the current study was to generate a stable variant of human TAFIa. Using a site-directed as well as a random mutagenesis approach to generate a library of TAFI mutants, we identified two mutations that increase TAFIa stability, i.e. a Ser(305) to Cys and a Thr(329) to Ile mutation, respectively. Combining these mutations in TAFI-Ala(147)-Ile(325), the most stable isoform of TAFIa (half-life of 9.4 +/- 0.4 min), revealed a TAFIa half-life of 70 +/- 3.1 min (i.e. an 11-fold increase versus 6.3 +/- 0.3 min for TAFIa-Ala(147)-Thr(325), the most frequently occurring isoform of TAFI in humans) at 37 C. Moreover, clot lysis ( induced by tissue plasminogen activator) experiments in which TAFI-Ala(147)-Cys(305)-Ile(325)- Ile(329) was added to TAFI-depleted plasma revealed a 50% clot lysis time of 313 +/- 77 min (i.e. a 3.0-fold increase versus 117 +/- 10 min for TAFI-Ala(147)-Thr(325)). The availability of a more stable TAFIa variant will facilitate the search for inhibitors and allow further structural analysis to elucidate the mechanisms of the instability of TAFIa.	Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fac Med, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Gils, A (corresponding author), Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, Campus Gasthuisberg,O&N2,PB 824,Herestr 49, B-3000 Louvain, Belgium.	Ann.Gils@pharm.kuleuven.be	Peeters, Marc/C-5525-2013; Declerck, Paul J/A-2330-2017; Lijnen, Roger/AAA-4085-2020	Peeters, Marc/0000-0003-4969-2303; Declerck, Paul J/0000-0003-1259-9105; 				BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; Brouwers GJ, 2001, BLOOD, V98, P1992, DOI 10.1182/blood.V98.6.1992; EATON DL, 1991, J BIOL CHEM, V266, P21833; Gils A, 2003, ARTERIOSCL THROM VAS, V23, P1122, DOI 10.1161/01.ATV.0000074145.58172.BD; Guimaraes AHC, 2004, J THROMB HAEMOST, V2, P780, DOI 10.1111/j.1538-7836.2004.00703.x; HENDRIKS D, 1989, J CLIN CHEM CLIN BIO, V27, P277; Leurs J, 2004, J THROMB HAEMOST, V2, P416, DOI 10.1111/j.1538-7836.2004.00605.x; Marx PF, 2005, J THROMB HAEMOST, V3, P1293, DOI 10.1111/j.1538-7836.2005.01322.x; Marx PF, 2004, J BIOL CHEM, V279, P6620, DOI 10.1074/jbc.M307337200; Marx PF, 2002, BIOCHEMISTRY-US, V41, P6688, DOI 10.1021/bi015982e; Mosnier LO, 1998, THROMB HAEMOSTASIS, V80, P829; Pereira PJB, 2002, J MOL BIOL, V321, P537, DOI 10.1016/S0022-2836(02)00648-4; Schatteman KA, 2000, CLIN CHIM ACTA, V292, P25, DOI 10.1016/S0009-8981(99)00205-3; Schneider M, 2003, J THROMB HAEMOST, V1, P147, DOI 10.1046/j.1538-7836.2003.00028.x; Schneider M, 2002, J BIOL CHEM, V277, P1021, DOI 10.1074/jbc.M104444200; Stromqvist M, 2001, THROMB HAEMOSTASIS, V85, P12, DOI 10.1055/s-0037-1612656; Valnickova Z, 1996, J BIOL CHEM, V271, P12937, DOI 10.1074/jbc.271.22.12937; Walker JB, 2004, J BIOL CHEM, V279, P27896, DOI 10.1074/jbc.M401027200; Walker JB, 2003, J BIOL CHEM, V278, P8913, DOI 10.1074/jbc.M205006200; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; Zhao L, 1998, THROMB HAEMOSTASIS, V80, P949	24	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15878	15883		10.1074/jbc.M509839200	http://dx.doi.org/10.1074/jbc.M509839200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595693	hybrid			2022-12-25	WOS:000237996000037
J	Chai, SC; Bruyere, JR; Maroney, MJ				Chai, Sergio C.; Bruyere, John R.; Maroney, Michael J.			Probes of the catalytic site of cysteine dioxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; DIAMINOPIMELIC ACID; CYSTINOSIS; OXIDATION; CYSTEINESULFINATE; DECARBOXYLASE; ACCUMULATION; PURIFICATION; CYSTEAMINE; EXPRESSION	The first major step of cysteine catabolism, the oxidation of cysteine to cysteine sulfinic acid, is catalyzed by cysteine dioxygenase (CDO). In the present work, we utilize recombinant rat liver CDO and cysteine derivatives to elucidate structural parameters involved in substrate recognition and x-ray absorption spectroscopy to probe the interaction of the active site iron center with cysteine. Kinetic studies using cysteine structural analogs show that most are inhibitors and that a terminal functional group bearing a negative charge ( e. g. a carboxylate) is required for binding. The substrate-binding site has no stringent restrictions with respect to the size of the amino acid. Lack of the amino or carboxyl groups at the alpha-carbon does not prevent the molecules from interacting with the active site. In fact, cysteamine is shown to be a potent activator of the enzyme without being a substrate. CDO was also rendered inactive upon complexation with the metal-binding inhibitors azide and cyanide. Unlike many non-heme iron dioxygenases that employ alpha-keto acids as cofactors, CDO was shown to be the only dioxygenase known to be inhibited by alpha-ketoglutarate.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Maroney, MJ (corresponding author), Univ Massachusetts, Dept Chem, Lederle Grad Res Tower,Room 701,710 N Pleasant St, Amherst, MA 01003 USA.	mmaroney@chem.umass.edu		Maroney, Michael/0000-0002-5598-3038; Chai, Sergio/0000-0002-8257-8599	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008515] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM008515, T32 GM08515] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGLEY PJ, 1995, J NUTR, V125, P933; BAGYINKA C, 1993, J AM CHEM SOC, V115, P3576, DOI 10.1021/ja00062a022; BROWN DT, 1988, DRUG INTEL CLIN PHAR, V22, P603, DOI 10.1177/106002808802200721; BUTLER JD, 1984, J CLIN INVEST, V74, P411, DOI 10.1172/JCI111436; Chai SC, 2005, J BIOL CHEM, V280, P9865, DOI 10.1074/jbc.M413733200; Cherqui S, 2002, MOL CELL BIOL, V22, P7622, DOI 10.1128/MCB.22.21.7622-7632.2002; Costas M, 2004, CHEM REV, V104, P939, DOI 10.1021/cr020628n; Davidson G, 2001, BIOCHEMISTRY-US, V40, P4569, DOI 10.1021/bi0018537; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; EWETZ L, 1966, BIOCHIM BIOPHYS ACTA, V128, P296, DOI 10.1016/0926-6593(66)90176-7; Fu HW, 1996, J BIOL CHEM, V271, P28541, DOI 10.1074/jbc.271.45.28541; GORDON C, 1992, LANCET, V339, P25, DOI 10.1016/0140-6736(92)90144-R; Kalatzis V, 2002, NEPHROL DIAL TRANSPL, V17, P1883, DOI 10.1093/ndt/17.11.1883; Kalatzis V, 2001, EMBO J, V20, P5940, DOI 10.1093/emboj/20.21.5940; Kang B, 1985, CHIN J STRUCT CHEM, V4, P119; KELLAND JG, 1986, J BIOL CHEM, V261, P3216; Khan S, 2004, J PHARM PHARMACOL, V56, P993, DOI 10.1211/0022357043897; LAM LKP, 1988, J BIOL CHEM, V263, P11814; LEHNERT R, 1978, Z ANORG ALLG CHEM, V444, P91, DOI 10.1002/zaac.19784440109; LOMBARDINI JB, 1969, J BIOL CHEM, V244, P1172; McCoy JG, 2006, P NATL ACAD SCI USA, V103, P3084, DOI 10.1073/pnas.0509262103; NOVELLI GD, 1954, J BIOL CHEM, V206, P533; PERRY TL, 1985, ANN NEUROL, V18, P482, DOI 10.1002/ana.410180411; Ressler T, 1997, J PHYS IV, V7, P269, DOI 10.1051/jp4/1997195; ROE AL, 1984, J AM CHEM SOC, V106, P1676, DOI 10.1021/ja00318a021; Ryle MJ, 2002, CURR OPIN CHEM BIOL, V6, P193, DOI 10.1016/S1367-5931(02)00302-2; SAKAKIBARA S, 1976, BIOCHIM BIOPHYS ACTA, V422, P273, DOI 10.1016/0005-2744(76)90138-8; SORBO B, 1965, BIOCHEM BIOPH RES CO, V18, P359, DOI 10.1016/0006-291X(65)90714-X; Stipanuk MH, 2004, AM J PHYSIOL-ENDOC M, V286, pE439, DOI 10.1152/ajpendo.00336.2003; Tsilou ET, 2003, BRIT J OPHTHALMOL, V87, P28, DOI 10.1136/bjo.87.1.28; Uden PC, 2004, J ANAL ATOM SPECTROM, V19, P65, DOI 10.1039/b307508g; WEINSTEIN CL, 1988, J BIOL CHEM, V263, P16568; Wilkinson LJ, 2002, TOXICOL IN VITRO, V16, P481, DOI 10.1016/S0887-2333(02)00031-0	33	36	37	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15774	15779		10.1074/jbc.M601269200	http://dx.doi.org/10.1074/jbc.M601269200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16611641	hybrid			2022-12-25	WOS:000237996000025
J	Kim, H; Livingston, DM				Kim, Haeyoung; Livingston, Dennis M.			A high mobility group protein binds to long CAG repeat tracts and establishes their chromatin organization in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY GENE; DNA-LIGASE-I; TRINUCLEOTIDE REPEATS; TRIPLET REPEATS; HUMAN-DISEASE; POSITIONED NUCLEOSOMES; LINKER HISTONES; BOX PROTEIN; CTG REPEATS; YEAST	Long CAG repeat tracts cause human hereditary neurodegenerative diseases and have a propensity to expand during parental passage. Unusual physical properties of CAG repeat tracts are thought to contribute to their instability. We investigated whether their unusual properties alter the organization of CAG repeat tract chromatin. We report that CAG repeat tracts, embedded in yeast chromosomes, have a noncanonical chromatin organization. Digestion of chromatin with the restriction enzyme Fnu4HI reveals hypersensitive sites occurring similar to 125 bp apart in the repeat tract. To determine whether a non-histone protein establishes this pattern, we performed a yeast one-hybrid screen using CAG repeat tracts embedded in front of two reporter genes. The screen identified the high mobility group box protein Hmo1. Chromatin immunoprecipitation of epitope-tagged Hmo1 selectively precipitates CAG repeat tracts DNAs that range from 26 to 126 repeat units. Moreover, deletion of HMO1 drastically alters the Fnu4HI digestion pattern of CAG repeat chromatin. These results show that Hmo1 binds to CAG repeat tracts in vivo and establish the basis of their novel chromatin organization.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Livingston, DM (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 321 Church St SE, Minneapolis, MN 55455 USA.	livin001@umn.edu	Kim, Haeyoung/C-3069-2008		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R43NS041823] Funding Source: NIH RePORTER; NINDS NIH HHS [NS41823] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; An WJ, 1998, J BIOL CHEM, V273, P26289, DOI 10.1074/jbc.273.41.26289; Asleson EN, 2003, GENETICS, V163, P91; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Chafin DR, 2000, EMBO J, V19, P5492, DOI 10.1093/emboj/19.20.5492; Chastain PD, 1998, J MOL BIOL, V275, P405, DOI 10.1006/jmbi.1997.1502; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; DORNFELD KJ, 1991, MOL CELL BIOL, V11, P2013, DOI 10.1128/MCB.11.4.2013; Everett CM, 2004, BRAIN, V127, P2385, DOI 10.1093/brain/awh278; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; GACY AM, 1995, CELL, V81, P533; Gadal O, 2002, EMBO J, V21, P5498, DOI 10.1093/emboj/cdf539; GAILLARD C, 1994, SCIENCE, V264, P433, DOI 10.1126/science.8153633; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Godde JS, 1996, J BIOL CHEM, V271, P15222, DOI 10.1074/jbc.271.25.15222; Ireland MJ, 2000, GENETICS, V155, P1657; James P, 1996, GENETICS, V144, P1425; Kamau E, 2004, J BIOL CHEM, V279, P55234, DOI 10.1074/jbc.M409459200; Keener J, 1997, P NATL ACAD SCI USA, V94, P13458, DOI 10.1073/pnas.94.25.13458; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Lipford JR, 2001, MOL CELL, V7, P21, DOI 10.1016/S1097-2765(01)00151-4; LOWARY PT, 1989, P NATL ACAD SCI USA, V86, P8266, DOI 10.1073/pnas.86.21.8266; Lu J, 1996, J BIOL CHEM, V271, P33678, DOI 10.1074/jbc.271.52.33678; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Mulvihill DJ, 2005, J BIOL CHEM, V280, P4498, DOI 10.1074/jbc.M413239200; Nightingale K, 1996, EMBO J, V15, P548, DOI 10.1002/j.1460-2075.1996.tb00387.x; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; Pearson CE, 1997, HUM MOL GENET, V6, P1117, DOI 10.1093/hmg/6.7.1117; Refsland EW, 2005, GENETICS, V171, P923, DOI 10.1534/genetics.105.043448; Ricke RM, 2004, MOL CELL, V16, P173, DOI 10.1016/j.molcel.2004.09.017; Schweitzer JK, 1997, HUM MOL GENET, V6, P349, DOI 10.1093/hmg/6.3.349; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Suda T, 1996, NUCLEIC ACIDS RES, V24, P4733, DOI 10.1093/nar/24.23.4733; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; THOMAS JO, 1976, FEBS LETT, V66, P274, DOI 10.1016/0014-5793(76)80521-2; Travers AA, 2003, EMBO REP, V4, P131, DOI 10.1038/sj.embor.embor741; Vicent GP, 2004, MOL CELL, V16, P439, DOI 10.1016/j.molcel.2004.10.025; Vriz S, 1995, BIOCHEM MOL BIOL INT, V37, P1137; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Widlund HR, 1997, J MOL BIOL, V267, P807, DOI 10.1006/jmbi.1997.0916; WOLFFE AP, 1998, CHROMATIN, P30; Zlatanova J, 1999, CRIT REV EUKAR GENE, V9, P245, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.90	49	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15735	15740		10.1074/jbc.M512816200	http://dx.doi.org/10.1074/jbc.M512816200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16603770	hybrid			2022-12-25	WOS:000237996000020
J	Mimura, F; Yamagishi, S; Arimura, N; Fujitani, M; Kubo, T; Kaibuchi, K; Yamashita, T				Mimura, Fumiaki; Yamagishi, Satoru; Arimura, Nariko; Fujitani, Masashi; Kubo, Takekazu; Kaibuchi, Kozo; Yamashita, Toshihide			Myelin-associated glycoprotein inhibits microtubule assembly by a rho-kinase-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD-INJURY; NEURITE OUTGROWTH; NOGO RECEPTOR; AXON GROWTH; SIGNALING PATHWAYS; CRMP-2; PHOSPHORYLATION; ACTIVATION; INTERACTS; PROTEIN	Myelin-associated glycoprotein (MAG) and Nogo are potent inhibitors of neurite outgrowth from a variety of neurons, and they have been identified as possible components of the central nervous system myelin that prevents axonal regeneration in the adult vertebrate central nervous system. The activation of RhoA and Rho-kinase is reported to be an essential part of the signaling mechanism of these proteins. Here, we report that the collapsing response mediator protein-2 (CRMP-2) is phosphorylated by a Rho-kinase-dependent mechanism downstream of MAG or Nogo-66. The over-expression of the nonphosphorylated form of CRMP-2 at threonine 555, which is the phosphorylation site for Rho-kinase, counteracts the inhibitory effect of MAG on the postnatal cerebellar neurons. Additionally, the expression of the dominant negative form of CRMP-2 or knockdown of the gene using small interference RNA (siRNA) mimics the effect of MAG in vitro. Consistent with the function of CRMP-2, which promotes microtubule assembly, microtubule levels are down-regulated in the cerebellar neurons that are stimulated with MAG in vitro. Reduction in the density of microtubules is also observed in the injured axons following the spinal cord injury, and this effect depends on the Rho-kinase activity. Our data suggest the important roles of CRMP-2 and microtubules in the inhibition of the axon regeneration by the myelin-derived inhibitors.	Chiba Univ, Grad Sch Med, Dept Neurobiol, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Anesthesiol, Chuo Ku, Chiba 2608670, Japan; Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Showa Ku, Nagoya, Aichi 4668550, Japan	Chiba University; Chiba University; Nagoya University	Yamashita, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Neurobiol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	t-yamashita@faculty.chiba-u.jp	Fujitani, Masashi/AAD-8874-2022	Fujitani, Masashi/0000-0002-1731-9793; Yamashita, Toshihide/0000-0003-4559-7018				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Arimura N, 2005, MOL CELL BIOL, V25, P9973, DOI 10.1128/MCB.25.22.9973-9984.2005; Arimura N, 2004, J NEUROBIOL, V58, P34, DOI 10.1002/neu.10269; Baas Peter W., 2001, Neuron, V32, P981, DOI 10.1016/S0896-6273(01)00556-6; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; BROWN A, 1992, J CELL BIOL, V119, P867, DOI 10.1083/jcb.119.4.867; Challacombe JF, 1997, J NEUROSCI, V17, P3085; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; EDSTROM A, 1975, VIRCHOWS ARCH B, V19, P101; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; GORDONWEEKS PR, 1991, BIOESSAYS, V13, P235, DOI 10.1002/bies.950130506; He Y, 2002, J NEUROSCI, V22, P5982; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; LIN CH, 1993, J CELL BIOL, V121, P1369, DOI 10.1083/jcb.121.6.1369; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Madura T, 2004, EMBO REP, V5, P412, DOI 10.1038/sj.embor.7400117; McKerracher L, 2002, NEURON, V36, P345, DOI 10.1016/S0896-6273(02)01018-8; Ng JL, 2004, NEURON, V44, P779, DOI 10.1016/j.neuron.2004.11.014; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975; Yamagishi S, 2005, J BIOL CHEM, V280, P20384, DOI 10.1074/jbc.M501945200; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011	39	121	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15970	15979		10.1074/jbc.M510934200	http://dx.doi.org/10.1074/jbc.M510934200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595691	hybrid			2022-12-25	WOS:000237996000048
J	Xu, Y; Williams, SJ; O'Brien, D; Davidge, ST				Xu, Yi; Williams, Sarah J.; O'Brien, Darryl; Davidge, Sandra T.			Hypoxia or nutrient restriction during pregnancy in rats leads to progressive cardiac remodeling and impairs postischemic recovery in adult male offspring	FASEB JOURNAL			English	Article						cardiac development; ischemia; reperfusion	INTRAUTERINE GROWTH RESTRICTION; FOR-GESTATIONAL-AGE; CARDIOVASCULAR-DISEASE; FIBRILLAR COLLAGEN; MATERNAL HYPOXIA; GENE-EXPRESSION; FETAL-GROWTH; RETARDATION; CARDIOPROTECTION; HYPERTENSION	Intrauterine growth restriction ( IUGR) increases the risk of developing adult-onset cardiovascular disease. We hypothesized that IUGR resulting from maternal hypoxia or nutrient restriction during late gestation will produce cardiac remodeling and impair cardiac recovery after ischemia/reperfusion (I/R) in adult male offspring aged 4 or 7 mo. Sprague-Dawley rats were randomized on day 15 of pregnancy to hypoxia (IUGR-H, 12% oxygen), nutrient restriction (IUGR-NR, 40% of control diet) or control ( room air) groups. In 4-mo IUGR-H offspring, left ventricular wt/body wt ratio (LVW/BW) and right ventricular wt/BW ratio (RVW/BW) increased, in association with increased collagen I and III expression, beta and alpha myosin heavy chain (beta/alpha MHC) ratio, and decreased matrix metalloproteinase (MMP)-2 activity compared to the other groups. Left ventricular end diastolic pressure was higher in perfused hearts. Functional recovery after I/R was remarkably reduced (10 +/- 3%) compared to both control (39 +/- 5%) and IUGR-NR rats (32 +/- 4%). At 7 mo, both IUGR-H and IUGR-NR offspring had increased LVW/BW, collagen I and III, beta/alpha MHC ratio, and decreased cardiac recovery and MMP-2 activity compared to control. These findings suggest that hypoxia or undernutrition during development leads to pathological cardiac remodeling, diastolic dysfunction, and increased sensitivity to ischemic injury during adult life.-Xu, Y., Williams, S. J. O'Brien, D., and Davidge, S. T. Hypoxia or nutrient restriction during pregnancy in rats leads to progressive cardiac remodeling and impairs postischemic recovery in adult male offspring.	Univ Alberta, Perinatal Res Ctr, Dept Obstet Gynecol & Physiol, Edmonton, AB T6G 2S2, Canada; Univ Adelaide, Dept Physiol, Ctr Early Origins Adult Hlth, Sch Mol & Biomed Sci, Adelaide, SA, Australia	University of Alberta; University of Adelaide	Davidge, ST (corresponding author), Univ Alberta, Perinatal Res Ctr, Dept Obstet Gynecol & Physiol, 232 HMRC, Edmonton, AB T6G 2S2, Canada.	sandra.davidge@ualberta.ca		Davidge, Sandra/0000-0002-5559-4905				ALPERT NR, 1982, FED PROC, V41, P192; ALPERT NR, 1979, AM J CARDIOL, V44, P947, DOI 10.1016/0002-9149(79)90227-3; Barker DJP, 2002, TRENDS ENDOCRIN MET, V13, P364, DOI 10.1016/S1043-2760(02)00689-6; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; Battista MC, 2005, J PHYSIOL-LONDON, V565, P197, DOI 10.1113/jphysiol.2004.078139; BERSOHN MM, 1977, CIRC RES, V40, P510, DOI 10.1161/01.RES.40.5.510; Briscoe TA, 2004, AM J OBSTET GYNECOL, V191, P847, DOI 10.1016/j.ajog.2004.01.050; BUTTRICK P, 1991, CIRC RES, V68, P645, DOI 10.1161/01.RES.68.3.645; Corstius HB, 2005, PEDIATR RES, V57, P796, DOI 10.1203/01.PDR.0000157726.65492.CD; de Onis M, 1998, EUR J CLIN NUTR, V52, pS5; DEGRAUW TJ, 1986, BIOL NEONATE, V49, P85, DOI 10.1159/000242515; EGHBALI M, 1988, J MOL CELL CARDIOL, V20, P267, DOI 10.1016/S0022-2828(88)80059-2; EGHBALI M, 1990, MOL CELL BIOCHEM, V96, P1; GLEED RD, 1991, J APPL PHYSIOL, V70, P1146, DOI 10.1152/jappl.1991.70.3.1146; Godfrey KM, 2000, AM J CLIN NUTR, V71, p1344S, DOI 10.1093/ajcn/71.5.1344s; Han HC, 2004, J PHYSIOL-LONDON, V558, P111, DOI 10.1113/jphysiol.2004.061697; Harada K, 1998, EARLY HUM DEV, V51, P197, DOI 10.1016/S0378-3782(97)00122-9; Hemmings DG, 2005, AM J PHYSIOL-HEART C, V289, pH674, DOI 10.1152/ajpheart.00191.2005; Kamitomo M, 2002, J SOC GYNECOL INVEST, V9, P335, DOI 10.1016/S1071-5576(02)00180-6; Kumaran K, 2000, HEART, V83, P272, DOI 10.1136/heart.83.3.272; Leipala JA, 2003, PEDIATR RES, V53, P989, DOI 10.1203/01.PDR.0000061564.86797.78; Li GH, 2003, J SOC GYNECOL INVEST, V10, P265, DOI 10.1016/S1071-5576(03)00074-1; McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Ostadalova I, 2002, PEDIATR RES, V52, P561, DOI 10.1203/01.PDR.0000030879.20888.5B; POPE B, 1980, FEBS LETT, V118, P205, DOI 10.1016/0014-5793(80)80219-5; Reiser PJ, 2001, AM J PHYSIOL-HEART C, V280, pH1814, DOI 10.1152/ajpheart.2001.280.4.H1814; Robert V, 1997, LAB INVEST, V76, P729; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; TAKAHASHI T, 1992, J CLIN INVEST, V89, P939, DOI 10.1172/JCI115675; Tsyvian P, 2002, ULTRASOUND OBST GYN, V20, P35, DOI 10.1046/j.1469-0705.2002.00734.x; VANGEIJN HP, 1980, AM J OBSTET GYNECOL, V137, P43, DOI 10.1016/0002-9378(80)90384-1; VEILLE JC, 1993, AM J PERINAT, V10, P275, DOI 10.1055/s-2007-994739; WEBER KT, 1988, AM HEART J, V116, P1641, DOI 10.1016/0002-8703(88)90763-6; WEBER KT, 1990, CIRCULATION, V82, P1387, DOI 10.1161/01.CIR.82.4.1387; WEBER KT, 1989, J AM COLL CARDIOL, V13, P1637, DOI 10.1016/0735-1097(89)90360-4; Williams SJ, 2005, J PHYSIOL-LONDON, V565, P125, DOI 10.1113/jphysiol.2005.084889; Williams SJ, 2005, AM J PHYSIOL-REG I, V288, pR360, DOI 10.1152/ajpregu.00178.2004; Xi L, 1999, LIFE SCI, V65, P935, DOI 10.1016/S0024-3205(99)00323-9; Xiao DL, 2000, J SOC GYNECOL INVEST, V7, P279, DOI 10.1016/S1071-5576(00)00066-6; Xu Y, 2000, HYPERTENSION, V36, P506, DOI 10.1161/01.HYP.36.4.506; Xu Y, 2004, AM J PHYSIOL-HEART C, V287, pH165, DOI 10.1152/ajpheart.00037.2004; Xu Y, 2003, CARDIOVASC RES, V57, P388, DOI 10.1016/S0008-6363(02)00705-8; Xu Y, 2002, AM J PHYSIOL-HEART C, V282, pH1206, DOI 10.1152/ajpheart.00839.2000	45	142	148	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1251	+		10.1096/fj.05-4917fje	http://dx.doi.org/10.1096/fj.05-4917fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16632594				2022-12-25	WOS:000240210300042
J	Sung, YM; He, G; Hwang, DH; Fischer, SM				Sung, Y. M.; He, G.; Hwang, D. H.; Fischer, S. M.			Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development	ONCOGENE			English	Article						prostaglandin E2; EP2 transgenic mice; proliferation; angiogenesis; skin carcinogenesis	NF-KAPPA-B; MULTISTAGE CARCINOGENESIS; GROWTH-FACTOR; SUBTYPE EP4; MOUSE SKIN; EXPRESSION; CELLS; E-2; PROMOTION; APOPTOSIS	We previously showed that the EP2 knockout mice were resistant to chemically induced skin carcinogenesis. The purpose of this study was to investigate the role of the overexpression of the EP2 receptor in mouse skin carcinogenesis. To determine the effect of overexpression of EP2, we used EP2 transgenic (TG) mice and wild-type (WT) mice in a DMBA (7,12-dimethylbenz[alpha]anthracene)/TPA (12-O-tetradecanoylphorbol-13-acetate) two-stage carcinogenesis protocol. EP2 TG mice developed significantly more tumors compared with WT mice. Overexpression of the EP2 receptor increased TPA-induced keratinocyte proliferation both in vivo and in vitro. In addition, the epidermis of EP2 TG mice 48 h after topical TPA treatment was significantly thicker compared to that of WT mice. EP2 TG mice showed significantly increased cyclic adenosine monophosphate levels in the epidermis after prostaglandin E2 (PGE2) treatment. The inflammatory response to TPA was increased in EP2 TG mice, as demonstrated by an increased number of macrophages in the dermis. Tumors and 7 x TPA-treated and DMBA-TPA-treated ( 6 weeks) skins from EP2 TG mice produced more blood vessels than those of WT mice as determined by CD-31 immunostaining. Vascular endothelial growth factor (VEGF) protein expression was significantly increased in squamous cell carcinoma (SCC) samples from EP2 TG mice compared that of WT mice. There was, however, no difference in the number of apoptotic cells in tumors from WT and EP2 TG mice. Together, our results suggest that the overexpression of the EP2 receptor plays a significant role in the protumorigenic action of PGE2 in mouse skin.	Univ Texas, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA; Univ Calif Davis, USDA, ARS, Western Human Nutr Res Ctr, Davis, CA 95616 USA	University of Texas System; UTMD Anderson Cancer Center; United States Department of Agriculture (USDA); University of California System; University of California Davis	Fischer, SM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA.	smficher@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672, R01CA100140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA100140] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chang SH, 2005, PROSTAG OTH LIPID M, V76, P48, DOI 10.1016/j.prostaglandins.2004.12.001; Chang SH, 2005, CANCER RES, V65, P4496, DOI 10.1158/0008-5472.CAN-05-0129; Conconi MT, 1996, ANN ANAT, V178, P229, DOI 10.1016/S0940-9602(96)80055-0; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; FISCHER SM, 1990, CARCINOGENESIS, V11, P991, DOI 10.1093/carcin/11.6.991; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; FURSTENBERGER G, 1989, CARCINOGENESIS, V10, P91, DOI 10.1093/carcin/10.1.91; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; Kawamori T, 2005, CARCINOGENESIS, V26, P353, DOI 10.1093/carcin/bgh322; Kitamura T, 2003, CANCER SCI, V94, P618, DOI 10.1111/j.1349-7006.2003.tb01492.x; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; MULLERDECKER K, 1995, MOL CARCINOGEN, V12, P31, DOI 10.1002/mc.2940120106; Murphy JE, 2003, J IMMUNOL, V170, P5697, DOI 10.4049/jimmunol.170.11.5697; Mutoh M, 2002, CANCER RES, V62, P28; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Seno H, 2002, CANCER RES, V62, P506; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Shao JY, 2003, CANCER RES, V63, P5218; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sheng HM, 1998, CANCER RES, V58, P362; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Sung YM, 2005, CANCER RES, V65, P9304, DOI 10.1158/0008-5472.CAN-05-1015; Suzukawa K, 2002, ENVIRON HEALTH PERSP, V110, P865, DOI 10.1289/ehp.02110865; Tiano HF, 2002, CANCER RES, V62, P3395; Ueda T, 2001, FEBS LETT, V491, P40, DOI 10.1016/S0014-5793(01)02145-7; Watanabe H, 1999, ANN ONCOL, V10, P136, DOI 10.1023/A:1008330012536; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3	31	52	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5507	5516		10.1038/sj.onc.1209538	http://dx.doi.org/10.1038/sj.onc.1209538			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16607275				2022-12-25	WOS:000240370400004
J	Lin-Lee, YC; Pham, LV; Tamayo, AT; Fu, LC; Zhou, HJ; Yoshimura, LC; Decker, GL; Ford, RJ				Lin-Lee, Yen-Chiu; Pham, Lan V.; Tamayo, Archito T.; Fu, Lingchen; Zhou, Hai-Jun; Yoshimura, Linda C.; Decker, Glenn L.; Ford, Richard J.			Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; T-CELL-RECEPTOR; ACTIVATION; BINDING; PROTEIN; GENE; SURVIVAL; BAFF; IDENTIFICATION	CD40 is a tumor necrosis factor (TNF) receptor superfamily, (TNFR; TNFRSF-5) member, that initiates important signaling pathways mediating cell growth, survival, and differentiation in B-lymphocytes. Although CD40 has been extensively studied as a plasma membrane- associated growth factor receptor, we demonstrate here that CD40 is present not only in the plasma membrane and cytoplasm but also in the nucleus of normal and neoplastic B-lymphoid cells. Confocal microscopy showed that transfected CD40-green fluorescent fusion protein entered B-cell nuclei. The CD40 protein contains a nuclear localization signal sequence that, when mutated, blocks entry of CD40 into the nucleus through the classic karyopherins (importins-alpha/beta) pathway. Nuclear fractionation studies revealed the presence of CD40 protein in the nucleoplasm fraction of activated B cells, and chromatin immunoprecipitation assays demonstrated that CD40 binds to and stimulates the BLyS/BAFF promoter, another TNF family member (TNFSF-13B) involved in cell survival in the B cell lineage. Like other nuclear growth factor receptors, CD40 appears to be a transcriptional regulator and is likely to play a larger and more complex role than previously demonstrated in regulating essential growth and survival pathways in B- lymphocytes.	Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Ford, RJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rford@mdanderson.org			NCI NIH HHS [CA-16672-26, CA-R01-100836] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100836, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Brodeur SR, 2003, IMMUNITY, V18, P837, DOI 10.1016/S1074-7613(03)00149-3; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Cheng Genhong, 2002, Curr Dir Autoimmun, V5, P51; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; FORD RJ, 1990, BLOOD, V75, P1311; FOY TM, 1993, J EXP MED, V178, P1567, DOI 10.1084/jem.178.5.1567; FU L, 2006, IN PRESS BLOOD; Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241; Girouard J, 2005, MOL IMMUNOL, V42, P773, DOI 10.1016/j.molimm.2004.07.048; Hakkarainen T, 2003, CLIN CANCER RES, V9, P619; Hanks BA, 2005, NAT MED, V11, P130, DOI 10.1038/nm1183; He B, 2004, J IMMUNOL, V172, P3268, DOI 10.4049/jimmunol.172.5.3268; Huang XG, 2004, P NATL ACAD SCI USA, V101, P17789, DOI 10.1073/pnas.0406111101; Inoue Y, 2004, J IMMUNOL, V172, P2147, DOI 10.4049/jimmunol.172.4.2147; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Krolewski JJ, 2005, J CELL BIOCHEM, V95, P478, DOI 10.1002/jcb.20451; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Mackay F, 2003, CYTOKINE GROWTH F R, V14, P311, DOI 10.1016/S1359-6101(03)00023-6; McCabe CD, 2005, NUCLEIC ACIDS RES, V33, P6782, DOI 10.1093/nar/gki979; Mecklenbrauker I, 2004, NATURE, V431, P456, DOI 10.1038/nature02955; Min W, 1998, J IMMUNOL, V161, P319; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NONOYAMA S, 1993, J EXP MED, V178, P1097, DOI 10.1084/jem.178.3.1097; OTTO H, 1992, NEUROCHEM INT, V21, P409, DOI 10.1016/0197-0186(92)90192-T; Patke A, 2004, CURR OPIN IMMUNOL, V16, P251, DOI 10.1016/j.coi.2004.01.007; Peng H, 2002, J NEUROCHEM, V81, P506, DOI 10.1046/j.1471-4159.2002.00833.x; Pham LV, 2003, J IMMUNOL, V171, P88, DOI 10.4049/jimmunol.171.1.88; Pham LV, 2002, IMMUNITY, V16, P37, DOI 10.1016/S1074-7613(01)00258-8; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; Reyes-Moreno C, 2004, J BIOL CHEM, V279, P7799, DOI 10.1074/jbc.M313168200; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Serra P, 2003, IMMUNITY, V19, P877, DOI 10.1016/S1074-7613(03)00327-3; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Weil R, 2004, CURR OPIN IMMUNOL, V16, P374, DOI 10.1016/j.coi.2004.03.003; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wells A, 2002, NAT REV MOL CELL BIO, V3, P697, DOI 10.1038/nrm905; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101	52	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18878	18887		10.1074/jbc.M513315200	http://dx.doi.org/10.1074/jbc.M513315200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16644731	hybrid			2022-12-25	WOS:000238687300068
J	Schiller, MR; Chakrabarti, K; King, GF; Schiller, NI; Eipper, BA; Maciejewski, MW				Schiller, Martin R.; Chakrabarti, Kausik; King, Glenn F.; Schiller, Noraisha I.; Eipper, Betty A.; Maciejewski, Mark W.			Regulation of RhoGEF activity by intramolecular and intermolecular SH3 domain interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; SRC HOMOLOGY-3 DOMAINS; STRUCTURAL BASIS; TYROSINE KINASE; PLECKSTRIN HOMOLOGY; COUPLING-CONSTANTS; AXON GUIDANCE; V-CRK; BINDING; ACTIVATION	RhoGEFs are central controllers of small G-proteins in cells and are regulated by several mechanisms. There are at least 22 human RhoGEFs that contain SH3 domains, raising the possibility that, like several other enzymes, SH3 domains control the enzymatic activity of guanine nucleotide exchange factor (GEF) domains through intra- and/or intermolecular interactions. The structure of the N-terminal SH3 domain of Kalirin was solved using NMR spectroscopy, and it folds much like other SH3 domains. However, NMR chemical shift mapping experiments showed that this Kalirin SH3 domain is unique, containing novel cooperative binding site(s) for intramolecular PXXP ligands. Intramolecular Kalirin SH3 domain/ligand interactions, as well as binding of the Kalirin SH3 domain to the adaptor protein Crk, inhibit the GEF activity of Kalirin. This study establishes a novel molecular mechanism whereby intramolecular and intermolecular Kalirin SH3 domain/ligand interactions modulate GEF activity, a regulatory mechanism that is likely used by other RhoGEF family members.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06019 USA; Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT 06019 USA; Univ Connecticut, Ctr Hlth, Ctr Struct Biol, Farmington, CT 06019 USA	University of Connecticut; University of Connecticut; University of Connecticut	Schiller, MR (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06019 USA.	schiller@nso.uchc.edu	King, Glenn F/J-5059-2012	King, Glenn F/0000-0002-2308-2200; Schiller, Martin R/0000-0003-1671-6823	NIDDK NIH HHS [DK32948] Funding Source: Medline; NIMH NIH HHS [MH65567] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032948, R37DK032948, R56DK032948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH065567] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Ago T, 2003, P NATL ACAD SCI USA, V100, P4474, DOI 10.1073/pnas.0735712100; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Barnett P, 2000, EMBO J, V19, P6382, DOI 10.1093/emboj/19.23.6382; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Brasher BB, 2001, ONCOGENE, V20, P7744, DOI 10.1038/sj.onc.1204978; Brazin KN, 2000, J MOL BIOL, V302, P607, DOI 10.1006/jmbi.2000.4091; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Chakrabarti K, 2005, MOL CELL BIOL, V25, P5106, DOI 10.1128/MCB.25.12.5106-5118.2005; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Estrach S, 2002, CURR BIOL, V12, P307, DOI 10.1016/S0960-9822(02)00658-9; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Ferreon JC, 2003, PROTEIN SCI, V12, P982, DOI 10.1110/ps.0238003; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Gmeiner WH, 2001, CELL BIOCHEM BIOPHYS, V35, P115, DOI 10.1385/CBB:35:2:115; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hansson H, 2001, FEBS LETT, V489, P67, DOI 10.1016/S0014-5793(00)02438-8; Harkiolaki M, 2003, EMBO J, V22, P2571, DOI 10.1093/emboj/cdg258; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUSTEN EJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P487, DOI 10.1006/abbi.1994.1336; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kim K, 2004, BIOCHEMISTRY-US, V43, P2422, DOI 10.1021/bi036173t; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; Kubiseski TJ, 2003, MOL CELL BIOL, V23, P6823, DOI 10.1128/MCB.23.19.6823-6835.2003; Kutsche K, 2000, NAT GENET, V26, P247, DOI 10.1038/80002; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; May V, 2002, J NEUROSCI, V22, P6980; Mayer BJ, 2001, J CELL SCI, V114, P1253; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Nakashima K, 1999, BIOCHEMISTRY-US, V38, P98, DOI 10.1021/bi982067t; Nishida M, 2001, EMBO J, V20, P2995, DOI 10.1093/emboj/20.12.2995; Ogura K, 2002, J BIOMOL NMR, V22, P37, DOI 10.1023/A:1013868731495; Penzes P, 2000, J BIOL CHEM, V275, P6395, DOI 10.1074/jbc.275.9.6395; Pires JR, 2003, J MOL BIOL, V326, P1427, DOI 10.1016/S0022-2836(03)00039-1; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Pursglove SE, 2002, J BIOL CHEM, V277, P755, DOI 10.1074/jbc.M108318200; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Schiller MR, 2005, EXP CELL RES, V307, P402, DOI 10.1016/j.yexcr.2005.03.024; Seabold GK, 2003, J BIOL CHEM, V278, P15040, DOI 10.1074/jbc.M212825200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Spencer AG, 2001, P NATL ACAD SCI USA, V98, P13132, DOI 10.1073/pnas.241504098; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; Vaynberg J, 2005, MOL CELL, V17, P513, DOI 10.1016/j.molcel.2004.12.031; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1993, J BIOMOL NMR, V3, P67; Weinstein DE, 1999, DEV BRAIN RES, V116, P29, DOI 10.1016/S0165-3806(99)00072-3; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Yuzawa S, 2004, J BIOL CHEM, V279, P29752, DOI 10.1074/jbc.M401457200; Zamanian JL, 2003, MOL BIOL CELL, V14, P1624, DOI 10.1091/mbc.E02-08-0494; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200; Zhang H, 2001, J BIOL CHEM, V276, P45598, DOI 10.1074/jbc.M107176200; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	72	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18774	18786		10.1074/jbc.M512482200	http://dx.doi.org/10.1074/jbc.M512482200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16644733	hybrid			2022-12-25	WOS:000238687300058
J	Bruchas, MR; Macey, TA; Lowe, JD; Chavkin, C				Bruchas, Michael R.; Macey, Tara A.; Lowe, Janet D.; Chavkin, Charles			Kappa opioid receptor activation of p38 MAPK is GRK3-and arrestin-dependent in neurons and astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; KINASE-C; TYROSINE KINASES; SALVINORIN-A; FAMILY; CELLS; SRC; SIGNALS; CASCADE	AtT-20 cells expressing the wild-type kappa opioid receptor (KOR) increased phospho-p38 MAPK following treatment with the kappa agonist U50,488. The increase was blocked by the kappa antagonist norbinaltorphimine and not evident in untransfected cells. In contrast, U50,488 treatment of AtT-20 cells expressing KOR having alanine substituted for serine-369 (KSA) did not increase phospho-p38. Phosphorylation of serine 369 in the KOR carboxyl terminus by G-protein receptor kinase 3 (GRK3) was previously shown to be required for receptor desensitization, and the results suggest that p38 MAPK activation by KOR may require arrestin recruitment. This hypothesis was tested by transfecting arrestin3-(R170E), a dominant positive form of arrestin that does not require receptor phosphorylation for activation. AtT-20 cells expressing both KSA and arrestin3-(R170E) responded to U50,488 treatment with an increase in phospho-p38 consistent with the hypothesis. Primary cultured astrocytes (glial fibrillary acidic protein-positive) and neurons (gamma-aminobutyric acid-positive) isolated from mouse striata also responded to U50,488 by increasing phos-pho-p38 immunolabeling. p38 activation was not evident in either striatal astrocytes or neurons isolated from KOR knock-out mice or GRK3 knock-out mice. Astrocytes pretreated with small interfering RNA for arrestin3 were also unable to activate p38 in response to U50,488 treatment. Furthermore, in striatal neurons, the kappa-mediated phos-pho-p38 labeling was colocalized with arrestin3. These findings suggest that KOR may activate p38 MAPK in brain by a GRK3 and arrestin-dependent mechanism.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Chavkin, C (corresponding author), Univ Washington, Dept Pharmacol, Box 357280,1959 Pacific Ave NE, Seattle, WA 98195 USA.	cchavkin@u.washington.edu	Chavkin, Charles/G-2797-2010; Bruchas, Michael/G-7616-2012		NIDA NIH HHS [P01 DA015916-04, P01 DA015916-05, T32 DA007278, F32 DA020430, R01 DA011672-03, P01 DA 15916, T32 DA007278-14, R01 DA011672, R01 DA011672-04, F32 DA 20430, P01 DA015916] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011672, P01DA015916, F32DA020430, T32DA007278] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Beaulieu JM, 2005, CELL, V122, P261, DOI 10.1016/j.cell.2005.05.012; Belcheva MM, 2005, J BIOL CHEM, V280, P27662, DOI 10.1074/jbc.M502593200; Bohn LM, 2000, J NEUROCHEM, V74, P564, DOI 10.1046/j.1471-4159.2000.740564.x; BOLSHAKOV VY, 2000, NATURE, V11, P1107; Brewer GJ, 1997, J NEUROSCI METH, V71, P143, DOI 10.1016/S0165-0270(96)00136-7; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; Chan ASL, 2005, J NEUROCHEM, V94, P1457, DOI 10.1111/j.1471-4159.2005.03304.x; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; Chavkin C, 2004, J PHARMACOL EXP THER, V308, P1197, DOI 10.1124/jpet.103.059394; DeLeo JA, 2001, PAIN, V90, P1, DOI 10.1016/S0304-3959(00)00490-5; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dhawan BN, 1996, PHARMACOL REV, V48, P567; GUTKIND JS, 2000, SCI STKE, V40; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hunton DL, 2005, MOL PHARMACOL, V67, P1229, DOI 10.1124/mol.104.006270; Kam AYF, 2004, J PHARMACOL EXP THER, V310, P301, DOI 10.1124/jpet.104.065078; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Lackey K, 2000, BIOORG MED CHEM LETT, V10, P223, DOI 10.1016/S0960-894X(99)00668-X; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Lowes VL, 2002, NEUROSIGNALS, V11, P5, DOI 10.1159/000057317; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Macey TA, 2004, MOL PHARMACOL, V66, P1635, DOI 10.1124/mol.104.001495; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McLaughlin JP, 2003, J BIOL CHEM, V278, P34631, DOI 10.1074/jbc.M304022200; McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Piros ET, 1996, NEUROCHEM RES, V21, P1277, DOI 10.1007/BF02532368; RONKEN E, 1993, J NEUROCHEM, V61, P1634, DOI 10.1111/j.1471-4159.1993.tb09797.x; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346; Thompson AC, 2000, J NEUROSCI, V20, P9333; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Wang Y, 2005, J PHARMACOL EXP THER, V312, P220, DOI 10.1124/jpet.104.073668; Xu M, 2004, J NEUROSCI, V24, P4576, DOI 10.1523/JNEUROSCI.5552-03.2004	43	182	188	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18081	18089		10.1074/jbc.M513640200	http://dx.doi.org/10.1074/jbc.M513640200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16648139	Green Accepted, hybrid			2022-12-25	WOS:000238490300059
J	Bui, TV; Han, Y; Radu, RA; Travis, GH; Mata, NL				Bui, Tam V.; Han, Yun; Radu, Roxana A.; Travis, Gabriel H.; Mata, Nathan L.			Characterization of native retinal fluorophores involved in biosynthesis of A2E and lipofuscin-associated retinopathies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTED EPITHELIAL-CELLS; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; STARGARDTS-DISEASE; ABCR; ACCUMULATION; MICE; PATHOGENESIS; MUTATIONS	Mutations in the photoreceptor-specific ABCA4 gene are associated with several inherited retinal and macular degenerations. A prominent phenotype of these diseases is the accumulation of cytotoxic lipofuscin fluorophores such as A2E within the retinal pigment epithelium. Another compound, dihydro-N-retinylidene-N-retinylphosphatidyl-ethanolamine (A2PE-H-2), also accumulates in retinas of mice and humans harboring ABCA4 mutations and was proposed to be a precursor of A2E. The role of A2PE-H-2 in the biogenesis of A2E and its relationship to other retinal fluorophores has not been previously investigated. We report spectral properties and structural relationships of the principal retinal fluorophores that accumulate in retina and retinal pigment epithelium of abca4(-/-) mice. A long wavelength fluorescence emission intrinsic to abca4(-/-) retinal explants is shown to emanate from A2PE-H-2. All-trans retinal dimer conjugates, which were also identified in the retinal explants, possessed distinct fluorescence and structural properties and, unlike A2PE-H-2, did not accumulate in an age-dependent manner. Derivative absorbance and fluorescence spectroscopy revealed that A2PE-H-2, A2E, and N-retinylidene-N-retinyl-phosphatidylethanolamine (A2PE), a known precursor of A2E, share common electronic and resonant structures. Importantly, collision-induced dissociation of A2PE-H-2 produced daughter ions that were identical to authentic A2E and its daughter ions. Finally, intravitreal administration of A2PE-H-2 to wild-type mice resulted in the formation of A2PE and A2E. These data validate a previously hypothesized bio-synthetic pathway for A2E and implicate A2PE-H-2 as a precursor in this pathway. Fluorescence properties of A2PE-H-2 and other related fluorophores characterized in this report have significance for evaluation of human retinal diseases characterized by aberrant fundus autofluorescence.	Sytera Inc, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Mata, NL (corresponding author), Sytera Inc, 505 Coast Blvd So,Ste 412, La Jolla, CA 92037 USA.	nmata@sytera.com	Radu, Roxana A./K-8924-2019; Travis, Gabriel Harvey/AIF-1062-2022	Travis, Gabriel Harvey/0000-0003-4020-9493; Radu, Roxana/0000-0002-5064-6403				Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; ANTONOV L, 1993, APPL SPECTROSC, V47, P1712, DOI 10.1366/0003702934334796; Beharry S, 2004, J BIOL CHEM, V279, P53972, DOI 10.1074/jbc.M405216200; Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje; Bermann M, 2001, EXP EYE RES, V72, P191; BOK D, 1993, J CELL SCI, P189; Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048; De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566; Delori F. C., 1995, RETINAL PIGMENT EPIT, V62, P37; DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327; DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718; Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3; ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; FEENEYBURNS L, 1988, INVEST OPHTH VIS SCI, V29, P708; Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899; Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102; Haralampus-Grynaviski NM, 2003, P NATL ACAD SCI USA, V100, P3179, DOI 10.1073/pnas.0630280100; Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051; Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; POINCELOT RP, 1970, BIOCHEMISTRY-US, V9, P1809, DOI 10.1021/bi00810a021; Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820; Reinboth JJ, 1997, EXP EYE RES, V65, P639, DOI 10.1006/exer.1997.0367; Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311; Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6; Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988; Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007; Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922; Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598	37	39	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18112	18119		10.1074/jbc.M601380200	http://dx.doi.org/10.1074/jbc.M601380200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16638746	hybrid			2022-12-25	WOS:000238490300062
J	Combe, JP; Basran, J; Hothi, P; Leys, D; Rigby, SEJ; Munro, AW; Scrutton, NS				Combe, Jonathan P.; Basran, Jaswir; Hothi, Parvinder; Leys, David; Rigby, Stephen E. J.; Munro, Andrew W.; Scrutton, Nigel S.			Lys-D48 is required for charge stabilization, rapid flavin reduction, and internal electron transfer in the catalytic cycle of dihydroorotate dehydrogenase B of Lactococcus lactis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC FUNCTION; CRYSTAL-STRUCTURE; MUTAGENESIS; MECHANISM; OXIDATION; SUBUNITS	Dihydroorotate dehydrogenase B (DHODB) catalyzes the oxidation of dihydroorotate (DHO) to orotate and is found in the pyrimidine biosynthetic pathway. The Lactococcus lactis enzyme is a dimer of heterodimers containing FMN, FAD, and a 2Fe-2S center. Lys-D48 is found in the catalytic subunit and its side-chain adopts different positions, influenced by ligand binding. Based on crystal structures of DHODB in the presence and absence of orotate, we hypothesized that Lys-D48 has a role in facilitating electron transfer in DHODB, specifically in stabilizing negative charge in the reduced FMN isoalloxazine ring. We show that mutagenesis of Lys-D48 to an alanine, arginine, glutamine, or glutamate residue (mutants K38A, K48R, K48Q, and K48E) impairs catalytic turnover substantially (similar to 50-500-fold reduction in turnover number). Stopped-flow studies demonstrate that loss of catalytic activity is attributed to poor rates of FMN reduction by substrate. Mutation also impairs electron transfer from the 2Fe-2S center to FMN. Addition of methylamine leads to partial rescue of flavin reduction activity. Nicotinamide coenzyme oxidation and reduction at the distal FAD site is unaffected by the mutations. Formation of the spin-interacting state between the FMN semiquinone-reduced 2Fe-2S centers observed in wild-type enzyme is retained in the mutant proteins, consistent with there being little perturbation of the superexchange paths that contribute to the efficiency of electron transfer between these cofactors. Our data suggest a key charge-stabilizing role for Lys-D48 during reduction of FMN by dihydroorotate, or by electron transfer from the 2Fe-2S center, and establish a commonmechanism of FMN reduction in the single FMN-containing A-type and the complex multicenter B-type DHOD enzymes.	Univ Manchester, Manchester Interdisciplinary Bioctr, Fac Life Sci, Manchester M60 1QD, Lancs, England; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Queen Mary Univ London, Dept Biol Sci, London E1 4NS, England; Univ Manchester, Manchester Interdisciplinary Bioctr, Sch Chem Engn & Analyt Sci, Manchester M60 1QD, Lancs, England	University of Manchester; University of Leicester; University of London; Queen Mary University London; University of Manchester	Scrutton, NS (corresponding author), Univ Manchester, Manchester Interdisciplinary Bioctr, Fac Life Sci, Jacksons Mill,POB 88,Sackville St, Manchester M60 1QD, Lancs, England.	nigel.scrutton@manchester.ac.uk	Munro, Andrew/G-5639-2019	Munro, Andrew/0000-0002-4642-180X	Biotechnology and Biological Sciences Research Council [C19031/2] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Argyrou A, 2000, BIOCHEMISTRY-US, V39, P10373, DOI 10.1021/bi001111d; BERTRAND P, 1979, BIOCHIM BIOPHYS ACTA, V579, P107, DOI 10.1016/0005-2795(79)90091-6; BERTRAND P, 1991, STRUCT BOND, V75, P1; DeLano WL, 2002, PYMOL USERS MANUAL; Dutton P L, 1978, Methods Enzymol, V54, P411; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; Hansen M, 2004, PROTEIN SCI, V13, P1031, DOI 10.1110/ps.03533004; Jensen KF, 1998, PATHS PYRIMIDINES, V6, P20; Jiang WJ, 2000, BIOCHEMISTRY-US, V39, P7990, DOI 10.1021/bi000630d; Kahler AE, 1999, ARCH BIOCHEM BIOPHYS, V371, P191, DOI 10.1006/abbi.1999.1455; LEATHERBARROW RJ, 1992, GRAFIT V3 0; Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0; Marcinkeviciene J, 1999, BIOCHEMISTRY-US, V38, P13129, DOI 10.1021/bi990674q; Mohsen AWA, 2004, BIOCHEMISTRY-US, V43, P6498, DOI 10.1021/bi036179i; Nielsen FS, 1996, J BIOL CHEM, V271, P29359, DOI 10.1074/jbc.271.46.29359; Norager S, 2002, STRUCTURE, V10, P1211, DOI 10.1016/S0969-2126(02)00831-6; Norager S, 2003, J BIOL CHEM, V278, P28812, DOI 10.1074/jbc.M303767200; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Palfey BA, 2001, BIOCHEMISTRY-US, V40, P4381, DOI 10.1021/bi0025666; Rowland P, 1997, STRUCTURE, V5, P239, DOI 10.1016/S0969-2126(97)00182-2; Rowland P, 1998, PROTEIN SCI, V7, P1269, DOI 10.1002/pro.5560070601; Rowland P, 2000, STRUCTURE, V8, P1227, DOI 10.1016/S0969-2126(00)00530-X; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03	23	4	4	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17977	17988		10.1074/jbc.M601417200	http://dx.doi.org/10.1074/jbc.M601417200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16624811	hybrid			2022-12-25	WOS:000238490300048
J	Monslow, J; Williams, JD; Fraser, DJ; Michael, DR; Foka, P; Kift-Morgan, AP; Luo, DD; Fielding, CA; Craig, KJ; Topley, N; Jones, SA; Ramji, DP; Bowen, T				Monslow, Jamie; Williams, John D.; Fraser, Donald J.; Michael, Daryn R.; Foka, Pelagia; Kift-Morgan, Ann P.; Luo, Dong Dong; Fielding, Ceri A.; Craig, Kathrine J.; Topley, Nicholas; Jones, Simon A.; Ramji, Dipak P.; Bowen, Timothy			Sp1 and sp3 mediate constitutive transcription of the human hyaluronan synthase 2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DIFFERENTIAL REGULATION; EPITHELIAL-CELLS; RETINOIC ACID; SP-FAMILY; EXPRESSION; BINDING; ACTIVATION; INDUCTION; RECEPTOR	The linear glycosaminoglycan hyaluronan (HA) is synthesized at the plasma membrane by the HA synthase (HAS) enzymes HAS1, -2, and -3 and performs multiple functions as part of the vertebrate extracellular matrix. Up-regulation of HA synthesis in the renal corticointerstitium, and the resultant extracellular matrix expansion, is a common feature of renal fibrosis. However, the regulation of expression of these HAS isoforms at transcriptional and translational levels is poorly understood. We have recently described the genomic structures of the human HAS genes, thereby identifying putative promoter regions for each isoform. Further analysis of the HAS2 gene identified the transcription initiation site and showed that region F3, comprising the proximal 121 bp of promoter sequence, mediated full constitutive transcription. In the present study, we have analyzed this region in the human renal proximal tubular epithelial cell line HK-2. Electrophoretic mobility shift and promoter assay data demonstrated that transcription factors Sp1 and Sp3 bound to three sites immediately upstream of the HAS2 transcription initiation site and that mutation of the consensus recognition sequences within these sites ablated their transcriptional response. Furthermore, subsequent knockdown of Sp1 or Sp3 using small interfering RNAs decreased constitutive HAS2 mRNA synthesis. In contrast, significant binding of HK-2 nuclear proteins by putative upstream NF-Y, CCAAT, and NF-kappa B recognition sites was not observed. The identification of Sp1 and Sp3 as principal mediators of HAS2 constitutive transcription augments recent findings identifying upstream promoter elements and provides further insights into the mechanism of HAS2 transcriptional activation.	Cardiff Univ, Sch Med, Inst Nephrol, Cardiff CF14 4XN, Wales; Cardiff Medictr, Cardiff Inst Tissue Engn & Repair, Cardiff CF14 4UJ, Wales; Cardiff Univ, Sch Biosci, Cardiff CF10 3US, Wales; Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, Wales	Cardiff University; Cardiff University; Cardiff University; Cardiff University	Bowen, T (corresponding author), Cardiff Univ, Sch Med, Inst Nephrol, Heath Pk, Cardiff CF14 4XN, Wales.	bowent@cf.ac.uk	Fielding, Ceri A/F-5638-2014; Foka, Pelagia/AAQ-4267-2020; Jones, Simon Arnett/Q-7017-2018; Ramji, Dipak/A-7092-2010	Fielding, Ceri A/0000-0002-5817-3153; Foka, Pelagia/0000-0002-6888-7678; Jones, Simon Arnett/0000-0001-7297-9711; Ramji, Dipak/0000-0002-6419-5578; Fraser, Donald/0000-0003-0102-9342	Wellcome Trust [057503] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abrams KL, 2004, J BIOL CHEM, V279, P15916, DOI 10.1074/jbc.M313531200; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Benz PS, 1996, KIDNEY INT, V50, P156, DOI 10.1038/ki.1996.298; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Bowen T, 1998, MOL PSYCHIATR, V3, P67, DOI 10.1038/sj.mp.4000293; BOWEN T, 2001, J AM SOC NEPHROL, V12, pA3650; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chao H, 2005, J BIOL CHEM, V280, P27513, DOI 10.1074/jbc.M411544200; Ducale AE, 2005, AM J PHYSIOL-GASTR L, V289, pG462, DOI 10.1152/ajpgi.00494.2004; Ehlting C, 2005, BIOCHEM J, V387, P737, DOI 10.1042/BJ20041101; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; Hoogendoorn B, 2003, HUM MOL GENET, V12, P2249, DOI 10.1093/hmg/ddg246; Hughes TR, 2002, J BIOL CHEM, V277, P11097, DOI 10.1074/jbc.M106774200; Husmann M, 2000, BIOCHEM J, V352, P763, DOI 10.1042/0264-6021:3520763; Irvine SA, 2005, NUCLEIC ACIDS RES, V33, P1423, DOI 10.1093/nar/gki280; Jones S, 2001, KIDNEY INT, V59, P1739, DOI 10.1046/j.1523-1755.2001.0590051739.x; Kim K, 2005, MOL ENDOCRINOL, V19, P843, DOI 10.1210/me.2004-0326; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lewington AJP, 2000, AM J PHYSIOL-REG I, V278, pR247, DOI 10.1152/ajpregu.2000.278.1.R247; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Mack JA, 2003, FASEB J, V17, P1352, DOI 10.1096/fj.02-0959fje; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; McLoughlin RM, 2003, J CLIN INVEST, V112, P598, DOI 10.1172/JCI200317129; McLoughlin RM, 2004, J IMMUNOL, V172, P5676, DOI 10.4049/jimmunol.172.9.5676; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mistry AR, 2003, BLOOD REV, V17, P71, DOI 10.1016/S0268-960X(02)00075-9; Monslow J, 2004, J BIOL CHEM, V279, P20576, DOI 10.1074/jbc.M312666200; Monslow J, 2003, INT J BIOCHEM CELL B, V35, P1272, DOI 10.1016/S1357-2725(03)00048-7; Mummert ME, 2005, IMMUNOL RES, V31, P189, DOI 10.1385/IR:31:3:189; Nishida Y, 2004, OSTEOARTHR CARTILAGE, V12, P374, DOI 10.1016/j.joca.2004.01.008; Ohkawa T, 1999, BBA-MOL CELL RES, V1448, P416, DOI 10.1016/S0167-4889(98)00155-4; Ohno S, 2005, ARTHRITIS RHEUM-US, V52, P800, DOI 10.1002/art.20937; Saavalainen K, 2005, J BIOL CHEM, V280, P14636, DOI 10.1074/jbc.M500206200; Safe S, 2004, PROG NUCLEIC ACID RE, V77, P1, DOI 10.1016/S0079-6603(04)77001-4; Sano N, 2001, NEPHRON, V89, P416, DOI 10.1159/000046113; Sayo T, 2002, J INVEST DERMATOL, V118, P43, DOI 10.1046/j.0022-202x.2001.01613.x; Shimada J, 2001, MOL ENDOCRINOL, V15, P1677, DOI 10.1210/me.15.10.1677; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Sibalic V, 1997, NEPHROL DIAL TRANSPL, V12, P1344, DOI 10.1093/ndt/12.7.1344; Spicer Andrew P, 2004, Birth Defects Res C Embryo Today, V72, P89, DOI 10.1002/bdrc.20006; Spicer AP, 1997, J BIOL CHEM, V272, P8957; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; Tammi R, 2005, J INVEST DERMATOL, V124, P898, DOI 10.1111/j.0022-202X.2005.23697.x; Tien JYL, 2005, DEV DYNAM, V233, P130, DOI 10.1002/dvdy.20328; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; WELLS A, 1993, TRANSPLANTATION, V55, P1346, DOI 10.1097/00007890-199306000-00025; WELLS AF, 1990, TRANSPLANTATION, V50, P240, DOI 10.1097/00007890-199008000-00014; Wilkinson TS, 2006, J CELL PHYSIOL, V206, P378, DOI 10.1002/jcp.20468; Wilkinson TS, 2004, AM J RESP CELL MOL, V31, P92, DOI 10.1165/rcmb.2003-0380OC; Wuthrich RP, 1999, NEPHROL DIAL TRANSPL, V14, P2554, DOI 10.1093/ndt/14.11.2554; Yamada Y, 2004, J INVEST DERMATOL, V122, P631, DOI 10.1111/j.0022-202X.2004.22332.x; Yang XP, 2005, ARTERIOSCL THROM VAS, V25, P1395, DOI 10.1161/01.ATV.0000168428.96177.24; Yu B, 2003, NUCLEIC ACIDS RES, V31, P5368, DOI 10.1093/nar/gkg706; Yung S, 2000, KIDNEY INT, V58, P1953, DOI 10.1111/j.1523-1755.2000.00367.x; Zhuo LS, 2004, J BIOL CHEM, V279, P38079, DOI 10.1074/jbc.R300039200; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	67	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18043	18050		10.1074/jbc.M510467200	http://dx.doi.org/10.1074/jbc.M510467200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16603733	hybrid			2022-12-25	WOS:000238490300055
J	Shaw, BF; Durazo, A; Nersissian, AM; Whitelegge, JP; Faull, KF; Valentine, JS				Shaw, Bryan Francis; Durazo, Armando; Nersissian, Aram M.; Whitelegge, Julian P.; Faull, Kym F.; Valentine, Joan Selverstone			Local unfolding in a destabilized, pathogenic variant of superoxide dismutase 1 observed with H/D exchange and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; AMIDE HYDROGEN-EXCHANGE; CU,ZN SUPEROXIDE-DISMUTASE; MOLECULAR-WEIGHT COMPLEXES; MOTOR-NEURON DEGENERATION; CU,ZN-SUPEROXIDE DISMUTASE; AGGREGATION RATES; BINDING SITE; METAL-IONS; WILD-TYPE	Hydrogen exchange monitored by mass spectrometry has been used to study the structural behavior of the pathogenic A4V variant of superoxide dismutase 1 (SOD1) in the metal-free (apo) form. Mass spectrometric data revealed that in the disulfide-intact (S-S) form, the A4V variant is destabilized at residues 50-53, in the disulfide subloop of the dimer interface, but many other regions of the A4V protein exhibited hydrogen exchange properties identical to that of the wild type protein. Additionally, mass spectrometry revealed that A4V apoSOD1(S-S) undergoes slow localized unfolding in a large segment of the beta-barrel that included beta 3, beta 4, and loops II and III. In the disulfide-reduced form, A4V apoSOD1 exchanged like a "random coil" polypeptide at 20 degrees C and began to populate folded states at 4 degrees C. These local and global unfolding events could facilitate intermolecular protein-protein interactions that cause the aggregation or neurotoxicity of A4V SOD1.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; Occidental Coll, Dept Chem, Los Angeles, CA 90041 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Occidental College	Valentine, JS (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	jsv@chem.ucla.edu	Shaw, Bryan/A-7001-2008; Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28222] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200; Assfalg M, 2003, J MOL BIOL, V330, P145, DOI 10.1016/S0022-2836(03)00533-3; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Banci L, 2003, BIOCHEMISTRY-US, V42, P9543, DOI 10.1021/bi034324m; Banci L, 2000, BIOCHEMISTRY-US, V39, P9108, DOI 10.1021/bi000067z; Banci L, 1995, EUR J BIOCHEM, V234, P855, DOI 10.1111/j.1432-1033.1995.855_a.x; Banci L, 2002, PROTEIN SCI, V11, P2479, DOI 10.1110/ps.0210802; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Canet D, 2002, NAT STRUCT BIOL, V9, P308, DOI 10.1038/nsb768; Cardoso RMF, 2002, J MOL BIOL, V324, P247, DOI 10.1016/S0022-2836(02)01090-2; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chung EW, 1997, PROTEIN SCI, V6, P1316, DOI 10.1002/pro.5560060620; DiDonato M, 2003, J MOL BIOL, V332, P601, DOI 10.1016/S0022-2836(03)00889-1; Doucette PA, 2004, J BIOL CHEM, V279, P54558, DOI 10.1074/jbc.M409744200; Dubay KF, 2004, J MOL BIOL, V341, P1317, DOI 10.1016/j.jmb.2004.06.043; Dumoulin M, 2005, J MOL BIOL, V346, P773, DOI 10.1016/j.jmb.2004.11.020; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; Engen JR, 1997, BIOCHEMISTRY-US, V36, P14384, DOI 10.1021/bi971635m; Fandrich M, 2003, P NATL ACAD SCI USA, V100, P15463, DOI 10.1073/pnas.0303758100; Ferraro DM, 2004, BIOCHEMISTRY-US, V43, P587, DOI 10.1021/bi035943y; Furukawa Y, 2005, J BIOL CHEM, V280, P17266, DOI 10.1074/jbc.M500482200; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kazmirski SL, 2002, NAT STRUCT BIOL, V9, P112, DOI 10.1038/nsb745; Khare SD, 2004, P NATL ACAD SCI USA, V101, P15094, DOI 10.1073/pnas.0406650101; Khare SD, 2005, PROTEINS, V61, P617, DOI 10.1002/prot.20629; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Lindberg MJ, 2005, P NATL ACAD SCI USA, V102, P9754, DOI 10.1073/pnas.0501957102; Lindberg MJ, 2004, P NATL ACAD SCI USA, V101, P15893, DOI 10.1073/pnas.0403979101; Lyons TJ, 1998, J BIOL INORG CHEM, V3, P650, DOI 10.1007/s007750050279; Miranker A, 1996, FASEB J, V10, P93, DOI 10.1096/fasebj.10.1.8566553; Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200; Ray SS, 2004, BIOCHEMISTRY-US, V43, P4899, DOI 10.1021/bi030246r; Ray SS, 2005, P NATL ACAD SCI USA, V102, P3639, DOI 10.1073/pnas.0408277102; Resing KA, 1998, BIOCHEMISTRY-US, V37, P463, DOI 10.1021/bi971750x; Rist W, 2003, J BIOL CHEM, V278, P51415, DOI 10.1074/jbc.M307160200; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; Rodriguez JA, 2005, P NATL ACAD SCI USA, V102, P10516, DOI 10.1073/pnas.0502515102; ROSEN DR, 1994, HUM MOL GENET, V3, P981, DOI 10.1093/hmg/3.6.981; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Shipp EL, 2003, BIOCHEMISTRY-US, V42, P1890, DOI 10.1021/bi026704y; Smith DL, 1997, J MASS SPECTROM, V32, P135, DOI 10.1002/(SICI)1096-9888(199702)32:2<135::AID-JMS486>3.0.CO;2-M; Stefani M, 2004, BBA-MOL BASIS DIS, V1739, P5, DOI 10.1016/j.bbadis.2004.08.004; Strange RW, 2003, J MOL BIOL, V328, P877, DOI 10.1016/S0022-2836(03)00355-3; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Wang J, 2005, HUM MOL GENET, V14, P2335, DOI 10.1093/hmg/ddi236; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Wang J, 2002, NEUROBIOL DIS, V9, P139, DOI 10.1006/nbdi.2001.0471; Wintrode PL, 2005, J MOL BIOL, V347, P911, DOI 10.1016/j.jmb.2005.01.064; Zhang ZQ, 1996, PROTEIN SCI, V5, P1282; Zhang ZQ, 1996, BIOCHEMISTRY-US, V35, P779, DOI 10.1021/bi952227q	52	54	54	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18167	18176		10.1074/jbc.M600623200	http://dx.doi.org/10.1074/jbc.M600623200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16644738	hybrid			2022-12-25	WOS:000238490300068
J	Tan, Y; Wu, C; De Veyra, T; Greer, PA				Tan, Yinfei; Wu, Chao; De Veyra, Teresa; Greer, Peter A.			Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; CROSS-TALK; HUMAN NEUTROPHILS; JNK ACTIVATION; CASPASE; PATHWAY; PROTEIN	The mu- and m-calpain proteases have been implicated in both pro-or anti-apoptotic functions. Here we compared cell death responses and apoptotic or survival signaling pathways in primary mouse embryonic fibroblasts (MEFs) derived from wild type or capn4 knock-out mice which lack both mu- and m-calpain activities. Capn4(-/-) MEFs displayed resistance to puromycin, camptothecin, etoposide, hydrogen peroxide, ultraviolet light, and serum starvation, which was consistent with pro-apoptotic roles for calpain. In contrast, capn4(-/-) MEFs were more susceptible to staurosporine (STS) and tumor necrosis factor alpha-induced cell death, which provided evidence for anti-apoptotic signaling roles for calpain. Bax activation, release of cytochrome c, and activation of caspase-9 and caspase-3 all correlated with the observed cell death responses of wild type or capn4(-/-) MEFs to the various challenges, suggesting that calpain might play distinct roles in transducing different death signals to the mitochondria. There was no evidence that calpain cleaved Bcl-2 family member proteins that regulate mitochondrial membrane permeability including Bcl-2, Bcl-xl, Bad, Bak, Bid, or Bim. However, activation of the phosphatidylinositol 3 (PI3)-kinase/ Akt survival signaling pathway was compromised in capn4(-/-) MEFs under all challenges regardless of the cell death outcome, and blocking Akt activation using the PI3-kinase inhibitor LY294002 abolished the protective effect of calpain to STS challenge. We conclude that the anti-apoptotic function of calpain in tumor necrosis factor alpha- and STS-challenged cells relates to a novel role in activating the PI3-kinase/Akt survival pathway.	Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; McMaster University; Queens University - Canada	Greer, PA (corresponding author), Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Botterell Hall,Rm A309, Kingston, ON K7L 3N6, Canada.	greerp@post.queensu.ca						Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Bizat N, 2003, J BIOL CHEM, V278, P43245, DOI 10.1074/jbc.M305057200; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen HC, 2006, J BIOMED SCI, V13, P261, DOI 10.1007/s11373-005-9052-8; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chi XJ, 1999, FEBS LETT, V459, P391, DOI 10.1016/S0014-5793(99)01281-8; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Claudio E, 1996, EXP CELL RES, V224, P63, DOI 10.1006/excr.1996.0111; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; CRISSMAN HA, 1973, J CELL BIOL, V59, P766, DOI 10.1083/jcb.59.3.766; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Debiasi RL, 1999, J VIROL, V73, P695, DOI 10.1128/JVI.73.1.695-701.1999; Demarchi F, 2005, CELL DEATH DIFFER, V12, P512, DOI 10.1038/sj.cdd.4401592; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hirpara JL, 2000, BLOOD, V95, P1773, DOI 10.1182/blood.V95.5.1773.005k17_1773_1780; Jayaraman T, 2000, J BIOL CHEM, V275, P6417, DOI 10.1074/jbc.275.9.6417; Kidd VJ, 2000, SEMIN CELL DEV BIOL, V11, P191, DOI 10.1006/scdb.2000.0165; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu T, 2002, BBA-MOL CELL RES, V1590, P16, DOI 10.1016/S0167-4889(02)00193-3; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; McDonald MC, 2001, FASEB J, V15, P171, DOI 10.1096/fj.99-0645com; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Miller AL, 2005, MOL ENDOCRINOL, V19, P1569, DOI 10.1210/me.2004-0528; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Reddy RK, 1999, J BIOL CHEM, V274, P28476, DOI 10.1074/jbc.274.40.28476; Ruiz-Vela A, 2001, J EXP MED, V194, P247, DOI 10.1084/jem.194.3.247; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102; Squier MKT, 1999, J CELL PHYSIOL, V178, P311, DOI 10.1002/(SICI)1097-4652(199903)178:3<311::AID-JCP5>3.3.CO;2-K; Squier MKT, 1997, J IMMUNOL, V158, P3690; Wan X, 2002, CELL DEATH DIFFER, V9, P414, DOI 10.1038/sj.cdd.4400982; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4	58	107	109	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17689	17698		10.1074/jbc.M601978200	http://dx.doi.org/10.1074/jbc.M601978200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16632474	hybrid			2022-12-25	WOS:000238490300018
J	Sun, XJ; Shih, AY; Johannssen, HC; Erb, H; Li, P; Murphy, TH				Sun, Xiaojian; Shih, Andy Y.; Johannssen, Helge C.; Erb, Heidi; Li, Ping; Murphy, Timothy H.			Two-photon imaging of glutathione levels in intact brain indicates enhanced redox buffering in developing neurons and cells at the cerebrospinal fluid and blood-brain interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN-1; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; OXIDATIVE STRESS; FOCAL ISCHEMIA; S-TRANSFERASES; COORDINATE REGULATION; REDUCED GLUTATHIONE; GLUTAMATE TOXICITY; CEREBRAL-ISCHEMIA	Glutathione is the major cellular thiol present in mammalian cells and is critical for maintenance of redox homeostasis. However, current assay systems for glutathione lack application to intact animal tissues. To map the levels of glutathione in intact brain with cellular resolution ( acute tissue slices and live animals), we have used two-photon imaging of monochlorobimane fluorescence, a selective enzyme-mediated marker for reduced glutathione. Previously, in vitro experiments using purified components and cultured glial cells attributed cellular monochlorobimane fluorescence to a glutathione S-transferase-dependent reaction with GSH. Our results indicate that cells at the cerebrospinal fluid or blood-brain interface, such as lateral ventricle ependymal cells (2.73 +/- 0.56mM; glutathione), meningeal cells (1.45 +/- 0.09 mM), and astroglia (0.91 +/- 0.08mM), contain high levels of glutathione. In comparison, layer II cortical neurons contained 20% (0.21 +/- 0.02mM) the glutathione content of nearby astrocytes. Neuronal glutathione labeling increased 250% by the addition of the cell-permeable glutathione precursor N-acetylcysteine indicating that the monochlorobimane level or glutathione S-transferase activity within neurons was not limiting. Regional mapping showed that glutathione was highest in cells lining the lateral ventricles, specifically ependymal cells and the subventricular zone, suggesting a possible function for glutathione in oxidant homeostasis of developing neuronal progenitors. Consistently, developing neurons in the subgranular zone of dentate gyrus contained 3-fold more glutathione than older neurons found in the neighboring granular layer. In conclusion, mapping of glutathione levels in intact brain demonstrates a unique role for enhanced redox potential in developing neurons and cells at the cerebrospinal fluid and blood-brain interface.	Univ British Columbia, Dept Psychiat, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Physiol, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Murphy, TH (corresponding author), Univ British Columbia, Dept Psychiat, Kinsmen Lab Neurol Res, 4N1-2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	thmurphy@interchange.ubc.ca	Murphy, Timothy H/I-4982-2014; Murphy, Timothy/AAW-1975-2021	Murphy, Timothy H/0000-0002-0093-4490; Murphy, Timothy/0000-0002-0093-4490				Abramov AY, 2003, J NEUROSCI, V23, P5088; AMARA A, 1994, BRAIN RES, V659, P237, DOI 10.1016/0006-8993(94)90885-0; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Anderson MF, 2003, NEUROCHEM RES, V28, P293, DOI 10.1023/A:1022385402197; Aoyama K, 2006, NAT NEUROSCI, V9, P119, DOI 10.1038/nn1609; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3; BEISWANGER CM, 1995, NEUROTOXICOLOGY, V16, P425; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Chatterjee S, 1999, GLIA, V27, P152; Chen YM, 2001, J NEUROCHEM, V77, P1601, DOI 10.1046/j.1471-4159.2001.00374.x; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; COOK JA, 1991, CANCER RES, V51, P1606; Cooper AJL, 1997, BIOL CHEM, V378, P793; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; Dringen R, 1999, J NEUROCHEM, V72, P2523, DOI 10.1046/j.1471-4159.1999.0722523.x; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; GHERSIEGEA JF, 1994, J NEUROCHEM, V62, P1089; GOTOH O, 1994, ACT NEUR S, V60, P318; Guegan C, 1998, EXP NEUROL, V154, P371, DOI 10.1006/exnr.1998.6913; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Herzenberg LA, 1997, P NATL ACAD SCI USA, V94, P1967, DOI 10.1073/pnas.94.5.1967; Hirrlinger J, 2002, J NEUROSCI RES, V69, P318, DOI 10.1002/jnr.10308; HJELLE OP, 1994, EUR J NEUROSCI, V6, P793, DOI 10.1111/j.1460-9568.1994.tb00990.x; Iwata-Ichikawa E, 1999, J NEUROCHEM, V72, P2334, DOI 10.1046/j.1471-4159.1999.0722334.x; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Keelan J, 2001, J NEUROSCI RES, V66, P873, DOI 10.1002/jnr.10085; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Kleinfeld D, 1998, P NATL ACAD SCI USA, V95, P15741, DOI 10.1073/pnas.95.26.15741; KLEINFELD D, 2000, IMAGING NEURONS LAB; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Li GN, 2005, DEV NEUROSCI-BASEL, V27, P93, DOI 10.1159/000085980; LIU TH, 1989, AM J PHYSIOL, V256, P589; LOWNDES HE, 1994, NEUROTOXICOLOGY, V15, P61; LYRER P, 1991, BRAIN RES, V567, P317, DOI 10.1016/0006-8993(91)90811-9; Matthias K, 2003, J NEUROSCI, V23, P1750; McKinnon SG, 1998, NEUROIMAG CLIN N AM, V8, P101; Meyer AJ, 2000, J MICROSC-OXFORD, V198, P174, DOI 10.1046/j.1365-2818.2000.00697.x; Meyer AJ, 2001, PLANT J, V27, P67, DOI 10.1046/j.1365-313x.2001.01071.x; MIZUI T, 1992, AM J PHYSIOL, V262, P313; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; NEWTON GL, 1981, ANAL BIOCHEM, V114, P383, DOI 10.1016/0003-2697(81)90498-X; NILSSON C, 1992, BRAIN RES REV, V17, P109, DOI 10.1016/0165-0173(92)90011-A; Nimmerjahn A, 2004, NAT METHODS, V1, P31, DOI 10.1038/nmeth706; Nishimura N, 2006, NAT METHODS, V3, P99, DOI 10.1038/NMETH844; Oheim M, 2001, J NEUROSCI METH, V111, P29, DOI 10.1016/S0165-0270(01)00438-1; Paxinos G, 1986, RAT BRAIN STEREOTACT; Perry G, 2001, SCIENCE, V291, P595; RATAN RR, 1994, J NEUROCHEM, V62, P376; REHNCRONA S, 1980, J NEUROCHEM, V34, P477, DOI 10.1111/j.1471-4159.1980.tb11170.x; Rice ME, 1998, NEUROSCIENCE, V82, P1213; SAGARA J, 1993, J NEUROCHEM, V61, P1672, DOI 10.1111/j.1471-4159.1993.tb09802.x; Sato H, 2002, J NEUROSCI, V22, P8028; Schaffer CB, 2006, PLOS BIOL, V4, P258, DOI 10.1371/journal.pbio.0040022; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Schubert D, 2001, J NEUROSCI, V21, P7455, DOI 10.1523/JNEUROSCI.21-19-07455.2001; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shih AY, 2005, J BIOL CHEM, V280, P22925, DOI 10.1074/jbc.M414635200; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Siddiq A, 2005, J BIOL CHEM, V280, P41732, DOI 10.1074/jbc.M504963200; SLIVKA A, 1987, BRAIN RES, V409, P275, DOI 10.1016/0006-8993(87)90712-8; SMITH GM, 1992, INT J DEV NEUROSCI, V10, P387, DOI 10.1016/0736-5748(92)90028-X; STJOHN PA, 1986, J NEUROSCI, V6, P1492; SUN X, 2005, SOC NEUR ABSTR; Sun XJ, 2005, BIOCHEM BIOPH RES CO, V326, P371, DOI 10.1016/j.bbrc.2004.11.031; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; Tauskela JS, 2000, GLIA, V30, P329, DOI 10.1002/(SICI)1098-1136(200006)30:4<329::AID-GLIA20>3.3.CO;2-I; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; UBLACKER GA, 1991, CANCER RES, V51, P1783; UEMURA Y, 1991, STROKE, V22, P1548, DOI 10.1161/01.STR.22.12.1548; Walz W, 1998, NEUROSCI LETT, V257, P127, DOI 10.1016/S0304-3940(98)00813-1; Wang XF, 2000, J NEUROCHEM, V74, P1434, DOI 10.1046/j.1471-4159.2000.0741434.x; Yu ZF, 1998, J NEUROSCI RES, V53, P613, DOI 10.1002/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1; Zhang SX, 2005, J NEUROSCI, V25, P5333, DOI 10.1523/JNEUROSCI.1085-05.2005	83	66	67	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17420	17431		10.1074/jbc.M601567200	http://dx.doi.org/10.1074/jbc.M601567200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16624809	hybrid			2022-12-25	WOS:000238326300068
J	Wagner, LE; Betzenhauser, MJ; Yule, DI				Wagner, Larry E., II; Betzenhauser, Matthew J.; Yule, David I.			ATP binding to a unique site in the type-1 S2(-) inositol 1,4,5-trisphosphate receptor defines susceptibility to phosphorylation by protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; LIGAND-BINDING; MUTATIONAL ANALYSIS; MOUSE CEREBELLUM; SPLICE VARIANTS; CA2+; CHANNELS; TRISPHOSPHATE; OLIGOMERIZATION; LOCALIZATION	The subtype- and splice variant-specific modulation of inositol 1,4,5-trisphosphate receptors (InsP3R) by interaction with cellular factors plays a fundamental role in defining the characteristics of Ca2+ release in individual cell types. In this study, we investigate the binding properties and functional consequences of the expression of a putative nucleotide binding fold ( referred to as the ATPC site) unique to the S2(-) splice variant of the type-1 InsP(3)R (InsP(3)R-1), the predominant splice variant in peripheral tissue. A glutathione S-transferase fusion protein encompassing amino acids 1574-1765 of the S2(-) InsP(3)R-1 and including the glycine-rich motif Gly-Tyr-Gly-Glu-Lys-Gly bound ATP specifically as measured by fluorescent trinitrophenyl-ATP binding. This binding was completely abrogated by a point mutation (G1690A) in the nucleotide binding fold. The functional sensitivity of S2(-) InsP(3)R-1 constructs was evaluated in DT403-KO-M3 cells, a null background for InsP3R, engineered to express muscarinic M3 receptors. The S2(-) InsP(3)R-1 containing the G1690A mutation was markedly less sensitive to agonist stimulation than wild type S2(-) InsP(3)R-1 or receptors containing a similar (Gly -> Ala) mutation in the established nucleotide binding sites in InsP(3)R-1 (the ATPA and ATPB sites). The ATP sensitivity of InsP(3)-induced Ca2+ release, however, was not altered by the G1690A mutation when measured in permeabilized DT40-3KO cells, suggesting a unique role for the ATPC site. Ca2+ release was dramatically potentiated following activation of cAMP-dependent protein kinase in DT40-3KO cells transiently expressing wild type S2(-) InsP(3)R or Gly -> Ala mutations in the ATPA and ATPB sites, but phosphorylation of the receptor and the potentiation of Ca2+ release were absent in cells expressing the G1690A mutation in S2(-) InsP(3)R. These data indicate that ATP binding specifically to the ATPC site in S2(-) InsP(3)R-1 controls the susceptibility of the receptor to protein kinase A-mediated phosphorylation, contributes to the functional sensitivity of the S2(-) InsP(3)R-1 and ultimately the sensitivity of cells to agonist stimulation.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester	Yule, DI (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Pharmacol & Physiol, 601 Elmwood Ave, Rochester, NY 14642 USA.	David_Yule@urmc.rochester.edu			NIDCR NIH HHS [T32-DE07202, R01-DE16999, R01-DE14756] Funding Source: Medline; NIDDK NIH HHS [R01-DK54568] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007202, R01DE016999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054568] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bezprozvanny I, 2005, CELL CALCIUM, V38, P261, DOI 10.1016/j.ceca.2005.06.030; Boehning D, 2001, J BIOL CHEM, V276, P13509, DOI 10.1074/jbc.C100094200; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; Dong K, 2005, EMBO J, V24, P1318, DOI 10.1038/sj.emboj.7600626; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; Futatsugi A, 2005, SCIENCE, V309, P2232, DOI 10.1126/science.1114110; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Hiratsuka T, 2003, EUR J BIOCHEM, V270, P3479, DOI 10.1046/j.1432-1033.2003.03748.x; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; Iwai M, 2005, J BIOL CHEM, V280, P10305, DOI 10.1074/jbc.M413824200; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; Li XD, 2005, CIRC RES, V96, P1274, DOI 10.1161/01.RES.0000172556.05576.4c; MAEDA N, 1991, J BIOL CHEM, V266, P1109; Maes K, 1999, CELL CALCIUM, V25, P143, DOI 10.1054/ceca.1998.0011; Maes K, 2001, J BIOL CHEM, V276, P3492, DOI 10.1074/jbc.M006082200; Maes K, 2000, CELL CALCIUM, V27, P257, DOI 10.1054/ceca.2000.0121; Mak DOD, 1999, J BIOL CHEM, V274, P22231, DOI 10.1074/jbc.274.32.22231; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; Mignen O, 2005, J PHYSIOL-LONDON, V567, P787, DOI 10.1113/jphysiol.2005.090209; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; NAKADE S, 1994, J BIOL CHEM, V269, P6735; NAKAGAWA T, 1991, J NEUROCHEM, V57, P1807, DOI 10.1111/j.1471-4159.1991.tb06385.x; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Pieper AA, 2001, NEUROSCIENCE, V102, P433, DOI 10.1016/S0306-4522(00)00470-X; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Soulsby MD, 2004, FEBS LETT, V557, P181, DOI 10.1016/S0014-5793(03)01487-X; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Tang TS, 2003, J NEUROSCI, V23, P403, DOI 10.1523/JNEUROSCI.23-02-00403.2003; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; Tu HP, 2005, BIOPHYS J, V88, P1046, DOI 10.1529/biophysj.104.049593; Tu HP, 2002, BIOPHYS J, V82, P1995, DOI 10.1016/S0006-3495(02)75548-3; Wagner LE, 2004, J BIOL CHEM, V279, P46242, DOI 10.1074/jbc.M405849200; Wagner LE, 2003, J BIOL CHEM, V278, P45811, DOI 10.1074/jbc.M306270200; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; Yoshikawa F, 1999, J BIOL CHEM, V274, P328, DOI 10.1074/jbc.274.1.328; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277	49	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17410	17419		10.1074/jbc.M601340200	http://dx.doi.org/10.1074/jbc.M601340200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16621795	hybrid			2022-12-25	WOS:000238326300067
J	Boitz, JM; Ullman, B				Boitz, Jan M.; Ullman, Buddy			A conditional mutant deficient in hypoxanthine-guanine phosphoribosyltransferase and xanthine phosphoribosyltransferase validates the purine salvage pathway of Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-ANALYSIS; STABLE TRANSFECTION; MOLECULAR-CLONING; ADENOSINE KINASE; EXPRESSION; METABOLISM; ADENINE; PROMASTIGOTES; IDENTIFICATION; LOCALIZATION	Leishmania donovani cannot synthesize purines de novo and express a multiplicity of enzymes that enable them to salvage purines from their hosts. Previous efforts to generate an L. donovani strain deficient in both hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and xanthine phosphoribosyltransferase (XPRT) using gene replacement approaches were not successful, lending indirect support to the hypothesis that either HGPRT or XPRT is crucial for purine salvage by the parasite. We now report the genetic confirmation of this hypothesis through the construction of a conditional Delta hgprt/Delta xprt mutant strain that exhibits an absolute requirement for 2'-deoxycoformycin, an inhibitor of the leishmanial adenine aminohydrolase enzyme, and either adenine or adenosine as a source of purine. Unlike wild type parasites, the Delta hgprt/Delta xprt strain cannot proliferate indefinitely without 2'-deoxycoformycin or with hypoxanthine, guanine, xanthine, guanosine, inosine, or xanthosine as the sole purine nutrient. The Delta hgprt/Delta xprt mutant infects murine bone marrow-derived macrophages < 5% as effectively as wild type parasites and cannot sustain an infection. These data establish genetically that either HGPRT or XPRT is absolutely essential for purine acquisition, parasite viability, and parasite infectivity of mouse macrophages, that all exogenous purines are funneled to hypoxanthine and/or xanthine by L. donovani, and that the purine sources within the macrophage to which the parasites have access are HGPRT or XPRT substrates.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol L224, Portland, OR 97239 USA	Oregon Health & Science University	Ullman, B (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol L224, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	ullmanb@ohsu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023682] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI23682] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen T, 1995, MOL BIOCHEM PARASIT, V74, P99, DOI 10.1016/0166-6851(95)02475-1; ALLEN TE, 1995, MOL BIOCHEM PARASIT, V73, P133, DOI 10.1016/0166-6851(94)00105-V; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; Breton M, 2005, INFECT IMMUN, V73, P6372, DOI 10.1128/IAI.73.10.6372-6382.2005; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; FREEDMAN DJ, 1993, MOL BIOCHEM PARASIT, V62, P37, DOI 10.1016/0166-6851(93)90175-W; Goyard S, 2003, MOL BIOCHEM PARASIT, V130, P31, DOI 10.1016/S0166-6851(03)00142-7; Hwang HY, 1997, J BIOL CHEM, V272, P19488, DOI 10.1074/jbc.272.31.19488; Hwang HY, 1996, J BIOL CHEM, V271, P30840, DOI 10.1074/jbc.271.48.30840; IOVANNISCI DM, 1984, J BIOL CHEM, V259, P4617; IOVANNISCI DM, 1984, MOL BIOCHEM PARASIT, V12, P139, DOI 10.1016/0166-6851(84)90131-2; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; Jardim A, 1999, J BIOL CHEM, V274, P34403, DOI 10.1074/jbc.274.48.34403; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KIDDER GW, 1979, P NATL ACAD SCI USA, V76, P3670, DOI 10.1073/pnas.76.8.3670; KOSZALKA GW, 1979, J BIOL CHEM, V254, P8185; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LOOKER DL, 1983, MOL BIOCHEM PARASIT, V9, P15, DOI 10.1016/0166-6851(83)90053-1; MARR JJ, 1978, BIOCHIM BIOPHYS ACTA, V544, P360, DOI 10.1016/0304-4165(78)90104-6; NELSON DJ, 1979, J BIOL CHEM, V254, P3959; Parsons M, 2001, MOL BIOCHEM PARASIT, V115, P19, DOI 10.1016/S0166-6851(01)00261-4; RAINEY P, 1983, P NATL ACAD SCI-BIOL, V80, P288, DOI 10.1073/pnas.80.1.288; Sambrook J, 1989, MOL CLONING LAB MANU, P9; Shi WX, 1999, J BIOL CHEM, V274, P21114, DOI 10.1074/jbc.274.30.21114; Shih S, 1998, J BIOL CHEM, V273, P1534, DOI 10.1074/jbc.273.3.1534; Sinha KM, 1999, BIOCHEM J, V339, P667, DOI 10.1042/0264-6021:3390667; Uzonna JE, 2004, J IMMUNOL, V172, P3793, DOI 10.4049/jimmunol.172.6.3793; Zarella-Boitz JM, 2004, MOL BIOCHEM PARASIT, V134, P43, DOI 10.1016/j.molbiopara.2003.08.016; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6	30	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16084	16089		10.1074/jbc.M600188200	http://dx.doi.org/10.1074/jbc.M600188200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16603734	hybrid			2022-12-25	WOS:000237996000061
J	Liu, CJ; Kong, W; Xu, K; Luan, Y; Ilalov, K; Sehgal, B; Yu, S; Howell, RD; Di Cesare, PE				Liu, Chuan-ju; Kong, Wei; Xu, Ke; Luan, Yi; Ilalov, Kiril; Sehgal, Bantoo; Yu, Shuang; Howell, Ronald D.; Di Cesare, Paul E.			ADAMTS-12 associates with and degrades cartilage oligomeric matrix protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; MULTIPLE THROMBOSPONDIN-1 REPEATS; AGGRECANASE-1 ADAMTS-4; RHEUMATOID-ARTHRITIS; ARTICULAR-CARTILAGE; BONE METABOLISM; SYNOVIAL-FLUID; SERUM MARKERS; KNEE INJURY; IN-VIVO	Loss of articular cartilage because of extracellular matrix breakdown is the hallmark of arthritis. Degradative fragments of cartilage oligomeric matrix protein (COMP), a prominent noncollagenous matrix component in articular cartilage, have been observed in the cartilage, synovial fluid, and serum of arthritis patients. The molecular mechanism of COMP degradation and the enzyme(s) responsible for it, however, remain largely unknown. ADAMTS-12 (a disintegrin and metalloprotease with thrombospondin motifs) was shown to associate with COMP both in vitro and in vivo. ADAMTS-12 selectively binds to only the epidermal growth factor-like repeat domain of COMP of the four functional domains tested. The four C-terminal TSP-1-like repeats of ADAMTS-12 are shown to be necessary and sufficient for its interaction with COMP. Recombinant ADAMTS-12 is capable of digesting COMP in vitro. The COMP-degrading activity of ADAMTS-12 requires the presence of Zn2+ and appropriate pH (7.5 - 9.5), and the level of ADAMTS-12 in the cartilage and synovium of patients with both osteoarthritis and rheumatoid arthritis is significantly higher than in normal cartilage and synovium. Together, these findings indicate that ADAMTS-12 is a new COMP-interacting and -degrading enzyme and thus may play an important role in the COMP degradation in the initiation and progression of arthritis.	NYU, Hosp Joint Dis, Musculoskeletal Res Ctr, Dept Orthopaed Surg, New York, NY 10003 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Shandong Univ, Sch Med, Inst Pathogen Biol, Shandong 250012, Peoples R China; Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; New York University; Shandong University; Yale University	Liu, CJ (corresponding author), NYU, Sch Med, Dept Orthopaed Surg, 301 E 17th St, New York, NY 10003 USA.	chuanju.liu@med.nyu.edu; pedicesare@aol.com	Liu, Chuan-ju/AAT-8165-2021	liu, chuanju/0000-0002-7181-8032; Xu, Ke Kate/0000-0002-2453-4475	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR052022] Funding Source: NIH RePORTER; NIAMS NIH HHS [R03 AR052022, AR052022] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Ambili M, 1999, J CELL BIOCHEM, V73, P218, DOI 10.1002/(SICI)1097-4644(19990501)73:2<218::AID-JCB8>3.3.CO;2-3; Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Chen AL, 2004, J ORTHOP RES, V22, P1188, DOI 10.1016/j.orthres.2004.02.013; Chen FH, 2005, J BIOL CHEM, V280, P32655, DOI 10.1074/jbc.M504778200; CHEN FHT, 2004, 50 ANN M ORTH RES SO; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Collins-Racie LA, 2004, MATRIX BIOL, V23, P219, DOI 10.1016/j.matbio.2004.05.004; Di Cesare PE, 2000, J ORTHOPAED RES, V18, P713, DOI 10.1002/jor.1100180506; Di Cesare PE, 1999, J ORTHOPAED RES, V17, P437; Di Cesare PE, 2002, MATRIX BIOL, V21, P461, DOI 10.1016/S0945-053X(02)00015-X; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DiCesare PE, 1996, J ORTHOPAED RES, V14, P946, DOI 10.1002/jor.1100140615; DiCesare PE, 1997, FEBS LETT, V412, P249, DOI 10.1016/S0014-5793(97)00789-8; Dickinson SC, 2003, MATRIX BIOL, V22, P267, DOI 10.1016/S0945-053X(03)00034-9; Dong JF, 2003, J BIOL CHEM, V278, P29633, DOI 10.1074/jbc.M301385200; Dong JF, 2002, BLOOD, V100, P4033, DOI 10.1182/blood-2002-05-1401; Duke J, 2003, APOPTOSIS, V8, P191, DOI 10.1023/A:1022926811397; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; Hashimoto G, 2004, J BIOL CHEM, V279, P32483, DOI 10.1074/jbc.M314216200; Hecht JT, 2001, MATRIX BIOL, V20, P251, DOI 10.1016/S0945-053X(01)00136-6; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kevorkian L, 2004, ARTHRITIS RHEUM-US, V50, P131, DOI 10.1002/art.11433; Kuno K, 2004, BIOCHEM BIOPH RES CO, V319, P1327, DOI 10.1016/j.bbrc.2004.05.105; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Lee NV, 2005, J BIOL CHEM, V280, P34796, DOI 10.1074/jbc.M506980200; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Llamazares M, 2003, J BIOL CHEM, V278, P13382, DOI 10.1074/jbc.M211900200; Lohmander LS, 1999, ARTHRITIS RHEUM, V42, P534, DOI 10.1002/1529-0131(199904)42:3<534::AID-ANR19>3.0.CO;2-J; LOHMANDER LS, 1994, ANN RHEUM DIS, V53, P8, DOI 10.1136/ard.53.1.8; Lopez JA, 2004, SEMIN HEMATOL, V41, P15, DOI 10.1053/j.seminhematol.2003.10.004; Mann HH, 2004, J BIOL CHEM, V279, P25294, DOI 10.1074/jbc.M403778200; MANSSON B, 1995, J CLIN INVEST, V95, P1071, DOI 10.1172/JCI117753; Martel-Pelletier J, 2001, BEST PRACT RES CL RH, V15, P805, DOI 10.1053/berh.2001.0195; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; Neidhart M, 1997, BRIT J RHEUMATOL, V36, P1151; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Ozbek S, 2002, EMBO J, V21, P5960, DOI 10.1093/emboj/cdf628; Petersson IF, 1998, BRIT J RHEUMATOL, V37, P46; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Salzet M, 2002, CURR PHARM DESIGN, V8, P493, DOI 10.2174/1381612023395664; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SAXNE T, 1992, BRIT J RHEUMATOL, V31, P583; Soejima K, 2003, BLOOD, V102, P3232, DOI 10.1182/blood-2003-03-0908; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Stracke JO, 2000, FEBS LETT, V478, P52, DOI 10.1016/S0014-5793(00)01819-6; Tao ZY, 2005, BLOOD, V106, P4139, DOI 10.1182/blood-2005-05-2029; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 2004, J BIOL CHEM, V279, P17554, DOI 10.1074/jbc.M313041200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2; Yoshida K, 2005, BBA-GEN SUBJECTS, V1725, P152, DOI 10.1016/j.bbagen.2005.06.009	65	80	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15800	15808		10.1074/jbc.M513433200	http://dx.doi.org/10.1074/jbc.M513433200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16611630	Green Accepted, hybrid			2022-12-25	WOS:000237996000028
J	Baek, HJ; Kang, YK; Roeder, RG				Baek, Hwa Jin; Kang, Yun Kyoung; Roeder, Robert G.			Human mediator enhances basal transcription by facilitating recruitment of transcription factor IIB during preinitiation complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; PROMOTER DNA; FUNCTIONAL-CHARACTERIZATION; DEPENDENT TRANSCRIPTION; IN-VIVO; INITIATION; TRAP/MEDIATOR; COACTIVATOR; HOLOENZYME	The multisubunit Mediator is a well established transcription coactivator for gene-specific activators. However, recent studies have shown that, although not essential for basal transcription by purified RNA polymerase II (pol II) and general initiation factors, Mediator is essential for basal transcription in nuclear extracts that contain a more physiological complement of factors (Mittler, G., Kremmer, E., Timmers, H. T., and Meisterernst, M. ( 2001) EMBO Rep. 2, 808 - 813; Baek, H. J., Malik, S., Qin, J., and Roeder, R. G. ( 2002) Mol. Cell. Biol. 22, 2842 - 2852). Here, mechanistic studies with immobilized DNA templates, purified factors, and factor-depleted HeLa extracts have shown (i) that Mediator enhancement of basal transcription correlates with Mediator- dependent recruitment of pol II and general initiation factors (transcription factor (TF) IIB and TFIIE) to the promoter; (ii) that Mediator and TFIIB, which both interact with pol II, are jointly required for pol II recruitment to the promoter and that TFIIB recruitment is Mediator- dependent, whereas Mediator recruitment is TFIIB-independent; (iii) that a high level of TFIIB can bypass the Mediator requirement for basal transcription and pol II recruitment in nuclear extract, thus indicating a conditional restriction of TFIIB function and a key role of Mediator in overcoming this restriction; and (iv) that an earlier rate-limiting step involves formation of a TFIID-Mediator-promoter complex. These results support a stepwise assembly model, rather than a preformed holoenzyme model, for Mediator-dependent assembly of a basal preinitiation complex and, more important, identify a step involving TFIIB as a key site of action of Mediator.	Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Rockefeller University	Roeder, RG (corresponding author), Rockefeller Univ, Biochem & Mol Biol Lab, 1230 York Ave,POB 166, New York, NY 10021 USA.	roeder@rockefeller.edu			NIDDK NIH HHS [DK071900] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071900] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asturias FJ, 2004, CURR OPIN STRUC BIOL, V14, P121, DOI 10.1016/j.sbi.2004.03.007; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; Bhaumik SR, 2004, GENE DEV, V18, P333, DOI 10.1101/gad.1148404; Bhoite LT, 2001, GENE DEV, V15, P2457, DOI 10.1101/gad.921601; Cantin GT, 2003, P NATL ACAD SCI USA, V100, P12003, DOI 10.1073/pnas.2035253100; Cho EJ, 1999, J BIOL CHEM, V274, P25807, DOI 10.1074/jbc.274.36.25807; Chou S, 1997, MOL CELL BIOL, V17, P6794, DOI 10.1128/MCB.17.12.6794; Cosma MP, 2001, MOL CELL, V7, P1213, DOI 10.1016/S1097-2765(01)00266-0; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; Fan HY, 1996, GENETICS, V142, P749; Fiedler U, 2000, BIOESSAYS, V22, P316, DOI 10.1002/(SICI)1521-1878(200004)22:4<316::AID-BIES2>3.0.CO;2-B; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gadbois EL, 1997, P NATL ACAD SCI USA, V94, P3145, DOI 10.1073/pnas.94.7.3145; Guermah M, 2001, MOL CELL BIOL, V21, P6882, DOI 10.1128/MCB.21.20.6882-6894.2001; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Johnson KM, 2002, GENE DEV, V16, P1852, DOI 10.1101/gad.995702; Kang JS, 2001, J BIOL CHEM, V276, P42003, DOI 10.1074/jbc.M105961200; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Liu Y, 2004, MOL CELL BIOL, V24, P1721, DOI 10.1128/MCB.24.4.1721-1735.2004; Malagon F, 2004, GENETICS, V166, P1215, DOI 10.1534/genetics.166.3.1215; Malik S, 2000, MOL CELL, V5, P753, DOI 10.1016/S1097-2765(00)80254-3; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Malik S, 2005, MOL CELL BIOL, V25, P2117, DOI 10.1128/MCB.25.6.2117-2129.2005; Malik S, 2004, MOL CELL BIOL, V24, P8244, DOI 10.1128/MCB.24.18.8244-8254.2004; Malik S, 2003, METHOD ENZYMOL, V364, P257; Malik S, 2002, MOL CELL BIOL, V22, P5626, DOI 10.1128/MCB.22.15.5626-5637.2002; Merker RJ, 2002, MOL CELL BIOL, V22, P8763, DOI 10.1128/MCB.22.24.8763-8773.2002; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Nair D, 2005, J BIOL CHEM, V280, P33739, DOI 10.1074/jbc.M506067200; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pal M, 2005, MOL CELL, V19, P101, DOI 10.1016/j.molcel.2005.05.024; Park JM, 2001, MOL CELL, V8, P9, DOI 10.1016/S1097-2765(01)00296-9; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Reeves WM, 2003, MOL CELL BIOL, V23, P349, DOI 10.1128/MCB.23.1.349-358.2003; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sato S, 2004, MOL CELL, V14, P685, DOI 10.1016/j.molcel.2004.05.006; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249; Takagi Y, 2006, J BIOL CHEM, V281, P80, DOI 10.1074/jbc.M508253200; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON NE, 1994, PROTEIN EXPRES PURIF, V5, P468, DOI 10.1006/prep.1994.1066; Wang G, 2005, MOL CELL, V17, P683, DOI 10.1016/j.molcel.2005.02.010; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015	50	73	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15172	15181		10.1074/jbc.M601983200	http://dx.doi.org/10.1074/jbc.M601983200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16595664	hybrid			2022-12-25	WOS:000237922200020
J	Sohn, H; Kim, YS; Kim, HT; Kim, CH; Cho, EW; Kang, HY; Kim, NS; Kim, CH; Ryu, SE; Lee, JH; Ko, JH				Sohn, Hosung; Kim, Yong-Sam; Kim, Hyun-Taek; Kim, Cheol-Hee; Cho, Eun-Wie; Kang, Hye-Yeon; Kim, Nam-Soon; Kim, Cheorl-Ho; Ryu, Seong Eon; Lee, Jeong-Hwa; Ko, Jeong Heon			Ganglioside GM3 is involved in neuronal cell death	FASEB JOURNAL			English	Article						GM3; 12-lipoxygenase; glycosphingolipid-enriched microdomains; ROS; neuronal cell death	GD3 GANGLIOSIDE; ARACHIDONIC-ACID; OXIDATIVE STRESS; RAT CEREBELLUM; APOPTOSIS; ASSOCIATION; ACTIVATION; GLUTAMATE; 12-LIPOXYGENASE; EXPRESSION	Gangliosides abundant in the nervous system have been implicated in a broad range of biological functions, including the regulation of cell proliferation and death. Glutamate-induced cell death, which is accompanied by an accumulation of reactive oxygen species (ROS), is a major contributor to pathological cell death within the nervous system. However, the mechanism underlying this neuronal cell death has not been fully elucidated. In this study, we report that ganglioside GM3 is involved in neuronal cell death. GM3 was up-regulated in the mouse hippocampal cell line HT22 death caused by glutamate. Increment in GM3 levels by both the exogenous addition of GM3 and the overexpression of the GM3 synthase gene induced neuronal cell death. Overexpression of GM3 synthase by microinjecting mRNA into zebrafish embryos resulted in neuronal cell death in the central nervous system (CNS). Conversely, RNA interference-mediated silencing of GM3 synthase rescued glutamate-induced neuronal death, as evidenced by the inhibition of massive ROS production and intracellular calcium ion influx. 12-lipoxygenase (12-lipoxygenase) (12-LOX) was recruited to glycosphingolipid-enriched microdomains (GEM) in a GM3-dependent manner during oxidative glutamate toxicity. Our findings suggest that GM3 acts as not only a mediator of oxidative HT22 death by glutamate but also a modulator of in vivo neuronal cell death.-Sohn, H., Kim, Y.-S., Kim, H.-T., Kim, C.-H., Cho, E.-W., Kang, H.-y., Kim, N.-S., Kim, C.-H., Ryu, S. E., Lee, J.-H., Ko, J.H. Ganglioside GM3 is involved in neuronal cell death.	Korea Res Inst Biosci & Biotechnol, Proteom Res Ctr, Taejon 305333, South Korea; Korea Res Inst Biosci & Biotechnol, Ctr Funct Anal Human Genome, Taejon 305333, South Korea; Chungnam Natl Univ, Taejon, South Korea; Sungkyunkwan Univ, Dept Biol Sci, Suwon, South Korea; Catholic Univ Korea, Coll Med, Dept Biochem, Seoul, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University; Sungkyunkwan University (SKKU); Catholic University of Korea	Ko, JH (corresponding author), Korea Res Inst Biosci & Biotechnol, Proteom Res Ctr, 52 Eoeun Dong, Taejon 305333, South Korea.	jhko@kribb.re.kr	Kim, Cheorl-Ho/T-6753-2019	Kim, Cheorl-Ho/0000-0002-6323-0714; Kim, Cheol-Hee/0000-0002-3019-0699				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Blader P, 2000, HUM MOL GENET, V9, P945, DOI 10.1093/hmg/9.6.945; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Brosamle C, 2002, GLIA, V39, P47, DOI 10.1002/glia.10088; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Coffey MJ, 2004, FEBS LETT, V576, P165, DOI 10.1016/j.febslet.2004.09.007; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; FREDMAN P, 1994, PROG BRAIN RES, V101, P225; Fujimoto Y, 2005, J NEURO-ONCOL, V71, P99, DOI 10.1007/s11060-004-9602-3; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garofalo T, 2003, J BIOL CHEM, V278, P8309, DOI 10.1074/jbc.M207618200; Garofalo T, 2002, J BIOL CHEM, V277, P11233, DOI 10.1074/jbc.M109601200; Giammarioli AM, 2001, FEBS LETT, V506, P45, DOI 10.1016/S0014-5793(01)02776-4; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; KAWAI K, 1994, NEUROSCI LETT, V174, P225, DOI 10.1016/0304-3940(94)90027-2; KIGUCHI K, 1990, J BIOCHEM-TOKYO, V107, P8, DOI 10.1093/oxfordjournals.jbchem.a123016; Kwon KJ, 2005, J NEUROSCI RES, V81, P73, DOI 10.1002/jnr.20520; Lebeau A, 2004, CELL DEATH DIFFER, V11, P875, DOI 10.1038/sj.cdd.4401395; LEDEEN RW, 1978, J SUPRAMOL STR CELL, V8, P1, DOI 10.1002/jss.400080102; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Li YH, 1997, J CELL BIOL, V139, P1317, DOI 10.1083/jcb.139.5.1317; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Molander M, 2000, J NEUROSCI RES, V60, P531, DOI 10.1002/(SICI)1097-4547(20000515)60:4<531::AID-JNR12>3.0.CO;2-6; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; NAKAMURA M, 1991, CANCER RES, V51, P1940; Nakatsuji Y, 2001, EXP NEUROL, V168, P290, DOI 10.1006/exnr.2000.7602; Nojiri H, 2002, CANCER DETECT PREV, V26, P114, DOI 10.1016/S0361-090X(02)00033-8; Noll ENE, 2001, EXP NEUROL, V168, P300, DOI 10.1006/exnr.2000.7603; Ono M, 1999, CANCER RES, V59, P2335; Ozeki Y, 1999, BRIT J PHARMACOL, V128, P1699, DOI 10.1038/sj.bjp.0702976; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; SAQR HE, 1993, J NEUROCHEM, V61, P395; SENN HJ, 1989, EUR J BIOCHEM, V181, P657, DOI 10.1111/j.1432-1033.1989.tb14773.x; Sioud M, 2004, TRENDS PHARMACOL SCI, V25, P22, DOI 10.1016/j.tips.2003.11.006; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Tagami S, 2002, J BIOL CHEM, V277, P3085, DOI 10.1074/jbc.M103705200; Tan S, 2001, J CELL BIOL, V152, P997, DOI 10.1083/jcb.152.5.997; Tan Shirlee, 2001, Current Topics in Medicinal Chemistry, V1, P497, DOI 10.2174/1568026013394741; Tan SL, 1998, J NEUROCHEM, V71, P95; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; THISSE C, 1993, DEVELOPMENT, V119, P1203; Watanabe R, 2002, CANCER RES, V62, P3850; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; WOLSWIJK G, 1995, GLIA, V13, P13, DOI 10.1002/glia.440130103; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Yamashita T, 2005, P NATL ACAD SCI USA, V102, P2725, DOI 10.1073/pnas.0407785102; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	57	57	60	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1248	+		10.1096/fj.05-4911fje	http://dx.doi.org/10.1096/fj.05-4911fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636105				2022-12-25	WOS:000240210300041
J	Greenberg, RS; Bernstein, AM; Benezra, M; Gelman, IH; Taliana, L; Masur, SK				Greenberg, Roseanne S.; Bernstein, Audrey M.; Benezra, Miriam; Gelman, Irwin H.; Taliana, Lavinia; Masur, Sandra K.			FAK-dependent regulation of myofibroblast differentiation	FASEB JOURNAL			English	Article						FGF; TGF beta; fibrosis	FIBROBLAST-GROWTH-FACTOR; FOCAL ADHESION KINASE; SMOOTH MUSCLE ACTIN; ENDOTHELIAL-CELL GROWTH; FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; TYROSINE PHOSPHORYLATION; NEUTRALIZING ANTIBODY; GRANULATION-TISSUE; CYCLIN D1	Fibroblasts and myofibroblasts both participate in wound healing. Transforming growth factor beta (TGF beta) induces fibroblasts to differentiate into myofibroblasts, whereas fibroblast growth factor and heparin (FGF/ h) induce myofibroblasts to "de-differentiate" into fibroblasts. TGF beta induces expression of smooth muscle alpha actin (SM alpha A) and incorporation into in stress fibers, a phenotype of differentiated myofibroblasts. Additionally, TGF beta induces the expression of fibronectin and fibronectin integrins. Fibronectin-generated signals contribute to the TGF beta-mediated myofibroblast differentiation. Because fibronectin signals are transmitted through focal adhesion kinase (FAK), it was predicted that FAK would be essential to TGF beta-mediated myofibroblast differentiation. To determine whether the FAK signaling pathway is required for myofibroblast differentiation, we used two approaches to decrease FAK in mouse embryo fibroblasts (MEFs): 1) FAK+/+ MEFs, in which FAK protein expression was greatly decreased by short hairpin RNA (shRNA), and 2) FAK-/-MEFs, which lack FAK. In both cases, the majority of cells were myofibroblasts, expressing SM alpha A in stress fibers even after treatment with FGF/ h. Furthermore, both the surface expression of FGFRs and FGF signaling were greatly reduced in FAK-/-MEFs. We conclude that FAK does not contribute to TGF beta-dependent myofibroblast differentiation. Instead, FAK was necessary for FGF/ h signaling in down-regulating expression of SM alpha A, which is synonymous with myofibroblast differentiation. FAK activation could contribute to regulating myofibroblast differentiation, thereby ameliorating fibrosis.	Mt Sinai Sch Med, Dept Ophthalmol, New York, NY 10029 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Icahn School of Medicine at Mount Sinai; Roswell Park Cancer Institute	Greenberg, RS (corresponding author), Mt Sinai Sch Med, Dept Ophthalmol, Box 1183,1 Gustave Levey Pl, New York, NY 10029 USA.	roseanne.greenberg@mssm.edu		Bernstein, Audrey/0000-0002-2537-2594	NATIONAL CANCER INSTITUTE [R24CA095823] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY017030, P30EY001867, R01EY009414, F32EY007049] Funding Source: NIH RePORTER; NCI NIH HHS [1-R24-CA095823] Funding Source: Medline; NEI NIH HHS [R01 EY09414, R01 EY009414, R01 EY017030, F32 EY07049, P30 EY001867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Armulik A, 2004, MOL BIOL CELL, V15, P2558, DOI 10.1091/mbc.E03-09-0700; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Bochaton-Piallat ML, 2000, INVEST OPHTH VIS SCI, V41, P2336; BORSI L, 1990, FEBS LETT, V261, P175, DOI 10.1016/0014-5793(90)80664-5; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLARK RAF, 1996, WOUND REPAIR OVERVIE; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; DARBY I, 1990, LAB INVEST, V63, P21; DAVID T, 1995, CORNEA, V14, P227, DOI 10.1097/00003226-199505000-00001; Denton CP, 2005, J BIOL CHEM, V280, P16053, DOI 10.1074/jbc.M413134200; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Ding Q, 2005, J BIOL CHEM, V280, P6802, DOI 10.1074/jbc.M409180200; Dugina V, 2001, J CELL SCI, V114, P3285; GARANA RMR, 1992, INVEST OPHTH VIS SCI, V33, P3271; George J, 2000, AM J PATHOL, V156, P115, DOI 10.1016/S0002-9440(10)64711-6; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GRESSNER AM, 1990, SEMIN LIVER DIS, V10, P30, DOI 10.1055/s-2008-1040455; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Han DC, 2001, ONCOGENE, V20, P346, DOI 10.1038/sj.onc.1204068; Hashimoto S, 2001, AM J RESP CRIT CARE, V163, P152, DOI 10.1164/ajrccm.163.1.2005069; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; Hinz B, 2003, THROMB HAEMOSTASIS, V90, P993, DOI 10.1160/TH03-05-0328; Hinz B, 2003, MOL BIOL CELL, V14, P2508, DOI 10.1091/mbc.E02-11-0729; Hinz B, 2002, J CELL BIOL, V157, P657, DOI 10.1083/jcb.200201049; Hinz B, 2001, AM J PATHOL, V159, P1009, DOI 10.1016/S0002-9440(10)61776-2; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; HOPPENREIJS VPT, 1994, INVEST OPHTH VIS SCI, V35, P931; Hsia DA, 2005, MOL CELL BIOL, V25, P9700, DOI 10.1128/MCB.25.21.9700-9712.2005; Ilic D, 2004, J CELL SCI, V117, P177, DOI 10.1242/jcs.00845; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Jester JV, 1996, CORNEA, V15, P505; Jester JV, 1997, CORNEA, V16, P177; Jester JV, 1999, INVEST OPHTH VIS SCI, V40, P1959; JESTER JV, 1995, INVEST OPHTH VIS SCI, V36, P809; Jester JV, 2003, EXP EYE RES, V77, P581, DOI 10.1016/S0014-4835(03)00188-X; Jester JV, 1999, PROG RETIN EYE RES, V18, P311, DOI 10.1016/S1350-9462(98)00021-4; Kawai-Kowase K, 2004, ARTERIOSCL THROM VAS, V24, P1384, DOI 10.1161/01.ATV.0000136548.17816.07; Kilkenny DM, 2003, J BIOL CHEM, V278, P17448, DOI 10.1074/jbc.M209698200; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Masur SK, 1999, INVEST OPHTH VIS SCI, V40, P904; Masur SK, 1996, P NATL ACAD SCI USA, V93, P4219, DOI 10.1073/pnas.93.9.4219; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Moissoglu K, 2005, BIOCHEM BIOPH RES CO, V330, P673, DOI 10.1016/j.bbrc.2005.03.025; Moller-Pedersen T, 1998, CURR EYE RES, V17, P736, DOI 10.1076/ceyr.17.7.736.5163; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Petridou S, 2000, INVEST OPHTH VIS SCI, V41, P89; Petroll WM, 1998, INVEST OPHTH VIS SCI, V39, P2018; RICH LF, 1992, CURR EYE RES, V11, P719, DOI 10.3109/02713689209000746; RIECK P, 1992, EXP EYE RES, V54, P987, DOI 10.1016/0014-4835(92)90163-M; RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; Roy SG, 2001, INT J BIOCHEM CELL B, V33, P723, DOI 10.1016/S1357-2725(01)00041-3; SAPPINO AP, 1990, AM J PATHOL, V137, P585; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; SHAH M, 1994, J CELL SCI, V107, P1137; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; SINGER II, 1984, J CELL BIOL, V98, P2091, DOI 10.1083/jcb.98.6.2091; SKALLI OGG, 1996, BIOL MYOFIBROBLAST R; Tashiro E, 2003, ONCOGENE, V22, P5630, DOI 10.1038/sj.onc.1206636; Tashiro E, 2003, CANCER RES, V63, P424; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Tseng SCG, 1999, J CELL PHYSIOL, V179, P325, DOI 10.1002/(SICI)1097-4652(199906)179:3<325::AID-JCP10>3.0.CO;2-X; TSUBOI R, 1990, J EXP MED, V172, P245, DOI 10.1084/jem.172.1.245; Uchio K, 1999, J VET MED SCI, V61, P769, DOI 10.1292/jvms.61.769; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Watanabe E, 1998, BASIC RES CARDIOL, V93, P30, DOI 10.1007/s003950050059; Yamauchi K, 2004, J BIOL CHEM, V279, P55104, DOI 10.1074/jbc.M407423200; YANAGISAWAMIWA A, 1992, SCIENCE, V257, P1401, DOI 10.1126/science.1382313; Young GD, 2004, J BIOL CHEM, V279, P38032, DOI 10.1074/jbc.M405658200; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	79	68	71	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					1006	+		10.1096/fj.05-4838fje	http://dx.doi.org/10.1096/fj.05-4838fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585062				2022-12-25	WOS:000240157700037
J	Gnecchi, M; He, HM; Noiseux, N; Liang, OD; Zhang, LM; Morello, F; Mu, H; Melo, LG; Pratt, RE; Ingwall, JS; Dzau, VJ				Gnecchi, Massimiliano; He, Huamei; Noiseux, Nicolas; Liang, Olin D.; Zhang, Lunan; Morello, Fulvio; Mu, Hui; Melo, Luis G.; Pratt, Richard E.; Ingwall, Joanne S.; Dzau, Victor J.			Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement	FASEB JOURNAL			English	Article						cell therapy; cytoprotection; inotropism; myocardial infarction; secreted factors	MARROW STROMAL CELLS; HUMAN BONE-MARROW; GROWTH-FACTOR-I; MYOCARDIAL REGENERATION; CARDIOMYOCYTE APOPTOSIS; ISCHEMIC-MYOCARDIUM; HEART FUNCTION; REPAIR; RAT; DIFFERENTIATE	We previously reported that intramyocardial injection of bone marrow-derived mesenchymal stem cells overexpressing Akt (Akt-MSCs) inhibits ventricular remodeling and restores cardiac function measured 2 wk after myocardial infarction. Here, we report that the functional improvement occurs in (c) 72 h. This early remarkable effect cannot be readily attributed to myocardial regeneration from the donor cells. Thus, we hypothesized that paracrine actions exerted by the cells through the release of soluble factors might be important mechanisms of tissue repair and functional improvement after injection of the Akt-MSCs. Indeed, in the current study we demonstrate that conditioned medium from hypoxic Akt-MSCs markedly inhibits hypoxia-induced apoptosis and triggers vigorous spontaneous contraction of adult rat cardiomyocytes in vitro. When injected into infarcted hearts, the Akt-MSC conditioned medium significantly limits infarct size and improves ventricular function relative to controls. Support to the paracrine hypothesis is provided by data showing that several genes, coding for factors ( VEGF, FGF-2, HGF, IGF-I, and TB4) that are potential mediators of the effects exerted by the Akt-MSC conditioned medium, are significantly up-regulated in the Akt-MSCs, particularly in response to hypoxia. Taken together, our data support Akt-MSC-mediated paracrine mechanisms of myocardial protection and functional improvement. -Gnecchi, M., He, H., Noiseux, N., Liang, O. D., Zhang, L., Morello, F., Mu, H., Melo, L. G., Pratt, R. E., Ingwall, J. S., Dzau, V. J. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Boston, MA USA	Duke University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Dzau, VJ (corresponding author), Duke Univ, Med Ctr, Dept Med, DUMC 3701, Durham, NC 27710 USA.	victor.dzau@duke.edu	Gnecchi, Massimiliano/J-8609-2018; Morello, Fulvio/G-8519-2011; Gnecchi, Massimiliano/X-7095-2019	Gnecchi, Massimiliano/0000-0001-7435-4328; Morello, Fulvio/0000-0002-7833-9632; Gnecchi, Massimiliano/0000-0001-7435-4328	NHLBI NIH HHS [HL 35610, HL73219, HL 72010, HL 63985, HL 58516, HL 5320] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005320, R01HL063985, R01HL035610, R01HL058516, R01HL073219, R01HL072010, R37HL035610] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anversa P, 2002, NATURE, V415, P240, DOI 10.1038/415240a; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Cittadini A, 1996, CIRCULATION, V93, P800, DOI 10.1161/01.CIR.93.4.800; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Couzin J, 2004, SCIENCE, V304, P192, DOI 10.1126/science.304.5668.192; Davani S, 2003, CIRCULATION, V108, P253, DOI 10.1161/01.cir.0000089186.09692.fa; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; Freestone NS, 1996, MOL CELL BIOCHEM, V164, P223, DOI 10.1007/BF00408662; FRIEDRICH J, 1995, CIRCULATION, V92, P3527, DOI 10.1161/01.CIR.92.12.3527; Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Kawada H, 2004, BLOOD, V104, P3581, DOI 10.1182/blood-2004-04-1488; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Mathur A, 2004, LANCET, V364, P183, DOI 10.1016/S0140-6736(04)16632-4; Melo LG, 2004, CIRCULATION, V109, P2386, DOI 10.1161/01.CIR.0000128597.37025.00; Min JY, 2002, ANN THORAC SURG, V74, P1568, DOI 10.1016/S0003-4975(02)03952-8; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f; Pochampally RR, 2004, P NATL ACAD SCI USA, V101, P9282, DOI 10.1073/pnas.0401558101; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Shake JG, 2002, ANN THORAC SURG, V73, P1919, DOI 10.1016/S0003-4975(02)03517-8; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Tomita S, 2002, J THORAC CARDIOV SUR, V123, P1132, DOI 10.1067/mtc.2002.120716; Wang JS, 2001, J THORAC CARDIOV SUR, V122, P699, DOI 10.1067/mtc.2001.116317	31	917	1004	1	79	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					661	669		10.1096/fj.05-5211com	http://dx.doi.org/10.1096/fj.05-5211com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581974				2022-12-25	WOS:000240130900012
J	Huang, SM; Mouri, A; Kokubo, H; Nakajima, R; Suemoto, T; Higuchi, M; Staufenbiel, M; Noda, Y; Yamaguchi, H; Nabeshima, T; Saido, TC; Iwata, N				Huang, Shu-Ming; Mouri, Akihiro; Kokubo, Hideko; Nakajima, Ryuichi; Suemoto, Takahiro; Higuchi, Makoto; Staufenbiel, Matthias; Noda, Yukihiro; Yamaguchi, Haruyasu; Nabeshima, Toshitaka; Saido, Takaomi C.; Iwata, Nobuhisa			Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; A-BETA; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; APOLIPOPROTEIN-E; DEGRADING ENDOPEPTIDASE; TRANSGENIC MICE; BRAIN; HIPPOCAMPUS; DEGRADATION	A subtle but chronic alteration in metabolic balance between amyloid-beta peptide(A beta) anabolic and catabolic activities is thought to cause A beta accumulation, leading to a decade-long pathological cascade of Alzheimer disease. However, it is still unclear whether a reduction of the catabolic activity of A beta in the brain causes neuronal dysfunction in vivo. In the present study, to clarify a possible connection between a reduction in neprilysin activity and impairment of synaptic and cognitive functions, we cross-bred amyloid precursor protein (APP) transgenic mice (APP23) with neprilysin-deficient mice and biochemically and immunoelectron-microscopically analyzed A beta accumulation in the brain. We also examined hippocampal synaptic plasticity using an in vivo recording technique and cognitive function using a battery of learning and memory behavior tests, including Y-maze, novel-object recognition, Morris water maze, and contextual fear conditioning tests at the age of 13-16 weeks. We present direct experimental evidence that reduced activity of neprilysin, the major A beta-degrading enzyme, in the brain elevates oligomeric forms of A beta at the synapses and leads to impaired hippocampal synaptic plasticity and cognitive function before the appearance of amyloid plaque load. Thus, reduced neprilysin activity appears to be a causative event that is at least partly responsible for the memory-associated symptoms of Alzheimer disease. This supports the idea that a strategy to reduce A beta oligomers in the brain by up-regulating neprilysin activity would contribute to alleviation of these symptoms.	RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan; Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Nagoya, Aichi 4668560, Japan; Gunma Univ, Sch Hlth Sci, Maebashi, Gumma 3718514, Japan; Natl Inst Radiol Sci, Mol Imaging Ctr, Chiba 2638555, Japan; Novartis Inst Biomed Res Basel, Nervous Syst Dept, CH-4002 Basel, Switzerland; Meijo Univ, Fac Pharm, Div Clin Sci Clin Pharm Practice Management & Res, Nagoya, Aichi 4688503, Japan	RIKEN; Nagoya University; Gunma University; National Institutes for Quantum Science & Technology; Novartis; Meijo University	Saido, TC (corresponding author), RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	saido@brain.riken.jp; iwatan@brain.riken.jp	Nakajima, Ryuichi/H-4540-2014; Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Nakajima, Ryuichi/0000-0002-0024-4422; Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903				Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Caccamo A, 2005, NEUROBIOL AGING, V26, P645, DOI 10.1016/j.neurobiolaging.2004.06.013; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Enya M, 1999, AM J PATHOL, V154, P271, DOI 10.1016/S0002-9440(10)65273-X; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Fukami S, 2002, NEUROSCI RES, V43, P39, DOI 10.1016/S0168-0102(02)00015-9; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Ishida A, 1997, NEUROREPORT, V8, P2133, DOI 10.1097/00001756-199707070-00009; Iwata N, 2005, PHARMACOL THERAPEUT, V108, P129, DOI 10.1016/j.pharmthera.2005.03.010; Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2002, J NEUROSCI RES, V70, P493, DOI 10.1002/jnr.10390; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kanemitsu H, 2003, NEUROSCI LETT, V350, P113, DOI 10.1016/S0304-3940(03)00898-X; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Kobayashi K, 2000, J NEUROSCI, V20, P2418; Koistinaho M, 2004, NAT MED, V10, P719, DOI 10.1038/nm1058; Kokubo H, 2005, BRAIN RES, V1031, P222, DOI 10.1016/j.brainres.2004.10.041; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lazarov O, 2002, J NEUROSCI, V22, P9785; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Manabe T, 1998, NATURE, V394, P577, DOI 10.1038/29073; Marr RA, 2003, J NEUROSCI, V23, P1992; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Morishima-Kawashima M, 2000, AM J PATHOL, V157, P2093, DOI 10.1016/S0002-9440(10)64847-X; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Nagai T, 2002, FASEB J, V16, P50, DOI 10.1096/fj.02-0448fje; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Reinhard C, 2005, EMBO J, V24, P3996, DOI 10.1038/sj.emboj.7600860; Roselli F, 2005, J NEUROSCI, V25, P11061, DOI 10.1523/JNEUROSCI.3034-05.2005; Saido TC, 2006, NEUROSCI RES, V54, P235, DOI 10.1016/j.neures.2005.12.015; Saito T, 2005, NAT MED, V11, P434, DOI 10.1038/nm1206; SAITO T, 2003, SCI AGING KNOWLEDGE, pPE1; Saria A, 1997, NEUROSCI LETT, V234, P27, DOI 10.1016/S0304-3940(97)00660-5; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Sze CI, 1997, J NEUROPATH EXP NEUR, V56, P933, DOI 10.1097/00005072-199708000-00011; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; TURNER AJ, 2004, NEPRILYSIN HDB PROTE, P419; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang DS, 2003, BIOCHEM BIOPH RES CO, V310, P236, DOI 10.1016/j.bbrc.2003.09.003; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	56	155	159	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17941	17951		10.1074/jbc.M601372200	http://dx.doi.org/10.1074/jbc.M601372200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636059	hybrid			2022-12-25	WOS:000238490300044
J	Liu, ZY; Tang, Y; Qiu, T; Cao, X; Clemens, TL				Liu, Zhongyu; Tang, Yi; Qiu, Tao; Cao, Xu; Clemens, Thomas L.			A dishevelled-1/Smad1 interaction couples WNT and bone morphogenetic protein signaling pathways in uncommitted bone marrow stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCHYMAL STEM-CELLS; TGF-BETA SUPERFAMILY; OSTEOBLAST DIFFERENTIATION; NEURAL CREST; IN-VITRO; TRANSDUCTION; GROWTH; DOMAIN; BMP; EXPRESSION	Genetic evidence from both humans and mice suggests that Wnt/beta-catenin and bone morphogenetic protein (BMP) signaling pathways are essential for bone marrow mesenchymal stem cells to differentiate into osteoblasts. Here we describe a mechanism through which BMPs antagonize Wnt signaling and retard bone marrow mesenchymal stem cell proliferation. Treatment with Wnt3a, but not BMP-2, stimulated Lef1-mediated transcriptional activity, whereas co-stimulation with both Wnt3a and BMP-2 markedly reduced Wnt3a-induced reporter activity. Immunoprecipitation assays in 293T cells transfected with individual Smads and Wnt pathway components revealed a specific interaction between Dvl-1 and Smad1 that was dependent on the presence of Wnt3a or BMP-2. Under unstimulated conditions, Dvl-1 and Smad1 are co-immunoprecipitated and form a complex through the linker region of Smad1. Wnt3a treatment transiently disrupted the Dvl-1/Smad1 interaction coincident with nuclear accumulation of beta-catenin. In contrast, when cells were exposed to both Wnt3a and BMP-2, there was an enhanced accumulation of the Dvl-1-Smad1 complex and a decreased nuclear accumulation of beta-catenin. Expression of a mutant Smad1 protein, which cannot be phosphorylated in response to BMP, eliminated the inhibitory effect of BMP on Wnt-induced beta-catenin accumulation and transcriptional activity. These results identify a potential mechanism whereby BMP-2 antagonizes Wnt signaling in osteoblast progenitors by promoting an interaction between Smad1 and Dvl-1 that restricts beta-catenin activation.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Clemens, TL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, 1670 Univ Blvd,VH G001, Birmingham, AL 35294 USA.	tclemens@path.uab.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049410] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR49410] Funding Source: Medline; NIDDK NIH HHS [DK57501] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnesen T, 2005, BIOCHEM J, V386, P433, DOI 10.1042/BJ20041071; Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006-291X(02)02951-0; Bejsovec A, 2005, CELL, V120, P11, DOI 10.1016/S0092-8674(04)01246-2; Brickley K, 2005, J BIOL CHEM, V280, P14723, DOI 10.1074/jbc.M409095200; Chen D, 2004, FRONT BIOSCI-LANDMRK, V9, P349, DOI 10.2741/1090; de la Fuente L, 2005, DEV BIOL, V282, P294, DOI 10.1016/j.ydbio.2005.03.036; Derfoul A, 2004, DIFFERENTIATION, V72, P209, DOI 10.1111/j.1432-0436.2004.07205003.x; Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22-5-849; Fanto M, 2004, J CELL SCI, V117, P527, DOI 10.1242/jcs.00973; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Gazzerro E, 2005, ENDOCRINOLOGY, V146, P3875, DOI 10.1210/en.2005-0053; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Kalajzic I, 2005, J BIOL CHEM, V280, P24618, DOI 10.1074/jbc.M413834200; Kleber M, 2004, CURR OPIN CELL BIOL, V16, P681, DOI 10.1016/j.ceb.2004.08.006; Kleber M, 2005, J CELL BIOL, V169, P309, DOI 10.1083/jcb.200411095; Koay MA, 2005, TRENDS MOL MED, V11, P129, DOI 10.1016/j.molmed.2005.01.004; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Leedham SJ, 2005, J CELL MOL MED, V9, P11, DOI 10.1111/j.1582-4934.2005.tb00333.x; Li LK, 2001, CANCER RES, V61, P4386; Li YX, 2005, CELL SIGNAL, V17, P985, DOI 10.1016/j.cellsig.2004.11.016; Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuo-Takasaki M, 2005, DEVELOPMENT, V132, P3885, DOI 10.1242/dev.01959; Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253; Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Nakagawa K, 2005, GENES CELLS, V10, P835, DOI 10.1111/j.1365-2443.2005.00880.x; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Otto WR, 2004, CELL PROLIFERAT, V37, P97, DOI 10.1111/j.1365-2184.2004.00303.x; Pan WJ, 2004, CELL RES, V14, P324, DOI 10.1038/sj.cr.7290232; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Schmidt C, 2005, ANAT EMBRYOL, V209, P349, DOI 10.1007/s00429-005-0459-9; Seto ES, 2004, TRENDS CELL BIOL, V14, P45, DOI 10.1016/j.tcb.2003.11.004; Swiercz R, 2005, BIOCHEM J, V386, P85, DOI 10.1042/BJ20041466; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Tuan RS, 2003, J BONE JOINT SURG AM, V85A, P137, DOI 10.2106/00004623-200300002-00019; Turkson J, 2005, J BIOL CHEM, V280, P32979, DOI 10.1074/jbc.M502694200; van Amerongen R, 2005, CELL CYCLE, V4, pE89; Van Raay TJ, 2004, DEV NEUROSCI-BASEL, V26, P352, DOI 10.1159/000082277; Varga AC, 2005, ONCOGENE, V24, P5713, DOI 10.1038/sj.onc.1208919; Warner DR, 2003, FEBS LETT, V539, P167, DOI 10.1016/S0014-5793(03)00155-8; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065; Zheng H, 2005, J BIOL CHEM, V280, P21612, DOI 10.1074/jbc.m502200200; Zhou SH, 2004, J BONE MINER RES, V19, P463, DOI 10.1359/JBMR.0301239	53	73	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17156	17163		10.1074/jbc.M513812200	http://dx.doi.org/10.1074/jbc.M513812200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16621789	hybrid			2022-12-25	WOS:000238326300040
J	Duvezin-Caubet, S; Rak, M; Lefebvre-Legendre, L; Tetaud, E; Bonnefoy, N; di Rago, JP				Duvezin-Caubet, Stephane; Rak, Malgorzata; Lefebvre-Legendre, Linnka; Tetaud, Emmanuel; Bonnefoy, Nathalie; di Rago, Jean-Paul			A "petite obligate" mutant of Saccharomyces cerevisiae - Functional mtDNA is lethal in cells lacking the delta subunit of mitochondrial F-1-atpase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COX2 MESSENGER-RNA; IN-VIVO ANALYSIS; ATP SYNTHASE; YEAST MITOCHONDRIA; TRANSLATIONAL ACTIVATION; GENE; DISRUPTION; EXPRESSION; ROTATION; MEMBRANE	Within the mitochondrial F1F0-ATP synthase, the nucleus-encoded delta-F1 subunit plays a critical role in coupling the enzyme proton translocating and ATP synthesis activities. In Saccharomyces cerevisiae, deletion of the delta subunit gene ( Delta delta) was shown to result in a massive destabilization of the mitochondrial genome ( mitochondrial DNA; mtDNA) in the form of 100% rho(-)/rho degrees petites ( i.e. cells missing a large portion (> 50%) of the mtDNA ( rho(-)) or totally devoid of mtDNA ( rho degrees)). Previous work has suggested that the absence of complete mtDNA ( rho(+)) in Delta delta yeast is a consequence of an uncoupling of the ATP synthase in the form of a passive proton transport through the enzyme ( i. e. not coupled to ATP synthesis). However, it was unclear why or how this ATP synthase defect destabilized the mtDNA. We investigated this question using a nonrespiratory gene ( ARG8(m)) inserted into the mtDNA. We first show that retention of functional mtDNA is lethal to Delta delta yeast. We further show that combined with a nuclear mutation ( Delta atp4) preventing the ATP synthase proton channel assembly, a lack of delta subunit fails to destabilize the mtDNA, and rho(+) Delta delta cells become viable. We conclude that Delta delta yeast cannot survive when it has the ability to synthesize the ATP synthase proton channel. Accordingly, the rho(-)/rho degrees mutation can be viewed as a rescuing event, because this mutation prevents the synthesis of the two mtDNA-encoded subunits ( Atp6p and Atp9p) forming the core of this channel. This is the first report of what we have called a "petite obligate" mutant of S. cerevisiae.	Univ Victor Segalen, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Univ Paris 06, Ctr Genet Mol, Lab Propre Associe, F-91198 Gif Sur Yvette, France	UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Sorbonne Universite	di Rago, JP (corresponding author), Univ Victor Segalen, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	jp.dirago@ibgc.u-bordeaux2.fr	Bonnefoy, Nathalie/GYD-2949-2022	Duvezin-Caubet, Stephane/0000-0002-0243-2697; Bonnefoy, Nathalie/0000-0002-5068-8849				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; BaudinBaillieu A, 1997, YEAST, V13, P353, DOI 10.1002/(SICI)1097-0061(19970330)13:4<353::AID-YEA86>3.0.CO;2-P; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Bonnefoy N, 2001, MOL CELL BIOL, V21, P2359, DOI 10.1128/MCB.21.7.2359-2372.2001; Bonnefoy N, 2001, METHOD CELL BIOL, V65, P381, DOI 10.1016/S0091-679X(01)65022-2; Bonnefoy N, 2000, MOL GEN GENET, V262, P1036, DOI 10.1007/PL00008646; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Contamine V, 2000, MICROBIOL MOL BIOL R, V64, P281, DOI 10.1128/MMBR.64.2.281-315.2000; DIRAGO JP, 1990, J BIOL CHEM, V265, P15750; Dunstan HM, 1997, GENETICS, V147, P87; Duvezin-Caubet S, 2003, P NATL ACAD SCI USA, V100, P13235, DOI 10.1073/pnas.2135169100; EPHRUSSI B, 1949, ANN I PASTEUR PARIS, V76, P351; Fillingame RH, 2000, NAT STRUCT BIOL, V7, P1002, DOI 10.1038/80902; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIRAUD MF, 1994, EUR J BIOCHEM, V245, P813; Green-Willms NS, 2001, J BIOL CHEM, V276, P6392, DOI 10.1074/jbc.M009856200; GUELIN E, 1993, J BIOL CHEM, V268, P161; Hansbro PM, 1998, CURR GENET, V33, P46, DOI 10.1007/s002940050307; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; HEIMBERG H, 1990, GENE, V90, P69, DOI 10.1016/0378-1119(90)90440-3; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JAUNIAUX JC, 1978, J BACTERIOL, V133, P1096, DOI 10.1128/JB.133.3.1096-1107.1978; Jie LZ, 1999, EMBO J, V18, P58, DOI 10.1093/emboj/18.1.58; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefebvre-Legendre L, 2001, J BIOL CHEM, V276, P6789, DOI 10.1074/jbc.M009557200; Mireau H, 2003, MOL GENET GENOMICS, V270, P1, DOI 10.1007/s00438-003-0879-2; Mueller DM, 2000, J BIOENERG BIOMEMBR, V32, P391, DOI 10.1023/A:1005532104617; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PAUL MF, 1992, THESIS U BORDEAUX 2; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Perez-Martinez X, 2003, EMBO J, V22, P5951, DOI 10.1093/emboj/cdg566; Priault M, 2005, CELL DEATH DIFFER, V12, P1613, DOI 10.1038/sj.cdd.4401697; RIGOULET M, 1979, FEBS LETT, V102, P18, DOI 10.1016/0014-5793(79)80919-9; Rose MD., 1990, METHODS YEAST GENETI; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Steele DF, 1996, P NATL ACAD SCI USA, V93, P5253, DOI 10.1073/pnas.93.11.5253; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; THORSNESS PE, 1993, GENETICS, V134, P21; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Xiao Y, 2000, J BIOL CHEM, V275, P6963, DOI 10.1074/jbc.275.10.6963	49	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16305	16313		10.1074/jbc.M513805200	http://dx.doi.org/10.1074/jbc.M513805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16608846	hybrid			2022-12-25	WOS:000238165700017
J	Tanaka, T; Nishimura, D; Wu, RC; Amano, M; Iso, T; Kedes, L; Nishida, H; Kaibuchi, K; Hamamori, Y				Tanaka, Toru; Nishimura, Dai; Wu, Ray-Chang; Amano, Mutsuki; Iso, Tatsuya; Kedes, Larry; Nishida, Hiroshi; Kaibuchi, Kozo; Hamamori, Yasuo			Nuclear Rho kinase, ROCK2, targets p300 acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; VENTRAL BODY-WALL; COILED-COIL; SMOOTH-MUSCLE; TRANSCRIPTIONAL ACTIVATION; COACTIVATOR ACTIVITY; MYOSIN PHOSPHATASE; ARACHIDONIC-ACID; ONCOPROTEIN E1A; FOCAL ADHESIONS	Rho-associated coiled-coil protein kinase ( ROCK) is an effector for the small GTPase Rho and plays a pivotal role in diverse cellular activities, including cell adhesion, cytokinesis, and gene expression, primarily through an alteration of actin cytoskeleton dynamics. Here, we show that ROCK2 is localized in the nucleus and associates with p300 acetyltransferase both in vitro and in cells. Nuclear ROCK2 is present in a large protein complex and partially cofractionates with p300 by gel filtration analysis. By immunofluorescence, ROCK2 partially colocalizes with p300 in distinct insoluble nuclear structures. ROCK2 phosphorylates p300 in vitro, and nuclear-restricted expression of constitutively active ROCK2 induces p300 phosphorylation in cells. p300 acetyltransferase activity is dependent on its phosphorylation status in cells, and p300 phosphorylation by ROCK2 results in an increase in its acetyltransferase activity in vitro. These observations suggest that nucleus-localized ROCK2 targets p300 for phosphorylation to regulate its acetyltransferase activity.	Baylor Coll Med, Dept Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, Dept Cellular & Mol Biol, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Nagoya Univ, Grad Sch Med, Inst Adv Res, Nagoya, Aichi 4668550, Japan; Gunma Univ, Sch Med, Dept Med & Biol Sci, Maebashi, Gumma 3718511, Japan; Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Med, Los Angeles, CA 90089 USA; Niigata Univ Pharm & Appl Life Sci, Niigata 9568603, Japan	Baylor College of Medicine; Baylor College of Medicine; Nagoya University; Gunma University; University of Southern California; University of Southern California; Niigata University	Hamamori, Y (corresponding author), Baylor Coll Med, Dept Med, Ctr Cardiovasc Dev, 1 Baylor Plaza,506D, Houston, TX 77030 USA.	hamamori@bcm.edu	Wu, Ray-chang/X-2018-2019; Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524; Iso, Tatsuya/0000-0001-5045-1676				Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Adnane J, 2002, CLIN CANCER RES, V8, P2225; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Antony P, 2003, MOL BRAIN RES, V115, P187, DOI 10.1016/S0169-328X(03)00207-9; Araki S, 2001, PFLUG ARCH EUR J PHY, V441, P596, DOI 10.1007/s004240000462; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BALBOA MA, 1995, J BIOL CHEM, V270, P29843; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bettinger BT, 2004, NAT REV MOL CELL BIO, V5, P410, DOI 10.1038/nrm1370; Bhowmick NA, 2003, P NATL ACAD SCI USA, V100, P15548, DOI 10.1073/pnas.2536483100; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blessing CA, 2004, TRENDS CELL BIOL, V14, P435, DOI 10.1016/j.tcb.2004.07.009; Brouillard F, 2003, J BIOL CHEM, V278, P39509, DOI 10.1074/jbc.M307123200; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, J CELL SCI, V114, P2363; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Chen XQ, 2002, J BIOL CHEM, V277, P12680, DOI 10.1074/jbc.M109839200; Chevrier V, 2002, J CELL BIOL, V157, P807, DOI 10.1083/jcb.200203034; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Feng JH, 1999, J BIOL CHEM, V274, P3744, DOI 10.1074/jbc.274.6.3744; Fomproix N, 2004, EXP CELL RES, V294, P140, DOI 10.1016/j.yexcr.2003.10.028; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Gonsior SM, 1999, J CELL SCI, V112, P797; Goodman RH, 2000, GENE DEV, V14, P1553; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; IRVINE RF, 2002, SCI STKE, pRE13; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Leung T, 1996, MOL CELL BIOL, V16, P5313; Leverrier Y, 2001, NAT CELL BIOL, V3, pE91, DOI 10.1038/35070151; Lu J, 2001, DEV BIOL, V240, P404, DOI 10.1006/dbio.2001.0403; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; Newton AL, 2000, J BIOL CHEM, V275, P15128, DOI 10.1074/jbc.M910396199; Pederson T, 2005, MOL BIOL CELL, V16, P5055, DOI 10.1091/mbc.E05-07-0656; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Poizat C, 2005, MOL CELL BIOL, V25, P2673, DOI 10.1128/MCB.25.7.2673-2687.2005; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Roovers K, 2003, DEV CELL, V5, P273, DOI 10.1016/S1534-5807(03)00206-5; Schmidt A, 2002, J BIOL CHEM, V277, P14581, DOI 10.1074/jbc.M111108200; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Sebbagh M, 2005, J EXP MED, V201, P465, DOI 10.1084/jem.20031877; See RH, 2001, J BIOL CHEM, V276, P16310, DOI 10.1074/jbc.M008113200; Shimizu T, 2003, J BIOL CHEM, V278, P46046, DOI 10.1074/jbc.M306458200; Shimizu Y, 2005, J CELL BIOL, V168, P941, DOI 10.1083/jcb.200411179; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Su LF, 2001, J BIOL CHEM, V276, P3231, DOI 10.1074/jbc.M005547200; Takahashi N, 1999, GENOMICS, V55, P235, DOI 10.1006/geno.1998.5344; Tanaka H, 2002, J CELL BIOL, V158, P321, DOI 10.1083/jcb.200202071; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Thumkeo D, 2005, GENES CELLS, V10, P825, DOI 10.1111/j.1365-2443.2005.00882.x; Thumkeo D, 2003, MOL CELL BIOL, V23, P5043, DOI 10.1128/MCB.23.14.5043-5055.2003; Ueda H, 2001, J BIOL CHEM, V276, P42527, DOI 10.1074/jbc.M102529200; VAN AL, 1997, GENE DEV, V11, P2295; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Wu Y, 2005, J MUSCLE RES CELL M, V26, P123, DOI 10.1007/s10974-005-2579-5; Yoneda A, 2005, J CELL BIOL, V170, P443, DOI 10.1083/jcb.200412043; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; Yuan LW, 2002, BBA-MOL CELL RES, V1592, P205, DOI 10.1016/S0167-4889(02)00327-0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	86	73	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15320	15329		10.1074/jbc.M510954200	http://dx.doi.org/10.1074/jbc.M510954200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574662	hybrid			2022-12-25	WOS:000237922200036
J	Petermann, I; Mayer, C; Stypmann, J; Biniossek, ML; Tobin, DJ; Engelen, MA; Dandekar, T; Grune, T; Schild, L; Peters, C; Reinheckel, T				Petermann, Ivonne; Mayer, Christian; Stypmann, Joerg; Biniossek, Martin L.; Tobin, Desmond J.; Engelen, Markus A.; Dandekar, Thomas; Grune, Tilman; Schild, Lorenz; Peters, Christoph; Reinheckel, Thomas			Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice	FASEB JOURNAL			English	Article						protease; cardiomyopathy; lysosome; proteome	DILATED CARDIOMYOPATHY; OXIDATIVE STRESS; HEART-FAILURE; POLYACRYLAMIDE-GELS; PROTEINS; PEPTIDE; PROLIFERATION; KERATINOCYTE; DEGRADATION; DISRUPTION	Although lysosomal proteases are expressed in the heart at considerable levels, their specific functions in this organ remain elusive. Mice deficient for the lysosomal cysteine protease cathepsin L (CTSL) develop a late onset dilated cardiomyopathy (DCM) that is characterized by cardiac chamber dilation, fibrosis, and impaired cardiac contraction at 12 month of age. Investigation of the pathogenic sequence of DCM in ctsl(-/-) mice revealed numerous dysmorphic lysosome-like structures in heart muscle as early as 3 days after birth, whereas skeletal muscle was not affected. Labeling of the acidic cell compartment of neonatal cardiomyocytes and detection of lysosomal markers after subcellular fractionation confirmed increased lysosome content in CTSL deficient myocardium; however, specific storage materials were not detected. The myocardium of ctsl(-/-) and ctsl(-/-) mice revealed no differences in incidence of cell death, proliferation, and capillary density during DCM progression. However, an observed increase in mRNA expression of natriuretic peptides in young adult mice indicates the activation of the adaptive "fetal" gene program, while proteome analysis revealed decreased levels of the sarcomere-associated proteins alpha-tropomyosin, desmin, and calsarcin 1, as well as considerable changes of metabolic enzymes. Bioinformatic pathway analysis suggested a switch to anaerobic catabolism and impairment of mitochondrial respiration. This interpretation was supported by a 50% reduction in resting state oxygen consumption and impaired respiration capacity in ctsl(-/-) myocardial homogenates. In summary, the data indicate an essential role of CTSL in maintaining the structure of the endosomal/lysosomal compartment in cardiomyocytes. Lysosomal impairment in ctsl(-/-) hearts results in metabolic and sarcomeric alterations that promote DCM development. Petermann, I., Mayer, C., Stypmann, J., Biniossek, M. L., Tobin, D. J., Engelen, M. A., Dandekar, T., Grune, T., Schild, L., Peters, C., Reinheckel, T. Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice.	Univ Freiburg, Inst Mol Med & Zellforsch, D-79104 Freiburg, Germany; Univ Munster, Univ Klinikum,Zentrum Klin Forsch Munster, Med Klin & Poliklin Kardiol & Angiol C, Zent Projektgrp Kleintierdiagnost Interdisziplina, Munster, Germany; Univ Bradford, Sch Life Sci, Bradford BD7 1DP, W Yorkshire, England; Biozentrum, Lehrstuhl Bioinformat, Wurzburg, Germany; Univ Dusseldorf, Environm Med Res Inst, D-4000 Dusseldorf, Germany; Otto Von Guericke Univ, Inst Klin Chem & Pathol Biochem, Bereich Pathol Biochem, Fak Med, Magdeburg, Germany	University of Freiburg; University of Munster; University of Bradford; University of Wurzburg; Heinrich Heine University Dusseldorf; Otto von Guericke University	Peters, C (corresponding author), Univ Freiburg, Inst Mol Med & Zellforsch, D-79104 Freiburg, Germany.	christoph.peters@mol-med.uni.freiburg-de	Reinheckel, Thomas/AAL-9761-2021; Engelen, Markus/AAV-8632-2020; Dandekar, Thomas/A-4431-2017; Tobin, Desmond/A-5228-2009	Reinheckel, Thomas/0000-0001-9866-9105; Dandekar, Thomas/0000-0003-1886-7625; Grune, Tilman/0000-0003-4775-9973; Tobin, Desmond/0000-0003-4566-9392				Ahn SG, 2003, GENE DEV, V17, P516, DOI 10.1101/gad.1044503; Bednarski E, 1997, J NEUROSCI, V17, P4006; Bromme D, 2002, CURR PHARM DESIGN, V8, P1639, DOI 10.2174/1381612023394179; Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4; Chevallet M, 2003, J BIOL CHEM, V278, P37146, DOI 10.1074/jbc.M305161200; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Foo RSY, 2005, J CLIN INVEST, V115, P565, DOI 10.1172/JCI200524569; Francis Gary S., 2001, American Journal of Medicine, V110, p37S; Frey N, 2004, NAT MED, V10, P1336, DOI 10.1038/nm1132; Garnier A, 2003, J PHYSIOL-LONDON, V551, P491, DOI 10.1113/jphysiol.2003.045104; Giordano FJ, 2005, J CLIN INVEST, V115, P500, DOI 10.1172/JCI200524408; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100; Huss JM, 2005, J CLIN INVEST, V115, P547, DOI 10.1172/JCI200524405; Ide T, 2001, CIRC RES, V88, P529, DOI 10.1161/01.RES.88.5.529; Kussmann M, 1997, J MASS SPECTROM, V32, P593; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Li H, 2000, P NATL ACAD SCI USA, V97, P3467, DOI 10.1073/pnas.97.7.3467; MAISCH B, 1996, CARDIOLOGY S1, V81, P2; Marin-Garcia J, 2001, CARDIOVASC RES, V52, P103, DOI 10.1016/S0008-6363(01)00368-6; Mason JW, 2003, CARDIOVASC RES, V60, P5, DOI 10.1016/S0008-6363(03)00437-1; MCMANUS JFA, 1948, STAIN TECHNOL, V23, P99, DOI 10.3109/10520294809106232; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Morita H, 2005, J CLIN INVEST, V115, P518, DOI 10.1172/JCI200524351; MOWRY RW, 1958, LAB INVEST, V7, P566; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Nian M, 2004, CIRC RES, V94, P1543, DOI 10.1161/01.RES.0000130526.20854.fa; Nishimune H, 2000, NAT CELL BIOL, V2, P906, DOI 10.1038/35046558; Nohl H, 2003, BIOCHEM SOC T, V31, P1308; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Perriard JC, 2003, TRENDS CARDIOVAS MED, V13, P30, DOI 10.1016/S1050-1738(02)00209-8; PERTOFT H, 1978, ANAL BIOCHEM, V88, P271, DOI 10.1016/0003-2697(78)90419-0; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Rawlings ND, 2000, NUCLEIC ACIDS RES, V28, P323, DOI 10.1093/nar/28.1.323; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; Somme L., 1993, Arctic Insect News, P2; Strauch OF, 2003, PEDIATR RES, V54, P701, DOI 10.1203/01.PDR.0000084085.65972.3F; Stypmann J, 2002, P NATL ACAD SCI USA, V99, P6234, DOI 10.1073/pnas.092637699; Suttner Stefan W, 2004, Curr Opin Crit Care, V10, P336, DOI 10.1097/01.ccx.0000135513.26376.4f; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Tobin DJ, 2002, AM J PATHOL, V160, P1807, DOI 10.1016/S0002-9440(10)61127-3; Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182; WONG SHY, 1987, CLIN CHEM, V33, P214; Yasothornsrikul S, 2003, P NATL ACAD SCI USA, V100, P9590, DOI 10.1073/pnas.1531542100	52	58	60	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1266	+		10.1096/fj.05-5517fje	http://dx.doi.org/10.1096/fj.05-5517fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636100				2022-12-25	WOS:000240210300047
J	Tomkova, K; El-Rifai, W; Vilgelm, A; Kelly, MC; Wang, TC; Zaika, AI				Tomkova, K.; El-Rifai, W.; Vilgelm, A.; Kelly, M. C.; Wang, T. C.; Zaika, A. I.			The gastrin gene promoter is regulated by p73 isoforms in tumor cells	ONCOGENE			English	Article						p53; p63; p73; gastric tumor; esophageal tumor; colorectal tumor	INTESTINAL EPITHELIAL-CELLS; GLYCINE-EXTENDED GASTRIN; WILD-TYPE P73; COLORECTAL-CARCINOMA; TRANSGENIC MICE; FAMILY-MEMBERS; HUMAN CANCERS; LUNG-CANCER; IN-VITRO; EXPRESSION	p73, a new p53 family member, is a transcription factor that is increasingly recognized in cancer research as an important player in tumorigenesis as well as in chemotherapeutic drug sensitivity. Despite the substantial structural and functional similarities to p53, accumulating evidence suggests that p53 and p73 may differently regulate their transcriptional targets. In this study, we have investigated the role of p73 in regulation of the gastrin gene promoter. Gastrin is a peptide hormone and an important factor in determining the progression of a number of human malignancies. Our results show that p73 can bind to the gastrin promoter. This leads to transcriptional upregulation of gastrin mRNA. We also found that the levels of gastrin and p73 transcripts correlate in primary gastric tumors. Taken together, our results demonstrate a novel mechanism for regulation of gastrin gene transcription and support a concept that p53 and p73 may have different biological roles in tumors.	Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Columbia Univ, Med Ctr, Div Digest & Liver Dis, New York, NY USA	Vanderbilt University; Vanderbilt University; Columbia University	Zaika, AI (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg, 1255 Light Hall, Nashville, TN 37232 USA.	alex.zaika@vanderbilt.edu		Vilgelm, Anna/0000-0002-4446-913X; Tomkova, Katarina/0000-0003-0482-5707; Wang, Timothy/0000-0001-5730-3019	NCI NIH HHS [CA-108956] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA108956] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aly A, 2004, BBA-REV CANCER, V1704, P1, DOI 10.1016/j.bbcan.2004.01.004; Aly A, 2001, INT J CANCER, V94, P307, DOI 10.1002/ijc.1483; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Brown D, 2003, ENDOCRINOLOGY, V144, P201, DOI 10.1210/en.2002-220501; Caplin M, 2000, BRIT J SURG, V87, P1035, DOI 10.1046/j.1365-2168.2000.01488.x; CICCOTOSTO GD, 1995, GASTROENTEROLOGY, V109, P1142, DOI 10.1016/0016-5085(95)90572-3; Cobb S, 2004, CANCER-AM CANCER SOC, V100, P1311, DOI 10.1002/cncr.20094; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; FINLEY GG, 1993, CANCER RES, V53, P2919; Fox JG, 2003, GASTROENTEROLOGY, V124, P1879, DOI 10.1016/S0016-5085(03)00406-2; Goetze JP, 2000, CANCER, V88, P2487, DOI 10.1002/1097-0142(20000601)88:11<2487::AID-CNCR9>3.0.CO;2-E; Guan M, 2003, JPN J CLIN ONCOL, V33, P215, DOI 10.1093/jjco/hyg045; Han S, 1999, EUR J SURG ONCOL, V25, P194, DOI 10.1053/ejso.1998.0626; HANSEN OH, 1976, GUT, V17, P536, DOI 10.1136/gut.17.7.536; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Kang MJ, 2000, CLIN CANCER RES, V6, P1767; KOCHMAN ML, 1992, BIOCHEM BIOPH RES CO, V189, P1165, DOI 10.1016/0006-291X(92)92326-S; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; Koh TJ, 2004, CANCER RES, V64, P196, DOI 10.1158/0008-5472.CAN-03-2112; Liu L, 2001, J INT MED RES, V29, P297, DOI 10.1177/147323000102900406; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Nimura Y, 1998, INT J CANCER, V78, P437, DOI 10.1002/(SICI)1097-0215(19981109)78:4<437::AID-IJC8>3.0.CO;2-V; Pilozzi E, 2003, J CLIN PATHOL-MOL PA, V56, P60, DOI 10.1136/mp.56.1.60; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Seva C, 1996, FEBS LETT, V378, P74, DOI 10.1016/0014-5793(95)01414-4; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 2003, AM J PHYSIOL-GASTR L, V284, pG328, DOI 10.1152/ajpgi.00351.2002; Stiewe T, 2004, CLIN CANCER RES, V10, P626, DOI 10.1158/1078-0432.CCR-0153-03; Sun XF, 2002, CLIN CANCER RES, V8, P165; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Tannapfel A, 2001, J PATHOL, V195, P163, DOI 10.1002/path.947; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Tomkova K, 2004, CANCER RES, V64, P6390, DOI 10.1158/0008-5472.CAN-04-2176; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Weber A, 2002, INT J CANCER, V99, P22, DOI 10.1002/ijc.10296; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179	41	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					6032	6036		10.1038/sj.onc.1209610	http://dx.doi.org/10.1038/sj.onc.1209610			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16636659				2022-12-25	WOS:000240826300012
J	Mizumoto, Y; Kyo, S; Ohno, S; Hashimoto, M; Nakamura, M; Maida, Y; Sakaguchi, J; Takakura, M; Inoue, M; Kiyono, T				Mizumoto, Y.; Kyo, S.; Ohno, S.; Hashimoto, M.; Nakamura, M.; Maida, Y.; Sakaguchi, J.; Takakura, M.; Inoue, M.; Kiyono, T.			Creation of tumorigenic human endometrial epithelial cells with intact chromosomes by introducing defined genetic elements	ONCOGENE			English	Article						endometrial cancer; carcinogenesis; immortalization; tumorigenicity; K-ras	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN TUMOR-CELLS; MICROSATELLITE INSTABILITY; 3T3-L1 ADIPOCYTES; IN-VITRO; PTEN; SUPPRESSOR; CARCINOGENESIS; CARCINOMA; HYPERPLASIA	Several genetic mutations have been identified in human endometrial cancers, but the specific combinations of mutations required to form endometrial cancer cells remain unknown. In the present study, we established an in vitro model of endometrial carcinogenesis, in which defined genetic elements were introduced into endometrial epithelial cells to create transformed endometrial cells at different stages. Introduction of the human papillomavirus type 16 E6/E7 gene and the human telomerase reverse transcriptase (hTERT) gene into human primary endometrial epithelial cells was sufficient to generate immortalized cells. Introduction of hTERT in early passages stabilized telomeres and created immortalized cells with normal karyotype, whereas introduction of hTERT in later passages generated immortalized cells but with widespread chromosome abnormalities. However, neither of those two immortalized cell lines exhibited tumorigenic phenotypes. Tumorigenic endometrial epithelial cells with invasive capacity were created by introducing a mutant K-ras allele into immortalized cells, keeping their chromosomes intact. Inhibiting the PTEN gene and activating Akt pathways did not create tumorigenic phenotypes, although the latter conferred anchorage-independent growth capacity. These findings suggest that neoplastic transformation of human endometrial cells can occur in the absence of widespread chromosomal abnormality, and that the combination of Rb inactivation, telomerase activation and altered K-ras signaling is sufficient for in vitro neoplastic transformation. The present experimental model can help clarify the genetic requirements for endometrial carcinogenesis, and it is useful for testing and developing specific inhibitors of specific oncogenic pathways.	Kanazawa Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Natl Canc Ctr, Res Inst, Div Virol, Kanazawa, Ishikawa, Japan	Kanazawa University; National Cancer Center - Japan	Kyo, S (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	satoruky@med.kanazawa-u.ac.jp	Kiyono, Tohru/H-5834-2011; Takakura, Masahiro/E-1080-2011					Akoum A, 1996, J REPROD MED, V41, P555; Arnold JT, 2001, HUM REPROD, V16, P836, DOI 10.1093/humrep/16.5.836; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Boland CR, 1998, CANCER RES, V58, P5248; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; ClassenLinke I, 1997, CELL TISSUE RES, V287, P171; ENOMOTO T, 1991, CANCER RES, V51, P5308; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hirasawa A, 2003, CLIN CANCER RES, V9, P5675; Inoue M, 2001, INT J GYNECOL CANCER, V11, P339, DOI 10.1046/j.1525-1438.2001.01046.x; Kanaya T, 2005, AM J CLIN PATHOL, V124, P89, DOI 10.1309/PAACLG8DXDK0X2B1; KATABUCHI H, 1995, CANCER RES, V55, P5556; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kyo S, 2003, AM J PATHOL, V163, P2259, DOI 10.1016/S0002-9440(10)63583-3; Levine RL, 1998, CANCER RES, V58, P3254; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maxwell GL, 1998, CANCER RES, V58, P2500; Mutter GL, 1999, J CLIN PATHOL-MOL PA, V52, P257, DOI 10.1136/mp.52.5.257; Niemann TH, 1997, GYNECOL ONCOL, V65, P232, DOI 10.1006/gyno.1997.4664; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sawada M, 2004, CELL DEATH DIFFER, V11, P997, DOI 10.1038/sj.cdd.4401438; Semczuk Andrzej, 2004, Archives of Gynecology and Obstetrics, V269, P104, DOI 10.1007/s00404-002-0449-6; Sonoda G, 1997, GENE CHROMOSOME CANC, V18, P115, DOI 10.1002/(SICI)1098-2264(199702)18:2<115::AID-GCC6>3.0.CO;2-5; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tang XQ, 2005, J BIOL CHEM, V280, P22523, DOI 10.1074/jbc.M501949200; Tashiro H, 1997, CANCER RES, V57, P3935; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zimonjic D, 2001, CANCER RES, V61, P8838	31	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5673	5682		10.1038/sj.onc.1209575	http://dx.doi.org/10.1038/sj.onc.1209575			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636665				2022-12-25	WOS:000240599100009
J	Yan, B; Wang, H; Wang, H; Zhuo, D; Li, F; Kon, T; Dewhirst, M; Li, CY				Yan, B.; Wang, H.; Wang, H.; Zhuo, D.; Li, F.; Kon, T.; Dewhirst, M.; Li, C-Y			Apoptotic DNA fragmentation factor maintains chromosome stability in a P53-independent manner	ONCOGENE			English	Article						apoptosis; DNA fragmentation; chromosome instability; tumor/cancer	CELL-CYCLE CHECKPOINTS; THYMIDINE KINASE LOCUS; SACCHAROMYCES-CEREVISIAE; NEUROBLASTOMA TUMORS; COLORECTAL CANCERS; MUTATION ASSAY; ENDONUCLEASE-G; DEGRADATION; INSTABILITY; LINE	DNA fragmentation factor (DFF)/caspase-activated DNase (CAD) is responsible for DNA fragmentation, a hallmark event during apoptosis. Although DNA fragmentation is an evolutionarily conserved process across species, its biological function is not clearly understood. In this study, we constructed cell lines expressing a mutant ICAD (inhibitor of CAD) protein that is resistant to caspase cleavage and therefore constantly binds to DFF/CAD and inhibits DNA fragmentation. We found that irradiation of these cells led to increased chromosome aberrations and aneuploidy when compared with their parental controls. The increased chromosome instability is observed irrespective of cellular P53 status, suggesting that the effect of DFF/CAD is independent of P53. Inhibition of apoptotic DNA fragmentation resulted in increased clonogenic survival of irradiated cells and a delay in removal of cells with DNA damages induced by radiation, an effect similar to that in cells with p53 mutations. Consistent with DFF/CAD's effect on clonogenic survival, tumors established from cells deficient in DNA fragmentation showed enhanced growth in nude mice. Therefore, our results suggest that DFF/CAD plays an important and P53-independent role in maintaining chromosome stability and suppressing tumor development.	Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Sichuan Univ, W China Affiliated Hosp 2, Chengdu, Peoples R China	Duke University; Duke University; Sichuan University	Li, CY (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Box 3455, Durham, NC 27710 USA.	chuanyuan.li@duke.edu	Dewhirst, Mark/Q-1302-2019; Li, Chuan-Yuan/H-4148-2013	Dewhirst, Mark/0000-0003-3459-6546; 				Abel F, 2004, INT J ONCOL, V25, P1297; Abel F, 2002, BRIT J CANCER, V86, P596, DOI 10.1038/sj.bjc.6600111; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; Judson H, 2000, HUM GENET, V106, P406, DOI 10.1007/s004390000257; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Konishi S, 2002, CANCER-AM CANCER SOC, V95, P2473, DOI 10.1002/cncr.10987; Lechardeur D, 2000, J CELL BIOL, V150, P321, DOI 10.1083/jcb.150.2.321; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; LIBER HL, 1982, MUTAT RES, V94, P467, DOI 10.1016/0027-5107(82)90308-6; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARIS JM, 1995, CANCER RES, V55, P4664; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SKOPEK TR, 1978, BIOCHEM BIOPH RES CO, V84, P411, DOI 10.1016/0006-291X(78)90185-7; Slane JM, 2000, BRAIN RES, V867, P70, DOI 10.1016/S0006-8993(00)02258-7; SPENCER F, 1990, GENETICS, V124, P237; Van Gele M, 1998, CANCER RES, V58, P1503; Van Gele M, 1998, GENE CHROMOSOME CANC, V23, P67, DOI 10.1002/(SICI)1098-2264(199809)23:1<67::AID-GCC10>3.0.CO;2-B; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Yan B, 2006, P NATL ACAD SCI USA, V103, P1504, DOI 10.1073/pnas.0507779103; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; YANDELL DW, 1986, CANCER GENET CYTOGEN, V20, P231, DOI 10.1016/0165-4608(86)90078-6	34	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5370	5376		10.1038/sj.onc.1209535	http://dx.doi.org/10.1038/sj.onc.1209535			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16619042				2022-12-25	WOS:000240144900002
J	Bader, S; Kortholt, A; Snippe, H; Van Haastert, PJM				Bader, Sonya; Kortholt, Arjan; Snippe, Helena; Van Haastert, Peter J. M.			DdPDE4, a novel cAMP-specific phosphodiesterase at the surface of dictyostelium cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CGMP-SPECIFIC PHOSPHODIESTERASE; SIGNAL-TRANSDUCTION PATHWAYS; TERMINAL DIFFERENTIATION; MOLECULAR-CLONING; DISCOIDEUM; GENE; IDENTIFICATION; PROMOTERS; BINDING	Dictyostelium discoideum cells possess multiple cyclic nucleotide phosphodiesterases that belong either to class I enzymes that are present in all eukaryotes or to the rare beta-lactamase class II. We describe here the identification and characterization of DdPDE4, the third class I enzyme of Dictyostelium. The deduced amino acid sequence predicts that DdPDE4 has a leader sequence, two transmembrane segments, and an extracellular catalytic domain that exhibits a high degree of homology with human cAMP-specific PDE8. Expression of the catalytic domain of DdPDE4 shows that the enzyme is a cAMP-specific phosphodiesterase with a Km of 10 mu M; cGMP is hydrolyzed at least 100-fold more slowly. The full-length protein is shown to be membrane-bound with catalytic activity exposed to the extracellular medium. Northern blots and activity measurements reveal that expression of DdPDE4 is low during single cell stages and increases at 9 h of starvation, corresponding with mound stage. A function during multicellular development is confirmed by the phenotype of ddpde4(-) knock-out strains, showing normal aggregation but impaired development from the mound stage on. These results demonstrate that DdPDE4 is a unique membrane-bound phosphodiesterase with an extracellular catalytic domain regulating intercellular cAMP during multicellular development.	Univ Groningen, Dept Mol Cell Biol, NL-9751 NN Haren, Netherlands	University of Groningen	Van Haastert, PJM (corresponding author), Univ Groningen, Dept Mol Cell Biol, Kerklaan 30, NL-9751 NN Haren, Netherlands.	P.J.M.van.Haastert@rug.nl	kortholt, arjan/L-9795-2017	kortholt, arjan/0000-0001-8174-6397				BARRA J, 1980, MOL GEN GENET, V177, P607; Bosgraaf L, 2002, EMBO J, V21, P4560, DOI 10.1093/emboj/cdf438; Bosgraaf L, 2002, MOL BIOL CELL, V13, P3878, DOI 10.1091/mbc.E02-05-0302; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; FAURE M, 1989, DEV BIOL, V131, P366, DOI 10.1016/S0012-1606(89)80010-7; FAURE M, 1990, MOL CELL BIOL, V10, P1921, DOI 10.1128/MCB.10.5.1921; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; Fisher DA, 1998, BIOCHEM BIOPH RES CO, V246, P570, DOI 10.1006/bbrc.1998.8684; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; FRANKE J, 1987, DEV BIOL, V124, P504, DOI 10.1016/0012-1606(87)90503-3; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; Goldberg JM, 2002, P NATL ACAD SCI USA, V99, P6749, DOI 10.1073/pnas.102167299; GREEN AA, 1975, CELL, V6, P129, DOI 10.1016/0092-8674(75)90003-3; HALL AL, 1993, DEV BIOL, V157, P73, DOI 10.1006/dbio.1993.1113; Han P, 1997, J BIOL CHEM, V272, P16152, DOI 10.1074/jbc.272.26.16152; Kim HJ, 1998, J BIOL CHEM, V273, P30859, DOI 10.1074/jbc.273.47.30859; Kreppel L, 2004, NUCLEIC ACIDS RES, V32, pD332, DOI 10.1093/nar/gkh138; Kuwayama H, 2001, BIOCHEM J, V353, P635, DOI 10.1042/0264-6021:3530635; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; Laub MT, 1998, MOL BIOL CELL, V9, P3521, DOI 10.1091/mbc.9.12.3521; Loomis WF, 1997, J CELL SCI, V110, P1141; Loughney K, 1998, GENE, V216, P139, DOI 10.1016/S0378-1119(98)00303-5; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; Meima ME, 2003, J BIOL CHEM, V278, P14356, DOI 10.1074/jbc.M209648200; Meima ME, 2002, MOL BIOL CELL, V13, P3870, DOI 10.1091/mbc.E02-05-0285; Meima ME, 1999, DEV BIOL, V212, P182, DOI 10.1006/dbio.1999.9352; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; Mohanty S, 2001, GENE DEV, V15, P1435, DOI 10.1101/gad.871101; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; PODGORSKI GJ, 1989, MOL CELL BIOL, V9, P3938, DOI 10.1128/MCB.9.9.3938; Roelofs J, 2002, J BIOL CHEM, V277, P9167, DOI 10.1074/jbc.M111437200; Rosman GJ, 1997, GENE, V191, P89, DOI 10.1016/S0378-1119(97)00046-2; Saran S, 2002, J MUSCLE RES CELL M, V23, P793, DOI 10.1023/A:1024483829878; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; Soderling SH, 1998, P NATL ACAD SCI USA, V95, P8991, DOI 10.1073/pnas.95.15.8991; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; Sucgang R, 1997, DEV BIOL, V192, P181, DOI 10.1006/dbio.1997.8720; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; Thomason PA, 1998, EMBO J, V17, P2838, DOI 10.1093/emboj/17.10.2838; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMCHIK KJ, 1981, SCIENCE, V212, P443, DOI 10.1126/science.6259734; TORPHY TJ, 1992, J BIOL CHEM, V267, P1798; Veltman DM, 2005, MOL BIOL CELL, V16, P976, DOI 10.1091/mbc.e04-08-0701; Wang N, 1996, EMBO J, V15, P3890, DOI 10.1002/j.1460-2075.1996.tb00763.x; Wang N, 1999, MOL CELL BIOL, V19, P4750; Weening KE, 2003, DEV BIOL, V255, P373, DOI 10.1016/S0012-1606(02)00077-5; Wessels DJ, 2000, MOL BIOL CELL, V11, P2803, DOI 10.1091/mbc.11.8.2803; WU L, 1995, DEV BIOL, V167, P1, DOI 10.1006/dbio.1995.1001; YEH RP, 1978, DEV BIOL, V66, P361, DOI 10.1016/0012-1606(78)90245-2; Yuasa K, 2001, EUR J BIOCHEM, V268, P168, DOI 10.1046/j.1432-1327.2001.01866.x	51	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20018	20026		10.1074/jbc.M600040200	http://dx.doi.org/10.1074/jbc.M600040200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16644729	Green Published, hybrid			2022-12-25	WOS:000239038200026
J	Bukys, MA; Orban, T; Kim, PY; Beck, DO; Nesheim, ME; Kalafatis, M				Bukys, Michael A.; Orban, Tivadar; Kim, Paul Y.; Beck, Daniel O.; Nesheim, Michael E.; Kalafatis, Michael			The structural integrity of anion binding exosite I of thrombin is required and sufficient for timely cleavage and activation of factor V and factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN ALPHA-THROMBIN; AMINO-ACID SUBSTITUTION; PARTICLE MESH EWALD; PROTEIN-C; FACTOR-XA; PROTHROMBIN ACTIVATION; TYROSINE SULFATION; PROEXOSITE-I; FUNCTIONAL-CHARACTERIZATION; HUMAN MEIZOTHROMBIN	alpha-Thrombin has two separate electropositive binding exosites ( anion binding exosite I, ABE-I and anion binding exosite II, ABE-II) that are involved in substrate tethering necessary for efficient catalysis. alpha-Thrombin catalyzes the activation of factor V and factor VIII following discrete proteolytic cleavages. Requirement for both anion binding exosites of the enzyme has been suggested for the activation of both procofactors by alpha-thrombin. We have used plasma-derived alpha-thrombin, alpha-thrombin ( a thrombin molecule that has only ABE-II available), and a recombinant prothrombin molecule rMZ-II (R155A/R284A/R271A) that can only be cleaved at Arg320 (resulting in an enzymatically active molecule that has only ABE-I exposed, rMZ-IIa) to ascertain the role of each exosite for procofactor activation. We have also employed a synthetic sulfated pentapeptide(DY(SO3-)DY(SO3-) Q, designated D5Q1,2) as an exosite-directed inhibitor of thrombin. The clotting time obtained with beta-thrombin was increased by similar to 8-fold, whereas rMZ-IIa was 4-fold less efficient in promoting clotting than alpha-thrombin under similar experimental conditions. alpha-Thrombin readily activated factor V following cleavages at Arg(709), Arg(1018), and Arg(1545) and factor VIII following proteolysis at Arg(372), Arg(740), and Arg(1689). Cleavage of both procofactors by alpha-thrombin was significantly inhibited by D5Q1,2. In contrast, beta-thrombin was unable to cleave factor V at Arg1545 and factor VIII at both Arg372 and Arg1689. The former is required for light chain formation and expression of optimum factor Va cofactor activity, whereas the latter two cleavages are a prerequisite for expression of factor VIIIa cofactor activity. beta-Thrombin was found to cleave factor V at Arg709 and factor VIII at Arg740, albeit less efficiently than alpha-thrombin. The sulfated pentapeptide inhibited moderately both cleavages by beta-thrombin. Under similar experimental conditions, membrane-bound rMZ-IIa cleaved and activated both procofactor molecules. Activation of the two procofactors by membrane-bound rMZ-IIa was severely impaired by D5Q1,2. Overall the data demonstrate that ABE-I alone of alpha-thrombin can account for the interaction of both procofactors with alpha-thrombin resulting in their timely and efficient activation. Because formation of meizothrombin precedes that of alpha-thrombin, our findings also imply that meizothrombin may be the physiological activator of both procofactors in vivo in the presence of a procoagulant membrane surface during the early stages of coagulation.	Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	University System of Ohio; Cleveland State University; Queens University - Canada; Cleveland Clinic Foundation	Kalafatis, M (corresponding author), Cleveland State Univ, Dept Chem, 2351 Euclid Ave,Sci Ctr SR370, Cleveland, OH 44115 USA.	m.kalafatis@csuohio.edu	Kim, Paul/GYV-3258-2022	Kim, Paul/0000-0003-0943-4924	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073343, P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-73343, HL-46703-6] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; Anderson PJ, 2003, J BIOL CHEM, V278, P44482, DOI 10.1074/jbc.M306917200; Anderson PJ, 2003, J BIOL CHEM, V278, P44489, DOI 10.1074/jbc.M306916200; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; ARNI RK, BIOCHEMISTRY, V32, P4727; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Beck DO, 2004, J BIOL CHEM, V279, P3084, DOI 10.1074/jbc.M306850200; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berendsen HJC, 1981, INTERMOLECULAR FORCE, P331, DOI [DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658-1_21]; BERLINER LJ, 1985, BIOCHEMISTRY-US, V24, P7005, DOI 10.1021/bi00345a038; BEZEAUD A, 1988, J BIOL CHEM, V263, P3576; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOISSEL JP, 1984, J BIOL CHEM, V259, P5691; BOVILL EG, 1995, ARTERIOSCL THROM VAS, V15, P754, DOI 10.1161/01.ATV.15.6.754; BRAUN PJ, 1988, THROMB RES, V50, P273, DOI 10.1016/0049-3848(88)90228-9; Brufatto N, 2003, J BIOL CHEM, V278, P6755, DOI 10.1074/jbc.M206413200; Bush LA, 2006, J BIOL CHEM, V281, P7183, DOI 10.1074/jbc.M512082200; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; COTE HCF, 1994, J BIOL CHEM, V269, P11374; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; Fischer BE, 1998, PROTEIN ENG, V11, P715, DOI 10.1093/protein/11.8.715; FRANZA BR, 1975, J BIOL CHEM, V250, P7057; GIROLAMI A, 1974, J LAB CLIN MED, V84, P654; Gomori G, 1942, J LAB CLIN MED, V27, P955; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; Hackeng TM, 1996, BIOCHEM J, V319, P399, DOI 10.1042/bj3190399; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; Healy AM, 1998, BLOOD, V92, P4188, DOI 10.1182/blood.V92.11.4188.423k09_4188_4197; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; HORTIN GL, 1990, BLOOD, V76, P946; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; JAMES HL, 1994, BLOOD COAGUL FIBRIN, V5, P841, DOI 10.1097/00001721-199410000-00025; JOSSO F, 1971, BLOOD-J HEMATOL, V38, P9, DOI 10.1182/blood.V38.1.9.9; Kalafatis M, 1996, BLOOD, V87, P4695, DOI 10.1182/blood.V87.11.4695.bloodjournal87114695; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; KANE WH, 1981, J BIOL CHEM, V256, P1002; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liaw PCY, 1998, J BIOL CHEM, V273, P8932, DOI 10.1074/jbc.273.15.8932; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; LIU LW, 1991, J BIOL CHEM, V266, P16977; LIU LW, 1991, J BIOL CHEM, V266, P23632; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LUNDBLAD RL, 1979, J BIOL CHEM, V254, P8524; Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290; MARQUETTE KA, 1995, BLOOD, V86, P3026; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; MIKKELSEN J, 1991, BIOCHEMISTRY-US, V30, P1533, DOI 10.1021/bi00220a013; Monteiro RQ, 2002, THROMB HAEMOSTASIS, V87, P288; Mutch NJ, 2001, THROMB HAEMOSTASIS, V86, P1028; Myles T, 2002, BLOOD, V100, P2820, DOI 10.1182/blood-2002-03-0843; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; Nogami K, 2005, J BIOL CHEM, V280, P18476, DOI 10.1074/jbc.M412778200; OFOSU FA, 1992, BIOCHEM J, V283, P893, DOI 10.1042/bj2830893; OMarcaigh AS, 1996, BLOOD, V88, P2611, DOI 10.1182/blood.V88.7.2611.bloodjournal8872611; Orfeo T, 2004, J BIOL CHEM, V279, P19580, DOI 10.1074/jbc.M400727200; Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; Pospisil CH, 2003, J BIOL CHEM, V278, P21584, DOI 10.1074/jbc.M300545200; PRIESTLE JP, 1993, PROTEIN SCI, V2, P1630, DOI 10.1002/pro.5560021009; RABIET MJ, 1986, J BIOL CHEM, V261, P5045; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; Roberts HR, 2003, THROMBOSIS HEMORRHAG, P575; Rose T, 2002, J BIOL CHEM, V277, P18875, DOI 10.1074/jbc.M110977200; ROSING J, 1986, J BIOL CHEM, V261, P4224; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Severs JC, 1999, RAPID COMMUN MASS SP, V13, P1016, DOI 10.1002/(SICI)1097-0231(19990615)13:11<1016::AID-RCM599>3.0.CO;2-5; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; Sijbers A., 2001, GROMACS USER MANUAL; Stevens WK, 1996, J BIOL CHEM, V271, P8062, DOI 10.1074/jbc.271.14.8062; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; Sun WY, 2000, BLOOD, V95, P711, DOI 10.1182/blood.V95.2.711; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TANS G, 1994, J BIOL CHEM, V269, P15969; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; Van Gunsteren WF, 1987, GROMOS 87 MANUAL; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; vantVeer C, 1997, J BIOL CHEM, V272, P7983, DOI 10.1074/jbc.272.12.7983; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; Weiler H, 2001, ARTERIOSCL THROM VAS, V21, P1531, DOI 10.1161/hq0901.094496; Weiler-Guettler H, 1998, J CLIN INVEST, V101, P1983, DOI 10.1172/JCI2006; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WU QY, 1994, J BIOL CHEM, V269, P3725	113	17	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18569	18580		10.1074/jbc.M600752200	http://dx.doi.org/10.1074/jbc.M600752200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16624813	hybrid, Green Published			2022-12-25	WOS:000238687300036
J	Delettre, C; Yuste, VJ; Moubarak, RS; Bras, M; Robert, N; Susin, SA				Delettre, Cecile; Yuste, Victor J.; Moubarak, Rana S.; Bras, Marlene; Robert, Nadine; Susin, Santos A.			Identification and characterization of AIFsh2, a mitochondrial apoptosis-inducing factor (AIF) isoform with NADH oxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERAMIDE-INDUCED APOPTOSIS; INDEPENDENT CELL-DEATH; REGULATES APOPTOSIS; NUCLEAR APOPTOSIS; CYTOCHROME-C; CANCER-CELLS; RELEASE; ACTIVATION; INDUCTION; PROTEASE	Apoptosis-inducing factor (AIF) is a bifunctional NADH oxidase involved in mitochondrial respiration and caspase-independent apoptosis. Three alternatively spliced mRNA isoforms of AIF have been identified previously: AIF, AIF-exB, and AIFsh. Here, we report the cloning and the biochemical characterization of a new isoform named AIF short 2 (AIFsh2). AIFsh2 transcript includes a previously unknown exon placed between exons 9 and 10 of AIF. The resulting AIFsh2 protein, which localizes in mitochondria, corresponds to the oxidoreductase domain of AIF. In this way, AIFsh2 exhibits similar NADH oxidase activity to AIF and generates reactive oxygen species. Like AIF, AIFsh2 is released from mitochondria to cytosol after an apoptotic insult in a calpain or cathepsin-dependent manner. However, in contrast to AIF, AIFsh2 does not induce nuclear apoptosis. Thus, it seems that the reactive oxygen species produced by the oxidoreductase domain of AIF/AIFsh2 are not important for AIF-dependent nuclear apoptosis. In addition, we demonstrate that the AIFsh2 mRNA is absent in normal brain tissue, whereas it is expressed in neuroblastoma-derived cells, suggesting a different regulation in normal and transformed cells from the brain lineage. Together, our results reveal that AIF yields an original and independent genetic regulation of the two AIF functions. This is an important issue to understand the physiological role of this protein.	Inst Pasteur, Apoptose & Syst Immunitaire, CNRS URA 1961, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Susin, SA (corresponding author), Inst Pasteur, Apoptose & Syst Immunitaire, CNRS URA 1961, 25 Rue Dr Roux, F-75015 Paris, France.	susin@pasteur.fr	Yuste, Victor J./C-7071-2008; Delettre, Cécile/AAC-3096-2020; Susin, Santos A/Q-6754-2017	Yuste, Victor J./0000-0001-5322-9261; Delettre, Cécile/0000-0003-3269-2155; Susin, Santos A/0000-0002-3366-1628; Moubarak, Rana/0000-0003-2096-1258				Abdullaev ZK, 2002, BIOCHEM J, V362, P749, DOI 10.1042/0264-6021:3620749; Bras M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P231, DOI 10.1007/s10541-005-0105-4; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Cande C, 2004, J CELL SCI, V117, P4461, DOI 10.1242/jcs.01356; Corbiere C, 2004, CELL RES, V14, P188, DOI 10.1038/sj.cr.7290219; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Delettre C, 2006, J BIOL CHEM, V281, P6413, DOI 10.1074/jbc.M509884200; Furre IE, 2005, CANCER RES, V65, P11051, DOI 10.1158/0008-5472.CAN-05-0510; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Halliwell B, 1999, FREE RADICAL RES, V31, P261, DOI 10.1080/10715769900300841; Joza N, 2005, MOL CELL BIOL, V25, P10261, DOI 10.1128/MCB.25.23.10261-10272.2005; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Liu T, 2004, ONCOGENE, V23, P39, DOI 10.1038/sj.onc.1206978; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Lopez-Huertas E, 1999, BIOCHEM J, V337, P531, DOI 10.1042/0264-6021:3370531; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Lorenzo HK, 2004, FEBS LETT, V557, P14, DOI 10.1016/S0014-5793(03)01464-9; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Nomura M, 2004, J CELL PHYSIOL, V201, P374, DOI 10.1002/jcp.20090; Park YC, 2005, LIFE SCI, V77, P2059, DOI 10.1016/j.lfs.2005.04.021; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Schmitt E, 2003, CANCER RES, V63, P8233; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Urbano A, 2005, EMBO J, V24, P2815, DOI 10.1038/sj.emboj.7600746; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yuste VJ, 2005, J BIOL CHEM, V280, P35670, DOI 10.1074/jbc.M504015200; Yuste VJ, 2005, CELL DEATH DIFFER, V12, P1445, DOI 10.1038/sj.cdd.4401687	39	51	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18507	18518		10.1074/jbc.M601751200	http://dx.doi.org/10.1074/jbc.M601751200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16644725	hybrid			2022-12-25	WOS:000238687300030
J	Gallo, SA; Wang, W; Rawat, SS; Jung, G; Waring, AJ; Cole, AM; Lu, H; Yan, XX; Daly, NL; Craik, DJ; Jiang, SB; Lehrer, RI; Blumenthal, R				Gallo, Stephen A.; Wang, Wei; Rawat, Satinder S.; Jung, Grace; Waring, Alan J.; Cole, Alexander M.; Lu, Hong; Yan, Xuxia; Daly, Norelle L.; Craik, David J.; Jiang, Shibo; Lehrer, Robert I.; Blumenthal, Robert			theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRUNCATED ALPHA-DEFENSINS; ENVELOPE GLYCOPROTEIN; SYNTHETIC PEPTIDE; MONOCLONAL-ANTIBODY; POTENT INHIBITORS; ATOMIC-STRUCTURE; MEMBRANE-FUSION; CORE STRUCTURE; COILED-COIL; TYPE-1 GP41	Retrocyclin-1, a 0-defensin, protects target cells from human immunodeficiency virus, type 1 (HIV-1) by preventing viral entry. To delineate its mechanism, we conducted fusion assays between susceptible target cells and effector cells that expressed HIV-1 Env. Retrocyclin-1 (4 mu M) completely blocked fusion mediated by HIV-1 Envs that used CXCR4 or CCR5 but had little effect on cell fusion mediated by HIV-2 and simian immunodeficiency virus Envs. Retrocyclin-1 inhibited HIV-1 Env-mediated fusion without impairing the lateral mobility of CD4, and it inhibited the fusion of CD4-deficient cells with cells bearing CD4-independent HIV-1 Env. Thus, it could act without cross-linking membrane proteins or inhibiting gp120-CD4 interactions. Retrocyclin-1 acted late in the HIV-1 Env fusion cascade but prior to 6-helix bundle formation. Surface plasmon resonance experiments revealed that retrocyclin bound the ectodomain of gp41 with high affinity in a glycan-independent manner and that it bound selectively to the gp41 C-terminal heptad repeat. Native-PAGE, enzyme-linked immunosorbent assay, and CD spectroscopic analyses all revealed that retrocyclin-1 prevented 6-helix bundle formation. This mode of action, although novel for an innate effector molecule, resembles the mechanism of peptidic entry inhibitors based on portions of the gp41 sequence.	NCI, CCR Nanobiol Program, NIH, Frederick, MD 21702 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32816 USA; New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; State University System of Florida; University of Central Florida; New York Blood Center; University of Queensland	Blumenthal, R (corresponding author), NCI, CCR Nanobiol Program, NIH, Frederick, MD 21702 USA.	blumen@helix.nih.gov	Craik, David/B-1695-2010; Daly, Norelle L/D-4302-2013; Jiang, Shibo/L-4500-2014	Craik, David/0000-0003-0007-6796; Daly, Norelle L/0000-0002-4697-6602; Jiang, Shibo/0000-0001-8283-7135; Gallo, Stephen/0000-0001-6043-2153	NATIONAL CANCER INSTITUTE [Z01BC008303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056921, R21AI056921] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [AI056921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bewley CA, 2002, J BIOL CHEM, V277, P14238, DOI 10.1074/jbc.M201453200; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; CHOU TC, 1999, CALCUWYN WINDOWS SOF; Cole AM, 2002, P NATL ACAD SCI USA, V99, P1813, DOI 10.1073/pnas.052706399; Cole AL, 2006, J IMMUNOL, V176, P6900, DOI 10.4049/jimmunol.176.11.6900; Dimitrov AS, 2005, BIOCHEMISTRY-US, V44, P12471, DOI 10.1021/bi051092d; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; Gallo SA, 2004, BIOCHEMISTRY-US, V43, P8230, DOI 10.1021/bi049957v; Gallo SA, 2001, BIOCHEMISTRY-US, V40, P12231, DOI 10.1021/bi0155596; Hoffman TL, 1999, P NATL ACAD SCI USA, V96, P6359, DOI 10.1073/pnas.96.11.6359; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Jiang SB, 2004, ANTIMICROB AGENTS CH, V48, P4349, DOI 10.1128/AAC.48.11.4349-4359.2004; Jiang SB, 1999, J VIROL METHODS, V80, P85, DOI 10.1016/S0166-0934(99)00041-5; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; Leikina E, 2005, NAT IMMUNOL, V6, P995, DOI 10.1038/ni1248; Leonova L, 2001, J LEUKOCYTE BIOL, V70, P461; Liu SW, 2003, PEPTIDES, V24, P1303, DOI 10.1016/j.peptides.2003.07.013; Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; Munk C, 2003, AIDS RES HUM RETROV, V19, P875, DOI 10.1089/088922203322493049; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Nguyen TX, 2003, PEPTIDES, V24, P1647, DOI 10.1016/j.peptides.2003.07.023; Owen SM, 2004, AIDS RES HUM RETROV, V20, P1157, DOI 10.1089/aid.2004.20.1157; Owen SM, 2004, J PEPT RES, V63, P469, DOI 10.1111/j.1399-3011.2004.00155.x; Popik W, 2004, J BIOL CHEM, V279, P704, DOI 10.1074/jbc.M306380200; Rawat SS, 2004, VIROLOGY, V318, P55, DOI 10.1016/j.virol.2003.08.042; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Selsted ME, 2004, CURR PROTEIN PEPT SC, V5, P365, DOI 10.2174/1389203043379459; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Wang W, 2004, J IMMUNOL, V173, P515, DOI 10.4049/jimmunol.173.1.515; Wang W, 2003, J IMMUNOL, V170, P4708, DOI 10.4049/jimmunol.170.9.4708; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Yasin B, 2004, J VIROL, V78, P5147, DOI 10.1128/JVI.78.10.5147-5156.2004	46	108	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18787	18792		10.1074/jbc.M602422200	http://dx.doi.org/10.1074/jbc.M602422200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16648135	hybrid			2022-12-25	WOS:000238687300059
J	Hsieh, RW; Rajan, SS; Sharma, SK; Guo, Y; DeSombre, ER; Mrksich, M; Greene, GL				Hsieh, Robert W.; Rajan, Shyamala S.; Sharma, Sanjay K.; Guo, Yuee; DeSombre, Eugene R.; Mrksich, Milan; Greene, Geoffrey L.			Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-BASED DESIGN; ETCH VIRUS PROTEASE; ER-ALPHA; CHROMOSOMAL LOCALIZATION; NUCLEAR RECEPTORS; STRUCTURAL BASIS; GENE-EXPRESSION; HIGH-THROUGHPUT; MOLECULAR-BASIS; BINDING DOMAIN	Estrogen receptors alpha (ER alpha) and beta(ER beta) have distinct functions and differential expression in certain tissues. These differences have stimulated the search for subtype-selective ligands. Therapeutically, such ligands offer the potential to target specific tissues or pathways regulated by one receptor subtype without affecting the other. As reagents, they can be utilized to probe the physiological functions of the ER subtypes to provide information complementary to that obtained from knock-out animals. A fluorescence resonance energy transfer-based assay was used to screen a 10,000-compound chemical library for ER agonists. From the screen, we identified a family of ER beta-selective agonists whose members contain bulky oxabicyclic scaffolds in place of the planar scaffolds common to most ER ligands. These agonists are 10-50-fold selective for ER beta in competitive binding assays and up to 60-fold selective in transactivation assays. The weak uterotrophic activity of these ligands in immature rats and their ability to stimulate expression of an ER beta regulated gene in human U2OS osteosarcoma cells provides more physiological evidence of their ER beta-selective nature. To provide insight into the molecular mechanisms of their activity and selectivity, we determined the crystal structures of the ER alpha ligand-binding domain (LBD) and a peptide from the glucocorticoid receptor-interacting protein 1 (GRIP1) coactivator complexed with the ligands OBCP-3M, OBCP-2M, and OBCP-1M. These structures illustrate how the bicyclic scaffolds of these ligands are accommodated in the flexible ligand-binding pocket of ER. A comparison of these structures with existing ER structures suggests that the ER beta selectivity of OBCP ligands can be attributed to a combination of their interactions with Met-336 in ER beta and Met-421 in ER alpha. These bicyclic ligands show promise as lead compounds that can target ER beta. In addition, our understanding of the molecular determinants of their subtype selectivity provides a useful starting point for developing other ER modulators belonging to this relatively new structural class.	Univ Chicago, Dept Chem, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago	Mrksich, M (corresponding author), Univ Chicago, Dept Chem, 929 E 57th St, Chicago, IL 60637 USA.	mmrksich@uchicago.edu; ggreene@uchicago.edu	Mrksich, Milan/G-2469-2011	Sharma, Sanjeev Kumar/0000-0002-3273-0708; Mrksich, Milan/0000-0002-4964-796X	NATIONAL CANCER INSTITUTE [R01CA089489] Funding Source: NIH RePORTER; NCI NIH HHS [CA 89489] Funding Source: Medline; NCRR NIH HHS [RR 07707] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chauzov VA, 1996, ZH OBSHCH KHIM+, V66, P2061; Chauzov VA, 1997, ZH OBSHCH KHIM+, V67, P166; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; DESOMBRE ER, 1988, J STEROID BIOCHEM, V29, P583, DOI 10.1016/0022-4731(88)90155-0; Dieckman L, 2002, PROTEIN EXPRES PURIF, V25, P1, DOI 10.1006/prep.2001.1602; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hamann LG, 2005, BIOORG MED CHEM LETT, V15, P1463, DOI 10.1016/j.bmcl.2004.12.077; Harris HA, 2003, ENDOCRINOLOGY, V144, P4241, DOI 10.1210/en.2003-0550; Harris HA, 2002, ENDOCRINOLOGY, V143, P4172, DOI 10.1210/en.2002-220403; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hegele-Hartung C, 2004, P NATL ACAD SCI USA, V101, P5129, DOI 10.1073/pnas.0306720101; Henke BR, 2002, J MED CHEM, V45, P5492, DOI 10.1021/jm020291h; Hillisch A, 2004, MOL ENDOCRINOL, V18, P1599, DOI 10.1210/me.2004-0050; KIAN TM, 2004, MOL BIOL CELL, V15, P1262; Korach KS, 2003, J STEROID BIOCHEM, V86, P387, DOI 10.1016/S0960-0760(03)00348-0; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lally JM, 1998, ACTA CRYSTALLOGR D, V54, P423, DOI 10.1107/S0907444997011086; Malamas MS, 2004, J MED CHEM, V47, P5021, DOI 10.1021/jm049719y; Manas ES, 2004, STRUCTURE, V12, P2197, DOI 10.1016/j.str.2004.09.015; Manas ES, 2004, J AM CHEM SOC, V126, P15106, DOI 10.1021/ja047633o; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mewshaw RE, 2005, J MED CHEM, V48, P3953, DOI 10.1021/jm058173s; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Monroe DG, 2003, J CELL BIOCHEM, V90, P315, DOI 10.1002/jcb.10633; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Muthyala RS, 2003, BIOORG MED CHEM LETT, V13, P4485, DOI 10.1016/j.bmcl.2003.08.061; Muthyala RS, 2003, J MED CHEM, V46, P1589, DOI 10.1021/jm0204800; Nemenoff RA, 2005, EUR J CANCER, V41, P2561, DOI 10.1016/j.ejca.2005.08.015; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pearce ST, 2004, CRIT REV ONCOL HEMAT, V50, P3, DOI 10.1016/j.critrevonc.2003.09.003; Phan J, 2002, J BIOL CHEM, V277, P50564, DOI 10.1074/jbc.M207224200; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Rajan SS, 2004, BIOCHEMISTRY-US, V43, P15472, DOI 10.1021/bi048665r; Reel JR, 1996, FUND APPL TOXICOL, V34, P288, DOI 10.1006/faat.1996.0198; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Sibley R, 2003, BIOORG MED CHEM LETT, V13, P1919, DOI 10.1016/S0960-894X(03)00307-X; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; Stols L, 2002, PROTEIN EXPRES PURIF, V25, P8, DOI 10.1006/prep.2001.1603; Stossi F, 2004, ENDOCRINOLOGY, V145, P3473, DOI 10.1210/en.2003-1682; Sun J, 2003, MOL ENDOCRINOL, V17, P247, DOI 10.1210/me.2002-0341; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Veeneman GH, 2005, CURR MED CHEM, V12, P1077, DOI 10.2174/0929867053764662; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594; Zhou HB, 2005, J MED CHEM, V48, P7261, DOI 10.1021/jm0506773	56	50	54	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17909	17919		10.1074/jbc.M513684200	http://dx.doi.org/10.1074/jbc.M513684200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16648639	hybrid			2022-12-25	WOS:000238490300041
J	de Luna, N; Gallardo, E; Soriano, M; Dominguez-Perles, R; de la Torre, C; Rojas-Garcia, R; Garcia-Verdugo, JM; Illa, I				de Luna, Noemi; Gallardo, Eduard; Soriano, Mario; Dominguez-Perles, Raul; de la Torre, Carolina; Rojas-Garcia, Ricardo; Garcia-Verdugo, Jose M.; Illa, Isabel			Absence of dysferlin alters myogenin expression and delays human muscle differentiation "in vitro"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIRDLE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; MEMBRANE REPAIR; UP-REGULATION; GENE MYF-5; INACTIVATION; INTERACTS; PROTEINS; MYOPATHY; MUTATION	Mutations in dysferlin cause a type of muscular dystrophy known as dysferlinopathy. Dysferlin may be involved in muscle repair and differentiation. We compared normal human skeletal muscle cultures expressing dysferlin with muscle cultures from dysferlinopathy patients. We quantified the fusion index of myoblasts as a measure of muscle development and conducted optic and electronic microscopy, immunofluorescence, Western blot, flow cytometry, and real-time PCR at different developmental stages. Short interference RNA was used to corroborate the results obtained in dysferlin-deficient cultures. A luciferase reporter assay was performed to study myogenin activity in dysferlin-deficient cultures. Myoblasts fusion was consistently delayed as compared with controls whereas the proliferation rate did not change. Electron microscopy showed that control cultured cells at 10 days were fusiform, whereas dysferlin-deficient cells were star-shaped and large. After 15 days the normal multinucleated appearance and structured myofibrils were not present in dysferlin-deficient cells. Strikingly, myogenin was not detected in myotubes from dysferlin-deficient cultures using Western blot, and mRNA analysis showed low levels (p < 0.05) compared with controls. Flow cytometry and immunofluorescence also showed reduced levels of myogenin in dysferlin-deficient cultures. When the dysferlin gene was knocked down (similar to 80%), myogenin mRNA leveled down to similar to 70%. MyoD and desmin mRNA levels in controls and dysferlin-deficient cultures were similar. The reporter luciferase assay demonstrated a low myogenin activity in dysferlin-deficient cultures. These results point to a functional link between dysferlin and myogenin, and both proteins may share a new signaling pathway involved in differentiation of skeletal muscle in vitro.	Univ Autonoma Barcelona, Hosp Santa Cruz & San Pablo, Neurol Serv, Barcelona 08025, Spain; Univ Autonoma Barcelona, Hosp Santa Cruz & San Pablo, Lab Neurol Expt, Barcelona 08025, Spain; Univ Valencia, Ctr Invest Principe Felipe, Valencia 46980, Spain; Univ Valencia, Inst Cavanilles, Valencia 46980, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona; Prince Felipe Research Center; University of Valencia; University of Valencia	Illa, I (corresponding author), Univ Autonoma Barcelona, Hosp Santa Cruz & San Pablo, Neurol Serv, C Pare Claret 167, Barcelona 08025, Spain.	iilla@santpau.es	García-Verdugo, José Manuel/L-8421-2017; De La Torre Gómez, Carolina/AAP-1738-2020; Domínguez-Perles, Raul/J-7456-2013; ILLA, Isabel/AAD-1816-2019; Dominguez-Perles, Raul/AAK-4212-2021; de Luna, Noemi/H-8705-2017	García-Verdugo, José Manuel/0000-0001-9872-6499; De La Torre Gómez, Carolina/0000-0001-9363-291X; Domínguez-Perles, Raul/0000-0001-6232-712X; Dominguez-Perles, Raul/0000-0001-6232-712X; de Luna, Noemi/0000-0002-4342-794X; Soriano Navarro, Mario/0000-0002-7245-2095; Gallardo, Eduard/0000-0002-3942-3436				Anderson LVB, 1999, AM J PATHOL, V154, P1017, DOI 10.1016/S0002-9440(10)65354-0; ASKANAS V, 1975, NEUROLOGY, V25, P58, DOI 10.1212/WNL.25.1.58; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; Biederer CH, 2000, J BIOL CHEM, V275, P26245, DOI 10.1074/jbc.M001430200; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; Bushby KMD, 1999, BRAIN, V122, P1403, DOI 10.1093/brain/122.8.1403; Bushby KMD, 2000, ACTA NEUROL BELG, V100, P142; Cooper RN, 1999, J CELL SCI, V112, P2895; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; De Luna N, 2004, J NEUROPATH EXP NEUR, V63, P1104, DOI 10.1093/jnen/63.10.1104; Doherty KR, 2003, TRENDS MOL MED, V9, P327, DOI 10.1016/S1471-4914(03)00136-9; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Illa I, 2001, ANN NEUROL, V49, P130, DOI 10.1002/1531-8249(200101)49:1<130::AID-ANA22>3.0.CO;2-0; Illa I, 1997, AM J PATHOL, V151, P81; Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Matsuda C, 2005, J NEUROPATH EXP NEUR, V64, P334, DOI 10.1093/jnen/64.4.334; Matsuda C, 2001, HUM MOL GENET, V10, P1761, DOI 10.1093/hmg/10.17.1761; MIYOSHI K, 1986, BRAIN, V109, P31, DOI 10.1093/brain/109.1.31; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	26	80	82	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17092	17098		10.1074/jbc.M601885200	http://dx.doi.org/10.1074/jbc.M601885200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16608842	hybrid			2022-12-25	WOS:000238326300032
J	Gamero, AM; Potla, R; Wegrzyn, J; Szelag, M; Edling, AE; Shimoda, K; Link, DC; Dulak, J; Baker, DP; Tanabe, Y; Grayson, JM; Larner, AC				Gamero, Ana M.; Potla, Ramesh; Wegrzyn, Joanna; Szelag, Magdelena; Edling, Andrea E.; Shimoda, Kazuya; Link, Daniel C.; Dulak, Jozef; Baker, Darren P.; Tanabe, Yoshinari; Grayson, Jason M.; Larner, Andrew C.			Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TYPE-1 INTERFERONS; GENE-EXPRESSION; I INTERFERON; ALPHA; GROWTH; INDUCTION; PHOSPHORYLATION; INHIBITION; DIFFERENTIATION	The growth-inhibitory effects of type 1 interferons ( IFNs) ( IFN alpha/beta) are complex, and the role of apoptosis in their antigrowth effects is variable and not well understood. We have examined primary murine interleukin-7-dependent bone marrow-derived pro-B cells, where IFN beta, but not IFN alpha, induces programmed cell death ( PCD). IFN beta-stimulated apoptosis is the same in pro-B cells derived from wild type and Stat1(-/-) mice. However, in pro-B cells from Tyk2(-/-) mice, where there is normal activation of Stat1 and Stat2, IFN beta-stimulated PCD is not observed. Loss of B cells in lymphocytic choriomeningitis virus-infected mice has been shown to be mediated through the expression of IFN alpha/beta( 1). In wild type mice infected with lymphocytic choriomeningitis virus, there is a greater loss of B cells in the bone marrow and spleen than in Tyk2(-/-) mice infected with the virus, suggesting that the expression of this kinase plays an in vivo role in IFN alpha/beta-mediated PCD. In contrast to IFN beta-stimulated tyrosine phosphorylation of Stat1 and Stat2, Stat3 tyrosine phosphorylation is defective in Tyk2(-/-) pro-B cells, suggesting that this Stat family member is required for apoptosis. In support of this hypothesis, inhibition of Stat3 activation in wild type B cells reverses the apoptotic effects of IFN beta. Furthermore, expression of a constitutively active form of Stat3 in Tyk2(-/-) B cells partially restores IFN beta-stimulated PCD. These results demonstrate an important role of Tyk2-mediated tyrosine phosphorylation of Stat3 in the ability of IFN beta to stimulate apoptosis of primary pro-B cells.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; NCI, Expt Immunol Lab, NIH, Frederick, MD 21702 USA; Kyushu Univ, Fukuoka 8128582, Japan; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Jagiellonian Univ, Dept Med Biotechnol, PL-30387 Krakow, Poland; Cleveland State Univ, Dept Biol, Cleveland, OH 44195 USA; Biogen Idec Inc, Cambridge, MA 02142 USA; Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA; Niigata Univ, Sch Med, Dept Med, Niigata 9518510, Japan	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyushu University; Washington University (WUSTL); Jagiellonian University; University System of Ohio; Cleveland State University; Biogen; Wake Forest University; Niigata University	Larner, AC (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	larnera@ccf.org						Binder D, 1997, J EXP MED, V185, P517, DOI 10.1084/jem.185.3.517; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Gamero AM, 2001, J BIOL CHEM, V276, P13547, DOI 10.1074/jbc.M007948200; Gamero AM, 2000, J BIOL CHEM, V275, P16574, DOI 10.1074/jbc.M910149199; Gongora R, 2000, J IMMUNOL, V165, P2362, DOI 10.4049/jimmunol.165.5.2362; Gongora R, 2001, IMMUNITY, V14, P727, DOI 10.1016/S1074-7613(01)00152-2; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; Lin Q, 1998, J EXP MED, V187, P79, DOI 10.1084/jem.187.1.79; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; Rani MRS, 1999, J BIOL CHEM, V274, P32507, DOI 10.1074/jbc.274.45.32507; Rani MRS, 2005, J INTERF CYTOK RES, V25, P788, DOI 10.1089/jir.2005.25.788; RODRIGUEZVILLANUEVA J, 1995, INT J CANCER, V61, P110, DOI 10.1002/ijc.2910610119; Sakamoto S, 2004, J BIOL CHEM, V279, P3245, DOI 10.1074/jbc.M309631200; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Shimoda K, 2002, J IMMUNOL, V169, P4707, DOI 10.4049/jimmunol.169.9.4707; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; TOMITA Y, 1982, INT J CANCER, V30, P161, DOI 10.1002/ijc.2910300206; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WANG JY, 1995, IMMUNITY, V3, P475, DOI 10.1016/1074-7613(95)90176-0; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479	32	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16238	16244		10.1074/jbc.M509516200	http://dx.doi.org/10.1074/jbc.M509516200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16601124	hybrid			2022-12-25	WOS:000238165700009
J	Gerdes, L; Bals, T; Klostermann, E; Karl, M; Philippar, K; Hunken, M; Soll, J; Schunemann, D				Gerdes, Lars; Bals, Thomas; Klostermann, Eva; Karl, Monique; Philippar, Katrin; Huenken, Mark; Soll, Juergen; Schuenemann, Danja			A second thylakoid membrane-localized Alb3/Oxal/YidC homologue is involved in proper chloroplast biogenesis in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; OUTER ENVELOPE MEMBRANE; PROTEIN INSERTION; YIDC; MITOCHONDRIA; MACHINERY; ALBINO3; IMPORT; FAMILY; SYSTEM	The integral membrane proteins Alb3, OxaI, and YidC belong to an evolutionary conserved protein family mediating protein insertion into the thylakoid membrane of chloroplasts, the inner membrane of mitochondria, and bacteria, respectively. Whereas OxaI and YidC are involved in the insertion of a wide range of membrane proteins, the function of Alb3 seems to be limited to the insertion of a subset of the light-harvesting chlorophyll-binding proteins. In this study, we identified a second chloroplast homologue of the Alb3/OxaI/YidC family, named Alb4. Alb4 is almost identical to the Alb3/OxaI/YidC domain of the previously described 110-kDa inner envelope protein Artemis. We show that Alb4 is expressed as a separate 55-kDa protein and that Artemis was identified mistakenly. Alb4 is located in the thylakoid membrane of Arabidopsis thaliana chloroplasts. Analysis of an Arabidopsis mutant ( Salk_ 136199) and RNA interference lines with a reduced level of Alb4 revealed chloroplasts with an altered ultrastructure. Mutant plastids are larger and more spherical in appearance, and the grana stacks within the mutant lines are less appressed than in the wild-type chloroplasts. These data indicate that Alb4 is required for proper chloroplast biogenesis.	Univ Munich, Dept Biol 1, D-80638 Munich, Germany; Ruhr Univ Bochum, Lehrstuhl Allgemeine & Mol Bot, D-44780 Bochum, Germany	University of Munich; Ruhr University Bochum	Schunemann, D (corresponding author), Univ Munich, Dept Biol 1, Marchioninistr 15, D-80638 Munich, Germany.	soll@lmu.de; Danja.Schuenemann@rub.de	Philippar, Katrin/F-7942-2018	Schuenemann, Danja/0000-0001-8894-7685; Gerdes, Lars/0000-0002-0483-8615; Philippar, Katrin/0000-0002-2140-4907				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Bellafiore S, 2002, PLANT CELL, V14, P2303, DOI 10.1105/tpc.003442; Chen MY, 2002, J BIOL CHEM, V277, P7670, DOI 10.1074/jbc.M110644200; Clausen C, 2004, PLANTA, V220, P30, DOI 10.1007/s00425-004-1325-3; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Dalbey RE, 2004, J CELL BIOL, V166, P769, DOI 10.1083/jcb.200405161; Di Cola A, 2005, BIOCHEM SOC T, V33, P1024, DOI 10.1042/BST20051024; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Fulgosi H, 2002, P NATL ACAD SCI USA, V99, P11501, DOI 10.1073/pnas.172032599; Funes S, 2004, FEBS LETT, V569, P89, DOI 10.1016/j.febslet.2004.05.055; Funes S, 2004, MOL BIOL CELL, V15, P1853, DOI 10.1091/mbc.e03-11-0789; Glick BS, 1996, PROTEIN SCI, V5, P2651, DOI 10.1002/pro.5560051229; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Herrmann JM, 2003, IUBMB LIFE, V55, P219, DOI 10.1080/1521654031000123349; Houben ENG, 2004, EMBO REP, V5, P970, DOI 10.1038/sj.embor.7400261; Jia LX, 2003, EMBO J, V22, P6438, DOI 10.1093/emboj/cdg624; Karimi M, 2005, TRENDS PLANT SCI, V10, P103, DOI 10.1016/j.tplants.2005.01.008; Klostermann E, 2002, BIOCHEM J, V368, P777, DOI 10.1042/BJ20021291; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; Lee YJ, 2001, PLANT CELL, V13, P2175, DOI 10.1105/tpc.13.10.2175; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; Moore M, 2003, J CELL BIOL, V162, P1245, DOI 10.1083/jcb.200307067; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Nagamori S, 2004, J CELL BIOL, V165, P53, DOI 10.1083/jcb.200402067; Ossenbuhl F, 2004, PLANT CELL, V16, P1790, DOI 10.1105/tpc.023226; Peeters NM, 2000, J MOL EVOL, V50, P413, DOI 10.1007/s002390010044; Philippar K, 2004, PLANT J, V37, P815, DOI 10.1111/j.1365-313X.2003.02006.x; Preuss M, 2005, J BIOL CHEM, V280, P13004, DOI 10.1074/jbc.M414093200; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Schuenemann D, 1999, J BIOL CHEM, V274, P12177, DOI 10.1074/jbc.274.17.12177; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; Spence E, 2004, J BIOL CHEM, V279, P55792, DOI 10.1074/jbc.M411041200; Sundberg E, 1997, PLANT CELL, V9, P717, DOI 10.1105/tpc.9.5.717; Szyrach G, 2003, EMBO J, V22, P6448, DOI 10.1093/emboj/cdg623; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Waegemann K, 1995, METHOD CELL BIOL, V50, P255, DOI 10.1016/S0091-679X(08)61035-3; Woolhead CA, 2001, J BIOL CHEM, V276, P40841, DOI 10.1074/jbc.M106523200; Yen MR, 2001, FEMS MICROBIOL LETT, V204, P223, DOI 10.1111/j.1574-6968.2001.tb10889.x; Yi L, 2005, MOL MEMBR BIOL, V22, P101, DOI 10.1080/09687860500041718	44	62	66	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16632	16642		10.1074/jbc.M513623200	http://dx.doi.org/10.1074/jbc.M513623200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16595657	hybrid			2022-12-25	WOS:000238165700056
J	Guha, M; Kumar, S; Choubey, V; Maity, P; Bandyopadhyay, U				Guha, Mithu; Kumar, Sanjay; Choubey, Vinay; Maity, Pallab; Bandyopadhyay, Uday			Apoptosis in liver during malaria: role of oxidative stress and implication of mitochondrial pathway	FASEB JOURNAL			English	Article						malaria; Plasmodium yoelii; apoptosis; oxidative stress	CYTOCHROME-C; HEPATOCYTE APOPTOSIS; PERIPHERAL-BLOOD; HEME OXYGENASE; CELL; ANTIOXIDANT; ACTIVATION; MECHANISMS; PROOXIDANT; INVOLVEMENT	Hepatic dysfunction is a common clinical complication in malaria, although its pathogenesis remains largely unknown. Using a variety of in vivo and ex vivo approaches, we have shown for the first time that malarial infection induces hepatic apoptosis through augmentation of oxidative stress. Apoptosis in hepatocyte has been confirmed by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin-nick-end labeling assay (TUNEL) and caspase-3 activation. Gene expression analysis using RT-PCR indicates the significant down-regulation of Bcl-2 and up-regulation of Bax expression in liver of malaria infected mice suggesting the involvement of mitochondrial pathway of apoptosis. The levels of Fas expression and caspase-8 activity in infected liver were same as that of uninfected control mice indicating death receptor ( Fas) pathway did not contribute to liver apoptosis during malarial infection. Moreover, evidence has been presented by confocal microscopy to show the translocation of Bax from cytosol to mitochondria in apoptotic hepatocyte, resulting in opening of permeability transition pores, which in turn decreases mitochondrial membrane potential and induces cytochrome c release into cytosol. Malarial infection induces the generation of hydroxyl radical (.OH) in liver, which may be responsible for the induction of oxidative stress and apoptosis as administration of .OH specific antioxidant as well as spin trap, alpha-phenyl-tert-butyl-nitrone in malaria-infected mice significantly inhibits the development of oxidative stress as well as induction of apoptosis. Thus, results suggest the implication of oxidative stress induced-mitochondrial pathway of apoptosis in the pathophysiology of hepatic dysfunction in malaria.-Guha, M., Kumar, S., Choubey, V., Maity, P., Bandyopadhyay, U. Apoptosis in liver during malaria: Role of oxidative stress and implication of mitochondrial pathway.	Cent Drug Res Inst, Div Drug Target Discovery & Dev, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Bandyopadhyay, U (corresponding author), Cent Drug Res Inst, Div Drug Target Discovery & Dev, Chatter Manzil Palace,Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India.	ubandyo_1964@yahoo.com	Maity, Pallab/L-3896-2017; Choubey, Vinay/H-3170-2015	Maity, Pallab/0000-0001-9769-3533; Choubey, Vinay/0000-0002-1953-5692; kumar, sanjay/0000-0002-2678-3387				ABDALLA SH, 1988, ANN TROP PAEDIATR, V8, P250, DOI 10.1080/02724936.1988.11748582; Agarwala Sanjiv S, 2002, Curr Treat Options Oncol, V3, P205, DOI 10.1007/s11864-002-0010-7; [Anonymous], 1998, MALARIA PARASITE BIO; Arruda MA, 2004, J IMMUNOL, V173, P2023, DOI 10.4049/jimmunol.173.3.2023; BABBS CF, 1990, METHOD ENZYMOL, V186, P137; Bandyopadhyay D, 2000, J PINEAL RES, V29, P143, DOI 10.1034/j.1600-079X.2000.290303.x; Bandyopadhyay U, 2002, LIFE SCI, V71, P2845, DOI 10.1016/S0024-3205(02)02143-4; Bandyopadhyay U, 1997, BIOCHEM PHARMACOL, V54, P241, DOI 10.1016/S0006-2952(97)00156-1; Bhattacharjee M, 2002, FREE RADICAL BIO MED, V32, P731, DOI 10.1016/S0891-5849(02)00757-8; Biswas K, 2003, J BIOL CHEM, V278, P10993, DOI 10.1074/jbc.M210328200; Brand VB, 2003, CELL PHYSIOL BIOCHEM, V13, P347, DOI 10.1159/000075122; Buege J A, 1978, Methods Enzymol, V52, P302; BURKITT MJ, 1991, P NATL ACAD SCI USA, V88, P8440, DOI 10.1073/pnas.88.19.8440; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; CLARK IA, 1989, FREE RADICAL BIO MED, V6, P315, DOI 10.1016/0891-5849(89)90058-0; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; COSSON P, 1993, RACHIS, V5, P5; Czaja MJ, 2002, ANTIOXID REDOX SIGN, V4, P759, DOI 10.1089/152308602760598909; Das D, 1997, FREE RADICAL BIO MED, V23, P8, DOI 10.1016/S0891-5849(96)00547-3; EISENSTEIN RS, 1990, ENZYME, V44, P42, DOI 10.1159/000468746; Erel O, 1997, CLIN BIOCHEM, V30, P631, DOI 10.1016/S0009-9120(97)00119-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gulbins E, 2003, EXP PHYSIOL, V88, P85, DOI 10.1113/eph8802503; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Helmby H, 2000, INFECT IMMUN, V68, P1485, DOI 10.1128/IAI.68.3.1485-1490.2000; Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088; Kumar KA, 2002, NEUROSCI LETT, V329, P319, DOI 10.1016/S0304-3940(02)00470-6; Kumar S, 2005, TOXICOL LETT, V157, P175, DOI 10.1016/j.toxlet.2005.03.004; Lang F, 2004, PFLUG ARCH EUR J PHY, V448, P319, DOI 10.1007/s00424-004-1254-9; Lang KS, 2005, CELL PHYSIOL BIOCHEM, V15, P195, DOI 10.1159/000086406; Leiriao P, 2005, J INFECT DIS, V191, P1576, DOI 10.1086/429635; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Mak S, 2001, CHEST, V120, P2035, DOI 10.1378/chest.120.6.2035; Matsumoto J, 2000, INFECT IMMUN, V68, P1183, DOI 10.1128/IAI.68.3.1183-1188.2000; Minana JB, 2002, HEPATOLOGY, V35, P1205, DOI 10.1053/jhep.2002.32969; Najera J. A., 2001, Parassitologia (Rome), V43, P1; Oliveira MF, 2002, FEBS LETT, V512, P139, DOI 10.1016/S0014-5793(02)02243-3; Omodeo-Sale F, 2001, BIOCHEM PHARMACOL, V61, P999, DOI 10.1016/S0006-2952(01)00558-5; Pabon A, 2003, CLIN BIOCHEM, V36, P71, DOI 10.1016/S0009-9120(02)00423-X; Pandey AV, 1997, MOL BIOCHEM PARASIT, V90, P281, DOI 10.1016/S0166-6851(97)00161-8; PERRIN LH, 1982, SEMIN HEMATOL, V19, P70; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Quaresma JAS, 2005, ACTA TROP, V94, P116, DOI 10.1016/j.actatropica.2005.03.003; Rodriguez-Acosta A, 1998, J SUBMICR CYTOL PATH, V30, P299; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Sanchez-Torres L, 2001, PARASITE IMMUNOL, V23, P617, DOI 10.1046/j.1365-3024.2001.00422.x; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shiff C, 2002, CLIN MICROBIOL REV, V15, P278, DOI 10.1128/CMR.15.2.278-293.2002; Siddiqi NJ, 1999, MOL CELL BIOCHEM, V196, P169, DOI 10.1023/A:1006944313291; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Srivastava A, 1996, Trop Gastroenterol, V17, P172; ToureBalde A, 1996, INFECT IMMUN, V64, P744, DOI 10.1128/IAI.64.3.744-750.1996; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; van de Sand C, 2005, MOL MICROBIOL, V58, P731, DOI 10.1111/j.1365-2958.2005.04888.x; Wissing D, 1998, FREE RADICAL BIO MED, V25, P57, DOI 10.1016/S0891-5849(98)00043-4; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	65	116	125	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1224	+		10.1096/fj.05-5338fje	http://dx.doi.org/10.1096/fj.05-5338fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16603602				2022-12-25	WOS:000240210300033
J	Valaperta, R; Chigorno, V; Basso, L; Prinetti, A; Bresciani, R; Preti, A; Miyagi, T; Sonnino, S				Valaperta, Rea; Chigorno, Vanna; Basso, Luisa; Prinetti, Alessandro; Bresciani, Roberto; Preti, Augusto; Miyagi, Taeko; Sonnino, Sandro			Plasma membrane production of ceramide from ganglioside GM3 in human fibroblasts	FASEB JOURNAL			English	Article						plasma membrane-associated sialidase; Neu3; GM3 synthase; glycosylhydrolases; apoptosis	HUMAN NEUROBLASTOMA-CELLS; HUMAN SKIN FIBROBLASTS; SPHINGOLIPID METABOLISM; PROTEIN-KINASE; GROWTH-CONTROL; SIALIDASE; DIFFERENTIATION; INTERNALIZATION; SPHINGOSINE; GLYCOLIPIDS	Ceramide is a key lipid molecule necessary to regulate some cellular processes, including apoptosis and cell differentiation. In this context, its production has been shown to occur via sphingomyelin hydrolysis or sphingosine acylation. Here, we show that in human fibroblasts, plasma membrane ceramide is also produced from ganglioside GM3 by detachment of sugar units. Membrane-bound glycosylhydrolases have a role in this process. In fact, the production of ceramide from GM3 has been observed even under experimental conditions able to block endocytosis or lysosomal activity, and the overexpression of the plasma membrane ganglioside sialidase Neu3 corresponded to a higher production of ceramide in the plasma membrane. The increased activity of Neu3 was paralleled by an increase of GM3 synthase mRNA and GM3 synthase activity. Neu3-overexpressing fibroblasts were characterized by a reduced proliferation rate and higher basal number of apoptotic cells in comparison with wild-type cells. A similar behavior was observed when normal fibroblasts were treated with exogenous C-2-ceramide.-Valaperta, R., Chigorno, V., Basso, L., Prinetti, A., Bresciani, R., Preti, A., Miyagi, T., and Sonnino, S. Plasma membrane production of ceramide from ganglioside GM3 in human fibroblasts.	Univ Milan, Dept Med Chem Biochem & Biotechnol, I-20090 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20090 Milan, Italy; Univ Brescia, Dept Biomed Sci & Biotechnol, Brescia, Italy; Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi, Japan	University of Milan; University of Milan; University of Brescia	Sonnino, S (corresponding author), Univ Milan, Dept Med Chem Biochem & Biotechnol, Via Fratelli Cervi 93, I-20090 Milan, Italy.	sandro.sonnino@unimi.it	Bresciani, Roberto/AAA-9728-2020; Sonnino, Sandro/R-4154-2017; Prinetti, Alessandro/R-4206-2017	Bresciani, Roberto/0000-0002-7881-7550; Sonnino, Sandro/0000-0001-8180-5908; Prinetti, Alessandro/0000-0003-0252-2593				Alessenko A V, 2000, Membr Cell Biol, V13, P303; Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CARTER HE, 1961, J LIPID RES, V2, P228; Chester MA, 1997, PURE APPL CHEM, V69, P2475, DOI 10.1351/pac199769122475; Chigorno V, 1997, EUR J BIOCHEM, V250, P661, DOI 10.1111/j.1432-1033.1997.00661.x; CHIGORNO V, 1986, ANAL BIOCHEM, V153, P283, DOI 10.1016/0003-2697(86)90094-1; Chigorno V, 1985, GLYCOCONJUGATE J, VV2, P279; Cordero OJ, 2001, EUR J BIOCHEM, V268, P3321, DOI 10.1046/j.1432-1327.2001.02237.x; Cornish-Bowden A, 1998, CARBOHYD RES, V312, P167; DAWSON G, 1972, J BIOL CHEM, V247, P5944; Fang DY, 2004, P NATL ACAD SCI USA, V101, P14782, DOI 10.1073/pnas.0404445101; FURLANETTO RW, 1988, ENDOCRINOLOGY, V122, P2044, DOI 10.1210/endo-122-5-2044; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hasegawa T, 2000, J BIOL CHEM, V275, P8007, DOI 10.1074/jbc.275.11.8007; ITO M, 1986, J BIOL CHEM, V261, P14278; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; Koh YH, 2005, J BIOL CHEM, V280, P32499, DOI 10.1074/jbc.M506199200; Kopitz J, 1997, EUR J CELL BIOL, V73, P1; KOPITZ J, 1994, BIOCHEM BIOPH RES CO, V199, P1188, DOI 10.1006/bbrc.1994.1356; KREUTTER D, 1987, J BIOL CHEM, V262, P1633; LEON A, 1981, J NEUROCHEM, V37, P350, DOI 10.1111/j.1471-4159.1981.tb00462.x; LEROY JG, 1972, PEDIATR RES, V6, P752, DOI 10.1203/00006450-197210000-00002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; Marks DL, 2005, METHODS, V36, P186, DOI 10.1016/j.ymeth.2004.12.001; Marques C, 2004, FASEB J, V18, P1424, DOI 10.1096/fj.04-1743fje; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Mauri L, 1999, GLYCOCONJUGATE J, V16, P197, DOI 10.1023/A:1007072203345; Mencarelli S, 2005, FEBS LETT, V579, P5501, DOI 10.1016/j.febslet.2005.08.081; MIYAGI T, 1990, J BIOCHEM-TOKYO, V107, P787, DOI 10.1093/oxfordjournals.jbchem.a123126; Monti E, 2000, BIOCHEM J, V349, P343, DOI 10.1042/0264-6021:3490343; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Papini N, 2004, J BIOL CHEM, V279, P16989, DOI 10.1074/jbc.M400881200; PARTINGTON CR, 1979, MOL PHARMACOL, V15, P484; Prinetti A, 2003, J BIOL CHEM, V278, P5574, DOI 10.1074/jbc.M207269200; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; RADSAK K, 1982, H-S Z PHYSIOL CHEM, V363, P263, DOI 10.1515/bchm2.1982.363.1.263; SCHEEL G, 1982, EUR J BIOCHEM, V127, P245, DOI 10.1111/j.1432-1033.1982.tb06862.x; SCHWARZMANN G, 1983, BIOCHEMISTRY-US, V22, P5041, DOI 10.1021/bi00290a025; Sonnino S, 2000, METHOD ENZYMOL, V311, P639; SONNINO S, 1978, J NEUROCHEM, V31, P947, DOI 10.1111/j.1471-4159.1978.tb00132.x; TETTAMANTI G, 1977, Biochemistry and Experimental Biology, V13, P45; TOYOKUNI T, 1991, J LABELLED COMPD RAD, V29, P567, DOI 10.1002/jlcr.2580290508; YATES AJ, 1989, J NEUROCHEM, V53, P162, DOI 10.1111/j.1471-4159.1989.tb07308.x	49	95	96	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1227	+		10.1096/fj.05-5077fje	http://dx.doi.org/10.1096/fj.05-5077fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16645048				2022-12-25	WOS:000240210300034
J	Zhu, NX; Gu, LB; Findley, HW; Chen, CS; Dong, JT; Yang, L; Zhou, MX				Zhu, Ningxi; Gu, Lubing; Findley, Harry W.; Chen, Ceshi; Dong, Jin-Tang; Yang, Lily; Zhou, Muxiang			KLF5 interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR-5; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; SMOOTH-MUSCLE-CELLS; TRANSCRIPTION FACTOR; GENE; APOPTOSIS; ELEMENT; CANCER; ACTIVATION	The Kruppel-like factor 5 (KLF5) is a transcription factor that regulates cellular signaling involved in cell proliferation and oncogenesis. Here, we report that KLF5 interacts with tumor suppressor p53 in regulating the expression of the inhibitor-of-apoptosis protein survivin, which may play a role in pathological process of cancer. The core promoter region of survivin contains multiple GT-boxes that have been characterized as KLF5 response elements. Deletion and mutation analyses as well as chromatin immunoprecipitation and electronic mobility shift assay indicated that KLF5 binds to the core survivin promoter and strongly induces its activity. Furthermore, we demonstrated that KLF5 protein is able to bind to p53 and abrogate the p53-regulated repression of survivin. Transfection of KLF5 into a KLF5-negative acute lymphoblastic leukemia cell line EU-8 enhanced survivin expression, and conversely, silencing of KLF5 by small interfering RNA in a KLF5-overexpressing acute lymphoblastic leukemia cell line EU-4 down-regulated survivin expression. The KLF5 small interfering RNA-mediated down-regulation of survivin sensitized EU-4 cells to apoptosis induced by chemotherapeutic drug doxorubicin. These findings identify a novel regulatory pathway for the expression of survivin under the control of KLF5 and p53. Deregulation of this pathway may result in overexpression of survivin in cancer, thus contributing to drug resistance.	Emory Univ, Sch Med, Div Pediat Hematol Oncol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Hematol Oncol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Emory University	Zhou, MX (corresponding author), Emory Univ, Sch Med, Div Pediat Hematol Oncol, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	mzhou@emory.edu		Dong, Jin-Tang/0000-0003-2349-5782	NCI NIH HHS [R01 CA 82323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082323] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chanchevalap S, 2004, FEBS LETT, V578, P99, DOI 10.1016/j.febslet.2004.10.079; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CH, 2006, INT J CANCER, V118, P1346, DOI 10.1002/ijc.21533; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hoshino Y, 2000, CIRCULATION, V102, P2528, DOI 10.1161/01.CIR.102.20.2528; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Ogata T, 2000, J THORAC CARDIOV SUR, V119, P983, DOI 10.1016/S0022-5223(00)70093-6; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Olie RA, 2000, CANCER RES, V60, P2805; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Rodel F, 2005, CANCER RES, V65, P4881, DOI 10.1158/0008-5472.CAN-04-3028; Rubinstein M, 2004, ENDOCRINOLOGY, V145, P3769, DOI 10.1210/en.2004-0173; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Sur I, 2002, EUR J CELL BIOL, V81, P323, DOI 10.1078/0171-9335-00257; Tu SP, 2003, CANCER RES, V63, P7724; Yang XXO, 2003, BLOOD, V101, P4492, DOI 10.1182/blood-2002-08-2579; Zhang P, 2005, BLOOD CELL MOL DIS, V35, P227, DOI 10.1016/j.bcmd.2005.04.009; Zhang T, 2001, CANCER RES, V61, P8664; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192; Zhu NX, 2004, ONCOGENE, V23, P7545, DOI 10.1038/sj.onc.1208038	43	92	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14711	14718		10.1074/jbc.M513810200	http://dx.doi.org/10.1074/jbc.M513810200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16595680	hybrid			2022-12-25	WOS:000237671300024
J	Beck, A; Kolisek, M; Bagley, LA; Fleig, A; Penner, R				Beck, Andreas; Kolisek, Martin; Bagley, Leigh Anne; Fleig, Andrea; Penner, Reinhold			Nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose regulate TRPM2 channels in T lymphocytes	FASEB JOURNAL			English	Article						TRPM2; cADPR; NAADP	HYDROGEN-PEROXIDE; CALCIUM-RELEASE; CATION CHANNELS; CA2+ RELEASE; NAADP; ACTIVATION; INFLUX; 2ND-MESSENGER; MESSENGERS; RECEPTORS	TRPM2 (previously designated TRPC7 or LTRPC2) is a Ca(2+)-permeable nonselective cation channel that contains a C-terminal enzymatic domain with pyrophosphatase activity, which specifically binds ADP-ribose. Cyclic ADP-ribose ( cADPR) and hydrogen peroxide (H(2)O(2)) can facilitate ADPR-mediated activation of heterologously expressed TRPM2. Here, we show that the two Ca(2+)-mobilizing second messengers cyclic ADP-ribose ( cADPR) and nicotinic acid adenine dinucleotide phosphate ( NAADP) strongly activate natively expressed TRPM2 channels in Jurkat T cells. TRPM2 activation by both agonists can be partially suppressed by the ADPR antagonist adenosine monophosphate ( AMP), which suggests that cADPR and NAADP lead to mobilization of endogenous ADPR presumably via metabolic conversion. The remaining channel activity is due to direct gating of TRPM2 by the two agonists and can be completely suppressed by 8-Br-cADPR, which suggests that cADPR and NAADP share a common binding site on TRPM2 that can regulate TRPM2 activity in synergy with ADPR. We conclude that cADPR and NAADP, in combination with ADPR, represent physiological co-activators of TRPM2 that contribute to Ca(2+)-influx in T lymphocytes and presumably other cell types that express this channel.	Queens Med Ctr, Ctr Biomed Res, Lab Cell & Mol Signaling, Honolulu, HI 96813 USA; Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA	The Queen's Medical Center; University of Hawaii System	Penner, R (corresponding author), Queens Med Ctr, Ctr Biomed Res, Lab Cell & Mol Signaling, 1301 Punchbowl St UHT 8, Honolulu, HI 96813 USA.	rpenner@hawaii.edu		Fleig, Andrea/0000-0001-8396-7249; Penner, Reinhold/0000-0002-5366-1537	NIAID NIH HHS [R01-AI50200] Funding Source: Medline; NIGMS NIH HHS [R01-GM 063954, R01-GM 65360] Funding Source: Medline; NINDS NIH HHS [R01-NS40927] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063954, R01GM065360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040927] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Billington RA, 2002, J PHYSIOL-LONDON, V544, P107, DOI 10.1113/jphysiol.2002.030098; Dousa TP, 1996, AM J PHYSIOL-CELL PH, V271, pC1007, DOI 10.1152/ajpcell.1996.271.4.C1007; Galione A, 2005, MOL INTERV, V5, P73, DOI 10.1124/mi.5.2.4; Galione A, 2000, Sci STKE, V2000, ppe1; Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Guse Andreas H., 2002, Current Molecular Medicine (Hilversum), V2, P273, DOI 10.2174/1566524024605707; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Heiner I, 2003, CELL CALCIUM, V33, P533, DOI 10.1016/S0143-4160(03)00058-7; Inamura K, 2003, J MEMBRANE BIOL, V191, P201, DOI 10.1007/s00232-002-1057-x; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; Kuhn FJP, 2004, J BIOL CHEM, V279, P46431, DOI 10.1074/jbc.M407263200; Langhorst MF, 2004, CELL SIGNAL, V16, P1283, DOI 10.1016/j.cellsig.2004.03.013; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; Lee HC, 1999, MOL CELL BIOCHEM, V193, P89; LEE S, 2000, JPL OPTICAL COMMUNIC, V2000, P1; Lund FE, 1998, IMMUNOL REV, V161, P79, DOI 10.1111/j.1600-065X.1998.tb01573.x; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Perraud AL, 2005, J BIOL CHEM, V280, P6138, DOI 10.1074/jbc.M411446200; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Santella L, 2005, MOL INTERV, V5, P70, DOI 10.1124/mi.5.2.3; Turner H, 2003, BIOCHEM J, V371, P341, DOI 10.1042/BJ20021381; Wilding M, 1998, AM J PHYSIOL-CELL PH, V275, pC1277, DOI 10.1152/ajpcell.1998.275.5.C1277; Yamasaki M, 2005, CURR BIOL, V15, P874, DOI 10.1016/j.cub.2005.04.033	30	148	151	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					962	+		10.1096/fj.05-5538fje	http://dx.doi.org/10.1096/fj.05-5538fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585058				2022-12-25	WOS:000240157700022
J	Leung, N; Turbide, C; Olson, M; Marcus, V; Jothy, S; Beauchemin, N				Leung, N.; Turbide, C.; Olson, M.; Marcus, V.; Jothy, S.; Beauchemin, N.			Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis	ONCOGENE			English	Article						CEACAM1; colon cancer; azoxymethane; knockout; CEA	INDEPENDENT PROGNOSTIC-SIGNIFICANCE; ABERRANT CRYPT FOCI; BILIARY GLYCOPROTEIN; COLORECTAL-CANCER; EPITHELIAL-CELLS; C-CAM; BETA-CATENIN; HEPATOCELLULAR CARCINOMAS; EXPRESSION PROFILES; SIGNAL-TRANSDUCTION	Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a glycoprotein that is part of the carcinoembryonic antigen and the immunoglobulin superfamilies. We have shown that it functions as a tumor suppressor and that this function depends upon the presence of the longer CEACAM1 cytoplasmic domain. In this report, we describe the generation of a Ceacam1-/- mouse. The Ceacam1-/- colon exhibits increased in vivo proliferation relative to the wild-type counterpart with a corresponding decreased expression of the p21(Cip1) and p27(Kip1) Cyclin D kinase inhibitors. The colonic villi undergo decreased apoptosis. Out of 35 litters of mice, no spontaneous tumors in any tissues normally expressing CEACAM1 were found over the lifespan of the animals, suggesting that CEACAM1 may not be involved in initiation of tumor development. However, when mice are treated with azoxymethane to induce colonic tumors, we find that Ceacam1-/- mice developed a significantly greater number of tumors than their littermate controls. Moreover, the tumor size was greater in the knockout mice relative to that in the wild-type mice. These results indicate that deletion of CEACAM1 favors progression of colon tumorigenesis.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Pathol, Montreal, PQ H3G 1Y6, Canada; St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5B 1W8, Canada; Univ Toronto, Toronto, ON, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, McIntyre Bldg,Room 711,3655 Promenade Sir William, Montreal, PQ H3G 1Y6, Canada.	Nicole.Beauchemin@mcgill.ca						Bamberger AM, 1998, AM J PATHOL, V152, P1401; Beauchemin N, 1999, EXP CELL RES, V252, P243; Blau DM, 2001, J VIROL, V75, P8173, DOI 10.1128/JVI.75.17.8173-8186.2001; Brabletz T, 2002, VIRCHOWS ARCH, V441, P1, DOI 10.1007/s00428-002-0642-9; Buckhaults P, 2001, CANCER RES, V61, P6996; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; Chan CHF, 2004, MOL THER, V9, P775, DOI 10.1016/j.ymthe.2004.03.009; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; COURNOYER D, 1988, CANCER RES, V48, P3153; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Eberhard A, 2000, CANCER RES, V60, P1388; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Estrera VT, 2001, J BIOL CHEM, V276, P15547, DOI 10.1074/jbc.M008156200; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fournes B, 2001, ONCOGENE, V20, P219, DOI 10.1038/sj.onc.1204058; Frangsmyr L, 1999, TUMOR BIOL, V20, P277, DOI 10.1159/000030075; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; Hemmila E, 2004, J VIROL, V78, P10156, DOI 10.1128/JVI.78.18.10156-10165.2004; HIXSON DC, 1985, CANCER RES, V45, P3742; HORST AK, 2006, IN PRESS J CLIN INVE; HSIEH JT, 1995, CANCER RES, V55, P190; Huang J, 1998, ANTICANCER RES, V18, P3203; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Ilantzis C, 1997, LAB INVEST, V76, P703; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Jantscheff P, 2003, J CLIN ONCOL, V21, P3638, DOI 10.1200/JCO.2003.55.135; Kinugasa T, 1998, INT J CANCER, V76, P148, DOI 10.1002/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.3.CO;2-J; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; Laack E, 2002, J CLIN ONCOL, V20, P4279, DOI 10.1200/JCO.2002.08.067; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Maltzman T, 1997, CARCINOGENESIS, V18, P2435, DOI 10.1093/carcin/18.12.2435; Muenzner P, 2000, INFECT IMMUN, V68, P3601, DOI 10.1128/IAI.68.6.3601-3607.2000; Muller MM, 2005, BLOOD, V105, P3925, DOI 10.1182/blood-2004-09-3618; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; Notterman DA, 2001, CANCER RES, V61, P3124; OKAMOTO M, 1995, CARCINOGENESIS, V16, P2659, DOI 10.1093/carcin/16.11.2659; Oliveira-Ferrer L, 2004, CANCER RES, V64, P8932, DOI 10.1158/0008-5472.CAN-04-0505; OLSEN A, 1994, GENOMICS, V23, P659, DOI 10.1006/geno.1994.1555; Papanikolaou A, 1998, CANCER LETT, V130, P29, DOI 10.1016/S0304-3835(98)00101-3; Phan D, 2004, CANCER RES, V64, P3072, DOI 10.1158/0008-5472.CAN-03-3730; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Quaroni A, 1997, GASTROENTEROLOGY, V113, P1198, DOI 10.1053/gast.1997.v113.pm9322515; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Robitaille J, 1999, EUR J BIOCHEM, V264, P534, DOI 10.1046/j.1432-1327.1999.00660.x; ROSENBERG M, 1993, CANCER RES, V53, P4938; Scholzel S, 2000, AM J PATHOL, V156, P595, DOI 10.1016/S0002-9440(10)64764-5; Singer BB, 2000, CANCER RES, V60, P1236; Singh J, 1997, INT J ONCOL, V10, P449; Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117; Tanaka K, 1997, INT J CANCER, V74, P15, DOI 10.1002/(SICI)1097-0215(19970220)74:1<15::AID-IJC3>3.0.CO;2-3; Thies A, 2002, J CLIN ONCOL, V20, P2530, DOI 10.1200/JCO.2002.05.033; Turbide C, 1997, CANCER RES, V57, P2781; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; VIVONA AA, 1993, CARCINOGENESIS, V14, P1777, DOI 10.1093/carcin/14.9.1777; Volpert O, 2002, J BIOL CHEM, V277, P35696, DOI 10.1074/jbc.M205319200; Wang QS, 2000, MOL CARCINOGEN, V28, P139, DOI 10.1002/1098-2744(200007)28:3<139::AID-MC2>3.0.CO;2-V; Wang QS, 1998, CARCINOGENESIS, V19, P2001, DOI 10.1093/carcin/19.11.2001; Wong SCC, 2004, CLIN CANCER RES, V10, P1401, DOI 10.1158/1078-0432.CCR-0157-03; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	69	71	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2006	25	40					5527	5536		10.1038/sj.onc.1209541	http://dx.doi.org/10.1038/sj.onc.1209541			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619040				2022-12-25	WOS:000240370400006
J	Pazzaglia, S; Tanori, M; Mancuso, M; Gessi, M; Pasquali, E; Leonardi, S; Oliva, MA; Rebessi, S; Di Majo, V; Covelli, V; Giangaspero, F; Saran, A				Pazzaglia, S.; Tanori, M.; Mancuso, M.; Gessi, M.; Pasquali, E.; Leonardi, S.; Oliva, M. A.; Rebessi, S.; Di Majo, V.; Covelli, V.; Giangaspero, F.; Saran, A.			Two-hit model for progression of medulloblastoma preneoplasia in Patched heterozygous mice	ONCOGENE			English	Article						medulloblastoma; preneoplasia; Patched; hedgehog; ionizing radiation; LOH	IONIZING-RADIATION; KNOCKOUT MICE; LARGE DELETIONS; MOUSE MODEL; CELL-LINES; HPRT LOCUS; TUMORIGENESIS; GROWTH; CEREBELLUM; MUTATION	Inactivation of one Ptc1 allele predisposes humans and mice to spontaneous medulloblastoma development, and irradiation of newborn Ptc1 heterozygous mice results in dramatic increase of medulloblastoma incidence. While a role for loss of wild-type (wt) Ptc1 (LOH) in radiation-induced medulloblastomas from Ptc1(neo67/+) mice is well established, the importance of this event in spontaneous medulloblastomas is still unclear. Here, we demonstrate that biallelic Ptc1 loss plays a crucial role in spontaneous medulloblastomas, as shown by high rate of wt Ptc1 loss in spontaneous tumors. In addition, remarkable differences in chromosomal events involving the Ptc1 locus in spontaneous and radiation-induced medulloblastomas suggest distinct mechanisms for Ptc1 loss. To assess when, during tumorigenesis, Ptc1 loss occurs, we characterized cerebellar abnormalities that precede tumor appearance in Ptc1(neo67/+) mice. We show that inactivation of only one copy of Ptc1 is sufficient to give rise to abnormal cerebellar proliferations with different degree of altered cell morphology, but lacking potential to progress to neoplasia. Furthermore, we identify biallelic Ptc1 loss as the event causally related to the transition from the preneoplastic stage to full blown medulloblastoma. These results underscore the utility of the Ptc1(neo67/+) mouse model for studies on the mechanisms of medulloblastoma and for development of new therapeutic strategies.	ENEA, CR Casaccia, Biotechnol Unit, I-00060 Rome, Italy; Natl Neurol Inst C Besta, Div Neuropathol, Milan, Italy; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; INM Neuromed, Isernia, Italy; ENEA, CR Casaccia, Radiat Protect Unit, I-00060 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy	Italian National Agency New Technical Energy & Sustainable Economics Development; IRCCS Istituto Neurologico Besta; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Neuromed; Italian National Agency New Technical Energy & Sustainable Economics Development; Sapienza University Rome	Pazzaglia, S (corresponding author), ENEA, CR Casaccia, Biotechnol Unit, Via Anguillarese 301, I-00060 Rome, Italy.	pazzaglia@casaccia.enea.it	Giangaspero, Felice/AAH-9253-2020; Oliva, Maria Antonietta/AAE-9115-2020; Giangaspero, Felice/Z-4961-2019; Gessi, Marco/K-2572-2018	Giangaspero, Felice/0000-0001-5382-2380; Oliva, Maria Antonietta/0000-0003-3460-696X; Giangaspero, Felice/0000-0001-5382-2380; Saran, Anna/0000-0002-5587-064X				Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Chintagumpala M, 2001, CURR OPIN ONCOL, V13, P154, DOI 10.1097/00001622-200105000-00004; Corcoran RB, 2001, J NEURO-ONCOL, V53, P307, DOI 10.1023/A:1012260318979; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Eberhart CG, 2003, BRAIN PATHOL, V13, P376; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HUTCHINSON F, 1995, J MOL BIOL, V254, P372, DOI 10.1006/jmbi.1995.0624; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kim JYH, 2003, DEV BIOL, V263, P50, DOI 10.1016/S0012-1606(03)00434-2; Kinzler KW, 1997, NATURE, V386, P763; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Mancuso M, 2004, CANCER RES, V64, P934, DOI 10.1158/0008-5472.CAN-03-2460; NELSON SL, 1995, RADIAT RES, V141, P2, DOI 10.2307/3579083; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Packer R J, 1999, Neuro Oncol, V1, P232, DOI 10.1093/neuonc/1.3.232; Pazzaglia S, 2006, CANCER LETT, V234, P124, DOI 10.1016/j.canlet.2005.03.047; Pazzaglia S, 2006, ONCOGENE, V25, P1165, DOI 10.1038/sj.onc.1209032; Pazzaglia S, 2000, MOL CARCINOGEN, V27, P219, DOI 10.1002/(SICI)1098-2744(200003)27:3<219::AID-MC9>3.0.CO;2-S; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Ponomareva ON, 2002, CANCER RES, V62, P1518; Shoemaker AR, 1998, P NATL ACAD SCI USA, V95, P10826, DOI 10.1073/pnas.95.18.10826; Turker MS, 1997, MUTAT RES-FUND MOL M, V374, P201, DOI 10.1016/S0027-5107(96)00230-8; Uziel T, 2005, GENE DEV, V19, P2656, DOI 10.1101/gad.1368605; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wetmore C, 2000, CANCER RES, V60, P2239; Yamada Y, 1996, RADIAT RES, V145, P481, DOI 10.2307/3579070; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	30	51	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2006	25	40					5575	5580		10.1038/sj.onc.1209544	http://dx.doi.org/10.1038/sj.onc.1209544			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16636673				2022-12-25	WOS:000240370400011
J	Yamada, A; Fujita, N; Sato, T; Okamoto, R; Ooshio, T; Hirota, T; Morimoto, K; Irie, K; Takai, Y				Yamada, A.; Fujita, N.; Sato, T.; Okamoto, R.; Ooshio, T.; Hirota, T.; Morimoto, K.; Irie, K.; Takai, Y.			Requirement of nectin, but not cadherin, for formation of claudin-based tight junctions in annexin II-knockdown MDCK cells	ONCOGENE			English	Article						adherens junctions; tight junctions; nectin; afadin; annexin II	CANINE KIDNEY-CELLS; ADHESION MOLECULE NECTIN; SMALL G-PROTEINS; ADHERENS JUNCTIONS; EPITHELIAL-CELLS; ALPHA-CATENIN; ACTIN-FILAMENTS; INTERCELLULAR-JUNCTIONS; FUNCTIONAL-ANALYSIS; TRANS-INTERACTIONS	Adherens junctions (AJs) and tight junctions (TJs) comprise a junctional complex which plays key roles not only in cell adhesion and polarization but also in regulation of cell movement and proliferation in epithelial cells. E-Cadherin and nectin are major cell-cell adhesion molecules (CAMs) at AJs, whereas claudin is a major CAM at TJs. We have shown that the cadherin-based cell-cell adhesion is not formed in MDCK cells in which annexin II, a Ca2+- and phospholipid-binding protein, is knocked down. Here, we found that TJs and the nectin-based cell-cell adhesions were formed in annexin II-knockdown cells. The formation of TJs in annexin II-knockdown MDCK cells required the nectin-based cell-cell adhesion and afadin, a nectin- and actin-filament-binding protein. In addition, it required the activation of Cdc42 and Rac small G proteins and subsequent reorganization of the IQGAP1-dependent actin cytoskeleton which were induced by the nectin- based cell-cell adhesion. These results indicate that the nectin-based cell-cell adhesion and afadin, but not the cadherin-based cell-cell adhesion, are necessary for the formation of TJs and that the signaling by nectin and the subsequent reorganization of the actin cytoskeleton are also necessary for the formation of TJs under certain conditions.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto, Japan	Osaka University; KAN Research Institute	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp						ABERCROMBIE M, 1953, EXP CELL RES, V5, P111, DOI 10.1016/0014-4827(53)90098-6; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Andreeva AY, 2001, J BIOL CHEM, V276, P38480, DOI 10.1074/jbc.M104923200; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FISHER HW, 1967, SCIENCE, V155, P581, DOI 10.1126/science.155.3762.581; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Fukuhara A, 2002, GENES CELLS, V7, P1059, DOI 10.1046/j.1365-2443.2002.00578.x; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; GONZALEZMARISCAL L, 1985, J MEMBRANE BIOL, V86, P113, DOI 10.1007/BF01870778; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Harris TJC, 2004, J CELL BIOL, V167, P135, DOI 10.1083/jcb.200406024; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Honda T, 2003, BIOCHEM BIOPH RES CO, V306, P104, DOI 10.1016/S0006-291X(03)00919-7; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Hoshino T, 2005, J BIOL CHEM, V280, P24095, DOI 10.1074/jbc.M414447200; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Katata T, 2003, ONCOGENE, V22, P2097, DOI 10.1038/sj.onc.1206255; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Ma TY, 2000, AM J PHYSIOL-GASTR L, V279, pG875, DOI 10.1152/ajpgi.2000.279.5.G875; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Okamoto R, 2005, GENES CELLS, V10, P435, DOI 10.1111/j.1365-2443.2005.00846.x; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Quinlan MP, 1999, CELL GROWTH DIFFER, V10, P839; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sakisaka T, 2004, CURR OPIN CELL BIOL, V16, P513, DOI 10.1016/j.ceb.2004.07.007; Sato T, 2006, J BIOL CHEM, V281, P5288, DOI 10.1074/jbc.M510070200; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; Sonoda N, 1999, J CELL BIOL, V147, P195, DOI 10.1083/jcb.147.1.195; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; STEVENSON BR, 1994, J CELL SCI, V107, P367; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Umeda K, 2004, J BIOL CHEM, V279, P44785, DOI 10.1074/jbc.M406563200; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yagi T, 2000, GENE DEV, V14, P1169; Yamada A, 2005, J BIOL CHEM, V280, P6016, DOI 10.1074/jbc.M408215200; Yamada A, 2004, GENES CELLS, V9, P843, DOI 10.1111/j.1365-2443.2004.00768.x; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595	65	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5085	5102		10.1038/sj.onc.1209525	http://dx.doi.org/10.1038/sj.onc.1209525			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16607281				2022-12-25	WOS:000240063700002
J	Massard, C; Zermati, Y; Pauleau, AL; Larochette, N; Wetivier, D; Sabatier, L; Kroemer, G; Soria, JC				Massard, C.; Zermati, Y.; Pauleau, A. -L; Larochette, N.; Wetivier, D.; Sabatier, L.; Kroemer, G.; Soria, J. -C			hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway	ONCOGENE			English	Article						apoptosis; Bax; Bcl-2; chemosensitization; p53	TELOMERASE REVERSE-TRANSCRIPTASE; HUMAN CANCER-CELLS; GENE-EXPRESSION; DOWN-REGULATION; APOPTOSIS; P53; GROWTH; BAX; RNA; RESPONSES	hTERT is the catalytic subunit of the telomerase and is hence required for telomerase maintenance activity and cancer cell immortalization. Here, we show that acute hTERT depletion has no adverse effects on the viability or proliferation of cervical and colon carcinoma cell lines, as evaluated within 72h after transfection with hTERT-specific small interfering RNAs (siRNAs). Within the same time frame, hTERT depletion facilitated the induction of apoptotic cell death by cisplatin, etoposide, mitomycin C and reactive oxygen species, yet failed to sensitize cells to death induction via the CD95 death receptor. Experiments performed with p53 knockout cells or chemical p53 inhibitors revealed that p53 was not involved in the chemosensitizing effect of hTERT knockdown. However, the proapoptotic Bcl-2 family protein Bax was involved in cell death induction by hTERT siRNAs. Depletion of hTERT facilitated the conformational activation of Bax induced by genotoxic agents. Moreover, Bax knockout abolished the chemosensitizing effect of hTERT siRNAs. Inhibition of mitochondrial membrane permeabilization by overexpression of Bcl-2 or expression of the cytomegalovirus-encoded protein vMIA (viral mitochondrial inhibitor of apoptosis), which acts as a specific Bax inhibitor, prevented the induction of cell death by the combination of hTERT depletion and chemotherapeutic agents. Altogether, our data indicate that hTERT inhibition may constitute a promising strategy for facilitating the induction of the mitochondrial pathway of apoptosis.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, Div Canc Med, F-94805 Villejuif, France; CEA, DSV, DRR, LRO, Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; CEA	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr; soria@igr.fr	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Soria, Jean-Charles/F-3619-2014; LAROCHETTE, Nathanael/R-4298-2017	KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; Sabatier, Laure/0000-0003-0552-6549				Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 1996, J IMMUNOL, V157, P512; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Del Bufalo D, 2005, CELL DEATH DIFFER, V12, P1429, DOI 10.1038/sj.cdd.4401670; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Folini M, 2005, EUR J CANCER, V41, P624, DOI 10.1016/j.ejca.2004.12.002; Goldmacher VS, 2005, APOPTOSIS, V10, P251, DOI 10.1007/s10495-005-0800-z; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Gorbunova V, 2003, J BIOL CHEM, V278, P7692, DOI 10.1074/jbc.M212944200; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Haendeler J, 2004, CIRC RES, V94, P768, DOI 10.1161/01.RES.0000121104.05977.F3; Haendeler J, 2003, FEBS LETT, V536, P180, DOI 10.1016/S0014-5793(03)00058-9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harborth J, 2001, J CELL SCI, V114, P4557; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Jacob D, 2005, CANCER GENE THER, V12, P109, DOI 10.1038/sj.cgt.7700773; Jiang F, 2004, J BIOL CHEM, V279, P53213, DOI 10.1074/jbc.M410395200; Kang HJ, 2004, J NEUROSCI, V24, P1280, DOI 10.1523/JNEUROSCI.4082-03.2004; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komata T, 2002, ONCOGENE, V21, P656, DOI 10.1038/sj.onc.1205072; Lantuejoul S, 2005, CLIN CANCER RES, V11, P2074, DOI 10.1158/1078-0432.CCR-04-1376; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Li S, 2005, J BIOL CHEM, V280, P23709, DOI 10.1074/jbc.M502782200; Li S, 2004, CANCER RES, V64, P4833, DOI 10.1158/0008-5472.CAN-04-0953; Lin TY, 2002, ONCOGENE, V21, P8020, DOI 10.1038/sj.onc.1205926; Lu CB, 2001, DEV BRAIN RES, V131, P167, DOI 10.1016/S0165-3806(01)00237-1; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Santos JH, 2004, AGING CELL, V3, P399, DOI 10.1111/j.1474-9728.2004.00124.x; Saretzki G, 2001, ANAL CELL PATHOL, V23, P39, DOI 10.1155/2001/630972; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Takakura M, 2005, MOL CELL BIOL, V25, P8037, DOI 10.1128/MCB.25.18.8037-8043.2005; Uziel O, 2005, BRIT J CANCER, V92, P1881, DOI 10.1038/sj.bjc.6602592; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu P, 2005, BIOCHEM BIOPH RES CO, V335, P36, DOI 10.1016/j.bbrc.2005.07.039; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang PS, 2003, FASEB J, V17, P767, DOI 10.1096/fj.02-0603fje; Zhou CX, 2003, MOL CANCER THER, V2, P789	58	118	133	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2006	25	33					4505	4514		10.1038/sj.onc.1209487	http://dx.doi.org/10.1038/sj.onc.1209487			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16619047				2022-12-25	WOS:000239457500001
J	Gazel, A; Banno, T; Walsh, R; Blumenberg, M				Gazel, Alix; Banno, Tomohiro; Walsh, Rebecca; Blumenberg, Miroslav			Inhibition of JNK promotes differentiation of epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; HUMAN SKIN; BARRIER FUNCTION; STRESS-RESPONSE; RETINOIC ACID; CELL MOTILITY; ACTIVATION; PROTEIN	In inflamed tissue, normal signal transduction pathways are altered by extracellular signals. For example, the JNK pathway is activated in psoriatic skin, which makes it an attractive target for treatment. To define comprehensively the JNK-regulated genes in human epidermal keratinocytes, we compared the transcriptional profiles of control and JNK inhibitor-treated keratinocytes, using DNA microarrays. We identified the differentially expressed genes 1, 4, 24, and 48 h after the treatment with SP600125. Surprisingly, the inhibition of JNK in keratinocyte cultures in vitro induces virtually all aspects of epidermal differentiation in vivo: transcription of cornification markers, inhibition of motility, withdrawal from the cell cycle, stratification, and even production of cornified envelopes. The inhibition of JNK also induces the production of enzymes of lipid and steroid metabolism, proteins of the diacylglycerol and inositol phosphate pathways, mitochondrial proteins, histones, and DNA repair enzymes, which have not been associated with differentiation previously. Simultaneously, basal cell markers, including integrins, hemidesmosome and extracellular matrix components, are suppressed. Promoter analysis of regulated genes finds that the binding sites for the forkhead family of transcription factors are over-represented in the SP600125-induced genes and c-Fos sites in the suppressed genes. The JNK-induced proliferation appears to be secondary to inhibition of differentiation. The results indicate that the inhibition of JNK in epidermal keratinocytes is sufficient to initiate their differentiation program and suggest that augmenting JNK activity could be used to delay cornification and enhance wound healing, whereas attenuating it could be a differentiation therapy-based approach for treating psoriasis.	York Univ, Sch Med, Dept Dermatol, New York, NY 10016 USA; York Univ, Sch Med, Dept Biochem, New York, NY 10016 USA; York Univ, Sch Med, Inst Canc, New York, NY 10016 USA; Univ Tsukuba, Inst Clin Med, Dept Dermatol, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba	Blumenberg, M (corresponding author), York Univ, Sch Med, Dept Dermatol, 550 1st Ave, New York, NY 10016 USA.	blumem01@med.nyu.edu		Blumenberg, Miroslav/0000-0002-8672-7774				Adachi M, 2003, DNA CELL BIOL, V22, P665, DOI 10.1089/104454903770238148; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Banno T, 2005, J BIOL CHEM, V280, P18973, DOI 10.1074/jbc.M411758200; Banno T, 2003, ANTIVIR THER, V8, P541; Banno T, 2004, J BIOL CHEM, V279, P32633, DOI 10.1074/jbc.M400642200; BERNERD F, 1992, J INVEST DERMATOL, V98, P902, DOI 10.1111/1523-1747.ep12460344; Bogoyevitch MA, 2004, BBA-PROTEINS PROTEOM, V1697, P89, DOI 10.1016/j.bbapap.2003.11.016; Brattsand M, 2005, J INVEST DERMATOL, V124, P198, DOI 10.1111/j.0022-202X.2004.23547.x; BRISSETTE JL, 1994, P NATL ACAD SCI USA, V91, P6453, DOI 10.1073/pnas.91.14.6453; Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755; Chen NY, 2001, CANCER RES, V61, P3908; D'Alessandro M, 2002, J CELL SCI, V115, P4341, DOI 10.1242/jcs.00120; DANKS JA, 1995, J HISTOCHEM CYTOCHEM, V43, P5, DOI 10.1177/43.1.7822764; Dashti SR, 2001, J BIOL CHEM, V276, P8059, DOI 10.1074/jbc.C000862200; De Haes P, 2003, J CELL BIOCHEM, V89, P663, DOI 10.1002/jcb.10540; Di WL, 2001, J INVEST DERMATOL, V117, P958, DOI 10.1046/j.0022-202x.2001.01468.x; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; ELIAS PM, 1984, J CLIN INVEST, V74, P1414, DOI 10.1172/JCI111552; Fang Peng, 2004, Novartis Found Symp, V262, P215; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Gamady A, 2003, J CELL BIOCHEM, V89, P440, DOI 10.1002/jcb.10508; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Janes SM, 2004, J CELL SCI, V117, P4157, DOI 10.1242/jcs.01302; Jang SI, 2002, J BIOL CHEM, V277, P42268, DOI 10.1074/jbc.M205593200; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; Jho SH, 2005, J INVEST DERMATOL, V124, P1034, DOI 10.1111/j.0022-202X.2005.23691.x; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kato JS, 2003, J INVEST DERMATOL, V120, P456, DOI 10.1046/j.1523-1747.2003.12053.x; Kretz M, 2003, J CELL SCI, V116, P3443, DOI 10.1242/jcs.00638; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Li W, 2004, J INVEST DERMATOL, V123, P622, DOI 10.1111/j.0022-202X.2004.23416.x; Matic M, 2004, METH MOL B, V289, P193; Mehic D, 2005, J INVEST DERMATOL, V124, P212, DOI 10.1111/j.0022-202X.2004.23558.x; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; Nickoloff BJ, 2004, J CLIN INVEST, V113, P1664, DOI 10.1172/JCI200422147; Ramaswamy NT, 1998, ONCOGENE, V16, P1501, DOI 10.1038/sj.onc.1201628; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Schluter H, 2004, EUR J CELL BIOL, V83, P655, DOI 10.1078/0171-9335-00434; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Silvers AL, 2003, NEOPLASIA, V5, P319, DOI 10.1016/S1476-5586(03)80025-8; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Sui SJH, 2005, NUCLEIC ACIDS RES, V33, P3154, DOI 10.1093/nar/gki624; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; Swerlick Robert A., 1995, Journal of Dermatology (Tokyo), V22, P845; Tada J, 1997, J CUTAN PATHOL, V24, P628, DOI 10.1111/j.1600-0560.1997.tb01094.x; Takahashi H, 2002, J DERMATOL SCI, V30, P94, DOI 10.1016/S0923-1811(02)00064-6; Thiboutot D, 2003, J INVEST DERMATOL, V120, P905, DOI 10.1046/j.1523-1747.2003.12244.x; Ting SB, 2005, SCIENCE, V308, P411, DOI 10.1126/science.1107511; Tsuruta D, 2002, TRENDS CELL BIOL, V12, P355, DOI 10.1016/S0962-8924(02)02316-4; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Werner S, 2001, TRENDS CELL BIOL, V11, P143, DOI 10.1016/S0962-8924(01)01955-9; Weston CR, 2004, P NATL ACAD SCI USA, V101, P14114, DOI 10.1073/pnas.0406061101; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; Yates S, 2002, WOUND REPAIR REGEN, V10, P5, DOI 10.1046/j.1524-475X.2002.10902.x; YUSPA SH, 1988, ANN NY ACAD SCI, V548, P191, DOI 10.1111/j.1749-6632.1988.tb18806.x; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904	71	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20530	20541		10.1074/jbc.M602712200	http://dx.doi.org/10.1074/jbc.M602712200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16648634	hybrid			2022-12-25	WOS:000239038200075
J	Nishitani, Y; Maruyama, D; Nonaka, T; Kita, A; Fukami, TA; Mio, T; Yamada-Okabe, H; Yamada-Okabe, T; Miki, K				Nishitani, Yuichi; Maruyama, Daisuke; Nonaka, Tsuyoshi; Kita, Akiko; Fukami, Takaaki A.; Mio, Toshiyuki; Yamada-Okabe, Hisafumi; Yamada-Okabe, Toshiko; Miki, Kunio			Crystal structures of N-acetylglucosamine-phosphate mutase, a member of the alpha-D-phosphohexomutase superfamily, and its substrate and product complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; GENE; IDENTIFICATION; PROGRAM; CLONING; ENZYME; PURIFICATION; RECOGNITION; MECHANISM; PMM/PGM	N-Acetylglucosamine-phosphate mutase (AGM1) is an essential enzyme in the synthetic process of UDP-N-acetylglucosamine (UDP-GlcNAc). UDP-GlcNAc is a UDP sugar that serves as a biosynthetic precursor of glycoproteins, mucopolysaccharides, and the cell wall of bacteria. Thus, a specific inhibitor of AGM1 from pathogenetic fungi could be a new candidate for an antifungal reagent that inhibits cell wall synthesis. AGM1 catalyzes the conversion of N-acetylglucosamine 6-phosphate (GlcNAc-6-P) into N-acetylglucosamine 1-phosphate (GlcNAc-1-P). This enzyme is a member of the alpha-D-phosphohexomutase superfamily, which catalyzes the intramolecular phosphoryl transfer of sugar substrates. Here we report the crystal structures of AGM1 from Candida albicans for the first time, both in the apoform and in the complex forms with the substrate and the product, and discuss its catalytic mechanism. The structure of AGM1 consists of four domains, of which three domains have essentially the same fold. The overall structure is similar to those of phosphohexomutases; however, there are two additional beta-strands in domain 4, and a circular permutation occurs in domain 1. The catalytic cleft is formed by four loops from each domain. The N-acetyl group of the substrate is recognized by Val-370 and Asn-389 in domain 3, from which the substrate specificity arises. By comparing the substrate and product complexes, it is suggested that the substrate rotates about 180 on the axis linking C-4 and the midpoint of the C-5-O-5 bond in the reaction.	Kyoto Univ, Grad Sch Sci, Sakyo Ku, Dept Chem, Kyoto 6068502, Japan; Chugai Pharmaceut Co Ltd, Kamakura Res Lab, Kamakura, Kanagawa 2478530, Japan; Yokohama City Univ, Sch Med, Dept Hyg, Yokohama, Kanagawa 2360004, Japan; Harima Inst, RIKEN SPring Ctr 8, Sayo, Hyogo 6795148, Japan	Kyoto University; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Yokohama City University; RIKEN	Miki, K (corresponding author), Kyoto Univ, Grad Sch Sci, Sakyo Ku, Dept Chem, Kyoto 6068502, Japan.	miki@kuchem.kyoto-u.ac.jp						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG PW, 1979, J BIOL CHEM, V254, P8353; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; FERNANDE.A, 1971, J BIOL CHEM, V246, P3485; HOFMANN M, 1994, EUR J BIOCHEM, V221, P741, DOI 10.1111/j.1432-1033.1994.tb18787.x; JANIN J, 1990, J BIOL CHEM, V265, P16027; Jia J, 1996, STRUCTURE, V4, P715, DOI 10.1016/S0969-2126(96)00077-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Liu YW, 1997, ACTA CRYSTALLOGR D, V53, P392, DOI 10.1107/S0907444997000875; MENGINLECREULX D, 1994, J BACTERIOL, V176, P5788, DOI 10.1128/JB.176.18.5788-5795.1994; MENGINLECREULX D, 1993, J BACTERIOL, V175, P6150, DOI 10.1128/JB.175.19.6150-6157.1993; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mio T, 1999, J BIOL CHEM, V274, P424, DOI 10.1074/jbc.274.1.424; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; Mio T, 2000, BBA-GENE STRUCT EXPR, V1492, P369, DOI 10.1016/S0167-4781(00)00120-2; Naught LE, 2001, ARCH BIOCHEM BIOPHYS, V396, P111, DOI 10.1006/abbi.2001.2618; Nishitani Y, 2006, ACTA CRYSTALLOGR F, V62, P419, DOI 10.1107/S1744309106010177; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; RAY WJ, 1989, BIOCHEMISTRY-US, V28, P559, DOI 10.1021/bi00428a022; Regni C, 2004, STRUCTURE, V12, P55, DOI 10.1016/j.str.2003.11.015; Regni C, 2002, STRUCTURE, V10, P269, DOI 10.1016/S0969-2126(02)00705-0; ROGERS TJ, 1980, MICROBIOL REV, V44, P660, DOI 10.1128/MMBR.44.4.660-682.1980; Shackelford GS, 2004, PROTEIN SCI, V13, P2130, DOI 10.1110/ps.04801104; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Todd AE, 2002, TRENDS BIOCHEM SCI, V27, P419, DOI 10.1016/S0968-0004(02)02158-8; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WATZELE G, 1989, J BIOL CHEM, V264, P8753; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Whitehouse DB, 1998, MOL BIOL EVOL, V15, P456, DOI 10.1093/oxfordjournals.molbev.a025942	39	33	35	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19740	19747		10.1074/jbc.M600801200	http://dx.doi.org/10.1074/jbc.M600801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16651269	hybrid			2022-12-25	WOS:000238847000087
J	Hinoi, E; Fujimori, S; Wang, LY; Hojo, H; Uno, K; Yoneda, Y				Hinoi, Eiichi; Fujimori, Sayumi; Wang, Liyang; Hojo, Hironori; Uno, Kyosuke; Yoneda, Yukio			Nrf2 negatively regulates osteoblast differentiation via interfering with Runx2-dependent transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; BONE-FORMATION; CHONDROCYTE DIFFERENTIATION; HYDROGEN-PEROXIDE; EXPRESSION; PROTEINS; CBFA1; STIMULATION; ASSOCIATION; RESORPTION	Nrf2 (nuclear factor E2 p45-related factor 2) is believed to be a transcription factor essential for the regulation of many detoxifying and antioxidative genes in different tissues. In the present study, we investigated the role of Nrf2 in the regulation of osteoblastic differentiation. nrf2 mRNA expression was significantly up-regulated in femur isolated from ovariectomized mice, whereas in situ hybridization analysis revealed that up-regulation of nrf2 mRNA was mainly found in osteoblasts attached on cancellous bone in femur of ovariectomized mice. Expression of Nrf2 protein was also seen in osteoblasts in neonatal mouse tibia and calvaria. In osteoblastic MC3T3-E1 cells stably transfected with nrf2 expression vector, significant inhibition was seen in the maturation-dependent increase in alkaline phosphatase activity as well as the mineralized matrix formation. Stable overexpression of nrf2 significantly impaired Runx2 (runt-related transcription factor 2)-dependent stimulation of osteocalcin promoter activity and recruitment of Runx2 on osteocalcin promoter without affecting the expression of runx2 mRNA. Coimmunoprecipitation and mammalian two-hybrid assay revealed a physical interaction between Runx2 and Nrf2, whereas cellular distribution of endogenous Runx2 was not apparently changed by nrf2 overexpression in MC3T3-E1 cells. Alternatively, Nrf2 bound to antioxidant-responsive element-like-2 sequence of osteocalcin promoter. The inhibition by nrf2 on runx2-dependent osteocalcin promoter activity was partially prevented by the introduction of reporter of deletion mutant for ARE-like-2 sequence of osteocalcin promoter. These data suggest that Nrf2 may negatively regulate cellular differentiation through inhibition of the Runx2-dependent transcriptional activity in osteoblasts.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University	Yoneda, Y (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan.	yyoneda@p.kanazawa-u.ac.jp	Yoneda, Yukio/ABI-1864-2020	Yoneda, Yukio/0000-0002-4624-177X; Hojo, Hironori/0000-0003-2245-6853				Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200; Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747; BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006-291X(05)80311-0; Beck GR, 2003, EXP CELL RES, V288, P288, DOI 10.1016/S0014-4827(03)00213-1; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Cappuccio FP, 1999, LANCET, V354, P971, DOI 10.1016/S0140-6736(99)01437-3; Chien KR, 2005, CELL, V120, P533, DOI 10.1016/j.cell.2005.02.006; Christensen JO, 1999, OSTEOPOROSIS INT, V10, P307, DOI 10.1007/s001980050232; D'Amico M, 2004, CANCER RES, V64, P4122, DOI 10.1158/0008-5472.CAN-03-2519; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FROST HM, 1992, BONE MINER, V18, P227, DOI 10.1016/0169-6009(92)90809-R; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Hamerman D, 2005, QJM-INT J MED, V98, P467, DOI 10.1093/qjmed/hci077; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Hinoi E, 2005, BIOCHEM PHARMACOL, V70, P70, DOI 10.1016/j.bcp.2005.04.025; Hinoi E, 2003, FASEB J, V17, P1532, DOI 10.1096/fj.02-0820fje; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Kobayashi T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004-1343; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Law MR, 1997, BMJ-BRIT MED J, V315, P841, DOI 10.1136/bmj.315.7112.841; Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004-1021; Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859; Lee JS, 2005, CANCER LETT, V224, P171, DOI 10.1016/j.canlet.2004.09.042; Li BJ, 2004, GENE DEV, V18, P1824, DOI 10.1101/gad.1223504; Maggio D, 2002, J Endocrinol Invest, V25, P101; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Miyoshi K, 2003, BIOL REPROD, V68, P1079, DOI 10.1095/biolreprod.102.010876; Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891-5849(01)00610-4; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Ogita K, 2004, NEUROPHARMACOLOGY, V46, P580, DOI 10.1016/j.neuropharm.2003.11.002; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Park BG, 2005, TOXICOLOGY, V215, P115, DOI 10.1016/j.tox.2005.07.003; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wang LY, 2005, BRIT J PHARMACOL, V146, P732, DOI 10.1038/sj.bjp.0706358; Wheeler MD, 2003, AM J PHYSIOL-GASTR L, V284, pG302, DOI 10.1152/ajpgi.00175.2002; Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yoshida C, 1999, GENES CELLS, V4, P643, DOI 10.1046/j.1365-2443.1999.00291.x; Zhang YS, 2004, MOL CANCER THER, V3, P885; Zhou S, 2001, J CELL BIOCHEM, P144; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	52	126	129	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18015	18024		10.1074/jbc.M600603200	http://dx.doi.org/10.1074/jbc.M600603200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16613847	hybrid			2022-12-25	WOS:000238490300052
J	Vij, N; Fang, SY; Zeitlin, PL				Vij, Neeraj; Fang, Shengyun; Zeitlin, Pamela L.			Selective inhibition of endoplasmic reticulum-associated degradation rescues Delta F508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; UBIQUITIN-PROTEASOME PATHWAY; VALOSIN-CONTAINING PROTEIN; EPITHELIAL-CELL LINE; CYSTIC-FIBROSIS; CONDUCTANCE REGULATOR; MULTIPLE-MYELOMA; THERAPEUTIC TARGET; GENE-THERAPY; CFTR	Endoplasmic reticulum (ER)-associated degradation (ERAD) is the major quality control pathway of the cell. The most common disease-causing protein folding mutation, Delta F508-cystic fibrosis transmembrane regulator (CFTR), is destroyed by ERAD to cause cystic fibrosis (CF). p97/valosin-containing protein (VCP) physically interacts with gp78/autocrine motility factor receptor to couple ubiquitination, retrotranslocation, and proteasome degradation of misfolded proteins. We show here that p97/VCP and gp78 form complexes with CFTR during translocation from the ER for degradation by the cytosolic proteasome. Interference in the VCP-CFTR complex promoted accumulation of immature CFTR in the ER and partial rescue of functional chloride channels to the cell surface. Moreover, under these conditions, interleukin-8 (IL8), the expression of which is regulated by the proteasome, was reduced. Inhibition of the proteasome with bortezomib (PS-341/Velcade) also rescued CFTR, but with less efficiency, and suppressed NF kappa B-mediated IL8 activation. The inhibition of the majorstress-inducible transcription factor CHOP (CCAAT/enhancer-binding protein homologous protein)/GADD153 together with bortezomib was most effective in repressing NF kappa B-mediated IL8 activation compared with interference of VCP, MLN-273 (proteasome inhibitor), or 4-phenylbutyrate (histone deacetylase inhibitor). Immunoprecipitation of Delta F508-CFTR from primary CF bronchial epithelial cells confirmed the interaction with VCP and associated chaperones in CF. We conclude that VCP is an integral component of ERAD and cellular stress pathways induced by the unfolded protein response and may be central to the efficacy of CF drugs that target the ubiquitin-proteasome pathway.	Johns Hopkins Sch Med, Dept Pediat, Div Pediat Resp Sci, Baltimore, MD 21287 USA; Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore	Zeitlin, PL (corresponding author), Johns Hopkins Sch Med, Dept Pediat, Div Pediat Resp Sci, 600 N Wolfe St,Pk 316, Baltimore, MD 21287 USA.	pzeitlin@jhmi.edu	Fang, Shengyun/H-3802-2011	Fang, Shengyun/0000-0001-7280-5463; Zeitlin, Pamela/0000-0002-2719-1834	NHLBI NIH HHS [R01 HL59410] Funding Source: Medline; NIGMS NIH HHS [R01 GM069967] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059410] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams J, 2001, SEMIN ONCOL, V28, P613, DOI 10.1053/sonc.2001.28609; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Bross PF, 2004, CLIN CANCER RES, V10, P3954, DOI 10.1158/1078-0432.CCR-03-0781; Choo-Kang LR, 2001, AM J PHYSIOL-LUNG C, V281, pL58, DOI 10.1152/ajplung.2001.281.1.L58; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; CROMARTIE WJ, 1977, J EXP MED, V146, P1585, DOI 10.1084/jem.146.6.1585; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Dalal S, 2004, MOL BIOL CELL, V15, P637, DOI 10.1091/mbc.E03-02-0097; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMANGO E, 1995, J CLIN INVEST, V96, P2204, DOI 10.1172/JCI118275; Gnann A, 2004, MOL BIOL CELL, V15, P4125, DOI 10.1091/mbc.e04-01-0024; Hatakeyama S, 2004, GENES CELLS, V9, P533, DOI 10.1111/j.1356-9597.2004.00742.x; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8-6-508; Kaneko C, 2003, BIOCHEM BIOPH RES CO, V300, P297, DOI 10.1016/S0006-291X(02)02834-6; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; Kitiphongspattana K, 2005, J BIOL CHEM, V280, P15727, DOI 10.1074/jbc.M410876200; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; KUNZELMANN K, 1993, AM J RESP CELL MOL, V8, P522, DOI 10.1165/ajrcmb/8.5.522; Lim M, 2004, AM J RESP CELL MOL, V31, P351, DOI 10.1165/rcmb.2002-0086OC; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Matsumoto M, 2004, EMBO J, V23, P659, DOI 10.1038/sj.emboj.7600081; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Mitchell BS, 2003, NEW ENGL J MED, V348, P2597, DOI 10.1056/NEJMp030092; Moran O, 2005, FEBS LETT, V579, P3979, DOI 10.1016/j.febslet.2005.06.026; Oberdorf J, 2006, J CELL SCI, V119, P303, DOI 10.1242/jcs.02732; Palombella VJ, 1998, P NATL ACAD SCI USA, V95, P15671, DOI 10.1073/pnas.95.26.15671; Rao RV, 2004, J BIOL CHEM, V279, P177, DOI 10.1074/jbc.M304490200; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Rowe SM, 2005, NEW ENGL J MED, V352, P1992, DOI 10.1056/NEJMra043184; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Srivastava M, 2004, P NATL ACAD SCI USA, V101, P7693, DOI 10.1073/pnas.0402030101; Wang Q, 2004, J STRUCT BIOL, V146, P44, DOI 10.1016/j.jsb.2003.11.014; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yen CH, 2000, J IMMUNOL, V165, P6372, DOI 10.4049/jimmunol.165.11.6372; Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313; Zhang LN, 2004, MOL THER, V10, P990, DOI 10.1016/j.ymthe.2004.08.009; Zhong XY, 2004, J BIOL CHEM, V279, P45676, DOI 10.1074/jbc.M409034200	49	135	142	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17369	17378		10.1074/jbc.M600509200	http://dx.doi.org/10.1074/jbc.M600509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16621797	hybrid			2022-12-25	WOS:000238326300063
J	Guo, Y; Atkinson, CE; Taylor, ME; Drickamer, K				Guo, Yuan; Atkinson, Claire E.; Taylor, Maureen E.; Drickamer, Kurt			All but the shortest polymorphic forms of the viral receptor DC-SIGNR assemble into stable homo- and heterotetramers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM-REPEAT POLYMORPHISM; INFECTION; BINDING; GENE; LECTINS; SUSCEPTIBILITY; RECOGNITION; CORONAVIRUS; NONINTEGRIN; MOLECULE	Polymorphisms that affect the length of the extracellular neck region of the endothelial receptor DC-SIGNR (dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related protein) have been linked to differences in susceptibility to infection by enveloped viruses. We have characterized the effects of these polymorphisms on the ability of DC-SIGNR to form tetramers containing the clusters of sugar-binding sites needed for binding to viral envelope glycoproteins. Chemical cross-linking and analytical ultracentrifugation experiments have been used to show that only the smallest form of DC-SIGNR is defective in homotetramer assembly. A novel affinity-tagging approach has been employed to demonstrate that, contrary to previous speculation, heterotetramers can be assembled efficiently from DC-SIGNR polypeptides of different lengths. The heterotetramers are stable and can be detected in fibroblasts transfected with multiple forms of DC-SIGNR. These results provide a molecular basis for interpreting the way polymorphisms affect interactions with viruses.	Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England	Imperial College London	Drickamer, K (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England.	k.drickamer@imperial.ac.uk	Guo, Yuan/B-1319-2018	Guo, Yuan/0000-0003-4607-7356; Taylor, Maureen/0000-0001-8300-4987	Wellcome Trust [075565] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Chan VSF, 2006, NAT GENET, V38, P38, DOI 10.1038/ng1698; Crocker PR, 1997, GLYCOCONJUGATE J, V14, P601, DOI 10.1023/A:1018588526788; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; Davis CW, 2006, J VIROL, V80, P1290, DOI 10.1128/JVI.80.3.1290-1301.2006; Davis KE, 1998, J NEUROSCI, V18, P2475; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; Feinberg H, 2005, J BIOL CHEM, V280, P1327, DOI 10.1074/jbc.M409925200; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; Gardner JP, 2003, P NATL ACAD SCI USA, V100, P4498, DOI 10.1073/pnas.0831128100; Gramberg T, 2006, VIROLOGY, V347, P354, DOI 10.1016/j.virol.2005.11.033; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; IOBST ST, 1994, J BIOL CHEM, V269, P15512; Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101; Lichterfeld M, 2003, CLIN IMMUNOL, V107, P55, DOI 10.1016/S1521-6616(02)00050-5; Liu HL, 2006, J INFECT DIS, V193, P698, DOI 10.1086/499820; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Nattermann J, 2006, J VIRAL HEPATITIS, V13, P42, DOI 10.1111/j.1365-2893.2005.00652.x; Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730; Soilleux EJ, 2003, CLIN SCI, V104, P437, DOI 10.1042/CS20020092; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937	20	14	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16794	16798		10.1074/jbc.M602430200	http://dx.doi.org/10.1074/jbc.M602430200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16621794	hybrid			2022-12-25	WOS:000238165700074
J	Jang, W; Gomer, RH				Jang, Wonhee; Gomer, Richard H.			A protein in crude cytosol regulates glucose-6-phosphatase activity in crude microsomes to regulate group size in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUMBER-COUNTING FACTOR; DIFFERENTIAL TIME-COURSE; PHOSPHATASE-ACTIVITY; SIGNAL-TRANSDUCTION; GLUCOSE-PRODUCTION; MESSENGER-RNA; LIVER; KIDNEY; CELLS; EXPRESSION	Dictyostelium discoideum form groups of similar to 2 x 10(4) cells. The group size is regulated in part by a negative feedback pathway mediated by a secreted multipolypeptide complex called counting factor ( CF). The CF signal transduction pathway involves CF-repressing internal glucose levels by increasing the Km of glucose-6-phosphatase. Little is known about how this enzyme is regulated. Glucose-6- phosphatase is associated with microsomes in both Dictyostelium and mammals. We find that the activity of glucose-6-phosphatase in crude microsomes from cells with high, normal, or low CF activity had a negative correlation with the amount of CF present in these cell lines. In crude cytosols ( supernatants from ultracentrifugation of cell lysates), the glucose-6-phosphatase activity had a positive correlation with CF accumulation. The crude cytosols were further fractionated into a fraction containing molecules greater than 10 kDa ( S > 10K) and molecules less than 10 KDa ( S < 10K). S > 10K from wild-type cells strongly repressed the activity of glucose-6-phosphatase in wild-type microsomes, whereas S > 10K from countin(-) cells ( cells with low CF activity) significantly increased the activity of glucose-6-phosphatase in wild-type microsomes by decreasing Km. The regulatory activities in the wild-type and countin(-) S > 10Ks are heat-labile and protease-sensitive, suggesting that they are proteins. S < 10K from both wild-type and countin(-) cells did not significantly change glucose-6-phosphatase activity. Together, the data suggest that, as a part of a pathway modulating multicellular group size, CF regulates one or more proteins greater than 10 KDa in crude cytosol that affect microsome-associated glucose-6-phosphatase activity.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, Howard Hughes Med Inst, Houston, TX 77005 USA	Rice University; Howard Hughes Medical Institute; Rice University	Gomer, RH (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS 140,6100 S Main St, Houston, TX 77005 USA.	richard@rice.edu		Jang, Wonhee/0000-0003-2470-8137; Gomer, Richard/0000-0003-2361-4307	NIGMS NIH HHS [R01 GM102280] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM102280] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; BJORNTOR.P, 1965, BIOCHIM BIOPHYS ACTA, V111, P375, DOI 10.1016/0304-4165(65)90047-4; Brock DA, 1996, DEVELOPMENT, V122, P2569; Brock DA, 1999, GENE DEV, V13, P1960, DOI 10.1101/gad.13.15.1960; Brock DA, 2003, J BIOL CHEM, V278, P52262, DOI 10.1074/jbc.M309101200; Brock DA, 2002, DEVELOPMENT, V129, P3657; BURCHELL A, 1994, MOL MEMBR BIOL, V11, P217, DOI 10.3109/09687689409160431; CORI GT, 1952, J BIOL CHEM, V199, P661; Foster JA, 2002, EXP BIOL MED, V227, P601, DOI 10.1177/153537020222700807; Foster JD, 1997, P SOC EXP BIOL MED, V215, P314; Gao T, 2002, J BIOL CHEM, V277, P32596, DOI 10.1074/jbc.M203075200; GARDNER LB, 1993, DIABETES, V42, P1614, DOI 10.2337/diabetes.42.11.1614; GILKES NR, 1977, BIOCHIM BIOPHYS ACTA, V464, P142, DOI 10.1016/0005-2736(77)90377-7; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; HERS HG, 1951, B SOC CHIM BIOL, V33, P21; HOHL HR, 1964, DEV BIOL, V9, P137, DOI 10.1016/0012-1606(64)90018-1; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; Jang W, 2002, J BIOL CHEM, V277, P39202, DOI 10.1074/jbc.M205635200; Jang WH, 2005, EUKARYOT CELL, V4, P72, DOI 10.1128/EC.4.1.72-81.2005; KOPACHIK W, 1982, J EMBRYOL EXP MORPH, V68, P23; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; Minassian C, 1996, MOL CELL BIOCHEM, V155, P37, DOI 10.1007/BF00714331; MINASSIAN C, 1994, COMP BIOCHEM PHYS B, V109, P99, DOI 10.1016/0305-0491(94)90146-5; MITHIEUX G, 1993, EUR J BIOCHEM, V213, P461, DOI 10.1111/j.1432-1033.1993.tb17782.x; Mithieux G, 1998, J BIOL CHEM, V273, P17, DOI 10.1074/jbc.273.1.17; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; Mithieux G, 2004, J BIOL CHEM, V279, P44231, DOI 10.1074/jbc.R400011200; Nordlie RC, 1999, ANNU REV NUTR, V19, P379, DOI 10.1146/annurev.nutr.19.1.379; NORDLIE RC, 1993, P SOC EXP BIOL MED, V203, P274; ROBBINS BL, 1991, LIFE SCI, V48, P1075, DOI 10.1016/0024-3205(91)90509-A; Roisin-Bouffay C, 2000, MOL CELL, V6, P953, DOI 10.1016/S1097-2765(05)00082-1; SHAFFER BM, 1958, Q J MICROSC SCI, V98, P393; Tang L, 2002, P NATL ACAD SCI USA, V99, P1371, DOI 10.1073/pnas.022516099; van de Werve G, 2000, EUR J BIOCHEM, V267, P1533, DOI 10.1046/j.1432-1327.2000.01160.x; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; VARNUMFINNEY B, 1987, CELL MOTIL CYTOSKEL, V8, P7, DOI 10.1002/cm.970080103; YUEN IS, 1995, J CELL BIOL, V129, P1251, DOI 10.1083/jcb.129.5.1251	39	7	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16377	16383		10.1074/jbc.M509995200	http://dx.doi.org/10.1074/jbc.M509995200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16606621	Green Accepted, hybrid			2022-12-25	WOS:000238165700026
J	Zhang, XQ; Ibrahimi, OA; Olsen, SK; Umemori, H; Mohammadi, M; Ornitz, DM				Zhang, Xiuqin; Ibrahimi, Omar A.; Olsen, Shaun K.; Umemori, Hisashi; Mohammadi, Moosa; Ornitz, David M.			Receptor specificity of the fibroblast growth factor family - The complete mammalian FGF family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							FACTOR HOMOLOGOUS FACTORS; LIGAND-BINDING SPECIFICITY; HEPARAN-SULFATE; STRUCTURAL BASIS; CELL-PROLIFERATION; NERVOUS-SYSTEM; FIBROBLAST-GROWTH-FACTOR-14 GENE; DEVELOPMENTAL EXPRESSION; ISTHMIC ORGANIZER; DERMATAN SULFATE	In mammals, fibroblast growth factors (FGFs) are encoded by 22 genes. FGFs bind and activate alternatively spliced forms of four tyrosine kinase FGF receptors (FGFRs 1-4). The spatial and temporal expression patterns of FGFs and FGFRs and the ability of specific ligand-receptor pairs to actively signal are important factors regulating FGF activity in a variety of biological processes. FGF signaling activity is regulated by the binding specificity of ligands and receptors and is modulated by extrinsic cofactors such as heparan sulfate proteoglycans. In previous studies, we have engineered BaF3 cell lines to express the seven principal FGFRs and used these cell lines to determine the receptor binding specificity of FGFs 1-9 by using relative mitogenic activity as the readout. Here we have extended these semiquantitative studies to assess the receptor binding specificity of the remaining FGFs 10-23. This study completes the mitogenesis-based comparison of receptor specificity of the entire FGF family under standard conditions and should help in interpreting and predicting in vivo biological activity.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Univ Michigan, Sch Med, Dept Biol Chem, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA	Washington University (WUSTL); New York University; University of Michigan System; University of Michigan	Ornitz, DM (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Campus Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	dornitz@wustl.edu	kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020	Mohammadi, Moosa/0000-0003-2434-9437; Zhang, Xiuqin/0000-0001-8692-7146; Umemori, Hisashi/0000-0001-7198-2062; Ornitz, David/0000-0003-1592-7629; Olsen, Shaun/0000-0002-1265-7101	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS065761] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL076664, R01 HL076664, R01 HL076664-03] Funding Source: Medline; NIDCR NIH HHS [R01 DE013686, DE013686] Funding Source: Medline; NINDS NIH HHS [R01 NS065761] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Arman E, 1999, P NATL ACAD SCI USA, V96, P11895, DOI 10.1073/pnas.96.21.11895; Beer HD, 2000, J BIOL CHEM, V275, P16091, DOI 10.1074/jbc.275.21.16091; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Benet-Pages A, 2005, HUM MOL GENET, V14, P385, DOI 10.1093/hmg/ddi034; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Burns RC, 2004, DEV BIOL, V265, P61, DOI 10.1016/j.ydbio.2003.09.021; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; COHEN MM, 1995, AM J MED GENET, V57, P82, DOI 10.1002/ajmg.1320570119; COHEN MM, 1990, AM J MED GENET, V35, P36, DOI 10.1002/ajmg.1320350108; Cohen MM, 2000, CRANIOSYNOSTOSIS DIA, V2nd; Colvin JS, 1999, DEV DYNAM, V216, P72; Colvin JS, 2001, DEVELOPMENT, V128, P2095; Colvin JS, 2001, CELL, V104, P875, DOI 10.1016/S0092-8674(01)00284-7; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; Dalski A, 2005, EUR J HUM GENET, V13, P118, DOI 10.1038/sj.ejhg.5201286; DiNapoli L, 2006, DEVELOPMENT, V133, P1519, DOI 10.1242/dev.02303; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; Ezzat S, 2005, HORM METAB RES, V37, P355, DOI 10.1055/s-2005-870151; Finch PW, 2004, ADV CANCER RES, V91, P69, DOI 10.1016/S0065-230X(04)91003-2; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; Goldfarb M, 2005, CYTOKINE GROWTH F R, V16, P215, DOI 10.1016/j.cytogfr.2005.02.002; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Hartung H, 1997, MECH DEVELOP, V64, P31, DOI 10.1016/S0925-4773(97)00042-7; Huang P, 2005, CYTOKINE GROWTH F R, V16, P151, DOI 10.1016/j.cytogfr.2005.03.002; Ibrahimi OA, 2005, PLAST RECONSTR SURG, V115, P264, DOI 10.1097/01.PRS.0000146703.08958.95; Ibrahimi OA, 2004, HUM MOL GENET, V13, P2313, DOI 10.1093/hmg/ddh235; Ibrahimi OA, 2001, P NATL ACAD SCI USA, V98, P7182, DOI 10.1073/pnas.121183798; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; Kobayashi K, 2006, LIFE SCI, V78, P2295, DOI 10.1016/j.lfs.2005.09.052; Kobayashi K, 2006, EUR J ENDOCRINOL, V154, P93, DOI 10.1530/eje.1.02053; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Larsson T, 2004, ENDOCRINOLOGY, V145, P3087, DOI 10.1210/en.2003-1768; Lavine KJ, 2005, DEV CELL, V8, P85, DOI 10.1016/j.devcel.2004.12.002; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Lewandoski M, 2000, NAT GENET, V26, P460, DOI 10.1038/82609; Liu AM, 2003, DEVELOPMENT, V130, P6175, DOI 10.1242/dev.00845; Liu CJ, 2003, J BIOL CHEM, V278, P1029, DOI 10.1074/jbc.M207074200; Liu CJ, 2001, J BIOL CHEM, V276, P18925, DOI 10.1074/jbc.M101606200; Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602; Lou JY, 2005, J PHYSIOL-LONDON, V569, P179, DOI 10.1113/jphysiol.2005.097220; Martinez S, 1999, DEVELOPMENT, V126, P1189; Maruoka Y, 1998, MECH DEVELOP, V74, P175, DOI 10.1016/S0925-4773(98)00061-6; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Miralles F, 1999, P NATL ACAD SCI USA, V96, P6267, DOI 10.1073/pnas.96.11.6267; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; MOHAMMADI M, 2005, CURR OPIN STRUCT BIO; Moon AM, 2006, DEV CELL, V10, P71, DOI 10.1016/j.devcel.2005.12.003; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Olsen SK, 2006, GENE DEV, V20, P185, DOI 10.1101/gad.1365406; Olsen SK, 2004, P NATL ACAD SCI USA, V101, P935, DOI 10.1073/pnas.0307287101; Olsen SK, 2003, J BIOL CHEM, V278, P34226, DOI 10.1074/jbc.M303183200; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ornitz DM, 2005, CYTOKINE GROWTH F R, V16, P205, DOI 10.1016/j.cytogfr.2005.02.003; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; Park WY, 1998, DEV BIOL, V201, P125, DOI 10.1006/dbio.1998.8994; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pirvola U, 2004, DEV BIOL, V273, P350, DOI 10.1016/j.ydbio.2004.06.010; Popovici C, 2005, BIOESSAYS, V27, P849, DOI 10.1002/bies.20261; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rice R, 2004, J CLIN INVEST, V113, P1692, DOI 10.1172/JCI200420384; Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899; SantosOcampo S, 1996, J BIOL CHEM, V271, P1726, DOI 10.1074/jbc.271.3.1726; Sato T, 2004, DEV GROWTH DIFFER, V46, P487; Schmahl J, 2004, DEVELOPMENT, V131, P3627, DOI 10.1242/dev.01239; Schoorlemmer J, 2002, J BIOL CHEM, V277, P49111, DOI 10.1074/jbc.M205520200; Schoorlemmer J, 2001, CURR BIOL, V11, P793, DOI 10.1016/S0960-9822(01)00232-9; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Steinberg Z, 2005, DEVELOPMENT, V132, P1223, DOI 10.1242/dev.01690; Strewler GJ, 2001, P NATL ACAD SCI USA, V98, P5945, DOI 10.1073/pnas.11154898; Taylor KR, 2005, J BIOL CHEM, V280, P5300, DOI 10.1074/jbc.m410412200; Thisse B, 2005, DEV BIOL, V287, P390, DOI 10.1016/j.ydbio.2005.09.011; Umemori H, 2004, CELL, V118, P257, DOI 10.1016/j.cell.2004.06.025; van Swieten JC, 2003, AM J HUM GENET, V72, P191, DOI 10.1086/345488; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; Wang Q, 2000, MECH DEVELOP, V90, P283, DOI 10.1016/S0925-4773(99)00241-5; Wang Q, 2002, NEURON, V35, P25, DOI 10.1016/S0896-6273(02)00744-4; White AC, 2006, DEVELOPMENT, V133, P1507, DOI 10.1242/dev.02313; White KE, 2001, KIDNEY INT, V60, P2079, DOI 10.1046/j.1523-1755.2001.00064.x; Wittmack EK, 2004, J NEUROSCI, V24, P6765, DOI 10.1523/JNEUROSCI.1628-04.2004; Wuechner C, 1996, INT J DEV BIOL, V40, P1185; Xu JS, 2000, DEVELOPMENT, V127, P1833; Xu JS, 1999, MECH DEVELOP, V83, P165, DOI 10.1016/S0925-4773(99)00034-9; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yan XM, 2005, GENES CELLS, V10, P489, DOI 10.1111/j.1365-2443.2005.00853.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Ye F, 2005, DIABETOLOGIA, V48, P277, DOI 10.1007/s00125-004-1638-6; Yeh BK, 2003, P NATL ACAD SCI USA, V100, P2266, DOI 10.1073/pnas.0436500100; Yu K, 2001, P NATL ACAD SCI USA, V98, P3641, DOI 10.1073/pnas.081082498; Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536; Yu XJ, 2005, ENDOCRINOLOGY, V146, P4647, DOI 10.1210/en.2005-0670; Yu XJ, 2005, CYTOKINE GROWTH F R, V16, P221, DOI 10.1016/j.cytogfr.2005.01.002; Zhang XQ, 2006, DEVELOPMENT, V133, P173, DOI 10.1242/dev.02175	109	883	1011	1	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15694	15700		10.1074/jbc.M601252200	http://dx.doi.org/10.1074/jbc.M601252200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16597617	hybrid, Green Accepted			2022-12-25	WOS:000237996000014
J	Jiang, LQ; Feng, X; Zhou, W; Knyazev, PG; Ullrich, A; Chen, Z				Jiang, L. Q.; Feng, X.; Zhou, W.; Knyazev, P. G.; Ullrich, A.; Chen, Z.			Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation	ONCOGENE			English	Article						Cbp; EGFR; cell transformation; Src; Csk	GLYCOSPHINGOLIPID-ENRICHED MICRODOMAINS; FAMILY TYROSINE KINASES; C-SRC; FACTOR RECEPTOR; TRANSMEMBRANE ADAPTER; AKT ACTIVATION; BREAST-CANCER; DNA-SYNTHESIS; LIPID RAFTS; PHOSPHORYLATION	Epidermal growth factor receptor (EGFR) and Src tyrosine kinase cooperate in regulating EGFR-mediated cell signaling and promoting cell transformation and tumorigenesis in pathological conditions. Activation of Src is tightly regulated by the C-terminal Src kinase (Csk). The Csk-binding protein (Cbp) is a ubiquitously expressed transmembrane protein. Its functions include suppression of T-cell receptor activation through recruiting Csk and inhibiting Src family kinase (SFK). However, a potential role of Cbp in EGF-induced cell activities has not been investigated. Here, we report that EGF-stimulation-induced Cbp tyrosine phosphorylation followed by Cbp-Csk association, in a SFK-dependent manner. Expression of wild-type (wt) Cbp remarkably suppressed EGF-induced activation of Src, ERK1/2, and Akt-1 enzymes, and NIH3T3 cell transformation, as well as colony formation of a breast cancer cell line (MDAMB468) in soft agar. In contrast, expression of CbpY317F or knockdown endogenous Cbp in NIH3T3 cells by RNA interference significantly enhanced EGF-induced activation of these enzymes and cell transformation. In addition, overexpression of multiple receptor tyrosine kinases (RTKs)-induced Cbp tyrosine phosphorylation. These results demonstrate that Cbp functions as a negative regulator of cell transformation and tumor cell growth through downregulation of Src activation, suggesting that Cbp might be broadly involved in RTKs-activated signaling pathways and tumorigenesis.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, SHARF Lab, Shanghai 200031, Peoples R China; Max Planck Inst Biochem, Chinese Acad Sci, Grad Sch, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Max Planck Society; Max Planck Society	Chen, Z (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Room 210,Bldg 23,320 Yue Yang Rd, Shanghai 200031, Peoples R China.	zjchen@sibs.ac.cn						Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Baumgartner M, 2003, BLOOD, V101, P1874, DOI 10.1182/blood-2002-02-0456; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; DI FP, 1987, CELL, V51, P1063; Dobenecker MW, 2005, MOL CELL BIOL, V25, P10533, DOI 10.1128/MCB.25.23.10533-10542.2005; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Ishizawar RC, 2004, J BIOL CHEM, V279, P23773, DOI 10.1074/jbc.M312368200; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim YN, 2002, EXP CELL RES, V280, P134, DOI 10.1006/excr.2002.5623; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Lev DC, 2004, BRIT J CANCER, V91, P795, DOI 10.1038/sj.bjc.6602051; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Matsuoka H, 2004, J BIOL CHEM, V279, P5975, DOI 10.1074/jbc.M311278200; Nguyen Dao M, 2004, Semin Thorac Cardiovasc Surg, V16, P3, DOI 10.1053/j.semtcvs.2003.12.002; Ohtake H, 2002, J IMMUNOL, V168, P2087, DOI 10.4049/jimmunol.168.5.2087; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Rae JM, 2004, BREAST CANCER RES TR, V83, P99, DOI 10.1023/B:BREA.0000010702.10130.29; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Shien Tadahiko, 2004, Breast Cancer, V11, P367, DOI 10.1007/BF02968044; Shima T, 2003, P NATL ACAD SCI USA, V100, P14897, DOI 10.1073/pnas.2432139100; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Tsuruda A, 2004, FEBS LETT, V560, P215, DOI 10.1016/S0014-5793(04)00115-2; Van Slyke P, 2005, MOL CELL BIOL, V25, P3831, DOI 10.1128/MCB.25.9.3831-3841.2005; Wang B, 2001, MOL CELL BIOL, V21, P1077, DOI 10.1128/MCB.21.4.1077-1088.2001; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Xu SL, 2005, MOL CELL BIOL, V25, P8486, DOI 10.1128/MCB.25.19.8486-8495.2005; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	49	32	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5495	5506		10.1038/sj.onc.1209554	http://dx.doi.org/10.1038/sj.onc.1209554			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16636672				2022-12-25	WOS:000240370400003
J	Yang, DQ; Halaby, MJ; Zhang, Y				Yang, D. -Q; Halaby, M. -J; Zhang, Y.			The identification of an internal ribosomal entry site in the 5 '-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage	ONCOGENE			English	Article						p53; translation; 5 '-UTR; IRES; DNA damage	UNTRANSLATED REGION; INDUCED APOPTOSIS; BINDING PROTEIN; PARTICIPATION; REPRESSION; PHOSPHORYLATION; IRRADIATION; INITIATION; SEGMENT; KINASE	The tumor suppressor p53 plays a crucial role in maintaining the genetic integrity of the cell and in suppressing cell transformation. Its cellular levels are usually low and rise substantially in response to DNA damage. Although research on p53 induction following DNA damage has mainly focused on the post-translational modification of p53 by Mdm2, it is known that protein translation also contributes to p53 induction. However, the mechanisms underlying translational regulation of the p53 protein in response to DNA damage are still poorly understood. We show that p53 synthesis increases dramatically in MCF-7 cells treated with etoposide. Interestingly, this increase is accompanied by an increase in the association of the translation initiation factor eIF-4E with its binding protein 4E-BP1, an inhibitor of cap-dependent protein translation. We further identified an internal ribosomal entry site (IRES) located in the 5'-untranslated region of the p53 transcript, that is capable of driving the cap-independent translation of a downstream cistron encoding Firefly luciferase in a dicistronic expression vector. Moreover, we found that the activity of the IRES element increases in response to etoposide-induced DNA damage in MCF-7 cells. These findings provide a novel mechanism for the regulation of p53 translation in response to DNA damage.	Univ S Dakota, Div Basic Biomed Sci, Sanford Sch Med, Vermillion, SD 57069 USA	University of South Dakota	Yang, DQ (corresponding author), Univ S Dakota, Div Basic Biomed Sci, Sanford Sch Med, 414 E Clark St,Lee Med Bldg, Vermillion, SD 57069 USA.	dyang@usd.edu						Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Holcik M, 2004, CURR CANCER DRUG TAR, V4, P299, DOI 10.2174/1568009043333005; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; KASTAN MB, 1991, CANCER RES, V51, P6304; KOMAR AA, 2005, J BIOL CHEM, V4, P4; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Quinn JE, 2003, CANCER RES, V63, P6221; Schumacher B, 2005, CELL, V120, P357, DOI 10.1016/j.cell.2004.12.009; Sherrill KW, 2004, J BIOL CHEM, V279, P29066, DOI 10.1074/jbc.M402727200; Spriggs KA, 2005, CELL DEATH DIFFER, V12, P585, DOI 10.1038/sj.cdd.4401642; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542	27	101	107	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4613	4619		10.1038/sj.onc.1209483	http://dx.doi.org/10.1038/sj.onc.1209483			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16607284				2022-12-25	WOS:000239457500011
J	de la Serna, IL; Ohkawa, Y; Higashi, C; Dutta, C; Osias, J; Kommajosyula, N; Tachibana, T; Imbalzano, AN				de la Serna, Ivana L.; Ohkawa, Yasuyuki; Higashi, Chiduru; Dutta, Chaitali; Osias, Jules; Kommajosyula, Naveen; Tachibana, Taro; Imbalzano, Anthony N.			The microphthalmia-associated transcription factor requires SWI/SNF enzymes to activate melanocyte-specific genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING COMPLEX; CELL-CYCLE ARREST; WAARDENBURG SYNDROME TYPE-2; RETINOBLASTOMA PROTEIN; MUSCLE DIFFERENTIATION; SIGNAL-TRANSDUCTION; STIMULATING HORMONE; MALIGNANT-MELANOMA; TUMOR SUPPRESSION; LINEAGE SURVIVAL	The microphthalmia transcription factor (Mitf) activates melanocyte-specific gene expression, is critical for survival and proliferation of melanocytes during development, and has been described as an oncogene in malignant melanoma. SWI/SNF complexes are ATP-dependent chromatin-remodeling enzymes that play a role in many developmental processes. To determine the requirement for SWI/SNF enzymes in melanocyte differentiation, we introduced Mitf into fibroblasts that inducibly express dominant negative versions of the SWI/SNF ATPases, Brahma or Brahma-related gene 1 (BRG1). These dominant negative SWI/SNF components have been shown to inhibit gene activation events that normally require SWI/SNF enzymes. We found that Mitf-mediated activation of a subset of endogenous melanocyte-specific genes required SWI/SNF enzymes but that cell-cycle regulation occurred independently of SWI/SNF function. Activation of tyrosinase-related protein 1, a melanocyte-specific gene, correlated with SWI/SNF-dependent changes in chromatin accessibility at the endogenous locus. Both BRG1 and Mitf could be localized to the tyrosinase-related protein 1 and tyrosinase promoters by chromatin immunoprecipitation, whereas immunofluorescence and immunoprecipitation experiments indicate that Mitf and BRG1 co-localized in the nucleus and physically interacted. Together these results suggest that Mitf can recruit SWI/SNF enzymes to melanocyte- specific promoters for the activation of gene expression via induced changes in chromatin structure at endogenous loci.	Med Univ Ohio, Dept Biochem & Canc Biol, Toledo, OH 43614 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Osaka City Univ, Dept Bioengn, Osaka 5588585, Japan	University of Massachusetts System; University of Massachusetts Worcester; Osaka Metropolitan University	de la Serna, IL (corresponding author), Med Univ Ohio, Dept Biochem & Canc Biol, 3035 Arlington Ave, Toledo, OH 43614 USA.	idelaserna@meduohio.edu	Ohkawa, Yasuyuki/C-4087-2016; Ohkawa, Yasuyuki/ABG-1839-2021	Ohkawa, Yasuyuki/0000-0001-6440-9954; Ohkawa, Yasuyuki/0000-0001-6440-9954	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056244] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32520] Funding Source: Medline; NIGMS NIH HHS [GM56244] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi S, 1999, J IMMUNOL, V163, P3363; Adachi S, 2000, J IMMUNOL, V164, P855, DOI 10.4049/jimmunol.164.2.855; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Aoki H, 2002, LIFE SCI, V71, P2171, DOI 10.1016/S0024-3205(02)01996-3; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Baxter LL, 2003, GENE EXPR PATTERNS, V3, P703, DOI 10.1016/j.modgep.2003.07.002; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bergstrom DA, 2002, MOL CELL, V9, P587, DOI 10.1016/S1097-2765(02)00481-1; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Bismuth K, 2005, PIGM CELL RES, V18, P349, DOI 10.1111/j.1600-0749.2005.00249.x; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Carey M, 2000, TRANSCRIPTIONAL REGU; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Cui KR, 2004, MOL CELL BIOL, V24, P4476, DOI 10.1128/MCB.24.10.4476-4486.2004; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Du JY, 2003, AM J PATHOL, V163, P333, DOI 10.1016/S0002-9440(10)63657-7; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Giraud S, 2004, ONCOGENE, V23, P7391, DOI 10.1038/sj.onc.1207972; Goding CR, 2000, GENE DEV, V14, P1712; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Hearing VJ, 2005, J DERMATOL SCI, V37, P3, DOI 10.1016/j.jdermsci.2004.08.014; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Holloway AF, 2003, J EXP MED, V197, P413, DOI 10.1084/jem.20021039; Houghton AN, 2002, CANCER CELL, V2, P275, DOI 10.1016/S1535-6108(02)00161-7; Hu DN, 2005, PHOTOCHEM PHOTOBIOL, V81, P506, DOI 10.1562/2004-08-24-IR-289.1; Imbalzano AN, 1998, CRIT REV EUKAR GENE, V8, P225, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.10; Jhappan C, 2003, ONCOGENE, V22, P3099, DOI 10.1038/sj.onc.1206450; Jiao ZX, 2004, PIGM CELL RES, V17, P352, DOI 10.1111/j.1600-0749.2004.00154.x; Joo A, 2004, ONCOGENE, V23, P726, DOI 10.1038/sj.onc.1207174; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Kemper JK, 2004, MOL CELL BIOL, V24, P7707, DOI 10.1128/MCB.24.17.7707-7719.2004; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kim JK, 2001, MOL CELL BIOL, V21, P7787, DOI 10.1128/MCB.21.22.7787-7795.2001; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Larribere L, 2005, GENE DEV, V19, P1980, DOI 10.1101/gad.335905; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; MENON IA, 1977, BRIT J DERMATOL, V97, P109, DOI 10.1111/j.1365-2133.1977.tb15439.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Rouzaud F, 2005, PEPTIDES, V26, P1858, DOI 10.1016/j.peptides.2004.11.041; Roy K, 2002, J BIOL CHEM, V277, P33818, DOI 10.1074/jbc.M205159200; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Seo S, 2005, DEVELOPMENT, V132, P105, DOI 10.1242/dev.01548; Shibahara S, 2001, J INVEST DERM SYMP P, V6, P99, DOI 10.1046/j.0022-202x.2001.00010.x; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Spilianakis C, 2003, EMBO J, V22, P5125, DOI 10.1093/emboj/cdg496; STEEL KP, 1992, DEVELOPMENT, V115, P1111; Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sullivan EK, 2001, MOL CELL BIOL, V21, P5826, DOI 10.1128/MCB.21.17.5826-5837.2001; Tachibana M, 2001, J INVEST DERM SYMP P, V6, P95, DOI 10.1046/j.0022-202x.2001.00017.x; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; Takeda K, 2000, HUM MOL GENET, V9, P125, DOI 10.1093/hmg/9.1.125; Udono T, 2000, BBA-GENE STRUCT EXPR, V1491, P205, DOI 10.1016/S0167-4781(00)00051-8; vanSteensel B, 1996, J CELL SCI, V109, P787; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; Wellbrock C, 2005, J CELL BIOL, V170, P703, DOI 10.1083/jcb.200505059; Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443; Wu M, 2000, GENE DEV, V14, P301; Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703; Yasumoto K, 1997, J BIOL CHEM, V272, P503; YAVUZER U, 1995, ONCOGENE, V10, P123; Young DW, 2005, J CELL BIOCHEM, V94, P720, DOI 10.1002/jcb.20332; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	95	69	70	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20233	20241		10.1074/jbc.M512052200	http://dx.doi.org/10.1074/jbc.M512052200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16648630	hybrid			2022-12-25	WOS:000239038200048
J	Chang, CC; Ogino, T; Mullins, DW; Oliver, JL; Yamshchikov, GV; Bandoh, N; Slingluff, CL; Ferrone, S				Chang, Chien-Chung; Ogino, Takeshi; Mullins, David W.; Oliver, Janine L.; Yamshchikov, Galina V.; Bandoh, Nobuyuki; Slingluff, Craig L., Jr.; Ferrone, Soldano			Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta(2)-microglobulin loss-of-function in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBEDDED TISSUE-SECTIONS; MONOCLONAL-ANTIBODIES; HLA-A; ENDOPLASMIC-RETICULUM; LOADING COMPLEX; FLOW-CYTOMETRY; HEAVY-CHAIN; PEPTIDE; EXPRESSION; MOLECULES	The major histocompatibility complex class I molecules consist of three subunits, the 45-kDa heavy chain, the 12-kDa beta(2)-microglobulin (beta(2)m), and an similar to 8-9-residue antigenic peptide. Without beta(2)m, the major histocompatibility complex class I molecules cannot assemble, thereby abolishing their transport to the cell membrane and the subsequent recognition by antigen-specific T cells. Here we report a case of defective antigen presentation caused by the expression of a beta(2)m with a Cys-to-Trp substitution at position 25 (beta(2)m(C25W)). This substitution causes misfolding and degradation of beta(2)m(C25W) but does not result in complete lack of human leukocyte antigen (HLA) class I molecule expression on the surface of melanoma VMM5B cells. Despite HLA class I expression, VMM5B cells are not recognized by HLA class I-restricted, melanoma antigen-specific cytotoxic T lymphocytes even following loading with exogenous peptides or transduction with melanoma antigen-expressing viruses. Lysis of VMM5B cells is restored only following reconstitution with exogenous or endogenous wild-type beta(2)m protein. Together, our results indicate impairment of antigenic peptide presentation because of a dysfunctional beta(2)m and provide a mechanism for the lack of close association between HLA class I expression and susceptibility of tumor cells to cytotoxic T lymphocytesmediated lysis in malignant diseases.	Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA; Univ Virginia, Human Immune Therapy Ctr, Charlottesville, VA 22908 USA	Roswell Park Cancer Institute; University of Virginia; University of Virginia; University of Virginia	Ferrone, S (corresponding author), Roswell Pk Canc Inst, Dept Immunol, Elm & Carlton St, Buffalo, NY 14263 USA.	soldano.ferrone@roswellpark.org	Mullins, David/J-1085-2019	Mullins, David/0000-0002-2644-350X; Oliver, Janine/0000-0002-3423-6834	NATIONAL CANCER INSTITUTE [R25CA160056, R01CA067108, R01CA057653] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA57653, P30 CA160056, R01 CA67108] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bandoh N, 2005, TISSUE ANTIGENS, V66, P185, DOI 10.1111/j.1399-0039.2005.00462.x; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Chang CC, 2005, J IMMUNOL, V174, P1462, DOI 10.4049/jimmunol.174.3.1462; Chang CC, 2004, CURR OPIN IMMUNOL, V16, P644, DOI 10.1016/j.coi.2004.07.015; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; Ferrone S, 2002, SEMIN CANCER BIOL, V12, P1, DOI 10.1006/scbi.2001.0396; Hansen TH, 1997, ADV IMMUNOL, V64, P105, DOI 10.1016/S0065-2776(08)60888-3; Hill DM, 2003, J BIOL CHEM, V278, P5630, DOI 10.1074/jbc.M208381200; KUSAMA M, 1989, J IMMUNOL, V143, P3844; LAMPSON LA, 1983, J IMMUNOL, V130, P2471; Mosse CA, 1998, J EXP MED, V187, P37, DOI 10.1084/jem.187.1.37; Ogino T, 2003, TISSUE ANTIGENS, V62, P385, DOI 10.1034/j.1399-0039.2003.00114.x; Ogino T, 2003, J IMMUNOL METHODS, V278, P33, DOI 10.1016/S0022-1759(03)00224-2; Perosa F, 2003, J IMMUNOL, V171, P1918, DOI 10.4049/jimmunol.171.4.1918; Ramal LM, 2000, TISSUE ANTIGENS, V55, P443, DOI 10.1034/j.1399-0039.2000.550507.x; REBAI N, 1983, TISSUE ANTIGENS, V22, P107; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Sernee MF, 1998, MOL IMMUNOL, V35, P177, DOI 10.1016/S0161-5890(98)00026-1; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; SUGAWARA S, 1987, J IMMUNOL METHODS, V100, P83; Wang X, 2003, TISSUE ANTIGENS, V62, P139, DOI 10.1034/j.1399-0039.2003.00087.x; Wang XH, 2005, J IMMUNOL METHODS, V299, P139, DOI 10.1016/j.jim.2005.02.006; Yamshchikov GV, 2005, J IMMUNOL, V174, P6863, DOI 10.4049/jimmunol.174.11.6863; Yamshchikov GV, 2001, INT J CANCER, V92, P703, DOI 10.1002/1097-0215(20010601)92:5<703::AID-IJC1250>3.0.CO;2-5; Yewdell J, 2002, MOL IMMUNOL, V39, P125, DOI 10.1016/S0161-5890(02)00092-5	30	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18763	18773		10.1074/jbc.M511525200	http://dx.doi.org/10.1074/jbc.M511525200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16648140	hybrid			2022-12-25	WOS:000238687300057
J	Behr, B; Hoffmann, C; Ottolina, G; Klotz, KN				Behr, Bjoern; Hoffmann, Carsten; Ottolina, Gianluca; Klotz, Karl-Norbert			Novel mutants of the human beta(1)-adrenergic receptor reveal amino acids relevant for receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STABLY TRANSFECTED RECEPTORS; PROTEIN-COUPLED RECEPTORS; 2ND EXTRACELLULAR LOOP; COMPARATIVE PHARMACOLOGY; AGONIST BINDING; VALIDATION; RHODOPSIN; SUBTYPES; DOCKING; SITE	Activation of G protein-coupled receptors like the beta(1)-adrenergic receptor results in conformational changes that ultimately lead to signal propagation through a G protein to an effector like adenylyl cyclase. In this study we identified amino acids that seem to be critical for activation of the human beta(1)-adrenergic receptor. Activation patterns of mutant receptors were analyzed using two structurally different ligands for beta-adrenergic receptors that both are mixed agonist/antagonists. Broxaterol and terbutaline are agonists at beta(2)- and beta(3)-receptors; however, they act as antagonists at the beta(1)-subtype. We reasoned that this functional selectivity may be reflected by a corresponding sequence pattern in the receptor subtypes. Therefore, we exchanged single amino acids of the beta(1)-adrenergic receptor for residues that were identical in the beta(2)- and beta(3)-subtypes but different in the beta(1)-receptor. Pharmacological characterization of such receptor mutants revealed that binding of a panel of agonists and antagonists including broxaterol and terbutaline was unaltered. However, two of the mutants (I185V and D212N) were activated by broxaterol and terbutaline, which acted as antagonists at the wild-type receptor. Two additional mutants (V120L and K253R) could be activated by terbutaline alone, which is structurally more closely related to endogenous catecholamines like epinephrine than to broxaterol. A model of the human beta(1)-adrenergic receptor showed that the four gain-of-function mutations are outside of the putative ligand-binding domain substantiating the lack of an effect of the mutations on binding characteristics. These results support the notion that Val-120, Ile-185, Asp-212, and Lys-253 are critically involved in conformational changes occurring during receptor activation.	Univ Wurzburg, Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany; CNR, Ist Chim Riconoscimento Mol, I-20131 Milan, Italy	University of Wurzburg; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR)	Klotz, KN (corresponding author), Univ Wurzburg, Inst Pharmakol & Toxikol, Versbacher Str 9, D-97078 Wurzburg, Germany.	klotz@toxi.uni-wuerzburg.de	Behr, Björn/AAS-1877-2021	Klotz, Karl-Norbert/0000-0003-3553-3205				Alves ID, 2004, MOL PHARMACOL, V65, P1248, DOI 10.1124/mol.65.5.1248; Baker JG, 2003, MOL PHARMACOL, V63, P1312, DOI 10.1124/mol.63.6.1312; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Conti P, 1998, BIOORGAN MED CHEM, V6, P401, DOI 10.1016/S0968-0896(97)10051-7; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DELEAN A, 1982, MOL PHARMACOL, V21, P5; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; Hetenyi C, 2002, PROTEIN SCI, V11, P1729, DOI 10.1110/ps.0202302; Hoffmann C, 1999, J BIOL CHEM, V274, P14639, DOI 10.1074/jbc.274.21.14639; Hoffmann C, 2004, N-S ARCH PHARMACOL, V369, P151, DOI 10.1007/s00210-003-0860-y; Isogaya M, 1999, MOL PHARMACOL, V56, P875, DOI 10.1124/mol.56.5.875; JAKOBS KH, 1976, J CYCLIC NUCL PROT, V2, P381; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Klotz KN, 1998, N-S ARCH PHARMACOL, V357, P1; Kobilka B, 2004, MOL PHARMACOL, V65, P1060, DOI 10.1124/mol.65.5.1060; KONKAR AA, 2000, P NATL ACAD SCI USA, V82, P3144; Laskowski RA, 1998, CURR OPIN STRUC BIOL, V8, P631, DOI 10.1016/S0959-440X(98)80156-5; Lattion AL, 1999, FEBS LETT, V457, P302, DOI 10.1016/S0014-5793(99)01064-9; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rezmann-Vitti LA, 2004, BIOCHEM PHARMACOL, V68, P675, DOI 10.1016/j.bcp.2004.04.021; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHOFIELD PR, 1978, NUCLEIC ACIDS RES, V15, P3636; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wieland K, 1996, P NATL ACAD SCI USA, V93, P9276, DOI 10.1073/pnas.93.17.9276	35	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18120	18125		10.1074/jbc.M601791200	http://dx.doi.org/10.1074/jbc.M601791200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16648137	hybrid			2022-12-25	WOS:000238490300063
J	Ganley, IG; Pfeffer, SR				Ganley, Ian G.; Pfeffer, Suzanne R.			Cholesterol accumulation sequesters Rab9 and disrupts late endosome function in NPC1-deficient cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIEMANN-PICK C1; MANNOSE 6-PHOSPHATE RECEPTOR; TRANS-GOLGI NETWORK; LIPOPROTEIN-DERIVED CHOLESTEROL; ORDERED LIPID DOMAINS; BIOLOGICAL-MEMBRANES; PLASMA-MEMBRANE; DISEASE; PROTEIN; TRAFFICKING	Niemann-Pick type C disease is an autosomal recessive disorder that leads to massive accumulation of cholesterol and glycosphingolipids in late endosomes and lysosomes. To understand how cholesterol accumulation influences late endosome function, we investigated the effect of elevated cholesterol on Rab9-dependent export of mannose 6-phosphate receptors from this compartment. Endogenous Rab9 levels were elevated 1.8-fold in Niemann-Pick type C cells relative to wild type cells, and its half-life increased 1.6-fold, suggesting that Rab9 accumulation is caused by impaired protein turnover. Reduced Rab9 degradation was accompanied by stabilization on endosome membranes, as shown by a reduction in the capacity of Rab9 for guanine nucleotide dissociation inhibitor-mediated extraction from Niemann-Pick type C membranes. Cholesterol appeared to stabilize Rab9 directly, as liposomes loaded with prenylated Rab9 showed decreased extractability with increasing cholesterol content. Rab9 is likely sequestered in an inactive form on Niemann-Pick type C membranes, as cation-dependent mannose 6-phosphate receptors were missorted to the lysosome for degradation, a process that was reversed by overexpression of GFP-tagged Rab9. In addition to using primary fibroblasts isolated from Niemann-Pick type C patients, RNA interference was utilized to recapitulate the disease phenotype in cultured cells, greatly facilitating the analysis of cholesterol accumulation and late endosome function. We conclude that cholesterol contributes directly to the sequestration of Rab9 on Niemann-Pick type C cell membranes, which in turn, disrupts mannose 6-phosphate receptor trafficking.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Pfeffer, SR (corresponding author), 279 Campus Dr, Stanford, CA 94305 USA.	pfeffer@stanford.edu		Ganley, Ian/0000-0003-1481-9407	NIDDK NIH HHS [R56 DK037332, R37 DK037332, DK 37332, R01 DK037332-27, R01 DK037332] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037332, R56DK037332, R37DK037332] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Carroll KS, 2001, SCIENCE, V292, P1373, DOI 10.1126/science.1056791; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chang TY, 2005, J BIOL CHEM, V280, P20917, DOI 10.1074/jbc.R400040200; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Choudhury A, 2004, MOL BIOL CELL, V15, P4500, DOI 10.1091/mbc.E04-05-0432; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Feng Y, 2001, METHOD ENZYMOL, V329, P175; Ganley IG, 2004, MOL BIOL CELL, V15, P5420, DOI 10.1091/mbc.E04-08-0747; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; GOLDSTEIN JL, 1992, EUR HEART J, V13, P34, DOI 10.1093/eurheartj/13.suppl_B.34; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; Holtta-Vuori M, 2002, MOL BIOL CELL, V13, P3107, DOI 10.1091/mbc.E02-01-0025; Ioannou YA, 2005, TRENDS BIOCHEM SCI, V30, P498, DOI 10.1016/j.tibs.2005.07.007; Itin C, 1997, J BIOL CHEM, V272, P27737, DOI 10.1074/jbc.272.44.27737; Itin C, 1999, MOL BIOL CELL, V10, P2191, DOI 10.1091/mbc.10.7.2191; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; Ko DC, 2003, P NATL ACAD SCI USA, V100, P2518, DOI 10.1073/pnas.0530027100; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; KORBFELD S, 1992, ANNU REV BIOCHEM, V61, P307; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Maxfield FR, 2005, NATURE, V438, P612, DOI 10.1038/nature04399; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Miwako I, 2001, J CELL SCI, V114, P1765; Mobius W, 2003, TRAFFIC, V4, P222; Mukhejee S, 2004, BBA-MOL CELL BIOL L, V1685, P28, DOI 10.1016/j.bbalip.2004.08.009; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Ohgami N, 2004, P NATL ACAD SCI USA, V101, P12473, DOI 10.1073/pnas.0405255101; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHIMMOLLER F, 1993, J CELL SCI, V106, P823; SOKOL J, 1988, J BIOL CHEM, V263, P3411; SOLDATI T, 1995, METHOD ENZYMOL, V257, P253; Sturley SL, 2004, BBA-MOL CELL BIOL L, V1685, P83, DOI 10.1016/j.bbalip.2004.08.014; Sugii S, 2003, J BIOL CHEM, V278, P27180, DOI 10.1074/jbc.M300542200; Sugii S, 2003, J LIPID RES, V44, P1033, DOI 10.1194/jlr.D200036-JLR200; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; Walter M, 2003, J LIPID RES, V44, P243, DOI 10.1194/jlr.M200230-JLR200; Wang TY, 2001, BIOCHEMISTRY-US, V40, P13031, DOI 10.1021/bi0112311; Wojtanik KM, 2003, J BIOL CHEM, V278, P14850, DOI 10.1074/jbc.M300488200; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	55	91	92	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17890	17899		10.1074/jbc.M601679200	http://dx.doi.org/10.1074/jbc.M601679200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16644737	Green Accepted, hybrid			2022-12-25	WOS:000238490300039
J	Orlandini, M; Spreafico, A; Bardelli, M; Rocchigiani, M; Salameh, A; Nucciotti, S; Capperucci, C; Frediani, B; Oliviero, S				Orlandini, Maurizio; Spreafico, Adriano; Bardelli, Monia; Rocchigiani, Marina; Salameh, Ahmad; Nucciotti, Sara; Capperucci, Caterina; Frediani, Bruno; Oliviero, Salvatore			Vascular endothelial growth factor-D activates VEGFR-3 expressed in osteoblasts inducing their differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCHONDRAL BONE-FORMATION; FACTOR RECEPTOR-3; TRANSGENIC MICE; IN-VITRO; ANGIOGENESIS; LYMPHANGIOGENESIS; SPECIFICITY; MIGRATION; CARTILAGE; SURVIVAL	Vascular endothelial growth factor (VEGF)-D is a member of the VEGF family of angiogenic growth factors that recognizes and activates the vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3 on blood and/or lymphatic vessels. We show that in the long bones of newborn mice, VEGF-D and VEGFR-3 are expressed in the osteoblasts of the growing plate. The treatment of primary human osteoblasts with recombinant VEGF-D induces the expression of osteocalcin and the formation of mineralized nodules in a dose-dependent manner. A monoclonal neutralizing antibody, anti-VEGF-D, or silencing of VEGFR-3 by lentiviral-mediated expression of VEGFR-3 small hairpin RNA affects VEGF-D-dependent osteocalcin expression and nodule formation. Moreover, in primary human osteoblasts, VEGF-D expression is under the control of VEGF, and inhibition of VEGF-D/VEGFR-3 signaling, by monoclonal antibodies or VEGFR-3 silencing, affects VEGF-dependent osteoblast differentiation. These experiments establish that VEGF-D/VEGFR-3 signaling plays a critical role in osteoblast maturation and suggest that VEGF-D is a downstream effector of VEGF in osteogenesis.	Univ Siena, Dipartimento Biol Mol, I-53100 Siena, Italy; Univ Siena, Dipartimento Med Clin & Sci Immunol, Sez Reumatol, I-53100 Siena, Italy	University of Siena; University of Siena	Oliviero, S (corresponding author), Univ Siena, Dipartimento Biol Mol, Via Fiorentina 1, I-53100 Siena, Italy.	oliviero@unisi.it	Orlandini, Maurizio/AAF-8247-2020; oliviero, salvatore/R-6657-2019; Spreafico, Adriano/K-2397-2018; spreafico, adriano/AAL-6492-2020	Orlandini, Maurizio/0000-0002-6112-4889; oliviero, salvatore/0000-0002-3405-765X; Spreafico, Adriano/0000-0002-8047-8666; 				Achen MG, 2002, GROWTH FACTORS, V20, P99, DOI 10.1080/08977190290031969; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Aldridge SE, 2005, BIOCHEM BIOPH RES CO, V335, P793, DOI 10.1016/j.bbrc.2005.07.145; Aoyama J, 2004, HISTOCHEM CELL BIOL, V122, P35, DOI 10.1007/s00418-004-0671-3; Avantaggiato V, 1998, MECH DEVELOP, V73, P221, DOI 10.1016/S0925-4773(98)00049-5; Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; CAMPBELL GH, 1984, AM J TROP MED HYG, V33, P1051, DOI 10.4269/ajtmh.1984.33.1051; Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359-6446(03)02866-6; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Frediani B, 2004, BONE, V35, P859, DOI 10.1016/j.bone.2004.06.001; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050-1738(00)00074-8; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Kubo H, 2000, BLOOD, V96, P546; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; Maes C, 2004, J CLIN INVEST, V113, P188, DOI 10.1172/JCI200419383; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Mayr-Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756-3282(01)00690-1; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; Orlandini M, 2003, J BIOL CHEM, V278, P44650, DOI 10.1074/jbc.M304255200; Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO;2-5; Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708; Rocchigiani M, 1998, GENOMICS, V47, P207, DOI 10.1006/geno.1997.5079; Salameh A, 2005, BLOOD, V106, P3423, DOI 10.1182/blood-2005-04-1388; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959-437X(00)00228-8; Witmer AN, 2001, J PATHOL, V195, P490, DOI 10.1002/path.969; Zelzer E, 2002, DEVELOPMENT, V129, P1893; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2; Zippo A, 2004, BLOOD, V103, P4536, DOI 10.1182/blood-2003-11-3827	39	66	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17961	17967		10.1074/jbc.M600413200	http://dx.doi.org/10.1074/jbc.M600413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16624815	Green Published, hybrid			2022-12-25	WOS:000238490300046
J	Hu, G; Lin, AP; McAlister-Henn, L				Hu, Gang; Lin, An-Ping; McAlister-Henn, Lee			Physiological consequences of loss of allosteric activation of yeast NAD(+)-specific isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BINDING-SITES; KINETIC-ANALYSIS; CYCLE MUTANTS; MITOCHONDRIAL; GENE; EXPRESSION; PURIFICATION; SUBUNIT; ACID	Based on allosteric regulatory properties, NAD(+)-specific isocitrate dehydrogenase (IDH) is believed to control flux through the tricarboxylic acid cycle in vivo. To distinguish growth phenotypes associated with regulatory dysfunction of this enzyme in Saccharomyces cerevisiae, we analyzed strains expressing well defined mutant forms of IDH or a non-allosteric bacterial NAD(+)-specific isocitrate dehydrogenase (IDHa). As previously reported, expression of mutant forms of IDH with severe catalytic defects but intact regulatory properties produced an inability to grow with acetate as the carbon source and a dramatic increase in the frequency of generation of petite colonies, phenotypes also exhibited by a strain (idh1 Delta idh2 Delta) lacking IDH. Reduced growth rates on acetate medium were also observed with expression of enzymes with severe regulatory defects or of the bacterial IDHa enzyme, suggesting that allosteric regulation is also important for optimal growth on this carbon source. However, expression of IDHa produced no effect on petite frequency, suggesting that the intermediate petite frequencies observed for strains expressing regulatory mutant forms of IDH are likely to correlate with the slight reductions in catalytic efficiency observed for these enzymes. Finally, rates of increase in oxygen consumption were measured during culture shifts from medium with glucose to medium with ethanol as the carbon source. Strains expressing wild-type or catalytically deficient mutant forms of IDH exhibited rapid respiratory transitions, whereas strains expressing regulatory mutant forms of IDH or the bacterial IDHa enzyme exhibited much slower respiratory transitions. This suggests an important physiological role for allosteric activation of IDH during changes in environmental conditions.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	McAlister-Henn, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	henn@uthscsa.edu			NIGMS NIH HHS [GM051265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson SL, 2005, BIOCHEMISTRY-US, V44, P16776, DOI 10.1021/bi0515568; BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; BARNES LD, 1972, BIOCHEMISTRY-US, V11, P4322, DOI 10.1021/bi00773a019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN FR, 1963, BIOCHEMISTRY-US, V2, P1023, DOI 10.1021/bi00905a020; Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391; Contreras-Shannon V, 2005, J BIOL CHEM, V280, P4469, DOI 10.1074/jbc.M410140200; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DAUM G, 1982, J BIOL CHEM, V257, P3028; de Jong L, 2000, FEBS LETT, V483, P62, DOI 10.1016/S0014-5793(00)02086-X; ELZINGA SDJ, 1993, NUCLEIC ACIDS RES, V21, P5328, DOI 10.1093/nar/21.23.5328; HATHAWAY JA, 1963, J BIOL CHEM, V238, P2875; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; Inoue H, 2002, FEMS MICROBIOL LETT, V214, P127, DOI 10.1111/j.1574-6968.2002.tb11335.x; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; Lin AP, 2003, J BIOL CHEM, V278, P12864, DOI 10.1074/jbc.M300154200; Lin AP, 2002, J BIOL CHEM, V277, P22475, DOI 10.1074/jbc.M202534200; Lin AP, 2001, BIOCHEMISTRY-US, V40, P14291, DOI 10.1021/bi0111707; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; McCammon MT, 2003, MOL BIOL CELL, V14, P958, DOI 10.1091/mbc.E02-07-0422; McCammon MT, 2003, ARCH BIOCHEM BIOPHYS, V419, P222, DOI 10.1016/j.abb.2003.08.022; McCammon MT, 1996, GENETICS, V144, P57; MCCAMMON MT, 1990, J BACTERIOL, V172, P5816, DOI 10.1128/jb.172.10.5816-5827.1990; Ovadi J, 2000, INT REV CYTOL, V192, P255; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Panisko EA, 2001, J BIOL CHEM, V276, P1204, DOI 10.1074/jbc.M005056200; Przybyla-Zawislak B, 1999, GENETICS, V152, P153; REEVES HC, 1972, BIOCHIM BIOPHYS ACTA, V258, P27, DOI 10.1016/0005-2744(72)90964-3; SUMEGI B, 1992, BIOCHEMISTRY-US, V31, P8720, DOI 10.1021/bi00152a006; Zhao WN, 1996, J BIOL CHEM, V271, P10347, DOI 10.1074/jbc.271.17.10347; Zhao WN, 1997, J BIOL CHEM, V272, P21811, DOI 10.1074/jbc.272.35.21811; Zhao WN, 1996, BIOCHEMISTRY-US, V35, P7873, DOI 10.1021/bi9605189	36	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16935	16942		10.1074/jbc.M512281200	http://dx.doi.org/10.1074/jbc.M512281200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16621803	hybrid			2022-12-25	WOS:000238326300014
J	Lamande, SR; Morgelin, M; Adams, NE; Selan, C; Allen, JM				Lamande, Shireen R.; Morgelin, Matthias; Adams, Naomi E.; Selan, Carly; Allen, Justin M.			The C5 domain of the collagen VI alpha 3(VI) chain is critical for extracellular microfibril formation and is present in the extracellular matrix of cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; IN-FRAME DELETION; BETHLEM MYOPATHY; VONWILLEBRAND-FACTOR; SEQUENCE-ANALYSIS; GLOBULAR DOMAINS; A-DOMAINS; MUTATIONS; COL6A3; GENES	Collagen VI, a microfibrillar protein found in virtually all connective tissues, is composed of three distinct subunits, alpha 1(VI), alpha 2(VI), and alpha 3(VI), which associate intracellularly to form triple helical heterotrimeric monomers then dimers and tetramers. The secreted tetramers associate end-to-end to form beaded microfibrils. Although the basic steps in assembly and the structure of the tetramers and microfibrils are well defined, details of the interacting protein domains involved in assembly are still poorly understood. To explore the role of the C-terminal globular regions in assembly, alpha 3(VI) cDNA expression constructs with C-terminal truncations were stably transfected into SaOS-2 cells. Control alpha 3(VI) N6-C5 chains with an intact C-terminal globular region (subdomains C1-C5), and truncated alpha 3(VI) N6-C1, N6-C2, N6-C3, and N6-C4 chains, all associated with endogenous alpha 1(VI) and alpha 2(VI) to form collagen VI monomers, dimers and tetramers, which were secreted. These data demonstrate that subdomains C2-C5 are not required for monomer, dimer or tetramer assembly, and suggest that the important chain selection interactions involve the C1 subdomains. In contrast to tetramers containing control alpha 3(VI) N6-C5 chains, tetramers containing truncated alpha 3(VI) chains were unable to associate efficiently end-to-end in the medium and did not form a significant extracellular matrix, demonstrating that the alpha 3(VI) C5 domain plays a crucial role in collagen VI microfibril assembly. The alpha 3(VI) C5 domain is present in the extracellular matrix of SaOS-2 N6-C5 expressing cells and fibroblasts demonstrating that processing of the C-terminal region of the alpha 3(VI) chain is not essential for microfibril formation.	Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp, Dept Pediat, Parkville, Vic 3052, Australia; Lund Univ, Dept Clin Sci, S-22184 Lund, Sweden	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; Lund University	Lamande, SR (corresponding author), Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.	shireen.lamande@mcri.edu.au		Lamande, Shireen/0000-0003-2938-2711				Aigner T, 2002, BIOCHEM BIOPH RES CO, V290, P743, DOI 10.1006/bbrc.2001.6227; Baker NL, 2005, HUM MOL GENET, V14, P279, DOI 10.1093/hmg/ddi025; Ball S, 2003, J BIOL CHEM, V278, P15326, DOI 10.1074/jbc.M209977200; Ball SG, 2001, J BIOL CHEM, V276, P7422, DOI 10.1074/jbc.M002816200; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; COLOMBATTI A, 1987, J BIOL CHEM, V262, P14454; Demir E, 2002, AM J HUM GENET, V70, P1446, DOI 10.1086/340608; ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; Fitzgerald J, 2001, J BIOL CHEM, V276, P187, DOI 10.1074/jbc.M008173200; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; HESSLE H, 1984, J BIOL CHEM, V259, P3955; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Ishikawa H, 2004, NEUROLOGY, V62, P620, DOI 10.1212/01.WNL.0000113023.84421.00; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; KADLER KE, 1990, ANN NY ACAD SCI, V580, P214, DOI 10.1111/j.1749-6632.1990.tb17930.x; Lamande SR, 2002, J BIOL CHEM, V277, P1949, DOI 10.1074/jbc.M109932200; Lamande SR, 1998, J BIOL CHEM, V273, P7423, DOI 10.1074/jbc.273.13.7423; Lamande SR, 1999, J BIOL CHEM, V274, P21817, DOI 10.1074/jbc.274.31.21817; Lamande SR, 1998, HUM MOL GENET, V7, P981, DOI 10.1093/hmg/7.6.981; Lampe AK, 2005, J MED GENET, V42, P673, DOI 10.1136/jmg.2002.002311; Lampe AK, 2005, J MED GENET, V42, P108, DOI 10.1136/jmg.2004.023754; MAYER U, 1994, EUR J BIOCHEM, V225, P573, DOI 10.1111/j.1432-1033.1994.00573.x; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; Pan TC, 2003, AM J HUM GENET, V73, P355, DOI 10.1086/377107; Pan TC, 1998, HUM MOL GENET, V7, P807, DOI 10.1093/hmg/7.5.807; Pepe G, 1999, BIOCHEM BIOPH RES CO, V258, P802, DOI 10.1006/bbrc.1999.0680; Scacheri PC, 2002, NEUROLOGY, V58, P593, DOI 10.1212/WNL.58.4.593; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; TRUEB B, 1986, EMBO J, V5, P2815, DOI 10.1002/j.1460-2075.1986.tb04573.x; Vanegas OC, 2001, P NATL ACAD SCI USA, V98, P7516	36	50	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16607	16614		10.1074/jbc.M510192200	http://dx.doi.org/10.1074/jbc.M510192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16613849	hybrid			2022-12-25	WOS:000238165700053
J	Kultti, A; Rilla, K; Tiihonen, R; Spicer, AP; Tammi, RH; Tammi, MI				Kultti, Anne; Rilla, Kirsi; Tiihonen, Riikka; Spicer, Andrew P.; Tammi, Raija H.; Tammi, Markku I.			Hyaluronan synthesis induces microvillus-like cell surface protrusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; IN-VIVO; EPIDERMAL-KERATINOCYTES; GROWTH; SYNTHASE; CANCER; ACID; GLYCOPROTEIN; ACTIVATION; EXPRESSION	Hyaluronan synthases (HASs) are plasma membrane enzymes that simultaneously elongate, bind, and extrude the growing hyaluronan chain directly into extracellular space. In cells transfected with green fluorescent protein (GFP)-tagged Has3, the dorsal surface was decorated by up to 150 slender, 3-20-mu m-long microvillus-type plasma membrane protrusions, which also contained filamentous actin, the hyaluronan receptor CD44, and lipid raft microdomains. Enzymatic activity of HAS was required for the growth of the microvilli, which were not present in cells transfected with other GFP proteins or inactive GFP-Has3 mutants or in cells incubated with exogenous soluble hyaluronan. The microvilli induced by HAS3 were gradually withered by introduction of an inhibitor of hyaluronan synthesis and rapidly retracted by hyaluronidase digestion, whereas they were not affected by competition with hyaluronan oligosaccharides and disruption of the CD44 gene, suggesting independence of hyaluronan receptors. The data bring out the novel concept that the glycocalyx created by dense arrays of hyaluronan chains, tethered to HAS during biosynthesis, can induce and maintain prominent microvilli.	Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland; Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Biotechnol, Houston, TX 77030 USA	University of Eastern Finland; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Tammi, MI (corresponding author), Univ Kuopio, Dept Anat, POB 1627, FIN-70211 Kuopio, Finland.	tammi@uku.fi	Tammi, Markku/AAQ-7878-2021	Rilla, Kirsi/0000-0002-7862-5727				Anttila MA, 2000, CANCER RES, V60, P150; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Bacso Z, 2004, CYTOM PART A, V61A, P105, DOI 10.1002/cyto.a.20081; Bakkers J, 2004, DEVELOPMENT, V131, P525, DOI 10.1242/dev.00954; Berndt C, 2004, CELL BIOL INT, V28, P829, DOI 10.1016/j.cellbi.2004.08.003; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Charras GT, 2005, NATURE, V435, P365, DOI 10.1038/nature03550; Chen WYJ, 1999, WOUND REPAIR REGEN, V7, P79, DOI 10.1046/j.1524-475X.1999.00079.x; D'Alterio C, 2005, J CELL BIOL, V171, P549, DOI 10.1083/jcb.200507072; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; Hager B, 1999, J INVEST DERMATOL, V112, P971, DOI 10.1046/j.1523-1747.1999.00605.x; HELDIN P, 1993, EXP CELL RES, V208, P422, DOI 10.1006/excr.1993.1264; Hommelgaard AM, 2004, MOL BIOL CELL, V15, P1557, DOI 10.1091/mbc.E03-08-0596; Ionov R, 2004, BBA-BIOMEMBRANES, V1667, P200, DOI 10.1016/j.bbamem.2004.10.007; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kakizaki I, 2004, J BIOL CHEM, V279, P33281, DOI 10.1074/jbc.M405918200; Karvinen S, 2003, J BIOL CHEM, V278, P49495, DOI 10.1074/jbc.M310445200; KITCHEN JR, 1995, BIOCHEM J, V309, P649, DOI 10.1042/bj3090649; Kosaki R, 1999, CANCER RES, V59, P1141; Lange K, 2002, AM J PHYSIOL-CELL PH, V282, pC1, DOI 10.1152/ajpcell.2002.282.1.C1; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Loomis PA, 2003, J CELL BIOL, V163, P1045, DOI 10.1083/jcb.200309093; McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396; MIDURA RJ, 1994, J BIOL CHEM, V269, P13200; MIDURA RJ, 1994, GLYCOBIOLOGY, V4, P333, DOI 10.1093/glycob/4.3.333; Millard TH, 2005, EMBO J, V24, P240, DOI 10.1038/sj.emboj.7600535; Misra S, 2005, J BIOL CHEM, V280, P20310, DOI 10.1074/jbc.M500737200; Mullegger J, 2003, BIOL CHEM, V384, P175, DOI 10.1515/BC.2003.019; Okumura S, 2001, EXP CELL RES, V271, P269, DOI 10.1006/excr.2001.5393; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Pellegrin S, 2005, CURR BIOL, V15, P129, DOI 10.1016/j.cub.2005.01.011; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pummill PE, 2001, J BIOL CHEM, V276, P39832, DOI 10.1074/jbc.M105489200; Rajagopal A, 2002, CANCER RES, V62, P391; Richards JS, 2005, MOL CELL ENDOCRINOL, V234, P75, DOI 10.1016/j.mce.2005.01.004; Rilla K, 2005, J BIOL CHEM, V280, P31890, DOI 10.1074/jbc.M504736200; Ropponen K, 1998, CANCER RES, V58, P342; Saotome I, 2004, DEV CELL, V6, P855, DOI 10.1016/j.devcel.2004.05.007; Scholl FG, 1999, J CELL SCI, V112, P4601; Spicer AP, 1999, BIOCHEM SOC T, V27, P109, DOI 10.1042/bst0270109; Sun MZ, 2005, BIOPHYS J, V89, P4320, DOI 10.1529/biophysj.104.058180; SUZUKI M, 1995, BIOCHEM J, V307, P817, DOI 10.1042/bj3070817; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Tzanakakis GN, 1996, APMIS, V104, P718, DOI 10.1111/j.1699-0463.1996.tb04934.x; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Weigel PH, 2002, IUBMB LIFE, V54, P201, DOI 10.1080/15216540214931; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	57	110	112	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15821	15828		10.1074/jbc.M512840200	http://dx.doi.org/10.1074/jbc.M512840200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595683	hybrid			2022-12-25	WOS:000237996000030
J	Neumann, M; Schulte, M; Junemann, N; Stocklein, W; Leimkuhler, S				Neumann, Meina; Schulte, Marc; Juenemann, Nora; Stoecklein, Walter; Leimkuehler, Silke			Rhodobacter capsulatus XdhC is involved in molybdenum cofactor binding and insertion into xanthine dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SULFITE OXIDASE; ESCHERICHIA-COLI; NITRATE REDUCTASE; AZOTOBACTER-VINELANDII; ARABIDOPSIS-THALIANA; CRYSTAL-STRUCTURES; MOLYBDOPTERIN; MECHANISM; CHAPERONE; BIOSYNTHESIS	Rhodobacter capsulatus xanthine dehydrogenase (XDH) is a cytoplasmic enzyme with an (alpha beta) 2 heterodimeric structure that is highly identical to homodimeric eukaryotic xanthine oxidoreductases. The crystal structure revealed that the molybdenum cofactor (Moco) is deeply buried within the protein. A protein involved in Moco insertion and XDH maturation has been identified, which was designated XdhC. XdhC was shown to be essential for the production of active XDH but is not a subunit of the purified enzyme. Here we describe the purification of XdhC and the detailed characterization of its role for XDH maturation. We could show that XdhC binds Moco in stoichiometric amounts, which subsequently can be inserted into Moco-free apo-XDH. A specific interaction between XdhC and XdhB was identified. We show that XdhC is required for the stabilization of the sulfurated form of Moco present in enzymes of the xanthine oxidase family. Our findings imply that enzyme-specific proteins exist for the biogenesis of molybdoenzymes, coordinating Moco binding and insertion into their respective target proteins. So far, the requirement of such proteins for molybdoenzyme maturation has been described only for prokaryotes.	Univ Potsdam, Inst Biochem & Biol, D-14476 Potsdam, Germany; Univ Potsdam, Dept Proteinanalyt, D-14476 Potsdam, Germany; Univ Potsdam, Dept Analyt Biochem, D-14476 Potsdam, Germany	University of Potsdam; University of Potsdam; University of Potsdam	Leimkuhler, S (corresponding author), Univ Potsdam, Inst Biochem & Biol, D-14476 Potsdam, Germany.	sleim@uni-potsdam.de	Neumann-Schaal, Meina/AAM-6389-2021	Leimkuhler, Silke/0000-0003-3238-2122				Amrani L, 2000, MOL MICROBIOL, V38, P114, DOI 10.1046/j.1365-2958.2000.02119.x; Bittner F, 2001, J BIOL CHEM, V276, P40381, DOI 10.1074/jbc.C100472200; Blasco F, 1998, MOL MICROBIOL, V28, P435, DOI 10.1046/j.1365-2958.1998.00795.x; Brokx SJ, 2005, BIOCHEMISTRY-US, V44, P10339, DOI 10.1021/bi050621a; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Genes O, 2005, J BIOL CHEM, V280, P15644, DOI 10.1074/jbc.M501119200; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Heidenreich T, 2005, J BIOL CHEM, V280, P4213, DOI 10.1074/jbc.M411195200; HILLE R, 1987, J BIOL CHEM, V262, P10914; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Ilbert M, 2003, J BIOL CHEM, V278, P28787, DOI 10.1074/jbc.M302730200; Ivanov NV, 2003, EUR J BIOCHEM, V270, P4744, DOI 10.1046/j.1432-1033.2003.03875.x; Jack RL, 2004, EMBO J, V23, P3962, DOI 10.1038/sj.emboj.7600409; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Leimkuhler S, 1999, J BACTERIOL, V181, P5930; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; Leimkuhler S, 1999, J BACTERIOL, V181, P2745; Leimkuhler S, 2004, J BIOL CHEM, V279, P40437, DOI 10.1074/jbc.M405778200; Leimkuhler S, 2003, J BIOL CHEM, V278, P26127, DOI 10.1074/jbc.M303092200; Leimkuhler S, 2003, J BIOL CHEM, V278, P20802, DOI 10.1074/jbc.M303091200; Leimkuhler S, 2001, J BIOL CHEM, V276, P1837, DOI 10.1074/jbc.M007304200; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Loiseau L, 2005, J BIOL CHEM, V280, P26760, DOI 10.1074/jbc.M504067200; Loschi L, 2004, J BIOL CHEM, V279, P50391, DOI 10.1074/jbc.M408876200; MASSEY V, 1970, J BIOL CHEM, V245, P6595; Massey V, 1970, Vitam Horm, V28, P505; Mihara H, 2002, APPL MICROBIOL BIOT, V60, P12, DOI 10.1007/s00253-002-1107-4; MILLER JB, 1987, J BACTERIOL, V169, P1853, DOI 10.1128/jb.169.5.1853-1860.1987; Oresnik IJ, 2001, MOL MICROBIOL, V40, P323, DOI 10.1046/j.1365-2958.2001.02391.x; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; RAJAGOPALAN KV, 1996, ESCHERICHIA COLI SAL; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; Tranier S, 2003, STRUCTURE, V11, P165, DOI 10.1016/S0969-2126(03)00008-X; Truglio JJ, 2002, STRUCTURE, V10, P115, DOI 10.1016/S0969-2126(01)00697-9; Vergnes A, 2006, J BIOL CHEM, V281, P2170, DOI 10.1074/jbc.M505902200; Vergnes A, 2004, J BIOL CHEM, V279, P41398, DOI 10.1074/jbc.M407087200; WAHL RC, 1984, ARCH BIOCHEM BIOPHYS, V230, P264, DOI 10.1016/0003-9861(84)90107-3; WAHL RC, 1982, J BIOL CHEM, V257, P3958; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	45	51	53	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15701	15708		10.1074/jbc.M601617200	http://dx.doi.org/10.1074/jbc.M601617200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16597619	hybrid			2022-12-25	WOS:000237996000015
J	Guo, LW; Muradov, H; Hajipour, AR; Sievert, MK; Artemyev, NO; Ruoho, AE				Guo, Lian-Wang; Muradov, Hakim; Hajipour, Abdol R.; Sievert, Michael K.; Artemyev, Nikolai O.; Ruoho, Arnold E.			The inhibitory gamma subunit of the rod cGMP phosphodiesterase binds the catalytic subunits in an extended linear structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; STATIONARY NIGHT BLINDNESS; TRANSDUCIN ALPHA-SUBUNIT; BETA-SUBUNIT; GAF DOMAINS; PHOTORECEPTOR PHOSPHODIESTERASE; RETINAL DEGENERATION; CARBOXYL-TERMINUS; OUTER SEGMENTS; PDE6	The unique feature of rod photoreceptor cGMP phosphodiesterase (PDE6) is the presence of inhibitory subunits (P gamma), which interact with the catalytic heterodimer (P alpha beta) to regulate its activity. This uniqueness results in an extremely high sensitivity and sophisticated modulations of rod visual signaling where the P gamma/P alpha beta interactions play a critical role. The quaternary organization of the alpha beta gamma gamma heterotetramer is poorly understood and contradictory patterns of interaction have been previously suggested. Here we provide evidence that supports a specific interaction, by systematically and differentially analyzing the P gamma-binding regions on P alpha and P beta through photolabel transfer from various P gamma positions throughout the entire molecule. The P gamma N- terminal Val(16)-Phe(30) region was found to interact with the P alpha beta GAFa domain, whereas its C terminus (Phe(73)-Ile(87)) interacted with the P alpha beta catalytic domain. The interactions of P gamma with these two domains were bridged by its central Ser(40)-Phe(50) region through interactions with GAFb and the linker between GAFb and the catalytic domain, indicating a linear and extended interaction between P alpha and P alpha beta. Furthermore, a photocross-linked product alpha beta gamma(gamma) was specifically generated by the double derivatized P gamma, in which one photoprobe was located in the polycationic region and the other in the C terminus. Taken together the evidence supports the conclusion that each P gamma molecule binds P alpha beta in an extended linear interaction and may even interact with both P alpha and P beta simultaneously.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Isfahan Univ Technol, Coll Chem, Pharmaceut Lab, Esfahan 84156, Iran	University of Wisconsin System; University of Wisconsin Madison; University of Iowa; Isfahan University of Technology	Guo, LW (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA.	lianwangguo@wisc.edu		Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [R01 EY010843, EY10843] Funding Source: Medline; NIGMS NIH HHS [GM33138] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033138] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; Artemyev NO, 1996, J BIOL CHEM, V271, P25382, DOI 10.1074/jbc.271.41.25382; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; Artemyev NO, 1998, METHODS, V14, P93, DOI 10.1006/meth.1997.0568; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Berger AL, 1997, J BIOL CHEM, V272, P2714, DOI 10.1074/jbc.272.5.2714; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; Burns ME, 2002, NEURON, V36, P81, DOI 10.1016/S0896-6273(02)00911-X; CATER P, 1987, SCIENCE, V237, P394; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; COTE RH, 2003, HDB CELL SIGNALING, P453; Dall'Acqua W, 2000, PROTEIN SCI, V9, P1; GAL A, 1994, NAT GENET, V7, P64, DOI 10.1038/ng0594-64; Granovsky AE, 2001, BIOCHEMISTRY-US, V40, P13209, DOI 10.1021/bi011127j; Granovsky AE, 2000, J BIOL CHEM, V275, P41258, DOI 10.1074/jbc.M008094200; Grant JE, 2006, J BIOL CHEM, V281, P6194, DOI 10.1074/jbc.M509511200; Guo LW, 2005, BIOCONJUGATE CHEM, V16, P685, DOI 10.1021/bc050016k; Guo LW, 2005, J BIOL CHEM, V280, P12585, DOI 10.1074/jbc.M410380200; Huai Q, 2004, P NATL ACAD SCI USA, V101, P9624, DOI 10.1073/pnas.0401120101; Kajimura N, 2002, J STRUCT BIOL, V139, P27, DOI 10.1016/S1047-8477(02)00502-6; Keil B., 1992, SPECIFICITY PROTEOLY, P335, DOI DOI 10.1007/978-3-642-48380-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li HZ, 2001, J BIOL CHEM, V276, P10589, DOI 10.1074/jbc.M007397200; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; LIPKIN VM, 1993, BIOCHIM BIOPHYS ACTA, V1176, P250, DOI 10.1016/0167-4889(93)90052-Q; Liu XQ, 2004, P NATL ACAD SCI USA, V101, P13903, DOI 10.1073/pnas.0405160101; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Muradov H, 2004, VISION RES, V44, P2437, DOI 10.1016/j.visres.2004.05.013; Muradov KG, 2003, BIOCHEMISTRY-US, V42, P3305, DOI 10.1021/bi027095x; Muradov KG, 2002, BIOCHEMISTRY-US, V41, P3884, DOI 10.1021/bi015935m; Natochin M, 1996, J BIOL CHEM, V271, P19964, DOI 10.1074/jbc.271.33.19964; Paglia MJ, 2002, J BIOL CHEM, V277, P5017, DOI 10.1074/jbc.M106328200; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Piri N, 2003, J BIOL CHEM, V278, P36999, DOI 10.1074/jbc.M303710200; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; QIN N, 1994, J BIOL CHEM, V269, P3265; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; STROOP SD, 1991, J BIOL CHEM, V266, P23802; Sung BJ, 2003, NATURE, V425, P98, DOI 10.1038/nature01914; Tcheudji JFK, 2001, J MOL BIOL, V310, P781, DOI 10.1006/jmbi.2001.4813; Tsang SH, 1996, SCIENCE, V272, P1026, DOI 10.1126/science.272.5264.1026; Tsang SH, 2002, VISION RES, V42, P439, DOI 10.1016/S0042-6989(01)00213-9; White JB, 2004, MOL VIS, V10, P738; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; Yamazaki M, 2002, J BIOL CHEM, V277, P40675, DOI 10.1074/jbc.M203469200; Zhang XJ, 2005, FRONT BIOSCI-LANDMRK, V10, P1191, DOI 10.2741/1612	52	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15412	15422		10.1074/jbc.M600595200	http://dx.doi.org/10.1074/jbc.M600595200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16595671	hybrid			2022-12-25	WOS:000237922200047
J	Chen, F; Eckman, EA; Eckman, CB				Chen, Feng; Eckman, Elizabeth A.; Eckman, Christopher B.			Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides	FASEB JOURNAL			English	Article						ginseng; Rg1; Rg3; RE; Tg2576	GAMMA-SECRETASE INHIBITOR; EVENT-RELATED POTENTIALS; FREE TG2576 MICE; COGNITIVE PERFORMANCE; GINKGO-BILOBA; CEREBROSPINAL-FLUID; PROTEIN-PRECURSOR; MEMORY DEFICITS; PANAX-GINSENG; ANIMAL-MODEL	For millennia, ginseng and some of its components have been used to treat a wide variety of medical conditions, including age-related memory impairment. Because of its purported effects and apparently low rate of side effects, ginseng remains one of the top selling natural product remedies in the United States. Given its potential role for improving age-related memory impairments and its common use in China for the treatment of Alzheimer's disease-like symptoms, we analyzed the effects of commercially available preparations of ginseng on the accumulation of the Alzheimer's amyloid beta peptide (A beta) in a cell-based model system. In this model system, ginseng treatment resulted in a significant reduction in the levels of A beta in the conditioned medium. We next examined the effects of several compounds isolated from ginseng and found that certain ginsenosides lowered A beta concentration in a dose-dependent manner with ginsenoside Rg3 having an approximate IC50 of under 25 mu M against A beta 42. Furthermore, we found that three of these isolated components, ginsenoside Rg1, Rg3, and RE, resulted in significant reductions in the amount of A beta detected in the brains of animals after single oral doses of these agents. The results indicate that ginseng itself, or purified ginsenosides, may have similarly useful effects in human disease. Chen, F., Eckman, E. A., Eckman, C. B. Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides.	Mayo Clin, Coll Med, Dept Pharmacol, Jacksonville, FL 32224 USA; Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Eckman, CB (corresponding author), Mayo Clin, Coll Med, Dept Pharmacol, Birdsall Bldg Rm 327,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	Eckman@mayo.edu	Eckman, Elizabeth/AAL-7316-2021	Eckman, Elizabeth/0000-0002-5391-4960				Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9; Bao HY, 2005, ARCH PHARM RES, V28, P335, DOI 10.1007/BF02977802; Barnes Patricia M, 2004, Adv Data, P1; Best JD, 2005, J PHARMACOL EXP THER, V313, P902, DOI 10.1124/jpet.104.081174; Bour A, 2004, NEUROBIOL LEARN MEM, V81, P27, DOI 10.1016/S1074-7427(03)00071-6; DANGELO L, 1986, J ETHNOPHARMACOL, V16, P15, DOI 10.1016/0378-8741(86)90063-2; Dergal JM, 2002, DRUG AGING, V19, P879, DOI 10.2165/00002512-200219110-00005; Dominguez DI, 2002, TRENDS PHARMACOL SCI, V23, P324, DOI 10.1016/S0165-6147(02)02038-2; GARCIA RR, 1988, PRENSA MED ARGENT, V75, P134; Gold JL, 2001, CURR OPIN CLIN NUTR, V4, P29, DOI 10.1097/00075197-200101000-00006; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harnack LJ, 2001, MAYO CLIN PROC, V76, P688, DOI 10.4065/76.7.688; Haugabook SJ, 2001, J NEUROSCI METH, V108, P171, DOI 10.1016/S0165-0270(01)00388-0; Haugabook SJ, 2001, FASEB J, V15, P16; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Huang KC, 1999, PHARM CHINESE HERBS; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Katada E, 2003, J GERIATR PSYCH NEUR, V16, P39, DOI 10.1177/0891988702250561; Katada E, 2004, CURR ALZHEIMER RES, V1, P63, DOI 10.2174/1567205043480609; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Kennedy DO, 2004, PHARMACOL BIOCHEM BE, V79, P401, DOI 10.1016/j.pbb.2004.07.014; Kennedy DO, 2003, PHARMACOL BIOCHEM BE, V75, P687, DOI 10.1016/S0091-3057(03)00126-6; Kennedy DO, 2003, PHARMACOL BIOCHEM BE, V75, P701, DOI 10.1016/S0091-3057(03)00120-5; Kennedy DO, 2002, PHYSIOL BEHAV, V75, P739, DOI 10.1016/S0031-9384(02)00665-0; Kennedy DO, 2001, NUTR NEUROSCI, V4, P295, DOI 10.1080/1028415X.2001.11747370; Kim YC, 1998, J NEUROSCI RES, V53, P426, DOI 10.1002/(SICI)1097-4547(19980815)53:4<426::AID-JNR4>3.3.CO;2-K; Koo BS, 2004, PHYTOTHER RES, V18, P488, DOI 10.1002/ptr.1457; Lanz TA, 2005, J PHARMACOL EXP THER, V312, P399, DOI 10.1124/jpet.104.073965; Lanz TA, 2004, J PHARMACOL EXP THER, V309, P49, DOI 10.1124/jpet.103.060715; Lian XY, 2005, ANN NEUROL, V57, P642, DOI 10.1002/ana.20450; Liu ZQ, 2003, J AGR FOOD CHEM, V51, P2555, DOI 10.1021/jf026228i; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Nishijo H, 2004, J PHARMACOL SCI, V95, P145, DOI 10.1254/jphs.FMJ04001X3; Oishi M, 1998, ALZ DIS ASSOC DIS, V12, P247, DOI 10.1097/00002093-199809000-00019; Petkov VD, 2003, AM J CHINESE MED, V31, P841, DOI 10.1142/S0192415X03001533; Polich John, 2005, Current Alzheimer Research, V2, P515, DOI 10.2174/156720505774932214; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; Scarpini E, 2003, LANCET NEUROL, V2, P539, DOI 10.1016/S1474-4422(03)00502-7; Sorensen H, 1996, CURR THER RES CLIN E, V57, P959, DOI 10.1016/S0011-393X(96)80114-7; Spinella M., 2001, PSYCHOPHARMACOLOGY H; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tohda C, 2005, NEUROSIGNALS, V14, P34, DOI 10.1159/000085384; Tohda C, 2004, NEUROPSYCHOPHARMACOL, V29, P860, DOI 10.1038/sj.npp.1300388; Vogler BK, 1999, EUR J CLIN PHARMACOL, V55, P567, DOI 10.1007/s002280050674; Winther K., 1997, Journal of the Neurological Sciences, V150, pS90, DOI 10.1016/S0022-510X(97)85276-8	49	119	126	2	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1269	+		10.1096/fj.05-5530fje	http://dx.doi.org/10.1096/fj.05-5530fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636099				2022-12-25	WOS:000240210300048
J	Koschinski, A; Repp, H; Unver, B; Dreyer, F; Brockmeier, D; Valeva, A; Bhakdi, S; Walev, I				Koschinski, Andreas; Repp, Holger; Uenver, Baris; Dreyer, Florian; Brockmeier, Dierk; Valeva, Angela; Bhakdi, Sucharit; Walev, Iwan			Why Escherichia coli alpha-hemolysin induces calcium oscillations in mammalian cells - the pore is on its own	FASEB JOURNAL			English	Article						pore-forming toxins; RTX toxins; gram-negative bacteria; membrane lesions	MEMBRANE; TOXIN; PROTEINS; CHANNELS; RECEPTOR	Escherichia coli alpha-hemolysin ( HlyA), archetype of a bacterial pore-forming toxin, has been reported to deregulate physiological Ca2+ channels, thus inducing periodic low-frequency Ca2+ oscillations that trigger transcriptional processes in mammalian cells. The present study was undertaken to delineate the mechanisms underlying the Ca2+ oscillations. Patch-clamp experiments were combined with single cell measurements of intracellular Ca2+ and with flow-cytometric analyses. Application of HlyA at subcytocidal concentrations provoked Ca2+ oscillations in human renal and endothelial cells. However, contrary to the previous report, the phenomenon could not be inhibited by the Ca2+ channel blocker nifedipine and Ca2+ oscillations showed no constant periodicity at all. Ca2+ oscillations were dependent on the pore-forming activity of HlyA: application of a nonhemolytic but bindable toxin had no effect. Washout experiments revealed that Ca2+ oscillations could not be maintained in the absence of toxin in the medium. Analogously, propidium iodide flux into cells occurred in the presence of HlyA, but cells rapidly became impermeable toward the dye after toxin washout, indicating resealing or removal of the membrane lesions. Finally, patchclamp experiments revealed temporal congruence between pore formation and Ca2+ influx. We conclude that the nonperiodic Ca2+ oscillations induced by HlyA are not due to deregulation of physiological Ca2+ channels but derive from pulsed influxes of Ca2+ as a consequence of formation and rapid closure of HlyA pores in mammalian cell membranes.	Univ Giessen, Rudolf Buchheim Inst Pharmacol, D-35392 Giessen, Germany; Johannes Gutenberg Univ Mainz, Inst Med Microbiol & Hyg, D-6500 Mainz, Germany	Justus Liebig University Giessen; Johannes Gutenberg University of Mainz	Repp, H (corresponding author), Univ Giessen, Rudolf Buchheim Inst Pharmacol, Frankfurter Str 107, D-35392 Giessen, Germany.	Holger.Repp@pharma.med.uni-giessen.de; walev@mail.uni-mainz.de						BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; Berjukow S, 1996, BRIT J PHARMACOL, V118, P748, DOI 10.1111/j.1476-5381.1996.tb15463.x; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bhakdi S, 1996, CURR TOP MICROBIOL, V216, P101; Cortajarena AL, 2001, J BIOL CHEM, V276, P12513, DOI 10.1074/jbc.M006792200; de Vries H, 1998, J PHOTOCH PHOTOBIO B, V43, P217, DOI 10.1016/S1011-1344(98)00111-0; Dragneva Y, 2001, INFECT IMMUN, V69, P2630, DOI 10.1128/IAI.69.4.2630-2635.2001; Frick M, 2001, BIOCHEM PHARMACOL, V61, P1161, DOI 10.1016/S0006-2952(01)00582-2; Hyland C, 2001, J BACTERIOL, V183, P5364, DOI 10.1128/JB.183.18.5364-5370.2001; Koschinski A, 2003, J GEN VIROL, V84, P1711, DOI 10.1099/vir.0.19062-0; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; Lewis RS, 2003, BIOCHEM SOC T, V31, P925; Menestrina G, 1996, J MEMBRANE BIOL, V149, P113, DOI 10.1007/s002329900012; MENESTRINA G, 1987, BIOCHIM BIOPHYS ACTA, V905, P109, DOI 10.1016/0005-2736(87)90014-9; Randall AD, 1998, J MEMBRANE BIOL, V161, P207, DOI 10.1007/s002329900327; Repp H, 2002, CELL MICROBIOL, V4, P483, DOI 10.1046/j.1462-5822.2002.00207.x; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; Savigni DL, 2003, BIOCHEM PHARMACOL, V65, P1215, DOI 10.1016/S0006-2952(03)00045-5; Schindel C, 2001, EUR J BIOCHEM, V268, P800, DOI 10.1046/j.1432-1327.2001.01937.x; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; Valeva A, 2000, MOL MICROBIOL, V36, P467, DOI 10.1046/j.1365-2958.2000.01865.x; Walev I, 2001, P NATL ACAD SCI USA, V98, P3185, DOI 10.1073/pnas.051429498; WALEV I, 2002, FASEB J, V216, P237; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85	25	39	40	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					973	+		10.1096/fj.05-4561fje	http://dx.doi.org/10.1096/fj.05-4561fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16597673				2022-12-25	WOS:000240157700026
J	Ishiyama, N; Creuzenet, C; Miller, WL; Demendi, M; Anderson, EM; Harauz, G; Lam, JS; Berghuis, AM				Ishiyama, Noboru; Creuzenet, Carole; Miller, Wayne L.; Demendi, Melinda; Anderson, Erin M.; Harauz, George; Lam, Joseph S.; Berghuis, Albert M.			Structural studies of FlaA1 from Helicobacter pylori reveal the mechanism for inverting 4,6-dehydratase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSE 4,6-DEHYDRATASE; UDP-N-ACETYLGLUCOSAMINE; CRYSTAL-STRUCTURE; CAMPYLOBACTER-JEJUNI; MANNOSE 4,6-DEHYDRATASE; PSEUDOMONAS-AERUGINOSA; GALACTOSE 4-EPIMERASE; MOLECULAR-STRUCTURE; PSEUDAMINIC ACID; C-6 DEHYDRATASE	FlaA1 from the human pathogen Helicobacter pylori is an enzyme involved in saccharide biosynthesis that has been shown to be essential for pathogenicity. Here we present five crystal structures of FlaA1 in the presence of substrate, inhibitors, and bound cofactor, with resolutions ranging from 2.8 to 1.9 angstrom. These structures reveal that the enzyme is a novel member of the short-chain dehydrogenase/ reductase superfamily. Additional electron microscopy studies show the enzyme to possess a hexameric doughnut-shaped quaternary structure. NMR analyses of "real time" enzyme-substrate reactions indicate that FlaA1 is a UDP-GlcNAc-inverting 4,6-dehydratase, suggesting that the enzyme catalyzes the first step in the biosynthetic pathway of a pseudaminic acid derivative, which is implicated in protein glycosylation. Guided by evidence from site-directed mutagenesis and computational simulations, a three-step reaction mechanism is proposed that involves Lys-133 functioning as both a catalytic acid and base.	McGill Univ, Dept Biochem, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	McGill University; McGill University; Western University (University of Western Ontario); University of Guelph	Berghuis, AM (corresponding author), McGill Univ, Dept Biochem, 740 Dr Penfield Ave,Rm 5202, Montreal, PQ H3A 1A4, Canada.	albert.berghuis@mcgill.ca	Berghuis, Albert M/A-6495-2008	Berghuis, Albert/0000-0002-2663-025X; Harauz, George/0000-0002-6114-9947; Ishiyama, Noboru/0000-0002-1426-6083				Allard STM, 2002, STRUCTURE, V10, P81, DOI 10.1016/S0969-2126(01)00694-3; Allard STM, 2004, J BIOL CHEM, V279, P2211, DOI 10.1074/jbc.M310134200; Allard STM, 2001, J MOL BIOL, V307, P283, DOI 10.1006/jmbi.2000.4470; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Appelmelk BJ, 2000, TRENDS MICROBIOL, V8, P565, DOI 10.1016/S0966-842X(00)01875-8; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chou WK, 2005, J BIOL CHEM, V280, P35922, DOI 10.1074/jbc.M507483200; Creuzenet C, 2000, J BIOL CHEM, V275, P34873, DOI 10.1074/jbc.M006369200; Creuzenet C, 2004, FEBS LETT, V559, P136, DOI 10.1016/S0014-5793(04)00057-2; Creuzenet C, 2002, J BIOL CHEM, V277, P26769, DOI 10.1074/jbc.M202882200; DUNN BE, 1990, J BIOL CHEM, V265, P9464; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; Gerratana B, 2001, BIOCHEMISTRY-US, V40, P9187, DOI 10.1021/bi0108249; Goon S, 2003, MOL MICROBIOL, V50, P659, DOI 10.1046/j.1365-2958.2003.03725.x; GRAHAM DY, 1988, J INFECT DIS, V157, P777, DOI 10.1093/infdis/157.4.777; Gross JW, 2001, BIOCHEMISTRY-US, V40, P12497, DOI 10.1021/bi011138c; Gunawan J, 2005, J BIOL CHEM, V280, P3555, DOI 10.1074/jbc.M411942200; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI [10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P, 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X]; Hegeman AD, 2002, BIOCHEMISTRY-US, V41, P2797, DOI 10.1021/bi011748c; Ishiyama N, 2004, J BIOL CHEM, V279, P22635, DOI 10.1074/jbc.M401642200; JOSENHANS C, 1995, J BACTERIOL, V177, P3010, DOI 10.1128/jb.177.11.3010-3020.1995; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; Kneidinger B, 2003, J BIOL CHEM, V278, P3615, DOI 10.1074/jbc.M203867200; Koropatkin NM, 2005, ACTA CRYSTALLOGR D, V61, P365, DOI 10.1107/S0907444904033876; MARSHALL BJ, 1984, LANCET, V1, P1311; Merkx-Jacques A, 2004, J BACTERIOL, V186, P2253, DOI 10.1128/JB.186.8.2253-2265.2004; Monteiro MA, 1998, J BIOL CHEM, V273, P11533, DOI 10.1074/jbc.273.19.11533; Mulichak AM, 2002, BIOCHEMISTRY-US, V41, P15578, DOI 10.1021/bi0266683; Murkin AS, 2004, BIOCHEMISTRY-US, V43, P14290, DOI 10.1021/bi048606d; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Nielsen JE, 2003, PROTEIN SCI, V12, P1894, DOI 10.1110/ps.03114903; Nielsen JE, 2003, PROTEIN SCI, V12, P313, DOI 10.1110/ps.0229903; Obhi RK, 2005, J BIOL CHEM, V280, P20902, DOI 10.1074/jbc.M413832200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; Schoenhofen IC, 2006, J BIOL CHEM, V281, P723, DOI 10.1074/jbc.M511021200; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; van Heel M, 2000, Q REV BIOPHYS, V33, P307, DOI 10.1017/S0033583500003644; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Vogan EM, 2004, BIOCHEMISTRY-US, V43, P3057, DOI 10.1021/bi035547f; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Webb NA, 2004, PROTEIN SCI, V13, P529, DOI 10.1110/ps.03393904	50	48	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24489	24495		10.1074/jbc.M602393200	http://dx.doi.org/10.1074/jbc.M602393200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16651261	hybrid			2022-12-25	WOS:000239847800044
J	Peduto, L; Reuter, VE; Sehara-Fujisawa, A; Shaffer, DR; Scher, HI; Blobel, CP				Peduto, L.; Reuter, V. E.; Sehara-Fujisawa, A.; Shaffer, D. R.; Scher, H. I.; Blobel, C. P.			ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression	ONCOGENE			English	Article						ADAM12; metalloprotease-disintegrin; prostate cancer; stromal/tumor cell interaction	EPIDERMAL-GROWTH-FACTOR; CELL-PROLIFERATION; CANCER; EGF; RECEPTOR	The interaction between stromal cells and tumor cells is emerging as a critical aspect of tumor progression. Yet there is a paucity of molecular markers for cells participating in such interactions, and only few genes are known to play a critical role in this process. Here, we describe the identification of ADAM12 (a disintegrin and metalloprotease 12) as a novel marker for a subpopulation of stromal cells that are adjacent to epithelial tumor cells in three mouse carcinoma models (models for prostate, breast and colon cancer). Moreover, we show that ADAM12 is essential for tumor development and progression in the W-10 mouse model for prostate cancer. These results suggest that ADAM12 might be a useful marker for stromal cells in mouse tumors that are likely to participate in stromal/tumor cell crosstalk, and that ADAM12 is a potential target for design of drugs that prevent carcinoma growth.	Cornell Univ, Weill Med Coll, Arthritis & Tissue Degenerat Program, Hosp Special Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Mol Biol, New York, NY 10021 USA; Kyoto Univ, Inst Frontier Med Sci, Dept Growth Regulat, Kyoto, Japan; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Kyoto University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Blobel, CP (corresponding author), Cornell Univ, Weill Med Coll, Arthritis & Tissue Degenerat Program, Hosp Special Surg, Caspary Res Bldg,Room 426,535 E 70th St, New York, NY 10021 USA.	blobelc@hss.edu		Peduto, Lucie/0000-0003-2414-4407	NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR012538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064750] Funding Source: NIH RePORTER; NCRR NIH HHS [C06-RR12538-01] Funding Source: Medline; NIGMS NIH HHS [GM64750] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam RM, 2002, ENDOCRINOLOGY, V143, P4599, DOI 10.1210/en.2002-220561; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Cunha GR, 2003, INT J CANCER, V107, P1, DOI 10.1002/ijc.11335; Desmouliere A, 2004, INT J DEV BIOL, V48, P509, DOI 10.1387/ijdb.041802ad; Freeman MR, 1998, J CELL BIOCHEM, V68, P328, DOI 10.1002/(SICI)1097-4644(19980301)68:3<328::AID-JCB4>3.0.CO;2-W; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; Kveiborg M, 2005, CANCER RES, V65, P4754, DOI 10.1158/0008-5472.CAN-05-0262; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; MANOVA K, 1992, J NEUROSCI, V12, P4663; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Peduto L, 2005, CANCER RES, V65, P9312, DOI 10.1158/0008-5472.CAN-05-1063; SCHUURMANS ALG, 1988, MOL CELL ENDOCRINOL, V60, P101, DOI 10.1016/0303-7207(88)90124-4; Shaffer DR, 2005, P NATL ACAD SCI USA, V102, P210, DOI 10.1073/pnas.0407362102; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Torring N, 2002, BJU INT, V89, P583, DOI 10.1046/j.1464-410X.2002.02665.x	22	78	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5462	5466		10.1038/sj.onc.1209536	http://dx.doi.org/10.1038/sj.onc.1209536			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16607276				2022-12-25	WOS:000240144900010
J	Guerra, S; Lopez-Fernandez, LA; Garcia, MA; Zaballos, A; Esteban, M				Guerra, Susana; Lopez-Fernandez, Luis A.; Garcia, Maria Angel; Zaballos, Angel; Esteban, Mariano			Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells - Involvement of the transcription factor ATF-3 in PKR-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; VACCINIA VIRUS RECOMBINANTS; INITIATION-FACTOR 2; ACTIVATING TRANSCRIPTION; STRESS-RESPONSE; TRANSLATIONAL CONTROL; CASPASE-9 ACTIVATION; REPRESSOR ATF3/LRF1; EXPRESSION; BINDING	The interferon-induced serine/threonine protein kinase (PKR) has an essential role in cell survival and cell death after viral infection and under stress conditions, but the host genes involved in these processes are not well defined. We used human cDNA microarrays to identify, in infected cells, genes differentially expressed after PKR expression and analyzed the requirement of catalytic activity of the enzyme. To express PKR, we used vaccinia virus (VV) recombinants producing wild type PKR (VV-PKR) and the catalytically inactive mutant K296R (VV-PKR-K296R). Most regulated genes were classified according to biological function, including apoptosis, stress, defense, and immune response. Transcriptional changes detected by microarray analysis were confirmed for selected genes by quantitative real time reverse transcription PCR. A total of 111 genes were regulated specifically by PKR catalytic activity. Of these, 97 were up-regulated, and 14 were down-regulated. The ATF-3 transcription factor, involved in stress-induced beta-cell apoptosis, was up-regulated. Activation of endogenous PKR with a VV mutant lacking the viral protein E3L (VV Delta E3L), a PKR inhibitor, triggered an increase in ATF-3 expression that was not observed in PKR-/- cells. Using null cells for ATF-3 and for the p65 subunit of NF-kappa B, we showed that induction of apoptosis by PKR at late times of infection was dependent on ATF-3 expression and regulated by NF-kappa B activation. Here, we identified human genes selectively induced by expression of active PKR in infected cells and linked ATF-3 to a novel mechanism used by PKR to induce apoptosis.	Ciudad Univ Cantoblanco, CSIC, Natl Biotechnol Ctr, Dept Mol & Cellular Biol, E-28049 Madrid, Spain; Ciudad Univ Cantoblanco, CSIC, Natl Biotechnol Ctr, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC)	Esteban, M (corresponding author), Ciudad Univ Cantoblanco, CSIC, Natl Biotechnol Ctr, Dept Mol & Cellular Biol, E-28049 Madrid, Spain.	mesteban@cnb.uam.es	Esteban, Mariano/ABG-5375-2020; Garcia, Maria Angel MA/I-5116-2016; Lopez-Fernandez, Luis A/B-7330-2011; Lopez-Fernandez, Luis A/I-9679-2019; Lopez-Fernandez, Luis/AAV-2580-2021; Zaballos, Ángel/O-2853-2015; guerra, susana/K-5972-2014	Esteban, Mariano/0000-0003-0846-2827; Garcia, Maria Angel MA/0000-0003-2003-3769; Lopez-Fernandez, Luis A/0000-0003-3964-5837; Lopez-Fernandez, Luis A/0000-0003-3964-5837; Lopez-Fernandez, Luis/0000-0003-3964-5837; guerra, susana/0000-0001-9067-2991; Zaballos, Angel/0000-0002-7555-5815				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BEATTIE E, 1995, J VIROL, V69, P499, DOI 10.1128/JVI.69.1.499-505.1995; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; Bottone FG, 2005, MOL CANCER THER, V4, P693, DOI 10.1158/1535-7163.MCT-04-0337; Brun A, 1996, VIROLOGY, V225, P227, DOI 10.1006/viro.1996.0592; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 1999, MOL CELL BIOL, V19, P4653; Gil J, 2004, J INTERF CYTOK RES, V24, P637, DOI 10.1089/1079990042475706; Gil J, 2002, FEBS LETT, V529, P249, DOI 10.1016/S0014-5793(02)03348-3; Guerra S, 2004, J VIROL, V78, P5820, DOI 10.1128/JVI.78.11.5820-5834.2004; Guerra S, 2003, J VIROL, V77, P6493, DOI 10.1128/JVI.77.11.6493-6506.2003; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Hua B, 2006, J BIOL CHEM, V281, P1620, DOI 10.1074/jbc.M508471200; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; JINDAL S, 1992, J VIROL, V66, P5357, DOI 10.1128/JVI.66.9.5357-5362.1992; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Kawauchi J, 2002, J BIOL CHEM, V277, P39025, DOI 10.1074/jbc.M202974200; Kazemi S, 2004, MOL CELL BIOL, V24, P3415, DOI 10.1128/MCB.24.8.3415-3429.2004; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Langland JO, 2002, VIROLOGY, V299, P133, DOI 10.1006/viro.2002.1479; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; Lehner PJ, 1996, CURR OPIN IMMUNOL, V8, P59, DOI 10.1016/S0952-7915(96)80106-3; Martin AG, 2002, J BIOL CHEM, V277, P50834, DOI 10.1074/jbc.M209369200; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Nawa T, 2002, ATHEROSCLEROSIS, V161, P281, DOI 10.1016/S0021-9150(01)00639-6; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pang QS, 2002, J BIOL CHEM, V277, P49638, DOI 10.1074/jbc.M209386200; Petryshyn R A, 1994, Prog Mol Subcell Biol, V14, P1; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Romano PR, 1998, MOL CELL BIOL, V18, P7304, DOI 10.1128/MCB.18.12.7304; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SEDGER L, 1994, J VIROL, V68, P4685, DOI 10.1128/JVI.68.7.4685-4689.1994; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Suarez P, 1996, J VIROL, V70, P2876; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Tamura K, 2005, EMBO J, V24, P2590, DOI 10.1038/sj.emboj.7600742; Ung TL, 2001, EMBO J, V20, P3728, DOI 10.1093/emboj/20.14.3728; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Xiang Y, 2002, J VIROL, V76, P5251, DOI 10.1128/JVI.76.10.5251-5259.2002; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yan CH, 2005, MOL CANCER THER, V4, P233; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; York IA, 1999, IMMUNOL REV, V172, P49, DOI 10.1111/j.1600-065X.1999.tb01355.x; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhang C, 2001, BIOCHEM BIOPH RES CO, V289, P718, DOI 10.1006/bbrc.2001.6044; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	73	28	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18734	18745		10.1074/jbc.M511983200	http://dx.doi.org/10.1074/jbc.M511983200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16613840	hybrid			2022-12-25	WOS:000238687300054
J	Foglietti, C; Filocamo, G; Cundari, E; De Rinaldis, E; Lahm, A; Cortese, R; Steinkuhler, C				Foglietti, Cristiana; Filocamo, Gessica; Cundari, Enrico; De Rinaldis, Emanuele; Lahm, Armin; Cortese, Riccardo; Steinkuhler, Christian			Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR; APOPTOSIS; COMPLEX; SMRTER; HDAC6; ACT	Zinc-dependent histone deacetylases (HDACs) are a family of hydrolases first identified as components of transcriptional repressor complexes, where they act by deacetylating lysine residues at the N-terminal extensions of core histones, thereby affecting transcription. To get more insight into the biological functions of the individual HDAC family members, we have used RNA interference in combination with microarray analysis in Drosophila S2 cells. Silencing of Drosophila HDAC1 (DHDAC1), but not of the other DHDAC family members, leads to increased histone acetylation. Silencing of either DHDAC1 or DHDAC3 leads to cell growth inhibition and deregulated transcription of both common and distinct groups of genes. Silencing DHDAC2 leads to increased tubulin acetylation levels but was not associated with a deregulation of gene expression. No growth of phenotype and no significant deregulation of gene expression was observed upon silencing of DHDAC4 and DHDACX. Loss of DHDAC1 or exposure of S2 cells to the small molecule HDAC inhibitor trichostatin both lead to a G(2) arrest and were associated with significantly overlapping gene expression signatures in which genes involved in nucleobase and lipid metabolism, DNA replication, cell cycle regulation, and signal transduction were over-represented. A large number of these genes were shown to also be deregulated upon loss of the co-repressor SIN3 (Pile, L. A., Spellman, P. T., Katzenberger, R.J., and Wassarman, D. A. (2003) J. Biol. Chem. 278, 37840-37848). We conclude the following. 1) DHDAC1 and -3 have distinct functions in the control of gene expression. 2) Under the tested conditions, DHDAC2, -4, and X have no detectable transcriptional functions in S2 cells. 3) The anti-proliferative and transcriptional effects of trichostatin are largely recapitulated by the loss of DHDAC1. 4) The deacetylase activity of DHDAC1 significantly contributes to the repressor function of SIN3.	IRBM Ist Ric Biom Mol P Angeletti, Merck Res Labs Rome, I-00040 Pomezia, Italy; CNR, I-00185 Rome, Italy	Merck & Company; Consiglio Nazionale delle Ricerche (CNR)	Steinkuhler, C (corresponding author), IRBM Ist Ric Biom Mol P Angeletti, Merck Res Labs Rome, Via Pontina Km 30,600, I-00040 Pomezia, Italy.	Christian_Steinkuhler@Merck.Com						Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cho YS, 2005, GENOMICS, V86, P606, DOI 10.1016/j.ygeno.2005.07.007; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; COHEN T, 2004, SCI STKE, pPE42; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Freitag M, 2005, CURR OPIN GENET DEV, V15, P191, DOI 10.1016/j.gde.2005.02.003; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Glaser KB, 2003, MOL CANCER THER, V2, P151; Greene Warner C, 2004, Novartis Found Symp, V259, P208; Gu Wei, 2004, Novartis Found Symp, V259, P197; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lee H, 2004, MOL CELL BIOL, V24, P765, DOI 10.1128/MCB.24.2.765-773.2004; Louis M, 2004, INT J ONCOL, V25, P1701; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Nathan D, 2003, P NATL ACAD SCI USA, V100, P13118, DOI 10.1073/pnas.2436173100; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Ott Melanie, 2004, Novartis Found Symp, V259, P182; Pile LA, 2003, J BIOL CHEM, V278, P37840, DOI 10.1074/jbc.M305996200; Pile LA, 2002, MOL CELL BIOL, V22, P4965, DOI 10.1128/MCB.22.14.4965-4976.2002; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Rosato RR, 2005, EXPERT OPIN THER TAR, V9, P809, DOI 10.1517/14728222.9.4.809; Rosato RR, 2003, CANCER RES, V63, P3637; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tsai CC, 1999, MOL CELL, V4, P175, DOI 10.1016/S1097-2765(00)80365-2; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Waltregny D, 2005, FASEB J, V19, P966, DOI 10.1096/fj.04-2303fje; Wang HE, 2005, BIOCHEM PHARMACOL, V69, P617, DOI 10.1016/j.bcp.2004.11.006; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Yang Y, 2003, NOVON, V13, P153, DOI 10.2307/3393581; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	49	80	83	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17968	17976		10.1074/jbc.M511945200	http://dx.doi.org/10.1074/jbc.M511945200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16632473	hybrid			2022-12-25	WOS:000238490300047
J	Liu, M; Aneja, R; Liu, CY; Sun, L; Gao, JM; Wang, HX; Dong, JT; Sarli, V; Giannis, A; Joshi, HC; Zhou, J				Liu, Min; Aneja, Ritu; Liu, Chunyong; Sun, Lei; Gao, Jinmin; Wang, Hongxia; Dong, Jin-Tang; Sarli, Vasiliki; Giannis, Athanassios; Joshi, Harish C.; Zhou, Jun			Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; SPINDLE ASSEMBLY CHECKPOINT; SMALL-MOLECULE INHIBITOR; HEAT-SHOCK PROTEINS; CANCER-CELLS; CONFERS RESISTANCE; APAF-1 APOPTOSOME; MOTOR PROTEINS; FACTOR-I; HEAT-SHOCK-PROTEIN-70	The microtubule-dependent motor protein Eg5 plays a critical role in spindle assembly and maintenance in mitosis. Herein we show that the suppression of Eg5 by a specific inhibitor arrested mitosis, induced apoptosis, and up-regulated Hsp70 in human multiple myeloma cells. Mechanistically, Hsp70 induction occurred at the transcriptional level via a cis-regulatory DNA element in Hsp70 promoter and was mediated by the phosphatidylinositol 3-kinase/Akt pathway. Eg5 inhibitor-mediated Hsp70 up-regulation is cyto-protective because blocking Hsp70 induction directly by antisense or small interfering RNA or indirectly by inhibiting the phosphatidylinositol 3-kinase/Akt pathway significantly increased Eg5 inhibitor-induced apoptosis. Furthermore, a farnesyltransferase inhibitor interacted synergistically with the Eg5 inhibitor in inducing apoptosis through disrupting the Akt/Hsp70 signaling axis. These findings provide the first evidence for Eg5 inhibitor activity in hematologic malignancy and identify Hsp70 up-regulation as a critical mechanism responsible for modulating myeloma cell sensitivity to Eg5 inhibitors. In addition, these findings suggest that a combination of Eg5 inhibitors with agents abrogating Hsp70 induction would be useful for myeloma therapy in the clinic.	Nankai Univ, Coll Life Sci, Dept Genet & Cell Biol, Tianjin 300071, Peoples R China; Nankai Univ, Coll Life Sci, Minist Educ, Key Lab Bioact Mat, Tianjin 300071, Peoples R China; Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Hematol & Oncol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Univ Leipzig, Inst Organ Chem, D-04103 Leipzig, Germany	Nankai University; Nankai University; Emory University; Emory University; Emory University; Leipzig University	Zhou, J (corresponding author), Nankai Univ, Coll Life Sci, Dept Genet & Cell Biol, 94 Weijin Rd, Tianjin 300071, Peoples R China.	junzhou@nankai.edu.cn	Sun, Lei/N-4783-2018; Zhou, Jun/D-4654-2017; Sarli, Vasiliki C/F-1121-2011; Wang, Hongxia/D-8812-2014; Gao, Jinmin/J-8967-2015	Zhou, Jun/0000-0001-7858-8260; Dong, Jin-Tang/0000-0003-2349-5782; Sarli, Vasiliki/0000-0002-6128-8277; Gao, Jinmin/0000-0002-5894-6515				Aneja R, 2006, BLOOD, V107, P2486, DOI 10.1182/blood-2005-08-3516; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Checchi PM, 2003, TRENDS PHARMACOL SCI, V24, P361, DOI 10.1016/S0165-6147(03)00161-5; CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X; Du W, 1999, CANCER RES, V59, P4208; Duhl DM, 2005, CURR OPIN DRUG DISC, V8, P431; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Gabai VL, 2005, ONCOGENE, V24, P3328, DOI 10.1038/sj.onc.1208495; Gartner M, 2005, CHEMBIOCHEM, V6, P1173, DOI 10.1002/cbic.200500005; Gehrmann M, 2002, BIOL CHEM, V383, P1715, DOI 10.1515/BC.2002.192; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; Hotha S, 2003, ANGEW CHEM INT EDIT, V42, P2379, DOI 10.1002/anie.200351173; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Hung JJ, 1998, J BIOL CHEM, V273, P31924, DOI 10.1074/jbc.273.48.31924; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Kim HP, 2005, J IMMUNOL, V175, P2622, DOI 10.4049/jimmunol.175.4.2622; Kim HS, 2005, FASEB J, V19, P1042, DOI 10.1096/fj.04-2841fje; Lee YJ, 1998, J BIOL CHEM, V273, P29857, DOI 10.1074/jbc.273.45.29857; Lobert S, 1997, Crit Care Nurse, V17, P71; Madamanchi NR, 2001, J BIOL CHEM, V276, P18915, DOI 10.1074/jbc.M008802200; Marcus AI, 2005, J BIOL CHEM, V280, P11569, DOI 10.1074/jbc.M413471200; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; Nylandsted J, 2000, ANN NY ACAD SCI, V926, P122; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ray S, 2004, J BIOL CHEM, V279, P35604, DOI 10.1074/jbc.M401851200; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Rowinsky EK, 1997, ANNU REV MED, V48, P353; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Tao WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Zhou J, 2002, J BIOL CHEM, V277, P17200, DOI 10.1074/jbc.M110369200; Zhou J, 2006, CANCER RES, V66, P445, DOI 10.1158/0008-5472.CAN-05-1779; Zhou J, 2004, CANCER RES, V64, P8708, DOI 10.1158/0008-5472.CAN-04-2538; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200; Zhou J, 2002, J CELL SCI, V115, P3547, DOI 10.1242/jcs.00029; Zhou Jun, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P65, DOI 10.2174/1568011053352569; Zhu Kuichun, 2003, Curr Opin Investig Drugs, V4, P1428	48	40	58	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18090	18097		10.1074/jbc.M601324200	http://dx.doi.org/10.1074/jbc.M601324200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16627469	hybrid			2022-12-25	WOS:000238490300060
J	McCauslin, CS; Heath, V; Colangelo, AM; Malik, R; Lee, S; Mallei, A; Mocchetti, I; Johnson, PF				McCauslin, Christine Seitz; Heath, Victoria; Colangelo, Anna Maria; Malik, Radek; Lee, Sook; Mallei, Alessandra; Mocchetti, Italo; Johnson, Peter F.			CAAT/enhancer-binding protein delta and cAMP-response element-binding protein mediate inducible expression of the nerve growth factor gene in the central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C6-2B GLIOMA-CELLS; C/EBP-BETA; RAT HIPPOCAMPUS; TRANSCRIPTION FACTORS; FACTOR BIOSYNTHESIS; MESSENGER-RNA; IN-VITRO; AGONIST CLENBUTEROL; ALZHEIMERS-DISEASE; ISCHEMIC DAMAGE	Nerve growth factor (NGF) synthesis in the rat cerebral cortex is induced by the beta 2-adrenergic receptor agonist clenbuterol (CLE). Because NGF is a crucial neurotrophic factor for basal forebrain cholinergic neurons, defining the mechanisms that regulate its transcription is important for developing therapeutic strategies to treat pathologies of these neurons. We previously showed that the transcription factor CCAAT/enhancer-binding protein delta(C/EBP delta) contributes to NGF gene regulation. Here we have further defined the function of C/EBP delta and identified a role for cAMP response element- binding protein ( CREB) in NGF transcription. Inhibition of protein kinase A in C6-2B glioma cells suppressed CLE induction of an NGF promoter-reporter construct, whereas overexpression of protein kinase A increased NGF promoter activity, particularly in combination with C/EBP delta. A CRE-like site that binds CREB was identified in the proximal NGF promoter, and C/EBP delta and CREB were found to associate with the NGF promoter in vivo. Deletion of the CRE and/or C/EBP sites reduced CLE responsiveness of the promoter. In addition, ectopic expression of C/EBP delta in combination with CLE treatment increased endogenous NGF mRNA levels in C6-2B cells. C/EBP delta null mice showed complete loss of NGF induction in the cerebral cortex following CLE treatment, demonstrating a critical role for C/EBP delta in regulating beta 2-adrenergic receptor-mediated NGF expression in vivo. Thus, our findings demonstrate a critical role for C/EBP delta in regional expression of NGF in the brain and implicate CREB in CLE-induced NGF gene transcription.	NCI, Lab Prot Dynam & Signaling, NIH, Ft Detrick, MD 21702 USA; Georgetown Univ, Ctr Med, Dept Neurosci, Washington, DC 20057 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University	Johnson, PF (corresponding author), NCI, Lab Prot Dynam & Signaling, NIH, Bldg 539,Rm 122,POB B, Ft Detrick, MD 21702 USA.	johnsopf@ncifcrf.gov	Colangelo, Anna Maria AM/Q-3597-2017; Malik, Radek/G-3578-2014; Johnson, Peter/A-1940-2012	Colangelo, Anna Maria AM/0000-0002-7971-4289; Malik, Radek/0000-0002-6783-1146; Mallei, Alessandra/0000-0001-6955-4755; Johnson, Peter/0000-0002-4145-4725	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029664] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NINDS NIH HHS [NS 29664] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALOE L, 1989, P NATL ACAD SCI USA, V86, P5636, DOI 10.1073/pnas.86.14.5636; Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; BERZAGHI MD, 1993, J NEUROSCI, V13, P3818; Chen YC, 2003, MOL CELL BIOL, V23, P4066, DOI 10.1128/MCB.23.12.4066-4082.2003; Colangelo AM, 1996, MOL BRAIN RES, V35, P1, DOI 10.1016/0169-328X(95)00171-N; Colangelo AM, 1998, P NATL ACAD SCI USA, V95, P10920, DOI 10.1073/pnas.95.18.10920; Colangelo AM, 1998, MOL BRAIN RES, V53, P218, DOI 10.1016/S0169-328X(97)00296-9; COLANGELO AM, 1994, GLIA, V12, P117, DOI 10.1002/glia.440120205; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; Culmsee C, 1999, EUR J PHARMACOL, V379, P33, DOI 10.1016/S0014-2999(99)00452-5; Culmsee C, 1999, NEUROCHEM INT, V35, P47, DOI 10.1016/S0197-0186(99)00032-7; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; FABRAZZO M, 1991, MOL PHARMACOL, V39, P144; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; Howe CL, 2001, NEUROBIOLOGY NEUROTR; IntroiniCollison IB, 1996, NEUROBIOL LEARN MEM, V65, P57, DOI 10.1006/nlme.1996.0006; Ji CH, 2003, MOL ENDOCRINOL, V17, P1834, DOI 10.1210/me.2002-0235; Jonhagen ME, 1998, DEMENT GERIATR COGN, V9, P246, DOI 10.1159/000017069; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KOLIATSOS V, 1998, NEUROTROPHIC FACTORS, P545; KUO CF, 1990, DEVELOPMENT, V109, P473; LI YC, 1994, GENE, V138, P257, DOI 10.1016/0378-1119(94)90819-2; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mabuchi T, 2001, J NEUROSCI, V21, P9204, DOI 10.1523/JNEUROSCI.21-23-09204.2001; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Menard C, 2002, NEURON, V36, P597, DOI 10.1016/S0896-6273(02)01026-7; MINNEMAN KP, 1981, ANNU REV NEUROSCI, V4, P419, DOI 10.1146/annurev.ne.04.030181.002223; MOCCHETTI I, 1989, P NATL ACAD SCI USA, V86, P3891, DOI 10.1073/pnas.86.10.3891; Mocchetti I, 2001, NEUROBIOLOGY NEUROTR, P631; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; SEEGERT D, 1994, J BIOL CHEM, V269, P8590; SEILER M, 1984, BRAIN RES, V300, P33, DOI 10.1016/0006-8993(84)91338-6; Semkova I, 1996, BRAIN RES, V717, P44, DOI 10.1016/0006-8993(95)01567-1; Sterneck E, 1998, P NATL ACAD SCI USA, V95, P10908, DOI 10.1073/pnas.95.18.10908; Sterneck E, 1998, J NEUROCHEM, V70, P2424; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; SUN FY, 1993, NEUROPSYCHOPHARMACOL, V8, P219, DOI 10.1038/npp.1993.24; Tao X, 2002, NEURON, V33, P383, DOI 10.1016/S0896-6273(01)00561-X; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Taubenfeld SM, 2001, J NEUROSCI, V21, P84, DOI 10.1523/JNEUROSCI.21-01-00084.2001; VOS P, 1987, J PHARMACOL EXP THER, V242, P707; Wedel A, 1996, CYTOKINE, V8, P335, DOI 10.1006/cyto.1996.0046; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yukawa K, 1998, J BIOL CHEM, V273, P31345, DOI 10.1074/jbc.273.47.31345; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	54	43	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17681	17688		10.1074/jbc.M600207200	http://dx.doi.org/10.1074/jbc.M600207200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16632469	hybrid			2022-12-25	WOS:000238490300017
J	Seo, HR; Chung, DY; Lee, YJ; Lee, DH; Kim, JI; Bae, S; Chung, HY; Lee, SJ; Jeoung, D; Lee, YS				Seo, Haeng Ran; Chung, Da-Yeon; Lee, Yoon-Jin; Lee, Dae-Hoon; Kim, Jong-Il; Bae, Sangwoo; Chung, Hee-Yong; Lee, Su-Jae; Jeoung, Dooil; Lee, Yun-Sil			Heat shock protein 25 or inducible heat shock protein 70 activates heat shock factor 1 - Dephosphorylation on serine 307 through inhibition of ERK1/2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; PROTEIN GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; MOLECULAR CHAPERONES; DNA-BINDING; FACTOR HSF1; FACTOR-I; STRESS; CELLS; PHOSPHATASE-1	The expression of heat shock proteins (HSPs) is known to be increased via activation of heat shock factor 1 (HSF1), and excess expression of HSPs exerts feedback inhibition of HSF1. However, the molecular mechanism to modulate such relationships between HSPs and HSF1 is not clear. In the present study, we show that stable transfection of either Hsp25 or inducible Hsp70 (Hsp70i) increased expression of endogenous HSPs such as HSP25 and HSP70i through HSF1 activation. However, these phenomena were abolished when the dominant negative Hsf1 mutant was transfected to HSP25 or HSP70i overexpressed cells. Moreover, the increased HSF1 activity by either HSP25 or HSP70i was found to result from dephosphorylation of HSF1 on serine 307 that increased the stability of HSF1. Either HSP25 or HSP70i inhibited ERK1/2 phosphorylation because of increased MKP1 phosphorylation by direct interaction of these HSPs with MKP1. Treatment of HOS and NCI-H358 cells, which showed high expressions of endogenous HSF1, with small interfering RNA (siRNA) of either HSP27(siHSP27) or HSP70i (siHSP70i) inhibited both HSP27 and HSP70i proteins; this was because of increased ERK1/2 phosphorylation and serine phosphorylation of HSF1. The results, therefore, suggested that when the HSF1 protein level was high in cancer cells, excess expression of HSP27 or HSP70i strongly facilitates the expression of HSP proteins through HSF1 activation, resulting in severe radio- or chemoresistance.	Korea Inst Radiol & Med Sci, Lab Radiat Effect, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Radiat Expt Therapeut, Seoul 139706, South Korea; Seoul Womens Univ, Coll Nat Sci, Dept Food & Microbial Technol, Seoul 139774, South Korea; Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea; Seegene Inc, Seoul 138050, South Korea; Kangwon Natl Univ, Coll Nat Sci, Div Life Sci, Chunchon 200701, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Seoul Women's University; Hanyang University; Kangwon National University	Lee, YS (corresponding author), 215-4 Gongneung Dong, Seoul 139706, South Korea.	yslee@kcch.re.kr	Lee, Yun-Sil/AAP-1378-2020	Lee, Yun-Sil/0000-0002-7538-8850; Chung, Hee Yong/0000-0001-7580-0537				Ahn JY, 2005, NUCLEIC ACIDS RES, V33, P3751, DOI 10.1093/nar/gki692; Boellmann F, 2004, P NATL ACAD SCI USA, V101, P4100, DOI 10.1073/pnas.0304768101; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200; Fink JK, 1999, SEMIN NEUROL, V19, P301, DOI 10.1055/s-2008-1040846; Garrido C, 1998, CANCER RES, V58, P5495; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Lee KH, 2005, J BIOL CHEM, V280, P13179, DOI 10.1074/jbc.M410059200; Lee YJ, 2002, RADIAT RES, V157, P371, DOI 10.1667/0033-7587(2002)157[0371:IOARBL]2.0.CO;2; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MIVECHI NF, 1995, CANCER RES, V55, P5512; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Morimoto RI, 1997, ESSAYS BIOCHEM, V32, P17; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pirkkala L, 2000, MOL CELL BIOL, V20, P2670, DOI 10.1128/MCB.20.8.2670-2675.2000; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; Sohaskey ML, 2002, MOL BIOL CELL, V13, P454, DOI 10.1091/mbc.01-11-0553; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1998, J BIOL CHEM, V273, P8749, DOI 10.1074/jbc.273.15.8749; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	33	32	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17220	17227		10.1074/jbc.M600062200	http://dx.doi.org/10.1074/jbc.M600062200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16624816	hybrid			2022-12-25	WOS:000238326300048
J	Tsai, KL; Huang, CY; Chang, CH; Sun, YJ; Chuang, WJ; Hsiao, CD				Tsai, Kuang-Lei; Huang, Cheng-Yang; Chang, Chia-Hao; Sun, Yuh-Ju; Chuang, Woei-Jer; Hsiao, Chwan-Deng			Crystal structure of the human FOXK1a-DNA complex and its implications on the diverse binding specificity of winged helix/forkhead proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; HELIX PROTEINS; PHOSPHATE NEUTRALIZATION; TRANSCRIPTION FACTORS; DOMAIN; RECOGNITION; ADJACENT; FACTOR-3; SEQUENCE; CLONING	Interleukin enhancer binding factor (ILF) is a human transcription factor and a new member of the winged helix/forkhead family. ILF can bind to purine-rich regulatory motifs such as the human T-cell leukemia virus-long terminal region and the interleukin-2 promoter. Here we report the 2.4 A crystal structure of two DNA binding domains of ILF (FOXK1a) binding to a 16-bp DNA duplex containing a promoter sequence. Electrophoretic mobility shift assay studies demonstrate that two ILF-DNA binding domain molecules cooperatively bind to DNA. In addition to the recognition helix recognizing the core sequences through the major groove, the structure shows that wing 1 interacts with the minor groove of DNA, and the H2-H3 loop region makes ionic bonds to the phosphate group, which permits the recognition of DNA. The structure also reveals that the presence of the C-terminal alpha-helix in place of a typical wing 2 in a member of this family alters the orientation of the C-terminal basic residues (RKRRPR) when binding to DNA outside the core sequence. These results provide a new insight into how the DNA binding specificities of winged helix/forkhead proteins may be regulated by their less conserved regions.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 300, Taiwan; Natl Cheng Kung Univ, Dept Biochem, Coll Med, Tainan 701, Taiwan	Academia Sinica - Taiwan; National Tsing Hua University; National Cheng Kung University	Chuang, WJ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	wjcnmr@mail.ncku.edu.tw	Hsiao, Chwan-Deng/AAZ-8869-2021; Hsiao, Chwan-Deng/D-7327-2013	Hsiao, Chwan-Deng/0000-0002-7012-1532; 				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buaas FW, 1999, MAMM GENOME, V10, P451, DOI 10.1007/s003359901022; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DeLano WL, 2002, PYMOL USERS MANUAL; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Granadino B., 2000, Current Genomics, V1, P353, DOI 10.2174/1389202003351319; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; Jin CW, 1999, J MOL BIOL, V292, P641, DOI 10.1006/jmbi.1999.3106; Jin CW, 1999, J MOL BIOL, V289, P683, DOI 10.1006/jmbi.1999.2819; Kaestner KH, 2000, GENE DEV, V14, P142; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LI C, 1992, GENOMICS, V13, P665, DOI 10.1016/0888-7543(92)90139-J; LI C, 1991, P NATL ACAD SCI USA, V88, P7739, DOI 10.1073/pnas.88.17.7739; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Liu PP, 2002, PROTEINS, V49, P543, DOI 10.1002/prot.10227; Luscombe NM, 2000, GENOME BIOL, V1; Marsden I, 1997, BIOCHEMISTRY-US, V36, P13248, DOI 10.1021/bi971514m; Marsden I, 1998, J MOL BIOL, V278, P293, DOI 10.1006/jmbi.1998.1703; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Nirula A, 1997, J BIOL CHEM, V272, P7736, DOI 10.1074/jbc.272.12.7736; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; Saleem RA, 2003, HUM MOL GENET, V12, P2993, DOI 10.1093/hmg/ddg324; Sheng WY, 2002, BIOCHEMISTRY-US, V41, P3286, DOI 10.1021/bi011908k; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; Strauss-Soukup JK, 1998, BIOPHYS CHEM, V72, P297, DOI 10.1016/S0301-4622(98)00112-4; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; van Dongen MJP, 2000, J MOL BIOL, V296, P351, DOI 10.1006/jmbi.1999.3476; Weigelt J, 2001, BIOCHEMISTRY-US, V40, P5861, DOI 10.1021/bi001663w; Yang Q, 1997, MOL CELL BIOL, V17, P5236, DOI 10.1128/MCB.17.9.5236	38	55	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17400	17409		10.1074/jbc.M600478200	http://dx.doi.org/10.1074/jbc.M600478200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16624804	hybrid			2022-12-25	WOS:000238326300066
J	Wines, BD; Trist, HM; Ramsland, PA; Hogarth, PM				Wines, Bruce D.; Trist, Halina M.; Ramsland, Paul A.; Hogarth, P. Mark			A common site of the Fc receptor gamma subunit interacts with the unrelated immunoreceptors Fc alpha RI and Fc epsilon RI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPANNING LEUCINE-ZIPPER; AFFINITY IGE RECEPTOR; T-CELL-RECEPTOR; SURFACE EXPRESSION; TRANSMEMBRANE DOMAINS; COLLAGEN RECEPTOR; GLYCOPROTEIN VI; HUMAN PLATELETS; CHAIN; ASSOCIATION	The transmembrane (TM) region of the Fc receptor-gamma (FcR gamma) chain is responsible for the association of this ubiquitous signal transduction subunit with many immunoreceptor ligand binding chains, making FcR gamma key to a number of leukocyte activities in immunity and disease. Some receptors contain a TM arginine residue that interacts with Asp-11 of the FcR gamma subunit, but otherwise the molecular basis for the FcR gamma subunit interactions is largely unknown. This study reports residues in the TM region of the FcR gamma subunit are important for association with the high affinity IgE receptor Fc epsilon RI and a leukocyte receptor cluster member, the IgA receptor Fc alpha RI. FcR gamma residue Leu-21 was essential for surface expression of Fc epsilon RI alpha/gamma(2) and Tyr-8, Leu-14, and Phe-15 contributed to expression. Likewise, detergent-stable FcR gamma association with Fc alpha RI was also dependent on Leu-14 and Leu-21 and in addition required residues Tyr-17, Tyr-25, and Cys-26. Modeling the TM regions of the FcR gamma dimer indicated these residues interacting with both Fc alpha RI and Fc epsilon RI are near the interface between the two FcR gamma TM helices. Furthermore, the FcR gamma residues interacting with Fc alpha RI form a leucine zipper-like interface with mutagenesis confirming a complementary interface comprising Fc alpha RI residues Leu-217, Leu-220, and Leu-224. The dependence of these two nonhomologous receptor interactions on FcR gamma Leu-14 and Leu-21 suggests that all the associated Fc receptors and the activating leukocyte receptor cluster members interact with this one site. Taken together these data provide a molecular basis for understanding how disparate receptor families assemble with the FcR gamma subunit.	Macfarlene Burnet Inst Med Res & Publ Hlth, Helen Macpherson Smith Trust Inflammatory Dis Lab, Melbourne, Vic 3084, Australia	Burnet Institute	Wines, BD (corresponding author), Macfarlene Burnet Inst Med Res & Publ Hlth, Helen Macpherson Smith Trust Inflammatory Dis Lab, Austin Hlth Campus,Studley Rd, Melbourne, Vic 3084, Australia.	b.wines@ari.unimelb.edu.au		Hogarth, Mark/0000-0002-0360-7890; Ramsland, Paul/0000-0002-2107-2738				Arase N, 1997, J EXP MED, V186, P1957, DOI 10.1084/jem.186.12.1957; Bakema JE, 2006, J IMMUNOL, V176, P3603, DOI 10.4049/jimmunol.176.6.3603; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; Bolliger L, 1999, J IMMUNOL, V163, P3867; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Call ME, 2005, ANNU REV IMMUNOL, V23, P101, DOI 10.1146/annurev.immunol.23.021704.115625; Cameron AJM, 2001, EUR J IMMUNOL, V31, P2718, DOI 10.1002/1521-4141(200109)31:9<2718::AID-IMMU2718>3.0.CO;2-7; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Feng JW, 2005, IMMUNITY, V22, P427, DOI 10.1016/j.immuni.2005.02.005; Garrity D, 2005, P NATL ACAD SCI USA, V102, P7641, DOI 10.1073/pnas.0502439102; Gurezka R, 2001, J BIOL CHEM, V276, P45580, DOI 10.1074/jbc.M105362200; Harrison PT, 1995, MOL MEMBR BIOL, V12, P309, DOI 10.3109/09687689509072432; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; JONES B, 1986, J IMMUNOL, V136, P348; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; Kanazawa N, 2004, IMMUNOBIOLOGY, V209, P179, DOI 10.1016/j.imbio.2004.03.004; Kanazawa N, 2003, J BIOL CHEM, V278, P32645, DOI 10.1074/jbc.M304226200; Kim MK, 2003, BLOOD, V101, P4479, DOI 10.1182/blood.V101.11.4479; KINET JP, 1985, BIOCHEMISTRY-US, V24, P7342, DOI 10.1021/bi00346a048; Krishnan S, 2003, J IMMUNOL, V170, P4189, DOI 10.4049/jimmunol.170.8.4189; Krishnan S, 2003, J IMMUNOL, V171, P3325, DOI 10.4049/jimmunol.171.7.3325; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MONTEIRO RC, 1992, J IMMUNOL, V148, P1764; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; MORTON HC, 1995, J BIOL CHEM, V270, P29781; Nakajima H, 1999, J IMMUNOL, V162, P5; Nolan GP, 1998, CURR OPIN BIOTECH, V9, P447, DOI 10.1016/S0958-1669(98)80027-X; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; QIAN DP, 1993, P NATL ACAD SCI USA, V90, P11875, DOI 10.1073/pnas.90.24.11875; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; Ruan WM, 2004, J BIOL CHEM, V279, P3273, DOI 10.1074/jbc.M309311200; Ruan WM, 2004, PROTEIN SCI, V13, P555, DOI 10.1110/ps.03357404; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; Tedla N, 2003, P NATL ACAD SCI USA, V100, P1174, DOI 10.1073/pnas.0337567100; Tedla N, 2002, AM J PATHOL, V160, P425, DOI 10.1016/S0002-9440(10)64861-4; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; van der Boog PJM, 2002, J IMMUNOL, V168, P1252, DOI 10.4049/jimmunol.168.3.1252; Volz A, 2001, IMMUNOL REV, V181, P39, DOI 10.1034/j.1600-065X.2001.1810103.x; Wines BD, 2004, J BIOL CHEM, V279, P26339, DOI 10.1074/jbc.M403684200	42	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17108	17113		10.1074/jbc.M601640200	http://dx.doi.org/10.1074/jbc.M601640200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16627486	hybrid			2022-12-25	WOS:000238326300034
J	Cavellan, E; Asp, P; Percipalle, P; Farrants, AKO				Cavellan, Erica; Asp, Patrik; Percipalle, Piergiorgio; Ostlund Farrants, Ann-Kristin			The WSTF-SNF2h chromatin remodeling complex interacts with several nuclear proteins in transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-I; MYB-BINDING-PROTEIN; III TRANSCRIPTION; WILLIAMS-SYNDROME; REPLICATION FOCI; GENE-EXPRESSION; RIBOSOMAL DNA; WSTF-ISWI; MYOSIN-I; RECEPTOR	The WSTF ( Williams syndrome transcription factor) protein is involved in vitamin D-mediated transcription and replication as a component of two distinct ATP-dependent chromatin remodeling complexes, WINAC and WICH, respectively. We show here that the WICH complex ( WSTF-SNF2h) interacts with several nuclear proteins as follows: Sf3b155/SAP155, RNA helicase II/Gu alpha, Myb-binding protein 1a, CSB, the proto-oncogene Dek, and nuclear myosin 1 in a large3-MDa assembly, B-WICH, during active transcription. B-WICH also contains RNAs, 45 S rRNA, 5 S rRNA, 7SL RNA, and traces of the U2 small nuclear RNA. The core proteins, WSTF, SNF2h, and nuclear myosin 1, are associated with the RNA polymerase III genes 5 S rRNA genes and 7SL, and post-transcriptional silencing of WSTF reduces the levels of these transcripts. Our results show that a WSTF-SNF2h assembly is involved in RNA polymerase III transcription, and we suggest that WSTF-SNF2h-NM1 forms a platform in transcription while providing chromatin remodeling.	Stockholm Univ, Arrhenius Labs E5, Dept Cell Biol, Wenner Gren Inst, SE-10691 Stockholm, Sweden; Karolinska Inst, SE-17177 Stockholm, Sweden	Stockholm University; Karolinska Institutet	Farrants, AKO (corresponding author), Stockholm Univ, Arrhenius Labs E5, Dept Cell Biol, Wenner Gren Inst, SE-10691 Stockholm, Sweden.	anki.ostlund@cellbio.su.se						Allard S, 2004, BBA-GENE STRUCT EXPR, V1677, P158, DOI 10.1016/j.bbaexp.2003.10.016; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Andrin C, 2004, J BIOL CHEM, V279, P25017, DOI 10.1074/jbc.M401805200; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Bachman N, 2005, GENE DEV, V19, P955, DOI 10.1101/gad.1299105; Badenhorst P, 2002, GENE DEV, V16, P3186, DOI 10.1101/gad.1032202; Barak O, 2003, EMBO J, V22, P6089, DOI 10.1093/emboj/cdg582; Boyd DC, 2000, GENE, V247, P33, DOI 10.1016/S0378-1119(00)00134-7; Bozhenok L, 2002, EMBO J, V21, P2231, DOI 10.1093/emboj/21.9.2231; Bradsher J, 2002, MOL CELL, V10, P819, DOI 10.1016/S1097-2765(02)00678-0; Corona DFV, 2004, BBA-GENE STRUCT EXPR, V1677, P113, DOI 10.1016/j.bbaexp.2003.09.018; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dirscherl SS, 2004, BIOCHEM CELL BIOL, V82, P482, DOI 10.1139/O04-044; Domitrovich AM, 2003, NUCLEIC ACIDS RES, V31, P2344, DOI 10.1093/nar/gkg331; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375; Fomproix N, 2004, EXP CELL RES, V294, P140, DOI 10.1016/j.yexcr.2003.10.028; Fujiki R, 2005, EMBO J, V24, P3881, DOI 10.1038/sj.emboj.7600853; Gallagher JEG, 2004, GENE DEV, V18, P2506, DOI 10.1101/gad.1226604; Gelbart ME, 2005, GENE DEV, V19, P942, DOI 10.1101/gad.1298905; Golas MM, 2003, SCIENCE, V300, P980, DOI 10.1126/science.1084155; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Hakimi MA, 2002, NATURE, V418, P994, DOI 10.1038/nature01024; Henning D, 2003, J BIOL CHEM, V278, P52307, DOI 10.1074/jbc.M310846200; Hirsch HA, 2004, MOL CELL BIOL, V24, P5989, DOI 10.1128/MCB.24.13.5989-5999.2004; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Hu P, 2003, MOL CELL, V12, P699, DOI 10.1016/j.molcel.2003.08.011; Jones LC, 2002, J BIOL CHEM, V277, P22515, DOI 10.1074/jbc.M200740200; Jones MH, 2000, GENOMICS, V63, P40, DOI 10.1006/geno.1999.6071; Kappes F, 2001, J BIOL CHEM, V276, P26317, DOI 10.1074/jbc.M100162200; Kato S, 2004, J STEROID BIOCHEM, V89-90, P173, DOI 10.1016/j.jsbmb.2004.03.100; Kinter M., 2000, PROTEIN SEQUENCING I, DOI 10.1002/0471721980; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Komura J, 2005, J BIOL CHEM, V280, P14530, DOI 10.1074/jbc.M500637200; Kramer A, 1999, J CELL BIOL, V145, P1355, DOI 10.1083/jcb.145.7.1355; Licht CL, 2003, AM J HUM GENET, V73, P1217, DOI 10.1086/380399; Lu XJ, 1998, GENOMICS, V54, P241, DOI 10.1006/geno.1998.5578; MacCallum DE, 2002, MOL BIOL CELL, V13, P25, DOI 10.1091/mbc.01-09-0441; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Mello JA, 2001, CURR OPIN GENET DEV, V11, P136, DOI 10.1016/S0959-437X(00)00170-2; Peoples RJ, 1998, CYTOGENET CELL GENET, V82, P238, DOI 10.1159/000015110; Percipalle P, 2006, EMBO REP, V7, P525, DOI 10.1038/sj.embor.7400657; Pestic-Dragovich L, 2000, SCIENCE, V290, P337, DOI 10.1126/science.290.5490.337; Philimonenko VV, 2004, NAT CELL BIOL, V6, P1165, DOI 10.1038/ncb1190; Poot RA, 2005, CELL CYCLE, V4, P543, DOI 10.4161/cc.4.4.1624; Poot RA, 2004, NAT CELL BIOL, V6, P1236, DOI 10.1038/ncb1196; Remboutsika E, 1999, J CELL SCI, V112, P1671; Santoro R, 2005, MOL CELL BIOL, V25, P2539, DOI 10.1128/MCB.25.7.2539-2546.2005; Sif S, 2004, J CELL BIOCHEM, V91, P1087, DOI 10.1002/jcb.20005; STUNKEL W, 1995, NUCLEIC ACIDS RES, V23, P109, DOI 10.1093/nar/23.1.109; Takahashi Y, 2000, GENE DEV, V14, P804; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Yang W, 2003, CELL CYCLE, V2, P120, DOI 10.4161/cc.2.2.329; Yang ZY, 2005, MOL CELL BIOL, V25, P241, DOI 10.1128/MCB.25.1.241-249.2005; Zhou YG, 2005, CURR BIOL, V15, P1434, DOI 10.1016/j.cub.2005.06.057	59	117	126	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16264	16271		10.1074/jbc.M600233200	http://dx.doi.org/10.1074/jbc.M600233200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16603771	hybrid			2022-12-25	WOS:000238165700012
J	Ni, Z; Okeley, NM; Smart, BP; Gelb, MH				Ni, Zhanglin; Okeley, Nicole M.; Smart, Brian P.; Gelb, Michael H.			Intracellular actions of group IIA secreted phospholipase A(2) and group IVA cytosolic phospholipase A(2) contribute to arachidonic acid release and prostaglandin production in rat gastric mucosal cells and transfected human embryonic kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-V; GROUP-X; SELECTIVE INHIBITOR; GROWTH-FACTOR; EXPRESSION; GENERATION; ENZYMES; POTENT; BIOSYNTHESIS; MICE	Gastric epithelial cells liberate prostaglandin E-2 in response to cytokines as part of the process of healing of gastric lesions. Treatment of the rat gastric epithelial cell line RGM1 with transforming growth factor-alpha and interleukin-1 beta leads to synergistic release of arachidonate and production of prostaglandin E-2. Results with highly specific and potent phospholipase A(2) inhibitors and with small interfering RNA show that cytosolic phospholipase A2-alpha and group IIA secreted phospholipase A(2) contribute to arachidonate release from cytokine-stimulated RGM1 cells. In the late phase of arachidonate release, group IIA secreted phospholipase A(2) is induced ( detected at the mRNA and protein levels), and the action of cytosolic phospholipase A(2)-alpha is required for this induction. Results with RGM1 cells and group IIA secreted phospholipase A(2)-transfected HEK293 cells show that the group IIA phospholipase acts prior to externalization from the cells. RGM1 cells also express group XIIA secreted phospholipase A(2), but this enzyme is not regulated by cytokines nor does it contribute to arachidonate release. The other eight secreted phospholipases A(2) were not detected in RGM1 cells at the mRNA level. These results clearly show that cytosolic and group IIA secreted phospholipases A(2) work together to liberate arachidonate from RGM1 cell phospholipids in response to cytokines.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.	gelb@chem.washington.edu	Ni, Zhanglin/E-5175-2010	gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [R01 HL050040, R01 HL050040-15, R01 HL036235-21, HL 50040, HL 36835, R01 HL036235] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040, R01HL036235] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiba S, 2000, BRIT J PHARMACOL, V131, P1004, DOI 10.1038/sj.bjp.0703637; Akiba S, 2001, J BIOL CHEM, V276, P21854, DOI 10.1074/jbc.M010201200; AKIBA S, 2001, PAF C TOK; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Bradley JD, 2005, J RHEUMATOL, V32, P417; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Hagishita S, 1996, J MED CHEM, V39, P3636, DOI 10.1021/jm960395q; Han WK, 2003, J BIOL CHEM, V278, P24153, DOI 10.1074/jbc.M300424200; Hirabayashi T, 2004, BIOL PHARM BULL, V27, P1168, DOI 10.1248/bpb.27.1168; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; Janssen MJW, 1999, BBA-MOL CELL BIOL L, V1440, P59, DOI 10.1016/S1388-1981(99)00122-5; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Kobayashi O, 1996, J GASTROEN HEPATOL, V11, P129, DOI 10.1111/j.1440-1746.1996.tb00049.x; Kuwata H, 2005, J BIOL CHEM, V280, P25830, DOI 10.1074/jbc.M500168200; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MCKEW JC, 2004, Patent No. 6797708; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 2002, J BIOL CHEM, V277, P19145, DOI 10.1074/jbc.M112385200; Nevalainen TJ, 2000, BBA-MOL CELL BIOL L, V1488, P83, DOI 10.1016/S1388-1981(00)00112-8; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; ROBERT A, 1979, GASTROENTEROLOGY, V77, P433; Rubin BB, 2005, J BIOL CHEM, V280, P7519, DOI 10.1074/jbc.M407438200; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Seno K, 2001, BIOORG MED CHEM LETT, V11, P587, DOI 10.1016/S0960-894X(01)00003-8; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Snyder DW, 1999, J PHARMACOL EXP THER, V288, P1117; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Wong DA, 2002, J EXP MED, V196, P349, DOI 10.1084/jem.20011443; Zeiher BG, 2005, CRIT CARE MED, V33, P1741, DOI 10.1097/01.CCM.0000171540.54520.69	35	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16245	16255		10.1074/jbc.M513874200	http://dx.doi.org/10.1074/jbc.M513874200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16603549	Green Accepted, hybrid			2022-12-25	WOS:000238165700010
J	Salako, MA; Carter, MJ; Kass, GEN				Salako, Michael A.; Carter, Michael J.; Kass, George E. N.			Coxsackievirus protein 2BC blocks host cell apoptosis by inhibiting caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLIOVIRUS-INFECTED CELLS; CYTOCHROME-C RELEASE; ENDOPLASMIC-RETICULUM; MEDIATED APOPTOSIS; STRUCTURAL BASIS; SEQUENCE ALIGNMENT; GENE-EXPRESSION; DEATH; ACTIVATION; MECHANISMS	Virus infection may induce host cell death by apoptosis, but some DNA viruses are capable of preventing this process. RNA viruses were thought not to display anti-apoptotic activities, as their spread appears to benefit from a rapid induction of cell death. Here, we report an anti-apoptotic activity in the Picornavirus Coxsackievirus B4(CVB4). CVB4 infection of HeLa cells induced negligible apoptosis over a period of 10 h. However, infected cells developed resistance to drug-induced apoptosis using staurosporine and actinomycin D and to death receptor-induced apoptosis using tumor necrosis factor-related apoptosis-inducing ligand. Despite this resistance, the apoptotic machinery was nonetheless fully activated in these drug-treated infected cells because the levels of pro-caspase-3 processing to its active form were similar to control cells. However, the DEVDase ( Asp-Glu-Val-Asp protease) activity of the processed caspase was significantly inhibited in the virus-infected staurosporine-treated cells compared with drug treatment alone. Likewise, extracts of CVB4-infected cells suppressed recombinant caspase-3 activity in vitro. Immunoprecipitation of activated caspase-3 from radiolabeled virus-infected cells revealed the co-precipitation of a 48-kDa protein that was tentatively identified as viral protein 2BC. Recombinant caspase-3 was found to co-precipitate with virus protein 2BC. Finally, when protein 2BC was expressed in HeLa cells, both staurosporine-induced apoptosis and in vitro caspase-3 DEVDase activity were significantly reduced. Taken together these data imply that CVB4 infection suppresses apoptosis through virus protein 2BC associating with caspase-3 and inhibiting its function. Thus, 2BC is the first reported RNA virus inhibitor of apoptosis protein.	Univ Surrey, Sch Biomed & Mol Sci, Guildford GU2 7XH, Surrey, England	University of Surrey	Kass, GEN (corresponding author), Univ Surrey, Sch Biomed & Mol Sci, Guildford GU2 7XH, Surrey, England.	g.kass@surrey.ac.uk	Kass, George/T-8520-2017	Kass, George/0000-0002-3343-5276				Agol VI, 2000, J VIROL, V74, P5534, DOI 10.1128/JVI.74.12.5534-5541.2000; Agol VI, 1998, VIROLOGY, V252, P343, DOI 10.1006/viro.1998.9438; ALDABE R, 1995, BIOCHEM BIOPH RES CO, V206, P64, DOI 10.1006/bbrc.1995.1010; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Banerjee R, 2004, J VIROL, V78, P9243, DOI 10.1128/JVI.78.17.9243-9256.2004; Barco A, 1998, J VIROL, V72, P3560, DOI 10.1128/JVI.72.5.3560-3570.1998; Barry M, 1998, CURR OPIN IMMUNOL, V10, P422, DOI 10.1016/S0952-7915(98)80116-7; Belov GA, 2003, J VIROL, V77, P45, DOI 10.1128/JVI.77.1.45-56.2003; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Bowles NE, 2003, CURR OPIN CARDIOL, V18, P182, DOI 10.1097/00001573-200305000-00002; Calandria C, 2004, VIRUS RES, V104, P39, DOI 10.1016/j.virusres.2004.02.042; Campanella M, 2004, J BIOL CHEM, V279, P18440, DOI 10.1074/jbc.M309494200; Carthy CM, 2003, VIROLOGY, V313, P147, DOI 10.1016/S0042-6822(03)00242-3; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Elphick LM, 2006, ANAL BIOCHEM, V349, P148, DOI 10.1016/j.ab.2005.11.031; Feuer R, 2004, MED MICROBIOL IMMUN, V193, P83, DOI 10.1007/s00430-003-0192-z; Feuer R, 2003, AM J PATHOL, V163, P1379, DOI 10.1016/S0002-9440(10)63496-7; Gosselin AS, 2003, J VIROL, V77, P790, DOI 10.1128/JVI.77.1.790-798.2003; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Huber S, 2004, VIRAL IMMUNOL, V17, P358, DOI 10.1089/vim.2004.17.358; JENKINS O, 1987, J GEN VIROL, V68, P1835, DOI 10.1099/0022-1317-68-7-1835; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Jones RA, 1998, HEPATOLOGY, V27, P1632, DOI 10.1002/hep.510270624; Joo CH, 2002, NEUROSCI LETT, V326, P175, DOI 10.1016/S0304-3940(02)00340-3; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Koyama AH, 2001, J GEN VIROL, V82, P2965, DOI 10.1099/0022-1317-82-12-2965; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Macanas-Pirard P, 2005, J PHARMACOL EXP THER, V313, P780, DOI 10.1124/jpet.104.081364; Moffat K, 2005, J VIROL, V79, P4382, DOI 10.1128/JVI.79.7.4382-4395.2005; Morgenstern B, 1996, P NATL ACAD SCI USA, V93, P12098, DOI 10.1073/pnas.93.22.12098; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Rasilainen S, 2004, J MED VIROL, V72, P586, DOI 10.1002/jmv.20043; Rasilainen S, 2004, J MED VIROL, V72, P451, DOI 10.1002/jmv.20003; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roberts LO, 2000, J GEN VIROL, V81, P1703, DOI 10.1099/0022-1317-81-7-1703; Romanova LI, 2005, VIROLOGY, V331, P292, DOI 10.1016/j.virol.2004.10.038; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Sanfilippo CM, 2004, J VIROL, V78, P224, DOI 10.1128/JVI.78.1.224-239.2004; Saraste A, 2003, CARDIOVASC PATHOL, V12, P255, DOI 10.1016/S1054-8807(03)00077-2; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shiozaki EN, 2004, TRENDS BIOCHEM SCI, V29, P486, DOI 10.1016/j.tibs.2004.07.003; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOLSKAYA EA, 1995, J VIROL, V69, P1181, DOI 10.1128/JVI.69.2.1181-1189.1995; Tran SEF, 2004, TRENDS BIOCHEM SCI, V29, P601, DOI 10.1016/j.tibs.2004.09.009; van Kuppeveld FJM, 2005, TRENDS MICROBIOL, V13, P41, DOI 10.1016/j.tim.2004.12.005; Wessely R, 2004, MED MICROBIOL IMMUN, V193, P71, DOI 10.1007/s00430-003-0203-0; Whitton JL, 2004, AUTOIMMUNITY, V37, P375, DOI 10.1080/08916930410001713089; Yuan J, 2005, CELL DEATH DIFFER, V12, P1097, DOI 10.1038/sj.cdd.4401652; Zhang HM, 2002, CIRC RES, V90, P1251, DOI 10.1161/01.RES.0000024690.69379.5C	62	16	18	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16296	16304		10.1074/jbc.M510662200	http://dx.doi.org/10.1074/jbc.M510662200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16608851	hybrid			2022-12-25	WOS:000238165700016
J	Soga, T; Baran, R; Suematsu, M; Ueno, Y; Ikeda, S; Sakurakawa, T; Kakazu, Y; Ishikawa, T; Robert, M; Nishioka, T; Tomita, M				Soga, Tomoyoshi; Baran, Richard; Suematsu, Makoto; Ueno, Yuki; Ikeda, Satsuki; Sakurakawa, Tadayuki; Kakazu, Yuji; Ishikawa, Takamasa; Robert, Martin; Nishioka, Takaaki; Tomita, Masaru			Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETAMINOPHEN-INDUCED HEPATOTOXICITY; IONIZATION MASS-SPECTROMETRY; RESISTANCE PROTEIN-1 MRP1; CAPILLARY-ELECTROPHORESIS; FUNCTIONAL GENOMICS; RAT-LIVER; METABOLISM; TOXICITY; MOUSE; INHIBITION	Metabolomics is an emerging tool that can be used to gain insights into cellular and physiological responses. Here we present a metabolome differential display method based on capillary electrophoresis time-of-flight mass spectrometry to profile liver metabolites following acetaminophen-induced hepatotoxicity. We globally detected 1,859 peaks in mouse liver extracts and highlighted multiple changes in metabolite levels, including an activation of the ophthalmate biosynthesis pathway. We confirmed that ophthalmate was synthesized from 2-aminobutyrate through consecutive reactions with gamma-glutamylcysteine and glutathione synthetase. Changes in ophthalmate level in mouse serum and liver extracts were closely correlated and ophthalmate levels increased significantly in conjunction with glutathione consumption. Overall, our results provide a broad picture of hepatic metabolite changes following acetaminophen treatment. In addition, we specifically found that serum ophthalmate is a sensitive indicator of hepatic GSH depletion, and may be a new biomarker for oxidative stress. Our method can thus pinpoint specific metabolite changes and provide insights into the perturbation of metabolic pathways on a large scale and serve as a powerful new tool for discovering low molecular weight biomarkers.	Keio Univ, Inst Adv Biosci, Dept Biochem & Integrat Med Biol, Shinjuku Ku, Tokyo 1608582, Japan; Human Metabolome Technol Inc, Yamagata 9970017, Japan; Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata 9970017, Japan	Keio University; Keio University	Soga, T (corresponding author), Keio Univ, Inst Adv Biosci, Dept Biochem & Integrat Med Biol, Shinjuku Ku, Tokyo 1608582, Japan.	soga@sfc.keio.ac.jp; msuem@sc.itc.keio.ac.jp	Soga, Tomoyoshi/B-8105-2014; Suematsu, Makoto/O-5762-2018; Suematsu, Makoto/I-8135-2013; Robert, Martin/B-3970-2009	Soga, Tomoyoshi/0000-0001-9502-2509; Suematsu, Makoto/0000-0002-7165-6336; Suematsu, Makoto/0000-0002-7165-6336; Robert, Martin/0000-0002-7082-5142				Aharoni Asaph, 2002, OMICS A Journal of Integrative Biology, V6, P217, DOI 10.1089/15362310260256882; BALLATORI N, 1994, J BIOL CHEM, V269, P19731; Coen M, 2004, J PHARMACEUT BIOMED, V35, P93, DOI 10.1016/j.jpba.2003.12.019; Coen M, 2003, CHEM RES TOXICOL, V16, P295, DOI 10.1021/tx0256127; Corrales FJ, 1999, J HEPATOL, V31, P887, DOI 10.1016/S0168-8278(99)80291-8; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; Douglas D.H., 1973, CARTOGRAPHICA INT J, V10, P112, DOI [10.3138/FM57-6770-U75U-7727, DOI 10.3138/FM57-6770-U75U-7727]; Fernie AR, 2004, NAT REV MOL CELL BIO, V5, P763, DOI 10.1038/nrm1451; Fiehn O, 2000, NAT BIOTECHNOL, V18, P1157, DOI 10.1038/81137; FRAENKEL DG, 1992, ANNU REV GENET, V26, P159; Gibson JD, 1996, CHEM RES TOXICOL, V9, P580, DOI 10.1021/tx950153d; Goto S, 2002, NUCLEIC ACIDS RES, V30, P402, DOI 10.1093/nar/30.1.402; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Hinson JA, 2004, DRUG METAB REV, V36, P805, DOI 10.1081/DMR-200033494; HUANG CS, 1988, P NATL ACAD SCI USA, V85, P2464, DOI 10.1073/pnas.85.8.2464; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; JOSHI UM, 1987, INT J BIOCHEM, V19, P1029, DOI 10.1016/0020-711X(87)90303-X; Katayama H, 1998, ANAL CHEM, V70, P5272, DOI 10.1021/ac980522l; Keppler D, 1997, BIOL CHEM, V378, P787; Leslie EM, 2003, J PHARMACOL EXP THER, V304, P643, DOI 10.1124/jpet.102.044073; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P185; OPPENHEIMER L, 1979, J BIOL CHEM, V254, P5184; ORLOWSKI M, 1978, BIOCHEM J, V170, P415, DOI 10.1042/bj1700415; Palmer ME, 1999, RAPID COMMUN MASS SP, V13, P256, DOI 10.1002/(SICI)1097-0231(19990228)13:4<256::AID-RCM459>3.0.CO;2-S; Plumb R, 2003, ANALYST, V128, P819, DOI 10.1039/b304296k; Raamsdonk LM, 2001, NAT BIOTECHNOL, V19, P45, DOI 10.1038/83496; Reijenga JC, 2002, J CHROMATOGR B, V770, P45, DOI 10.1016/S0378-4347(01)00527-8; Reilly TP, 2001, BIOCHEM BIOPH RES CO, V282, P321, DOI 10.1006/bbrc.2001.4576; Reo NV, 2002, DRUG CHEM TOXICOL, V25, P375, DOI 10.1081/DCT-120014789; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; Ruepp SU, 2002, TOXICOL SCI, V65, P135, DOI 10.1093/toxsci/65.1.135; Shiomi M, 1998, HEPATOLOGY, V27, P108, DOI 10.1002/hep.510270118; Soga T, 2002, ANAL CHEM, V74, P2233, DOI 10.1021/ac020064n; Soga T, 2003, J PROTEOME RES, V2, P488, DOI 10.1021/pr034020m; Soga T, 2000, ANAL CHEM, V72, P1236, DOI 10.1021/ac990976y; Spinnler HE, 1996, P NATL ACAD SCI USA, V93, P3373, DOI 10.1073/pnas.93.8.3373; Tirmenstein MA, 2000, CHEM-BIOL INTERACT, V127, P201, DOI 10.1016/S0009-2797(00)00180-0; Vendemiale G, 1996, BIOCHEM PHARMACOL, V52, P1147, DOI 10.1016/0006-2952(96)00414-5; VERMEULEN NPE, 1992, DRUG METAB REV, V24, P367, DOI 10.3109/03602539208996298; WALEY SG, 1953, BIOCHIM BIOPHYS ACTA, V10, P27, DOI 10.1016/0006-3002(53)90206-6; Wallace JL, 2004, BRIT J PHARMACOL, V143, P1, DOI 10.1038/sj.bjp.0705781; Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.3.489; Yang CS, 1997, BIOCHEM PHARMACOL, V53, P357, DOI 10.1016/S0006-2952(96)00729-0; Zalups RK, 1997, DRUG METAB DISPOS, V25, P516	47	527	544	2	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16768	16776		10.1074/jbc.M601876200	http://dx.doi.org/10.1074/jbc.M601876200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16608839	hybrid			2022-12-25	WOS:000238165700071
J	Zhao, B; Li, YF; Buono, C; Waldo, SW; Jones, NL; Mori, M; Kruth, HS				Bin Zhao; Li, Yifu; Buono, Chiara; Waldo, Stephen W.; Jones, Nancy L.; Mori, Masahiro; Kruth, Howard S.			Constitutive receptor-independent low density lipoprotein uptake and cholesterol accumulation by macrophages differentiated from human monocytes with macrophage-colony-stimulating factor (M-CSF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOAM CELL-FORMATION; MEDIATED ENDOCYTOSIS; FAMILIAL HYPERCHOLESTEROLEMIA; ATHEROSCLEROTIC LESIONS; SCAVENGER RECEPTOR; CULTURED-CELLS; EXPRESSION; APOPTOSIS; MICE; MACROPINOCYTOSIS	Recently, we have shown that macrophage uptake of low density lipoprotein (LDL) and cholesterol accumulation can occur by nonreceptor mediated fluid-phase macropinocytosis when macrophages are differentiated from human monocytes in human serum and the macrophages are activated by stimulation of protein kinase C (Kruth, H. S., Jones, N. L., Huang, W., Zhao, B., Ishii, I., Chang, J., Combs, C. A., Malide, D., and Zhang, W. Y. ( 2005) J. Biol. Chem. 280, 2352 - 2360). Differentiation of human monocytes in human serum produces a distinct macrophage phenotype. In this study, we examined the effect on LDL uptake of an alternative macrophage differentiation phenotype. Differentiation of macrophages from human monocytes in fetal bovine serum with macrophage-colony-stimulating factor (M-CSF) produced a macrophage phenotype demonstrating constitutive fluid-phase uptake of native LDL leading to macrophage cholesterol accumulation. Fluid-phase endocytosis of LDL by M-CSF human macrophages showed non-saturable uptake of LDL that did not down-regulate over 48 h. LDL uptake was mediated by continuous actin-dependent macropinocytosis of LDL by these M-CSF-differentiated macrophages. M-CSF is a cytokine present within atherosclerotic lesions. Thus, macropinocytosis of LDL by macrophages differentiated from monocytes under the influence of M-CSF is a plausible mechanism to account for macrophage foam cell formation in atherosclerotic lesions. This mechanism of macrophage foam cell formation does not depend on LDL modification or macrophage receptors.	NHLBI, Sect Expt Atherosclerosis, NIH, Bethesda, MD 20892 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University	Kruth, HS (corresponding author), NHLBI, Sect Expt Atherosclerosis, NIH, Bldg 10,Rm 5N-113,10 Ctr Dr,MSC 1422, Bethesda, MD 20892 USA.	kruthh@nhlbi.nih.gov		LI, YIFU/0000-0002-7077-7689	Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [HL-41990] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002832, R01HL041990] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akagawa KS, 2002, INT J HEMATOL, V76, P27, DOI 10.1007/BF02982715; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BROWN MS, 1976, SCIENCE, V191, P150, DOI 10.1126/science.174194; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CLINTON SK, 1992, AM J PATHOL, V140, P301; DeVries-Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078; FOLCH J, 1957, J BIOL CHEM, V226, P497; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; GAMBLE W, 1978, J LIPID RES, V19, P1068; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; Hashimoto S, 1997, BLOOD, V89, P315, DOI 10.1182/blood.V89.1.315.315_315_321; HEIDEMAN CL, 1982, BIOCHIM BIOPHYS ACTA, V711, P431, DOI 10.1016/0005-2760(82)90057-1; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HOFF HF, 1978, BIOCHEM BIOPH RES CO, V85, P1424, DOI 10.1016/0006-291X(78)91162-2; Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; Kruth HS, 2005, J BIOL CHEM, V280, P2352, DOI 10.1074/jbc.M407167200; Kruth HS, 2002, J BIOL CHEM, V277, P34573, DOI 10.1074/jbc.M205059200; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; LESNIK P, 1992, P NATL ACAD SCI USA, V89, P10370, DOI 10.1073/pnas.89.21.10370; Li YK, 2004, J BIOL CHEM, V279, P37030, DOI 10.1074/jbc.M405195200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCHANT CE, 1995, FEBS LETT, V358, P175, DOI 10.1016/0014-5793(94)01393-F; Moore KJ, 2005, J CLIN INVEST, V115, P2192, DOI 10.1172/JCI24061; Mori M, 2001, J LIPID RES, V42, P1771; Qiao JH, 1997, AM J PATHOL, V150, P1687; RACOOSIN EL, 1992, J CELL SCI, V102, P867; ROSENFELD ME, 1992, AM J PATHOL, V140, P291; ROUIS M, 1990, ARTERIOSCLEROSIS, V10, P246, DOI 10.1161/01.ATV.10.2.246; SCHECHTER L, 1981, J LIPID RES, V22, P63; SHEPHERD J, 1979, J LIPID RES, V20, P999; SLATER HR, 1982, J BIOL CHEM, V257, P307; SMITH EB, 1990, EUR HEART J, V11, P72, DOI 10.1093/eurheartj/11.suppl_E.72; SMITH EB, 1983, BIOCHIM BIOPHYS ACTA, V754, P249, DOI 10.1016/0005-2760(83)90139-X; SMITH EB, 1981, HAEMOSTASIS THROMBOS, P554; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SPADY DK, 1987, J LIPID RES, V28, P32; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200	41	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15757	15762		10.1074/jbc.M510714200	http://dx.doi.org/10.1074/jbc.M510714200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16606620	hybrid			2022-12-25	WOS:000237996000023
J	Boniface, A; Bouhss, A; Mengin-Lecreulx, D; Blanot, D				Boniface, Audrey; Bouhss, Ahmed; Mengin-Lecreulx, Dominique; Blanot, Didier			The MurE synthetase from Thermotoga maritima is endowed with an unusual D-lysine adding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANYL-D-GLUTAMATE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; ALANINE LIGASE; PEPTIDOGLYCAN BIOSYNTHESIS; DIAMINOPIMELIC ACID; CRYSTAL-STRUCTURE; OVER-PRODUCTION; CELL WALL; PURIFICATION	The peptidoglycan of Thermotoga maritima, an extremely thermophilic eubacterium, was shown to contain no diaminopimelic acid and approximate amounts of both enantiomers of lysine (Huber, R., Langworthy, T. A., Konig, H., Thomm, M., Woese, C. R., Sleytr, U. B., and Stetter, K.O. (1986) Arch. Microbiol. 144, 324 333). To assess the possible involvement of the MurE activity in the incorporation of D-lysine, the murE gene from this organism was cloned in Escherichia coli, and the corresponding protein was purified as the C-terminal His6-tagged form. In vitro assays showed that D-lysine and meso-diaminopimelic acid were added to UDP-N-acetylmuramoyldipeptide with 25 and 10% efficiencies, respectively, relative to L-lysine. The purified enzyme was used to synthesize the L- and D-lysine-containing UDP-N-acetylmuramoyl-tripeptides; chemical analysis revealed an unusual structure for the D-lysine-containing nucleotide, namely acylation of the epsilon-amino function of D-lysine by the D-glutamyl residue. In vitro assays with MurF and MraY enzymes from T. maritima showed that this novel nucleotide was not a substrate for MurF but that it could be directly processed into tripeptide lipid I by MraY, thereby substantiating the role of MurE in the incorporation of D-lysine into peptidoglycan.	Univ Paris 11, IBBMC, UMR8619, CNRS,Lab Bacterial Envelopes & Antibiot, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Blanot, D (corresponding author), Univ Paris 11, IBBMC, UMR8619, CNRS,Lab Bacterial Envelopes & Antibiot, Batiment 430, F-91405 Orsay, France.	didier.blanot@ebp.u-psud.fr		MENGIN-LECREULX, Dominique/0000-0003-3205-0275				Auger G, 1996, FEBS LETT, V391, P171, DOI 10.1016/0014-5793(96)00619-9; Auger G, 1998, PROTEIN EXPRES PURIF, V13, P23, DOI 10.1006/prep.1997.0850; Bertrand JA, 1999, J MOL BIOL, V289, P579, DOI 10.1006/jmbi.1999.2800; BLANOT D, 1994, CARBOHYD RES, V252, P107; Bouhss A, 2004, J BIOL CHEM, V279, P29974, DOI 10.1074/jbc.M314165200; Bouhss A, 1997, BIOCHEMISTRY-US, V36, P11556, DOI 10.1021/bi970797f; BRAUN V, 1969, EUR J BIOCHEM, V10, P426, DOI 10.1111/j.1432-1033.1969.tb00707.x; Caravano A, 2003, CHEM-EUR J, V9, P5888, DOI 10.1002/chem.200305141; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; Davis R., 1980, ADV BACTERIAL GENETI; DEMENTIN S, 2001, THESIS U PARIS SUD O; Eveland SS, 1997, BIOCHEMISTRY-US, V36, P6223, DOI 10.1021/bi9701078; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Gordon E, 2001, J BIOL CHEM, V276, P10999, DOI 10.1074/jbc.M009835200; GREENSTEIN JP, 1961, CHEM AMINO ACIDS, V1, P435; GUINAND M, 1969, BIOCHEMISTRY-US, V8, P200, DOI 10.1021/bi00829a029; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIGER D, 1995, EUR J BIOCHEM, V230, P80, DOI 10.1111/j.1432-1033.1995.0080i.x; Mengin-Lecreulx D, 1999, J BACTERIOL, V181, P5909, DOI 10.1128/JB.181.19.5909-5914.1999; MENGINLECREULX D, 1982, J BACTERIOL, V151, P1109, DOI 10.1128/JB.151.3.1109-1117.1982; MENGINLECREULX D, 1989, J BACTERIOL, V171, P6126, DOI 10.1128/jb.171.11.6126-6134.1989; MENGINLECREULX D, 1994, J BACTERIOL, V176, P4321, DOI 10.1128/jb.176.14.4321-4327.1994; MICHAUD C, 1990, EUR J BIOCHEM, V194, P853, DOI 10.1111/j.1432-1033.1990.tb19479.x; Pompeo F, 1998, J BACTERIOL, V180, P4799, DOI 10.1128/JB.180.18.4799-4803.1998; ROSENTHAL S, 1964, BIOCHIM BIOPHYS ACTA, V83, P378, DOI 10.1016/0926-6526(64)90025-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Spraggon G, 2004, PROTEINS, V55, P1078, DOI 10.1002/prot.20034; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; VANHEIJENOORT J, 1968, B SOC CHIM FR, P2828; VANHEIJENOORT Y, 1992, J BACTERIOL, V174, P3549, DOI 10.1128/JB.174.11.3549-3557.1992	33	39	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15680	15686		10.1074/jbc.M506311200	http://dx.doi.org/10.1074/jbc.M506311200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595662	hybrid			2022-12-25	WOS:000237996000012
J	Shimizu, Y; Ueda, T				Shimizu, Yoshihiro; Ueda, Takuya			SmpB triggers GTP hydrolysis of elongation factor Tu on ribosomes by compensating for the lack of codon-anticodon interaction during trans- translation initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-MESSENGER RNA; AMINOACYL-TRANSFER-RNA; SMALL PROTEIN-B; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; STALLED RIBOSOME; TERNARY COMPLEX; QUALITY-CONTROL; EF-TU; TMRNA	Bacterial tmRNA rescues ribosomes that stall because of defective mRNAs via the trans-translation process. Although entry of the charged transfer messenger RNA ( tmRNA) into the ribosome proceeded in the absence of elongation factor (EF-Tu) and in the presence of EF-Tu and the antibiotic kirromycin, evidence was found for the involvement of EF-Tu in trans-translation initiation. The polyalanine synthesis system attained by using a tmRNA variant consisting of only the tRNA-like domain revealed that it was completely dependent on the presence of SmpB and greatly enhanced by EF-Tu and EF-G. Actually, ribosome-dependent GTPase activity of EF-Tu was stimulated by the addition of SmpB and tmRNA but independently of template mRNA, demonstrating that SmpB compensates for the lack of codon-anticodon interaction during the first step of the trans-translation initiation. Based on these results, we suggest that SmpB structurally mimics the anticodon arm of tRNA and elicits GTP hydrolysis of EF-Tu upon tmRNA accommodation in the A site of the ribosome.	Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Kashiwa, Chiba 2778562, Japan	University of Tokyo	Ueda, T (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, FSB401,5-1-5,Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	ueda@k.u-tokyo.ac.jp	Ueda, Takuya/K-5217-2014; Shimizu, Yoshihiro/A-6472-2016	Ueda, Takuya/0000-0002-7760-8271; Shimizu, Yoshihiro/0000-0003-3499-1394				Barends S, 2000, BIOCHEMISTRY-US, V39, P2652, DOI 10.1021/bi992439d; Barends S, 2002, FEBS LETT, V514, P78, DOI 10.1016/S0014-5793(02)02306-2; Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Gutmann S, 2003, NATURE, V424, P699, DOI 10.1038/nature01831; Haebel PW, 2004, CURR OPIN STRUC BIOL, V14, P58, DOI 10.1016/j.sbi.2004.01.010; Hallier M, 2004, J BIOL CHEM, V279, P25978, DOI 10.1074/jbc.M314086200; Hanada T, 2001, GENES CELLS, V6, P1019, DOI 10.1046/j.1365-2443.2001.00491.x; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Hanawa-Suetsugu K, 2001, NUCLEIC ACIDS RES, V29, P4663, DOI 10.1093/nar/29.22.4663; Hayes CS, 2003, MOL CELL, V12, P903, DOI 10.1016/S1097-2765(03)00385-X; Ivanova N, 2005, J MOL BIOL, V350, P897, DOI 10.1016/j.jmb.2005.05.033; Ivanova N, 2005, NUCLEIC ACIDS RES, V33, P3529, DOI 10.1093/nar/gki666; Ivanova N, 2004, J MOL BIOL, V338, P33, DOI 10.1016/j.jmb.2004.02.043; Joseph S, 1998, EMBO J, V17, P3478, DOI 10.1093/emboj/17.12.3478; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Metzinger L, 2005, NUCLEIC ACIDS RES, V33, P2384, DOI 10.1093/nar/gki534; Nameki N, 2000, FEBS LETT, V470, P345, DOI 10.1016/S0014-5793(00)01349-1; Nissen P, 1999, STRUCTURE, V7, P143, DOI 10.1016/S0969-2126(99)80021-5; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; Rudinger-Thirion J, 1999, RNA, V5, P989, DOI 10.1017/S135583829999101X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; Shimizu Y, 2002, FEBS LETT, V514, P74, DOI 10.1016/S0014-5793(02)02333-5; Stark H, 2002, NAT STRUCT BIOL, V9, P849, DOI 10.1038/nsb859; Stepanov VG, 2003, EUR J BIOCHEM, V270, P463, DOI 10.1046/j.1432-1033.2003.03401.x; Sundermeier TR, 2005, P NATL ACAD SCI USA, V102, P2316, DOI 10.1073/pnas.0409694102; Tomari Y, 2000, GENES CELLS, V5, P689, DOI 10.1046/j.1365-2443.2000.00360.x; Ueno T, 2004, MOL CELL, V14, P423, DOI 10.1016/S1097-2765(04)00261-8; Valle M, 2003, NAT STRUCT BIOL, V10, P899, DOI 10.1038/nsb1003; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; Williams KP, 1999, EMBO J, V18, P5423, DOI 10.1093/emboj/18.19.5423; Wower J, 2002, BIOCHEMISTRY-US, V41, P8826, DOI 10.1021/bi0201365; Yamamoto Y, 2003, RNA, V9, P408, DOI 10.1261/rna.2174803	37	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15987	15996		10.1074/jbc.M512165200	http://dx.doi.org/10.1074/jbc.M512165200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16601123	hybrid			2022-12-25	WOS:000237996000050
J	Yoo, YD; Wu, XY; Egile, C; Li, R; Guan, JL				Yoo, Youngdong; Wu, Xiaoyang; Egile, Coumaran; Li, Rong; Guan, Jun-Lin			Interaction of N-WASP with hnRNPK and its role in filopodia formation and cell spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; NUCLEAR RIBONUCLEOPROTEIN-K; FOCAL ADHESION KINASE; ACTIN-DEPOLYMERIZING PROTEIN; MESSENGER-RNA; ARP2/3 COMPLEX; BINDING-PROTEIN; TRANSCRIPTIONAL REPRESSOR; MICROSPIKE FORMATION; NEURITE EXTENSION	N-WASP is a member of the WASP family of proteins, which play essential roles in actin dynamics during cell adhesion and migration. hnRNPK is a member of the heterogeneous nuclear ribonucleoprotein complex, which has also been implicated in the regulation of cell spreading. Here, we identify a direct interaction between N-WASP and hnRNPK. We show that this interaction is mediated by the N-terminal WH1 domain of N-WASP and the segment of hnRNPK containing its K interaction (KI) domain. Furthermore, these two proteins are co-localized at the cell periphery in the spreading initiation center during the early stage of cell spreading. We found that co-expression of hnRNPK with N-WASP reverses the stimulation of cell spreading by N-WASP, and this effect is correlated with hnRNPK binding to N-WASP. Expression of hnRNPK does not affect subcellular localization of N-WASP protein. However, co-expression of hnRNPK with N-WASP reduced filopodia formation stimulated by N-WASP in spreading cells. Together, these results identify hnRNPK as a new negative regulator of N-WASP and suggest that hnRNPK may regulate the initial stage of cell spreading by direct association with N-WASP in the spreading initiation center.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Cornell University; Harvard University; Harvard Medical School	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.	jg19@cornell.edu			NHLBI NIH HHS [HL73394] Funding Source: Medline; NIGMS NIH HHS [GM48050] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073394] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banzai Y, 2000, J BIOL CHEM, V275, P11987, DOI 10.1074/jbc.275.16.11987; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Burton EA, 2005, MOL CELL BIOL, V25, P8834, DOI 10.1128/MCB.25.20.8834-8843.2005; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chen CY, 2000, GENE DEV, V14, P1236; Christopher RA, 2000, INT J MOL MED, V5, P575; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; de Hoog CL, 2004, CELL, V117, P649, DOI 10.1016/S0092-8674(04)00456-8; Denisenko O, 2002, MOL CELL BIOL, V22, P286, DOI 10.1128/MCB.22.1.286-297.2002; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Expert-Bezancon A, 2002, J BIOL CHEM, V277, P16614, DOI 10.1074/jbc.M201083200; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Grishin NV, 2001, NUCLEIC ACIDS RES, V29, P638, DOI 10.1093/nar/29.3.638; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Han DC, 2001, ONCOGENE, V20, P346, DOI 10.1038/sj.onc.1204068; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Ma L, 1998, J CELL BIOL, V140, P1125; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; NACKEN V, 1994, NUCLEIC ACIDS RES, V22, P1509, DOI 10.1093/nar/22.8.1509; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Snapper SB, 2001, NAT CELL BIOL, V3, P897, DOI 10.1038/ncb1001-897; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Takenawa T, 2001, J CELL SCI, V114, P1801; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Wakatsuki T, 2003, J CELL SCI, V116, P1617, DOI 10.1242/jcs.00340; Welch MD, 1999, TRENDS CELL BIOL, V9, P423, DOI 10.1016/S0962-8924(99)01651-7; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; Wu XY, 2004, J BIOL CHEM, V279, P9565, DOI 10.1074/jbc.M310739200; Yamaguchi H, 2000, P NATL ACAD SCI USA, V97, P12631, DOI 10.1073/pnas.190351397; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	63	25	29	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15352	15360		10.1074/jbc.M511825200	http://dx.doi.org/10.1074/jbc.M511825200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574661	hybrid			2022-12-25	WOS:000237922200040
J	Gigante, B; Morlino, G; Gentile, MT; Persico, MG; De Falco, S				Gigante, Bruna; Morlino, Giulia; Gentile, Maria Teresa; Persico, Maria Graziella; De Falco, Sandro			Plgf(-/-) eNos(-/-) mice show defective angiogenesis associated with increased oxidative stress in response to tissue ischemia	FASEB JOURNAL			English	Article						hindlimb ischemia; macrophage infiltration; nitric oxide	ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; IN-VIVO; GENE; EXPRESSION; RECEPTOR; DISEASE; BINDING; LACKING; VEGF	Neo-angiogenesis is a complex phenomenon modulated by the concerted action of several molecular factors. We have generated a congenic line of knockout mice carrying null mutations of both placental growth factor ( PlGF) and endothelial nitric oxide synthase ( eNOS), two genes that play a pivotal role in the regulation of pathological angiogenesis. In the present study, we describe the phenotype of this new experimental animal model after surgically induced hind-limb ischemia. Plgf(-/-), eNos(-/-), Plgf(-/-) eNos(-/-), and wild-type C57BL/6J mice were studied. Plgf(-/-) eNos(-/-) mice showed the most severe phenotype: self-amputation, and death occurred in up to 47% of the animals studied; in ischemic legs, capillary density was severely reduced; macrophage infiltration and oxidative stress increased as compared to the other groups of animals. These changes were associated with an up-regulation of both inducible NOS ( iNOS) expression and vascular endothelial growth factor ( VEGF) protein levels in ischemic limbs, and to an increased extent of protein nitration. Our results demonstrate that the deletion of these two genes, Plgf, which acts in synergism with VEGF, and eNos, a downstream mediator of VEGF, determines a significant change in the vascular response to an ischemic stimulus and that oxidative stress within the ischemic tissue represents a crucial factor to maintain tissue homeostasis.	CNR, Inst Genet & Biophys Adriano Buzzati Traverso, I-80131 Naples, Italy; Ist Ric & Cura Caratere Sci Neuromed, Pozzilli, IS, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); IRCCS Neuromed	De Falco, S (corresponding author), CNR, Inst Genet & Biophys Adriano Buzzati Traverso, Via P Castellino 111, I-80131 Naples, Italy.	defalco@igb.cnr.it	De Falco, Sandro/P-6724-2015; Gigante, Bruna/I-9252-2012	De Falco, Sandro/0000-0002-6501-1697; GENTILE, Maria Teresa/0000-0003-4239-5330; Gigante, Bruna/0000-0003-4508-7990				Amano K, 2003, HYPERTENSION, V41, P156, DOI 10.1161/01.HYP.0000053552.86367.12; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Bonthu S, 1997, ARTERIOSCL THROM VAS, V17, P2333, DOI 10.1161/01.ATV.17.11.2333; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; De Falco S, 2002, TRENDS CARDIOVAS MED, V12, P241, DOI 10.1016/S1050-1738(02)00168-8; Epstein SE, 2001, CIRCULATION, V104, P115, DOI 10.1161/01.CIR.104.1.115; Errico M, 2004, J BIOL CHEM, V279, P43929, DOI 10.1074/jbc.M401418200; Ferdinandy P, 2003, BRIT J PHARMACOL, V138, P532, DOI 10.1038/sj.bjp.0705080; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Gigante Bruna, 2004, Angiogenesis, V7, P277, DOI 10.1007/s10456-004-4179-1; Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB; Hiratsuka S, 2005, MOL CELL BIOL, V25, P346, DOI 10.1128/MCB.25.1.346-354.2005; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Khatri JJ, 2004, CIRCULATION, V109, P520, DOI 10.1161/01.CIR.0000109698.70638.2B; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; MONCADA S, 1991, PHARMACOL REV, V43, P109; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Namba T, 2003, CIRCULATION, V108, P2250, DOI 10.1161/01.CIR.0000093190.53478.78; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; PARK JE, 1994, J BIOL CHEM, V269, P25646; Pipp F, 2003, CIRC RES, V92, P378, DOI 10.1161/01.RES.0000057997.77714.72; Poon BY, 2003, CIRCULATION, V108, P1107, DOI 10.1161/01.CIR.0000086321.04702.AC; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Ramanathan MD, 2003, EXP BIOL MED, V228, P697, DOI 10.1177/153537020322800608; Richard DE, 2000, J BIOL CHEM, V275, P26765; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Simons M, 2003, NAT REV DRUG DISCOV, V2, P863, DOI 10.1038/nrd1226; Steudel W, 1997, CIRC RES, V81, P34, DOI 10.1161/01.RES.81.1.34; Su YR, 2002, J LIPID RES, V43, P2180, DOI 10.1194/jlr.D200020-JLR200; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; Westenfeld R, 2002, KIDNEY INT, V61, P834, DOI 10.1046/j.1523-1755.2002.00229.x; Williams SM, 2004, BIOESSAYS, V26, P170, DOI 10.1002/bies.10401; Zhu XY, 2004, CIRCULATION, V109, P2109, DOI 10.1161/01.CIR.0000125742.65841.8B; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	39	48	52	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					970	+		10.1096/fj.05-4481fje	http://dx.doi.org/10.1096/fj.05-4481fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16608872				2022-12-25	WOS:000240157700025
J	Diry, M; Tomkiewicz, C; Koehle, C; Coumoul, X; Bock, KW; Barouki, R; Transy, C				Diry, M.; Tomkiewicz, C.; Koehle, C.; Coumoul, X.; Bock, K. Walter; Barouki, R.; Transy, C.			Activation of the dioxin/aryl hydrocarbon receptor (AhR) modulates cell plasticity through a JNK-dependent mechanism	ONCOGENE			English	Article						dioxin; Ah receptor; JNK; epithelial plasticity; cell motility; cell scattering	SIGNALING CASCADE; PROTEIN-KINASES; EXPRESSION; MOTILITY; CHEMICALS; ADHESION; ELEGANS; PATHWAY; LACKING; SEVESO	Environmental chemicals such as dioxin adversely affect immune, neurological and reproductive functions and have been implicated in cancer development. However, the mechanisms responsible for dioxin toxicity are still poorly understood. Here, we show that dioxin and related pollutants trigger a marked morphological change in epithelial cells that remodel their cytoskeleton to increase interaction with extra cellular matrix while loosening cell cell contacts. Furthermore, dioxin-treated cells show increased motility. These dioxin-mediated effects are mimicked by constitutive expression and activation of the intracellular dioxin receptor (aryl hydrocarbon receptor (AhR)). They correlate with activation of the Jun NH2-terminal kinase (JNK) and are reverted by treatment with a JNK inhibitor. Dioxin-induced effects occur 48 h post-treatment initiation, a time scale, which argues for a genomic effect of the AhR, linked to induction of target genes. This novel Ahr action on cell plasticity points to a role in cancer progression.	INSERM, U567, CNRS, Dept Malad Infect,Inst Cochin,UMR8104,UFR Biomed, F-75014 Paris, France; Univ Tubingen, Inst Toxicol, D-72074 Tubingen, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Eberhard Karls University of Tubingen	Transy, C (corresponding author), INSERM, U567, CNRS, Dept Malad Infect,Inst Cochin,UMR8104,UFR Biomed, 27 Rue Faubourg St Jacques,UMR-S 490, F-75014 Paris, France.	transy@cochin.inserm.fr	COUMOUL, Xavier/AAR-3649-2020	COUMOUL, Xavier/0000-0003-2928-9648				Baccarelli A, 2002, ENVIRON HEALTH PERSP, V110, P1169, DOI 10.1289/ehp.021101169; Coumoul X, 2001, CANCER RES, V61, P3942; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Fashena SJ, 2002, J CELL SCI, V115, P99; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Foekens JA, 2000, CANCER RES, V60, P636; Frueh FW, 2001, TOXICOL LETT, V122, P189, DOI 10.1016/S0378-4274(01)00364-2; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; Huang X, 2004, DEVELOPMENT, V131, P819, DOI 10.1242/dev.00959; Kohle C, 2002, ARCH BIOCHEM BIOPHYS, V402, P172, DOI 10.1016/S0003-9861(02)00076-0; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Marchand A, 2005, MOL PHARMACOL, V67, P444, DOI 10.1124/mol.104.004010; Mulero-Navarro S, 2005, J BIOL CHEM, V280, P28731, DOI 10.1074/jbc.M504538200; Nesaretnam K, 1998, EUR J CANCER, V34, P389, DOI 10.1016/S0959-8049(97)10026-0; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Pastor-Pareja JC, 2004, DEV CELL, V7, P387, DOI 10.1016/j.devcel.2004.07.022; Pelclova D, 2001, ARCH ENVIRON HEALTH, V56, P493, DOI 10.1080/00039890109602897; Pesatori AC, 2003, IND HEALTH, V41, P127, DOI 10.2486/indhealth.41.127; Poellinger L, 2000, FOOD ADDIT CONTAM A, V17, P261, DOI 10.1080/026520300283333; Puga A, 2000, BIOCHEM PHARMACOL, V60, P1129, DOI 10.1016/S0006-2952(00)00403-2; Qin HT, 2004, DEV BIOL, V270, P64, DOI 10.1016/j.ydbio.2004.02.004; Safe S, 2003, CHEM RES TOXICOL, V16, P807, DOI 10.1021/tx034036r; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sisci D, 2004, ONCOGENE, V23, P8920, DOI 10.1038/sj.onc.1208098; Tan ZQ, 2002, BIOCHEM PHARMACOL, V64, P771, DOI 10.1016/S0006-2952(02)01138-3; Weiss C, 2005, ONCOGENE, V24, P4975, DOI 10.1038/sj.onc.1208679; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; Yamamoto O, 2003, J DERMATOL SCI, V32, P85, DOI 10.1016/S0923-1811(03)00097-5; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	31	103	114	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2006	25	40					5570	5574		10.1038/sj.onc.1209553	http://dx.doi.org/10.1038/sj.onc.1209553			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619036	Green Submitted			2022-12-25	WOS:000240370400010
J	Dong, J; Tsai-Morris, CH; Dufau, ML				Dong, Juying; Tsai-Morris, Chon-Hwa; Dufau, Maria L.			A novel estradiol/estrogen receptor alpha-dependent transcriptional mechanism controls expression of the human prolactin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D-RECEPTOR; NF-KAPPA-B; INTERLEUKIN-6 GENE-EXPRESSION; BREAST-CANCER CELLS; ESTROGEN-RECEPTOR; HORMONE-RECEPTOR; C/EBP-BETA; FACTOR TFIIB; PREINITIATION COMPLEX; PROMOTER UTILIZATION	Prolactin exerts diverse functions in target tissues through its membrane receptors, and is a potent mitogen in normal and neoplastic breast cells. Estradiol (E-2) induces human prolactin receptor (hPRLR) gene expression through stimulation of its generic promoter (PIII). This study identifies a novel E-2-regulated non-estrogen responsive element-dependent transcriptional mechanism that mediates E-2- induced hPRLR expression. E2 stimulated transcriptional activity in MCF7A(2) cells transfected with PIII lacking an estrogen responsive element, and increased hPRLR mRNA and protein. The abolition of the E2 effect by mutation of Sp1 or C/EBP elements that bind Sp1/Sp3 and C/EBP beta within PIII indicated the cooperation of these transfactors in E-2-induced transcription of the hPRLR. DNA affinity protein assay showed that E-2 induced estrogen receptor alpha (ER alpha) binding to Sp1/Sp3 and C/EBP beta DNA-protein complexes. The ligand-binding domain of ER beta was essential for its physical interaction with C/EBP beta, and E-2 promoted this association, and its DNA binding domain was required for transactivation of PIII. Co-immunoprecipitation studies revealed tethering of C/EBP beta to Sp1 by E-2-activated ER beta. Chromatin immunoprecipitation analysis showed that E-2 induced recruitment of C/EBP beta, ER beta, SRC1, p300, pCAF, TFIIB, and Pol II, with no change in Sp1/Sp3. E-2 also induced promoter-associated acetylation of H3 and H4. These findings demonstrate that an E-2/ER alpha, Sp1, and C/EBP beta complex with recruitment of coactivators and TFIIB and Pol II are required for E-2-activated transcriptional expression of the hPRLR through PIII. Estradiol produced in breast stroma and adipose tissue, which are major sources of estrogen in post-menopausal women, could up-regulate hPRLR gene expression and stimulate breast tumor growth.	NICHD, Sect Mol Endocrinol, ERRB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dufau, ML (corresponding author), NICHD, Sect Mol Endocrinol, ERRB, NIH, Bldg 49,Rm 6A-36,49 Convent Dr,MSC 4510, Bethesda, MD 20892 USA.	dufaum@mail.nih.gov		Tsai Morris, Chon Hwa/0000-0002-8113-0979	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000150] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000150] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abu-Bedair FA, 2000, TUMORI J, V86, P24, DOI 10.1177/030089160008600105; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARTSCH C, 1989, CANCER, V64, P426, DOI 10.1002/1097-0142(19890715)64:2<426::AID-CNCR2820640215>3.0.CO;2-O; Bhatavdekar JM, 2000, EUR J SURG ONCOL, V26, P540, DOI 10.1053/ejso.2000.0943; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Chen HW, 1997, MOL CELL ENDOCRINOL, V129, P55, DOI 10.1016/S0303-7207(97)04040-9; Chen WY, 1999, CLIN CANCER RES, V5, P3583; DOWSETT M, 1983, BRIT J CANCER, V47, P763, DOI 10.1038/bjc.1983.129; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Foti D, 2003, MOL CELL BIOL, V23, P2720, DOI 10.1128/MCB.23.8.2720-2732.2003; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Galien R, 1996, MOL ENDOCRINOL, V10, P713, DOI 10.1210/me.10.6.713; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; Harvey PW, 2005, J APPL TOXICOL, V25, P179, DOI 10.1002/jat.1063; Hu YL, 1996, ENDOCRINOLOGY, V137, P3897, DOI 10.1210/en.137.9.3897; Hu ZZ, 1999, J CLIN ENDOCR METAB, V84, P1153, DOI 10.1210/jc.84.3.1153; Hu ZZ, 2002, ENDOCRINOLOGY, V143, P2139, DOI 10.1210/en.143.6.2139; Hu ZZ, 1998, J BIOL CHEM, V273, P26225, DOI 10.1074/jbc.273.40.26225; Hu ZZ, 1997, J BIOL CHEM, V272, P14263, DOI 10.1074/jbc.272.22.14263; Hu ZZ, 2001, J BIOL CHEM, V276, P41086, DOI 10.1074/jbc.M102109200; Hu ZZ, 1998, TRENDS ENDOCRIN MET, V9, P94, DOI 10.1016/S1043-2760(98)00027-7; Husmann M, 2000, BIOCHEM J, V352, P763, DOI 10.1042/0264-6021:3520763; ING NH, 1992, J BIOL CHEM, V267, P17617; INGRAM DM, 1990, MED J AUSTRALIA, V153, P469, DOI 10.5694/j.1326-5377.1990.tb126153.x; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Khanna-Gupta A, 2000, BLOOD, V95, P3734; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Leondires MP, 2002, J STEROID BIOCHEM, V82, P263, DOI 10.1016/S0960-0760(02)00184-X; LopezRodriguez C, 1997, J BIOL CHEM, V272, P29120, DOI 10.1074/jbc.272.46.29120; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; Masuyama H, 1997, MOL ENDOCRINOL, V11, P218, DOI 10.1210/me.11.2.218; Meng JP, 2004, CANCER RES, V64, P5677, DOI 10.1158/0008-5472.CAN-04-1019; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Peirce SK, 2004, ONCOGENE, V23, P1248, DOI 10.1038/sj.onc.1207245; Peirce SK, 2001, J ENDOCRINOL, V171, pR1, DOI 10.1677/joe.0.171R001; POTTRATZ ST, 1994, J CLIN INVEST, V93, P944, DOI 10.1172/JCI117100; RAY A, 1994, J BIOL CHEM, V269, P12940; Ray P, 1997, FEBS LETT, V409, P79, DOI 10.1016/S0014-5793(97)00487-0; Sabbah M, 1998, BIOCHEM J, V336, P639, DOI 10.1042/bj3360639; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; STEIN B, 1995, MOL CELL BIOL, V15, P4971; UJHAZY P, 1994, INT J CANCER, V59, P83, DOI 10.1002/ijc.2910590117; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; WILLIS KJ, 1977, BMJ-BRIT MED J, V1, P425, DOI 10.1136/bmj.1.6058.425; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x; Zhang Y, 2003, MOL CELL BIOL, V23, P6958, DOI 10.1128/MCB.23.19.6958-6972.2003; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200	51	77	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18825	18836		10.1074/jbc.M512826200	http://dx.doi.org/10.1074/jbc.M512826200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16651265	hybrid			2022-12-25	WOS:000238687300063
J	Hassan, AH; Awad, S; Prochasson, P				Hassan, Ahmed H.; Awad, Salma; Prochasson, Philippe			The Swi2/Snf2 bromodomain is required for the displacement of SAGA and the octamer transfer of SAGA-acetylated nucleosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE COMPLEXES; CHROMATIN-MODIFYING COMPLEXES; TANDEM AFFINITY PURIFICATION; ACTIVATOR INTERACTIONS; SELECTIVE RECOGNITION; ORDERED RECRUITMENT; REMODELING COMPLEX; STRUCTURAL BASIS; SWI/SNF COMPLEX; TRANSCRIPTION	The SWI/SNF and SAGA chromatin-modifying complexes contain bromodomains that help anchor these complexes to acetylated promoter nucleosomes. To study the importance of bromodomains in these complexes, we have compared the chromatin-remodeling and octamer-transfer activity of the SWI/SNF complex to a mutant complex that lacks the Swi2/Snf2 bromodomain. Here we show that the SWI/SNF complex can remodel or transfer SAGA-acetylated nucleosomes more efficiently than the Swi2/Snf2 bromodomain-deleted complex. These results demonstrate that the Swi2/Snf2 bromodomain is important for the remodeling as well as for the octamer-transfer activity of the complex on H3-acetylated nucleosomes. Moreover, we show that, although the wild-type SWI/SNF complex displaces SAGA that is bound to acetylated nucleosomes, the bromodomain mutant SWI/SNF complex is less efficient in SAGA displacement. Thus, the Swi2/Snf2 bromodomain is required for the full functional activity of SWI/SNF on acetylated nucleosomes and is important for the displacement of SAGA from acetylated promoter nucleosomes.	UAE Univ, Dept Biochem, Fac Med & Hlth Sci, Al Ain, U Arab Emirates; Stowers Inst Med Res, Kansas City, MO 64110 USA	United Arab Emirates University; Stowers Institute for Medical Research	Hassan, AH (corresponding author), UAE Univ, Dept Biochem, Fac Med & Hlth Sci, POB 17666, Al Ain, U Arab Emirates.	ahmedh@uaeu.ac.ae	Hassan, Ahmed/AAB-7241-2019	Mahmoud, Salma/0000-0003-1475-9483; Al-Marzouqi, Ahmed/0000-0003-4586-5676				Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Carrozza MJ, 2003, METHOD ENZYMOL, V371, P536; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Graumann J, 2004, MOL CELL PROTEOMICS, V3, P226, DOI 10.1074/mcp.M300099-MCP200; Hassan AH, 2001, FRONT BIOSCI, V6, pD1054, DOI 10.2741/Hassan; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Hudson BP, 2000, J MOL BIOL, V304, P355, DOI 10.1006/jmbi.2000.4207; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jambunathan N, 2005, GENETICS, V171, P913, DOI 10.1534/genetics.105.046938; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Johnson CN, 2005, BIOCHEM CELL BIOL, V83, P405, DOI 10.1139/O05-115; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; Kanno T, 2004, MOL CELL, V13, P33, DOI 10.1016/S1097-2765(03)00482-9; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Lechner MS, 2005, BIOCHEM BIOPH RES CO, V331, P929, DOI 10.1016/j.bbrc.2005.04.016; Lee KK, 2004, BIOCHEM SOC T, V32, P899, DOI 10.1042/BST0320899; Matangkasombut O, 2003, MOL CELL, V11, P353, DOI 10.1016/S1097-2765(03)00033-9; Mujtaba S, 2004, MOL CELL, V13, P251, DOI 10.1016/S1097-2765(03)00528-8; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Neely KE, 2002, MOL CELL BIOL, V22, P1615, DOI 10.1128/MCB.22.6.1615-1625.2002; Ornaghi P, 1999, J MOL BIOL, V287, P1, DOI 10.1006/jmbi.1999.2577; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Prochasson P, 2003, MOL CELL, V12, P983, DOI 10.1016/S1097-2765(03)00366-6; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Qiu HF, 2004, MOL CELL BIOL, V24, P4104, DOI 10.1128/MCB.24.10.4104-4117.2004; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Roberts SM, 1997, GENETICS, V147, P451; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Swanson MJ, 2003, MOL CELL BIOL, V23, P2800, DOI 10.1128/MCB.23.8.2800-2820.2003; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wang W, 2003, CURR TOP MICROBIOL, V274, P143; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	58	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18126	18134		10.1074/jbc.M602851200	http://dx.doi.org/10.1074/jbc.M602851200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16648632	hybrid			2022-12-25	WOS:000238490300064
J	Marsellach, FX; Huertas, D; Azorin, F				Marsellach, Francesc-Xavier; Huertas, Dori; Azorin, Fernando			The multi-KH domain protein of Saccharomyces cerevisiae Scp160p contributes to the regulation of telomeric silencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LOCALIZATION; ENDOPLASMIC-RETICULUM; BINDING PROTEIN; MRNP COMPLEXES; VIGILIN; HETEROCHROMATIN; NUCLEAR; DISTINCT; GENE; ESTABLISHMENT	Multi-KH domain proteins are highly evolutionarily conserved proteins that associate to polyribosomes and participate in RNA metabolism. Recent evidence indicates that multi-KH domain proteins also contribute to the structural organization of heterochromatin both in mammals and Drosophila. Here, we show that the multi-KH domain protein of Saccharomyces cerevisiae, Scp160p, contributes to silencing at telomeres and at the mating-type locus, but not to ribosomal silencing. The contribution of Scp160p to silencing is independent of its binding to the ribosome as deletion of the last two KH domains, which mediate ribosomal binding, has no effect on silencing. Disruption of SCP160 increases cell ploidy but this effect is also independent of the contribution of Scp160p to telomeric silencing as strong relief of silencing is observed in Delta scp160 cells with normal ploidy and, vice versa, Delta scp160 cells with highly increased ploidy show no significant silencing defects. The TPE phenotype of Delta scp160 cells associates to a decreased Sir3p deposition at telomeres and, in good agreement, silencing is rescued by SIR3 overexpression and in a Delta rif1 Delta rif2 mutant. Scp160p shows a distinct perinuclear localization that is independent of its ability to bind ribosomes. Moreover, telomere clustering at the nuclear envelope is perturbed in Delta scp160 cells and disruption of the histone deacetylase RPD3, which is known to improve telomere clustering, rescues telomeric silencing in Delta scp160 cells. These results are discussed in the context of a model in which Scp160p contributes to silencing by helping telomere clustering.	CSIC, Dept Mol & Cellular Biol, Inst Biol Mol Barcelona, E-08028 Barcelona, Spain; IRB, E-08028 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona	Azorin, F (corresponding author), CSIC, Dept Mol & Cellular Biol, Inst Biol Mol Barcelona, Parc Cient Barcelona,Josep Samitier 1-5, E-08028 Barcelona, Spain.	fambmc@ibmb.csic.es	Azorin, Fernando/N-4388-2014; Marsellach, Xavi/P-7835-2017	Azorin, Fernando/0000-0002-8426-7858; Marsellach, Xavi/0000-0002-2435-6904				Andrulis ED, 2002, MOL CELL BIOL, V22, P8292, DOI 10.1128/MCB.22.23.8292-8301.2002; Baum S, 2004, BIOCHEM J, V380, P823, DOI 10.1042/BJ20031962; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cortes A, 1999, EMBO J, V18, P3820, DOI 10.1093/emboj/18.13.3820; de Heredia ML, 2004, CURR OPIN CELL BIOL, V16, P80, DOI 10.1016/j.ceb.2003.11.002; Dodson RE, 1997, J BIOL CHEM, V272, P12249, DOI 10.1074/jbc.272.19.12249; Frey S, 2001, J BIOL CHEM, V276, P15905, DOI 10.1074/jbc.M009430200; Gartenberg MR, 2004, CELL, V119, P955, DOI 10.1016/j.cell.2004.11.008; Grishin NV, 2001, NUCLEIC ACIDS RES, V29, P638, DOI 10.1093/nar/29.3.638; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hediger F, 2002, CURR BIOL, V12, P2076, DOI 10.1016/S0960-9822(02)01338-6; Hicke L, 1997, MOL BIOL CELL, V8, P13, DOI 10.1091/mbc.8.1.13; Huertas D, 2004, CURR BIOL, V14, P1611, DOI 10.1016/j.cub.2004.09.024; Kruse C, 1996, BIOCHEM J, V320, P247, DOI 10.1042/bj3200247; Kruse C, 1998, BIOCHEM J, V329, P615, DOI 10.1042/bj3290615; Kruse C, 2000, BIOCHEM J, V346, P107, DOI 10.1042/0264-6021:3460107; Kugler S, 1996, FEBS LETT, V382, P330, DOI 10.1016/0014-5793(96)00204-9; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Lang BD, 2000, NUCLEIC ACIDS RES, V28, P1576, DOI 10.1093/nar/28.7.1576; Lang BD, 2001, NUCLEIC ACIDS RES, V29, P2567, DOI 10.1093/nar/29.12.2567; Li AM, 2004, NUCLEIC ACIDS RES, V32, P4768, DOI 10.1093/nar/gkh812; Li AM, 2003, NUCLEIC ACIDS RES, V31, P1830, DOI 10.1093/nar/gkg284; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Maillet L, 2001, EMBO REP, V2, P203, DOI 10.1093/embo-reports/kve044; Mendelsohn BA, 2003, NUCLEIC ACIDS RES, V31, P5838, DOI 10.1093/nar/gkg810; Mishra K, 1999, CURR BIOL, V9, P1123, DOI 10.1016/S0960-9822(99)80483-7; Nasmyth K, 1997, CURR OPIN CELL BIOL, V9, P396, DOI 10.1016/S0955-0674(97)80013-0; Pemberton LF, 1997, MOL CELL BIOL, V17, P4830, DOI 10.1128/MCB.17.8.4830; PLENZ G, 1994, HUM GENET, V93, P575; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; SCHMIDT C, 1992, EUR J BIOCHEM, V206, P625, DOI 10.1111/j.1432-1033.1992.tb16967.x; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Sun ZW, 1999, GENETICS, V152, P921; SUSSEL L, 1993, MOL CELL BIOL, V13, P3919, DOI 10.1128/MCB.13.7.3919; Taddei A, 2004, BBA-GENE STRUCT EXPR, V1677, P120, DOI 10.1016/j.bbaexp.2003.11.014; Vollbrandt T, 2004, INT J BIOCHEM CELL B, V36, P1306, DOI 10.1016/j.biocel.2003.11.006; Wang QQ, 2005, CURR BIOL, V15, P384, DOI 10.1016/j.cub.2005.01.046; Weber V, 1997, EUR J BIOCHEM, V249, P309, DOI 10.1111/j.1432-1033.1997.00309.x; WINTERSBERGER U, 1995, YEAST, V11, P929, DOI 10.1002/yea.320111004; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748	45	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18227	18235		10.1074/jbc.M601671200	http://dx.doi.org/10.1074/jbc.M601671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16632467	hybrid			2022-12-25	WOS:000238490300075
J	Stessin, AM; Zippin, JH; Kamenetsky, M; Hess, KC; Buck, J; Levin, LR				Stessin, Alexander M.; Zippin, Jonathan H.; Kamenetsky, Margarita; Hess, Kenneth C.; Buck, Jochen; Levin, Lonny R.			Soluble adenylyl cyclase mediates nerve growth factor-induced activation of Rap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; SPLICE VARIANTS; MAP KINASE; CYCLIC-AMP; CAMP; BICARBONATE; INHIBITION	Nerve growth factor (NGF) and the ubiquitous second messenger cyclic AMP (cAMP) are both implicated in neuronal differentiation. Multiple studies indicate that NGF signals to at least a subset of its targets via cAMP, but the link between NGF and cAMP has remained elusive. Here, we have described the use of small molecule inhibitors to differentiate between the two known sources of cAMP in mammalian cells, bicarbonate- and calcium-responsive soluble adenylyl cyclase (sAC) and G protein-regulated transmembrane adenylyl cyclases. These inhibitors, along with sAC-specific small interfering RNA, reveal that sAC is uniquely responsible for the NGF-elicited rise in cAMP and is essential for the NGF-induced activation of the small G protein Rap1 in PC12 cells. In contrast and as expected, transmembrane adenylyl cyclase-generated cAMP is responsible for Rap1 activation by the G protein-coupled receptor ligand PACAP (pituitary adenylyl cyclase-activating peptide). These results identify sAC as a mediator of NGF signaling and reveal the existence of distinct pathways leading to cAMP-dependent signal transduction.	Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Tri Inst MD PhD Program, New York, NY 10021 USA	Cornell University; Cornell University	Buck, J (corresponding author), Cornell Univ, Weill Med Coll, Dept Pharmacol, 1300 York Ave, New York, NY 10021 USA.	jobuck@med.cornell.edu	Hess, Kenneth/K-6546-2019	Hess, Kenneth/0000-0003-1377-6070; Levin, Lonny/0000-0002-5204-6356	NIAID NIH HHS [AI64842, R01 AI064842] Funding Source: Medline; NICHD NIH HHS [R01 HD038722, HD42060, HD38722] Funding Source: Medline; NIGMS NIH HHS [GM62328, R01 GM062328] Funding Source: Medline; NINDS NIH HHS [R01 NS055255-01A1, R01 NS055255] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055255] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; BRAUN T, 1990, P SOC EXP BIOL MED, V194, P58; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; BUNDEY RA, 2004, SCI STKE 2004, V231, pPE19; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; Esposito G, 2004, P NATL ACAD SCI USA, V101, P2993, DOI 10.1073/pnas.0400050101; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gao Y, 2003, J NEUROSCI, V23, P11770; Geng WD, 2005, AM J PHYSIOL-CELL PH, V288, pC1305, DOI 10.1152/ajpcell.00584.2004; Gille A, 2004, J BIOL CHEM, V279, P19955, DOI 10.1074/jbc.M312560200; GLOWACKA D, 1992, J NEUROSCI RES, V31, P263, DOI 10.1002/jnr.490310207; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; Han H, 2005, J EXP MED, V202, P353, DOI 10.1084/jem.20050778; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; HERNANDEZ A, 1995, PEPTIDES, V16, P927, DOI 10.1016/0196-9781(95)00059-S; Hess KC, 2005, DEV CELL, V9, P249, DOI 10.1016/j.devcel.2005.06.007; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; Jaiswal BS, 2003, P NATL ACAD SCI USA, V100, P10676, DOI 10.1073/pnas.1831008100; Jaiswal BS, 2001, J BIOL CHEM, V276, P31698, DOI 10.1074/jbc.M011698200; JOHNSON RA, 1994, METHOD ENZYMOL, V238, P56; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KNIPPER M, 1993, FEBS LETT, V324, P147, DOI 10.1016/0014-5793(93)81382-A; Lai HL, 1997, J BIOL CHEM, V272, P4970, DOI 10.1074/jbc.272.8.4970; Litvin TN, 2003, J BIOL CHEM, V278, P15922, DOI 10.1074/jbc.M212475200; Lu LG, 2000, EXP CELL RES, V259, P370, DOI 10.1006/excr.2000.4984; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Obara Y, 2004, J CELL SCI, V117, P6085, DOI 10.1242/jcs.01527; OKAMURA N, 1990, BIOCHIM BIOPHYS ACTA, V1035, P83, DOI 10.1016/0304-4165(90)90177-X; Pastor-Soler N, 2003, J BIOL CHEM, V278, P49523, DOI 10.1074/jbc.M309543200; Reed BY, 2002, J CLIN ENDOCR METAB, V87, P1476, DOI 10.1210/jc.87.4.1476; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P4055, DOI 10.1073/pnas.74.9.4055; SEVERIN ES, 1988, ADV ENZYME REGUL, V27, P357, DOI 10.1016/0065-2571(88)90026-X; Sinclair ML, 2000, MOL REPROD DEV, V56, P6, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;6::AID-MRD2&gt;3.0.CO;2-M; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Steegborn C, 2005, J BIOL CHEM, V280, P31754, DOI 10.1074/jbc.M507144200; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zippin JH, 2004, J CELL BIOL, V164, P527, DOI 10.1083/jcb.200311119; Zippin JH, 2002, FASEB J, V16, P82, DOI 10.1096/fj.02-0598fje	45	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17253	17258		10.1074/jbc.M603500200	http://dx.doi.org/10.1074/jbc.M603500200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16627466	Green Accepted, hybrid			2022-12-25	WOS:000238326300052
J	Venkatachalam, K; Hofmann, T; Montell, C				Venkatachalam, Kartik; Hofmann, Thomas; Montell, Craig			Lysosomal localization of TRPML3 depends on TRPML2 and the mucolipidosis-associated protein TRPML1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION CHANNEL; BETA-HEXOSAMINIDASE; MALE-FERTILITY; WILD-TYPE; IV; ENDOCYTOSIS; MUTATIONS; SUBUNIT; IDENTIFICATION; DROSOPHILA	Mucolipidosis type IV is an autosomal recessive lysosomal storage disorder characterized by severe neurodegeneration, achlorhydria, and visual impairments such as corneal opacity and strabismus. The disease arises due to mutations in a group 2 transient receptor potential (TRP)-related cation channel, TRPML1. Mammals encode two additional TRPML proteins named TRPML2 and TRPML3. Information regarding the propensity of these proteins to multimerize, their subcellular distribution and mechanisms that regulate their trafficking are limited. Here we demonstrate that TRPMLs interact to form homo- and heteromultimers. Moreover, the presence of either TRPML1 or TRPML2 specifically influences the spatial distribution of TRPML3. TRPML1 and TRPML2 homomultimers are lysosomal proteins, whereas TRPML3 homomultimers are in the endoplasmic reticulum. However, TRPML3 localizes to lysosomes when coexpressed with either TRPML1 or TRPML2 and is comparably mislocalized when lysosomal targeting of TRPML1 and TRPML2 is disrupted. Conversely, TRPML3 does not cause retention of TRPML1 or TRPML2 in the endoplasmic reticulum. These data demonstrate that there is a hierarchy controlling the subcellular distributions of the TRPMLs such that TRPML1 and TRPML2 dictate the localization of TRPML3 and not vice versa.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Univ Marburg, Inst Pharmakol & Toxikol, D-35033 Marburg, Germany	Johns Hopkins University; Philipps University Marburg	Montell, C (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 408 Wood Basic Sci Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	cmontell@jhmi.edu	Montell, Craig/AAH-3357-2021	Montell, Craig/0000-0001-5637-1482	NEI NIH HHS [EY10852, R01 EY010852-13, R01 EY010852] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010852] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altarescu G, 2002, NEUROLOGY, V59, P306, DOI 10.1212/WNL.59.3.306; Amiri H, 2003, CELL CALCIUM, V33, P463, DOI 10.1016/S0143-4160(03)00061-7; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; Bach G, 2001, MOL GENET METAB, V73, P197, DOI 10.1006/mgme.2001.3195; Bach G, 2005, PFLUG ARCH EUR J PHY, V451, P313, DOI 10.1007/s00424-004-1361-7; Bargal R, 2000, NAT GENET, V26, P118, DOI 10.1038/79095; Bargal R, 2002, NEUROPEDIATRICS, V33, P199, DOI 10.1055/s-2002-34496; Bargal R, 2001, HUM MUTAT, V17, P397, DOI 10.1002/humu.1115; Bassi MT, 2000, AM J HUM GENET, V67, P1110, DOI 10.1016/S0002-9297(07)62941-3; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; Chubanov V, 2004, P NATL ACAD SCI USA, V101, P2894, DOI 10.1073/pnas.0305252101; Di Palma F, 2002, P NATL ACAD SCI USA, V99, P14994, DOI 10.1073/pnas.222425399; DOSREMEDIOS CG, 1995, J STRUCT BIOL, V115, P175, DOI 10.1006/jsbi.1995.1042; Fares H, 2001, NAT GENET, V28, P64, DOI 10.1038/ng0501-64; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gao ZQ, 2003, CURR BIOL, V13, P2175, DOI 10.1016/j.cub.2003.11.053; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Hersh BM, 2002, P NATL ACAD SCI USA, V99, P4355, DOI 10.1073/pnas.062065399; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kiselyov K, 2005, J BIOL CHEM, V280, P43218, DOI 10.1074/jbc.M508210200; Manzoni M, 2004, FEBS LETT, V567, P219, DOI 10.1016/j.febslet.2004.04.080; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Nesti E, 2004, MOL BIOL CELL, V15, P4073, DOI 10.1091/mbc.E03-11-0788; NEUFELD EF, 1989, J BIOL CHEM, V264, P10927; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; PROIA RL, 1984, J BIOL CHEM, V259, P3350; Rous BA, 2002, MOL BIOL CELL, V13, P1071, DOI 10.1091/mbc.01-08-0409; Savina A, 2005, TRAFFIC, V6, P131, DOI 10.1111/j.1600-0854.2004.00257.x; SCHAHEEN L, 2006, DEV BIOL; Soyombo AA, 2006, J BIOL CHEM, V281, P7294, DOI 10.1074/jbc.M508211200; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Sun M, 2000, HUM MOL GENET, V9, P2471, DOI 10.1093/hmg/9.17.2471; Treusch S, 2004, P NATL ACAD SCI USA, V101, P4483, DOI 10.1073/pnas.0400709101; Watnick TJ, 2003, CURR BIOL, V13, P2179, DOI 10.1016/S0960-9822(03)00913-8; Xu H, 2004, EMBO J, V23, P811, DOI 10.1038/sj.emboj.7600112; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	43	113	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17517	17527		10.1074/jbc.M600807200	http://dx.doi.org/10.1074/jbc.M600807200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16606612	Green Accepted, hybrid			2022-12-25	WOS:000238326300078
J	Gustin, JA; Korgaonkar, CK; Pincheira, R; Li, QT; Donner, DB				Gustin, Jason A.; Korgaonkar, Chandrashekhar K.; Pincheira, Roxana; Li, Qiutang; Donner, David B.			Akt regulates basal and induced processing of NF-kappa B2 (p100) to p52	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MICE LACKING; IKK-ALPHA; KINASE-ALPHA; PHOSPHOINOSITIDE 3-KINASE; EMBRYONIC LETHALITY; HEMATOPOIETIC-CELLS; ACTIVATION PATHWAYS; SIGNAL-TRANSDUCTION; LIVER DEGENERATION	NF-kappa B is a family of transcription factors important for innate and adaptive immunity. NF-kappa B is restricted to the cytoplasm by inhibitory proteins that are degraded when specifically phosphorylated, permitting NF-kappa B to enter the nucleus and activate target genes. Phosphorylation of the inhibitory proteins is mediated by an I kappa B kinase (IKK) complex, which can be composed of two subunits with enzymatic activity, IKK alpha and IKK beta. The preferred substrate for IKK beta is I kappa B alpha, degradation of which liberates p65 (RelA) to enter the nucleus where it induces genes important to innate immunity. IKK alpha activates a non-canonical NF-kappa B pathway in which p100 (NF- kappa B2) is processed to p52. Once produced, p52 can enter the nucleus and induce genes important to adaptive immunity. This study shows that Akt binds to and increases the activity of IKK alpha and thereby increases p52 production in cells. Constitutively active Akt augments non-canonical NF-alpha B activity, whereas kinase dead Akt or inhibition of phosphatidylinositol 3-kinase have the opposite effect. Basal and ligand-induced p52 production is reduced in mouse embryo fibroblasts deficient in Akt1 and Akt2 compared with parental cells. These observations show that Akt plays a role in activation of basal and induced non-canonical NF-kappa B activity.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA	University of California System; University of California San Francisco; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; Salk Institute	Donner, DB (corresponding author), Univ Calif San Francisco, Dept Surg, 1600 Divisadero St,Box 1932, San Francisco, CA 94143 USA.	donnerd@surgery.ucsf.edu		Pincheira, Roxana/0000-0003-4277-5245	NCI NIH HHS [CA 67891] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA067891, R01CA067891] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Borlado LR, 2000, FASEB J, V14, P895; BOURS V, 1994, ONCOGENE, V9, P1699; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; de Wit H, 1998, LEUKEMIA, V12, P363, DOI 10.1038/sj.leu.2400950; Deane JA, 2004, ANNU REV IMMUNOL, V22, P563, DOI 10.1146/annurev.immunol.22.012703.104721; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; Donahue AC, 2004, INT IMMUNOL, V16, P1789, DOI 10.1093/intimm/dxh180; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gold MR, 2003, TRENDS IMMUNOL, V24, P104, DOI 10.1016/S1471-4906(03)00022-X; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kishimoto H, 2003, CELL STRUCT FUNCT, V28, P11; Koike R, 1996, EUR J IMMUNOL, V26, P669, DOI 10.1002/eji.1830260324; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin J, 2001, J CELL SCI, V114, P243; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Ohashi PS, 2002, NAT REV IMMUNOL, V2, P427, DOI 10.1038/nri822; Ozes ON, 1999, NATURE, V401, P82; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Ramakrishnan P, 2004, IMMUNITY, V21, P477, DOI 10.1016/j.immuni.2004.08.009; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamada T, 2000, J IMMUNOL, V165, P804, DOI 10.4049/jimmunol.165.2.804; Yang CH, 2005, J BIOL CHEM, V280, P31530, DOI 10.1074/jbc.M503120200; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	81	61	64	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16473	16481		10.1074/jbc.M507373200	http://dx.doi.org/10.1074/jbc.M507373200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16613850	hybrid			2022-12-25	WOS:000238165700037
J	Schuttelkopf, AW; Hamilton, G; Watts, C; van Aalten, DMF				Schuettelkopf, Alexander W.; Hamilton, Garth; Watts, Colin; van Aalten, Daan M. F.			Structural basis of reduction-dependent activation of human cystatin F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; CYSTEINE PROTEASES; PROTEIN; INHIBITION; PEPTIDASE; DESIGN; LOCALIZATION; COMPLEX; PAPAIN; ERRORS	Cystatins are important natural cysteine protease inhibitors targeting primarily papain-like cysteine proteases, including cathepsins and parasitic proteases like cruzipain, but also mammalian asparaginyl endopeptidase. Mammalian cystatin F, which is expressed almost exclusively in hematopoietic cells and accumulates in lysosome-like organelles, has been implicated in the regulation of antigen presentation and other immune processes. It is an unusual cystatin superfamily member with a redox-regulated activation mechanism and a restricted specificity profile. We describe the 2.1 angstrom crystal structure of human cystatin F in its dimeric "off" state. The two monomers interact in a fashion not seen before for cystatins or cystatin-like proteins that is crucially dependent on an unusual intermolecular disulfide bridge, suggesting how reduction leads to monomer formation and activation. Strikingly, core sugars for one of the two N-linked glycosylation sites of cystatin F are well ordered, and their conformation and interactions with the protein indicate that this unique feature of cystatin F may modulate its inhibitory properties, in particular its reduced affinity toward asparaginyl endopeptidase compared with other cystatins.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	van Aalten, DMF (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dow St, Dundee DD1 5EH, Scotland.	dava@davapc1.bioch.dundee.ac.uk		Watts, Colin/0000-0001-6183-2087; van Aalten, Daan/0000-0002-1499-6908	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Adkison AM, 2002, J CLIN INVEST, V109, P363, DOI 10.1172/JCI13462; Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; Alvarez-Fernandez M, 2005, J BIOL CHEM, V280, P18221, DOI 10.1074/jbc.M411914200; Arunachalam B, 2000, P NATL ACAD SCI USA, V97, P745, DOI 10.1073/pnas.97.2.745; Bahadur RP, 2003, PROTEINS, V53, P708, DOI 10.1002/prot.10461; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALBIN M, 1994, J BIOL CHEM, V269, P23156; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; Cappello F, 2004, EXP CELL RES, V297, P607, DOI 10.1016/j.yexcr.2004.03.048; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chowdhury SF, 2002, J MED CHEM, V45, P5321, DOI 10.1021/jm020238t; DIECKMANN T, 1993, J MOL BIOL, V234, P1048, DOI 10.1006/jmbi.1993.1658; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Halfon S, 1998, J BIOL CHEM, V273, P16400, DOI 10.1074/jbc.273.26.16400; Hashimoto S, 2000, BLOOD, V96, P2206, DOI 10.1182/blood.V96.6.2206.h8002206_2206_2214; Honey K, 2003, NAT REV IMMUNOL, V3, P472, DOI 10.1038/nri1110; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Janowski R, 2004, J MOL BIOL, V341, P151, DOI 10.1016/j.jmb.2004.06.013; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; Jenko S, 2003, J MOL BIOL, V326, P875, DOI 10.1016/S0022-2836(02)01432-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang A, 2000, J RHEUMATOL, V27, P1970; Langerholc T, 2005, FEBS J, V272, P1535, DOI 10.1111/j.1742-4658.2005.04594.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morita M, 1999, CANCER RES, V59, P151; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nathanson CM, 2002, EUR J BIOCHEM, V269, P5502, DOI 10.1046/j.1432-1033.2002.03252.x; Ni DTN, 2003, J BIOL CHEM, V278, P38980, DOI 10.1074/jbc.M305930200; Ni J, 1998, J BIOL CHEM, V273, P24797, DOI 10.1074/jbc.273.38.24797; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pape T, 2004, J APPL CRYSTALLOGR, V37, P843, DOI 10.1107/S0021889804018047; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Podgorski I, 2003, BIOCHEM SOC SYMP, V70, P263, DOI 10.1042/bss0700263; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; Turk B, 2002, BIOL CHEM, V383, P1035, DOI 10.1515/BC.2002.112; Turk B, 1997, BIOL CHEM, V378, P141; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Ward YD, 2002, J MED CHEM, V45, P5471, DOI 10.1021/jm020209i	46	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16570	16575		10.1074/jbc.M601033200	http://dx.doi.org/10.1074/jbc.M601033200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16601115	hybrid			2022-12-25	WOS:000238165700048
J	Wang, Y; Lam, KSL; Chan, L; Chan, KW; Lam, JBB; Lam, MC; Hoo, RCL; Mak, WWN; Cooper, GJS; Xu, AM				Wang, Yu; Lam, Karen S. L.; Chan, Lawrence; Chan, Kok Weng; Lam, Janice B. B.; Lam, Michael C.; Hoo, Ruby C. L.; Mak, William W. N.; Cooper, Garth J. S.; Xu, Aimin			Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; INSULIN-RESISTANCE; LYSYL HYDROXYLASE-3; DEFICIENT MICE; PROTEIN; GLUCOSE; ACRP30/ADIPONECTIN; SENSITIVITY; MODULATION; HYPOADIPONECTINEMIA	Adiponectin is a multifunctional adipokine that circulates as several oligomeric complexes in the blood stream. However, the molecular basis that regulates the production of the adiponectin oligomers remains largely elusive. We have shown previously that several conserved lysine residues ( positions 68, 71, 80, and 104) within the collagenous domain of adiponectin are modified by hydroxylation and glycosylation (Wang, Y., Xu, A., Knight, C., Xu, L. Y., and Cooper, G. J. (2002) J. Biol. Chem. 277, 19521 - 19529). Here, we investigated the potential roles of these post-translational modifications in oligomeric complex formation of adiponectin. Gel filtration chromatography revealed that adiponectin produced from mammalian cells formed trimeric, hexameric, and high molecular weight(HMW) oligomeric complexes. These three oligomeric forms were differentially glycosylated, with the HMW oligomer having the highest carbohydrate content. Disruption of hydroxylation and glycosylation by substitution of the four conserved lysines with arginines selectively abrogated the intracellular assembly of the HMW oligomers in vitro as well as in vivo. In type 2 diabetic patients, both the ratios of HMW to total adiponectin and the degree of adiponectin glycosylation were significantly decreased compared with healthy controls. Functional studies of adiponectin-null mice revealed that abrogation of lysine hydroxylation/glycosylation markedly decreased the ability of adiponectin to stimulate phosphorylation of AMP-activated protein kinase in liver tissue. Chronic treatment of db/db diabetic mice with wild-type adiponectin alleviated hyperglycemia, hypertriglyceridemia, hepatic steatosis, and insulin resistance, whereas full-length adiponectin without proper post-translational modifications and HMW oligomers showed substantially decreased activities. Taken together, these data suggest that hydroxylation and glycosylation of the lysine residues within the collagenous domain of adiponectin are critically involved in regulating the formation of its HMW oligomeric complex and consequently contribute to the insulin-sensitizing activity of adiponectin in hepatocytes.	Univ Hong Kong, Genome Res Ctr, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Res Ctr Heart Brain Hormone & Healthy Aging, Hong Kong, Hong Kong, Peoples R China; Baylor Coll Med, Div Endocrinol Diabet & Metab, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Div Endocrinol Diabet & Metab, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Auckland, Sch Biol Sci, Auckland 1001, New Zealand	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; Baylor College of Medicine; Baylor College of Medicine; University of Auckland	Wang, Y (corresponding author), Univ Hong Kong, Genome Res Ctr, Fac Med Bldg,21Sassoon Rd,Pokfulam, Hong Kong, Hong Kong, Peoples R China.	yuwanghk@hkucc.hku.hk	Cooper, Garth JS/I-3201-2015; Lam, Karen Siu Ling/C-4315-2009; Hoo, Ruby/C-4556-2009; Xu, Aimin/D-3291-2013; Wang, Yu/B-4534-2009	Cooper, Garth JS/0000-0001-5241-3163; Xu, Aimin/0000-0002-0668-033X; wang, yu/0000-0001-8697-2940	NHLBI NIH HHS [HL 51586] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajaj M, 2004, J CLIN ENDOCR METAB, V89, P200, DOI 10.1210/jc.2003-031315; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Bobbert T, 2005, DIABETES, V54, P2712, DOI 10.2337/diabetes.54.9.2712; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Combs TP, 2004, ENDOCRINOLOGY, V145, P367, DOI 10.1210/en.2003-1068; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Hammarstedt A, 2005, DIABETOLOGIA, V48, P96, DOI 10.1007/s00125-004-1612-3; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101; Hug C, 2002, BIOTECHNIQUES, V33, P654, DOI 10.2144/02333dd01_11829a; Kamada Y, 2003, GASTROENTEROLOGY, V125, P1796, DOI 10.1053/j.gastro.2003.08.029; Kobayashi H, 2004, CIRC RES, V94, pE27, DOI 10.1161/01.RES.0000119921.86460.37; Lopez-Bermejo A, 2004, CLIN ENDOCRINOL, V60, P256, DOI 10.1046/j.1365-2265.2004.01977.x; Ma K, 2002, J BIOL CHEM, V277, P34658, DOI 10.1074/jbc.C200362200; Masaki T, 2004, HEPATOLOGY, V40, P177, DOI 10.1002/hep.20282; Matsuzawa Y, 2004, ARTERIOSCL THROM VAS, V24, P29, DOI 10.1161/01.ATV.0000099786.99623.EF; Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19; Ouchi N, 2003, HYPERTENSION, V42, P231, DOI 10.1161/01.HYP.0000083488.67550.B8; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; Rautavuoma K, 2004, P NATL ACAD SCI USA, V101, P14120, DOI 10.1073/pnas.0404966101; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shibata R, 2004, NAT MED, V10, P1384, DOI 10.1038/nm1137; Shibata R, 2005, NAT MED, V11, P1096, DOI 10.1038/nm1295; Takahashi T, 2005, J INT MED RES, V33, P207, DOI 10.1177/147323000503300208; Tonelli J, 2004, DIABETES, V53, P1621, DOI 10.2337/diabetes.53.6.1621; Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200; Tsao TS, 2003, J BIOL CHEM, V278, P50810, DOI 10.1074/jbc.M309469200; Tschritter O, 2003, DIABETES, V52, P239, DOI 10.2337/diabetes.52.2.239; Waki H, 2003, J BIOL CHEM, V278, P40352, DOI 10.1074/jbc.M300365200; Wang CG, 2002, MATRIX BIOL, V21, P559, DOI 10.1016/S0945-053X(02)00071-9; Wang Y, 2005, J BIOL CHEM, V280, P18341, DOI 10.1074/jbc.M501149200; Wang Y, 2004, PROTEOMICS, V4, P3933, DOI 10.1002/pmic.200400826; Wang Y, 2002, J BIOL CHEM, V277, P19521, DOI 10.1074/jbc.M200601200; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Xu AM, 2005, P NATL ACAD SCI USA, V102, P6086, DOI 10.1073/pnas.0408452102; Xu AM, 2004, ENDOCRINOLOGY, V145, P487, DOI 10.1210/en.2003-1140; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Xu AM, 2005, J BIOL CHEM, V280, P18073, DOI 10.1074/jbc.M414231200; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yamauchi Toshimasa, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P243, DOI 10.2174/1568008033340090; Zuurmond AM, 2005, MATRIX BIOL, V24, P261, DOI 10.1016/j.matbio.2005.04.002	48	199	213	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16391	16400		10.1074/jbc.M513907200	http://dx.doi.org/10.1074/jbc.M513907200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16621799	hybrid			2022-12-25	WOS:000238165700028
J	Xu, Y; Zhou, YL; Luo, W; Zhu, QS; Levy, D; MacDougald, OA; Snead, ML				Xu, Yucheng; Zhou, Yan Larry; Luo, Wen; Zhu, Qin-Shi; Levy, Daniel; MacDougald, Ormond A.; Snead, Malcolm L.			NF-Y and CCAAT/enhancer-binding protein alpha synergistically activate the mouse amelogenin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-FACTOR-Y; C/EBP-RELATED PROTEINS; TRANSCRIPTION FACTOR; DNA-BINDING; ADIPOCYTE DIFFERENTIATION; DISPLACEMENT PROTEIN; CELL-PROLIFERATION; ADIPOSE-TISSUE; DEFICIENT MICE; GLOBIN GENE	Amelogenin is the major protein component of the forming enamel matrix. In situ hybridization revealed a periodicity for amelogenin mRNA hybridization signals ranging from low to high transcript abundance on serial sections of developing mouse teeth. This in vivo observation led us to examine the amelogenin promoter for the activity of transcription factor(s) that account for this expression aspect of the regulation for the amelogenin gene. We have previously shown that CCAAT/enhancer-binding protein alpha(C/EBP alpha) is a potent transactivator of the mouse X-chromosomal amelogenin gene acting at the C/EBP alpha cis-element located in the -70/+52 minimal promoter. The minimal promoter contains a reversed CCAAT box (-58/-54) that is four base pairs downstream from the C/EBP alpha binding site. Similar to the C/EBP alpha binding site, the integrity of the reversed CCAAT box is also required for maintaining the activity of the basal promoter. We therefore focused on transcription factors that interact with the reversed CCAAT box. Using electrophoretic mobility shift assays we demonstrated that NF-Y was directly bound to this reversed CCAAT site. Co-transfection of C/EBP alpha and NF-Y synergistically increased the promoter activity. In contrast, increased expression of NF-Y alone had only marginal effects on the promoter. A dominant-negative DNA binding-deficient NF-Y mutant (NF-YAm29) dramatically decreased the promoter activity both in the absence or presence of exogenous expression of C/EBP alpha. We identified protein-protein interactions between C/ EBP alpha and NF-Y by a co-immunoprecipitation analysis. These results suggest that C/EBP alpha and NF-Y synergistically activate the mouse amelogenin gene and can contribute to its physiological regulation during amelogenesis.	Univ So Calif, CCMB, Los Angeles, CA 90033 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA	University of Southern California; University of Southern California; University of Michigan System; University of Michigan	Snead, ML (corresponding author), Univ So Calif, CCMB, CSA 142,2250 Alcazar St, Los Angeles, CA 90033 USA.	mlsnead@usc.edu	Levy, Daniel/ABB-2752-2021	MacDougald, Ormond/0000-0001-6907-7960	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE006988] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-06988] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; COUWENHOVEN RI, 1990, J HISTOCHEM CYTOCHEM, V38, P1853, DOI 10.1177/38.12.2254649; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; Jackson SM, 1998, J LIPID RES, V39, P767; Jacobs SBR, 2003, MOL ENDOCRINOL, V17, P1470, DOI 10.1210/me.2002-0286; Jernvall J, 2000, MECH DEVELOP, V92, P19, DOI 10.1016/S0925-4773(99)00322-6; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KIM CG, 1990, J BIOL CHEM, V265, P13362; Kimura T, 1998, J BIOL CHEM, V273, P27505, DOI 10.1074/jbc.273.42.27505; LAGERSTROM M, 1990, AM J HUM GENET, V46, P120; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lane MD, 1996, INT J OBESITY, V20, pS91; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Matuoka K, 2002, AGEING RES REV, V1, P639, DOI 10.1016/S1568-1637(02)00026-0; Matuoka K, 1999, EXP CELL RES, V253, P365, DOI 10.1006/excr.1999.4605; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; Osada S, 1996, FEBS LETT, V390, P44, DOI 10.1016/0014-5793(96)00622-9; Osada S, 1996, J BIOL CHEM, V271, P3891; Paine ML, 2001, MATRIX BIOL, V20, P273, DOI 10.1016/S0945-053X(01)00153-6; Paine ML, 1997, J BONE MINER RES, V12, P221, DOI 10.1359/jbmr.1997.12.2.221; Paine ML, 2002, J BIOL CHEM, V277, P17112, DOI 10.1074/jbc.M110473200; Park SK, 2004, DIABETES, V53, P2757, DOI 10.2337/diabetes.53.11.2757; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ross SE, 2004, MOL CELL BIOL, V24, P675, DOI 10.1128/MCB.24.2.675-686.2004; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; SNEAD ML, 1988, DEVELOPMENT, V104, P77; Snead ML, 1996, CONNECT TISSUE RES, V35, P41, DOI 10.3109/03008209609029173; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; Taira T, 1999, J BIOL CHEM, V274, P24270, DOI 10.1074/jbc.274.34.24270; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Ueda A, 1998, J BIOL CHEM, V273, P19339, DOI 10.1074/jbc.273.30.19339; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhou YL, 2000, J BIOL CHEM, V275, P29066, DOI 10.1074/jbc.M002031200; Zhou YL, 2000, J BIOL CHEM, V275, P12273, DOI 10.1074/jbc.275.16.12273; Zhu J, 2003, BLOOD, V102, P2420, DOI 10.1182/blood-2003-01-0251; Zhu QS, 2004, J BIOL CHEM, V279, P29902, DOI 10.1074/jbc.M400438200; ZORBAS H, 1992, J BIOL CHEM, V267, P8478	60	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16090	16098		10.1074/jbc.M510514200	http://dx.doi.org/10.1074/jbc.M510514200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595692	hybrid			2022-12-25	WOS:000237996000062
J	Wang, T; Allie, R; Conant, K; Haughey, N; Turchan-Chelowo, J; Hahn, K; Rosen, A; Steiner, J; Keswani, S; Jones, M; Calabresi, PA; Nath, A				Wang, Tongguang; Allie, Rameeza; Conant, Katherine; Haughey, Norman; Turchan-Chelowo, Jadwiga; Hahn, Katrin; Rosen, Antony; Steiner, Joseph; Keswani, Sanjay; Jones, Melina; Calabresi, Peter A.; Nath, Avindra			Granzyme B mediates neurotoxicity through a G-protein-coupled receptor	FASEB JOURNAL			English	Article						T cell; multiple sclerosis; pertussis toxin; cAMP; caspase-3; immune reconstitution syndrome	REMITTING MULTIPLE-SCLEROSIS; CYTOTOXIC T-LYMPHOCYTES; LONG-TERM-MEMORY; BRAIN ATROPHY; CELL-DEATH; VENTRICULAR ENLARGEMENT; RASMUSSENS ENCEPHALITIS; CEREBRAL ATROPHY; AXONAL DAMAGE; LATE-PHASE	Neuroinflammatory diseases such as multiple sclerosis ( MS) are characterized by focal regions of demyelination and axonal loss associated with infiltrating T cells. However, the role of activated T cells in causing neuronal injury remains unclear. CD4 and CD8 T cells were isolated from normal donors and polyclonally activated using plate-bound anti-CD3 and soluble anti-CD28. The conditioned T cell supernatants caused toxicity to cultured human fetal neurons, which could be blocked by immunodepleting the supernatants of granzyme B (GrB). Recombinant GrB also caused toxicity in neurons by caspase-dependent pathways but no toxicity was seen in astrocytes. The neurotoxicity was independent of perforin and could not be blocked by mannose-6-phosphate. However, GrB-induced neurotoxicity was sensitive to pertussis toxin, implicating the stimulation of Gi alpha protein-coupled receptors. GrB caused a decrease in cAMP levels but only modest increases in intracellular calcium. The effect on intracellular calcium could be markedly potentiated by stromal-derived factor 1 alpha. GrB-induced neurotoxicity could also be blocked by vitamin E and a neuroimmunophilin ligand. In conclusion, GrB may be an important mediator of neuronal injury in T cell-mediated neuroinflammatory disorders.	Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Internal Med, Baltimore, MD USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Johns Hopkins University; Johns Hopkins University; University of Kentucky	Nath, A (corresponding author), Johns Hopkins Univ, Dept Neurol, Pathol Bldg Rm 509,600 N Wolfe St, Baltimore, MD 21287 USA.	anath1@jhmi.edu	Calabresi, Peter A./AAF-2288-2019	Hahn, Katrin/0000-0002-6013-0072	NIMH NIH HHS [P01MH070056] Funding Source: Medline; NINDS NIH HHS [R01NS043990, R01NS039253] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH070056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039253, R01NS043990] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Adrain C, 2005, J BIOL CHEM, V280, P4663, DOI 10.1074/jbc.M410915200; Bauer J, 2002, CURR OPIN NEUROL, V15, P197, DOI 10.1097/00019052-200204000-00012; Bien CG, 2002, ANN NEUROL, V51, P311, DOI 10.1002/ana.10100; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Bjartmar C, 2001, NEUROLOGY, V57, P1248, DOI 10.1212/WNL.57.7.1248; Brex PA, 2000, NEUROLOGY, V54, P1689, DOI 10.1212/WNL.54.8.1689; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Comi G, 2002, NEUROLOGIA, V17, P244; Dalton CM, 2004, J NEUROL, V251, P407, DOI 10.1007/s00415-004-0332-4; Dalton CM, 2002, J NEUROL NEUROSUR PS, V73, P141, DOI 10.1136/jnnp.73.2.141; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Fox NC, 2000, NEUROLOGY, V54, P807, DOI 10.1212/WNL.54.4.807; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Giuliani F, 2003, J IMMUNOL, V171, P368, DOI 10.4049/jimmunol.171.1.368; Hardmeier M, 2003, ARCH NEUROL-CHICAGO, V60, P1736, DOI 10.1001/archneur.60.12.1736; Haughey NJ, 1999, J NEUROCHEM, V73, P1363, DOI 10.1046/j.1471-4159.1999.0731363.x; Hoftberger R, 2004, BRAIN PATHOL, V14, P43; Kalkers NF, 2002, ARCH NEUROL-CHICAGO, V59, P1572, DOI 10.1001/archneur.59.10.1572; Kalman B, 2003, NEUROMOL MED, V3, P147, DOI 10.1385/NMM:3:3:147; Kuhlmann T, 2002, BRAIN, V125, P2202, DOI 10.1093/brain/awf235; Kurschus FC, 2005, BLOOD, V105, P2049, DOI 10.1182/blood-2004-06-2180; Lazarini F, 2000, EUR J NEUROSCI, V12, P117, DOI 10.1046/j.1460-9568.2000.00894.x; Leist TP, 2001, ARCH NEUROL-CHICAGO, V58, P57, DOI 10.1001/archneur.58.1.57; LovettRacke AE, 1997, J NEUROIMMUNOL, V78, P162, DOI 10.1016/S0165-5728(97)00097-0; Lu FM, 2000, J NEUROL SCI, V177, P95, DOI 10.1016/S0022-510X(00)00343-9; MAGNAN A, 1995, ENFANCE, V1, P37; Martens PB, 1997, ARTHRITIS RHEUM, V40, P1106, DOI 10.1002/art.1780400615; Medana I, 2001, AM J PATHOL, V159, P809, DOI 10.1016/S0002-9440(10)61755-5; Miller RF, 2004, ACTA NEUROPATHOL, V108, P17, DOI 10.1007/s00401-004-0852-0; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Neumann H, 2002, TRENDS NEUROSCI, V25, P313, DOI 10.1016/S0166-2236(02)02154-9; Pashenkov M, 2003, J NEUROIMMUNOL, V135, P154, DOI 10.1016/S0165-5728(02)00441-1; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Pinkoski MJ, 2001, J BIOL CHEM, V276, P12060, DOI 10.1074/jbc.M009038200; Raja SM, 2003, CURR OPIN IMMUNOL, V15, P528, DOI 10.1016/S0952-7915(03)00111-0; Redmond IT, 2000, ACTA NEUROL SCAND, V102, P99, DOI 10.1034/j.1600-0404.2000.102002099.x; Scholz C, 1998, J IMMUNOL, V160, P1532; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; Tepe NM, 2000, J RECEPT SIGNAL TR R, V20, P75, DOI 10.3109/10799890009150038; Trapani JA, 2003, J CELL BIOL, V160, P223, DOI 10.1083/jcb.200210150; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; Trapani JA, 2001, GENOME BIOL, V2; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; van Leeuwen EMM, 2004, J IMMUNOL, V173, P1834, DOI 10.4049/jimmunol.173.3.1834; Vanhoose AM, 2004, NEUROSCI LETT, V370, P80, DOI 10.1016/j.neulet.2004.07.093; Wong ST, 1999, NEURON, V23, P787, DOI 10.1016/S0896-6273(01)80036-2; Wulff H, 2003, J CLIN INVEST, V111, P1703, DOI 10.1172/JCI200316921; Zivadinov R, 2004, J NEUROL SCI, V223, P185, DOI 10.1016/j.jns.2004.05.010; Zivadinov R, 2001, J NEUROL NEUROSUR PS, V70, P773, DOI 10.1136/jnnp.70.6.773; Zivadinov R, 2001, NEUROLOGY, V57, P1239, DOI 10.1212/WNL.57.7.1239	52	51	53	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1209	+		10.1096/fj.05-5022fje	http://dx.doi.org/10.1096/fj.05-5022fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636104				2022-12-25	WOS:000240210300028
J	Ishikawa, F; Shimazu, H; Shultz, LD; Fukata, M; Nakamura, R; Lyons, B; Shimoda, K; Shimoda, S; Kanemaru, T; Nakamura, KI; Ito, H; Kaji, Y; Perry, ACF; Harada, M				Ishikawa, Fumihiko; Shimazu, Hideki; Shultz, Leonard D.; Fukata, Mitsuhiro; Nakamura, Ryu; Lyons, Bonnie; Shimoda, Kazuya; Shimoda, Shinji; Kanemaru, Takaaki; Nakamura, Kei-ichiro; Ito, Hiroyuki; Kaji, Yoshikazu; Perry, Anthony C. F.; Harada, Mine			Purified human hematopoietic stem cells contribute to the generation of cardiomyocytes through cell fusion	FASEB JOURNAL			English	Article							ADULT BONE-MARROW; MYOCARDIAL INFARCTS; PROGENITOR CELLS; OVAL CELLS; MICE; DIFFERENTIATE; HEPATOCYTES; LIVER; PLASTICITY; BLOOD	To obtain insights into the cardiomyogenic potential of hematopoietic tissue, we intravenously (i.v.) injected purified hematopoietic stem/progenitor cells into newborn recipients that may fully potentiate the developmental plasticity of stem cells. Transplantation of mouse bone marrow ( BM) lineage antigen-negative (Lin(-)) cells resulted in the generation of the cells that displayed cardiomyocyte- specific antigenic profiles and contractile function when transplanted into syngeneic newborn recipients. To clarify the mechanism underlying the cardiomyogenic potential, green fluorescent protein (GFP)-labeled BM Lin(-)ScaI(+) hematopoietic progenitors were transplanted into neonatal mice constitutively expressing cyan fluorescence protein ( CFP). Lambda image acquisition and linear unmixing analysis using confocal microscopy successfully separated GFP and CFP, and revealed that odonor GFP(+) cardiomyocytes coexpressed host-derived CFP. We further reconstituted human hemopoietic- and immune systems in mice by injecting human cord blood (CB)-derived Lin(-)CD34(+)CD38(-) hematopoietic stem cells (HSCs) into neonatal T cell(-)B cell(-)NK cell(-) immune-deficient NOD/SCID/IL2r gamma(null) mice. Fluoroescence in situ hybridization analysis of recipient cardiac tissues demonstrated that human and murine chromosomes were colocalized in the same cardiomyocytes, indicating that cell fusion occurred between human hematopoietic progeny and mouse cardiomyocytes. These syngeneic- and xenogeneic neonatal transplantations provide compelling evidence that hematopoietic stem/progenitor cells contribute to the postnatal generation of cardiomyocytes through cell fusion, not through transdifferentiation.	Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosystem Sci, Higashi Ku, Fukuoka 8128582, Japan; Kurume Univ, Sch Med, Dept Anat 2, Kurume, Fukuoka 830, Japan; Zeiss Japan, Tokyo, Japan; RIKEN, Ctr Dev Biol, Lab Mammalian Mol Embryol, Kobe, Hyogo, Japan; Jackson Lab, Bar Harbor, ME 04609 USA; RIKEN, Ctr Allergy & Immunol, Res Unit Human Dis Model, Yokohama, Kanagawa, Japan	Kyushu University; Kurume University; RIKEN; Jackson Laboratory; RIKEN	Ishikawa, F (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosystem Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	f_ishika@intmed1.med.kyushu-u.ac.jp	石川, 文彦/L-4488-2014	Perry, Tony/0000-0003-3136-5355	NHLBI NIH HHS [HL077642] Funding Source: Medline; PHS HHS [A130389] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077642] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Dickinson ME, 2001, BIOTECHNIQUES, V31, P1272, DOI 10.2144/01316bt01; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Ishikawa F, 2002, EXP HEMATOL, V30, P488, DOI 10.1016/S0301-472X(02)00784-1; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Jang YY, 2004, NAT CELL BIOL, V6, P532, DOI 10.1038/ncb1132; Kajstura J, 2005, CIRC RES, V96, P127, DOI 10.1161/01.RES.0000151843.79801.60; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Matsuura K, 2004, J BIOL CHEM, V279, P11384, DOI 10.1074/jbc.M310822200; Matsuura K, 2004, J CELL BIOL, V167, P351, DOI 10.1083/jcb.200312111; Misteli T, 1997, NAT BIOTECHNOL, V15, P961, DOI 10.1038/nbt1097-961; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Orlic D, 2001, ANN NY ACAD SCI, V938, P221; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Prockop DJ, 2004, NEW ENGL J MED, V350, P2302, DOI 10.1056/NEJMcibr040806; Reinecke H, 2004, CIRC RES, V94, pE56, DOI 10.1161/01.RES.0000125294.04612.81; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wang X, 2003, P NATL ACAD SCI USA, V100, P11881, DOI 10.1073/pnas.1734199100; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	36	61	68	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					950	+		10.1096/fj.05-4863fje	http://dx.doi.org/10.1096/fj.05-4863fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585061				2022-12-25	WOS:000240157700018
J	Rastaldi, MP; Armelloni, S; Berra, S; Calvaresi, N; Corbelli, A; Giardino, LA; Li, M; Wang, GQ; Fornasieri, A; Villa, A; Heikkila, E; Soliymani, R; Boucherot, A; Cohen, CD; Kretzler, M; Nitsche, A; Ripamonti, M; Malgaroli, A; Pesaresi, M; Forloni, GL; Schlondoff, D; Holthofer, H; D'Amico, G				Rastaldi, Maria Pia; Armelloni, Silvia; Berra, Silvia; Calvaresi, Novella; Corbelli, Alessandro; Giardino, Laura Anna; Li, Min; Wang, Guo Quin; Fornasieri, Alessandro; Villa, Antonello; Heikkila, Eija; Soliymani, Rabah; Boucherot, Anissa; Cohen, Clemens David; Kretzler, Matthias; Nitsche, Almut; Ripamonti, Maddalena; Malgaroli, Antonio; Pesaresi, Marzia; Forloni, Gian Luigi; Schloendoff, Detlef; Holthofer, Harry; D'Amico, Giuseppe			Glomerular podocytes contain neuron-like functional synaptic vesicles	FASEB JOURNAL			English	Article						synaptic communication; exocytosis; endocytosis; visceral epithelial cells; renal glomerulus	DEPENDENT GLUTAMATE RELEASE; LONG-TERM POTENTIATION; SLIT DIAPHRAGM; PROTEIN; EXPRESSION; MOUSE; RAT; DIFFERENTIATION; ASTROCYTES; RECEPTORS	Although patients with chronic renal failure are increasing worldwide, many aspects of kidney biology remain to be elucidated. Recent research has uncovered several molecular properties of the glomerular filtration barrier, in which podocytes, highly differentiated, ramified cells that enwrap the glomerular basement membrane, have been reported to be mainly responsible for filter's selectivity. We previously described that podocytes express Rab3A, a GTPase restricted to cell types that are capable of highly regulated exocytosis, such as neuronal cells. Here, we first demonstrate by a proteomic study that Rab3A in podocytes coimmmunoprecipitates with molecules once thought to be synapse specific. We then show that podocytes possess structures resembling synaptic vesicles, which contain glutamate, coexpress Rab3A and synaptotagmin 1, and undergo spontaneous and stimulated exocytosis and recycling, with glutamate release. Finally, from the results of a cDNA microarray study, we describe the presence of a series of neuron- and synapse-specific molecules in normal human glomeruli and confirm the glomerular protein expression of both metabotropic and ionotropic glutamate receptors. These data point toward a synaptic-like mechanism of communication among glomerular cells, which perfectly fits with the molecular composition of the glomerular filter and puts in perspective several previous observations, proposing a different working hypothesis for understanding glomerular signaling dynamics.	San Carlos Borromeo Hosp, Renal Immunopathol Lab, Associaz Nuova Nefrol & Fdn Amico Ric Malattie Re, Dept Nephrol & Immunol, I-20153 Milan, Italy; Univ Milan, Microscopy & Image Anal Consortium, Dept Neurosci & Biomed Techol, Monza, Italy; Biomedicum, Helsinki, Finland; Biomedicum, Prot Chem Unit, Helsinki, Finland; Univ Munich, Med Policlin, Munich, Germany; Univ Vita Salute S Raffaele, Neurobiol Learning Unit, Segrate, Italy; Sanofi Aventis, Frankfurt, Germany; Mario Negri Inst Pharmacol Res, Biol Neurodegenerat Dis Lab, I-20157 Milan, Italy	San Carlo Borromeo Hospital; University of Milan; University of Helsinki; University of Helsinki; University of Munich; Sanofi-Aventis; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Rastaldi, MP (corresponding author), San Carlos Borromeo Hosp, Renal Immunopathol Lab, Associaz Nuova Nefrol & Fdn Amico Ric Malattie Re, Dept Nephrol & Immunol, Via Pio 2,3, I-20153 Milan, Italy.	mp.rastaldi@fastwebnet.it	Corbelli, Alessandro/ABG-3900-2020; Villa, Antonello/B-4781-2012; Berra, Silvia/E-2863-2015; Forloni, Gianluigi/AAB-2115-2020; Malgaroli, Antonio/I-5090-2013; Li, Min/AAL-7828-2021; Ripamonti, Maddalena/AAN-2430-2020; Li, Min/AFJ-8435-2022; Armelloni, Silvia/AAP-8617-2021; Li, Min/AAF-5252-2022	Corbelli, Alessandro/0000-0001-8545-8050; Berra, Silvia/0000-0003-1151-7040; Forloni, Gianluigi/0000-0001-5374-3914; Malgaroli, Antonio/0000-0003-3758-7477; Li, Min/0000-0003-1350-9909; Ripamonti, Maddalena/0000-0002-2664-8898; Armelloni, Silvia/0000-0001-6431-2642; Villa, Antonello/0000-0002-3820-8072				Ahola H, 2003, J AM SOC NEPHROL, V14, P1731, DOI 10.1097/01.ASN.0000075553.33781.9F; APVENSTADT H, 2003, PHYSIOL REV, V83, P253; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Bek M, 1999, NEPHROL DIAL TRANSPL, V14, P581, DOI 10.1093/ndt/14.3.581; Beltran PJ, 2003, J COMP NEUROL, V456, P384, DOI 10.1002/cne.10532; Benson DL, 2001, NAT REV NEUROSCI, V2, P899, DOI 10.1038/35104078; Benzing T, 2004, J AM SOC NEPHROL, V15, P1382, DOI 10.1097/01.ASN.0000130167.30769.55; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Cohen CD, 2005, J AM SOC NEPHROL, V16, P1958, DOI 10.1681/ASN.2005020204; Cohen CD, 2002, KIDNEY INT, V61, P133, DOI 10.1046/j.1523-1755.2002.00113.x; Cousin MA, 1999, J NEUROCHEM, V73, P2227, DOI 10.1046/j.1471-4159.1999.0732227.x; Gloy J, 2000, AM J PHYSIOL-RENAL, V278, pF999, DOI 10.1152/ajprenal.2000.278.6.F999; Hinoi E, 2004, EUR J BIOCHEM, V271, P1, DOI 10.1046/j.1432-1033.2003.03907.x; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; Kobayashi Naoto, 2004, Anatomical Science International, V79, P1, DOI 10.1111/j.1447-073x.2004.00066.x; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Miner JH, 2005, J AM SOC NEPHROL, V16, P857, DOI 10.1681/ASN.2004121139; MUNDEL P, 1991, J HISTOCHEM CYTOCHEM, V39, P1047, DOI 10.1177/39.8.1856454; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; Nitschke R, 2001, J AM SOC NEPHROL, V12, P678, DOI 10.1681/ASN.V124678; OConnell KL, 1997, ELECTROPHORESIS, V18, P349, DOI 10.1002/elps.1150180309; Peitsch WK, 2003, J AM SOC NEPHROL, V14, P1452, DOI 10.1097/01.ASN.0000069222.63700.DE; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Raats CJI, 2000, AM J PATHOL, V156, P1749, DOI 10.1016/S0002-9440(10)65046-8; Rastaldi MP, 2003, AM J PATHOL, V163, P889, DOI 10.1016/S0002-9440(10)63449-9; REEVES W, 1978, LAB INVEST, V39, P90; RODEWALD R, 1974, J CELL BIOL, V60, P423, DOI 10.1083/jcb.60.2.423; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Schluter OM, 2004, J NEUROSCI, V24, P6629, DOI 10.1523/JNEUROSCI.1610-04.2004; Shen K, 2003, CELL, V112, P619, DOI 10.1016/S0092-8674(03)00113-2; Sudhof TC, 2001, ANNU REV NEUROSCI, V24, P933, DOI 10.1146/annurev.neuro.24.1.933; Yamagata M, 2003, CURR OPIN CELL BIOL, V15, P621, DOI 10.1016/S0955-0674(03)00107-8	34	81	88	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					976	+		10.1096/fj.05-4962fje	http://dx.doi.org/10.1096/fj.05-4962fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585060				2022-12-25	WOS:000240157700027
J	Cheon, SS; Wei, QX; Gurung, A; Youn, A; Bright, T; Poon, R; Whetstone, H; Guha, A; Alman, BA				Cheon, Sophia S.; Wei, Qingxia; Gurung, Ananta; Youn, Andrew; Bright, Tamara; Poon, Raymond; Whetstone, Heather; Guha, Abhijit; Alman, Benjamin A.			Beta-catenin regulates wound size and mediates the effect of TGF-beta in cutaneous healing	FASEB JOURNAL			English	Article						beta-catenin; wound healing; transgenic mice	GROWTH-FACTOR-BETA; DEPENDENT TRANSCRIPTIONAL ACTIVATION; MARROW-DERIVED CELLS; MICE LACKING SMAD3; AGGRESSIVE FIBROMATOSIS; WNT; DIFFERENTIATION; EXPRESSION; PROLIFERATION; GENE	After cutaneous injury, a variety of cell types are activated to reconstitute the epithelial and dermal components of the skin. beta-Catenin plays disparate roles in keratinocytes and fibroblasts, inhibiting keratinocyte migration and activating fibroblast proliferation, suggesting that beta-catenin could either inhibit or enhance the healing process. How beta-catenin functions in concert with other signaling pathways important in the healing process is unknown. Wound size was examined in mice expressing conditional null or conditional stabilized alleles of beta-catenin, regulated by an adenovirus expressing cre-recombinase. The size of the wounds in the mice correlated with the protein level of beta-catenin. Using mice expressing these conditional alleles, we found that the wound phenotype imparted by Smad3 deficiency and by the injection of TGF beta before wounding is mediated in part by beta-catenin. TGF beta was not able to regulate proliferation in beta-catenin null fibroblasts, whereas keratinocyte proliferation rate was independent of beta-catenin. When mice are treated with lithium, beta-catenin-mediated signaling was activated in cutaneous wounds, which healed with a larger size. These results demonstrate a crucial role for beta-catenin in regulating cutaneous wound size. Furthermore, these data implicate mesenchymal cells as playing a critical role regulating wound size.-Cheon, S. S., Wei, Q., Gurung, A., Youn, A., Bright, T., Poon, R., Whetstone, H., Guha, A., Alman, B. A. Beta-catenin regulates wound size and mediates the effect of TGF-beta in cutaneous healing.	Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; Hosp Sick Children, Program Canc Res, Arthur & Sonia Labatts Brain Tumor Ctr, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Alman, BA (corresponding author), 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	benjamin.alman@sickkids.ca						Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Badiavas EV, 2003, J CELL PHYSIOL, V196, P245, DOI 10.1002/jcp.10260; Behrens J, 2000, J CELL SCI, V113, P911; Brault V, 2001, DEVELOPMENT, V128, P1253; Cheon S, 2005, LAB INVEST, V85, P416, DOI 10.1038/labinvest.3700237; Cheon SS, 2004, EXP CELL RES, V293, P267, DOI 10.1016/j.yexcr.2003.09.029; Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016; De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753; Dehpour AR, 2002, PHARMACOL TOXICOL, V90, P89, DOI 10.1034/j.1600-0773.2002.900206.x; Denys H, 2004, BRIT J CANCER, V90, P1443, DOI 10.1038/sj.bjc.6601661; Derfoul A, 2004, DIFFERENTIATION, V72, P209, DOI 10.1111/j.1432-0436.2004.07205003.x; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Falanga V, 2004, WOUND REPAIR REGEN, V12, P320, DOI 10.1111/j.1067-1927.2004.012316.x; Fathke C, 2004, STEM CELLS, V22, P812, DOI 10.1634/stemcells.22-5-812; Flanders KC, 2002, AM J PATHOL, V160, P1057, DOI 10.1016/S0002-9440(10)64926-7; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Harada N, 2002, CANCER RES, V62, P1971; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Kong Y, 2004, CANCER RES, V64, P5795, DOI 10.1158/0008-5472.CAN-03-3112; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; McClain SA, 1996, AM J PATHOL, V149, P1257; MIESCHER GC, 1989, IMMUNOL LETT, V23, P113, DOI 10.1016/0165-2478(89)90122-3; MONTAGNA W, 1987, AM J DERMATOPATH, V9, P26, DOI 10.1097/00000372-198702000-00006; Muller HAJ, 1999, DEVELOPMENT, V126, P577; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Philipp K, 2005, INT J MOL MED, V15, P299; Poon R, 2001, ONCOGENE, V20, P451, DOI 10.1038/sj.onc.1204107; Posthaus H, 2002, J CELL SCI, V115, P4587, DOI 10.1242/jcs.00141; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Scheid A, 2000, EXP PHYSIOL, V85, P687, DOI 10.1017/S0958067000021035; Schiller M, 2004, J DERMATOL SCI, V35, P83, DOI 10.1016/j.jdermsci.2003.12.006; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stojadinovic O, 2005, AM J PATHOL, V167, P59, DOI 10.1016/S0002-9440(10)62953-7; Sylvester KG, 2000, WOUND REPAIR REGEN, V8, P36, DOI 10.1046/j.1524-475x.2000.00036.x; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	49	169	184	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					692	701		10.1096/fj.05-4759com	http://dx.doi.org/10.1096/fj.05-4759com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581977				2022-12-25	WOS:000240130900015
J	Liu, Y; Borchert, GL; Surazynski, A; Hu, CA; Phang, JM				Liu, Y.; Borchert, G. L.; Surazynski, A.; Hu, C. -A; Phang, J. M.			Proline oxidase activates both intrinsic and extrinsic pathways for apoptosis: the role of ROS/superoxides, NFAT and MEK/ERK signaling	ONCOGENE			English	Article						proline oxidase; apoptosis; superoxide radicals; NFAT; ERK; metabolism	COLORECTAL-CANCER CELLS; MITOCHONDRIAL SUPEROXIDE ANIONS; T-CELLS; P53-INDUCED GENE-6; PROTEIN-KINASES; RECEPTOR GENE; EXPRESSION; DEATH; PUMA; FAS	Proline oxidase (POX), often considered a 'housekeeping enzyme' might play an important role in apoptosis. We have shown that POX generated proline-dependent reactive oxygen species (ROS), specifically superoxide radicals, and induced apoptosis through the mitochondrial (intrinsic) pathway. In our current report, we used DLD-1 colorectal cancer cells stably transfected with the POX gene under the control of a tetracycline-inducible promoter and found POX-stimulated expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL), DR5 and cleavage of caspase-8. Importantly, apoptosis measured by flow cytometry was partially inhibited by Z-IETD-FMK, a specific inhibitor of caspase-8. These findings suggest that the extrinsic (death receptor) pathway also is activated by POX. Furthermore, the mechanism of this effect on the extrinsic pathway, specifically, the induction of TRAIL by POX, may be mediated by NFAT transcription factors. Additionally, POX expression also dramatically decreased phosphorylation of MEK and ERK, and the decrease was partially reversed by expression of manganese superoxide dismutase (MnSOD). Overexpression of constitutively active form of MEK, acMEK, partially blocked POX-induced apoptosis. These findings suggest the involvement of MEK/ERK signaling and further confirm the role of ROS/superoxides in POX-induced apoptosis. Combined with previously published data, we conclude that POX may induce apoptosis through both intrinsic and extrinsic pathways and is involved in nuclear factor of activated T cells (NFAT) signaling and regulation of the MEK/ERK pathway. It is suggested that, as a nutrition factor, POX may modulate apoptosis signals induced by p53 or other anti-cancer agents and enhance apoptosis in stress situations.	Natl Canc Inst, Ctr Canc Res, Comparat Carcinogenesis Lab, Metab & Canc Susceptibil Sect, Frederick, MD 21702 USA; SAIC Federick Inc, Basic Res Program, Frederick, MD USA; Univ New Mexico, Hlth Sci Ctr, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of New Mexico; University of New Mexico's Health Sciences Center	Liu, Y (corresponding author), Natl Canc Inst, Ctr Canc Res, Comparat Carcinogenesis Lab, Metab & Canc Susceptibil Sect, Frederick, MD 21702 USA.	liuy@ncifcrf.gov; phang@ncifcrf.gov	Surażynski, Arkadiusz/ABG-2795-2020	Surażynski, Arkadiusz/0000-0003-4475-873X	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC000157] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC010743] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams E, 1970, Int Rev Connect Tissue Res, V5, P1; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Delwing D, 2003, BRAIN RES, V991, P180, DOI 10.1016/j.brainres.2003.08.014; Donald SP, 2001, CANCER RES, V61, P1810; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; Dussmann H, 2003, J BIOL CHEM, V278, P12645, DOI 10.1074/jbc.M210826200; HAGEDORN CH, 1983, ARCH BIOCHEM BIOPHYS, V225, P95, DOI 10.1016/0003-9861(83)90010-3; Hamilton G, 2004, J CLIN ONCOL, V22, p235S; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083; Loo G, 2003, J NUTR BIOCHEM, V14, P64, DOI 10.1016/S0955-2863(02)00251-6; Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Pani G, 2004, CURR MED CHEM, V11, P1299, DOI 10.2174/0929867043365297; Phang J. M., 2001, METABOLIC MOL BASES, P1821; PHANG JM, 1982, J CELL PHYSIOL, V110, P255, DOI 10.1002/jcp.1041100306; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rivera A, 2005, J BIOL CHEM, V280, P29346, DOI 10.1074/jbc.M504852200; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Wenzel U, 2004, CARCINOGENESIS, V25, P703, DOI 10.1093/carcin/bgh079; Wenzel U, 2003, INT J CANCER, V106, P666, DOI 10.1002/ijc.11294; Wilson DJ, 1999, CELL IMMUNOL, V194, P67, DOI 10.1006/cimm.1999.1486; Wu GS, 2000, ADV EXP MED BIOL, V465, P143; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	38	134	137	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5640	5647		10.1038/sj.onc.1209564	http://dx.doi.org/10.1038/sj.onc.1209564			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16619034				2022-12-25	WOS:000240599100005
J	Preston, A; Petersen, BO; Duus, JO; Kubler-Kielb, J; Ben-Menachem, G; Li, JJ; Vinogradov, E				Preston, Andrew; Petersen, Bent O.; Duus, Jens O.; Kubler-Kielb, Joanna; Ben-Menachem, Gil; Li, Jianjun; Vinogradov, Evgeny			Complete structures of Bordetella bronchiseptica and Bordetella parapertussis lipopolysaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-TRACT INFECTION; BIOSYNTHESIS LOCUS; O-ANTIGEN; PERTUSSIS; POLYSACCHARIDES; HOST; WLB	The structures of the lipopolysaccharide (LPS) core and O antigen of Bordetella bronchiseptica and Bordetella parapertussis are known, but how these two regions are linked to each other had not been determined. We have studied LPS from several strains of these microorganisms to determine the complete carbohydrate structure of the LPS. LPS was analyzed using different chemical degradations, NMR spectroscopy, and mass spectrometry. This identified a novel pentasaccharide fragment that links the O chain to the core in all the LPS studied. In addition, although the O chain of these bacteria was reported as a homopolymer of 1,4-linked 2,3-diacetamido-2,3-dideoxy-alpha-galacturonic acid, we discovered that the polymer contains several amidated uronic acids, the number of which varies between strains. These new data describe the complete structure of the LPS carbohydrate backbone for both Bordetella species and help to explain the complex genetics of LPS biosynthesis in these bacteria.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada; Carlsberg Lab, DK-2500 Copenhagen, Denmark; NICHD, NIH, Bethesda, MD 20892 USA	National Research Council Canada; University of Guelph; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Vinogradov, E (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	evguenii.vinogradov@nrc-cnrc.gc.ca	Duus, Jens Øllgaard/N-4279-2013	Duus, Jens Øllgaard/0000-0003-3625-1250; Preston, Andrew/0000-0002-1489-280X; Vinogradov, Evgeny/0000-0002-5364-1376	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008843] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008843] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Allen A, 1996, MOL MICROBIOL, V19, P37, DOI 10.1046/j.1365-2958.1996.354877.x; Allen AG, 1998, MOL MICROBIOL, V29, P27, DOI 10.1046/j.1365-2958.1998.00878.x; Bjornstad ON, 2005, TRENDS MICROBIOL, V13, P355, DOI 10.1016/j.tim.2005.06.007; Burns VC, 2003, INFECT IMMUN, V71, P86, DOI 10.1128/IAI.71.1.86-94.2003; Caroff M, 2002, MICROBES INFECT, V4, P915, DOI 10.1016/S1286-4579(02)01612-X; Caroff M, 2001, J ENDOTOXIN RES, V7, P63, DOI 10.1177/09680519010070011101; Caroff M, 2000, FEBS LETT, V477, P8, DOI 10.1016/S0014-5793(00)01720-8; Cummings CA, 2004, J BACTERIOL, V186, P1484, DOI 10.1128/JB.186.5.1484-1492.2004; Diavatopoulos DA, 2005, PLOS PATHOG, V1, P373, DOI 10.1371/journal.ooat.0010045; DIFABIO JL, 1992, FEMS MICROBIOL LETT, V97, P275, DOI 10.1111/j.1574-6968.1992.tb05475.x; GUEIRARD P, 1995, J CLIN MICROBIOL, V33, P2002, DOI 10.1128/JCM.33.8.2002-2006.1995; Harvill ET, 2000, INFECT IMMUN, V68, P6720, DOI 10.1128/IAI.68.12.6720-6728.2000; KJAER M, 1994, METHODS ENZYMOL, V239, P288; Li JJ, 2005, RAPID COMMUN MASS SP, V19, P1305, DOI 10.1002/rcm.1927; Mattoo S, 2005, CLIN MICROBIOL REV, V18, P326, DOI 10.1128/CMR.18.2.326-382.2005; Parkhill J, 2003, NAT GENET, V35, P32, DOI 10.1038/ng1227; Preston A, 1999, INFECT IMMUN, V67, P3763, DOI 10.1128/IAI.67.8.3763-3767.1999; Preston A, 2002, MICROB PATHOGENESIS, V33, P91, DOI 10.1006/mpat.2002.0511; Preston A, 2001, J ENDOTOXIN RES, V7, P251, DOI 10.1177/09680519010070040601; SHAHIN RD, 1994, INFECT IMMUN, V62, P722, DOI 10.1128/IAI.62.2.722-725.1994; STAINER DW, 1970, J GEN MICROBIOL, V63, P211, DOI 10.1099/00221287-63-2-211; Stevenson A, 2003, FEMS IMMUNOL MED MIC, V37, P121, DOI 10.1016/S0928-8244(03)00068-3; Vinogradov E, 2000, EUR J BIOCHEM, V267, P2439, DOI 10.1046/j.1432-1327.2000.01262.x; Vinogradov E, 2000, EUR J BIOCHEM, V267, P7230, DOI 10.1046/j.1432-1327.2000.01835.x; WOOLFREY BF, 1991, CLIN MICROBIOL REV, V4, P243, DOI 10.1128/CMR.4.3.243-255.1991	25	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18135	18144		10.1074/jbc.M513904200	http://dx.doi.org/10.1074/jbc.M513904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16632471	hybrid			2022-12-25	WOS:000238490300065
J	Hales, TG; Deeb, TZ; Tang, HY; Bollan, KA; King, DP; Johnson, SJ; Connolly, CN				Hales, Tim G.; Deeb, Tarek Z.; Tang, Haiyan; Bollan, Karen A.; King, Dale P.; Johnson, Sara J.; Connolly, Christopher N.			An asymmetric contribution to gamma-aminobutyric type a receptor function of a conserved lysine within TM2-3 of alpha 1, beta 2, and gamma 2 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHILDHOOD ABSENCE EPILEPSY; CELL-SURFACE EXPRESSION; FEBRILE SEIZURES; GABA(A) RECEPTORS; CHARGED RESIDUES; AGONIST BINDING; ALPHA-SUBUNITS; MUTATION; CHANNEL; ACTIVATION	Mutations that impair the expression and/or function of gamma-aminobutyric acid type A (GABA(A)) receptors can lead to epilepsy. The familial epilepsy gamma 2(K289M) mutation affects a basic residue conserved in the TM2-3 linker of most GABA(A) subunits. We investigated the effect on expression and function of the Lys -> Met mutation in mouse alpha 1(K278M), beta 2(K274M), and gamma 2( K289M) subunits. Compared with cells expressing wild-type and alpha 1 beta 2 gamma 2(K289M) receptors, cells expressing alpha 1(K278M)beta 2 gamma 2 and alpha 1 beta 2(K274M)gamma 2 receptors exhibited reduced agonist-evoked current density and reduced GABA potency, with no change in single channel conductance. The low current density of alpha 1 beta 2(K274M)gamma 2 receptors coincided with reduced surface expression. By contrast the surface expression of alpha 1(K278M)beta 2 gamma 2 receptors was similar to wild-type and alpha 1 beta 2 gamma 2(K289M) receptors suggesting that the alpha 1(K278M) impairs function. In keeping with this interpretation GABA-activated channels mediated by alpha 1(K278M)gamma 2 receptors had brief open times. To a lesser extent gamma 2(K289M) also reduced mean open time, whereas beta 2(K274M) had no effect. We used propofol as an alternative GABA(A) receptor agonist to test whether the functional deficits of mutant subunits were specific to GABA activation. Propofol was less potent as an activator of alpha 1(K278M)beta 2 gamma 2 receptors. By contrast, neither beta 2(K274M) nor gamma 2(K289M) affected the potency of propofol. The beta 2(K274M) construct was unique in that it reduced the efficacy of propofol activation relative to GABA. These data suggest that the alpha 1 subunit Lys-278 residue plays a pivotal role in channel gating that is not dependent on occupancy of the GABA binding site. Moreover, the conserved TM2-3 loop lysine has an asymmetric function in different GABAA subunits.	George Washington Univ, Dept Physiol & Pharmacol, Washington, DC 20037 USA; George Washington Univ, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA; Univ Dundee, Ninewells Hosp & Med Sch, Dept Pharmacol & Neurosci, Dundee DD1 9SY, Scotland	George Washington University; George Washington University; University of Dundee	Hales, TG (corresponding author), George Washington Univ, Med Ctr, Dept Pharmacol, 2300 Eye St NW, Washington, DC 20037 USA.	phmtgh@gwumc.edu		Johnson, Sara/0000-0001-6308-6401; Connolly, Christopher/0000-0002-0445-8874	NIGMS NIH HHS [GM058037] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Absalom NL, 2003, J BIOL CHEM, V278, P50151, DOI 10.1074/jbc.M305357200; ADODRA S, 1995, BRIT J PHARMACOL, V115, P953, DOI 10.1111/j.1476-5381.1995.tb15903.x; Akk G, 2004, J PHYSIOL-LONDON, V558, P59, DOI 10.1113/jphysiol.2004.066571; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; Bianchi MT, 2002, J NEUROSCI, V22, P5321; Bollan K, 2003, J BIOL CHEM, V278, P4747, DOI 10.1074/jbc.M210229200; Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; Bowser DN, 2002, P NATL ACAD SCI USA, V99, P15170, DOI 10.1073/pnas.212320199; CamposCaro A, 1996, P NATL ACAD SCI USA, V93, P6118, DOI 10.1073/pnas.93.12.6118; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; Connolly CN, 2004, BIOCHEM SOC T, V32, P529, DOI 10.1042/BST0320529; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Cossette P, 2002, NAT GENET, V31, P184, DOI 10.1038/ng885; Crestani F, 1999, NAT NEUROSCI, V2, P833, DOI 10.1038/12207; Davies PA, 2001, J PHYSIOL-LONDON, V537, P101, DOI 10.1111/j.1469-7793.2001.0101k.x; Davies PA, 1997, BRIT J PHARMACOL, V120, P899, DOI 10.1038/sj.bjp.0700987; Davies PA, 2003, J BIOL CHEM, V278, P712, DOI 10.1074/jbc.M208814200; Dibbens LM, 2004, HUM MOL GENET, V13, P1315, DOI 10.1093/hmg/ddh146; Elmslie FV, 1996, J MED GENET, V33, P435, DOI 10.1136/jmg.33.5.435; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fisher JL, 2004, NEUROPHARMACOLOGY, V46, P629, DOI 10.1016/j.neuropharm.2003.11.015; Gallagher MJ, 2004, J NEUROSCI, V24, P5570, DOI 10.1523/JNEUROSCI.1301-04.2004; Haas KF, 1999, J PHYSIOL-LONDON, V514, P27, DOI 10.1111/j.1469-7793.1999.027af.x; Hales TG, 2005, MOL CELL NEUROSCI, V29, P120, DOI 10.1016/j.mcn.2005.01.002; HALES TG, 1991, BRIT J PHARMACOL, V104, P619, DOI 10.1111/j.1476-5381.1991.tb12479.x; Harkin LA, 2002, AM J HUM GENET, V70, P530, DOI 10.1086/338710; Kang JQ, 2006, J NEUROSCI, V26, P2590, DOI 10.1523/JNEUROSCI.4243-05.2006; Kang JQ, 2004, J NEUROSCI, V24, P8672, DOI 10.1523/JNEUROSCI.2717-04.2004; Kash TL, 2004, J BIOL CHEM, V279, P4887, DOI 10.1074/jbc.M311441200; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Lummis SCR, 2005, NATURE, V438, P248, DOI 10.1038/nature04130; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; Marini C, 2003, BRAIN, V126, P230, DOI 10.1093/brain/awg018; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009; O'Mara M, 2005, BIOPHYS J, V88, P3286, DOI 10.1529/biophysj.104.051664; Ramakrishnan L, 2004, BIOCHEMISTRY-US, V43, P7534, DOI 10.1021/bi036181+; Sala F, 2005, J BIOL CHEM, V280, P6642, DOI 10.1074/jbc.M411048200; Sancar F, 2004, J BIOL CHEM, V279, P47034, DOI 10.1074/jbc.M403388200; Shan Q, 2003, J NEUROCHEM, V86, P498, DOI 10.1046/j.1471-4159.2003.01872.x; Sigel E, 1999, J NEUROCHEM, V73, P1758, DOI 10.1046/j.1471-4159.1999.731758.x; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Tretter V, 1997, J NEUROSCI, V17, P2728; TWYMAN RE, 1989, ANN NEUROL, V25, P213, DOI 10.1002/ana.410250302; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/ng0501-49; Waruiru C, 2004, ARCH DIS CHILD, V89, P751, DOI 10.1136/adc.2003.028449	47	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17034	17043		10.1074/jbc.M603599200	http://dx.doi.org/10.1074/jbc.M603599200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16627470	hybrid			2022-12-25	WOS:000238326300025
J	Moreno, E; San Cristobal, P; Rivera, M; Vazquez, N; Bobadilla, NA; Gamba, G				Moreno, Erika; San Cristobal, Pedro; Rivera, Manuel; Vazquez, Norma; Bobadilla, Norma A.; Gamba, Gerardo			Affinity-defining domains in the Na-Cl cotransporter - A different location for Cl- and thiazide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-2CL(-) COTRANSPORTER; APICAL NA+-K+-2CL(-); MOLECULAR-CLONING; ION-TRANSPORT; CHLORIDE; GLYCOSYLATION; LOCALIZATION; ACTIVATION; EXPRESSION; VARIANTS	The thiazide-sensitive Na+-Cl- cotransporter (NCC) is the major pathway for salt reabsorption in the distal convoluted tubule, serves as a receptor for thiazide-type diuretics, and is involved in inherited diseases associated with abnormal blood pressure. Little is known regarding the structure-function relationship in this cotransporter. Previous studies from our group reveal that mammalian NCC exhibits higher affinity for ions and thiazides than teleost NCC and suggest a role for glycosylation upon thiazide affinity. Here we have constructed a series of chimeric and mutant cDNAs between rat and flounder NCC to define the role of glycosylation status, the amino-terminal domain, the carboxyl-terminal domain, the extracellular glycosylated loop, and the transmembrane segments upon affinity for Na+, Cl-, and metolazone. Xenopus laevis oocytes were used as the heterologous expression system. We observed that elimination of glycosylation sites in flounder NCC did not affect the affinity of the cotransporter for metolazone. Also, swapping the amino-terminal domain, the carboxyl-terminal domain, the glycosylation sites, or the entire extracellular glycosylation loop between rat and flounder NCC had no effect upon ions or metolazone affinity. In contrast, interchanging transmembrane regions between rat and flounder NCC revealed that affinity-modifying residues for chloride are located within the transmembrane 1-7 region and for thiazides are located within the transmembrane 8-12 region, whereas both segments seem to be implicated in defining sodium affinity. These observations strongly suggest that binding sites for chloride and thiazide in NCC are different.	Univ Nacl Autonoma Mexico, Inst Invest Biomed, Inst Nacl Ciencias Med & Nutr, Mol Physiol Unit, Mexico City 14000, DF, Mexico; Univ Autonoma Estado Hidalgo, Inst Ciencias Salud, Hidalgo 42160, Mexico	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Universidad Nacional Autonoma de Mexico; Universidad Autonoma del Estado de Hidalgo	Gamba, G (corresponding author), Univ Nacl Autonoma Mexico, Inst Invest Biomed, Inst Nacl Ciencias Med & Nutr, Mol Physiol Unit, Vasco Quiroga 15, Mexico City 14000, DF, Mexico.	gamba@biomedicas.unam.mx	Rivera, Manuel/AAG-1449-2020; Gamba, Gerardo/P-4873-2016	Rivera, Manuel/0000-0001-9343-8383; Gamba, Gerardo/0000-0002-4378-9043; Moreno Martinez, Reyna Erika/0000-0002-7563-0379	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064635] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ELLISON DH, 1987, AM J PHYSIOL, V253, pF546, DOI 10.1152/ajprenal.1987.253.3.F546; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; Gamba G, 2005, PHYSIOL REV, V85, P423, DOI 10.1152/physrev.00011.2004; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gamba G, 2000, CURR OPIN NEPHROL HY, V9, P535, DOI 10.1097/00041552-200009000-00013; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; Gimenez I, 2002, J BIOL CHEM, V277, P8767, DOI 10.1074/jbc.C200021200; Hoover RS, 2003, J AM SOC NEPHROL, V14, P271, DOI 10.1097/01.ASN.0000043903.93452.D0; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Isenring P, 2001, COMP BIOCHEM PHYS A, V130, P487, DOI 10.1016/S1095-6433(01)00420-2; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; Mastroianni N, 1996, GENOMICS, V35, P486, DOI 10.1006/geno.1996.0388; Mastroianni N, 1996, AM J HUM GENET, V59, P1019; Mayan H, 2002, J CLIN ENDOCR METAB, V87, P3248, DOI 10.1210/jc.87.7.3248; Meade P, 2003, AM J PHYSIOL-RENAL, V284, pF1145, DOI 10.1152/ajprenal.00421.2002; Monroy A, 2000, AM J PHYSIOL-RENAL, V279, pF161, DOI 10.1152/ajprenal.2000.279.1.F161; Moreno E, 2004, J BIOL CHEM, V279, P16553, DOI 10.1074/jbc.M400602200; Paredes A, 2006, AM J PHYSIOL-RENAL, V290, pF1094, DOI 10.1152/ajprenal.00071.2005; Plata C, 1999, AM J PHYSIOL-RENAL, V276, pF359, DOI 10.1152/ajprenal.1999.276.3.F359; Plata C, 2002, J BIOL CHEM, V277, P11004, DOI 10.1074/jbc.M110442200; Plotkin MD, 1996, KIDNEY INT, V50, P174, DOI 10.1038/ki.1996.300; Rinehart J, 2005, P NATL ACAD SCI USA, V102, P16777, DOI 10.1073/pnas.0508303102; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Tovar-Palacio C, 2004, AM J PHYSIOL-RENAL, V287, pF570, DOI 10.1152/ajprenal.00124.2004; TRAN JM, 1990, AM J PHYSIOL, V258, pF908, DOI 10.1152/ajprenal.1990.258.4.F908; VAZQUEZ N, 2002, AM J PHYSIOL-RENAL, V282, pF99; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; Yang CL, 2003, J CLIN INVEST, V111, P1039, DOI 10.1172/JCI200317443	32	33	34	1	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17266	17275		10.1074/jbc.M602614200	http://dx.doi.org/10.1074/jbc.M602614200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16624820	hybrid			2022-12-25	WOS:000238326300054
J	Remacle, AG; Chekanov, AV; Golubkov, VS; Savinov, AY; Rozanov, DV; Strongin, AY				Remacle, Albert G.; Chekanov, Alexei V.; Golubkov, Vladislav S.; Savinov, Alexei Y.; Rozanov, Dmitri V.; Strongin, Alex Y.			O-glycosylation regulates autolysis of cellular membrane type-1 matrix metalloproteinase (MT1-MMP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; TRANS-GOLGI NETWORK; 1-MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; CANCER-CELLS; INTRACELLULAR TRAFFICKING; EXTRACELLULAR-MATRIX; RAPID TRAFFICKING; COMPLEX-FORMATION; PLASMA-MEMBRANE	MT1-MMP is a key enzyme in cancer cell invasion and metastasis. The activity of cellular MT1-MMP is regulated by furin-like proprotein convertases, TIMPs, shedding, autoproteolysis, dimerization, exocytosis, endocytosis, and recycling. Our data demonstrate that, in addition to these already known mechanisms, MT1MMPis regulated by O-glycosylation of its hinge region. Insignificant autolytic degradation is characteristic for naturally expressed, glycosylated, MT1-MMP. In turn, extensive autolytic degradation, which leads to the inactivation of the protease and the generation of its C-terminal membrane-tethered degraded species, is a feature of overexpressed MT1-MMP. We have determined that incomplete glycosylation stimulates extensive autocatalytic degradation and self-inactivation of MT1-MMP. Self-proteolysis commences during the secretory process of MT1-MMP through the cell compartment to the plasma membrane. The strongly negatively charged sialic acid is the most important functional moiety of the glycopart of MT1-MMP. We hypothesize that sialic acid of the O-glycosylation cassette restricts the access of the catalytic domain to the hinge region and to the autolytic cleavage site and protects MT1-MMP from autolysis. Overall, our results point out that there is a delicate balance between glycosylation and self-proteolysis of MT1-MMP in cancer cells and that when this balance is upset the catalytically potent MT1- MMP pool is self-proteolyzed.	Burnham Inst Med Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Strongin, AY (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019; Golubkov, Vladislav/L-6828-2017	Strongin, Alex/0000-0003-3765-3016; 	NATIONAL CANCER INSTITUTE [R01CA077470, R01CA083017] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER; NCI NIH HHS [CA77470, CA83017] Funding Source: Medline; NCRR NIH HHS [RR020843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Atiya-Nasagi Y, 2005, J CELL SCI, V118, P1363, DOI 10.1242/jcs.01710; Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Buck TM, 2004, AM J PHYSIOL-CELL PH, V287, pC1292, DOI 10.1152/ajpcell.00561.2003; Deryugina EI, 2004, TRAFFIC, V5, P627, DOI 10.1111/j.1600-0854.2004.00206.x; Deryugina EI, 2002, CANCER RES, V62, P580; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; DEVINE PL, 1990, BIOTECHNIQUES, V8, P492; Duguay SJ, 1998, J BIOL CHEM, V273, P18443, DOI 10.1074/jbc.273.29.18443; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Engelmann K, 2005, GLYCOBIOLOGY, V15, P1111, DOI 10.1093/glycob/cwi099; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Golubkov VS, 2005, J BIOL CHEM, V280, P25079, DOI 10.1074/jbc.M502779200; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; Gouyer V, 2001, FRONT BIOSCI, V6, pD1235, DOI 10.2741/gouyer; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Hesek D, 2006, J ORG CHEM, V71, P2885, DOI 10.1021/jo052546f; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Huet G, 2003, BIOCHIMIE, V85, P323, DOI 10.1016/S0300-9084(03)00056-7; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jenssen K, 2004, BIOCONJUGATE CHEM, V15, P594, DOI 10.1021/bc034225l; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kang TB, 2002, CANCER RES, V62, P675; Katayama A, 2004, CLIN CANCER RES, V10, P634, DOI 10.1158/1078-0432.CCR-0864-02; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Kotra LP, 2002, BIOORG CHEM, V30, P356, DOI 10.1016/S0045-2068(02)00501-1; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Maquoi E, 2003, BIOCHEM J, V373, P19, DOI 10.1042/BJ20030170; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Patsos G, 2005, BIOCHEM SOC T, V33, P721, DOI 10.1042/BST0330721; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Remacle AG, 2005, J CELL SCI, V118, P4975, DOI 10.1242/jcs.02610; REMACLE AG, 2006, ONCOGENE; Rozanov DV, 2004, J BIOL CHEM, V279, P46551, DOI 10.1074/jbc.M405284200; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Rozanov DV, 2003, J BIOL CHEM, V278, P8257, DOI 10.1074/jbc.M213246200; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; ROZANOV DV, 2006, IN PRESS CANC RES; Rudiger H, 2001, GLYCOCONJUGATE J, V18, P589, DOI 10.1023/A:1020687518999; Ryckaert S, 2005, J BIOTECHNOL, V119, P379, DOI 10.1016/j.jbiotec.2005.04.010; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Toth M, 2005, BIOCHEM J, V387, P497, DOI 10.1042/BJ20041324; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Urena JM, 1999, J CELL SCI, V112, P773; Wang P, 2004, J BIOL CHEM, V279, P20461, DOI 10.1074/jbc.M400264200; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Wang X, 2001, J BIOL CHEM, V276, P35953, DOI 10.1074/jbc.M103680200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Zhai YL, 2005, CANCER RES, V65, P6543, DOI 10.1158/0008-5472.CAN-05-0231; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2; Zucker S, 2002, LAB INVEST, V82, P1673, DOI 10.1097/01.LAB.0000041713.74852.2A	70	44	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16897	16905		10.1074/jbc.M600295200	http://dx.doi.org/10.1074/jbc.M600295200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16627478	hybrid			2022-12-25	WOS:000238326300010
J	Sharma, M; Leung, L; Brocardo, M; Henderson, J; Flegg, C; Henderson, BR				Sharma, Manisha; Leung, Louie; Brocardo, Mariana; Henderson, Jasmine; Flegg, Cameron; Henderson, Beric R.			Membrane localization of adenomatous polyposis coli protein at cellular protrusions - Targeting sequences and regulation by beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APC TUMOR-SUPPRESSOR; NUCLEAR EXPORT; MICROTUBULES; EB1; BINDING; COLOCALIZATION; ACTIVATION; MUTATIONS; SUBUNIT; CDC42	Adenomatous polyposis coli protein (APC) translocates to, and stabilizes, the plus-ends of microtubules. In microtubule-dependent cellular protrusions, APC frequently accumulates in peripheral clusters at the basal membrane. APC targeting to membrane clusters is important for cell migration, but the localization mechanism is poorly understood. In this study, we performed deletion mapping and defined a minimal sequence (amino acids 1-2226) that efficiently targets APC to membrane clusters. This sequence lacks DLG-1 and EB1 binding sites, suggesting that these partners are not absolutely required for APC membrane targeting. A series of APC sequences were transiently expressed in cells and compared for their ability to compete endogenous APC at the membrane; potent inhibition of endogenous APC targeting was elicited by the Armadillo- (binds KAP3A, B56 alpha, and ASEF) and beta-catenin-binding domains. The Armadillo domain was predicted to inhibit APC membrane localization through sequestration of the kinesin-KAP3A complex. The role of beta-catenin in APC membrane localization was unexpected but affirmed by overexpressing the APC binding sequence of beta-catenin, which similarly reduced APC membrane staining. Furthermore, we used RNA interference to show that loss of beta-catenin reduced APC at membrane clusters in migrating cells. In addition, we report that transiently expressed APC-yellow fluorescent protein co-localized with beta-catenin, KAP3A, EB1, and DLG-1 at membrane clusters, but only beta-catenin stimulated APC anchorage at the membrane. Our findings identify beta-catenin as a regulator of APC targeting to membrane clusters and link these two proteins to cell migration.	Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead Millennium Inst, Darcy Rd,POB 412, Westmead, NSW 2145, Australia.	beric_henderson@wmi.usyd.edu.au		Sharma, Manisha/0000-0003-1892-9865; Brocardo, Mariana/0000-0002-3962-7308				Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Barth AIM, 2002, J CELL SCI, V115, P1583; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Brocardo M, 2005, EMBO REP, V6, P184, DOI 10.1038/sj.embor.7400329; Cui HY, 2002, EXP CELL RES, V280, P12, DOI 10.1006/excr.2002.5506; Dikovskaya D, 2001, TRENDS CELL BIOL, V11, P378, DOI 10.1016/S0962-8924(01)02069-4; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Galea MA, 2001, J BIOL CHEM, V276, P45833, DOI 10.1074/jbc.M107149200; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, J BIOL CHEM, V277, P24258, DOI 10.1074/jbc.M110602200; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Iizuka-Kogo A, 2005, HISTOCHEM CELL BIOL, V123, P67, DOI 10.1007/s00418-004-0729-2; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Louie RK, 2004, J CELL SCI, V117, P1117, DOI 10.1242/jcs.00939; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Penman GA, 2005, J CELL SCI, V118, P4741, DOI 10.1242/jcs.02589; Polakis P, 2000, GENE DEV, V14, P1837; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1995, CANCER RES, V55, P2972; Votin V, 2005, J CELL SCI, V118, P5699, DOI 10.1242/jcs.02679; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	38	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17140	17149		10.1074/jbc.M513027200	http://dx.doi.org/10.1074/jbc.M513027200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16621792	hybrid			2022-12-25	WOS:000238326300038
J	Vines, A; Cahoon, S; Goldberg, I; Saxena, U; Pillarisetti, S				Vines, Angela; Cahoon, Sientay; Goldberg, Ira; Saxena, Uday; Pillarisetti, Sivaram			Novel anti-inflammatory role for glycogen synthase kinase-3 beta in the inhibition of tumor necrosis factor-alpha- and interleukin-1 beta-induced inflammatory gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LIVER DEGENERATION; PROTEIN-KINASE; ACTIVATION; GLYCOGEN-SYNTHASE-KINASE-3-BETA; PHOSPHORYLATION; SUBUNIT; LITHIUM; GSK3; MICE	Glycogen synthase kinase-3 beta(GSK-3 beta) is a serine/threonine kinase with a broad array of cellular targets, such as cytoskeletal proteins and transcription factors. Recent studies with GSK-3 beta-null mice showed impaired NF kappa B-mediated survival responses. Because NF kappa B serves a dual role as a key regulator of cytokine-induced inflammatory gene expression and apoptosis, we investigated whether modulation of GSK-3 beta expression affects cytokine-induced and NF kappa B-mediated inflammatory gene expression. We observed that tumor necrosis factor-alpha( TNF-alpha) and interleukin-1 beta(IL-1 beta) treatment of primary cultures of human microvascular cells reduced net endogenous active GSK-3 beta protein levels while inducing inflammatory cytokine(IL-6 and monocyte chemoattractant protein-1 (MCP-1)) expression. Interestingly, inhibition of GSK-3 beta by antisense oligonucleotides or pharmacological agent ( 10 mM lithium) potentiated TNF-induced expression of IL-6 and MCP-1 by 2-6-fold suggesting that inhibition of GSK-3 beta under inflammatory conditions ( exposure to TNF-alpha and IL-1 beta) may contribute to enhanced cytokine expression. Overexpression of GSK-3 beta in endothelial cells, in contrast, significantly inhibited ( by 70%, p < 0.01) both TNF-alpha and IL-1 beta-induced expression of IL-6, MCP-1, and vascular cell adhesion molecule-1. Using adenoviruses in lipopolysaccharide-stimulated mice, overexpression of GSK-3 beta significantly decreased TNF-alpha expression in lung and heart tissues ( 38 and 15%, respectively), further confirming the anti-inflammatory role of GSK-3 beta. Overexpression of GSK-3 beta did not affect the TNF-alpha-induced nuclear translocation of NF kappa B but reduced the nuclear half-life of TNF-alpha-induced NF kappa B considerably ( by as much as 9 h) and enhanced phosphorylation ( by as much as 33%). Interestingly, neither endothelial cell survival nor NF kappa B-mediated expression of anti-apoptotic genes was affected by GSK-3 beta overexpression. We conclude that GSK-3 beta selectively regulates NF kappa B-mediated inflammatory gene expression by controlling the flow of NF kappa B activity between transcription of inflammatory and survival genes.	Reddy US Therapeut, Dr Reddys Labs, Norcross, GA 30071 USA; Columbia Univ, Dept Med, New York, NY 10032 USA	Dr. Reddy's Laboratories Ltd.; Columbia University	Vines, A (corresponding author), Reddy US Therapeut, Dr Reddys Labs, 3065 Northwoods Circle, Norcross, GA 30071 USA.	avines@reddyus.com						Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Dominguez I, 2001, DEV BIOL, V235, P303, DOI 10.1006/dbio.2001.0317; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Jang MK, 2001, J BIOL CHEM, V276, P20005, DOI 10.1074/jbc.M010211200; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rudolph D, 2000, GENE DEV, V14, P854; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Whittle BJR, 2006, BRIT J PHARMACOL, V147, P575, DOI 10.1038/sj.bjp.0706509; WOODGETT JR, 2001, SCI STKE, pRE12	19	43	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16985	16990		10.1074/jbc.M602446200	http://dx.doi.org/10.1074/jbc.M602446200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16601113	hybrid			2022-12-25	WOS:000238326300020
J	Wiater, E; Harrison, CA; Lewis, KA; Gray, PC; Vale, WW				Wiater, Ezra; Harrison, Craig A.; Lewis, Kathy A.; Gray, Peter C.; Vale, Wylie W.			Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan - Functional separation of betaglycan co-receptor actions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT SOLUBLE BETAGLYCAN; RECEPTOR-TYPE-III; TGF-BETA; LIGAND-BINDING; ACTIVIN; DOMAIN; EXPRESSION; CELL; MEMBRANE; PROTEIN	Betaglycan is a co-receptor that mediates signaling by transforming growth factor beta (TGF beta) superfamily members, including the distinct and often opposed actions of TGF beta s and inhibins. Loss of betaglycan expression, or abrogation of betaglycan function, is implicated in several human and animal diseases, although both betaglycan actions and the ligands involved in these disease states remain unclear. Here we identify a domain spanning amino acids 591-700 of the betaglycan extracellular domain as the only inhibin-binding region in betaglycan. This binding site is within the betaglycan ZP domain, but inhibin binding is not integral to the ZP motif of other proteins. We show that the inhibin and TGF beta-binding residues of this domain overlap and identify individual amino acids essential for binding of each ligand. Mutation of Val(614) to Tyr abolishes both inhibin and TGF beta binding to this domain. Full-length betaglycan V614Y, and other mutations, retain TGF beta binding activity via a distinct site, but are unable to bind inhibin-A. These betaglycan mutants fail to mediate inhibin antagonism of activin signaling but can present TGF beta to T beta RII. Separating the co-receptor actions of betaglycan toward inhibin and TGF beta will allow the clarification of the role of betaglycan in disease states such as renal cell carcinoma and endometrial adenocarcinoma.	Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia	Salk Institute; Prince Henry's Institute of Medical Research	Vale, WW (corresponding author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	vale@salk.edu		Harrison, Craig/0000-0003-1059-3682	NICHD NIH HHS [HD-13527] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Bandyopadhyay A, 2005, PROSTATE, V63, P81, DOI 10.1002/pros.20166; Bandyopadhyay A, 2002, CANCER RES, V62, P4690; BILEZIKJIAN LM, 1991, MOL ENDOCRINOL, V5, P1389, DOI 10.1210/mend-5-10-1389; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Copland JA, 2003, ONCOGENE, V22, P8053, DOI 10.1038/sj.onc.1206835; Drummond AE, 2003, MOL CELL ENDOCRINOL, V202, P53, DOI 10.1016/S0303-7207(03)00062-5; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Esparza-Lopez J, 2001, J BIOL CHEM, V276, P14588, DOI 10.1074/jbc.M008866200; Florio P, 2005, EUR J ENDOCRINOL, V152, P277, DOI 10.1530/eje.1.01849; FUKUSHIMA D, 1993, J BIOL CHEM, V268, P22710; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Harrison CA, 2004, J BIOL CHEM, V279, P28036, DOI 10.1074/jbc.M402782200; Jovine L, 2002, NAT CELL BIOL, V4, P457, DOI 10.1038/ncb802; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756-3282(96)00138-X; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Massague J, 2000, GENE DEV, V14, P627; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; Matzuk MM, 2000, MOL CELL ENDOCRINOL, V163, P61, DOI 10.1016/S0303-7207(99)00241-5; Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067; Pepin MC, 1995, FEBS LETT, V377, P368, DOI 10.1016/0014-5793(95)01378-4; PEPIN MC, 1994, P NATL ACAD SCI USA, V91, P6997, DOI 10.1073/pnas.91.15.6997; Phillips DJ, 2000, BIOESSAYS, V22, P689, DOI 10.1002/1521-1878(200008)22:8<689::AID-BIES2>3.0.CO;2-5; Risbridger GP, 2001, MOL CELL ENDOCRINOL, V180, P149, DOI 10.1016/S0303-7207(01)00497-X; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; STEVERS KL, 2003, MOL CELL BIOL, V23, P4371; VAUGHAN JM, 1993, ENDOCRINOLOGY, V132, P2038, DOI 10.1210/en.132.5.2038; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; Wiater E, 2003, J BIOL CHEM, V278, P7934, DOI 10.1074/jbc.M209710200; Zhao JS, 1998, MECH DEVELOP, V75, P67, DOI 10.1016/S0925-4773(98)00083-5	37	68	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17011	17022		10.1074/jbc.M601459200	http://dx.doi.org/10.1074/jbc.M601459200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16621788	hybrid			2022-12-25	WOS:000238326300023
J	Simon-Nobbe, B; Denk, U; Schneider, PB; Radauer, C; Teige, M; Crameri, R; Hawranek, T; Lang, R; Richter, K; Schmid-Grendelmeier, P; Nobbe, S; Hartl, A; Breitenbach, M				Simon-Nobbe, Birgit; Denk, Ursula; Schneider, Peter Bernhard; Radauer, Christian; Teige, Markus; Crameri, Reto; Hawranek, Thomas; Lang, Roland; Richter, Klaus; Schmid-Grendelmeier, Peter; Nobbe, Stephan; Hartl, Arnulf; Breitenbach, Michael			NADP-dependent mannitol dehydrogenase, a major allergen of Cladosporium herbarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; SENSITIZATION; EXPRESSION; BINDING; STRESS; COMMUNITY; ENOLASES; CLONING; ASTHMA; ROLES	Cladosporium herbarum is an important allergenic fungal species that has been reported to cause allergic diseases in nearly all climatic zones. 5-30% of the allergic population displays IgE antibodies against molds. Sensitization to Cladosporium has often been associated with severe asthma and less frequently with chronic urticaria and atopic eczema. However, no dominant major allergen of this species has been found so far. We present cloning, production, and characterization of NADP-dependent mannitol dehydrogenase of C. herbarum ( Cla h 8) and show that this protein is a major allergen that is recognized by IgE antibodies of similar to 57% of all Cladosporium allergic patients. This is the highest percentage of patients reacting with any Cladosporium allergen characterized so far. Cla h 8 was purified to homogeneity by standard chromatographic methods, and both N-terminal and internal amino acid sequences of protein fragments were determined. Enzymatic analysis of the purified natural protein revealed that this allergen represents a NADP-dependent mannitol dehydrogenase that interconverts mannitol and D-fructose. It is a soluble, non-glycosylated cytoplasmic protein. Two-dimensional protein analysis indicated that mannitol dehydrogenase is present as a single isoform. The cDNA encoding Cla h 8 was cloned from a lambda-ZAP library constructed from hyphae and spores. The recombinant non-fusion protein was expressed in Escherichia coli and purified to homogeneity. Its immunological and biochemical identity with the natural protein was shown by enzyme activity tests, CD spectroscopy, IgE immunoblots with sera of patients, and by skin prick testing of Cladosporium allergic patients. This protein therefore is a new major allergen of C. herbarum.	Salzburg Univ, Dept Cell Biol, A-5020 Salzburg, Austria; Med Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Max F Perutz Labs, Dept Biochem, A-1030 Vienna, Austria; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Salzburg Univ, Dermatol Clin, St Johanns Spital Salzburg, A-5020 Salzburg, Austria; Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; Paracelsus Med Univ, A-5020 Salzburg, Austria	Salzburg University; Medical University of Vienna; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Swiss Institute of Allergy & Asthma Research; Salzburg University; University of Zurich; University Zurich Hospital; Paracelsus Private Medical University	Breitenbach, M (corresponding author), Salzburg Univ, Dept Cell Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.	michael.breitenbach@sbg.ac.at	Radauer, Christian/AAN-6260-2021; Teige, Markus/R-6443-2016	Radauer, Christian/0000-0001-9920-4449; Teige, Markus/0000-0001-7204-1379; Hartl, Arnulf/0000-0001-9626-6425	Austrian Science Fund FWF [S 9302] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; Al-Mousawi MSH, 2004, J ALLERGY CLIN IMMUN, V114, P1389, DOI 10.1016/j.jaci.2004.09.005; Al-Suwaini AS, 2001, MYCOSES, V44, P401, DOI 10.1046/j.1439-0507.2001.00665.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitenbach M, 1997, INT ARCH ALLERGY IMM, V113, P114, DOI 10.1159/000237521; Breitenbach M, 2002, CHEM IMMUNOL, V81, P48; Carlsen KCL, 2002, ALLERGY, V57, P529, DOI 10.1034/j.1398-9995.2002.13305.x; Clark AJ, 2003, PLANTA, V216, P614, DOI 10.1007/s00425-002-0833-2; DREBORG S, 1989, J AM ACAD DERMATOL, V21, P820, DOI 10.1016/S0190-9622(89)70256-5; Falsone SF, 2002, J BIOL CHEM, V277, P16512, DOI 10.1074/jbc.M200833200; HASNAIN SM, 1985, NEW ZEAL MED J, V98, P342; Hasnain SM, 2004, MYCOPATHOLOGIA, V157, P171, DOI 10.1023/B:MYCO.0000020592.72238.a6; Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x; Horer S, 2001, J BIOL CHEM, V276, P27555, DOI 10.1074/jbc.M102850200; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161, DOI 10.1128/CMR.8.2.161; Jennings DB, 1998, P NATL ACAD SCI USA, V95, P15129, DOI 10.1073/pnas.95.25.15129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NIEHAUS WG, 1982, J BACTERIOL, V151, P243, DOI 10.1128/JB.151.1.243-250.1982; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Perello AE, 2003, AUSTRALAS PLANT PATH, V32, P327, DOI 10.1071/AP03019; Rivas S, 2005, ANNU REV PHYTOPATHOL, V43, P395, DOI 10.1146/annurev.phyto.43.040204.140224; Ruijter GJG, 2003, EUKARYOT CELL, V2, P690, DOI 10.1128/EC.2.4.690-698.2003; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Shen B, 1999, PLANT PHYSIOL, V121, P45, DOI 10.1104/pp.121.1.45; Sheveleva EV, 2000, J EXP BOT, V51, P115, DOI 10.1093/jexbot/51.342.115; Simon-Nobbe B, 2000, J ALLERGY CLIN IMMUN, V106, P887, DOI 10.1067/mai.2000.110799; STOOP JMH, 1995, PLANT PHYSIOL, V108, P1219, DOI 10.1104/pp.108.3.1219; Stoop JMH, 1998, APPL ENVIRON MICROB, V64, P4689; SUSANI M, 1995, BIOCHEM BIOPH RES CO, V215, P250, DOI 10.1006/bbrc.1995.2460; Weichel M, 2003, ALLERGY, V58, P198, DOI 10.1034/j.1398-9995.2003.23822.x; Weichel M, 2003, CLIN EXP ALLERGY, V33, P72, DOI 10.1046/j.1365-2222.2003.01574.x; Zhang L, 1996, CLIN EXP ALLERGY, V26, P88, DOI 10.1111/j.1365-2222.1996.tb00060.x; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	33	31	36	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16354	16360		10.1074/jbc.M513638200	http://dx.doi.org/10.1074/jbc.M513638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16608840	Green Published, hybrid			2022-12-25	WOS:000238165700023
J	Dawson, NS; Zawieja, DC; Wu, MH; Granger, HJ				Dawson, Nancy S.; Zawieja, David C.; Wu, Mack H.; Granger, Harris J.			Signaling pathways mediating VEGF(165)-induced calcium transients and membrane depolarization in human endothelial cells	FASEB JOURNAL			English	Article						endothelium; membrane potential; intracellular calcium; signal transduction	CAPACITATIVE CA2+ ENTRY; ACTIVATED CL-CURRENTS; GROWTH-FACTOR; NITRIC-OXIDE; VASCULAR-PERMEABILITY; TYROSINE KINASE; MICROVASCULAR PERMEABILITY; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; CYTOSOLIC CALCIUM	Cytosolic calcium and membrane potential were monitored simultaneously in quiescent human umbilical vein endothelial cells (HUVEC) exposed to vascular endothelial growth factor (VEGF)(165) using the fluorescent indicators indo-1 AM and DiSBAC(2)(3), respectively. Application of VEGF(165) to cells elicits a rapid rise in cytosolic calcium followed by a slower decline toward control values. Peak calcium is associated with a slight membrane hyperpolarization; however, as calcium falls toward control, a strong depolarization develops and is sustained throughout a 10-min period of VEGF(165) stimulation. Both the VEGF(165)-mediated rise in cytosolic calcium and membrane depolarization are eliminated by inhibitors of VEGFR-2, tyrosine kinase, src kinase and inositol-1,4,5 triphosphate-operated calcium channels. Calcium entry, which is initially facilitated by transient hyperpolarization, is restricted by a substantial, sustained depolarization that developed during the downstroke of the calcium spike. Inhibition of plasmalemmal calcium channels diminished the magnitude and duration of the calcium spike, suggesting that extracellular calcium influx, secondary to stores release, is a significant component of the calcium transient. Inhibition of chloride channels substantially reduced membrane depolarization. In addition, the depolarization is modulated by PI3 kinase in a ras-independent manner. In summary, intracellular calcium and membrane potential are influenced by several key signaling cascades of VEGFR-2 activation in HUVEC.	Texas A&M Univ Sys, Lymphat Biol Div, Cardiovasc Res Inst, Hlth Sci Ct,Coll Med, College Stn, TX 77843 USA; Texas A&M Univ Sys, Dept Med Physiol, Coll Med, Hlth Sci Ctr, College Stn, TX 77843 USA; Univ Calif Davis, Med Ctr, Dept Surg, MIND Inst, Sacramento, CA 95817 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of California System; University of California Davis	Granger, HJ (corresponding author), Texas A&M Univ Sys, Lymphat Biol Div, Cardiovasc Res Inst, Hlth Sci Ct,Coll Med, College Stn, TX 77843 USA.	dcz@tamu.edu	Wu, Mack/I-6536-2012	Zawieja, David/0000-0002-2644-6524	NHLBI NIH HHS [HL-075199, HL-058062] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058062, R01HL075199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Bates DO, 1996, AM J PHYSIOL-HEART C, V271, pH2520, DOI 10.1152/ajpheart.1996.271.6.H2520; Bates DO, 1997, AM J PHYSIOL-HEART C, V273, pH687, DOI 10.1152/ajpheart.1997.273.2.H687; BROCK TA, 1991, AM J PATHOL, V138, P213; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CRISCUOLO GR, 1989, J NEUROSURG, V71, P884, DOI 10.3171/jns.1989.71.6.0884; Cunningham SA, 1999, AM J PHYSIOL-CELL PH, V276, pC176, DOI 10.1152/ajpcell.1999.276.1.C176; Dedkova EN, 2002, J PHYSIOL-LONDON, V539, P77, DOI 10.1113/jphysiol.2001.013258; Diver JM, 2001, CELL CALCIUM, V30, P323, DOI 10.1054/ceca.2001.0239; Doanes AM, 1999, BIOCHEM BIOPH RES CO, V255, P545, DOI 10.1006/bbrc.1999.0227; Faehling M, 2002, FASEB J, V16, P1805, DOI 10.1096/fj.01-0938fje; Faehling M, 2001, INT J BIOCHEM CELL B, V33, P337, DOI 10.1016/S1357-2725(01)00021-8; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Fong TAT, 1999, CANCER RES, V59, P99; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GERICKE M, 1994, EUR J PHARM-MOLEC PH, V269, P381, DOI 10.1016/0922-4106(94)90046-9; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HE P, 1994, J APPL PHYSIOL, V76, P2288, DOI 10.1152/jappl.1994.76.6.2288; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; Kawaji J., 2003, Transactions of the Magnetics Society of Japan, V3, P1, DOI 10.3379/tmjpn2001.3.1; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; LUCKHOFF A, 1990, N-S ARCH PHARMACOL, V342, P94; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Nilius B, 1997, J PHYSIOL-LONDON, V498, P381, DOI 10.1113/jphysiol.1997.sp021865; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; NILIUS B, 1994, BRIT J PHARMACOL, V112, P1049, DOI 10.1111/j.1476-5381.1994.tb13189.x; Otun H, 1996, CELL CALCIUM, V19, P315, DOI 10.1016/S0143-4160(96)90072-X; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Pocock TM, 2000, AM J PHYSIOL-HEART C, V279, pH1625, DOI 10.1152/ajpheart.2000.279.4.H1625; SCHILLING WP, 1989, AM J PHYSIOL, V257, pH778, DOI 10.1152/ajpheart.1989.257.3.H778; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Shi CJ, 2002, INVEST OPHTH VIS SCI, V43, P1525; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Tilly BC, 1996, MOL BIOL CELL, V7, P1419, DOI 10.1091/mbc.7.9.1419; VACA L, 1995, AM J PHYSIOL-CELL PH, V269, pC733, DOI 10.1152/ajpcell.1995.269.3.C733; VOETS T, 1995, PFLUG ARCH EUR J PHY, V431, P132, DOI 10.1007/BF00374387; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Whittles CE, 2002, MICROCIRCULATION, V9, P513, DOI 10.1038/sj.mn.7800164; Wu HM, 1999, AM J PHYSIOL-HEART C, V276, pH535, DOI 10.1152/ajpheart.1999.276.2.H535; Wu HM, 1996, AM J PHYSIOL-HEART C, V271, pH2735, DOI 10.1152/ajpheart.1996.271.6.H2735; Wu MH, 2005, J PHYSIOL-LONDON, V563, P95, DOI 10.1113/jphysiol.2004.076075; Wu SW, 2000, J BIOL CHEM, V275, P18887, DOI 10.1074/jbc.M002795200; ZICHE M, 1993, AM J PHYSIOL, V265, pH569, DOI 10.1152/ajpheart.1993.265.2.H569	50	32	32	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					991	+		10.1096/fj.05-3923fje	http://dx.doi.org/10.1096/fj.05-3923fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16581961				2022-12-25	WOS:000240157700032
J	Rauter, I; Krauth, MT; Flicker, S; Gieras, A; Westritschnig, K; Vrtala, S; Balic, N; Spitzauer, S; Huss-Marp, J; Brockow, K; Darsow, U; Ring, J; Behrendt, H; Semper, H; Valent, P; Valenta, R				Rauter, Ingrid; Krauth, Maria-Theresa; Flicker, Sabine; Gieras, Anna; Westritschnig, Kerstin; Vrtala, Susanne; Balic, Nadja; Spitzauer, Susanne; Huss-Marp, Johannes; Brockow, Knut; Darsow, Ulf; Ring, Johannes; Behrendt, Heidrun; Semper, Hans; Valent, Peter; Valenta, Rudolf			Allergen cleavage by effector cell-derived proteases regulates allergic inflammation	FASEB JOURNAL			English	Article						allergy; mast cells; tryptase; allergen	GRASS-POLLEN ALLERGEN; PHLEUM-PRATENSE POLLEN; MAST-CELL; MAJOR ALLERGEN; STRUCTURAL-CHARACTERIZATION; SECRETORY GRANULES; GENE FRAGMENTATION; IGE-RECOGNITION; MOLECULAR-BASIS; P-V	The key event of allergic inflammation, allergen-induced crosslinking of mast cell-bound IgE antibodies, is accompanied by release of inflammatory mediators, cytokines, and proteases, in particular beta-tryptase. We provide evidence that protease-mediated cleavage of allergens represents a mechanism that regulates allergen-induced mast cell activation. When used in molar ratios as they occur in vivo, purified beta-tryptase cleaved major grass and birch pollen allergens, resulting in defined peptide fragments as mapped by mass spectrometry. Tryptase-cleaved allergens showed reduced IgE reactivity and allergenic activity. The biological relevance is demonstrated by the fact that lysates from activated human mast cells containing tryptase levels as they occur in vivo cleaved allergens. Additionally, protamine, an inhibitor of heparin-dependent effector cell proteases, augmented allergen-induced release of mediators from effector cells. Protease-mediated allergen cleavage may represent an important mechanism for terminating allergen-induced effector cell activation.	Med Univ Vienna, Div Immunopathol, Dept Pathophysiol, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria; Med Univ Vienna, Med & Chem Lab Diagnost, Vienna, Austria; Tech Univ Munich, ZAUM Ctr Allergy & Environm, Div Environm Dermatol & Allergy GSF, Dept Dermatol & Allergy, D-8000 Munich, Germany	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Technical University of Munich	Valenta, R (corresponding author), Med Univ Vienna, Div Immunopathol, Dept Pathophysiol, Ctr Physiol & Pathophysiol, 3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Test, Test/Y-7921-2019; Ring, Johannes/GLN-4341-2022; Gieras, Anna/S-8345-2019; Gamperl, Susi/V-2715-2019; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016	Ring, Johannes/0000-0001-8236-3152; Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095; Vrtala, Susanne/0000-0003-4250-8243; Gieras, Anna/0000-0002-5147-2281; Valenta, Rudolf/0000-0001-5944-3365; Flicker, Sabine/0000-0003-4768-8693				Ball T, 1999, FASEB J, V13, P1277, DOI 10.1096/fasebj.13.11.1277; Ball T, 2005, FEBS J, V272, P217, DOI 10.1111/j.1432-1033.2004.04403.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Brockow K, 2002, J ALLERGY CLIN IMMUN, V109, P82, DOI 10.1067/mai.2002.120524; Bufe A, 1998, AM J RESP CRIT CARE, V157, P1269, DOI 10.1164/ajrccm.157.4.9709040; De Marino S, 1999, STRUCT FOLD DES, V7, P943; ECCLESTON E, 1973, NATURE-NEW BIOL, V244, P73, DOI 10.1038/newbio244073b0; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Flicker S, 2002, EUR J IMMUNOL, V32, P2156, DOI 10.1002/1521-4141(200208)32:8<2156::AID-IMMU2156>3.0.CO;2-A; Flicker S, 2000, J IMMUNOL, V165, P3849, DOI 10.4049/jimmunol.165.7.3849; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Hoffmann A, 1997, J ALLERGY CLIN IMMUN, V99, P227, DOI 10.1016/S0091-6749(97)70101-5; IRANI AMA, 1992, BLOOD, V80, P3009; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P88, DOI 10.1016/0091-6749(94)90075-2; MACGLASHAM DW, 2002, IGE ANTIIGE THERAPY; Maglio O, 2002, PROTEIN ENG, V15, P635, DOI 10.1093/protein/15.8.635; Mellon MB, 2002, J IMMUNOL, V168, P290, DOI 10.4049/jimmunol.168.1.290; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; ONG EK, 1995, MOL IMMUNOL, V32, P295, DOI 10.1016/0161-5890(94)00127-M; Pejler G, 1996, FEBS LETT, V383, P170, DOI 10.1016/0014-5793(96)00239-6; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; PETERSEN A, 1994, CLIN EXP ALLERGY, V24, P250, DOI 10.1111/j.1365-2222.1994.tb00227.x; Saito H, 1996, J IMMUNOL, V157, P343; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1987, AM REV RESPIR DIS, V135, P1186; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; Suphioglu C, 1998, MOL IMMUNOL, V35, P293, DOI 10.1016/S0161-5890(98)00050-9; Tkaczyk C, 2004, INT ARCH ALLERGY IMM, V133, P305, DOI 10.1159/000077213; TOBIN MC, 1986, MOL IMMUNOL, V23, P245, DOI 10.1016/0161-5890(86)90050-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENT P, 1991, Progress in Growth Factor Research, V3, P27, DOI 10.1016/0955-2235(91)90011-R; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 2004, ADV IMMUNOL, V82, P105, DOI 10.1016/S0065-2776(04)82003-0; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Vrtala S, 1998, J IMMUNOL, V160, P6137; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; VRTALA S, 1993, J IMMUNOL, V151, P4773; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; Vrtala S, 1999, J IMMUNOL, V163, P5489; Xu K, 1998, J CELL SCI, V111, P2385; Zhao XY, 2004, ANALYST, V129, P817, DOI 10.1039/b407322c	47	23	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					967	+		10.1096/fj.05-3999fje	http://dx.doi.org/10.1096/fj.05-3999fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585063				2022-12-25	WOS:000240157700024
J	Gonzalez, L; Freije, JMP; Cal, S; Lopez-Otin, C; Serrano, M; Palmero, I				Gonzalez, L.; Freije, J. M. P.; Cal, S.; Lopez-Otin, C.; Serrano, M.; Palmero, I.			A functional link between the tumour suppressors ARF and p33ING1	ONCOGENE			English	Article						ARF; p53; ING1; tumour suppressor	NF-KAPPA-B; ALTERNATIVE TRANSCRIPTS; PHD FINGER; ING FAMILY; P53; P19(ARF); PROTEINS; GENE; MDM2; ACTIVATION	The ARF tumour suppressor protein plays a critical role in the activation of p53 in response to oncogenic stress. ARF can activate p53 through nucleolar sequestration of Mdm2. However, several lines of evidence indicate that this is not the only way of action of ARF, and alternative mechanisms must exist. p33ING1 is a putative tumour suppresor, which induces cell-cycle arrest and apoptosis in a p53-dependent manner. Here, we describe that ARF and p33ING1 can interact in vivo. We also show that the subcellular localization of ING1 can be modulated by ARF protein levels, causing a displacement from nuclear to nucleolar localization. Finally, the ability of p33ING1 to cause cell-cycle arrest and induction of p21CIP1, or Mdm2, is impaired in ARF-deficient primary mouse fibroblasts. Based on these observations, we propose that the interaction with p33ING1 represents a novel mechanism for the tumour suppression function of ARF.	Univ Autonoma Madrid, CSIC, Inst Biomed Res, E-28029 Madrid, Spain; Univ Oviedo, Inst Oncol, Dept Biochem & Mol Biol, Oviedo, Spain; Spanish Natl Canc Ctr, CNIO, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); University of Oviedo; Centro Nacional de Investigaciones Oncologicas (CNIO)	Palmero, I (corresponding author), Univ Autonoma Madrid, CSIC, Inst Biomed Res, Arturo Duperier 4, E-28029 Madrid, Spain.	ipalmero@iib.uam.es	Serrano, Manuel/H-2634-2015; Freije, José M.P./A-6535-2008; López-Otín, Carlos/AAB-2106-2020; Palmero, Ignacio/B-4346-2013	Serrano, Manuel/0000-0001-7177-9312; Freije, José M.P./0000-0002-4688-8266; López-Otín, Carlos/0000-0001-6964-1904; 				Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Calabro V, 2004, MOL CELL BIOL, V24, P8529, DOI 10.1128/MCB.24.19.8529-8540.2004; Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; D'Amico M, 2004, CANCER RES, V64, P4122, DOI 10.1158/0008-5472.CAN-03-2519; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Goeman F, 2005, MOL CELL BIOL, V25, P422, DOI 10.1128/MCB.25.1.422-431.2005; Gong W, 2005, INT J BIOCHEM CELL B, V37, P1054, DOI 10.1016/j.biocel.2004.09.008; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kuo ML, 2003, CANCER RES, V63, P1046; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Leung KM, 2002, CANCER RES, V62, P4890; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nouman GS, 2003, J CLIN PATHOL, V56, P491, DOI 10.1136/jcp.56.7.491; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Scott M, 2001, J CELL SCI, V114, P3455; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shimada H, 2002, ONCOGENE, V21, P1208, DOI 10.1038/sj.onc.1205176; Shinoura N, 1999, CANCER RES, V59, P5521; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Xin HW, 2004, J BIOL CHEM, V279, P9539, DOI 10.1074/jbc.M311587200; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172	45	34	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5173	5179		10.1038/sj.onc.1209526	http://dx.doi.org/10.1038/sj.onc.1209526			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16607280				2022-12-25	WOS:000240063700010
J	Biton, S; Dar, I; Mittelman, L; Pereg, Y; Barzilai, A; Shiloh, Y				Biton, Sharon; Dar, Inbal; Mittelman, Leonid; Pereg, Yaron; Barzilai, Ari; Shiloh, Yosef			Nuclear ataxia-telangiectasia mutated (ATM) mediates the cellular response to DNA double strand breaks in human neuron-like cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; LIGASE IV DEFICIENCY; PROTEIN-KINASE; NEUROBLASTOMA-CELLS; IONIZING-RADIATION; ALZHEIMERS-DISEASE; SIGNALING PATHWAYS; OXIDATIVE STRESS; GENE-PRODUCT; DEFECTIVE NEUROGENESIS	The protein kinase ATM (ataxia-telangiectasia mutated) activates the cellular response to double strand breaks (DSBs), a highly cytotoxic DNA lesion. ATM is activated by DSBs and in turn phosphorylates key players in numerous damage response pathways. ATM is missing or inactivated in the autosomal recessive disorder ataxia-telangiectasia (A-T), which is characterized by neuronal degeneration, immunodeficiency, genomic instability, radiation sensitivity, and cancer predisposition. The predominant symptom of A-T is a progressive loss of movement coordination due to ongoing degeneration of the cerebellar cortex and peripheral neuropathy. A major deficiency in understanding A-T is the lack of information on the role of ATM in neurons. It is unclear whether the ATM-mediated DSB response operates in these cells similarly to proliferating cells. Furthermore, ATM was reported to be cytoplasmic in neurons and suggested to function in these cells in capacities other than the DNA damage response. Recently we obtained genetic molecular evidence that the neuronal degeneration in A-T does result from defective DNA damage response. We therefore undertook to investigate this response in a model system of human neuron-like cells (NLCs) obtained by neuronal differentiation in culture. ATM was largely nuclear in NLCs, and their ATM-mediated responses to DSBs were similar to those of proliferating cells. Knocking down ATM did not interfere with neuronal differentiation but abolished ATM-mediated damage responses in NLCs. We concluded that nuclear ATM mediates the DSB response in NLCs similarly to in proliferating cells. Attempts to understand the neurodegeneration in A-T should be directed to investigating the DSB response in the nervous system.	Tel Aviv Univ, David & Inez Myers Lab Genet Res, Dept Mol Genet & Biochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Interdept Core Facil, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University	Shiloh, Y (corresponding author), Tel Aviv Univ, David & Inez Myers Lab Genet Res, Dept Mol Genet & Biochem, IL-69978 Tel Aviv, Israel.	yossih@post.tau.ac.il			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31763] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abner CW, 2004, DNA REPAIR, V3, P1141, DOI 10.1016/j.dnarep.2004.03.009; Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; ADAMS KE, 2006, IN PRESS ONCOGENE; Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Allen DR, 2001, GENE DEV, V15, P554, DOI 10.1101/gad.869001; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; Brooks PJ, 2002, MUTAT RES-FUND MOL M, V509, P93, DOI 10.1016/S0027-5107(02)00222-1; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Caldecott KW, 2004, DNA REPAIR, V3, P875, DOI 10.1016/j.dnarep.2004.04.011; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; Chen K, 2003, J BIOL CHEM, V278, P39527, DOI 10.1074/jbc.M304423200; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Clements PM, 2004, DNA REPAIR, V3, P1493, DOI 10.1016/j.dnarep.2004.06.017; Copani A, 2001, TRENDS NEUROSCI, V24, P25, DOI 10.1016/S0166-2236(00)01663-5; Crawford T O, 1998, Semin Pediatr Neurol, V5, P287, DOI 10.1016/S1071-9091(98)80007-7; Crawford TO, 2000, NEUROLOGY, V54, P1505, DOI 10.1212/WNL.54.7.1505; Davydov V, 2003, NEUROBIOL AGING, V24, P953, DOI 10.1016/S0197-4580(02)00229-4; Ellis J, 2005, HUM GENE THER, V16, P1241, DOI 10.1089/hum.2005.16.1241; Ellis J, 2005, CURR GENE THER, V5, P367, DOI 10.2174/1566523054546233; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Frappart PO, 2005, NAT MED, V11, P538, DOI 10.1038/nm1228; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gueven N, 2004, HUM MOL GENET, V13, P1081, DOI 10.1093/hmg/ddh122; Heraud C, 2004, J NEUROSCI RES, V75, P320, DOI 10.1002/jnr.10866; Herrup K, 2004, J NEUROSCI, V24, P9232, DOI 10.1523/JNEUROSCI.3347-04.2004; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hill DP, 1997, DEV BRAIN RES, V102, P53, DOI 10.1016/S0165-3806(97)00076-X; Hill DP, 1998, BRAIN RES PROTOC, V2, P183, DOI 10.1016/S1385-299X(97)00041-X; Jacobsen E, 2004, MOL BRAIN RES, V128, P1, DOI 10.1016/j.molbrainres.2004.05.023; Kamsler A, 2001, CANCER RES, V61, P1849; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182; Kruman II, 2004, CELL CYCLE, V3, P769; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Kuljis RO, 1999, BRAIN RES, V842, P351, DOI 10.1016/S0006-8993(99)01813-2; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Latella L, 2004, MOL CELL BIOL, V24, P6350, DOI 10.1128/MCB.24.14.6350-6361.2004; Lee Y, 2000, GENE DEV, V14, P2576, DOI 10.1101/gad.837100; Lee Y, 2001, J NEUROSCI, V21, P6687, DOI 10.1523/JNEUROSCI.21-17-06687.2001; Lee Y, 2000, APOPTOSIS, V5, P523, DOI 10.1023/A:1009637512917; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; McKinnon PJ, 2001, TRENDS MOL MED, V7, P233, DOI 10.1016/S1471-4914(01)02035-4; McMurray CT, 2005, MUTAT RES-FUND MOL M, V577, P260, DOI 10.1016/j.mrfmmm.2005.03.006; McShea A, 1999, MED HYPOTHESES, V52, P525, DOI 10.1054/mehy.1997.0680; Mochan TA, 2004, DNA REPAIR, V3, P945, DOI 10.1016/j.dnarep.2004.03.017; Mosesso P, 2005, CELL MOL LIFE SCI, V62, P485, DOI 10.1007/s00018-004-4441-0; Nouspikel T, 2002, DNA REPAIR, V1, P59, DOI 10.1016/S1568-7864(01)00005-2; Oka A, 2000, NEUROSCI LETT, V292, P167, DOI 10.1016/S0304-3940(00)01462-2; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; PAHLMAN S, 1995, EUR J CANCER, V31A, P453, DOI 10.1016/0959-8049(95)00033-F; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Raschella G, 2001, MED PEDIATR ONCOL, V36, P104, DOI 10.1002/1096-911X(20010101)36:1<104::AID-MPO1024>3.0.CO;2-9; Rolig RL, 2000, TRENDS NEUROSCI, V23, P417, DOI 10.1016/S0166-2236(00)01625-8; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Shastry P, 2001, INT J NEUROSCI, V108, P109, DOI 10.3109/00207450108986509; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Shiloh Y, 2004, NAT CELL BIOL, V6, P923, DOI 10.1038/ncb1004-923; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smith MZ, 1999, NEUROSCI LETT, V271, P45, DOI 10.1016/S0304-3940(99)00509-1; Soares HD, 1998, NEUROSCIENCE, V86, P1045, DOI 10.1016/S0306-4522(98)00117-1; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Taylor AMR, 2004, DNA REPAIR, V3, P1219, DOI 10.1016/j.dnarep.2004.04.009; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Weizman N, 2003, J BIOL CHEM, V278, P6741, DOI 10.1074/jbc.M211168200; Wilda M, 2000, HUM MOL GENET, V9, P1739, DOI 10.1093/hmg/9.12.1739; Wilson DM, 1999, J HISTOCHEM CYTOCHEM, V47, P1095, DOI 10.1177/002215549904700814; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yang Y, 2005, J NEUROSCI, V25, P2522, DOI 10.1523/JNEUROSCI.4946-04.2005; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Young DB, 2005, J BIOL CHEM, V280, P27587, DOI 10.1074/jbc.M411689200	91	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17482	17491		10.1074/jbc.M601895200	http://dx.doi.org/10.1074/jbc.M601895200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16627474	hybrid			2022-12-25	WOS:000238326300074
J	Fu, LZ; Tomita, A; Wang, H; Buchholz, DR; Shi, YB				Fu, Liezhen; Tomita, Akihiro; Wang, Hua; Buchholz, Daniel R.; Shi, Yun-Bo			Transcriptional regulation of the Xenopus laevis stromelysin-3 gene by thyroid hormone is mediated by a DNA element in the first intron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE STROMELYSIN-3; RETINOIC ACID RECEPTORS; EXTRACELLULAR-MATRIX; COREPRESSOR COMPLEX; HISTONE ACETYLATION; EXPRESSION PATTERN; RESPONSE GENES; TADPOLE TAIL; IN-VIVO; ACTIVATION	The matrix metalloproteinase (MMP) stromelysin-3 (ST3) (MMP11) was first isolated as a breast cancer-associated gene and is expressed in diverse human carcinomas and various developmental processes involving apoptosis. The Xenopus laevis ST3 is highly up-regulated by thyroid hormone (T3) during amphibian metamorphosis, and its expression is spatially and temporally correlated with apoptosis in different tissues. Furthermore, it has been shown in vivo and in organ cultures to play a critical role in regulating T3-induced epithelial cell death during intestinal metamorphosis. Earlier studies suggest that ST3 is a direct T3 response gene, although a thyroid hormone response element (TRE) was not found in the initial analysis of the ST3 promoter. Here, we have identified a strong TRE consisting of two nearly perfect direct repeats of the consensus nuclear hormone receptor binding element AGGTCA separated by 4 bp in the first intron of the Xenopus ST3 gene. We show that the heterodimers of T3 receptor (TR) and 9-cis-retinoic acid receptor bind to the TRE both in vitro and in vivo in the context of chromatin. Furthermore, T3 induces strong activation of the promoter through the intronic TRE. Interestingly, although the unliganded TR/9-cis-retinoic acid receptor was able to recruit corepressors to the promoter, it had little repressive effect on the promoter in vivo. These results suggest that the intronic TRE mediates the inductive effect of T3 and that promoter context plays an important role in gene repression by unliganded TR.	NICHD, Sect Mol Morphogenesis, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA; Ohio State Univ, Dept Food Sci & Technol, Columbus, OH 43210 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University System of Ohio; Ohio State University	Shi, YB (corresponding author), NICHD, Sect Mol Morphogenesis, Lab Gene Regulat & Dev, NIH, Bldg 18 T,Rm 106 LGRD, Bethesda, MD 20892 USA.	shi@helix.nih.gov	Wang, Hua/E-4269-2011	Shi, Yun-Bo/0000-0002-6330-0639	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001901] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001901] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; Basset P, 1997, CRIT REV ONCOL HEMAT, V26, P43, DOI 10.1016/S1040-8428(97)00010-3; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Berry DL, 1998, DEV BIOL, V203, P12, DOI 10.1006/dbio.1998.8974; Berry DL, 1998, DEV BIOL, V203, P24, DOI 10.1006/dbio.1998.8975; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; Buchholz DR, 2003, MOL CELL BIOL, V23, P6750, DOI 10.1128/MCB.23.19.6750-6758.2003; Buchholz DR, 2004, MOL CELL BIOL, V24, P9026, DOI 10.1128/MCB.24.20.9026-9037.2004; Damjanovski S, 1999, CELL RES, V9, P91, DOI 10.1038/sj.cr.7290009; Dodd M.H.I., 1976, P467; Fu LZ, 2005, J BIOL CHEM, V280, P27856, DOI 10.1074/jbc.M413275200; Hsia SCV, 2002, MOL CELL BIOL, V22, P4043, DOI 10.1128/MCB.22.12.4043-4052.2002; Hsia SCV, 2001, CELL RES, V11, P8, DOI 10.1038/sj.cr.7290061; Ishizuya-Oka A, 2000, J CELL BIOL, V150, P1177, DOI 10.1083/jcb.150.5.1177; IshizuyaOka A, 1996, CELL TISSUE RES, V283, P325, DOI 10.1007/s004410050542; Jung JC, 2002, DEV DYNAM, V223, P402, DOI 10.1002/dvdy.10069; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; Lee MH, 2004, J CELL SCI, V117, P4015, DOI 10.1242/jcs.01223; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; Li JW, 1998, NUCLEIC ACIDS RES, V26, P3018, DOI 10.1093/nar/26.12.3018; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Lochter A, 1999, APMIS, V107, P128, DOI 10.1111/j.1699-0463.1999.tb01535.x; Ludwig MG, 2000, J BIOL CHEM, V275, P39981, DOI 10.1074/jbc.M007529200; Lund LR, 1996, DEVELOPMENT, V122, P181; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1992, Matrix Suppl, V1, P237; Nagase H, 1998, Cell Res, V8, P179; OOFUSA K, 1994, INT J DEV BIOL, V38, P345; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Parks WC, 1998, BIOL EXTRAC, P263; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Puzianowska-Kuznicka M, 1997, MOL CELL BIOL, V17, P4738, DOI 10.1128/MCB.17.8.4738; RANJAN M, 1994, J BIOL CHEM, V269, P24699; Sachs LM, 2000, P NATL ACAD SCI USA, V97, P13138, DOI 10.1073/pnas.260141297; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Shi Y.-B., 1999, AMPHIBIAN METAMORPHO; Shi YB, 2001, CELL RES, V11, P245, DOI 10.1038/sj.cr.7290093; SHI YB, 1993, J BIOL CHEM, V268, P20312; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; Tomita A, 2004, MOL CELL BIOL, V24, P3337, DOI 10.1128/MCB.24.8.3337-3346.2004; Tomita A, 2003, J BIOL CHEM, V278, P30788, DOI 10.1074/jbc.M303309200; Uria J A, 1998, Cell Res, V8, P187; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WANG Z, 1993, J BIOL CHEM, V268, P16270; Wei L, 2005, HISTOL HISTOPATHOL, V20, P177, DOI 10.14670/HH-20.177; Woessner JF, 2004, HDB PROTEOLYTIC ENZY; WONG JM, 1995, J BIOL CHEM, V270, P18479, DOI 10.1074/jbc.270.31.18479; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696	52	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16870	16878		10.1074/jbc.M603041200	http://dx.doi.org/10.1074/jbc.M603041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16606608	hybrid			2022-12-25	WOS:000238326300007
J	Mohs, A; Popiel, M; Li, YJ; Baum, J; Brodsky, B				Mohs, Angela; Popiel, Magdalena; Li, Yingjie; Baum, Jean; Brodsky, Barbara			Conformational features of a natural break in the type IV collagen Gly-X-Y repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; TRIPLE-HELICAL PEPTIDE; AMINO-ACID-SEQUENCE; MOLECULAR-STRUCTURE; HYDROGEN-EXCHANGE; MUTATIONS; DOMAIN; INTERRUPTIONS; STABILITY; DISEASES	Fibrillar collagens have an absolute requirement for Gly as every 3rd residue, whereas breaks in the Gly-X-Y repeating pattern are found normally in the triple helix domains of non-fibrillar collagens, such as type IV collagen in basement membranes. In this study, a model 30-mer peptide is designed to include the interruption GPOGAAVMGPOGPO found in the alpha 5 chain of type IV collagen. The GAAVM peptide forms a stable triple helix, with T-m = 29 degrees C. When compared with a control peptide with Gly as every 3rd residue, the GAAVM peptide has a marked decrease in the 225 nm maximum of its CD spectrum and a 10 degrees C drop in stability. A 50% decrease in calorimetric enthalpy is observed, which may result from disruption of ordered water structure anchored by regularly placed backbone carbonyls. NMR studies on specific N-15-labeled residues within the GAAVM peptide indicate a normal triple helical structure for Gly-Pro-Hyp residues flanking the break. The sequence within the break is not disordered but shows altered hydrogen exchange rates and an abnormal Val chemical shift. It was previously reported that a peptide designed to model a similar kind of interruption in the peptide (Pro-Hyp-Gly)(10), (GPOGPOPOGPO), is unable to form a stable triple helix, and replacement of GAA by GPO or VM by PO within the GAAVM break decreases the stability. Thus, rigid imino acids are unfavorable within a break, despite their favorable stabilization of the triple helix itself. These results suggest some non-random structure typical of this category of breaks in the Gly-X-Y repeat of the triple helix.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Brodsky, B (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes La, Piscataway, NJ 08854 USA.	brodsky@umdnj.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045302, R01GM045302, R01GM060048] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60048, GM45302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Baum Jean, 1999, Current Opinion in Structural Biology, V9, P122, DOI 10.1016/S0959-440X(99)80016-5; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Borza DB, 2001, J BIOL CHEM, V276, P28532, DOI 10.1074/jbc.M103690200; Boydston JA, 2005, J BACTERIOL, V187, P5310, DOI 10.1128/JB.187.15.5310-5317.2005; BRAZEL D, 1987, EUR J BIOCHEM, V168, P529, DOI 10.1111/j.1432-1033.1987.tb13450.x; Brodsky B, 2005, ADV PROTEIN CHEM, V70, P301, DOI 10.1016/S0065-3233(05)70009-7; BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279; Buevich AV, 2004, J BIOL CHEM, V279, P46890, DOI 10.1074/jbc.M407061200; Byers P, 2002, CONNECTIVE TISSUE IT, P385, DOI DOI 10.1002/0471221929.CH8; Deprez P, 2000, BIOCHEM J, V350, P283, DOI 10.1042/0264-6021:3500283; FAN P, 1993, BIOCHEMISTRY-US, V32, P13299, DOI 10.1021/bi00211a043; FURCHT LT, 1994, LAB INVEST, V70, P781; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; Grant ME, 2002, COLLAGEN FAMILY STRU, P159, DOI DOI 10.1002/0471221929.CH2; HOFMANN H, 1984, J MOL BIOL, V172, P325, DOI 10.1016/S0022-2836(84)80029-7; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; Kramer RZ, 2001, J MOL BIOL, V311, P131, DOI 10.1006/jmbi.2001.4849; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; Lemmink HH, 1997, HUM MUTAT, V9, P477; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; LONG CG, 1995, BIOPOLYMERS, V35, P621, DOI 10.1002/bip.360350608; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; MILES AJ, 1994, J BIOL CHEM, V269, P30939; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Persikov AV, 2005, J BIOL CHEM, V280, P19343, DOI 10.1074/jbc.M501657200; Persikov AV, 2004, PROTEIN SCI, V13, P893, DOI 10.1110/ps.03501704; RAMACHANDRAN GN, 1955, NATURE, V176, P593, DOI 10.1038/176593a0; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; Wallis R, 2004, J BIOL CHEM, V279, P14065, DOI 10.1074/jbc.M400171200; Xu Y, 2002, J BIOL CHEM, V277, P27312, DOI 10.1074/jbc.M201163200; YURCHENCO PD, 1988, AM J PATHOL, V132, P278; ZHOU J, 1992, J BIOL CHEM, V267, P12475	38	34	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17197	17202		10.1074/jbc.M601763200	http://dx.doi.org/10.1074/jbc.M601763200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16613845	hybrid			2022-12-25	WOS:000238326300045
J	Nakamura, M; Yamaguchi, S				Nakamura, Morihiko; Yamaguchi, Seiji			The ubiquitin-like protein MNSF beta regulates ERK-MAPK cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSPECIFIC SUPPRESSOR FACTOR; PRO-APOPTOTIC MEMBER; SUMO-1 MODIFICATION; INTERFERON-GAMMA; KINASE; POLYPEPTIDE; ALPHA; ACTIVATION; PATHWAY; CELLS	MNSF beta is a ubiquitously expressed member of the ubiquitin-like family that has been implicated in various biological functions. Previous studies have demonstrated that MNSF beta covalently binds to intracellular proapoptotic protein Bcl-G in mitogen-activated murine T cells. In this study, we further investigated the intracellular mechanism of action of MNSF beta in macrophage cell line, Raw 264.7 cells. We present evidence that MNSF beta(.)Bcl-G complex associates with ERKs in non-stimulated Raw 264.7. We found that MNSF beta(.)Bcl-G directly bound to ERKs and inhibited ERK activation by MEK1. In Raw 264.7 cells treated with MNSF beta small interfering RNA (siRNA) lipopolysaccharide (LPS)-induced ERK1/2 activation was enhanced and LPS-induced JNK and p38 activation was unaffected. SiRNA-mediated knockdown of MNSF beta increased tumor necrosis factor alpha (TNF alpha) expression at mRNA and protein levels in LPS-stimulated Raw 264.7 cells. Finally, we found that transfection with MNSF beta expression construct resulted in a significant inhibition of LPS-induced ERK activation and TNF alpha production. Co-transfection experiments with MNSF beta and Bcl-G greatly enhanced this inhibition. Collectively, these findings indicate that MNSF beta might be implicated in the macrophage response to LPS.	Shimane Univ, Ctr Collaborat, Dept Cooperat Med Res, Izumo, Shimane 6938501, Japan; Shimane Univ, Fac Med, Dept Pediat, Izumo, Shimane 6938501, Japan	Shimane University; Shimane University	Nakamura, M (corresponding author), Shimane Univ, Ctr Collaborat, Dept Cooperat Med Res, Izumo, Shimane 6938501, Japan.	nkmr0515@med.shimane-u.ac.jp		Nakamura, Morihiko/0000-0003-1079-9787				Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Fu SL, 2006, BIOCHEM BIOPH RES CO, V339, P137, DOI 10.1016/j.bbrc.2005.11.005; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hemelaar J, 2003, J BIOL CHEM, V278, P51841, DOI 10.1074/jbc.M308762200; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; LOEB KR, 1994, MOL CELL BIOL, V14, P8408, DOI 10.1128/MCB.14.12.8408; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Malakhova O, 2002, J BIOL CHEM, V277, P14703, DOI 10.1074/jbc.M111527200; Marx J, 2005, SCIENCE, V307, P836, DOI 10.1126/science.307.5711.836; Miled C, 2005, CANCER RES, V65, P5096, DOI 10.1158/0008-5472.CAN-04-4232; Nakamura M, 1999, J BIOL CHEM, V274, P18026, DOI 10.1074/jbc.274.25.18026; Nakamura M, 1996, J Immunol, V156, P532; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; NAKAMURA M, 1986, J IMMUNOL, V136, P2904; Nakamura M, 2003, EUR J BIOCHEM, V270, P4052, DOI 10.1046/j.1432-1033.2003.03790.x; Nakamura M, 1998, BIOCHEM J, V330, P683, DOI 10.1042/bj3300683; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Passmore LA, 2004, BIOCHEM J, V379, P513, DOI 10.1042/BJ20040198; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Schroder NW, 2001, J BIOL CHEM, V276, P9713, DOI 10.1074/jbc.M008954200; Shi L, 2002, AM J PHYSIOL-CELL PH, V282, pC1205, DOI 10.1152/ajpcell.00511.2001; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang XZ, 2004, J BIOL CHEM, V279, P49460, DOI 10.1074/jbc.M406059200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563	38	24	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16861	16869		10.1074/jbc.M509907200	http://dx.doi.org/10.1074/jbc.M509907200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16621790	hybrid			2022-12-25	WOS:000238326300006
J	Boers, W; Aarrass, S; Linthorst, C; Pinzani, M; Elferink, RO; Bosma, P				Boers, Willem; Aarrass, Saida; Linthorst, Chris; Pinzani, Massimo; Elferink, Ronald Oude; Bosma, Piter			Transcriptional profiling reveals novel markers of liver fibrogenesis - Gremlin and insulin-like growth factor-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; SMOOTH-MUSCLE-ACTIN; ACTIVATION IN-VIVO; GENE-EXPRESSION; REGULATORY ROLE; FACTOR RECEPTOR; FIBROSIS; BETA; IGF; (MYO)FIBROBLASTS	Activated hepatic stellate cells ( HSC) that transdifferentiate to myofibroblasts in the injured liver are responsible for scar formation that leads to fibrosis and eventually cirrhosis. To investigate the gene expression profile during different stages of this process, we performed serial analysis of gene expression, representing a quantitative and qualitative description of all expressed genes. Stellate cells were isolated from human livers and cultured. Serial analysis of gene expression was performed on RNA isolated from quiescent, activated, and transdifferentiated HSC. Comparison of the three resulting transcriptomes showed that less than 5% of all genes changed significantly in expression. Established markers of liver fibrosis showed enhanced expression in accordance with the transdifferentiation process. In addition, induction was seen for several genes not yet recognized to be involved in liver fibrosis, such as insulin-like growth factor-binding proteins ( IGFBP) and antagonists of bone morphogenic proteins: follistatin and gremlin. The induction of these genes was validated in vivo in mice developing liver fibrosis. The expression of IGFBPs and gremlin was measurable in the livers of these mice, whereas it was low or undetectable in control mice without liver fibrosis. Since gremlin modulates the activity of bone morphogenic growth factors, it may represent a novel pathway and a target for therapeutic intervention and together with IGFBPs it could be a specific marker of liver fibrosis. In conclusion, the comparison of the three transcriptomes of ( activated) stellate cells reveals novel genes involved in fibrogenesis and provides an appreciation of the sequence and timing of the fibrotic process in liver.	Univ Amsterdam, Acad Med Ctr, AMC Liver Ctr, NL-1105 BK Amsterdam, Netherlands; Univ Florence, Dept Internal Med, Lab Hepatol, I-50134 Florence, Italy	University of Amsterdam; Academic Medical Center Amsterdam; University of Florence	Boers, W (corresponding author), Univ Amsterdam, Acad Med Ctr, AMC Liver Ctr, Meibergdreef 69-71, NL-1105 BK Amsterdam, Netherlands.	w.boers@amc.uva.nl						Arthur MJP, 1998, DIGESTION, V59, P376, DOI 10.1159/000007492; BLOMHOFF R, 1991, FASEB J, V5, P271, DOI 10.1096/fasebj.5.3.2001786; CASINI A, 1993, GASTROENTEROLOGY, V105, P245, DOI 10.1016/0016-5085(93)90033-9; Conchillo M, 2005, J HEPATOL, V43, P630, DOI 10.1016/j.jhep.2005.03.025; Friedman SL, 2003, J HEPATOL, V38, pS38, DOI 10.1016/S0168-8278(02)00429-4; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Gentilini A, 1998, J CELL PHYSIOL, V174, P240; GRESSNER AM, 1991, EUR J CLIN CHEM CLIN, V29, P293; GRESSNER AM, 1995, J HEPATOL, V22, P28; Hautekeete ML, 1997, VIRCHOWS ARCH, V430, P195, DOI 10.1007/BF01324802; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Iredale JP, 1996, HEPATOLOGY, V24, P176, DOI 10.1002/hep.510240129; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178; KNITTEL T, 1992, GASTROENTEROLOGY, V102, P1724, DOI 10.1016/0016-5085(92)91736-N; MARRA F, 1994, GASTROENTEROLOGY, V107, P1110, DOI 10.1016/0016-5085(94)90236-4; Murphy M, 2002, EXP NEPHROL, V10, P241; Patella S, 2006, AM J PHYSIOL-GASTR L, V290, pG137, DOI 10.1152/ajpgi.00080.2005; PINZANI M, 1995, HEPATOLOGY, V21, P232, DOI 10.1002/hep.1840210136; RAMADORI G, 1990, VIRCHOWS ARCH B, V59, P349, DOI 10.1007/BF02899424; ROCKEY DC, 1992, J SUBMICR CYTOL PATH, V24, P193; Ruijter JM, 2002, PHYSIOL GENOMICS, V11, P37, DOI 10.1152/physiolgenomics.00042.2002; Sanz S, 2005, GUT, V54, P134, DOI 10.1136/gut.2003.024505; Scharf JG, 1998, HEPATOLOGY, V27, P1275, DOI 10.1002/hep.510270513; Schorderet DF, 2000, BIOCHEM BIOPH RES CO, V274, P267, DOI 10.1006/bbrc.2000.3116; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; Shibanuma M, 2002, CELL STRUCT FUNCT, V27, P21, DOI 10.1247/csf.27.21; Skrtic S, 1999, ENDOCRINOLOGY, V140, P5729, DOI 10.1210/en.140.12.5729; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; TIGGELMAN AMB, 1995, J HEPATOL, V23, P295, DOI 10.1016/0168-8278(95)80474-9; TIGGELMAN AMB, 1995, J HEPATOL, V23, P307, DOI 10.1016/0168-8278(95)80475-7; van Kampen AHC, 2000, BIOINFORMATICS, V16, P899, DOI 10.1093/bioinformatics/16.10.899; vanNieuwkerk CMJ, 1996, GASTROENTEROLOGY, V111, P165, DOI 10.1053/gast.1996.v111.pm8698195; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wada W, 2004, ENDOCRINOLOGY, V145, P2753, DOI 10.1210/en.2003-1663; WONG L, 1994, J CLIN INVEST, V94, P1563, DOI 10.1172/JCI117497; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V269, P110, DOI 10.1006/bbrc.2000.2272; Yuen MF, 2002, SCAND J GASTROENTERO, V37, P233, DOI 10.1080/003655202753416939; Zeisberg M, 2003, AM J PHYSIOL-RENAL, V285, pF1060, DOI 10.1152/ajprenal.00191.2002; Zimmermann EM, 2000, AM J PHYSIOL-GASTR L, V278, pG447, DOI 10.1152/ajpgi.2000.278.3.G447	43	87	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16289	16295		10.1074/jbc.M600711200	http://dx.doi.org/10.1074/jbc.M600711200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16606614	hybrid			2022-12-25	WOS:000238165700015
J	Sugawara, E; Nestorovich, EM; Bezrukov, SM; Nikaido, H				Sugawara, Etsuko; Nestorovich, Ekaterina M.; Bezrukov, Sergey M.; Nikaido, Hiroshi			Pseudomonas aeruginosa porin OprF exists in two different conformations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PROTEIN OPRF; BACTERIAL-CELL-SURFACE; GRAM-NEGATIVE BACTERIA; OUTER-MEMBRANE; ESCHERICHIA-COLI; OMPA PROTEIN; SYNTHETIC PEPTIDES; GROWTH TEMPERATURE; DIFFUSION PORES; MOLECULAR-BASIS	The major nonspecific porin of Pseudomonas aeruginosa, OprF, produces a large channel yet allows only a slow diffusion of various solutes. Here we provide an explanation of this apparent paradox. We first show, by introduction of tobacco etch virus protease cleavage site in the middle of OprF protein, that most of OprF population folds as a two-domain protein with an N-terminal beta-barrel domain and a C-terminal periplasmic domain rich in alpha-helices. However, sedimentation of unilamellar proteoliposomes through an iso-osmotic gradient showed that only about 5% of the OprF population produced open channels. Gel filtration showed that the open channel conformers tended to occur in oligomeric associations. Because the open channel conformer is likely to fold as a single domain protein with a large beta-barrel, we reasoned that residues near the C terminus may be exposed on cell surface in this conformer. Introduction of a cysteine residue at position 312 produced a functional mutant protein. By using bulky biotinylation reagents on intact cells, we showed that this cysteine residue was not exposed on cell surface in most of the OprF population. However, the minority OprF population that was biotinylated in such experiments was enriched for the conformer with pore-forming activity and had a 10-fold higher pore-forming specific activity than the bulk OprF population. Finally trypsin treatment, which preferentially cleaves the C-terminal domain of the two-domain conformer, did not affect the pore-forming activity of OprF nor did it digest the minority conformer whose residue 312 is exposed on cell surface.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; NICHD, Lab Phys & Struct Biol, NIH, Bethesda, MD 20892 USA	University of California System; University of California Berkeley; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Nikaido, H (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 426 Barker Hall, Berkeley, CA 94720 USA.	nhiroshi@berkeley.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009644, R37AI009644] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 09644, R37 AI009644, R01 AI009644-37, R01 AI009644, R01 AI009644-36] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES BN, 1960, J BIOL CHEM, V235, P769; ANGUS BL, 1982, ANTIMICROB AGENTS CH, V21, P299, DOI 10.1128/AAC.21.2.299; Azghani AO, 2002, MICROB PATHOGENESIS, V33, P109, DOI 10.1006/mpat.2002.0514; BELLIDO F, 1992, J BACTERIOL, V174, P5196, DOI 10.1128/JB.174.16.5196-5203.1992; CARRINGTON JC, 1988, P NATL ACAD SCI USA, V85, P3391, DOI 10.1073/pnas.85.10.3391; CHEN R, 1980, P NATL ACAD SCI-BIOL, V77, P4592, DOI 10.1073/pnas.77.8.4592; Chevalier S, 2000, RES MICROBIOL, V151, P619, DOI 10.1016/S0923-2508(00)90128-1; COWAN SW, 1993, CURR OPIN STRUC BIOL, V3, P501, DOI 10.1016/0959-440X(93)90075-V; De E, 1997, MICROBIOL-UK, V143, P1029, DOI 10.1099/00221287-143-3-1029; DEMOT R, 1994, MOL MICROBIOL, V12, P333; DEMOT R, 1992, MOL GEN GENET, V231, P489, DOI 10.1007/BF00292721; DEMOT R, 1994, MICROBIOL-UK, V140, P1377, DOI 10.1099/00221287-140-6-1377; DUCHENE M, 1989, J BACTERIOL, V171, P4130; GILLELAND HE, 1995, CURR MICROBIOL, V31, P279, DOI 10.1007/BF00314580; GILLELAND LB, 1995, INFECT IMMUN, V63, P2347, DOI 10.1128/IAI.63.6.2347-2351.1995; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Grizot S, 2004, MOL MICROBIOL, V51, P1027, DOI 10.1111/j.1365-2958.2003.03903.x; HANCOCK REW, 1979, BIOCHIM BIOPHYS ACTA, V554, P323, DOI 10.1016/0005-2736(79)90373-0; HENKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28; HUGHES EE, 1992, INFECT IMMUN, V60, P3497, DOI 10.1128/IAI.60.9.3497-3503.1992; Jaouen T, 2004, APPL ENVIRON MICROB, V70, P6665, DOI 10.1128/AEM.70.11.6665-6669.2004; Jap BK, 1996, PHYSIOL REV, V76, P1073, DOI 10.1152/physrev.1996.76.4.1073; KOEBNIK R, 1995, MOL MICROBIOL, V16, P1269, DOI 10.1111/j.1365-2958.1995.tb02348.x; LIU J, 1994, BIOCHEMISTRY-US, V33, P13274, DOI 10.1021/bi00249a014; NAKAE T, 1975, J BIOL CHEM, V250, P7359; Nestorovich EM, 2006, J BIOL CHEM, V281, P16230, DOI 10.1074/jbc.M600650200; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; RACKER E, 1979, ARCH BIOCHEM BIOPHYS, V198, P470, DOI 10.1016/0003-9861(79)90521-6; RAWLING EG, 1995, INFECT IMMUN, V63, P38, DOI 10.1128/IAI.63.1.38-42.1995; Rawling EG, 1998, J BACTERIOL, V180, P3556, DOI 10.1128/JB.180.14.3556-3562.1998; Rebiere-Huet J, 2002, FEMS MICROBIOL LETT, V215, P121, DOI 10.1016/S0378-1097(02)00920-5; RIED G, 1994, MOL GEN GENET, V243, P127, DOI 10.1007/BF00280309; Schulz GE, 1993, CURR OPIN CELL BIOL, V5, P701, DOI 10.1016/0955-0674(93)90143-E; Singh SP, 2003, INFECT IMMUN, V71, P3937, DOI 10.1128/IAI.71.7.3937-3946.2003; Sugawara E., 1997, Biophysical Journal, V72, pA138; SUGAWARA E, 1994, J BIOL CHEM, V269, P17981; SUGAWARA E, 1992, J BIOL CHEM, V267, P2507; Sugawara E, 1996, J BACTERIOL, V178, P6067, DOI 10.1128/jb.178.20.6067-6069.1996; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TRIAS J, 1988, BIOCHIM BIOPHYS ACTA, V938, P493, DOI 10.1016/0005-2736(88)90148-4; WONG RSY, 1995, GENE, V158, P55, DOI 10.1016/0378-1119(95)00155-Y; WONG RSY, 1993, MOL MICROBIOL, V10, P283, DOI 10.1111/j.1365-2958.1993.tb01954.x; WOODRUFF WA, 1989, J BACTERIOL, V171, P3304, DOI 10.1128/jb.171.6.3304-3309.1989; WOODRUFF WA, 1986, J BACTERIOL, V167, P473, DOI 10.1128/jb.167.2.473-479.1986; WYLIE JL, 1995, J BACTERIOL, V177, P3021, DOI 10.1128/jb.177.11.3021-3026.1995; YONEYAMA H, 1986, EUR J BIOCHEM, V157, P33, DOI 10.1111/j.1432-1033.1986.tb09634.x; YOSHIHARA E, 1989, J BIOL CHEM, V264, P6297; YOSHIHARA E, 1988, BIOCHEM BIOPH RES CO, V156, P470, DOI 10.1016/S0006-291X(88)80865-9; YOSHIMURA F, 1982, J BACTERIOL, V152, P636; YOSHIMURA F, 1983, J BIOL CHEM, V258, P2308	55	64	68	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16220	16229		10.1074/jbc.M600680200	http://dx.doi.org/10.1074/jbc.M600680200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16595653	hybrid, Green Accepted			2022-12-25	WOS:000238165700007
J	Xia, WL; Mruk, DD; Lee, WM; Cheng, CY				Xia, Weiliang; Mruk, Dolores D.; Lee, Will M.; Cheng, C. Yan			Differential interactions between transforming growth factor-beta 3/T beta R1, TAB1, and CD2AP disrupt blood-testis barrier and sertoli-germ cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORING JUNCTION DYNAMICS; SEMINIFEROUS EPITHELIUM; ADHERENS JUNCTIONS; CADMIUM CHLORIDE; PROTEIN-KINASE; SMOOTH-MUSCLE; GENE-TRANSFER; RAT TESTIS; IN-VITRO; TIGHT	The biochemical basis that regulates the timely and selective opening of the blood-testis barrier (BTB) to migrating preleptotene/ leptotene spermatocytes at stage VIII of the epithelial cycle in adult rat testes is virtually unknown. Recent studies have shown that cytokines (e. g. transforming growth factor (TGF)-beta 3) may play a crucial role in this event. However, much of this information relies on the use of toxicants (e. g. CdCl2), making it difficult to relay these findings to normal testicular physiology. Here we report that overexpression of TGF-beta 3 in primary Sertoli cells cultured in vitro indeed perturbed the tight junction (TJ) barrier with a concomitant decline in the production of BTB constituent proteins as follows: occludin, N-cadherin, and ZO-1. Additionally, local administration of TGF-beta 3 to testes in vivo was shown to reversibly perturb the BTB integrity and Sertoli-germ cell adhesion via the p38 MAPK and ERK signaling pathways. Most importantly, the simultaneous activation of p38 and ERK signaling pathways is dependent on the association of the TGF-beta 3-T beta R1 complex with adaptors TAB1 and CD2AP because if T beta R1 was associated preferentially with CD2AP, only Sertoli-germ cell adhesion was perturbed without compromising the BTB. Collectively, these data illustrate that local production of TGF-beta 3, and perhaps other TGF-beta s and cytokines, by Sertoli and germ cells into the microenvironment at the BTB during spermatogenesis transiently perturbs the BTB and Sertoli-germ cell adhesion to facilitate germ cell migration when the activated T beta RI interacts with adaptors TAB1 and CD2AP. However, TGF-beta 3 selectively disrupts Sertoli-germ cell adhesion in the seminiferous epithelium to facilitate germ cell migration without compromising BTB when T beta RI interacts only with adaptor CD2AP.	Biomed Res Ctr, Populat Council, New York, NY 10021 USA; Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China	Population Council; University of Hong Kong	Cheng, CY (corresponding author), Biomed Res Ctr, Populat Council, 1230 York Ave, New York, NY 10021 USA.	Y-Cheng@popcbr.rockefeller.edu	Xia, Weiliang/C-2650-2008; XIA, WEILIANG/AEA-0835-2022; Lee, Will M/D-2357-2009	Xia, Weiliang/0000-0002-0256-4219; XIA, WEILIANG/0000-0002-0256-4219; Cheng, C Yan/0000-0003-3117-3791	NICHD NIH HHS [U54 HD 029990, U01 HD 45908] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD029990] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD045908] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anway MD, 2001, BIOL REPROD, V65, P1289, DOI 10.1095/biolreprod65.4.1289; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Chaudhary J, 2001, ENDOCRINOLOGY, V142, P1727, DOI 10.1210/en.142.5.1727; Cheng CY, 2005, CONTRACEPTION, V72, P251, DOI 10.1016/j.contraception.2005.03.008; Chung NPY, 2001, ENDOCRINOLOGY, V142, P1878, DOI 10.1210/en.142.5.1878; Chung NPY, 2001, BIOL REPROD, V65, P1340, DOI 10.1095/biolreprod65.5.1340; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Gnessi L, 1997, ENDOCR REV, V18, P541, DOI 10.1210/er.18.4.541; Gronning LM, 1999, EUR J ENDOCRINOL, V141, P75, DOI 10.1530/eje.0.1410075; Grunkemeyer JA, 2005, J BIOL CHEM, V280, P29677, DOI 10.1074/jbc.M504004200; Hong CY, 2003, MOL CELL BIOL, V23, P6000, DOI 10.1128/MCB.23.17.6000-6012.2003; JANECKI A, 1992, TOXICOL APPL PHARM, V112, P51, DOI 10.1016/0041-008X(92)90278-Z; Kiefer K, 2004, PHARM RES-DORDR, V21, P1009, DOI 10.1023/B:PHAM.0000029291.62615.ec; Lee NPY, 2004, J ANDROL, V25, P200; Lui WY, 2003, BIOL REPROD, V68, P2189, DOI 10.1095/biolreprod.102.011379; Lui WY, 2003, INT J ANDROL, V26, P147, DOI 10.1046/j.1365-2605.2003.00410.x; Lui WY, 2003, ENDOCRINOLOGY, V144, P1139, DOI 10.1210/en.2002-0211; Lui WY, 2001, ENDOCRINOLOGY, V142, P1865, DOI 10.1210/en.142.5.1865; Lui WY, 2003, BIOL REPROD, V68, P1597, DOI 10.1095/biolreprod.102.011387; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022; Mruk DD, 2004, TRENDS ENDOCRIN MET, V15, P439, DOI 10.1016/j.tem.2004.09.009; Mruk DD, 2000, E SCHERING RES FDN W, P197; Murata T, 2001, J HEPATOL, V35, P474, DOI 10.1016/S0168-8278(01)00169-6; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PELLETIER RM, 1992, MICROSC RES TECHNIQ, V20, P3, DOI 10.1002/jemt.1070200104; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; RUSSELL L, 1977, AM J ANAT, V148, P313, DOI 10.1002/aja.1001480303; RUSSELL LD, 1987, GAMETE RES, V17, P43, DOI 10.1002/mrd.1120170106; Schiffer M, 2004, J BIOL CHEM, V279, P37004, DOI 10.1074/jbc.M403534200; SETCHELL BP, 1970, J ENDOCRINOL, V47, P81, DOI 10.1677/joe.0.0470081; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Siu MKY, 2005, J BIOL CHEM, V280, P25029, DOI 10.1074/jbc.M501049200; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; SKINNER MK, 1993, SERTOLI CELL, P238; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vogl AW, 2000, ARCH HISTOL CYTOL, V63, P1, DOI 10.1679/aohc.63.1; WEBER JE, 1983, AM J ANAT, V167, P163, DOI 10.1002/aja.1001670203; Welsch T, 2005, AM J PHYSIOL-RENAL, V289, pF1134, DOI 10.1152/ajprenal.00178.2005; Wiebe JP, 2000, J ANDROL, V21, P625; Wong CH, 2005, CURR TOP DEV BIOL, V71, P263, DOI 10.1016/S0070-2153(05)71008-5; Wong CH, 2004, J CELL SCI, V117, P783, DOI 10.1242/jcs.00900; Xia WL, 2005, CYTOKINE GROWTH F R, V16, P469, DOI 10.1016/j.cytogfr.2005.05.007; Xia WL, 2005, J CELL PHYSIOL, V205, P141, DOI 10.1002/jcp.20377; Xia WL, 2005, DEV BIOL, V280, P321, DOI 10.1016/j.ydbio.2004.12.036; XU H, 1992, NUCLEIC ACIDS RES, V20, P6425, DOI 10.1093/nar/20.23.6425; Yan HHN, 2005, P NATL ACAD SCI USA, V102, P11722, DOI 10.1073/pnas.0503855102	51	77	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16799	16813		10.1074/jbc.M601618200	http://dx.doi.org/10.1074/jbc.M601618200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16617054	hybrid, Green Published			2022-12-25	WOS:000238165700075
J	Conklin, PL; Gatzek, S; Wheeler, GL; Dowdle, J; Raymond, MJ; Rolinski, S; Isupov, M; Littlechild, JA; Smirnoff, N				Conklin, Patricia L.; Gatzek, Stephan; Wheeler, Glen L.; Dowdle, John; Raymond, Marjorie J.; Rolinski, Susanne; Isupov, Mikhail; Littlechild, Jennifer A.; Smirnoff, Nicholas			Arabidopsis thaliana VTC4 encodes L-galactose-1-P phosphatase, a plant ascorbic acid biosynthetic enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO SYNTHESIS; GDP-L-FUCOSE; VITAMIN-C; L-GALACTOSE; INOSITOL MONOPHOSPHATASE; CELL-WALL; MYOINOSITOL MONOPHOSPHATASE; RHAMNOGALACTURONAN-II; MUR1 GENE; DEFICIENT	In plants, a proposed ascorbate ( vitamin C) biosynthesis pathway occurs via GDP-D-mannose (GDP-D-Man), GDP-L-galactose (GDPLGal), and L-galactose. However, the steps involved in the synthesis of L-Gal from GDP-L-Gal in planta are not fully characterized. Here we present evidence for an in vivo role for L-Gal-1-P phosphatase in plant ascorbate biosynthesis. We have characterized a low ascorbate mutant (vtc4-1) of Arabidopsis thaliana, which exhibits decreased ascorbate biosynthesis. Genetic mapping and sequencing of the VTC4 locus identified a mutation (P92L) in a gene with predicted L-Gal-1-P phosphatase activity (At3g02870). Pro-92 is within a beta-bulge that is conserved in related myo-inositol monophosphatases. The mutation is predicted to disrupt the positioning of catalytic amino acid residues within the active site. Accordingly, L-Gal-1-P phosphatase activity in vtc4-1 was similar to 50% of wild-type plants. In addition, vtc4-1 plants incorporate significantly more radiolabel from [2-H-3] Man into L-galactosyl residues suggesting that the mutation increases the availability of GDP-L-Gal for polysaccharide synthesis. Finally, a homozygous T-DNA insertion line, which lacks a functional At3g02870 gene product, is also ascorbate-deficient (50% of wild type) and deficient in L-Gal-1-P phosphatase activity. Genetic complementation tests revealed that the insertion mutant and VTC4-1 are alleles of the same genetic locus. The significantly lower ascorbate and perturbed L-Gal metabolism in vtc4-1 and the T-DNA insertion mutant indicate that L-Gal-1-P phosphatase plays a role in plant ascorbate biosynthesis. The presence of ascorbate in the T-DNA insertion mutant suggests there is a bypass to this enzyme or that other pathways also contribute to ascorbate biosynthesis.	Univ Exeter, Sch Biosci, Exeter EX4 4QD, Devon, England; SUNY Coll Cortland, Dept Biol Sci, Cortland, NY 13045 USA	University of Exeter; State University of New York (SUNY) System; SUNY Cortland	Smirnoff, N (corresponding author), Univ Exeter, Sch Biosci, Geoffrey Pope Bldg,Stocker Rd, Exeter EX4 4QD, Devon, England.	N.Smirnoff@exeter.ac.uk	Smirnoff, Nicholas/GZN-1978-2022; Isupov, Mikhail/AAA-8280-2019; Wheeler, Glen L/E-5034-2011; Littlechild, Jenny/AAE-4096-2020	Smirnoff, Nicholas/0000-0001-5630-5602; Isupov, Michail/0000-0001-6842-4289				Agius F, 2003, NAT BIOTECHNOL, V21, P177, DOI 10.1038/nbt777; Barth C, 2004, PLANT PHYSIOL, V134, P1784, DOI 10.1104/pp.103.032185; BAYDOUN EAH, 1988, J PLANT PHYSIOL, V132, P484, DOI 10.1016/S0176-1617(88)80068-3; BONE R, 1994, BIOCHEMISTRY-US, V33, P9460, DOI 10.1021/bi00198a011; Bonin CP, 2000, PLANT J, V21, P445, DOI 10.1046/j.1365-313x.2000.00698.x; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; Buettner GR, 2004, VITAMIN C: FUNCTION AND BIOCHEMISTRY IN ANIMALS AND PLANTS, P173; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; Conklin PL, 2004, PLANT CELL ENVIRON, V27, P959, DOI 10.1111/j.1365-3040.2004.01203.x; Conklin PL, 1996, P NATL ACAD SCI USA, V93, P9970, DOI 10.1073/pnas.93.18.9970; Conklin PL, 1997, PLANT PHYSIOL, V115, P1277, DOI 10.1104/pp.115.3.1277; Conklin PL, 1999, P NATL ACAD SCI USA, V96, P4198, DOI 10.1073/pnas.96.7.4198; Conklin PL, 2000, GENETICS, V154, P847; Davey MW, 1999, PLANT PHYSIOL, V121, P535, DOI 10.1104/pp.121.2.535; De Tullio MC, 2004, VITAMIN C: FUNCTION AND BIOCHEMISTRY IN ANIMALS AND PLANTS, P159; Duffels A, 2000, BIOORGAN MED CHEM, V8, P2519, DOI 10.1016/S0968-0896(00)00187-5; Filkowski J, 2004, PLANT J, V38, P60, DOI 10.1111/j.1365-313X.2004.02020.x; Frossard E, 2000, J SCI FOOD AGR, V80, P861, DOI 10.1002/(SICI)1097-0010(20000515)80:7&lt;861::AID-JSFA601&gt;3.0.CO;2-P; Fry S. C, 1988, GROWING PLANT CELL W, DOI DOI 10.1016/0031-9422(88)83079-6; Ganzhorn AJ, 1997, PROTEIN ENG, V10, P61; Gatzek S, 2002, PLANT J, V30, P541, DOI 10.1046/j.1365-313X.2002.01315.x; GHEBREGZABHER M, 1976, J CHROMATOGR, V127, P133, DOI 10.1016/S0021-9673(00)80168-5; Gil-Mascarell R, 1999, PLANT J, V17, P373, DOI 10.1046/j.1365-313X.1999.00385.x; Gill R, 2005, ACTA CRYSTALLOGR D, V61, P545, DOI 10.1107/S0907444905004038; Gillaspy GE, 1995, PLANT CELL, V7, P2175, DOI 10.1105/tpc.7.12.2175; Jander G, 2002, PLANT PHYSIOL, V129, P440, DOI 10.1104/pp.003533; King CG, 1932, SCIENCE, V75, P357, DOI 10.1126/science.75.1944.357-a; Laing WA, 2004, P NATL ACAD SCI USA, V101, P16976, DOI 10.1073/pnas.0407453101; Lorence A, 2004, PLANT PHYSIOL, V134, P1200, DOI 10.1104/pp.103.033936; Lukowitz W, 2001, P NATL ACAD SCI USA, V98, P2262, DOI 10.1073/pnas.051625798; May J, 2004, VITAMIN C: FUNCTION AND BIOCHEMISTRY IN ANIMALS AND PLANTS, P139; Millar AH, 2003, PLANT PHYSIOL, V133, P443, DOI 10.1104/pp.103.028399; Muller-Moule P, 2003, PLANT PHYSIOL, V133, P748, DOI 10.1104/pp.103.026252; Muller-Moule P, 2002, PLANT PHYSIOL, V128, P970, DOI 10.1104/pp.010924; O'Neill MA, 2001, SCIENCE, V294, P846, DOI 10.1126/science.1062319; Ostergaard J, 1997, J BIOL CHEM, V272, P30009, DOI 10.1074/jbc.272.48.30009; Pallanca JE, 2000, J EXP BOT, V51, P669, DOI 10.1093/jexbot/51.345.669; Pastori GM, 2003, PLANT CELL, V15, P939, DOI 10.1105/tpc.010538; Radzio JA, 2003, PLANT MOL BIOL, V53, P837, DOI 10.1023/B:PLAN.0000023671.99451.1d; Reuhs BL, 2004, PLANTA, V219, P147, DOI 10.1007/s00425-004-1205-x; Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P224, DOI 10.1093/nar/gkg076; ROBERTS RM, 1971, ARCH BIOCHEM BIOPHYS, V145, P685, DOI 10.1016/S0003-9861(71)80029-2; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Seifert GJ, 2004, CURR OPIN PLANT BIOL, V7, P277, DOI 10.1016/j.pbi.2004.03.004; Sessions A, 2002, PLANT CELL, V14, P2985, DOI 10.1105/tpc.004630; Smirnoff N, 2001, ANNU REV PLANT PHYS, V52, P437, DOI 10.1146/annurev.arplant.52.1.437; Svirbely JL, 1932, NATURE, V129, P576, DOI 10.1038/129576a0; Tabata K, 2001, PLANT J, V27, P139, DOI 10.1046/j.1365-313x.2001.01074.x; Wheeler GL, 1998, NATURE, V393, P365, DOI 10.1038/30728; Wolucka BA, 2003, J BIOL CHEM, V278, P47483, DOI 10.1074/jbc.M309135200; Wolucka BA, 2001, P NATL ACAD SCI USA, V98, P14843, DOI 10.1073/pnas.011578198; Zablackis E, 1996, SCIENCE, V272, P1808, DOI 10.1126/science.272.5269.1808; ZHANG YP, 1993, BIOCHEM BIOPH RES CO, V190, P1080, DOI 10.1006/bbrc.1993.1159	53	125	140	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15662	15670		10.1074/jbc.M601409200	http://dx.doi.org/10.1074/jbc.M601409200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595667	hybrid			2022-12-25	WOS:000237996000010
J	Madsen, MA; Deryugina, EI; Niessen, S; Cravatt, BF; Quigley, JP				Madsen, Mark A.; Deryugina, Elena I.; Niessen, Sherry; Cravatt, Benjamin F.; Quigley, James P.			Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-CELL INTRAVASATION; ENZYME-ACTIVITY PROFILES; PLASMINOGEN-ACTIVATOR; TUMOR-GROWTH; IN-VIVO; METASTATIC CASCADE; SERINE-PROTEASE; PROSTATE-CANCER; INHIBITOR PAI-1; CARCINOMA CELLS	Entry of malignant cells into the vasculature (i.e. intravasation) requires proteolytic remodeling of the extracellular matrix so that tumor cells may pass through the local stroma and penetrate the vessel wall. The circulatory system then provides a means of transporting tumor cells to distant sites where they extravasate and establish metastatic lesions. This study utilizes activity-based protein profiling to compare the active serine hydrolase repertoire in high intravasating (HT-hi/diss) and low intravasating (HT-lo/diss) variants of the human fibrosarcomaHT-1080 cell line to determine which enzyme(s) play a role in intravasation. Activity-based protein profiling revealed multiple serine hydrolases with altered activity between HT-hi/diss and HT-lo/diss cells, with the largest difference being the activity of urokinase-type plasminogen activator (uPA). Levels of inactive uPA zymogen were similar between the two cell variants, but only HT-hi/diss conditioned medium contained active uPA, suggesting that uPA activation may contribute to the enhanced intravasation of HT-hi/diss cells. To analyze the role of uPA activity specifically in the process of intravasation, we grafted cells from the two HT-1080 variants onto the chorioallantoic membrane of chick embryos and measured levels of tumor cell intravasation in the distal chorioallantoic membrane using quantitative human-specific Alu PCR. Inhibition of uPA activity with natural ( plasminogen activator inhibitor-1) or synthetic ( amiloride) inhibitors diminished HT-hi/diss Matrigel invasion in vitro and intravasation and metastasis in vivo. Additionally, treatment of HTlo/diss tumors with exogenous active uPA increased the number of intravasated cells in vivo. These results indicate that active uPA promotes tumor cell intravasation and that uPA activation appears to be a key step in tumor progression.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Quigley, JP (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jquigley@scripps.edu			NCI NIH HHS [CA105412, CA55852] Funding Source: Medline; NHLBI NIH HHS [HL07695] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105412, R01CA055852] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Almholt K, 2005, INT J CANCER, V113, P525, DOI 10.1002/ijc.20631; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bauer TW, 2005, CANCER RES, V65, P7775, DOI 10.1158/0008-5472.CAN-05-0946; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Curino A, 2002, ONCOGENE, V21, P8830, DOI 10.1038/sj.onc.1205951; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; de Bock CE, 2005, FEBS J, V272, P3572, DOI 10.1111/j.1742-4658.2005.04778.x; Demetriou MC, 2004, EXP CELL RES, V294, P550, DOI 10.1016/j.yexcr.2003.11.023; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 2005, CANCER RES, V65, P10959, DOI 10.1158/0008-5472.CAN-05-2228; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Evans Douglas M., 1998, Invasion and Metastasis, V18, P252, DOI 10.1159/000024518; Evens DM, 1998, CLIN EXP METASTAS, V16, P353; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Frandsen TL, 2001, CANCER RES, V61, P532; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; GORETZKI L, 1992, FEBS LETT, V297, P112, DOI 10.1016/0014-5793(92)80339-I; Greenbaum D, 2002, MOL CELL PROTEOMICS, V1, P60, DOI 10.1074/mcp.T100003-MCP200; Gutierrez LS, 2000, CANCER RES, V60, P5839; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hynes RO, 2003, CELL, V113, P821, DOI 10.1016/S0092-8674(03)00468-9; Jankun J, 1999, Cancer Biochem Biophys, V17, P109; Jessani N, 2004, P NATL ACAD SCI USA, V101, P13756, DOI 10.1073/pnas.0404727101; Jessani N, 2002, P NATL ACAD SCI USA, V99, P10335, DOI 10.1073/pnas.162187599; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.can-03-3645; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; LIOTTA LA, 1986, CANCER RES, V46, P1; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Ludwig T, 2005, BIOESSAYS, V27, P1181, DOI 10.1002/bies.20306; Ma Z, 2001, J CELL SCI, V114, P3387; Min HY, 1996, CANCER RES, V56, P2428; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; Palmieri D, 2002, J BIOL CHEM, V277, P40950, DOI 10.1074/jbc.M202333200; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; PEDERSEN H, 1994, CANCER RES, V54, P120; PEDERSEN H, 1994, CANCER RES, V54, P4671; Ploug M, 2001, BIOCHEMISTRY-US, V40, P12157, DOI 10.1021/bi010662g; Pulukuri SM, 2005, J BIOL CHEM, V280, P36529, DOI 10.1074/jbc.M503111200; PYKE C, 1991, CANCER RES, V51, P4067; Quigley JP, 1998, CELL, V94, P281, DOI 10.1016/S0092-8674(00)81470-1; Saghatelian A, 2004, P NATL ACAD SCI USA, V101, P10000, DOI 10.1073/pnas.0402784101; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Speers AE, 2004, CHEMBIOCHEM, V5, P41, DOI 10.1002/cbic.200300721; Swiercz R, 1999, ONCOL REP, V6, P523; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; YU H, 1990, CANCER RES, V50, P7623; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767; Zijlstra A, 2002, CANCER RES, V62, P7083	57	42	48	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15997	16005		10.1074/jbc.M601223200	http://dx.doi.org/10.1074/jbc.M601223200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16611636	hybrid			2022-12-25	WOS:000237996000051
J	Lu, L; Ma, YY; Zhang, JR				Lu, Ling; Ma, Yueyun; Zhang, Jing-Ren			Streptococcus pneumoniae recruits complement factor H through the amino terminus yof CbpA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PNEUMOCOCCAL SURFACE PROTEIN; BORRELIA-BURGDORFERI; BINDING-SITE; NEISSERIA-GONORRHOEAE; RESISTANCE MECHANISMS; SECRETORY COMPONENT; SERUM RESISTANCE; IMMUNE EVASION; PSPC; DISEASE	Streptococcus pneumoniae, a human pathogen, is naturally capable of colonizing the upper airway and sometimes disseminating to remote tissue sites. Previous studies have shown that S. pneumoniae is able to evade complement-mediated innate immunity by recruiting complement factor H ( FH), a complement alternative pathway inhibitor. Pneumococcal binding to FH has been attributed to choline-binding protein A ( CbpA) of S. pneumoniae and its allelic variants, all of which are surface-exposed proteins. In this study, we sought to determine the molecular basis of the CbpA-FH binding interaction. Initial deletional analysis of the CbpA protein in strain D39 ( capsular serotype 2) revealed that the N-terminal region of 89 amino acids in the mature CbpA protein is required for FH binding. Immunofluorescence microscopy analysis showed that this region of CbpA is also necessary for FH deposition to the surface of the intact pneumococci. Moreover, recombinant proteins representing the 104 amino acids of the N-terminal CbpA alone was sufficient for high affinity binding to FH( K-D < 1nM). The FH binding activity was finally localized to a 12-amino acid motif in the N-terminal CbpA by peptide mapping. Further kinetic analysis suggested that additional amino acids downstream of the 12-amino acid motif provide necessary structural or conformational support for the CbpA-FH interaction. The 12-amino acid motif and its adjacent regions contain highly conserved residues among various CbpA alleles, suggesting that this region may mediate FH binding in multiple pneumococcal strains.	Albany Med Ctr, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA	Albany Medical College	Zhang, JR (corresponding author), Albany Med Ctr, Ctr Immunol & Microbial Dis, M-C 151,Rm MS453,47 New Scotland Ave, Albany, NY 12208 USA.	zhangj@mail.amc.edu	ma, yue/GXE-9897-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006917] Funding Source: NIH RePORTER; NIAID NIH HHS [AI054753] Funding Source: Medline; NIDCD NIH HHS [DC006917] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Alcantara RB, 2001, INFECT IMMUN, V69, P3569, DOI 10.1128/IAI.69.6.3569-3575.2001; Alitalo A, 2004, J IMMUNOL, V172, P6195, DOI 10.4049/jimmunol.172.10.6195; Areschoug T, 2002, J BIOL CHEM, V277, P12642, DOI 10.1074/jbc.M112072200; AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_A.35; Balachandran P, 2002, INFECT IMMUN, V70, P2526, DOI 10.1128/IAI.70.5.2526-2534.2002; BERRY AM, 1989, INFECT IMMUN, V57, P2037, DOI 10.1128/IAI.57.7.2037-2042.1989; Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998; Blom AM, 2000, J IMMUNOL, V164, P5328, DOI 10.4049/jimmunol.164.10.5328; Briles DE, 1997, MICROB DRUG RESIST, V3, P401, DOI 10.1089/mdr.1997.3.401; Brooks-Walter A, 1999, INFECT IMMUN, V67, P6533; Brown JS, 2002, P NATL ACAD SCI USA, V99, P16969, DOI 10.1073/pnas.012669199; Cheng Q, 2000, BIOCHEMISTRY-US, V39, P5450, DOI 10.1021/bi992157d; Dave S, 2004, INDIAN J MED RES, V119, P66; Dave S, 2004, J IMMUNOL, V173, P471, DOI 10.4049/jimmunol.173.1.471; Dave S, 2001, INFECT IMMUN, V69, P3435, DOI 10.1128/IAI.69.5.3435-3437.2001; de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005; Duthy TG, 2002, INFECT IMMUN, V70, P5604, DOI 10.1128/IAI.70.10.5604-5611.2002; Elm C, 2004, J BIOL CHEM, V279, P6296, DOI 10.1074/jbc.M310528200; FISCHETTI VA, 1995, INFECT IMMUN, V63, P149, DOI 10.1128/IAI.63.1.149-153.1995; Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541; GORDON DL, 1986, J INFECT DIS, V154, P619, DOI 10.1093/infdis/154.4.619; Gordon SB, 2000, INFECT IMMUN, V68, P2286, DOI 10.1128/IAI.68.4.2286-2293.2000; Hakansson A, 2001, INFECT IMMUN, V69, P3372, DOI 10.1128/IAI.69.5.3372-3381.2001; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; Hammerschmidt S, 2000, MOL MICROBIOL, V36, P726, DOI 10.1046/j.1365-2958.2000.01897.x; Hava D, 2002, MOL MICROBIOL, V45, P1389, DOI 10.1046/j.1365-2958.2002.t01-1-03106.x; Hellwage J, 2001, J BIOL CHEM, V276, P8427, DOI 10.1074/jbc.M007994200; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HOSEA SW, 1980, J INFECT DIS, V142, P903, DOI 10.1093/infdis/142.6.903; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; Iannelli F, 2004, INFECT IMMUN, V72, P3077, DOI 10.1128/IAI.72.5.3077-3080.2004; Iannelli F, 2002, GENE, V284, P63, DOI 10.1016/S0378-1119(01)00896-4; Janoff EN, 1997, MICROB DRUG RESIST, V3, P215, DOI 10.1089/mdr.1997.3.215; Janoff EN, 1999, J CLIN INVEST, V104, P1139, DOI 10.1172/JCI6310; Janulczyk R, 2000, J BIOL CHEM, V275, P37257, DOI 10.1074/jbc.M004572200; Jarva H, 2004, J IMMUNOL, V172, P3111, DOI 10.4049/jimmunol.172.5.3111; Jarva H, 2003, MOL IMMUNOL, V40, P95, DOI 10.1016/S0161-5890(03)00108-1; Jarva H, 2002, J IMMUNOL, V168, P1886, DOI 10.4049/jimmunol.168.4.1886; Kraiczy P, 2004, J BIOL CHEM, V279, P2421, DOI 10.1074/jbc.M308343200; Kraiczy P, 2001, EUR J IMMUNOL, V31, P1674, DOI 10.1002/1521-4141(200106)31:6&lt;1674::AID-IMMU1674&gt;3.0.CO;2-2; Lau PCY, 2002, J MICROBIOL METH, V49, P193, DOI 10.1016/S0167-7012(01)00369-4; Lu L, 2003, J BIOL CHEM, V278, P48178, DOI 10.1074/jbc.M306906200; Luo RS, 2005, EMBO J, V24, P34, DOI 10.1038/sj.emboj.7600490; MCDANIEL LS, 1987, J EXP MED, V165, P381, DOI 10.1084/jem.165.2.381; McDowell JV, 2005, J BACTERIOL, V187, P1317, DOI 10.1128/JB.187.4.1317-1323.2005; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; Metts MS, 2003, INFECT IMMUN, V71, P3587, DOI 10.1128/IAI.71.6.3587-3596.2003; MORRISON DA, 1984, J BACTERIOL, V159, P870, DOI 10.1128/JB.159.3.870-876.1984; Musher DM, 2000, PRINCIPLES PRACTICE, P2128; Neeleman C, 1999, INFECT IMMUN, V67, P4517, DOI 10.1128/IAI.67.9.4517-4524.1999; PATON JC, 1984, INFECT IMMUN, V43, P1085, DOI 10.1128/IAI.43.3.1085-1087.1984; PEARCE BJ, 1993, MOL MICROBIOL, V9, P1037, DOI 10.1111/j.1365-2958.1993.tb01233.x; Prodinger WM, 1999, FUNDAMENTAL IMMUNOLO, P967; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Ram S, 1998, J EXP MED, V188, P671, DOI 10.1084/jem.188.4.671; Rautemaa R, 1999, MICROBES INFECT, V1, P785, DOI 10.1016/S1286-4579(99)80081-1; Rosenow C, 1997, MOL MICROBIOL, V25, P819, DOI 10.1111/j.1365-2958.1997.mmi494.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sharma AK, 1997, INFECT IMMUN, V65, P484, DOI 10.1128/IAI.65.2.484-487.1997; Smith J.A., 2000, CURRENT PROTOCOLS MO; STIGTER D, 1990, BIOCHEMISTRY-US, V29, P1262, DOI 10.1021/bi00457a023; Stolt PC, 2004, BIOCHEMISTRY-US, V43, P10979, DOI 10.1021/bi049092l; Sung CK, 2001, APPL ENVIRON MICROB, V67, P5190, DOI 10.1128/AEM.67.11.5190-5196.2001; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Tu AHT, 1999, INFECT IMMUN, V67, P4720, DOI 10.1128/IAI.67.9.4720-4724.1999; YOTHER J, 1994, J BACTERIOL, V176, P2976, DOI 10.1128/JB.176.10.2976-2985.1994; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8	69	78	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15464	15474		10.1074/jbc.M602404200	http://dx.doi.org/10.1074/jbc.M602404200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16597618	hybrid			2022-12-25	WOS:000237922200053
J	Regni, C; Schramm, AM; Beamer, LJ				Regni, Catherine; Schramm, Andrew M.; Beamer, Lesa J.			The reaction of phosphohexomutase from Pseudomonas aeruginosa - Structural insights into a simple processive enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOGLUCOMUTASE; PMM/PGM; MODEL; PHOSPHOMANNOMUTASE/PHOSPHOGLUCOMUTASE; INHIBITORS; MECHANISM; PATHWAY	The enzyme phosphomannomutase/phosphoglucomutase ( PMM/PGM) from Pseudomonas aeruginosa catalyzes the reversible conversion of 1-phospho to 6-phospho-sugars. The reaction entails two phosphoryl transfers, with an intervening 180 degrees reorientation of the reaction intermediate ( e. g. glucose 1,6-bisphosphate) during catalysis. Reorientation of the intermediate occurs without dissociation from the active site of the enzyme and is, thus, a simple example of processivity, as defined by multiple rounds of catalysis without release of substrate. Structural characterization of two PMM/PGM-intermediate complexes with glucose 1,6-bisphosphate provides new insights into the reaction catalyzed by the enzyme, including the reorientation of the intermediate. Kinetic analyses of site-directed mutants prompted by the structural studies reveal active site residues critical for maintaining association with glucose 1,6-bisphosphate during its unique dynamic reorientation in the active site of PMM/PGM.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Beamer, LJ (corresponding author), Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA.	beamerl@missouri.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059653] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08396-13, GM59653] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Naught LE, 2005, BIOCHEMISTRY-US, V44, P6831, DOI 10.1021/bi0501380; Naught LE, 2003, BIOCHEMISTRY-US, V42, P9946, DOI 10.1021/bi034673g; Naught LE, 2002, BIOCHEMISTRY-US, V41, P9637, DOI 10.1021/bi025862m; Naught LE, 2001, ARCH BIOCHEM BIOPHYS, V396, P111, DOI 10.1006/abbi.2001.2618; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parsiegla G, 2000, BIOCHEMISTRY-US, V39, P11238, DOI 10.1021/bi001139p; PERCIVAL MD, 1992, BIOCHEMISTRY-US, V31, P505, DOI 10.1021/bi00117a029; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; RAY WJ, 1964, J BIOL CHEM, V239, P1228; Regni C, 2004, STRUCTURE, V12, P55, DOI 10.1016/j.str.2003.11.015; Regni C, 2002, STRUCTURE, V10, P269, DOI 10.1016/S0969-2126(02)00705-0; Regni CA, 2000, ACTA CRYSTALLOGR D, V56, P761, DOI 10.1107/S0907444900004431; Shackelford GS, 2004, PROTEIN SCI, V13, P2130, DOI 10.1110/ps.04801104; Shatsky M, 2004, PROTEINS, V56, P143, DOI 10.1002/prot.10628; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; Viadiu H, 2000, MOL CELL, V5, P889, DOI 10.1016/S1097-2765(00)80329-9; Zhang GF, 2005, BIOCHEMISTRY-US, V44, P9404, DOI 10.1021/bi050558p	26	39	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15564	15571		10.1074/jbc.M600590200	http://dx.doi.org/10.1074/jbc.M600590200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16595672	hybrid			2022-12-25	WOS:000237922200063
J	Baratier, J; Peris, L; Brocard, J; Gory-Faure, S; Dufour, F; Bosc, C; Fourest-Lieuvin, A; Blanchoin, L; Salin, P; Job, D; Andrieux, A				Baratier, Julie; Peris, Leticia; Brocard, Jacques; Gory-Faure, Sylvie; Dufour, Fabrice; Bosc, Christophe; Fourest-Lieuvin, Anne; Blanchoin, Laurent; Salin, Paul; Job, Didier; Andrieux, Annie			Phosphorylation of microtubule-associated protein STOP by calmodulin kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-STABLE MICROTUBULES; HIPPOCAMPAL-NEURONS; SUBSTRATE-SPECIFICITY; ACTIN-FILAMENTS; IN-VIVO; CYTOSKELETON; DYNAMICS; CELLS; LTP; IDENTIFICATION	STOP proteins are microtubule-associated, calmodulin-regulated proteins responsible for the high degree of stabilization displayed by neuronal microtubules. STOP suppression in mice induces synaptic defects affecting both short and long term synaptic plasticity in hippocampal neurons. Interestingly, STOP has been identified as a component of synaptic structures in neurons, despite the absence of microtubules in nerve terminals, indicating the existence of mechanisms able to induce a translocation of STOP from microtubules to synaptic compartments. Here we have tested STOP phosphorylation as a candidate mechanism for STOP relocalization. We show that, both in vitro and in vivo, STOP is phosphorylated by the multifunctional enzyme calcium/calmodulin-dependent protein kinase II (CaMKII), which is a key enzyme for synaptic plasticity. This phosphorylation occurs on at least two independent sites. Phosphorylated forms of STOP do not bind microtubules in vitro and do not co-localize with microtubules in cultured differentiating neurons. Instead, phosphorylated STOP co-localizes with actin assemblies along neurites or at branching points. Correlatively, we find that STOP binds to actin in vitro. Finally, in differentiated neurons, phosphorylated STOP co-localizes with clusters of synaptic proteins, whereas unphosphorylated STOP does not. Thus, STOP phosphorylation by CaMKII may promote STOP translocation from microtubules to synaptic compartments where it may interact with actin, which could be important for STOP function in synaptic plasticity.	CEA, Lab Cytosquelette, U366, DRDCCS,INSERM, F-38054 Grenoble 9, France; CEA, DRDC, PCV, Lab Biol Vegetale,CNRS,UMR 5168, F-38054 Grenoble 9, France; CNRS, UMR 5167, Fac Med Laennec, F-69372 Lyon 08, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Andrieux, A (corresponding author), CEA, Lab Cytosquelette, U366, DRDCCS,INSERM, 17 Rue Martyrs, F-38054 Grenoble 9, France.	annie.andrieux@cea.fr	Fourest-Lieuvin, Anne/AGA-6504-2022; peris, leticia/P-9249-2017; ANDRIEUX, ANNIE/B-2134-2017; Bosc, Christophe/Q-8877-2019; Bosc, Christophe/P-3401-2017; Brocard, Jacques/I-3135-2017	Fourest-Lieuvin, Anne/0000-0003-1325-6788; peris, leticia/0000-0002-0668-1252; ANDRIEUX, ANNIE/0000-0002-4022-6405; Bosc, Christophe/0000-0002-3195-6692; Bosc, Christophe/0000-0002-3195-6692; Gory, Sylvie/0000-0001-5743-8079; Salin, Paul/0000-0001-5221-9109; Brocard, Jacques/0000-0002-0752-5737				Allison DW, 1998, J NEUROSCI, V18, P2423; Andrieux A, 2002, GENE DEV, V16, P2350, DOI 10.1101/gad.223302; BAAS PW, 1991, J NEUROSCI RES, V30, P134, DOI 10.1002/jnr.490300115; Bosc C, 1996, P NATL ACAD SCI USA, V93, P2125, DOI 10.1073/pnas.93.5.2125; Bosc C, 2001, J BIOL CHEM, V276, P30904, DOI 10.1074/jbc.M011614200; Dehmelt L, 2004, J NEUROBIOL, V58, P18, DOI 10.1002/neu.10284; Dent EW, 2001, J NEUROSCI, V21, P9757, DOI 10.1523/JNEUROSCI.21-24-09757.2001; DOTTI CG, 1988, J NEUROSCI, V8, P1454; ERCK C, 2005, P NATL ACAD SCI US; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Fukazawa' Y, 2003, NEURON, V38, P447, DOI 10.1016/S0896-6273(03)00206-X; Gleason MR, 2003, NAT NEUROSCI, V6, P217, DOI 10.1038/nn1011; Guillaud L, 1998, J CELL BIOL, V142, P167, DOI 10.1083/jcb.142.1.167; Halpain S, 2003, NAT NEUROSCI, V6, P101, DOI 10.1038/nn0203-101; Hannah MJ, 1999, ANNU REV CELL DEV BI, V15, P733, DOI 10.1146/annurev.cellbio.15.1.733; JOB D, 1984, BIOCHEMISTRY-US, V23, P3025, DOI 10.1021/bi00308a028; JOB D, 1983, P NATL ACAD SCI-BIOL, V80, P3894, DOI 10.1073/pnas.80.13.3894; JOB D, 1981, P NATL ACAD SCI-BIOL, V78, P4679, DOI 10.1073/pnas.78.8.4679; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kodama A, 2003, CELL, V115, P343, DOI 10.1016/S0092-8674(03)00813-4; Krucker T, 2000, P NATL ACAD SCI USA, V97, P6856, DOI 10.1073/pnas.100139797; Lisman J, 2003, NEURON, V38, P361, DOI 10.1016/S0896-6273(03)00257-5; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; MASSON D, 1993, J CELL BIOL, V123, P357, DOI 10.1083/jcb.123.2.357; Ozer RS, 2000, MOL BIOL CELL, V11, P3573, DOI 10.1091/mbc.11.10.3573; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; Peng JM, 2004, J BIOL CHEM, V279, P21003, DOI 10.1074/jbc.M400103200; PIROLLET F, 1989, BIOCHEMISTRY-US, V28, P835, DOI 10.1021/bi00428a064; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Yang YM, 1999, CELL, V98, P229, DOI 10.1016/S0092-8674(00)81017-X	32	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19561	19569		10.1074/jbc.M509602200	http://dx.doi.org/10.1074/jbc.M509602200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16651267	Green Submitted, hybrid			2022-12-25	WOS:000238847000070
J	Huang, LS; Wojciechowski, G; de Montellano, PRO				Huang, Liusheng; Wojciechowski, Grzegorz; de Montellano, Paul R. Ortiz			Role of heme-protein covalent bonds in mammalian peroxidases - Protection of the heme by a single engineered heme-protein link in horseradish peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTHETIC HEME; OXIDATION; LACTOPEROXIDASE; MYELOPEROXIDASE; THIOCYANATE; PRODUCTS; CHLORIDE	Oxidation of SCN-, Br-, and Cl- (X-) by horseradish peroxidase (HRP) and other plant and fungal peroxidases results in the addition of HOX to the heme vinyl group. This reaction is not observed with lactoperoxidase (LPO), in which the heme is covalently bound to the protein via two ester bonds between carboxylic side chains and heme methyl groups. To test the hypothesis that the heme of LPO and other mammalian peroxidases is protected from vinyl group modification by the hemeprotein covalent bonds, we prepared the F41E mutant of HRP in which the heme is attached to the protein via a covalent bond between Glu(41) and the heme 3-methyl. We also examined the E375D mutant of LPO in which only one of the two normal covalent heme links is retained. The prosthetic heme groups of F41E HRP and E375D LPO are essentially not modified by the HOBr produced by these enzymes. The double E375D/D225E mutant of LPO that can form no covalent bonds is inactive and could not be examined. These results unambiguously demonstrate that a single heme-protein link is sufficient to protect the heme from vinyl group modification even in a protein ( HRP) that is normally highly susceptible to this reaction. The results directly establish that one function of the covalent heme-protein bonds in mammalian peroxidases is to protect their prosthetic group from their highly reactive metabolic products.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, Genentech Hall GH-N572D,600 16th St, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu	Wojciechowski, Grzegorz/ABI-7751-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32488] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Colas C, 2003, CHEM REV, V103, P2305, DOI 10.1021/cr0204303; Colas C, 2004, J BIOL CHEM, V279, P24131, DOI 10.1074/jbc.M401687200; Colas C, 2002, J BIOL CHEM, V277, P7191, DOI 10.1074/jbc.M109523200; Dunforb HB, 1999, HEME PEROXIDASES, P349; Fiedler TJ, 2000, J BIOL CHEM, V275, P11964, DOI 10.1074/jbc.275.16.11964; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; He X, 2005, J BIOL CHEM, V280, P22697, DOI 10.1074/jbc.M502632200; Huang LS, 2006, ARCH BIOCHEM BIOPHYS, V446, P77, DOI 10.1016/j.abb.2005.11.011; Huang LS, 2005, J AM CHEM SOC, V127, P5345, DOI 10.1021/ja050278x; Kooter IM, 1999, J BIOL CHEM, V274, P26794, DOI 10.1074/jbc.274.38.26794; Munir IZ, 2000, ENZYME MICROB TECH, V26, P337, DOI 10.1016/S0141-0229(99)00180-5; Rae TD, 1998, J BIOL CHEM, V273, P27968, DOI 10.1074/jbc.273.43.27968; SHAH MM, 1993, ARCH BIOCHEM BIOPHYS, V300, P253, DOI 10.1006/abbi.1993.1035; van Dalen CJ, 2001, BIOCHEM J, V358, P233, DOI 10.1042/0264-6021:3580233; VANTAMELEN EE, 1963, J AM CHEM SOC, V85, P3295, DOI 10.1021/ja00903a054; Wojciechowski G, 2005, J AM CHEM SOC, V127, P15871, DOI 10.1021/ja054084t	16	42	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					18983	18988		10.1074/jbc.M602307200	http://dx.doi.org/10.1074/jbc.M602307200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16651262	hybrid			2022-12-25	WOS:000238847000011
J	Dragin, N; Dalton, TP; Miller, ML; Shertzer, HG; Nebert, DW				Dragin, Nadine; Dalton, Timothy P.; Miller, Marian L.; Shertzer, Howard G.; Nebert, Daniel W.			For dioxin-induced birth defects, mouse or human CYP1A2 in maternal liver protects whereas mouse CYP1A1 and CYP1B1 are inconsequential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; REACTIVE OXYGEN PRODUCTION; HALOGENATED AROMATIC-HYDROCARBONS; OXIDATIVE STRESS-RESPONSE; HUMAN AH RECEPTOR; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; ENZYME-ACTIVITY; KNOCKOUT MICE; CYTOCHROME-P450 GENES; MEDIATED INDUCTION	Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin) induces cleft palate and hydronephrosis in mice, when exposed in utero; these effects are mediated by the aryl hydrocarbon receptor. The Cyp1a1, Cyp1a2, and Cyp1b1 genes are up-regulated by the aryl hydrocarbon receptor. To elucidate their roles in dioxin-induced teratogenesis, we compared Cyp1a1(-/-), Cyp1a2(-/-), and Cyp1b1(-/-) knock-out mice with Cyp1(+/+) wild-type mice. Dioxin was administered (25 mu g/kg, gavage) on gestational day 10, and embryos were examined on gestational day 18. The incidence of cleft palate and hydronephrosis was not significantly different in fetuses from Cyp1a1(-/-), Cyp1b1(-/-), and Cyp1(+/+) wild-type mice. To fetuses carried by Cyp1a2(-/-) dams, however, this dose of dioxin was lethal; this effect was absolutely dependent on the maternal Cyp1a2 genotype and independent of the embryonic Cyp1a2 genotype. Dioxin levels were highest in adipose tissue, mammary gland, and circulating blood of Cyp1a2(-/-) mothers, compared with that in the Cyp1(+/+) mothers, who showed highest dioxin levels in liver. More dioxin reached the embryos from Cyp1a2(-/-) dams, compared with that from Cyp1(+/+) dams. Fetuses from Cyp1a2(-/-) dams exhibited a similar to 6- fold increased sensitivity to cleft palate, hydronephrosis, and lethality. Using the humanized hCYP1A1_1A2 transgenic mouse (expressing the human CYP1A1 and CYP1A2 genes in the absence of mouse Cyp1a2 gene), the teratogenic effects of dioxin reverted to the wild-type phenotype. These data indicate that maternal mouse hepatic CYP1A2, by sequestering dioxin and thus altering the pharmacokinetics, protects the embryos from toxicity and birth defects; substitution of the human CYP1A2 trans-gene provides the same protection. In contrast, neither CYP1A1 nor CYP1B1 appears to play a role in dioxin-mediated teratogenesis.	Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Ctr Environm Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Nebert, DW (corresponding author), Univ Cincinnati, Med Ctr, Dept Environm Hlth, POB 670056, Cincinnati, OH 45267 USA.	dan.nebert@uc.edu		Dragin, Nadine/0000-0002-5250-322X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008147, R01ES010133, P30ES006096] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES06096, R01 ES08147, R01 ES10133] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson GD, 1998, ANN PHARMACOTHER, V32, P554, DOI 10.1345/aph.17332; Bagchi D, 2000, FREE RADICAL BIO MED, V28, P895, DOI 10.1016/S0891-5849(00)00173-8; BIRNBAUM LS, 1987, TOXICOL APPL PHARM, V90, P206, DOI 10.1016/0041-008X(87)90328-0; BRADFIELD CA, 1988, MOL PHARMACOL, V34, P682; Bryant PL, 2001, TOXICOL SCI, V62, P103, DOI 10.1093/toxsci/62.1.103; Buters JTM, 1999, DRUG METAB REV, V31, P437, DOI 10.1081/DMR-100101929; Carlson DB, 2002, J BIOCHEM MOL TOXIC, V16, P317, DOI 10.1002/jbt.10051; Cauchi S, 2001, CARCINOGENESIS, V22, P1819, DOI 10.1093/carcin/22.11.1819; Cheung C, 2005, CHEM RES TOXICOL, V18, P1471, DOI 10.1021/tx050136g; Choudhary D, 2005, ARCH BIOCHEM BIOPHYS, V436, P50, DOI 10.1016/j.abb.2005.02.001; Choudhary D, 2003, ARCH BIOCHEM BIOPHYS, V414, P91, DOI 10.1016/S0003-9861(03)00174-7; Cole P, 2003, REGUL TOXICOL PHARM, V38, P378, DOI 10.1016/j.yrtph.2003.08.002; COUTURE LA, 1990, TERATOLOGY, V42, P619, DOI 10.1002/tera.1420420606; Dalton TP, 2002, CHEM-BIOL INTERACT, V141, P77, DOI 10.1016/S0009-2797(02)00067-4; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V267, P184, DOI 10.1006/bbrc.1999.1913; Derkenne S, 2005, PHARMACOGENET GENOM, V15, P503, DOI 10.1097/01.fpc.0000167326.00411.50; DeVito MJ, 1997, TOXICOL APPL PHARM, V147, P267, DOI 10.1006/taap.1997.8261; Dey A, 1999, BIOCHEM PHARMACOL, V58, P525, DOI 10.1016/S0006-2952(99)00110-0; Diliberto JJ, 1999, TOXICOL APPL PHARM, V159, P52, DOI 10.1006/taap.1999.8720; Diliberto JJ, 1997, BIOCHEM BIOPH RES CO, V236, P431, DOI 10.1006/bbrc.1997.6973; EATON DL, 1995, PHARMACOGENETICS, V5, P259, DOI 10.1097/00008571-199510000-00001; Elferink Cornelis J, 2003, Prog Cell Cycle Res, V5, P261; EMA M, 1994, J BIOL CHEM, V269, P27337; Evans MV, 2000, TOXICOL SCI, V54, P71, DOI 10.1093/toxsci/54.1.71; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Fujii-Kuriyama Y, 2005, BIOCHEM BIOPH RES CO, V338, P311, DOI 10.1016/j.bbrc.2005.08.162; GALLO MA, 1986, TOXICOL LETT, V32, P123, DOI 10.1016/0378-4274(86)90058-5; Galvan N, 2003, TOXICOL APPL PHARM, V193, P84, DOI 10.1016/S0041-008X(03)00338-7; Gonzalez FJ, 1995, TOXICOL LETT, V82-3, P117, DOI 10.1016/0378-4274(95)03548-6; Gorman N, 2002, HEPATOLOGY, V35, P912, DOI 10.1053/jhep.2002.32487; Greaves P, 2005, BIOCHEM BIOPH RES CO, V331, P147, DOI 10.1016/j.bbrc.2005.03.136; Guengerich FP, 1999, MUTAT RES-FUND MOL M, V428, P115, DOI 10.1016/S1383-5742(99)00039-3; Hankinson O, 2005, ARCH BIOCHEM BIOPHYS, V433, P379, DOI 10.1016/j.abb.2004.09.031; Hanneman WH, 1996, TOXICOLOGY, V112, P19, DOI 10.1016/0300-483X(96)03346-X; Harper PA, 2002, CHEM-BIOL INTERACT, V141, P161, DOI 10.1016/S0009-2797(02)00071-6; Hassoun EA, 2002, J TOXICOL ENV HEAL A, V65, P825, DOI 10.1080/00984100290071054; Hassoun EA, 1996, COMP BIOCHEM PHYS C, V113, P393, DOI 10.1016/0742-8413(96)00011-4; Hombach-Klonisch S, 2005, CURR MED CHEM, V12, P599, DOI 10.2174/0929867053362857; Jandacek RJ, 2004, LIPIDS, V39, P993, DOI 10.1007/s11745-004-1321-4; Jandacek RJ, 2004, GASTROENTEROLOGY, V127, P139, DOI 10.1053/j.gastro.2004.04.007; Jiang ZW, 2006, PHARMACOGENET GENOM, V16, P359, DOI 10.1097/01.fpc.0000204994.99429.46; Jiang ZW, 2005, HUM MUTAT, V25, P196, DOI 10.1002/humu.20134; KAWAJIRI K, 1995, PHARMACOGENETICS, V5, pS70, DOI 10.1097/00008571-199512001-00004; Kern PA, 2002, TOXICOLOGY, V171, P117, DOI 10.1016/S0300-483X(01)00564-9; Koyano S, 2005, DRUG METAB DISPOS, V33, P1254, DOI 10.1124/dmd.105.004655; Lahvis GP, 2005, MOL PHARMACOL, V67, P714, DOI 10.1124/mol.104.008888; Liang HCL, 1996, P NATL ACAD SCI USA, V93, P1671, DOI 10.1073/pnas.93.4.1671; Lin TM, 2002, TOXICOL SCI, V68, P479, DOI 10.1093/toxsci/68.2.479; Ma Q, 2001, CURR DRUG METAB, V2, P149, DOI 10.2174/1389200013338603; Mandal PK, 2005, J COMP PHYSIOL B, V175, P221, DOI 10.1007/s00360-005-0483-3; MEEHAN RR, 1988, P NATL ACAD SCI USA, V85, P2662, DOI 10.1073/pnas.85.8.2662; Micka J, 1997, PHARMACOGENETICS, V7, P95, DOI 10.1097/00008571-199704000-00002; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Mimura J, 2003, BBA-GEN SUBJECTS, V1619, P263, DOI 10.1016/S0304-4165(02)00485-3; Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; NEBERT DW, 1968, J BIOL CHEM, V243, P6242; NEBERT DW, 1989, CRIT REV TOXICOL, V20, P153, DOI 10.3109/10408448909017908; OLNES MJ, 1994, EXP CLIN IMMUNOGENET, V11, P102; Osteen KG, 1997, SEMIN REPROD ENDOCR, V15, P301, DOI 10.1055/s-2008-1068760; Peters JM, 1999, TOXICOL SCI, V47, P86, DOI 10.1093/toxsci/47.1.86; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1982, NATURE, V300, P271, DOI 10.1038/300271a0; POLAND A, 1994, MOL PHARMACOL, V46, P915; POLAND A, 1989, MOL PHARMACOL, V36, P113; Puga A, 2005, BIOCHEM PHARMACOL, V69, P199, DOI 10.1016/j.bcp.2004.06.043; Puga A, 2002, TOXICOLOGY, V181, P171, DOI 10.1016/S0300-483X(02)00276-7; Puga A, 2000, BIOCHEM PHARMACOL, V59, P997, DOI 10.1016/S0006-2952(99)00406-2; Redgrave TG, 2005, J NUTR BIOCHEM, V16, P383, DOI 10.1016/j.jnutbio.2004.12.014; SAFE S, 1991, PHARMACOL TOXICOL, V69, P400, DOI 10.1111/j.1600-0773.1991.tb01321.x; Saghir SA, 2005, TOXICOLOGY, V215, P48, DOI 10.1016/j.tox.2005.06.009; Schwarz M, 2005, REGUL TOXICOL PHARM, V43, P19, DOI 10.1016/j.yrtph.2005.05.008; Senft AP, 2002, FREE RADICAL BIO MED, V33, P1268, DOI 10.1016/S0891-5849(02)01014-6; Shen DX, 2005, J BIOL CHEM, V280, P25305, DOI 10.1074/jbc.M500095200; Shertzer HG, 1998, BIOCHEM BIOPH RES CO, V253, P44, DOI 10.1006/bbrc.1998.9753; Shertzer HG, 2004, FREE RADICAL BIO MED, V36, P618, DOI 10.1016/j.freeradbiomed.2003.11.014; Shertzer HG, 2001, TOXICOL METHOD, V11, P81; Shertzer HG, 2004, FREE RADICAL BIO MED, V36, P605, DOI 10.1016/j.freeradbiomed.2003.11.013; Shimada T, 2003, XENOBIOTICA, V33, P957, DOI 10.1080/0049825031000140896; Sinclair PR, 2000, TOXICOL APPL PHARM, V162, P60, DOI 10.1006/taap.1999.8832; Smith AG, 2001, TOXICOL APPL PHARM, V173, P89, DOI 10.1006/taap.2001.9167; Steenland K, 2004, ENVIRON HEALTH PERSP, V112, P1265, DOI 10.1289/ehp.7219; STEGEMAN JJ, 1995, MOL PHARMACOL, V47, P296; Swanson HI, 2002, CHEM-BIOL INTERACT, V141, P63, DOI 10.1016/S0009-2797(02)00066-2; Thomae TL, 2004, J BIOL CHEM, V279, P30189, DOI 10.1074/jbc.M403690200; Tsuneoka Y, 2003, J NATL CANCER I, V95, P1227, DOI 10.1093/jnci/djg025; Uno S, 2004, MOL PHARMACOL, V65, P1225, DOI 10.1124/mol.65.5.1225; Uno S, 2006, MOL PHARMACOL, V69, P1103, DOI 10.1124/mol.105.021501; Uno S, 2004, TOXICOL APPL PHARM, V196, P410, DOI 10.1016/j.taap.2004.01.014; Uno S, 2001, BIOCHEM BIOPH RES CO, V289, P1049, DOI 10.1006/bbrc.2001.6110; Vorderstrasse BA, 2004, TOXICOL SCI, V78, P248, DOI 10.1093/toxsci/kfh062; WEBER LWD, 1993, FUND APPL TOXICOL, V21, P523, DOI 10.1006/faat.1993.1129; Wong JMY, 2001, PHARMACOGENETICS, V11, P85, DOI 10.1097/00008571-200102000-00010	93	47	51	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18591	18600		10.1074/jbc.M601159200	http://dx.doi.org/10.1074/jbc.M601159200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16636061	hybrid			2022-12-25	WOS:000238687300038
J	Cathelin, S; Rebe, C; Haddaoui, L; Simioni, N; Verdier, F; Fontenay, M; Launay, S; Mayeux, P; Solary, E				Cathelin, Severine; Rebe, Cedric; Haddaoui, Lamya; Simioni, Nicolas; Verdier, Frederique; Fontenay, Michaela; Launay, Sophie; Mayeux, Patrick; Solary, Eric			Identification of proteins cleaved downstream of caspase activation in monocytes undergoing macrophage differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BETA-CONVERTING ENZYME; NECROSIS-FACTOR-ALPHA; KINASE GAMMA-PAK; INHIBITOR TYPE-2; INDUCED APOPTOSIS; PROTEOME ANALYSIS; DENDRITIC CELLS; HL-60 CELLS; HNRNP H	We have shown previously that caspases were specifically involved in the differentiation of peripheral blood monocytes into macrophages while not required for monocyte differentiation into dendritic cells. To identify caspase targets in monocytes undergoing macrophagic differentiation, we used the human monocytic leukemic cell line U937, whose macrophagic differentiation induced by exposure to 12-O-tetradecanoylphorbol 13-acetate (TPA) can be prevented by expression of the baculovirus caspase-inhibitory protein p35. A comparative two-dimensional gel proteomic analysis of empty vector- and p35-transfected cells after 12 h of exposure to 20 nM TPA, followed by mass spectrometry analysis, identified 38 differentially expressed proteins. Those overexpressed in p35-expressing cells (n = 16) were all full-length, whereas half of those overexpressed in control cells (n = 22) were N- or C-terminal cleavage fragments. The cleavage or degradation of seven of these proteins was confirmed in peripheral blood monocytes undergoing macrophage colony-stimulating factor-induced macrophagic differentiation. In U937 cells exposed to TPA, these proteolytic events can be inhibited by expression of a caspase-8 dominant negative mutant or the cowpox virus CrmA caspase inhibitor. These cleavages provide new insights to analyze the role of caspases in this specific differentiation program.	Fac Med, INSERM, UMR 517, IFR100, F-21079 Dijon, France; Univ Burgundy, IFR 100, F-21079 Dijon, France; CHRU, Hosp Le Bocage, Dept Hematol, F-21034 Dijon, France; INSERM, Dept Hematol, U567, F-75014 Paris, France; Univ Paris 05, F-75014 Paris, France; CNRS, UMR 8104, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Solary, E (corresponding author), Fac Med, INSERM, UMR 517, IFR100, 7 Blvd Jeanne DArc, F-21079 Dijon, France.	esolary@u-bourgogne.fr	Verdier, Frédérique/P-1512-2017; REBE, Cédric/AAD-4316-2019	REBE, Cédric/0000-0001-8831-145X; Fontenay, Michaela/0000-0002-5492-6349; Solary, Eric/0000-0002-8629-1341				Adrain C, 2004, J BIOL CHEM, V279, P36923, DOI 10.1074/jbc.M402638200; ANTALIS TM, 1992, EUR J BIOCHEM, V205, P203, DOI 10.1111/j.1432-1033.1992.tb16769.x; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Bailly M, 2003, TRENDS CELL BIOL, V13, P163, DOI 10.1016/S0962-8924(03)00030-8; Bakri Y, 2005, BLOOD, V105, P2707, DOI 10.1182/blood-2004-04-1448; Barnoy S, 2003, FEBS LETT, V546, P213, DOI 10.1016/S0014-5793(03)00573-8; BECKER S, 1987, J IMMUNOL, V139, P3703; Bredemeyer AJ, 2004, P NATL ACAD SCI USA, V101, P11785, DOI 10.1073/pnas.0402353101; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Candiano G, 2004, ELECTROPHORESIS, V25, P1327, DOI 10.1002/elps.200305844; CHAPMAN HA, 1982, CELL, V28, P653, DOI 10.1016/0092-8674(82)90220-3; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; Chou CC, 2001, MOL PHARMACOL, V59, P38, DOI 10.1124/mol.59.1.38; Chou MY, 1999, MOL CELL BIOL, V19, P69; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; DeMali KA, 2004, TRENDS BIOCHEM SCI, V29, P565, DOI 10.1016/j.tibs.2004.09.001; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fromm L, 1997, DEV GENET, V20, P276, DOI 10.1002/(SICI)1520-6408(1997)20:3<276::AID-DVG10>3.0.CO;2-6; GAN HX, 1995, J IMMUNOL, V155, P1304; Gao H, 2005, J BIOL CHEM, V280, P10988, DOI 10.1074/jbc.M412720200; Gerner C, 2002, CELL DEATH DIFFER, V9, P671, DOI 10.1038/sj.cdd.4401010; Gerner C, 2000, J BIOL CHEM, V275, P39018, DOI 10.1074/jbc.M006495200; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Honore B, 1999, FEBS LETT, V456, P274, DOI 10.1016/S0014-5793(99)00911-4; Hsu CY, 2000, INT J CANCER, V88, P392, DOI 10.1002/1097-0215(20001101)88:3<392::AID-IJC11>3.0.CO;2-7; Hsu CY, 2003, BRIT J CANCER, V89, P1320, DOI 10.1038/sj.bjc.6601100; Huh JR, 2004, PLOS BIOL, V2, P43, DOI 10.1371/journal.pbio.0020015; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; JENSEN PH, 1994, BRIT J CANCER, V70, P834, DOI 10.1038/bjc.1994.407; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; KATAGIRI K, 1993, J IMMUNOL, V150, P585; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P231; KUMAR S, 1991, J BIOL CHEM, V266, P20960; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; Lee A, 2001, J BIOL CHEM, V276, P20735, DOI 10.1074/jbc.M009723200; Lee AY, 2004, PROTEOMICS, V4, P3429, DOI 10.1002/pmic.200400979; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; LEHTO VP, 1982, LAB INVEST, V47, P391; Lian XH, 2004, BIOL CELL, V96, P109, DOI 10.1016/j.biolcel.2003.09.007; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427; Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Prasad S, 1998, INT J ONCOL, V13, P757; RABILLOUD T, 1998, 2 DIMENSIONAL GEL EL; Redner RL, 2002, LEUKEMIA, V16, P1927, DOI 10.1038/sj.leu.2402720; Ritchie H, 2000, EXP CELL RES, V260, P20, DOI 10.1006/excr.2000.4957; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; Serrano K, 2004, CELL MOTIL CYTOSKEL, V58, P242, DOI 10.1002/cm.20011; Shcherbina A, 1999, BLOOD, V93, P4222, DOI 10.1182/blood.V93.12.4222.412k34_4222_4231; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Xu GZ, 2001, NATURE, V410, P494, DOI 10.1038/35068604; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YonedaKato N, 1996, ONCOGENE, V12, P265; Yu H, 2002, BLOOD, V99, P2810, DOI 10.1182/blood.V99.8.2810; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588	74	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17779	17788		10.1074/jbc.M600537200	http://dx.doi.org/10.1074/jbc.M600537200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636047	hybrid			2022-12-25	WOS:000238490300028
J	Feng, H; Ren, M; Rubin, CS				Feng, Hui; Ren, Min; Rubin, Charles S.			Conserved domains subserve novel mechanisms and functions in DKF-1, a Caenorhabditis elegans protein kinase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; COUPLED RECEPTOR ACTIVATION; CYSTEINE-RICH DOMAIN/; PHORBOL ESTER; IN-VIVO; PKC-MU; SIGNAL-TRANSDUCTION; REGULATORY SUBUNIT; MOLECULAR-CLONING; BINDING DOMAIN	Protein kinase D (PKD) isoforms are effectors in signaling pathways controlled by diacylglycerol. PKDs contain conserved diacylglycerol binding (C1a, C1b), pleckstrin homology (PH), and Ser/Thr kinase domains. However, the properties of conserved domains may vary within the context of distinct PKD polypeptides. Such functional/structural malleability (plasticity) was explored by studying Caenorhabditis elegans D kinase family-1 (DKF-1), a PKD that governs locomotion in vivo. Phorbol ester binding with C1b alone activates classical PKDs by relieving C1-mediated inhibition. In contrast, C1a avidly ligated phorbol 12-myristate 13-acetate (PMA) and anchored DKF-1 at the plasma membrane. C1b bound PMA (moderate affinity) and cooperated with C1a in targeting DKF-1 to membranes. Mutations at a "Pro11" position in C1 domains were inactivating; kinase activity was minimal at PMA concentrations that stimulated wild type DKF-1 similar to 10-fold. DKF-1 mutants exhibited unchanged, maximum kinase activity after cells were incubated with high PMA concentrations. Titration in situ revealed that translocation and activation of wild type and mutant DKF-1 were tightly and quantitatively linked at all PMA concentrations. Thus, C1 domains positively regulated phosphotransferase activity by docking DKF-1 with pools of activating lipid. A PH domain inhibits kinase activity in classical PKDs. The DKF-1 PH module neither inhibited catalytic activity nor bound phosphoinositides. Consequently, the PH module is an obligatory, positive regulator of DKF-1 activity that is compromised by mutation of Lys(298) or Trp(396). Phosphorylation of Thr(588) switched on DKF-1 kinase activity. Persistent phosphorylation of Thr588 (activation loop) promoted ubiquitinylation and proteasome-mediated degradation of DKF-1. Each DKF-1 domain displayed novel properties indicative of functional malleability (plasticity).	Yeshiva Univ Albert Einstein Coll Med, Dept Pharmacol, Atran Labs, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rubin, CS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Pharmacol, Atran Labs, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rubin@aecom.yu.edu						Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; Burbea M, 2002, NEURON, V35, P107, DOI 10.1016/S0896-6273(02)00749-3; Cantrell DA, 2003, CURR OPIN IMMUNOL, V15, P294, DOI 10.1016/S0952-7915(03)00052-9; Chen J, 2005, MOL PHARMACOL, V67, P152, DOI 10.1124/mol.104.004200; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; Doppler H, 2005, J BIOL CHEM, V280, P15013, DOI 10.1074/jbc.C400575200; Feng H, 2006, J BIOL CHEM, V281, P17801, DOI 10.1074/jbc.M511899200; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; Hall C, 2005, TRENDS BIOCHEM SCI, V30, P169, DOI 10.1016/j.tibs.2005.02.003; Hausser A, 2005, NAT CELL BIOL, V7, P880, DOI 10.1038/ncb1289; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; HYVONEN, 1997, EMBO J, V16, P3396; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; Kipreos E. T., 2005, WORMBOOK, V1, P24, DOI [10.1895/wormbook.1.36.1, DOI 10.1895/WORMBOOK.1.7.1]; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; Kubiseski TJ, 2003, MOL CELL BIOL, V23, P6823, DOI 10.1128/MCB.23.19.6823-6835.2003; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Mihailovic T, 2004, CANCER RES, V64, P8939, DOI 10.1158/0008-5472.CAN-04-0981; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 2003, DEV CELL, V4, P561, DOI 10.1016/S1534-5807(03)00087-X; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ohki-Hamazaki H, 2005, INT J DEV BIOL, V49, P293, DOI 10.1387/ijdb.041954ho; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Rey O, 2001, BIOCHEM BIOPH RES CO, V287, P21, DOI 10.1006/bbrc.2001.5530; Rossman KL, 2003, J BIOL CHEM, V278, P18393, DOI 10.1074/jbc.M300127200; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Srivastava J, 2002, BIOCHEM J, V368, P349, DOI 10.1042/BJ20020737; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zhang LH, 2001, J BIOL CHEM, V276, P10463, DOI 10.1074/jbc.M008990200; Zhang W, 2005, J BIOL CHEM, V280, P19036, DOI 10.1074/jbc.M414674200; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	66	11	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17815	17826		10.1074/jbc.M511898200	http://dx.doi.org/10.1074/jbc.M511898200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16613842	hybrid			2022-12-25	WOS:000238490300031
J	Sakai, K; Suzuki, H; Oda, H; Akaike, T; Azuma, Y; Murakami, T; Sugi, K; Ito, T; Ichinose, H; Koyasu, S; Shirai, M				Sakai, Kouhei; Suzuki, Harumi; Oda, Hiroyo; Akaike, Takaaki; Azuma, Yoshinao; Murakami, Tomoyuki; Sugi, Kazuro; ito, Takeh Ito; Ichinose, Hiroshi; Koyasu, Shigeo; Shirai, Mutsunori			Phosphoinositide 3-kinase in nitric oxide synthesis in macrophage - Critical dimerization of inducible nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDIA-PNEUMONIAE; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOTHELIAL-CELLS; TETRAHYDROBIOPTERIN SYNTHESIS; NEGATIVE REGULATION; P85-ALPHA SUBUNIT; REACTIVE NITROGEN; MICE LACKING; IN-VIVO; INHIBITOR	Phosphoinositide 3-kinase (PI3K) has important functions in various biological systems, including immune response. Although the role of PI3K in signaling by antigen-specific receptors of the adaptive immune system has been extensively studied, less is known about the function of PI3K in innate immunity. In the present study, we demonstrate that macrophages deficient for PI3K (p85 alpha regulatory subunit) are impaired in nitric oxide ( NO) production upon lipopolysaccharide and interferon-gamma stimulation and thus vulnerable for intracellular bacterial infection such as Chlamydophila pneumoniae. Although expression of inducible nitric-oxide synthase (iNOS) is induced normally in PI3K-deficient macrophages, dimer formation of iNOS protein is significantly impaired. The amount of intracellular tetrahydrobiopterin, a critical stabilizing cofactor for iNOS dimerization, is decreased in the absence of PI3K. In addition, induction of GTP cyclohydrolase 1, a rate-limiting enzyme for biosynthesis of tetrahydrobiopterin, is greatly reduced. Our current results demonstrate a critical role of class IA type PI3K in the bactericidal activity of macrophages by regulating their NO production through GTP cyclohydrolase 1 induction.	Yamaguchi Univ, Sch Med, Dept Microbiol & Immunol, Yamaguchi 7558505, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Microbiol, Kumamoto 8608556, Japan; Natl Sanyou Hosp, Dept Clin Res, Yamaguchi 7550241, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1608582, Japan	Yamaguchi University; Kumamoto University; Tokyo Institute of Technology; Keio University	Suzuki, H (corresponding author), Yamaguchi Univ, Sch Med, Dept Microbiol & Immunol, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.	suzukih@yamaguchi-u.ac.jp	Ichinose, Hiroshi/D-8986-2015; Suzuki, Harumi/L-1271-2013; Koyasu, Shigeo/J-5583-2015	Ichinose, Hiroshi/0000-0001-6008-6860; Suzuki, Harumi/0000-0003-3616-9361; Koyasu, Shigeo/0000-0001-9585-3038				Akaike T, 1997, J BIOCHEM-TOKYO, V122, P459; Aktan F, 2004, LIFE SCI, V75, P639, DOI 10.1016/j.lfs.2003.10.042; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Azenabor AA, 2003, J INFECTION, V46, P120, DOI 10.1053/jinf.2002.1098; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Chang CI, 1998, AM J PHYSIOL-HEART C, V274, pH342, DOI 10.1152/ajpheart.1998.274.1.H342; Chen YQ, 1998, J IMMUNOL, V161, P4950; Closs EI, 2000, MOL PHARMACOL, V57, P68; Coombes BK, 2002, CELL MICROBIOL, V4, P447, DOI 10.1046/j.1462-5822.2002.00203.x; CORRALIZA IM, 1995, BIOCHEM BIOPH RES CO, V206, P667, DOI 10.1006/bbrc.1995.1094; CORRALIZA IM, 1994, J IMMUNOL METHODS, V174, P231, DOI 10.1016/0022-1759(94)90027-2; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; Diaz-Guerra MJM, 1999, J IMMUNOL, V162, P6184; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Eissa NT, 2001, AM J RESP CELL MOL, V24, P616, DOI 10.1165/ajrcmb.24.5.4324; Fruman DA, 2000, NAT GENET, V26, P379, DOI 10.1038/81715; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fukao T, 2003, TRENDS IMMUNOL, V24, P358, DOI 10.1016/S1471-4906(03)00139-X; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Fukao T, 2002, NAT IMMUNOL, V3, P875, DOI 10.1038/ni825; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gilchrist M, 2003, J BIOL CHEM, V278, P50607, DOI 10.1074/jbc.M307777200; Gobert AP, 2000, INFECT IMMUN, V68, P4653, DOI 10.1128/IAI.68.8.4653-4657.2000; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; GROSS SS, 1992, J BIOL CHEM, V267, P25722; Hayashi Y, 1999, J BIOL CHEM, V274, P20597, DOI 10.1074/jbc.274.29.20597; Huang J, 2002, P NATL ACAD SCI USA, V99, P3914, DOI 10.1073/pnas.062578399; Igietseme JU, 1998, INFECT IMMUN, V66, P1282, DOI 10.1128/IAI.66.4.1282-1286.1998; Ishii M, 2001, INT J BIOCHEM CELL B, V33, P65, DOI 10.1016/S1357-2725(00)00070-4; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Kolodziejski PJ, 2003, P NATL ACAD SCI USA, V100, P14263, DOI 10.1073/pnas.2435290100; Kolodziejski PJ, 2002, P NATL ACAD SCI USA, V99, P12315, DOI 10.1073/pnas.192345199; Komeima K, 2000, J BIOL CHEM, V275, P28139; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; LEWIS RS, 1995, J BIOL CHEM, V270, P29350, DOI 10.1074/jbc.270.49.29350; Matsushima H, 1999, INFECT IMMUN, V67, P3175, DOI 10.1128/IAI.67.6.3175-3179.1999; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Monick MM, 2001, J IMMUNOL, V166, P4713, DOI 10.4049/jimmunol.166.7.4713; Morgan DL, 2004, TOXICOL IN VITRO, V18, P139, DOI 10.1016/j.tiv.2003.08.007; Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741; Nagatsu I, 1995, J NEURAL TRANSM-GEN, V102, P175, DOI 10.1007/BF01281153; Nakai K, 2003, FREE RADICAL BIO MED, V35, P929, DOI 10.1016/S0891-5849(03)00463-5; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; Nicholson B, 2001, J BIOL CHEM, V276, P15881, DOI 10.1074/jbc.M010030200; Ohtsuka M, 2002, J PHARMACOL EXP THER, V303, P52, DOI 10.1124/jpet.102.035857; Park SJ, 2002, CELL BIOL TOXICOL, V18, P121, DOI 10.1023/A:1015384201785; Park YC, 1997, BIOCHEM BIOPH RES CO, V240, P692, DOI 10.1006/bbrc.1997.7722; Ramsey KH, 1998, INFECT IMMUN, V66, P835, DOI 10.1128/IAI.66.2.835-838.1998; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; Ravi K, 2004, P NATL ACAD SCI USA, V101, P2619, DOI 10.1073/pnas.0300464101; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Rothfuchs AG, 2001, J IMMUNOL, V167, P6453, DOI 10.4049/jimmunol.167.11.6453; Rottenberg ME, 1999, J IMMUNOL, V162, P2829; Salh B, 1998, J IMMUNOL, V161, P6947; Schaffer MR, 1997, J IMMUNOL, V158, P2375; Shirai M, 2000, J INFECT DIS, V181, pS524, DOI 10.1086/315616; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Suzuki H, 2003, NAT IMMUNOL, V4, P280, DOI 10.1038/ni890; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Watanabe N, 2003, BLOOD, V102, P541, DOI 10.1182/blood-2002-11-3327; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yasui K, 2002, J LEUKOCYTE BIOL, V72, P1020	73	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17736	17742		10.1074/jbc.M601896200	http://dx.doi.org/10.1074/jbc.M601896200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636057	hybrid			2022-12-25	WOS:000238490300023
J	Sucharitakul, J; Chaiyen, P; Entsch, B; Ballou, DP				Sucharitakul, Jeerus; Chaiyen, Pimchai; Entsch, Barrie; Ballou, David P.			Kinetic mechanisms of the oxygenase from a two-component enzyme, p-hydroxyphenylacetate 3-hydroxylase from Acinetobacter baumannii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE HALF-REACTION; 2-METHYL-3-HYDROXYPYRIDINE-5-CARBOXYLIC ACID OXYGENASE; PARA-HYDROXYBENZOATE HYDROXYLASE; BACTERIAL LUCIFERASE REACTION; PHENOL HYDROXYLASE; 4-HYDROXYPHENYLACETATE 3-MONOOXYGENASE; BIOCHEMICAL-CHARACTERIZATION; STREPTOMYCES-COELICOLOR; DEPENDENT MONOOXYGENASE; AROMATIC HYDROXYLASES	p-Hydroxyphenylacetate hydroxylase ( HPAH) from Acinetobacter baumannii catalyzes the hydroxylation of p-hydroxyphenylacetate (HPA) to form 3,4-dihydroxyphenylacetate ( DHPA). The enzyme system is composed of two proteins: an FMN reductase (C1) and an oxygenase that uses FMNH- (C-2). We report detailed transient kinetics studies at 4 degrees C of the reaction mechanism of C2. C2 binds rapidly and tightly to reduced FMN (K-d, 1.2 +/- 0.2 mu M), but less tightly to oxidized FMN ( Kd, 250 +/- 50 mu M). The complex of C-2-FMNH- reacted with oxygen to form C(4a)-hydroperoxy-FMN at 1.1 +/- 0.1 x 106 M (-1) s(-1), whereas the C-2-FMNH--HPA complex reacted with oxygen to form C(4a)-hydroperoxy-FMN-HPA more slowly (k = 4.8 +/- 0.2 x 10(4) M-1 s(-1)). The kinetic mechanism of C2 was shown to be a preferential random order type, in which HPA or oxygen can initially bind to the C-2-FMNH- complex, but the preferred path was oxygen reacting with C-2-FMNH- to form the C(4a)-hydroperoxy-FMN intermediate prior to HPA binding. Hydroxylation occurs from the ternary complex with a rate constant of 20 s(-1) to form the C-2-C(4a)-hydroxy-FMN-DHPA complex. At high HPA concentrations (> 0.5 mM), HPA formed a dead end complex with the C-2-C(4a)-hydroxy-FMN intermediate (similar to single component flavoprotein hydroxylases), thus inhibiting the bound flavin from returning to the oxidized form. When FADH(-) was used, C(4a)-hydroperoxy-FAD, C(4a)-hydroxy-FAD, and product were formed at rates similar to those with FMNH-. Thus, C-2 has the unusual ability to use both common flavin cofactors in catalysis.	Mahidol Univ, Fac Sci, Dept Biochem, Bangkok 10400, Thailand; Mahidol Univ, Fac Sci, Ctr Excellence Prot Struct & Funct, Bangkok 10400, Thailand; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	Mahidol University; Mahidol University; University of Michigan System; University of Michigan	Chaiyen, P (corresponding author), Mahidol Univ, Fac Sci, Dept Biochem, Rama 6 Rd, Bangkok 10400, Thailand.	scpcy@mucc.mahidol.ac.th	Chaiyen, Pimchai/A-8236-2010; Chaiyen, Pimchai/R-5052-2019; dballou@umich.edu, David P/A-1298-2007	Chaiyen, Pimchai/0000-0002-8533-1604; 	NIGMS NIH HHS [GM64711] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064711] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD H, 1992, BIOCHEMISTRY-US, V31, P3807, DOI 10.1021/bi00130a011; ARUNACHALAM U, 1994, J BIOL CHEM, V269, P11795; ARUNACHALAM U, 1992, J BIOL CHEM, V267, P25848; Ballou DP, 2005, BIOCHEM BIOPH RES CO, V338, P590, DOI 10.1016/j.bbrc.2005.09.081; Becker D, 1997, EUR J BIOCHEM, V249, P739, DOI 10.1111/j.1432-1033.1997.t01-1-00739.x; Chaiyen P, 2004, BIOCHEMISTRY-US, V43, P3933, DOI 10.1021/bi035734d; Chaiyen P, 1997, BIOCHEMISTRY-US, V36, P13856, DOI 10.1021/bi9715122; Chaiyen P, 1997, BIOCHEMISTRY-US, V36, P8060, DOI 10.1021/bi970089u; Chaiyen P, 2001, EUR J BIOCHEM, V268, P5550, DOI 10.1046/j.1432-1033.2001.02490.x; CHAKRABORTY S, 2005, FLAVINS FLAVOPROTEIN, P161; DETMER K, 1985, J BIOL CHEM, V260, P5998; DUCH DS, 1971, ANAL BIOCHEM, V44, P42, DOI 10.1016/0003-2697(71)90343-5; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; Entsch B, 2005, ARCH BIOCHEM BIOPHYS, V433, P297, DOI 10.1016/j.abb.2004.09.029; ENTSCH B, 1976, J BIOL CHEM, V251, P7367; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; Galan B, 2000, J BACTERIOL, V182, P627, DOI 10.1128/JB.182.3.627-636.2000; GHISLA S, 1977, EUR J BIOCHEM, V76, P139, DOI 10.1111/j.1432-1033.1977.tb11579.x; Gisi MR, 2003, J BACTERIOL, V185, P2786, DOI 10.1128/JB.185.9.2786-2792.2003; Kadiyala V, 1998, APPL ENVIRON MICROB, V64, P2479; Kantz A, 2005, ARCH BIOCHEM BIOPHYS, V442, P102, DOI 10.1016/j.abb.2005.07.020; KEMAL C, 1976, J AM CHEM SOC, V98, P3955, DOI 10.1021/ja00429a035; KIM IC, 1995, APPL ENVIRON MICROB, V61, P1252, DOI 10.1128/AEM.61.4.1252-1256.1995; Kirchner U, 2003, J BIOL CHEM, V278, P47545, DOI 10.1074/jbc.M307397200; Lei BF, 1996, J BACTERIOL, V178, P5699, DOI 10.1128/jb.178.19.5699-5705.1996; Louie TM, 2003, BIOCHEMISTRY-US, V42, P7509, DOI 10.1021/bi034092r; Louie TM, 2002, J BACTERIOL, V184, P3492, DOI 10.1128/JB.184.13.3492-3500.2002; MACHEROUX P, 1993, BIOCHEMISTRY-US, V32, P14183, DOI 10.1021/bi00214a017; MASSEY V, 1971, FLAVINS FLAVOPROTEIN; Otto K, 2004, J BACTERIOL, V186, P5292, DOI 10.1128/JB.186.16.5292-5302.2004; Palfey B. A., 1995, ACTIVE OXYGEN BIOCH, P37, DOI DOI 10.1007/978-94-011-0609-2_2; Palfey B. A., 1998, COMPREHENSIVE BIOL C, VIII, P83; Palfey BA, 2002, BIOCHEMISTRY-US, V41, P8438, DOI 10.1021/bi012073g; POWLOWSKI J, 1990, J BIOL CHEM, V265, P4969; SCHOPFER LM, 1980, J BIOL CHEM, V255, P5355; Sheng DW, 2001, BIOCHEMISTRY-US, V40, P11156, DOI 10.1021/bi011153h; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Sucharitakul J, 2005, BIOCHEMISTRY-US, V44, P10434, DOI 10.1021/bi050615e; Suske WA, 1999, J BIOL CHEM, V274, P33355, DOI 10.1074/jbc.274.47.33355; TAYLOR MG, 1990, J BIOL CHEM, V265, P13687; TAYLOR MG, 1991, J BIOL CHEM, V266, P8291; Thotsaporn K, 2004, BBA-GENE STRUCT EXPR, V1680, P60, DOI 10.1016/j.bbaexp.2004.08.003; Valton J, 2006, J BIOL CHEM, V281, P27, DOI 10.1074/jbc.M506146200; Valton J, 2004, J BIOL CHEM, V279, P44362, DOI 10.1074/jbc.M407722200; Xun LY, 2000, APPL ENVIRON MICROB, V66, P481, DOI 10.1128/AEM.66.2.481-486.2000; YORITA K, 1993, J BIOL CHEM, V268, P4134	46	73	75	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17044	17053		10.1074/jbc.M512385200	http://dx.doi.org/10.1074/jbc.M512385200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16627482	hybrid			2022-12-25	WOS:000238326300026
J	Yelamanchili, SV; Pendyala, G; Brunk, I; Darna, M; Albrecht, U; Ahnert-Hilger, G				Yelamanchili, Sowmya V.; Pendyala, Gurudutt; Brunk, Irene; Darna, Mahesh; Albrecht, Urs; Ahnert-Hilger, Gudrun			Differential sorting of the vesicular glutamate transporter 1 into a defined vesicular pool is regulated by light signaling involving the clock gene Period2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOPHYSIN-SYNAPTOBREVIN COMPLEX; READILY RELEASABLE POOL; VESICLES; PROTEIN; MPER2	Synaptic strength depends on the amount of neurotransmitter stored in synaptic vesicles. The vesicular transmitter content has recently been shown to be directly dependent on the expression levels of vesicular neurotransmitter transporters indicating that the transport capacity of synaptic vesicles is a critical determinant for synaptic efficacy. Using synaptic vesicles prepared from whole brain at different times of the day we now show that the amount of vesicular glutamate transporter (VGLUT) 1 undergoes strong diurnal cycling. VGLUT1 protein levels are high before the start of the light period, decline at noon, increase again before start of the dark period, and decline again at midnight. Mice kept in complete darkness showed within a 24-h period only a single peak of VGLUT1 expression in the middle of the rest phase. In contrast, mice lacking the period gene Period 2, a core component of the circadian clock, did not show any light-cycle-dependent changes of VGLUT1 levels. No other of several synaptic vesicle proteins examined underwent circadian cycling. Circadian cycling of VGLUT1 was not seen when analyzing homogenate or synaptosomes, the starting fraction for vesicle preparation. Circadian cycling of VGLUT1 was also not reflected at the mRNA level. We conclude that nerve terminals are endowed with mechanisms that regulate quantal size by changing the copy number of transporters in synaptic vesicles. A reduced amount of VGLUT1 per vesicle is probably achieved by means of selective sorting controlled by clock genes.	Charite Univ Med Berlin, AG Funct Cell Biol, Ctr Anat, D-10115 Berlin, Germany; Univ Fribourg, Div Biochem, Dept Med, CH-1700 Fribourg, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Fribourg	Ahnert-Hilger, G (corresponding author), Charite Univ Med Berlin, AG Funct Cell Biol, Ctr Anat, Phillippstr 12, D-10115 Berlin, Germany.	gudrun.ahnert@charite.de	Albrecht, Urs/A-9831-2011	Albrecht, Urs/0000-0002-0663-8676; Brunk, Irene/0000-0002-2668-7002				Ahnert-Hilger G, 2004, REV PHYSIOL BIOCH P, V150, P140, DOI 10.1007/s10254-003-0020-2; Albrecht U, 2001, J BIOL RHYTHM, V16, P100, DOI 10.1177/074873001129001791; Albrecht U, 2003, CURR OPIN GENET DEV, V13, P271, DOI 10.1016/S0959-437X(03)00055-8; Albrecht U, 2002, METHODS, V28, P465, DOI 10.1016/S1046-2023(02)00266-9; Albrecht U., 1998, HUMAN GENOME METHODS, P93; Becher A, 1999, J NEUROSCI, V19, P1922; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Cheng MY, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-17; Cheng MY, 2002, NATURE, V417, P405, DOI 10.1038/417405a; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; FISCHER V, 1991, NATURE, V349, P79; FREMEAU RT, 2004, SCIENCEXPRESS; Hilfiker S, 2005, J NEUROSCI, V25, P2658, DOI 10.1523/JNEUROSCI.4278-04.2005; Hinz B, 2001, EUR J CELL BIOL, V80, P615, DOI 10.1078/0171-9335-00196; Holzberg D, 2003, J NEUROENDOCRINOL, V15, P339, DOI 10.1046/j.1365-2826.2003.00992.x; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; Kramer A, 2001, SCIENCE, V294, P2511, DOI 10.1126/science.1067716; Moriyama Y, 2004, J BIOCHEM, V135, P155, DOI 10.1093/jb/mvh018; Pryde JG, 1998, METH MOL B, V88, P23; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rizzoli SO, 2004, SCIENCE, V303, P2037, DOI 10.1126/science.1094682; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Rutter J, 2002, ANNU REV BIOCHEM, V71, P307, DOI 10.1146/annurev.biochem.71.090501.142857; Spanagel R, 2005, NAT MED, V11, P35, DOI 10.1038/nm1163; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Takamori S, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-22-j0002.2001; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; Winter S, 2005, J NEUROSCI, V25, P4672, DOI 10.1523/JNEUROSCI.0549-05.2005; Wojcik SM, 2004, P NATL ACAD SCI USA, V101, P7158, DOI 10.1073/pnas.0401764101; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	31	34	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15671	15679		10.1074/jbc.M600378200	http://dx.doi.org/10.1074/jbc.M600378200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595674	Green Submitted, hybrid			2022-12-25	WOS:000237996000011
J	Fasanaro, P; Magenta, A; Zaccagnini, G; Cicchillitti, L; Fucile, S; Eusebi, F; Biglioli, P; Capogrossi, MC; Martelli, F				Fasanaro, Pasquale; Magenta, Alessandra; Zaccagnini, Germana; Cicchillitti, Lucia; Fucile, Sergio; Eusebi, Fabrizio; Biglioli, Paolo; Capogrossi, Maurizio C.; Martelli, Fabio			Cyclin D1 degradation enhances endothelial cell survival upon oxidative stress	FASEB JOURNAL			English	Article						endothelium; ubiquitin-proteasome pathway; calcium signaling; apoptosis	HYDROGEN-PEROXIDE; CARDIOVASCULAR INJURY; CYCLE ARREST; D1; PHOSPHORYLATION; ACTIVATION; INHIBITION; APOPTOSIS; CALMODULIN; EXPRESSION	The understanding of endothelial cell responses to oxidative stress may provide insights into aging mechanisms and into the pathogenesis of numerous cardiovascular diseases. In this study, we examined the regulation and the functional role of cyclin D1, a crucial player in cell proliferation and survival. On H2O2 treatment, endothelial cells showed a rapid down-modulation of cyclin D1. Other D-cyclins were similarly regulated, and this decrease was also observed after exposure to other oxidative stress-inducing stimuli, namely 1,3-bis (2 chloroethyl)-1 nitrosourea treatment and ischemia. H2O2 treatment induced cyclin D1 ubiquitination followed by proteasome degradation. Phospholipase C inhibition prevented cyclin D1 degradation, and its activation triggered cyclin D1 down-modulation in the absence of oxidative stress. Activated phospholipase C generates inositol-1,4,5-trisphosphate (IP3) and Ca2+ release from internal stores. We found that both IP3-receptor inhibition and intracellular Ca2+ chelation prevented cyclin D1 degradation induced by oxidative stress. Furthermore, Ca2+ increase was transduced by Ca2+/calmodulin-dependent protein kinase (CaMK). In fact, H2O2 stimulated CaMK activity, CaMK inhibitors prevented H2O2-induced cyclin D1 downmodulation, and CaMK overexpression induced cyclin D1 degradation. Finally, overriding of cyclin D1 downmodulation via its forced overexpression or via CaMK inhibition increased cell sensitivity to H2O2-induced apoptotic cell death. Thus, cyclin D1 degradation enhances endothelial cell survival on oxidative stress. Fasanaro, P., Magenta, A., Zaccagnini, G., Cicchillitti, L., Fucile, S., Eusebi, F., Biglioli, P., Capogrossi, M. C., Martelli, F. Cyclin D1 degradation enhances endothelial cell survival upon oxidative stress.	IRCCS, Lab Patol Vasc, Ist Dermopat Immacolata, I-00167 Rome, Italy; IRCCS, Ctr Cardiol Monzino, Milan, Italy; Univ Roma La Sapienza, Dipartimento Fisiol Umana & Farmacol, Rome, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Centro Cardiologico Monzino; Sapienza University Rome	Martelli, F (corresponding author), IRCCS, Lab Patol Vasc, Ist Dermopat Immacolata, Via Monti di Creta 104, I-00167 Rome, Italy.	f.martelli@idi.it	Martelli, Fabio/AAL-3788-2020; magenta, alessandra/A-9473-2017; Fucile, Sergio/B-3934-2010; Zaccagnini, Germana/J-7722-2016	Martelli, Fabio/0000-0002-8624-7738; magenta, alessandra/0000-0002-9054-337X; Fucile, Sergio/0000-0003-0698-1148; Zaccagnini, Germana/0000-0002-9441-4735				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Bae YS, 2003, MOL PHARMACOL, V63, P1043, DOI 10.1124/mol.63.5.1043; Barnouin K, 2002, J BIOL CHEM, V277, P13761, DOI 10.1074/jbc.M111123200; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bilato C, 1997, J CLIN INVEST, V100, P693, DOI 10.1172/JCI119582; Browder T, 2000, CANCER RES, V60, P1878; Cai H, 2001, ARTERIOSCL THROM VAS, V21, P1571, DOI 10.1161/hq1001.097028; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Fucile S, 2000, P NATL ACAD SCI USA, V97, P3643, DOI 10.1073/pnas.050582497; Fukami-Kobayashi J, 1999, EXP CELL RES, V246, P338, DOI 10.1006/excr.1998.4306; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB; Griendling KK, 2003, CIRCULATION, V108, P2034, DOI 10.1161/01.CIR.0000093661.90582.c4; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Howe CJ, 2004, J BIOL CHEM, V279, P44573, DOI 10.1074/jbc.M404175200; Hu QH, 1998, CIRCULATION, V97, P268, DOI 10.1161/01.CIR.97.3.268; Kahl CR, 2004, J BIOL CHEM, V279, P15411, DOI 10.1074/jbc.M312543200; Kahl CR, 2004, MOL BIOL CELL, V15, P1833, DOI 10.1091/mbc.e03-10-0730; Katayama K, 2001, FEBS LETT, V509, P382, DOI 10.1016/S0014-5793(01)03200-8; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; Leroy C, 2001, EMBO J, V20, P2896, DOI 10.1093/emboj/20.11.2896; Li DWC, 2005, MOL BIOL CELL, V16, P4437, DOI 10.1091/mbc.E05-01-0010; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; Martelli F, 1999, P NATL ACAD SCI USA, V96, P2858, DOI 10.1073/pnas.96.6.2858; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Noda T, 2001, FASEB J, V15, P2131, DOI 10.1096/fj.01-0131com; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Pirkmaier A, 2003, CLIN CANCER RES, V9, P1877; Pratt MAC, 2003, J BIOL CHEM, V278, P14219, DOI 10.1074/jbc.M209650200; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Schmitt JM, 2004, J BIOL CHEM, V279, P24064, DOI 10.1074/jbc.M401501200; Shao JH, 2002, BIOCHEM BIOPH RES CO, V290, P1101, DOI 10.1006/bbrc.2001.6314; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Zaccagnini G, 2004, CIRCULATION, V109, P2917, DOI 10.1161/01.CIR.0000129309.58874.0F; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200	49	38	39	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1242	+		10.1096/fj.05-4695fje	http://dx.doi.org/10.1096/fj.05-4695fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16603604				2022-12-25	WOS:000240210300039
J	Tokgoz, Z; Bohnsack, RN; Haas, AL				Tokgoz, Zeynep; Bohnsack, Richard N.; Haas, Arthur L.			Pleiotropic effects of ATP center dot Mg2+ binding in the catalytic cycle of ubiquitin-activating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; TRANSFER-RNA-SYNTHETASE; TRANSITION-STATE; PROTEIN; MECHANISM; CONJUGATION; ATP; SUPERFAMILY; ADENYLATE; INSIGHTS	Conjugation of ubiquitin and other Class 1 ubiquitin-like polypeptides to specific protein targets serves diverse regulatory functions in eukaryotes. The obligatory first step of conjugation requires ATP-coupled activation of the ubiquitin like protein by members of a superfamily of evolutionarily related enzymes. Kinetic and equilibrium studies of the human ubiquitin-activating enzyme (HsUba1a) reveal that mutations within the ATP(.)Mg(2+) binding site have remarkably pleiotropic effects on the catalytic phenotype of the enzyme. Mutation of Asp(576) or Lys(528) results in dramatically impaired binding affinities for ATP(.)Mg(2+) a shift from ordered to random addition in co-substrate binding, and a significantly reduced rate of ternary complex formation that shifts the rate-limiting step to ubiquitin adenylate formation. Mutations at neither position affect the affinity of HsUbc2b binding; however, differences in k(cat) values determined from ternary complex formation versus HsUbc2b transthiolation suggest that binding of the E2 enhances the rate of bound ubiquitin adenylate formation. These results confirm that Asp(576) and Lys(528) are important for ATP(.)Mg(2+) binding but are essential catalytic groups for ubiquitin adenylate transition state stabilization. The latter mechanistic effect explicates the observed loss-of-function phenotype associated with mutation of residues paralogous to Asp(576) within the activating enzymes for other ubiquitin-like proteins.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Medical College of Wisconsin	Haas, AL (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	ahaas@lsuhsc.edu	Gromley, Zeynep/AAG-3958-2022; Gromley, Zeynep/AEG-5353-2022		NIGMS NIH HHS [GM 34009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bohnsack RN, 2003, J BIOL CHEM, V278, P26823, DOI 10.1074/jbc.M303177200; BORGFORD TJ, 1987, BIOCHEMISTRY-US, V26, P7246, DOI 10.1021/bi00397a008; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; Desogus G, 2000, BIOCHEMISTRY-US, V39, P8418, DOI 10.1021/bi0006722; Dittmar GAG, 2002, SCIENCE, V295, P2442, DOI 10.1126/science.1069989; FAN C, 1995, P NATL ACAD SCI USA, V92, P1172, DOI 10.1073/pnas.92.4.1172; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1983, BIOCHEMISTRY-US, V22, P4388, DOI 10.1021/bi00288a007; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; Haas AL, 1997, FASEB J, V11, P1257; HARMARK K, 1992, BIOCHEMISTRY-US, V31, P7367, DOI 10.1021/bi00147a022; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Larsen CN, 2002, J PROTEOME RES, V1, P411, DOI 10.1021/pr025522n; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Lois LM, 2005, EMBO J, V24, P439, DOI 10.1038/sj.emboj.7600552; MITRUKA BM, CLIN BIOCH HEMATOLOG; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1994, J BIOL CHEM, V269, P7115; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Schmitt E, 1998, EMBO J, V17, P5227, DOI 10.1093/emboj/17.17.5227; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; SEGAL IH, 1975, ENZYME KINETICS; Siepmann TJ, 2003, J BIOL CHEM, V278, P9448, DOI 10.1074/jbc.M211240200; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Walden H, 2003, MOL CELL, V12, P1427, DOI 10.1016/S1097-2765(03)00452-0; Walden H, 2003, NATURE, V422, P330, DOI 10.1038/nature01456; WELLS TNC, 1986, BIOCHEMISTRY-US, V25, P1881, DOI 10.1021/bi00356a007; Ye DM, 2001, J BIOL CHEM, V276, P37630, DOI 10.1074/jbc.M105631200; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362	46	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14729	14737		10.1074/jbc.M513562200	http://dx.doi.org/10.1074/jbc.M513562200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16595681	hybrid			2022-12-25	WOS:000237671300026
J	Almog, N; Henke, V; Flores, L; Hlatky, L; Kung, AL; Wright, RD; Berger, R; Hutchinson, L; Naumov, GN; Bender, E; Akslen, LA; Achilles, EG; Folkman, J				Almog, Nava; Henke, Vanessa; Flores, Ludmila; Hlatky, Lynn; Kung, Andrew L.; Wright, Renee D.; Berger, Raanan; Hutchinson, Lloyd; Naumov, George N.; Bender, Elise; Akslen, Lars A.; Achilles, Eike-Gert; Folkman, Judah			Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis	FASEB JOURNAL			English	Article							GROWTH-FACTOR; CANCER; THROMBOSPONDIN-1; EXPRESSION; MATRIX-METALLOPROTEINASE-9; DISEASE; SWITCH; CELLS	The disease state of cancer appears late in tumor development. Before being diagnosed, a tumor can remain for prolonged periods of time in a dormant state. Dormant human cancer is commonly defined as a microscopic tumor that does not expand in size and remains asymptomatic. Dormant tumors represent an early stage in tumor development and may therefore be a potential target for nontoxic, antiangiogenic therapy that could prevent tumor recurrence. Here, we characterize an experimental model that recapitulates the clinical dormancy of human tumors in mice. We demonstrate that these microscopic dormant cancers switch to the angiogenic phenotype at a predictable time. We further show that while angiogenic liposarcomas expand rapidly after inoculation of tumor cells in mice, nonangiogenic dormant liposarcomas remain microscopic up to one-third of the normal severe combined immune deficiency ( SCID) mouse life span, although they contain proliferating tumor cells. Nonangiogenic dormant tumors follow a similar growth pattern in subcutaneous (s.c.) and orthotopic environments. Throughout the dormancy period, development of intratumoral vessels is impaired. In nonangogenic dormant tumors, small clusters of endothelial cells without lumens are observed early after tumor cell inoculation, but the nonangiogenic tumor cannot sustain these vessels, and they disappear within weeks. There is a concomitant decrease in microvessel density, and the nonangiogenic dormant tumor remains harmless to the host. In contrast, microvessel density in tumors increases rapidly after the angiogenic switch and correlates with rapid expansion of tumor mass. Both tumor types cultured in vitro contain fully transformed cells, but only cells from the nonangiogenic human liposarcoma secrete relatively high levels of the angiogenesis inhibitors thrombospondin-1 and TIMP-1. This model suggests that as improved blood or urine molecular biomarkers are developed, the microscopic, nonangiogenic, dormant phase of human cancer may be vulnerable to antiangiogenic therapy years before symptoms, or before anatomical location of a tumor can be detected, by conventional methods.	Harvard Univ, Sch Med, Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Hamburg Hosp, Clin Hepatobiliary Surg & Visceral Transplantat, D-2000 Hamburg, Germany	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf	Folkman, J (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA.	judah.folkman@childrens.harvard.edu	Akslen, Lars A/C-1202-2017; Akslen, Lars A./AAG-6097-2021; Kung, Andrew/AAL-2384-2020; Kung, Andrew L/AEU-0826-2022	Akslen, Lars A/0000-0003-2710-9543; Akslen, Lars A./0000-0003-2710-9543; Kung, Andrew L/0000-0002-9091-488X; Henke, Vanessa Giselle/0000-0001-5579-3640	NCI NIH HHS [CA-64481, CA-78496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064481, R01CA078496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achilles EG, 2001, J NATL CANCER I, V93, P1075, DOI 10.1093/jnci/93.14.1075; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Armstrong SA, 2003, CANCER CELL, V3, P173, DOI 10.1016/S1535-6108(03)00003-5; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; Bode W, 1999, ANN NY ACAD SCI, V878, P73, DOI 10.1111/j.1749-6632.1999.tb07675.x; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Demicheli R, 2001, SEMIN CANCER BIOL, V11, P297, DOI 10.1006/scbi.2001.0385; Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a; FOLKMAN J, 2000, CANC MED, V5, P132; Govindarajan B, 2005, J BIOL CHEM, V280, P13936, DOI 10.1074/jbc.M500411200; Gupta K, 1999, Angiogenesis, V3, P147, DOI 10.1023/A:1009018702832; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3; Hart IR, 1999, J PATHOL, V187, P91, DOI 10.1002/(SICI)1096-9896(199901)187:1<91::AID-PATH234>3.0.CO;2-J; Henson DE, 2001, PATHOLOGY INCIPIENT, P1; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Margosio B, 2003, BLOOD, V102, P4399, DOI 10.1182/blood-2003-03-0893; Naumov GN, 2006, JNCI-J NATL CANCER I, V98, P316, DOI 10.1093/jnci/djj068; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Uhr JW, 1997, NAT MED, V3, P505, DOI 10.1038/nm0597-505; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8	24	80	81	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					947	+		10.1096/fj.05-3946fje	http://dx.doi.org/10.1096/fj.05-3946fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16638967				2022-12-25	WOS:000240157700017
J	Fitau, J; Boulday, G; Coulon, F; Quillard, T; Charreau, B				Fitau, Juliette; Boulday, Gwenola; Coulon, Flora; Quillard, Thibaut; Charreau, Beatrice			The adaptor molecule Lnk negatively regulates tumor necrosis factor-alpha-dependent VCAM-1 expression in endothelial cells through inhibition of the ERK1 and -2 pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE PATHWAYS; GENE-EXPRESSION; SIGNALING PATHWAYS; CYCLE PROGRESSION; APOPTOSIS; ACTIVATION; HOMEOSTASIS; PI3K/AKT; CLONING	Lnk, with APS and SH2-B (Src homology 2-B), belongs to a family of SH2-containing proteins with potential adaptor functions. Lnk regulates growth factor and cytokine receptor-mediated pathways implicated in lymphoid, myeloid, and platelet homeostasis. We have previously shown that Lnk is expressed and up-regulated in vascular endothelial cells (ECs) in response to tumor necrosis factor-alpha(TNF alpha). In this study, we have shown that, in ECs, Lnk down-regulates the expression, at both mRNA and protein levels, of the proinflammatory molecules VCAM-1 and E-selectin induced by TNF alpha. Mechanistically, our data indicated that, in response to TNF alpha, NF kappa B/p65 phosphorylation and translocation as well as I kappa B alpha phosphorylation and degradation were unchanged, suggesting that Lnk does not modulate NF kappa B activity. However, Lnk activates phosphatidylinositol 3-kinase (PI3K) as reflected by Akt phosphorylation. Our results identify endothelial nitric-oxide synthase as a downstream target of Lnk-mediated activation of the PI3K/Akt pathway and HO-1 as a new substrate of Akt. We found that sustained Lnk-mediated activation of PI3K in TNF alpha-activated ECs correlated with the inhibition of ERK1/2 phosphorylation, whereas phosphorylation of p38 and c-Jun NH2-terminal kinase (JNK) mitogen-activated protein kinases (MAPKs) was unchanged. ERK1/2 inhibition decreases VCAM-1 expression in TNF alpha-treated ECs. Collectively, our results identify the adaptor Lnk as a negative regulator in the TNF alpha-signaling pathway mediating ERK inhibition and suggest a role for Lnk in the interplay between PI3K and ERK triggered by TNF alpha in ECs.	CHU Nantes, Hotel Dieu, INSERM, U643,ITERT, F-44093 Nantes, France; Univ Nantes, Unite Format & Rech Med, F-44093 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite	Charreau, B (corresponding author), CHU Nantes, Hotel Dieu, INSERM, U643,ITERT, 30 Bd Jean Monnet, F-44093 Nantes, France.	Beatrice.Charreau@univ-nantes.fr	Quillard, Thibaut/K-8150-2015; CHARREAU, Beatrice/AAK-8186-2020; Boulday, Gwenola/AAV-3768-2020	Quillard, Thibaut/0000-0002-8096-2597; CHARREAU, Beatrice/0000-0001-5870-4615; Boulday, Gwenola/0000-0002-5591-1659				Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002; Boulday G, 2002, TRANSPLANTATION, V74, P1352, DOI 10.1097/00007890-200211150-00026; Carmeliet P, 1998, KIDNEY INT, V53, P1519, DOI 10.1046/j.1523-1755.1998.00936.x; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chiu D, 2005, FEBS J, V272, P4372, DOI 10.1111/j.1742-4658.2005.04850.x; Dimmeler S, 2002, CURR OPIN LIPIDOL, V13, P531, DOI 10.1097/00041433-200210000-00009; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Krupnick AS, 2002, TRANSPLANTATION, V74, P871, DOI 10.1097/00007890-200209270-00022; Le Bas-Bernardet S, 2003, AM J TRANSPLANT, V3, P167, DOI 10.1034/j.1600-6143.2003.00021.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopaczynski W, 1999, ACTA BIOCHIM POL, V46, P51, DOI 10.18388/abp.1999_4183; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Mantovani A, 1997, IMMUNOL TODAY, V18, P231, DOI 10.1016/S0167-5699(97)81662-3; Nobuhisa I, 2003, MOL CELL BIOL, V23, P8486, DOI 10.1128/MCB.23.23.8486-8494.2003; Pascual M, 2002, NEW ENGL J MED, V346, P580, DOI 10.1056/NEJMra011295; Pober JS, 2002, ARTHRITIS RES THER, V4, pS109, DOI 10.1186/ar576; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Salinas M, 2004, FEBS LETT, V578, P90, DOI 10.1016/j.febslet.2004.10.077; Shelton JG, 2004, CELL CYCLE, V3, P372; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Soares MP, 2004, J IMMUNOL, V172, P3553, DOI 10.4049/jimmunol.172.6.3553; Soares MP, 2002, ANTIOXID REDOX SIGN, V4, P321, DOI 10.1089/152308602753666370; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Suttles J, 1999, J BIOL CHEM, V274, P5835, DOI 10.1074/jbc.274.9.5835; Takaki S, 1997, J BIOL CHEM, V272, P14562, DOI 10.1074/jbc.272.23.14562; Takaki S, 2003, J IMMUNOL, V170, P703, DOI 10.4049/jimmunol.170.2.703; Takaki S, 2002, J EXP MED, V195, P151, DOI 10.1084/jem.20011170; Takaki S, 2000, IMMUNITY, V13, P599, DOI 10.1016/S1074-7613(00)00060-1; Tong W, 2005, BLOOD, V105, P4604, DOI 10.1182/blood-2004-10-4093; Tong W, 2004, J EXP MED, V200, P569, DOI 10.1084/jem.20040762; Velazquez L, 2002, J EXP MED, V195, P1599, DOI 10.1084/jem.20011883; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163	40	47	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20148	20159		10.1074/jbc.M510997200	http://dx.doi.org/10.1074/jbc.M510997200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16644735	hybrid			2022-12-25	WOS:000239038200039
J	Sanchez-Ruiloba, L; Cabrera-Poch, N; Rodriguez-Martinez, M; Lopez-Menendez, C; Jean-Mairet, RM; Higuero, AM; Iglesias, T				Sanchez-Ruiloba, Lucia; Cabrera-Poch, Noemi; Rodriguez-Martinez, Maria; Lopez-Menendez, Celia; Martin Jean-Mairet, Roberto; Higuero, Alonso M.; Iglesias, Teresa			Protein kinase D intracellular localization and activity control kinase D-interacting substrate of 220-kDa traffic through a postsynaptic density-95/discs large/zonula occludens-1-binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PDZ PROTEINS; D ACTIVATION; C-MU; GOLGI; PHOSPHORYLATION; TRANSPORT; COMPLEX; FAMILY; MEMBER	Protein kinase D (PKD) controls protein traffic from the trans-Golgi network (TGN) to the plasma membrane of epithelial cells in an isoform-specific manner. However, whether the different PKD isoforms could be selectively regulating the traffic of their specific substrates remains unexplored. We identified the C terminus of the different PKDs that constitutes a postsynaptic density-95/discs large/zonula occludens-1 (PDZ)-binding motif in PKD1 and PKD2, but not in PKD3, to be responsible for the differential control of kinase D-interacting substrate of 220-kDa (Kidins220) surface localization, a neural membrane protein identified as the first substrate of PKD1. A kinase-inactive mutant of PKD3 is only able to alter the localization of Kidins220 at the plasma membrane when its C terminus has been substituted by the PDZ- binding motif of PKD1 or PKD2. This isoform-specific regulation of Kidins220 transport might not be due to differences among kinase activity or substrate selectivity of the PKD isoenzymes but more to the adaptors bound to their unique C terminus. Furthermore, by mutating the autophosphorylation site Ser(916), located at the critical position-2 of the PDZ-binding domain within PKD1, or by phorbol ester stimulation, we demonstrate that the phosphorylation of this residue is crucial for Kidins220-regulated transport. We also discovered that Ser(916) trans-phosphorylation takes place among PKD1 molecules. Finally, we demonstrate that PKD1 association to intracellular membranes is critical to control Kidins220 traffic. Our findings reveal the molecular mechanism by which PKD localization and activity control the traffic of Kidins220, most likely by modulating the recruitment of PDZ proteins in an isoform-specific and phosphorylation dependent manner.	Autonomous Univ Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Iglesias, T (corresponding author), Autonomous Univ Madrid, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, E-28029 Madrid, Spain.	tiglesias@iib.uam.es	Menendez, Celia Lopez/ABG-7555-2020; Vacas, Teresa Iglesias/ABF-8663-2020; Higuero, Alonso/L-7300-2014	Menendez, Celia Lopez/0000-0002-5967-1955; Vacas, Teresa Iglesias/0000-0002-4326-9005; Higuero, Alonso/0000-0003-3304-3616; Sanchez-Ruiloba, Lucia/0000-0001-5418-2290				Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Brone B, 2005, AM J PHYSIOL-CELL PH, V288, pC20, DOI 10.1152/ajpcell.00368.2004; Cabrera-Poch N, 2004, J BIOL CHEM, V279, P28592, DOI 10.1074/jbc.M312242200; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chang MS, 2004, J NEUROSCI RES, V78, P186, DOI 10.1002/jnr.20262; Chung HJ, 2000, J NEUROSCI, V20, P7258; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Harris BZ, 2001, J CELL SCI, V114, P3219; Hausser A, 2005, NAT CELL BIOL, V7, P880, DOI 10.1038/ncb1289; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Kneussel M, 2005, EMBO REP, V6, P22, DOI 10.1038/sj.embor.7400319; Kong HY, 2001, J NEUROSCI, V21, P176, DOI 10.1523/JNEUROSCI.21-01-00176.2001; Leonard AS, 2003, P NATL ACAD SCI USA, V100, P2029, DOI 10.1073/pnas.252782799; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Matthews SA, 2003, J BIOL CHEM, V278, P9086, DOI 10.1074/jbc.M211295200; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Mok H, 2002, J NEUROSCI, V22, P5253; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rey O, 2001, BIOCHEM BIOPH RES CO, V287, P21, DOI 10.1006/bbrc.2001.5530; Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; Rongo C, 2001, CYTOKINE GROWTH F R, V12, P349, DOI 10.1016/S1359-6101(01)00011-9; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200; Yano H, 2004, J NEUROBIOL, V58, P244, DOI 10.1002/neu.10321; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	41	63	63	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18888	18900		10.1074/jbc.M603044200	http://dx.doi.org/10.1074/jbc.M603044200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16651260	hybrid			2022-12-25	WOS:000238687300069
J	Frese, S; Schubert, WD; Findeis, AC; Marquardt, T; Roske, YS; Stradal, TEB; Heinz, DW				Frese, Susanne; Schubert, Wolf-Dieter; Findeis, Antje C.; Marquardt, Tobias; Roske, Yvette S.; Stradal, Theresia E. B.; Heinz, Dirk W.			The phosphotyrosine peptide binding specificity of Nck1 and Nck2 Src homology 2 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; FOCAL ADHESION KINASE; ACTIN-BASED MOTILITY; GROWTH-FACTOR; CRYSTAL-STRUCTURE; HIGH-AFFINITY; SH2 DOMAIN; PROTEIN; TYROSINE; COMPLEX	Nck proteins are essential Src homology (SH) 2 and SH3 domain-bearing adapters that modulate actin cytoskeleton dynamics by linking proline-rich effector molecules to tyrosine kinases or phosphorylated signaling intermediates. Two mammalian pathogens, enteropathogenic Escherichia coli and vaccinia virus, exploit Nck as part of their infection strategy. Conflicting data indicate potential differences in the recognition specificities of the SH2 domains of the isoproteins Nck1 (Nck alpha) and Nck2 (Nck beta and Grb4). We have characterized the binding specificities of both SH2 domains and find them to be essentially indistinguishable. Crystal structures of both domains in complex with phosphopeptides derived from the enteropathogenic E. coli protein Tir concur in identifying highly conserved, specific recognition of the phosphopeptide. Differential peptide recognition can therefore not account for the preference of either Nck in particular signaling pathways. Binding studies using sequentially mutated, high affinity phosphopeptides establish the sequence variability tolerated in peptide recognition. Based on this binding motif, we identify potential new binding partners of Nck1 and Nck2 and confirm this experimentally for the Arf-GAP GIT1.	German Res Ctr Biotechnol, Div Struct Biol, D-38124 Braunschweig, Germany; Paul Scherrer Inst, Biomol Res, CH-5232 Villigen, Switzerland; Prot Struct Factory, D-14059 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Stradal, TEB (corresponding author), German Res Ctr Biotechnol, Div Struct Biol, Mascheroder Weg 1, D-38124 Braunschweig, Germany.	ths@gbf.de; dih@gbf.de	Schubert, Wolf-Dieter/A-5617-2009	Schubert, Wolf-Dieter/0000-0003-4998-519X; Stradal, Theresia/0000-0002-0352-9474				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Bong YS, 2004, BIOCHEM J, V377, P499, DOI 10.1042/BJ20031449; Bradshaw JM, 2003, ADV PROTEIN CHEM, V61, P161; Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; Brown MC, 2005, MOL BIOL CELL, V16, P4316, DOI 10.1091/mbc.E05-02-0131; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Campellone KG, 2004, J CELL BIOL, V164, P407, DOI 10.1083/jcb.200306032; Chen HD, 2005, FEMS MICROBIOL REV, V29, P83, DOI 10.1016/j.femsre.2004.07.002; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; Clarke SC, 2003, CLIN MICROBIOL REV, V16, P365, DOI 10.1128/CMR.16.3.365-378.2003; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; Cowan-Jacob SW, 2005, STRUCTURE, V13, P861, DOI 10.1016/j.str.2005.03.012; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Goicoechea SM, 2002, INT J BIOCHEM CELL B, V34, P791, DOI 10.1016/S1357-2725(02)00002-X; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Houtman JCD, 2004, BIOCHEMISTRY-US, V43, P4170, DOI 10.1021/bi0357311; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalman D, 1999, NAT CELL BIOL, V1, P389, DOI 10.1038/14087; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Kim S, 2003, J BIOL CHEM, V278, P6291, DOI 10.1074/jbc.M212287200; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LEMMON MA, 1994, BIOCHEMISTRY-US, V33, P5070, DOI 10.1021/bi00183a010; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Liu XL, 2005, FEBS J, V272, P228, DOI 10.1111/j.1432-1033.2004.04408.x; Lougheed JC, 2004, J BIOL CHEM, V279, P44039, DOI 10.1074/jbc.M406703200; Manabe R, 2002, J CELL SCI, V115, P1497; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MOON HW, 1983, INFECT IMMUN, V41, P1340, DOI 10.1128/IAI.41.3.1340-1351.1983; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Phillips N, 2004, NAT CELL BIOL, V6, P618, DOI 10.1038/ncb1148; Pramatarova A, 2003, MOL CELL BIOL, V23, P7210, DOI 10.1128/MCB.23.20.7210-7221.2003; Ran XY, 2005, J BIOL CHEM, V280, P19205, DOI 10.1074/jbc.M500330200; Rietdorf J, 2001, NAT CELL BIOL, V3, P992, DOI 10.1038/ncb1101-992; Rosenshine I, 1996, EMBO J, V15, P2613, DOI 10.1002/j.1460-2075.1996.tb00621.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Su ZD, 2004, EUR J BIOCHEM, V271, P1725, DOI 10.1111/j.1432-1033.2004.04078.x; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yu L, 2000, NATURE, V405, P1073, DOI 10.1038/35016618; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	71	76	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18236	18245		10.1074/jbc.M512917200	http://dx.doi.org/10.1074/jbc.M512917200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636066	hybrid			2022-12-25	WOS:000238490300076
J	Hamano, Y; Matsuura, N; Kitamura, M; Takagi, H				Hamano, Yoshimitsu; Matsuura, Nobuyasu; Kitamura, Miwa; Takagi, Hiroshi			A novel enzyme conferring streptothricin resistance alters the toxicity of streptothricin D from broad-spectrum to bacteria-specific	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 2,3-DIHYDROXYBENZOIC ACID; STREPTOMYCES-NOURSEI; NUCLEOTIDE-SEQUENCE; LABORATORY-ANIMALS; SELECTABLE MARKER; GENE DISRUPTION; NOURSEOTHRICIN; BIOSYNTHESIS; ISOCHORISMATASE	Streptothricins (STs) produced by Streptomyces strains are broad-spectrum antibiotics. All STs consist of a carbamoylated D-gulosamine to which the beta-lysine homopolymer ( 1 to 7 residues) and the amide form of the unusual amino acid streptolidine ( streptolidine lactam) are attached. Although many ST-resistance genes have been identified in bacteria, including clinically isolated pathogens and ST-producing Streptomyces strains, only one resistance mechanism has been identified to date. This mechanism involves the modification of the ST molecule by monoacetylation of the moiety of the beta-lysine(s). In this study, we successfully isolated a novel ST-resistance gene (sttH) from Streptomyces albulus, which is a known ST non-producer. The in vitro analysis of SttH demonstrated that this enzyme catalyzes the hydrolysis of the amide bond of streptolidine lactam, thereby conferring ST resistance. Interestingly, the selective toxicity of ST-D possessing 3x beta-lysine moiety was altered from broad-spectrum to bacteria-specific by the hydrolysis of streptolidine lactam, although ST-F (1x beta-lysine) was detoxified by SttH in both prokaryotes and eukaryotes (yeasts). STs have not been clinically developed due to their toxicities; however, in this study, we showed that hydrolyzed ST-D (ST-D-acid) exhibits potent antibacterial activity even when its toxicity against eukaryotic cells is reduced by SttH. This suggests that ST-D-acid is a potential candidate for clinical development or for use as a new lead compound for drug discovery.	Fukui Prefectural Univ, Dept Biosci, Fukui 9101195, Japan; Okayama Univ Sci, Dept Life Sci, Okayama 7000005, Japan	Fukui Prefectural University; Okayama University of Science	Hamano, Y (corresponding author), 4-1-1 Matsuoka Kenjojima, Fukui 9101195, Japan.	hamano@fpu.ac.jp		Takagi, Hiroshi/0000-0002-1786-3174; Hamano, Yoshimitsu/0000-0001-5117-5116				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; Caruthers J, 2005, PROTEIN SCI, V14, P2887, DOI 10.1110/ps.051783005; CHAMBERLAIN DA, 1994, AUST J PLANT PHYSIOL, V21, P95, DOI 10.1071/PP9940095; Colovos C, 1998, STRUCTURE, V6, P1329, DOI 10.1016/S0969-2126(98)00132-4; FernandezMoreno MA, 1997, J BACTERIOL, V179, P6929, DOI 10.1128/jb.179.22.6929-6936.1997; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Grammel N, 2002, EUR J BIOCHEM, V269, P347, DOI 10.1046/j.0014-2956.2001.02657.x; HARTL A, 1986, ARCH EXP VET MED, V40, P727; Hentges P, 2005, YEAST, V22, P1013, DOI 10.1002/yea.1291; HOFFMANN H, 1986, ARCH EXP VET MED, V40, P710; HOFFMANN H, 1986, ARCH EXP VET MED, V40, P699; HORINOUCHI S, 1987, J BACTERIOL, V169, P1929, DOI 10.1128/jb.169.5.1929-1937.1987; Idnurm A, 2004, EUKARYOT CELL, V3, P420, DOI 10.1128/EC.3.2.420-429.2004; IGARASHI H, 1984, INFECT IMMUN, V44, P175, DOI 10.1128/IAI.44.1.175-181.1984; INAMORI Y, 1988, CHEM PHARM BULL, V36, P1577; Jackson MD, 2002, J ORG CHEM, V67, P2934, DOI 10.1021/jo016182c; JOSHI PB, 1995, GENE, V156, P145, DOI 10.1016/0378-1119(95)00042-5; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; KRUGEL H, 1988, GENE, V62, P209, DOI 10.1016/0378-1119(88)90559-8; NAHLIK MS, 1987, J BACTERIOL, V169, P4163, DOI 10.1128/jb.169.9.4163-4170.1987; NAHLIK MS, 1989, J BACTERIOL, V171, P784, DOI 10.1128/jb.171.2.784-790.1989; Parsons JF, 2003, BIOCHEMISTRY-US, V42, P5684, DOI 10.1021/bi027385d; Partridge SR, 2005, J CLIN MICROBIOL, V43, P4298, DOI 10.1128/JCM.43.8.4298-4300.2005; Peirano G, 2005, J ANTIMICROB CHEMOTH, V55, P301, DOI 10.1093/jac/dki012; Sambrook J, 2001, MOL CLONING LAB MANU; Shen JQ, 2005, INFECT IMMUN, V73, P1239, DOI 10.1128/IAI.73.2.1239-1242.2005; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Singh R, 2005, J ANTIMICROB CHEMOTH, V56, P216, DOI 10.1093/jac/dki161; Takagi H, 2000, J BIOSCI BIOENG, V89, P94, DOI 10.1016/S1389-1723(00)88059-7; TAKEMOTO T, 1980, CHEM PHARM BULL, V28, P2884; TANIYAMA H, 1971, J ANTIBIOT, V24, P662, DOI 10.7164/antibiotics.24.662; Vakulenko SB, 2003, CLIN MICROBIOL REV, V16, P430, DOI 10.1128/CMR.16.3.430-450.2003; Waksman SA, 1943, J BACTERIOL, V46, P299, DOI 10.1128/JB.46.3.299-310.1943; YOUNG IG, 1969, BIOCHIM BIOPHYS ACTA, V177, P401, DOI 10.1016/0304-4165(69)90302-X	36	20	23	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16842	16848		10.1074/jbc.M602294200	http://dx.doi.org/10.1074/jbc.M602294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16641084	hybrid			2022-12-25	WOS:000238326300004
J	Sandur, SK; Ichikawa, H; Sethi, G; Ahn, KS; Aggarwal, BB				Sandur, Santosh K.; Ichikawa, Haruyo; Sethi, Gautam; Ahn, Kwang Seok; Aggarwal, Bharat B.			Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappa B activation and NF-kappa B-regulated gene products through modulation of p65 and I kappa B alpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; CYCLIN D1; TRANSCRIPTIONAL REGULATION; MATRIX METALLOPROTEASE-9; DEPENDENT INDUCTION; ANTICANCER ACTIVITY; CELL-PROLIFERATION; TYROSINE KINASE; MEDICINAL-PLANT	Plumbagin, derived from the medicinal plant Plumbago zeylanica, modulates cellular proliferation, carcinogenesis, and radioresistance, all known to be regulated by the activation of the transcription factor NF-kappa B, suggesting plumbagin might affect the NF-kappa B activation pathway. We found that plumbagin inhibited NF-kappa B activation induced by TNF, and other carcinogens and inflammatory stimuli ( e. g. phorbol 12-myristate 13-acetate, H2O2, cigarette smoke condensate, interleukin-1 beta, lipopolysaccharide, and okadaic acid). Plumbagin also suppressed the constitutive NF-kappa B activation in certain tumor cells. The suppression of NF-kappa B activation correlated with sequential inhibition of the tumor necrosis factor ( TNF)-induced activation of I kappa B alpha kinase, I kappa B alpha phosphorylation, I kappa B alpha degradation, p65 phosphorylation, p65 nuclear translocation, and the NF-kappa B-dependent reporter gene expression activated by TNF, TNFR1, TRAF2, NIK, IKK-beta, and the p65 subunit of NF-kappa B. Plumbagin also suppressed the direct binding of nuclear p65 and recombinant p65 to the DNA, and this binding was reversed by dithiothreitol both in vitro and in vivo. However, plumbagin did not inhibit p65 binding to DNA when cells were transfected with the p65 plasmid containing cysteine 38 mutated to serine. Plumbagin down-regulated the expression of NF-kappa B-regulated anti-apoptotic (IAP1, IAP2, Bcl-2, Bcl-xL, cFLIP, Bfl-1/A1, and survivin), proliferative ( cyclin D1 and COX-2), and angiogenic ( matrix metalloproteinase-9 and vascular endothelial growth factor) gene products. This led to potentiation of apoptosis induced by TNF and paclitaxel and inhibited cell invasion. Overall, our results indicate that plumbagin is a potent inhibitor of the NF-kappa B activation pathway that leads to suppression of NF-kappa B-regulated gene products. This may explain its cell growth modulatory, anticarcinogenic, and radiosensitizing effects previously described.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab,Unit 143, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013; Sethi, Gautam/F-2372-2011; Ahn, Kwang Seok/G-4249-2013	Sethi, Gautam/0000-0002-8677-8475; 	NCI NIH HHS [P01 CA91844, P50CA97007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844, P50CA097007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Aggarwal S, 2006, MOL PHARMACOL, V69, P195, DOI 10.1124/mol.105.017400; [Anonymous], 1973, J U POONA SCI SECT; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200; BINDER RG, 1989, PHYTOCHEMISTRY, V28, P2799, DOI 10.1016/S0031-9422(00)98092-0; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chen XF, 2002, CANCER RES, V62, P1213; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DAstafort D, 1829, J PHARM SCI, V14, P441; Devi P. Uma, 1998, Indian Journal of Experimental Biology, V36, P891; Ding YX, 2005, J PHARM PHARMACOL, V57, P111, DOI 10.1211/0022357055119; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Fang JG, 2005, J BIOL CHEM, V280, P25284, DOI 10.1074/jbc.M414645200; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Ganasoundari A, 1997, BRIT J RADIOL, V70, P599, DOI 10.1259/bjr.70.834.9227253; Garcia-Pineres AJ, 2001, J BIOL CHEM, V276, P39713, DOI 10.1074/jbc.M101985200; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hazra B, 2002, PHYTOTHER RES, V16, P133, DOI 10.1002/ptr.867; HEDIN PA, 1980, J AGR FOOD CHEM, V28, P340, DOI 10.1021/jf60228a026; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ichikawa H, 2005, J IMMUNOL, V174, P7383, DOI 10.4049/jimmunol.174.11.7383; Inbaraj JJ, 2004, CHEM RES TOXICOL, V17, P55, DOI 10.1021/tx034132s; Jaiswal AS, 2002, ONCOGENE, V21, P5912, DOI 10.1038/sj.onc.1205789; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; KRISHNASWAMY M, 1980, INDIAN J EXP BIOL, V18, P876; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Liang MC, 2006, BIOCHEM PHARMACOL, V71, P634, DOI 10.1016/j.bcp.2005.11.013; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Naresh RAR, 1996, J PHARM PHARMACOL, V48, P1128, DOI 10.1111/j.2042-7158.1996.tb03907.x; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PARIMALA R, 1993, MOL CELL BIOCHEM, V125, P59, DOI 10.1007/BF00926835; Prasad V. Satya, 1996, Indian Journal of Experimental Biology, V34, P857; SHARMA I, 1991, Indian Journal of Physiology and Pharmacology, V35, P10; Shishodia S, 2003, CANCER RES, V63, P4375; Shrivastava A, 1999, ANTIOXID REDOX SIGN, V1, P181, DOI 10.1089/ars.1999.1.2-181; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; Singh U. V., 1997, Indian Journal of Physiology and Pharmacology, V41, P171; Srinivas G, 2004, MOL CARCINOGEN, V39, P15, DOI 10.1002/mc.10164; Srinivas P, 2004, MOL CARCINOGEN, V40, P201, DOI 10.1002/mc.20031; Sugie S, 1998, CANCER LETT, V127, P177, DOI 10.1016/S0304-3835(98)00035-4; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tilak JC, 2004, REDOX REP, V9, P219, DOI 10.1179/135100004225005976; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8	64	277	283	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17023	17033		10.1074/jbc.M601595200	http://dx.doi.org/10.1074/jbc.M601595200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16624823	hybrid			2022-12-25	WOS:000238326300024
J	Yoshida, T; Qin, L; Egger, LA; Inouye, M				Yoshida, Takeshi; Qin, Ling; Egger, Linda A.; Inouye, Masayori			Transcription regulation of ompF and ompC by a single transcription factor, OmpR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RESPONSE REGULATOR; STRUCTURAL-ANALYSIS; PROMOTER REGION; BINDING; PROTEIN; DOMAIN; ENVZ; GENE; EXPRESSION	The ompF and ompC genes of Escherichia coli are reciprocally regulated by a single transcription factor, phosphorylated OmpR (OmpR-P), depending upon medium osmolarity. This regulation involves activation of ompF and its repression with concomitant activation of ompC. This occurs through OmpR-P binding to four (F1, F2, F3, and F4) and three (C1, C2, and C3) sites located upstream of the ompF and ompC promoters, respectively, through a novel mechanism. Here we show that there is a distinct OmpR-P binding hierarchy within F1, F2, and F3 sites as well as within C1, C2, and C3 sites. Each of these sites contains two tandem 10-bp OmpR-P-binding subsites, a-site and b-site (from 5' to 3' direction). OmpR-P has higher affinity to the downstream b-site than to the upstream a-site in each case. Six OmpR-P molecules bind to F and C sites two-by-two in a discontinuous "galloping" manner. We propose that this tight hierarchical binding of a transcription factor, OmpR, allows distinct stepwise regulation of ompF and ompC transcription, which minimizes their overlapping expression upon changes in the medium osmolarity to achieve the reciprocal expression of ompF and ompC.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.	inouye@rwja.umdnj.edu	Qin, Ling/B-3147-2012	Yoshida, Takeshi/0000-0003-0133-5067	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076587] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM076587] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachhawat P, 2005, STRUCTURE, V13, P1353, DOI 10.1016/j.str.2005.06.006; Bergstrom LC, 1998, GENES CELLS, V3, P777, DOI 10.1046/j.1365-2443.1998.00228.x; Buckler DR, 2002, STRUCTURE, V10, P153, DOI 10.1016/S0969-2126(01)00706-7; Cai SJ, 2002, J BIOL CHEM, V277, P24155, DOI 10.1074/jbc.M110715200; Chen S, 2004, J BACTERIOL, V186, P6689, DOI 10.1128/JB.186.20.6689-6697.2004; Dutta R, 2000, J BIOL CHEM, V275, P38645, DOI 10.1074/jbc.M005872200; FERRARIO M, 1995, J BACTERIOL, V177, P103, DOI 10.1128/jb.177.1.103-113.1995; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; HARLOCKER SL, 1995, J BIOL CHEM, V270, P26849, DOI 10.1074/jbc.270.45.26849; Harrison-McMonagle P, 1999, J MOL BIOL, V285, P555, DOI 10.1006/jmbi.1998.2375; Head CG, 1998, J MOL BIOL, V281, P857, DOI 10.1006/jmbi.1998.1985; HUANG KJ, 1994, J BACTERIOL, V176, P1309, DOI 10.1128/jb.176.5.1309-1315.1994; Inouye M., 2003, HISTIDINE KINASES SI, P25; MartinezHackert E, 1997, STRUCTURE, V5, P109, DOI 10.1016/S0969-2126(97)00170-6; MIZUNO T, 1984, P NATL ACAD SCI-BIOL, V81, P1966, DOI 10.1073/pnas.81.7.1966; MIZUNO T, 1986, J BACTERIOL, V168, P86, DOI 10.1128/jb.168.1.86-95.1986; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; RAMPERSAUD A, 1994, J BIOL CHEM, V269, P12559; Robinson VL, 2003, J BACTERIOL, V185, P4186, DOI 10.1128/JB.185.14.4186-4194.2003; Toro-Roman A, 2005, J MOL BIOL, V349, P11, DOI 10.1016/j.jmb.2005.03.059; Yoshida T, 2002, MOL MICROBIOL, V46, P1283, DOI 10.1046/j.1365-2958.2002.03240.x	21	109	112	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17114	17123		10.1074/jbc.M602112200	http://dx.doi.org/10.1074/jbc.M602112200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16618701	hybrid			2022-12-25	WOS:000238326300035
J	Lamerz, AC; Haselhorst, T; Bergfeld, AK; von Itzstein, M; Gerardy-Schahn, R				Lamerz, Anne-Christin; Haselhorst, Thomas; Bergfeld, Anne K.; von Itzstein, Mark; Gerardy-Schahn, Rita			Molecular cloning of the Leishmania major UDP-glucose pyrophosphorylase, functional characterization, and ligand binding analyses using NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALIC-ACID BIOSYNTHESIS; BIFUNCTIONAL KEY ENZYME; TRANSFER DIFFERENCE NMR; GALACTOPYRANOSE MUTASE; OLIGOMERIZATION STATUS; KINETIC-PROPERTIES; ESCHERICHIA-COLI; HUMAN LIVER; GALACTOSE; PURIFICATION	The dense glycocalyx surrounding the protozoan parasite Leishmania is an essential virulence factor. It protects the parasite from hostile environments in the sandfly vector and mammalian host and supports steps of development and invasion. Therefore, new therapeutic concepts concentrate on disturbing glycocalyx biosynthesis. Deletion of genes involved in the metabolism of galactose and mannose have been shown to drastically reduce Leishmania virulence. Here we report the identification of Leishmania major UDP-glucose pyrophosphorylase ( UGP). UGP catalyzes the formation of UDP-glucose from glucose 1-phosphate and UTP. This activation step enables glucose to enter metabolic pathways and is crucial for the activation of galactose. UDP-galactose is made from UDP-glucose by nucleotide-donor transfer to galactose 1-phosphate or by epimerization of the glucose moiety. Isolated in a complementation cloning approach, the activity of L. major UGP was proven in vitro. Moreover, purified protein was used to investigate enzyme kinetics, quaternary organization, and binding of ligands. Whereas sequestration by oligomerization is a known regulatory mechanism for eukaryotic UGPs, the recombinant as well as native L. major UGP migrated as monomer in size exclusion chromatography and in accord with this showed simple Michaelis-Menten kinetics toward all substrates. In saturation transfer difference ( STD)-NMR studies, we clearly demonstrated that the molecular geometry at position 4 of glucose is responsible for substrate specificity. Furthermore, the gamma-phosphate group of UTP is essential for binding and for induction of the open conformation, which then allows entry of glucose 1-phosphate. Our data provide the first direct proof for the ordered bi-bi mechanism suggested in earlier studies.	Hannover Med Sch, Zentrum Biochem, D-30625 Hannover, Germany; Griffith Univ, Inst Glycom, Gold Coast 9726, Australia	Hannover Medical School; Griffith University	Gerardy-Schahn, R (corresponding author), Hannover Med Sch, Zentrum Biochem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	gerardy-schahn.rita@mh-hannover.de	Haselhorst, Thomas/A-5066-2015; von Itzstein, Mark/E-4823-2010	Haselhorst, Thomas/0000-0002-3373-8680; 				Bakker H, 2005, BIOL CHEM, V386, P657, DOI 10.1515/BC.2005.076; Bakker H, 2005, GLYCOBIOLOGY, V15, P193, DOI 10.1093/glycob/cwh159; Benie AJ, 2004, J BIOL CHEM, V279, P55722, DOI 10.1074/jbc.M410239200; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Beverley SM, 2005, EUKARYOT CELL, V4, P1147, DOI 10.1128/EC.4.6.1147-1154.2005; Blume A, 2004, J BIOL CHEM, V279, P55715, DOI 10.1074/jbc.M410238200; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; Duggleby RG, 1996, EUR J BIOCHEM, V235, P173, DOI 10.1111/j.1432-1033.1996.00173.x; ELLING L, 1994, J BIOTECHNOL, V34, P157, DOI 10.1016/0168-1656(94)90085-X; Geisler M, 2004, PLANT MOL BIOL, V56, P783, DOI 10.1007/s11103-004-4953-x; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; Kleczkowski LA, 2005, PHYTOCHEMISTRY, V66, P2815, DOI 10.1016/j.phytochem.2005.09.034; KNOP JK, 1970, J BIOL CHEM, V245, P2499; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martz F, 2002, BIOCHEM J, V367, P295, DOI 10.1042/BJ20020772; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; Naderer T, 2004, CURR MOL MED, V4, P649, DOI 10.2174/1566524043360069; NAKANO K, 1989, J BIOCHEM-TOKYO, V106, P528, DOI 10.1093/oxfordjournals.jbchem.a122886; Oelmann S, 2001, J BIOL CHEM, V276, P26291, DOI 10.1074/jbc.M011124200; Pan F, 2001, J BACTERIOL, V183, P3991, DOI 10.1128/JB.183.13.3991-3998.2001; Pedersen LL, 2003, CELL MOL LIFE SCI, V60, P259, DOI 10.1007/s000180300021; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; PENG HL, 1993, FEBS LETT, V329, P153, DOI 10.1016/0014-5793(93)80213-E; Reiter WD, 2001, PLANT MOL BIOL, V47, P95, DOI 10.1023/A:1010671129803; REMES B, 1980, J BACTERIOL, V143, P1054, DOI 10.1128/JB.143.2.1054-1056.1980; Sacks DL, 2000, P NATL ACAD SCI USA, V97, P406, DOI 10.1073/pnas.97.1.406; SOWOKINOS JR, 1993, PLANT PHYSIOL, V101, P1073, DOI 10.1104/pp.101.3.1073; Spath GF, 2003, P NATL ACAD SCI USA, V100, P9536, DOI 10.1073/pnas.1530604100; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; TSUBOI KK, 1969, J BIOL CHEM, V244, P1008; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; TURNQUIST RL, 1974, J BIOL CHEM, V249, P7695; VOET D, 2002, FUNDAMENTALS BIOCH, P331; *WHO EXP COMM, 1984, LEISHMANIASIS; Yuan Y, 2005, BIOCHEMISTRY-US, V44, P14080, DOI 10.1021/bi0513406; Zhang K, 2004, MOL BIOCHEM PARASIT, V136, P11, DOI 10.1016/j.molbiopara.2004.02.012	46	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16314	16322		10.1074/jbc.M600076200	http://dx.doi.org/10.1074/jbc.M600076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16611637	hybrid			2022-12-25	WOS:000238165700018
J	Obregon, DF; Rezai-Zadeh, K; Bai, Y; Sun, N; Hou, HY; Ehrhart, J; Zeng, J; Mori, T; Arendash, GW; Shytle, D; Town, T; Tan, J				Obregon, Demian F.; Rezai-Zadeh, Kavon; Bai, Yun; Sun, Nan; Hou, Huayan; Ehrhart, Jared; Zeng, Jin; Mori, Takashi; Arendash, Gary W.; Shytle, Doug; Town, Terrence; Tan, Jun			ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; BETA-SECRETASE; DISINTEGRIN METALLOPROTEASE; CONVERTING-ENZYME; APP; INHIBITION; EPIGALLOCATECHIN-3-GALLATE; INVOLVEMENT; ADAM-10; MICE	Recently, we have shown that green tea polyphenol (-)- epigallocatechin-3-gallate (EGCG) exerts a beneficial role on reducing brain A beta levels, resulting in mitigation of cerebral amyloidosis in a mouse model of Alzheimer disease. EGCG seems to accomplish this by modulating amyloid precursor protein (APP) processing, resulting in enhanced cleavage of the alpha-COOH-terminal fragment (alpha-CTF) of APP and corresponding elevation of the NH2-terminal APP product, soluble APP-alpha (sAPP-alpha). These beneficial effects were associated with increased alpha-secretase cleavage activity, but no significant alteration in beta- or gamma-secretase activities. To gain insight into the molecular mechanism whereby EGCG modulates APP processing, we evaluated the involvement of three candidate alpha-secretaseenzymes, a-disintegrin and metalloprotease (ADAM) 9, 10, or 17, in EGCG-induced non-amyloidogenic APP metabolism. Results show that EGCG treatment of N2a cells stably transfected with "Swedish" mutant human APP (SweAPP N2a cells) leads to markedly elevated active (similar to 60 kDa mature form) ADAM10 protein. Elevation of active ADAM10 correlates with increased alpha-CTF cleavage, and elevated sAPP-alpha. To specifically test the contribution of ADAM10 to non-amyloidogenic APP metabolism, small interfering RNA knockdown of ADAM9, - 10, or - 17 mRNA was employed. Results show that ADAM10(but not ADAM9 or - 17) is critical for EGCG-mediated alpha-secretase cleavage activity. In summary, ADAM10 activation is necessary for EGCG promotion of non-amyloidogenic (alpha-secretase cleavage) APP processing. Thus, ADAM10 represents an important pharmacotherapeutic target for the treatment of cerebral amyloidosis in Alzheimer disease.	Univ S Florida, Coll Med, Dept Psychiat & Behav Med, Silver Child Dev Ctr,Neuroimmunol Lab, Tampa, FL 33613 USA; Univ S Florida, Byrd Alzheimers Ctr & Res Inst, Tampa, FL 33613 USA; Univ S Florida, Ctr Excellence Aging & Brain Repair, Dept Neurosurg, Tampa, FL 33613 USA; Saitama Med Sch, Inst Med Sci, Moroyama, Saitama 3508550, Japan; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06519 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Saitama Medical University; Yale University	Tan, J (corresponding author), Univ S Florida, Coll Med, Dept Psychiat & Behav Med, Silver Child Dev Ctr,Neuroimmunol Lab, 3515 E Fletcher Ave, Tampa, FL 33613 USA.	jtan@hsc.usf.edu	Shytle, Roland D/J-4249-2012; Tan, Jun/I-5339-2012					Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Bernstein HG, 2003, J NEUROCYTOL, V32, P153, DOI 10.1023/B:NEUR.0000005600.61844.a6; Bigelow RLH, 2006, ONCOGENE, V25, P1922, DOI 10.1038/sj.onc.1209227; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CHAO CC, 1992, J INFECT DIS, V166, P847, DOI 10.1093/infdis/166.4.847; Chen M, 2004, BIOCHEM BIOPH RES CO, V316, P332, DOI 10.1016/j.bbrc.2004.02.052; Chubinskaya S, 2001, J HISTOCHEM CYTOCHEM, V49, P1165, DOI 10.1177/002215540104900910; Cisse MA, 2005, J BIOL CHEM, V280, P40624, DOI 10.1074/jbc.M506069200; Colciaghi F, 2004, NEUROLOGY, V62, P498, DOI 10.1212/01.WNL.0000106953.49802.9C; Colciaghi F, 2002, MOL MED, V8, P67, DOI 10.1007/BF03402076; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Ehrhart J, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-29; Fujimura Y, 2005, BIOCHEM BIOPH RES CO, V336, P674, DOI 10.1016/j.bbrc.2005.08.146; Funamoto S, 2004, BIOCHEMISTRY-US, V43, P13532, DOI 10.1021/bi049399k; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Gandhi S, 2004, J MOL NEUROSCI, V24, P137, DOI 10.1385/JMN:24:1:137; Golde TE, 2000, BBA-MOL BASIS DIS, V1502, P172, DOI 10.1016/S0925-4439(00)00043-0; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hooper NM, 2002, CURR MED CHEM, V9, P1107, DOI 10.2174/0929867023370121; Hotoda N, 2002, BIOCHEM BIOPH RES CO, V293, P800, DOI 10.1016/S0006-291X(02)00302-9; Huse JT, 2000, MOL NEUROBIOL, V22, P81; Ju J, 2005, CANCER RES, V65, P10623, DOI 10.1158/0008-5472.CAN-05-1949; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Levites Y, 2003, FASEB J, V17, P952, DOI 10.1096/fj.02-0881fje; Levites Y, 2002, J BIOL CHEM, V277, P30574, DOI 10.1074/jbc.M202832200; Lopez-Perez E, 2001, J NEUROCHEM, V76, P1532, DOI 10.1046/j.1471-4159.2001.00180.x; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; Mattson MP, 1999, J NEUROCHEM, V73, P532, DOI 10.1046/j.1471-4159.1999.0730532.x; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Park JW, 2001, BIOCHEM BIOPH RES CO, V286, P721, DOI 10.1006/bbrc.2001.5415; Pereira C, 2005, CNS NEUROL DISORD-DR, V4, P383, DOI 10.2174/1568007054546117; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Rezai-Zadeh K, 2005, J NEUROSCI, V25, P8807, DOI 10.1523/JNEUROSCI.1521-05.2005; Rodriguez SK, 2006, INT J CANCER, V118, P1635, DOI 10.1002/ijc.21545; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Sah JF, 2004, J BIOL CHEM, V279, P12755, DOI 10.1074/jbc.M312333200; Sambamurti K, 2002, NEUROMOL MED, V1, P1, DOI 10.1385/NMM:1:1:1; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shimizu M, 2005, J EXP THER ONCOL, V5, P69; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Stein TD, 2004, J NEUROSCI, V24, P7707, DOI 10.1523/JNEUROSCI.2211-04.2004; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Stoeck A, 2006, BIOCHEM J, V393, P609, DOI 10.1042/BJ20051013; Tan J, 2002, NAT NEUROSCI, V5, P1288, DOI 10.1038/nn968; Tan J, 2000, J NEUROSCI, V20, P7587; Vardy ERLC, 2005, TRENDS MOL MED, V11, P464, DOI 10.1016/j.molmed.2005.08.004; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	54	158	167	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16419	16427		10.1074/jbc.M600617200	http://dx.doi.org/10.1074/jbc.M600617200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16624814	hybrid			2022-12-25	WOS:000238165700031
J	Szivak, I; Lamb, N; Heilmeyer, LMG				Szivak, Ilona; Lamb, Ned; Heilmeyer, Ludwig M. G.			Subcellular localization and structural function of endogenous phosphorylated phosphatidylinositol 4-kinase (PI4K92)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; NUCLEAR-LOCALIZATION; PHOSPHOLIPASE-C; GOLGI-COMPLEX; PROTEIN; KINASE; 4,5-BISPHOSPHATE; TRANSCRIPTION; MEMBRANE; SPECKLES	Anti-phosphopeptide antibodies were raised against phosphatidylinositol 4-kinase (PI4K92) phosphorylation sites (Suer, S., Sickmann, A., Meyer, H. E., Herberg, F. W., and Heilmeyer, L. M. Jr. (2001) Eur. J. Biochem. 268, 2099-2106). Characterization proved three of them (anti-pSer-294, anti-pSer-496, and anti-pThr-504 antibody) to be highly specific, recognizing solely PI4K92 phosphorylated at these sites, respectively. Indirect immunofluorescence reveals that PI4K92 phosphorylated on Ser-294 localizes exclusively at the Golgi. The enzyme phosphorylated on Ser-496 and Thr-504 is detected in nuclear speckles. Phosphorylation of Ser-294 on PI4K92 increases the lipid kinase activity and thus serves better in maintaining Golgi function and morphology (compare Hausser, A., Storz, P., Martens, S., Link, G., Toker, A., and Pfizenmaier, K. (2005) Nat. Cell Biol. 7, 880-886). Microinjection of anti-pSer-496, but not of anti-pSer-294 or anti-pThr-504 antibody, into the cytoplasm or into the nucleus of HS68 cells leads to development of hotspots, probably representing aggregated PI4K92, and in later stages, cells become apoptotic and finally die. The association of phosphorylated PI4K92 with nuclear speckles is dynamic and follows the morphological alteration of speckles upon inhibition of mRNA transcription with alpha-amanitin. Overexpressed PI4K92 phosphorylated on Ser-294 is not transported to the nucleus, and that phosphorylated on Ser-496 is found in the nucleus and mislocalized at the Golgi complex. We conclude that nuclear phosphatidylinositol 4-phosphate, and consequently, synthesis of polyphosphoinositides are required for a correct nuclear function.	Ruhr Univ Bochum, Inst Physiol Chem, D-44801 Bochum, Germany; CNRS, Inst Genet Humaine, F-34396 Montpellier 5, France	Ruhr University Bochum; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Heilmeyer, LMG (corresponding author), Ruhr Univ Bochum, Inst Physiol Chem, Univ Str 150,MA 2-141, D-44801 Bochum, Germany.	Ludwig.Heilmeyer@ruhr-uni-bochum.de						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Brown RL, 2003, BIOCHEM BIOPH RES CO, V306, P394, DOI 10.1016/S0006-291X(03)00982-3; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; CZERNIK AJ, 1991, METHOD ENZYMOL B, V201, P264; de Graaf P, 2002, J CELL SCI, V115, P1769; Deleris P, 2003, J BIOL CHEM, V278, P38884, DOI 10.1074/jbc.M300816200; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Gehrmann T, 1996, BBA-MOL CELL RES, V1311, P53, DOI 10.1016/0167-4889(95)00180-8; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Hausser A, 2005, NAT CELL BIOL, V7, P880, DOI 10.1038/ncb1289; Haycock JW, 1998, J NEUROCHEM, V71, P1670; Hegewald H, 1996, ANAL BIOCHEM, V242, P152, DOI 10.1006/abio.1996.0443; Heilmeyer LMG, 2003, IUBMB LIFE, V55, P59, DOI 10.1080/1521654031000090896; Isenberg G, 1998, INT REV CYTOL, V178, P73; JAVOIS LC, 1999, IMMONOCYTOCHEMICAL, P11; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Maraldi NM, 1999, J CELL PHYSIOL, V181, P203, DOI 10.1002/(SICI)1097-4652(199911)181:2<203::AID-JCP3>3.0.CO;2-O; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MAZZOTTI G, 1995, J HISTOCHEM CYTOCHEM, V43, P181, DOI 10.1177/43.2.7822774; Misteli T, 2000, J CELL SCI, V113, P1841; Osborne SL, 2001, J CELL SCI, V114, P2501; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Schacht J, 1981, Methods Enzymol, V72, P626; Sindic A, 2001, J BIOL CHEM, V276, P17754, DOI 10.1074/jbc.M006533200; Suer S, 2001, EUR J BIOCHEM, V268, P2099, DOI 10.1046/j.1432-1327.2001.02089.x; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401; Zhao XH, 2000, J BIOL CHEM, V275, P14642, DOI 10.1074/jbc.275.19.14642; ZINI N, 1993, EXP CELL RES, V208, P257, DOI 10.1006/excr.1993.1245	40	18	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16740	16749		10.1074/jbc.M511645200	http://dx.doi.org/10.1074/jbc.M511645200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16606619	hybrid, Green Published			2022-12-25	WOS:000238165700068
J	Kim, JH; Kim, HW; Jeon, H; Suh, PG; Ryu, SH				Kim, Jung Hwan; Kim, Hyun-Wook; Jeon, Hyeona; Suh, Pann-Ghill; Ryu, Sung Ho			Phospholipase D1 regulates cell migration in a lipase activity-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; C-SRC; RHO; D2; D1; RECEPTOR; ALPHA; ACTIN; AUTOPHOSPHORYLATION; CYTOSKELETON	Cell migration, a complex biological process, requires dynamic cytoskeletal remodeling. Phospholipase D (PLD) generates phosphatidic acid, a lipid second messenger. Although PLD activity has been proposed to play a role in cytoskeletal rearrangement, the manner in which PLD participates in the rearrangement process remains obscure. In this study, by silencing endogenous PLD isozymes using small interfering RNA in HeLa cells, we demonstrate that endogenous PLD1 is required for the normal organization of the actin cytoskeleton, and, more importantly, for cell motility. PLD1 silencing in HeLa cells resulted in dramatic changes in cellular morphology, including the accumulation of stress fibers, as well as cell elongation and flattening, which appeared to be caused by an increased number of focal adhesions, which ultimately culminated in enhanced cell-substratum interactions. Accordingly, serum-induced cell migration was profoundly inhibited by PLD1-silencing. Moreover, the augmented cell substratum interaction and retarded cell migration induced by PLD1-silencing could be restored by the adding back not only of wild type, but also of lipase-inactive PLD1 into knockdown cells. Taken together, our results strongly suggest that endogenous PLD1 is a critical factor in the organization of the actin-based cytoskeleton, with regard to cell adhesion and migration. These effects of PLD1 appear to operate in a lipase activity-independent manner. We also discuss the regulation of Src family kinases by PLD1, as related to the modulation of Pyk2 and cell migration.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH)	Ryu, SH (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea.	sungho@postech.ac.kr	Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048; Kim, Jung Hwan/0000-0001-8548-4435				Ahn BH, 2003, MOL CELL BIOL, V23, P3103, DOI 10.1128/MCB.23.9.3103-3115.2003; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Astier A, 1997, J BIOL CHEM, V272, P228; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Cockcroft S, 2002, MOL IMMUNOL, V38, P1277, DOI 10.1016/S0161-5890(02)00075-5; Cockcroft S, 2001, CELL MOL LIFE SCI, V58, P1674, DOI 10.1007/PL00000805; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Czarny M, 1999, J BIOL CHEM, V274, P2717, DOI 10.1074/jbc.274.5.2717; Du GW, 2003, J CELL BIOL, V162, P305, DOI 10.1083/jcb.200302033; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; Frohman MA, 1996, CURR BIOL, V6, P945, DOI 10.1016/S0960-9822(02)00634-6; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Garcia-Garcia E, 2002, J LEUKOCYTE BIOL, V72, P1092; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Ghiso JAA, 1997, INT J CANCER, V71, P881, DOI 10.1002/(SICI)1097-0215(19970529)71:5<881::AID-IJC29>3.0.CO;2-9; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Hur EM, 2004, J BIOL CHEM, V279, P5852, DOI 10.1074/jbc.M311687200; ILLC D, 1995, NATURE, V377, P539; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Jang IH, 2003, J BIOL CHEM, V278, P18184, DOI 10.1074/jbc.M208438200; Kam Y, 2001, MOL CELL BIOL, V21, P4055, DOI 10.1128/MCB.21.12.4055-4066.2001; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; Lee HY, 2004, J BIOL CHEM, V279, P16339, DOI 10.1074/jbc.M310976200; Lee SD, 2000, J NEUROCHEM, V75, P1053, DOI 10.1046/j.1471-4159.2000.0751053.x; Lee TG, 1997, BBA-LIPID LIPID MET, V1347, P199, DOI 10.1016/S0005-2760(97)00083-0; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Okigaki M, 2003, P NATL ACAD SCI USA, V100, P10740, DOI 10.1073/pnas.1834348100; Panetti TS, 2002, FRONT BIOSCI-LANDMRK, V7, pD143, DOI 10.2741/panetti; Park SY, 2004, J BIOL CHEM, V279, P33315, DOI 10.1074/jbc.M313527200; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wehrle-Haller B, 2002, TRENDS CELL BIOL, V12, P382, DOI 10.1016/S0962-8924(02)02321-8; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	45	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15747	15756		10.1074/jbc.M509844200	http://dx.doi.org/10.1074/jbc.M509844200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16608858	hybrid			2022-12-25	WOS:000237996000022
J	Ulyanov, NB; Mujeeb, A; Du, ZH; Tonelli, M; Parslow, TG; James, TL				Ulyanov, Nikolai B.; Mujeeb, Anwer; Du, Zhihua; Tonelli, Marco; Parslow, Tristram G.; James, Thomas L.			NMR structure of the full-length linear dimer of stem-loop-1 RNA in the HIV-1 dimer initiation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-LOOP SL2; NUCLEOCAPSID PROTEIN; DIPOLAR COUPLINGS; PACKAGING SIGNAL; EXTENDED-DUPLEX; KISSING-LOOP; DNA DUPLEX; DIMERIZATION; DYNAMICS; DOMAIN	The packaging signal of HIV-1 RNA contains a stem-loop structure, SL1, which serves as the dimerization initiation site for two identical copies of the genome and is important for packaging of the RNAgenome into the budding virion and for overall infectivity. SL1 spontaneously dimerizes via a palindromic hexanucleotide sequence in its apical loop, forming a metastable kissing dimer form. Incubation with nucleocapsid protein causes this form to refold to a thermodynamically stable mature linear dimer. Here, we present an NMR structure of the latter form of the full-length SL1 sequence of the Lai HIV-1 isolate. The structure was refined using nuclear Overhauser effect and residual dipolar coupling data. The structure presents a symmetric homodimer of two RNA strands of 35 nucleotides each; it includes five stems separated by four internal loops. The central palindromic stem is surrounded by two symmetric adenine-rich 1-2 internal loops, A-bulges. All three adenines in each A-bulge are stacked inside the helix, consistent with the solution structures of shorter SL1 constructs determined previously. The outer 4-base pair stems and, proximal to them, purine-rich 1-3 internal loops, or G-bulges, are the least stable parts of the molecule. The G-bulges display high conformational variability in the refined ensemble of structures, despite the availability of many structural restraints for this region. Nevertheless, most conformations share a similar structural motif: a guanine and an adenine from opposite strands form a GA mismatch stacked on the top of the neighboring stem. The two remaining guanines are exposed, one in the minor groove and another in the major groove side of the helix, consistent with secondary structure probing data for SL1. These guanines may be recognized by the nucleocapsid protein, which binds tightly to the G-bulge in vitro.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Wisconsin, Natl Magnet Resonance Facil Madison, Madison, WI 53706 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison; Emory University	James, TL (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St,Genentech Hall, San Francisco, CA 94143 USA.	james@picasso.ucsf.edu	Ulyanov, Nikolai B/G-6998-2014		NCRR NIH HHS [P41RR02301, RR02781, P41 RR-01081, RR08438] Funding Source: Medline; NIAID NIH HHS [AI036636] Funding Source: Medline; NIGMS NIH HHS [P41GM66326] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301, S10RR008438, S10RR002781, P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM066326] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amarasinghe GK, 2000, J MOL BIOL, V299, P145, DOI 10.1006/jmbi.2000.3710; Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979; Baba S, 2005, J BIOCHEM, V138, P583, DOI 10.1093/jb/mvi158; Batey RT, 1995, METHOD ENZYMOL, V261, P300; BORGIAS BA, 1990, J MAGN RESON, V87, P475, DOI 10.1016/0022-2364(90)90305-S; Case D. A., 2002, AMBER 7 0; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; Clever JL, 1997, J VIROL, V71, P3407, DOI 10.1128/JVI.71.5.3407-3414.1997; Clever JL, 1996, J VIROL, V70, P5902, DOI 10.1128/JVI.70.9.5902-5908.1996; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Du ZH, 2004, BIOCHEMISTRY-US, V43, P5757, DOI 10.1021/bi0363228; Ennifar E, 1999, STRUCTURE, V7, P1439, DOI 10.1016/S0969-2126(00)80033-7; Ennifar E, 2001, NAT STRUCT BIOL, V8, P1064, DOI 10.1038/nsb727; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Girard F, 1999, J BIOMOL STRUCT DYN, V16, P1145, DOI 10.1080/07391102.1999.10508323; GODDARD TD, 1998, SPARKY; Greatorex J, 2002, J MOL BIOL, V322, P543, DOI 10.1016/S0022-2836(02)00776-3; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; KEEPERS JW, 1984, J MAGN RESON, V57, P404, DOI 10.1016/0022-2364(84)90257-9; KERWOOD DJ, 1991, EUR J BIOCHEM, V197, P583, DOI 10.1111/j.1432-1033.1991.tb15947.x; Lavery R, 1996, CURVES 5 1 HELICAL A; Lawrence DC, 2003, J MOL BIOL, V326, P529, DOI 10.1016/S0022-2836(02)01305-0; Liu H, 1995, J BIOMOL NMR, V6, P390; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Mujeeb A, 1999, FEBS LETT, V458, P387, DOI 10.1016/S0014-5793(99)01183-7; Mujeeb A, 1998, NAT STRUCT BIOL, V5, P432, DOI 10.1038/nsb0698-432; Paillart JC, 2004, NAT REV MICROBIOL, V2, P461, DOI 10.1038/nrmicro903; Paoletti AC, 2002, BIOCHEMISTRY-US, V41, P15423, DOI 10.1021/bi026307n; Pappalardo L, 1998, J MOL BIOL, V282, P801, DOI 10.1006/jmbi.1998.2046; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Shubsda MF, 2002, BIOCHEMISTRY-US, V41, P5276, DOI 10.1021/bi016045+; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; SMALLCOMBE SH, 1993, J AM CHEM SOC, V115, P4776, DOI 10.1021/ja00064a043; Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Tsui V, 2000, J BIOMOL NMR, V16, P9, DOI 10.1023/A:1008302430561; Ulyanov NB, 2002, J BIOMOL NMR, V22, P265, DOI 10.1023/A:1014987532546; Ulyanov NB, 1995, METHOD ENZYMOL, V261, P90; ULYANOV NB, 1995, BIOPHYS J, V68, P13, DOI 10.1016/S0006-3495(95)80181-5; ULYANOV NB, 1993, J BIOMOL NMR, V3, P547; ULYANOV NB, 1992, BIOCHEMISTRY-US, V31, P3918, DOI 10.1021/bi00131a005; Weigelt J, 1998, J AM CHEM SOC, V120, P10778, DOI 10.1021/ja982649y; Wu ZG, 2003, J BIOMOL NMR, V26, P297, DOI 10.1023/A:1024047103398; Yuan YQ, 2003, BIOCHEMISTRY-US, V42, P5259, DOI 10.1021/bi034084a; ZHURKIN VB, 1978, BIOPOLYMERS, V17, P377, DOI 10.1002/bip.1978.360170209; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046; ZHURKIN VB, 1980, MOL BIOL+, V14, P882; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	53	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16168	16177		10.1074/jbc.M601711200	http://dx.doi.org/10.1074/jbc.M601711200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16603544	hybrid			2022-12-25	WOS:000237996000070
J	Guerriero, CJ; Weixel, KM; Bruns, JR; Weisz, OA				Guerriero, Christopher J.; Weixel, Kelly M.; Bruns, Jennifer R.; Weisz, Ora A.			Phosphatidylinositol 5-kinase stimulates apical biosynthetic delivery via an Arp2/3-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; ALDRICH-SYNDROME PROTEIN; PLASMA-MEMBRANE; ACTIN CYTOSKELETON; N-WASP; MEDIATED ENDOCYTOSIS; ARP2/3 COMPLEX; CELL-SURFACE; MDCK CELLS; RECRUITMENT	The mechanisms by which polarized epithelial cells target distinct carriers enriched in newly synthesized proteins to the apical or basolateral membrane remain largely unknown. Here we investigated the effect of phosphatidylinositol metabolism and modulation of the actin cytoskeleton, two regulatory mechanisms that have individually been suggested to function in biosynthetic traffic, on polarized traffic in Madin-Darby canine kidney cells. Overexpression of phosphatidylinositol 5-kinase (PI5K) increased actin comet frequency in Madin-Darby canine kidney cells and concomitantly stimulated trans-Golgi network (TGN) to apical membrane delivery of the raft-associated protein influenza hemagglutinin (HA), but did not affect delivery of a non-raft-associated apical protein or a basolateral marker. Modulation of actin comet formation by pharmacologic means, by overexpression of the TGN-localized inositol polyphosphate 5-phosphatase Ocrl, or by blockade of Arp2/3 function had parallel effects on the rate of apical delivery of HA. Moreover, HA released from a TGN block was colocalized in transport carriers in association with PI5K and actin comets. Inhibition of Arp2/3 function in combination with microtubule depolymerization led to a virtual block in HA delivery, suggesting synergistic coordination of these cytoskeletal assemblies in membrane transport. Our results suggest a previously unidentified role for actin comet-mediated propulsion in the biosynthetic delivery of a subset of apical proteins.	Univ Pittsburgh, Lab Epithelial Cell Biol, Renal Electrolyte Div, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weisz, OA (corresponding author), 3550 Terrace St, Pittsburgh, PA 15261 USA.	weisz@pitt.edu		Guerriero, Christopher/0000-0002-1046-2300	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064613, T32DK061296, R01DK054407] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK054407, DK64613, T32-DK61296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; Allen PG, 2003, NAT CELL BIOL, V5, P972, DOI 10.1038/ncb1059; Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Ang AL, 2004, J CELL BIOL, V167, P531, DOI 10.1083/jcb.200408165; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; Benesch S, 2005, J CELL SCI, V118, P3103, DOI 10.1242/jcs.02444; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; Brough D, 2005, J CELL SCI, V118, P3019, DOI 10.1242/jcs.02426; Bruns JR, 2002, J BIOL CHEM, V277, P2012, DOI 10.1074/jbc.M108571200; Cao H, 2005, NAT CELL BIOL, V7, P483, DOI 10.1038/ncb1246; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; Carreno S, 2004, J CELL BIOL, V165, P781, DOI 10.1083/jcb.200403120; Chen JL, 2005, J CELL BIOL, V169, P383, DOI 10.1083/jcb.200501157; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Choudhury R, 2005, MOL BIOL CELL, V16, P3467, DOI 10.1091/mbc.E05-02-0120; Dressman MA, 2000, J HISTOCHEM CYTOCHEM, V48, P179, DOI 10.1177/002215540004800203; Dubois T, 2005, NAT CELL BIOL, V7, P353, DOI 10.1038/ncb1244; Ellis MA, 2004, J BIOL CHEM, V279, P52735, DOI 10.1074/jbc.M410533200; Fucini RV, 2002, MOL BIOL CELL, V13, P621, DOI 10.1091/mbc.01-11-0547; Fucini RV, 2000, J BIOL CHEM, V275, P18824, DOI 10.1074/jbc.M000024200; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Grindstaff KK, 1998, MOL BIOL CELL, V9, P685, DOI 10.1091/mbc.9.3.685; Heimann K, 1999, J BIOL CHEM, V274, P10743, DOI 10.1074/jbc.274.16.10743; Heine M, 2005, J BIOL CHEM, V280, P25637, DOI 10.1074/jbc.M502265200; Henkel JR, 1998, MOL BIOL CELL, V9, P2477, DOI 10.1091/mbc.9.9.2477; Henkel JR, 1999, J BIOL CHEM, V274, P9854, DOI 10.1074/jbc.274.14.9854; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; Huijbregts RPH, 2000, TRAFFIC, V1, P195, DOI 10.1034/j.1600-0854.2000.010301.x; Jacob R, 2003, CURR BIOL, V13, P607, DOI 10.1016/S0960-9822(03)00188-X; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; Jones DH, 2000, J BIOL CHEM, V275, P13962, DOI 10.1074/jbc.C901019199; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; LEFRANCOIS L, 1982, VIROLOGY, V121, P168, DOI 10.1016/0042-6822(82)90126-X; Lorra C, 1999, NAT CELL BIOL, V1, pE113, DOI 10.1038/12939; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Maples CJ, 1997, J BIOL CHEM, V272, P6741, DOI 10.1074/jbc.272.10.6741; Matas OB, 2004, TRAFFIC, V5, P838, DOI 10.1111/j.1600-0854.2004.00225.x; Merrifield CJ, 2004, TRENDS CELL BIOL, V14, P352, DOI 10.1016/j.tcb.2004.05.008; Merrifield CJ, 2004, EUR J CELL BIOL, V83, P13, DOI 10.1078/0171-9335-00356; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Noda Y, 2001, J CELL BIOL, V155, P77, DOI 10.1083/jcb.200108042; OLIVOSGLANDER IM, 1995, AM J HUM GENET, V57, P817; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Orzech E, 2000, J BIOL CHEM, V275, P15207, DOI 10.1074/jbc.275.20.15207; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; RINDLER MJ, 1987, J CELL BIOL, V104, P231, DOI 10.1083/jcb.104.2.231; Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Schuck S, 2004, J CELL SCI, V117, P5955, DOI 10.1242/jcs.01596; Stamnes M, 2002, CURR OPIN CELL BIOL, V14, P428, DOI 10.1016/S0955-0674(02)00349-6; Suchy SF, 2002, AM J HUM GENET, V71, P1420, DOI 10.1086/344517; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Toomre D, 1999, J CELL SCI, V112, P21; Ungewickell A, 2004, P NATL ACAD SCI USA, V101, P13501, DOI 10.1073/pnas.0405664101; van Rheenen J, 2005, EMBO J, V24, P1664, DOI 10.1038/sj.emboj.7600655; Vieira OV, 2005, J CELL BIOL, V170, P521, DOI 10.1083/jcb.200503078; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Wei YJ, 2002, J BIOL CHEM, V277, P46586, DOI 10.1074/jbc.M206860200; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Weixel KM, 2005, J BIOL CHEM, V280, P10501, DOI 10.1074/jbc.M414304200; Yang SA, 2004, J BIOL CHEM, V279, P42331, DOI 10.1074/jbc.M404335200; Yeaman C, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P239	69	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15376	15384		10.1074/jbc.M601239200	http://dx.doi.org/10.1074/jbc.M601239200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16601114	hybrid			2022-12-25	WOS:000237922200043
J	Sriram, K; Matheson, JM; Benkovic, SA; Miller, DB; Luster, MI; O'Callaghan, JP				Sriram, Krishnan; Matheson, Joanna M.; Benkovic, Stanley A.; Miller, Diane B.; Luster, Michael I.; O'Callaghan, James P.			Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha	FASEB JOURNAL			English	Article						brain; neurodegeneration; neuroinflammation; neuroprotection; microglia	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; FIBRILLARY ACIDIC PROTEIN; DOPAMINERGIC NEUROTOXICITY; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; MICE LACKING; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; SUBSTANTIA-NIGRA; OXIDATIVE STRESS	Enhanced expression of tumor necrosis factor ( TNF)-alpha, is associated with the neuropathological effects underlying disease-, trauma- and chemically induced neurodegeneration. Previously, we have shown that deficiency of TNF receptors protects against MPTP-induced striatal dopaminergic neurotoxicity, findings suggestive of a role for TNF-alpha in neurodegeneration. Here, we demonstrate that deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP. MPTP-induced expression of microglia-derived factors, TNF-alpha, MCP-1, and IL-1 alpha, preceded the degeneration of striatal dopaminergic nerve terminals and astrogliosis, as assessed by loss of striatal dopamine and TH, and an increase in striatal GFAP. Pharmacological neuroprotection with the dopamine reuptake inhibitor, nomifensine, abolished striatal dopaminergic neurotoxicity and associated microglial activation. Similarly, in mice lacking TNF receptors, microglial activation was suppressed, findings consistent with a role for TNF-alpha in striatal MPTP neurotoxicity. In the hippocampus, however, TNF receptor-deficient mice showed exacerbated neuronal damage after MPTP, as evidenced by Fluoro Jade-B staining (to identify degenerating neurons) and decreased microtubule-associated protein-2 (MAP-2) immunoreactivity. These effects were not accompanied by microglial activation, but were associated with increased oxidative stress (nitrosylation of tyrosine residues). These findings suggest that TNF-alpha exerts a neurotrophic/ neuroprotective effect in hippocampus. The marked differences we observed in the regional density, distribution and/or activity of microglia and microgliaderived factors may influence the region-specific role for this cell type. Taken together, our results are indicative of a region-specific and dual role for TNF-alpha in the brain: a promoter of neurodegeneration in striatum and a protector against neurodegeneration in hippocampus. -Sriram, K., Matheson, J.M., Benkovic, S. A., Miller, D. B., Luster, M. I., O'Callaghan, J. P. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP- induced neurotoxicity: role of TNF-alpha.	NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	O'Callaghan, JP (corresponding author), NIOSH, CDC, M-S L-3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.	jdo5@cdc.gov	O'Callaghan, James/O-2958-2013; Sriram, Krishnan/F-1039-2014	Sriram, Krishnan/0000-0001-7005-1872				Albensi BC, 2000, SYNAPSE, V35, P151; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; Benkovic SA, 2004, BRAIN RES, V1024, P59, DOI 10.1016/j.brainres.2004.07.021; Bezard E, 1997, EXP NEUROL, V148, P288, DOI 10.1006/exnr.1997.6648; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; BORIT A, 1975, BRAIN, V98, P101, DOI 10.1093/brain/98.1.101; Botchkina GI, 1999, MOL MED, V5, P372, DOI 10.1007/BF03402126; BRADBURY AJ, 1986, NEUROPHARMACOLOGY, V25, P939, DOI 10.1016/0028-3908(86)90025-0; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Calabresi P, 2000, TRENDS NEUROSCI, V23, pS57, DOI 10.1016/S1471-1931(00)00017-3; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Ferger B, 2004, J NEUROCHEM, V89, P822, DOI 10.1111/j.1471-4159.2004.02399.x; FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K; FRANCIS JW, 1995, NEUROTOXICOL TERATOL, V17, P7, DOI 10.1016/0892-0362(94)00048-I; Freyaldenhoven TE, 1997, BRAIN RES, V759, P9, DOI 10.1016/S0006-8993(97)00045-0; Galasso JM, 2000, NEUROREPORT, V11, P231, DOI 10.1097/00001756-200002070-00002; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; HEIKKILA RE, 1985, LIFE SCI, V36, P231, DOI 10.1016/0024-3205(85)90064-5; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; Hunot S, 2001, CLIN NEUROSCI RES, V1, P434, DOI 10.1016/S1566-2772(01)00022-6; ICHITANI Y, 1991, BRAIN RES, V549, P350, DOI 10.1016/0006-8993(91)90481-A; Imam SZ, 2001, J NEUROCHEM, V76, P745, DOI 10.1046/j.1471-4159.2001.00029.x; Imamura K, 2003, ACTA NEUROPATHOL, V106, P518, DOI 10.1007/s00401-003-0766-2; JONSSON G, 1985, N-S ARCH PHARMACOL, V331, P1, DOI 10.1007/BF00498844; Joseph SA, 1996, PEPTIDES, V17, P655, DOI 10.1016/0196-9781(96)00063-0; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; LEE SC, 1993, J IMMUNOL, V150, P2659; Leng A, 2005, NEUROSCI LETT, V375, P107, DOI 10.1016/j.neulet.2004.10.077; Little AR, 2002, NEUROSCIENCE, V115, P307, DOI 10.1016/S0306-4522(02)00359-7; MARTIN PM, 1995, J NEUROSCI METH, V58, P181, DOI 10.1016/0165-0270(94)00175-G; Masliah E., 2000, NEURODEGENERATIVE DE, P131; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; McGeer PL, 1998, ALZ DIS ASSOC DIS, V12, pS1; MERRILL JE, 1992, J IMMUNOTHER, V12, P167, DOI 10.1097/00002371-199210000-00004; Miller RG, 2001, AMYOTROPH LATERAL SC, V2, P3, DOI 10.1080/146608201300079355; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; O'Callaghan JP, 2004, J NEUROSCI METH, V135, P159, DOI 10.1016/j.jneumeth.2003.12.006; O'Callaghan JP, 1999, ANAL BIOCHEM, V274, P18, DOI 10.1006/abio.1999.4260; O'Callaghan JP, 1998, ANN NY ACAD SCI, V844, P40; OCALLAGHAN JP, 1990, BRAIN RES, V521, P73, DOI 10.1016/0006-8993(90)91526-M; OCALLAGHAN JP, 1995, NEUROCHEM INT, V26, P115, DOI 10.1016/0197-0186(94)00106-5; OCALLAGHAN JP, 1993, ANN NY ACAD SCI, V679, P195, DOI 10.1111/j.1749-6632.1993.tb18299.x; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; PERRY TL, 1985, NEUROSCI LETT, V58, P321, DOI 10.1016/0304-3940(85)90074-6; Raivich Gennadij, 1996, Keio Journal of Medicine, V45, P239; Ransohoff Richard M., 1996, Cytokine and Growth Factor Reviews, V7, P35, DOI 10.1016/1359-6101(96)00003-2; REINHARD JF, 1988, NEUROSCI LETT, V95, P246, DOI 10.1016/0304-3940(88)90665-9; Ren LQ, 1999, MOL BRAIN RES, V65, P198, DOI 10.1016/S0169-328X(99)00016-9; Rousselet E, 2002, EXP NEUROL, V177, P183, DOI 10.1006/exnr.2002.7960; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SCHNEIDER JS, 1988, J NEUROPATH EXP NEUR, V47, P452, DOI 10.1097/00005072-198807000-00006; Shen YQ, 2005, J NEUROIMMUNOL, V158, P14, DOI 10.1016/j.jneuroim.2004.06.011; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; Sriram K, 2006, J NEUROCHEM, V96, P706, DOI 10.1111/j.1471-4159.2005.03566.x; Sriram K, 2004, J BIOL CHEM, V279, P19936, DOI 10.1074/jbc.M309304200; Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje; Sriram K, 1997, BRAIN RES, V749, P44, DOI 10.1016/S0006-8993(96)01271-1; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; TAKADA M, 1993, NEUROSCI LETT, V150, P49, DOI 10.1016/0304-3940(93)90105-T; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Teismann P, 2001, NEUROREPORT, V12, P1049, DOI 10.1097/00001756-200104170-00037; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709	79	185	192	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					670	682		10.1096/fj.05-5106com	http://dx.doi.org/10.1096/fj.05-5106com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581975	Green Submitted			2022-12-25	WOS:000240130900013
J	Chedin, F; Handa, N; Dillingham, MS; Kowalczykowski, SC				Chedin, Frederic; Handa, Naofumi; Dillingham, Mark S.; Kowalczykowski, Stephen C.			The AddAB helicase/nuclease forms a stable complex with its cognate chi sequence during translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECBCD ENZYME; HOT-SPOT-CHI; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; RECOMBINATION HOTSPOT; DNA RECOMBINATION; EXONUCLEOLYTIC DEGRADATION; HOMOLOGOUS RECOMBINATION; LACTOCOCCUS-LACTIS; REPLICATION FORKS	The Bacillus subtilis AddAB enzyme possesses ATP-dependent helicase and nuclease activities, which result in the unwinding and degradation of double-stranded DNA (dsDNA) upon translocation. Similar to its functional counterpart, the Escherichia coli RecBCD enzyme, it also recognizes and responds to a specific DNA sequence, referred to as Chi (chi). Recognition of chi triggers attenuation of the 3'- to 5'-nuclease, which permits the generation of recombinogenic 3'-overhanging, single-stranded DNA (ssDNA), terminating at chi. Although the RecBCD enzyme briefly pauses at chi, no specific binding of RecBCD to chi during translocation has been documented. Here, we show that the AddAB enzyme transiently binds to its cognate chi sequence (chi(Bs):5'-AGCGG-3') during translocation. The binding of AddAB enzyme to the 3'-end of the chi(Bs)-specific ssDNA results in protection from degradation by exonuclease I. This protection is gradually reduced with time and lost upon phenol extraction, showing that the binding is non-covalent. Addition of AddAB enzyme to processed, chi(Bs)-specific ssDNA that had been stripped of all protein does not restore nuclease protection, indicating that AddAB enzyme binds to chi(Bs) with high affinity only during translocation. Finally, protection of chi(Bs)-specific ssDNA is still observed when translocation occurs in the presence of competitor chi(Bs)-carrying ssDNA, showing that binding occurs in cis. We suggest that this transient binding of AddAB to chi(Bs) is an integral part of the AddAB-chi(Bs) interaction and propose that this molecular event underlies a general mechanism for regulating the biochemical activities and biological functions of RecBCD-like enzymes.	Univ Calif Davis, Ctr Genet & Dev, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Ctr Genet & Dev, Microbiol Sect, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu	Handa, Naofumi/H-6640-2017	Handa, Naofumi/0000-0003-3695-1871; Chedin, Frederic/0000-0002-1306-5335; Dillingham, Mark/0000-0002-4612-7141	NIGMS NIH HHS [GM-41347] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Anderson DG, 1999, J BIOL CHEM, V274, P27139, DOI 10.1074/jbc.274.38.27139; Anderson DG, 1998, J MOL BIOL, V282, P275, DOI 10.1006/jmbi.1998.2013; BISWAS I, 1995, P NATL ACAD SCI USA, V92, P2244, DOI 10.1073/pnas.92.6.2244; BRUAND C, 1995, EMBO J, V14, P2642, DOI 10.1002/j.1460-2075.1995.tb07262.x; Chedin F, 2000, J MOL BIOL, V298, P7, DOI 10.1006/jmbi.2000.3556; Chedin F, 1998, MOL MICROBIOL, V29, P1369, DOI 10.1046/j.1365-2958.1998.01018.x; Chedin F, 2002, MOL MICROBIOL, V43, P823, DOI 10.1046/j.1365-2958.2002.02785.x; Dillingham MS, 2003, NATURE, V423, P893, DOI 10.1038/nature01673; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; El Karoui M, 1998, P NATL ACAD SCI USA, V95, P626, DOI 10.1073/pnas.95.2.626; Haijema BJ, 1996, J BACTERIOL, V178, P5086, DOI 10.1128/jb.178.17.5086-5091.1996; Handa N, 2005, MOL CELL, V17, P745, DOI 10.1016/j.molcel.2005.02.011; Handa N, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-5; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Kooistra J, 1997, MOL MICROBIOL, V23, P137, DOI 10.1046/j.1365-2958.1997.1991570.x; KOOISTRA J, 1993, MOL MICROBIOL, V7, P915, DOI 10.1111/j.1365-2958.1993.tb01182.x; Kulkarni A, 2004, NUCLEIC ACIDS RES, V32, P3672, DOI 10.1093/nar/gkh675; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; MYERS RS, 1995, P NATL ACAD SCI USA, V92, P6244, DOI 10.1073/pnas.92.14.6244; Quiberoni A, 2001, J BACTERIOL, V183, P4071, DOI 10.1128/JB.183.13.4071-4078.2001; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; Singleton MR, 2004, NATURE, V432, P187, DOI 10.1038/nature02988; Spies M, 2003, CELL, V114, P647, DOI 10.1016/S0092-8674(03)00681-0; Taylor AF, 2003, NATURE, V423, P889, DOI 10.1038/nature01674; Taylor AF, 1999, GENE DEV, V13, P890, DOI 10.1101/gad.13.7.890; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226; Wang JD, 2000, J BIOL CHEM, V275, P507, DOI 10.1074/jbc.275.1.507	34	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18610	18617		10.1074/jbc.M600882200	http://dx.doi.org/10.1074/jbc.M600882200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16632468	Green Submitted, hybrid			2022-12-25	WOS:000238687300040
J	Doukhanina, EV; Chen, S; van der Zalm, E; Godzik, A; Reed, J; Dickman, MB				Doukhanina, Elena V.; Chen, Shaorong; van der Zalm, Esther; Godzik, Adam; Reed, John; Dickman, Martin B.			Identification and functional characterization of the BAG protein family in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CHAPERONE; BCL-2; INHIBITOR-1; STRATEGIES; APOPTOSIS; MEMBERS; PLANTS; HSC70; HSP70	The genes that control mammalian programmed cell death are conserved across wide evolutionary distances. Although plant cells can undergo apoptosis-like cell death, plant homologs of mammalian regulators of apoptosis have, in general, not been found. This is in part due to the lack of primary sequence conservation between animal and putative plant regulators of apoptosis. Thus, alternative approaches beyond sequence similarities are required to find functional plant homologs of apoptosis regulators. Here, we present the results of using advanced bioinformatic tools to uncover the Arabidopsis family of BAG proteins. The mammalian BAG (Bcl-2-associated athanogene) proteins are a family of chaperone regulators that modulate a number of diverse processes ranging from proliferation to growth arrest and cell death. Such proteins are distinguished by a conserved BAG domain that directly interacts with Hsp70 and Hsc70 proteins to regulate their activity. Our searches of the Arabidopsis thaliana genome sequence revealed seven homologs of the BAG protein family. We further show that plant BAG family members are also multifunctional and remarkably similar to their animal counterparts, as they regulate apoptosis-like processes ranging from pathogen attack to abiotic stress and development.	Texas A&M Univ, Inst Plant Genom & Biotechnol, College Stn, TX 77843 USA; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68583 USA; Burnham Inst, La Jolla, CA 92037 USA	Texas A&M University System; Texas A&M University College Station; University of Nebraska System; University of Nebraska Lincoln; Sanford Burnham Prebys Medical Discovery Institute	Dickman, MB (corresponding author), Texas A&M Univ, Inst Plant Genom & Biotechnol, 2123 TAMU Bldg 1513, College Stn, TX 77843 USA.	mbdickman@tamu.edu	Godzik, Adam/A-7279-2009; Godzik, Adam/AAW-1467-2020	Godzik, Adam/0000-0002-2425-852X; Godzik, Adam/0000-0002-2425-852X	NIGMS NIH HHS [GM 67329] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200; Bateman Alex, 2002, Brief Bioinform, V3, P236, DOI 10.1093/bib/3.3.236; Briknarova K, 2002, J BIOL CHEM, V277, P31172, DOI 10.1074/jbc.M202792200; Chae HJ, 2003, GENE, V323, P101, DOI 10.1016/j.gene.2003.09.011; Chen SR, 2004, PLANT PHYSIOL, V135, P1630, DOI 10.1104/pp.103.038091; Chen SR, 2003, FREE RADICAL BIO MED, V34, P1315, DOI 10.1016/S0891-5849(03)00146-1; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Dickman MB, 2004, SHEFF BIOL SCI, P26; Dickman MB, 2001, P NATL ACAD SCI USA, V98, P6957, DOI 10.1073/pnas.091108998; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Hansen G, 2000, MOL PLANT MICROBE IN, V13, P649, DOI 10.1094/MPMI.2000.13.6.649; Hoeberichts FA, 2003, BIOESSAYS, V25, P47, DOI 10.1002/bies.10175; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Lincoln JE, 2002, P NATL ACAD SCI USA, V99, P15217, DOI 10.1073/pnas.232579799; LOCKSHIN RA, 1998, WHEN CELLS DIE COMPR; Merlot S, 1997, PLANT PHYSIOL, V114, P751, DOI 10.1104/pp.114.3.751; Moribe Y, 2001, EUR J BIOCHEM, V268, P3432, DOI 10.1046/j.1432-1327.2001.02244.x; Nakai K, 2000, ADV PROTEIN CHEM, V54, P277, DOI 10.1016/S0065-3233(00)54009-1; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; Sanchez P, 2000, PLANT J, V21, P393, DOI 10.1046/j.1365-313x.2000.00690.x; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Townsend PA, 2003, CANCER RES, V63, P4150; Velikova V, PLANT SCI, V151, P59, DOI [10.1016/S0168-9452(03)00121-3, 10.1016/S0168-9452(99)00197-1, DOI 10.1016/S0168-9452(99)00197-1]; Wang M, 1996, PLANT MOL BIOL, V32, P1125, DOI 10.1007/BF00041396; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	32	145	165	7	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18793	18801		10.1074/jbc.M511794200	http://dx.doi.org/10.1074/jbc.M511794200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16636050	hybrid			2022-12-25	WOS:000238687300060
J	Llamas, A; Otte, T; Multhaup, G; Mendel, RR; Schwarz, G				Llamas, Angel; Otte, Tanja; Multhaup, Gerd; Mendel, Ralf R.; Schwarz, Guenter			The mechanism of nucleotide-assisted molybdenum insertion into molybdopterin - A novel route toward metal cofactor assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT SULFUR METABOLISM; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ARABIDOPSIS-THALIANA; PROTEIN GEPHYRIN; SULFITE OXIDASE; FINAL STAGES; BIOSYNTHESIS; MOLYBDATE; BINDING	The molybdenum cofactor (Moco) is synthesized by an ancient and conserved biosynthetic pathway. In plants, the two-domain protein Cnx1 catalyzes the insertion of molybdenum into molybdopterin (MPT), a metal-free phosphorylated pyranopterin carrying an ene-dithiolate. Recently, we identified a novel biosynthetic intermediate, adenylated molybdopterin (MPT-AMP), which is synthesized by the C-terminal G domain of Cnx1. Here, we show that MPT-AMP and molybdate bind in an equimolar and cooperative way to the other N-terminal E domain (Cnx1E). Tungstate and sulfate compete for molybdate, which demonstrates the presence of an anion-binding site for molybdate. Cnx1E catalyzes the Zn2+-/Mg2+-dependent hydrolysis of MPT-AMP but only when molybdate is bound as co-substrate. MPT-AMP hydrolysis resulted in stoichiometric release of Moco that was quantitatively incorporated into plant apo-sulfite oxidase. Upon Moco formation AMP is release as second product of the reaction. When comparing MPT-AMP hydrolysis with the formation of Moco and AMP a 1.5-fold difference in reaction rates were observed. Together with the strict dependence of the reaction on molybdate the formation of adenylated molybdate as reaction intermediate in the nucleotide-assisted metal transfer reaction to molybdopterin is proposed.	Univ Cologne, Inst Biochem, D-50674 Cologne, Germany; Tech Univ Carolo Wilhelmina Braunschweig, Inst Plant Biol, D-38106 Braunschweig, Germany; Free Univ Berlin, Inst Chem & Biochem, D-14195 Berlin, Germany	University of Cologne; Braunschweig University of Technology; Free University of Berlin	Schwarz, G (corresponding author), Univ Cologne, Inst Biochem, Otto Fischer Str 12-14, D-50674 Cologne, Germany.	gschwarz@uni-koeln.de	Llamas, Angel/B-7104-2015; Schwarz, Guenter/ABE-9643-2021; Llamas, Angel/L-1638-2014	Llamas, Angel/0000-0001-6042-9472; Schwarz, Guenter/0000-0002-2118-9338; Llamas, Angel/0000-0001-6042-9472				AMY NK, 1981, J BACTERIOL, V148, P274, DOI 10.1128/JB.148.1.274-282.1981; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; Bick JA, 1998, CURR OPIN PLANT BIOL, V1, P240, DOI 10.1016/S1369-5266(98)80111-8; Bittner F, 2001, J BIOL CHEM, V276, P40381, DOI 10.1074/jbc.C100472200; CARDENAS J, 1974, ANAL BIOCHEM, V60, P372, DOI 10.1016/0003-2697(74)90244-9; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Eilers T, 2001, J BIOL CHEM, V276, P46989, DOI 10.1074/jbc.M108078200; Enemark JH, 2002, MET IONS BIOL SYST, V39, P621; Grunden AM, 1997, ARCH MICROBIOL, V168, P345, DOI 10.1007/s002030050508; Hanna E, 2002, ARCH BIOCHEM BIOPHYS, V406, P275, DOI 10.1016/S0003-9861(02)00428-9; Hasona A, 1998, J BACTERIOL, V180, P1466, DOI 10.1128/JB.180.6.1466-1472.1998; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Joshi MS, 1996, J BACTERIOL, V178, P4310, DOI 10.1128/jb.178.14.4310-4312.1996; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; KREDICH NM, 1996, ESCHERICHIA COLI SAL, P514; Kuper J, 2000, P NATL ACAD SCI USA, V97, P6475, DOI 10.1073/pnas.110568497; Kuper J, 2004, NATURE, V430, P803, DOI 10.1038/nature02681; Kuper J, 2003, ARCH BIOCHEM BIOPHYS, V411, P36, DOI 10.1016/S0003-9861(02)00714-2; Kuper J, 2003, FEMS MICROBIOL LETT, V218, P187, DOI 10.1016/S0378-1097(02)01121-7; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Leimkuhler S, 2001, J BIOL CHEM, V276, P1837, DOI 10.1074/jbc.M007304200; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; Llamas A, 2004, J BIOL CHEM, V279, P55241, DOI 10.1074/jbc.M409862200; Magalon A, 2002, J BIOL CHEM, V277, P48199, DOI 10.1074/jbc.M205806200; Mendel RR, 1999, CRIT REV PLANT SCI, V18, P33, DOI 10.1016/S0735-2689(99)00386-X; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; Millar LJ, 2001, MOL GENET GENOMICS, V266, P445, DOI 10.1007/s004380100543; Nichols JD, 2005, J BIOL CHEM, V280, P7817, DOI 10.1074/jbc.M413783200; Pau RN, 2002, MET IONS BIOL SYST, V39, P31; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Reiss J, 2003, HUM MUTAT, V21, P569, DOI 10.1002/humu.10223; Reiss J, 2001, AM J HUM GENET, V68, P208, DOI 10.1086/316941; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schwarz G, 2005, CELL MOL LIFE SCI, V62, P2792, DOI 10.1007/s00018-005-5269-y; Schwarz G, 2004, HUM MOL GENET, V13, P1249, DOI 10.1093/hmg/ddh136; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Schwarz G, 2001, J MOL BIOL, V312, P405, DOI 10.1006/jmbi.2001.4952; Schwarz G, 2000, PLANT CELL, V12, P2455, DOI 10.1105/tpc.12.12.2455; SCHWENN JD, 1980, J CHROMATOGR, V193, P285, DOI 10.1016/S0021-9673(00)81497-1; Seubert P A, 1979, Ciba Found Symp, P19; Simons A, 2002, BIOCHEMISTRY-US, V41, P9310, DOI 10.1021/bi0258647; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; Vergnes A, 2004, J BIOL CHEM, V279, P41398, DOI 10.1074/jbc.M407087200; WAHL RC, 1984, ARCH BIOCHEM BIOPHYS, V230, P264, DOI 10.1016/0003-9861(84)90107-3; Witte CP, 1998, FEBS LETT, V431, P205, DOI 10.1016/S0014-5793(98)00756-X; Xiang S, 2001, STRUCTURE, V9, P299, DOI 10.1016/S0969-2126(01)00588-3; Yoshiba S, 2004, J BIOL CHEM, V279, P37163, DOI 10.1074/jbc.M403817200; Zyryanov AB, 2002, BIOCHEM J, V367, P901, DOI 10.1042/BJ20020880	49	88	91	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18343	18350		10.1074/jbc.M601415200	http://dx.doi.org/10.1074/jbc.M601415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16636046	hybrid			2022-12-25	WOS:000238687300011
J	Simmons, CR; Liu, Q; Huang, QQ; Hao, Q; Begley, TP; Karplus, PA; Stipanuk, MH				Simmons, Chad R.; Liu, Qun; Huang, Qingqiu; Hao, Quan; Begley, Tadhg P.; Karplus, P. Andrew; Stipanuk, Martha H.			Crystal structure of mammalian cysteine dioxygenase - A novel mononuclear iron center for cysteine thiol oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL OXYGENASE COMPONENT; QUERCETIN 2,3-DIOXYGENASE; PROTEASOME SYSTEM; ENZYMES; PROTEIN; MECHANISM; METABOLISM; PARKINSONS; EXPRESSION; OXIDASE	Cysteine dioxygenase is a mononuclear iron-dependent enzyme responsible for the oxidation of cysteine with molecular oxygen to form cysteine sulfinate. This reaction commits cysteine to either catabolism to sulfate and pyruvate or the taurine biosynthetic pathway. Cysteine dioxygenase is a member of the cupin superfamily of proteins. The crystal structure of recombinant rat cysteine dioxygenase has been determined to 1.5-angstrom resolution, and these results confirm the canonical cupin beta-sandwich fold and the rare cysteinyltyrosine intramolecular cross-link (between Cys(93) and Tyr(157)) seen in the recently reported murine cysteine dioxygenase structure. In contrast to the catalytically inactive mononuclear Ni(II) metallo-center present in the murine structure, crystallization of a catalytically competent preparation of rat cysteine dioxygenase revealed a novel tetrahedrally coordinated mononuclear iron center involving three histidines (His(86), His(88), and His(140)) and a water molecule. Attempts to acquire a structure with bound ligand using either co-crystallization or soaking crystals with cysteine revealed the formation of a mixed disulfide involving Cys(164) near the active site, which may explain previously observed substrate inhibition. This work provides a framework for understanding the molecular mechanisms involved in thiol dioxygenation and sets the stage for exploration of the chemistry of both the novel mononuclear iron center and the catalytic role of the cysteinyl-tyrosine linkage.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Cornell Univ, Macromol Diffract Facil, Cornell High Energy Synchrotron Source, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Oregon State University; Cornell University; Cornell University; Cornell University	Karplus, PA (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 Ag & Life Sci Bldg, Corvallis, OR 97331 USA.	karplusp@science.oregonstate.edu; mhs6@cornell.edu	Hao, Quan/C-4304-2009; Liu, Qun/A-8757-2011; Begley, Tadhg/B-5801-2015	Liu, Qun/0000-0002-1179-290X; Karplus, Paul/0000-0001-8725-6292; Hao, Quan/0000-0002-9642-0514	NCRR NIH HHS [RR-01646] Funding Source: Medline; NIDDK NIH HHS [DK044083, DK056649] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044083, R37DK044083, R01DK056649] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Adachi M, 2003, P NATL ACAD SCI USA, V100, P7395, DOI 10.1073/pnas.0832158100; Adachi M, 2001, J MOL BIOL, V305, P291, DOI 10.1006/jmbi.2000.4310; BRADLEY H, 1994, J RHEUMATOL, V21, P1192; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bugg TDH, 2003, TETRAHEDRON, V59, P7075, DOI 10.1016/S0040-4020(03)00944-X; Bugg TDH, 1998, NAT PROD REP, V15, P513; Chai SC, 2005, J BIOL CHEM, V280, P9865, DOI 10.1074/jbc.M413733200; DAVIES MH, 1995, J HEPATOL, V22, P551, DOI 10.1016/0168-8278(95)80450-1; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Dominy JE, 2006, BIOCHEM J, V394, P267, DOI 10.1042/BJ20051510; Dong XS, 2005, J BACTERIOL, V187, P2483, DOI 10.1128/JB.187.7.2483-2490.2005; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Dunwell JM, 2001, TRENDS BIOCHEM SCI, V26, P740, DOI 10.1016/S0968-0004(01)01981-8; Dunwell JM, 2000, MICROBIOL MOL BIOL R, V64, P153, DOI 10.1128/MMBR.64.1.153-179.2000; EWETZ L, 1966, BIOCHIM BIOPHYS ACTA, V128, P296, DOI 10.1016/0926-6593(66)90176-7; Furusawa Y, 2004, J MOL BIOL, V342, P1041, DOI 10.1016/j.jmb.2004.07.062; Fusetti F, 2002, STRUCTURE, V10, P259, DOI 10.1016/S0969-2126(02)00704-9; Gopal B, 2005, BIOCHEMISTRY-US, V44, P193, DOI 10.1021/bi0484421; Hao Q, 2004, J APPL CRYSTALLOGR, V37, P498, DOI 10.1107/S0021889804008696; Hao Q, 2003, J APPL CRYSTALLOGR, V36, P1274, DOI 10.1107/S0021889803014031; HEAFIELD MT, 1990, NEUROSCI LETT, V110, P216, DOI 10.1016/0304-3940(90)90814-P; HEAFIELD MTE, 1992, CURR OPIN NEUROL NEU, V5, P288; Hirschberger LL, 2001, GENE, V277, P153, DOI 10.1016/S0378-1119(01)00691-6; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; Hwang L, 2003, MOL BIOL CELL, V14, P2314, DOI 10.1091/mbc.E03-01-0027; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; Jaroszewski L, 2004, PROTEINS, V56, P611, DOI 10.1002/prot.20130; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Just VJ, 2004, J BIOL CHEM, V279, P19867, DOI 10.1074/jbc.M313820200; KARLSEN RL, 1981, BRAIN RES, V208, P167; Kauppi B, 1998, STRUCTURE, V6, P571, DOI 10.1016/S0969-2126(98)00059-8; KO TP, 1993, PLANT PHYSIOL, V101, P729, DOI 10.1104/pp.101.3.729; Kooter IM, 2002, EUR J BIOCHEM, V269, P2971, DOI 10.1046/j.1432-1033.2002.02973.x; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; Li H, 1997, J NEUROCHEM, V69, P1530; LOMBARDINI JB, 1969, J BIOL CHEM, V244, P1172; Mathisen GA, 1996, NEUROCHEM RES, V21, P293, DOI 10.1007/BF02531643; McBean GJ, 2001, BIOCHEM SOC T, V29, P717, DOI 10.1042/BST0290717; McCoy JG, 2006, P NATL ACAD SCI USA, V103, P3084, DOI 10.1073/pnas.0509262103; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEDERSEN OO, 1980, INVEST OPHTH VIS SCI, V19, P886; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; Rogers MS, 2001, ADV PROTEIN CHEM, V58, P387; Rohwerder T, 2003, MICROBIOL-SGM, V149, P1699, DOI 10.1099/mic.0.26212-0; SACCO M, 1981, J BACTERIOL, V146, P117, DOI 10.1128/JB.146.1.117-120.1981; Schnell R, 2005, J BIOL CHEM, V280, P27319, DOI 10.1074/jbc.M502560200; Schubert D, 2001, J NEUROSCI, V21, P7455, DOI 10.1523/JNEUROSCI.21-19-07455.2001; Simmons CR, 2006, PROTEIN EXPRES PURIF, V47, P74, DOI 10.1016/j.pep.2005.10.025; Simmons CR, 2005, ACTA CRYSTALLOGR F, V61, P1013, DOI 10.1107/S1744309105033737; Stipanuk MH, 2002, J NUTR, V132, P3369, DOI 10.1093/jn/132.11.3369; Stipanuk MH, 2004, ANNU REV NUTR, V24, P539, DOI 10.1146/annurev.nutr.24.012003.132418; Stipanuk MH, 2004, AM J PHYSIOL-ENDOC M, V286, pE439, DOI 10.1152/ajpendo.00336.2003; Stipanuk MH, 2004, AMINO ACIDS, V26, P99, DOI 10.1007/s00726-003-0001-4; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Woo EJ, 2000, NAT STRUCT BIOL, V7, P1036; YAMAGUCHI K, 1978, J BIOCHEM-TOKYO, V83, P479, DOI 10.1093/oxfordjournals.jbchem.a131935; Zhang Y, 2005, BIOCHEMISTRY-US, V44, P7632, DOI 10.1021/bi047353l; Zhou CZ, 2005, PROTEIN SCI, V14, P209, DOI 10.1110/ps.041121305	62	128	130	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18723	18733		10.1074/jbc.M601555200	http://dx.doi.org/10.1074/jbc.M601555200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16611640	hybrid			2022-12-25	WOS:000238687300053
J	Zhu, L; Zhang, YL; Teh, JS; Zhang, JJ; Connell, N; Rubin, H; Inouye, M				Zhu, Ling; Zhang, Yonglong; Teh, Jiah-Shin; Zhang, Junjie; Connell, Nancy; Rubin, Harvey; Inouye, Masayori			Characterization of mRNA interferases from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CELL-DEATH; PERSISTENCE; MAZF; ANTIMICROBIALS; MODULE; MODEL; LOCI	mRNA interferases are sequence-specific endoribonucleases encoded by the toxin-antitoxin systems in the bacterial genomes. MazF from Escherichia coli has been shown to be an mRNA inter-ferase that specifically cleaves at ACA sequences in single-stranded RNAs. It has been shown that MazF induction in E. coli effectively inhibits protein synthesis leading to cell growth arrest in the quasi-dormant state. Here we have demonstrated that Mycobacterium tuberculosis contains at least seven genes encoding MazF homologues (MazF-mt1 to -mt7), four of which (MazF-mt1, -mt3, -mt4, and -mt6) caused cell growth arrest when induced in E. coli. MazF-mt1 and MazF-mt6 were purified and characterized for their mRNA interferase specificities. We showed that MazF-mt1 preferentially cleaves the era mRNA between U and A in UAC triplet sequences, whereas MazF-mt6 preferentially cleaves U-rich regions in the era mRNA both in vivo and in vitro. These results indicate that M. tuberculosis contains sequence-specific mRNA interferases, which may play a role in the persistent dormancy of this devastating pathogen in human tissues.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Med & Dent New Jersey, Ctr BioDef, Dept Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Ln, Piscataway, NJ 08854 USA.	Inouye@umdnj.edu	Zhu, Ling/M-3887-2013; Connell, Nancy/AFN-1305-2022	Zhu, Ling/0000-0003-0776-1630; Zhang, Junjie/0000-0001-8809-1485	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043420] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI43420] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Arcus VL, 2005, TRENDS MICROBIOL, V13, P360, DOI 10.1016/j.tim.2005.06.008; Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Dahl JL, 2003, P NATL ACAD SCI USA, V100, P10026, DOI 10.1073/pnas.1631248100; Engelberg-Kulka H, 2005, J CELL SCI, V118, P4327, DOI 10.1242/jcs.02619; Gerdes K, 2005, NAT REV MICROBIOL, V3, P371, DOI 10.1038/nrmicro1147; Kamada K, 2003, MOL CELL, V11, P875, DOI 10.1016/S1097-2765(03)00097-2; Keren I, 2004, FEMS MICROBIOL LETT, V230, P13, DOI 10.1016/S0378-1097(03)00856-5; Li GY, 2006, J MOL BIOL, V357, P139, DOI 10.1016/j.jmb.2005.12.035; Pandey DP, 2005, NUCLEIC ACIDS RES, V33, P966, DOI 10.1093/nar/gki201; Spoering AL, 2001, J BACTERIOL, V183, P6746, DOI 10.1128/JB.183.23.6746-6751.2001; Suzuki M, 2005, MOL CELL, V18, P253, DOI 10.1016/j.molcel.2005.03.011; Ying Z, 2005, ANNU REV PHARMACOL, V45, P529, DOI 10.1146/annurev.pharmtox.45.120403.100120; Zhang JJ, 2004, J BIOL CHEM, V279, P20678, DOI 10.1074/jbc.M314284200; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7; Zhang YL, 2005, J BIOL CHEM, V280, P3143, DOI 10.1074/jbc.M411811200	17	106	132	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18638	18643		10.1074/jbc.M512693200	http://dx.doi.org/10.1074/jbc.M512693200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16611633	hybrid			2022-12-25	WOS:000238687300043
J	Cho, YS; Kim, EJ; Park, UH; Sin, HS; Um, SJ				Cho, Yang-Sook; Kim, Eun-Joo; Park, Ui-Hyun; Sin, Hong-Sig; Um, Soo-Jong			Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEXES; MURINE HOX-2 GENES; NUCLEAR RECEPTOR; IN-VIVO; TRANSCRIPTIONAL REGULATION; PROTEIN METHYLTRANSFERASE; FUNCTIONAL-ANALYSIS; P160 COACTIVATORS; POLYCOMB-GROUP; COMBS GENE	Additional sex comb-like 1 (ASXL1, 170 kDa), a mammalian homolog of Drosophila ASX, was identified as a protein that interacts with retinoic acid receptor (RAR) in the presence of retinoic acid (RA). Systematic binding assays showed that the C-terminal nuclear receptor box (LVMQLL) of ASXL1 and the activation function-2 activation domain (AF-2AD) core of the RAR are critical for ligand-dependent interaction. The interaction was confirmed using in vitro glutathione S-transferase pulldown and in vivo immunoprecipitation (IP) assays. Confocal microscopy revealed that ASXL1 localizes in the nucleus. In addition to the intrinsic transactivation function of ASXL1, its cotransfection together with an RA-responsive luciferase reporter increased the RAR activity. This ASXL1 activity appears to be mediated through the functional cooperation with SRC-1, as shown by GST pulldown, IP, chromatin IP, and transcription assays. In the presence of ASXL1, more acetylated histone H3 was accumulated on the RA-responsive promoter in response to RA. Finally, stable expression of ASXL1 increased the expression of endogenous RA-regulated genes and enhanced the antiproliferative potential of RA. Overall, these results suggest that ASXL1 is a novel coactivator of RAR that cooperates with SRC-1 and implicates it as a potential antitumor target of RA in RA-resistant cancer cells.	Sejong Univ, Dept Biosci & Biotechnol, Seoul 143747, South Korea; Sejong Univ, Seoul 143747, South Korea; Chebigen Inc, Seoul, South Korea	Sejong University; Sejong University	Um, SJ (corresponding author), Sejong Univ, Dept Biosci & Biotechnol, 98 Kunja Dong, Seoul 143747, South Korea.	umsj@sejong.ac.kr						AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1; Aoyagi S, 2005, VITAM HORM, V70, P281, DOI 10.1016/S0083-6729(05)70009-1; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Bel-Vialar S, 2000, DEV BIOL, V224, P238, DOI 10.1006/dbio.2000.9791; Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen YH, 2005, MOL CELL BIOL, V25, P5965, DOI 10.1128/MCB.25.14.5965-5972.2005; Chen YT, 2004, MOL CELL BIOL, V24, P9930, DOI 10.1128/MCB.24.22.9930-9941.2004; CONLON RA, 1992, DEVELOPMENT, V116, P357; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Dupe V, 1997, DEVELOPMENT, V124, P399; Fisher CL, 2003, GENE, V306, P115, DOI 10.1016/S0378-1119(03)00430-X; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Katoh M, 2004, INT J ONCOL, V24, P1617; Katoh M, 2003, INT J ONCOL, V23, P845; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Langston AW, 1997, J BIOL CHEM, V272, P2167, DOI 10.1074/jbc.272.4.2167; LANGSTON AW, 1994, CURR OPIN GENET DEV, V4, P550, DOI 10.1016/0959-437X(94)90071-A; Li C, 1998, CANCER LETT, V124, P205, DOI 10.1016/S0304-3835(97)00475-8; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Ma H, 1999, MOL CELL BIOL, V19, P6164; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; Marshall H, 1996, FASEB J, V10, P969, DOI 10.1096/fasebj.10.9.8801179; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Milne TA, 1999, MOL GEN GENET, V261, P753, DOI 10.1007/s004380050018; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; Plevin MJ, 2005, TRENDS BIOCHEM SCI, V30, P66, DOI 10.1016/j.tibs.2004.12.001; Ragvin A, 2004, J MOL BIOL, V337, P773, DOI 10.1016/j.jmb.2004.01.051; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Sinclair DAR, 1998, DEVELOPMENT, V125, P1207; Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Tsai CC, 2004, VITAM HORM, V68, P93; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wei LN, 2003, ANNU REV PHARMACOL, V43, P47, DOI 10.1146/annurev.pharmtox.43.100901.140301	50	118	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17588	17598		10.1074/jbc.M512616200	http://dx.doi.org/10.1074/jbc.M512616200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16606617	hybrid			2022-12-25	WOS:000238490300008
J	Gottig, N; Elias, EV; Quiroga, R; Nores, MJ; Solari, AJ; Touz, MC; Lujan, HD				Gottig, Natalia; Elias, Eliana V.; Quiroga, Rodrigo; Nores, Maria J.; Solari, Alberto J.; Touz, Maria C.; Lujan, Hugo D.			Active and passive mechanisms drive secretory granule biogenesis during differentiation of the intestinal parasite Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYST WALL; PRIMITIVE EUKARYOTE; ENDOPLASMIC-RETICULUM; PROTEIN TRAFFICKING; CARBOXYPEPTIDASE E; REGULATED PATHWAY; SURFACE PROTEIN; GOLGI STACK; ENCYSTATION; EXPRESSION	The parasitic protozoan Giardia lamblia undergoes important changes to survive outside the intestine of its host by differentiating into infective cysts. During encystation, three cyst wall proteins (CWPs) are specifically expressed and concentrated within encystation-specific secretory vesicles (ESVs). ESVs are electron-dense secretory granules that transport CWPs before exocytosis and extracellular polymerization into a rigid cyst wall. Because secretory granules form at the trans-Golgi in higher eukaryotes and because Giardia lacks an identifiable Golgi apparatus, the aim of this work was to investigate the molecular basis of secretory granule formation in Giardia by examining the role of CWPs in this process. Although CWP1, CWP2, and CWP3 are structurally similar in their 26-kDa leucine-rich overlapping region, CWP2 is distinguished by the presence of a 13-kDa C-terminal basic extension. In non-encysting trophozoites, expression of different CWP chimeras showed that the CWP2 basic extension is necessary for biogenesis of ESVs, which occurs in a compartment derived from the endoplasmic reticulum. Nevertheless, the CWP2 basic extension per se is insufficient to trigger ESV formation, indicating that other domains in CWPs are also required. We found that CWP2 is a key regulator of ESV formation by acting as an aggregation factor for CWP1 and CWP3 through interactions mediated by its conserved region. CWP2 also acts as a ligand for sorting via its C-terminal basic extension. These findings show that granule biogenesis requires complex interactions among granule components and membrane receptors.	Consejo Nacl Invest Cient & Tecn, Inst Invest Med Mercedes & Martin Ferreyra, RA-5000 Cordoba, Argentina; Univ Nacl Buenos Aires, Fac Med, Ctr Invest Reprod, RA-1121 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Lujan, HD (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Invest Med Mercedes & Martin Ferreyra, Friuli 2434, RA-5000 Cordoba, Argentina.	hlujan@immf.uncor.edu	Quiroga, Rodrigo/GLT-7145-2022; Elias, Eliana Vanina/AAF-1997-2021	Quiroga, Rodrigo/0000-0001-5015-0531; TOUZ, MARIA/0000-0002-6769-6896; Solari, Alberto J./0000-0002-3497-9742				Abdul-Wahid A, 2004, BIOCHEM BIOPH RES CO, V324, P1069, DOI 10.1016/j.bbrc.2004.09.167; Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; Alvarez C, 1999, J CELL BIOL, V147, P1205, DOI 10.1083/jcb.147.6.1205; Arias AE, 2000, J CELL SCI, V113, P2075; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; Benchimol M, 2004, FEMS MICROBIOL LETT, V235, P81, DOI [10.1016/j.femsle.2004.04.014, 10.1111/j.1574-6968.2004.tb09570.x]; Blagoveshchenskaya AD, 2002, MOL BIOL CELL, V13, P1582, DOI 10.1091/mbc.01-09-0462; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; BUSER CA, 1995, MOL MEMBR BIOL, V12, P69, DOI 10.3109/09687689509038498; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; Davids BJ, 2004, MOL BIOCHEM PARASIT, V136, P173, DOI 10.1016/j.molbiopara.2004.03.011; FAUBERT G, 1991, EXP PARASITOL, V72, P345, DOI 10.1016/0014-4894(91)90080-G; Geiser M, 2001, BIOTECHNIQUES, V31, P88, DOI 10.2144/01311st05; GILLIN FD, 1991, PARASITOL TODAY, V7, P113, DOI 10.1016/0169-4758(91)90169-O; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; Hehl AB, 2000, MOL BIOL CELL, V11, P1789, DOI 10.1091/mbc.11.5.1789; Hehl AB, 2004, MOL MICROBIOL, V53, P19, DOI 10.1111/j.1365-2958.2004.04115.x; Heidtman M, 2005, MOL BIOL CELL, V16, P1673, DOI 10.1091/mbc.E04-10-0873; Huh YH, 2003, J BIOL CHEM, V278, P40581, DOI 10.1074/jbc.M304942200; Irminger JC, 1997, J BIOL CHEM, V272, P27532, DOI 10.1074/jbc.272.44.27532; Joiner KA, 2002, J CELL BIOL, V157, P557, DOI 10.1083/jcb.200112144; Kaasch AJ, 2000, CURR OPIN MICROBIOL, V3, P422, DOI 10.1016/S1369-5274(00)00115-6; Kawagoe Y, 2005, PLANT CELL, V17, P1141, DOI 10.1105/tpc.105.030668; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Lanfredi-Rangel A, 1999, FEMS MICROBIOL LETT, V181, P245, DOI [10.1016/S0378-1097(99)00546-7, 10.1111/j.1574-6968.1999.tb08851.x]; Lanfredi-Rangel A, 2003, J STRUCT BIOL, V143, P153, DOI 10.1016/S1047-8477(03)00123-0; LEVANONY H, 1992, J CELL BIOL, V119, P1117, DOI 10.1083/jcb.119.5.1117; Lujan HD, 1996, BIOL CELL, V86, P11, DOI 10.1016/0248-4900(96)89519-0; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; LUJAN HD, 1995, J BIOL CHEM, V270, P4612, DOI 10.1074/jbc.270.9.4612; Lujan HD, 2003, CELL MICROBIOL, V5, P427, DOI 10.1046/j.1462-5822.2003.00284.x; Lujan HD, 1997, MICROBIOL MOL BIOL R, V61, P294; Marti M, 2003, TRENDS PARASITOL, V19, P440, DOI 10.1016/S1471-4922(03)00201-0; Marti M, 2003, J BIOL CHEM, V278, P24837, DOI 10.1074/jbc.M302082200; Marti M, 2003, MOL BIOL CELL, V14, P1433, DOI 10.1091/mbc.E02-08-0467; McArthur AG, 2001, MOL BIOL EVOL, V18, P1455, DOI 10.1093/oxfordjournals.molbev.a003931; MCCAFFERY JM, 1994, EXP PARASITOL, V79, P220, DOI 10.1006/expr.1994.1086; MCCAFFERY JM, 1994, EXP PARASITOL, V79, P236, DOI 10.1006/expr.1994.1087; Michaux G, 2004, TRAFFIC, V5, P69, DOI 10.1111/j.1600-0854.2004.00157.x; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; NASH TE, 1992, MOL BIOCHEM PARASIT, V51, P219, DOI 10.1016/0166-6851(92)90072-R; NASH TE, 1988, J IMMUNOL, V141, P636; Ngo HM, 2004, MOL MICROBIOL, V52, P1531, DOI 10.1111/j.1365-2958.2004.04056.x; RAMBOURG A, 1992, ANAT RECORD, V232, P169, DOI 10.1002/ar.1092320202; REINER DS, 1990, EUR J CELL BIOL, V53, P142; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; Stefanic S, 2006, J BIOL CHEM, V281, P7595, DOI 10.1074/jbc.M510940200; Sun CH, 2003, J BIOL CHEM, V278, P21701, DOI 10.1074/jbc.M302023200; Thiele C, 1997, CURR BIOL, V7, pR496, DOI 10.1016/S0960-9822(06)00247-8; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D; Touz MC, 2002, BIOCHEM J, V364, P703, DOI 10.1042/BJ20020025; Touz MC, 2003, J BIOL CHEM, V278, P6420, DOI 10.1074/jbc.M208354200; Touz MC, 2002, J BIOL CHEM, V277, P50557, DOI 10.1074/jbc.M202558200; Touz MC, 2002, J BIOL CHEM, V277, P8474, DOI 10.1074/jbc.M110250200	58	39	39	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18156	18166		10.1074/jbc.M602081200	http://dx.doi.org/10.1074/jbc.M602081200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16611634	hybrid, Green Published			2022-12-25	WOS:000238490300067
J	Liu, SP; Knafels, JD; Chang, JS; Waszak, GA; Baldwin, ET; Deibel, MR; Thomsen, DR; Homa, FL; Wells, PA; Tory, MC; Poorman, RA; Gao, H; Qiu, XY; Seddon, AP				Liu, Shenping; Knafels, John D.; Chang, Jeanne S.; Waszak, Gregory A.; Baldwin, Eric T.; Deibel, Martin R., Jr.; Thomsen, Darrell R.; Homa, Fred L.; Wells, Peter A.; Tory, Monica C.; Poorman, Roger A.; Gao, Hua; Qiu, Xiayang; Seddon, Andrew P.			Crystal structure of the herpes simplex virus 1 DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; NONNUCLEOSIDE INHIBITORS; HUMAN CYTOMEGALOVIRUS; ANTIVIRAL DRUGS; C-TERMINUS; RESISTANCE; REPLICATION; EXONUCLEASE; ACYCLOVIR; PROGRAM	Herpesviruses are the second leading cause of human viral diseases. Herpes Simplex Virus types 1 and 2 and Varicella-zoster virus produce neurotropic infections such as cutaneous and genital herpes, chickenpox, and shingles. Infections of a lymphotropic nature are caused by cytomegalovirus, HSV-6, HSV-7, and Epstein-Barr virus producing lymphoma, carcinoma, and congenital abnormalities. Yet another series of serious health problems are posed by infections in immunocompromised individuals. Common therapies for herpes viral infections employ nucleoside analogs, such as Acyclovir, and target the viral DNA polymerase, essential for viral DNA replication. Although clinically useful, this class of drugs exhibits a narrow antiviral spectrum, and resistance to these agents is an emerging problem for disease management. Abetter understanding of herpes virus replication will help the development of new safe and effective broad spectrum anti-herpetic drugs that fill an unmet need. Here, we present the first crystal structure of a herpesvirus polymerase, the Herpes Simplex Virus type 1 DNA polymerase, at 2.7 angstrom resolution. The structural similarity of this polymerase to other alpha polymerases has allowed us to construct high confidence models of a replication complex of the polymerase and of Acyclovir as a DNA chain terminator. We propose a novel inhibition mechanism in which a representative of a series of non-nucleosidic viral polymerase inhibitors, the 4-oxo-dihydroquinolines, binds at the polymerase active site interacting non-covalently with both the polymerase and the DNA duplex.	Pfizer Inc, Exploratory Med Sci, Groton, CT 06340 USA	Pfizer	Liu, SP (corresponding author), Pfizer Inc, Exploratory Med Sci, Eastern Point Rd, Groton, CT 06340 USA.	shenping.liu@pfizer.com		Baldwin, Eric/0000-0001-8186-2777				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Bacon TH, 2003, CLIN MICROBIOL REV, V16, P114, DOI 10.1128/CMR.16.1.114-128.2003; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bellizzi JJ, 2000, P NATL ACAD SCI USA, V97, P4573, DOI 10.1073/pnas.080508097; BRUNGER AT, 1992, XPLOR VERSION 3 1; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Coen DM, 2003, NAT REV DRUG DISCOV, V2, P278, DOI 10.1038/nrd1065; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; De Clercq E, 2001, J CLIN VIROL, V22, P73, DOI 10.1016/S1386-6532(01)00167-6; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DIGARD P, 1993, J VIROL, V67, P398, DOI 10.1128/JVI.67.1.398-406.1993; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Gilbert C, 2002, DRUG RESIST UPDATE, V5, P88, DOI 10.1016/S1368-7646(02)00021-3; Huang L, 1999, P NATL ACAD SCI USA, V96, P447, DOI 10.1073/pnas.96.2.447; Hwang YT, 1999, J VIROL, V73, P5326, DOI 10.1128/JVI.73.7.5326-5332.1999; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; KNOPF KW, 1979, EUR J BIOCHEM, V98, P231, DOI 10.1111/j.1432-1033.1979.tb13181.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REARDON JE, 1989, J BIOL CHEM, V264, P7405; Rodriguez AC, 2000, J MOL BIOL, V299, P447, DOI 10.1006/jmbi.2000.3728; Schnute ME, 2005, J MED CHEM, V48, P5794, DOI 10.1021/jm050162b; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Thomsen DR, 2003, J VIROL, V77, P1868, DOI 10.1128/JVI.77.3.1868-1876.2003; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wathen MW, 2002, REV MED VIROL, V12, P167, DOI 10.1002/rmv.354; Zhao YX, 1999, STRUCTURE, V7, P1189, DOI 10.1016/S0969-2126(00)80053-2; Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0	34	133	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18193	18200		10.1074/jbc.M602414200	http://dx.doi.org/10.1074/jbc.M602414200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16638752	hybrid			2022-12-25	WOS:000238490300071
J	Surana, NK; Buscher, AZ; Hardy, GG; Grass, S; Kehl-Fie, T; St Geme, JW				Surana, Neeraj K.; Buscher, Amy Z.; Hardy, Gail G.; Grass, Susan; Kehl-Fie, Thomas; St Geme, Joseph W., III			Translocator proteins in the two-partner secretion family have multiple domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONTYPABLE HAEMOPHILUS-INFLUENZAE; PERTUSSIS FILAMENTOUS HEMAGGLUTININ; CIRCULAR-DICHROISM SPECTRA; OUTER-MEMBRANE PROTEINS; HIGH-LEVEL EXPRESSION; C-TERMINAL DOMAINS; ESCHERICHIA-COLI; BORDETELLA-PERTUSSIS; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE	The two-partner secretion pathway in Gram-negative bacteria consists of a TpsA exoprotein and a cognate TpsB outer membrane translocator protein. Previous work has demonstrated that the TpsB protein forms a beta-barrel structure with pore forming activity and facilitates translocation of the TpsA protein across the outer membrane. In this study, we characterized the functional domains of the Haemophilus influenzae HMW1B protein, a TpsB protein that interacts with the H. influenzae HMW1 adhesin. Using c-Myc epitope tag insertions and cysteine substitution mutagenesis, we discovered that HMW1B contains an N-terminal surface-localized domain, an internal periplasmic domain, and a C-terminal membrane anchor. Functional and biochemical analysis of the c-Myc epitope tag insertions and a series of HMW1B deletion constructs demonstrated that the periplasmic domain is required for secretion of HMW1 and that the C-terminal membrane anchor (HMW1B-(234-545)) is capable of oligomerization and pore formation. Similar to our observations with HMW1B, examination of a Bordetella pertussis TpsB protein called FhaC revealed that the C terminus of FhaC (FhaC-(232-585)) is capable of pore formation. We speculate that all TpsB proteins have a modular structure, with a periplasmic domain that interacts with the cognate TpsA protein and with pore forming activity contained within the C terminus.	Duke Univ, Ctr Med, Childrens Hlth Ctr, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Ctr Med, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Duke University; Duke University; Washington University (WUSTL); Washington University (WUSTL)	St Geme, JW (corresponding author), Duke Univ, Ctr Med, Childrens Hlth Ctr, Dept Pediat, Rm T901,DUMC 3352, Durham, NC 27710 USA.	j.stgeme@duke.edu		Kehl-Fie, Thomas/0000-0001-8234-1113; Hardy, Gail/0000-0002-6101-4217	NHLBI NIH HHS [T32 HL 007317] Funding Source: Medline; NIAID NIH HHS [T32 AI 07172] Funding Source: Medline; NIDCD NIH HHS [R01 DC 02873] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002873] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BARENKAMP SJ, 1994, INFECT IMMUN, V62, P3320, DOI 10.1128/IAI.62.8.3320-3328.1994; BARENKAMP SJ, 1992, INFECT IMMUN, V60, P1302, DOI 10.1128/IAI.60.4.1302-1313.1992; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; CARLONE GM, 1986, J CLIN MICROBIOL, V24, P330, DOI 10.1128/JCM.24.3.330-332.1986; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Clantin B, 2004, P NATL ACAD SCI USA, V101, P6194, DOI 10.1073/pnas.0400291101; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Geme JWS, 1998, MOL MICROBIOL, V27, P617; Grass S, 2000, MOL MICROBIOL, V36, P55, DOI 10.1046/j.1365-2958.2000.01812.x; Grass S, 2003, MOL MICROBIOL, V48, P737, DOI 10.1046/j.1365-2958.2003.03450.x; Guedin S, 2000, J BIOL CHEM, V275, P30202, DOI 10.1074/jbc.M005515200; Henderson NS, 2004, J BIOL CHEM, V279, P53747, DOI 10.1074/jbc.M409192200; Jacob-Dubuisson F, 1999, J BIOL CHEM, V274, P37731, DOI 10.1074/jbc.274.53.37731; Jacob-Dubuisson F, 2001, MOL MICROBIOL, V40, P306, DOI 10.1046/j.1365-2958.2001.02278.x; JacobDubuisson F, 1997, J BACTERIOL, V179, P775, DOI 10.1128/jb.179.3.775-783.1997; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; KASUGA TADAYOSHI, 1954, KITASATO ARCH EXPTL MED, V27, P37; Konninger UW, 1999, MOL MICROBIOL, V32, P1212, DOI 10.1046/j.1365-2958.1999.01433.x; Lee HW, 2003, BIOCHEM BIOPH RES CO, V307, P820, DOI 10.1016/S0006-291X(03)01269-5; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; NAKAMURA K, 1976, J BIOCHEM, V80, P1411, DOI 10.1093/oxfordjournals.jbchem.a131414; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; Prilipov A, 1998, FEMS MICROBIOL LETT, V163, P65, DOI 10.1111/j.1574-6968.1998.tb13027.x; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J, 2001, MOL CLONING LAB MANU; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHIEBEL E, 1989, J BIOL CHEM, V264, P16311; SCHIRMER T, 1993, PROTEIN SCI, V2, P1361, DOI 10.1002/pro.5560020820; Schulz GE, 2000, CURR OPIN STRUC BIOL, V10, P443, DOI 10.1016/S0959-440X(00)00120-2; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; STGEME JW, 1993, P NATL ACAD SCI USA, V90, P2875, DOI 10.1073/pnas.90.7.2875; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUGAWARA E, 1992, J BIOL CHEM, V267, P2507; Surana NK, 2004, P NATL ACAD SCI USA, V101, P14497, DOI 10.1073/pnas.0404679101; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; Veiga E, 2002, EMBO J, V21, P2122, DOI 10.1093/emboj/21.9.2122; WILLEMS RJL, 1994, MOL MICROBIOL, V11, P337, DOI 10.1111/j.1365-2958.1994.tb00314.x; YOSHIMURA F, 1983, J BIOL CHEM, V258, P2308	43	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18051	18058		10.1074/jbc.M600036200	http://dx.doi.org/10.1074/jbc.M600036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16648638	hybrid			2022-12-25	WOS:000238490300056
J	Henshaw, J; Horne-Bitschy, A; van Bueren, AL; Money, VA; Bolam, DN; Czjzek, M; Ekborg, NA; Weiner, RM; Hutcheson, SW; Davies, GJ; Boraston, AB; Gilbert, HJ				Henshaw, Joanna; Horne-Bitschy, Ami; van Bueren, Alicia Lammerts; Money, Victoria A.; Bolam, David N.; Czjzek, Mirjam; Ekborg, Nathan A.; Weiner, Ronald M.; Hutcheson, Steven W.; Davies, Gideon J.; Boraston, Alisdair B.; Gilbert, Harry J.			Family 6 carbohydrate binding modules in beta-agarases display exquisite selectivity for the non-reducing termini of agarose chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; CELLULOMONAS-FIMI; RECOGNITION; XYLANASE; PROTEIN; DOMAINS; SITES; REVEALS; COMPLEX; GLUCOAMYLASE	Carbohydrate recognition is central to the biological and industrial exploitation of plant structural polysaccharides. These insoluble polymers are recalcitrant to microbial degradation, and enzymes that catalyze this process generally contain non-catalytic carbohydrate binding modules (CBMs) that potentiate activity by increasing substrate binding. Agarose, a repeat of the disaccharide 3,6-anhydro-alpha-L-galactose-(1,3)-beta-D-galactopyranose-(1,4), is the dominant matrix polysaccharide in marine algae, yet the role of CBMs in the hydrolysis of this important polymer has not previously been explored. Here we show that family 6 CBMs, present in two different beta-agarases, bind specifically to the non-reducing end of agarose chains, recognizing only the first repeat of the disaccharide. The crystal structure of one of these modules Aga16B-CBM6-2, in complex with neoagarohexaose, reveals the mechanism by which the protein displays exquisite specificity, targeting the equatorial O4 and the axial O3 of the anhydro-L-galactose. Targeting of the CBM6 to the non-reducing end of agarose chains may direct the appended catalytic modules to areas of the plant cell wall attacked by beta-agarases where the matrix polysaccharide is likely to be more amenable to further enzymic hydrolysis.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ Paris 06, CNRS, Stn Biol Roscoff, UMR 7139, F-29682 Roscoff, France; Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA	Newcastle University - UK; University of Victoria; University of York - UK; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; University System of Maryland; University of Maryland College Park	Gilbert, HJ (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	H.J.Gilbert@ncl.ac.uk	Money, Victoria/E-8851-2013; Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X; Boraston, Alisdair/0000-0001-6417-0592; Bolam, David/0000-0003-0314-3122	Biotechnology and Biological Sciences Research Council [BB/C005074/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Abou Hachem M, 2000, BIOCHEM J, V345, P53, DOI 10.1042/0264-6021:3450053; Abou-Hachem M, 2002, BIOCHEMISTRY-US, V41, P5720, DOI 10.1021/bi012094a; Allouch J, 2004, STRUCTURE, V12, P623, DOI 10.1016/j.str.2004.02.020; ARNOTT S, 1974, J MOL BIOL, V90, P269, DOI 10.1016/0022-2836(74)90372-6; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bolam DN, 2004, J BIOL CHEM, V279, P22953, DOI 10.1074/jbc.M313317200; Bolam DN, 2001, BIOCHEMISTRY-US, V40, P2468, DOI 10.1021/bi002564l; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2005, BIOCHEM J, V385, P479, DOI 10.1042/BJ20041473; Boraston AB, 2006, J BIOL CHEM, V281, P587, DOI 10.1074/jbc.M509958200; Boraston AB, 2003, J BIOL CHEM, V278, P6120, DOI 10.1074/jbc.M209554200; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Boraston AB, 2003, J MOL BIOL, V327, P659, DOI 10.1016/S0022-2836(03)00152-9; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Boudet AM, 2003, TRENDS PLANT SCI, V8, P576, DOI 10.1016/j.tplants.2003.10.001; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Carvalho AL, 2004, J BIOL CHEM, V279, P34785, DOI 10.1074/jbc.M405867200; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Coutinho PM, 1999, ROY SOC CH, P3; Creagh AL, 1996, P NATL ACAD SCI USA, V93, P12229, DOI 10.1073/pnas.93.22.12229; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; Ekborg NA, 2006, APPL ENVIRON MICROB, V72, P3396, DOI 10.1128/AEM.72.5.3396-3405.2006; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERREIRA LMA, 1993, BIOCHEM J, V294, P349, DOI 10.1042/bj2940349; Flint J, 2005, J BIOL CHEM, V280, P23718, DOI 10.1074/jbc.M501551200; Freelove ACJ, 2001, J BIOL CHEM, V276, P43010, DOI 10.1074/jbc.M107143200; Giardina T, 2001, J MOL BIOL, V313, P1149, DOI 10.1006/jmbi.2001.5097; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Haggett NMW, 1997, J MOL MODEL, V3, P301; Hazlewood GP, 1998, PROG NUCLEIC ACID RE, V61, P211, DOI 10.1016/S0079-6603(08)60828-4; Henrissat B, 1998, FEBS LETT, V425, P352, DOI 10.1016/S0014-5793(98)00265-8; Henshaw JL, 2004, J BIOL CHEM, V279, P21552, DOI 10.1074/jbc.M401620200; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jamal-Talabani S, 2004, STRUCTURE, V12, P1177, DOI 10.1016/j.str.2004.04.022; KELLETT LE, 1990, BIOCHEM J, V272, P369, DOI 10.1042/bj2720369; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Labropoulos KC, 2002, CARBOHYD POLYM, V50, P393, DOI 10.1016/S0144-8617(02)00084-X; Leslie AGW, 1992, RECENT CHANGES MOSFL; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; MAGLIONE G, 1992, APPL ENVIRON MICROB, V58, P3593, DOI 10.1128/AEM.58.11.3593-3597.1992; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Notenboom V, 2001, BIOCHEMISTRY-US, V40, P6248, DOI 10.1021/bi0101704; Pell G, 2003, BIOCHEMISTRY-US, V42, P9316, DOI 10.1021/bi0347510; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Pires VMR, 2004, J BIOL CHEM, V279, P21560, DOI 10.1074/jbc.M401599200; Proctor MR, 2005, P NATL ACAD SCI USA, V102, P2697, DOI 10.1073/pnas.0500051102; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Simpson PJ, 2002, BIOCHEMISTRY-US, V41, P5712, DOI 10.1021/bi012093i; Southall SM, 1999, FEBS LETT, V447, P58, DOI 10.1016/S0014-5793(99)00263-X; Subramaniyan S, 2002, CRIT REV BIOTECHNOL, V22, P33, DOI 10.1080/07388550290789450; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; Vaaje-Kolstad G, 2005, J BIOL CHEM, V280, P28492, DOI 10.1074/jbc.M504468200; van Bueren AL, 2005, J BIOL CHEM, V280, P530, DOI 10.1074/jbc.M410113200; Warren RAJ, 1996, ANNU REV MICROBIOL, V50, P183, DOI 10.1146/annurev.micro.50.1.183; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z	61	68	69	1	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17099	17107		10.1074/jbc.M600702200	http://dx.doi.org/10.1074/jbc.M600702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16601125	hybrid			2022-12-25	WOS:000238326300033
J	Sangadala, S; Boden, SD; Viggeswarapu, M; Liu, YS; Titus, L				Sangadala, Sreedhara; Boden, Scott D.; Viggeswarapu, Manjula; Liu, Yunshan; Titus, Louisa			LIM mineralization protein-1 potentiates bone morphogenetic protein responsiveness via a novel interaction with Smurf1 resulting in decreased ubiquitination of Smads	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; OSTEOBLAST DIFFERENTIATION; DEGRADATION; LIGASE; LMP-1; VIVO; PATHWAY; TRANSCRIPTION; TRANSDUCTION; RECEPTOR	Development and repair of the skeletal system and other organs is highly dependent on precise regulation of bone morphogenetic proteins (BMPs), their receptors, and their intracellular signaling proteins known as Smads. The use of BMPs clinically to induce bone formation has been limited in part by the requirement of much higher doses of recombinant proteins in primates than were needed in cell culture or rodents. Therefore, control of cellular responsiveness to BMPs is now a critical area that is poorly understood. We determined that LMP-1, a LIM domain protein capable of inducing de novo bone formation, interacts with Smurf1 (Smad ubiquitin regulatory factor 1) and prevents ubiquitination of Smads. In the region of LMP responsible for bone formation, there is a motif that directly interacts with the Smurf1 WW2 domain and can effectively compete with Smad1 and Smad5 for binding. We have shown that small peptides containing this motif can mimic the ability to block Smurf1 from binding Smads. This novel interaction of LMP-1 with the WW2 domain of Smurf1 to block Smad binding results in increased cellular responsiveness to exogenous BMP and demonstrates a novel regulatory mechanism for the BMP signaling pathway.	Atlanta Vet Affairs Med Ctr, Atlanta, GA 30329 USA; Emory Univ, Sch Med, Dept Orthopaed Surg, Atlanta, GA 30329 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University	Boden, SD (corresponding author), 59 Execut Pk S,Suite 3000, Atlanta, GA 30329 USA.	Scott_boden@emory.org						Boden SD, 1998, SPINE, V23, P2486, DOI 10.1097/00007632-199812010-00003; Boden SD, 1998, ENDOCRINOLOGY, V139, P5125, DOI 10.1210/en.139.12.5125; Boden SD, 2002, SPINE, V27, P2662, DOI 10.1097/00007632-200212010-00005; Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623-200308000-00017; Diefenderfer DL, 2003, J BONE JOINT SURG AM, V85A, P19, DOI 10.2106/00004623-200300003-00005; Ducy P, 2000, KIDNEY INT, V57, P2207, DOI 10.1046/j.1523-1755.2000.00081.x; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198; Goulet JA, 1997, CLIN ORTHOP RELAT R, P76; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; Guy PM, 1999, MOL BIOL CELL, V10, P1973, DOI 10.1091/mbc.10.6.1973; Hassel S, 2003, J BONE JOINT SURG AM, V85A, P44, DOI 10.2106/00004623-200300003-00009; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu YS, 2004, BONE, V35, P673, DOI 10.1016/j.bone.2004.04.017; Liu YS, 2002, J BONE MINER RES, V17, P406, DOI 10.1359/jbmr.2002.17.3.406; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Martin GJ, 1999, J SPINAL DISORD, V12, P179, DOI 10.1097/00002517-199906000-00001; Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137; Minamide A, 2003, J BONE JOINT SURG AM, V85A, P1030, DOI 10.2106/00004623-200306000-00007; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Nakayama T, 1998, GENES CELLS, V3, P387, DOI 10.1046/j.1365-2443.1998.00196.x; Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744; ten Dijke P, 2003, J BONE JOINT SURG AM, V85A, P34; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955-2235(89)90015-X; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Ying SX, 2003, J BIOL CHEM, V278, P39029, DOI 10.1074/jbc.M301193200; Yoon ST, 2004, SPINE, V29, P2603, DOI 10.1097/01.brs.0000146103.94600.85; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	37	51	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17212	17219		10.1074/jbc.M511013200	http://dx.doi.org/10.1074/jbc.M511013200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16611643	hybrid			2022-12-25	WOS:000238326300047
J	Alana, I; Parker, JC; Gault, VA; Flatt, PR; O'Harte, FPM; Malthouse, JPG; Hewage, CM				Alana, Inigo; Parker, Jeremy C.; Gault, Victor A.; Flatt, Peter R.; O'Harte, Finbarr P. M.; Malthouse, J. Paul G.; Hewage, Chandralal M.			NMR and alanine scan studies of glucose-dependent insulinotropic polypeptide in water	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE-1; PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM; GIP; DEGRADATION; ANALOGS; SPECTRA; PROGRAM	Glucose-dependent insulinotropic polypeptide ( GIP) is an incretin hormone that stimulates the secretion of insulin after ingestion of food. GIP also promotes the synthesis of fatty acids in adipose tissue. Therefore, it is not surprising that numerous literature reports have shown that GIP is linked to diabetes and obesity-related diseases. In this study, we present the solution structure of GIP in water determined by NMR spectroscopy. The calculated structure is characterized by the presence of an alpha-helical motif between residues Ser11 and Gln29. The helical conformation of GIP is further supported by CD spectroscopic studies. Six GIP-( 1-42) Ala(1-7) analogues were synthesized by replacing individual N-terminal residues with alanine. Alanine scan studies of these N-terminal residues showed that the GIP-( 1-42) Ala(6) was the only analogue to show insulin-secreting activity similar to that of the native GIP. However, when compared with glucose, its insulinotropic ability was reduced. For the first time, these NMR and modeling results contribute to the understanding of the structural requirements for the biological activity of GIP.	Univ Coll Dublin, Sch Biomol & Biomed Sci, Ctr Synth & Chem Biol, UCD Conway Inst, Dublin 4, Ireland; Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland	University College Dublin; Ulster University	Hewage, CM (corresponding author), Univ Coll Dublin, Sch Biomol & Biomed Sci, Ctr Synth & Chem Biol, UCD Conway Inst, Dublin 4, Ireland.	Chandralal.Hewage@ucd.ie	Malthouse, Jonathan/AAP-8357-2020	Malthouse, Jonathan/0000-0002-8372-6549; O'Harte, Finbarr/0000-0002-7199-4239; Parker, Jeremy/0000-0002-3935-7563; HEWAGE, CHANDRALAL/0000-0002-6626-3829; Gault, Victor/0000-0001-8501-1013; Flatt, Peter/0000-0001-8548-7943				Ahren B, 2005, ENDOCRINOLOGY, V146, P2055, DOI 10.1210/en.2004-1174; Alana I, 2004, BIOCHEM BIOPH RES CO, V325, P281, DOI 10.1016/j.bbrc.2004.10.033; Andersen NH, 2002, BIOORGAN MED CHEM, V10, P79, DOI 10.1016/S0968-0896(01)00263-2; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BORGIAS BA, 1988, J MAGN RESON, V79, P493, DOI 10.1016/0022-2364(88)90085-6; Brandt I, 2005, BIOCHEM PHARMACOL, V70, P134, DOI 10.1016/j.bcp.2005.04.009; BUCHAN AMJ, 1978, HISTOCHEMISTRY, V56, P37, DOI 10.1007/BF00492251; Chang XQ, 2001, MAGN RESON CHEM, V39, P477, DOI 10.1002/mrc.880; Deacon CF, 2001, DIABETES, V50, P1588, DOI 10.2337/diabetes.50.7.1588; Ehses JA, 2003, ENDOCRINOLOGY, V144, P4433, DOI 10.1210/en.2002-0068; FLATT PR, 1981, DIABETOLOGIA, V20, P573; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Gault VA, 2003, CELL BIOL INT, V27, P41, DOI 10.1016/S1065-6995(02)00255-X; Gault VA, 2002, J ENDOCRINOL, V175, P525, DOI 10.1677/joe.0.1750525; GODDARD TD, 2005, SPARKY, V3; Green BD, 2005, DIABETES OBES METAB, V7, P595, DOI 10.1111/j.1463-1326.2004.00455.x; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hinke SA, 2004, LIFE SCI, V75, P1857, DOI 10.1016/j.lfs.2004.03.024; Holst JJ, 2002, BIODRUGS, V16, P175, DOI 10.2165/00063030-200216030-00002; Irwin N, 2005, J PHARMACOL EXP THER, V314, P1187, DOI 10.1124/jpet.105.086082; Kelly SM, 2000, CURR PROTEIN PEPT SC, V1, P349, DOI 10.2174/1389203003381315; Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lobley A, 2001, BIOPHYS J, V80, p373A; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Manhart S, 2003, BIOCHEMISTRY-US, V42, P3081, DOI 10.1021/bi026868e; McClenaghan NH, 1996, DIABETES, V45, P1132, DOI 10.2337/diabetes.45.8.1132; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; Miyawaki K, 2002, NAT MED, V8, P738, DOI 10.1038/nm727; O'Harte FPM, 2002, DIABETOLOGIA, V45, P1281, DOI 10.1007/s00125-002-0894-6; OBEN J, 1991, J ENDOCRINOL, V130, P267, DOI 10.1677/joe.0.1300267; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; *TRIP INC, 2005, TRIP SYBYL FORC FIEL; Trumper A, 2001, MOL ENDOCRINOL, V15, P1559, DOI 10.1210/me.15.9.1559; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2	41	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16370	16376		10.1074/jbc.M510414200	http://dx.doi.org/10.1074/jbc.M510414200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16621806	hybrid			2022-12-25	WOS:000238165700025
J	Chen, BS; Braud, S; Badger, JD; Isaac, JTR; Roche, KW				Chen, Bo-Shiun; Braud, Stephanie; Badger, John D., II; Isaac, John T. R.; Roche, Katherine W.			Regulation of NR1/NR2C N-methyl-D-aspartate (NMDA) receptors by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; AMPA RECEPTOR; SYNAPTIC PLASTICITY; DEVELOPING CEREBELLUM; GLUTAMATE RECEPTORS; SURFACE EXPRESSION; GUANYLATE KINASES; GLUR1 SUBUNIT; C-TERMINUS; TRAFFICKING	NR2C-containing N-methyl-D-aspartate (NMDA) receptors are highly expressed in cerebellar granule cells where they mediate the majority of current in the adult. NMDA receptors composed of NR1/NR2C exhibit a low conductance and reduced sensitivity to Mg2+, compared with the more commonly studied NR2A- and NR2B-containing receptors. Despite these interesting features, very little is known about the regulation of NR2C function. Here we investigate the role of phosphorylation of NR2C in regulating NMDA receptor trafficking and ion channel properties. We identify a phosphorylation site, serine 1244 (Ser(1244)), near the extreme COOH terminus of NR2C, which is phosphorylated by both cAMP-dependent protein kinase and protein kinase C. This residue is located adjacent to the consensus PDZ ligand, a region that regulates protein-protein interactions and receptor trafficking in NR2A and NR2B. We show that Ser(1244) on NR2C is phosphorylated in vitro, in heterologous cells, and in neurons. Moreover, we demonstrate for the first time that NR2C interacts with the PSD-95 family of PDZ domain-containing proteins but that phosphorylation of Ser(1244) does not influence this PDZ interaction. Furthermore, Ser(1244) phosphorylation does not regulate surface expression of NR1/NR2C receptors. However, we find that this site does regulate the kinetics of the ion channel: a phosphomimetic mutation at Ser(1244) accelerates both the rise and decay of NMDA-evoked currents in excised patches from HEK-293 cells. Therefore, phosphorylation of Ser(1244) does not regulate trafficking but unexpectedly affects ion channel function, suggesting that phosphorylation of Ser(1244) on NR2C may be important in defining the functional properties of NMDA receptor-mediated currents in the cerebellum.	NINDS, NIH, Bethesda, MD 20892 USA; Univ Bristol, Dept Anat, MRC, Ctr Synapt Plast, Bristol BS8 1TD, Avon, England	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Bristol	Roche, KW (corresponding author), NINDS, NIH, Bldg 35,Rm 2C903, Bethesda, MD 20892 USA.	rochek@ninds.nih.gov	Chen, Bo-Shiun/E-2736-2010; Chen, Bo-Shiun/H-4633-2012; Roche, Katherine/W-9893-2019	Roche, Katherine/0000-0001-7282-6539	Intramural NIH HHS Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002994, ZIANS003011, Z01NS002994, Z01NS003011] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Chung HJ, 2000, J NEUROSCI, V20, P7258; Chung HJ, 2004, J NEUROSCI, V24, P10248, DOI 10.1523/JNEUROSCI.0546-04.2004; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Crump FT, 2001, J NEUROSCI, V21, P5079, DOI 10.1523/JNEUROSCI.21-14-05079.2001; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; FARRANT M, 1994, NATURE, V368, P335, DOI 10.1038/368335a0; Fu ZY, 2005, J PHYSIOL-LONDON, V563, P867, DOI 10.1113/jphysiol.2004.079467; Hayashi T, 2004, J NEUROSCI, V24, P6152, DOI 10.1523/JNEUROSCI.0799-04.2004; Hayes DM, 2003, BIOCHEM BIOPH RES CO, V310, P8, DOI 10.1016/j.bbrc.2003.08.115; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; Lavezzari G, 2004, J NEUROSCI, V24, P6383, DOI 10.1523/JNEUROSCI.1890-04.2004; Lavezzari G, 2003, NEUROPHARMACOLOGY, V45, P729, DOI 10.1016/S0028-3908(03)00308-3; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Song I, 2002, TRENDS NEUROSCI, V25, P578, DOI 10.1016/S0166-2236(02)02270-1; Suzuki K, 2005, J NEUROSCI, V25, P9535, DOI 10.1523/JNEUROSCI.2191-05.2005; Takahashi T, 1996, J NEUROSCI, V16, P4376; Vicini S, 1998, J NEUROPHYSIOL, V79, P555, DOI 10.1152/jn.1998.79.2.555; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N	35	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16583	16590		10.1074/jbc.M513029200	http://dx.doi.org/10.1074/jbc.M513029200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16606616	hybrid			2022-12-25	WOS:000238165700050
J	Layer, G; Ollagnier-de Choudens, S; Sanakis, Y; Fontecave, M				Layer, Gunhild; Ollagnier-de Choudens, Sandrine; Sanakis, Yiannis; Fontecave, Marc			Iron-sulfur cluster biosynthesis - Characterization of Escherichia coli CyaY as an iron donor for the assembly of [2Fe-2S] clusters in the scaffold IscU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRATAXIN HOMOLOG YFH1; SALMONELLA-ENTERICA; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; HEME-SYNTHESIS; FE/S PROTEINS; YGGX PROTEIN; GENE-CLUSTER; DNA-DAMAGE; IN-VIVO	The biogenesis of iron-sulfur [ Fe-S] clusters requires the coordinated delivery of both iron and sulfide. Sulfide is provided by cysteine desulfurases that use L-cysteine as sulfur source. So far, the physiological iron donor has not been clearly identified. CyaY, the bacterial ortholog of frataxin, an iron binding protein thought to be involved in iron-sulfur cluster formation in eukaryotes, is a good candidate because it was shown to bind iron. Nevertheless, no functional in vitro studies showing an involvement of CyaY in [ Fe-S] cluster biosynthesis have been reported so far. In this paper we demonstrate for the first time a specific interaction between CyaY and IscS, a cysteine desulfurase participating in iron-sulfur cluster assembly. Analysis of the iron-loaded CyaY protein demonstrated a strong binding of Fe3+ and a weak binding of Fe2+ by CyaY. Biochemical analysis showed that the CyaY-Fe3+ protein corresponds to a mixture of monomer, intermediate forms ( dimer-pentamers), and oligomers with the intermediate one corresponding to the only stable and soluble iron-containing form of CyaY. Using spectroscopic methods, this form was further demonstrated to be functional in vitro as an iron donor during [ Fe-S] cluster assembly on the scaffold protein IscU in the presence of IscS and cysteine. All of these results point toward a link between CyaY and [ Fe-S] cluster biosynthesis, and a possible mechanism for the process is discussed.	Univ Grenoble 1, CNRS,UMR 5047, CEA,Ctr Redox Biol, DRDC,Lab Chim & Biochim,CB, F-38054 Grenoble 09, France; NCSR Demokritos, Inst Sci Mat, Athens 15310, Greece; Univ Ioannina, Dept Biol Applicat & Technol, GR-45110 Ioannina, Greece	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); National Centre of Scientific Research "Demokritos"; University of Ioannina	Ollagnier-de Choudens, S (corresponding author), Univ Grenoble 1, CNRS,UMR 5047, CEA,Ctr Redox Biol, DRDC,Lab Chim & Biochim,CB, 17 Ave Martyrs, F-38054 Grenoble 09, France.	sollagnier@cea.fr; mfontecave@cea.fr						Adinolfi S, 2004, EUR J BIOCHEM, V271, P2093, DOI 10.1111/j.1432-1033.2004.04112.x; Adinolfi S, 2002, HUM MOL GENET, V11, P1865, DOI 10.1093/hmg/11.16.1865; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Aloria K, 2004, EMBO REP, V5, P1096, DOI 10.1038/sj.embor.7400272; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Barras F, 2005, ADV MICROB PHYSIOL, V50, P41, DOI 10.1016/S0065-2911(05)50002-X; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Beinert H, 1978, Methods Enzymol, V54, P435; Bou-Abdallah F, 2004, J MOL BIOL, V341, P605, DOI 10.1016/j.jmb.2004.05.072; Bou-Abdallah F, 2002, J BIOL CHEM, V277, P37064, DOI 10.1074/jbc.M205712200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Cho SJ, 2000, P NATL ACAD SCI USA, V97, P8932, DOI 10.1073/pnas.160270897; Crichton R R, 1990, Adv Protein Chem, V40, P281, DOI 10.1016/S0065-3233(08)60288-0; Ding BJ, 2005, BIOCHEM J, V389, P797, DOI 10.1042/BJ20050405; Ding H, 2004, J BIOL CHEM, V279, P37499, DOI 10.1074/jbc.M404533200; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gralnick J, 2001, P NATL ACAD SCI USA, V98, P8030, DOI 10.1073/pnas.151243198; Gralnick JA, 2003, J BIOL CHEM, V278, P20708, DOI 10.1074/jbc.M301577200; Gully D, 2003, FEBS LETT, V548, P90, DOI 10.1016/S0014-5793(03)00746-4; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Huynen MA, 2001, HUM MOL GENET, V10, P2463, DOI 10.1093/hmg/10.21.2463; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Kato S, 2002, P NATL ACAD SCI USA, V99, P5948, DOI 10.1073/pnas.082123599; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Lange H, 2004, J BIOL CHEM, V279, P29101, DOI 10.1074/jbc.M403721200; Lee MG, 2000, ACTA CRYSTALLOGR D, V56, P920, DOI 10.1107/S0907444900005916; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Li DS, 1999, FEBS LETT, V456, P13, DOI 10.1016/S0014-5793(99)00896-0; Lill R, 2005, IUBMB LIFE, V57, P701, DOI 10.1080/15216540500305860; Mihara H, 2002, APPL MICROBIOL BIOT, V60, P12, DOI 10.1007/s00253-002-1107-4; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Nair M, 2004, STRUCTURE, V12, P2037, DOI 10.1016/j.str.2004.08.012; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Nuth M, 2002, J AM CHEM SOC, V124, P8774, DOI 10.1021/ja0264596; O'Neill HA, 2005, BIOCHEMISTRY-US, V44, P537, DOI 10.1021/bi048459j; O'Neill HA, 2005, J MOL BIOL, V345, P433, DOI 10.1016/j.jmb.2004.10.074; Ollagnier-de Choudens S, 2003, J BIOL CHEM, V278, P17993, DOI 10.1074/jbc.M300285200; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Osborne MJ, 2005, PROTEIN SCI, V14, P1673, DOI 10.1110/ps.051358105; Pandolfo M, 2002, MITOCHONDRION, V2, P87, DOI 10.1016/S1567-7249(02)00039-9; Park S, 2003, J BIOL CHEM, V278, P31340, DOI 10.1074/jbc.M303158200; Park S, 2003, J BACTERIOL, V185, P1942, DOI 10.1128/JB.185.6.1942-1950.2003; Ramazzotti A, 2004, FEBS LETT, V557, P215, DOI 10.1016/S0014-5793(03)01498-4; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Skovran E, 2004, J BACTERIOL, V186, P7626, DOI 10.1128/JB.186.22.7626-7634.2004; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Vivas E, 2006, J BACTERIOL, V188, P1175, DOI 10.1128/JB.188.3.1175-1179.2006; Yoon T, 2004, J BIOL CHEM, V279, P25943, DOI 10.1074/jbc.C400107200; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	57	134	138	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16256	16263		10.1074/jbc.M513569200	http://dx.doi.org/10.1074/jbc.M513569200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16603772	hybrid			2022-12-25	WOS:000238165700011
J	Sheth, SS; Bodnar, JS; Ghazalpour, A; Thipphavong, CK; Tsutsumi, S; Tward, AD; Demant, P; Kodama, T; Aburatani, H; Lusis, AJ				Sheth, S. S.; Bodnar, J. S.; Ghazalpour, A.; Thipphavong, C. K.; Tsutsumi, S.; Tward, A. D.; Demant, P.; Kodama, T.; Aburatani, H.; Lusis, A. J.			Hepatocellular carcinoma in Txnip-deficient mice	ONCOGENE			English	Article						hepatocellular carcinoma; mouse model; Txnip; thioredoxin	THIOREDOXIN-INTERACTING PROTEIN; DIFFERENTIALLY EXPRESSED GENES; MESSENGER-RNA; 1,25-DIHYDROXYVITAMIN D-3; COMBINED HYPERLIPIDEMIA; PLASMINOGEN-ACTIVATOR; LIVER-REGENERATION; UP-REGULATION; E-CADHERIN; IN-VITRO	The molecular pathogenesis and the genetic aberrations that lead to the progression of hepato cellular carcinoma (HCC) are largely unknown. Here, we demonstrate that the thioredoxin interacting protein (Txnip) gene is a candidate tumor suppressor gene in vivo. We previously showed that the recombinant inbred congenic strain HcB-19 has a spontaneous mutation of the Txnip gene, and we now show that the strain has dramatically increased incidence of HCC, and that the HCC cosegregates with the Txnip mutation. Approximately 40% of the Txnip deficient mice developed hepatic tumors with an increased prevalence in male mice. Visible tumors develop as early as 8 months of age. Histological analysis confirmed the morphology of HCC in the Txnip-deficient mice. Molecular markers of HCC, alpha-fetoprotein and p53, were increased in tumors of Txnip-deficient mice. The upregulation of p53 preceded tumor development; however, bromodeoxyuridine (BrdU) labeling of normal hepatic tissue of Txnip-deficient mice did not reveal increased cell proliferation. Finally, microarray analyses of tumor, non-tumor adjacent, and normal tissue of Txnip-deficient mice highlighted the genetic differences leading to the predisposition and onset of HCC. Our findings suggest that Txnip de. ciency is sufficient to initiate HCC and suggest novel mechanisms in hepatocarcinogenesis.	Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci 47 123, Dept Human Genet,Mol Biol Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Beckman Coulter Inc, Biomed Res Div, Fullerton, CA USA; Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Tokyo, Japan; Univ Calif San Francisco, Dept Microbiol & Immunol, George Williams Hooper Fdn, San Francisco, CA 94143 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Meguro Ku, Tokyo, Japan; Univ Calif Los Angeles, Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Beckman Coulter Inc.; University of Tokyo; University of California System; University of California San Francisco; Roswell Park Cancer Institute; University of Tokyo; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Lusis, AJ (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci 47 123, Dept Human Genet,Mol Biol Inst, Los Angeles, CA 90095 USA.	jlusis@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28481] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; Bodnar JS, 2002, NAT GENET, V30, P110, DOI 10.1038/ng811; Buendia MA, 2002, MED PEDIATR ONCOL, V39, P530, DOI 10.1002/mpo.10180; Capiati DA, 2004, J CELL BIOCHEM, V93, P384, DOI 10.1002/jcb.20165; Castellani LW, 1998, NAT GENET, V18, P374, DOI 10.1038/ng0498-374; Chen F, 2004, CANCER RES, V64, P5425, DOI 10.1158/0008-5472.CAN-04-0806; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DRAGANI TA, 1989, MOL CARCINOGEN, V2, P355, DOI 10.1002/mc.2940020610; Dudoit S, 2002, GENOME BIOL, V3; Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207; Escrich E, 2004, MOL CARCINOGEN, V40, P73, DOI 10.1002/mc.20028; Faith DA, 2004, PROSTATE, V61, P215, DOI 10.1002/pros.20095; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Furutani M, 1996, HEPATOLOGY, V24, P1441, DOI 10.1053/jhep.1996.v24.pm0008938178; Goldberg SF, 2003, CANCER RES, V63, P432; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; HSU HC, 1993, CANCER RES, V53, P4691; Ikarashi M, 2002, ANTICANCER RES, V22, P4045; Jeon JH, 2005, CANCER RES, V65, P4485, DOI 10.1158/0008-5472.CAN-04-2271; Jiang F, 2004, J BIOL CHEM, V279, P53213, DOI 10.1074/jbc.M410395200; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Koteish A, 2002, ALCOHOL CLIN EXP RES, V26, P1710, DOI 10.1097/01.ALC.0000036923.77613.59; Lee KN, 2005, IMMUNITY, V22, P195, DOI 10.1016/j.immuni.2004.12.012; Lee YI, 2004, J BIOL CHEM, V279, P15460, DOI 10.1074/jbc.M309280200; MARONPOT RR, 1995, TOXICOLOGY, V101, P125, DOI 10.1016/0300-483X(95)03112-S; Minn AH, 2005, ENDOCRINOLOGY, V146, P2397, DOI 10.1210/en.2004-1378; Miyaguchi S, 2000, HEPATO-GASTROENTEROL, V47, P468; Pajukanta P, 2001, MAMM GENOME, V12, P238, DOI 10.1007/s003350010265; Pourgholami MH, 2000, CANCER LETT, V151, P97, DOI 10.1016/S0304-3835(99)00416-4; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Saitoh T, 2001, J NEUROCHEM, V78, P1267, DOI 10.1046/j.1471-4159.2001.00505.x; Scherpereel A, 2003, CANCER RES, V63, P6084; Sergeev IN, 2004, J STEROID BIOCHEM, V89-90, P419, DOI 10.1016/j.jsbmb.2004.03.010; Sheth SS, 2005, J LIPID RES, V46, P123, DOI 10.1194/jlr.M400341-JLR200; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; Solmi R, 2004, INT J ONCOL, V25, P1049; Tackels-Horne D, 2001, CANCER-AM CANCER SOC, V92, P395, DOI 10.1002/1097-0142(20010715)92:2<395::AID-CNCR1335>3.0.CO;2-U; Takahashi Y, 2002, ONCOL REP, V9, P75; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Yamada Y, 1999, LAB INVEST, V79, P1059; Yang XQ, 1998, BREAST CANCER RES TR, V48, P33, DOI 10.1023/A:1005929714900; Zhou L, 2000, PATHOL INT, V50, P392, DOI 10.1046/j.1440-1827.2000.01059.x	50	113	117	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3528	3536		10.1038/sj.onc.1209394	http://dx.doi.org/10.1038/sj.onc.1209394			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16607285				2022-12-25	WOS:000238448200005
J	Alderwick, LJ; Seidel, M; Sahm, H; Besra, GS; Eggeling, L				Alderwick, Luke J.; Seidel, Mathias; Sahm, Hermann; Besra, Gurdyal S.; Eggeling, Lothar			Identification of a novel arabinofuranosyltransferase (AftA) involved in cell wall Arabinan biosynthesis in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACID BIOSYNTHESIS; STRUCTURAL FEATURES; MASS-SPECTROMETRY; ARABINOGALACTAN; ETHAMBUTOL; INACTIVATION; EMB; CORYNEBACTERIANEAE; PEPTIDOGLYCAN; RECOGNITION	The cell wall mycolyl-arabinogalactan-peptidoglycan complex is essential in mycobacterial species, such as Mycobacterium tuberculosis, and is the target of several anti-tubercular drugs. For instance, ethambutol targets arabinogalactan biosynthesis through inhibition of the arabinofuranosyltransferases Mt-EmbA and Mt-EmbB. Following a detailed bioinformatics analysis of genes surrounding the conserved emblocus, we present the identification and characterization of a novel arabinofuranosyltransferase AftA (Rv3792). The enzyme catalyzes the addition of the first key arabinofuranosyl residue from the sugar donor beta-D-arabinofuranosyl-1-monophosphoryldecaprenol to the galactan domain of the cell wall, thus "priming" the galactan for further elaboration by the arabinofuranosyltransferases. Because aftA is an essential gene in M. tuberculosis, we deleted its orthologue in Corynebacterium glutamicum to produce a slow growing but viable mutant. Analysis of its cell wall revealed the complete absence of arabinose resulting in a truncated cell wall structure possessing only a galactan core with a concomitant loss of cell wall-bound mycolates. Complementation of the mutant was fully restored to the wild type phenotype by Cg-aftA. In addition, by developing an in vitro assay using recombinant Escherichia coli expressing Mt-aftA and use of cell wall galactan as an acceptor, we demonstrated the transfer of arabinose from beta-D-arabinofuranosyl-1-monophosphoryldecaprenol to galactan, and unlike the Mt-Emb proteins, Mt-AftA was not inhibited by ethambutol. This newly discovered glycosyltransferase represents an attractive drug target for further exploitation by chemotherapeutic intervention.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Res Ctr, Inst Biotechnol 1, D-52425 Julich, Germany	University of Birmingham	Besra, GS (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	g.besra@bham.ac.uk		Alderwick, Luke/0000-0002-1257-6053; Besra, Gurdyal/0000-0002-5605-0395	MRC [G9901077] Funding Source: UKRI; Medical Research Council [G9901077] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ACHARYA PVN, 1970, J BACTERIOL, V102, P733, DOI 10.1128/JB.102.3.733-739.1970; Alderwick LJ, 2005, J BIOL CHEM, V280, P32362, DOI 10.1074/jbc.M506339200; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; Berg S, 2005, J BIOL CHEM, V280, P5651, DOI 10.1074/jbc.M411418200; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DAFFE M, 1993, CARBOHYD RES, V249, P383, DOI 10.1016/0008-6215(93)84102-C; Dover LG, 2004, FEMS MICROBIOL REV, V28, P225, DOI 10.1016/j.femsre.2003.10.001; Eggeling L, 2005, HDB CORYNEBACTERIUM, P535; Escuyer VE, 2001, J BIOL CHEM, V276, P48854, DOI 10.1074/jbc.M102272200; Gande R, 2004, J BIOL CHEM, V279, P44847, DOI 10.1074/jbc.M408648200; Huang HR, 2005, J BIOL CHEM, V280, P24539, DOI 10.1074/jbc.M504068200; Kremer L, 2001, J BIOL CHEM, V276, P26430, DOI 10.1074/jbc.M102022200; Lee RE, 1998, BIOORG MED CHEM LETT, V8, P951, DOI 10.1016/S0960-894X(98)00147-4; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; Lee RE, 1997, GLYCOBIOLOGY, V7, P1121, DOI 10.1093/glycob/7.8.1121; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; Mikusova K, 2000, J BIOL CHEM, V275, P33890, DOI 10.1074/jbc.M006875200; Mikusova K, 2005, J BACTERIOL, V187, P8020, DOI 10.1128/JB.187.23.8020-8025.2005; Mills JA, 2004, J BIOL CHEM, V279, P43540, DOI 10.1074/jbc.M407782200; Nakamura Y, 2003, GENE, V317, P149, DOI 10.1016/S0378-1119(03)00653-X; Pan F, 2001, J BACTERIOL, V183, P3991, DOI 10.1128/JB.183.13.3991-3998.2001; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; Puech V, 2001, MICROBIOL-SGM, V147, P1365, DOI 10.1099/00221287-147-5-1365; Radmacher E, 2005, MICROBIOL-SGM, V151, P1359, DOI 10.1099/mic.0.27804-0; Sahm H, 2000, BIOL CHEM, V381, P899, DOI 10.1515/BC.2000.111; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; Telenti A, 1997, NAT MED, V3, P567, DOI 10.1038/nm0597-567; Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x	39	121	133	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15653	15661		10.1074/jbc.M600045200	http://dx.doi.org/10.1074/jbc.M600045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595677	hybrid, Green Published			2022-12-25	WOS:000237996000009
J	Brailoiu, E; Churamani, D; Pandey, V; Brailoiu, GC; Tuluc, F; Patel, S; Dun, NJ				Brailoiu, Eugen; Churamani, Dev; Pandey, Vinita; Brailoiu, G. Cristina; Tuluc, Florin; Patel, Sandip; Dun, Nae J.			Messenger-specific role for nicotinic acid adenine dinucleotide phosphate in neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; FROG NEUROMUSCULAR-JUNCTION; NAADP MOBILIZES CA2+; PANCREATIC-ACINAR; INOSITOL TRISPHOSPHATE; CA2+-MOBILIZING MESSENGER; PHEOCHROMOCYTOMA CELLS; TRANSMITTER RELEASE; RYANODINE RECEPTORS; CALCIUM	Cells possess several Ca2+-mobilizing messengers, which couple stimulation at the cell surface by a multitude of extracellular cues to the regulation of intracellular Ca2+-sensitive targets. Recent studies suggest that agonists differentially select from this molecular palette to generate their characteristic Ca2+ signals but it is still unclear whether different messengers mediate different functions or whether they act in a redundant fashion. In this study, we compared the effects of nicotinic acid adenine dinucleotide phosphate (NAADP), a novel Ca2+-mobilizing messenger, with that of the prototypical messenger inositol trisphosphate on cytosolic Ca2+ levels and differentiation status of PC12 cells. We demonstrate that liposomal delivery of NAADP mediated release of Ca2+ from acidic Ca2+ stores and that this stimulus was sufficient to drive differentiation of the cells to a neuronal-like phenotype. In sharp contrast, cell fate was unaffected by more transient Ca2+ signals generated by inositol trisphosphate-evoked release of endoplasmic reticulum Ca2+ stores. Our data establish for the first time (i) the presence of novel NAADP-sensitive Ca2+ stores in PC12 cells, (ii) a role for NAADP in differentiation, and (iii) that Ca2+-dependent function can be messenger-specific. Thus, differential recruitment of intracellular Ca2+-mobilizing messengers and their target Ca2+ stores may represent a robust means of maintaining stimulus fidelity in the control of Ca2+-dependent cell function.	UCL, Dept Physiol, London WC1E 6BT, England; Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19122 USA	University of London; University College London; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Patel, S (corresponding author), UCL, Dept Physiol, Old Squash Courts,Gower St, London WC1E 6BT, England.	patel.s@ucl.ac.uk	Tuluc, Petronel/C-2527-2011; Patel, Sandip/O-9591-2015	Patel, Sandip/0000-0001-7247-2013	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Berridge G, 2002, BIOCHEM J, V365, P295, DOI 10.1042/BJ20020180; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berry DM, 1999, ENDOCRINOLOGY, V140, P4779, DOI 10.1210/en.140.10.4779; Boittin FX, 2002, CIRC RES, V91, P1168, DOI 10.1161/01.RES.0000047507.22487.85; Brailoiu E, 2005, J BIOL CHEM, V280, P5646, DOI 10.1074/jbc.M408746200; Brailoiu E, 2003, BIOCHEM J, V373, P313, DOI 10.1042/BJ20030472; Brailoiu E, 2001, MOL PHARMACOL, V60, P718; Brailoiu E, 2000, NEUROSCIENCE, V95, P927; Burdakov D, 2000, CURR BIOL, V10, P993, DOI 10.1016/S0960-9822(00)00649-7; Cancela JM, 2003, PFLUG ARCH EUR J PHY, V446, P322, DOI 10.1007/s00424-003-1035-x; Cancela JM, 2002, EMBO J, V21, P909, DOI 10.1093/emboj/21.5.909; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Chameau P, 2001, PFLUG ARCH EUR J PHY, V443, P289, DOI 10.1007/s004240100691; Chiarella P, 2004, J CELL SCI, V117, P4127, DOI 10.1242/jcs.01283; Churamani D, 2004, BIOCHEM J, V380, P449, DOI 10.1042/BJ20031754; Churchill GC, 2000, J BIOL CHEM, V275, P38687, DOI 10.1074/jbc.M005827200; Churchill GC, 2001, EMBO J, V20, P2666, DOI 10.1093/emboj/20.11.2666; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; Dammermann W, 2005, J BIOL CHEM, V280, P21394, DOI 10.1074/jbc.M413085200; Das KP, 2004, NEUROTOXICOL TERATOL, V26, P397, DOI 10.1016/j.ntt.2004.02.006; Dickinson GD, 2003, BIOCHEM J, V375, P805, DOI 10.1042/BJ20030672; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Eckfeldt CE, 2005, NAT REV MOL CELL BIO, V6, P726, DOI 10.1038/nrm1713; Ferrari MB, 1999, DEV BIOL, V213, P269, DOI 10.1006/dbio.1999.9387; Ferrari MB, 1996, DEV BIOL, V178, P484, DOI 10.1006/dbio.1996.0233; Galione A, 2005, MOL INTERV, V5, P73, DOI 10.1124/mi.5.2.4; Genazzani AA, 2002, TRENDS PHARMACOL SCI, V23, P165, DOI 10.1016/S0165-6147(00)01990-8; Gerasimenko JV, 2003, J CELL BIOL, V163, P271, DOI 10.1083/jcb.200306134; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hohenegger M, 2002, BIOCHEM J, V367, P423, DOI 10.1042/BJ20020584; Kinnear NP, 2004, J BIOL CHEM, V279, P54319, DOI 10.1074/jbc.M406132200; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Lee HC, 2005, J BIOL CHEM, V280, P33693, DOI 10.1074/jbc.R500012200; LI LW, 1995, J CELL PHYSIOL, V163, P105, DOI 10.1002/jcp.1041630112; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Moccia F, 2003, FASEB J, V17, P1907, DOI 10.1096/fj.03-0178fje; Mojzisova A, 2001, PFLUG ARCH EUR J PHY, V441, P674, DOI 10.1007/s004240000465; Munshi CB, 2002, J BIOL CHEM, V277, P49453, DOI 10.1074/jbc.M209313200; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Papadimitriou E, 2000, J DRUG TARGET, V8, P335, DOI 10.3109/10611860008997910; Patel S, 2000, J BIOL CHEM, V275, P36495, DOI 10.1074/jbc.C000458200; Patel S, 2004, BIOL CELL, V96, P19, DOI 10.1016/j.biolcel.2003.12.001; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; Petersen OH, 1999, TRENDS NEUROSCI, V22, P488, DOI 10.1016/S0166-2236(99)01456-3; Pisaniello A, 2003, J CELL SCI, V116, P1589, DOI 10.1242/jcs.00358; REBER BFX, 1991, J PHYSIOL-LONDON, V435, P145, DOI 10.1113/jphysiol.1991.sp018502; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; SeigneurinVenin S, 1996, EXP CELL RES, V223, P301, DOI 10.1006/excr.1996.0085; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; Wang J, 1998, DEVELOPMENT, V125, P4293; Xie ZJ, 1999, J BIOL CHEM, V274, P20421, DOI 10.1074/jbc.274.29.20421; Yamasaki M, 2005, CURR BIOL, V15, P874, DOI 10.1016/j.cub.2005.04.033; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200	65	81	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15923	15928		10.1074/jbc.M602249200	http://dx.doi.org/10.1074/jbc.M602249200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595650	hybrid			2022-12-25	WOS:000237996000043
J	Ranganathan, A; Yazicioglu, MN; Cobb, MH				Ranganathan, Aarati; Yazicioglu, Mustafa N.; Cobb, Melanie H.			The nuclear localization of ERK2 occurs by mechanisms both independent of and dependent on energy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; EXPORT SIGNAL; TRANSLOCATION; TRANSPORT; IDENTIFICATION; CELLS; MEK1; PHOSPHORYLATION; SPECIFICITY	The mitogen-activated protein (MAP) kinases ERK1 and ERK2 often accumulate in the nuclei of stimulated cells to mediate changes in transcription. The mechanisms underlying stimulus-dependent redistribution of these kinases remain unclear. We have used a permeabilized cell reconstitution assay in HeLa cells and human foreskin fibroblasts to explore the processes by which ERK2 enters and exits the nucleus. We previously reported that entry of unphosphorylated ERK2 into the nucleus occurs by facilitated diffusion not requiring cytosolic transport factors. We find that export, like import, can occur by an energy- and carrier-independent mechanism. An energy-dependent mechanism of ERK2 export can also be distinguished, mediated at least in part through the exportin CRM1. We have also examined import and export of thiophosphorylated, active ERK2. Import of active ERK2 is significantly enhanced by the addition of exogenous transport factors and an energy regeneration system. These studies support a model in which multiple constitutive and regulated processes control the subcellular distribution of ERK2.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Blvd, Dallas, TX 75390 USA.	Melanie.Cobb@UTSouthwestern.edu		Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Burack WR, 2005, J BIOL CHEM, V280, P3832, DOI 10.1074/jbc.M410031200; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lorenzen JA, 2001, DEVELOPMENT, V128, P1403; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Menice CB, 1997, J BIOL CHEM, V272, P25157, DOI 10.1074/jbc.272.40.25157; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Whitehurst A, 2004, MOL CELL BIOL, V24, P10145, DOI 10.1128/MCB.24.23.10145-10150.2004; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Yao Z, 2001, ONCOGENE, V20, P7588, DOI 10.1038/sj.onc.1204963; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	33	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15645	15652		10.1074/jbc.M513866200	http://dx.doi.org/10.1074/jbc.M513866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595679	hybrid			2022-12-25	WOS:000237996000008
J	Tomkiewicz, D; Nouwen, N; van Leeuwen, R; Tans, S; Driessen, AJM				Tomkiewicz, Danuta; Nouwen, Nico; van Leeuwen, Ruud; Tans, Sander; Driessen, Arnold J. M.			SecA supports a constant rate of preprotein translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI MEMBRANE-VESICLES; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; CYTOPLASMIC MEMBRANE; INVITRO TRANSLOCATION; STEPWISE MOVEMENT; SECRETORY PROTEIN; CATALYTIC CYCLE; PLASMA-MEMBRANE	In Escherichia coli, secretory proteins (preproteins) are translocated across the cytoplasmic membrane by the Sec system composed of a protein-conducting channel, SecYEG, and an ATP-dependent motor protein, SecA. After binding of the preprotein to SecYEG-bound SecA, cycles of ATP binding and hydrolysis by SecA are thought to drive the stepwise translocation of the preprotein across the membrane. To address how the length of a preprotein substrate affects the SecA-driven translocation process, we constructed derivatives of the precursor of the outer membrane protein A ( proOmpA) with 2, 4, 6, and 8 in-tandem repeats of the periplasmic domain. With increasing polypeptide length, an increasing delay in the time before full-length translocation was observed, but the translocation rate expressed as amino acid translocation per minute remained constant. These data indicate that in the ATP-dependent reaction, SecA drives a constant rate of preprotein translocation consistent with a stepping mechanism of translocation.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Univ Groningen, Mat Sci Ctr Plus, NL-9751 NN Haren, Netherlands; Inst Atom & Mol Phys, Fdn Fundamental Res Matter, NL-1098 SJ Amsterdam, Netherlands	University of Groningen; University of Groningen; AMOLF	Driessen, AJM (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@rug.nl	Tans, Sander/AAS-2901-2020; van Leeuwen, R.G.H./L-4481-2015; Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				Alder NN, 2003, CELL, V112, P231, DOI 10.1016/S0092-8674(03)00032-1; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; de Keyzer J, 2002, J BIOL CHEM, V277, P46059, DOI 10.1074/jbc.M208449200; DRIESSEN AJM, 1992, EMBO J, V11, P847, DOI 10.1002/j.1460-2075.1992.tb05122.x; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MACINTYRE S, 1991, MOL GEN GENET, V227, P224; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Nouwen N, 2001, FEBS LETT, V508, P103, DOI 10.1016/S0014-5793(01)03033-2; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; RIED G, 1994, MOL GEN GENET, V243, P127, DOI 10.1007/BF00280309; Sato K, 1997, J BIOL CHEM, V272, P5880, DOI 10.1074/jbc.272.9.5880; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; Topping TB, 1997, J BIOL CHEM, V272, P19314, DOI 10.1074/jbc.272.31.19314; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YAMANE K, 1987, J BIOL CHEM, V262, P2358	28	51	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15709	15713		10.1074/jbc.M600205200	http://dx.doi.org/10.1074/jbc.M600205200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16601117	hybrid, Green Published, Green Submitted			2022-12-25	WOS:000237996000016
J	Parcellier, A; Brunet, M; Schmitt, E; Col, E; Didelot, C; Hammann, A; Nakayama, K; Nakayama, KI; Khochbin, S; Solary, E; Garrido, C				Parcellier, Arnaud; Brunet, Mathilde; Schmitt, Elise; Col, Edwige; Didelot, Celine; Hammann, Arlette; Nakayama, Keiko; Nakayama, Keiichi I.; Khochbin, Saadi; Solary, Eric; Garrido, Carmen			HSP27 favors ubiquitination and proteasomal degradation of p27(Kip1) and helps S-phase re-entry in stressed cells	FASEB JOURNAL			English	Article						stress proteins; proteasome; ubiquitin; cell death; cell proliferation	CDK INHIBITOR P27; HEAT-SHOCK PROTEINS; CYTOCHROME-C; DEPENDENT DEGRADATION; MEDIATED DEGRADATION; NUCLEAR EXPORT; IN-VITRO; PHOSPHORYLATION; CARCINOMA; PATHWAY	Stress-inducible HSP27 protects cells from death through various mechanisms. We have recently demonstrated that HSP27 can also enhance the degradation of some proteins through the proteasomal pathway. Here, we show that one of these proteins is the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1). The ubiquitination and degradation of this protein that favors progression through the cell cycle was previously shown to involve either a Skp2-dependent mechanism, i.e., at the S-/G(2)-transition, or a KPC (Kip1 ubiquitination-promoting complex)-dependent mechanism, i.e., at the G(0)/G(1) transition. In this work, we demonstrate that, in response to serum depletion, p27(Kip1) cellular content first increases then progressively decreases as cells begin to die. In this stressful condition, HSP27 favors p27(Kip1) ubiquitination and degradation by the proteasome. A similar observation was made in response to stress induced by the NO donor glyceryl trinitrate (GTN). HSP27-mediated ubiquitination of p27(Kip1) does not require its phosphorylation on Thr(187) or Ser-10, nor does it depend on the SCFSkp2 ubiquitin ligase E3 complex. It facilitates the G(1)/S transition, which suggests that, in stressful conditions, HSP27 might render quiescent cells competent to re-enter the cell cycle.	INSERM, Fac Med, U517, IFR100, F-21000 Dijon, France; INSERM, U309, La Tronche, France; Tohoku Univ, Ctr Translat & Adv Anim Res Human Dis, Sendai, Miyagi 980, Japan; Kyushu Univ, Med Inst Bioregulat, Div Cell Biol, Fukuoka 812, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Tohoku University; Kyushu University	Garrido, C (corresponding author), INSERM, Fac Med, U517, IFR100, 7 Blvd Jeanne DArc, F-21000 Dijon, France.	cgarrido@u-bourgogne.fr	Khochbin, Saadi/M-8090-2013; Garrido, carmen/G-1633-2018; Garrido, Carolina/GWM-5557-2022	Khochbin, Saadi/0000-0002-0455-0857; Garrido, carmen/0000-0003-1368-1493; Mirjolet Didelot, Celine/0000-0003-0047-9421; Solary, Eric/0000-0002-8629-1341				Aldrian S, 2002, CELL STRESS CHAPERON, V7, P177, DOI 10.1379/1466-1268(2002)007<0177:OOHATM>2.0.CO;2; Arrigo AP, 2000, PATHOL BIOL, V48, P280; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; den Engelsman J, 2003, J BIOL CHEM, V278, P4699, DOI 10.1074/jbc.M211403200; Duan HJ, 2001, MOL CARCINOGEN, V30, P37, DOI 10.1002/1098-2744(200101)30:1<37::AID-MC1011>3.0.CO;2-7; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Friant S, 2003, EMBO J, V22, P3783, DOI 10.1093/emboj/cdg375; GABAI VL, 1995, BIOCHEM MOL BIOL INT, V35, P95; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1996, EUR J BIOCHEM, V237, P653, DOI 10.1111/j.1432-1033.1996.0653p.x; Garrido C, 2003, CELL DEATH DIFFER, V10, P619, DOI 10.1038/sj.cdd.4401229; Garrido C, 2002, CELL DEATH DIFFER, V9, P483, DOI 10.1038/sj.cdd.4401005; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; Geisler JP, 1998, GYNECOL ONCOL, V69, P14, DOI 10.1006/gyno.1998.4961; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Ito Hidenori, 2003, Nihon Yakurigaku Zasshi, V121, P27; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; Mese H, 2002, ONCOL REP, V9, P341; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakano T, 1996, SYST COMPUT JPN, V27, P1, DOI 10.1002/scj.4690270601; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; OESTERREICH S, 1993, CANCER RES, V53, P4443; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Parcellier A, 2003, BIOCHEM BIOPH RES CO, V304, P505, DOI 10.1016/S0006-291X(03)00623-5; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Reidlinger J, 1997, J BIOL CHEM, V272, P24899, DOI 10.1074/jbc.272.40.24899; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Rosner M, 2004, J BIOL CHEM, V279, P48707, DOI 10.1074/jbc.M405528200; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334	56	92	98	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1179	+		10.1096/fj.05-4184fje	http://dx.doi.org/10.1096/fj.05-4184fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16641199				2022-12-25	WOS:000240210300018
J	Boesten, LSM; Zadelaar, ASM; van Nieuwkoop, A; Hu, L; Jonkers, J; de Water, BV; Gijbels, MJJ; van der Made, I; de Winther, MPJ; Havekes, LM; van Vlijmen, BJM				Boesten, Lianne S. M.; Zadelaar, A. Susanne M.; van Nieuwkoop, Anita; hu, Lii Hu; Jonkers, Jos; de Water, Bob van; Gijbels, Marion J. J.; van der Made, Ingeborg; de Winther, Menno P. J.; Havekes, Louis M.; van Vlijmen, Bart J. M.			Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoE-deficient mice	FASEB JOURNAL			English	Article						genetically altered mice; tumor suppressor gene; proliferation; apoptosis	CELL-PROLIFERATION; GENE; PLAQUE; RB; INACTIVATION; RESTENOSIS; ACTIVATION; EXPRESSION; P27(KIP1); PARADIGM	The cellular composition of an atherosclerotic lesion is determined by cell infiltration, proliferation, and apoptosis. The tumor suppressor gene retinoblastoma (Rb) has been shown to regulate both cell proliferation and cell death in many cell types. To study the role of macrophage Rb in the development of atherosclerosis, we used apoE-deficient mice with a macrophage-restricted deletion of Rb (Rb-del mice) and control littermates (Rb-fl mice). After 12 wk feeding a cholesterol-rich diet, the Rbdel mice showed a 51% increase in atherosclerotic lesion area with a 39% increase in the relative number of advanced lesions. Atherosclerotic lesions showed a 13% decrease in relative macrophage area and a 46% increase in relative smooth muscle cell area, reflecting the more advanced state of the lesions. The increase in atherosclerosis was independent of in vitro macrophage modified lipoprotein uptake or cytokine production. Whereas macrophage-restricted Rb deletion did not affect lesional macrophage apoptosis, a clear 2.6-fold increase in lesional macrophage proliferation was observed. These studies demonstrate that macrophage Rb is a suppressing factor in the progression of atherosclerosis by reducing macrophage proliferation.	CO TNO Qual Life, Dept Gen Internal Med, Leiden Univ Med Ctr, Gaubius Lab, NL-2310 CE Leiden, Netherlands; Leiden Univ Med Ctr, Dept Cardiol, Leiden, Netherlands; Leiden Univ Med Ctr, Ctr Hemostasis & Thrombosis Res, Dept Hematol, Leiden, Netherlands; Netherlands Canc Inst, Amsterdam, Netherlands; Leiden Amsterdam Ctr Drug Res, Div Toxicol, Leiden, Netherlands; Cardiovasc Res Inst, Dept Mol Genet, Maastricht, Netherlands; Maastricht Univ, Dept Pathol, Maastricht, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Netherlands Cancer Institute; Leiden University; Leiden University - Excl LUMC; Maastricht University; Maastricht University	Boesten, LSM (corresponding author), CO TNO Qual Life, Dept Gen Internal Med, Leiden Univ Med Ctr, Gaubius Lab, Zernikedreef 9,POB 2215, NL-2310 CE Leiden, Netherlands.	lsmboesten@diac-leiden.nl	de Winther, Menno/E-8721-2012; Jonkers, Jos/AAG-3246-2019	Jonkers, Jos/0000-0002-9264-9792; de Winther, Menno/0000-0002-4038-6636				Bennett MR, 1998, CIRC RES, V82, P704, DOI 10.1161/01.RES.82.6.704; Bergh G, 1999, BLOOD, V94, P1971; Boesten LSM, 2005, CARDIOVASC RES, V66, P179, DOI 10.1016/j.cardiores.2005.01.001; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Dickson BC, 2003, CARDIOVASC PATHOL, V12, P237, DOI 10.1016/S1054-8807(03)00072-3; Diez-Juan A, 2004, BLOOD, V103, P158, DOI 10.1182/blood-2003-07-2319; Diez-Juan A, 2001, FASEB J, V15, P1989, DOI 10.1096/fj.01-0130com; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; El-Omar Magdi M., 2001, Curr Interv Cardiol Rep, V3, P296; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; Fuster V, 1996, HAEMOSTASIS, V26, P269; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Iavarone A, 2004, NATURE, V432, P1040, DOI 10.1038/nature03068; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kanters E, 2003, J CLIN INVEST, V112, P1176, DOI 10.1172/JCI18580; Kockx M, 1999, BLOOD, V93, P2991; Kockx MM, 1998, AM J PATHOL, V152, P885; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Marino S, 2000, GENE DEV, V14, P994; Merched AJ, 2004, CIRCULATION, V110, P3830, DOI 10.1161/01.CIR.0000148681.01282.89; Merched AJ, 2003, ARTERIOSCL THROM VAS, V23, P1608, DOI 10.1161/01.ATV.0000084825.88022.53; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; NISHINA PM, 1990, J LIPID RES, V31, P859; O'Brien KD, 2005, ARTERIOSCL THROM VAS, V25, P785, DOI 10.1161/01.ATV.0000158383.65277.2b; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5; Smith RC, 1997, CIRCULATION, V96, P1899, DOI 10.1161/01.CIR.96.6.1899; van der Hoeven BL, 2005, INT J CARDIOL, V99, P9, DOI 10.1016/j.ijcard.2004.01.021; van Vlijmen BJM, 2001, CIRC RES, V88, P780, DOI 10.1161/hh0801.089261; Vooijs M, 1998, ONCOGENE, V17, P1, DOI 10.1038/sj.onc.1202169; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	40	24	26	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					953	+		10.1096/fj.05-4530fje	http://dx.doi.org/10.1096/fj.05-4530fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585057				2022-12-25	WOS:000240157700019
J	Liu, CJ; Kong, W; Ilalov, K; Yu, S; Xu, K; Prazak, L; Fajardo, M; Sehgal, B; Di Cesare, PE				Liu, Chuan-ju; Kong, Wei; Ilalov, Kiril; Yu, Shuang; Xu, Ke; Prazak, Lisa; Fajardo, Marc; Sehgal, Bantoo; Di Cesare, Paul E.			ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein	FASEB JOURNAL			English	Article						degradation; arthritis; COMP	MULTIPLE EPIPHYSEAL DYSPLASIA; MYOBLAST DIFFERENTIATION; THROMBOSPONDIN MOTIFS; RHEUMATOID-ARTHRITIS; ARTICULAR-CARTILAGE; BONE METABOLISM; SYNOVIAL-FLUID; SERUM MARKERS; CELL-LINE; PSEUDOACHONDROPLASIA	Degradative fragments of cartilage oligomeric matrix protein (COMP) have been observed in arthritic patients. The physiological enzyme(s) that degrade COMP, however, remain unknown. We performed a yeast two-hybrid screen (Y2H) to search for proteins that associate with COMP to identify an interaction partner that might degrade it. One screen using the epidermal growth factor (EGF) domain of COMP as bait led to the discovery of ADAMTS-7. Rat ADAMTS-7 is composed of 1595 amino acids, and this protein exhibits higher expression in the musculoskeletal tissues. COMP binds directly to ADAMTS-7 in vitro and in native articular cartilage. ADAMTS-7 selectively interacts with the EGF repeat domain but not with the other three functional domains of COMP, whereas the four C-terminal TSP motifs of ADAMTS-7 are required and sufficient for association with COMP. The recombinant catalytic domain and intact ADAMTS-7 are capable of digesting COMP in vitro. The enzymatic activity of ADAMTS-7 requires the presence of Zn2+ and appropriate pH (7.5-9.5), and the concentration of ADAMTS-7 in cartilage and synovium of patients with rheumatoid arthritis is significantly increased as compared to normal cartilage and synovium. ADAMTS-7 is the first metalloproteinase found to bind directly to and degrade COMP.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA	New York University; Yale University	Liu, CJ (corresponding author), NYU, Sch Med, Dept Orthopaed Surg, 301 E 17th St, New York, NY 10003 USA.	Chuanju.liu@med.nyu.edu; pedicesare@aol.com	Liu, Chuan-ju/AAT-8165-2021	Xu, Ke Kate/0000-0002-2453-4475; liu, chuanju/0000-0002-7181-8032	NIAMS NIH HHS [R03 AR052022, AR052022-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR052022] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bevitt DJ, 2003, BBA-GENE STRUCT EXPR, V1626, P83, DOI 10.1016/S0167-4781(03)00047-2; BRIGGS MD, 1993, GENOMICS, V18, P656, DOI 10.1016/S0888-7543(05)80369-6; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Chen AL, 2004, J ORTHOP RES, V22, P1188, DOI 10.1016/j.orthres.2004.02.013; CHEN FHT, 2004, 50 ANN M ORTH RES SO; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Collins-Racie LA, 2004, MATRIX BIOL, V23, P219, DOI 10.1016/j.matbio.2004.05.004; Di Cesare PE, 2000, J ORTHOPAED RES, V18, P713, DOI 10.1002/jor.1100180506; Di Cesare PE, 1999, J ORTHOPAED RES, V17, P437; Di Cesare PE, 2002, MATRIX BIOL, V21, P461, DOI 10.1016/S0945-053X(02)00015-X; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DiCesare PE, 1996, J ORTHOPAED RES, V14, P946, DOI 10.1002/jor.1100140615; DiCesare PE, 1997, FEBS LETT, V412, P249, DOI 10.1016/S0014-5793(97)00789-8; Dickinson SC, 2003, MATRIX BIOL, V22, P267, DOI 10.1016/S0945-053X(03)00034-9; Duke J, 2003, APOPTOSIS, V8, P191, DOI 10.1023/A:1022926811397; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; HECHT JT, 1993, GENOMICS, V18, P661, DOI 10.1016/S0888-7543(05)80370-2; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Hecht JT, 2001, MATRIX BIOL, V20, P251, DOI 10.1016/S0945-053X(01)00136-6; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kraus VB, 2002, ARTHRITIS RHEUM-US, V46, P420, DOI 10.1002/art.10124; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Liu CJ, 2001, J BIOL CHEM, V276, P18925, DOI 10.1074/jbc.M101606200; LLAMAZARES M, 2003, J BIOL CHEM, V31, P31; Lohmander LS, 1999, ARTHRITIS RHEUM, V42, P534, DOI 10.1002/1529-0131(199904)42:3<534::AID-ANR19>3.0.CO;2-J; Mann HH, 2004, J BIOL CHEM, V279, P25294, DOI 10.1074/jbc.M403778200; MANSSON B, 1995, J CLIN INVEST, V95, P1071, DOI 10.1172/JCI117753; Martel-Pelletier J, 2001, BEST PRACT RES CL RH, V15, P805, DOI 10.1053/berh.2001.0195; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Misumi K, 2002, EQUINE VET J, V34, P602, DOI 10.2746/042516402776180205; Mittaz L, 2004, BIOL REPROD, V70, P1096, DOI 10.1095/biolreprod.103.023911; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; Neidhart M, 1997, BRIT J RHEUMATOL, V36, P1151; Neidhart M, 1996, J RHEUMATOL, V23, P476; Ozbek S, 2002, EMBO J, V21, P5960, DOI 10.1093/emboj/cdf628; Petersson IF, 1998, BRIT J RHEUMATOL, V37, P46; POOLE RA, 1993, JOINT CARTILAGE DEGR; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Salzet M, 2002, CURR PHARM DESIGN, V8, P493, DOI 10.2174/1381612023395664; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SAXNE T, 1992, BRIT J RHEUMATOL, V31, P583; Somerville RPT, 2004, J BIOL CHEM, V279, P35159, DOI 10.1074/jbc.M402380200; Stracke JO, 2000, FEBS LETT, V478, P52, DOI 10.1016/S0014-5793(00)01819-6; Susic S, 1997, CLIN GENET, V51, P219; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2	64	109	121	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					988	+		10.1096/fj.05-3877fje	http://dx.doi.org/10.1096/fj.05-3877fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585064	Green Accepted			2022-12-25	WOS:000240157700031
J	Remacle, AG; Rozanov, DV; Fugere, M; Day, R; Strongin, AY				Remacle, A. G.; Rozanov, D. V.; Fugere, M.; Day, R.; Strongin, A. Y.			Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP	ONCOGENE			English	Article						MT1-MMP; furin; internalization; proprotein convertase; PA83; anthrax	TYPE-1 MATRIX-METALLOPROTEINASE; 3-DIMENSIONAL EXTRACELLULAR-MATRIX; TRANS-GOLGI NETWORK; 1-MATRIX METALLOPROTEINASE; ANTHRAX TOXIN; TISSUE INHIBITOR; PROPROTEIN CONVERTASES; CRYSTAL-STRUCTURE; CANCER-CELLS; MEMBRANE	Invasion-promoting membrane type-1 matrix metallo-proteinase (MT1-MMP) functions in cancer cells as an oncogene and as a mediator of proteolytic events on the cell surface. To exert its functional activity, MT1-MMP requires proteolytic removal of the prodomain sequence. There are two potential furin cleavage motifs, R-89-R-P-R-C-93 and R-108-R-K-R-Y-112, in the prodomain sequence of MT1-MMP. Our data suggest an important role of furin and related proprotein convertases (PCs) in mediating both the activation of MT1-MMP and the levels of functionally active MT1-MMP at the surface of cancer cells. We have determined that the peptide sequence that spans the first cleavage site is susceptible to furin and PC5/6, whereas the second sequence is susceptible to furin and also to PC5/6, PC7 and PACE4. In the structure of the MT1-MMP proenzyme, the R-89-R-P-R-C-93 site, however, is inaccessible to PCs. Our studies also demonstrated a direct functional link between the activation and the uptake rate of the proenzyme and the enzyme of MT1-MMP. Thus, the uptake rate of the latent MT1-MMP proenzyme noticeably exceeded that of the active enzyme. We conclude that furin and related PCs are the essential components of the specialized cellular machinery that controls the levels of the functionally active, mature, MT1-MMP enzyme on the cell surface to continually support the potency of pericellular proteolysis.	Burnham Inst Med Rs, La Jolla, CA 92037 USA; Univ Sherbrooke, Fac Med, Inst Pharmacol, Dept Pharmacol, Sherbrooke, PQ J1K 2R1, Canada	Sanford Burnham Prebys Medical Discovery Institute; University of Sherbrooke	Strongin, AY (corresponding author), Burnham Inst Med Rs, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NATIONAL CANCER INSTITUTE [R01CA077470, R01CA083017] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER; NCI NIH HHS [CA77470, CA83017] Funding Source: Medline; NCRR NIH HHS [RR020843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Bradley KA, 2003, BIOCHEM PHARMACOL, V65, P309, DOI 10.1016/S0006-2952(02)01455-7; Cao J, 2005, J BIOL CHEM, V280, P10974, DOI 10.1074/jbc.M412370200; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; Chun TH, 2004, J CELL BIOL, V167, P757, DOI 10.1083/jcb.200405001; Deryugina EI, 2004, TRAFFIC, V5, P627, DOI 10.1111/j.1600-0854.2004.00206.x; Deryugina EI, 1997, J CELL SCI, V110, P2473; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Fugere M, 2005, TRENDS PHARMACOL SCI, V26, P294, DOI 10.1016/j.tips.2005.04.006; Fugere M, 2002, J BIOL CHEM, V277, P7648, DOI 10.1074/jbc.M107467200; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Holmbeck K, 2004, J CELL PHYSIOL, V200, P11, DOI 10.1002/jcp.20065; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kridel SJ, 2002, J BIOL CHEM, V277, P23788, DOI 10.1074/jbc.M111574200; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Liu SH, 2003, EXPERT OPIN BIOL TH, V3, P843, DOI 10.1517/14712598.3.5.843; Mazzone M, 2004, J CELL SCI, V117, P6275, DOI 10.1242/jcs.01563; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Rozanov DV, 2003, J BIOL CHEM, V278, P8257, DOI 10.1074/jbc.M213246200; Rozanov DV, 2002, J BIOL CHEM, V277, P9318, DOI 10.1074/jbc.M110711200; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; Scobie HM, 2005, CURR OPIN MICROBIOL, V8, P106, DOI 10.1016/j.mib.2004.12.005; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; SITRIN RG, 1990, CANCER RES, V50, P4957; Stawowy P, 2005, CIRCULATION, V111, P2820, DOI 10.1161/CIRCULATIONAHA.104.502617; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Toth M, 2005, BIOCHEM J, V387, P497, DOI 10.1042/BJ20041324; Wang P, 2004, J BIOL CHEM, V279, P20461, DOI 10.1074/jbc.M400264200; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387	50	56	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2006	25	41					5648	5655		10.1038/sj.onc.1209572	http://dx.doi.org/10.1038/sj.onc.1209572			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636666				2022-12-25	WOS:000240599100006
J	Mallappa, C; Yadav, V; Negi, P; Chattopadhyay, S				Mallappa, Chandrashekara; Yadav, Vandana; Negi, Prem; Chattopadhyay, Sudip			A basic leucine zipper transcription factor, G-box-binding factor 1, regulates blue light-mediated photomorphogenic growth in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PHYTOCHROME-A; NEGATIVE REGULATOR; CIRCADIAN-RHYTHMS; BZIP PROTEINS; HIGHER-PLANTS; HY5; PROMOTERS	Several transcriptional regulators have been identified and demonstrated to play either positive or negative regulatory roles in seedling development. However, the regulatory coordination between hypocotyl elongation and cotyledon expansion during early seedling development in plants remains unknown. We report the identification of a Z-box binding factor (ZBF2) and its functional characterization in cryptochrome-mediated blue light signaling. ZBF2 encodes a G-box binding factor (GBF1), which is a basic leucine zipper transcription factor. Our DNA-protein interaction studies reveal that ZBF2/GBF1 also interacts with the Z-box light-responsive element of light-regulated promoters. Genetic analyses of gbf1 mutants and overexpression studies suggest that GBF1 acts as a repressor of blue light-mediated inhibition in hypocotyl elongation, however, it acts as a positive regulator of cotyledon expansion during photomorphogenic growth. Furthermore, whereas GBF1 acts as a positive regulator of lateral root formation, it differentially regulates the expression of light-inducible genes. Taken together, these results demonstrate that GBF1 is a unique transcriptional regulator of photomorphogenesis in blue light.	Natl Ctr Plant Genome Res, Lab 101, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Plant Genome Research (NIPGR)	Chattopadhyay, S (corresponding author), Natl Ctr Plant Genome Res, Lab 101, Aruna Asaf Ali Marg, New Delhi 110067, India.	sudipchatto@yahoo.com	Chattopadhyay, Sudip/P-8491-2014; YADAV, VANDANA/B-7720-2011					Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; Ballesteros ML, 2001, GENE DEV, V15, P2613, DOI 10.1101/gad.915001; Barnes SA, 1996, PLANT J, V10, P1155, DOI 10.1046/j.1365-313X.1996.10061155.x; Batschauer A, 1996, PLANT J, V9, P63, DOI 10.1046/j.1365-313X.1996.09010063.x; Boter M, 2004, GENE DEV, V18, P1577, DOI 10.1101/gad.297704; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; Chattopadhyay S, 1998, PLANT J, V15, P69, DOI 10.1046/j.1365-313X.1998.00180.x; Chattopadhyay S, 1998, PLANT CELL, V10, P673, DOI 10.1105/tpc.10.5.673; Chen M, 2004, ANNU REV GENET, V38, P87, DOI 10.1146/annurev.genet.38.072902.092259; Deng XW, 1999, SEMIN CELL DEV BIOL, V10, P121, DOI 10.1006/scdb.1999.0287; DONALD RGK, 1990, EMBO J, V9, P1717, DOI 10.1002/j.1460-2075.1990.tb08295.x; Fairchild CD, 2000, GENE DEV, V14, P2377; GILMARTIN PM, 1992, PLANT CELL, V4, P839, DOI 10.1105/tpc.4.7.839; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HA SB, 1988, P NATL ACAD SCI USA, V85, P8017, DOI 10.1073/pnas.85.21.8017; Holm M, 2002, GENE DEV, V16, P1247, DOI 10.1101/gad.969702; Huq E, 2002, EMBO J, V21, P2441, DOI 10.1093/emboj/21.10.2441; Kim JY, 2003, PLANT CELL, V15, P2399, DOI 10.1105/tpc.014498; Laubinger S, 2004, PLANT CELL, V16, P2293, DOI 10.1105/tpc.104.024216; Lin CT, 2002, PLANT CELL, V14, pS207, DOI 10.1105/tpc.000646; Liu W, 2003, PLANT J, V36, P189, DOI 10.1046/j.1365-313X.2003.01866.x; Lorenzo O, 2004, PLANT CELL, V16, P1938, DOI 10.1105/tpc.022319; MENKENS AE, 1995, TRENDS BIOCHEM SCI, V20, P506, DOI 10.1016/S0968-0004(00)89118-5; Mizoguchi T, 2002, DEV CELL, V2, P629, DOI 10.1016/S1534-5807(02)00170-3; Moller SG, 2003, PLANT CELL, V15, P1111, DOI 10.1105/tpc.008649; Nagy F, 2002, ANNU REV PLANT BIOL, V53, P329, DOI 10.1146/annurev.arplant.53.100301.135302; Neff MM, 2000, GENE DEV, V14, P257; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; Oyama T, 1997, GENE DEV, V11, P2983, DOI 10.1101/gad.11.22.2983; PARKS BM, 1993, PLANT CELL, V5, P39, DOI 10.1105/tpc.5.1.39; Puente P, 1996, EMBO J, V15, P3732, DOI 10.1002/j.1460-2075.1996.tb00743.x; Quail PH, 2002, CURR OPIN CELL BIOL, V14, P180, DOI 10.1016/S0955-0674(02)00309-5; Saijo Y, 2003, GENE DEV, V17, P2642, DOI 10.1101/gad.1122903; Schepens I, 2004, CURR OPIN PLANT BIOL, V7, P564, DOI 10.1016/j.pbi.2004.07.004; SCHINDLER U, 1992, EMBO J, V11, P1275, DOI 10.1002/j.1460-2075.1992.tb05171.x; Seo HS, 2003, NATURE, V423, P995, DOI 10.1038/nature01696; Soh MS, 2000, PLANT CELL, V12, P2061, DOI 10.1105/tpc.12.11.2061; Spiegelman JI, 2000, PLANT CELL, V12, P2485, DOI 10.1105/tpc.12.12.2485; Steindler C, 1999, DEVELOPMENT, V126, P4235; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P445, DOI 10.1146/annurev.pp.46.060195.002305; Terzaghi WB, 1997, PLANT J, V11, P967, DOI 10.1046/j.1365-313X.1997.11050967.x; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; Yadav V, 2005, PLANT CELL, V17, P1953, DOI 10.1105/tpc.105.032060; Yadav V, 2002, PLANT J, V31, P741, DOI 10.1046/j.1365-313X.2002.01395.x; Yang JP, 2005, PLANT CELL, V17, P804, DOI 10.1105/tpc.104.030205	47	77	91	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22190	22199		10.1074/jbc.M601172200	http://dx.doi.org/10.1074/jbc.M601172200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16638747	hybrid			2022-12-25	WOS:000239387100066
J	Lehmann, IT; Bobrovskaya, L; Gordon, SL; Dunkley, PR; Dickson, PW				Lehmann, Ingo T.; Bobrovskaya, Larisa; Gordon, Sarah L.; Dunkley, Peter R.; Dickson, Phillip W.			Differential regulation of the human tyrosine hydroxylase isoforms via hierarchical phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; PROTEIN-KINASE-II; ENZYME-ACTIVITY; MAP-KINASE; SER(19); SER(40); SERINE-31; SER(31); GENE; CATECHOLAMINES	Tyrosine hydroxylase (TH) is the rate- limiting enzyme in the biosynthesis of the catecholamines dopamine, noradrenaline, and adrenaline. In response to short term stimuli TH activity is primarily controlled by phosphorylation of serine 40. We have previously shown that phosphorylation of serine 19 in TH can indirectly activate TH via a hierarchical mechanism by increasing the rate of phosphorylation of serine 40. Here we show that phosphorylation of serine 31 in rat TH increases the rate of serine 40 phosphorylation 9-fold in vitro. Phosphorylation of serine 31 in intact bovine chromaffin cells potentiated the forskolin-induced increase in serine 40 phosphorylation and TH activity more than 2-fold. Humans are unique in that they contain four TH isoforms but to date no significant differences have been shown in the regulation of these isoforms. Phosphorylation of the human TH isoform 1 at serine 31 by extracellular signal-regulated protein kinase (ERK) also produced a 9-fold increase in the rate of phosphorylation of serine 40, whereas little effect was seen in the TH isoforms 3 and 4. ERK did not phosphorylate human TH isoform 2. The effect of serine 19 phosphorylation on serine 40 (44 in TH2) phosphorylation is stronger in TH2 than in TH1. Thus hierarchical phosphorylation provides a mechanism whereby the two major human TH isoforms ( 1 and 2) can be differentially regulated with only isoform 1 responding to the ERK pathway, whereas isoform 2 is more sensitive to calcium-mediated events.	Univ Newcastle, Fac Hlth, Sch Biomed Sci, Newcastle, NSW 2308, Australia; Univ Newcastle, Fac Hlth, Hunter Med Res Inst, Newcastle, NSW 2308, Australia	University of Newcastle; Hunter Medical Research Institute; University of Newcastle	Dickson, PW (corresponding author), Univ Newcastle, Fac Hlth, Sch Biomed Sci, Newcastle, NSW 2308, Australia.	phil.dickson@newcastle.edu.au	Bobrovskaya, Larisa/D-3573-2011	Bobrovskaya, Larisa/0000-0002-5793-6147				Bevilaqua LRM, 2001, J BIOL CHEM, V276, P40411, DOI 10.1074/jbc.M105280200; Bobrovskaya L, 2004, J NEUROCHEM, V90, P857, DOI 10.1111/j.1471-4159.2004.02550.x; Bobrovskaya L, 2001, J NEUROCHEM, V78, P490, DOI 10.1046/j.1471-4159.2001.00445.x; Bobrovskaya L, 1998, J NEUROCHEM, V70, P2565; BUNN SJ, 1995, J NEUROCHEM, V64, P1370; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; Dunkley PR, 2004, J NEUROCHEM, V91, P1025, DOI 10.1111/j.1471-4159.2004.02797.x; Fitzpatrick PF, 1999, ANNU REV BIOCHEM, V68, P355, DOI 10.1146/annurev.biochem.68.1.355; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; HAAVIK J, 1991, EUR J BIOCHEM, V199, P371, DOI 10.1111/j.1432-1033.1991.tb16133.x; HALLORAN SM, 1994, J BIOL CHEM, V269, P30960; HAYCOCK JW, 1993, NEUROCHEM RES, V18, P15, DOI 10.1007/BF00966919; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; Haycock JW, 2002, J NEUROCHEM, V81, P947, DOI 10.1046/j.1471-4159.2002.00881.x; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HAYCOCK JW, 1993, J NEUROCHEM, V60, P493, DOI 10.1111/j.1471-4159.1993.tb03177.x; HAYCOCK JW, 1991, J NEUROCHEM, V56, P2139, DOI 10.1111/j.1471-4159.1991.tb03477.x; Itagaki C, 1999, BIOCHEMISTRY-US, V38, P15673, DOI 10.1021/bi9914255; Jarvie P E, 1995, Methods Mol Biol, V41, P239; KANEDA N, 1987, BIOCHEM BIOPH RES CO, V146, P971, DOI 10.1016/0006-291X(87)90742-X; Kansy JW, 2004, J NEUROCHEM, V91, P374, DOI 10.1111/j.1471-4159.2004.02723.x; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Kumer SC, 1996, J NEUROCHEM, V67, P443; LEBOURDELLES B, 1991, J BIOL CHEM, V266, P17124; LIVETT BG, 1984, PHYSIOL REV, V64, P1103, DOI 10.1152/physrev.1984.64.4.1103; Moy LY, 2004, J BIOL CHEM, V279, P54487, DOI 10.1074/jbc.M406636200; OMALLEY KL, 1987, BIOCHEMISTRY-US, V26, P2910; Ramsey AJ, 1998, BIOCHEMISTRY-US, V37, P8980, DOI 10.1021/bi980582l; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; RIBEIRO P, 1992, P NATL ACAD SCI USA, V89, P9593, DOI 10.1073/pnas.89.20.9593; ROSTAS JAP, 1988, J NEUROCHEM, V50, P945, DOI 10.1111/j.1471-4159.1988.tb03003.x; Royo M, 2004, ARCH BIOCHEM BIOPHYS, V423, P247, DOI 10.1016/j.abb.2003.12.027; Salvatore MF, 2000, J NEUROCHEM, V75, P225, DOI 10.1046/j.1471-4159.2000.0750225.x; Sura GR, 2004, J NEUROCHEM, V90, P970, DOI 10.1111/j.1471-4159.2004.02566.x; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; Toska K, 2002, J NEUROCHEM, V83, P775, DOI 10.1046/j.1471-4159.2002.01172.x; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404	37	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17644	17651		10.1074/jbc.M512194200	http://dx.doi.org/10.1074/jbc.M512194200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16644734	hybrid			2022-12-25	WOS:000238490300013
J	Bathori, G; Csordas, G; Garcia-Perez, C; Davies, E; Hajnoczky, G				Bathori, Gyorgy; Csordas, Gyorgy; Garcia-Perez, Cecilia; Davies, Erika; Hajnoczky, Gyorgy			Ca2+-dependent control of the permeability properties of the mitochondrial outer membrane and voltage-dependent anion-selective channel (VDAC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; TRANSITION PORE; CELL-DEATH; ENDOPLASMIC-RETICULUM; ION-CHANNEL; OXIDATIVE-PHOSPHORYLATION; INTACT MITOCHONDRIA; RYANODINE RECEPTORS; SIGNAL PROPAGATION; CALCIUM SIGNALS	Cell function depends on the distribution of cytosolic and mitochondrial factors across the outer mitochondrial membrane (OMM). Passage of metabolites through the OMM has been attributed to the voltage-dependent anion-selective channel (VDAC), which can form a large conductance and permanently open a channel in lipid bilayers. However, recent data indicate that the transport of metabolites through the OMM is controlled in the cells. Recognizing that the bilayer studies had been commonly conducted at supraphysiological [Ca2+] and [K+], we determined the effect of Ca2+ on VDAC activity. In liposomes, the purified VDAC displays Ca2+ -dependent control of the molecular cut-off size and shows Ca2+ -regulated Ca2+ permeability in the physiological [Ca2+] range. In bilayer experiments, at submicromolar [Ca2+], the purified VDAC or isolated OMM does not show sustained large conductance but rather exhibits gating between a nonconducting state and various subconductance states. Ca2+ addition causes a reversible increase in the conductance and may evoke channel opening to full conductance. Furthermore, single cell imaging data indicate that Ca2+ may facilitate the cation and ATP transport across the OMM. Thus, the VDAC gating is dependent on the physiological concentrations of cations, allowing the OMM to control the passage of ions and some small molecules. The OMM barrier is likely to decrease during the calcium signal.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Hajnoczky, G (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Suite 261 JAH, Philadelphia, PA 19107 USA.	gyorgy.hajnoczky@jefferson.edu		Csordas, Gyorgy/0000-0003-3156-1460	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051526, R01DK051526] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51526] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Banerjee J, 2004, BIOCHEM BIOPH RES CO, V323, P310, DOI 10.1016/j.bbrc.2004.08.094; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; BATHORI G, 1993, BIOCHIM BIOPHYS ACTA, V1145, P168, DOI 10.1016/0005-2736(93)90394-F; BENZ R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P311, DOI 10.1016/0005-2736(90)90279-W; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Cesura AM, 2003, J BIOL CHEM, V278, P49812, DOI 10.1074/jbc.M304748200; Colombini M, 2004, MOL CELL BIOCHEM, V256, P107, DOI 10.1023/B:MCBI.0000009862.17396.8d; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; Csordas G, 2003, J BIOL CHEM, V278, P42273, DOI 10.1074/jbc.M305248200; Csordas G, 2001, CELL CALCIUM, V29, P249, DOI 10.1054/ceca.2000.0191; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V894, P109, DOI 10.1016/0005-2728(87)90180-0; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FONTAINE EM, 1995, BIOCHEM BIOPH RES CO, V213, P138, DOI 10.1006/bbrc.1995.2108; FORTE M, 1987, J BIOENERG BIOMEMBR, V19, P341, DOI 10.1007/BF00768537; Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hajnoczky G, 2002, CELL CALCIUM, V32, P363, DOI 10.1016/S0143416002001872; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Henry-Mowatt J, 2004, ONCOGENE, V23, P2850, DOI 10.1038/sj.onc.1207534; Jonas EA, 1999, SCIENCE, V286, P1347, DOI 10.1126/science.286.5443.1347; KINNALLY KW, 1987, FEBS LETT, V226, P83, DOI 10.1016/0014-5793(87)80555-0; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Komarov AG, 2005, BIOPHYS J, V89, P3950, DOI 10.1529/biophysj.105.070037; Lemasters JJ, 2006, BBA-MOL BASIS DIS, V1762, P181, DOI 10.1016/j.bbadis.2005.10.006; Lemeshko VV, 2004, EUR BIOPHYS J BIOPHY, V33, P352, DOI 10.1007/s00249-003-0362-3; LIU MY, 1992, J BIOENERG BIOMEMBR, V24, P41, DOI 10.1007/BF00769529; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; MORAN O, 1992, EUR BIOPHYS J BIOPHY, V20, P311, DOI 10.1007/BF00196590; Pacher P, 2002, P NATL ACAD SCI USA, V99, P2380, DOI 10.1073/pnas.032423699; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Porcelli AM, 2005, BIOCHEM BIOPH RES CO, V326, P799, DOI 10.1016/j.bbrc.2004.11.105; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto Rosario, 2004, Sci STKE, V2004, pre1, DOI 10.1126/stke.2152004re1; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Rostovtseva TK, 2000, P NATL ACAD SCI USA, V97, P7819, DOI 10.1073/pnas.140115397; Rudel T, 1996, CELL, V85, P391, DOI 10.1016/S0092-8674(00)81117-4; SAKS VA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P134, DOI 10.1016/0005-2728(93)90166-D; Shao L, 1996, BIOPHYS J, V71, P778, DOI 10.1016/S0006-3495(96)79277-9; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; SZABO I, 1993, FEBS LETT, V330, P206, DOI 10.1016/0014-5793(93)80274-X; SZABO I, 1993, FEBS LETT, V330, P201, DOI 10.1016/0014-5793(93)80273-W; Vander Heiden MG, 1999, MOL CELL, V3, P159; Yehezkel G, 2006, J BIOL CHEM, V281, P5938, DOI 10.1074/jbc.M510104200; Zalk R, 2005, BIOCHEM J, V386, P73, DOI 10.1042/BJ20041356; ZIZI M, 1994, J BIOL CHEM, V269, P1614	57	166	171	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17347	17358		10.1074/jbc.M600906200	http://dx.doi.org/10.1074/jbc.M600906200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16597621	hybrid			2022-12-25	WOS:000238326300061
J	Gross, J; Cho, WK; Lezhneva, L; Falk, J; Krupinska, K; Shinozaki, K; Seki, M; Herrmann, RG; Meurer, J				Gross, Jeferson; Cho, Won Kyong; Lezhneva, Lina; Falk, Jon; Krupinska, Karin; Shinozaki, Kazuo; Seki, Motoaki; Herrmann, Reinhold G.; Meurer, Joerg			A plant locus essential for phylloquinone (vitamin K-1) biosynthesis originated from a fusion of four eubacterial genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOCHORISMATE SYNTHASE GENES; SYNECHOCYSTIS SP PCC-6803; PHOTOSYSTEM-I; ARABIDOPSIS-THALIANA; PROTEIN INTERACTIONS; SALICYLIC-ACID; COMPLEXES; PATHWAY; SITE; CHLOROPLASTS	Phylloquinone is a compound present in all photosynthetic plants serving as cofactor for Photosystem I-mediated electron transport. Newly identified seedling-lethal Arabidopsis thaliana mutants impaired in the biosynthesis of phylloquinone possess reduced Photosystem I activity. The affected gene, called PHYLLO, consists of a fusion of four previously individual eubacterial genes, menF, menD, menC, and menH, required for the biosynthesis of phylloquinone in photosynthetic cyanobacteria and the respiratory menaquinone in eubacteria. The fact that homologous men genes reside as polycistronic units in eubacterial chromosomes and in plastomes of red algae strongly suggests that PHYLLO derived from a plastid operon during endosymbiosis. The principle architecture of the fused PHYLLO locus is conserved in the nuclear genomes of plants, green algae, and the diatom alga Thalassiosira pseudonana. The latter arose from secondary endosymbiosis of a red algae and a eukaryotic host indicating selective driving forces for maintenance and/or independent generation of the composite gene cluster within the nuclear genomes. Besides, individual menF genes, encoding active isochorismate synthases (ICS), have been established followed by splitting of the essential 3' region of the menF module of PHYLLO only in genomes of higher plants. This resulted in inactivation of the ICS activity encoded by PHYLLO and enabled a metabolic branch from the phylloquinone biosynthetic route to independently regulate the synthesis of salicylic acid required for plant defense. Therefore, gene fusion, duplication, and fission events adapted a eubacterial multienzymatic system to the metabolic requirements of plants.	Univ Munich, Dept Biol 1, D-80638 Munich, Germany; Univ Kiel, Inst Bot, D-24098 Kiel, Germany; RIKEN, Yokohama Inst, Genom Sci Ctr, Plant Funct Genom Res Grp,Plant Mutat Explorat Te, Yokohama, Kanagawa 2300045, Japan	University of Munich; University of Kiel; RIKEN	Meurer, J (corresponding author), Univ Munich, Dept Biol 1, Menzinger Str 67, D-80638 Munich, Germany.	joerg.meurer@lrz.uni-muenchen.de	Seki, Motoaki/I-2854-2012; Meurer, Jörg/F-8479-2010; Cho, Won Kyong/I-5098-2012; Shinozaki, Kazuo/G-4202-2013	Seki, Motoaki/0000-0001-8288-0467; Meurer, Jörg/0000-0003-2973-9514; Cho, Won Kyong/0000-0002-8416-5173; Shinozaki, Kazuo/0000-0002-6317-9867				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amann K, 2004, PLANT CELL, V16, P3084, DOI 10.1105/tpc.104.024935; Andersson JO, 2002, EUKARYOT CELL, V1, P304, DOI 10.1128/EC.1.2.304-310.2002; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Bridge A, 2000, BBA-BIOMEMBRANES, V1463, P448, DOI 10.1016/S0005-2736(99)00239-4; Brodersen P, 2005, PLANT PHYSIOL, V138, P1037, DOI 10.1104/pp.105.059303; Buss K, 2001, BBA-GENE STRUCT EXPR, V1522, P151, DOI 10.1016/S0167-4781(01)00325-6; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; Golbeck JH, 2003, ANNU REV BIOPH BIOM, V32, P237, DOI 10.1146/annurev.biophys.32.110601.142356; Gross J, 2003, GENET MOL BIOL, V26, P477, DOI 10.1590/S1415-47572003000400012; James CL, 2002, BIOCHEMISTRY-US, V41, P3726, DOI 10.1021/bi0159074; Johnson TW, 2000, J BIOL CHEM, V275, P8523, DOI 10.1074/jbc.275.12.8523; Johnson TW, 2003, BBA-BIOENERGETICS, V1557, P67, DOI 10.1016/S0005-2728(02)00396-1; Kennedy SP, 2001, GENOME RES, V11, P1641, DOI 10.1101/gr.190201; KLUGHAMMER C, 1994, PLANTA, V192, P261, DOI 10.1007/BF01089043; Lezhneva L, 2004, PLANT J, V38, P740, DOI 10.1111/j.1365-313X.2004.02081.x; Lezhneva L, 2004, PLANT J, V37, P174, DOI 10.1046/j.1365-313X.2003.01952.x; Lochner K, 2003, BIOFACTORS, V18, P73, DOI 10.1002/biof.5520180209; Lopez PJ, 2005, CURR OPIN BIOTECH, V16, P180, DOI 10.1016/j.copbio.2005.02.002; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Martin W, 2002, P NATL ACAD SCI USA, V99, P12246, DOI 10.1073/pnas.182432999; Meganathan R, 2001, VITAM HORM, V61, P173; Meurer J, 1996, PLANTA, V198, P385, DOI 10.1007/BF00620055; Rowland BM, 1996, J BACTERIOL, V178, P854, DOI 10.1128/jb.178.3.854-861.1996; Sakuragi Y, 2002, BIOCHEMISTRY-US, V41, P394, DOI 10.1021/bi011297w; Saxena SP, 2001, APOPTOSIS, V6, P57, DOI 10.1023/A:1009624111275; SCHULTZ G, 1981, EUR J BIOCHEM, V117, P329, DOI 10.1111/j.1432-1033.1981.tb06341.x; Seki M, 2002, SCIENCE, V296, P141, DOI 10.1126/science.1071006; Shimada H, 2005, PLANT J, V41, P627, DOI 10.1111/j.1365-313X.2004.02326.x; Teichmann SA, 2004, GENETICS, V167, P2121, DOI 10.1534/genetics.103.024505; Tsoka S, 2000, NAT GENET, V26, P141, DOI 10.1038/79847; Wildermuth MC, 2001, NATURE, V414, P562, DOI 10.1038/35107108; Winkel BSJ, 2004, ANNU REV PLANT BIOL, V55, P85, DOI 10.1146/annurev.arplant.55.031903.141714; Yanai I, 2001, P NATL ACAD SCI USA, V98, P7940, DOI 10.1073/pnas.141236298; Yanai I, 2002, GENOME BIOL, V3	35	95	104	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17189	17196		10.1074/jbc.M601754200	http://dx.doi.org/10.1074/jbc.M601754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16617180	hybrid			2022-12-25	WOS:000238326300044
J	Kuzuhara, T; Sei, Y; Yamaguchi, K; Suganuma, M; Fujiki, H				Kuzuhara, Takashi; Sei, Yoshihisa; Yamaguchi, Kentaro; Suganuma, Masami; Fujiki, Hirota			DNA and RNA as new binding targets of green tea catechins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; CANCER-CELL-LINES; (-)-EPIGALLOCATECHIN GALLATE; PREVENTION; INHIBITION; POLYPHENOL; EXPRESSION; PROMOTER; HUMANS; DAMAGE	The significance of catechins, the main constituent of green tea, is being increasingly recognized with regard to cancer prevention. Catechins have been studied for interactions with various proteins, but the mechanisms of the various catechins are not yet elucidated. Based on our previous observation that nucleic acids extracted from catechin-treated cells are colored, we studied whether catechins directly interact with nucleic acids using surface plasmon resonance assay(Biacore) and cold spray ionization-mass spectrometry. These two methods clearly showed that (-)-epigallocatechin gallate (EGCG) binds to both DNA and RNA molecules: the Biacore assay indicated that four catechins bound to DNA oligomers, and cold spray ionization-mass spectrometry analysis showed one to three EGCG molecules bound to single strand 18 mers of DNA and RNA. Moreover, one or two molecules of EGCG bound to double-stranded (AG-CT) oligomers of various nucleotide lengths. These results suggest that multiple binding sites of EGCG are present in DNA and RNA oligomers. Double-stranded DNA(dsDNA) oligomers were detected only as EGCG-bound forms at high temperature, whereas at low temperature both the free and bound forms were detected, suggesting that EGCG protects dsDNA oligomers from dsDNA melting to single-stranded DNA. Because both galloyl and catechol groups of EGCG are essential for DNA binding, both groups seem to hold strands of DNA via their branching structure. These findings reveal for the first time the link between catechins and polynucleotides and will intensify our understanding of the effects of catechins on DNA in terms of cancer prevention.	Univ Tokushima, Fac Pharmaceut Sci, Biochem Lab, Yamashiro, Tokushima 7708514, Japan; Tokushima Bunri Univ, Fac Pharmaceut Sci, Analyt Chem Lab, Sanuki, Kagawa 7692193, Japan	Tokushima University; Tokushima Bunri University	Kuzuhara, T (corresponding author), Univ Tokushima, Fac Pharmaceut Sci, Biochem Lab, Yamashiro, Tokushima 7708514, Japan.	kuzuhara@ph.bunri-u.ac.jp		Kuzuhara, Takashi/0000-0003-0565-6060				Balasubramanian S, 2004, J BIOL CHEM, V279, P24007, DOI 10.1074/jbc.M314331200; Berger SJ, 2001, BIOCHEM BIOPH RES CO, V288, P101, DOI 10.1006/bbrc.2001.5736; Bertram B, 2003, MUTAT RES-GEN TOX EN, V534, P77, DOI 10.1016/S1383-5718(02)00245-0; Fang MZ, 2003, CANCER RES, V63, P7563; Fujiki H, 1999, J CANCER RES CLIN, V125, P589, DOI 10.1007/s004320050321; Fujiki H, 2005, CHEM REC, V5, P119, DOI 10.1002/tcr.20039; Fujiki H, 2005, J ENVIRON SCI HEAL C, V23, P3, DOI 10.1081/GNC-200051849; Fujiki H, 2002, P JPN ACAD B-PHYS, V78, P263, DOI 10.2183/pjab.78.263; Fujiki H, 2002, CANCER LETT, V188, P9, DOI 10.1016/S0304-3835(02)00379-8; FUJIKI H, 1992, DRUGS FUTURE, V17, P462; Fujimoto N, 2002, INT J ONCOL, V20, P1233; Johnson MK, 2000, MUTAT RES-DNA REPAIR, V459, P211, DOI 10.1016/S0921-8777(99)00074-9; Kitano K, 1997, BIOPHYS CHEM, V65, P157, DOI 10.1016/S0301-4622(96)02254-5; Kramata P, 2005, CARCINOGENESIS, V26, P1965, DOI 10.1093/carcin/bgi162; Mizushina Y, 2005, BIOCHEM BIOPH RES CO, V333, P101, DOI 10.1016/j.bbrc.2005.05.093; Nakachi K, 2000, BIOFACTORS, V13, P49, DOI 10.1002/biof.5520130109; *NCI DCPC, 1996, J CELL BIOCHEM, V26, P236; Okabe S, 1999, JPN J CANCER RES, V90, P733, DOI 10.1111/j.1349-7006.1999.tb00808.x; Okabe S, 2001, BIOL PHARM BULL, V24, P883, DOI 10.1248/bpb.24.883; Okabe S, 1997, JPN J CANCER RES, V88, P639, DOI 10.1111/j.1349-7006.1997.tb00431.x; OKUDA T, 1985, CHEM PHARM BULL, V33, P1424; Sakamoto S, 2003, ANGEW CHEM INT EDIT, V42, P905, DOI 10.1002/anie.200390239; Sueoka N, 2001, ANN NY ACAD SCI, V928, P274; Suganuma M, 1998, CARCINOGENESIS, V19, P1771, DOI 10.1093/carcin/19.10.1771; Suganuma M, 1996, CANCER RES, V56, P3711; Suganuma M, 2000, BIOFACTORS, V13, P67, DOI 10.1002/biof.5520130112; WANG ZY, 1992, CANCER RES, V52, P1943; Yamaguchi K, 2003, J MASS SPECTROM, V38, P473, DOI 10.1002/jms.488; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; YOSHIZAWA S, 1992, ACS SYM SER, V507, P316; Yoshizawa S., 1987, PHYTOTHER RES, V1, P44, DOI [10.1002/ptr.2650010110, DOI 10.1002/PTR.2650010110]	31	107	118	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17446	17456		10.1074/jbc.M601196200	http://dx.doi.org/10.1074/jbc.M601196200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16641087	hybrid			2022-12-25	WOS:000238326300070
J	Poea-Guyon, S; Amar, M; Fossier, P; Morel, N				Poea-Guyon, Sandrine; Amar, Muriel; Fossier, Philippe; Morel, Nicolas			Alternative splicing controls neuronal expression of v-ATPase subunit a1 and sorting to nerve terminals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; CHOLINERGIC SYNAPTIC VESICLES; IN-VIVO DISSOCIATION; HIPPOCAMPAL-NEURONS; 116-KDA POLYPEPTIDE; MEMBRANE-FUSION; PLASMA-MEMBRANE; ISOFORMS; TRANSPORT	Vacuolar proton ATPase accumulates protons inside various intracellular organelles such as synaptic vesicles; its membrane domain V0 could also be involved in membrane fusion. These different functions could require vacuolar proton ATPases possessing different V0 subunit a isoforms. In vertebrates, four genes encode isoforms a1-a4, and a1 variants are also generated by alternative splicing. We identified a novel a1 splice variant a1-IV and showed that the two a1 variants containing exon Care specifically expressed in neurons. Single neurons coexpress a2, a1-I, and a1-IV, and these subunit a isoforms are targeted to different membrane compartments. Recombinant a2 was accumulated in the trans-Golgi network, and a1-I was concentrated in axonal varicosities, whereas a1-IV was sorted to both distal dendrites and axons. Our results indicate that alternative splicing of exon N controls differential sorting of a1 variants to nerve terminals or distal dendrites, whereas exon C regulates their neuronal expression.	CNRS, Neurobiol Cellulaire & Mol Lab, UPR 9040, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Morel, N (corresponding author), CNRS, Neurobiol Cellulaire & Mol Lab, UPR 9040, F-91198 Gif Sur Yvette, France.	nicolas.morel@nbcm.cnrs-gif.fr						Bayer MJ, 2003, J CELL BIOL, V162, P211, DOI 10.1083/jcb.200212004; Fache MP, 2004, J CELL BIOL, V166, P571, DOI 10.1083/jcb.200312155; FULDNER HH, 1982, EUR J BIOCHEM, V121, P519, DOI 10.1111/j.1432-1033.1982.tb05817.x; Goslin K., 1998, CULTURING NERVE CELL, P339; HICKS BW, 1992, J NEUROCHEM, V58, P1211, DOI 10.1111/j.1471-4159.1992.tb11331.x; Hiesinger PR, 2005, CELL, V121, P607, DOI 10.1016/j.cell.2005.03.012; Kane PM, 1999, J BIOL CHEM, V274, P17275, DOI 10.1074/jbc.274.24.17275; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P17941, DOI 10.1074/jbc.M010790200; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Malkus P, 2004, MOL BIOL CELL, V15, P5075, DOI 10.1091/mbc.E04-06-0514; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MICHAELSON DM, 1980, LIFE SCI, V27, P39, DOI 10.1016/0024-3205(80)90017-X; Morel N, 2003, J CELL SCI, V116, P4751, DOI 10.1242/jcs.00791; Morel N, 2001, J NEUROCHEM, V79, P485, DOI 10.1046/j.1471-4159.2001.00611.x; Morel N, 1998, J NEUROCHEM, V71, P1702; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; PENG SB, 1994, J BIOL CHEM, V269, P17262; Pennuto M, 2003, MOL BIOL CELL, V14, P4909, DOI 10.1091/mbc.E03-06-0380; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Pietrement C, 2006, BIOL REPROD, V74, P185, DOI 10.1095/biolreprod.105.043752; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Sampo B, 2003, NEURON, V37, P611, DOI 10.1016/S0896-6273(03)00058-8; STADLER H, 1984, EMBO J, V3, P3333, DOI 10.1002/j.1460-2075.1984.tb02300.x; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Tsuzuki K, 2001, J NEUROCHEM, V77, P1650, DOI 10.1046/j.1471-4159.2001.00388.x; West AE, 1997, J CELL BIOL, V139, P917, DOI 10.1083/jcb.139.4.917	32	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17164	17172		10.1074/jbc.M600927200	http://dx.doi.org/10.1074/jbc.M600927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16621796	hybrid			2022-12-25	WOS:000238326300041
J	Cooper, A; Shaul, Y				Cooper, Arik; Shaul, Yosef			Clathrin-mediated endocytosis and lysosomal cleavage of hepatitis B virus capsid-like core particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; CELL-PENETRATING PEPTIDES; ESCHERICHIA-COLI; COATED PITS; T-CELLS; PROTEIN; SURFACE; OLIGONUCLEOTIDES; EXPRESSION; RESPONSES	The hepatitis B virus (HBV) core particle serves as a protective capsid shell for the viral genome and is highly immunogenic. Recombinant capsid-like core particles are used as effective carriers of foreign T and B cell epitopes and as delivery vehicles for oligonucleotides. The core monomer contains an arginine-rich C terminus that directs core particle attachment to cells via membrane heparan sulfate proteoglycans. Here we investigated the mechanism of recombinant core particle uptake and its intracellular fate following heparan sulfate binding. We found that the core particles are internalized in an energy-dependent manner. Core particle uptake is inhibited by chlorpromazine and by cytosol acidification known to block clathrin-mediated endocytosis but not by nystatin, which blocks lipid raft endocytosis. Particle uptake is abolished by expression of dominant negative forms of eps15 and Rab5, adaptors involved in clathrin-mediated endocytosis and early endosome transport, respectively. Endocytosed particles are transported to lysosomes where the core monomer is endoproteolytically cleaved into its distinct domains. Using protease inhibitors, cathepsin B was identified as the enzyme responsible for core monomer cleavage. Finally we found that monomer cleavage promotes particle dissociation within cells. Together, our results show that HBV capsid-like core particles are internalized through clathrin-mediated endocytosis, leading to lysosomal cleavage of the core monomer and particle dissociation.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	yosef.shaul@weizmann.ac.il						Benmerah A, 1999, J CELL SCI, V112, P1303; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; Ceresa BP, 2001, J BIOL CHEM, V276, P9649, DOI 10.1074/jbc.M010387200; CHANG C, 1994, J VIROL, V68, P5225, DOI 10.1128/JVI.68.8.5225-5231.1994; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cooper A, 2005, BIOCHEM BIOPH RES CO, V327, P1094, DOI 10.1016/j.bbrc.2004.12.118; Cooper A, 2005, J IMMUNOL, V175, P3165, DOI 10.4049/jimmunol.175.5.3165; CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2; Diepolder HM, 1999, GASTROENTEROLOGY, V116, P650, DOI 10.1016/S0016-5085(99)70187-3; Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200; GALLINA A, 1989, J VIROL, V63, P4645, DOI 10.1128/JVI.63.11.4645-4652.1989; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Hollinger F.B., 2001, FIELDS VIROLOGY, P2971; Konig S, 1998, J VIROL, V72, P4997; Melikov K, 2005, CELL MOL LIFE SCI, V62, P2739, DOI 10.1007/s00018-005-5293-y; MIYANOHARA A, 1986, J VIROL, V59, P176, DOI 10.1128/JVI.59.1.176-180.1986; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; Pumpens P, 2001, INTERVIROLOGY, V44, P98, DOI 10.1159/000050037; Riedl P, 2002, EUR J IMMUNOL, V32, P1709, DOI 10.1002/1521-4141(200206)32:6<1709::AID-IMMU1709>3.0.CO;2-D; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Schirmbeck R, 2003, J IMMUNOL, V171, P5198, DOI 10.4049/jimmunol.171.10.5198; SEIFER M, 1994, J VIROL, V68, P5548, DOI 10.1128/JVI.68.9.5548-5555.1994; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; Storni T, 2004, J IMMUNOL, V172, P6129, DOI 10.4049/jimmunol.172.10.6129; Storni T, 2004, J IMMUNOL, V172, P1777, DOI 10.4049/jimmunol.172.3.1777; Vanlandschoot P, 2005, J GEN VIROL, V86, P75, DOI 10.1099/vir.0.80580-0; Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03-12-0921; Vitelli R, 1997, J BIOL CHEM, V272, P4391, DOI 10.1074/jbc.272.7.4391; WINGFIELD PT, 1995, BIOCHEMISTRY-US, V34, P4919, DOI 10.1021/bi00015a003; Wynne SA, 1999, MOL CELL, V3, P771, DOI 10.1016/S1097-2765(01)80009-5; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; ZHOU SL, 1991, J VIROL, V65, P5457, DOI 10.1128/JVI.65.10.5457-5464.1991	33	60	63	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16563	16569		10.1074/jbc.M601418200	http://dx.doi.org/10.1074/jbc.M601418200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16618702	hybrid			2022-12-25	WOS:000238165700047
J	Cohen, DM; Kutscher, B; Chen, H; Murphy, DB; Craig, SW				Cohen, Daniel M.; Kutscher, Brett; Chen, Hui; Murphy, Douglas B.; Craig, Susan W.			A conformational switch in vinculin drives formation and dynamics of a talin-vinculin complex at focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; ALPHA-ACTININ; CELL MECHANICS; INTEGRIN; ACTIVATION; PAXILLIN; HEAD; FIBRONECTIN; SURVIVAL; REQUIRES	Dynamic interactions between the cytoskeleton and integrins control cell adhesion, but regulatory mechanisms remain largely undefined. Here, we tested the extent to which the autoinhibitory head-tail interaction (HTI) in vinculin regulates formation and lifetime of the talin-vinculin complex, a proposed mediator of integrin cytoskeletonbonds. Inanectopicrecruitmentassay, mutationalreduction of HTI drove assembly of talin-vinculin complexes, whereas ectopic complexes did not form between talin and wild-type vinculin. Moreover, reduction of HTI altered the dynamic assembly of vinculin and talin in focal adhesions. Using fluorescence recovery after photobleaching, we show that the focal adhesion residency time of vinculin was enhanced up to 3-fold by HTI mutations. The slow dynamics of vinculin correlated with exposure of its cryptic talin-binding site, and a talin-binding site mutation rescued the dynamics of activated vinculin. Significantly, HTI-deficient vinculin inhibited the focal adhesion dynamics of talin, but not paxillin or alpha-actinin. These data show that talin conformation in cells permits vinculin binding, whereas the autoinhibited conformation of vinculin constitutes the barrier to complex formation. Down-regulation of HTI in vinculin to K-d similar to 10(-7) is sufficient to induce talin binding, and HTI is essential to the dynamics of vinculin and talin at focal adhesions. We therefore conclude that vinculin conformation, as modulated by the strength of HTI, directly regulates the formation and lifetime of talin-vinculin complexes in cells.	Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Elect Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Craig, SW (corresponding author), Johns Hopkins Sch Med, Dept Biol Chem, 503 WBSB,725 N Wolfe St, Baltimore, MD 21205 USA.	scraig@jhmi.edu		Cohen, Daniel/0000-0002-7963-668X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041605, R56GM041605] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41605] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alenghat FJ, 2000, BIOCHEM BIOPH RES CO, V277, P93, DOI 10.1006/bbrc.2000.3636; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; Bois PRJ, 2005, MOL CELL BIOL, V25, P6112, DOI 10.1128/MCB.25.14.6112-6122.2005; Bois PRJ, 2006, J BIOL CHEM, V281, P7228, DOI 10.1074/jbc.M510397200; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Chandrasekar I, 2005, J CELL SCI, V118, P1461, DOI 10.1242/jcs.01734; Chen H, 2005, J CELL BIOL, V169, P459, DOI 10.1083/jcb.200410100; Cluzel C, 2005, J CELL BIOL, V171, P383, DOI 10.1083/jcb.200503017; Cohen DM, 2005, J BIOL CHEM, V280, P17109, DOI 10.1074/jbc.M414704200; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; DAMSKY CH, 1985, J CELL BIOL, V100, P1528, DOI 10.1083/jcb.100.5.1528; Fillingham I, 2005, STRUCTURE, V13, P65, DOI 10.1016/j.str.2004.11.006; Fraley TS, 2005, J BIOL CHEM, V280, P15479, DOI 10.1074/jbc.M500631200; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Gingras AR, 2006, BIOCHEMISTRY-US, V45, P1805, DOI 10.1021/bi052136l; Gingras AR, 2005, J BIOL CHEM, V280, P37217, DOI 10.1074/jbc.M508060200; Goldmann WH, 2002, BIOCHEM BIOPH RES CO, V290, P749, DOI 10.1006/bbrc.2001.6243; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Klonis N, 2002, EUR BIOPHYS J BIOPHY, V31, P36, DOI 10.1007/s00249-001-0202-2; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; NEFF NT, 1982, J CELL BIOL, V95, P654, DOI 10.1083/jcb.95.2.654; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; Patel B, 2006, J BIOL CHEM, V281, P7458, DOI 10.1074/jbc.M508058200; PISTOR S, 1994, EMBO J, V13, P758, DOI 10.1002/j.1460-2075.1994.tb06318.x; Ren XD, 2000, J CELL SCI, V113, P3673; Subauste MC, 2004, J CELL BIOL, V165, P371, DOI 10.1083/jcb.200308011; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Tsuruta D, 2002, FASEB J, V16, P866, DOI 10.1096/fj.01-0878fje; von Wichert G, 2003, EMBO J, V22, P5023, DOI 10.1093/emboj/cdg492; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wehrle-Haller B, 2002, TRENDS CELL BIOL, V12, P382, DOI 10.1016/S0962-8924(02)02321-8; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Xu WM, 1998, DEVELOPMENT, V125, P327; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200	43	117	119	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16006	16015		10.1074/jbc.M600738200	http://dx.doi.org/10.1074/jbc.M600738200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16608855	hybrid			2022-12-25	WOS:000237996000052
J	Liu, ZM; Kostenko, EV; Mahon, GM; Olabisi, OO; Whitehead, IP				Liu, Zhuoming; Kostenko, Elena V.; Mahon, Gwendolyn M.; Olabisi, Oyenike O.; Whitehead, Ian P.			Transformation by the Rho-specific guanine nucleotide exchange factor Dbs requires ROCK I-mediated phosphorylation of myosin light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE-RHO; BINDING PROTEIN-RHO; HOMOLOGY DOMAIN; C-JUN; CYTOSKELETAL ORGANIZATION; SERINE/THREONINE KINASE; RAS TRANSFORMATION; MYELOID-LEUKEMIA; PUTATIVE TARGET; FAMILY PROTEINS	Dbs was identified in a cDNA-based expression screen for sequences that can cause malignant growth when expressed in murine fibroblasts. In previous studies we have shown that Dbs is a Rho-specific guanine nucleotide exchange factor that can activate RhoA and/or Cdc42 in a cell-specific manner. In this current study we have used a combination of genetic and pharmacological approaches to examine the relative contributions of RhoA(.)PRK and RhoA(.)ROCK signaling to Dbs transformation. Our analysis indicates that ROCK is activated in Dbs-transformed cells and that Dbs transformation is dependent upon ROCK I activity. In contrast, there appears to be no requirement for PRK activation in Dbs transformation. Dbs transformation is also associated with increased phosphorylation of myosin light chain and stress fiber formation, both of which occur in a ROCK-dependent manner. Suppression of myosin light chain expression by small interfering RNAs impairs Dbs focus formation, thus establishing a direct link between actinomyosin contraction and Rho-specific guanine nucleotide exchange factor transformation.	Univ Med & Dent New Jersey, Dept Microbiol & Mol Genet, New Jersey Med Sch, Int Ctr Publ Hlth, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Whitehead, IP (corresponding author), Univ Med & Dent New Jersey, Dept Microbiol & Mol Genet, New Jersey Med Sch, Int Ctr Publ Hlth, 225 Warren St, Newark, NJ 07103 USA.	whiteip@umdnj.edu	Liu, Zhuoming/I-6950-2013	Liu, Zhuoming/0000-0002-8466-3199	NATIONAL CANCER INSTITUTE [R01CA097066] Funding Source: NIH RePORTER; NCI NIH HHS [CA97066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cheng L, 2004, J BIOL CHEM, V279, P12786, DOI 10.1074/jbc.M313099200; Cheng L, 2002, MOL CELL BIOL, V22, P6895, DOI 10.1128/MCB.22.19.6895-6905.2002; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Himmel KL, 2002, J BIOL CHEM, V277, P13463, DOI 10.1074/jbc.M110981200; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Jaffe AB, 2005, CURR BIOL, V15, P405, DOI 10.1016/j.cub.2004.12.082; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kostenko EV, 2005, J BIOL CHEM, V280, P2807, DOI 10.1074/jbc.M411139200; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Maru Y, 2001, INT J HEMATOL, V73, P308, DOI 10.1007/BF02981955; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Rossman KL, 2003, J BIOL CHEM, V278, P18393, DOI 10.1074/jbc.M300127200; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Torbett NE, 2003, J BIOL CHEM, V278, P32344, DOI 10.1074/jbc.M303532200; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Xie XZ, 2005, CELL SIGNAL, V17, P461, DOI 10.1016/j.cellsig.2004.09.012; Zhu YM, 2004, FASEB J, V18, P1722, DOI 10.1096/fj.04-1876fje; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	49	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16043	16051		10.1074/jbc.M601823200	http://dx.doi.org/10.1074/jbc.M601823200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16613852	hybrid			2022-12-25	WOS:000237996000056
J	Bouhy, D; Malgrange, B; Multon, S; Poirrier, AL; Scholtes, F; Schoenen, J; Franzen, R				Bouhy, Delphine; Malgrange, Brigitte; Multon, Sylvie; Poirrier, Anne-Lise; Scholtes, Felix; Schoenen, Jean; Franzen, Rachelle			Delayed GM-CSF treatment stimulates axonal regeneration and functional recovery in paraplegic rats via an increased BDNF expression by endogenous macrophages	FASEB JOURNAL			English	Article						spinal cord injury; axonal regrowth; cytokine; neurotrophin	SPINAL-CORD-INJURY; NECROSIS-FACTOR-ALPHA; NEUROTROPHIC FACTOR; COMPRESSION-INJURY; LOCOMOTOR RECOVERY; UP-REGULATION; BRAIN; PROMOTE; CELLS; TRANSPLANTATION	Macrophages (monocytes/microglia) could play a critical role in central nervous system repair. We have previously found a synchronism between the regression of spontaneous axonal regeneration and the deactivation of macrophages 3-4 wk after a compression-injury of rat spinal cord. To explore whether reactivation of endogenous macrophages might be beneficial for spinal cord repair, we have studied the effects of granulocyte-macrophage colony stimulating factor (GM-CSF) in the same paraplegia model and in cell cultures. There was a significant, though transient, improvement of locomotor recovery after a single delayed intraperitoneal injection of 2 mu g GM-CSF, which also increased significantly the expression of Cr3 and brain-derived neurotrophic factor ( BDNF) by macrophages at the lesion site. At longer survival delays, axonal regeneration was significantly enhanced in GMCSF-treated rats. In vitro, BV2 microglial cells expressed higher levels of BDNF in the presence of GM-CSF and neurons cocultured with microglial cells activated by GM-CSF generated more neurites, an effect blocked by a BDNF antibody. These experiments suggest that GM-CSF could be an interesting treatment option for spinal cord injury and that its beneficial effects might be mediated by BDNF.-Bouhy, D., Malgrange, B., Multon, S., Poirrier, A. L., Scholtes, F., Schoenen, J., Franzen, R. Delayed GM-CSF treatment stimulates axonal regeneration and functional recovery in paraplegic rats via an increased BDNF expression by endogenous macrophages.	Univ Liege, Res Ctr Cellular & Mol Neurobiol, B-4000 Cointe Ougree, Belgium	University of Liege	Franzen, R (corresponding author), Univ Liege, Res Ctr Cellular & Mol Neurobiol, Tour Pathol B36,1er Etage,Local 1-4A, B-4000 Cointe Ougree, Belgium.	rfranzen@ulg.ac.be	malgrange, brigitte/A-4887-2019; Malgrange, Brigitte/F-8384-2010	malgrange, brigitte/0000-0002-8957-2528; Poirrier, Anne-Lise/0000-0002-1247-2334				Ankeny DP, 2001, EXP NEUROL, V170, P85, DOI 10.1006/exnr.2001.7699; Barouch R, 2001, J NEUROIMMUNOL, V112, P72, DOI 10.1016/S0165-5728(00)00408-2; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bomstein Y, 2003, J NEUROIMMUNOL, V142, P10, DOI 10.1016/S0165-5728(03)00260-1; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; Brook GA, 1998, J NEUROSCI RES, V53, P51, DOI 10.1002/(SICI)1097-4547(19980701)53:1<51::AID-JNR6>3.0.CO;2-I; BUNGE RP, 1993, ADV NEUROL, V59, P75; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; COLLINS HL, 1992, EUR J IMMUNOL, V22, P1447, DOI 10.1002/eji.1830220617; DELREE P, 1989, J NEUROSCI RES, V23, P198, DOI 10.1002/jnr.490230210; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Franzen R, 2004, NEUROSCI LETT, V361, P76, DOI 10.1016/j.neulet.2003.12.018; Franzen R, 1998, J NEUROSCI RES, V51, P316, DOI 10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.0.CO;2-J; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Guner H, 2003, INT J GYNECOL OBSTET, V83, P317, DOI 10.1016/S0020-7292(03)00296-0; Ha Y, 2005, J NEUROSURG-SPINE, V2, P55, DOI 10.3171/spi.2005.2.1.0055; Hashimoto M, 2005, NEUROREPORT, V16, P99, DOI 10.1097/00001756-200502080-00004; Hauben E, 2003, TRENDS PHARMACOL SCI, V24, P7, DOI 10.1016/S0165-6147(02)00013-5; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Ikeda O, 2001, ACTA NEUROPATHOL, V102, P239; KAMEGAI M, 1990, BRAIN RES, V532, P323, DOI 10.1016/0006-8993(90)91775-C; Kannan Y, 2000, NEUROIMMUNOMODULAT, V8, P132, DOI 10.1159/000054273; Kim JK, 2004, NEUROREPORT, V15, P2161, DOI 10.1097/00001756-200410050-00003; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; Koda M, 2004, J NEUROTRAUM, V21, P329, DOI 10.1089/089771504322972112; Lacroix S, 2002, J COMP NEUROL, V454, P213, DOI 10.1002/cne.10407; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; Lu J, 2002, BRAIN, V125, P14, DOI 10.1093/brain/awf014; Mabon PJ, 2000, EXP NEUROL, V166, P52, DOI 10.1006/exnr.2000.7488; Mamounas LA, 2000, J NEUROSCI, V20, P771, DOI 10.1523/JNEUROSCI.20-02-00771.2000; MARTIN D, 1992, J NEUROSCI RES, V32, P539, DOI 10.1002/jnr.490320409; McLay RN, 1997, BRAIN, V120, P2083, DOI 10.1093/brain/120.11.2083; Nakajima K, 2001, J NEUROSCI RES, V65, P322, DOI 10.1002/jnr.1157; Park HC, 2005, TISSUE ENG, V11, P913, DOI 10.1089/ten.2005.11.913; Plant GW, 2003, J NEUROTRAUM, V20, P1, DOI 10.1089/08977150360517146; Poirrier AL, 2004, J NEUROSCI RES, V75, P253, DOI 10.1002/jnr.10852; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Saada A, 1996, J CELL BIOL, V133, P159, DOI 10.1083/jcb.133.1.159; Schwartz M, 1999, NEUROSURGERY, V44, P1041, DOI 10.1097/00006123-199905000-00057; Shibata A, 2003, J NEUROIMMUNOL, V142, P112, DOI 10.1016/S0165-5728(03)00253-4; STERN AC, 1992, INFECTION, V20, pS124, DOI 10.1007/BF01705031; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Verdu E, 2003, GLIA, V42, P275, DOI 10.1002/glia.10217; Watanabe T, 1999, J NEUROTRAUM, V16, P255, DOI 10.1089/neu.1999.16.255; Wu HH, 2003, CANCER-AM CANCER SOC, V98, P2410, DOI 10.1002/cncr.11810; You SW, 2003, RESTOR NEUROL NEUROS, V21, P39; YOUNG W, 1994, ANN NY ACAD SCI, V743, P241, DOI 10.1111/j.1749-6632.1994.tb55796.x; Zylinska K, 1999, Pituitary, V2, P211, DOI 10.1023/A:1009905427902	55	85	87	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1239	+		10.1096/fj.05-4382fje	http://dx.doi.org/10.1096/fj.05-4382fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636109				2022-12-25	WOS:000240210300038
J	Flourakis, M; Van Coppenolle, F; Lehen'kyi, V; Beck, B; Skryma, R; Prevarskaya, N				Flourakis, Matthieu; Van Coppenolle, Fabien; Lehen'kyi, V'yacheslav; Beck, Benjamin; Skryma, Roman; Prevarskaya, Natalia			Passive calcium leak via translocon is a first step for iPLA(2)-pathway regulated store operated channels activation	FASEB JOURNAL			English	Article						calcium leak; store-operated channels; translocon; iPLA2, calcium homeostasis	ENDOPLASMIC-RETICULUM; ER MEMBRANE; PROTEIN TRANSLOCATION; PERMEABILITY; MESSENGER; INFLUX; CELLS; PORE	Calcium concentration within the endoplasmic reticulum ( ER) plays an essential role in cell physiopathology. One of the most enigmatic mechanisms responsible for Ca2+ concentration in the ER is passive calcium leak. Previous studies have shown that the translocon complex is permeable to calcium. However, the involvement of the translocon in the passive calcium leak has not been directly demonstrated. Furthermore, the question whether the passive store depletion via the translocon could activate SOC ( store operated channels) replenishing the ER, remains still unresolved. In this study, for the first time, we show that thapsigargin and calcium chelators deplete ER via translocon. Indeed, using confocal imaging, we demonstrate that when the number of opened translocons was lowered neither thapsigargin nor calcium chelators could induce ER store depletion. We also demonstrate that calcium leakage occurring via the translocon activates store-operated current, which is, by its kinetic and pharmacology, similar to that evoked by thapsigargin and EGTA ( but not IP3), thus highlighting our hypothesis that calcium leakage via the translocon is a first step for activation of the specific iPLA2-regulated SOC. As the translocon is present in yeast and mammalian cells, our findings suggest that translocon-related calcium signaling is a common phenomenon.	Univ Sci & Technol Lille, Lab Physiol Cellulaire, INSERM U800, F-59655 Villeneuve Dascq, France; Univ Lille 1, F-59655 Villeneuve Dascq, France; Equipe Labellisee Ligue Natl Contre Canc, Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille	Flourakis, M (corresponding author), Univ Sci & Technol Lille, Lab Physiol Cellulaire, INSERM U800, Batiment SN3, F-59655 Villeneuve Dascq, France.	flourakismatt@yahoo.fr; fabien.vancoppenolle@univ-lille1.fr; natacha.prevarskaya@univ-lille1.fr	LEHEN'KYI, V'yacheslav/AAJ-6008-2020	LEHEN'KYI, V'yacheslav/0000-0003-0806-8766; Beck, Benjamin/0000-0001-8162-7566; Flourakis, Matthieu/0000-0002-5366-9125; Prevarskaya, natacha/0000-0003-0316-197X				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BOLOTINA VM, 2004, SCI STKE, pPE34; Gregory RB, 1999, BIOCHEM J, V341, P401, DOI 10.1042/0264-6021:3410401; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Heritage D, 2001, J BIOL CHEM, V276, P22655, DOI 10.1074/jbc.M102409200; Hofer AM, 1996, FASEB J, V10, P302, DOI 10.1096/fasebj.10.2.8641563; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; Ioannou M, 1998, MOL PHARMACOL, V53, P1089; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kaneko M, 2003, LIFE SCI, V74, P199, DOI 10.1016/j.lfs.2003.09.007; Lomax RB, 2002, J BIOL CHEM, V277, P26479, DOI 10.1074/jbc.M201845200; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; Potter MD, 2002, J BIOL CHEM, V277, P23314, DOI 10.1074/jbc.M202559200; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Roy A, 2003, J BIOL CHEM, V278, P4397, DOI 10.1074/jbc.M207295200; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Van Coppenolle F, 2004, J CELL SCI, V117, P4135, DOI 10.1242/jcs.01274; Vanden Abeele F, 2004, J BIOL CHEM, V279, P30326, DOI 10.1074/jbc.M400106200	25	71	71	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1215	+		10.1096/fj.05-5254fje	http://dx.doi.org/10.1096/fj.05-5254fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16611832				2022-12-25	WOS:000240210300030
J	Li, R; Soosairajah, J; Harari, D; Citri, A; Price, J; Ng, HL; Morton, CJ; Parker, MW; Yarden, Y; Bernard, O				Li, Rong; Soosairajah, Juliana; Harari, Daniel; Citri, Ami; Price, John; Ng, Hooi Ling; Morton, Craig J.; Parker, Michael W.; Yarden, Yosef; Bernard, Ora			Hsp90 increases LIM kinase activity by promoting its homo-dimerization	FASEB JOURNAL			English	Article						Rho-GTPases; actin dynamics; half-life; transphosphorylation	ACTIN DYNAMICS; CHAPERONE COMPLEX; PROTEIN; COFILIN; PHOSPHORYLATION; CANCER; DOMAIN; ERBB-2/HER2; ACTIVATION; REGULATOR	LIM kinase 1 (LIMK1) is a serine protein kinase that regulates the actin cytoskeleton by phosphorylation and inactivation of actin depolymerizing factor cofilin. LIMK1 activity is regulated by the Rho-GTPases via their serine/threonine kinase effectors Rho-kinase and p21-activated kinases 1 and 4 that phosphorylate LIMK1 on threonine 508 in its activation loop. The purpose of this study was to elucidate the pathway leading to the stability of LIMK1, a protein with a half-life of similar to 20 h. Because the half-life of kinase-dead LIMK1 is only 4 h, it is suggestive that trans- or auto-phosphorylation is responsible for the stabilization of LIMK1. Using known Hsp90 inhibitors, we have shown that the half-life of LIMK1 in cells depends on the presence of active Hsp90. Furthermore, endogenous LIMK1 coimmunoprecipitated with endogenous Hsp90 and this interaction promoted LIMK1 homodimer formation as seen by cross-linking experiments. Hsp90 binds LIMK1 via a recognition sequence within the LIMK1 kinase domain, homologous to that of ErbB-2. Mutation of a proline residue within this sequence to glutamic acid reduces its interaction with Hsp90, inhibits homodimer formation, and reduces its half-life to 4 h. These findings implicate Hsp90 in the stabilization of LIMK1 by promoting homodimer formation and transphosphorylation.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Ben Gurion Univ Negev, Bioinformat Support Unit, IL-84105 Beer Sheva, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	St. Vincent's Institute of Medical Research; Walter & Eliza Hall Institute; Ben Gurion University; Weizmann Institute of Science	Bernard, O (corresponding author), St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.	obernard@svi.edu.au	Morton, Craig/GON-8638-2022; Parker, Michael W/F-9069-2013; Citri, Ami/R-8973-2019; YARDEN, YOSEF/K-1467-2012	Morton, Craig/0000-0001-5452-5193; Parker, Michael W/0000-0002-3101-1138; Citri, Ami/0000-0002-9914-0278; Price, John/0000-0002-8244-1023				Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Birkenfeld J, 2003, BIOCHEM J, V369, P45, DOI 10.1042/BJ20021152; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Citri A, 2004, EMBO REP, V5, P1165, DOI 10.1038/sj.embor.7400300; Citri A, 2004, CELL CYCLE, V3, P51; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Foletta VC, 2004, EXP CELL RES, V294, P392, DOI 10.1016/j.yexcr.2003.11.024; Foletta VC, 2003, J CELL BIOL, V162, P1089, DOI 10.1083/jcb.200212060; Gohla A, 2002, CURR BIOL, V12, P1704, DOI 10.1016/S0960-9822(02)01184-3; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hiraoka J, 1996, FEBS LETT, V399, P117, DOI 10.1016/S0014-5793(96)01303-8; Ikebe C, 1997, GENOMICS, V46, P504, DOI 10.1006/geno.1997.5060; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Murphy PJM, 2003, J BIOL CHEM, V278, P34764, DOI 10.1074/jbc.M304469200; NUNOUE K, 1995, ONCOGENE, V11, P701; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Xu WP, 2005, NAT STRUCT MOL BIOL, V12, P120, DOI 10.1038/nsmb885; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100	28	39	44	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1218	+		10.1096/fj.05-5258fje	http://dx.doi.org/10.1096/fj.05-5258fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16641196				2022-12-25	WOS:000240210300031
J	Schmelter, M; Ateghang, B; Helmig, S; Wartenberg, M; Sauer, H				Schmelter, Maike; Ateghang, Bernadette; Helmig, Simone; Wartenberg, Maria; Sauer, Heinrich			Embryonic stem cells utilize reactive oxygen species as transducers of mechanical strain-induced cardiovascular differentiation	FASEB JOURNAL			English	Article							LAMINAR SHEAR-STRESS; KAPPA-B ACTIVATION; CARDIOMYOCYTE DIFFERENTIATION; TRANSCRIPTION FACTOR; NAD(P)H OXIDASE; CARDIAC-HYPERTROPHY; OXIDATIVE STRESS; CYCLIC STRAIN; IN-VITRO; STRETCH	Growing stem cells are subjected to mechanical forces, which may initiate differentiation programs. Mechanical strain stimulated cardiovascular differentiation of mouse embryonic stem (ES) cells as evaluated by quantification of contracting cardiac foci and capillary areas, respectively. Mechanical strain rapidly elevated intracellular reactive oxygen species (ROS). After 24 h up-regulation of NADPH oxidase subunits p22-phox, p47-phox, p67-phox, and Nox-4 as well as Nox-1 and Nox-4 mRNA was observed. In parallel, mechanical strain increased hypoxia-inducible factor-1 alpha (HIF-1 alpha) and vascular endothelial growth factor (VEGF) mRNA and protein as well as MEF2C and GATA-4 mRNA, which are involved in cardiovascular development. Furthermore, phosphorylation of extracellular-regulated kinase 1,2 (ERK1,2), p38, and c-jun N-terminal kinase (c-Jun NH2-terminal kinase (JNK)) was observed. Stimulation of cardiovascular commitment, HIF-1 alpha, VEGF, and MEF2C expression as well as MAPK activation were abolished by free radical scavengers, whereas GATA-4 expression was increased. Cardiomyogenesis was inhibited by the p38 inhibitor SB203580, the ERK1,2 inhibitor UO126, and the JNK inhibitor SP600125. Vasculogenesis/ angiogenesis was blunted following inhibition of ERK1,2 and JNK, whereas p38 inhibition was ineffective. Our data outline a role of ROS as mechanotransducing molecules in mechanical strain-stimulated cardiovascular differentiation of ES cells, and point toward a microenvironment of elevated ROS required for signaling cascades initiating cardiovascular differentiation programs.	Univ Giessen, Dept Physiol, D-35392 Giessen, Germany; GKSS Res Inst, Dept Cell Biol, Teltow, Germany	Justus Liebig University Giessen; Helmholtz Association; Helmholtz-Zentrum Geesthacht - Zentrum fur Material- und Kustenforschung	Sauer, H (corresponding author), Univ Giessen, Dept Physiol, Aulweg 129, D-35392 Giessen, Germany.	heinrich.sauer@physiologie.med.uni-giessen.de						Aikawa R, 2001, BIOCHEM BIOPH RES CO, V289, P901, DOI 10.1006/bbrc.2001.6068; Ali MH, 2002, CRIT CARE MED, V30, pS198, DOI 10.1097/00003246-200205001-00005; ALI MH, 2004, AM J PHYSL LUNG CELL; Amma H, 2005, BRIT J PHARMACOL, V145, P364, DOI 10.1038/sj.bjp.0706182; Benjamin M., 2003, European Journal of Morphology, V41, P3, DOI 10.1076/ejom.41.1.3.28102; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Chen QH, 2003, J VASC SURG, V37, P660, DOI 10.1067/mva.2003.95; Cowan DB, 2003, ARTERIOSCL THROM VAS, V23, P1754, DOI 10.1161/01.ATV.0000093546.10162.B2; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; Epstein ND, 2003, CELL, V112, P147, DOI 10.1016/S0092-8674(03)00037-0; Grepin C, 1997, DEVELOPMENT, V124, P2387; Griendling KK, 2004, HEART, V90, P491, DOI 10.1136/hrt.2003.029397; Griendling KK, 1999, CIRC RES, V85, P562, DOI 10.1161/01.RES.85.6.562; Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C; Heil M, 2004, CIRC RES, V95, P449, DOI 10.1161/01.RES.0000141145.78900.44; Heng BC, 2004, CARDIOVASC RES, V62, P34, DOI 10.1016/j.cardiores.2003.12.022; Hescheler J, 2002, Methods Mol Biol, V185, P169; Hescheler J, 1999, CELLS TISSUES ORGANS, V165, P153, DOI 10.1159/000016695; Hwang J, 2003, CIRC RES, V93, P1225, DOI 10.1161/01.RES.0000104087.29395.66; HWOARD AB, 1997, AM J PHYSIOL, V272, pC421; Illi B, 2005, CIRC RES, V96, P501, DOI 10.1161/01.RES.0000159181.06379.63; Li YH, 2004, AM J PHYSIOL-HEART C, V287, pH1712, DOI 10.1152/ajpheart.00124.2004; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Liu MY, 2000, J APPL PHYSIOL, V89, P2078, DOI 10.1152/jappl.2000.89.5.2078; Moore KA, 2005, DEV DYNAM, V232, P268, DOI 10.1002/dvdy.20237; Murfee WL, 2004, ANN BIOMED ENG, V32, P1662, DOI 10.1007/s10439-004-7819-0; Na L, 2003, BIRTH DEFECTS RES A, V67, P174, DOI 10.1002/bdra.10030; Nonaka S, 2002, NATURE, V418, P96, DOI 10.1038/nature00849; Park YM, 2004, BIOCHEM BIOPH RES CO, V313, P812, DOI 10.1016/j.bbrc.2003.11.173; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; Reckova M, 2003, CIRC RES, V93, P77, DOI 10.1161/01.RES.0000079488.91342.B7; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; Sauer H, 1999, J CELL BIOCHEM, V75, P710, DOI 10.1002/(SICI)1097-4644(19991215)75:4<710::AID-JCB16>3.0.CO;2-Z; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Sauer H, 2005, EXP CELL RES, V304, P380, DOI 10.1016/j.yexcr.2004.11.026; Sauer H, 2004, EXP CELL RES, V294, P313, DOI 10.1016/j.yexcr.2003.10.032; Sauer H, 2000, FEBS LETT, V476, P218, DOI 10.1016/S0014-5793(00)01747-6; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Skalak Thomas C., 1996, Microcirculation (Philadelphia), V3, P143, DOI 10.3109/10739689609148284; Sorescu Dan, 2002, Congest Heart Fail, V8, P132, DOI 10.1111/j.1527-5299.2002.00717.x; Sun HY, 2005, AM J PHYSIOL-HEART C, V288, pH1900, DOI 10.1152/ajpheart.01244.2003; Taber LA, 2001, ANNU REV BIOMED ENG, V3, P1, DOI 10.1146/annurev.bioeng.3.1.1; Tenhunen O, 2004, J BIOL CHEM, V279, P24852, DOI 10.1074/jbc.M314317200; Torres M, 2003, BIOFACTORS, V17, P287, DOI 10.1002/biof.5520170128; TURNER CH, 1995, AM J PHYSIOL, V269, P438; Ushio-Fukai M, 2004, MOL CELL BIOCHEM, V264, P85, DOI 10.1023/B:MCBI.0000044378.09409.b5; Voronov DA, 2004, DEV BIOL, V272, P339, DOI 10.1016/j.ydbio.2004.04.033; Voronov DA, 2002, DEV DYNAM, V224, P413, DOI 10.1002/dvdy.10121; Wang DS, 2001, ENDOTHELIUM-NEW YORK, V8, P283, DOI 10.3109/10623320109090806; Wartenberg M, 2001, FASEB J, V15, P995, DOI 10.1096/fj.00-0350com; Waters CM, 2004, AM J PHYSIOL-LUNG C, V287, pL484, DOI 10.1152/ajplung.00161.2004; Wu R, 2004, J HYPERTENS, V22, P793, DOI 10.1097/00004872-200404000-00023; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yamamoto K, 1999, J BIOL CHEM, V274, P21840, DOI 10.1074/jbc.274.31.21840; Yamamoto K, 2005, AM J PHYSIOL-HEART C, V288, pH1915, DOI 10.1152/ajpheart.00956.2004; Zhao M, 1999, MOL CELL BIOL, V19, P21	56	208	221	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1182	+		10.1096/fj.05-4723fje	http://dx.doi.org/10.1096/fj.05-4723fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636108				2022-12-25	WOS:000240210300019
J	Zhang, M; Haapasalo, A; Kim, DY; Ingano, LAM; Pettingell, WH; Kovacs, DM				Zhang, Mei; Haapasalo, Annakaisa; Kim, Doo Yeon; Ingano, Laura A. MacKenzie; Pettingell, Warren H.; Kovacs, Dora M.			Presenilin/gamma-secretase activity regulates protein clearance from the endocytic recycling compartment	FASEB JOURNAL			English	Article						amyloid precursor protein; transferrin; trafficking; Alzheimer's disease; neurodegeneration	AMYLOID PRECURSOR PROTEIN; SPORADIC ALZHEIMERS-DISEASE; P75 NEUROTROPHIN RECEPTOR; HAMSTER OVARY CELLS; TRANS-GOLGI NETWORK; GAMMA-SECRETASE; PLASMA-MEMBRANE; BETA-SECRETASE; E-CADHERIN; INTRACELLULAR DOMAIN	The presenilin (PS)/gamma-secretase complex proteolytically cleaves more than 20 different proteins in addition to the amyloid precursor protein (APP). These substrates are almost exclusively type I membrane proteins. Many undergo internalization from the cell surface followed by degradation or recycling back to the plasma membrane through the endocytic recycling compartment (ERC). Evidence shows that the PSs also regulate intracellular trafficking of APP and its C-terminal fragments (CTFs). To investigate whether PS/gamma-secretase activity is required for normal endosomal recycling, we performed live cell imaging experiments with fluorescently labeled transferrin, reported to specifically traffic through the ERC. By using pharmacological gamma-secretase inhibitors or cell lines lacking functional PS/gamma-secretase, here we show that PS/gamma-secretase activity is required for clearance of transferrin from the ERC. Interestingly, lack of PS/gamma-secretase function also resulted in the accumulation of APP and APP-CTFs in the ERC in addition to the cell surface. Familial Alzheimer's disease mutations in APP-CTFs did not affect endocytic recycling of these proteins. Our results suggest that PS/gamma-secretase activity is required for normal endosomal recycling of soluble and membrane- associated proteins through the ERC and propose a new mechanism by which impaired PS/gamma-secretase function may eventually contribute to neurodegeneration.	Synta Pharmaceut Corp, Lexington, MA 02421 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp,Dept Neurol,MIND, Neurobiol Dis Lab,Genet & Aging Res Unit, Charlestown, MA USA	Harvard University; Massachusetts General Hospital	Kovacs, DM (corresponding author), Synta Pharmaceut Corp, 45 Hartwell Ave, Lexington, MA 02421 USA.	dora_kovacs@hms.harvard.edu		Haapasalo, Annakaisa/0000-0003-0959-2957				Baulac S, 2003, NEUROBIOL DIS, V14, P194, DOI 10.1016/S0969-9961(03)00123-2; Beglopoulos V, 2004, J BIOL CHEM, V279, P46907, DOI 10.1074/jbc.M409544200; Bishop NE, 2003, INT REV CYTOL, V232, P1, DOI 10.1016/S0074-7696(03)32001-7; Brodsky F M, 1992, Trends Cell Biol, V2, P109, DOI 10.1016/0962-8924(92)90015-F; Bronfman FC, 2003, J NEUROSCI, V23, P3209; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; Cam JA, 2004, J BIOL CHEM, V279, P29639, DOI 10.1074/jbc.M313893200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cataldo AM, 2004, J NEUROPATH EXP NEUR, V63, P821, DOI 10.1093/jnen/63.8.821; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Catalucci A, 2003, RIV NEURORADIOL, V16, P23, DOI 10.1177/19714009030160S102; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; Chyung JH, 2003, J BIOL CHEM, V278, P51035, DOI 10.1074/jbc.M304989200; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Daugherty BL, 2001, TRAFFIC, V2, P908, DOI 10.1034/j.1600-0854.2001.21206.x; DE SB, 1999, NATURE, V398, P518; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Deb S, 2000, BRIT J PSYCHIAT, V176, P468, DOI 10.1192/bjp.176.5.468; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Grant B, 2001, NAT CELL BIOL, V3, P573, DOI 10.1038/35078549; Grbovic OM, 2003, J BIOL CHEM, V278, P31261, DOI 10.1074/jbc.M304122200; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; HYMAN BT, 1995, ARCH NEUROL-CHICAGO, V52, P373, DOI 10.1001/archneur.1995.00540280059019; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kaether C, 2004, J CELL BIOL, V167, P809, DOI 10.1083/jcb.200410090; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kim DY, 2005, J BIOL CHEM, V280, P23251, DOI 10.1074/jbc.M412938200; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Lah JJ, 1997, J NEUROSCI, V17, P1971; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Leem JY, 2002, NEUROBIOL DIS, V11, P64, DOI 10.1006/nbdi.2002.0546; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; Ling Y, 2003, INT J BIOCHEM CELL B, V35, P1505, DOI 10.1016/S1357-2725(03)00133-X; Lock JG, 2005, MOL BIOL CELL, V16, P1744, DOI 10.1091/mbc.E04-10-0867; Lopez-Perez E, 2001, J NEUROCHEM, V76, P1532, DOI 10.1046/j.1471-4159.2001.00180.x; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Mathews PM, 2002, J BIOL CHEM, V277, P36415, DOI 10.1074/jbc.M205208200; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; PASTERNAK SH, 2003, J BIOL CHEM; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Rechards M, 2003, TRAFFIC, V4, P553, DOI 10.1034/j.1600-0854.2003.t01-1-00114.x; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Selkoe DJ, 2004, ANN INTERN MED, V140, P627, DOI 10.7326/0003-4819-140-8-200404200-00047; Seto ES, 2002, GENE DEV, V16, P1314, DOI 10.1101/gad.989602; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Takahashi RH, 2002, HISTOL HISTOPATHOL, V17, P239, DOI 10.14670/HH-17.239; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Torp R, 2003, NEUROSCIENCE, V120, P291, DOI 10.1016/S0306-4522(03)00320-8; Uemura K, 2003, J NEUROSCI RES, V74, P184, DOI 10.1002/jnr.10753; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VETRIVEL KS, 2004, J BIOL CHEM; von Rotz RC, 2004, J CELL SCI, V117, P4435, DOI 10.1242/jcs.01323; Wang H, 2004, J BIOL CHEM, V279, P40560, DOI 10.1074/jbc.M404345200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong HK, 2005, J BIOL CHEM, V280, P23009, DOI 10.1074/jbc.M414648200; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; YAMASHIRO DJ, 1984, J CELL BIOCHEM, V26, P231, DOI 10.1002/jcb.240260404; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu WH, 2004, INT J BIOCHEM CELL B, V36, P2531, DOI 10.1016/j.biocel.2004.05.010; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898; Zuk PA, 1999, J BIOL CHEM, V274, P22303, DOI 10.1074/jbc.274.32.22303	96	48	49	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1176	+		10.1096/fj.05-5531fje	http://dx.doi.org/10.1096/fj.05-5531fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16645046				2022-12-25	WOS:000240210300017
J	Artus, C; Maquarre, E; Moubarak, RS; Delettre, C; Jasmin, C; Susin, SA; Robert-Lezenes, J				Artus, C.; Maquarre, E.; Moubarak, R. S.; Delettre, C.; Jasmin, C.; Susin, S. A.; Robert-Lezenes, J.			CD44 ligation induces caspase-independent cell death via a novel calpain/AIF pathwayin human erythroleukemia cells	ONCOGENE			English	Article						CD44; apoptosis; calpain; AIF; erythroleukemia	ACUTE MYELOID-LEUKEMIA; CYTOCHROME-C RELEASE; ANTI-CD44 MONOCLONAL-ANTIBODIES; CANCER-CELLS; FACTOR AIF; POLY(ADP-RIBOSE) POLYMERASE-1; ERYTHROID-DIFFERENTIATION; NUCLEAR TRANSLOCATION; APOPTOSIS; MITOCHONDRIA	Ligation of the cell surface molecule CD44 by anti-CD44 monoclonal antibodies (mAbs) has been shown to induce cell differentiation, cell growth inhibition and in some cases, apoptosis in myeloid leukemic cells. We report, herein, that exposure of human erythroleukemic HEL cells to the anti-CD44 mAb A3D8 resulted in cell growth inhibition followed by caspase-independent apoptosis-like cell death. This process was associated with the disruption of mitochondrial membrane potential (Delta Psi m), the mitochondrial release of apoptosis-inducing factor (AIF), but not of cytochrome c, and the nuclear translocation of AIF. All these effects including cell death, loss of mitochondrial Delta Psi m and AIF release were blocked by pretreatment with the poly(ADP-ribose) polymerase inhibitor isoquinoline. A significant protection against cell death was also observed by using small interfering RNA for AIF. Moreover, we show that calpain protease was activated before the appearance of apoptosis, and that calpain inhibitors or transfection of calpain-siRNA decrease A3D8-induced cell death, and block AIF release. These data suggest that CD44 ligation triggers a novel caspase-independent cell death pathway via calpain-dependent AIF release in erythroleukemic HEL cells.	Hop Paul Brousse, INSERM, U602, F-94807 Villejuif, France; Inst Pasteur, Apoptose & Syst Immunitaire Grp, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Robert-Lezenes, J (corresponding author), Hop Paul Brousse, INSERM, U602, 14 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	lezenes@vjf.inserm.fr	Delettre, Cécile/AAC-3096-2020; Susin, Santos A/Q-6754-2017	Delettre, Cécile/0000-0003-3269-2155; Susin, Santos A/0000-0002-3366-1628; Moubarak, Rana/0000-0003-2096-1258				Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Altznauer F, 2004, J BIOL CHEM, V279, P5947, DOI 10.1074/jbc.M308576200; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Bras M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P231, DOI 10.1007/s10541-005-0105-4; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; BROWN LR, 1977, BIOCHIM BIOPHYS ACTA, V468, P389, DOI 10.1016/0005-2736(77)90290-5; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Cerisano V, 2004, ONCOGENE, V23, P5664, DOI 10.1038/sj.onc.1207741; Charrad RS, 2002, BLOOD, V99, P290, DOI 10.1182/blood.V99.1.290; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Chen M, 2004, CARDIOVASC RES, V63, P682, DOI 10.1016/j.cardiores.2004.04.018; Cheung ECC, 2005, J NEUROSCI, V25, P1324, DOI 10.1523/JNEUROSCI.4261-04.2005; Corbiere C, 2004, CELL RES, V14, P188, DOI 10.1038/sj.cr.7290219; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Dejean LM, 2005, MOL BIOL CELL, V16, P2424, DOI 10.1091/mbc.E04-12-1111; Donovan M, 2004, BBA-MOL CELL RES, V1644, P133, DOI 10.1016/j.bbamcr.2003.08.011; Gadhoum Z, 2004, LEUKEMIA LYMPHOMA, V45, P1501, DOI 10.1080/1042819042000206687; Gadhoum Z, 2004, BLOOD, V103, P1059, DOI 10.1182/blood-2003-04-1218; Gao G, 2000, J CELL BIOCHEM, V80, P53; Ghaffari S, 1999, EXP HEMATOL, V27, P978, DOI 10.1016/S0301-472X(99)00023-5; Hafid-Medheb K, 2003, BLOOD, V101, P2575, DOI 10.1182/blood-2002-02-0478; Henry-Mowatt J, 2004, ONCOGENE, V23, P2850, DOI 10.1038/sj.onc.1207534; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Ishitsuka K, 2005, ONCOGENE, V24, P5888, DOI 10.1038/sj.onc.1208739; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lipton SA, 2002, CELL, V111, P147, DOI 10.1016/S0092-8674(02)01046-2; Liu T, 2004, ONCOGENE, V23, P39, DOI 10.1038/sj.onc.1206978; Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Lu T, 2002, BBA-MOL CELL RES, V1590, P16, DOI 10.1016/S0167-4889(02)00193-3; Maquarre E, 2005, LEUKEMIA, V19, P2296, DOI 10.1038/sj.leu.2403944; Mateo W, 2002, BLOOD, V100, P2882, DOI 10.1182/blood-2001-12-0217; Mathiasen IS, 2002, J BIOL CHEM, V277, P30738, DOI 10.1074/jbc.M201558200; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Park YC, 2005, LIFE SCI, V77, P2059, DOI 10.1016/j.lfs.2005.04.021; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Poindessous-Jazat V, 2002, LEUKEMIA, V16, P233, DOI 10.1038/sj.leu.2402350; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Roue G, 2003, BIOCHIMIE, V85, P741, DOI 10.1016/S0300-9084(03)00129-9; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Song GL, 2004, LEUKEMIA RES, V28, P1089, DOI 10.1016/j.leukres.2004.02.005; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008; Yuste VJ, 2005, CELL DEATH DIFFER, V12, P1445, DOI 10.1038/sj.cdd.4401687; Zada AAP, 2003, ONCOGENE, V22, P2296, DOI 10.1038/sj.onc.1206330; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	61	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5741	5751		10.1038/sj.onc.1209581	http://dx.doi.org/10.1038/sj.onc.1209581			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16636662				2022-12-25	WOS:000240765800005
J	Wu, Y; Fan, Y; Xue, B; Luo, L; Shen, J; Zhang, S; Jiang, Y; Yin, Z				Wu, Y.; Fan, Y.; Xue, B.; Luo, L.; Shen, J.; Zhang, S.; Jiang, Y.; Yin, Z.			Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals	ONCOGENE			English	Article						glutathione S-transferase P1-1; TNF-alpha; TRAF2; ASK1; apoptosis	NF-KAPPA-B; INDUCED CELL-DEATH; TNF RECEPTOR 1; PROTEIN-KINASE; TERMINAL KINASE; INDUCED ACTIVATION; STRUCTURAL BASIS; HEAT-SHOCK; APOPTOSIS; ASK1	Human glutathione S-transferase P1-1 (GSTP1-1) is an ubiquitously expressed protein that plays an important role in the detoxification and xenobiotics metabolism. It has been shown that GSTP1-1 interacts with c-Jun NH2-terminal kinase (JNK) and suppresses its activity. Here, we report a novel function of GSTP1-1 in regulating tumor necrosis factor-alpha (TNF-alpha)-triggered signaling. The present experiments showed that GSTP1-1 physically associated with tumor necrosis factor receptor-associated factor 2(TRAF2) in vivo and in vitro. Overexpression of GSTP1-1 inhibited TRAF2-induced activation of both JNK and p38 but not of nuclear factor-KB (NF-KB). Glutathione S-transferase P1-1 also attenuated TRAF2-enhanced apoptosis signal-regulating kinase 1 (ASK1) autophosphorylation and inhibited TRAF2-ASK1-induced cell apoptosis by suppressing the interaction of TRAF2 and ASK1. Conversely, silencing of GSTP1-1 expression through RNA interference (RNAi) resulted in increase of TNF-alpha-dependent TRAF2-ASK1 association followed by hyper-activation of ASK1 and JNK. A mutant GSTP1-1 lacking TRAF domain-binding motif exhibited a significant decline of capacity to bind TRAF2 and block TRAF2-ASK1 signaling compared with the wild type of GSTP1-1. Moreover, the glutathione-conjugating activity of GSTP1-1 was not involved in the regulation of TRAF2 signaling. These findings indicate that GSTP1-1 plays an important regulatory role in TNF-alpha-induced signaling by forming ligand-binding interactions with TRAF2, which provides a new insight for analysing the protective effects of GSTP1-1 in tumor cells.	Nanjing Normal Univ, Coll Life Sci, Jiangsu Prov Key Lab Mol & Med Biotechnol, Nanjing 210097, JiangSu, Peoples R China; Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210008, Peoples R China; So Med Univ, Dept Pathophysiol, Key Lab Funct Proteom Guangdong Prov, Guangzhou, Peoples R China	Nanjing Normal University; Nanjing University; Southern Medical University - China	Yin, Z (corresponding author), Nanjing Normal Univ, Coll Life Sci, Jiangsu Prov Key Lab Mol & Med Biotechnol, 122 Ninghai Rd, Nanjing 210097, JiangSu, Peoples R China.	yinzhimin@njnu.edu.cn		Xue, Bin/0000-0002-5472-1300				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Arch RH, 1999, ANNU REV CELL DEV BI, V15, P113, DOI 10.1146/annurev.cellbio.15.1.113; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Chung JY, 2002, J CELL SCI, V115, P679; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dorion S, 2002, J BIOL CHEM, V277, P30792, DOI 10.1074/jbc.M203642200; Fan YM, 2005, CELL BIOL INT, V29, P695, DOI 10.1016/j.cellbi.2005.04.006; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Fessler MB, 2002, J BIOL CHEM, V277, P31291, DOI 10.1074/jbc.M200755200; Gate Laurent, 2001, Expert Opin Ther Targets, V5, P477; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; Gotoh Y, 2004, BIOCHEM BIOPH RES CO, V314, P688, DOI 10.1016/j.bbrc.2003.12.148; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Lo HW, 2004, CANCER RES, V64, P9131, DOI 10.1158/0008-5472.CAN-04-0283; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lu M, 2004, ONCOGENE, V23, P3945, DOI 10.1038/sj.onc.1207500; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; MOSCOW JA, 1989, CANCER RES, V49, P1422; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Noguchi T, 2005, J BIOL CHEM, V280, P37033, DOI 10.1074/jbc.M506771200; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Ryoo K, 2004, J BIOL CHEM, V279, P43589, DOI 10.1074/jbc.M404359200; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SHEA TC, 1988, CANCER RES, V48, P527; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TEW KD, 1994, CANCER RES, V54, P4313; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Townsend Danyelle, 2003, Am J Pharmacogenomics, V3, P157, DOI 10.2165/00129785-200303030-00002; Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940; Townsend DM, 2002, MOL CANCER THER, V1, P1089; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; XIA ZP, 2005, SCI STKE, V272, pPE7; Xu LG, 2004, J BIOL CHEM, V279, P17278, DOI 10.1074/jbc.C400063200; Xue B, 2005, FEBS LETT, V579, P4081, DOI 10.1016/j.febslet.2005.06.034; Ye H, 2000, P NATL ACAD SCI USA, V97, P8961, DOI 10.1073/pnas.160241997; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yin ZM, 2000, CANCER RES, V60, P4053; Yin ZM, 2001, ACTA BIOCH BIOPH SIN, V33, P185; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548; Zhou L, 2005, BLOOD, V105, P1198, DOI 10.1182/blood-2003-12-4299	71	168	174	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5787	5800		10.1038/sj.onc.1209576	http://dx.doi.org/10.1038/sj.onc.1209576			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16636664				2022-12-25	WOS:000240765800009
J	Chiaradonna, F; Sacco, E; Manzoni, R; Giorgio, M; Vanoni, M; Alberghina, L				Chiaradonna, F.; Sacco, E.; Manzoni, R.; Giorgio, M.; Vanoni, M.; Alberghina, L.			Ras-dependent carbon metabolism and transformation in mouse broblasts	ONCOGENE			English	Article						transformed cells; Ras; glucose metabolism; apoptosis; cell cycle	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; DEPRIVATION-INDUCED CYTOTOXICITY; HUMAN CANCER-CELLS; HUMAN TUMOR-CELLS; GLUCOSE DEPRIVATION; OXIDATIVE STRESS; PANCREATIC-CANCER; ANTISENSE OLIGONUCLEOTIDES; MALIGNANT-TRANSFORMATION; SIGNAL-TRANSDUCTION	Mutational activation of ras genes is required for the onset and maintenance of different malignancies. Here we show, using a combination of molecular physiology, nutritional perturbations and transcriptional pro. ling, that full penetrance of phenotypes related to oncogenic Ras activation, including the shift of carbon metabolism towards fermentation and upregulation of key cell cycle regulators, is dependent upon glucose availability. These responses are induced by Ras activation, being specifically reverted by downregulation of the Ras pathway obtained through the expression of a dominant-negative Ras-specific guanine nucleotide exchange protein. Our data allow to link directly to ras activation the alteration in energy metabolism of cancer cells, their fragility towards glucose shortage and ensuing apoptotic death.	Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy	University of Milano-Bicocca; IRCCS European Institute of Oncology (IEO)	Alberghina, L (corresponding author), Univ Milano Bicocca, Dept Biotechnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.	lilia.alberghina@unimib.it	Vanoni, Marco/AAA-3699-2021; Sacco, Elena/T-3274-2018; CHIARADONNA, Ferdinando/K-4959-2016; Giorgio, Marco/I-9425-2012	Vanoni, Marco/0000-0002-8690-2587; Sacco, Elena/0000-0002-3190-7671; CHIARADONNA, Ferdinando/0000-0001-8529-2732; Giorgio, Marco/0000-0002-5842-6042; Alberghina, Lilia/0000-0003-1694-931X				Ahmad IM, 2005, J BIOL CHEM, V280, P4254, DOI 10.1074/jbc.M411662200; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alberghina L, 2004, CHEMBIOCHEM, V5, P1322, DOI 10.1002/cbic.200400170; Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357-2725(96)00178-1; BAGGETTO LG, 1992, BIOCHIMIE, V74, P959, DOI 10.1016/0300-9084(92)90016-8; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Blum R, 2005, CANCER RES, V65, P999; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; BOS JL, 1995, EUR J CANCER, V31A, P1051, DOI 10.1016/0959-8049(95)00168-I; Bossu P, 2000, ONCOGENE, V19, P2147, DOI 10.1038/sj.onc.1203539; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chiaradonna F, 2005, BIOCHEM SOC T, V33, P297, DOI 10.1042/BST0330297; Cochet O, 1999, CANCER DETECT PREV, V23, P506, DOI 10.1046/j.1525-1500.1999.99058.x; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; deVries JE, 1996, PATHOL RES PRACT, V192, P658, DOI 10.1016/S0344-0338(96)80087-2; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; GRUNICKE HH, 1993, CRIT REV ONCOGENESIS, V4, P389; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hellerstein MK, 2004, CURR OPIN MOL THER, V6, P249; Hlavata L, 2003, EMBO J, V22, P3337, DOI 10.1093/emboj/cdg314; Jinno S, 1999, P NATL ACAD SCI USA, V96, P13197, DOI 10.1073/pnas.96.23.13197; KAHN S, 1987, ANTICANCER RES, V7, P639; Kato-Stankiewicz J, 2002, P NATL ACAD SCI USA, V99, P14398, DOI 10.1073/pnas.222222699; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Kijima H, 2004, INT J ONCOL, V24, P559; Kita K, 1999, INT J CANCER, V80, P553, DOI 10.1002/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6; Kitano H, 2004, NAT REV CANCER, V4, P227, DOI 10.1038/nrc1300; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kocher HM, 2005, NEPHROL DIAL TRANSPL, V20, P886, DOI 10.1093/ndt/gfh744; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mabuchi T, 2000, J BIOL CHEM, V275, P10492, DOI 10.1074/jbc.275.14.10492; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Mazurek S, 2003, ANTICANCER RES, V23, P1149; Mazurek S, 1999, J CELL PHYSIOL, V181, P136; Messer JI, 2004, AM J PHYSIOL-CELL PH, V286, pC565, DOI 10.1152/ajpcell.00146.2003; MONIA BP, 1992, J BIOL CHEM, V267, P19954; Nheu T, 2004, CELL CYCLE, V3, P71; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; Rajendran JG, 2004, CLIN CANCER RES, V10, P2245, DOI 10.1158/1078-0432.CCR-0688-3; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Rebollo A, 1999, ONCOGENE, V18, P4930, DOI 10.1038/sj.onc.1202875; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Robey IF, 2005, NEOPLASIA, V7, P324, DOI 10.1593/neo.04430; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Rolland F, 2002, FEMS YEAST RES, V2, P183, DOI 10.1111/j.1567-1364.2002.tb00084.x; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Russell JS, 1999, CANCER RES, V59, P5239; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shoshan-Barmatz V, 2003, CELL BIOCHEM BIOPHYS, V39, P279, DOI 10.1385/CBB:39:3:279; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Takeuchi M, 2000, GENE THER, V7, P518, DOI 10.1038/sj.gt.3301125; Takuwa N, 2001, MOL CELL ENDOCRINOL, V177, P25, DOI 10.1016/S0303-7207(01)00439-7; Thomas S, 1998, EUR J BIOCHEM, V258, P956, DOI 10.1046/j.1432-1327.1998.2580956.x; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vanoni M, 1999, J BIOL CHEM, V274, P36656, DOI 10.1074/jbc.274.51.36656; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; YAMAMOTO F, 1984, NUCLEIC ACIDS RES, V12, P8873, DOI 10.1093/nar/12.23.8873	75	86	86	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5391	5404		10.1038/sj.onc.1209528	http://dx.doi.org/10.1038/sj.onc.1209528			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16607279				2022-12-25	WOS:000240144900004
J	Li, H; Watts, GS; Oshiro, MM; Futscher, BW; Domann, FE				Li, H.; Watts, G. S.; Oshiro, M. M.; Futscher, B. W.; Domann, F. E.			AP-2 alpha and AP-2 gamma are transcriptional targets of p53 in human breast carcinoma cells	ONCOGENE			English	Article						activator protein-2; p53; tumor suppressor gene; breast carcinoma	FACTOR AP-2; DOWN-REGULATION; EPIDERMAL MORPHOGENESIS; GENE-EXPRESSION; HUMAN-MELANOMA; DNA-BINDING; CANCER; DIFFERENTIATION; METASTASIS; APOPTOSIS	Activating enhancer-binding protein 2 alpha (AP-2 alpha) and activating enhancer-binding protein 2 gamma (AP-2 gamma) are transcription factors that bind GC-rich consensus sequences and regulate the expression of many downstream genes. AP-2 alpha and AP-2 gamma interact with p53 both physically and functionally. Expression microarray results in human breast carcinoma cells with forced p53 expression revealed AP-2 gamma as a putative transcriptional target of p53. To command extend these findings we measured the effects of forced p53 expression in human breast carcinoma cells by real-time reverse transcription-PCR, Western blotting, electrophoretic gel mobility shift assays, promoter reporter, chromatin immunoprecipitation and chromatin accessibility assays. Wild-type p53 expression rapidly induced not only AP-2 gamma but also AP-2 alpha mRNA. The subsequent increase in these proteins led to increased AP-2 DNA-binding and transactivating activity. Candidate p53-binding sites were identified in the AP-2 alpha and AP-2 gamma promoters. p53 binding to these cis-elements in vivo was also observed, together with a relaxation of chromatin structure in these regions. Finally, expression of either AP-2 alpha or gamma inhibited growth of human breast carcinoma cells in vitro. Taken together, our findings indicate that these AP-2 genes are targets for transcriptional activation by p53 and suggest that AP-2 proteins may mediate some of the downstream effects of p53 expression such as inhibition of proliferation.	Univ Iowa, Free Rad & Radiat Biol Program, Dept Radiat Oncol, Iowa City, IA 52242 USA; Univ Arizona, Bone Marrow Transplant Program, Arizona Canc Ctr, Tucson, AZ 85721 USA; Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA	University of Iowa; Arizona Center Cancer Care; University of Arizona; University of Arizona	Domann, FE (corresponding author), Univ Iowa, Free Rad & Radiat Biol Program, Dept Radiat Oncol, Med Lab B180, Iowa City, IA 52242 USA.	Frederick-domann@uiowa.edu		Domann, Frederick/0000-0002-0489-2179	NCI NIH HHS [CA66081, CA65662, CA73612, P30 CA023074] Funding Source: Medline; NIEHS NIH HHS [P30 ES006694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065662, R56CA073612, P01CA066081, P30CA023074, R29CA065662, R29CA073612, R01CA073612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; CHEN PH, 1993, CLIN CHEM, V39, P2186; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang Y, 1998, BIOCHEM BIOPH RES CO, V249, P307, DOI 10.1006/bbrc.1998.9139; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Karjalainen JM, 2000, BRIT J CANCER, V82, P2015; Koster MI, 2006, DEV BIOL, V289, P253, DOI 10.1016/j.ydbio.2005.10.041; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Marreiros A, 2003, GENE, V302, P155, DOI 10.1016/S0378-1119(02)01101-0; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Paggi MG, 2001, ONCOGENE, V20, P2570, DOI 10.1038/sj.onc.1204356; Pellikainen J, 2002, CLIN CANCER RES, V8, P3487; PETSKO G, 2002, CURRENT PROTOCOLS BI; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ruiz M, 2001, CLIN CANCER RES, V7, P4086; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; STABACH PR, 2005, ONCOGENE; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Watts GS, 2004, NEOPLASIA, V6, P187, DOI 10.1593/neo.03292; West-Mays JA, 2003, DIFFERENTIATION, V71, P206, DOI 10.1046/j.1432-0436.2003.710302.x; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200	40	23	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5405	5415		10.1038/sj.onc.1209534	http://dx.doi.org/10.1038/sj.onc.1209534			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16636674				2022-12-25	WOS:000240144900005
J	Rodacker, V; Toustrup-Jensen, M; Vilsen, B				Rodacker, Vivien; Toustrup-Jensen, Mads; Vilsen, Bente			Mutations Phe785Leu and Thr618Met in Na+, K+-ATPase, associated with familial rapid-onset dystonia parkinsonism, interfere with Na+ interaction by distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; SARCOPLASMIC-RETICULUM CA2+-ATPASE; 4TH TRANSMEMBRANE SEGMENT; SITE-DIRECTED MUTAGENESIS; RAT-KIDNEY NA+,K+-ATPASE; CATION-BINDING; CALCIUM-PUMP; CONFORMATIONAL-CHANGES; FUNCTIONAL CONSEQUENCES; COORDINATING RESIDUES	The Na+, K+-ATPase plays key roles in brain function. Recently, missense mutations in the Na+, K+-ATPase were found associated with familial rapid-onset dystonia parkinsonism (FRDP). Here, we have characterized the functional consequences of FRDP mutations Phe785Leu and Thr618Met. Both mutations lead to functionally altered, but active, Na+, K+-pumps, that display reduced apparent affinity for cytoplasmic Na+, but the underlying mechanism differs between the mutants. In Phe785Leu, the interaction of the E-1 form with Na+ is defective, and the E-1-E-2 equilibrium is not displaced. In Thr618Met, the Na+ affinity is reduced because of displacement of the conformational equilibrium in favor of the K+-occluded E-2(K-2) form. In both mutants, K+ interaction at the external activating sites of the E2P phosphoenzyme is normal. The change of cellular Na+ homeostasis is likely a major factor contributing to the development of FRDP in patients carrying the Phe785Leu or Thr618Met mutation. Phe785Leu moreover interferes with Na+ interaction on the extracellular side and reduces the affinity for ouabain significantly. Analysis of two additional Phe(785) mutants, Phe785Leu/Leu786Phe and Phe785Tyr, demonstrated that the aromatic function of the side chain, as well as its exact position, is critical for Na+ and ouabain binding. The effects of substituting Phe(785) could be explained by structural modeling, demonstrating that Phe(785) participates in a hydrophobic network between three transmembrane segments. Thr(618) is located in the cytoplasmic part of the molecule near the catalytic site, and the structural modeling indicates that the Thr618Met mutation interferes with the bonding pattern in the catalytic site in the E1 form, thereby destabilizing E-1 relative to E-2(K-2).	Aarhus Univ, Inst Physiol & Biophys, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Vilsen, B (corresponding author), Aarhus Univ, Inst Physiol & Biophys, Dept Physiol, Ole Worms Alle 1160, DK-8000 Aarhus C, Denmark.	bv@fi.au.dk		Vilsen, Bente/0000-0002-4727-9382; Toustrup-Jensen, Mads Schak/0000-0003-2064-5861; Schack, Vivien/0000-0002-1365-3938				Aguiar PD, 2004, NEURON, V43, P169, DOI 10.1016/j.neuron.2004.06.028; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; Brashear A, 1999, MOVEMENT DISORD, V14, P132, DOI 10.1002/1531-8257(199901)14:1<132::AID-MDS1022>3.0.CO;2-J; Cannon SC, 2004, NEURON, V43, P153, DOI 10.1016/j.neuron.2004.07.002; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; De Fusco M, 2003, NAT GENET, V33, P192, DOI 10.1038/ng1081; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Einholm AP, 2005, P NATL ACAD SCI USA, V102, P11254, DOI 10.1073/pnas.0501201102; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; Jacobsen MD, 2002, BIOCHEMISTRY-US, V41, P1451, DOI 10.1021/bi015891h; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Li CM, 2005, P NATL ACAD SCI USA, V102, P12706, DOI 10.1073/pnas.0505980102; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MCGRAIL KM, 1991, J NEUROSCI, V11, P381, DOI 10.1523/jneurosci.11-02-00381.1991; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; POST RL, 1972, J BIOL CHEM, V247, P6530; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; Qiu LY, 2005, J BIOL CHEM, V280, P32349, DOI 10.1074/jbc.M505168200; SHAMRAJ OI, 1994, P NATL ACAD SCI USA, V91, P12952, DOI 10.1073/pnas.91.26.12952; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Toustrup-Jensen M, 2003, J BIOL CHEM, V278, P38653, DOI 10.1074/jbc.M305521200; Toustrup-Jensen M, 2002, J BIOL CHEM, V277, P38607, DOI 10.1074/jbc.M203665200; Toustrup-Jensen M, 2001, BIOCHEMISTRY-US, V40, P5521, DOI 10.1021/bi002367m; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vanmolkot KRJ, 2003, ANN NEUROL, V54, P360, DOI 10.1002/ana.10674; Vilsen B, 1999, BIOCHEMISTRY-US, V38, P11389, DOI 10.1021/bi990951t; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; Vilsen B, 1997, ANN NY ACAD SCI, V834, P297, DOI 10.1111/j.1749-6632.1997.tb52260.x	44	64	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18539	18548		10.1074/jbc.M601780200	http://dx.doi.org/10.1074/jbc.M601780200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16632466	hybrid			2022-12-25	WOS:000238687300033
J	Darnowski, JW; Goulette, FA; Guan, YJ; Chatterjee, D; Yang, ZF; Cousens, LP; Chin, YE				Darnowski, James W.; Goulette, Frederick A.; Guan, Ying-jie; Chatterjee, Devasis; Yang, Zhong-Fa; Cousens, Leslie P.; Chin, Y. Eugene			Stat3 cleavage by caspases - Impact on full-length Stat3 expression, fragment formation, and transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED APOPTOSIS; INDUCE APOPTOSIS; PROTEIN-KINASE; NEGATIVE REGULATION; SIGNAL TRANSDUCER; INTERFERON-ALPHA; CELL-DEATH; ACTIVATION; GENE; STAUROSPORINE	Stat3 and its isoforms belong to a family of cytoplasmic transcription factors that affect the synthesis of various proteins. Caspases are cysteinyl-aspartate proteases that function under apoptotic and non-apoptotic conditions. We now report that, in addition to transcriptional splicing, Stat3 fragmentation can be mediated by caspases. Caspase activation in DU145 cells was achieved by staurosporine (STS) exposure, and Western analysis revealed a reduction in full-length Stat3 (fl-Stat3) expression that was caspase-mediated. This proteolytic relationship was further studied by exposing purified Stat3 protein to a mixture of active caspases under cell-free conditions. This demonstrated that caspases directly cleaved Stat3 and Stat3 cleavage was accompanied by the apparent formation of cleavage fragment(s). Stat3 cleavage fragments, reflecting multiple caspase cleavage sites, also were observed in vitro following STS exposure in DU145 cells and in HEK293T cells transfected to express Stat3 truncation mutants. The impact of cleavage on Stat3 transcriptional activity next was assessed and revealed that cleavage of fl-Stat3 was accompanied by reductions in Stat3-DNA binding, Stat3-driven reporter protein (luciferase) activity, and the expression of selected Stat3-dependent genes. Further, reduced Stat3 expression correlated with increased sensitivity to apoptotic stimuli. In concomitant experiments, reporter activity was assessed in Stat3 truncation mutant-expressing HEK293T cells and revealed that, under non-apoptotic conditions, expression of different Stat3 fragments induced differential effects on Stat3-driven luciferase activity. These findings demonstrate that fl- Stat3 undergoes proteolytic processing by caspases that reduces its expression and leads to the formation of cleavage fragments that may modulate Stat3 transcriptional activity.	Brown Univ, Dept Med, Providence, RI 02903 USA; Rhode Isl Hosp, Dept Surg, Providence, RI 02903 USA; Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Lifespan Health Rhode Island; Rhode Island Hospital	Darnowski, JW (corresponding author), Brown Univ, Dept Med, 593 Eddy St,Aldrich Bldg,Rm 700, Providence, RI 02903 USA.	jdarnowski@lifespan.org			NCI NIH HHS [CA 102128] Funding Source: Medline; NCRR NIH HHS [P20 RR 17695] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102128] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017695] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adams JM, 1999, COLD SPRING HARB SYM, V64, P351, DOI 10.1101/sqb.1999.64.351; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Atkinson EA, 1998, J BIOL CHEM, V273, P21261, DOI 10.1074/jbc.273.33.21261; Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; Barton BE, 2004, MOL CANCER THER, V3, P1183; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bressin C, 2006, ANTI-CANCER DRUG, V17, P181, DOI 10.1097/00001813-200602000-00009; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Calabresi P, 2001, CANCER RES, V61, P6816; Chatterjee D, 2001, CANCER RES, V61, P7148; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Cousens LP, 2005, J IMMUNOL, V174, P320, DOI 10.4049/jimmunol.174.1.320; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Darnowski James W., 2004, Proceedings of the American Association for Cancer Research Annual Meeting, V45, P1195; Darnowski JW, 2004, CANCER CHEMOTH PHARM, V54, P249, DOI 10.1007/s00280-004-0806-1; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; De Maria R, 1999, BLOOD, V93, P796, DOI 10.1182/blood.V93.3.796.403k23_796_803; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Fulda S, 1997, CANCER RES, V57, P3823; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Hendry L, 2004, EUR J BIOCHEM, V271, P4613, DOI 10.1111/j.1432-1033.2004.04424.x; Hoey T, 2003, EMBO J, V22, P4237, DOI 10.1093/emboj/cdg393; Huang HF, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-2; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; King P, 1998, J BIOL CHEM, V273, P8699, DOI 10.1074/jbc.273.15.8699; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Maritano D, 2004, NAT IMMUNOL, V5, P401, DOI 10.1038/ni1052; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; Matsui W, 2003, BRIT J HAEMATOL, V121, P251, DOI 10.1046/j.1365-2141.2003.04255.x; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V158, P105, DOI 10.1016/S0006-291X(89)80183-4; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Oda A, 2002, BLOOD, V99, P1850, DOI 10.1182/blood.V99.5.1850; Olson NE, 2003, J IMMUNOL, V170, P6065, DOI 10.4049/jimmunol.170.12.6065; Pestka S, 1997, SEMIN ONCOL, V24, P918; Petak I, 2000, CANCER RES, V60, P2643; Pfeffer LM, 1998, CANCER RES, V58, P2489; Ribizzi I, 2002, BONE MARROW TRANSPL, V29, P313, DOI 10.1038/sj.bmt.1703359; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Smulson ME, 1998, CANCER RES, V58, P3495; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; TAKIZAWA T, 1995, VIROLOGY, V209, P288, DOI 10.1006/viro.1995.1260; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Thyrell L, 2002, ONCOGENE, V21, P1251, DOI 10.1038/sj.onc.1205179; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; WALKER PR, 1991, CANCER RES, V51, P1078; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6; YANAGIHARA N, 1991, J NEUROCHEM, V56, P294, DOI 10.1111/j.1471-4159.1991.tb02595.x; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200; Yang E, 1999, MOL CELL BIOL, V19, P5106; Yang J, 2005, CANCER RES, V65, P939; Yokosawa N, 2002, J VIROL, V76, P12683, DOI 10.1128/JVI.76.24.12683-12690.2002; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yuan ZL, 2004, MOL CELL BIOL, V24, P9390, DOI 10.1128/MCB.24.21.9390-9400.2004; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	74	39	39	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17707	17717		10.1074/jbc.M600088200	http://dx.doi.org/10.1074/jbc.M600088200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636048	hybrid			2022-12-25	WOS:000238490300020
J	Murtazina, R; Kovbasnjuk, O; Donowitz, M; Li, XH				Murtazina, Rakhilya; Kovbasnjuk, Olga; Donowitz, Mark; Li, Xuhang			Na+/H+ exchanger NHE3 activity and trafficking are lipid raft-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; C-TERMINAL DOMAINS; ILEAL BRUSH-BORDER; PHOSPHATIDYLINOSITOL 3-KINASE; CHOLESTEROL DEPLETION; ISOFORM NHE3; CELL-LINE; INHIBITION; LOCALIZATION; TRANSPORT	A previous study showed that similar to 25-50% of rabbit ileal brush border (BB) Na+/H+ exchanger NHE3 is in lipid rafts (LR) (Li, X., Galli, T., Leu, S., Wade, J.B., Weinman E.J., Leung, G., Cheong, A., Louvard, D., and Donowitz, M. (2001) J. Physiol. (Lond.) 537, 537-552). Here, we examined the role of LR in NHE3 transport activity using a simpler system: opossum kidney (OK) cells (a renal proximal tubule epithelial cell line) containing NHE3. similar to 50% of surface (biotinylated) NHE3 in OK cells distributed in LR by density gradient centrifugation. Disruption of LR with methyl-beta-cyclodextrin (M beta CD) decreased NHE3 activity and increased K'(H+)(i), but Km(Na+) was not affected. The M beta CD effect was completely reversed by repletion of cholesterol, but not by an inactive analog of cholesterol (cholestane-3 beta, 5 alpha, 6 beta-triol). The M beta CD effect was specific for NHE3 activity because it did not alter Na+-dependentL-Ala uptake. M beta CD did not alter OK cell BB topology and did not change the surface amount of NHE3, but greatly reduced the rate of NHE3 endocytosis. The effects of inhibiting phosphatidylinositol 3-kinase and of M beta CD on NHE3 activity were not additive, indicating a common inhibitory mechanism. In contrast, 8-bromo-cAMP and M beta CD inhibition of NHE3 was additive, indicating different mechanisms for inhibition of NHE3 activity. Approximately 50% of BBNHE3 and only similar to 11% of intracellular NHE3 in polarized OK cells were in LR. In summary, the BB pool of NHE3 in LR is functionally active because M beta CD treatment decreased NHE3 basal activity. The LR pool is necessary for multiple kinetic aspects of normal NHE3 activity, including V-max and K'(H+)(i), and also for multiple aspects of NHE3 trafficking, including at least basal endocytosis and phosphatidylinositol 3-kinase dependent basal exocytosis. Because the C-terminal domain of NHE3 is necessary for its regulation and because the changes in NHE3 kinetics with M beta CD resemble those with second messenger regulation of NHE3, these results suggest that the NHE3 C terminus may be involved in the M beta CD sensitivity of NHE3.	Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Donowitz, M (corresponding author), Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, 925 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mdonowit@jhmi.edu; xuhang@jhmi.edu			NIDDK NIH HHS [R24 DK 64388, R01 DK 61765, R01 DK 26523, P01 DK 44484, K01 DK 62264] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026523, R24DK064388, P01DK044484, R01DK061765, K01DK062264] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhter S, 2000, BIOCHEMISTRY-US, V39, P1990, DOI 10.1021/bi991739s; Akhter S, 2002, AM J PHYSIOL-CELL PH, V283, pC927, DOI 10.1152/ajpcell.00613.2001; Bullis BL, 2002, EUR J BIOCHEM, V269, P4887, DOI 10.1046/j.1432-1033.2002.03202.x; Butchbach MER, 2004, J BIOL CHEM, V279, P34388, DOI 10.1074/jbc.M403938200; Cha B, 2005, J BIOL CHEM, V280, P16642, DOI 10.1074/jbc.M500505200; Crossthwaite AJ, 2005, J BIOL CHEM, V280, P6380, DOI 10.1074/jbc.M411987200; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Fivaz M, 1999, TRENDS CELL BIOL, V9, P212, DOI 10.1016/S0962-8924(99)01567-6; Gekle M, 2001, J PHYSIOL-LONDON, V531, P619, DOI 10.1111/j.1469-7793.2001.0619h.x; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Hill WG, 2002, J BIOL CHEM, V277, P33541, DOI 10.1074/jbc.C200309200; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; HORNBECK P, 2003, CURRENT PROTOCOLS MO; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; Inoue M, 2004, J BIOL CHEM, V279, P49160, DOI 10.1074/jbc.M408942200; Janecki AJ, 2000, J BIOL CHEM, V275, P8133, DOI 10.1074/jbc.275.11.8133; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; Kovbasnjuk ON, 2000, J MEMBRANE BIOL, V176, P19, DOI 10.1007/s002320001072; Kowalski MP, 2004, J IMMUNOL, V172, P418, DOI 10.4049/jimmunol.172.1.418; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; Lam RS, 2004, BBA-BIOMEMBRANES, V1667, P241, DOI 10.1016/j.bbamem.2004.11.004; Lee-Kwon W, 2003, J BIOL CHEM, V278, P16494, DOI 10.1074/jbc.M300580200; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Li X, 2004, GASTROENTEROLOGY, V126, P122, DOI 10.1053/j.gastro.2003.10.061; Li XH, 2004, J PHYSIOL-LONDON, V556, P791, DOI 10.1113/jphysiol.2004.060921; Li XH, 2001, J PHYSIOL-LONDON, V537, P537, DOI 10.1111/j.1469-7793.2001.00537.x; Locke D, 2005, BIOCHEMISTRY-US, V44, P13027, DOI 10.1021/bi050495a; Magnani F, 2004, J BIOL CHEM, V279, P38770, DOI 10.1074/jbc.M400831200; MALSTROM K, 1987, BIOCHIM BIOPHYS ACTA, V902, P269, DOI 10.1016/0005-2736(87)90305-1; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; Noel J, 1996, J CELL SCI, V109, P929; Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Rosenberg A, 1995, BIOL SIALIC ACIDS; Runembert I, 2002, J CELL SCI, V115, P713; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Shogomori H, 2005, J BIOL CHEM, V280, P18931, DOI 10.1074/jbc.M500247200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Su XH, 2003, BIOCHEMISTRY-US, V42, P1086, DOI 10.1021/bi020427d; VANDENBOSCH L, 1989, BIOCHIM BIOPHYS ACTA, V979, P91, DOI 10.1016/0005-2736(89)90527-0; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Yang XJ, 2000, AM J PHYSIOL-CELL PH, V279, pC410, DOI 10.1152/ajpcell.2000.279.2.C410; Zachos NC, 2005, ANNU REV PHYSIOL, V67, P411, DOI 10.1146/annurev.physiol.67.031103.153004; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753	55	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17845	17855		10.1074/jbc.M601740200	http://dx.doi.org/10.1074/jbc.M601740200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16648141	hybrid			2022-12-25	WOS:000238490300034
J	Ohno, S; Im, HJ; Knudson, CB; Knudson, W				Ohno, Shigeru; Im, Hee-Jeong; Knudson, Cheryl B.; Knudson, Warren			Hyaluronan oligosaccharides induce matrix metalloproteinase 13 via transcriptional activation of NF kappa B and p38 MAP kinase in articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CARTILAGE CHONDROLYSIS; MATRIX-METALLOPROTEINASE 13; INTEGRIN RECEPTOR SUBUNIT; TUMOR-CELL MIGRATION; PERICELLULAR MATRIX; GENE-EXPRESSION; CARCINOMA-CELLS; PROTEOGLYCAN SYNTHESIS; OSTEOGENIC PROTEIN-1; CD44 INTERACTION	Hyaluronan exerts a variety of biological effects on cells including changes in cell migration, proliferation, and matrix metabolism. However, the signaling pathways associated with the action of hyaluronan on cells have not been clearly defined. In some cells, signaling is induced by the loss of cell-hyaluronan interactions. The goal of this study was to use hyaluronan oligosaccharides as a molecular tool to explore the effects of changes in cell-hyaluronan interactions and determine the underlying molecular events that become activated. In this study, hyaluronan oligosaccharides induced the loss of extracellular matrix proteoglycan and collagen from cultured slices of normal adult human articular cartilage. This loss was coincident with an increased expression of matrix metalloproteinase (MMP)13. MMP-13 expression was also induced in articular chondrocytes by hyaluronan (HA) hexasaccharides but not by HA tetrasaccharides nor high molecular weight hyaluronan. MMP-13 promoter-reporter constructs in CD44- null COS-7 cells revealed that both CD44-dependent and CD44-independent events mediate the induction of MMP-13 by hyaluronan oligosaccharides. Electromobility gel shift assays demonstrated the activation of chondrocyte NF kappa B by hyaluronan oligosaccharides. NF kappa B activation was also documented in C-28/I2 immortalized human chondrocytes by luciferase promoter assays and phosphorylation of IKK-alpha/beta. The link between activation of NF kappa B and MMP-13 induction by HA oligosaccharides was further confirmed through the use of the NF kappa B inhibitor helenalin. Inhibition of MAP kinases also demonstrated the involvement of p38 MAP kinase in the hyaluronan oligosaccharide induction of MMP-13. Our findings suggest that hyaluronan-CD44 interactions affect matrix metabolism via activation of NF kappa B and p38 MAP kinase.	Rush Univ, Rush Med Coll, Med Ctr, Dept Biochem, Chicago, IL 60612 USA	Rush University	Knudson, W (corresponding author), Rush Univ, Rush Med Coll, Med Ctr, Dept Biochem, 1735 W Harrison St, Chicago, IL 60612 USA.	Warren_Knudson@rush.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039507, T32AR007590, P50AR039239, R01AR043384] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR043384, P50 AR 39239, P50 AR039239, R01 AR039507, R01 AR 43384, R01 AR043384-15, T32 AR007590, T32 AR 07590, R01 AR039507-14] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Al-Assaf S, 2003, ARCH BIOCHEM BIOPHYS, V411, P73, DOI 10.1016/S0003-9861(02)00724-5; BAKER MS, 1989, ARTHRITIS RHEUM, V32, P461, DOI 10.1002/anr.1780320416; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Chow G, 1998, ARTHRITIS RHEUM-US, V41, P1411, DOI 10.1002/1529-0131(199808)41:8<1411::AID-ART10>3.0.CO;2-Z; Embry JJ, 2003, ARTHRITIS RHEUM-US, V48, P3431, DOI 10.1002/art.11323; Fieber C, 2004, J CELL SCI, V117, P359, DOI 10.1242/jcs.00831; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Freemont AJ, 1997, ANN RHEUM DIS, V56, P542, DOI 10.1136/ard.56.9.542; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HodgeDufour J, 1997, J IMMUNOL, V159, P2492; Homandberg GA, 2003, OSTEOARTHR CARTILAGE, V11, P177, DOI 10.1016/S1063-4584(02)00371-0; Homandberg GA, 2002, OSTEOARTHR CARTILAGE, V10, P938, DOI 10.1053/joca.2002.0854; Homandberg GA, 2002, OSTEOARTHR CARTILAGE, V10, P381, DOI 10.1053/joca.2002.0524; Im HJ, 2003, J BIOL CHEM, V278, P25386, DOI 10.1074/jbc.M302048200; Ito T, 2004, AM J PATHOL, V164, P1979, DOI 10.1016/S0002-9440(10)63758-3; Jiang H, 2002, J BIOL CHEM, V277, P10531, DOI 10.1074/jbc.M108654200; Jimenez MJG, 2001, J CELL BIOL, V155, P1333, DOI 10.1083/jcb.200106147; Kang Y, 1999, J ORTHOPAED RES, V17, P858, DOI 10.1002/jor.1100170611; KIMURA JH, 1979, J BIOL CHEM, V254, P2600; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; Knudson W, 2000, ARTHRITIS RHEUM-US, V43, P1165, DOI 10.1002/1529-0131(200005)43:5<1165::AID-ANR27>3.0.CO;2-H; KNUDSON W, 1984, BIOCHEMISTRY-US, V23, P368, DOI 10.1021/bi00297a028; Knudson W, 1996, EXP CELL RES, V228, P216, DOI 10.1006/excr.1996.0320; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; Knudson W, 2002, CELL MOL LIFE SCI, V59, P36, DOI 10.1007/s00018-002-8403-0; KNUDSON W, 2004, CURR OPIN ORTHOP, V15, P369; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lisignoli G, 2001, ARTHRITIS RHEUM-US, V44, P1800, DOI 10.1002/1529-0131(200108)44:8<1800::AID-ART317>3.0.CO;2-1; Loeser RF, 2003, J BIOL CHEM, V278, P24577, DOI 10.1074/jbc.M304530200; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Makihira S, 1999, J BIOL CHEM, V274, P11417, DOI 10.1074/jbc.274.16.11417; Maleski MP, 1996, EXP CELL RES, V225, P55, DOI 10.1006/excr.1996.0156; Maroudas A, 1998, ARCH BIOCHEM BIOPHYS, V350, P61, DOI 10.1006/abbi.1997.0492; MCDONALD JA, 1989, AM J PHYSIOL, V257, pL331, DOI 10.1152/ajplung.1989.257.6.L331; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MORALES TI, 1988, J BIOL CHEM, V263, P3632; NEMEC RE, 1987, BIOCHEM BIOPH RES CO, V149, P249, DOI 10.1016/0006-291X(87)91632-9; NG CK, 1989, BIOCHEM J, V263, P761, DOI 10.1042/bj2630761; Nishida Y, 2004, OSTEOARTHR CARTILAGE, V12, P374, DOI 10.1016/j.joca.2004.01.008; OGATA Y, 1992, EXP CELL RES, V201, P245, DOI 10.1016/0014-4827(92)90271-9; Ohno S, 2005, ARTHRITIS RHEUM-US, V52, P800, DOI 10.1002/art.20937; Ohno-Nakahara M, 2004, J BIOCHEM, V135, P567, DOI 10.1093/jb/mvh069; Peterson RS, 2004, J CELL BIOL, V166, P1081, DOI 10.1083/jcb.200402138; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rasmussen TB, 2003, ARCH VIROL, V148, P2005, DOI 10.1007/s00705-003-0145-2; SHIMAZU A, 1993, ARTHRITIS RHEUM, V36, P247, DOI 10.1002/art.1780360217; Shlopov BV, 2000, ARTHRITIS RHEUM-US, V43, P195, DOI 10.1002/1529-0131(200001)43:1<195::AID-ANR24>3.0.CO;2-G; Shlopov BV, 1997, ARTHRITIS RHEUM-US, V40, P2065, DOI 10.1002/art.1780401120; SOLURSH M, 1980, DEV BIOL, V75, P121, DOI 10.1016/0012-1606(80)90148-7; Stove J, 2002, J ORTHOPAED RES, V20, P551, DOI 10.1016/S0736-0266(01)00141-3; Tanaka S, 1998, SEMIN ARTHRITIS RHEU, V27, P392, DOI 10.1016/S0049-0172(98)80019-X; Tawada A, 2002, GLYCOBIOLOGY, V12, P421, DOI 10.1093/glycob/cwf048; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2; WILLIAMS JM, 1993, J ORTHOPAED RES, V11, P705, DOI 10.1002/jor.1100110513; Williams JM, 2003, OSTEOARTHR CARTILAGE, V11, P44, DOI 10.1053/joca.2002.0864; Wobus M, 2002, APPL IMMUNOHISTO M M, V10, P34, DOI 10.1097/00022744-200203000-00006; WOESSNER JF, 1991, J RHEUMATOL, V18, P99	72	88	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17952	17960		10.1074/jbc.M602750200	http://dx.doi.org/10.1074/jbc.M602750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16648633	Green Accepted, hybrid			2022-12-25	WOS:000238490300045
J	Torres-Collado, AX; Kisiel, W; Iruela-Arispe, ML; Rodriguez-Manzaneque, JC				Torres-Collado, Antoni X.; Kisiel, Walter; Iruela-Arispe, Maria L.; Rodriguez-Manzaneque, Juan C.			ADAMTS1 interacts with, cleaves, and modifies the extracellular location of the matrix inhibitor tissue factor pathway inhibitor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITORS; PROTEASE INHIBITOR; MESSENGER-RNA; MOLECULAR-CLONING; TYPE-1 REPEATS; CDNA CLONING; METALLOPROTEINASES; DEGRADATION; PROTEOLYSIS; EXPRESSION	ADAMTS1 is an extracellular metalloproteinase known to participate in a variety of biological processes that includes inflammation, angiogenesis, and development of the urogenital system. Many of its functions rely on its catalytic activity, which thus far has been limited to the cleavage of the matrix proteoglycans aggrecan and versican. However, it is likely that other substrates exist. Using a yeast two-hybrid screen, we identified the Kunitz-type inhibitor, tissue factor pathway inhibitor-2 (TFPI-2), as a binding partner of ADAMTS1. The interaction was confirmed by several biochemical and cell-based assays. In addition, our studies revealed alterations in the pattern of TFPI-2-secreted isoforms and in its extracellular location caused by the specific action of ADAMTS1. Interestingly, we found that TFPI-2 is a novel substrate of ADAMTS1. The cleavage removes a protease-sensitive C-terminal region in TFPI-2, altering its binding properties. The proposed role of TFPI-2 as a maintenance factor of extracellular remodeling suggests the indirect function of ADAMTS1 as an additional homeostatic player by its ability to alter the extracellular location of TFPI-2 and, therefore, to disrupt the remodeling machinery, a phenomenon directly associated to pathologies such as atherosclerosis and tumor progression.	Univ Autonoma Barcelona, Inst Recerca Hosp Univ Vall Hebron, Med Oncol Res Program, Barcelona 08035, Spain; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Univ Calif Los Angeles, Dept Mol Cellular & Dev Biol, Los Angeles, CA 90095 USA	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of New Mexico; University of New Mexico's Health Sciences Center; University of California System; University of California Los Angeles	Rodriguez-Manzaneque, JC (corresponding author), Univ Autonoma Barcelona, Inst Recerca Hosp Univ Vall Hebron, Med Oncol Res Program, Psg Vall Hebron 119-129, Barcelona 08035, Spain.	jcrodrig@ir.vhebron.net	Rodriguez-Manzaneque, Juan Carlos/F-3899-2012; Torres, antonio/D-8131-2018; Iruela-Arispe, M. Luisa/AAJ-1297-2020	Rodriguez-Manzaneque, Juan Carlos/0000-0001-5951-7029; Torres, antonio/0000-0001-8423-4725; Iruela-Arispe, M. Luisa/0000-0002-3050-4168	NHLBI NIH HHS [HL 64119] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064119] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aho S, 1998, MATRIX BIOL, V17, P401, DOI 10.1016/S0945-053X(98)90100-7; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200; Belaaouaj AA, 2000, J BIOL CHEM, V275, P27123; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Chand HS, 2004, BLOOD, V103, P1069, DOI 10.1182/blood-2003-06-1930; Cunningham AC, 2002, BIOCHEM J, V367, P451, DOI 10.1042/BJ20020696; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Folberg R, 2004, APMIS, V112, P508, DOI 10.1111/j.1600-0463.2004.apm11207-0810.x; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Handsley MM, 2005, INT J CANCER, V115, P849, DOI 10.1002/ijc.20945; Herman MP, 2001, J CLIN INVEST, V107, P1117, DOI 10.1172/JCI10403; Iino M, 1998, ARTERIOSCL THROM VAS, V18, P40, DOI 10.1161/01.ATV.18.1.40; Iochmann S, 2002, THROMB RES, V105, P217, DOI 10.1016/S0049-3848(02)00018-X; Jonnsson-Rylander AC, 2005, ARTERIOSCL THROM VAS, V25, P180, DOI 10.1161/01.ATV.0000150045.27127.37; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Li A, 1998, THROMB HAEMOSTASIS, V80, P423, DOI 10.1055/s-0037-1615224; Liu YY, 1999, ARCH BIOCHEM BIOPHYS, V370, P112, DOI 10.1006/abbi.1999.1371; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Mast AE, 2000, J BIOL CHEM, V275, P31715, DOI 10.1074/jbc.M006595200; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Mittaz L, 2004, BIOL REPROD, V70, P1096, DOI 10.1095/biolreprod.103.023911; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Neaud V, 2000, J BIOL CHEM, V275, P35565, DOI 10.1074/jbc.M006101200; Ohkura N, 1997, BLOOD, V90, P1883, DOI 10.1182/blood.V90.5.1883; Overall CM, 2004, BIOL CHEM, V385, P493, DOI 10.1515/BC.2004.058; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V319, P55, DOI 10.1006/abbi.1995.1266; Rao CN, 1999, BIOCHEM BIOPH RES CO, V255, P94, DOI 10.1006/bbrc.1999.0153; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; RAO CN, 1995, J INVEST DERMATOL, V104, P379, DOI 10.1111/1523-1747.ep12665851; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; Ruf W, 2003, CANCER RES, V63, P5381; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Schmidt A, 2005, J BIOL CHEM, V280, P34441, DOI 10.1074/jbc.M501903200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Udagawa K, 1998, PLACENTA, V19, P217, DOI 10.1016/S0143-4004(98)90011-X; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WERLING RW, 1993, THROMB HAEMOSTASIS, V69, P366	52	47	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17827	17837		10.1074/jbc.M513465200	http://dx.doi.org/10.1074/jbc.M513465200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16641089	hybrid			2022-12-25	WOS:000238490300032
J	Walz, C; Crowley, BJ; Hudon, HE; Gramlich, JL; Neuberg, DS; Podar, K; Griffin, JD; Sattler, M				Walz, Christoph; Crowley, Brian J.; Hudon, Heidi E.; Gramlich, Jessica L.; Neuberg, Donna S.; Podar, Klaus; Griffin, James D.; Sattler, Martin			Activated Jak2 with the V617F point mutation promotes G(1)/S phase transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; G1 PHASE; GROWTH; ERYTHROPOIETIN; STAT5; GENE; GENERATION; INHIBITOR; PROTEIN	Hematopoietic stem cells in myeloproliferative diseases mostly retain the potential to differentiate but are characterized by hyper-responsiveness to growth factors, as well as partial factor-independent growth. The V617F activating point mutation in Jak2 has recently been associated with myeloproliferative disorders. Using various cell line models, mechanisms that contribute to Jak2V617-mediated signaling were investigated. Treatment of the Jak2V617F mutant-expressing erythroid leukemia cell line HEL with a small molecule Jak2 inhibitor was associated with a dose-dependent G(1) cell cycle arrest. This inhibition correlated with decreased expression of cyclin D2 and increased expression of the cell cycle inhibitor p27(Kip). Inhibition of Jak2V617F with a Jak2-targeted small interfering RNA approach resulted in a similar phenotype. Mechanisms leading to altered p27(Kip) and cyclin D2 likely involve inhibition of STAT5, a major target of Jak2 in hematopoietic cells, because a constitutively active form of STAT5 reduced p27(Kip) and increased cyclin D2 expression. Jak2V617F and constitutively active STAT5 also induced high levels of reactive oxygen species, which are sufficient to promote G(1)/S phase transition. In contrast, treatment of HEL cells with the antioxidant N-acetylcysteine decreased cell growth or expression of cyclin D2 and increased expression of p27(Kip). Similar results were obtained in BaF3 cells transfected with Jak2V617F, but these cells required coexpression of the erythropoietin receptor for optimal signaling. These results suggest that regulation of cyclin D2 and p27(Kip) in combination with redox-dependent processes promotes G(1)/S phase transition downstream of Jak2V617F/STAT5 and therefore hint at potential novel targets for drug development that may aid traditional therapy.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sattler, M (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	martin_sattler@dfci.harvard.edu	Podar, Klaus/ABD-1112-2020	Podar, Klaus/0000-0002-7414-3632	NIDDK NIH HHS [DK 66996] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Griesinger F, 2005, GENE CHROMOSOME CANC, V44, P329, DOI 10.1002/gcc.20235; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jones AV, 2006, BLOOD, V107, P3339, DOI 10.1182/blood-2005-09-3917; Kieran MW, 1996, P NATL ACAD SCI USA, V93, P9126, DOI 10.1073/pnas.93.17.9126; Kim KY, 2001, J BIOL CHEM, V276, P40591, DOI 10.1074/jbc.M100975200; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Menon SG, 2003, CANCER RES, V63, P2109; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Reiter A, 2005, CANCER RES, V65, P2662, DOI 10.1158/0008-5472.CAN-04-4263; Saharinen P, 2003, MOL BIOL CELL, V14, P1448, DOI 10.1091/mbc.E02-06-0342; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sattler M, 1999, BLOOD, V93, P2928; Sattler M, 2003, CANCER RES, V63, P5462; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; Sekharam M, 1998, TOXICOL APPL PHARM, V149, P210, DOI 10.1006/taap.1997.8361; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Staerk J, 2005, J BIOL CHEM, V280, P41893, DOI 10.1074/jbc.C500358200; Steensma DP, 2005, BLOOD, V106, P1207, DOI 10.1182/blood-2005-03-1183; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thompson JE, 2002, BIOORG MED CHEM LETT, V12, P1219, DOI 10.1016/S0960-894X(02)00106-3; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Walters DK, 2005, BLOOD, V105, P2952, DOI 10.1182/blood-2004-07-2758; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yamaoka K, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-253; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200	42	83	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18177	18183		10.1074/jbc.M600064200	http://dx.doi.org/10.1074/jbc.M600064200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16632470	hybrid			2022-12-25	WOS:000238490300069
J	Zhang, Q; Furukawa, K; Chen, HH; Sakakibara, T; Urano, T; Furukawa, K				Zhang, Qing; Furukawa, Keiko; Chen, Ho-Hsiang; Sakakibara, Takumi; Urano, Takeshi; Furukawa, Koichi			Metastatic potential of mouse lewis lung cancer cells is regulated via ganglioside GM1 by modulating the matrix metalloprotease-9 localization in lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; GELATINASE B MMP-9; ALPHA-3-BETA-1 INTEGRIN; DEPENDENT SECRETION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; GENE-EXPRESSION; IV COLLAGENASE; IN-VIVO; TUMOR	To analyze mechanisms for cancer metastasis, we established high metastatic sublines from mouse Lewis lung cancer (P29) by repeated injection. Sublines established from the two subclones H7 and C4 commonly exhibited increased proliferation and invasion activity and reduced expression of ganglioside GM1, although they showed different preferences in their target organs of metastasis. The high metastatic sublines secreted higher levels of activated matrix metalloprotease (MMP)-9 as well as pro-MMP-9 in the culture medium than the parent lines. Furthermore, they contained MMP-9 at the glycolipid-enriched microdomain (GEM)/rafts fractionated by the sucrose density gradient ultracentrifugation of Triton X-100 extracts, whereas the parent cells showed faint bands at the fraction. When high metastatic sublines were treated with methyl-beta-cyclodextrin, their invasion activities were dramatically suppressed, and the MMP-9 secretion was also suppressed. All these results indicated that GEM/rafts play crucial roles in the increased invasion and high metastatic potential. To clarify the implication of reduced GM1 expression, low GM1-expressing cell lines were established using an RNA interference-expression vector of the GM1 synthase. Low GM1-expressing cell lines showed increased proliferation and invasion, enrichment in the GEM/rafts, and increased secretion of MMP-9. Among adhesion molecules, only integrin beta 1 was detected in GEM/rafts with stronger intensity in high metastatic lines and low GM1-expressing cells. Taken together, integrins seemed to be enriched in the GEM/rafts by reduced GM1 levels, and subsequently MMP-9 was recruited to the GEM/rafts, resulting in its efficient secretion and activation, and eventually in the increased invasion and metastatic potentials.	Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Grad Sch Med, Dept Surg 2, Showa Ku, Nagoya, Aichi 4660065, Japan	Nagoya University; Nagoya University	Furukawa, K (corresponding author), Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp		Urano, Takeshi/0000-0003-3383-3554				Agrez M, 1999, INT J CANCER, V81, P90, DOI 10.1002/(SICI)1097-0215(19990331)81:1<90::AID-IJC16>3.0.CO;2-K; Aixinjueluo W, 2005, J BIOL CHEM, V280, P29828, DOI 10.1074/jbc.M414041200; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Chen HH, 2003, INT J CANCER, V103, P169, DOI 10.1002/ijc.10797; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; DiPersio CM, 2000, J CELL SCI, V113, P2909; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellis LM, 2004, SEMIN ONCOL, V31, P3, DOI 10.1053/j.seminoncol.2004.11.028; Fedarko NS, 2004, FASEB J, V18, P734, DOI 10.1096/fj.03-0966fje; Fisher LW, 2004, CLIN CANCER RES, V10, P8501, DOI 10.1158/1078-0432.CCR-04-1072; Fridman R, 2003, CANCER METAST REV, V22, P153, DOI 10.1023/A:1023091214123; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P143, DOI 10.1023/A:1026524820177; Hamamura K, 2005, INT J ONCOL, V26, P897; Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harlozinska A, 2005, ANTICANCER RES, V25, P3327; Hassanieh L, 2003, HYBRIDOMA HYBRIDOM, V22, P285, DOI 10.1089/153685903322538809; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Iyer V, 2005, J CELL SCI, V118, P1185, DOI 10.1242/jcs.01708; Kannagi R, 2004, GLYCOCONJUGATE J, V20, P353; Karadag A, 2005, CANCER RES, V65, P11545, DOI 10.1158/0008-5472.CAN-05-2861; Karamessinis PM, 2002, LAB INVEST, V82, P1081, DOI 10.1097/01.LAB.0000022224.86237.31; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; LARJAVA H, 1993, J CELL PHYSIOL, V157, P190, DOI 10.1002/jcp.1041570125; Laude AJ, 2004, MOL MEMBR BIOL, V21, P193, DOI 10.1080/09687680410001700517; Mira E, 2004, J CELL SCI, V117, P1847, DOI 10.1242/jcs.01035; Mitsuda T, 2002, J BIOL CHEM, V277, P11239, DOI 10.1074/jbc.M107756200; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; Mook ORF, 2004, BBA-REV CANCER, V1705, P69, DOI 10.1016/j.bbcan.2004.09.006; Morgan MR, 2004, J BIOL CHEM, V279, P26533, DOI 10.1074/jbc.M401736200; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; NAKANISHI H, 1992, BIOCHEM J, V288, P215, DOI 10.1042/bj2880215; Nathanson SD, 2003, CANCER, V98, P413, DOI 10.1002/cncr.11464; Nishio M, 2004, J BIOL CHEM, V279, P33368, DOI 10.1074/jbc.M403816200; Parkin ET, 1999, BIOCHEM J, V344, P23, DOI 10.1042/0264-6021:3440023; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Razani B, 2001, J BIOL CHEM, V276, P38121; Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Sein TT, 2000, ONCOGENE, V19, P5539, DOI 10.1038/sj.onc.1203932; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stan RV, 2005, BBA-MOL CELL RES, V1746, P334, DOI 10.1016/j.bbamcr.2005.08.008; Stefanidakis M, 2004, J IMMUNOL, V172, P7060, DOI 10.4049/jimmunol.172.11.7060; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Taraboletti G, 2002, AM J PATHOL, V160, P673, DOI 10.1016/S0002-9440(10)64887-0; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wang XQ, 2003, J BIOL CHEM, V278, P25591, DOI 10.1074/jbc.M302211200; Wang XQ, 2002, J BIOL CHEM, V277, P47028, DOI 10.1074/jbc.M208257200; Williams TM, 2004, J BIOL CHEM, V279, P24745, DOI 10.1074/jbc.M402064200; Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200; Wize J, 1998, INFLAMM RES, V47, P325, DOI 10.1007/s000110050336; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; YAMASHIRO S, 1993, CANCER RES, V53, P5395; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhao JM, 1999, J BIOL CHEM, V274, P13744, DOI 10.1074/jbc.274.20.13744	61	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					18145	18155		10.1074/jbc.M512566200	http://dx.doi.org/10.1074/jbc.M512566200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636068	hybrid			2022-12-25	WOS:000238490300066
J	Bhar, D; Karren, MA; Babst, M; Shaw, JM				Bhar, Debjani; Karren, Mary Anne; Babst, Markus; Shaw, Janet M.			Dimeric Dnm1-G385D interacts with mdv1 on mitochondria and can be stimulated to assemble into fission complexes containing Mdv1 and Fis1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; WD REPEAT PROTEIN; SACCHAROMYCES-CEREVISIAE; EFFECTOR DOMAIN; OUTER-MEMBRANE; ATP DEPLETION; DIVISION; FUSION; YEAST; DNM1P	Interactions between yeast Dnm1p, Mdv1p, and Fis1p are required to form fission complexes that catalyze division of the mitochondrial compartment. During the formation of mitochondrial fission complexes, the Dnm1p GTPase self-assembles into large multimeric complexes on the outer mitochondrial membrane that are visualized as punctate structures by fluorescent labeling. Although it is clear that Fis1p center dot Mdv1p complexes on mitochondria are required for the initial recruitment of Dnm1p, it is not clear whether Dnm1p puncta assemble before or after this recruitment step. Here we show that the minimum oligomeric form of cytoplasmic Dnm1p is a dimer. The middle domain mutant protein Dnm1G385Dp forms dimers in vivo but fails to assemble into punctate structures. However, this dimeric mutant stably interacts with Mdv1p on the outer mitochondrial membrane, demonstrating that assembly of stable Dnm1p multimers is not required for Dnm1p-Mdv1p association or for mitochondrial recruitment of Dnm1p. Dnm1G385Dp is reported to be a terminal dimer in vitro. We describe conditions that allow assembly of Dnm1G385Dp into functional fission complexes on mitochondria in vivo. Using these conditions, we demonstrate that multimerization of Dnm1p is required to promote reorganization of Mdv1p from a uniform mitochondrial localization into punctate fission complexes. Our studies also reveal that Fis1p is present in these assembled fission complexes. Based on our results, we propose that Dnm1p dimers are initially recruited to the membrane via interaction with Mdv1p center dot Fis1p complexes. These dimers then assemble into multimers that subsequently promote the reorganization of Mdv1p into punctate fission complexes.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Shaw, JM (corresponding author), Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84112 USA.	shaw@biochem.utah.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53466, R01 GM053466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; Cerveny KL, 2003, MOL BIOL CELL, V14, P4126, DOI 10.1091/mbc.E03-02-0092; Cerveny KL, 2001, MOL BIOL CELL, V12, P309, DOI 10.1091/mbc.12.2.309; CLARKE BL, 1985, J BIOL CHEM, V260, P128; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Fekkes P, 2000, J CELL BIOL, V151, P333, DOI 10.1083/jcb.151.2.333; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Frederick RL, 2004, J CELL BIOL, V167, P87, DOI 10.1083/jcb.200405100; Fukushima NH, 2001, MOL BIOL CELL, V12, P2756, DOI 10.1091/mbc.12.9.2756; Griffin EE, 2005, J CELL BIOL, V170, P237, DOI 10.1083/jcb.200503148; GUTHRIE C, 1991, YEAST GENETICS MOL B, P12; Hermann GJ, 1998, ANNU REV CELL DEV BI, V14, P265, DOI 10.1146/annurev.cellbio.14.1.265; Ingerman E, 2005, J CELL BIOL, V170, P1021, DOI 10.1083/jcb.200506078; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Karren MA, 2005, J CELL BIOL, V171, P291, DOI 10.1083/jcb.200506158; Kondo-Okamoto N, 2003, J BIOL CHEM, V278, P48997, DOI 10.1074/jbc.M308436200; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Maniatis T., 1982, MOL CLONING LAB MANU; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Mozdy AD, 2003, NAT REV MOL CELL BIO, V4, P468, DOI 10.1038/nrm1125; Naylor K, 2006, J BIOL CHEM, V281, P2177, DOI 10.1074/jbc.M507943200; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Osteryoung KW, 2003, SCIENCE, V302, P1698, DOI 10.1126/science.1082192; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; Schwoebel ED, 2002, J CELL BIOL, V157, P963, DOI 10.1083/jcb.200111077; Scorrano L, 2003, CELL DEATH DIFFER, V10, P1287, DOI 10.1038/sj.cdd.4401310; Sesaki H, 2003, MOL BIOL CELL, V14, P2342, DOI 10.1091/mbc.E02-12-0788; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; SHERMAN F, 1986, METHODS YEAST GENETI, P121; SHETTY M, 1992, AM J PHYSIOL, V262, pC527, DOI 10.1152/ajpcell.1992.262.2.C527; Suzuki M, 2005, J BIOL CHEM, V280, P21444, DOI 10.1074/jbc.M414092200; Szabadkai G, 2004, MOL CELL, V16, P59, DOI 10.1016/j.molcel.2004.09.026; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; Tieu Q, 2002, J CELL BIOL, V158, P445, DOI 10.1083/jcb.200205031; Westermann B, 2003, BBA-MOL CELL RES, V1641, P195, DOI 10.1016/S0167-4889(03)00091-0; Westermann B, 2002, EMBO REP, V3, P527, DOI 10.1093/embo-reports/kvf113; Westermann B, 2002, FUNGAL GENET BIOL, V36, P91, DOI 10.1016/S1087-1845(02)00019-1; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Zhu PP, 2004, J BIOL CHEM, V279, P35967, DOI 10.1074/jbc.M404105200	50	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17312	17320		10.1074/jbc.M513530200	http://dx.doi.org/10.1074/jbc.M513530200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16601120	hybrid			2022-12-25	WOS:000238326300058
J	Hekman, M; Albert, S; Galmiche, A; Rennefahrt, UEE; Fueller, J; Fischer, A; Puehringer, D; Wiese, S; Rapp, UR				Hekman, Mirko; Albert, Stefan; Galmiche, Antoine; Rennefahrt, Ulrike E. E.; Fueller, Jochen; Fischer, Andreas; Puehringer, Dirk; Wiese, Stefan; Rapp, Ulf R.			Reversible membrane interaction of BAD requires two C-terminal lipid binding domains in conjunction with 14-3-3 protein binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH AGONIST BAD; CELL-DEATH; MITOCHONDRIAL-MEMBRANE; MODEL MEMBRANES; BCL-2 PROTEINS; KINASE RAF-1; PHOSPHORYLATION; SURVIVAL; RAFTS; APOPTOSIS	BAD is a Bcl-2 homology domain 3 (BH3)-only proapoptotic member of the Bcl-2 protein family that is regulated by phosphorylation in response to survival factors. Binding of BAD to mitochondria is thought to be exclusively mediated by its BH3 domain. We show here that BAD binds to lipids with high affinities, predominantly to negatively charged phospholipids, such as phosphatidylserine, phosphatidic acid, and cardiolipin, as well as to cholesterol-rich liposomes. Two lipid binding domains (LBD1 and LBD2) with different binding preferences were identified, both located in the C-terminal part of the BAD protein. BAD facilitates membrane translocation of Bcl-X-L in a process that requires LBD2. Integrity of LBD1 and LBD2 is also required for proapoptotic activity in vivo. Phosphorylation of BAD does not affect membrane binding but renders BAD susceptible to membrane extraction by 14-3-3 proteins. BAD can be removed efficiently by 14-3-3 zeta, -eta, -tau and less efficiently by other 14-3-3 isoforms. The assembled BAD center dot 14-3-3 complex exhibited high affinity for cholesterol-rich liposomes but low affinity for mitochondrial membranes. We conclude that BAD is a membrane-associated protein that has the hallmarks of a receptor rather than a ligand. Lipid binding is essential for the proapoptotic function of BAD in vivo. The data support a model in which BAD shuttles in a phosphorylation-dependent manner between mitochondria and other membranes and where 14-3-3 is a key regulator of this relocation. The dynamic interaction of BAD with membranes is tied to activation and membrane translocation of Bcl-X-L.	Univ Wurzburg, Inst Med Radiat & Cell Res, D-97078 Wurzburg, Germany; Univ Wurzburg, Inst Clin Neurobiol, D-97078 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Radiat & Cell Res, Versbacher Str 5, D-97078 Wurzburg, Germany.	rappur@mail.uni-wuerzburg.de						Aktories K, 2005, NAT REV MICROBIOL, V3, P397, DOI 10.1038/nrmicro1150; Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; Ayllon V, 2002, J IMMUNOL, V168, P3387, DOI 10.4049/jimmunol.168.7.3387; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DREXLER HCA, 2006, APOPTOSIS CANC THERA, P490; Fleischer A, 2004, MOL CANCER RES, V2, P674; Garcia A, 2003, BIOCHIMIE, V85, P727, DOI 10.1016/j.biochi.2003.09.005; Gennis R.B., 1988, BIOMEMBRANES MOL STR; Gotz R, 2005, NAT NEUROSCI, V8, P1169, DOI 10.1038/nn1524; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hekman M, 2002, J BIOL CHEM, V277, P24090, DOI 10.1074/jbc.M200576200; HOVIUS R, 1993, FEBS LETT, V330, P71, DOI 10.1016/0014-5793(93)80922-H; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Jin SH, 2005, J BIOL CHEM, V280, P24698, DOI 10.1074/jbc.M413374200; Kerkhoff E, 2002, BBA-MOL CELL RES, V1589, P151, DOI 10.1016/S0167-4889(02)00168-4; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Martinez-Senac MD, 2002, BIOPHYS J, V82, P233, DOI 10.1016/S0006-3495(02)75390-3; Martinez-Senac MD, 2001, BIOCHEMISTRY-US, V40, P9983; Martinez-Senac MD, 2000, BIOCHEMISTRY-US, V39, P7744, DOI 10.1021/bi000256h; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Rapp UR, 2004, BBA-MOL CELL RES, V1644, P149, DOI 10.1016/j.bbamcr.2003.10.015; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; Subramanian RR, 2001, EXP CELL RES, V271, P142, DOI 10.1006/excr.2001.5376; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	37	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17321	17336		10.1074/jbc.M600292200	http://dx.doi.org/10.1074/jbc.M600292200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16603546	hybrid			2022-12-25	WOS:000238326300059
J	Sayed, AA; Cook, SK; Williams, DL				Sayed, Ahmed A.; Cook, Shawna K.; Williams, David L.			Redox balance mechanisms in Schistosoma mansoni rely on peroxiredoxins and albumin and implicate peroxiredoxins as novel drug targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; SUCCINATE-DEHYDROGENASE; THIOREDOXIN PEROXIDASE; 2-CYS PEROXIREDOXINS; ANTIOXIDANT ENZYMES; ENDOTHELIAL-CELLS; GENE-EXPRESSION; SULFINIC ACID	Schistosoma mansoni, a causative agent of schistosomiasis, resides in the hepatic portal circulation of their human host up to 30 years without being eliminated by the host immune attack. Production of an antioxidant "firewall," which would neutralize the oxidative assault generated by host immune defenses, is one proposed survival mechanism of the parasite. Schistosomes lack catalase, the main H2O2-neutralizing enzyme of many organisms, and their glutathione peroxidases are in the phospholipid class with poor reactivity toward H2O2. Evidence implicates peroxiredoxins (Prx) as providing the main enzymatic activity to reduce H2O2 in the parasite. Quantitative monitoring of Prx mRNAs during parasite life cycle indicated that Prx proteins are differentially expressed, with highest expression occurring in adult stages ( oxidative resistant stages). Incubation of schistosomula with Prx1 double-stranded RNA knocked down total Prx enzymatic activity and resulted in lowered survival of cultured parasites compared with controls demonstrating that Prx are essential parasite proteins. These results represent the first report of lethal gene silencing in Schistosoma. Investigation of downstream effects of Prx silencing revealed an abrupt increase of lipid peroxides and the generation of several oxidized proteins. Using mass spectrometry, parasite albumin and actin were identified as the main oxidized proteins. Gene expression analysis showed that schistosome albumin was induced by oxidative stress. This study highlights Prx proteins as essential parasite proteins and potential new targets for anti-schistosome drug development and albumin as a novel, sacrificial oxidant scavenging protein in parasite redox regulation.	Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA	Illinois State University	Williams, DL (corresponding author), Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA.	dlwilli@ilstu.edu			NIAID NIH HHS [AI-054403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI054403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alger HM, 2002, MOL BIOCHEM PARASIT, V121, P129, DOI 10.1016/S0166-6851(02)00031-2; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bergmeyer HU., 1974, METHODS ENZYMATIC AN, P574, DOI [10.1016/B978-0-12-091302-2.50010-4, DOI 10.1016/B978-0-12-091302-2.50010-4]; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; BROPHY PM, 1990, PARASITOLOGY, V100, P345, DOI 10.1017/S0031182000061369; BUBANOV AV, 2004, SCIENCE, V304, P596; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Chang TS, 2004, J BIOL CHEM, V279, P50994, DOI 10.1074/jbc.M409482200; Chang TS, 2004, J BIOL CHEM, V279, P41975, DOI 10.1074/jbc.M407707200; Cioli D, 2004, INT J PARASITOL, V34, P979, DOI 10.1016/j.ijpara.2004.05.001; COLIGAN JE, 2001, CURRENT PROTOCOLS IM, V1, P12; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; DUVALL RH, 1967, AM J TROP MED HYG, V16, P483, DOI 10.4269/ajtmh.1967.16.483; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fenwick A, 2003, TRENDS PARASITOL, V19, P509, DOI 10.1016/j.pt.2003.09.005; Gourlay CW, 2004, J CELL BIOL, V164, P803, DOI 10.1083/jcb.200310148; GREEN JD, 1980, J HISTOCHEM CYTOCHEM, V28, P408, DOI 10.1177/28.5.6966645; GUTTERIDGE JMC, 1992, BIOCHIM BIOPHYS ACTA, V1159, P248, DOI 10.1016/0167-4838(92)90052-F; HALLIWELL B, 1990, ARCH BIOCHEM BIOPHYS, V280, P1, DOI 10.1016/0003-9861(90)90510-6; HALLIWELL B, 1988, BIOCHEM PHARMACOL, V37, P569, DOI 10.1016/0006-2952(88)90126-8; Hotez PJ, 2006, PLOS MED, V3, P576, DOI 10.1371/journal.pmed.0030102; Igleslas J, 1999, AM J PHYSIOL-RENAL, V277, pF711, DOI 10.1152/ajprenal.1999.277.5.F711; Immenschuh S, 2005, ANTIOXID REDOX SIGN, V7, P768, DOI 10.1089/ars.2005.7.768; King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Kwatia MA, 2000, J PARASITOL, V86, P908, DOI 10.1645/0022-3395(2000)086[0908:MAECOS]2.0.CO;2; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Lewis FA, 1998, CURRENT PROTOCOLS IM, V28; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LoVerde PT, 1998, PARASITOL TODAY, V14, P284, DOI 10.1016/S0169-4758(98)01261-7; Maiorino M, 1996, EUR J BIOCHEM, V238, P838, DOI 10.1111/j.1432-1033.1996.0838w.x; MEI HP, 1995, EXP PARASITOL, V80, P319, DOI 10.1006/expr.1995.1038; Mei HP, 1997, EXP PARASITOL, V86, P69, DOI 10.1006/expr.1997.4150; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; MKOJI GM, 1988, INT J PARASITOL, V18, P661, DOI 10.1016/0020-7519(88)90101-4; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Roche C, 1996, MOL BIOCHEM PARASIT, V75, P187, DOI 10.1016/0166-6851(95)02523-5; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sayed AA, 2004, J BIOL CHEM, V279, P26159, DOI 10.1074/jbc.M401748200; Skelly PJ, 2003, INT J PARASITOL, V33, P363, DOI 10.1016/S0020-7519(03)00030-4; Tang JX, 1999, BIOPHYS J, V76, P2208, DOI 10.1016/S0006-3495(99)77376-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tielens AGM, 2002, TRENDS BIOCHEM SCI, V27, P564, DOI 10.1016/S0968-0004(02)02193-X; Utomo A, 2004, J BIOL CHEM, V279, P43522, DOI 10.1074/jbc.M407141200; Vermeire JJ, 2004, MOL BIOCHEM PARASIT, V135, P153, DOI 10.1016/j.molbiopara.2003.12.013; Wang XS, 2003, J BIOL CHEM, V278, P25179, DOI 10.1074/jbc.M302706200; WILLIAMS DL, 1992, MOL BIOCHEM PARASIT, V52, P127, DOI 10.1016/0166-6851(92)90042-I; Williams DL, 2001, INFECT IMMUN, V69, P1134, DOI 10.1128/IAI.69.2.1134-1141.2001; Woo HA, 2005, J BIOL CHEM, V280, P3125, DOI 10.1074/jbc.C400496200; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405	56	93	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17001	17010		10.1074/jbc.M512601200	http://dx.doi.org/10.1074/jbc.M512601200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16606626	hybrid			2022-12-25	WOS:000238326300022
J	Swaney, JS; Patel, HH; Yokoyama, U; Head, BP; Roth, DM; Insel, PA				Swaney, James S.; Patel, Hemal H.; Yokoyama, Utako; Head, Brian P.; Roth, David M.; Insel, Paul A.			Focal adhesions in (myo) fibroblasts scaffold adenylyl cyclase with phosphorylated caveolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE 1B; SMOOTH-MUSCLE-CELLS; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR; OXIDATIVE-STRESS; ANGIOTENSIN-II; MYOFIBROBLAST DIFFERENTIATION; IN-VIVO; MEMBRANE; TRANSFORMATION	Fibroblast-myofibroblast transformation, a critical event for enhanced extracellular matrix deposition, involves formation of an actin stress fiber contractile apparatus that radiates from focal adhesions (FA) in the plasma membrane. Activation of adenylyl cyclase (AC, i.e. increases in cAMP) negatively regulates such transformation. Caveolae and their resident protein caveolins scaffold signaling molecules, including AC isoforms, whereas phosphorylated caveolin-1 (phospho-cav-1) may localize at FA. Here, we used adult rat cardiac fibroblasts to examine distribution and expression of AC, phospho-cav-1, and FA proteins to define mechanisms that link increases in cAMP to caveolin-1 phosphorylation, actin/FA assembly, and fibroblast-myofibroblast transformation. Sucrose density gradient centrifugation, immunoblot, and immunohistochemical analysis revealed that, unlike cav-1, phospho-cav-1 enriches in membrane fractions that express FA proteins and localize at the ends of actin stress fibers. We detected AC in both cav-1 and phospho-cav-1 immunoprecipitates, but FA kinase (FAK), phospho-FAK (FAK Tyr-397), paxillin, and vinculin were detected only in phospho-cav-1 immunoprecipitates. Treatment with the AC activator forskolin or a cAMP analog increased cav-1 phosphorylation but decreased FAK Tyr-397 phosphorylation in a cAMP-dependent protein kinase-dependent manner. These events preceded actin cytoskeletal disruption, an effect that was blocked by small interfering RNA knock-down of cav-1. Inhibition of protein tyrosine phosphatase 1B abrogated cAMP-mediated disruption of actin cytoskeleton, cav-1 phosphorylation, and FAK Tyr-397 dephosphorylation. The data thus define a novel organization of signaling molecules that regulate fibroblasts: scaffolding of AC by phospho-cav-1 at FA sites in a caveolae-free microdomain along with components that mediate inhibition of actin/FA assembly and fibroblast-myofibroblast transformation via increases in cAMP.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Grad Program Mol Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; Vet Affairs Med Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	pinsel@ucsd.edu	Yokoyama, Utako/AAD-1404-2022; Patel, Hemal/C-7325-2019	Yokoyama, Utako/0000-0003-1803-0155; Patel, Hemal/0000-0001-6722-9625	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL053773, R01HL063885] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53773, HL63885, HL7261] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arias-Salgado EG, 2005, J CELL BIOL, V170, P837, DOI 10.1083/jcb.200503125; Brown RD, 2005, ANNU REV PHARMACOL, V45, P657, DOI 10.1146/annurev.pharmtox.45.120403.095802; Bulin C, 2005, ARTERIOSCL THROM VAS, V25, P84, DOI 10.1161/01.ATV.0000146814.81581.68; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; Chen DB, 2005, BIOL REPROD, V73, P761, DOI 10.1095/biolreprod.105.040881; Colonna C, 2005, EXP CELL RES, V304, P432, DOI 10.1016/j.yexcr.2004.11.019; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; Desmouliere A, 2003, LAB INVEST, V83, P1689, DOI 10.1097/01.LAB.0000101911.53973.90; Dugina V, 2001, J CELL SCI, V114, P3285; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Head BP, 2005, J BIOL CHEM, V280, P31036, DOI 10.1074/jbc.M502540200; HEWITSON TD, 1995, AM J NEPHROL, V15, P411, DOI 10.1159/000168875; Hnasko Robert, 2003, Mol Interv, V3, P445, DOI 10.1124/mi.3.8.445; Kawabe J, 2004, AM J PHYSIOL-HEART C, V286, pH1845, DOI 10.1152/ajpheart.00593.2003; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Lee H, 2006, BIOCHEMISTRY-US, V45, P234, DOI 10.1021/bi051560j; Lee H, 2002, J BIOL CHEM, V277, P34556, DOI 10.1074/jbc.M204367200; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Liang FB, 2005, J BIOL CHEM, V280, P24857, DOI 10.1074/jbc.M502780200; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Lotersztajn S, 2005, ANNU REV PHARMACOL, V45, P605, DOI 10.1146/annurev.pharmtox.45.120403.095906; Mimura Y, 2005, J INVEST DERMATOL, V124, P886, DOI 10.1111/j.0022-202X.2005.23701.x; MITCHELL J, 1989, LAB INVEST, V60, P643; Ostrom RS, 2003, J BIOL CHEM, V278, P24461, DOI 10.1074/jbc.M212659200; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pathre P, 2001, J NEUROSCI RES, V63, P143, DOI 10.1002/1097-4547(20010115)63:2<143::AID-JNR1006>3.0.CO;2-1; Pike LJ, 2005, BBA-MOL CELL RES, V1746, P260, DOI 10.1016/j.bbamcr.2005.05.005; Sanguinetti AR, 2003, BIOCHEM J, V376, P159, DOI 10.1042/BJ20030336; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Sun Y, 2004, J LAB CLIN MED, V143, P41, DOI 10.1016/j.lab.2003.07.004; Swaney JS, 2005, P NATL ACAD SCI USA, V102, P437, DOI 10.1073/pnas.0408704102; Tao JC, 2001, J BIOL CHEM, V276, P29520, DOI 10.1074/jbc.M103721200; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wiesmann C, 2004, NAT STRUCT MOL BIOL, V11, P730, DOI 10.1038/nsmb803; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007	48	60	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17173	17179		10.1074/jbc.M513097200	http://dx.doi.org/10.1074/jbc.M513097200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16618703	hybrid			2022-12-25	WOS:000238326300042
J	Xu, WX; Ahmed, S; Moriyama, H; Chollet, R				Xu, Wenxin; Ahmed, Shaheen; Moriyama, Hideaki; Chollet, Raymond			The importance of the strictly conserved, C-terminal glycine residue in phosphoenolpyruvate carboxylase for overall catalysis - Mutagenesis and truncation of Gly-961 in the sorghum C4 leaf isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; BINDING-SITE; SWISS-MODEL; EXPRESSION; MAIZE; PHOSPHORYLATION; ENZYME; POLYPEPTIDES	Phosphoenolpyruvate carboxylase (PEPC) is a "multifaceted," allosteric enzyme involved in C4 acid metabolism in green plants/microalgae and prokaryotes. Before the elucidation of the three-dimensional structures of maize C4 leaf and Escherichia coli PEPC, our truncation analysis of the sorghum C4 homologue revealed important roles for the enzyme's C-terminal alpha-helix and its appended QNTG(961) tetrapeptide in polypeptide stability and overall catalysis, respectively. Collectively, these functional and structural observations implicate the importance of the PEPC C-terminal tetrapeptide for both catalysis and negative allosteric regulation. We have now more finely dissected this element of PEPC structure-function by modification of the absolutely conserved C-terminal glycine of the sorghum C4 isoform by site-specific mutagenesis (G961(A/V/D)) and truncation (Delta C1/C4). Although the C4 polypeptide failed to accumulate in a PEPC- strain(XH11) of E. coli transformed with the Asp mutant, the other variants were produced at wild-type levels. Although neither of these four mutants displayed an apparent destabilization of the purified PEPC homotetramer, all were compromised catalytically in vivo and in vitro. Functional complementation of XH11 cells under selective growth conditions was restricted progressively by the Ala, Delta C1 and Val, and Delta C4 modifications. Likewise, steady-state kinetic analysis of the purified mutant enzymes revealed corresponding negative trends in k(cat) and k(cat)/K-0.5 (phosphoenolpyruvate) but not in K-0.5 or the Hill coefficient. Homology modeling of these sorghum C-terminal variants against the structure of the closely related maize C4 isoform predicted perturbations in active-site molecular cavities and/or ion-pairing with essential, invariant Arg-638. These collective observations reveal that even a modest, neutral alteration of the PEPC C-terminal hydrogen atom side chain is detrimental to enzyme function.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA; Univ Nebraska, Dept Plant Sci Initiat, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Chollet, R (corresponding author), Univ Nebraska, Dept Biochem, N246 Beadle Ctr, Lincoln, NE 68588 USA.	rchollet1@unl.edu	Chollet, Raymond/G-2509-2010					BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bates PA, 2001, PROTEINS, P39; Blasing OE, 2000, J BIOL CHEM, V275, P27917; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brady GP, 2000, J COMPUT AID MOL DES, V14, P383, DOI 10.1023/A:1008124202956; BUDDE RJA, 1986, PLANT PHYSIOL, V82, P1107, DOI 10.1104/pp.82.4.1107; Chen LM, 2002, PLANT CELL PHYSIOL, V43, P159, DOI 10.1093/pcp/pcf019; Chollet R, 1996, ANNU REV PLANT PHYS, V47, P273, DOI 10.1146/annurev.arplant.47.1.273; CRETIN C, 1991, PLANT MOL BIOL, V17, P83, DOI 10.1007/BF00036808; Dong LY, 1999, ARCH BIOCHEM BIOPHYS, V371, P124, DOI 10.1006/abbi.1999.1433; Dong LY, 1997, BIOSCI BIOTECH BIOCH, V61, P545, DOI 10.1271/bbb.61.545; DUFF SMG, 1995, EUR J BIOCHEM, V228, P92, DOI 10.1111/j.1432-1033.1995.tb20234.x; Ermolova NV, 2003, PROTEIN EXPRES PURIF, V29, P123, DOI 10.1016/S1046-5928(03)00014-7; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Izui K, 2004, ANNU REV PLANT BIOL, V55, P69, DOI 10.1146/annurev.arplant.55.031903.141619; Kai Y, 1999, P NATL ACAD SCI USA, V96, P823, DOI 10.1073/pnas.96.3.823; Kai Y, 2003, ARCH BIOCHEM BIOPHYS, V414, P170, DOI 10.1016/S0003-9861(03)00170-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mamedov TG, 2005, PLANT J, V42, P832, DOI 10.1111/j.1365-313X.2005.02416.x; Matsumura H, 2002, STRUCTURE, V10, P1721, DOI 10.1016/S0969-2126(02)00913-9; Matsumura H, 1999, FEBS LETT, V458, P93, DOI 10.1016/S0014-5793(99)01103-5; Miyao M, 2003, ARCH BIOCHEM BIOPHYS, V414, P197, DOI 10.1016/S0003-9861(03)00117-6; Nimmo HG, 2003, ARCH BIOCHEM BIOPHYS, V414, P189, DOI 10.1016/S0003-9861(03)00115-2; Patel HM, 2004, J BACTERIOL, V186, P5129, DOI 10.1128/jb.186.15.5129-5137.2004; Rivoal J, 2001, J BIOL CHEM, V276, P12588, DOI 10.1074/jbc.M010150200; Sanchez R, 2006, PLANTA, V223, P901, DOI 10.1007/s00425-005-0144-5; Satagopan S, 2004, J BIOL CHEM, V279, P14240, DOI 10.1074/jbc.M313215200; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sokal R. R., 1981, BIOMETRY; Sullivan S, 2004, PLANT PHYSIOL, V135, P2078, DOI 10.1104/pp.104.042762; Svensson P, 2003, ARCH BIOCHEM BIOPHYS, V414, P180, DOI 10.1016/S0003-9861(03)00165-6; Takahashi-Terada A, 2005, J BIOL CHEM, V280, P11798, DOI 10.1074/jbc.M408768200; TERADA K, 1991, EUR J BIOCHEM, V202, P797, DOI 10.1111/j.1432-1033.1991.tb16435.x; WANG YH, 1992, J BIOL CHEM, V267, P16759; YANO M, 1995, J BIOCHEM-TOKYO, V117, P1196, DOI 10.1093/oxfordjournals.jbchem.a124844	36	13	15	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17238	17245		10.1074/jbc.M602299200	http://dx.doi.org/10.1074/jbc.M602299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16624802	hybrid			2022-12-25	WOS:000238326300050
J	Stojanovic, A; Marjanovic, JA; Brovkovych, VM; Peng, XD; Hay, N; Skidgel, RA; Du, XP				Stojanovic, Aleksandra; Marjanovic, Jasna A.; Brovkovych, Viktor M.; Peng, Xiaoding; Hay, Nissim; Skidgel, Randal A.; Du, Xiaoping			A phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating platelet secretion and aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE; GUANOSINE 3',5'-MONOPHOSPHATE; INTEGRIN ALPHA(IIB)BETA(3); RELEASE REACTION; CYCLIC-GMP; ACTIVATION; AKT; INHIBITION; 3-KINASE	Phosphoinositide 3-kinase ( PI3K) and Akt play important roles in platelet activation. However, the downstream mechanisms mediating their functions are unclear. We have recently shown that nitric-oxide ( NO) synthase 3 and cGMP-dependent protein kinase stimulate platelet secretion and aggregation. Here we show that PI3K-mediated Akt activation plays an important role in agonist-stimulated platelet NO synthesis and cGMP elevation. Agonist-induced elevation of NO and cGMP was inhibited by Akt inhibitors and reduced in Akt-1 knock-out platelets. Akt-1 knock-out or Akt inhibitor-treated platelets showed reduced platelet secretion and aggregation in response to low concentrations of agonists, which can be reversed by low concentrations of 8-bromo-cGMP or sodium nitroprusside ( an NO donor). Similarly, PI3K inhibitors diminished elevation of cGMP and inhibited platelet secretion and the second wave platelet aggregation, which was also partially reversed by 8-bromo-cGMP. These results indicate that the NO-cGMP pathway is an important downstream mechanism mediating PI3K and Akt signals leading to platelet secretion and aggregation. Conversely, the PI3K-Akt pathway is the major upstream mechanism responsible for activating the NO-cGMP pathway in platelets. Thus, this study delineates a novel platelet activation pathway involving sequential activation of PI3K, Akt, nitric-oxide synthase 3, sGC, and cGMP-dependent protein kinase.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Du, XP (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	xdu@uic.edu	Peng, Xiao-ding/B-2478-2012	Peng, Xiao-ding/0000-0002-9214-0136	NHLBI NIH HHS [HL 68819, HL 62350, HL 60678] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062350, R01HL068819, P01HL060678] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brovkovych V, 1999, J PHARMACEUT BIOMED, V19, P135, DOI 10.1016/S0731-7085(98)00090-9; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chen JH, 2004, BLOOD, V104, P1703, DOI 10.1182/blood-2003-10-3428; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; CHIANG TM, 1976, J LAB CLIN MED, V88, P215; CHIANG TM, 1975, J BIOL CHEM, V250, P6916; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Du XP, 2004, BLOOD, V103, P4371, DOI 10.1182/blood-2004-02-0507; Feil R, 2005, TRENDS MOL MED, V11, P71, DOI 10.1016/j.molmed.2004.12.001; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HASLAM RJ, 1975, NATURE, V253, P455, DOI 10.1038/253455a0; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li ZY, 2006, BLOOD, V107, P965, DOI 10.1182/blood-2005-03-1308; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; Li ZY, 2004, J BIOL CHEM, V279, P42469, DOI 10.1074/jbc.M401532200; Li ZY, 2003, J BIOL CHEM, V278, P30725, DOI 10.1074/jbc.M301838200; Li ZY, 2003, BLOOD, V101, P4423, DOI 10.1182/blood-2002-10-3210; Li ZY, 2003, CELL, V112, P77, DOI 10.1016/S0092-8674(02)01254-0; Marjanovic JA, 2005, J BIOL CHEM, V280, P37430, DOI 10.1074/jbc.M506518200; Marshall SJ, 2004, BLOOD, V103, P2601, DOI 10.1182/blood-2003-09-3319; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; MELLION BT, 1981, BLOOD, V57, P946; MELLION BT, 1983, MOL PHARMACOL, V23, P653; Reed GL, 2000, BLOOD, V96, P3334; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; SAXON A, 1976, BLOOD, V47, P957; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Watanabe N, 2003, BLOOD, V102, P541, DOI 10.1182/blood-2002-11-3327; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	35	102	106	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16333	16339		10.1074/jbc.M512378200	http://dx.doi.org/10.1074/jbc.M512378200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16613861	hybrid			2022-12-25	WOS:000238165700020
J	Freibaum, BD; Counter, CM				Freibaum, Brian D.; Counter, Christopher M.			hSnm1B is a novel telomere-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENGTH REGULATOR; COMPLEX; SNM1; TRF1; END; REPAIR; LINK; POT1; POLYADENYLATION; SUSCEPTIBILITY	Artemis, a member of the beta-CASP family, has been implicated in the regulation of both telomere stability and length. Prompted by this, we examined whether the other two putative DNA-binding members of this family, hSnm1A and hSnm1B, may associate with telomeres. hSnm1A was found to not interact with the telomere. Conversely, hSnm1B was found to associate with telomeres in vivo by both immunofluorescence and chromatin immunoprecipitation. Furthermore, the C terminus of hSnm1B was shown to interact with the TRF homology domain of TRF2 indicating that hSnm1B is likely recruited to the telomere via interaction with the double-stranded telomere-binding protein TRF2.	Duke Univ, Med Ctr, Dept Radiat Oncol, Dept Pharmaceol & Canc Biol, Durham, NC 27710 USA	Duke University	Counter, CM (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Dept Pharmaceol & Canc Biol, Durham, NC 27710 USA.	count004@mc.duke.edu		Counter, Christopher M/0000-0003-0748-3079	NATIONAL CANCER INSTITUTE [R01CA082481] Funding Source: NIH RePORTER; NCI NIH HHS [CA82481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahkter S, 2005, MOL CELL BIOL, V25, P10071, DOI 10.1128/MCB.25.22.10071-10078.2005; Akhter S, 2004, MOL CELL BIOL, V24, P10448, DOI 10.1128/MCB.24.23.10448-10455.2004; Aravind L, 1999, In Silico Biol, V1, P69; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Cabuy E, 2005, RADIAT RES, V164, P53, DOI 10.1667/RR3376; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Demuth I, 2004, ONCOGENE, V23, P8611, DOI 10.1038/sj.onc.1207895; Dronkert MLG, 2000, MOL CELL BIOL, V20, P4553, DOI 10.1128/MCB.20.13.4553-4561.2000; Fairall L, 2001, MOL CELL, V8, P351, DOI 10.1016/S1097-2765(01)00321-5; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Houghtaling BR, 2004, CURR BIOL, V14, P1621, DOI 10.1016/j.cub.2004.08.052; Ishiai M, 2004, MOL CELL BIOL, V24, P10733, DOI 10.1128/MCB.24.24.10733-10741.2004; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Li XR, 2005, DNA REPAIR, V4, P163, DOI 10.1016/j.dnarep.2004.08.012; Li XR, 2003, DNA REPAIR, V2, P121, DOI 10.1016/S1568-7864(02)00192-1; Liu D, 2004, J BIOL CHEM, V279, P51338, DOI 10.1074/jbc.M409293200; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MITCHELL AR, 1985, CHROMOSOMA, V92, P369, DOI 10.1007/BF00327469; Richie CT, 2002, MOL CELL BIOL, V22, P8635, DOI 10.1128/MCB.22.24.8635-8647.2002; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404; Zhang XS, 2002, DNA REPAIR, V1, P379, DOI 10.1016/S1568-7864(02)00015-0	34	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15033	15036		10.1074/jbc.C600038200	http://dx.doi.org/10.1074/jbc.C600038200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16606622	hybrid			2022-12-25	WOS:000237922200003
J	Song, P; Kaczmarek, LK				Song, Ping; Kaczmarek, Leonard K.			Modulation of Kv3.1b potassium channel phosphorylation in auditory neurons by conventional and novel protein kinase C isozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERIAL SMOOTH-MUSCLE; K+ CHANNELS; TYROSINE PHOSPHORYLATION; ENDOTHELIAL-CELLS; SUBUNIT KV3.1B; PHORBOL ESTER; RAT-BRAIN; PKC-ALPHA; ACTIVATION; EXPRESSION	In fast-spiking neurons such as those in the medial nucleus of the trapezoid body ( MNTB) in the auditory brainstem, Kv3.1 potassium channels are required for high frequency firing. The Kv3.1b splice variant of this channel predominates in the mature nervous system and is a substrate for phosphorylation by protein kinase C ( PKC) at Ser-503. In resting neurons, basal phosphorylation at this site decreases Kv3.1 current, reducing neuronal ability to follow high frequency stimulation. We used a phospho-specific antibody to determine which PKC isozymes control serine 503 phosphorylation in Kv3.1b-tranfected cells and in auditory neurons in brainstem slices. By using isozyme-specific inhibitors, we found that the novel PKC-delta isozyme, together with the novel PKC-epsilon and conventional PKCs, contributed to the basal phosphorylation of Kv3.1b in MNTB neurons. In contrast, only PKC-epsilon and conventional PKCs mediate increases in phosphorylation produced by pharmacological activation of PKC in MNTB neurons or by metabotropic glutamate receptor activation in Kv3.1/mGluR1-cotransfected cells. We also measured the time course of dephosphorylation and recovery of basal phosphorylation of Kv3.1b following brief high frequency electrical stimulation of the trapezoid body, and we determined that the recovery process is mediated by both novel PKC-epsilon and PKC-epsilon isozymes and by conventional PKCs. The association between Kv3.1b and PKC isozymes was confirmed by reciprocal coimmunoprecipitation of Kv3.1b with multiple PKC isozymes. Our results suggest that the Kv3.1b channel is regulated by both conventional and novel PKC isozymes and that novel PKC-delta contributes specifically to the maintenance of basal phosphorylation in auditory neurons.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Kaczmarek, LK (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.	Leonard.Kaczmarek@yale.edu			NIDCD NIH HHS [DC01919] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001919] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ahmmed GU, 2004, J BIOL CHEM, V279, P20941, DOI 10.1074/jbc.M313975200; Antz C, 1999, NAT STRUCT BIOL, V6, P146; Asada A, 2000, IMMUNOLOGY, V101, P309, DOI 10.1046/j.1365-2567.2000.00110.x; AUGUSTINE CK, 1990, J GEN PHYSIOL, V95, P245, DOI 10.1085/jgp.95.2.245; Barman SA, 2004, AM J PHYSIOL-LUNG C, V286, pL1275, DOI 10.1152/ajplung.00259.2003; Barman SA, 2004, AM J PHYSIOL-LUNG C, V286, pL149, DOI 10.1152/ajplung.00207.2003; Brew HM, 1995, J NEUROSCI, V15, P8011; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; Chou CY, 1998, J PHYSIOL-LONDON, V512, P435, DOI 10.1111/j.1469-7793.1998.435be.x; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; CRITZ SD, 1993, J NEUROCHEM, V60, P1175, DOI 10.1111/j.1471-4159.1993.tb03273.x; DERIEMER SA, 1985, NATURE, V313, P313, DOI 10.1038/313313a0; Doolen S, 2002, FEBS LETT, V516, P187, DOI 10.1016/S0014-5793(02)02554-1; Du J, 1996, J NEUROSCI, V16, P506; Grigg JJ, 2000, HEARING RES, V140, P77, DOI 10.1016/S0378-5955(99)00187-2; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Hori T, 1999, J NEUROSCI, V19, P7262, DOI 10.1523/JNEUROSCI.19-17-07262.1999; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JORIS PX, 1995, J NEUROPHYSIOL, V73, P1043, DOI 10.1152/jn.1995.73.3.1043; Kaczmarek LK, 2005, HEARING RES, V206, P133, DOI 10.1016/j.heares.2004.11.023; KANEMASA T, 1995, J NEUROPHYSIOL, V74, P207, DOI 10.1152/jn.1995.74.1.207; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; Kopp-Scheinpflug C, 2003, JARO-J ASSOC RES OTO, V4, P1, DOI 10.1007/s10162-002-2010-5; Leao RM, 2002, J NEUROPHYSIOL, V87, P2297, DOI 10.1152/jn.2002.87.5.2297; LENZ S, 1994, SYNAPSE, V18, P55, DOI 10.1002/syn.890180108; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Ma R, 2002, AM J PHYSIOL-CELL PH, V283, pC1390, DOI 10.1152/ajpcell.00141.2002; Macica CM, 2003, J NEUROSCI, V23, P1133, DOI 10.1523/JNEUROSCI.23-04-01133.2003; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; Malmberg A B, 2000, Prog Brain Res, V129, P51; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Metzger F, 2003, CEREBELLUM, V2, P206, DOI 10.1080/14734220310016150; Misonou H, 2004, NAT NEUROSCI, V7, P711, DOI 10.1038/nn1260; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; Obara K, 2002, BRIT J PHARMACOL, V137, P1362, DOI 10.1038/sj.bjp.0704960; ONO Y, 1987, FEBS LETT, V226, P125, DOI 10.1016/0014-5793(87)80564-1; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Parameshwaran-Iyer S, 2003, J NEUROBIOL, V55, P165, DOI 10.1002/neu.10198; PERNEY T M, 1991, Current Opinion in Cell Biology, V3, P663, DOI 10.1016/0955-0674(91)90039-2; PERNEY TM, 1992, J NEUROPHYSIOL, V68, P756, DOI 10.1152/jn.1992.68.3.756; Perney TM, 1997, J COMP NEUROL, V386, P178; Rudy B, 2001, TRENDS NEUROSCI, V24, P517, DOI 10.1016/S0166-2236(00)01892-0; Rudy B, 1999, ANN NY ACAD SCI, V868, P304, DOI 10.1111/j.1749-6632.1999.tb11295.x; Saito Y, 2002, J BIOL CHEM, V277, P23216, DOI 10.1074/jbc.M200605200; Saitoh N, 2001, P NATL ACAD SCI USA, V98, P14017, DOI 10.1073/pnas.241333598; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; Song P, 2005, NAT NEUROSCI, V8, P1335, DOI 10.1038/nn1533; Strassheim D, 1999, J BIOL CHEM, V274, P18675, DOI 10.1074/jbc.274.26.18675; STRONG JA, 1987, NATURE, V325, P714, DOI 10.1038/325714a0; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Trussell LO, 1999, ANNU REV PHYSIOL, V61, P477, DOI 10.1146/annurev.physiol.61.1.477; Vilarino N, 2001, CELL SIGNAL, V13, P177, DOI 10.1016/S0898-6568(01)00138-3; Wang LY, 1998, J PHYSIOL-LONDON, V509, P183, DOI 10.1111/j.1469-7793.1998.183bo.x; Wang LY, 1998, P NATL ACAD SCI USA, V95, P1882, DOI 10.1073/pnas.95.4.1882; WEISER M, 1995, J NEUROSCI, V15, P4298; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Zhang XA, 2001, MOL BIOL CELL, V12, P351, DOI 10.1091/mbc.12.2.351	62	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15582	15591		10.1074/jbc.M512866200	http://dx.doi.org/10.1074/jbc.M512866200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16595659	hybrid			2022-12-25	WOS:000237922200065
J	Castellano, R; Vire, B; Pion, M; Quivy, V; Olive, D; Hirsch, I; Van Lint, C; Collette, Y				Castellano, Remy; Vire, Berengere; Pion, Marjorie; Quivy, Vincent; Olive, Daniel; Hirsch, Ivan; Van Lint, Carine; Collette, Yves			Active transcription of the human FASL/CD95L/TNFSF6 promoter region in T lymphocytes involves chromatin remodeling - Role of dna methylation and protein acetylation suggest distinct mechanisms of transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-LIGAND EXPRESSION; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; FACTOR-KAPPA-B; GENE-EXPRESSION; CELL ACTIVATION; INDUCED APOPTOSIS; CD95 LIGAND; POSITIONED NUCLEOSOME; HISTONE-DEACETYLASE; IMMUNE PRIVILEGE	Fas ligand (FasL/CD95L/TNFSF6), a member of the tumor necrosis factor family, initiates apoptosis in lymphoid and nonlymphoid tissues by binding to its receptor Fas (CD95/TNFRSF6). Although the transcriptional control of TNFSF6 gene expression is subjected to intense study, the role of its chromatin organization and accessibility to the transcriptional machinery is not known. Here, we determined the chromatin organization of TNFSF6 gene 5' regulatory regions. Using the indirect end-labeling technique, a unique region named HSS1 and encompassing nucleotides -189 to +185 according to the transcriptional start site, was identified throughout a 20-kilobase nucleosomal DNA domain surrounding the promoter. The HSS1 region displayed hypersensitivity to in vivo DNase I digestion in TNFSF6-expressing cells only, including upon T cell activation. Hypersensitivity to micrococcal nuclease digestion and to specific restriction enzyme digestion suggested the precise positioning of two nucleosomes across the transcription start site and minimal promoter region, likely interfering with TNFSF6 active transcription in T lymphocytes. Indeed, HSS1 hypersensitivity to nuclease digestion strictly correlated with TNFSF6 transcription, including in primary and leukemia T cells. HSS1 chromatin remodeling preceded detectable TNFSF6 mRNA accumulation and was blocked by cycloheximide that also prevented TNFSF6 transcription. However, DNA methylation levels of the TNFSF6 HSS1 region did not correlate with transcriptional activation. Induction of global protein acetylation by treatment with histone deacetylase inhibitors was not accompanied by HSS1 chromatin remodeling and/or TNFSF6 transcription. We conclude that chromatin remodeling is a primary event in the activation of TNFSF6 expression in primary and leukemia T cells and that mechanisms independent of protein deacetylation and of DNA methylation of the TNFSF6 promoter region are involved in the repression of TNFSF6 gene expression.	Univ Mediterranee, INSERM, UMR 599, Ctr Rech & Cancerol Marseille, F-13009 Marseille, France; INSERM, U372, Unite Pathogenie Infect Lentivirus, F-13009 Marseille, France; Univ Libre Bruxelles, Inst Biol & Med Mol, Lab Virol Mol, B-6041 Gosselies, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Libre de Bruxelles	Collette, Y (corresponding author), Univ Mediterranee, INSERM, UMR 599, Ctr Rech & Cancerol Marseille, 27 Blvd Lei Roure, F-13009 Marseille, France.	collette@marseille.inserm.fr	COLLETTE, Yves/F-2270-2013; Hirsch, Ivan/J-7726-2015; Pion, Marjorie/D-8139-2012; Pion, Marjorie/AAB-5812-2022; Pion, Marjorie/D-8139-2012	COLLETTE, Yves/0000-0001-5359-7099; Hirsch, Ivan/0000-0003-1701-1438; Pion, Marjorie/0000-0003-1828-4745; Pion, Marjorie/0000-0002-6406-747X				Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; ANEL A, 1994, EUR J IMMUNOL, V24, P2469, DOI 10.1002/eji.1830241032; Attema JL, 2002, J IMMUNOL, V169, P2466, DOI 10.4049/jimmunol.169.5.2466; Ayroldi E, 1999, BLOOD, V94, P3456, DOI 10.1182/blood.V94.10.3456.422k33_3456_3467; BAGNASCO M, 1989, EUR J IMMUNOL, V19, P823, DOI 10.1002/eji.1830190507; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Bossi G, 1999, NAT MED, V5, P90, DOI 10.1038/4779; Bruniquel D, 2003, NAT IMMUNOL, V4, P235, DOI 10.1038/ni887; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Chou CF, 2000, J BIOMED SCI, V7, P136, DOI 10.1159/000025439; Collette Y, 1997, EUR J IMMUNOL, V27, P3283, DOI 10.1002/eji.1830271227; COSTELLO R, 1993, EUR J IMMUNOL, V23, P608, DOI 10.1002/eji.1830230304; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Fry CJ, 2002, SCIENCE, V295, P1847, DOI 10.1126/science.1070260; Gamble MJ, 2002, TRENDS BIOCHEM SCI, V27, P165, DOI 10.1016/S0968-0004(02)02076-5; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Goriely S, 2003, BLOOD, V101, P4894, DOI 10.1182/blood-2002-09-2851; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kashii Y, 1999, J IMMUNOL, V163, P5358; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kavurma MM, 2003, CELL DEATH DIFFER, V10, P36, DOI 10.1038/sj.cdd.4401179; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Latinis KM, 1997, J IMMUNOL, V158, P4602; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Li JH, 1998, J IMMUNOL, V161, P3943; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; Li-Weber M, 1998, EUR J IMMUNOL, V28, P2373, DOI 10.1002/(SICI)1521-4141(199808)28:08<2373::AID-IMMU2373>3.0.CO;2-T; Li-Weber M, 1999, EUR J IMMUNOL, V29, P3017, DOI 10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lomvardas S, 2002, CELL, V110, P261, DOI 10.1016/S0092-8674(02)00822-X; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Maecker HL, 2002, CANCER CELL, V2, P139, DOI 10.1016/S1535-6108(02)00095-8; McClure RF, 1999, J BIOL CHEM, V274, P7756, DOI 10.1074/jbc.274.12.7756; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Norian LA, 2000, J IMMUNOL, V164, P4471, DOI 10.4049/jimmunol.164.9.4471; NUNES J, 1993, INT IMMUNOL, V5, P311, DOI 10.1093/intimm/5.3.311; O'Connell J, 2001, NAT MED, V7, P271, DOI 10.1038/85395; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Poulaki V, 2001, DRUG RESIST UPDATE, V4, P233, DOI 10.1054/drup.2001.0210; Ramenghi U, 2000, BLOOD, V95, P3176; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Sampalo A, 2000, BLOOD, V96, P3168; Sieg S, 1997, J IMMUNOL, V159, P1192; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Smale ST, 2002, ANNU REV IMMUNOL, V20, P427, DOI 10.1146/annurev.immunol.20.100301.064739; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Takemoto N, 2000, J IMMUNOL, V165, P6687, DOI 10.4049/jimmunol.165.12.6687; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; Wang RX, 1998, ONCOGENE, V17, P1503, DOI 10.1038/sj.onc.1202059; Wang RX, 2001, J IMMUNOL, V166, P1983, DOI 10.4049/jimmunol.166.3.1983; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; Weinmann AS, 2001, NAT IMMUNOL, V2, P51, DOI 10.1038/83168; Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.3.CO;2-2; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhang J, 2001, J CLIN INVEST, V107, P1459, DOI 10.1172/JCI12159	79	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14719	14728		10.1074/jbc.M602373200	http://dx.doi.org/10.1074/jbc.M602373200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16595663	hybrid			2022-12-25	WOS:000237671300025
J	Blanke, S; Jackle, H				Blanke, Stephen; Jaeckle, Herbert			Novel guanine nucleotide exchange factor GEFmeso of Drosophila melanogaster interacts with ral and rho GTPase Cdc42	FASEB JOURNAL			English	Article						DH domain; gastrulation; DRal activity	ACTIVATING PROTEIN; STRUCTURAL BASIS; DBL FAMILY; IDENTIFICATION; EFFECTOR; EXOCYST; ARF; MECHANISMS; HOMOLOGY; PATHWAY	This article reports the identification and characterization of a DBL-like guanine nucleotide exchange factor (GEF) in Drosophila, called GEFmeso, as a novel binding target of the Ras-like GTPase Ral. Previous studies suggested that some aspects of Ral activity, which is involved in multiple cellular processes, are mediated through regulation of Rho GTPases. Here we show in vitro association of GEFmeso with the GTP-bound active form of Ral and the nucleotide-free form of the Rho GTPase Cdc42. GEFmeso fails to bind to other Rho GTPases, showing that Cdc42 is a specific interaction partner of this GEF. Unlike Ral and Cdc42, which are ubiquitously expressed, GEFmeso exerts distinct spatio-temporal expression patterns during embryonic development, suggesting a tissue-restricted function of the GEF in vivo. Based on previous observations that mutations in Cdc42 or overexpression of mutant alleles of Cdc42 lead to distinct effects on wing development, the effects of overexpression of dominant-negative and activated versions of Ral on wing development were analyzed. In addition, GEFmeso overexpression studies as well as RNAi experiments were performed. The results suggest that Ral, GEFmeso and Cdc42 act in the same developmental pathway and that GEFmeso mediates activation of Cdc42 in response to activated Ral in the context of Drosophila wing development. -Blanke, S., Jackle, H. Novel guanine nucleotide exchange factor GEFmeso of Drosophila melanogaster interacts with Ral and Rho GTPase Cdc42.	Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, D-37077 Gottingen, Germany	Max Planck Society	Jackle, H (corresponding author), Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, Fassberg 11, D-37077 Gottingen, Germany.	vp-bms@gv.mpg.de						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Baron M, 2000, MOL GEN GENET, V264, P98, DOI 10.1007/s004380000287; Bhullar RP, 1996, BBA-MOL CELL RES, V1311, P181, DOI 10.1016/0167-4889(96)00002-X; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; EMKEY R, 1991, J BIOL CHEM, V266, P9703; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Frankel P, 2005, EMBO J, V24, P54, DOI 10.1038/sj.emboj.7600497; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Geneva JL, 2000, DEV BIOL, V221, P181, DOI 10.1006/dbio.2000.9671; Gildea JJ, 2002, CANCER RES, V62, P982; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Mirey G, 2003, MOL CELL BIOL, V23, P1112, DOI 10.1128/MCB.23.3.1112-1124.2003; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Park SH, 1995, ONCOGENE, V11, P2349; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Sawamoto K, 1999, J CELL BIOL, V146, P361, DOI 10.1083/jcb.146.2.361; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VAN AL, 1997, GENE DEV, V11, P2295; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	42	9	9	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					683	691		10.1096/fj.05-5376com	http://dx.doi.org/10.1096/fj.05-5376com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581976				2022-12-25	WOS:000240130900014
J	Dirkx, AEM; Egbrink, MGAO; Castermans, K; van der Schaft, DWJ; Thijssen, VLJL; Dings, RPM; Kwee, L; Mayo, KH; Wagstaff, J; Steege, JCABT; Griffioen, AW				Dirkx, Anita E. M.; Egbrink, Mirjam G. A. oude; Castermans, Karolien; van der Schaft, Daisy W. J.; Thijssen, Victor L. J. L.; Dings, Ruud P. M.; Kwee, Lucy; Mayo, Kevin H.; Wagstaff, John; Steege, Jessica C. A. Bouma-ter; Griffioen, Arjan W.			Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors	FASEB JOURNAL			English	Article						angiogenesis; endothelial adhesion molecules; anginex; endostatin	ADHESION MOLECULE-1 EXPRESSION; FIBROBLAST-GROWTH-FACTOR; TRANSENDOTHELIAL MIGRATION; HUMAN MALIGNANCIES; IN-VITRO; BREAST; CANCER; IMMUNOTHERAPY; ANGIOSTATIN; INHIBITOR	Tumor escape from immunity, as well as the failure of several anti-cancer vaccination and cellular immunotherapy approaches, is suggested to be due to the angiogenesis-mediated suppression of endothelial cell (EC) adhesion molecules involved in leukocyte-vessel wall interactions. We hypothesized that inhibition of angiogenesis would overcome this escape from immunity. We investigated this in vivo by means of intravital microscopy and ex vivo by immunohistochemistry in two mouse tumor models. Angiogenesis inhibitors anginex, endostatin, and angiostatin, and the chemotherapeutic agent paclitaxel were found to significantly stimulate leukocyte-vessel wall interactions by circumvention of EC anergy in vivo, i.e., by the up-regulation of endothelial adhesion molecules in tumor vessels. This was confirmed by in vitro studies of cultured EC at the protein and mRNA levels. The new angiostatic designer peptide anginex was most potent at overcoming EC anergy; the enhanced leuko cyte-vessel interactions led to an increase in the numbers of tumor infiltrating leukocytes. While anginex inhibited tumor growth and microvessel density significantly, the amount of infiltrated leukocytes (CD45), as well as the number of CD8(+) cytotoxic T lymphocytes, was enhanced markedly. The current results suggest that immunotherapy strategies can be improved by combination with anti-angiogenesis. -Dirkx, A. E. M., oude Egbrink, M. G. A., Castermans, K., van der Schaft, D. W. J., Thijssen, V. L. J. L., Dings, R. P. M., Kwee, L., Mayo, K. H., Wagstaff, J., Bouma-ter Steege, J. C. A., Griffioen, A. W. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.	Maastricht Univ & Univ Hosp, Dept Internal Med, Res Inst Growth & Dev GROW, Angiogenesis Lab, Maastricht, Netherlands; Maastricht Univ & Univ Hosp, Dept Pathol, Res Inst Growth & Dev GROW, Angiogenesis Lab, Maastricht, Netherlands; Maastricht Univ & Univ Hosp, Maastricht, Netherlands; Maastricht Univ, Cardiovasc Res Inst Maastricht, Microcirculat Lab, Dept Physiol, Maastricht, Netherlands; Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; University of Minnesota System; University of Minnesota Twin Cities	Griffioen, AW (corresponding author), Univ Hosp Maastricht, Dept Pathol, POB 5800, NL-6202 AZ Maastricht, Netherlands.	aw.griffioen@path.unimaas.nl	Egbrink, Mirjam oude/AAZ-7305-2020; Dings, Ruud/R-3772-2019; Thijssen, Victor LJL/B-2792-2009; Dings, Ruud/C-6188-2008	Dings, Ruud/0000-0001-7686-1331; Thijssen, Victor LJL/0000-0002-6146-1842; Wagstaff, John/0000-0002-1140-5981	NATIONAL CANCER INSTITUTE [R01CA096090] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-96090] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed B, 2003, INT J CANCER, V105, P20, DOI 10.1002/ijc.11010; Bocci G, 2002, CANCER RES, V62, P6938; Bouma-ter-Steege JCA, 2004, CLIN CANCER RES, V10, P7171; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; CREAMER D, 2003, ANGIOGENESIS, V5, P231; Demaria S, 2001, CLIN CANCER RES, V7, P3025; Dings RPM, 2003, CANCER RES, V63, P382; Dirkx AEM, 2003, CANCER RES, V63, P2322; Dvorak HF, 2005, J THROMB HAEMOST, V3, P1835, DOI 10.1111/j.1538-7836.2005.01361.x; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Griffioen AW, 1997, CANCER J - FRANCE, V10, P249; Griffioen AW, 1996, CANCER RES, V56, P1111; Griffioen AW, 1999, INT J CANCER, V80, P315, DOI 10.1002/(SICI)1097-0215(19990118)80:2<315::AID-IJC23>3.0.CO;2-L; Griffioen AW, 1996, BLOOD, V88, P667, DOI 10.1182/blood.V88.2.667.bloodjournal882667; GRIFFIOEN AW, 2001, BIOCHEM J, P233; Hellwig SMM, 1997, CANCER LETT, V120, P203, DOI 10.1016/S0304-3835(97)00310-8; JANSSEN GHGW, 1994, AM J PHYSIOL, V267, pH1199, DOI 10.1152/ajpheart.1994.267.3.H1199; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kisker O, 2001, CANCER RES, V61, P7669; KUSAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P1070, DOI 10.1016/0006-291X(91)91529-L; Leek RD, 1996, CANCER RES, V56, P4625; Luo JY, 1998, BIOCHEM BIOPH RES CO, V245, P906, DOI 10.1006/bbrc.1998.8529; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; Nair S, 2003, BLOOD, V102, P964, DOI 10.1182/blood-2002-12-3738; Niethammer AG, 2002, NAT MED, V8, P1369, DOI 10.1038/nm794; Nooijen PTGA, 1998, AM J PATHOL, V152, P679; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PIALI L, 1995, J EXP MED, V181, P811, DOI 10.1084/jem.181.2.811; Reiss Y, 1998, EUR J IMMUNOL, V28, P3086, DOI 10.1002/(SICI)1521-4141(199810)28:10<3086::AID-IMMU3086>3.3.CO;2-Q; Ribas A, 2003, J CLIN ONCOL, V21, P2415, DOI 10.1200/JCO.2003.06.041; Rosenberg SA, 2004, NEW ENGL J MED, V350, P1461, DOI 10.1056/NEJMcibr045001; Satchi-Fainaro R, 2005, CANCER CELL, V7, P251, DOI 10.1016/j.ccr.2005.02.007; SLAAF DW, 1982, INT J MICROCIRC, V1, P121; TEICHER BA, 1992, CANCER RES, V52, P6702; Thijssen VLJL, 2004, EXP CELL RES, V299, P286, DOI 10.1016/j.yexcr.2004.06.014; Tromp SC, 2000, INT IMMUNOL, V12, P671, DOI 10.1093/intimm/12.5.671; van der Schaft DWJ, 2002, FASEB J, V16, P1991, DOI 10.1096/fj.02-0509fje; WAHL ML, 2005, J CELL BIOCH; Wei YQ, 2000, NAT MED, V6, P1160, DOI 10.1038/80506; YAMAOKA M, 1993, CANCER RES, V53, P5233; Zhang H, 2002, AM J PATHOL, V160, P2219, DOI 10.1016/S0002-9440(10)61169-8; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	44	195	200	2	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					621	630		10.1096/fj.05-4493com	http://dx.doi.org/10.1096/fj.05-4493com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581970				2022-12-25	WOS:000240130900008
J	Mager, DE; Wan, RQ; Brown, M; Cheng, AW; Wareski, P; Abernethy, DR; Mattson, MP				Mager, Donald E.; Wan, Ruiqian; Brown, Martin; Cheng, Aiwu; Wareski, Przemyslaw; Abernethy, Darrell R.; Mattson, Mark P.			Caloric restriction and intermittent fasting alter spectral measures of heart rate and blood pressure variability in rats	FASEB JOURNAL			English	Article; Proceedings Paper	34th Annual Meeting of the Society-for-Neuroscience	OCT 23-27, 2004	San Diego, CA	Soc Neurosci		blood pressure; heart rate; autonomic nervous system; nutrition	SYMPATHETIC NERVOUS-SYSTEM; DIETARY RESTRICTION; PAROXETINE; AGE; METABOLISM; RESISTANCE; DISEASE; GLUCOSE; RISK	Dietary restriction (DR) has been shown to increase life span, delay or prevent age-associated diseases, and improve functional and metabolic cardiovascular risk factors in rodents and other species. To investigate the effects of DR on beat-to-beat heart rate and diastolic blood pressure variability (HRV and DPV) in male Sprague-Dawley rats, we implanted telemetric transmitters and animals were maintained on either intermittent fasting (every other day feeding) or calorie-restricted (40% caloric reduction) diets. Using power spectral analysis, we evaluated the temporal profiles of the low- and high-frequency oscillatory components in heart rate and diastolic blood pressure signals to assess cardiac autonomic activity. Body weight, heart rate, and systolic and diastolic blood pressure were all found to decrease in response to DR. Both methods of DR produced decreases in the low-frequency component of DPV spectra, a marker for sympathetic tone, and the high-frequency component of HRV spectra, a marker for parasympathetic activity, was increased. These parameters required at least 1 month to become maximal, but returned toward baseline values rapidly once rats resumed ad libitum diets. These results suggest an additional cardiovascular benefit of DR that merits further studies of this potential effect in humans.-Mager, D. E., Wan, R., Brown, M., Cheng, A., Wareski, P., Abernethy, D. R., Mattson, M. P. Caloric restriction and intermittent fasting alter spectral measures of heart rate and blood pressure variability in rats.	NIA, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA; NIA, Clin Invest Lab, Intramural Res Program, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Mattson, MP (corresponding author), NIA, Neurosci Lab, Intramural Res Program, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	mattsonm@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE ON AGING [Z01AG000315, ZIAAG000315] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Camm AJ, 1996, CIRCULATION, V93, P1043; CERUTTI C, 1991, AM J PHYSIOL, V261, pH1292, DOI 10.1152/ajpheart.1991.261.4.H1292; Chung HY, 2001, ANN NY ACAD SCI, V928, P327; CRAFT N, 1995, AM J PHYSIOL-HEART C, V268, pH1441, DOI 10.1152/ajpheart.1995.268.4.H1441; Duan WZ, 2004, ANN NEUROL, V55, P590, DOI 10.1002/ana.20075; Duan WZ, 2003, ENDOCRINOLOGY, V144, P2446, DOI 10.1210/en.2002-0113; Duan WZ, 2001, J NEUROCHEM, V76, P619, DOI 10.1046/j.1471-4159.2001.00071.x; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Heilbronn LK, 2005, AM J CLIN NUTR, V81, P69; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Liao DP, 1997, AM J EPIDEMIOL, V145, P696, DOI 10.1093/aje/145.8.696; MALLIANI A, 1991, CIRCULATION, V84, P482, DOI 10.1161/01.CIR.84.2.482; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Mattison JA, 2003, EXP GERONTOL, V38, P35, DOI 10.1016/S0531-5565(02)00146-8; Mattson MP, 2005, J NUTR BIOCHEM, V16, P129, DOI 10.1016/j.jnutbio.2004.12.007; Nakagawa T, 2002, DIABETES-METAB RES, V18, P185, DOI 10.1002/dmrr.290; Pahlavani MA, 2000, FRONT BIOSCI-LANDMRK, V5, pD580, DOI 10.2741/Pahlavani; Spaulding CC, 1997, MECH AGEING DEV, V93, P87, DOI 10.1016/S0047-6374(96)01824-6; THOMAS J, 1993, J GERONTOL, V48, pB151, DOI 10.1093/geronj/48.4.B151; Tucker P, 1997, J CLIN PSYCHOPHARM, V17, P370; Vega VL, 2004, SHOCK, V22, P248, DOI 10.1097/01.shk.0000133590.09659.a1; Wan RQ, 2003, FASEB J, V17, P1133, DOI 10.1096/fj.02-0996fje; Wan RQ, 2003, J NUTR, V133, P1921, DOI 10.1093/jn/133.6.1921; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; Yeragani VK, 1999, NEUROPSYCHOBIOLOGY, V40, P124, DOI 10.1159/000026608; YOUNG JB, 1977, SCIENCE, V196, P1473, DOI 10.1126/science.867049; YOUNG JB, 1982, J CHRON DIS, V35, P879, DOI 10.1016/0021-9681(82)90118-7	30	167	169	0	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					631	637		10.1096/fj.05-5263com	http://dx.doi.org/10.1096/fj.05-5263com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581971				2022-12-25	WOS:000240130900009
J	Cheruku, SR; Xu, Z; Dutia, R; Lobel, P; Storch, J				Cheruku, Sunita R.; Xu, Zhi; Dutia, Roxanne; Lobel, Peter; Storch, Judith			Mechanism of cholesterol transfer from the Niemann-Pick type C2 protein to model membranes supports a role in lysosomal cholesterol transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID TRANSFER; LIPOPROTEIN-DERIVED CHOLESTEROL; STEROL-SENSING DOMAIN; BINDING PROTEIN; UNILAMELLAR VESICLES; C1 PROTEIN; SPONTANEOUS EXCHANGE; NPC2 PROTEIN; DISEASE; FIBROBLASTS	Cells acquire cholesterol either by de novo synthesis in the endoplasmic reticulum or by internalization of cholesterol-containing lipoproteins, particularly low density lipoprotein (LDL), via receptor-mediated endocytosis. The inherited disorder Niemann-Pick type C (NPC), in which abnormal LDL-cholesterol trafficking from the endo/lysosomal compartment leads to substantial cholesterol and glycolipid accumulation in lysosomes, is caused by defects in either of two genes that encode for proteins designated as NPC1 and NPC2. NPC2 is a small intralysosomal protein that has been characterized biochemically as a cholesterol binding protein. We determined the rate and mechanism by which NPC2 delivers cholesterol to model phospholipid membranes. A fluorescence dequenching assay was used to monitor the kinetics of cholesterol transfer from the protein to membranes. The endogenous tryptophan fluorescence of the NPC2 was quenched upon binding of cholesterol, and the subsequent addition of acceptor vesicles resulted in dequenching of the tryptophan signal, enabling the monitoring of cholesterol transfer to membranes. The rates of cholesterol transfer were evaluated as a function of acceptor vesicle concentration, acceptor vesicle phospholipid headgroup composition, and aqueous phase properties. The results suggest that NPC2 rapidly transports cholesterol to phospholipid vesicles via a collisional mechanism which involves a direct interaction with the acceptor membrane. Transfer of cholesterol to membranes is faster in an acidic environment and is greatly enhanced by the presence of the unique lysosomal/late endosomal phospholipid lyso-bisphosphatidic acid (LBPA) (also known as bismonoacylglycerol phosphate). Finally, we found that the rate of transfer of cholesterol from vesicles to NPC2 was dramatically increased by the presence of lyso-bisphosphatidic acid in the donor vesicles. These results support a role for the NPC2 protein in the egress of LDL derived cholesterol out of the endosomal/lysosomal compartment.	Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Storch, J (corresponding author), Rutgers State Univ, Dept Nutr Sci, 96 Lipman Dr, New Brunswick, NJ 08901 USA.	storch@aesop.rutgers.edu		Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK038389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker CS, 1993, BIOL REPROD S1, V48, P86; BAR LK, 1987, BIOCHEMISTRY-US, V26, P5460, DOI 10.1021/bi00391a037; BAR LK, 1986, BIOCHEMISTRY-US, V25, P6701, DOI 10.1021/bi00369a056; Barenholz Y, 2004, SUB CELL BIOCHEM, V37, P167; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHARLTON SC, 1982, BIOCHEMISTRY-US, V21, P4023, DOI 10.1021/bi00260a018; Chen FW, 2005, BIOCHEM J, V390, P549, DOI 10.1042/BJ20050236; Chen JCH, 1998, BIOCHEMISTRY-US, V37, P5107, DOI 10.1021/bi972989g; Chikh K, 2004, MOL GENET METAB, V83, P220, DOI 10.1016/j.ymgme.2004.06.013; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Davies JP, 2000, J BIOL CHEM, V275, P24367, DOI 10.1074/jbc.M002184200; Friedland N, 2003, P NATL ACAD SCI USA, V100, P2512, DOI 10.1073/pnas.0437840100; FROVLOV A, 2003, J BIOL CHEM, V28, P25517; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; KIM HK, 1992, J BIOL CHEM, V267, P20051; KIM HK, 1992, J BIOL CHEM, V267, P77; Ko DC, 2003, P NATL ACAD SCI USA, V100, P2518, DOI 10.1073/pnas.0530027100; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kundra R, 1999, J BIOL CHEM, V274, P31039, DOI 10.1074/jbc.274.43.31039; LANGE Y, 1983, J BIOL CHEM, V258, P6920; Lascombe MB, 2002, ACTA CRYSTALLOGR D, V58, P1442, DOI 10.1107/S0907444902011745; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; NICHOLS JW, 1981, BIOCHEMISTRY-US, V20, P2783, DOI 10.1021/bi00513a012; Ohgami N, 2004, P NATL ACAD SCI USA, V101, P12473, DOI 10.1073/pnas.0405255101; Okamura N, 1999, BBA-MOL CELL BIOL L, V1438, P377, DOI 10.1016/S1388-1981(99)00070-0; Patterson M., 2001, METABOLIC MOL BASES, VII, P3611; PENTCHEV PG, 1994, BBA-MOL BASIS DIS, V1225, P235, DOI 10.1016/0925-4439(94)90001-9; ROSEMAN MA, 1980, BIOCHEMISTRY-US, V19, P439, DOI 10.1021/bi00544a006; Sleat DE, 2004, P NATL ACAD SCI USA, V101, P5886, DOI 10.1073/pnas.0308456101; STEINBERG SJ, 1994, J MED GENET, V31, P317, DOI 10.1136/jmg.31.4.317; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; VANIER MT, 1991, BIOCHIM BIOPHYS ACTA, V1096, P328, DOI 10.1016/0925-4439(91)90069-L; Vanier MT, 1996, AM J HUM GENET, V58, P118	38	155	160	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31594	31604		10.1074/jbc.M602765200	http://dx.doi.org/10.1074/jbc.M602765200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16606609	Bronze			2022-12-25	WOS:000241235300045
J	Dunne, J; Cullmann, C; Ritter, M; Soria, NM; Drescher, B; Debernardi, S; Skoulakis, S; Hartmann, O; Krause, M; Krauter, J; Neubauer, A; Young, BD; Heidenreich, O				Dunne, J.; Cullmann, C.; Ritter, M.; Soria, N. Martinez; Drescher, B.; Debernardi, S.; Skoulakis, S.; Hartmann, O.; Krause, M.; Krauter, J.; Neubauer, A.; Young, B. D.; Heidenreich, O.			siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8 ; 21)-positive cell lines and primary AML blasts	ONCOGENE			English	Article						RNA interference; siRNA; gene expression profiling; acute myeloid leukaemia; AML1/MTG8	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; T(8/21) FUSION PROTEIN; EPITHELIAL-CELLS; MESSENGER-RNA; GROWTH ARREST; TARGET GENE; C/EBP-ALPHA; AML1-ETO; BINDING	The chromosomal translocation t(8; 21) is associated with 10 - 15% of all cases of acute myeloid leukaemia (AML). The resultant fusion protein AML1/MTG8 interferes with haematopoietic gene expression and is an important regulator of leukaemogenesis. We studied the effects of small interfering RNA (siRNA)-mediated AML1/MTG8 depletion on global gene expression in t(8; 21)- positive leukaemic cell lines and in primary AML blasts using cDNA arrays, oligonucleotide arrays and real-time reverse transcription-polymerase chain reaction (RT-PCR). Suppression of AML1/MTG8 results in the increased expression of genes associated with myeloid differentiation, such as AZU1, BPI, CTSG, LYZ and RNASE2 as well as of antiproliferative genes such as IGFBP7, MS4A3 and SLA both in blasts and in cell lines. Furthermore, expression levels of several genes affiliated with drug resistance or indicative of poor prognosis AML (BAALC, CD34, PRG2, TSPAN7) are affected by AML1/MTG8 depletion. In conclusion, siRNA-mediated suppression of AML1/MTG8 cause very similar changes in gene expression pattern in t(8; 21)- positive cell lines and in primary AML blasts. Furthermore, the results suggest that the specific targeting of AML1/MTG8 function may be a promising approach for complementing existing treatment strategies.	Univ Tubingen, Dept Mol Biol, Interfac Inst Cell Biol, Fac Biol, D-72076 Tubingen, Germany; Barts & London Queen Marys Sch Med & Dent, Canc Res UK Med Oncol Lab, London, England; Univ Hosp Marburg, Dept Haematol Oncol & Immunol, Marburg, Germany; Hannover Med Sch, Dept Haematol Haemostaseol & Oncol, D-3000 Hannover, Germany; Univ Marburg, Inst Med Biometry & Epidemiol, Marburg, Germany; Univ Marburg, Inst Mol Biol & Tumour Res, Marburg, Germany	Eberhard Karls University of Tubingen; Cancer Research UK; University of London; Queen Mary University London; University Hospital of Giessen & Marburg; Hannover Medical School; Philipps University Marburg; Philipps University Marburg	Heidenreich, O (corresponding author), Univ Tubingen, Dept Mol Biol, Interfac Inst Cell Biol, Fac Biol, Morgenstelle 15, D-72076 Tubingen, Germany.	olaf.heidenreich@uni-tuebingen.de	Heidenreich, Olaf/AAP-5045-2021	Heidenreich, Olaf/0000-0001-5404-6483	Cancer Research UK [A6438, A6789] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; ASOU H, 1991, BLOOD, V77, P2031; Baldus CD, 2003, EXP HEMATOL, V31, P1051, DOI 10.1016/j.exphem.2003.08.004; Baldus CD, 2003, BLOOD, V102, P1613, DOI 10.1182/blood-2003-02-0359; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562; Basecke J, 2005, LEUKEMIA LYMPHOMA, V46, P265, DOI 10.1080/10428190400010767; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Debernardi S, 2003, GENE CHROMOSOME CANC, V37, P149, DOI 10.1002/gcc.10198; Donato JL, 2002, J CLIN INVEST, V109, P51, DOI 10.1172/JCI14025; ERICKSON P, 1992, BLOOD, V80, P1825; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Frank R, 1995, ONCOGENE, V11, P2667; Garwicz D, 2005, HAEMATOLOGICA, V90, P38; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Heuser M, 2005, HAEMATOLOGICA, V90, P1484; Hiebert SW, 1996, CURR TOP MICROBIOL, V211, P253; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; KUSEC R, 1994, LEUKEMIA, V8, P735; Landberg G, 2001, ONCOGENE, V20, P3497, DOI 10.1038/sj.onc.1204471; LAUSENJ, 2006, ONCOGENE, V25, P1349; Lebigot I, 2003, BLOOD, V102, P4555, DOI 10.1182/blood-2003-06-2077; Lennartsson A, 2003, BIOCHEM BIOPH RES CO, V311, P853, DOI 10.1016/j.bbrc.2003.10.067; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Martinez N, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-44; MATOZAKI S, 1995, BRIT J HAEMATOL, V89, P805; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Morohoshi F, 2000, GENE, V241, P287, DOI 10.1016/S0378-1119(99)00481-3; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Mutaguchi K, 2003, CANCER RES, V63, P7717; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; Puccetti E, 2002, CANCER RES, V62, P7050; Rhoades KL, 2000, BLOOD, V96, P2108; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Ross ME, 2004, BLOOD, V104, P3679, DOI 10.1182/blood-2004-03-1154; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tonks A, 2003, BLOOD, V101, P624, DOI 10.1182/blood-2002-06-1732; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WEISS J, 1987, BLOOD, V69, P652; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yagi T, 2003, BLOOD, V102, P1849, DOI 10.1182/blood-2003-02-0578; Yamanaka Y, 1997, J BIOL CHEM, V272, P30729, DOI 10.1074/jbc.272.49.30729; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937; ZIMMER M, 1992, P NATL ACAD SCI USA, V89, P8215, DOI 10.1073/pnas.89.17.8215	68	55	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6067	6078		10.1038/sj.onc.1209638	http://dx.doi.org/10.1038/sj.onc.1209638			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652140				2022-12-25	WOS:000241101200004
J	Litvan, J; Briva, A; Wilson, MS; Budinger, GRS; Sznajder, JI; Ridge, KM				Litvan, Juan; Briva, Arturo; Wilson, Mindy S.; Budinger, G. R. Scott; Sznajder, Jacob Iasha; Ridge, Karen M.			beta-adrenergic receptor stimulation and adenoviral overexpression of superoxide dismutase prevent the hypoxia-mediated decrease in Na,K-ATPase and alveolar fluid reabsorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS-SYNDROME; LUNG EDEMA CLEARANCE; LEFT ATRIAL PRESSURE; NA-K-ATPASE; EPITHELIAL-CELLS; LIQUID CLEARANCE; SODIUM-CHANNELS; RAT LUNGS; TRANSPORT; ISOPROTERENOL	Hypoxia has been shown to cause lung edema and impair lung edema clearance. In the present study, we exposed isolated rat lungs to pO(2) = 40 mm Hg for 60 min or rats to 8% O-2 for up to 24 h and then measured changes in alveolar fluid reabsorption (AFR) and Na, K-ATPase function. Low levels of oxygen severely impaired AFR in both ex vivo and in vivo models. The decrease in AFR was associated with a decrease in Na, K-ATPase activity and protein abundance in the basolateral membranes from peripheral lung tissue of hypoxic rats. beta-Adrenergic agonists restored AFR in rats exposed to 8% O-2 (from 0.02 +/- 0.07 ml/h to 0.59 +/- 0.03 ml/ h), which was associated with parallel increases in Na, K-ATPase protein abundance in the basolateral membrane. Hypoxia is associated with increased production of reactive oxygen species. Therefore, we examined whether overexpression of SOD2, manganese superoxide dismutase, would prevent the hypoxia-mediated decrease in AFR. Spontaneously breathing rats were infected with a replication-deficient human type 5 adenovirus containing cDNA for SOD2. An otherwise identical virus that contained no cDNA was used as a control (Adnull). Hypoxic Adnull rats had decreased rates of AFR (0.12 +/- 0.1 ml/ h) as compared with hypoxic AdSOD2 and normoxic control rats (0.47 +/- 0.04 ml/ h and 0.49 +/- 0.02 ml/ h, respectively), with parallel changes in Na, K- ATPase.	Northwestern Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA; Vet Affairs Chicago Hlth Care Syst, Med Serv, Chicago, IL 60611 USA	Northwestern University	Ridge, KM (corresponding author), Northwestern Univ, Sch Med, Div Pulm & Crit Care Med, 240 E Huron,McGaw M328, Chicago, IL 60611 USA.	kridge@northwestern.edu	Wilson, Melinda/L-2711-2013	Wilson, Melinda/0000-0003-0190-6958	NHLBI NIH HHS [P01-HL71643, R01-HL48129, R01-HL079190] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048129, P01HL071643, R01HL079190] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azzam ZS, 2004, AM J RESP CRIT CARE, V170, P730, DOI 10.1164/rccm.200308-1127OC; Azzam ZS, 2002, CIRCULATION, V105, P497, DOI 10.1161/hc0402.102848; Azzam ZS, 2001, J APPL PHYSIOL, V90, P1088, DOI 10.1152/jappl.2001.90.3.1088; Barnard ML, 1999, AM J RESP CRIT CARE, V160, P982, DOI 10.1164/ajrccm.160.3.9812003; Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20, DOI 10.1152/ajplung.1999.276.1.L20; Carpenter TC, 2003, AM J PHYSIOL-LUNG C, V284, pL77, DOI 10.1152/ajplung.00181.2002; Clerici C, 2000, J APPL PHYSIOL, V88, P1890, DOI 10.1152/jappl.2000.88.5.1890; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Dumasius V, 2001, CIRC RES, V89, P907, DOI 10.1161/hh2201.100204; Eaton Douglas C, 2004, Proc Am Thorac Soc, V1, P10, DOI 10.1513/pats.2306008; Matalon S, 2002, J APPL PHYSIOL, V93, P1852, DOI 10.1152/japplphysiol.01241.2001; Pesce L, 2003, AM J PHYSIOL-LUNG C, V285, pL802, DOI 10.1152/ajplung.00266.2002; Planes C, 1996, AM J PHYSIOL-LUNG C, V271, pL70, DOI 10.1152/ajplung.1996.271.1.L70; Planes C, 1997, AM J RESP CELL MOL, V17, P508, DOI 10.1165/ajrcmb.17.4.2680; Ridge KM, 2003, CIRC RES, V92, P453, DOI 10.1161/01.RES.0000059414.10360.F2; Ridge KM, 2002, MOL BIOL CELL, V13, P1381, DOI 10.1091/mbc.01-07-0323; RUTSCHMAN DH, 1993, J APPL PHYSIOL, V75, P1574, DOI 10.1152/jappl.1993.75.4.1574; Saldias F, 1998, AM J PHYSIOL-LUNG C, V274, pL694, DOI 10.1152/ajplung.1998.274.5.L694; Saldias FJ, 2001, AM J PHYSIOL-LUNG C, V281, pL591, DOI 10.1152/ajplung.2001.281.3.L591; Saldias FJ, 1999, J APPL PHYSIOL, V87, P30, DOI 10.1152/jappl.1999.87.1.30; Saldias FJ, 2000, AM J RESP CRIT CARE, V162, P282, DOI 10.1164/ajrccm.162.1.9809058; Sartori C, 2004, EUR RESPIR J, V23, P916, DOI 10.1183/09031936.04.00115304; Sartori C, 2002, NEW ENGL J MED, V346, P1631, DOI 10.1056/NEJMoa013183; Suzuki S, 1999, J APPL PHYSIOL, V87, P962, DOI 10.1152/jappl.1999.87.3.962; Sznajder JI, 2001, AM J RESP CRIT CARE, V163, P1293, DOI 10.1164/ajrccm.163.6.ed1801d; Vivona ML, 2001, AM J RESP CELL MOL, V25, P554, DOI 10.1165/ajrcmb.25.5.4420; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035; Wodopia R, 2000, AM J PHYSIOL-LUNG C, V279, pL1110, DOI 10.1152/ajplung.2000.279.6.L1110	29	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19892	19898		10.1074/jbc.M602064200	http://dx.doi.org/10.1074/jbc.M602064200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16636055	hybrid			2022-12-25	WOS:000239038200012
J	Anguera, MC; Field, MS; Perry, C; Ghandour, H; Chiang, EP; Selhub, J; Shane, B; Stover, PJ				Anguera, Montserrat C.; Field, Martha S.; Perry, Cheryll; Ghandour, Haifa; Chiang, En-Pei; Selhub, Jacob; Shane, Barry; Stover, Patrick J.			Regulation of folate-mediated one-carbon metabolism by 10-formyltetrahydrofolate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; GENOMIC DNA METHYLATION; SERINE HYDROXYMETHYLTRANSFERASE; METHENYLTETRAHYDROFOLATE SYNTHETASE; HOMOCYSTEINE REMETHYLATION; MEMBRANE-TRANSPORT; MAMMALIAN-CELLS; REDUCTASE GENE; IDENTIFICATION; NEUROBLASTOMA	10-Formyltetrahydrofolate dehydrogenase (FDH) catalyzes the NADP(+)-dependent conversion of 10-formyltetrahydrofolate to CO2 and tetrahydrofolate (THF) and is an abundant high affinity folate-binding protein. Although several activities have been ascribed to FDH, its metabolic role in folate-mediated one-carbon metabolism is not well understood. FDH has been proposed to: 1) inhibit purine biosynthesis by depleting 10-formyl-THF pools, 2) maintain cellular folate concentrations by sequestering THF, 3) deplete the supply of folate-activated one-carbon units, and 4) stimulate the generation of THF-activated one-carbon unit synthesis by channeling folate cofactors to other folate-dependent enzymes. The metabolic functions of FDH were investigated in neuroblastoma, which do not contain detectable levels of FDH. Both low and high FDH expression reduced total cellular folate concentrations by 60%, elevated rates of folate catabolism, and depleted cellular 5-methyl-THF and S-adenosylmethionine levels. Low FDH expression increased the formyl-THF/THF ratio nearly 10-fold, whereas THF accounted for nearly 50% of total folate in neuroblastoma with high FDH expression. FDH expression did not affect the enrichment of exogenous formate into methionine, serine, or purines and did not suppress de novo purine nucleotide biosynthesis. We conclude that low FDH expression facilitates the incorporation of one-carbon units into the one-carbon pool, whereas high levels of FDH expression deplete the folate-activated one-carbon pool by catalyzing the conversion of 10-formyl-THF to THF. Furthermore, FDH does not increase cellular folate concentrations by sequestering THF in neuroblastoma nor does it inhibit or regulate de novo purine biosynthesis. FDH expression does deplete cellular 5-methyl-THF and S-adenosylmethionine levels indicating that FDH impairs the folate-dependent homocysteine remethylation cycle.	Cornell Univ, Div Nutrit Sci, Ithaca, NY 14853 USA; Cornell Univ, Grad Field Biochem Mol & Cellular Biol, Ithaca, NY 14853 USA; Tufts Univ, Jean Mayer US Dept Agr Human Nutrit Res, Vitamin Metab Lab, Boston, MA 02111 USA; Univ Calif Berkeley, Dept Nutrit Sci & Toxicol, Berkeley, CA 94720 USA	Cornell University; Cornell University; Tufts University; University of California System; University of California Berkeley	Stover, PJ (corresponding author), Cornell Univ, Div Nutrit Sci, 315 Savage Hall, Ithaca, NY 14853 USA.	pjs13@cornell.edu	Chiang, EnPei/K-1694-2013	Chiang, EnPei/0000-0002-0158-0962; Field, Martha/0000-0001-7547-5180	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007158] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35687] Funding Source: Medline; NIDDK NIH HHS [DK07158-28] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anguera MC, 2003, J BIOL CHEM, V278, P29856, DOI 10.1074/jbc.M302883200; Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; Bagley PJ, 2000, CLIN CHEM, V46, P404; BARLOWE C K, 1988, Biofactors, V1, P171; CHAMPION KM, 1994, P NATL ACAD SCI USA, V91, P11338, DOI 10.1073/pnas.91.24.11338; CHEN L, 1996, J BIOL CHEM, P271; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P504, DOI 10.1021/bi00376a024; COOK RJ, 1991, J BIOL CHEM, V266, P4965; Davis SR, 2004, AM J PHYSIOL-ENDOC M, V286, pE272, DOI 10.1152/ajpendo.00351.2003; Field MS, 2006, J BIOL CHEM, V281, P4215, DOI 10.1074/jbc.M510624200; Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299; Friso S, 2002, ANAL CHEM, V74, P4526, DOI 10.1021/ac020050h; Fu TF, 1999, ARCH BIOCHEM BIOPHYS, V367, P161, DOI 10.1006/abbi.1999.1262; Girgis S, 1998, GENE, V210, P315, DOI 10.1016/S0378-1119(98)00085-7; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; GOYETTE P, 1995, AM J HUM GENET, V56, P1052; Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200; Hong M, 1999, BIOCHEM MOL BIOL INT, V47, P407; Jhaveri MS, 2001, MOL PHARMACOL, V60, P1288, DOI 10.1124/mol.60.6.1288; Kim DW, 1996, BIOCHEMISTRY-US, V35, P15772, DOI 10.1021/bi9619684; KREBS HA, 1976, BIOCHEM J, V158, P341, DOI 10.1042/bj1580341; Krupenko SA, 2002, CELL GROWTH DIFFER, V13, P227; LIN BF, 1993, J BIOL CHEM, V268, P21674; LIN BF, 1994, J BIOL CHEM, V269, P9705; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; Shane B., 1995, FOLATE HLTH DIS, V2, P1; Sierra EE, 1999, SEMIN ONCOL, V26, P11; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; STRONG WB, 1989, BIOCHEMISTRY-US, V28, P9430, DOI 10.1021/bi00450a028; Suh JR, 2001, ANNU REV NUTR, V21, P255, DOI 10.1146/annurev.nutr.21.1.255; Titus SA, 2000, J BIOL CHEM, V275, P36811, DOI 10.1074/jbc.M005163200; Wagner C, 1995, FOLATE HLTH DIS, P23	33	73	76	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18335	18342		10.1074/jbc.M510623200	http://dx.doi.org/10.1074/jbc.M510623200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16627483	hybrid			2022-12-25	WOS:000238687300010
J	Nie, DT; Krishnamoorthy, S; Jin, RX; Tang, KQ; Chen, YC; Qiao, Y; Zacharek, A; Guo, YD; Milanini, J; Pages, G; Honn, KV				Nie, Daotai; Krishnamoorthy, Sriram; Jin, Rongxian; Tang, Keqin; Chen, YuChyu; Qiao, Yan; Zacharek, Alex; Guo, Yande; Milanini, Julie; Pages, Gilles; Honn, Kenneth V.			Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; PLATELET-TYPE 12-LIPOXYGENASE; KINASE-C ZETA; FACTOR GENE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL REGULATION; ADVANCED-STAGE; EXPRESSION; HYPOXIA; CARCINOMA	12-Lipoxygenase utilizes arachidonic acid to synthesize 12(S)-hydroperoxyeicosatetraenoic acid, which is converted to the end product 12(S)-hydroxyeicosatetraenoic acid, an eicosanoid that promotes tumorigenesis and metastasis. Increased expression of 12-lipoxygenase has been documented in a number of carcinomas. When overexpressed inhumanprostate or breast cancer, 12-lipoxygenase promotes tumor angiogenesis and growth in vivo. The present study was undertaken to delineate the mechanisms by which 12-lipoxygenase enhances angiogenesis. Herein we report that nordihydroguaiaretic acid, a pan inhibitor of lipoxygenases and baicalein, a selective inhibitor of 12-lipoxygenase, reduced VEGF expression in human prostate cancer PC-3 cells. Overexpression of 12-lipoxygenase in PC-3 cells resulted in a 3-fold increase in VEGF protein level when compared with vector control cells. An increase in PI 3-kinase activity was found in 12-LOX-transfected PC-3 cells and inhibition of PI 3-kinase by LY294002 significantly reduced VEGF expression. Northern blot and real time PCR analyses revealed an elevated VEGF transcript level in PC-3 cells transfected with a 12-lipoxygenase expression construct. Using a VEGF promoter luciferase construct (-1176/+54), we found a 10-fold increase in VEGF promoter activity in 12-lipoxygenase-transfected PC-3 cells. The region located between -88 and -66 of the VEGF promoter was identified as 12-lipoxygenase responsive using VEGF promoter-based luciferase assays. Further analysis with mutant constructs indicated Sp1 as a transcription factor required for 12-lipoxygenase stimulation of VEGF. Neutralization of VEGF by a function-blocking antibody significantly decreased the ability of 12-lipoxygenase-transfected PC-3 cells to stimulate endothelial cell migration, suggesting VEGF as an important effect or for 12-lipoxygenase-mediated stimulation of tumor angiogenesis.	Wayne State Univ, Sch Med, Dept Radiat Oncol, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48202 USA; Karmanos Canc Inst, Detroit, MI 48202 USA; Univ Nice, CNRS, UMR 6543, Ctr Biochim, F-06108 Nice, France	Wayne State University; Wayne State University; Barbara Ann Karmanos Cancer Institute; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Honn, KV (corresponding author), Wayne State Univ, Sch Med, Dept Radiat Oncol, 431 Chem Bldg, Detroit, MI 48202 USA.	k.v.honn@wayne.edu	Pages, Gilles/N-7135-2017	Milanini, Julie/0000-0002-5861-2830	NCI NIH HHS [CA-29997] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029997] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Connolly JM, 1998, CANCER LETT, V132, P107, DOI 10.1016/S0304-3835(98)00171-2; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GAO X, 1995, UROLOGY, V46, P227, DOI 10.1016/S0090-4295(99)80198-8; Giri D, 1999, HUM PATHOL, V30, P419, DOI 10.1016/S0046-8177(99)90117-X; Gupta VK, 2002, CANCER J, V8, P47, DOI 10.1097/00130404-200201000-00009; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HONN KV, 1994, CANCER METAST REV, V13, P365, DOI 10.1007/BF00666105; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Kelavkar UP, 2001, CARCINOGENESIS, V22, P1765, DOI 10.1093/carcin/22.11.1765; Lara Primo N Jr, 2004, Clin Prostate Cancer, V3, P165; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lin JQ, 1999, CANCER RES, V59, P2891; Liu XH, 1999, CLIN EXP METASTAS, V17, P687, DOI 10.1023/A:1006728119549; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; McMenamin ME, 1999, CANCER RES, V59, P4291; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Miura H, 1997, J HEPATOL, V27, P854, DOI 10.1016/S0168-8278(97)80323-6; Mukhopadhyay D, 2004, SEMIN CANCER BIOL, V14, P123, DOI 10.1016/j.semcancer.2003.09.019; NATARAJAN R, 1998, FRONT BIOSCI, V3, P81; Nie D, 1998, CANCER RES, V58, P4047; Nithipatikom K, 2006, CANCER LETT, V233, P219, DOI 10.1016/j.canlet.2005.03.025; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pidgeon GP, 2003, CANCER RES, V63, P4258; Pidgeon GP, 2002, CANCER RES, V62, P2721; Piogeon GP, 2003, INT J CANCER, V105, P459, DOI 10.1002/ijc.11134; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Szekeres CK, 2000, BIOCHEM BIOPH RES CO, V275, P690, DOI 10.1006/bbrc.2000.3348; Tai SK, 2003, AM J PATHOL, V163, P2009, DOI 10.1016/S0002-9440(10)63559-6; TANG DG, 1995, BIOCHEM BIOPH RES CO, V211, P462, DOI 10.1006/bbrc.1995.1836; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; Timar J, 2000, INT J CANCER, V87, P37, DOI 10.1002/1097-0215(20000701)87:1<37::AID-IJC6>3.0.CO;2-L; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xie KP, 2004, CYTOKINE GROWTH F R, V15, P297, DOI 10.1016/j.cytogfr.2004.04.003; Yoshimura R, 2004, INT J MOL MED, V13, P41; Zhong H, 1999, CANCER RES, V59, P5830	44	89	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18601	18609		10.1074/jbc.M601887200	http://dx.doi.org/10.1074/jbc.M601887200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16638750	hybrid			2022-12-25	WOS:000238687300039
J	Rhee, SH; Kim, H; Moyer, MP; Pothoulakis, C				Rhee, Sang Hoon; Kim, Ho; Moyer, Mary P.; Pothoulakis, Charalabos			Role of MyD88 in phosphatidylinositol 3-kinase activation by flagellin/toll-like receptor 5 engagement in colonic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PHOSPHOINOSITIDE 3-KINASE; GROWTH-FACTOR; RECEPTOR; MACROPHAGES; EXPRESSION; PHOSPHORYLATION; PATHWAYS; IMMUNITY; SIGNALS	Bacterial flagellin, recognized by Toll-like receptor (TLR) 5, is suggested to be involved in colonic inflammation. However, the detailed signaling mechanisms mediated by flagellin/TLR5 engagement are not clear. Here we dissected the biochemical mechanism by which TLR5 engagement mediates phosphatidylinositol 3-kinase (PI3K) activation in colonic epithelial cells. We demonstrate that silencing TLR5 expression in nontransformed human colonic epithelial cells blocks flagellin-induced PI3K activation, indicating specific activation of PI3K by flagellin/TLR5 engagement. Moreover, we determine that TLR5 recruits the p85 regulatory subunit of PI3K to its cytoplasmic TIR domain in response to flagellin. However, the Src homology binding "YXXM" motif in the cytoplasmic TIR domain of TLR5 is not involved in p85 recruitment, implying that TLR5 indirectly recruits p85. Indeed, we demonstrate that the adaptor molecule MyD88 associates with TLR5 and silencing MyD88 expression blocks PI3K activation by disrupting the association between TLR5 and p85. Furthermore, we show that MyD88 associates with p85 in response to flagellin. Additionally, we determine that blocking PI3K activation reduces interleukin-8 production induced by flagellin in human colonic epithelial cells. Together, MyD88 bridges TLR5 engagement to PI3K activation in response to flagellin.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Gastrointestinal Neuropeptide Ctr,Div Gastroenter, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Pothoulakis, C (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Gastrointestinal Neuropeptide Ctr,Div Gastroenter, Dana 601,330 Brookline Ave, Boston, MA 02215 USA.	cpothoul@bidmc.harvard.edu						Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Aksoy E, 2005, EUR J IMMUNOL, V35, P2200, DOI 10.1002/eji.200425801; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Barrett KE, 2001, GASTROENTEROLOGY, V120, P1543; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Ferrand A, 2005, CANCER RES, V65, P2770, DOI 10.1158/0008-5472.CAN-04-0978; Fukao T, 2003, TRENDS IMMUNOL, V24, P358, DOI 10.1016/S1471-4906(03)00139-X; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; O'Neill LAJ, 2004, TRENDS IMMUNOL, V25, P687, DOI 10.1016/j.it.2004.10.005; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Rhee SH, 2005, P NATL ACAD SCI USA, V102, P13610, DOI 10.1073/pnas.0502174102; Rhee SH, 2004, J BIOL CHEM, V279, P25179, DOI 10.1074/jbc.M400967200; Rhee SH, 2003, J BIOL CHEM, V278, P22506, DOI 10.1074/jbc.M208633200; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; Sheng H, 2003, GUT, V52, P1472, DOI 10.1136/gut.52.10.1472; Smythies LE, 2005, J CLIN INVEST, V115, P66, DOI 10.1172/JCI200519229; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wu HY, 2003, J BIOL CHEM, V278, P40425, DOI 10.1074/jbc.C300225200	26	73	74	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18560	18568		10.1074/jbc.M513861200	http://dx.doi.org/10.1074/jbc.M513861200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16644730	hybrid			2022-12-25	WOS:000238687300035
J	Cheng, G; Diebold, BA; Hughes, Y; Lambeth, JD				Cheng, Guangjie; Diebold, Becky A.; Hughes, Yasmin; Lambeth, J. David			Nox1-dependent reactive oxygen generation is regulated by Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; NADPH OXIDASE; SUPEROXIDE-PRODUCTION; ACTIVATION DOMAIN; P67(PHOX); P47(PHOX); CELLS; RAS; TRANSFORMATION; REGION	Rac1 has been implicated in the generation of reactive oxygen species (ROS) in several cell types, but the enzymatic origin of the ROS has not been proven. The present studies demonstrate that Nox1, a homolog of the phagocyte NADPH-oxidase component gp91(phox), is activated by Rac1. When Nox1 is co-expressed along with its regulatory subunits NOXO1 and NOXA1, significant ROS generation is seen. Herein, co-expression of constitutively active Rac1(G12V), but not wild- type Rac1, resulted in marked further stimulation of activity. Decreased Rac1 expression using small interfering RNA reduced Nox1-dependent ROS. CDC42(G12V) failed to increase activity, and small interfering RNA directed against CDC42 failed to decrease activity, pointing to specificity for Rac. TPR domain mutants of NOXA1 that interfere with Rac1 binding were ineffective in supporting Nox1-dependent ROS generation. Immunoprecipitation experiments demonstrated a complex containing Rac1(G12V), NOXO1, NOXA1, and Nox1. CDC42(G12V) could not substitute for Rac1( G12V) in such a complex. Nox1 formed a complex with Rac1(G12V) that was independent of NOXA1 and NOXO1, consistent with direct binding of Rac1(G12V) to Nox1. Rac1(G12V) interaction with NOXA1 was enhanced by Nox1 and NOXO1, suggesting cooperative binding. A model is presented comparing activation by regulatory subunits of Nox1 versus gp91(phox) (Nox2) in which Rac1 activation provides a major trigger that acutely activates Nox1-dependent ROS generation.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Emory University	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, 615 Michael St, Atlanta, GA 30322 USA.	noxdoc@mac.com		Cheng, Guangjie/0000-0002-9368-379X	NATIONAL CANCER INSTITUTE [R01CA084138, R01CA105116, R56CA105116] Funding Source: NIH RePORTER; NCI NIH HHS [CA 105116, CA 84138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Archer Herbert, 2002, Methods Mol Biol, V189, P67; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Cheng GJ, 2004, J BIOL CHEM, V279, P34250, DOI 10.1074/jbc.M400660200; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; Dinauer MC, 2003, CURR OPIN HEMATOL, V10, P8, DOI 10.1097/00062752-200301000-00003; Fortemaison N, 2005, EUR J ENDOCRINOL, V152, P127, DOI 10.1530/eje.1.01815; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Gorin Y, 2003, AM J PHYSIOL-RENAL, V285, pF219, DOI 10.1152/ajprenal.00414.2002; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kamiguti AS, 2005, J IMMUNOL, V175, P8424, DOI 10.4049/jimmunol.175.12.8424; Kawahara T, 2005, J BIOL CHEM, V280, P31859, DOI 10.1074/jbc.M501882200; Kawahara T, 2005, AM J PHYSIOL-CELL PH, V288, pC450, DOI 10.1152/ajpcell.00319.2004; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Kong G, 2001, J KOREAN MED SCI, V16, P712, DOI 10.3346/jkms.2001.16.6.712; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023; Niedergang F, 2005, CURR TOP MICROBIOL, V291, P43; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Park HS, 2006, BIOCHEM BIOPH RES CO, V339, P985, DOI 10.1016/j.bbrc.2005.11.108; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Sarfstein R, 2004, J BIOL CHEM, V279, P16007, DOI 10.1074/jbc.M312394200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Ueyama T, 2006, MOL CELL BIOL, V26, P2160, DOI 10.1128/MCB.26.6.2160-2174.2006; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Yeh LH, 1999, AM J PHYSIOL-CELL PH, V276, pC838, DOI 10.1152/ajpcell.1999.276.4.C838; Yuzawa S, 2004, J BIOL CHEM, V279, P29752, DOI 10.1074/jbc.M401457200; Yuzawa S, 2004, GENES CELLS, V9, P443, DOI 10.1111/j.1356-9597.2004.00733.x; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	43	217	225	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17718	17726		10.1074/jbc.M512751200	http://dx.doi.org/10.1074/jbc.M512751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16636067	hybrid			2022-12-25	WOS:000238490300021
J	Keusekotten, K; Leonhardt, RM; Ehses, S; Knittler, MR				Keusekotten, Kirstin; Leonhardt, Ralf M.; Ehses, Sarah; Knittler, Michael R.			Biogenesis of functional antigenic peptide transporter TAP requires assembly of pre-existing TAP1 with newly synthesized TAP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; MAJOR HISTOCOMPATIBILITY COMPLEX; DISULFIDE CROSS-LINKING; PROCESSING TAP; CLASS-I; MEMBRANE-PROTEINS; ABC TRANSPORTER; QUALITY-CONTROL; SUBUNITS; EXPRESSION	The transporter associated with antigen processing (TAP) is essential for the delivery of antigenic peptides from the cytosol into the endoplasmic reticulum (ER), where they are loaded onto major histocompatibility complex class I molecules. TAP is a heterodimeric transmembrane protein that comprises the homologous subunits TAP1 and TAP2. As for many other oligomeric protein complexes, which are synthesized in the ER, the process of subunit assembly is essential for TAP to attain a native functional state. Here, we have analyzed the individual requirements of TAP1 and TAP2 for the formation of a functional TAP complex. Unlike TAP1, TAP2 is very unstable when expressed in isolation. We show that heterodimerization of TAP subunits is required for maintaining a stable level of TAP2. By using an in vitro expression system we demonstrate that the biogenesis of functional TAP depends on the assembly of preexisting TAP1 with newly synthesized TAP2, but not vice versa. The pore forming core transmembrane domain ( core TMD) of in vitro expressed TAP2 is necessary and sufficient to allow functional complex formation with pre-existing TAP1. We propose that the observed assembly mechanism of TAP protects newly synthesized TAP2 from rapid degradation and controls the number of transport active transporter molecules. Our findings open up new possibilities to investigate functional and structural properties of TAP and provide a powerful model system to address the biosynthetic assembly of oligomeric transmembrane proteins in the ER.	Fed Res Inst Anim Hlth, Friedrich Loeffler Inst, Inst Immunol, D-72076 Tubingen, Germany; Univ Cologne, Inst Genet, D-50674 Cologne, Germany	Friedrich Loeffler Institute; University of Cologne	Knittler, MR (corresponding author), Fed Res Inst Anim Hlth, Friedrich Loeffler Inst, Inst Immunol, Paul Ehrlich Str 28, D-72076 Tubingen, Germany.	michael.knittler@fli.bund.de		Leonhardt, Ralf Max/0000-0001-6673-8217				Antoniou AN, 2002, IMMUNOLOGY, V106, P182, DOI 10.1046/j.1365-2567.2002.01415.x; Beguin P, 2000, MOL BIOL CELL, V11, P1657, DOI 10.1091/mbc.11.5.1657; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Carveth K, 2002, J BIOL CHEM, V277, P39507, DOI 10.1074/jbc.M205759200; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Daumke O, 2001, EUR J BIOCHEM, V268, P4776, DOI 10.1046/j.1432-1327.2001.02406.x; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; Du K, 2005, NAT STRUCT MOL BIOL, V12, P17, DOI 10.1038/nsmb882; Ehses S, 2005, J IMMUNOL, V174, P328, DOI 10.4049/jimmunol.174.1.328; Gatto C, 2001, AM J PHYSIOL-CELL PH, V281, pC982, DOI 10.1152/ajpcell.2001.281.3.C982; Herzer K, 2003, J VIROL, V77, P8299, DOI 10.1128/JVI.77.15.8299-8309.2003; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; Koch J, 2005, FEBS LETT, V579, P4413, DOI 10.1016/j.febslet.2005.07.006; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; Lankat-Buttgereit B, 1999, FEBS LETT, V464, P108, DOI 10.1016/S0014-5793(99)01676-2; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 2004, J BIOL CHEM, V279, P18232, DOI 10.1074/jbc.M400229200; Loo TW, 2004, J BIOL CHEM, V279, P7692, DOI 10.1074/jbc.M311825200; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; Ritz U, 2001, MOL MED, V7, P149, DOI 10.1007/BF03401948; Tarasova NI, 2005, J MED CHEM, V48, P3768, DOI 10.1021/jm049065t; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Vos JC, 1999, J IMMUNOL, V163, P6679; Zhang JT, 1996, MOL BIOL CELL, V7, P1709, DOI 10.1091/mbc.7.11.1709; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	28	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17545	17551		10.1074/jbc.M602360200	http://dx.doi.org/10.1074/jbc.M602360200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16624807	hybrid			2022-12-25	WOS:000238490300003
J	Holt, M; Varoqueaux, F; Wiederhold, K; Takamori, S; Urlaub, H; Fasshauer, D; Jahn, R				Holt, Matthew; Varoqueaux, Frederique; Wiederhold, Katrin; Takamori, Shigeo; Urlaub, Henning; Fasshauer, Dirk; Jahn, Reinhard			Identification of SNAP-47, a novel Qbc-SNARE with ubiquitous expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL EXPRESSION; CRYSTAL-STRUCTURE; PROTEINS; COMPLEX; SYNTAXIN; PALMITOYLATION; EXOCYTOSIS; TRANSPORT; VESICLES; CELLS	The SNARE proteins are essential components of the intracellular fusion machinery. It is thought that they form a tight four-helix complex between membranes, in effect initiating fusion. Most SNAREs contain a single coiled-coil region, referred to as the SNARE motif, directly adjacent to a single transmembrane domain. The neuronal SNARE SNAP-25 defines a subfamily of SNARE proteins with two SNARE helices connected by a longer linker, comprising also the proteins SNAP-23 and SNAP-29. We now report the initial characterization of a novel vertebrate homologue termed SNAP-47. Northern blot and immunoblot analysis revealed ubiquitous tissue distribution, with particularly high levels in nervous tissue. In neurons, SNAP-47 shows a widespread distribution on intracellular membranes and is also enriched in synaptic vesicle fractions. In vitro, SNAP-47 substituted for SNAP-25 in SNARE complex formation with the neuronal SNAREs syntaxin 1a and synaptobrevin 2, and it also substituted for SNAP-25 in proteoliposome fusion. However, neither complex assembly nor fusion was as efficient as with SNAP-25.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Max Planck Inst Biophys Chem, Dept Bioanalyt Mass Spect Grp, D-37077 Gottingen, Germany; Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany	Max Planck Society; Max Planck Society; Max Planck Society	Jahn, R (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Fassberg 11, D-37077 Gottingen, Germany.	rjahn@gwdg.de	Fasshauer, Dirk/B-1563-2013; Varoqueaux, Frederique/AAC-1834-2021; Holt, Matthew/AAJ-1813-2020	Fasshauer, Dirk/0000-0002-1040-4282; Varoqueaux, Frederique/0000-0002-3614-3121; Holt, Matthew/0000-0002-8958-4027; Jahn, Reinhard/0000-0003-1542-3498				Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Augustin I, 1999, BIOCHEM J, V337, P363, DOI 10.1042/0264-6021:3370363; BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Dresbach T, 2004, MOL CELL NEUROSCI, V27, P227, DOI 10.1016/j.mcn.2004.06.013; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 2004, J BIOL CHEM, V279, P7613, DOI 10.1074/jbc.M312064200; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Feng D, 2002, BLOOD, V99, P4006, DOI 10.1182/blood.V99.11.4006; Friedman HV, 2000, NEURON, V27, P57, DOI 10.1016/S0896-6273(00)00009-X; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hartinger J, 1996, ANAL BIOCHEM, V240, P126, DOI 10.1006/abio.1996.0339; Herzog E, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-22-j0001.2001; HESS DT, 1992, J NEUROSCI, V12, P4634; HOEKSTRA D, 1993, METHOD ENZYMOL, V220, P15, DOI 10.1016/0076-6879(93)20070-J; Hong Wanjin, 2005, Biochim Biophys Acta, V1744, P493; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Koticha DK, 2002, J CELL SCI, V115, P3341; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; Liu YT, 2002, MOL BIOL CELL, V13, P3314, DOI 10.1091/mbc.E02-04-0204; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Schuette CG, 2004, P NATL ACAD SCI USA, V101, P2858, DOI 10.1073/pnas.0400044101; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimohama S, 1998, BIOCHEM BIOPH RES CO, V251, P394, DOI 10.1006/bbrc.1998.9480; Speidel D, 2003, J BIOL CHEM, V278, P52802, DOI 10.1074/jbc.M304727200; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tao-Cheng JH, 2000, J NEUROCYTOL, V29, P67, DOI 10.1023/A:1007168231323; Wang GY, 1997, J CELL SCI, V110, P505; Washbourne P, 2001, BIOCHEM J, V357, P625, DOI 10.1042/0264-6021:3570625; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Wong SH, 1999, MOL BIOL CELL, V10, P119, DOI 10.1091/mbc.10.1.119; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	45	74	79	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17076	17083		10.1074/jbc.M513838200	http://dx.doi.org/10.1074/jbc.M513838200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16621800	hybrid, Green Published			2022-12-25	WOS:000238326300030
J	Sobolik-Delmaire, T; Katafiasz, D; Wahl, JK				Sobolik-Delmaire, Tammy; Katafiasz, Dawn; Wahl, James K., III			Carboxyl terminus of plakophilin-1 recruits it to plasma membrane, whereas amino terminus recruits desmoplakin and promotes desmosome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENT ANCHORAGE; PLAKOGLOBIN-BINDING; EPITHELIAL-CELLS; PLAQUE COMPONENTS; CADHERIN FUNCTION; HUMAN EPIDERMIS; CULTURED-CELLS; PROTEIN; EXPRESSION; FAMILY	Plakophilins are armadillo repeat-containing proteins, initially identified as desmosomal plaque proteins that have subsequently been shown to also localize to the nucleus. Loss of plakophilin-1 is the underlying cause of ectodermal dysplasia/skin fragility syndrome, and skin from these patients exhibits desmosomes that are reduced in size and number. Thus, it has been suggested that plakophilin-1 plays an important role in desmosome stability and/or assembly. In this study, we used a cell culture system (A431DE cells) that expresses all of the proteins necessary to assemble a desmosome, except plakophilin-1. Using this cell line, we sought to determine the role of plakophilin-1 in de novo desmosome assembly. When exogenous plakophilin-1 was expressed in these cells, desmosomes were assembled, as assessed by electron microscopy and immunofluorescence localization of desmoplakin, into punctate structures. Deletion mutagenesis experiments revealed that amino acids 686-726 in the carboxyl terminus of plakophilin-1 are required for its localization to the plasma membrane. In addition, we showed that amino acids 1-34 in the amino terminus were necessary for subsequent recruitment of desmoplakin to the membrane and desmosome assembly.	Univ Nebraska, Med Ctr, Coll Dent, Dept Oral Biol,Med Ctr, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Nebraska Ctr Cellular Signaling, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wahl, JK (corresponding author), Univ Nebraska, Med Ctr, Coll Dent, Dept Oral Biol,Med Ctr, 987696 Nebraska Med Ctr, Omaha, NE 68198 USA.	jwahl@unmc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR018759] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMAGAI M, 1995, J INVEST DERMATOL, V104, P27, DOI 10.1111/1523-1747.ep12613462; ARNEMANN J, 1993, J CELL SCI, V104, P741; Bonne S, 1999, J CELL SCI, V112, P2265; Bornslaeger EA, 2001, J CELL SCI, V114, P727; Cheng X, 2004, J DERMATOL, V31, P171, DOI 10.1111/j.1346-8138.2004.tb00654.x; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; Godsel LM, 2005, J CELL BIOL, V171, P1045, DOI 10.1083/jcb.200510038; GREEN KJ, 1991, EXP CELL RES, V193, P134, DOI 10.1016/0014-4827(91)90547-8; Grossmann KS, 2004, J CELL BIOL, V167, P149, DOI 10.1083/jcb.200402096; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HATZFELD M, 1994, J CELL SCI, V107, P2259; Hatzfeld M, 2000, J CELL BIOL, V149, P209, DOI 10.1083/jcb.149.1.209; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; KING IA, 1993, J INVEST DERMATOL, V100, P373, DOI 10.1111/1523-1747.ep12471843; Klymkowsky MW, 1999, MICROSC RES TECHNIQ, V45, P43, DOI 10.1002/(SICI)1097-0029(19990401)45:1<43::AID-JEMT4>3.3.CO;2-3; Koeser J, 2003, EXP CELL RES, V285, P114, DOI 10.1016/S0014-4827(03)00016-8; Kowalczyk AP, 1999, J BIOL CHEM, V274, P18145, DOI 10.1074/jbc.274.26.18145; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962-8924(01)02180-8; LEWIS JE, 1994, J INVEST DERMATOL, V102, P870, DOI 10.1111/1523-1747.ep12382690; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; McGrath JA, 1997, NAT GENET, V17, P240, DOI 10.1038/ng1097-240; McMillan JR, 2003, J INVEST DERMATOL, V121, P96, DOI 10.1046/j.1523-1747.2003.12324.x; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; Moll I, 1997, J INVEST DERMATOL, V108, P139, DOI 10.1111/1523-1747.ep12332388; Palka HL, 1997, J CELL SCI, V110, P2359; SCHMIDT A, 1994, EUR J CELL BIOL, V65, P229; Schmidt A, 1999, DIFFERENTIATION, V64, P291, DOI 10.1046/j.1432-0436.1999.6450291.x; Schmidt A, 1997, CELL TISSUE RES, V290, P481, DOI 10.1007/s004410050956; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; South AP, 2003, J CELL SCI, V116, P3303, DOI 10.1242/jcs.00636; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; TROYANOVSKY SM, 1994, J CELL BIOL, V127, P151, DOI 10.1083/jcb.127.1.151; TROYANOVSKY SM, 1994, P NATL ACAD SCI USA, V91, P10790, DOI 10.1073/pnas.91.23.10790; Vasioukhin V, 2001, NAT CELL BIOL, V3, P1076, DOI 10.1038/ncb1201-1076; Wahl JK, 2002, HYBRIDOMA HYBRIDOM, V21, P37, DOI 10.1089/15368590252917629; Wahl JK, 1996, J CELL SCI, V109, P1143	41	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					16962	16970		10.1074/jbc.M600570200	http://dx.doi.org/10.1074/jbc.M600570200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16632867	hybrid			2022-12-25	WOS:000238326300017
J	Jennings-Gee, JE; Tsuji, Y; Pietsch, EC; Moran, E; Mymryk, JS; Torti, FM; Torti, SV				Jennings-Gee, Jamie E.; Tsuji, Yoshiaki; Pietsch, E. Christine; Moran, Elizabeth; Mymryk, J. S.; Torti, Frank M.; Torti, Suzy V.			Coordinate inhibition of cytokine-mediated induction of ferritin H, manganese superoxide dismutase, and interleukin-6 by the adenovirus E1A oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; ALPHA-INDUCED APOPTOSIS; GENE-EXPRESSION; OXIDATIVE STRESS; HEAVY-CHAIN; TRANSCRIPTIONAL ACTIVATION; ENDOTHELIAL-CELLS; COACTIVATOR P300; SENSITIZES CELLS	Adenovirus E1A sensitizes cells to the cytotoxic action of tumor necrosis factor alpha(TNF-alpha). This effect has been attributed to direct blockade of NF-kappa B activation, as well as to increased activation of components of the apoptotic pathway and decreases in inhibitors of apoptosis. In this report we evaluated the mechanism by which E1A modulates the expression of the cytokine-inducible cytoprotective genes manganese superoxide dismutase (MnSOD), interleukin-6 (IL-6), and ferritin heavy chain (FH). We observed that E1A blocks induction of MnSOD, IL-6, and FH by TNF-alpha or IL-1 alpha. Because NF-kappa B plays a role in cytokine-dependent induction of MnSOD, IL-6, and FH, we assessed the effect of E1A on NF-kappa B in cells treated with TNF. I kappa B, the inhibitor of NF-kappa B, was degraded similarly in the presence and absence of E1A. TNF induced a quantitatively and temporally equivalent activation of NF-kappa B in control and E1A-transfected cells. However, TNF-dependent acetylation of NF-kappa B was diminished in cells expressing E1A. E1A mutants unable to bind p400 or the Rb family proteins were still capable of repressing TNF-dependent induction of FH. However, mutants of E1A that abrogated binding of p300/CBP blocked the ability of E1A to repress TNF-dependent induction of FH. These results suggest that p300/ CBP is a critical control point in NF-kappa B-dependent transcriptional regulation of cytoprotective genes by cytokines.	Wake Forest Univ, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27157 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; London Reg Canc Program, Canc Res Lab Program, London, ON N6A 4L6, Canada	Wake Forest University; Wake Forest University; Wake Forest University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Western University (University of Western Ontario)	Torti, SV (corresponding author), Wake Forest Univ, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.	storti@wfubmc.edu			NIDDK NIH HHS [R37 DK 42412] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042412] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES RS, 1990, J VIROL, V64, P4115, DOI 10.1128/JVI.64.9.4115-4122.1990; Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; BALLA G, 1992, J BIOL CHEM, V267, P18148; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEUTLER BA, 1985, J IMMUNOL, V135, P3969; Bishopric NH, 1997, J BIOL CHEM, V272, P20584, DOI 10.1074/jbc.272.33.20584; BOYD D, 1985, J BIOL CHEM, V260, P1755; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2005, METHODS, V36, P368, DOI 10.1016/j.ymeth.2005.03.011; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cook JL, 2002, P NATL ACAD SCI USA, V99, P9966, DOI 10.1073/pnas.162082999; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; Djavaheri-Mergny M, 2004, FEBS LETT, V578, P111, DOI 10.1016/j.febslet.2004.10.082; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; JELSMA TN, 1988, VIROLOGY, V163, P494, DOI 10.1016/0042-6822(88)90290-5; KENYON DJ, 1991, VIROLOGY, V180, P818, DOI 10.1016/0042-6822(91)90099-W; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; Kishimoto T, 2005, CLIN REV ALLERG IMMU, V28, P177, DOI 10.1385/CRIAI:28:3:177; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; KWAK EL, 1995, J BIOL CHEM, V270, P15285, DOI 10.1074/jbc.270.25.15285; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LE JM, 1987, LAB INVEST, V56, P234; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Legrand-Poels S, 2000, BIOCHEM J, V349, P765, DOI 10.1042/bj3490765; Liu ZG, 2005, CELL RES, V15, P24, DOI 10.1038/sj.cr.7290259; MATSUSHIMA K, 1986, J IMMUNOL, V136, P4496; May MJ, 1996, BRIT J PHARMACOL, V118, P1761, DOI 10.1111/j.1476-5381.1996.tb15602.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; NEVINS JR, 1987, MICROBIOL REV, V51, P419, DOI 10.1128/MMBR.51.4.419-430.1987; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Orino K, 2001, BIOCHEM J, V357, P241, DOI 10.1042/0264-6021:3570241; Orino K, 1999, FEBS LETT, V461, P334, DOI 10.1016/S0014-5793(99)01443-X; Pacini A, 1999, J BIOL CHEM, V274, P35107, DOI 10.1074/jbc.274.49.35107; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pietsch EC, 2003, J BIOL CHEM, V278, P2361, DOI 10.1074/jbc.M210664200; RODRIGUES M, 1990, VIRUS RES, V15, P231, DOI 10.1016/0168-1702(90)90030-F; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; SHENK T, 1991, ADV CANCER RES, V57, P47; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; Tsuji Y, 2000, MOL CELL BIOL, V20, P5818, DOI 10.1128/MCB.20.16.5818-5827.2000; TSUJI Y, 1993, J IMMUNOL, V150, P1897; TSUJI Y, 1993, J BIOL CHEM, V268, P7270; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; VANHINSBERGH VWM, 1988, BLOOD, V72, P1467; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Zhang X, 2005, VIROLOGY, V340, P285, DOI 10.1016/j.virol.2005.06.020; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225	68	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16428	16435		10.1074/jbc.M600038200	http://dx.doi.org/10.1074/jbc.M600038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16611629	hybrid			2022-12-25	WOS:000238165700032
J	Lodowski, DT; Tesmer, VM; Benovic, JL; Tesmer, JJG				Lodowski, David T.; Tesmer, Valerie M.; Benovic, Jeffrey L.; Tesmer, John J. G.			The structure of G protein-coupled receptor kinase (GRK)-6 defines a second lineage of GRKs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CRYSTAL-STRUCTURE; RHODOPSIN KINASE; SELECTIVE REGULATION; CATALYTIC SUBUNIT; ALPHA-SUBUNITS; BINDING-SITE; IN-VITRO; COMPLEX; FAMILY	We describe the 2.6-angstrom crystal structure of human G protein-coupled receptor kinase (GRK)-6, a key regulator of dopaminergic signaling and lymphocyte chemotaxis. GRK6 is a member of the GRK4 subfamily of GRKs, which is represented in most, if not all, metazoans. Comparison of GRK6 with GRK2 confirms that the catalytic core of all GRKs consists of intimately associated kinase and regulator of G protein signaling (RGS) homology domains. Despite being in complex with an ATP analog, the kinase domain of GRK6 remains in an open, presumably inactive conformation, suggesting that G protein-coupled receptors activate GRKs by inducing kinase domain closure. The structure reveals a putative phospholipid-binding site near the N terminus of GRK6 and structural elements within the kinase substrate channel that likely influence G protein-coupled receptor access and specificity. The crystalline GRK6 RGS homology domain forms an extensive dimer interface using conserved hydrophobic residues distinct from those in GRK2 that bind G alpha(q), although dimerization does not appear to occur in solution and is not required for receptor phosphorylation.	Univ Michigan, Dept Pharmacol, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Texas, Dept Chem & Biochem, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Thomas Jefferson Univ, Dept Biochem & Mol Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	University of Michigan System; University of Michigan; University of Texas System; University of Texas Austin; Jefferson University	Tesmer, JJG (corresponding author), Univ Michigan, Dept Pharmacol, Inst Life Sci, 210 Washtenaw Ave, Ann Arbor, MI 48109 USA.	johntesmer@umich.edu		Tesmer, John/0000-0003-1125-3727	NHLBI NIH HHS [HL 071818] Funding Source: Medline; NIGMS NIH HHS [GM 44944] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; Bezard E, 2005, NEUROBIOL DIS, V18, P323, DOI 10.1016/j.nbd.2004.10.005; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Chen Z, 2005, NAT STRUCT MOL BIOL, V12, P191, DOI 10.1038/nsmb888; Day PW, 2003, BIOCHEMISTRY-US, V42, P9176, DOI 10.1021/bi034442+; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Gainetdinov RR, 2003, NEURON, V38, P291, DOI 10.1016/S0896-6273(03)00192-2; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; HAGA K, 1992, J BIOL CHEM, V267, P2222; Holton J, 2004, P NATL ACAD SCI USA, V101, P1537, DOI 10.1073/pnas.0306241101; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Johnson LR, 2004, MOL CELL BIOL, V24, P10169, DOI 10.1128/MCB.24.23.10169-10179.2004; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kavelaars A, 2003, J IMMUNOL, V171, P6128, DOI 10.4049/jimmunol.171.11.6128; Koch WJ, 2004, MOL CELL BIOCHEM, V263, P5, DOI 10.1023/B:MCBI.0000041843.64809.48; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Krasel C, 2001, J BIOL CHEM, V276, P1911, DOI 10.1074/jbc.M008773200; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Lodowski DT, 2005, BIOCHEMISTRY-US, V44, P6958, DOI 10.1021/bi050119q; Lodowski DT, 2003, ACTA CRYSTALLOGR D, V59, P936, DOI 10.1107/S0907444903002622; Lombardi MS, 1999, FASEB J, V13, P715, DOI 10.1096/fasebj.13.6.715; Loudon RP, 1996, BLOOD, V88, P4547, DOI 10.1182/blood.V88.12.4547.bloodjournal88124547; Loudon RP, 1997, J BIOL CHEM, V272, P27422, DOI 10.1074/jbc.272.43.27422; Milligan G, 2004, MOL PHARMACOL, V66, P1, DOI 10.1124/mol.104.000497.; Narayana N, 1997, STRUCTURE, V5, P921, DOI 10.1016/S0969-2126(97)00246-3; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Noble B, 2003, J BIOL CHEM, V278, P47466, DOI 10.1074/jbc.M308257200; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Premont RT, 1999, J BIOL CHEM, V274, P29381, DOI 10.1074/jbc.274.41.29381; Pronin AN, 2002, METHOD ENZYMOL, V343, P547; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tesmer VM, 2005, SCIENCE, V310, P1686, DOI 10.1126/science.1118890; Usui K, 2000, INT J MOL MED, V5, P335; Vroon A, 2004, J LEUKOCYTE BIOL, V75, P698, DOI 10.1189/jlb.0703320; Willets JM, 2003, TRENDS PHARMACOL SCI, V24, P626, DOI 10.1016/j.tips.2003.10.003; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Winn MD, 2003, J SYNCHROTRON RADIAT, V10, P23, DOI 10.1107/S0909049502017235; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yu QM, 1999, J NEUROCHEM, V73, P1222, DOI 10.1046/j.1471-4159.1999.0731222.x	65	80	84	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16785	16793		10.1074/jbc.M601327200	http://dx.doi.org/10.1074/jbc.M601327200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16613860	hybrid			2022-12-25	WOS:000238165700073
J	Nestorovich, EM; Sugawara, E; Nikaido, H; Bezrukov, SM				Nestorovich, Ekaterina M.; Sugawara, Etsuko; Nikaido, Hiroshi; Bezrukov, Sergey M.			Pseudomonas aeruginosa porin OprF - Properties of the channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-BILAYER-MEMBRANES; GRAM-NEGATIVE BACTERIA; OUTER-MEMBRANE; ESCHERICHIA-COLI; ALPHA-HEMOLYSIN; SINGLE-CHANNEL; PROTEIN OPRF; ION CHANNELS; PORES; POLYMERS	Using ion channel reconstitution in planar lipid bilayers, we examined the channel-forming activity of subfractions of Pseudomonas aeruginosa OprF, which was shown to exist in two different conformations: a minority single domain conformer and a majority two-domain conformer ( Sugawara, E., Nestorovich, E. M., Bezrukov, S. M., and Nikaido, H. ( 2006) J. Biol. Chem. 281, 16220 16229). With the fraction depleted for the single domain conformer, we were unable to detect formation of any channels with well defined conductance levels. With the unfractionated OprF, we saw only rare channel formation. However, with the single domain-enriched fraction of OprF, we observed regular insertion of channels with highly reproducible conductances. Single OprF channels demonstrate rich kinetic behavior exhibiting spontaneous transitions between several subconformations that differ in ionic conductance and radius measured in polymer exclusion experiments. Although we showed that the effective radius of the most conductive conformation exceeds that of the general outer membrane porin of Escherichia coli, OmpF, we also found that a single OprF channel mainly exists in weakly conductive subconformations and switches to the fully open state for a short time only. Therefore, the low permeability of OprF reported earlier may be due to two factors: mainly to the paucity of the single domain conformer in the OprF population and secondly to the predominance of weakly conductive subconformations within the single domain conformer.	NICHHD, Lab Phys & Struct Biol, NIH, Bethesda, MD 20892 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California Berkeley	Bezrukov, SM (corresponding author), NICHHD, Lab Phys & Struct Biol, NIH, Bldg 9 Rm,1N124,9 Mem Dr, Bethesda, MD 20892 USA.	bezrukos@mail.nih.gov			NIAID NIH HHS [R01 AI009644-37, R01 AI009644-36, R01 AI009644] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009644] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELLIDO F, 1992, J BACTERIOL, V174, P5196, DOI 10.1128/JB.174.16.5196-5203.1992; BENZ R, 1981, BIOCHIM BIOPHYS ACTA, V646, P298, DOI 10.1016/0005-2736(81)90336-9; Bezrukov SM, 2000, FEBS LETT, V476, P224, DOI 10.1016/S0014-5793(00)01753-1; Bezrukov SM, 2001, BIOL MEMBRANY, V18, P453; Bezrukov SM, 1996, MACROMOLECULES, V29, P8517, DOI 10.1021/ma960841j; BEZRUKOV SM, 1993, BIOPHYS J, V64, P16, DOI 10.1016/S0006-3495(93)81336-5; Bond PJ, 2002, BIOPHYS J, V83, P763, DOI 10.1016/S0006-3495(02)75207-7; Brinkman FSL, 2000, J BACTERIOL, V182, P5251, DOI 10.1128/JB.182.18.5251-5255.2000; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; FINKELSTEIN A, 1985, ANN NY ACAD SCI, V456, P26, DOI 10.1111/j.1749-6632.1985.tb14840.x; HANCOCK REW, 1979, BIOCHIM BIOPHYS ACTA, V554, P323, DOI 10.1016/0005-2736(79)90373-0; HANCOCK REW, 1978, J BACTERIOL, V136, P381, DOI 10.1128/JB.136.1.381-390.1978; Krasilnikov OV, 1998, J MEMBRANE BIOL, V161, P83; Krasilnikov OV, 2004, MACROMOLECULES, V37, P2650, DOI 10.1021/ma030374n; KRASILNIKOV OV, 1992, FEMS MICROBIOL IMMUN, V105, P93; Kullman L, 2002, BIOPHYS J, V82, P803, DOI 10.1016/S0006-3495(02)75442-8; Nestorovich EM, 2003, BIOPHYS J, V85, P3718, DOI 10.1016/S0006-3495(03)74788-2; Nestorovich EM, 2002, P NATL ACAD SCI USA, V99, P9789, DOI 10.1073/pnas.152206799; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; Rawling EG, 1998, J BACTERIOL, V180, P3556, DOI 10.1128/JB.180.14.3556-3562.1998; RENKIN EM, 1954, J GEN PHYSIOL, V38, P225; Rostovtseva TK, 2002, BIOPHYS J, V82, P160, DOI 10.1016/S0006-3495(02)75383-6; Saint N, 2000, FEMS MICROBIOL LETT, V190, P261, DOI 10.1111/j.1574-6968.2000.tb09296.x; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Sugawara E, 2006, J BIOL CHEM, V281, P16220, DOI 10.1074/jbc.M600680200; Ternovsky VI, 2004, FEBS LETT, V576, P433, DOI 10.1016/j.febslet.2004.09.051; WOODRUFF WA, 1986, J BACTERIOL, V167, P473, DOI 10.1128/jb.167.2.473-479.1986; YOSHIMURA F, 1983, J BIOL CHEM, V258, P2308; Zakharian E, 2003, FEBS LETT, V555, P229, DOI 10.1016/S0014-5793(03)01236-5	30	58	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16230	16237		10.1074/jbc.M600650200	http://dx.doi.org/10.1074/jbc.M600650200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16617058	Green Accepted, hybrid			2022-12-25	WOS:000238165700008
J	Wei, HJ; Wang, XH; Gan, BY; Urvalek, AM; Melkoumian, ZK; Guan, JL; Zhao, JH				Wei, Huijun; Wang, Xianhui; Gan, Boyi; Urvalek, Alison M.; Melkoumian, Zara K.; Guan, Jun-Lin; Zhao, Jihe			Sumoylation delimits KLF8 transcriptional activity associated with the cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; KRUPPEL-LIKE FACTOR; BOX-BINDING-PROTEIN; SUMO-1 MODIFICATION; REPRESSES TRANSCRIPTION; GENE ACTIVATION; ZINC-FINGERS; P53 ACTIVITY; C-JUN; CANCER	KLF8 (Kruppel-like factor 8) is a member of the Kruppel transcription factor family that binds CACCC elements in DNA and activates or represses their target genes in a context-dependent manner. Here we present sumoylation as a novel mechanism that regulates KLF8 post-translationally. We found that KLF8 can be covalently modified by small ubiqitin-like modifier (SUMO)-1, SUMO-2, and SUMO-3 in vivo. We showed that KLF8 interacted with the PIAS family of SUMO E3 ligases PIAS1, PIASy, and PIASx alpha but not with E2 SUMO-conjugating enzyme Ubc9. Furthermore, we demonstrated that the E2 and E3 ligases enhanced the sumoylation of KLF8. In addition, site-directed mutagenesis identified lysine 67 as the major sumoylation site on KLF8. Lysine 67 to arginine mutation strongly enhanced activity of KLF8 as a repressor or activator to its physiological target promoters and as an inducer of the G(1) cell cycle progression. Taken together, our results demonstrated that sumoylation of KLF8 negatively regulates its transcriptional activity and cellular functions.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA	Albany Medical College; Cornell University	Zhao, JH (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave,MC-165, Albany, NY 12208 USA.	zhaojh@mail.amc.edu	Gan, Boyi/HDM-4206-2022		NHLBI NIH HHS [HL 73394] Funding Source: Medline; NIGMS NIH HHS [GM 52890] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052890] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alarcon-Vargas D, 2002, CANCER BIOL THER, V1, P237, DOI 10.4161/cbt.74; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen XY, 2001, MOL CELL BIOL, V21, P3118, DOI 10.1128/MCB.21.9.3118-3125.2001; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kadare G, 2003, J BIOL CHEM, V278, P47434, DOI 10.1074/jbc.M308562200; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kang JE, 2005, CELL PHYSIOL BIOCHEM, V16, P23, DOI 10.1159/000087728; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Lee YS, 2005, EMBO REP, V6, P949, DOI 10.1038/sj.embor.7400511; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; Marx J, 2005, SCIENCE, V307, P836, DOI 10.1126/science.307.5711.836; Matsumura T, 2005, J BIOL CHEM, V280, P12123, DOI 10.1074/jbc.M410578200; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nishida T, 2001, J BIOL CHEM, V276, P39060, DOI 10.1074/jbc.M103955200; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rui HL, 2002, J BIOL CHEM, V277, P42981, DOI 10.1074/jbc.M208099200; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Terui Y, 2004, J BIOL CHEM, V279, P28257, DOI 10.1074/jbc.M403153200; Toews MW, 2004, CURR GENET, V45, P383, DOI 10.1007/s00294-004-0495-7; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wong KA, 2004, MOL CELL BIOL, V24, P5577, DOI 10.1128/MCB.24.12.5577-5586.2004; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5	52	67	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16664	16671		10.1074/jbc.M513135200	http://dx.doi.org/10.1074/jbc.M513135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16617055	hybrid			2022-12-25	WOS:000238165700060
J	Xie, YM; Massa, SM; Ensslen-Craig, SE; Major, DL; Yang, T; Tisi, MA; Derevyanny, VD; Runge, WO; Mehta, BP; Moore, LA; Brady-Kalnay, SM; Longo, FM				Xie, Youmei; Massa, Stephen M.; Ensslen-Craig, Sonya E.; Major, Denice L.; Yang, Tao; Tisi, Michelle A.; Derevyanny, Vicki D.; Runge, William O.; Mehta, Brijesh P.; Moore, Laura A.; Brady-Kalnay, Susann M.; Longo, Frank M.			Protein-tyrosine phosphatase (PTP) wedge domain peptides - A novel approach for inhibition of PTP function and augmentation of protein-tyrosine kinase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE OUTGROWTH; NERVOUS-SYSTEM; HOMOPHILIC BINDING; CRYSTAL-STRUCTURE; RECEPTOR; GROWTH; MU; DIFFERENTIATION; EXPRESSION; TRANSDUCTION	Inhibition of protein-tyrosine phosphatases (PTPs) counterbalancing protein-tyrosine kinases (PTKs) offers a strategy for augmenting PTK actions. Conservation of PTP catalytic sites limits development of specific PTP inhibitors. A number of receptor PTPs, including the leukocyte common antigen-related (LAR) receptor and PTP mu, contain a wedge-shaped helix-loop-helix located near the first catalytic domain. Helix-loop-helix domains in other proteins demonstrate homophilic binding and inhibit function; therefore, we tested the hypothesis that LAR wedge domain peptides would exhibit homophilic binding, bind to LAR, and inhibit LAR function. Fluorescent beads coated with LAR or PTP mu wedge peptides demonstrated PTP-specific homophilic binding, and LAR wedge peptide-coated beads precipitated LAR protein. Administration of LAR wedge Tat peptide to PC12 cells resulted in increased proliferation, decreased cell death, increased neurite outgrowth, and augmented Trk PTK-mediated responses to nerve growth factor (NGF), a phenotype matching that found in PC12 cells with reduced LAR levels. PTP mu wedge Tat peptide had no effect on PC12 cells but blocked the PTP mu-dependent phenotype of neurite outgrowth of retinal ganglion neurons on a PTP mu substrate, whereas LAR wedge peptide had no effect. The survival- and neurite-promoting effect of the LAR wedge peptide was blocked by the Trk inhibitor K252a, and reciprocal co-immunoprecipitation demonstrated LAR/ TrkA association. The addition of LAR wedge peptide inhibited LAR co-immunoprecipitation with TrkA, augmented NGF-induced activation of TrkA, ERK, and AKT, and in the absence of exogenous NGF, induced activation of TrkA, ERK, and AKT. PTP wedge domain peptides provide a unique PTP inhibition strategy and offer a novel approach for augmenting PTK function.	Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA; Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Lab Computat Neurochem & Drug Discovery, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA; Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	Stanford University; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; Case Western Reserve University; Case Western Reserve University	Longo, FM (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, 300 Pasteur Dr, Stanford, CA 94305 USA.	longo@stanford.edu		Craig, Sonya/0000-0002-2535-4951	NEI NIH HHS [R01 EY 12251, R01 EY012251, P01 EY 11373] Funding Source: Medline; NIA NIH HHS [R01 AG 09873] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012251, P30EY011373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009873] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beattie EC, 1996, COLD SPRING HARB SYM, V61, P389; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Bixby JL, 2000, NEUROREPORT, V11, pR5, DOI 10.1097/00001756-200007140-00001; Blanchetot C, 2002, J BIOL CHEM, V277, P47263, DOI 10.1074/jbc.M205810200; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; BRADYKALNAY SM, 2001, CELL ADHESION FRONTI, V39, P217; Burden-Gulley SM, 2002, J NEUROSCI, V22, P3615; Burden-Gulley SM, 1999, J CELL BIOL, V144, P1323, DOI 10.1083/jcb.144.6.1323; Caselli A, 2002, BIOCHEM BIOPH RES CO, V296, P692, DOI 10.1016/S0006-291X(02)00928-2; Castellon R, 2003, J NEUROSCI RES, V72, P239, DOI 10.1002/jnr.10566; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Ensslen SE, 2004, MOL CELL NEUROSCI, V25, P558, DOI 10.1016/j.mcn.2003.12.003; Ensslen-Craig SE, 2005, MOL CELL NEUROSCI, V28, P177, DOI 10.1016/j.mcn.2004.08.011; Ensslen-Craig SE, 2004, DEV BIOL, V275, P12, DOI 10.1016/j.ydbio.2004.08.009; Feiken E, 2000, J BIOL CHEM, V275, P15350, DOI 10.1074/jbc.275.20.15350; Goldfarb AN, 1996, J BIOL CHEM, V271, P2683, DOI 10.1074/jbc.271.5.2683; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Johnson KG, 2003, PHYSIOL REV, V83, P1, DOI 10.1152/physrev.00016.2002; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; LONGO FM, 1993, J BIOL CHEM, V268, P26503; Majeti R, 2001, CHEM REV, V101, P2441, DOI 10.1021/cr000085m; Marsh HN, 2003, J CELL BIOL, V163, P999, DOI 10.1083/jcb.200309036; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Nieddu E, 2005, FASEB J, V19, P632, DOI 10.1096/fj.04-2369fje; Olson VA, 2001, J VIROL, V75, P6042, DOI 10.1128/JVI.75.13.6042-6051.2001; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958; Rosdahl JA, 2003, J NEUROBIOL, V56, P199, DOI 10.1002/neu.10231; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Stoker AW, 2001, CURR OPIN NEUROBIOL, V11, P95, DOI 10.1016/S0959-4388(00)00179-3; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; Tisi MA, 2000, J NEUROBIOL, V42, P477, DOI 10.1002/(SICI)1097-4695(200003)42:4<477::AID-NEU8>3.0.CO;2-B; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Van der Zee CEEM, 2003, EUR J NEUROSCI, V17, P991, DOI 10.1046/j.1460-9568.2003.02516.x; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; VIELMETTER J, 1990, EXP BRAIN RES, V81, P283; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WALTER J, 1987, DEVELOPMENT, V101, P685; Xie YM, 2001, J NEUROSCI, V21, P5130, DOI 10.1523/JNEUROSCI.21-14-05130.2001; Yang T, 2003, J NEUROSCI, V23, P3353; Yeo TT, 1997, J NEUROSCI RES, V47, P348, DOI 10.1002/(SICI)1097-4547(19970201)47:3<348::AID-JNR13>3.0.CO;2-Y; ZHANG JS, 1995, J CELL BIOL, V128, P415, DOI 10.1083/jcb.128.3.415; Zhang JS, 1998, MOL CELL NEUROSCI, V10, P271, DOI 10.1006/mcne.1998.0663; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616; ZHOU J, 1995, J NEUROCHEM, V65, P1146	57	61	66	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16482	16492		10.1074/jbc.M603131200	http://dx.doi.org/10.1074/jbc.M603131200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16613844	hybrid			2022-12-25	WOS:000238165700038
J	Di Noia, MA; Van Driesche, S; Palmieri, F; Yang, LM; Quan, S; Goodman, AI; Abraham, NG				Di Noia, Maria Antonietta; Van Driesche, Sarah; Palmieri, Ferdinando; Yang, Li-Ming; Quan, Shuo; Goodman, Alvin I.; Abraham, Nader G.			Heme oxygenase-1 enhances renal mitochondrial transport carriers and cytochrome c oxidase activity in experimental diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DAMAGE; SENSORY NEURONS; INNER MEMBRANE; BLOOD-PRESSURE; TYPE-1; RAT; APOPTOSIS; GROWTH; HYPERGLYCEMIA; DEFICIENCY	Up-regulation of heme oxygenase (HO-1) by either cobalt protoporphyrin (CoPP) or human gene transfer improves vascular and renal function by several mechanisms, including increases in antioxidant levels and decreases in reactive oxygen species (ROS) in vascular and renal tissue. The purpose of the present study was to determine the effect of HO-1 overexpression on mitochondrial transporters, cytochrome c oxidase, and anti-apoptotic proteins in diabetic rats ( streptozotocin, (STZ)-induced type 1 diabetes). Renal mitochondrial carnitine, deoxynucleotide, and ADP/ATP carriers were significantly reduced in diabetic compared with nondiabetic rats (p < 0.05). The citrate carrier was not significantly decreased in diabetic tissue. CoPP administration produced a robust increase in carnitine, citrate, deoxynucleotide, dicarboxylate, and ADP/ATP carriers and no significant change in oxoglutarate and aspartate/glutamate carriers. The increase in mitochondrial carriers (MCs) was associated with a significant increase in cytochrome c oxidase activity. The administration of tin mesoporphyrin (SnMP), an inhibitor of HO-1 activity, prevented the restoration of MCs in diabetic rats. Human HO-1 cDNA transfer into diabetic rats increased both HO-1 protein and activity, and restored mitochondrial ADP/ATP and deoxynucleotide carriers. The increase in HO-1 by CoPP administration was associated with a significant increase in the phosphorylation of AKT and levels of BcL-XL proteins. These observations in experimental diabetes suggest that the cytoprotective mechanism of HO-1 against oxidative stress involves an increase in the levels of MCs and anti-apoptotic proteins as well as in cytochrome c oxidase activity.	New York Med Coll, Dept Pharmacol & Med, Valhalla, NY 10595 USA; Univ Bari, Dept Pharmacobiol, I-70125 Bari, Italy	New York Medical College; Universita degli Studi di Bari Aldo Moro	Palmieri, F (corresponding author), New York Med Coll, Dept Pharmacol & Med, Valhalla, NY 10595 USA.	fpalm@farmbiol.uniba.it			NHLBI NIH HHS [HL34300, HL55601] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034300] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham NG, 2005, FREE RADICAL BIO MED, V39, P1, DOI 10.1016/j.freeradbiomed.2005.03.010; Abraham NG, 2004, AM J PHYSIOL-HEART C, V287, pH2468, DOI 10.1152/ajpheart.01187.2003; Abraham NG, 2003, CIRC RES, V93, P507, DOI 10.1161/01.RES.0000091828.36599.34; ABRAHAM NG, 1986, BIOCHIM BIOPHYS ACTA, V870, P339, DOI 10.1016/0167-4838(86)90238-4; Bojunga J, 2004, DIABETOLOGIA, V47, P2072, DOI 10.1007/s00125-004-1572-7; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; CAMADRO JM, 1984, J BIOL CHEM, V259, P5678; Chen W, 2004, ENDOCRINOLOGY, V145, P627, DOI 10.1210/en.2003-1274; Dai CS, 2003, J BIOL CHEM, V278, P27080, DOI 10.1074/jbc.M211947200; Detaille D, 2005, DIABETES, V54, P2179, DOI 10.2337/diabetes.54.7.2179; Dulak J, 2004, ANTIOXID REDOX SIGN, V6, P858, DOI 10.1089/1523086041797980; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Green K, 2004, DIABETES, V53, pS110, DOI 10.2337/diabetes.53.2007.S110; Hayashi S, 1999, CIRC RES, V85, P663, DOI 10.1161/01.RES.85.8.663; Hsieh RH, 2005, ANN NY ACAD SCI, V1042, P365, DOI 10.1196/annals.1338.061; Huang TJ, 2005, EXP NEUROL, V194, P279, DOI 10.1016/j.expneurol.2005.03.001; Huang TJ, 2005, MOL CELL NEUROSCI, V28, P42, DOI 10.1016/j.mcn.2004.08.009; Huang TJ, 2003, DIABETES, V52, P2129, DOI 10.2337/diabetes.52.8.2129; Iyer SN, 1996, P NATL ACAD SCI USA, V93, P9960, DOI 10.1073/pnas.93.18.9960; Kang SW, 2001, KIDNEY INT, V59, P1354, DOI 10.1046/j.1523-1755.2001.0590041354.x; KAPLAN RS, 1990, ARCH BIOCHEM BIOPHYS, V280, P181, DOI 10.1016/0003-9861(90)90534-6; Kowluru A, 2005, BIOCHEM PHARMACOL, V69, P1681, DOI 10.1016/j.bcp.2005.03.018; Kruger AL, 2005, CIRCULATION, V111, P3126, DOI 10.1161/CIRCULATIONAHA.104.517102; Lin Y, 2005, J BIOL CHEM, V280, P4617, DOI 10.1074/jbc.M411863200; MAINES MD, 1977, J BIOL CHEM, V252, P5900; MAINES MD, 1986, J BIOL CHEM, V261, P411; Mishra R, 2005, KIDNEY INT, V67, P82, DOI 10.1111/j.1523-1755.2005.00058.x; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Parish Rebecca, 2005, Curr Diab Rep, V5, P177, DOI 10.1007/s11892-005-0006-3; Raizada MK, 2000, J HYPERTENS, V18, P353; Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948; Sabaawy HE, 2001, HYPERTENSION, V38, P210, DOI 10.1161/01.HYP.38.2.210; SANO K, 1985, PEDIATR RES, V19, P587, DOI 10.1203/00006450-198506000-00017; Shen X, 2004, AM J PHYSIOL-ENDOC M, V287, pE896, DOI 10.1152/ajpendo.00047.2004; Siculella L, 2002, BIOCHEM BIOPH RES CO, V299, P418, DOI 10.1016/S0006-291X(02)02666-9; Singleton JR, 2003, DIABETES, V52, P2867, DOI 10.2337/diabetes.52.12.2867; Sparks LM, 2005, DIABETES, V54, P1926, DOI 10.2337/diabetes.54.7.1926; Srinivasan S, 2000, DIABETES, V49, P1932, DOI 10.2337/diabetes.49.11.1932; STANLEY CA, 1992, NEW ENGL J MED, V327, P19, DOI 10.1056/NEJM199207023270104; Sun FY, 2005, DIABETES RES CLIN PR, V67, P110, DOI 10.1016/j.diabres.2004.06.008; SUNAMURA M, 2003, ANGIOGENESIS, V47, P181; Taille C, 2004, J BIOL CHEM, V279, P28681, DOI 10.1074/jbc.M310661200; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Tsang A, 2005, DIABETES, V54, P2360, DOI 10.2337/diabetes.54.8.2360; Turkseven S, 2005, AM J PHYSIOL-HEART C, V289, pH701, DOI 10.1152/ajpheart.00024.2005; VARMA S, 2005, AM J PHYSL HEART CIR; Volti GL, 2005, ANTIOXID REDOX SIGN, V7, P704, DOI 10.1089/ars.2005.7.704; Yang LM, 2004, HYPERTENSION, V43, P1221, DOI 10.1161/01.HYP.0000126287.62060.e6; Ye G, 2004, DIABETES, V53, P1336, DOI 10.2337/diabetes.53.5.1336; Zhang XC, 2005, J BIOL CHEM, V280, P8714, DOI 10.1074/jbc.M408092200	51	95	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15687	15693		10.1074/jbc.M510595200	http://dx.doi.org/10.1074/jbc.M510595200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16595661	Green Published, hybrid			2022-12-25	WOS:000237996000013
J	Ming, L; Wang, P; Bank, A; Yu, J; Zhang, L				Ming, Lihua; Wang, Peng; Bank, Alexander; Yu, Jian; Zhang, Lin			PUMA dissociates bax and bcl-X-L to induce apoptosis in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BH3-ONLY PROTEINS; MITOCHONDRIAL APOPTOSIS; GENE-EXPRESSION; BH3 DOMAINS; DEATH; FAMILY; SURVIVAL; P53; ACTIVATION; MEDIATOR	PUMA is a BH3-only Bcl-2 family protein that plays an essential role in DNA damage-induced apoptosis. PUMA interacts with antiapoptotic Bcl-2 and Bcl-X-L and is dependent on Bax to induce apoptosis. In this study, we investigated how the interactions of PUMA with the antiapoptotic proteins coordinate with Bax to initiate apoptosis in HCT116 colon cancer cells. We found that Bcl-X-L was most effective among several antiapoptotic proteins in suppressing PUMA-induced apoptosis and PUMA-dependent apoptosis induced by the DNA-damaging agent adriamycin. Mutant Bcl-X-L that cannot interact with Bax was unable to protect cells from PUMA-mediated apoptosis. Knockdown of Bcl-X-L by RNA interference significantly enhanced PUMA-mediated apoptosis in HCT116 cells but not in PUMA-knockout cells. Furthermore, Bax was found to be dissociated preferentially from Bcl-X-L in HCT116 cells but not in the PUMA-knockout cells, in response to PUMA induction and adriamycin treatment. PUMA inhibited the association of Bax and Bcl-X-L in vitro by directly binding to Bcl-X-L through its BH3 domain. Finally, we found that wild-type Bax, but not mutant Bax deficient in either multimerization or mitochondrial localization, was able to restore PUMA-induced apoptosis in the BAX-knockout cells. Together, these results indicate that PUMA initiates apoptosis in part by dissociating Bax and Bcl-X-L, thereby promoting Bax multimerization and mitochondrial translocation.	Univ Pittsburgh, Inst Canc, Dept Pathol, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, L (corresponding author), Univ Pittsburgh, Inst Canc, Dept Pathol, Hillman Canc Ctr, UPCI Res Pavil,Rm 2-42D,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	zhanglx@upmc.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903	NATIONAL CANCER INSTITUTE [R01CA106348] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106348, CA106348] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amundson SA, 2000, CANCER RES, V60, P6101; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kohli M, 2004, P NATL ACAD SCI USA, V101, P16897, DOI 10.1073/pnas.0403405101; Krajewska M, 1996, CANCER RES, V56, P2422; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Simonian PL, 1996, J BIOL CHEM, V271, P32073, DOI 10.1074/jbc.271.50.32073; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wang XD, 2001, GENE DEV, V15, P2922; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2004, CURR OPIN ONCOL, V16, P19, DOI 10.1097/00001622-200401000-00005; Yu J, 2003, CANCER BIOL THER, V2, P694; Yu J, 2003, CANCER CELL, V4, P248, DOI 10.1016/S1535-6108(03)00249-6; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhu HB, 2005, MOL CANCER THER, V4, P451; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	39	149	154	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16034	16042		10.1074/jbc.M513587200	http://dx.doi.org/10.1074/jbc.M513587200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16608847	hybrid			2022-12-25	WOS:000237996000055
J	Subbaiah, CC; Palaniappan, A; Duncan, K; Rhoads, DM; Huber, SC; Sachs, MM				Subbaiah, Chalivendra C.; Palaniappan, Ashok; Duncan, Kateri; Rhoads, David M.; Huber, Steven C.; Sachs, Martin M.			Mitochondrial localization and putative signaling function of sucrose synthase in maize	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ASSOCIATION; PLANT MITOCHONDRIAL; GENE-EXPRESSION; PROTEIN; CELLULOSE; IMPORT; TRANSLOCATION; GERMINATION; INHIBITION; PEPTIDES	In many organisms, an increasing number of proteins seem to play two or more unrelated roles. Here we report that maize sucrose synthase ( SUS) is distributed in organelles not involved in sucrose metabolism and may have novel roles beyond sucrose degradation. Bioinformatics analysis predicts that among the three maize SUS isoforms, SH1 protein has a putative mitochondrial targeting peptide (mTP). We validated this prediction by the immunodetection of SUS in mitochondria. Analysis with isoform-specific antisera revealed that both SH1 and SUS1 are represented in mitochondria, although the latter lacks a canonical mTP. The SUS2 isoform is not detectable in mitochondria, despite its presence in the cytosol. In maize primary roots, the mitochondrion-associated SUS (mtSUS; which includes SH1 and SUS1) is present mostly in the root tip, indicating tissue-specific regulation of SUS compartmentation. Unlike the glycolytic enzymes that occur attached to the outside of mitochondria, SH1 and SUS1 are intramitochondrial. The low abundance of SUS in mitochondria, its high Km value for sucrose, and the lack of sucrose in mitochondria suggest that mtSUS plays a non-sucrolytic role. Co-immunoprecipitation studies indicate that SUS interacts with the voltage-dependent anion channel in an isoform-specific and anoxia-enhanced manner and may be involved in the regulation of solute fluxes into and out of mitochondria. In several plant species, at least one of the SUS proteins possesses a putative mTP, indicating the conservation of the noncatalytic function across plant species. Taken together, these observations suggest that SUS has a novel noncatalytic function in plant cells.	Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; Univ Illinois, Dept Crop Sci, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA; USDA ARS, Medwest Area Photosynthesis Res Unit, Urbana, IL USA; Univ Illinois, USDA ARS, MWA Soybean Maize Germplasm, Urbana, IL 61801 USA; Univ Illinois, Genet Res Unit, Urbana, IL 61801 USA	Arizona State University; Arizona State University-Tempe; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Agriculture (USDA); United States Department of Agriculture (USDA); University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Subbaiah, CC (corresponding author), Arizona State Univ, Sch Life Sci, Box 874501, Tempe, AZ 85287 USA.	Subbaiah.Chalivendra@asu.edu	Palaniappan, Ashok/AAD-9018-2020	Palaniappan, Ashok/0000-0003-2841-9527				Albrecht G, 2003, PLANTA, V217, P252, DOI 10.1007/s00425-003-0995-6; AMOR Y, 1995, P NATL ACAD SCI USA, V92, P9353, DOI 10.1073/pnas.92.20.9353; Armstrong W, 1991, PLANT LIFE OXYGEN DE, P267; Arpagaus S, 2002, J BIOL CHEM, V277, P1780, DOI 10.1074/jbc.M109416200; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Baud S, 2004, J EXP BOT, V55, P397, DOI 10.1093/jxb/erh047; Biswas TK, 2002, J BIOL CHEM, V277, P45704, DOI 10.1074/jbc.M202565200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YC, 1989, THEOR APPL GENET, V78, P553, DOI 10.1007/BF00290842; Chourey PS, 1998, MOL GEN GENET, V259, P88, DOI 10.1007/s004380050792; CHOUREY PS, 2006, IN PRESS MAIZE GENET, V80; CROMPTON M, 1988, BIOCHEM J, V255, P357; Dai H, 1998, EUR J CELL BIOL, V75, P198, DOI 10.1016/S0171-9335(98)80062-9; Davis AJ, 1998, MOL BIOL CELL, V9, P2577, DOI 10.1091/mbc.9.9.2577; de Lanerolle P, 2005, NAT STRUCT MOL BIOL, V12, P742, DOI 10.1038/nsmb983; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; DUNCAN KA, 2006, IN PRESS PLANT CELL; ELION EA, 1999, CURRENT PROTOCOLS MO, V4; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fraunberg MV, 2003, J BIOL CHEM, V278, P13376, DOI 10.1074/jbc.M300151200; Giege P, 2003, PLANT CELL, V15, P2140, DOI 10.1105/tpc.012500; Haigler CH, 2001, PLANT MOL BIOL, V47, P29, DOI 10.1023/A:1010615027986; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Hardin SC, 2004, PLANT PHYSIOL, V134, P1427, DOI 10.1104/pp.103.036780; Holtgrawe D, 2005, PHYSIOL PLANTARUM, V125, P141, DOI 10.1111/j.1399-3054.2005.00548.x; HUBER SC, 1986, PLANT PHYSIOL, V81, P1008, DOI 10.1104/pp.81.4.1008; Jap BK, 1996, PHYSIOL REV, V76, P1073, DOI 10.1152/physrev.1996.76.4.1073; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Laloi M, 1999, CELL MOL LIFE SCI, V56, P918, DOI 10.1007/s000180050484; Logan DC, 2001, PLANT PHYSIOL, V125, P662, DOI 10.1104/pp.125.2.662; Lonosky PM, 2004, PLANT PHYSIOL, V134, P560, DOI 10.1104/pp.103.032003; Lunn JE, 2002, PLANT PHYSIOL, V128, P1490, DOI 10.1104/pp.010898; Martin W, 1998, PLANT PHYSIOL, V118, P9, DOI 10.1104/pp.118.1.9; Michalecka AM, 2003, PLANT PHYSIOL, V133, P642, DOI 10.1104/pp.103.024208; Murcha MW, 2005, PLANT PHYSIOL, V138, P2134, DOI 10.1104/pp.105.062745; Murcha MW, 2003, PLANT PHYSIOL, V131, P1737, DOI 10.1104/pp.102.016808; NAKASHIMA RA, 1989, J BIOENERG BIOMEMBR, V21, P461, DOI 10.1007/BF00762518; Rolland F, 2005, BIOCHEM SOC T, V33, P269, DOI 10.1042/BST0330269; Roper JM, 1997, EUR J BIOCHEM, V246, P32, DOI 10.1111/j.1432-1033.1997.t01-1-00032.x; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SAAB IN, 1995, PLANT PHYSIOL, V108, P439, DOI 10.1104/pp.108.1.439; Salerno GL, 2003, TRENDS PLANT SCI, V8, P63, DOI 10.1016/S1360-1385(02)00029-8; Schricker R, 2002, J BIOL CHEM, V277, P28757, DOI 10.1074/jbc.M201561200; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Sjoling S, 1998, TRENDS PLANT SCI, V3, P136, DOI 10.1016/S1360-1385(98)01212-6; Small I, 2004, PROTEOMICS, V4, P1581, DOI 10.1002/pmic.200300776; STEWART CR, 1990, PLANT PHYSIOL, V92, P755, DOI 10.1104/pp.92.3.755; Strobel G, 2002, MOL BIOL CELL, V13, P1439, DOI 10.1091/mbc.01-08-0396; Subbaiah CC, 2000, J EXP BOT, V51, P721, DOI 10.1093/jexbot/51.345.721; SUBBAIAH CC, 1994, PLANT PHYSIOL, V105, P369, DOI 10.1104/pp.105.1.369; SUBBAIAH CC, 1994, PLANT CELL, V6, P1747, DOI 10.1105/tpc.6.12.1747; Sweetlove LJ, 2001, FEBS LETT, V508, P272, DOI 10.1016/S0014-5793(01)03069-1; von Zychlinski A, 2005, MOL CELL PROTEOMICS, V4, P1072, DOI 10.1074/mcp.M500018-MCP200; Whelan J, 1996, BBA-MOL CELL RES, V1312, P48, DOI 10.1016/0167-4889(96)00014-6; Wieprecht T, 2000, BIOCHEMISTRY-US, V39, P15297, DOI 10.1021/bi001774v; Winter H, 1997, FEBS LETT, V420, P151, DOI 10.1016/S0014-5793(97)01506-8; Zara V, 2001, J MOL BIOL, V310, P965, DOI 10.1006/jmbi.2001.4833; Zeng Ying, 1998, Plant Physiology (Rockville), V116, P1573, DOI 10.1104/pp.116.4.1573; Zhang XP, 2002, TRENDS PLANT SCI, V7, P14, DOI 10.1016/S1360-1385(01)02180-X	59	65	72	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15625	15635		10.1074/jbc.M600355200	http://dx.doi.org/10.1074/jbc.M600355200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16606624	hybrid			2022-12-25	WOS:000237996000006
J	Vivithanaporn, P; Yan, S; Swanson, GT				Vivithanaporn, Pornpun; Yan, Sheng; Swanson, Geoffrey T.			Intracellular trafficking of KA2 kainate receptors mediated by interactions with coatomer protein complex I (COPI) and 14-3-3 chaperone systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SYNAPTIC-TRANSMISSION; SURFACE EXPRESSION; MEMBRANE-PROTEINS; RETENTION SIGNAL; GABA(B) RECEPTOR; SUBUNIT; ER; TRANSPORT; CHANNELS	Assembly and trafficking of neurotransmitter receptors are processes contingent upon interactions between intracellular chaperone systems and discrete determinants in the receptor proteins. Kainate receptor subunits, which form ionotropic glutamate receptors with diverse roles in the central nervous system, contain a variety of trafficking determinants that promote either membrane expression or intracellular sequestration. In this report, we identify the coatomer protein complex I ( COPI) vesicle coat as a critical mechanism for retention of the kainate receptor subunit KA2 in the endoplasmic reticulum. COPI subunits immunoprecipitated with KA2 subunits from both cerebellum and COS-7 cells, and beta-COP protein interacted directly with immobilized KA2 peptides containing the arginine-rich retention/retrieval determinant. Association between COPI proteins and KA2 subunits was significantly reduced upon alanine substitution of this signal in the cytoplasmic tail of KA2. Temperature-sensitive degradation of COPI complex proteins was correlated with an increase in plasma membrane localization of the homologous KA2 receptor. Assembly of heteromeric GluR6a/KA2 receptors markedly reduced association of KA2 and COPI. Finally, the reduction in COPI binding was correlated with an increased association with 14-3-3 proteins, which mediate forward trafficking of other integral signaling proteins. These interactions therefore represent a critical early checkpoint for biosynthesis of functional KARs.	Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA	Northwestern University; Feinberg School of Medicine; University of Texas System; University of Texas Medical Branch Galveston	Swanson, GT (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA.	gtswanson@northwestern.edu			NIMH NIH HHS [R03 MH65289] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH065289] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Brock C, 2005, MOL BIOL CELL, V16, P5572, DOI 10.1091/mbc.E05-05-0400; Coussen F, 2005, NEURON, V47, P555, DOI 10.1016/j.neuron.2005.06.033; Delaney AJ, 2002, NEURON, V36, P475, DOI 10.1016/S0896-6273(02)01008-5; Gassmann M, 2005, MOL PHARMACOL, V68, P137, DOI 10.1124/mol.104.010256; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Huettner JE, 2003, PROG NEUROBIOL, V70, P387, DOI 10.1016/S0301-0082(03)00122-9; Jaskolski F, 2005, TRENDS PHARMACOL SCI, V26, P20, DOI 10.1016/j.tips.2004.11.008; Jaskolski F, 2004, J NEUROSCI, V24, P2506, DOI 10.1523/JNEUROSCI.5116-03.2004; Jeanclos EM, 2001, J BIOL CHEM, V276, P28281, DOI 10.1074/jbc.M011549200; Keller SH, 2001, J BIOL CHEM, V276, P18384, DOI 10.1074/jbc.M100691200; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Lerma J, 2003, NAT REV NEUROSCI, V4, P481, DOI 10.1038/nrn1118; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; McMahon HT, 2004, CURR OPIN CELL BIOL, V16, P379, DOI 10.1016/j.ceb.2004.06.009; Michelsen K, 2005, EMBO REP, V6, P717, DOI 10.1038/sj.embor.7400480; Nufer O, 2003, CURR BIOL, V13, pR391, DOI 10.1016/S0960-9822(03)00318-X; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Rajan S, 2002, J PHYSIOL-LONDON, V545, P13, DOI 10.1113/jphysiol.2002.027052; Ren Z, 2003, J BIOL CHEM, V278, P52700, DOI 10.1074/jbc.M309585200; Ren Z, 2003, J NEUROSCI, V23, P6608; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Yan S, 2004, J NEUROSCI, V24, P679, DOI 10.1523/JNEUROSCI.4985-03.2004; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	26	37	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15475	15484		10.1074/jbc.M512098200	http://dx.doi.org/10.1074/jbc.M512098200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16595684	hybrid			2022-12-25	WOS:000237922200054
J	Fears, CY; Gladson, CL; Woods, A				Fears, Constance Y.; Gladson, Candece L.; Woods, Anne			Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; TUMORIGENIC ACTIVITY; SOLUBLE SYNDECAN-1; ECTODOMAINS; ADHESION; PROLIFERATION; INHIBITION; MYELOMA	Angiogenesis is the formation of new blood vessels from the existing vasculature and is necessary for tumor growth. Syndecan-2 (S2) is highly expressed in the microvasculature of mouse gliomas. When S2 expression was down-regulated in mouse brain microvascular endothelial cells (MvEC), this inhibited cell motility and reduced the formation of capillary tube-like structures in vitro. Pro-angiogenic growth factors and enzymes up-regulated during glioma tumorigenesis stimulated shedding of the S2 ectodomain from endothelial cells in vitro. The effect of shed S2 on angiogenic processes was investigated by incorporating recombinant S2 ectodomain (S2ED) into in vitro angiogenesis assays. S2ED promoted membrane protrusion, migration, capillary tube formation, and cell-cell interactions. We therefore propose that S2 is necessary for angiogenesis of MvEC, proangiogenic factors expressed during glioma progression regulate S2 shedding, and shed S2 ectodomain may increase endothelial cell angiogenic processes.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Woods, A (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, THT 946,1530 3rd Ave, Birmingham, AL 35294 USA.	anwoods@uab.edu			NATIONAL CANCER INSTITUTE [R01CA097110] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054605] Funding Source: NIH RePORTER; NCI NIH HHS [CA 97110] Funding Source: Medline; NHLBI NIH HHS [T32 HL 07918] Funding Source: Medline; NIDDK NIH HHS [DK 54605] Funding Source: Medline; NIGMS NIH HHS [GM 50194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bayer-Garner IB, 2001, MODERN PATHOL, V14, P1052, DOI 10.1038/modpathol.3880435; Chen E, 2004, BLOOD, V103, P1710, DOI 10.1182/blood-2003-06-1783; Chen LG, 2004, J BIOL CHEM, V279, P15715, DOI 10.1074/jbc.C300430200; Chen LG, 2002, BIOCHEM J, V366, P481, DOI 10.1042/BJ20020711; Clasper S, 1999, J BIOL CHEM, V274, P24113, DOI 10.1074/jbc.274.34.24113; Contreras HR, 2001, BIOCHEM BIOPH RES CO, V286, P742, DOI 10.1006/bbrc.2001.5459; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; Davies EJ, 2004, CLIN CANCER RES, V10, P5178, DOI 10.1158/1078-0432.CCR-03-0103; Dunn IF, 2000, J NEURO-ONCOL, V50, P121, DOI 10.1023/A:1006436624862; Elenius V, 2004, J BIOL CHEM, V279, P41928, DOI 10.1074/jbc.M404506200; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Gulyas M, 2003, J PATHOL, V199, P479, DOI 10.1002/path.1312; Hajjar K A, 2000, Curr Atheroscler Rep, V2, P417, DOI 10.1007/s11883-000-0080-6; Halden Y, 2004, BIOCHEM J, V377, P533, DOI 10.1042/BJ20030729; Han I, 2004, J MOL HISTOL, V35, P319; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; Kim Y, 2003, ONCOGENE, V22, P826, DOI 10.1038/sj.onc.1206068; Klass CM, 2000, J CELL SCI, V113, P493; Kramer KL, 2002, CELL, V111, P981, DOI 10.1016/S0092-8674(02)01200-X; Kusano Y, 2004, J BIOCHEM, V135, P129, DOI 10.1093/jb/mvh015; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Marshall LJ, 2003, J IMMUNOL, V171, P2057, DOI 10.4049/jimmunol.171.4.2057; Park H, 2002, J BIOL CHEM, V277, P29730, DOI 10.1074/jbc.M202435200; Rooprai HK, 2000, BRIT J CANCER, V82, P52, DOI 10.1054/bjoc.1999.0876; Seidel C, 2000, BLOOD, V95, P388, DOI 10.1182/blood.V95.2.388; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Thorns V, 2003, ANTICANCER RES, V23, P3937; Wang DY, 2000, J CELL SCI, V113, P4221; Wang Maode, 2003, Brain Tumor Pathol, V20, P65, DOI 10.1007/BF02483449; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; Yang Y, 2002, BLOOD, V100, P610, DOI 10.1182/blood.V100.2.610; Yao Y, 2001, ACTA NEUROCHIR, V143, P159, DOI 10.1007/s007010170122; ZAGZAG D, 1990, CANCER RES, V50, P7393	35	103	107	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14533	14536		10.1074/jbc.C600075200	http://dx.doi.org/10.1074/jbc.C600075200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16574663	hybrid			2022-12-25	WOS:000237671300003
J	Kakuda, N; Funamoto, S; Yagishita, S; Takami, M; Osawa, S; Dohmae, N; Ihara, Y				Kakuda, Nobuto; Funamoto, Satoru; Yagishita, Sousuke; Takami, Mako; Osawa, Satoko; Dohmae, Naoshi; Ihara, Yasuo			Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by beta-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE GAMMA-SECRETASE; TRANSMEMBRANE DOMAIN; ALZHEIMERS-DISEASE; A-BETA; INTRAMEMBRANE CLEAVAGE; PRESENILIN-1 MUTATIONS; CYTOPLASMIC DOMAIN; ZETA-CLEAVAGE; COMPLEX; APP	We showed previously that cells expressing wild-type (WT) beta-amyloid precursor protein (APP) or coexpressing WTAPP and WT presenilin (PS) 1/2 produced APP intracellular domains (AICD) 49-99 and 50-99, with the latter predominating. On the other hand, the cells expressing mutant (MT) APP or coexpressing WTAPP and MTPS1/2 produced a greater proportion of AICD-(49-99) than AICD-(50-99). In addition, the expression of amyloid beta-protein ( A beta) 49 in cells resulted in predominant production of A beta 40 and that of A beta 48 leads to preferential production of A beta 42. These observations suggest that epsilon-cleavage and gamma-cleavage are interrelated. To determine the stoichiometry between A beta andAICD, we have established a 3-[(3-cholamidopropyl) dimethylammonio]-2-hydroxy-1-propanesulfonic acid-solubilized gamma-secretase assay system that exhibits high specific activity. By using this assay system, we have shown that equal amounts of A beta and AICD are produced from beta-carboxyl-terminal fragment (C99) by gamma-secretase, irrespective of WT or MTAPP and PS1/2. Although various A beta species, including A beta 40, A beta 42, A beta 43, A beta 45, A beta 48, and A beta 49, are generated, only two species of AICD, AICD-(49-99) and AICD( 50-99), are detected. We also have found that M233T MTPS1 produced only one species of AICD, AICD-(49-99), and only one for its counterpart, A beta 48, in contrast to WT and other MTPS1s. These strongly suggest that epsilon-cleavage is the primary event, and the produced A beta 48 andA beta 49 rapidly undergo gamma-cleavage, resulting in generation of various A beta species.	Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Life Sci, Grad Sch Arts & Sci, Tokyo 1538902, Japan; RIKEN, Inst Phys & Chem Res, Characterizat Ctr, Biomol Characterizat Div, Wako, Saitama 3510198, Japan	University of Tokyo; University of Tokyo; RIKEN	Ihara, Y (corresponding author), Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yihara@m.u-tokyo.ac.jp	Dohmae, Naoshi/C-2040-2011; Kakuda, Nobuto/ABB-5608-2021	Dohmae, Naoshi/0000-0002-5242-9410; Kakuda, Nobuto/0000-0001-7011-6891				Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 2005, CELL, V122, P318, DOI 10.1016/j.cell.2005.07.021; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Funamoto S, 2004, BIOCHEMISTRY-US, V43, P13532, DOI 10.1021/bi049399k; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Hayashi I, 2004, J BIOL CHEM, V279, P38040, DOI 10.1074/jbc.M405597200; Hecimovic S, 2004, NEUROBIOL DIS, V17, P205, DOI 10.1016/j.nbd.2004.04.018; Horikoshi Y, 2004, BIOCHEM BIOPH RES CO, V319, P733, DOI 10.1016/j.bbrc.2004.05.051; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Kinoshita A, 2002, J NEUROCHEM, V82, P839, DOI 10.1046/j.1471-4159.2002.01016.x; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Nyabi O, 2002, NAT CELL BIOL, V4, pE164, DOI 10.1038/ncb0702-e164a; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Qi Y, 2003, BIOCHEMISTRY-US, V42, P1042, DOI 10.1021/bi0267590; Qi-Takahara Y, 2005, J NEUROSCI, V25, P436, DOI 10.1523/JNEUROSCI.1575-04.2005; Ryan KA, 2005, J CELL BIOL, V171, P327, DOI 10.1083/jcb.200505078; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Sato T, 2005, FEBS LETT, V579, P2907, DOI 10.1016/j.febslet.2005.04.037; Sato T, 2003, J BIOL CHEM, V278, P24294, DOI 10.1074/jbc.M211161200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Shindo N, 1997, ANAL BIOCHEM, V249, P79, DOI 10.1006/abio.1997.2155; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Tomita S, 1998, J BIOL CHEM, V273, P19304, DOI 10.1074/jbc.273.30.19304; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wiley JC, 2005, J NEUROCHEM, V94, P1189, DOI 10.1111/j.1471-4159.2005.03266.x; Yagishita S, 2006, BIOCHEMISTRY-US, V45, P3952, DOI 10.1021/bi0521846; Zhao GJ, 2005, J BIOL CHEM, V280, P37689, DOI 10.1074/jbc.M507993200; Zhao GJ, 2004, J BIOL CHEM, V279, P50647, DOI 10.1074/jbc.C400473200	44	128	131	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14776	14786		10.1074/jbc.M513453200	http://dx.doi.org/10.1074/jbc.M513453200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16595682	hybrid			2022-12-25	WOS:000237671300031
J	Kolonin, MG; Sun, J; Do, KA; Vidal, CI; Ji, Y; Baggerly, KA; Pasqualini, R; Arap, W				Kolonin, Mikhail G.; Sun, Jessica; Do, Kim-Anh; Vidal, Claudia I.; Ji, Yuan; Baggerly, Keith A.; Pasqualini, Renata; Arap, Wadih			Synchronous selection of homing peptides for multiple tissues by in vivo phage display	FASEB JOURNAL			English	Article						vascular; receptor; ligand; combinatorial peptide library; phage display	PLACENTAL-LACTOGEN; EXTRACELLULAR DOMAIN; PRL RECEPTOR; PROLACTIN; MOUSE; VASCULATURE; EXPRESSION; ISLETS; TARGET	In vivo phage display is a technology used to reveal organ-specific vascular ligand-receptor systems in animal models and, recently, in patients, and to validate them as potential therapy targets. Here, we devised an efficient approach to simultaneously screen phage display libraries for peptides homing to any number of tissues without the need for an individual subject for each target tissue. We tested this approach in mice by selecting homing peptides for six different organs in a single screen and prioritizing them by using software compiled for statistical validation of peptide biodistribution specificity. We identified a number of motif-containing biological candidates for ligands binding to organ-selective receptors based on similarity of the selected peptide motifs to mouse proteins. To demonstrate that this methodology can lead to targetable ligand-receptor systems, we validated one of the pancreas-homing peptides as a mimic peptide of natural prolactin receptor ligands. This new comprehensive strategy for screening phage libraries in vivo provides an advantage over the conventional approach because multiple organs internally control for organ selectivity of each other in the successive rounds of selection. It may prove particularly relevant for patient studies, allowing efficient high-throughput selection of targeting ligands for multiple organs in a single screen.	Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Pasqualini, R (corresponding author), 1515 Holcombe Blvd, Houston, TX 77030 USA.	rpasqual@mdanderson.org; warap@mdanderson.org		Kolonin, Mikhail/0000-0002-3743-7869	NATIONAL CANCER INSTITUTE [U54CA090810, P50CA090270, P30CA016672, R33CA103030, R21CA111853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067683] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672, CA90270, CA111853, CA103030, CA90810] Funding Source: Medline; NIDDK NIH HHS [DK67683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; BIGNON C, 1994, J BIOL CHEM, V269, P3318; BRELJE TC, 1993, ENDOCRINOLOGY, V132, P879, DOI 10.1210/en.132.2.879; Brelje TC, 2002, J HISTOCHEM CYTOCHEM, V50, P365, DOI 10.1177/002215540205000308; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Carlin BP, 1996, STAT MED, V15, P1093, DOI 10.1002/(SICI)1097-0258(19960615)15:11<1093::AID-SIM231>3.0.CO;2-0; Elkins PA, 2000, NAT STRUCT BIOL, V7, P808, DOI 10.1038/79047; Freemark M, 2002, ENDOCRINOLOGY, V143, P1378, DOI 10.1210/en.143.4.1378; Gelman A, 1996, Stat Methods Med Res, V5, P339, DOI 10.1177/096228029600500402; Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249; Goffin V, 2002, ANNU REV PHYSIOL, V64, P47, DOI 10.1146/annurev.physiol.64.081501.131049; Kolonin M, 2001, CURR OPIN CHEM BIOL, V5, P308, DOI 10.1016/S1367-5931(00)00207-6; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; Kolonin MG, 2002, P NATL ACAD SCI USA, V99, P13055, DOI 10.1073/pnas.162468499; KOLONIN MG, 2003, GENETICS ANGIOGENESI; Krebs LT, 2000, GENE DEV, V14, P1343; Lee KE, 2003, BIOINFORMATICS, V19, P90, DOI 10.1093/bioinformatics/19.1.90; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; Pasqualini R, 2000, CANCER RES, V60, P722; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; PASQUALINI R, 2001, PHAGE DISPLAY LAB MA; Pentz RD, 2003, HASTINGS CENT REP, V33, P20, DOI 10.2307/3527910; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Vasavada RC, 2000, J BIOL CHEM, V275, P15399, DOI 10.1074/jbc.275.20.15399; Wang YF, 1997, MOL ENDOCRINOL, V11, P1353, DOI 10.1210/me.11.9.1353; Wiemers DO, 2003, ENDOCRINOLOGY, V144, P313, DOI 10.1210/en.2002-220724; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zurita AJ, 2004, CANCER RES, V64, P435, DOI 10.1158/0008-5472.CAN-03-2675	30	111	127	2	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					979	+		10.1096/fj.05-5186fje	http://dx.doi.org/10.1096/fj.05-5186fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16581960				2022-12-25	WOS:000240157700028
J	Menne, J; Park, JK; Agrawal, R; Lindschau, C; Kielstein, JT; Kirsch, T; Marx, A; Muller, D; Bahlmann, FH; Meier, M; Bode-Boger, SM; Haller, H; Fliser, D				Menne, Jan; Park, Joon-Keun; Agrawal, Rahul; Lindschau, Carsten; Kielstein, Jan T.; Kirsch, Torsten; Marx, Axel; Muller, Dominik; Bahlmann, Ferdinand H.; Meier, Matthias; Bode-Boeger, Stefanie M.; Haller, Hermann; Fliser, Danilo			Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers	FASEB JOURNAL			English	Article						angiotensin II; protein kinase C; asymmetric dimethylarginine; lercanidipine	PROTEIN-KINASE-C; SMOOTH-MUSCLE CELLS; NITRIC-OXIDE SYNTHASE; STAGE RENAL-DISEASE; ANGIOTENSIN-II; ASYMMETRICAL DIMETHYLARGININE; ENDOTHELIAL-CELLS; GROWTH-FACTOR; HUMAN RENIN; TNF-ALPHA	Long-acting third-generation dihydropyridine calcium channel blockers (CCBs) improve endothelial dysfunction and prevent cardiovascular events in humans, but their cellular and molecular mechanisms of tissue protection are not elucidated in detail. We assessed organ (renal) protection by the highly lipophilic CCB lercanidipine in a double-transgenic rat (dTGR) model with overexpression of human renin and angiotensinogen genes. We randomly treated dTGR with lercanidipine (2.5 mg/ kg/ day; n = 20) or vehicle (n = 20) for 3 wk. Furthermore, we explored the influence of lercanidipine on protein kinase C (PKC) signaling in vivo and in vitro using endothelial and vascular smooth muscle cell cultures. Cumulative mortality was 60% in untreated dTGR, whereas none of the lercanidipine-treated animals died (P < 0.001). We found significantly less albuminuria and improved renal function in lercanidipine-treated dTGR (both P < 0.05). Lercanidipine treatment also significantly (P < 0.05) reduced blood levels of the endogenous NOS inhibitor asymmetric dimethylarginine. On histological examination, we observed significantly less tissue inflammation and fibrosis in lercanidipine-treated animals (both P < 0.05). Lercanidipine significantly inhibited angiotensin (ANG) I-mediated PKC-alpha and -delta activation in vivo and in vitro, partly due to reduced intracellular calcium flux. As a result, lercanidipine improved endothelial cell permeability in vitro. Lercanidipine prevents tissue injury and improves survival in a model of progressive organ damage. These effects may result, at least in part, from inhibition of tissue inflammation as well as improved NO bioavailability. Modulation of PKC activity may be an important underlying intracellular mechanism.	Hannover Med Sch, Dept Internal Med, D-30625 Hannover, Germany; Berlin Chem AG, Berlin, Germany; Klinikum Charite, Franz Vollhard Clin, Berlin, Germany; Univ Magdeburg, Inst Clin Pharmacol, D-39106 Magdeburg, Germany	Hannover Medical School; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Otto von Guericke University	Menne, J (corresponding author), Hannover Med Sch, Dept Internal Med, Carl Neuberg Str 1, D-30625 Hannover, Germany.	janmenne@gmx.de	Kielstein, Jan T./I-2956-2019; Kirsch, Torsten/B-7773-2015; Lindschau, Carsten/G-1798-2011; Lindschau, Carsten/AAE-6721-2020	Kielstein, Jan T./0000-0001-8110-9064; Kirsch, Torsten/0000-0002-0751-5432; Lindschau, Carsten/0000-0003-1960-099X; Bode-Boger, Stefanie/0000-0002-5132-6591; Muller, Dominik N/0000-0003-3650-5644				BERK BC, 1987, J BIOL CHEM, V262, P5057; Berkels R, 2003, PHARMACOLOGY, V69, P171, DOI 10.1159/000073659; Boger RH, 1998, CIRCULATION, V98, P1842, DOI 10.1161/01.CIR.98.18.1842; Bohlender J, 1997, HYPERTENSION, V29, P428, DOI 10.1161/01.HYP.29.1.428; Braz JC, 2004, NAT MED, V10, P248, DOI 10.1038/nm1000; Chang YJ, 2002, J BIOL CHEM, V277, P7118, DOI 10.1074/jbc.M109924200; Cominacini L, 1999, J HYPERTENS, V17, P1837, DOI 10.1097/00004872-199917121-00009; Cooke JP, 2004, CIRCULATION, V109, P1813, DOI 10.1161/01.CIR.0000126823.07732.D5; Dayoub H, 2003, CIRCULATION, V108, P3042, DOI 10.1161/01.CIR.0000101924.04515.2E; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; Grossman E, 2004, PROG CARDIOVASC DIS, V47, P34, DOI 10.1016/j.pcad.2004.04.006; Hahn HS, 2003, CIRC RES, V93, P1111, DOI 10.1161/01.RES.0000105087.79373.17; HALLER H, 1994, HYPERTENSION, V23, P848, DOI 10.1161/01.HYP.23.6.848; HALLER H, 1993, AM J KIDNEY DIS, V21, P26; Haller H, 1998, LANCET, V351, P945; HALLER H, 1994, KIDNEY INT, V46, P1653, DOI 10.1038/ki.1994.465; Hempel A, 1997, CIRC RES, V81, P363, DOI 10.1161/01.RES.81.3.363; Hempel A, 1999, CIRCULATION, V99, P2523, DOI 10.1161/01.CIR.99.19.2523; Hilgers KF, 1996, KIDNEY BLOOD PRESS R, V19, P254, DOI 10.1159/000174085; Hisayama T, 1999, Nihon Yakurigaku Zasshi, V114 Suppl 1, p86P; ISHIDOYA S, 1995, KIDNEY INT, V47, P1285, DOI 10.1038/ki.1995.183; Kielstein JT, 2004, CIRCULATION, V109, P172, DOI 10.1161/01.CIR.0000105764.22626.B1; Kielstein JT, 1999, J AM SOC NEPHROL, V10, P594; Kilian K, 2004, J BIOL CHEM, V279, P34472, DOI 10.1074/jbc.M405916200; Leiper J, 2002, P NATL ACAD SCI USA, V99, P13527, DOI 10.1073/pnas.212269799; Luft FC, 1999, HYPERTENSION, V33, P212, DOI 10.1161/01.HYP.33.1.212; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Martens-Lobenhoffer J, 2003, J CHROMATOGR B, V798, P231, DOI 10.1016/j.jchromb.2003.09.050; Menne J, 2004, DIABETES, V53, P2101, DOI 10.2337/diabetes.53.8.2101; Mervaala E, 2000, HYPERTENSION, V35, P587, DOI 10.1161/01.HYP.35.2.587; Muth JN, 2001, CIRCULATION, V103, P140; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oriji GK, 1999, PROSTAG LEUKOTR ESS, V61, P113, DOI 10.1054/plef.1999.0079; Orth SR, 1996, KIDNEY INT, V49, P868, DOI 10.1038/ki.1996.120; Osicka TM, 2001, CLIN SCI, V100, P249, DOI 10.1042/CS20000194; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Ruschitzka F, 1999, J Hypertens Suppl, V17, pS25; Sabbatini M, 2000, J PHARMACOL EXP THER, V294, P948; Taddei S, 2003, HYPERTENSION, V41, P950, DOI 10.1161/01.HYP.0000063361.70525.3C; Valkonen VP, 2001, LANCET, V358, P2127, DOI 10.1016/S0140-6736(01)07184-7; Woo CH, 2005, AM J PHYSIOL-LUNG C, V288, pL307, DOI 10.1152/ajplung.00105.2004; Yoo JH, 2001, ATHEROSCLEROSIS, V158, P425, DOI 10.1016/S0021-9150(01)00444-0; Zhang L, 2004, J BIOL CHEM, V279, P28315, DOI 10.1074/jbc.C400115200; Zoccali C, 2001, LANCET, V358, P2113, DOI 10.1016/S0140-6736(01)07217-8	44	17	17	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					994	996		10.1096/fj.05-4087fje	http://dx.doi.org/10.1096/fj.05-4087fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16597674				2022-12-25	WOS:000240157700033
